token,label,label_gpt
22,B,O
-,I,O
oxacalcitriol,I,B
suppresses,O,O
secondary,O,O
hyperparathyroidism,O,O
without,O,O
inducing,O,O
low,O,O
bone,O,O
turnover,O,O
in,O,O
dogs,O,O
with,O,O
renal,O,O
failure,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Calcitriol,B,B
therapy,O,O
suppresses,O,O
serum,O,O
levels,O,O
of,O,O
parathyroid,O,O
hormone,O,O
(,O,O
PTH,O,B
),O,O
in,O,O
patients,O,O
with,O,O
renal,O,O
failure,O,O
but,O,O
has,O,O
several,O,O
drawbacks,O,O
",",O,O
including,O,O
hypercalcemia,O,B
and,O,O
/,O,O
or,O,O
marked,O,O
suppression,O,O
of,O,O
bone,O,O
turnover,O,O
",",O,O
which,O,O
may,O,O
lead,O,O
to,O,O
adynamic,O,O
bone,O,O
disease,O,O
.,O,O
A,O,O
new,O,O
vitamin,B,B
D,I,I
analogue,O,I
",",O,O
22,B,O
-,I,O
oxacalcitriol,I,B
(,O,O
OCT,B,I
),O,O
",",O,O
has,O,O
been,O,O
shown,O,O
to,O,O
have,O,O
promising,O,O
characteristics,O,O
.,O,O
This,O,O
study,O,O
was,O,O
undertaken,O,O
to,O,O
determine,O,O
the,O,O
effects,O,O
of,O,O
OCT,B,I
on,O,O
serum,O,O
PTH,O,B
levels,O,O
and,O,O
bone,O,O
turnover,O,O
in,O,O
states,O,O
of,O,O
normal,O,O
or,O,O
impaired,O,O
renal,O,O
function,O,O
.,O,O
:,O,O
Sixty,O,O
dogs,O,O
were,O,O
either,O,O
nephrectomized,O,O
(,O,O
Nx,O,O
",",O,O
N,O,O
=,O,O
38,O,O
),O,O
or,O,O
sham,O,O
-,O,O
operated,O,O
(,O,O
Sham,O,O
",",O,O
N,O,O
=,O,O
22,O,O
),O,O
.,O,O
The,O,O
animals,O,O
received,O,O
supplemental,O,O
phosphate,B,B
to,O,O
enhance,O,O
PTH,O,B
secretion,O,O
.,O,O
Fourteen,O,O
weeks,O,O
after,O,O
the,O,O
start,O,O
of,O,O
phosphate,B,B
supplementation,O,O
",",O,O
half,O,O
of,O,O
the,O,O
Nx,O,O
and,O,O
Sham,O,O
dogs,O,O
received,O,O
doses,O,O
of,O,O
OCT,B,B
(,O,O
three,O,O
times,O,O
per,O,O
week,O,O
),O,O
;,O,O
the,O,O
other,O,O
half,O,O
were,O,O
given,O,O
vehicle,O,O
for,O,O
60,O,O
weeks,O,O
.,O,O
Thereafter,O,O
",",O,O
the,O,O
treatment,O,O
modalities,O,O
for,O,O
a,O,O
subset,O,O
of,O,O
animals,O,O
were,O,O
crossed,O,O
over,O,O
for,O,O
an,O,O
additional,O,O
eight,O,O
months,O,O
.,O,O
Biochemical,O,O
and,O,O
hormonal,O,O
indices,O,O
of,O,O
calcium,B,B
and,O,O
bone,O,O
metabolism,O,O
were,O,O
measured,O,O
throughout,O,O
the,O,O
study,O,O
",",O,O
and,O,O
bone,O,O
biopsies,O,O
were,O,O
done,O,O
at,O,O
baseline,O,O
",",O,O
60,O,O
weeks,O,O
after,O,O
OCT,B,B
or,O,O
vehicle,O,O
treatment,O,O
",",O,O
and,O,O
at,O,O
the,O,O
end,O,O
of,O,O
the,O,O
crossover,O,O
period,O,O
.,O,O
RESULTS,O,O
:,O,O
In,O,O
Nx,O,O
dogs,O,O
",",O,O
OCT,B,B
significantly,O,O
decreased,O,O
serum,O,O
PTH,O,B
levels,O,O
soon,O,O
after,O,O
the,O,O
induction,O,O
of,O,O
renal,O,O
insufficiency,O,O
.,O,O
In,O,O
long,O,O
-,O,O
standing,O,O
secondary,O,O
hyperparathyroidism,O,O
",",O,O
OCT,B,B
(,O,O
0,O,O
.,O,O
microg,O,O
/,O,O
kg,O,O
),O,O
stabilized,O,O
serum,O,O
PTH,O,B
levels,O,O
during,O,O
the,O,O
first,O,O
months,O,O
.,O,O
Serum,O,O
PTH,O,B
levels,O,O
rose,O,O
thereafter,O,O
",",O,O
but,O,O
the,O,O
rise,O,O
was,O,O
less,O,O
pronounced,O,O
compared,O,O
with,O,O
baseline,O,O
than,O,O
the,O,O
rise,O,O
seen,O,O
in,O,O
Nx,O,O
control,O,O
.,O,O
These,O,O
effects,O,O
were,O,O
accompanied,O,O
by,O,O
episodes,O,O
of,O,O
hypercalcemia,O,B
and,O,O
hyperphosphatemia,O,B
.,O,O
In,O,O
animals,O,O
with,O,O
normal,O,O
renal,O,O
function,O,O
",",O,O
OCT,B,B
induced,O,O
a,O,O
transient,O,O
decrease,O,O
in,O,O
serum,O,O
PTH,O,B
levels,O,O
at,O,O
a,O,O
dose,O,O
of,O,O
0,O,O
.,O,O
1,O,O
microg,O,O
/,O,O
kg,O,O
",",O,O
which,O,O
was,O,O
not,O,O
sustained,O,O
with,O,O
lowering,O,O
of,O,O
the,O,O
doses,O,O
.,O,O
In,O,O
Nx,O,O
dogs,O,O
",",O,O
OCT,B,B
reversed,O,O
abnormal,O,O
bone,O,O
formation,O,O
",",O,O
such,O,O
as,O,O
woven,O,O
osteoid,O,B
and,O,O
fibrosis,O,O
",",O,O
but,O,O
did,O,O
not,O,O
significantly,O,O
alter,O,O
the,O,O
level,O,O
of,O,O
bone,O,O
turnover,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
OCT,B,B
improved,O,O
mineralization,O,O
lag,O,O
time,O,O
",",O,O
(,O,O
that,O,O
is,O,O
",",O,O
the,O,O
rate,O,O
at,O,O
which,O,O
osteoid,O,B
mineralizes,O,O
),O,O
in,O,O
both,O,O
Nx,O,O
and,O,O
Sham,O,O
dogs,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
even,O,O
though,O,O
OCT,B,B
does,O,O
not,O,O
completely,O,O
prevent,O,O
the,O,O
occurrence,O,O
of,O,O
hypercalcemia,O,B
in,O,O
experimental,O,O
dogs,O,O
with,O,O
renal,O,O
insufficiency,O,O
",",O,O
it,O,O
may,O,O
be,O,O
of,O,O
use,O,O
in,O,O
the,O,O
management,O,O
of,O,O
secondary,O,O
hyperparathyroidism,O,B
because,O,O
it,O,O
does,O,O
not,O,O
induce,O,O
low,O,O
bone,O,O
turnover,O,O
and,O,O
",",O,O
therefore,O,O
",",O,O
does,O,O
not,O,O
increase,O,O
the,O,O
risk,O,O
of,O,O
adynamic,O,O
bone,O,O
disease,O,O
.,O,O
Hypotension,O,O
",",O,O
bradycardia,O,O
",",O,O
and,O,O
asystole,O,O
after,O,O
high,O,O
-,O,O
dose,O,O
intravenous,O,O
methylprednisolone,B,B
in,O,O
a,O,O
monitored,O,O
patient,O,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
hypotension,O,O
",",O,O
bradycardia,O,O
",",O,O
and,O,O
asystole,O,O
after,O,O
intravenous,O,O
administration,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
methylprednisolone,B,B
in,O,O
a,O,O
73,O,O
-,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
who,O,O
underwent,O,O
electrocardiographic,O,O
(,O,O
ECG,O,B
),O,O
monitoring,O,O
throughout,O,O
the,O,O
episode,O,O
.,O,O
There,O,O
was,O,O
a,O,O
history,O,O
of,O,O
ischemic,O,B
cardiac,O,I
disease,O,I
9,O,O
years,O,O
earlier,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
admitted,O,O
with,O,O
a,O,O
pulmonary,O,B
-,O,O
renal,O,I
syndrome,O,I
with,O,O
hemoptysis,O,O
",",O,O
rapidly,O,O
progressive,O,O
renal,O,B
failure,O,I
",",O,O
and,O,O
hypoxemia,O,O
that,O,O
required,O,O
mechanical,O,O
ventilation,O,O
in,O,O
the,O,O
intensive,O,O
care,O,O
unit,O,O
.,O,O
After,O,O
receiving,O,O
advanced,O,O
cardiopulmonary,O,B
resuscitation,O,I
",",O,O
the,O,O
patient,O,O
recovered,O,O
cardiac,O,B
rhythm,O,I
.,O,O
The,O,O
ECG,O,O
showed,O,O
a,O,O
junctional,O,O
rhythm,O,O
without,O,O
ventricular,O,O
arrhythmia,O,O
.,O,O
This,O,O
study,O,O
reviews,O,O
the,O,O
current,O,O
proposed,O,O
mechanisms,O,O
of,O,O
sudden,O,O
death,O,O
after,O,O
a,O,O
high,O,O
dose,O,O
of,O,O
intravenous,O,B
methylprednisolone,B,I
(,O,O
IVMP,B,B
),O,O
.,O,O
These,O,O
mechanisms,O,O
are,O,O
not,O,O
well,O,O
understood,O,O
because,O,O
",",O,O
in,O,O
most,O,O
cases,O,O
",",O,O
the,O,O
patients,O,O
were,O,O
not,O,O
monitored,O,O
at,O,O
the,O,O
moment,O,O
of,O,O
the,O,O
event,O,O
.,O,O
Rapid,O,O
infusion,O,O
and,O,O
underlying,O,O
cardiac,O,O
disease,O,O
were,O,O
important,O,O
risk,O,O
factors,O,O
in,O,O
the,O,O
case,O,O
reported,O,O
here,O,O
",",O,O
and,O,O
the,O,O
authors,O,O
discount,O,O
ventricular,O,O
arrhythmia,O,O
as,O,O
the,O,O
main,O,O
mechanism,O,O
.,O,O
Worsening,O,O
of,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
by,O,O
motor,O,O
and,O,O
mental,O,O
tasks,O,O
.,O,O
Ten,O,O
patients,O,O
who,O,O
had,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
with,O,O
disabling,O,O
dyskinesia,O,O
were,O,O
included,O,O
in,O,O
this,O,O
study,O,O
to,O,O
evaluate,O,O
the,O,O
role,O,O
of,O,O
mental,O,O
(,O,O
mental,O,O
calculation,O,O
),O,O
and,O,O
motor,O,O
(,O,O
flexion,O,O
/,O,O
extension,O,O
of,O,O
right,O,O
fingers,O,O
",",O,O
flexion,O,O
/,O,O
extension,O,O
of,O,O
left,O,O
fingers,O,O
",",O,O
flexion,O,O
/,O,O
extension,O,O
of,O,O
the,O,O
neck,O,O
",",O,O
speaking,O,O
aloud,O,O
),O,O
tasks,O,O
on,O,O
the,O,O
worsening,O,O
of,O,O
peak,O,O
-,O,O
dose,O,O
dyskinesia,O,O
following,O,O
administration,O,O
of,O,O
an,O,O
effective,O,O
single,O,O
dose,O,O
of,O,O
apomorphine,B,B
.,O,O
Compared,O,O
with,O,O
the,O,O
score,O,O
at,O,O
rest,O,O
(,O,O
1,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
),O,O
",",O,O
a,O,O
significant,O,O
aggravation,O,O
of,O,O
the,O,O
dyskinesia,O,B
score,O,O
was,O,O
observed,O,O
during,O,O
speaking,O,O
aloud,O,O
(,O,O
5,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
1,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
movements,O,O
of,O,O
right,O,O
(,O,O
4,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
0,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
left,O,O
(,O,O
3,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
movements,O,O
of,O,O
the,O,O
neck,O,O
(,O,O
5,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
0,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
",",O,O
and,O,O
mental,O,O
calculation,O,O
(,O,O
3,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
0,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
activation,O,O
tasks,O,O
such,O,O
as,O,O
could,O,O
be,O,O
used,O,O
for,O,O
objective,O,O
assessment,O,O
of,O,O
dyskinesia,O,O
severity,O,O
.,O,O
Urine,O,O
N,O,B
-,O,I
acetyl,O,I
-,O,I
beta,O,I
-,O,I
D,O,I
-,O,I
glucosaminidase,O,I
-,O,I
-,O,I
a,O,O
marker,O,O
of,O,O
tubular,O,O
damage,O,O
?,O,O
BACKGROUND,O,O
:,O,O
Although,O,O
an,O,O
indicator,O,O
of,O,O
renal,O,O
tubular,O,O
dysfunction,O,O
",",O,O
an,O,O
increased,O,O
urinary,O,O
N,O,B
-,O,I
acetyl,O,I
-,O,I
beta,O,I
-,O,I
D,O,I
-,O,I
glucosaminidase,O,I
(,O,I
NAG,O,I
),O,I
activity,O,O
might,O,O
reflect,O,O
increased,O,O
lysosomal,O,O
activity,O,O
in,O,O
renal,O,O
tubular,O,O
cells,O,O
.,O,O
METHODS,O,O
:,O,O
Puromycin,B,B
aminonucleoside,I,I
(,O,O
PAN,B,B
),O,O
was,O,O
administered,O,O
to,O,O
Sprague,O,O
Dawley,O,O
rats,O,O
to,O,O
induce,O,O
proteinuria,O,O
.,O,O
Total,O,O
protein,O,B
",",O,O
albumin,O,B
",",O,O
NAG,O,B
activity,O,O
and,O,O
protein,O,O
electrophoretic,O,O
pattern,O,O
were,O,O
assessed,O,O
in,O,O
daily,O,O
urine,O,O
samples,O,O
for,O,O
33,O,O
days,O,O
.,O,O
The,O,O
morphological,O,O
appearance,O,O
of,O,O
the,O,O
kidneys,O,O
was,O,O
examined,O,O
on,O,O
days,O,O
three,O,O
",",O,O
four,O,O
",",O,O
six,O,O
",",O,O
eight,O,O
and,O,O
thirty,O,O
three,O,O
and,O,O
the,O,O
NAG,O,B
isoenzyme,O,O
patterns,O,O
on,O,O
days,O,O
zero,O,O
",",O,O
four,O,O
",",O,O
eight,O,O
and,O,O
thirty,O,O
three,O,O
.,O,O
RESULTS,O,O
:,O,O
Following,O,O
intravenous,O,O
PAN,B,B
urine,O,O
volume,O,O
and,O,O
urine,O,O
NAG,O,B
activity,O,O
increased,O,O
significantly,O,O
by,O,O
day,O,O
two,O,O
",",O,O
but,O,O
returned,O,O
to,O,O
normal,O,O
by,O,O
day,O,O
four,O,O
.,O,O
After,O,O
day,O,O
four,O,O
all,O,O
treated,O,O
animals,O,O
exhibited,O,O
a,O,O
marked,O,O
rise,O,O
in,O,O
urine,O,O
albumin,O,B
",",O,O
total,O,O
protein,O,O
excretion,O,O
and,O,O
NAG,O,B
activity,O,O
.,O,O
Electrophoresis,O,O
showed,O,O
a,O,O
generalised,O,O
increase,O,O
in,O,O
middle,O,O
and,O,O
high,O,O
molecular,O,O
weight,O,O
urine,O,O
proteins,O,O
from,O,O
day,O,O
four,O,O
onwards,O,O
.,O,O
Protein,O,B
droplets,O,O
first,O,O
appeared,O,O
prominent,O,O
in,O,O
tubular,O,O
cells,O,O
on,O,O
day,O,O
four,O,O
.,O,O
Peak,O,O
urine,O,O
NAG,O,B
activity,O,O
and,O,O
a,O,O
change,O,O
in,O,O
NAG,O,B
isoenzyme,O,O
pattern,O,O
coincided,O,O
with,O,O
both,O,O
the,O,O
peak,O,O
proteinuria,O,O
and,O,O
the,O,O
reduction,O,O
in,O,O
intracellular,O,O
protein,O,B
and,O,O
NAG,O,B
droplets,O,O
(,O,O
day,O,O
six,O,O
onwards,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
This,O,O
animal,O,O
model,O,O
demonstrates,O,O
that,O,O
an,O,O
increase,O,O
in,O,O
lysosomal,O,O
turnover,O,O
and,O,O
hence,O,O
urine,O,O
NAG,O,B
activity,O,O
",",O,O
occurs,O,O
when,O,O
increased,O,O
protein,O,B
is,O,O
presented,O,O
to,O,O
the,O,O
tubular,O,O
cells,O,O
.,O,O
Urine,O,O
NAG,O,B
activity,O,O
is,O,O
thus,O,O
a,O,O
measure,O,O
of,O,O
altered,O,O
function,O,O
in,O,O
the,O,O
renal,O,B
tubules,O,O
and,O,O
not,O,O
simply,O,O
an,O,O
indicator,O,O
of,O,O
damage,O,O
.,O,O
Cauda,O,O
equina,O,O
syndrome,O,O
after,O,O
spinal,O,O
anaesthesia,O,O
with,O,O
hyperbaric,O,O
5,O,B
%,O,O
lignocaine,B,B
:,O,O
a,O,O
review,O,O
of,O,O
six,O,O
cases,O,O
of,O,O
cauda,O,O
equina,O,O
syndrome,O,O
reported,O,O
to,O,O
the,O,O
Swedish,O,O
Pharmaceutical,O,O
Insurance,O,O
1993,O,O
-,O,O
1997,O,O
.,O,O
Six,O,O
cases,O,O
of,O,O
cauda,O,B
equina,O,I
syndrome,O,I
with,O,O
varying,O,O
severity,O,O
were,O,O
reported,O,O
to,O,O
the,O,O
Swedish,O,O
Pharmaceutical,O,O
Insurance,O,O
during,O,O
the,O,O
period,O,O
1993,O,O
-,O,O
1997,O,O
.,O,O
All,O,O
were,O,O
associated,O,O
with,O,O
spinal,O,O
anaesthesia,O,O
using,O,O
hyperbaric,O,O
5,O,B
%,O,I
lignocaine,B,I
.,O,O
Five,O,O
cases,O,O
had,O,O
single,O,O
-,O,O
shot,O,O
spinal,O,O
anaesthesia,O,O
and,O,O
one,O,O
had,O,O
a,O,O
repeat,O,O
spinal,O,O
anaesthetic,O,O
due,O,O
to,O,O
inadequate,O,O
block,O,O
.,O,O
The,O,O
dose,O,O
of,O,O
hyperbaric,O,O
5,O,B
%,O,I
lignocaine,B,I
administered,O,O
ranged,O,O
from,O,O
60,O,O
to,O,O
120,O,O
mg,O,O
.,O,O
Three,O,O
of,O,O
the,O,O
cases,O,O
were,O,O
most,O,O
likely,O,O
caused,O,O
by,O,O
direct,O,O
neurotoxicity,O,O
of,O,O
hyperbaric,O,O
5,O,B
%,O,I
lignocaine,B,I
.,O,O
In,O,O
the,O,O
other,O,O
3,O,O
cases,O,O
",",O,O
direct,O,O
neurotoxicity,O,O
was,O,O
also,O,O
probable,O,O
",",O,O
but,O,O
unfortunately,O,O
radiological,O,O
investigations,O,O
were,O,O
not,O,O
done,O,O
to,O,O
definitely,O,O
exclude,O,O
a,O,O
compressive,O,O
aetiology,O,O
.,O,O
All,O,O
cases,O,O
sustained,O,O
permanent,O,O
neurological,O,O
deficits,O,O
.,O,O
We,O,O
recommend,O,O
that,O,O
hyperbaric,O,O
lignocaine,B,B
should,O,O
be,O,O
administered,O,O
in,O,O
concentrations,O,O
not,O,O
greater,O,O
than,O,O
2,O,O
%,O,O
and,O,O
at,O,O
a,O,O
total,O,O
dose,O,O
preferably,O,O
not,O,O
exceeding,O,O
60,O,O
mg,O,O
.,O,O
Systemic,O,O
toxicity,O,O
following,O,O
administration,O,O
of,O,O
sirolimus,B,B
(,O,O
formerly,O,O
rapamycin,B,I
),O,O
for,O,O
psoriasis,O,O
:,O,O
association,O,O
of,O,O
capillary,O,O
leak,O,O
syndrome,O,O
with,O,O
apoptosis,O,O
of,O,O
lesional,O,O
lymphocytes,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Sirolimus,B,B
(,O,O
formerly,O,O
rapamycin,B,O
),O,O
is,O,O
an,O,O
immunosuppressive,O,O
agent,O,O
that,O,O
interferes,O,O
with,O,O
T,O,B
-,O,O
cell,O,O
activation,O,O
.,O,O
After,O,O
2,O,O
individuals,O,O
with,O,O
psoriasis,O,O
developed,O,O
a,O,O
capillary,O,O
leak,O,O
syndrome,O,O
following,O,O
treatment,O,O
with,O,O
oral,O,O
sirolimus,B,B
lesional,O,O
skin,O,O
cells,O,O
and,O,O
activated,O,O
peripheral,O,O
blood,O,O
cells,O,O
were,O,O
analyzed,O,O
for,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
OBSERVATIONS,O,O
:,O,O
A,O,O
keratome,O,O
skin,O,O
specimen,O,O
from,O,O
1,O,O
patient,O,O
with,O,O
sirolimus,B,B
-,O,O
induced,O,O
capillary,O,O
leak,O,O
syndrome,O,O
had,O,O
a,O,O
2,O,O
.,O,O
3,O,O
-,O,O
fold,O,O
increase,O,O
in,O,O
percentage,O,O
of,O,O
apoptotic,O,O
cells,O,O
(,O,O
to,O,O
48,O,O
%,O,O
),O,O
compared,O,O
with,O,O
an,O,O
unaffected,O,O
sirolimus,B,B
-,O,O
treated,O,O
patient,O,O
with,O,O
psoriasis,O,O
(,O,O
21,O,O
%,O,O
),O,O
.,O,O
Activated,O,O
peripheral,O,O
blood,O,O
T,O,O
cells,O,O
from,O,O
patients,O,O
with,O,O
psoriasis,O,O
tended,O,O
to,O,O
exhibit,O,O
greater,O,O
spontaneous,O,O
or,O,O
dexamethasone,B,B
-,O,O
induced,O,O
apoptosis,O,O
than,O,O
did,O,O
normal,O,O
T,O,O
cells,O,O
",",O,O
particularly,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
sirolimus,B,B
.,O,O
CONCLUSIONS,O,O
:,O,O
Severe,O,O
adverse,O,O
effects,O,O
of,O,O
sirolimus,B,B
include,O,O
fever,O,O
",",O,O
anemia,O,O
",",O,O
and,O,O
capillary,O,B
leak,O,I
syndrome,O,I
.,O,O
These,O,O
symptoms,O,O
may,O,O
be,O,O
the,O,O
result,O,O
of,O,O
drug,O,O
-,O,O
induced,O,O
apoptosis,O,O
of,O,O
lesional,O,O
leukocytes,O,O
",",O,O
especially,O,O
activated,O,O
T,O,B
lymphocytes,O,I
",",O,O
and,O,O
possibly,O,O
release,O,O
of,O,O
inflammatory,O,O
mediators,O,O
.,O,O
Because,O,O
patients,O,O
with,O,O
severe,O,O
psoriasis,O,O
may,O,O
develop,O,O
capillary,O,B
leak,O,I
from,O,O
various,O,O
systemic,O,O
therapies,O,O
",",O,O
clinical,O,O
monitoring,O,O
is,O,O
advisable,O,O
for,O,O
patients,O,O
with,O,O
inflammatory,O,O
diseases,O,O
who,O,O
are,O,O
treated,O,O
with,O,O
immune,O,O
modulators,O,O
.,O,O
Effect,O,O
of,O,O
lithium,B,B
maintenance,O,I
therapy,O,I
on,O,O
thyroid,O,B
and,O,O
parathyroid,O,B
function,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
assess,O,O
changes,O,O
induced,O,O
by,O,O
lithium,B,B
maintenance,O,I
therapy,O,I
on,O,O
the,O,O
incidence,O,O
of,O,O
thyroid,O,B
",",O,O
parathyroid,O,B
and,O,O
ion,O,O
alterations,O,O
.,O,O
These,O,O
were,O,O
evaluated,O,O
with,O,O
respect,O,O
to,O,O
the,O,O
duration,O,O
of,O,O
lithium,B,B
therapy,O,I
",",O,O
age,O,O
",",O,O
sex,O,O
",",O,O
and,O,O
family,O,O
history,O,O
(,O,O
whether,O,O
or,O,O
not,O,O
the,O,O
patient,O,O
had,O,O
a,O,O
first,O,O
-,O,O
degree,O,O
relative,O,O
with,O,O
thyroid,O,B
disease,O,O
),O,O
.,O,O
DESIGN,O,O
:,O,O
Prospective,O,O
study,O,O
.,O,O
SETTING,O,O
:,O,O
Affective,O,O
Disorders,O,O
Clinic,O,O
at,O,O
St,O,O
.,O,O
Mary,O,O
',O,O
s,O,O
Hospital,O,O
",",O,O
Montreal,O,O
.,O,O
PATIENTS,O,O
:,O,O
One,O,O
hundred,O,O
and,O,O
one,O,O
patients,O,O
(,O,O
28,O,O
men,O,O
and,O,O
73,O,O
women,O,O
),O,O
with,O,O
bipolar,O,O
disorder,O,O
receiving,O,O
lithium,B,B
maintenance,O,O
therapy,O,O
ranging,O,O
from,O,O
1,O,O
year,O,O
',O,O
s,O,O
to,O,O
32,O,O
years,O,O
',O,O
duration,O,O
.,O,O
The,O,O
control,O,O
group,O,O
consisted,O,O
of,O,O
82,O,O
patients,O,O
with,O,O
no,O,O
psychiatric,O,O
or,O,O
endocrinological,O,O
diagnoses,O,O
from,O,O
the,O,O
hospital,O,O
',O,O
s,O,O
out,O,O
-,O,O
patient,O,O
clinics,O,O
.,O,O
OUTCOME,O,O
MEASURES,O,O
:,O,O
Laboratory,O,O
analyses,O,O
of,O,O
calcium,B,B
",",O,O
magnesium,B,B
and,O,O
thyroid,O,B
-,O,O
stimulating,O,O
hormone,O,O
levels,O,O
performed,O,O
before,O,O
beginning,O,O
lithium,B,O
therapy,O,O
and,O,O
at,O,O
biannual,O,O
follow,O,O
-,O,O
up,O,O
.,O,O
RESULTS,O,O
:,O,O
Hypothyroidism,O,O
developed,O,O
in,O,O
40,O,O
patients,O,O
",",O,O
excluding,O,O
8,O,O
patients,O,O
who,O,O
were,O,O
hypothyroid,O,O
at,O,O
baseline,O,O
.,O,O
All,O,O
patients,O,O
having,O,O
first,O,O
-,O,O
degree,O,O
relatives,O,O
affected,O,O
by,O,O
thyroid,O,B
illness,O,O
had,O,O
accelerated,O,O
onset,O,O
of,O,O
hypothyroidism,O,O
(,O,O
3,O,O
.,O,O
7,O,O
years,O,O
after,O,O
onset,O,O
of,O,O
lithium,B,B
therapy,O,O
),O,O
compared,O,O
with,O,O
patients,O,O
without,O,O
a,O,O
family,O,O
history,O,O
(,O,O
8,O,O
.,O,O
6,O,O
years,O,O
after,O,O
onset,O,O
of,O,O
lithium,B,B
therapy,O,O
),O,O
.,O,O
Women,O,O
over,O,O
60,O,O
years,O,O
of,O,O
age,O,O
were,O,O
more,O,O
often,O,O
affected,O,O
by,O,O
hypothyroidism,O,B
than,O,O
women,O,O
under,O,O
60,O,O
years,O,O
of,O,O
age,O,O
(,O,O
34,O,O
.,O,O
6,O,O
%,O,O
versus,O,O
31,O,O
.,O,O
9,O,O
%,O,O
),O,O
.,O,O
Magnesium,B,B
levels,O,O
in,O,O
patients,O,O
on,O,O
lithium,B,B
treatment,O,O
were,O,O
unchanged,O,O
from,O,O
baseline,O,O
levels,O,O
.,O,O
After,O,O
lithium,B,B
treatment,O,O
",",O,O
calcium,B,B
levels,O,O
were,O,O
higher,O,O
than,O,O
either,O,O
baseline,O,O
levels,O,O
or,O,O
control,O,O
levels,O,O
.,O,O
Thus,O,O
",",O,O
lithium,B,B
treatment,O,O
counteracted,O,O
the,O,O
decrease,O,O
in,O,O
plasma,O,O
calcium,B,B
levels,O,O
associated,O,O
with,O,O
aging,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Familial,O,O
thyroid,O,O
illness,O,O
is,O,O
a,O,O
risk,O,O
factor,O,O
for,O,O
hypothyroidism,O,O
and,O,O
hypercalcemia,O,B
during,O,O
lithium,B,B
therapy,O,O
.,O,O
Severe,O,O
immune,O,B
hemolytic,O,I
anemia,O,I
associated,O,O
with,O,O
prophylactic,O,O
use,O,O
of,O,O
cefotetan,B,B
in,O,O
obstetric,O,O
and,O,O
gynecologic,O,O
procedures,O,O
.,O,O
Second,O,O
-,O,O
and,O,O
third,O,O
-,O,O
generation,O,O
cephalosporins,B,B
",",O,O
especially,O,O
cefotetan,B,B
",",O,O
are,O,O
increasingly,O,O
associated,O,O
with,O,O
severe,O,O
",",O,O
sometimes,O,O
fatal,O,O
immune,O,B
hemolytic,O,I
anemia,O,I
.,O,O
We,O,O
noticed,O,O
that,O,O
10,O,O
of,O,O
our,O,O
35,O,O
cases,O,O
of,O,O
cefotetan,B,B
-,O,O
induced,O,O
hemolytic,O,I
anemias,O,I
were,O,O
in,O,O
patients,O,O
who,O,O
had,O,O
received,O,O
cefotetan,B,B
prophylactically,O,O
for,O,O
obstetric,O,O
and,O,O
gynecologic,O,O
procedures,O,O
.,O,O
Eight,O,O
of,O,O
these,O,O
cases,O,O
of,O,O
severe,O,O
immune,O,O
hemolytic,O,B
anemia,O,I
are,O,O
described,O,O
.,O,O
Effects,O,O
of,O,O
nonsteroidal,O,B
anti,O,I
-,O,I
inflammatory,O,I
drugs,O,I
on,O,O
hemostasis,O,O
in,O,O
patients,O,O
with,O,O
aneurysmal,O,O
subarachnoid,O,O
hemorrhage,O,O
.,O,O
Platelet,O,O
function,O,O
is,O,O
impaired,O,O
by,O,O
nonsteroidal,O,B
anti,O,I
-,O,I
inflammatory,O,I
drugs,O,I
(,O,O
NSAIDs,O,B
),O,O
with,O,O
prominent,O,O
anti,O,O
-,O,O
inflammatory,O,O
properties,O,O
.,O,O
Their,O,O
safety,O,O
in,O,O
patients,O,O
undergoing,O,O
intracranial,O,O
surgery,O,O
is,O,O
under,O,O
debate,O,O
.,O,O
Patients,O,O
with,O,O
aneurysmal,O,O
subarachnoid,O,O
hemorrhage,O,O
(,O,O
SAH,O,B
),O,O
were,O,O
randomized,O,O
to,O,O
receive,O,O
either,O,O
ketoprofen,B,B
",",O,O
100,O,O
mg,O,O
",",O,O
three,O,O
times,O,O
a,O,O
day,O,O
(,O,O
ketoprofen,B,O
group,O,O
",",O,O
n,O,O
=,O,O
9,O,O
),O,O
or,O,O
a,O,O
weak,O,O
NSAID,O,B
",",O,O
acetaminophen,B,B
",",O,O
1,O,O
g,O,O
",",O,O
three,O,O
times,O,O
a,O,O
day,O,O
(,O,O
acetaminophen,B,O
group,O,O
",",O,O
n,O,O
=,O,O
9,O,O
),O,O
starting,O,O
immediately,O,O
after,O,O
the,O,O
diagnosis,O,O
of,O,O
aneurysmal,O,O
SAH,O,B
.,O,O
Treatment,O,O
was,O,O
continued,O,O
for,O,O
3,O,O
days,O,O
postoperatively,O,O
.,O,O
Test,O,O
blood,O,O
samples,O,O
were,O,O
taken,O,O
before,O,O
treatment,O,O
and,O,O
surgery,O,O
as,O,O
well,O,O
as,O,O
on,O,O
the,O,O
first,O,O
",",O,O
third,O,O
",",O,O
and,O,O
fifth,O,O
postoperative,O,O
mornings,O,O
.,O,O
Maximal,O,O
platelet,O,O
aggregation,O,O
induced,O,O
by,O,O
6,O,O
microM,O,O
of,O,O
adenosine,B,B
diphosphate,I,I
decreased,O,O
after,O,O
administration,O,O
of,O,O
ketoprofen,B,B
.,O,O
Aggregation,O,O
was,O,O
lower,O,O
(,O,O
P,O,O
<,O,O
.,O,O
),O,O
in,O,O
the,O,O
ketoprofen,B,B
group,O,O
than,O,O
in,O,O
the,O,O
acetaminophen,B,B
group,O,O
just,O,O
before,O,O
surgery,O,O
and,O,O
on,O,O
the,O,O
third,O,O
postoperative,O,O
day,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
maximal,O,O
platelet,O,O
aggregation,O,O
increased,O,O
in,O,O
the,O,O
acetaminophen,B,B
group,O,O
on,O,O
the,O,O
third,O,O
postoperative,O,O
day,O,O
as,O,O
compared,O,O
with,O,O
the,O,O
pretreatment,O,O
platelet,O,O
aggregation,O,O
results,O,O
(,O,O
P,O,B
<,O,O
.,O,O
),O,O
.,O,O
One,O,O
patient,O,O
in,O,O
the,O,O
ketoprofen,B,B
group,O,O
developed,O,O
a,O,O
postoperative,O,O
intracranial,O,O
hematoma,O,O
.,O,O
Coagulation,O,O
(,O,O
prothrombin,O,B
time,O,I
[,O,O
PT,O,B
],O,O
",",O,O
activated,O,B
partial,O,I
thromboplastin,O,I
time,O,I
[,O,O
APPT,O,B
],O,O
",",O,O
fibrinogen,O,B
concentration,O,I
",",O,O
and,O,O
antithrombin,O,B
III,O,I
[,O,O
AT,O,B
III,O,I
],O,O
was,O,O
comparable,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
.,O,O
Ketoprofen,B,B
but,O,O
not,O,O
acetaminophen,B,B
impaired,O,O
platelet,O,O
function,O,O
in,O,O
patients,O,O
with,O,O
SAH,O,B
.,O,O
If,O,O
ketoprofen,B,B
is,O,O
used,O,O
before,O,O
surgery,O,O
on,O,O
cerebral,O,O
artery,O,O
aneurysms,O,O
",",O,O
it,O,O
may,O,O
pose,O,O
an,O,O
additional,O,O
risk,O,O
factor,O,O
for,O,O
hemorrhage,O,O
.,O,O
Nitric,B,B
oxide,I,I
synthase,O,I
expression,O,O
in,O,O
the,O,O
course,O,O
of,O,O
lead,B,B
-,O,I
induced,O,I
hypertension,O,I
.,O,O
We,O,O
recently,O,O
showed,O,O
elevated,O,O
reactive,O,O
oxygen,B,B
species,O,I
(,O,O
ROS,O,B
),O,O
",",O,O
reduced,O,O
urinary,O,O
excretion,O,O
of,O,O
NO,B,B
metabolites,O,I
(,O,O
NOx,O,B
),O,O
",",O,O
and,O,O
increased,O,O
NO,B,B
sequestration,O,O
as,O,O
nitrotyrosine,B,B
in,O,O
various,O,O
tissues,O,O
in,O,O
rats,O,O
with,O,O
lead,B,B
-,O,I
induced,O,I
hypertension,O,I
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
discern,O,O
whether,O,O
the,O,O
reduction,O,O
in,O,O
urinary,O,O
NOx,O,B
in,O,O
lead,B,B
-,O,I
induced,O,I
hypertension,O,I
is,O,O
",",O,O
in,O,O
part,O,O
",",O,O
due,O,O
to,O,O
depressed,O,O
NO,B,B
synthase,O,I
(,O,I
NOS,O,I
),O,I
expression,O,O
.,O,O
Male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
a,O,O
lead,B,B
-,O,I
treated,O,I
group,O,O
(,O,O
given,O,O
lead,B,O
acetate,I,O
",",O,O
100,O,O
ppm,O,O
",",O,O
in,O,O
drinking,O,O
water,O,O
and,O,O
regular,O,O
rat,O,O
chow,O,O
),O,O
",",O,O
a,O,O
group,O,O
given,O,O
lead,B,O
and,O,O
vitamin,B,O
E,I,O
-,O,O
fortified,O,O
chow,O,O
",",O,O
or,O,O
a,O,O
normal,O,O
control,O,O
group,O,O
given,O,O
either,O,O
regular,O,O
food,O,O
and,O,O
water,O,O
or,O,O
vitamin,B,O
E,I,O
-,O,O
fortified,O,O
food,O,O
for,O,O
12,O,O
weeks,O,O
.,O,O
Tail,O,O
blood,O,O
pressure,O,O
",",O,O
urinary,O,O
NOx,O,B
excretion,O,O
",",O,O
plasma,O,O
malondialdehyde,B,B
(,O,O
MDA,B,I
),O,O
",",O,O
and,O,O
endothelial,O,O
and,O,O
inducible,O,O
NOS,O,B
(,O,O
eNOS,O,I
and,O,O
iNOS,O,I
),O,O
isotypes,O,O
in,O,O
the,O,O
aorta,O,O
and,O,O
kidney,O,O
were,O,O
measured,O,O
.,O,O
The,O,O
lead,B,O
-,O,O
treated,O,O
group,O,O
exhibited,O,O
a,O,O
rise,O,O
in,O,O
blood,O,O
pressure,O,O
and,O,O
plasma,O,O
MDA,B,B
concentration,O,O
",",O,O
a,O,O
fall,O,O
in,O,O
urinary,O,O
NOx,O,B
excretion,O,O
",",O,O
and,O,O
a,O,O
paradoxical,O,O
rise,O,O
in,O,O
vascular,O,O
and,O,O
renal,O,O
tissue,O,O
eNOS,O,B
and,O,O
iNOS,O,I
expression,O,O
.,O,O
Vitamin,B,B
E,I,I
supplementation,O,O
ameliorated,O,O
hypertension,O,O
",",O,O
lowered,O,O
plasma,O,O
MDA,B,B
concentration,O,O
",",O,O
and,O,O
raised,O,O
urinary,O,O
NOx,O,B
excretion,O,O
while,O,O
significantly,O,O
lowering,O,O
vascular,O,O
",",O,O
but,O,O
not,O,O
renal,O,O
",",O,O
tissue,O,O
eNOS,O,B
and,O,O
iNOS,O,B
expression,O,O
.,O,O
Vitamin,B,B
E,I,I
supplementation,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
either,O,O
blood,O,O
pressure,O,O
",",O,O
plasma,O,O
MDA,B,B
",",O,O
or,O,O
NOS,O,B
expression,O,O
in,O,O
the,O,O
control,O,O
group,O,O
.,O,O
The,O,O
study,O,O
also,O,O
revealed,O,O
significant,O,O
inhibition,O,O
of,O,O
NOS,O,B
enzymatic,O,O
activity,O,O
by,O,O
lead,B,O
in,O,O
cell,O,O
-,O,O
free,O,O
preparations,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
lead,B,O
-,O,O
induced,O,O
hypertension,O,O
in,O,O
this,O,O
model,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
compensatory,O,O
upregulation,O,O
of,O,O
renal,O,O
and,O,O
vascular,O,O
eNOS,O,B
and,O,O
iNOS,O,B
expression,O,O
.,O,O
This,O,O
is,O,O
",",O,O
in,O,O
part,O,O
",",O,O
due,O,O
to,O,O
ROS,O,B
-,O,O
mediated,O,O
NO,B,B
inactivation,O,O
",",O,O
lead,B,O
-,O,O
associated,O,O
inhibition,O,O
of,O,O
NOS,O,B
activity,O,O
",",O,O
and,O,O
perhaps,O,O
stimulatory,O,O
actions,O,O
of,O,O
increased,O,O
shear,O,O
stress,O,O
associated,O,O
with,O,O
hypertension,O,O
.,O,O
Glyceryl,B,B
trinitrate,I,I
induces,O,O
attacks,O,O
of,O,O
migraine,O,O
without,O,O
aura,O,O
in,O,O
sufferers,O,O
of,O,O
migraine,O,O
with,O,O
aura,O,O
.,O,O
Migraine,O,O
with,O,O
aura,O,O
and,O,O
migraine,O,O
without,O,O
aura,O,O
have,O,O
the,O,O
same,O,O
pain,O,O
phase,O,O
",",O,O
thus,O,O
indicating,O,O
that,O,O
migraine,O,O
with,O,O
aura,O,O
and,O,O
migraine,O,O
without,O,O
aura,O,O
share,O,O
a,O,O
common,O,O
pathway,O,O
of,O,O
nociception,O,O
.,O,O
In,O,O
recent,O,O
years,O,O
",",O,O
increasing,O,O
evidence,O,O
has,O,O
suggested,O,O
that,O,O
the,O,O
messenger,O,O
molecule,O,O
nitric,B,B
oxide,I,I
(,O,O
NO,B,B
),O,O
is,O,O
involved,O,O
in,O,O
pain,O,O
mechanisms,O,O
of,O,O
migraine,O,O
without,O,O
aura,O,O
.,O,O
In,O,O
order,O,O
to,O,O
clarify,O,O
whether,O,O
the,O,O
same,O,O
is,O,O
for,O,O
migraine,O,O
with,O,O
aura,O,O
",",O,O
in,O,O
the,O,O
present,O,O
study,O,O
we,O,O
examined,O,O
the,O,O
headache,O,O
response,O,O
to,O,O
intravenous,O,O
infusion,O,O
of,O,O
glyceryl,B,B
trinitrate,I,I
(,O,O
GTN,B,B
),O,O
(,O,O
0,O,O
.,O,O
5,O,O
microg,O,O
/,O,O
kg,O,O
/,O,O
min,O,O
for,O,O
20,O,O
min,O,O
),O,O
in,O,O
12,O,O
sufferers,O,O
of,O,O
migraine,O,O
with,O,O
aura,O,O
.,O,O
The,O,O
specific,O,O
aim,O,O
was,O,O
to,O,O
elucidate,O,O
whether,O,O
an,O,O
aura,O,O
and,O,O
/,O,O
or,O,O
an,O,O
attack,O,O
of,O,O
migraine,O,O
without,O,O
aura,O,O
could,O,O
be,O,O
induced,O,O
.,O,O
Fourteen,O,O
healthy,O,O
subjects,O,O
served,O,O
as,O,O
controls,O,O
.,O,O
Aura,O,O
symptoms,O,O
were,O,O
not,O,O
elicited,O,O
in,O,O
any,O,O
subject,O,O
.,O,O
Headache,O,O
was,O,O
more,O,O
severe,O,O
in,O,O
migraineurs,O,O
than,O,O
in,O,O
the,O,O
controls,O,O
during,O,O
and,O,O
immediately,O,O
after,O,O
GTN,B,B
infusion,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
as,O,O
well,O,O
as,O,O
during,O,O
the,O,O
following,O,O
11,O,O
h,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
controls,O,O
",",O,O
the,O,O
GTN,B,B
-,O,O
induced,O,O
headache,O,O
gradually,O,O
disappeared,O,O
",",O,O
whereas,O,O
in,O,O
migraineurs,O,O
peak,O,O
headache,O,O
intensity,O,O
occurred,O,O
at,O,O
a,O,O
mean,O,O
time,O,O
of,O,O
240,O,O
min,O,O
post,O,O
-,O,O
infusion,O,O
.,O,O
At,O,O
this,O,O
time,O,O
the,O,O
induced,O,O
headache,O,O
in,O,O
6,O,O
of,O,O
12,O,O
migraineurs,O,O
fulfilled,O,O
the,O,O
diagnostic,O,O
criteria,O,O
for,O,O
migraine,O,B
without,O,I
aura,O,I
of,O,I
the,O,I
International,O,I
Headache,O,I
Society,O,I
.,O,O
The,O,O
results,O,O
therefore,O,O
suggest,O,O
that,O,O
NO,B,B
is,O,O
involved,O,O
in,O,O
the,O,O
pain,O,O
mechanisms,O,O
of,O,O
migraine,O,B
with,O,I
aura,O,I
.,O,O
Since,O,O
cortical,O,O
spreading,O,O
depression,O,O
has,O,O
been,O,O
shown,O,O
to,O,O
liberate,O,O
NO,B,B
in,O,O
animals,O,O
",",O,O
this,O,O
finding,O,O
may,O,O
help,O,O
our,O,O
understanding,O,O
of,O,O
the,O,O
coupling,O,O
between,O,O
cortical,O,O
spreading,O,O
depression,O,O
and,O,O
headache,O,O
in,O,O
migraine,O,B
with,O,I
aura,O,I
.,O,O
Rapid,O,O
reversal,O,O
of,O,O
life,O,O
-,O,O
threatening,O,O
diltiazem,B,B
-,O,O
induced,O,O
tetany,O,O
with,O,O
calcium,B,B
chloride,I,I
.,O,O
We,O,O
describe,O,O
a,O,O
patient,O,O
who,O,O
developed,O,O
tetany,O,O
with,O,O
sudden,O,O
respiratory,O,O
arrest,O,O
after,O,O
the,O,O
infusion,O,O
of,O,O
intravenous,O,O
diltiazem,B,B
.,O,O
The,O,O
administration,O,O
of,O,O
calcium,B,B
chloride,I,I
rapidly,O,O
resolved,O,O
the,O,O
patient,O,O
',O,O
s,O,O
tetany,O,O
with,O,O
prompt,O,O
recovery,O,O
of,O,O
respiratory,O,O
function,O,O
",",O,O
averting,O,O
the,O,O
need,O,O
for,O,O
more,O,O
aggressive,O,O
airway,O,O
management,O,O
and,O,O
ventilatory,O,O
support,O,O
.,O,O
The,O,O
emergency,O,O
physician,O,O
should,O,O
be,O,O
aware,O,O
that,O,O
life,O,O
-,O,O
threatening,O,O
tetany,O,O
may,O,O
accompany,O,O
the,O,O
administration,O,O
of,O,O
intravenous,O,O
diltiazem,B,B
and,O,O
that,O,O
calcium,B,B
chloride,I,I
may,O,O
be,O,O
a,O,O
rapid,O,O
and,O,O
effective,O,O
remedy,O,O
.,O,O
Predictors,O,O
of,O,O
decreased,O,O
renal,O,O
function,O,O
in,O,O
patients,O,O
with,O,O
heart,O,O
failure,O,O
during,O,O
angiotensin,B,O
-,O,O
converting,O,O
enzyme,O,O
inhibitor,O,O
therapy,O,O
:,O,O
results,O,O
from,O,O
the,O,O
studies,O,O
of,O,O
left,O,O
ventricular,O,O
dysfunction,O,O
(,O,O
SOLVD,O,O
),O,O
BACKGROUND,O,O
:,O,O
Although,O,O
angiotensin,B,O
-,O,O
converting,O,O
enzyme,O,O
inhibitor,O,O
therapy,O,O
reduces,O,O
mortality,O,O
rates,O,O
in,O,O
patients,O,O
with,O,O
congestive,O,O
heart,O,O
failure,O,O
(,O,O
CHF,O,O
),O,O
",",O,O
it,O,O
may,O,O
also,O,O
cause,O,O
decreased,O,O
renal,O,O
function,O,O
.,O,O
Little,O,O
information,O,O
is,O,O
available,O,O
to,O,O
predict,O,O
which,O,O
patients,O,O
are,O,O
at,O,O
highest,O,O
risk,O,O
for,O,O
this,O,O
complication,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
quantify,O,O
specific,O,O
clinical,O,O
predictors,O,O
of,O,O
reduction,O,O
in,O,O
renal,O,B
function,O,O
in,O,O
patients,O,O
with,O,O
CHF,O,O
who,O,O
are,O,O
prescribed,O,O
angiotensin,B,B
-,O,I
converting,O,I
enzyme,O,I
inhibitor,O,I
therapy,O,O
.,O,O
METHOD,O,O
:,O,O
We,O,O
analyzed,O,O
data,O,O
from,O,O
the,O,O
Studies,O,O
of,O,O
Left,O,O
Ventricular,O,O
Dysfunction,O,O
(,O,O
SOLVD,O,O
),O,O
",",O,O
a,O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
of,O,O
enalapril,B,O
for,O,O
the,O,O
treatment,O,O
of,O,O
CHF,O,O
.,O,O
There,O,O
were,O,O
3379,O,O
patients,O,O
randomly,O,O
assigned,O,O
to,O,O
enalapril,B,B
with,O,O
a,O,O
median,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
974,O,O
days,O,O
and,O,O
3379,O,O
patients,O,O
randomly,O,O
assigned,O,O
to,O,O
placebo,O,B
with,O,O
a,O,O
mean,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
967,O,O
days,O,O
.,O,O
Decreased,O,O
renal,O,O
function,O,O
was,O,O
defined,O,O
as,O,O
a,O,O
rise,O,O
in,O,O
serum,O,B
creatinine,B,B
>,O,O
/,O,O
=,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
dL,O,O
(,O,O
44,O,O
micromol,O,B
/,O,O
L,O,O
from,O,O
baseline,O,O
.,O,O
We,O,O
used,O,O
time,O,O
-,O,O
to,O,O
-,O,O
event,O,O
analysis,O,O
to,O,O
identify,O,O
potential,O,O
predictors,O,O
of,O,O
decrease,O,O
in,O,O
renal,O,O
function,O,O
including,O,O
age,O,O
",",O,O
baseline,O,O
ejection,O,O
fraction,O,O
",",O,O
baseline,O,O
creatinine,B,B
",",O,O
low,O,O
systolic,O,O
blood,O,O
pressure,O,O
(,O,O
<,O,O
100,O,O
mm,O,O
Hg,O,O
),O,O
",",O,O
history,O,O
of,O,O
hypertension,O,O
",",O,O
diabetes,O,O
",",O,O
and,O,O
use,O,O
of,O,O
antiplatelet,O,B
",",O,O
diuretic,B,B
",",O,O
and,O,O
beta,O,B
-,O,I
blocker,O,I
therapy,O,I
.,O,O
RESULTS,O,O
:,O,O
Patients,O,O
randomly,O,O
assigned,O,O
to,O,O
enalapril,B,B
had,O,O
a,O,O
33,O,O
%,O,O
greater,O,O
likelihood,O,O
of,O,O
decreased,O,O
renal,O,O
function,O,O
than,O,O
controls,O,O
(,O,O
P,O,O
=,O,O
.,O,O
By,O,O
multivariate,O,O
analysis,O,O
",",O,O
in,O,O
both,O,O
the,O,O
placebo,O,O
and,O,O
enalapril,B,B
groups,O,O
older,O,O
age,O,O
",",O,O
diuretic,B,O
therapy,O,O
",",O,O
and,O,O
diabetes,O,O
were,O,O
associated,O,O
with,O,O
decreased,O,O
renal,O,O
function,O,O
",",O,O
whereas,O,O
beta,O,B
-,O,I
blocker,O,I
therapy,O,O
and,O,O
higher,O,O
ejection,O,O
fraction,O,O
were,O,O
renoprotective,O,O
.,O,O
Older,O,O
age,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
greater,O,O
risk,O,O
of,O,O
developing,O,O
decreased,O,O
renal,O,B
function,O,O
in,O,O
both,O,O
groups,O,O
",",O,O
but,O,O
significantly,O,O
more,O,O
so,O,O
in,O,O
the,O,O
enalapril,B,B
group,O,O
(,O,O
enalapril,B,B
:,O,O
risk,O,O
ratio,O,O
[,O,O
RR,O,O
],O,O
1,O,O
.,O,O
42,O,O
per,O,O
10,O,O
years,O,O
",",O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
[,O,O
CI,O,O
],O,O
1,O,O
.,O,O
32,O,O
-,O,O
1,O,O
.,O,O
52,O,O
with,O,O
enalapril,B,B
;,O,O
placebo,O,O
:,O,O
RR,O,O
1,O,O
.,O,O
18,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
12,O,O
-,O,O
1,O,O
.,O,O
25,O,O
),O,O
.,O,O
Diuretic,B,B
therapy,O,O
was,O,O
likewise,O,O
associated,O,O
with,O,O
a,O,O
greater,O,O
risk,O,O
of,O,O
decreased,O,O
renal,O,B
function,O,O
in,O,O
the,O,O
enalapril,B,B
group,O,O
(,O,O
RR,O,O
1,O,O
.,O,O
89,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
70,O,O
-,O,O
2,O,O
.,O,O
),O,O
than,O,O
in,O,O
the,O,O
placebo,O,B
group,O,O
(,O,O
RR,O,O
1,O,O
.,O,O
35,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
-,O,O
1,O,O
.,O,O
66,O,O
),O,O
.,O,O
Conversely,O,O
",",O,O
enalapril,B,B
had,O,O
a,O,O
relative,O,O
renoprotective,O,O
effect,O,O
(,O,O
RR,O,O
1,O,O
.,O,O
33,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
13,O,O
-,O,O
1,O,O
.,O,O
53,O,O
),O,O
compared,O,O
with,O,O
placebo,O,O
(,O,O
RR,O,O
1,O,O
.,O,O
96,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
57,O,O
-,O,O
2,O,O
.,O,O
44,O,O
),O,O
in,O,O
patients,O,O
with,O,O
diabetes,O,O
.,O,O
A,O,O
lower,O,O
risk,O,O
of,O,O
renal,O,B
impairment,O,I
was,O,O
seen,O,O
in,O,O
both,O,O
groups,O,O
with,O,O
beta,O,B
-,O,I
blocker,O,I
therapy,O,I
(,O,O
RR,O,O
0,O,O
.,O,O
70,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
.,O,O
57,O,O
-,O,O
0,O,O
.,O,O
85,O,O
higher,O,O
baseline,O,O
ejection,O,O
fraction,O,O
(,O,O
RR,O,O
0,O,O
.,O,O
93,O,O
per,O,O
5,O,O
%,O,O
increment,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
.,O,O
96,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Enalapril,B,B
use,O,O
caused,O,O
a,O,O
33,O,O
%,O,O
increase,O,O
in,O,O
the,O,O
risk,O,O
of,O,O
decreased,O,O
renal,O,O
function,O,O
in,O,O
patients,O,O
with,O,O
CHF,O,O
.,O,O
Diuretic,B,B
use,O,O
and,O,O
advanced,O,O
age,O,O
increased,O,O
this,O,O
risk,O,O
.,O,O
Diabetes,O,B
was,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
risk,O,O
of,O,O
renal,O,O
impairment,O,O
in,O,O
all,O,O
patients,O,O
with,O,O
CHF,O,O
",",O,O
but,O,O
this,O,O
risk,O,O
was,O,O
reduced,O,O
in,O,O
the,O,O
enalapril,B,B
group,O,O
compared,O,O
with,O,O
the,O,O
placebo,O,O
group,O,O
.,O,O
beta,O,B
-,O,O
Blocker,O,O
therapy,O,O
and,O,O
higher,O,O
ejection,O,O
fraction,O,O
were,O,O
renoprotective,O,O
in,O,O
all,O,O
patients,O,O
regardless,O,O
of,O,O
therapy,O,O
.,O,O
Hypomania,O,B
-,O,O
like,O,O
syndrome,O,O
induced,O,O
by,O,O
olanzapine,B,B
.,O,O
We,O,O
report,O,O
a,O,O
female,O,O
patient,O,O
with,O,O
a,O,O
diagnosis,O,O
of,O,O
a,O,O
not,O,O
otherwise,O,O
specified,O,O
psychotic,O,O
disorder,O,O
(,O,O
DSM,O,B
-,O,I
IV,O,I
),O,O
who,O,O
developed,O,O
hypomania,O,O
shortly,O,O
after,O,O
the,O,O
introduction,O,O
of,O,O
olanzapine,B,B
treatment,O,O
.,O,O
Acetazolamide,B,B
-,O,O
induced,O,O
Gerstmann,O,B
syndrome,O,I
.,O,O
Acute,O,O
confusion,O,O
induced,O,O
by,O,O
acetazolamide,B,B
is,O,O
a,O,O
well,O,O
known,O,O
adverse,O,O
drug,O,O
reaction,O,O
in,O,O
patients,O,O
with,O,O
renal,O,O
impairment,O,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
acetazolamide,B,B
-,O,O
induced,O,O
Gerstmann,O,B
syndrome,O,I
in,O,O
a,O,O
patient,O,O
with,O,O
normal,O,O
renal,O,O
function,O,O
",",O,O
to,O,O
highlight,O,O
predisposing,O,O
factors,O,O
that,O,O
are,O,O
frequently,O,O
overlooked,O,O
.,O,O
Vasopressin,B,B
in,O,O
the,O,O
treatment,O,O
of,O,O
milrinone,B,B
-,O,O
induced,O,O
hypotension,O,O
in,O,O
severe,O,O
heart,O,O
failure,O,O
.,O,O
The,O,O
use,O,O
of,O,O
phosphodiesterase,O,O
inhibitors,O,O
such,O,O
as,O,O
milrinone,B,B
in,O,O
the,O,O
treatment,O,O
of,O,O
severe,O,O
heart,O,O
failure,O,O
is,O,O
frequently,O,O
restricted,O,O
because,O,O
they,O,O
cause,O,O
vasodilation,O,O
and,O,O
hypotension,O,O
.,O,O
In,O,O
patients,O,O
with,O,O
decompensated,O,O
heart,O,O
failure,O,O
with,O,O
hypotension,O,O
after,O,O
treatment,O,O
with,O,O
milrinone,B,B
",",O,O
low,O,O
doses,O,O
of,O,O
vasopressin,B,B
restored,O,O
blood,O,O
pressure,O,O
without,O,O
inhibiting,O,O
the,O,O
inotropic,O,O
effect,O,O
of,O,O
milrinone,B,B
.,O,O
Treatment,O,O
of,O,O
tacrolimus,B,B
-,O,O
related,O,O
adverse,O,O
effects,O,O
by,O,O
conversion,O,O
to,O,O
cyclosporine,B,B
in,O,O
liver,O,O
transplant,O,O
recipients,O,O
.,O,O
When,O,O
tacrolimus,B,B
side,O,O
effects,O,O
persist,O,O
despite,O,O
dose,O,O
reduction,O,O
",",O,O
conversion,O,O
to,O,O
cyclosporine,B,B
-,O,O
based,O,O
immunosuppression,O,O
(,O,O
CyA,O,B
),O,O
is,O,O
necessary,O,O
.,O,O
We,O,O
characterized,O,O
tacrolimus,B,B
side,O,O
effects,O,O
that,O,O
warranted,O,O
discontinuation,O,O
of,O,O
the,O,O
drug,O,O
",",O,O
and,O,O
outcomes,O,O
after,O,O
conversion,O,O
.,O,O
Of,O,O
388,O,O
liver,O,B
recipients,O,O
who,O,O
received,O,O
tacrolimus,B,B
as,O,O
primary,O,O
immunosuppression,O,O
",",O,O
70,O,O
required,O,O
conversion,O,O
to,O,O
CyA,O,B
.,O,O
We,O,O
recorded,O,O
indication,O,O
for,O,O
conversion,O,O
",",O,O
whether,O,O
conversion,O,O
was,O,O
early,O,O
or,O,O
late,O,O
after,O,O
transplantation,O,O
",",O,O
tacrolimus,B,B
dose,O,O
and,O,O
trough,O,O
blood,O,O
level,O,O
at,O,O
conversion,O,O
",",O,O
and,O,O
incidence,O,O
of,O,O
rejection,O,O
after,O,O
conversion,O,O
.,O,O
Conversion,O,B
was,O,O
early,O,O
in,O,O
29,O,O
patients,O,O
(,O,O
41,O,O
.,O,O
4,O,O
%,O,O
),O,O
and,O,O
late,O,O
in,O,O
41,O,O
(,O,O
58,O,O
.,O,O
6,O,O
%,O,O
),O,O
.,O,O
Indications,O,O
for,O,O
early,O,O
conversion,O,O
were,O,O
neurotoxicity,O,B
(,O,O
20,O,O
),O,O
",",O,O
(,O,O
insulin,O,B
-,O,I
dependent,O,I
),O,I
diabetes,O,I
mellitus,O,I
(,O,I
IDDM,O,I
),O,I
(,O,O
5,O,O
),O,O
",",O,O
nephrotoxicity,O,B
(,O,O
3,O,O
),O,O
",",O,O
gastrointestinal,O,B
(,O,O
GI,O,O
),O,O
toxicity,O,O
(,O,O
6,O,O
),O,O
",",O,O
and,O,O
cardiomyopathy,O,B
(,O,O
1,O,O
),O,O
",",O,O
and,O,O
for,O,O
late,O,O
conversion,O,O
were,O,O
neurotoxicity,O,B
(,O,O
15,O,O
),O,O
",",O,O
IDDM,O,B
(,O,O
12,O,O
),O,O
",",O,O
nephrotoxicity,O,B
(,O,O
3,O,O
),O,O
",",O,O
GI,O,B
),O,O
",",O,O
hepatotoxicity,O,B
(,O,O
6,O,O
),O,O
",",O,O
post,O,O
-,O,O
transplant,O,O
lmphoproliferate,O,O
disease,O,O
(,O,O
PTLD,O,O
),O,O
(,O,O
2,O,O
),O,O
",",O,O
cardiomyopathy,O,B
(,O,O
1,O,O
),O,O
",",O,O
hemolytic,O,B
anemia,O,I
(,O,O
1,O,O
),O,O
",",O,O
and,O,O
pruritus,O,B
(,O,O
1,O,O
),O,O
.,O,O
All,O,O
early,O,O
-,O,O
conversion,O,O
patients,O,O
showed,O,O
improvement,O,O
/,O,O
resolution,O,O
of,O,O
symptoms,O,O
.,O,O
Among,O,O
late,O,O
-,O,O
conversion,O,O
patients,O,O
",",O,O
37,O,O
(,O,O
90,O,O
.,O,O
2,O,O
%,O,O
),O,O
had,O,O
improvement,O,O
/,O,O
resolution,O,O
;,O,O
in,O,O
4,O,O
(,O,O
9,O,O
.,O,O
8,O,O
%,O,O
),O,O
",",O,O
adverse,O,O
effects,O,O
persisted,O,O
.,O,O
The,O,O
overall,O,O
rejection,O,O
rate,O,O
was,O,O
30,O,O
%,O,O
.,O,O
Sixty,O,O
-,O,O
two,O,O
patients,O,O
(,O,O
88,O,O
.,O,O
6,O,O
%,O,O
),O,O
are,O,O
alive,O,O
with,O,O
functioning,O,O
grafts,O,O
686,O,O
+,O,O
/,O,O
-,O,O
362,O,O
days,O,O
(,O,O
range,O,O
",",O,O
154,O,O
-,O,O
1433,O,O
days,O,O
),O,O
after,O,O
conversion,O,O
.,O,O
When,O,O
tacrolimus,B,B
side,O,O
effects,O,O
are,O,O
unresponsive,O,O
to,O,O
dose,O,O
reduction,O,O
",",O,O
conversion,O,O
to,O,O
CyA,O,B
can,O,O
be,O,O
accomplished,O,O
safely,O,O
",",O,O
with,O,O
no,O,O
increased,O,O
risk,O,O
of,O,O
rejection,O,O
and,O,O
excellent,O,O
long,O,O
-,O,O
term,O,O
outcome,O,O
.,O,O
Ocular,O,B
manifestations,O,O
of,O,O
juvenile,O,B
rheumatoid,O,I
arthritis,O,I
.,O,O
We,O,O
followed,O,O
210,O,O
cases,O,O
of,O,O
juvenile,O,B
rheumatoid,O,I
arthritis,O,I
closely,O,O
for,O,O
eleven,O,O
years,O,O
.,O,O
Thirty,O,O
-,O,O
six,O,O
of,O,O
the,O,O
210,O,O
patients,O,O
(,O,O
17,O,O
.,O,O
2,O,O
%,O,O
),O,O
developed,O,O
iridocyclitis,O,B
.,O,O
Iridocyclitis,O,B
was,O,O
seen,O,O
most,O,O
frequently,O,O
in,O,O
young,O,O
female,O,O
patients,O,O
(,O,O
0,O,O
to,O,O
4,O,O
years,O,O
),O,O
with,O,O
the,O,O
monoarticular,O,O
or,O,O
pauciatricular,O,O
form,O,O
of,O,O
the,O,O
arthritis,O,O
.,O,O
However,O,O
",",O,O
30,O,O
%,O,O
of,O,O
the,O,O
patients,O,O
developed,O,O
uveitis,O,B
after,O,O
16,O,O
years,O,O
of,O,O
age,O,O
.,O,O
Although,O,O
61,O,O
%,O,O
of,O,O
patients,O,O
had,O,O
a,O,O
noncontributory,O,O
ocular,O,O
history,O,O
on,O,O
entry,O,O
",",O,O
42,O,O
%,O,O
had,O,O
active,O,O
uveitis,O,B
on,O,O
entry,O,O
.,O,O
Our,O,O
approach,O,O
was,O,O
effective,O,O
in,O,O
detecting,O,O
uveitis,O,B
in,O,O
new,O,O
cases,O,O
and,O,O
exacerbations,O,O
of,O,O
uveitis,O,B
in,O,O
established,O,O
cases,O,O
.,O,O
Forty,O,O
-,O,O
four,O,O
percent,O,O
of,O,O
patients,O,O
with,O,O
uveitis,O,B
had,O,O
one,O,O
or,O,O
more,O,O
identifiable,O,O
signs,O,O
or,O,O
symptoms,O,O
",",O,O
such,O,O
as,O,O
red,O,O
eye,O,O
",",O,O
ocular,O,O
pain,O,O
",",O,O
decreased,O,O
visual,O,O
acuity,O,O
",",O,O
or,O,O
photophobia,O,O
",",O,O
in,O,O
order,O,O
of,O,O
decreasing,O,O
frequency,O,O
.,O,O
Even,O,O
after,O,O
early,O,O
detection,O,O
and,O,O
prompt,O,O
treatment,O,O
",",O,O
41,O,O
%,O,O
of,O,O
cases,O,O
of,O,O
uveitis,O,B
did,O,O
not,O,O
respond,O,O
to,O,O
more,O,O
than,O,O
six,O,O
months,O,O
of,O,O
intensive,O,O
topical,O,O
treatment,O,O
with,O,O
corticosteroids,B,B
and,O,O
mydriatics,O,B
.,O,O
Despite,O,O
this,O,O
",",O,O
there,O,O
was,O,O
a,O,O
dramatic,O,O
decrease,O,O
in,O,O
the,O,O
50,O,O
%,O,O
incidence,O,O
of,O,O
blinding,O,O
complications,O,O
of,O,O
uveitis,O,B
cited,O,O
in,O,O
earlier,O,O
studies,O,O
.,O,O
Cataract,O,B
and,O,O
band,O,B
keratopathy,O,I
occurred,O,O
in,O,O
only,O,O
22,O,O
and,O,O
13,O,O
%,O,O
of,O,O
our,O,O
group,O,O
",",O,O
respectively,O,O
.,O,O
We,O,O
used,O,O
chloroquine,B,B
or,O,O
hydroxychloroquine,B,B
in,O,O
173,O,O
of,O,O
210,O,O
cases,O,O
and,O,O
found,O,O
only,O,O
one,O,O
case,O,O
of,O,O
chorioretinopathy,O,B
attributable,O,O
to,O,O
these,O,O
drugs,O,O
.,O,O
Systemically,O,O
administered,O,O
corticosteroids,B,B
were,O,O
used,O,O
in,O,O
75,O,O
of,O,O
210,O,O
cases,O,O
;,O,O
a,O,O
significant,O,O
number,O,O
of,O,O
posterior,O,B
subcapsular,O,I
cataracts,O,I
was,O,O
found,O,O
.,O,O
Typical,O,O
keratoconjunctivitis,O,B
sicca,O,I
developed,O,O
in,O,O
three,O,O
of,O,O
the,O,O
uveitis,O,B
cases,O,O
.,O,O
This,O,O
association,O,O
with,O,O
uveitis,O,B
and,O,O
JRA,O,O
was,O,O
not,O,O
noted,O,O
previously,O,O
.,O,O
Surgical,O,O
treatment,O,O
of,O,O
cataracts,O,B
",",O,O
band,O,B
keratopathy,O,I
",",O,O
and,O,O
glaucoma,O,B
achieved,O,O
uniformly,O,O
discouraging,O,O
results,O,O
.,O,O
Cyclophosphamide,B,B
-,O,I
induced,O,I
cystitis,O,I
in,O,O
freely,O,O
-,O,O
moving,O,O
conscious,O,O
rats,O,O
:,O,O
behavioral,O,O
approach,O,O
to,O,O
a,O,O
new,O,O
model,O,O
of,O,O
visceral,O,O
pain,O,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
develop,O,O
a,O,O
model,O,O
of,O,O
visceral,O,O
pain,O,O
in,O,O
rats,O,O
using,O,O
a,O,O
behavioral,O,O
approach,O,O
.,O,O
Cyclophosphamide,B,B
(,O,O
CP,B,B
),O,O
",",O,O
an,O,O
antitumoral,O,O
agent,O,O
known,O,O
to,O,O
produce,O,O
toxic,O,O
effects,O,O
on,O,O
the,O,O
bladder,O,O
wall,O,O
through,O,O
its,O,O
main,O,O
toxic,O,O
metabolite,O,O
acrolein,B,B
",",O,O
was,O,O
used,O,O
to,O,O
induce,O,O
cystitis,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
CP,B,B
was,O,O
administered,O,O
at,O,O
doses,O,O
of,O,O
50,O,O
",",O,O
100,O,O
and,O,O
200,O,O
mg,O,O
.,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
p,O,O
.,O,O
to,O,O
male,O,O
rats,O,O
",",O,O
and,O,O
their,O,O
behavior,O,O
observed,O,O
and,O,O
scored,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
morphine,B,B
(,O,O
0,O,O
.,O,O
5,O,O
to,O,O
4,O,B
mg,O,I
.,O,O
/,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
v,O,O
.,O,O
on,O,O
CP,B,B
-,O,I
induced,O,I
behavioral,O,I
modifications,O,I
were,O,O
tested,O,O
administered,O,O
alone,O,O
and,O,O
after,O,O
naloxone,B,B
(,O,O
1,O,O
mg,O,I
.,O,O
/,O,O
kg,O,O
.,O,O
s,O,O
.,O,O
c,O,O
.,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
90,O,O
minutes,O,O
after,O,O
CP,B,B
injection,O,I
",",O,O
that,O,O
is,O,O
",",O,O
at,O,O
the,O,O
time,O,O
of,O,O
administration,O,O
of,O,O
morphine,B,B
",",O,O
the,O,O
bladder,O,O
was,O,O
removed,O,O
in,O,O
some,O,O
rats,O,O
for,O,O
histological,O,O
examination,O,O
.,O,O
Finally,O,O
",",O,O
to,O,O
show,O,O
that,O,O
the,O,O
bladder,O,O
is,O,O
essential,O,O
for,O,O
the,O,O
CP,B,B
-,O,I
induced,O,O
behavioral,O,O
modifications,O,O
",",O,O
female,O,O
rats,O,O
also,O,O
received,O,O
CP,B,B
at,O,O
doses,O,O
of,O,O
200,O,O
mg,O,O
.,O,O
/,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
p,O,O
.,O,O
and,O,O
of,O,O
20,O,O
mg,O,O
.,O,O
by,O,O
the,O,O
intravesical,O,O
route,O,O
",",O,O
and,O,O
acrolein,B,B
at,O,O
doses,O,O
of,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
.,O,O
by,O,O
the,O,O
intravesical,O,O
route,O,O
and,O,O
of,O,O
5,O,O
mg,O,O
.,O,O
/,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
v,O,O
.,O,O
RESULTS,O,O
:,O,O
CP,B,B
dose,O,O
-,O,O
relatedly,O,O
induced,O,O
marked,O,O
behavioral,O,O
modifications,O,O
in,O,O
male,O,O
rats,O,O
:,O,O
breathing,O,O
rate,O,O
decrease,O,O
",",O,O
closing,O,O
of,O,O
the,O,O
eyes,O,O
and,O,O
occurrence,O,O
of,O,O
specific,O,O
postures,O,O
.,O,O
Morphine,B,B
dose,O,O
-,O,O
dependently,O,O
reversed,O,O
these,O,O
behavioral,O,O
disorders,O,O
.,O,O
A,O,O
dose,O,O
of,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
.,O,O
/,O,O
kg,O,O
.,O,O
produced,O,O
a,O,O
reduction,O,O
of,O,O
almost,O,O
50,O,O
%,O,O
of,O,O
the,O,O
behavioral,O,O
score,O,O
induced,O,O
by,O,O
CP,B,B
200,O,O
mg,O,O
.,O,O
/,O,O
kg,O,O
.,O,O
This,O,O
effect,O,O
was,O,O
completely,O,O
prevented,O,O
by,O,O
pretreatment,O,O
with,O,O
naloxone,B,B
.,O,O
At,O,O
the,O,O
time,O,O
of,O,O
administration,O,O
of,O,O
morphine,B,B
",",O,O
histological,O,O
modifications,O,O
of,O,O
the,O,O
bladder,O,O
wall,O,O
",",O,O
such,O,O
as,O,O
chorionic,O,O
and,O,O
muscle,O,O
layer,O,O
edema,O,O
",",O,O
were,O,O
observed,O,O
.,O,O
In,O,O
female,O,O
rats,O,O
",",O,O
CP,B,B
200,O,I
mg,O,I
.,O,O
/,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
p,O,O
produced,O,O
the,O,O
same,O,O
marked,O,O
behavioral,O,O
modifications,O,O
as,O,O
those,O,O
observed,O,O
in,O,O
male,O,O
rats,O,O
.,O,O
Administered,O,O
at,O,O
the,O,O
dose,O,O
of,O,O
20,O,B
mg,O,I
.,O,O
intravesically,O,O
",",O,O
CP,B,B
did,O,O
not,O,O
produce,O,O
any,O,O
behavioral,O,O
effects,O,O
",",O,O
whereas,O,O
acrolein,B,B
at,O,O
0,O,B
.,O,O
5,O,I
mg,O,I
.,O,O
intravesically,O,O
induced,O,O
behavioral,O,O
modifications,O,O
identical,O,O
to,O,O
those,O,O
under,O,O
CP,B,B
200,O,I
mg,O,I
.,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
p,O,O
.,O,O
",",O,O
with,O,O
the,O,O
same,O,O
maximal,O,O
levels,O,O
.,O,O
Conversely,O,O
",",O,O
acrolein,B,B
5,O,O
mg,O,O
.,O,O
/,O,O
kg,O,O
.,O,O
i,O,O
.,O,O
v,O,O
.,O,O
did,O,O
not,O,O
produce,O,O
any,O,O
behavioral,O,O
effects,O,O
at,O,O
all,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Overall,O,O
",",O,O
these,O,O
results,O,O
indicate,O,O
that,O,O
this,O,O
experimental,O,O
model,O,O
of,O,O
CP,B,B
-,O,I
induced,O,O
cystitis,O,O
may,O,O
be,O,O
an,O,O
interesting,O,O
new,O,O
behavioral,O,O
model,O,O
of,O,O
inflammatory,O,O
visceral,O,O
pain,O,O
",",O,O
allowing,O,O
a,O,O
better,O,O
understanding,O,O
of,O,O
these,O,O
painful,O,O
syndromes,O,O
and,O,O
thus,O,O
a,O,O
better,O,O
therapeutic,O,O
approach,O,O
to,O,O
them,O,O
.,O,O
Prednisolone,B,B
-,O,O
induced,O,O
muscle,O,O
dysfunction,O,O
is,O,O
caused,O,O
more,O,O
by,O,O
atrophy,O,O
than,O,O
by,O,O
altered,O,O
acetylcholine,B,B
receptor,O,I
expression,O,O
.,O,O
Large,O,O
doses,O,O
of,O,O
glucocorticoids,O,B
can,O,O
alter,O,O
muscle,O,O
physiology,O,O
and,O,O
susceptibility,O,O
to,O,O
neuromuscular,O,O
blocking,O,O
drugs,O,O
by,O,O
mechanisms,O,O
not,O,O
clearly,O,O
understood,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
moderate,O,O
and,O,O
large,O,O
doses,O,O
of,O,O
prednisolone,B,B
on,O,O
muscle,O,O
function,O,O
and,O,O
pharmacology,O,O
",",O,O
and,O,O
their,O,O
relationship,O,O
to,O,O
changes,O,O
in,O,O
muscle,O,O
size,O,O
and,O,O
acetylcholine,B,B
receptor,O,I
(,O,I
AChR,O,I
),O,I
expression,O,O
.,O,O
With,O,O
institutional,O,O
approval,O,O
",",O,O
35,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
randomly,O,O
allocated,O,O
to,O,O
receive,O,O
daily,O,O
subcutaneous,O,O
doses,O,O
of,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
prednisolone,B,B
(,O,O
P10,O,O
group,O,O
),O,O
",",O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
prednisolone,B,B
(,O,O
P100,O,O
group,O,O
),O,O
",",O,O
or,O,O
an,O,O
equal,O,O
volume,O,O
of,O,O
saline,O,B
(,O,O
S,O,O
group,O,O
),O,O
for,O,O
7,O,O
days,O,O
.,O,O
A,O,O
fourth,O,O
group,O,O
of,O,O
rats,O,O
was,O,O
pair,O,O
fed,O,O
(,O,O
food,O,O
restricted,O,O
),O,O
with,O,O
the,O,O
P100,O,O
rats,O,O
for,O,O
7,O,O
days,O,O
(,O,O
FR,O,O
group,O,O
),O,O
.,O,O
On,O,O
Day,O,O
8,O,O
",",O,O
the,O,O
nerve,O,O
-,O,O
evoked,O,O
peak,O,O
twitch,O,O
tensions,O,O
",",O,O
tetanic,O,O
tensions,O,O
",",O,O
and,O,O
fatigability,O,O
",",O,O
and,O,O
the,O,O
dose,O,O
-,O,O
response,O,O
curves,O,O
of,O,O
d,B,B
-,I,I
tubocurarine,I,I
in,O,O
the,O,O
tibialis,O,O
cranialis,O,O
muscle,O,O
were,O,O
measured,O,O
in,O,O
vivo,O,O
and,O,O
related,O,O
to,O,O
muscle,O,O
mass,O,O
or,O,O
expression,O,O
of,O,O
AChRs,O,B
.,O,O
Rate,O,O
of,O,O
body,O,O
weight,O,O
gain,O,O
was,O,O
depressed,O,O
in,O,O
the,O,O
P100,O,O
",",O,O
FR,O,O
",",O,O
and,O,O
P10,O,O
groups,O,O
compared,O,O
with,O,O
the,O,O
S,O,O
group,O,O
.,O,O
Tibialis,O,B
muscle,O,I
mass,O,I
was,O,O
smaller,O,O
in,O,O
the,O,O
P100,O,O
group,O,O
than,O,O
in,O,O
the,O,O
P10,O,O
or,O,O
S,O,O
groups,O,O
.,O,O
The,O,O
evoked,O,O
peak,O,O
twitch,O,O
and,O,O
tetanic,O,O
tensions,O,O
were,O,O
less,O,O
in,O,O
the,O,O
P100,O,O
group,O,O
than,O,O
in,O,O
the,O,O
P10,O,O
or,O,O
S,O,O
groups,O,O
",",O,O
however,O,O
",",O,O
tension,O,O
per,O,O
milligram,O,O
of,O,O
muscle,O,O
mass,O,O
was,O,O
greater,O,O
in,O,O
the,O,O
P100,O,O
group,O,O
than,O,O
in,O,O
the,O,O
S,O,O
group,O,O
.,O,O
The,O,O
50,O,O
%,O,O
effective,O,O
d,B,B
-,I,I
tubocurarine,I,I
(,O,O
microg,O,B
/,O,I
kg,O,I
),O,O
in,O,O
the,O,O
tibialis,O,B
muscle,O,I
was,O,O
smaller,O,O
in,O,O
the,O,O
P10,O,O
(,O,O
33,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
5,O,O
.,O,O
4,O,B
),O,O
than,O,O
in,O,O
the,O,O
S,O,B
(,O,O
61,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
5,O,O
.,O,O
0,O,O
),O,O
or,O,O
the,O,O
P100,O,B
(,O,O
71,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
9,O,O
.,O,O
6,O,O
),O,O
groups,O,O
.,O,O
AChR,O,B
expression,O,O
was,O,O
less,O,O
in,O,O
the,O,O
P10,O,B
group,O,O
than,O,O
in,O,O
the,O,O
S,O,B
group,O,O
.,O,O
The,O,O
evoked,O,O
tensions,O,O
correlated,O,O
with,O,O
muscle,O,O
mass,O,O
(,O,O
r,O,O
(,O,O
2,O,O
),O,O
=,O,O
0,O,O
.,O,O
32,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
however,O,O
",",O,O
not,O,O
with,O,O
expression,O,O
of,O,O
AChR,O,B
.,O,O
The,O,O
50,O,O
%,O,O
effective,O,O
dose,O,O
of,O,O
d,B,O
-,I,O
tubocurarine,I,B
did,O,O
not,O,O
correlate,O,O
with,O,O
muscle,O,O
mass,O,O
or,O,O
AChR,O,B
expression,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
neuromuscular,O,O
dysfunction,O,O
after,O,O
prednisolone,B,B
is,O,O
dose,O,O
-,O,O
dependent,O,O
",",O,O
and,O,O
derives,O,O
primarily,O,O
from,O,O
muscle,O,O
atrophy,O,O
and,O,O
derives,O,O
less,O,O
so,O,O
from,O,O
changes,O,O
in,O,O
AChR,O,B
expression,O,O
.,O,O
IMPLICATIONS,O,O
:,O,O
The,O,O
mechanisms,O,O
by,O,O
which,O,O
chronic,O,O
glucocorticoid,O,O
therapy,O,O
alters,O,O
neuromuscular,O,O
physiology,O,O
and,O,O
pharmacology,O,O
are,O,O
unclear,O,O
.,O,O
We,O,O
suggest,O,O
that,O,O
the,O,O
observed,O,O
effects,O,O
are,O,O
dose,O,O
-,O,O
dependent,O,O
and,O,O
derive,O,O
primarily,O,O
from,O,O
muscle,O,O
atrophy,O,O
and,O,O
derive,O,O
less,O,O
from,O,O
changes,O,O
in,O,O
acetylcholine,B,B
receptor,O,I
expression,O,I
.,O,O
Apomorphine,B,B
:,O,O
an,O,O
underutilized,O,O
therapy,O,O
for,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
.,O,O
Apomorphine,B,B
was,O,O
the,O,O
first,O,O
dopaminergic,O,O
drug,O,O
ever,O,O
used,O,O
to,O,O
treat,O,O
symptoms,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
.,O,O
While,O,O
powerful,O,O
antiparkinsonian,O,O
effects,O,O
had,O,O
been,O,O
observed,O,O
as,O,O
early,O,O
as,O,O
1951,O,O
",",O,O
the,O,O
potential,O,O
of,O,O
treating,O,O
fluctuating,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
by,O,O
subcutaneous,O,O
administration,O,O
of,O,O
apomorphine,B,B
has,O,O
only,O,O
recently,O,O
become,O,O
the,O,O
subject,O,O
of,O,O
systematic,O,O
study,O,O
.,O,O
A,O,O
number,O,O
of,O,O
small,O,O
scale,O,O
clinical,O,O
trials,O,O
have,O,O
unequivocally,O,O
shown,O,O
that,O,O
intermittent,O,O
subcutaneous,O,O
apomorphine,B,B
injections,O,O
produce,O,O
antiparkinsonian,O,O
benefit,O,O
close,O,O
if,O,O
not,O,O
identical,O,O
to,O,O
that,O,O
seen,O,O
with,O,O
levodopa,B,B
and,O,O
that,O,O
apomorphine,B,B
rescue,O,O
injections,O,O
can,O,O
reliably,O,O
revert,O,O
off,O,O
-,O,O
periods,O,O
even,O,O
in,O,O
patients,O,O
with,O,O
complex,O,O
on,O,O
-,O,O
off,O,O
motor,O,O
swings,O,O
.,O,O
Continuous,O,O
subcutaneous,O,O
apomorphine,B,B
infusions,O,O
can,O,O
reduce,O,O
daily,O,O
off,O,O
-,O,O
time,O,O
by,O,O
more,O,O
than,O,O
50,O,O
%,O,O
in,O,O
this,O,O
group,O,O
of,O,O
patients,O,O
",",O,O
which,O,O
appears,O,O
to,O,O
be,O,O
a,O,O
stronger,O,O
effect,O,O
than,O,O
that,O,O
generally,O,O
seen,O,O
with,O,O
add,O,O
-,O,O
on,O,O
therapy,O,O
oral,O,O
dopamine,B,B
agonists,O,O
or,O,O
COMT,O,B
inhibitors,O,O
.,O,O
Extended,O,O
follow,O,O
-,O,O
up,O,O
studies,O,O
of,O,O
up,O,O
to,O,O
8,O,O
years,O,O
have,O,O
demonstrated,O,O
long,O,O
-,O,O
term,O,O
persistence,O,O
of,O,O
apomorphine,B,B
efficacy,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
there,O,O
is,O,O
convincing,O,O
clinical,O,O
evidence,O,O
that,O,O
monotherapy,O,O
with,O,O
continuous,O,O
subcutaneous,O,B
apomorphine,B,B
infusions,O,O
is,O,O
associated,O,O
with,O,O
marked,O,O
reductions,O,O
of,O,O
preexisting,O,O
levodopa,B,B
-,O,I
induced,O,I
dyskinesias,O,I
.,O,O
The,O,O
main,O,O
side,O,O
effects,O,O
of,O,O
subcutaneous,O,B
apomorphine,B,I
treatment,O,O
are,O,O
related,O,O
to,O,O
cutaneous,O,O
tolerability,O,O
problems,O,O
",",O,O
whereas,O,O
sedation,O,O
and,O,O
psychiatric,O,O
complications,O,O
play,O,O
a,O,O
lesser,O,O
role,O,O
.,O,O
Given,O,O
the,O,O
marked,O,O
degree,O,O
of,O,O
efficacy,O,O
of,O,O
subcutaneous,O,O
apomorphine,B,B
treatment,O,O
in,O,O
fluctuating,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
",",O,O
this,O,O
approach,O,O
seems,O,O
to,O,O
deserve,O,O
more,O,O
widespread,O,O
clinical,O,O
use,O,O
.,O,O
Probing,O,O
peripheral,O,O
and,O,O
central,O,O
cholinergic,O,B
system,O,O
responses,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
pharmacological,O,O
response,O,O
to,O,O
drugs,O,O
that,O,O
act,O,O
on,O,O
the,O,O
cholinergic,O,B
system,O,O
of,O,O
the,O,O
iris,O,O
has,O,O
been,O,O
used,O,O
to,O,O
predict,O,O
deficits,O,O
in,O,O
central,O,O
cholinergic,O,B
functioning,O,O
due,O,O
to,O,O
diseases,O,O
such,O,O
as,O,O
Alzheimer,O,B
',O,O
s,O,O
disease,O,O
",",O,O
yet,O,O
correlations,O,O
between,O,O
central,O,O
and,O,O
peripheral,O,O
responses,O,O
have,O,O
not,O,O
been,O,O
properly,O,O
studied,O,O
.,O,O
This,O,O
study,O,O
assessed,O,O
the,O,O
effect,O,O
of,O,O
normal,O,O
aging,O,O
on,O,O
(,O,O
1,O,O
),O,O
the,O,O
tropicamide,B,B
-,O,O
induced,O,O
increase,O,O
in,O,O
pupil,O,O
diameter,O,O
",",O,O
and,O,O
(,O,O
2,O,O
),O,O
the,O,O
reversal,O,O
of,O,O
this,O,O
effect,O,O
with,O,O
pilocarpine,B,B
.,O,O
Scopolamine,B,B
was,O,O
used,O,O
as,O,O
a,O,O
positive,O,O
control,O,O
to,O,O
detect,O,O
age,O,O
-,O,O
dependent,O,O
changes,O,O
in,O,O
central,O,O
cholinergic,O,O
functioning,O,O
in,O,O
the,O,O
elderly,O,O
.,O,O
DESIGN,O,O
:,O,O
Randomized,O,O
double,O,O
-,O,O
blind,O,O
controlled,O,O
trial,O,O
.,O,O
PARTICIPANTS,O,O
:,O,O
Ten,O,O
healthy,O,O
elderly,O,O
(,O,O
mean,O,O
age,O,O
70,O,O
),O,O
and,O,O
9,O,O
young,O,O
(,O,O
mean,O,O
age,O,O
33,O,O
),O,O
volunteers,O,O
.,O,O
INTERVENTIONS,O,O
:,O,O
Pupil,O,O
diameter,O,O
was,O,O
monitored,O,O
using,O,O
a,O,O
computerized,O,O
infrared,O,O
pupillometer,O,O
over,O,O
4,O,O
hours,O,O
.,O,O
The,O,O
study,O,O
involved,O,O
4,O,O
sessions,O,O
.,O,O
In,O,O
1,O,O
session,O,O
",",O,O
tropicamide,B,B
(,O,O
20,O,O
microL,O,O
",",O,O
0,O,O
.,O,O
%,O,O
),O,O
was,O,O
administered,O,O
to,O,O
one,O,O
eye,O,O
and,O,O
placebo,O,O
to,O,O
the,O,O
other,O,O
.,O,O
In,O,O
another,O,O
session,O,O
",",O,O
tropicamide,B,B
(,O,O
20,O,O
microL,O,O
",",O,O
0,O,O
.,O,O
%,O,O
),O,O
was,O,O
administered,O,O
to,O,O
both,O,O
eyes,O,O
",",O,O
followed,O,O
23,O,O
minutes,O,O
later,O,O
by,O,O
the,O,O
application,O,O
of,O,O
pilocarpine,B,B
(,O,O
20,O,O
microL,O,O
",",O,O
0,O,O
.,O,O
1,O,O
%,O,O
),O,O
to,O,O
one,O,O
eye,O,O
and,O,O
placebo,O,B
to,O,O
the,O,O
other,O,O
.,O,O
All,O,O
eye,O,O
drops,O,O
were,O,O
given,O,O
in,O,O
a,O,O
randomized,O,O
order,O,O
.,O,O
In,O,O
2,O,O
separate,O,O
sessions,O,O
",",O,O
a,O,O
single,O,O
dose,O,O
of,O,O
scopolamine,B,B
(,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
",",O,O
intravenously,O,O
),O,O
or,O,O
placebo,O,O
was,O,O
administered,O,O
",",O,O
and,O,O
the,O,O
effects,O,O
on,O,O
word,O,O
recall,O,O
were,O,O
measured,O,O
using,O,O
the,O,O
Buschke,O,O
Selective,O,O
Reminding,O,O
Test,O,O
over,O,O
2,O,O
hours,O,O
.,O,O
OUTCOME,O,O
MEASURES,O,O
:,O,O
Pupil,O,O
size,O,O
at,O,O
time,O,O
points,O,O
after,O,O
administration,O,O
of,O,O
tropicamide,B,B
and,O,O
pilocarpine,B,B
;,O,O
scopolamine,B,B
-,O,O
induced,O,O
impairment,O,O
in,O,O
word,O,O
recall,O,O
.,O,O
RESULTS,O,O
:,O,O
There,O,O
was,O,O
no,O,O
significant,O,O
difference,O,O
between,O,O
elderly,O,O
and,O,O
young,O,O
volunteers,O,O
in,O,O
pupillary,O,O
response,O,O
to,O,O
tropicamide,B,B
at,O,O
any,O,O
time,O,O
point,O,O
(,O,O
p,O,O
>,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
elderly,O,O
group,O,O
had,O,O
a,O,O
significantly,O,O
greater,O,O
pilocarpine,B,B
-,O,O
induced,O,O
net,O,O
decrease,O,O
in,O,O
pupil,O,O
size,O,O
85,O,O
",",O,O
125,O,O
",",O,O
165,O,O
and,O,O
215,O,O
minutes,O,O
after,O,O
administration,O,O
",",O,O
compared,O,O
with,O,O
the,O,O
young,O,O
group,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Compared,O,O
with,O,O
the,O,O
young,O,O
group,O,O
",",O,O
the,O,O
elderly,O,O
group,O,O
had,O,O
greater,O,O
scopolamine,B,B
-,O,I
induced,O,O
impairment,O,O
in,O,O
word,O,O
recall,O,O
60,O,O
",",O,O
90,O,O
and,O,O
120,O,O
minutes,O,O
after,O,O
administration,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSION,O,O
:,O,O
There,O,O
is,O,O
an,O,O
age,O,O
-,O,O
related,O,O
pupillary,O,O
response,O,O
to,O,O
pilocarpine,B,B
that,O,O
is,O,O
not,O,O
found,O,O
with,O,O
tropicamide,B,B
.,O,O
Thus,O,O
",",O,O
pilocarpine,B,B
may,O,O
be,O,O
useful,O,O
to,O,O
assess,O,O
variations,O,O
in,O,O
central,O,O
cholinergic,O,O
function,O,O
in,O,O
elderly,O,O
patients,O,O
.,O,O
Pain,O,B
responses,O,O
in,O,O
methadone,B,B
-,O,O
maintained,O,O
opioid,O,B
abusers,O,O
.,O,O
Providing,O,O
pain,O,O
management,O,O
for,O,O
known,O,O
opioid,O,B
abusers,O,O
is,O,O
a,O,O
challenging,O,O
clinical,O,O
task,O,O
",",O,O
in,O,O
part,O,O
because,O,O
little,O,O
is,O,O
known,O,O
about,O,O
their,O,O
pain,O,O
experience,O,O
and,O,O
analgesic,O,O
requirements,O,O
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
describe,O,O
pain,O,O
tolerance,O,O
and,O,O
analgesic,O,O
response,O,O
in,O,O
a,O,O
sample,O,O
of,O,O
opioid,O,B
addicts,O,O
stabilized,O,O
in,O,O
methadone,B,B
-,O,O
maintenance,O,O
(,O,O
MM,O,O
),O,O
treatment,O,O
(,O,O
n,O,O
=,O,O
60,O,O
),O,O
in,O,O
comparison,O,O
to,O,O
matched,O,O
nondependent,O,O
control,O,O
subjects,O,O
(,O,O
n,O,O
=,O,O
60,O,O
),O,O
.,O,O
By,O,O
using,O,O
a,O,O
placebo,O,B
-,O,O
controlled,O,O
",",O,O
two,O,O
-,O,O
way,O,O
factorial,O,O
design,O,O
",",O,O
tolerance,O,O
to,O,O
cold,O,B
-,O,I
pressor,O,I
(,O,O
CP,O,B
),O,O
pain,O,O
was,O,O
examined,O,O
",",O,O
both,O,O
before,O,O
and,O,O
after,O,O
oral,O,O
administration,O,O
of,O,O
therapeutic,O,O
doses,O,O
of,O,O
common,O,O
opioid,O,B
(,O,O
hydromorphone,B,B
2,O,O
mg,O,O
),O,O
and,O,O
nonsteroidal,O,B
anti,O,I
-,O,I
inflammatory,O,I
(,O,O
ketorolac,B,B
10,O,O
mg,O,O
),O,O
analgesic,O,O
agents,O,O
.,O,O
Results,O,O
showed,O,O
that,O,O
MM,O,O
individuals,O,O
were,O,O
significantly,O,O
less,O,O
tolerant,O,O
of,O,O
CP,O,B
pain,O,O
than,O,O
control,O,O
subjects,O,O
",",O,O
replicating,O,O
previous,O,O
work,O,O
.,O,O
Analgesic,O,O
effects,O,O
were,O,O
significant,O,O
neither,O,O
for,O,O
medication,O,O
nor,O,O
group,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
MM,O,O
opioid,O,B
abusers,O,O
represent,O,O
a,O,O
pain,O,O
-,O,O
intolerant,O,O
subset,O,O
of,O,O
clinical,O,O
patients,O,O
.,O,O
Their,O,O
complaints,O,O
of,O,O
pain,O,O
should,O,O
be,O,O
evaluated,O,O
seriously,O,O
and,O,O
managed,O,O
aggressively,O,O
.,O,O
High,O,O
-,O,O
dose,O,O
methylprednisolone,B,B
may,O,O
do,O,O
more,O,O
harm,O,O
for,O,O
spinal,O,O
cord,O,O
injury,O,O
.,O,O
Because,O,O
of,O,O
the,O,O
National,O,B
Acute,O,I
Spinal,O,I
Cord,O,I
Injury,O,I
Studies,O,I
(,O,O
NASCIS,O,B
),O,O
",",O,O
high,O,O
-,O,O
dose,O,O
methylprednisolone,B,B
became,O,O
the,O,O
standard,O,O
of,O,O
care,O,O
for,O,O
the,O,O
acute,O,O
spinal,O,O
cord,O,O
injury,O,O
.,O,O
In,O,O
the,O,O
NASCIS,O,B
",",O,O
there,O,O
was,O,O
no,O,O
mention,O,O
regarding,O,O
the,O,O
possibility,O,O
of,O,O
acute,O,O
corticosteroid,B,B
myopathy,O,I
that,O,O
high,O,O
-,O,O
dose,O,O
methylprednisolone,B,O
may,O,O
cause,O,O
.,O,O
The,O,O
dosage,O,O
of,O,O
methylprednisolone,B,B
recommended,O,O
by,O,O
the,O,O
NASCIS,O,O
3,O,O
is,O,O
the,O,O
highest,O,O
dose,O,O
of,O,O
steroids,B,B
ever,O,O
being,O,O
used,O,O
during,O,O
a,O,O
2,O,O
-,O,O
day,O,O
period,O,O
for,O,O
any,O,O
clinical,O,O
condition,O,O
.,O,O
We,O,O
hypothesize,O,O
that,O,O
it,O,O
may,O,O
cause,O,O
some,O,O
damage,O,O
to,O,O
the,O,O
muscle,O,O
of,O,O
spinal,O,O
cord,O,O
injury,O,O
patients,O,O
.,O,O
Further,O,O
",",O,O
steroid,B,B
myopathy,O,I
recovers,O,O
naturally,O,O
and,O,O
the,O,O
neurological,O,O
improvement,O,O
shown,O,O
in,O,O
the,O,O
NASCIS,O,O
may,O,O
be,O,O
just,O,O
a,O,O
recording,O,O
of,O,O
this,O,O
natural,O,O
motor,O,O
recovery,O,O
from,O,O
the,O,O
steroid,B,B
myopathy,O,I
",",O,O
instead,O,O
of,O,O
any,O,O
protection,O,O
that,O,O
methylprednisolone,B,B
offers,O,O
to,O,O
the,O,O
spinal,O,O
cord,O,O
injury,O,O
.,O,O
To,O,O
our,O,O
knowledge,O,O
",",O,O
this,O,O
is,O,O
the,O,O
first,O,O
discussion,O,O
considering,O,O
the,O,O
possibility,O,O
that,O,O
the,O,O
methylprednisolone,B,B
recommended,O,O
by,O,O
NASCIS,O,O
may,O,O
cause,O,O
acute,O,O
corticosteroid,B,O
myopathy,O,O
.,O,O
Conversion,O,O
to,O,O
rapamycin,B,B
immunosuppression,O,O
in,O,O
renal,O,O
transplant,O,O
recipients,O,O
:,O,O
report,O,O
of,O,O
an,O,O
initial,O,O
experience,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
is,O,O
to,O,O
evaluate,O,O
the,O,O
effects,O,O
of,O,O
RAPA,B,B
conversion,O,O
in,O,O
patients,O,O
undergoing,O,O
cyclosporine,B,B
(,O,O
CsA,B,O
),O,O
or,O,O
tacrolimus,B,B
(,O,O
Tac,B,O
),O,O
toxicity,O,O
.,O,O
METHODS,O,O
:,O,O
Twenty,O,O
renal,O,O
transplant,O,O
recipients,O,O
were,O,O
switched,O,O
to,O,O
fixed,O,O
dose,O,O
rapamycin,B,B
(,O,O
RAPA,B,B
),O,O
(,O,O
5,O,O
mg,O,O
/,O,O
day,O,O
),O,O
0,O,O
to,O,O
204,O,O
months,O,O
posttransplant,O,O
.,O,O
Drug,O,O
monitoring,O,O
was,O,O
not,O,O
initially,O,O
used,O,O
to,O,O
adjust,O,O
doses,O,O
.,O,O
The,O,O
indications,O,O
for,O,O
switch,O,O
were,O,O
chronic,O,O
CsA,B,B
or,O,O
Tac,B,B
nephrotoxicity,O,O
(,O,O
12,O,O
),O,O
",",O,O
acute,O,O
CsA,B,B
or,O,O
Tac,B,B
toxicity,O,O
(,O,O
3,O,O
),O,O
",",O,O
severe,O,O
facial,O,O
dysmorphism,O,O
(,O,O
2,O,O
),O,O
",",O,O
posttransplant,O,O
lymphoproliferative,O,O
disorder,O,O
(,O,O
PTLD,O,B
),O,O
in,O,O
remission,O,O
(,O,O
2,O,O
),O,O
",",O,O
and,O,O
hepatotoxicity,O,O
in,O,O
1,O,O
.,O,O
Follow,O,O
-,O,O
up,O,O
is,O,O
7,O,O
to,O,O
24,O,O
months,O,O
.,O,O
RESULTS,O,O
:,O,O
In,O,O
the,O,O
12,O,O
patients,O,O
switched,O,O
because,O,O
of,O,O
chronic,O,O
nephrotoxicity,O,B
there,O,O
was,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
serum,O,B
creatinine,B,I
[,O,O
233,O,O
+,O,O
/,O,O
-,O,O
34,O,O
to,O,O
210,O,O
+,O,O
/,O,O
-,O,O
56,O,O
micromol,O,O
/,O,O
liter,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
at,O,O
6,O,O
months,O,O
],O,O
dysmorphism,O,O
improved,O,O
in,O,O
two,O,O
patients,O,O
.,O,O
No,O,O
relapse,O,O
of,O,O
PTLD,O,B
was,O,O
observed,O,O
.,O,O
Five,O,O
patients,O,O
developed,O,O
pneumonia,O,B
(,O,O
two,O,O
Pneumocystis,O,B
carinii,O,I
pneumonia,O,I
",",O,O
one,O,O
infectious,O,B
mononucleosis,O,I
with,O,O
polyclonal,O,O
PTLD,O,B
lung,O,O
infiltrate,O,O
),O,O
and,O,O
two,O,O
had,O,O
bronchiolitis,O,B
obliterans,O,I
.,O,O
There,O,O
were,O,O
no,O,O
deaths,O,O
.,O,O
RAPA,B,O
was,O,O
discontinued,O,O
in,O,O
four,O,O
patients,O,O
",",O,O
because,O,O
of,O,O
pneumonia,O,B
in,O,O
two,O,O
",",O,O
PTLD,O,B
in,O,O
one,O,O
",",O,O
and,O,O
oral,O,O
aphtous,O,O
ulcers,O,O
in,O,O
one,O,O
.,O,O
RAPA,B,B
levels,O,O
were,O,O
high,O,O
(,O,O
>,O,O
15,O,O
ng,O,O
/,O,O
ml,O,O
),O,O
in,O,O
7,O,O
of,O,O
13,O,O
(,O,O
54,O,O
%,O,O
),O,O
patients,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
RAPA,B,B
conversion,O,O
provides,O,O
adequate,O,O
immunosuppression,O,O
to,O,O
enable,O,O
CsA,B,O
withdrawal,O,O
.,O,O
However,O,O
",",O,O
when,O,O
converting,O,O
patients,O,O
to,O,O
RAPA,B,B
drug,O,O
levels,O,O
should,O,O
be,O,O
monitored,O,O
to,O,O
avoid,O,O
over,O,O
-,O,O
immunosuppression,O,O
and,O,O
adequate,O,O
antiviral,O,O
and,O,O
Pneumocystis,O,B
carinii,O,I
pneumonia,O,I
prophylaxis,O,O
should,O,O
be,O,O
given,O,O
.,O,O
Electro,O,B
-,O,O
oculography,O,O
",",O,O
electroretinography,O,B
",",O,O
visual,O,O
evoked,O,O
potentials,O,O
",",O,O
and,O,O
multifocal,O,O
electroretinography,O,B
in,O,O
patients,O,O
with,O,O
vigabatrin,B,B
-,O,O
attributed,O,O
visual,O,O
field,O,O
constriction,O,O
.,O,O
PURPOSE,O,O
:,O,O
Symptomatic,O,O
visual,O,O
field,O,O
constriction,O,O
thought,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
vigabatrin,B,B
has,O,O
been,O,O
reported,O,O
.,O,O
The,O,O
current,O,O
study,O,O
investigated,O,O
the,O,O
visual,O,O
fields,O,O
and,O,O
visual,O,O
electrophysiology,O,O
of,O,O
eight,O,O
patients,O,O
with,O,O
known,O,O
vigabatrin,B,B
-,O,O
attributed,O,O
visual,O,O
field,O,O
loss,O,O
",",O,O
three,O,O
of,O,O
whom,O,O
were,O,O
reported,O,O
previously,O,O
.,O,O
Six,O,O
of,O,O
the,O,O
patients,O,O
were,O,O
no,O,O
longer,O,O
receiving,O,O
vigabatrin,B,B
.,O,O
METHODS,O,O
:,O,O
The,O,O
central,O,O
and,O,O
peripheral,O,O
fields,O,O
were,O,O
examined,O,O
with,O,O
the,O,O
Humphrey,O,O
Visual,O,O
Field,O,O
Analyzer,O,O
.,O,O
Full,O,O
visual,O,O
electrophysiology,O,O
",",O,O
including,O,O
flash,O,O
electroretinography,O,B
(,O,O
ERG,O,I
),O,O
",",O,O
pattern,O,O
electroretinography,O,B
",",O,O
multifocal,O,O
ERG,O,B
using,O,O
the,O,O
VERIS,O,O
system,O,O
",",O,O
electro,O,O
-,O,O
oculography,O,O
",",O,O
and,O,O
flash,O,O
and,O,O
pattern,O,O
visual,O,O
evoked,O,O
potentials,O,O
",",O,O
was,O,O
undertaken,O,O
.,O,O
RESULTS,O,O
:,O,O
Seven,O,O
patients,O,O
showed,O,O
marked,O,O
visual,O,O
field,O,O
constriction,O,O
with,O,O
some,O,O
sparing,O,O
of,O,O
the,O,O
temporal,O,O
visual,O,O
field,O,O
.,O,O
The,O,O
eighth,O,O
exhibited,O,O
concentric,O,O
constriction,O,O
.,O,O
Most,O,O
electrophysiological,O,O
responses,O,O
were,O,O
usually,O,O
just,O,O
within,O,O
normal,O,O
limits,O,O
;,O,O
two,O,O
patients,O,O
had,O,O
subnormal,O,O
Arden,O,B
electro,O,I
-,O,I
oculography,O,I
indices,O,O
;,O,O
and,O,O
one,O,O
patient,O,O
showed,O,O
an,O,O
abnormally,O,O
delayed,O,O
photopic,O,B
b,O,I
wave,O,I
.,O,O
However,O,O
",",O,O
five,O,O
patients,O,O
showed,O,O
delayed,O,O
30,O,O
-,O,O
Hz,O,O
flicker,O,O
b,O,O
waves,O,O
",",O,O
and,O,O
seven,O,O
patients,O,O
showed,O,O
delayed,O,O
oscillatory,O,O
potentials,O,O
.,O,O
Multifocal,O,O
ERG,O,O
showed,O,O
abnormalities,O,O
that,O,O
sometimes,O,O
correlated,O,O
with,O,O
the,O,O
visual,O,O
field,O,O
appearance,O,O
and,O,O
confirmed,O,O
that,O,O
the,O,O
deficit,O,O
occurs,O,O
at,O,O
the,O,O
retinal,O,O
level,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Marked,O,O
visual,O,O
field,O,O
constriction,O,O
appears,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
vigabatrin,B,B
therapy,O,O
.,O,O
The,O,O
field,O,O
defects,O,O
and,O,O
some,O,O
electrophysiological,O,O
abnormalities,O,O
persist,O,O
when,O,O
vigabatrin,B,B
therapy,O,O
is,O,O
withdrawn,O,O
.,O,O
Myocardial,O,B
ischemia,O,O
due,O,O
to,O,O
coronary,O,B
artery,O,I
spasm,O,O
during,O,O
dobutamine,B,B
stress,O,I
echocardiography,O,I
.,O,O
Dobutamine,B,B
stress,O,I
echocardiography,O,I
(,O,O
DSE,O,B
),O,O
is,O,O
a,O,O
useful,O,O
and,O,O
safe,O,O
provocation,O,O
test,O,O
for,O,O
myocardial,O,B
ischemia,O,O
.,O,O
Until,O,O
now,O,O
",",O,O
the,O,O
test,O,O
has,O,O
been,O,O
focused,O,O
only,O,O
on,O,O
the,O,O
organic,O,O
lesion,O,O
in,O,O
the,O,O
coronary,O,B
artery,O,I
",",O,O
and,O,O
positive,O,O
DSE,O,O
has,O,O
indicated,O,O
the,O,O
presence,O,O
of,O,O
significant,O,O
fixed,O,O
coronary,O,B
artery,O,I
stenosis,O,I
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
is,O,O
to,O,O
examine,O,O
whether,O,O
myocardial,O,O
ischemia,O,O
due,O,O
to,O,O
coronary,O,B
spasm,O,I
is,O,O
induced,O,O
by,O,O
dobutamine,B,B
.,O,O
We,O,O
performed,O,O
DSE,O,O
on,O,O
51,O,O
patients,O,O
with,O,O
coronary,O,B
spastic,O,I
angina,O,I
but,O,O
without,O,O
significant,O,O
fixed,O,O
coronary,O,B
artery,O,I
stenosis,O,I
.,O,O
All,O,O
patients,O,O
had,O,O
anginal,O,O
attacks,O,O
at,O,O
rest,O,O
with,O,O
ST,O,O
elevation,O,O
on,O,O
the,O,O
electrocardiogram,O,O
(,O,O
variant,O,O
angina,O,O
),O,O
.,O,O
Coronary,O,B
spasm,O,I
was,O,O
induced,O,O
by,O,O
intracoronary,O,O
injection,O,O
of,O,O
acetylcholine,B,B
",",O,O
and,O,O
no,O,O
fixed,O,O
coronary,O,B
artery,O,I
stenosis,O,I
was,O,O
documented,O,O
on,O,O
angiograms,O,O
in,O,O
all,O,O
patients,O,O
.,O,O
DSE,O,O
was,O,O
performed,O,O
with,O,O
intravenous,O,O
dobutamine,B,B
infusion,O,O
with,O,O
an,O,O
incremental,O,O
doses,O,O
of,O,O
5,O,O
",",O,O
10,O,O
",",O,O
20,O,O
",",O,O
30,O,O
",",O,O
and,O,O
40,O,O
microg,O,B
/,O,I
kg,O,I
/,O,I
min,O,I
every,O,O
5,O,O
minutes,O,O
.,O,O
Of,O,O
the,O,O
51,O,O
patients,O,O
",",O,O
7,O,O
patients,O,O
showed,O,O
asynergy,O,O
with,O,O
ST,O,B
elevation,O,O
.,O,O
All,O,O
7,O,O
patients,O,O
(,O,O
13,O,O
.,O,O
7,O,O
%,O,O
),O,O
had,O,O
chest,O,O
pain,O,O
during,O,O
asynergy,O,O
",",O,O
and,O,O
both,O,O
chest,O,O
pain,O,O
and,O,O
electrocardiographic,O,O
changes,O,O
were,O,O
preceded,O,O
by,O,O
asynergy,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
dobutamine,B,B
can,O,O
provoke,O,O
coronary,O,B
spasm,O,O
in,O,O
some,O,O
patients,O,O
with,O,O
coronary,O,B
spastic,O,I
angina,O,I
.,O,O
When,O,O
DSE,O,O
is,O,O
performed,O,O
to,O,O
evaluate,O,O
coronary,O,B
artery,O,I
disease,O,I
",",O,O
not,O,O
only,O,O
fixed,O,O
coronary,O,B
stenosis,O,I
",",O,O
but,O,O
also,O,O
coronary,O,B
spasm,O,O
should,O,O
be,O,O
considered,O,O
as,O,O
a,O,O
genesis,O,O
of,O,O
asynergy,O,O
.,O,O
Effect,O,O
of,O,O
intravenous,O,O
metoprolol,B,B
or,O,O
intravenous,O,O
metoprolol,B,B
plus,O,O
glucagon,O,B
on,O,O
dobutamine,B,B
-,O,O
induced,O,O
myocardial,O,O
ischemia,O,O
.,O,O
STUDY,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
determine,O,O
the,O,O
effect,O,O
of,O,O
metoprolol,B,B
on,O,O
dobutamine,B,O
stress,O,O
testing,O,O
with,O,O
technetium,B,B
-,I,I
99m,I,I
sestamibi,I,I
single,O,O
-,O,O
photon,O,O
emission,O,O
computed,O,O
tomography,O,O
imaging,O,O
and,O,O
ST,O,B
-,O,I
segment,O,I
monitoring,O,I
",",O,O
and,O,O
to,O,O
assess,O,O
the,O,O
impact,O,O
of,O,O
intravenous,O,O
glucagon,O,B
on,O,O
metoprolol,B,O
',O,O
s,O,O
effects,O,O
.,O,O
DESIGN,O,O
:,O,O
Randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
.,O,O
SETTING,O,O
:,O,O
Community,O,O
hospital,O,O
.,O,O
PATIENTS,O,O
:,O,O
Twenty,O,O
-,O,O
two,O,O
patients,O,O
with,O,O
known,O,O
reversible,O,O
perfusion,O,O
defects,O,O
.,O,O
INTERVENTION,O,O
:,O,O
Patients,O,O
underwent,O,O
dobutamine,B,B
stress,O,I
tests,O,I
per,O,O
standard,O,O
protocol,O,O
.,O,O
Before,O,O
dobutamine,B,B
was,O,O
begun,O,O
",",O,O
no,O,O
therapy,O,O
was,O,O
given,O,O
during,O,O
the,O,O
first,O,O
visit,O,O
",",O,O
and,O,O
patients,O,O
were,O,O
randomized,O,O
on,O,O
subsequent,O,O
visits,O,O
to,O,O
receive,O,O
metoprolol,B,B
or,O,O
metoprolol,B,B
plus,O,O
glucagon,O,B
1,O,O
mg,O,O
.,O,O
Metoprolol,B,B
was,O,O
dosed,O,O
to,O,O
achieve,O,O
a,O,O
resting,O,O
predobutamine,B,O
heart,O,O
rate,O,O
below,O,O
65,O,O
beats,O,O
/,O,O
minute,O,O
or,O,O
a,O,O
total,O,O
intravenous,O,O
dose,O,O
of,O,O
20,O,O
mg,O,O
.,O,O
MEASUREMENTS,O,O
AND,O,O
MAIN,O,O
RESULTS,O,O
:,O,O
Metoprolol,B,B
reduced,O,O
maximum,O,O
heart,O,O
rate,O,O
31,O,O
%,O,O
",",O,O
summed,O,O
stress,O,O
scores,O,O
29,O,O
%,O,O
",",O,O
and,O,O
summed,O,O
difference,O,O
scores,O,O
43,O,O
%,O,O
versus,O,O
control,O,O
.,O,O
Metoprolol,B,B
plus,O,O
glucagon,O,B
also,O,O
reduced,O,O
the,O,O
maximum,O,O
heart,O,O
rate,O,O
29,O,O
%,O,O
versus,O,O
control,O,O
.,O,O
Summed,O,O
stress,O,O
and,O,O
summed,O,O
difference,O,O
scores,O,O
were,O,O
not,O,O
significantly,O,O
reduced,O,O
",",O,O
although,O,O
they,O,O
were,O,O
18,O,O
%,O,O
and,O,O
30,O,O
%,O,O
lower,O,O
",",O,O
respectively,O,O
",",O,O
than,O,O
control,O,O
.,O,O
No,O,O
significant,O,O
differences,O,O
were,O,O
found,O,O
in,O,O
any,O,O
parameter,O,O
between,O,O
metoprolol,B,B
and,O,O
metoprolol,B,B
-,O,O
glucagon,O,B
.,O,O
CONCLUSION,O,O
:,O,O
During,O,O
dobutamine,B,O
stress,O,O
testing,O,O
",",O,O
metoprolol,B,B
attenuates,O,O
or,O,O
eliminates,O,O
evidence,O,O
of,O,O
myocardial,O,O
ischemia,O,O
.,O,O
Glucagon,O,B
1,O,O
mg,O,O
",",O,O
although,O,O
somewhat,O,O
effective,O,O
",",O,O
does,O,O
not,O,O
correct,O,O
this,O,O
effect,O,O
to,O,O
the,O,O
extent,O,O
that,O,O
it,O,O
can,O,O
be,O,O
administered,O,O
clinically,O,O
.,O,O
Evidence,O,O
of,O,O
functional,O,O
somatotopy,O,O
in,O,O
GPi,O,B
from,O,O
results,O,O
of,O,O
pallidotomy,O,O
.,O,O
The,O,O
objective,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
explore,O,O
the,O,O
functional,O,O
anatomy,O,O
of,O,O
the,O,O
globus,O,O
pallidus,O,O
internus,O,O
(,O,O
GPi,O,B
),O,O
by,O,O
studying,O,O
the,O,O
effects,O,O
of,O,O
unilateral,O,O
pallidotomy,O,O
on,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
and,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
(,O,O
LID,O,B
),O,O
.,O,O
We,O,O
found,O,O
significant,O,O
positive,O,O
correlations,O,O
between,O,O
the,O,O
preoperative,O,O
levodopa,B,B
responsiveness,O,O
of,O,O
motor,O,O
signs,O,O
and,O,O
the,O,O
levodopa,B,B
responsiveness,O,O
of,O,O
scores,O,O
in,O,O
timed,O,O
tests,O,O
(,O,O
Core,O,B
Assessment,O,I
Program,O,I
for,O,I
Intracerebral,O,I
Transplantations,O,I
),O,O
in,O,O
the,O,O
contralateral,O,O
limbs,O,O
and,O,O
the,O,O
improvement,O,O
in,O,O
these,O,O
scores,O,O
after,O,O
surgery,O,O
",",O,O
whereas,O,O
there,O,O
was,O,O
no,O,O
correlation,O,O
with,O,O
the,O,O
improvement,O,O
in,O,O
LID,O,B
.,O,O
We,O,O
also,O,O
found,O,O
a,O,O
highly,O,O
significant,O,O
correlation,O,O
(,O,O
P,O,B
:,O,O
<,O,O
0,O,O
.,O,O
",",O,O
r,O,O
=,O,O
0,O,O
.,O,O
8,O,O
),O,O
between,O,O
the,O,O
volume,O,O
of,O,O
the,O,O
ventral,O,O
lesion,O,O
in,O,O
the,O,O
GPi,O,B
and,O,O
the,O,O
improvement,O,O
in,O,O
LID,O,B
in,O,O
the,O,O
contralateral,O,O
limbs,O,O
",",O,O
whereas,O,O
there,O,O
was,O,O
no,O,O
correlation,O,O
between,O,O
the,O,O
ventral,O,O
volume,O,O
and,O,O
the,O,O
improvement,O,O
in,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
.,O,O
The,O,O
volumes,O,O
of,O,O
the,O,O
total,O,O
lesion,O,O
cylinder,O,O
and,O,O
the,O,O
dorsal,O,O
lesion,O,O
did,O,O
not,O,O
correlate,O,O
with,O,O
the,O,O
outcome,O,O
of,O,O
either,O,O
dyskinesias,O,B
or,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
.,O,O
The,O,O
differential,O,O
predictive,O,O
value,O,O
of,O,O
levodopa,B,B
responsiveness,O,O
for,O,O
the,O,O
outcome,O,O
of,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
and,O,O
LID,O,B
and,O,O
the,O,O
different,O,O
correlations,O,O
of,O,O
ventral,O,O
lesion,O,O
volume,O,O
with,O,O
dyskinesias,O,B
and,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
indicate,O,O
that,O,O
different,O,O
anatomical,O,O
or,O,O
pathophysiological,O,O
substrates,O,O
may,O,O
be,O,O
responsible,O,O
for,O,O
the,O,O
generation,O,O
of,O,O
parkinsonian,O,O
',O,O
off,O,O
',O,O
signs,O,O
and,O,O
dyskinesias,O,B
.,O,O
Whereas,O,O
cells,O,O
in,O,O
a,O,O
wider,O,O
area,O,O
of,O,O
the,O,O
GPi,O,B
may,O,O
be,O,O
implicated,O,O
in,O,O
parkinsonism,O,O
",",O,O
the,O,O
ventral,O,O
GPi,O,B
seems,O,O
to,O,O
be,O,O
crucial,O,O
for,O,O
the,O,O
manifestation,O,O
of,O,O
LID,O,B
.,O,O
We,O,O
suggest,O,O
that,O,O
our,O,O
observations,O,O
are,O,O
additional,O,O
proof,O,O
of,O,O
the,O,O
functional,O,O
somatotopy,O,O
of,O,O
the,O,O
systems,O,O
within,O,O
the,O,O
GPi,O,B
that,O,O
mediate,O,O
parkinsonism,O,O
and,O,O
dyskinesias,O,O
",",O,O
especially,O,O
along,O,O
the,O,O
dorsoventral,O,O
trajectory,O,O
used,O,O
in,O,O
pallidotomy,O,B
.,O,O
The,O,O
outcome,O,O
of,O,O
pallidotomy,O,O
in,O,O
which,O,O
the,O,O
lesion,O,O
involves,O,O
the,O,O
ventral,O,O
and,O,O
dorsal,O,O
GPi,O,B
could,O,O
be,O,O
the,O,O
net,O,O
effect,O,O
of,O,O
alteration,O,O
in,O,O
the,O,O
activity,O,O
of,O,O
pathways,O,O
which,O,O
mediate,O,O
different,O,O
symptoms,O,O
",",O,O
and,O,O
hence,O,O
could,O,O
be,O,O
variable,O,O
.,O,O
Screening,O,O
for,O,O
stimulant,O,O
use,O,O
in,O,O
adult,O,O
emergency,O,O
department,O,O
seizure,O,O
patients,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
objective,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
the,O,O
prevalence,O,O
of,O,O
positive,O,O
plasma,O,O
drug,O,O
screening,O,O
for,O,O
cocaine,B,B
or,O,O
amphetamine,B,B
in,O,O
adult,O,O
emergency,O,O
department,O,O
seizure,O,O
patients,O,O
.,O,O
METHODS,O,O
:,O,O
This,O,O
prospective,O,O
study,O,O
evaluated,O,O
consecutive,O,O
eligible,O,O
seizure,O,O
patients,O,O
who,O,O
had,O,O
a,O,O
plasma,O,O
sample,O,O
collected,O,O
as,O,O
part,O,O
of,O,O
their,O,O
clinical,O,O
evaluation,O,O
.,O,O
Plasma,O,O
was,O,O
tested,O,O
for,O,O
amphetamine,B,B
and,O,O
the,O,O
cocaine,B,B
metabolite,O,I
benzoylecgonine,B,I
using,O,O
enzyme,O,O
-,O,O
mediated,O,O
immunoassay,O,O
methodology,O,O
.,O,O
Plasma,O,O
samples,O,O
with,O,O
benzoylecgonine,B,B
greater,O,O
than,O,O
150,O,O
ng,O,O
/,O,O
mL,O,O
or,O,O
an,O,O
amphetamine,B,B
greater,O,O
than,O,O
500,O,O
ng,O,O
/,O,O
mL,O,O
were,O,O
defined,O,O
as,O,O
positive,O,O
.,O,O
Patient,O,O
demographics,O,O
",",O,O
history,O,O
of,O,O
underlying,O,O
drug,O,B
or,O,O
alcohol,B,B
-,O,O
related,O,O
seizure,O,O
disorder,O,O
",",O,O
estimated,O,O
time,O,O
from,O,O
seizure,O,O
to,O,O
sample,O,O
collection,O,O
",",O,O
history,O,O
or,O,O
suspicion,O,O
of,O,O
cocaine,O,B
or,O,O
amphetamine,O,B
abuse,O,O
",",O,O
results,O,O
of,O,O
clinical,O,O
urine,O,O
testing,O,O
for,O,O
drugs,O,O
of,O,O
abuse,O,O
",",O,O
and,O,O
assay,O,O
results,O,O
were,O,O
recorded,O,O
without,O,O
patient,O,O
identifiers,O,O
.,O,O
RESULTS,O,O
:,O,O
Fourteen,O,O
of,O,O
248,O,O
(,O,O
5,O,O
.,O,O
6,O,O
%,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
2,O,O
.,O,O
7,O,O
%,O,O
-,O,O
8,O,O
%,O,O
),O,O
plasma,O,O
samples,O,O
were,O,O
positive,O,O
by,O,O
immunoassay,O,O
testing,O,O
for,O,O
benzoylecgonine,B,B
and,O,O
no,O,O
samples,O,O
(,O,O
0,O,O
%,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
-,O,O
1,O,O
.,O,O
2,O,O
%,O,O
),O,O
were,O,O
positive,O,O
for,O,O
amphetamine,B,B
.,O,O
Positive,O,O
test,O,O
results,O,O
were,O,O
more,O,O
common,O,O
in,O,O
patient,O,O
visits,O,O
where,O,O
there,O,O
was,O,O
a,O,O
history,O,O
or,O,O
suspicion,O,O
of,O,O
cocaine,O,O
or,O,O
amphetamine,O,O
abuse,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
During,O,O
this,O,O
study,O,O
period,O,O
",",O,O
routine,O,O
plasma,O,O
screening,O,O
for,O,O
cocaine,B,B
and,O,O
amphetamines,B,B
in,O,O
adult,O,O
seizure,O,O
patients,O,O
had,O,O
a,O,O
low,O,O
yield,O,O
.,O,O
As,O,O
a,O,O
result,O,O
",",O,O
routine,O,O
plasma,O,O
screening,O,O
would,O,O
yield,O,O
few,O,O
cases,O,O
of,O,O
stimulant,O,O
drug,O,O
in,O,O
which,O,O
there,O,O
was,O,O
neither,O,O
a,O,O
history,O,O
nor,O,O
suspicion,O,O
of,O,O
drug,O,O
abuse,O,O
in,O,O
this,O,O
population,O,O
.,O,O
Contribution,O,O
of,O,O
sodium,B,B
valproate,I,I
to,O,O
the,O,O
syndrome,O,O
of,O,O
inappropriate,O,O
secretion,O,O
of,O,O
antidiuretic,O,B
hormone,O,I
.,O,O
We,O,O
report,O,O
the,O,O
case,O,O
of,O,O
a,O,O
62,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
who,O,O
was,O,O
administered,O,O
sodium,B,B
valproate,I,I
(,O,O
VPA,B,B
),O,O
and,O,O
who,O,O
subsequently,O,O
developed,O,O
the,O,O
syndrome,O,O
of,O,O
inappropriate,O,O
secretion,O,O
of,O,O
antidiuretic,O,B
hormone,O,I
(,O,O
SIADH,O,B
),O,O
.,O,O
He,O,O
had,O,O
been,O,O
taking,O,O
VPA,B,B
for,O,O
treatment,O,O
of,O,O
idiopathic,O,O
generalized,O,O
tonic,O,O
-,O,O
clonic,O,O
convulsions,O,O
since,O,O
he,O,O
was,O,O
56,O,O
years,O,O
old,O,O
.,O,O
After,O,O
substituting,O,O
VPA,B,B
with,O,O
zonisamide,B,B
",",O,O
the,O,O
serum,O,O
sodium,B,B
level,O,I
returned,O,O
to,O,O
normal,O,O
.,O,O
We,O,O
consider,O,O
this,O,O
episode,O,O
of,O,O
SIADH,O,B
to,O,O
be,O,O
the,O,O
result,O,O
of,O,O
a,O,O
combination,O,O
of,O,O
factors,O,O
including,O,O
a,O,O
weakness,O,O
of,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
and,O,O
the,O,O
long,O,O
-,O,O
term,O,O
administration,O,O
of,O,O
VPA,B,B
.,O,O
Association,O,O
of,O,O
nitric,B,B
oxide,I,I
production,O,O
and,O,O
apoptosis,O,O
in,O,O
a,O,O
model,O,O
of,O,O
experimental,O,O
nephropathy,O,B
.,O,O
BACKGROUND,O,O
:,O,O
In,O,O
recent,O,O
studies,O,O
increased,O,O
amounts,O,O
of,O,O
nitric,B,B
oxide,I,I
(,O,O
NO,B,B
),O,O
and,O,O
apoptosis,O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
various,O,O
pathological,O,O
conditions,O,O
in,O,O
the,O,O
kidney,O,O
.,O,O
We,O,O
have,O,O
studied,O,O
the,O,O
role,O,O
of,O,O
NO,B,B
and,O,O
its,O,O
association,O,O
with,O,O
apoptosis,O,O
in,O,O
an,O,O
experimental,O,O
model,O,O
of,O,O
nephrotic,O,O
syndrome,O,O
induced,O,O
by,O,O
a,O,O
single,O,O
injection,O,O
of,O,O
adriamycin,B,B
(,O,O
ADR,B,B
),O,O
.,O,O
METHODS,O,O
:,O,O
The,O,O
alteration,O,O
in,O,O
the,O,O
NO,B,B
pathway,O,O
was,O,O
assessed,O,O
by,O,O
measuring,O,O
nitrite,B,B
levels,O,O
in,O,O
serum,O,O
/,O,O
urine,O,O
and,O,O
by,O,O
evaluating,O,O
the,O,O
changes,O,O
in,O,O
vascular,O,O
reactivity,O,O
of,O,O
the,O,O
isolated,O,O
perfused,O,O
rat,O,O
kidney,O,O
(,O,O
IPRK,O,O
),O,O
system,O,O
.,O,O
Rats,O,O
were,O,O
stratified,O,O
into,O,O
control,O,O
groups,O,O
and,O,O
ADR,B,O
-,O,O
induced,O,O
nephropathy,O,O
groups,O,O
.,O,O
These,O,O
two,O,O
groups,O,O
were,O,O
then,O,O
divided,O,O
into,O,O
:,O,O
group,O,O
1,O,O
",",O,O
animals,O,O
receiving,O,O
saline,O,O
;,O,O
and,O,O
group,O,O
2,O,O
",",O,O
animals,O,O
receiving,O,O
aminoguanidine,B,B
(,O,O
AG,B,O
),O,O
which,O,O
is,O,O
a,O,O
specific,O,O
inhibitor,O,O
of,O,O
inducible,O,O
-,O,O
NO,B,B
synthase,O,O
.,O,O
On,O,O
day,O,O
21,O,O
",",O,O
rats,O,O
were,O,O
sacrificed,O,O
after,O,O
obtaining,O,O
material,O,O
for,O,O
biochemical,O,O
analysis,O,O
.,O,O
RESULTS,O,O
:,O,O
Histopathological,O,O
examination,O,O
of,O,O
the,O,O
kidneys,O,O
of,O,O
rats,O,O
treated,O,O
with,O,O
ADR,B,B
revealed,O,O
focal,O,O
areas,O,O
of,O,O
mesangial,O,O
proliferation,O,O
and,O,O
mild,O,O
tubulointerstitial,O,O
inflammation,O,O
.,O,O
They,O,O
also,O,O
had,O,O
significantly,O,O
higher,O,O
levels,O,O
of,O,O
proteinuria,O,B
compared,O,O
with,O,O
control,O,O
and,O,O
treatment,O,O
groups,O,O
(,O,O
P,O,B
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Urine,O,O
nitrite,B,B
levels,O,O
were,O,O
significantly,O,O
increased,O,O
in,O,O
the,O,O
ADR,B,B
-,O,O
nephropathy,O,I
group,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
IPRK,O,O
phenylephrine,B,B
and,O,O
acetylcholine,B,B
related,O,O
responses,O,O
were,O,O
significantly,O,O
impaired,O,O
in,O,O
the,O,O
ADR,B,B
-,O,O
nephropathy,O,I
group,O,O
.,O,O
Apoptosis,O,O
was,O,O
not,O,O
detected,O,O
in,O,O
controls,O,O
.,O,O
However,O,O
",",O,O
in,O,O
the,O,O
ADR,B,B
-,O,O
nephropathy,O,I
group,O,O
",",O,O
numerous,O,O
apoptotic,O,O
cells,O,O
were,O,O
identified,O,O
in,O,O
the,O,O
tubulointerstitial,O,O
areas,O,O
.,O,O
Double,O,O
staining,O,O
revealed,O,O
numerous,O,O
interstitial,O,O
apoptotic,O,B
cells,O,O
to,O,O
stain,O,O
for,O,O
ED1,O,B
",",O,O
a,O,O
marker,O,O
for,O,O
monocytes,O,B
/,O,O
macrophages,O,I
.,O,O
Treatment,O,O
with,O,O
AG,B,B
prevented,O,O
the,O,O
impairment,O,O
of,O,O
renal,O,O
vascular,O,O
bed,O,O
responses,O,O
and,O,O
reduced,O,O
both,O,O
urine,O,O
nitrite,B,B
levels,O,O
and,O,O
apoptosis,O,B
to,O,O
control,O,O
levels,O,O
.,O,O
CONCLUSION,O,O
:,O,O
We,O,O
suggest,O,O
that,O,O
interactions,O,O
between,O,O
NO,B,B
and,O,O
apoptosis,O,B
are,O,O
important,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
the,O,O
ADR,B,B
-,O,O
induced,O,O
nephrosis,O,O
.,O,O
Dual,O,O
effects,O,O
of,O,O
melatonin,B,B
on,O,O
barbiturate,B,B
-,O,I
induced,O,I
narcosis,O,I
in,O,O
rats,O,O
.,O,O
Melatonin,B,B
affects,O,O
the,O,O
circadian,O,O
sleep,O,O
/,O,O
wake,O,O
cycle,O,O
",",O,O
but,O,O
it,O,O
is,O,O
not,O,O
clear,O,O
whether,O,O
it,O,O
may,O,O
influence,O,O
drug,O,O
-,O,O
induced,O,O
narcosis,O,O
.,O,O
Sodium,B,B
thiopenthal,I,I
was,O,O
administered,O,O
intraperitoneally,O,O
into,O,O
male,O,O
rats,O,O
pre,O,O
-,O,O
treated,O,O
with,O,O
melatonin,B,B
(,O,O
0,O,O
.,O,O
",",O,O
0,O,O
.,O,O
5,O,O
",",O,O
5,O,O
and,O,O
50,O,B
mg,O,I
/,O,I
kg,O,I
),O,O
.,O,O
Melatonin,B,B
pre,O,O
-,O,O
treatment,O,O
affected,O,O
in,O,O
a,O,O
dual,O,O
manner,O,O
barbiturate,B,B
narcosis,O,I
",",O,O
however,O,O
",",O,O
no,O,O
dose,O,O
-,O,O
effect,O,O
correlation,O,O
was,O,O
found,O,O
.,O,O
In,O,O
particular,O,O
",",O,O
low,O,O
doses,O,O
reduced,O,O
the,O,O
latency,O,O
to,O,O
and,O,O
prolonged,O,O
the,O,O
duration,O,O
of,O,O
barbiturate,B,B
narcosis,O,I
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
highest,O,O
dose,O,O
of,O,O
melatonin,B,B
(,O,O
50,O,B
mg,O,I
/,O,I
kg,O,I
),O,O
caused,O,O
a,O,O
paradoxical,O,O
increase,O,O
in,O,O
the,O,O
latency,O,O
and,O,O
produced,O,O
a,O,O
sustained,O,O
reduction,O,O
of,O,O
the,O,O
duration,O,O
of,O,O
narcosis,O,O
",",O,O
and,O,O
a,O,O
reduction,O,O
in,O,O
mortality,O,O
rate,O,O
.,O,O
Melatonin,B,B
0,O,O
.,O,O
5,O,O
and,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
influenced,O,O
the,O,O
duration,O,O
but,O,O
not,O,O
the,O,O
latency,O,O
of,O,O
ketamine,B,B
-,O,O
or,O,O
diazepam,B,B
-,O,O
induced,O,O
narcosis,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
dual,O,O
action,O,O
of,O,O
melatonin,B,B
on,O,O
pharmacological,O,O
narcosis,O,O
seems,O,O
to,O,O
be,O,O
specific,O,O
for,O,O
the,O,O
barbiturate,B,O
mechanism,O,O
of,O,O
action,O,O
.,O,O
Reduced,O,O
cardiotoxicity,O,O
and,O,O
preserved,O,O
antitumor,O,O
efficacy,O,O
of,O,O
liposome,O,B
-,O,O
encapsulated,O,O
doxorubicin,B,B
and,O,O
cyclophosphamide,B,B
compared,O,O
with,O,O
conventional,O,O
doxorubicin,B,B
and,O,O
cyclophosphamide,B,B
in,O,O
a,O,O
randomized,O,O
",",O,O
multicenter,O,O
trial,O,O
of,O,O
metastatic,O,O
breast,O,O
cancer,O,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
determine,O,O
whether,O,O
Myocet,B,B
(,O,O
liposome,O,B
-,O,I
encapsulated,O,I
doxorubicin,B,I
;,O,O
The,O,O
Liposome,O,B
Company,O,I
",",O,O
Elan,O,B
Corporation,O,I
",",O,O
Princeton,O,B
",",O,O
NJ,O,B
),O,O
in,O,O
combination,O,O
with,O,O
cyclophosphamide,B,B
significantly,O,O
reduces,O,O
doxorubicin,B,B
cardiotoxicity,O,O
while,O,O
providing,O,O
comparable,O,O
antitumor,O,O
efficacy,O,O
in,O,O
first,O,O
-,O,O
line,O,O
treatment,O,O
of,O,O
metastatic,O,O
breast,O,O
cancer,O,O
(,O,O
MBC,O,B
),O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
Two,O,O
hundred,O,O
ninety,O,O
-,O,O
seven,O,O
patients,O,O
with,O,O
MBC,O,B
and,O,O
no,O,O
prior,O,O
chemotherapy,O,O
for,O,O
metastatic,O,O
disease,O,O
were,O,O
randomized,O,O
to,O,O
receive,O,O
either,O,O
60,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
of,O,O
Myocet,B,B
(,O,O
M,O,B
),O,O
or,O,O
conventional,O,O
doxorubicin,B,B
(,O,O
A,O,B
),O,O
",",O,O
in,O,O
combination,O,O
with,O,O
600,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
of,O,O
cyclophosphamide,B,B
(,O,O
C,O,B
),O,O
",",O,O
every,O,O
3,O,O
weeks,O,O
until,O,O
disease,O,O
progression,O,O
or,O,O
unacceptable,O,O
toxicity,O,O
.,O,O
Cardiotoxicity,O,O
was,O,O
defined,O,O
by,O,O
reductions,O,O
in,O,O
left,O,B
-,O,I
ventricular,O,I
ejection,O,I
fraction,O,I
",",O,O
assessed,O,O
by,O,O
serial,O,O
multigated,O,O
radionuclide,O,O
angiography,O,O
scans,O,O
",",O,O
or,O,O
congestive,O,B
heart,O,I
failure,O,I
(,O,O
CHF,O,B
),O,O
.,O,O
Antitumor,O,O
efficacy,O,O
was,O,O
assessed,O,O
by,O,O
objective,O,O
tumor,O,B
response,O,I
rates,O,I
(,O,O
World,O,B
Health,O,I
Organization,O,I
criteria,O,I
),O,O
",",O,O
time,O,O
to,O,O
progression,O,O
",",O,O
and,O,O
survival,O,O
.,O,O
RESULTS,O,O
:,O,O
Six,O,O
percent,O,O
of,O,O
MC,O,O
patients,O,O
versus,O,O
21,O,O
%,O,O
(,O,O
including,O,O
five,O,O
cases,O,O
of,O,O
CHF,O,O
),O,O
developed,O,O
cardiotoxicity,O,O
(,O,O
P,O,O
=,O,O
.,O,O
),O,O
.,O,O
Median,O,O
cumulative,O,O
doxorubicin,B,B
dose,O,O
at,O,O
onset,O,O
was,O,O
more,O,O
than,O,O
2,O,O
",",O,O
220,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
for,O,O
MC,O,O
versus,O,O
480,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
for,O,O
AC,O,O
(,O,O
P,O,O
=,O,O
.,O,O
",",O,O
hazard,O,O
ratio,O,O
",",O,O
5,O,O
.,O,O
),O,O
.,O,O
MC,O,O
patients,O,O
also,O,O
experienced,O,O
less,O,O
grade,O,O
4,O,O
neutropenia,O,O
.,O,O
Antitumor,O,O
efficacy,O,O
of,O,O
MC,O,B
versus,O,O
AC,O,B
was,O,O
comparable,O,O
:,O,O
objective,O,O
response,O,O
rates,O,O
",",O,O
43,O,O
%,O,O
versus,O,O
43,O,O
%,O,O
;,O,O
median,O,O
time,O,O
to,O,O
progression,O,O
",",O,O
5,O,O
.,O,O
1,O,O
%,O,O
versus,O,O
5,O,O
.,O,O
5,O,O
months,O,O
;,O,O
median,O,O
time,O,O
to,O,O
treatment,O,O
failure,O,O
",",O,O
4,O,O
.,O,O
6,O,O
versus,O,O
4,O,O
.,O,O
4,O,O
months,O,O
;,O,O
and,O,O
median,O,O
survival,O,O
",",O,O
19,O,O
versus,O,O
16,O,O
months,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Myocet,B,B
improves,O,O
the,O,O
therapeutic,O,O
index,O,O
of,O,O
doxorubicin,B,B
by,O,O
significantly,O,O
reducing,O,O
cardiotoxicity,O,O
and,O,O
grade,O,O
4,O,O
neutropenia,O,B
and,O,O
provides,O,O
comparable,O,O
antitumor,O,O
efficacy,O,O
",",O,O
when,O,O
used,O,O
in,O,O
combination,O,O
with,O,O
cyclophosphamide,B,B
as,O,O
first,O,O
-,O,O
line,O,O
therapy,O,O
for,O,O
MBC,O,O
.,O,O
The,O,O
role,O,O
of,O,O
nitrergic,O,B
system,O,O
in,O,O
lidocaine,B,B
-,O,I
induced,O,I
convulsion,O,I
in,O,O
the,O,O
mouse,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
N,B,B
-,I,I
nitro,I,I
-,I,I
L,I,I
-,I,I
arginine,I,I
-,I,I
methyl,I,I
ester,I,I
(,O,O
L,B,B
-,I,I
NAME,I,I
),O,O
a,O,O
nitric,B,B
oxide,I,I
(,O,O
NO,B,B
),O,O
synthase,O,O
inhibitor,O,O
and,O,O
L,B,B
-,I,I
arginine,I,I
",",O,O
a,O,O
NO,B,B
precursor,O,O
",",O,O
were,O,O
investigated,O,O
on,O,O
lidocaine,B,B
-,O,I
induced,O,I
convulsions,O,I
.,O,O
In,O,O
the,O,O
first,O,O
experiment,O,O
",",O,O
four,O,O
groups,O,O
of,O,O
mice,O,O
received,O,O
physiological,O,O
saline,O,B
(,O,O
0,O,O
.,O,O
9,O,O
%,O,O
),O,O
",",O,O
L,B,B
-,I,I
arginine,I,I
(,O,O
300,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
",",O,O
L,B,B
-,I,I
NAME,I,I
(,O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
and,O,O
diazepam,B,B
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
respectively,O,O
.,O,O
Thirty,O,O
minutes,O,O
after,O,O
these,O,O
injections,O,O
",",O,O
all,O,O
mice,O,O
received,O,O
lidocaine,B,B
(,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
second,O,O
experiment,O,O
",",O,O
four,O,O
groups,O,O
of,O,O
mice,O,O
received,O,O
similar,O,O
treatment,O,O
in,O,O
the,O,O
first,O,O
experiment,O,O
",",O,O
and,O,O
30,O,O
min,O,O
after,O,O
these,O,O
injections,O,O
",",O,O
all,O,O
mice,O,O
received,O,O
a,O,O
higher,O,O
dose,O,O
of,O,O
lidocaine,B,B
(,O,O
80,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
.,O,O
L,B,B
-,I,I
NAME,I,I
(,O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
and,O,O
diazepam,B,B
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
significantly,O,O
decreased,O,O
the,O,O
incidence,O,O
of,O,O
lidocaine,B,B
(,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
-,O,O
induced,O,O
convulsions,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
L,B,B
-,I,I
arginine,I,I
treatment,O,O
increased,O,O
the,O,O
incidence,O,O
of,O,O
lidocaine,B,B
(,O,O
80,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
-,O,O
induced,O,O
convulsions,O,O
significantly,O,O
.,O,O
These,O,O
results,O,O
may,O,O
suggest,O,O
that,O,O
NO,B,B
is,O,O
a,O,O
proconvulsant,O,O
mediator,O,O
in,O,O
lidocaine,B,B
-,O,O
induced,O,O
convulsions,O,O
.,O,O
Erythropoietin,O,B
restores,O,O
the,O,O
anemia,O,B
-,O,O
induced,O,O
reduction,O,O
in,O,O
cyclophosphamide,B,B
cytotoxicity,O,O
in,O,O
rat,O,O
tumors,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
examine,O,O
the,O,O
impact,O,O
of,O,O
anemia,O,B
prevention,O,O
by,O,O
recombinant,O,O
human,O,O
erythropoietin,O,B
(,O,O
rHuEPO,O,O
),O,O
treatment,O,O
on,O,O
the,O,O
cytotoxicity,O,O
of,O,O
cyclophosphamide,B,B
in,O,O
solid,O,O
experimental,O,O
tumors,O,O
.,O,O
Anemia,O,B
was,O,O
induced,O,O
using,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
carboplatin,B,B
(,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
resulting,O,O
in,O,O
a,O,O
long,O,O
-,O,O
lasting,O,O
reduction,O,O
(,O,O
30,O,O
%,O,O
),O,O
of,O,O
the,O,O
hemoglobin,O,B
concentration,O,O
.,O,O
In,O,O
a,O,O
second,O,O
group,O,O
",",O,O
the,O,O
development,O,O
of,O,O
anemia,O,B
was,O,O
prevented,O,O
by,O,O
rHuEPO,O,B
(,O,O
1000,O,O
IU,O,O
/,O,O
kg,O,O
),O,O
administered,O,O
s,O,O
.,O,O
three,O,O
times,O,O
/,O,O
week,O,O
starting,O,O
7,O,O
days,O,O
before,O,O
carboplatin,B,O
application,O,O
.,O,O
Four,O,O
days,O,O
after,O,O
carboplatin,B,O
treatment,O,O
",",O,O
tumors,O,O
(,O,O
DS,O,B
-,O,I
sarcoma,O,I
of,O,I
the,O,I
rat,O,I
),O,O
were,O,O
implanted,O,O
s,O,O
.,O,O
the,O,O
hind,O,O
food,O,O
dorsum,O,O
.,O,O
Neither,O,O
carboplatin,B,B
nor,O,O
rHuEPO,O,B
treatment,O,O
influenced,O,O
tumor,O,O
growth,O,O
rate,O,O
per,O,O
se,O,O
.,O,O
When,O,O
tumors,O,O
were,O,O
treated,O,O
with,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
cyclophosphamide,B,B
(,O,O
60,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
5,O,O
days,O,O
after,O,O
implantation,O,O
",",O,O
a,O,O
growth,O,O
delay,O,O
with,O,O
a,O,O
subsequent,O,O
regrowth,O,O
of,O,O
the,O,O
tumors,O,O
was,O,O
observed,O,O
.,O,O
In,O,O
the,O,O
anemia,O,O
group,O,O
",",O,O
the,O,O
growth,O,O
delay,O,O
was,O,O
significantly,O,O
shorter,O,O
compared,O,O
with,O,O
nonanemic,O,O
controls,O,O
(,O,O
13,O,O
.,O,O
3,O,O
days,O,O
versus,O,O
8,O,O
.,O,O
6,O,O
days,O,O
),O,O
.,O,O
In,O,O
the,O,O
group,O,O
where,O,O
anemia,O,B
was,O,O
prevented,O,O
by,O,O
rHuEPO,O,B
treatment,O,O
",",O,O
growth,O,O
delay,O,O
was,O,O
comparable,O,O
with,O,O
that,O,O
of,O,O
nonanemic,O,O
controls,O,O
(,O,O
13,O,O
.,O,O
3,O,O
days,O,O
),O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
chemotherapy,O,O
-,O,O
induced,O,O
anemia,O,B
reduces,O,O
cytotoxicity,O,O
of,O,O
cyclophosphamide,B,B
in,O,O
tumors,O,O
",",O,O
whereas,O,O
correction,O,O
of,O,O
anemia,O,B
by,O,O
rHuEPO,O,B
treatment,O,O
(,O,O
epoetin,O,B
alpha,O,I
),O,O
increases,O,O
the,O,O
sensitivity,O,O
",",O,O
probably,O,O
as,O,O
a,O,O
result,O,O
of,O,O
an,O,O
improved,O,O
oxygen,B,B
supply,O,O
to,O,O
tumor,O,O
tissue,O,O
.,O,O
Fatal,O,O
haemorrhagic,O,O
myocarditis,O,O
secondary,O,O
to,O,O
cyclophosphamide,B,B
therapy,O,O
.,O,O
Haemorrhagic,O,O
myocarditis,O,O
is,O,O
a,O,O
rare,O,O
but,O,O
important,O,O
complication,O,O
of,O,O
cyclophosphamide,B,B
therapy,O,O
.,O,O
Echocardiographic,O,O
identification,O,O
of,O,O
the,O,O
disorder,O,O
can,O,O
be,O,O
made,O,O
.,O,O
We,O,O
believe,O,O
that,O,O
the,O,O
ultrasound,O,O
features,O,O
of,O,O
this,O,O
disorder,O,O
have,O,O
not,O,O
been,O,O
previously,O,O
reported,O,O
.,O,O
Effects,O,O
of,O,O
verapamil,B,B
on,O,O
atrial,O,O
fibrillation,O,O
and,O,O
its,O,O
electrophysiological,O,O
determinants,O,O
in,O,O
dogs,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Atrial,O,O
tachycardia,O,O
-,O,O
induced,O,O
remodeling,O,O
promotes,O,O
the,O,O
occurrence,O,O
and,O,O
maintenance,O,O
of,O,O
atrial,O,O
fibrillation,O,O
(,O,O
AF,O,B
),O,O
and,O,O
decreases,O,O
L,O,O
-,O,O
type,O,O
Ca,B,B
(,O,O
2,O,O
+,O,O
),O,O
current,O,O
.,O,O
There,O,O
is,O,O
also,O,O
a,O,O
clinical,O,O
suggestion,O,O
that,O,O
acute,O,O
L,O,O
-,O,O
type,O,O
Ca,B,B
(,O,O
2,O,O
),O,O
channel,O,O
blockade,O,O
can,O,O
promote,O,O
AF,O,B
",",O,O
consistent,O,O
with,O,O
an,O,O
AF,O,B
promoting,O,O
effect,O,O
of,O,O
Ca,B,B
(,O,O
2,O,O
+,O,O
),O,O
channel,O,O
inhibition,O,O
.,O,O
METHODS,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
potential,O,O
mechanisms,O,O
of,O,O
AF,O,O
promotion,O,O
by,O,O
Ca,B,B
(,O,O
2,O,I
+,O,I
),O,O
channel,O,O
blockers,O,O
",",O,O
we,O,O
administered,O,O
verapamil,B,B
to,O,O
morphine,B,O
-,O,O
chloralose,B,O
anesthetized,O,O
dogs,O,O
.,O,O
Diltiazem,B,B
was,O,O
used,O,O
as,O,O
a,O,O
comparison,O,O
drug,O,O
and,O,O
autonomic,O,O
blockade,O,O
with,O,O
atropine,B,B
and,O,O
nadolol,B,B
was,O,O
applied,O,O
in,O,O
some,O,O
experiments,O,O
.,O,O
Epicardial,O,O
mapping,O,O
with,O,O
240,O,O
epicardial,O,O
electrodes,O,O
was,O,O
used,O,O
to,O,O
evaluate,O,O
activation,O,O
during,O,O
AF,O,O
.,O,O
RESULTS,O,O
:,O,O
Verapamil,B,B
caused,O,O
AF,O,B
promotion,O,O
in,O,O
six,O,O
dogs,O,O
",",O,O
increasing,O,O
mean,O,O
duration,O,O
of,O,O
AF,O,B
induced,O,O
by,O,O
burst,O,O
pacing,O,O
",",O,O
from,O,O
8,O,O
+,O,O
/,O,O
-,O,O
4,O,O
s,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
S,O,O
.,O,O
E,O,O
.,O,O
),O,O
to,O,O
95,O,O
+,O,O
/,O,O
-,O,O
39,O,O
s,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
vs,O,O
.,O,O
control,O,O
),O,O
at,O,O
a,O,O
loading,O,O
dose,O,O
of,O,O
0,O,O
.,O,O
1,O,O
mg,O,B
/,O,O
kg,O,O
and,O,O
228,O,O
+,O,O
/,O,O
-,O,O
101,O,O
s,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
vs,O,O
.,O,O
control,O,O
),O,O
at,O,O
a,O,O
dose,O,O
of,O,O
0,O,O
.,O,O
2,O,O
mg,O,B
/,O,O
kg,O,O
.,O,O
Underlying,O,O
electrophysiological,O,O
mechanisms,O,O
were,O,O
studied,O,O
in,O,O
detail,O,O
in,O,O
five,O,O
additional,O,O
dogs,O,O
under,O,O
control,O,O
conditions,O,O
and,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
the,O,O
higher,O,O
dose,O,O
of,O,O
verapamil,B,B
.,O,O
In,O,O
these,O,O
experiments,O,O
",",O,O
verapamil,B,B
shortened,O,O
mean,O,O
effective,O,O
refractory,O,O
period,O,O
(,O,O
ERP,O,B
),O,O
from,O,O
122,O,O
+,O,O
/,O,O
-,O,O
5,O,O
to,O,O
114,O,O
+,O,O
/,O,O
-,O,O
4,O,O
ms,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
at,O,O
a,O,O
cycle,O,O
length,O,O
of,O,O
300,O,O
ms,O,O
",",O,O
decreased,O,O
ERP,O,B
heterogeneity,O,O
(,O,O
from,O,O
15,O,O
+,O,O
/,O,O
-,O,O
1,O,O
to,O,O
10,O,O
+,O,O
/,O,O
-,O,O
1,O,O
%,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
",",O,O
heterogeneously,O,O
accelerated,O,O
atrial,O,O
conduction,O,O
and,O,O
decreased,O,O
the,O,O
cycle,O,O
length,O,O
of,O,O
AF,O,B
(,O,O
94,O,O
+,O,O
/,O,O
-,O,O
4,O,O
to,O,O
84,O,O
+,O,O
/,O,O
-,O,O
3,O,O
ms,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Diltiazem,B,B
did,O,O
not,O,O
affect,O,O
ERP,O,B
",",O,O
AF,O,B
cycle,O,O
length,O,O
or,O,O
AF,O,B
duration,O,O
",",O,O
but,O,O
produced,O,O
conduction,O,O
acceleration,O,O
similar,O,O
to,O,O
that,O,O
caused,O,O
by,O,O
verapamil,B,B
(,O,O
n,O,O
=,O,O
5,O,O
),O,O
.,O,O
In,O,O
the,O,O
presence,O,O
of,O,O
autonomic,O,O
blockade,O,O
",",O,O
verapamil,B,B
failed,O,O
to,O,O
promote,O,O
AF,O,B
and,O,O
increased,O,O
",",O,O
rather,O,O
than,O,O
decreasing,O,O
",",O,O
refractoriness,O,O
.,O,O
Neither,O,O
verapamil,B,B
nor,O,O
diltiazem,B,B
affected,O,O
atrial,O,O
conduction,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
autonomic,O,O
blockade,O,O
.,O,O
Epicardial,O,O
mapping,O,O
suggested,O,O
that,O,O
verapamil,B,B
promoted,O,O
AF,O,O
by,O,O
increasing,O,O
the,O,O
number,O,O
of,O,O
simultaneous,O,O
wavefronts,O,O
reflected,O,O
by,O,O
separate,O,O
zones,O,O
of,O,O
reactivation,O,O
in,O,O
each,O,O
cycle,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Verapamil,B,B
promotes,O,O
AF,O,O
in,O,O
normal,O,O
dogs,O,O
by,O,O
promoting,O,O
multiple,O,O
circuit,O,O
reentry,O,O
",",O,O
an,O,O
effect,O,O
dependent,O,O
on,O,O
intact,O,O
autonomic,O,O
tone,O,O
and,O,O
not,O,O
shared,O,O
by,O,O
diltiazem,B,B
.,O,O
Calcitonin,O,B
gene,O,I
-,O,I
related,O,I
peptide,O,I
levels,O,O
during,O,O
nitric,B,B
oxide,I,I
-,O,I
induced,O,I
headache,O,I
in,O,O
patients,O,O
with,O,O
chronic,O,O
tension,O,O
-,O,O
type,O,O
headache,O,O
.,O,O
It,O,O
has,O,O
been,O,O
proposed,O,O
that,O,O
nitric,B,B
oxide,I,I
(,O,O
NO,B,B
),O,O
induced,O,O
headache,O,O
in,O,O
primary,O,O
headaches,O,O
may,O,O
be,O,O
associated,O,O
with,O,O
release,O,O
of,O,O
calcitonin,O,B
gene,O,I
-,O,I
related,O,I
peptide,O,I
(,O,O
CGRP,O,B
),O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
aimed,O,O
to,O,O
investigate,O,O
plasma,O,O
levels,O,O
of,O,O
CGRP,O,B
during,O,O
headache,O,O
induced,O,O
by,O,O
the,O,O
NO,B,B
donor,O,O
glyceryl,B,O
trinitrate,I,O
(,O,O
GTN,B,B
),O,O
in,O,O
16,O,O
patients,O,O
with,O,O
chronic,O,O
tension,O,O
-,O,O
type,O,O
headache,O,O
and,O,O
16,O,O
healthy,O,O
controls,O,O
.,O,O
The,O,O
subjects,O,O
were,O,O
randomly,O,O
allocated,O,O
to,O,O
receive,O,O
0,O,O
.,O,O
5,O,B
microg,O,I
/,O,I
kg,O,I
/,O,I
min,O,I
GTN,B,B
or,O,O
placebo,O,O
over,O,O
20,O,O
min,O,O
on,O,O
two,O,O
headache,O,O
-,O,O
free,O,O
days,O,O
.,O,O
Blood,O,O
samples,O,O
were,O,O
collected,O,O
at,O,O
baseline,O,O
",",O,O
10,O,O
",",O,O
20,O,O
and,O,O
60,O,O
min,O,O
after,O,O
start,O,O
of,O,O
infusion,O,O
.,O,O
Both,O,O
patients,O,O
and,O,O
controls,O,O
developed,O,O
significantly,O,O
stronger,O,O
immediate,O,O
headache,O,O
on,O,O
the,O,O
GTN,B,B
day,O,O
than,O,O
on,O,O
the,O,O
placebo,O,O
day,O,O
and,O,O
the,O,O
headache,O,O
was,O,O
significantly,O,O
more,O,O
pronounced,O,O
in,O,O
patients,O,O
than,O,O
in,O,O
controls,O,O
.,O,O
There,O,O
was,O,O
no,O,O
difference,O,O
between,O,O
the,O,O
area,O,O
under,O,O
the,O,O
CGRP,O,B
curve,O,O
(,O,O
AUCCGRP,O,B
),O,O
on,O,O
GTN,B,B
vs,O,O
.,O,O
placebo,O,O
day,O,O
in,O,O
either,O,O
patients,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
65,O,O
),O,O
or,O,O
controls,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
48,O,O
),O,O
.,O,O
The,O,O
AUCCGRP,O,B
recorded,O,O
on,O,O
the,O,O
GTN,B,B
day,O,O
did,O,O
not,O,O
differ,O,O
between,O,O
patients,O,O
and,O,O
controls,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
36,O,O
),O,O
.,O,O
Both,O,O
in,O,O
patients,O,O
and,O,O
controls,O,O
",",O,O
CGRP,O,B
levels,O,O
changed,O,O
significantly,O,O
over,O,O
time,O,O
",",O,O
on,O,O
both,O,O
the,O,O
GTN,B,B
and,O,O
placebo,O,O
days,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
present,O,O
study,O,O
indicates,O,O
that,O,O
NO,B,B
-,O,O
induced,O,O
immediate,O,O
headache,O,O
is,O,O
not,O,O
associated,O,O
with,O,O
release,O,O
of,O,O
CGRP,O,B
.,O,O
Fluconazole,B,B
-,O,O
induced,O,O
torsade,O,O
de,O,O
pointes,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
present,O,O
a,O,O
case,O,O
of,O,O
fluconazole,B,B
-,O,O
associated,O,O
torsade,O,O
de,O,O
pointes,O,O
(,O,O
TDP,O,O
),O,O
and,O,O
discuss,O,O
fluconazole,B,B
',O,O
s,O,O
role,O,O
in,O,O
causing,O,O
TDP,O,O
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
68,O,O
-,O,O
year,O,O
-,O,O
old,O,O
white,O,O
woman,O,O
with,O,O
Candida,O,B
glabrata,O,I
isolated,O,O
from,O,O
a,O,O
presacral,O,O
abscess,O,O
developed,O,O
TDP,O,O
eight,O,O
days,O,O
after,O,O
commencing,O,O
oral,O,O
fluconazole,B,B
The,O,O
patient,O,O
had,O,O
no,O,O
other,O,O
risk,O,O
factors,O,O
for,O,O
TDP,O,O
",",O,O
including,O,O
coronary,O,O
artery,O,O
disease,O,O
",",O,O
cardiomyopathy,O,O
",",O,O
congestive,O,O
heart,O,O
failure,O,O
",",O,O
and,O,O
electrolyte,O,O
abnormalities,O,O
There,O,O
was,O,O
a,O,O
temporal,O,O
association,O,O
between,O,O
the,O,O
initiation,O,O
of,O,O
fluconazole,B,B
and,O,O
TDP,O,O
.,O,O
The,O,O
TDP,O,B
resolved,O,O
when,O,O
fluconazole,B,B
was,O,O
discontinued,O,O
;,O,O
however,O,O
",",O,O
the,O,O
patient,O,O
continued,O,O
to,O,O
have,O,O
premature,O,O
ventricular,O,O
contractions,O,O
and,O,O
nonsustained,O,O
ventricular,O,O
tachycardia,O,O
(,O,O
NSVT,O,B
),O,O
until,O,O
six,O,O
days,O,O
after,O,O
drug,O,O
cessation,O,O
DISCUSSION,O,O
:,O,O
Use,O,O
of,O,O
the,O,O
Naranjo,O,O
probability,O,O
scale,O,O
indicates,O,O
a,O,O
probable,O,O
relationship,O,O
between,O,O
the,O,O
use,O,O
of,O,O
fluconazole,B,B
and,O,O
the,O,O
development,O,O
of,O,O
TDP,O,B
.,O,O
The,O,O
possible,O,O
mechanism,O,O
is,O,O
depression,O,O
of,O,O
rapidly,O,O
activating,O,O
delayed,O,O
rectifier,O,O
potassium,B,B
currents,O,O
.,O,O
In,O,O
our,O,O
patient,O,O
",",O,O
there,O,O
was,O,O
no,O,O
other,O,O
etiology,O,O
identified,O,O
that,O,O
could,O,O
explain,O,O
QT,O,O
prolongation,O,O
or,O,O
TDP,O,O
The,O,O
complete,O,O
disappearance,O,O
of,O,O
NSVT,O,O
and,O,O
premature,O,O
ventricular,O,O
contractions,O,O
followed,O,O
by,O,O
normalization,O,O
of,O,O
QT,O,O
interval,O,O
after,O,O
the,O,O
drug,O,O
was,O,O
stopped,O,O
strongly,O,O
suggests,O,O
fluconazole,B,B
as,O,O
the,O,O
etiology,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Clinicians,O,O
should,O,O
be,O,O
aware,O,O
that,O,O
fluconazole,B,B
",",O,O
even,O,O
at,O,O
low,O,O
doses,O,O
",",O,O
may,O,O
cause,O,O
prolongation,O,O
of,O,O
the,O,O
QT,O,B
interval,O,O
",",O,O
leading,O,O
to,O,O
TDP,O,B
.,O,O
Serial,O,O
electrocardiographic,O,O
monitoring,O,O
may,O,O
be,O,O
considered,O,O
when,O,O
fluconazole,B,B
is,O,O
administered,O,O
in,O,O
patients,O,O
who,O,O
are,O,O
at,O,O
risk,O,O
for,O,O
ventricular,O,O
arrhythmias,O,O
.,O,O
Cutaneous,O,O
leucocytoclastic,O,O
vasculitis,O,O
associated,O,O
with,O,O
oxacillin,B,B
.,O,O
A,O,O
67,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
who,O,O
was,O,O
treated,O,O
with,O,O
oxacillin,B,B
for,O,O
one,O,O
week,O,O
because,O,O
of,O,O
Staphylococcus,O,B
aureus,O,I
bacteremia,O,O
",",O,O
developed,O,O
renal,O,B
failure,O,O
and,O,O
diffuse,O,O
",",O,O
symmetric,O,O
",",O,O
palpable,O,O
purpuric,O,O
lesions,O,O
on,O,O
his,O,O
feet,O,O
.,O,O
Necrotic,O,B
blisters,O,O
were,O,O
noted,O,O
on,O,O
his,O,O
fingers,O,O
.,O,O
Skin,O,B
biopsies,O,O
showed,O,O
findings,O,O
diagnostic,O,O
of,O,O
leucocytoclastic,O,B
vasculitis,O,O
.,O,O
Oxacillin,B,B
was,O,O
discontinued,O,O
and,O,O
patient,O,O
was,O,O
treated,O,O
with,O,O
corticosteroids,B,B
.,O,O
The,O,O
rash,O,O
disappeared,O,O
after,O,O
three,O,O
weeks,O,O
and,O,O
renal,O,O
function,O,O
returned,O,O
to,O,O
normal,O,O
.,O,O
Leucocytoclastic,O,B
vasculitis,O,I
presents,O,O
as,O,O
palpable,O,O
purpura,O,O
of,O,O
the,O,O
lower,O,O
extremities,O,O
often,O,O
accompanied,O,O
by,O,O
abdominal,O,O
pain,O,O
",",O,O
arthralgia,O,O
",",O,O
and,O,O
renal,O,O
involvement,O,O
.,O,O
Etiologic,O,O
factors,O,O
or,O,O
associated,O,O
disorders,O,O
include,O,O
infections,O,O
",",O,O
medications,O,O
",",O,O
collagen,O,B
vascular,O,I
disease,O,I
and,O,O
neoplasia,O,O
.,O,O
However,O,O
",",O,O
in,O,O
half,O,O
of,O,O
the,O,O
cases,O,O
no,O,O
etiologic,O,O
factor,O,O
is,O,O
identified,O,O
.,O,O
Usually,O,O
it,O,O
is,O,O
a,O,O
self,O,O
-,O,O
limited,O,O
disorder,O,O
",",O,O
but,O,O
corticosteroid,B,O
therapy,O,O
may,O,O
be,O,O
needed,O,O
in,O,O
life,O,O
-,O,O
threatening,O,O
cases,O,O
since,O,O
early,O,O
treatment,O,O
with,O,O
corticosteroids,B,O
in,O,O
severe,O,O
cases,O,O
can,O,O
prevent,O,O
complications,O,O
.,O,O
Oxacillin,B,B
should,O,O
be,O,O
included,O,O
among,O,O
the,O,O
drugs,O,O
that,O,O
can,O,O
cause,O,O
leucocytoclastic,O,B
vasculitis,O,O
.,O,O
The,O,O
renal,O,O
pathology,O,O
in,O,O
a,O,O
case,O,O
of,O,O
lithium,B,B
-,O,I
induced,O,I
diabetes,O,I
insipidus,O,I
.,O,O
A,O,O
case,O,O
of,O,O
lithium,B,B
-,O,I
induced,O,I
diabetes,O,I
insipidus,O,I
is,O,O
reported,O,O
.,O,O
At,O,O
necropsy,O,O
microscopy,O,O
shoed,O,O
unique,O,O
and,O,O
extensive,O,O
damage,O,O
to,O,O
cells,O,O
lining,O,O
the,O,O
distal,O,O
nephron,O,O
.,O,O
It,O,O
is,O,O
suggested,O,O
that,O,O
these,O,O
changes,O,O
represent,O,O
a,O,O
specific,O,O
toxic,O,O
effect,O,O
of,O,O
lithium,B,B
",",O,O
reported,O,O
here,O,O
for,O,O
the,O,O
first,O,O
time,O,O
in,O,O
man,O,O
.,O,O
Cholestatic,O,B
jaundice,O,I
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
metformin,B,B
.,O,O
We,O,O
report,O,O
a,O,O
patient,O,O
who,O,O
developed,O,O
cholestatic,O,B
jaundice,O,I
shortly,O,O
after,O,O
initiation,O,O
of,O,O
treatment,O,O
with,O,O
metformin,B,B
hydrochloride,I,I
.,O,O
Ultrasound,O,O
of,O,O
the,O,O
liver,O,B
and,O,O
abdominal,O,O
CT,O,O
were,O,O
normal,O,O
.,O,O
An,O,O
ERCP,O,O
showed,O,O
normal,O,O
biliary,O,O
anatomy,O,O
.,O,O
A,O,O
percutaneous,O,O
liver,O,B
biopsy,O,O
was,O,O
obtained,O,O
showing,O,O
marked,O,O
cholestasis,O,B
",",O,O
with,O,O
portal,O,O
edema,O,O
",",O,O
ductular,O,O
proliferation,O,O
",",O,O
and,O,O
acute,O,O
inflammation,O,O
.,O,O
Metformin,B,B
hydrochloride,I,I
was,O,O
discontinued,O,O
",",O,O
and,O,O
the,O,O
patient,O,O
',O,O
s,O,O
jaundice,O,B
resolved,O,O
slowly,O,O
over,O,O
a,O,O
period,O,O
of,O,O
several,O,O
months,O,O
.,O,O
Given,O,O
the,O,O
onset,O,O
of,O,O
his,O,O
jaundice,O,O
2,O,O
wk,O,O
after,O,O
the,O,O
initiation,O,O
of,O,O
metformin,B,B
",",O,O
we,O,O
believe,O,O
that,O,O
this,O,O
case,O,O
represents,O,O
an,O,O
example,O,O
of,O,O
metformin,B,B
-,O,O
associated,O,O
hepatotoxicity,O,O
",",O,O
the,O,O
first,O,O
such,O,O
case,O,O
reported,O,O
.,O,O
Systemic,O,O
toxicity,O,O
and,O,O
resuscitation,O,O
in,O,O
bupivacaine,B,B
-,O,O
",",O,O
levobupivacaine,B,B
-,O,O
",",O,O
or,O,O
ropivacaine,B,B
-,O,O
infused,O,O
rats,O,O
.,O,O
We,O,O
compared,O,O
the,O,O
systemic,O,O
toxicity,O,O
of,O,O
bupivacaine,B,B
",",O,O
levobupivacaine,B,B
",",O,O
and,O,O
ropivacaine,B,B
in,O,O
anesthetized,O,O
rats,O,O
.,O,O
We,O,O
also,O,O
compared,O,O
the,O,O
ability,O,O
to,O,O
resuscitate,O,O
rats,O,O
after,O,O
lethal,O,O
doses,O,O
of,O,O
these,O,O
local,O,O
anesthetics,O,O
.,O,O
Bupivacaine,B,B
",",O,O
levobupivacaine,B,B
",",O,O
or,O,O
ropivacaine,B,B
was,O,O
infused,O,O
at,O,O
a,O,O
rate,O,O
of,O,O
2,O,O
mg,O,O
.,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
.,O,O
min,O,O
(,O,O
-,O,O
1,O,O
),O,O
while,O,O
electrocardiogram,O,O
",",O,O
electroencephalogram,O,O
",",O,O
and,O,O
arterial,O,O
pressure,O,O
were,O,O
continuously,O,O
monitored,O,O
.,O,O
When,O,O
asystole,O,O
was,O,O
recorded,O,O
",",O,O
drug,O,O
infusion,O,O
was,O,O
stopped,O,O
and,O,O
a,O,O
resuscitation,O,O
sequence,O,O
was,O,O
begun,O,O
.,O,O
Epinephrine,B,B
0,O,I
.,O,O
mg,O,I
/,O,I
kg,O,I
was,O,O
administered,O,O
at,O,O
1,O,O
-,O,O
min,O,O
intervals,O,O
while,O,O
external,O,O
cardiac,O,O
compressions,O,O
were,O,O
applied,O,O
.,O,O
Resuscitation,O,O
was,O,O
considered,O,O
successful,O,O
when,O,O
a,O,O
systolic,O,O
arterial,O,O
pressure,O,O
>,O,O
or,O,O
=,O,O
100,O,O
mm,O,O
Hg,O,O
was,O,O
achieved,O,O
within,O,O
5,O,O
min,O,O
.,O,O
The,O,O
cumulative,O,O
doses,O,O
of,O,O
levobupivacaine,B,B
and,O,O
ropivacaine,B,B
that,O,O
produced,O,O
seizures,O,O
were,O,O
similar,O,O
and,O,O
were,O,O
larger,O,O
than,O,O
those,O,O
of,O,O
bupivacaine,B,B
.,O,O
The,O,O
cumulative,O,O
doses,O,O
of,O,O
levobupivacaine,B,B
that,O,O
produced,O,O
dysrhythmias,O,O
and,O,O
asystole,O,O
were,O,O
smaller,O,O
than,O,O
the,O,O
corresponding,O,O
doses,O,O
of,O,O
ropivacaine,B,B
",",O,O
but,O,O
they,O,O
were,O,O
larger,O,O
than,O,O
those,O,O
of,O,O
bupivacaine,B,B
.,O,O
The,O,O
number,O,O
of,O,O
successful,O,O
resuscitations,O,O
did,O,O
not,O,O
differ,O,O
among,O,O
groups,O,O
.,O,O
However,O,O
",",O,O
a,O,O
smaller,O,O
dose,O,O
of,O,O
epinephrine,B,B
was,O,O
required,O,O
in,O,O
the,O,O
Ropivacaine,B,O
group,O,O
than,O,O
in,O,O
the,O,O
other,O,O
groups,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
systemic,O,O
toxicity,O,O
of,O,O
levobupivacaine,B,O
is,O,O
intermediate,O,O
between,O,O
that,O,O
of,O,O
ropivacaine,B,O
and,O,O
bupivacaine,B,O
when,O,O
administered,O,O
at,O,O
the,O,O
same,O,O
rate,O,O
and,O,O
that,O,O
ropivacaine,B,O
-,O,O
induced,O,O
cardiac,O,O
arrest,O,O
appears,O,O
to,O,O
be,O,O
more,O,O
susceptible,O,O
to,O,O
treatment,O,O
than,O,O
that,O,O
induced,O,O
by,O,O
bupivacaine,B,O
or,O,O
levobupivacaine,B,O
.,O,O
Amphotericin,B,B
B,I,I
-,O,I
induced,O,O
seizures,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
AIDS,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
report,O,O
a,O,O
case,O,O
of,O,O
multiple,O,O
episodes,O,O
of,O,O
seizure,O,O
activity,O,O
in,O,O
an,O,O
AIDS,O,O
patent,O,O
following,O,O
amphotericin,B,B
B,I,I
infusion,O,O
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
46,O,O
-,O,O
year,O,O
-,O,O
old,O,O
African,O,O
-,O,O
American,O,O
man,O,O
experienced,O,O
recurrent,O,O
grand,O,O
mal,O,O
seizures,O,O
during,O,O
intravenous,O,O
infusion,O,O
of,O,O
amphotericin,B,B
B,I,I
",",O,O
then,O,O
petit,O,O
mal,O,O
seizures,O,O
as,O,O
the,O,O
infusion,O,O
was,O,O
stopped,O,O
and,O,O
the,O,O
drug,O,O
concentrations,O,O
decreased,O,O
with,O,O
time,O,O
.,O,O
The,O,O
patients,O,O
concurrent,O,O
medications,O,O
included,O,O
didanosine,B,B
",",O,O
hydroxyzine,B,B
",",O,O
promethazine,B,B
",",O,O
hydrocortisone,B,B
",",O,O
and,O,O
prochlorperazine,B,B
.,O,O
Despite,O,O
administration,O,O
of,O,O
phenytoin,B,B
and,O,O
lorazepam,B,B
",",O,O
the,O,O
seizures,O,O
persisted,O,O
and,O,O
occurred,O,O
only,O,O
during,O,O
amphotercin,B,B
B,I,I
administration,O,O
.,O,O
DISCUSSION,O,O
:,O,O
AIDS,O,B
and,O,O
cryptococcal,O,B
meningitis,O,I
",",O,O
both,O,O
of,O,O
which,O,O
the,O,O
patient,O,O
had,O,O
",",O,O
can,O,O
potentially,O,O
cause,O,O
seizures,O,O
.,O,O
The,O,O
patient,O,O
had,O,O
a,O,O
history,O,O
of,O,O
alcohol,O,B
abuse,O,I
;,O,O
alcohol,B,B
intake,O,O
as,O,O
well,O,O
as,O,O
withdrawal,O,O
can,O,O
also,O,O
cause,O,O
seizures,O,O
.,O,O
Didanosine,B,B
also,O,O
has,O,O
a,O,O
potential,O,O
for,O,O
inducing,O,O
seizures,O,O
.,O,O
However,O,O
",",O,O
these,O,O
other,O,O
potential,O,O
causes,O,O
of,O,O
seizure,O,O
were,O,O
ruled,O,O
out,O,O
.,O,O
The,O,O
time,O,O
course,O,O
of,O,O
events,O,O
suggested,O,O
that,O,O
amphotericin,B,B
B,I,I
was,O,O
the,O,O
cause,O,O
of,O,O
the,O,O
seizures,O,O
in,O,O
this,O,O
AIDS,O,O
patient,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Amphotericin,B,B
B,I,I
seems,O,O
to,O,O
be,O,O
the,O,O
probable,O,O
cause,O,O
of,O,O
the,O,O
seizures,O,O
.,O,O
To,O,O
date,O,O
",",O,O
only,O,O
three,O,O
cases,O,O
of,O,O
seizures,O,O
associated,O,O
with,O,O
amphotericin,B,B
B,I,I
have,O,O
been,O,O
reported,O,O
in,O,O
the,O,O
literature,O,O
",",O,O
but,O,O
healthcare,O,O
providers,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
the,O,O
potential,O,O
for,O,O
this,O,O
rare,O,O
adverse,O,O
effect,O,O
.,O,O
Sirolimus,B,B
and,O,O
mycophenolate,B,B
mofetil,I,I
for,O,O
calcineurin,O,B
-,O,I
free,O,I
immunosuppression,O,I
in,O,O
renal,O,O
transplant,O,O
recipients,O,O
.,O,O
Calcineurin,O,B
inhibitors,O,O
",",O,O
such,O,O
as,O,O
cyclosporine,B,B
and,O,O
tacrolimus,B,B
",",O,O
have,O,O
been,O,O
available,O,O
for,O,O
almost,O,O
20,O,O
years,O,O
.,O,O
Although,O,O
these,O,O
drugs,O,O
are,O,O
highly,O,O
effective,O,O
and,O,O
represent,O,O
the,O,O
mainstay,O,O
of,O,O
transplant,O,O
immunosuppression,O,O
",",O,O
they,O,O
are,O,O
associated,O,O
with,O,O
acute,O,B
and,O,O
chronic,O,B
nephrotoxicity,O,I
.,O,O
Acute,O,B
nephrotoxicity,O,I
",",O,O
which,O,O
occurs,O,O
in,O,O
the,O,O
early,O,O
period,O,O
after,O,O
transplantation,O,O
",",O,O
leads,O,O
to,O,O
a,O,O
higher,O,O
rate,O,O
of,O,O
dialysis,O,O
",",O,O
and,O,O
chronic,O,B
nephrotoxicity,O,I
may,O,O
eventually,O,O
result,O,O
in,O,O
graft,O,O
loss,O,O
.,O,O
Acute,O,O
and,O,O
chronic,O,O
nephrotoxicity,O,O
is,O,O
becoming,O,O
more,O,O
common,O,O
as,O,O
the,O,O
use,O,O
of,O,O
marginal,O,O
kidneys,O,O
for,O,O
transplantation,O,O
increases,O,O
.,O,O
Two,O,O
recently,O,O
available,O,O
immunosuppressive,O,O
agents,O,O
",",O,O
mycophenolate,B,B
mofetil,I,I
and,O,O
sirolimus,B,B
(,O,O
rapamycin,B,I
),O,O
",",O,O
have,O,O
no,O,O
nephrotoxicity,O,O
.,O,O
The,O,O
use,O,O
of,O,O
these,O,O
drugs,O,O
in,O,O
combination,O,O
with,O,O
other,O,O
agents,O,O
has,O,O
led,O,O
to,O,O
the,O,O
development,O,O
of,O,O
new,O,O
paradigms,O,O
of,O,O
immunosuppressive,O,O
therapy,O,O
.,O,O
This,O,O
paper,O,O
reviews,O,O
the,O,O
results,O,O
of,O,O
clinical,O,O
trials,O,O
that,O,O
have,O,O
investigated,O,O
these,O,O
new,O,O
approaches,O,O
to,O,O
immunosuppression,O,O
in,O,O
renal,O,O
transplant,O,O
recipients,O,O
.,O,O
Tolerability,O,O
of,O,O
nimesulide,B,B
and,O,O
paracetamol,B,B
in,O,O
patients,O,O
with,O,O
NSAID,B,O
-,O,O
induced,O,O
urticaria,O,O
/,O,O
angioedema,O,O
.,O,O
Previous,O,O
studies,O,O
evaluated,O,O
the,O,O
tolerance,O,O
of,O,O
nimesulide,B,B
and,O,O
paracetamol,B,B
in,O,O
subjects,O,O
with,O,O
cutaneous,O,O
",",O,O
respiratory,O,O
and,O,O
anaphylactoid,O,O
reactions,O,O
induced,O,O
by,O,O
nonsteroidal,B,O
anti,I,O
-,I,O
inflammatory,I,O
drugs,I,O
(,O,O
NSAIDs,B,O
),O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
investigated,O,O
tolerability,O,O
and,O,O
reliability,O,O
of,O,O
nimesulide,B,B
and,O,O
paracetamol,B,B
in,O,O
a,O,O
very,O,O
large,O,O
number,O,O
of,O,O
patients,O,O
with,O,O
an,O,O
exclusive,O,O
well,O,O
-,O,O
documented,O,O
history,O,O
of,O,O
NSAID,B,B
-,O,O
induced,O,O
urticaria,O,O
/,O,O
angioedema,O,O
.,O,O
Furthermore,O,O
",",O,O
we,O,O
evaluated,O,O
whether,O,O
some,O,O
factors,O,O
have,O,O
the,O,O
potential,O,O
to,O,O
increase,O,O
the,O,O
risk,O,O
of,O,O
reaction,O,O
to,O,O
paracetamol,B,B
and,O,O
nimesulide,B,B
.,O,O
A,O,O
single,O,O
-,O,O
placebo,O,O
-,O,O
controlled,O,O
oral,O,O
challenge,O,O
procedure,O,O
with,O,O
nimesulide,B,B
or,O,O
paracetamol,B,B
was,O,O
applied,O,O
to,O,O
829,O,O
patients,O,O
with,O,O
a,O,O
history,O,O
of,O,O
NSAID,B,B
-,O,O
induced,O,O
urticaria,O,O
/,O,O
angioedema,O,O
.,O,O
A,O,O
total,O,O
of,O,O
75,O,O
/,O,O
829,O,O
(,O,O
9,O,O
.,O,O
4,O,O
%,O,O
),O,O
patients,O,O
experienced,O,O
reactions,O,O
to,O,O
nimesulide,B,B
or,O,O
paracetamol,B,B
.,O,O
Of,O,O
the,O,O
715,O,O
patients,O,O
tested,O,O
with,O,O
nimesulide,B,B
62,O,O
(,O,O
8,O,O
.,O,O
6,O,O
%,O,O
),O,O
showed,O,O
a,O,O
positive,O,O
test,O,O
",",O,O
while,O,O
of,O,O
114,O,O
subjects,O,O
submitted,O,O
to,O,O
the,O,O
challenge,O,O
with,O,O
paracetamol,B,B
",",O,O
13,O,O
(,O,O
9,O,O
.,O,O
6,O,O
%,O,O
),O,O
did,O,O
not,O,O
tolerate,O,O
this,O,O
drug,O,O
.,O,O
Furthermore,O,O
",",O,O
18,O,O
.,O,O
28,O,O
%,O,O
of,O,O
patients,O,O
with,O,O
a,O,O
history,O,O
of,O,O
chronic,O,O
urticaria,O,B
and,O,O
11,O,O
.,O,O
8,O,O
%,O,O
of,O,O
subjects,O,O
with,O,O
an,O,O
history,O,O
of,O,O
NSAID,B,B
-,O,I
induced,O,I
urticaria,O,I
/,O,I
angioedema,O,I
or,O,O
angioedema,O,I
alone,O,O
(,O,O
with,O,O
or,O,O
without,O,O
chronic,O,O
urticaria,O,O
),O,O
resulted,O,O
to,O,O
be,O,O
intolerant,O,O
to,O,O
alternative,O,O
drugs,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
our,O,O
results,O,O
confirm,O,O
the,O,O
good,O,O
tolerability,O,O
of,O,O
nimesulide,B,B
and,O,O
paracetamol,B,B
in,O,O
patients,O,O
who,O,O
experienced,O,O
urticaria,O,O
/,O,O
angioedema,O,O
caused,O,O
by,O,O
NSAIDs,B,B
.,O,O
However,O,O
",",O,O
the,O,O
risk,O,O
of,O,O
reaction,O,O
to,O,O
these,O,O
alternative,O,O
study,O,O
drugs,O,O
is,O,O
statistically,O,O
increased,O,O
by,O,O
a,O,O
history,O,O
of,O,O
chronic,O,O
urticaria,O,O
and,O,O
",",O,O
above,O,O
all,O,O
",",O,O
by,O,O
a,O,O
history,O,O
of,O,O
NSAID,B,B
-,O,O
induced,O,O
angioedema,O,O
.,O,O
Comparison,O,O
of,O,O
aqueous,O,B
and,O,O
gellan,O,B
ophthalmic,O,I
timolol,B,I
with,O,O
placebo,O,O
on,O,O
the,O,O
24,O,O
-,O,O
hour,O,O
heart,O,O
rate,O,O
response,O,O
in,O,O
patients,O,O
on,O,O
treatment,O,O
for,O,O
glaucoma,O,O
.,O,O
PURPOSE,O,O
:,O,O
Topical,O,O
beta,O,B
-,O,I
blocker,O,I
treatment,O,O
is,O,O
routine,O,O
therapy,O,O
in,O,O
the,O,O
management,O,O
of,O,O
patients,O,O
with,O,O
glaucoma,O,O
.,O,O
Therapy,O,O
results,O,O
in,O,O
systemic,O,O
absorption,O,O
",",O,O
however,O,O
",",O,O
the,O,O
degree,O,O
of,O,O
reduction,O,O
of,O,O
resting,O,O
and,O,O
peak,O,O
heart,O,O
rate,O,O
has,O,O
not,O,O
been,O,O
quantified,O,O
.,O,O
DESIGN,O,O
:,O,O
This,O,O
trial,O,O
evaluated,O,O
the,O,O
effect,O,O
of,O,O
placebo,O,B
",",O,O
0,O,O
.,O,O
5,O,O
%,O,O
aqueous,O,O
timolol,B,B
(,O,O
timolol,B,I
solution,O,I
),O,O
and,O,O
a,O,O
0,O,O
.,O,O
5,O,O
%,O,O
timolol,B,B
suspension,O,I
that,O,O
forms,O,O
a,O,O
gel,O,O
on,O,O
application,O,O
to,O,O
the,O,O
conjunctiva,O,B
(,O,O
timolol,B,I
gellan,O,I
),O,O
on,O,O
the,O,O
24,O,O
-,O,O
hour,O,O
heart,O,O
rate,O,O
in,O,O
patients,O,O
currently,O,O
being,O,O
treated,O,O
for,O,O
glaucoma,O,O
to,O,O
quantify,O,O
the,O,O
reduction,O,O
in,O,O
mean,O,O
heart,O,O
rate,O,O
.,O,O
METHODS,O,O
:,O,O
Forty,O,O
-,O,O
three,O,O
Caucasian,O,O
patients,O,O
with,O,O
primary,O,O
open,O,O
-,O,O
angle,O,O
glaucoma,O,B
or,O,O
ocular,O,O
hypertension,O,O
with,O,O
a,O,O
mean,O,O
(,O,O
+,O,O
/,O,O
-,O,O
SD,O,O
),O,O
age,O,O
of,O,O
63,O,O
(,O,O
+,O,O
/,O,O
-,O,O
8,O,O
),O,O
years,O,O
were,O,O
randomized,O,O
and,O,O
crossed,O,O
over,O,O
in,O,O
a,O,O
double,O,O
-,O,O
masked,O,O
manner,O,O
to,O,O
14,O,O
days,O,O
of,O,O
treatment,O,O
with,O,O
placebo,O,B
(,O,O
morning,O,O
and,O,O
evening,O,O
in,O,O
both,O,O
eyes,O,O
),O,O
",",O,O
timolol,B,B
solution,O,O
(,O,O
morning,O,O
and,O,O
evening,O,O
in,O,O
both,O,O
eyes,O,O
),O,O
",",O,O
or,O,O
timolol,B,B
gellan,O,O
(,O,O
morning,O,O
in,O,O
both,O,O
eyes,O,O
with,O,O
placebo,O,O
in,O,O
the,O,O
evening,O,O
),O,O
.,O,O
On,O,O
the,O,O
13th,O,O
day,O,O
of,O,O
each,O,O
period,O,O
",",O,O
heart,O,O
rate,O,O
was,O,O
recorded,O,O
continuously,O,O
during,O,O
a,O,O
typical,O,O
",",O,O
ambulant,O,O
24,O,O
-,O,O
hour,O,O
period,O,O
.,O,O
RESULTS,O,O
:,O,O
Both,O,O
timolol,B,B
solution,O,O
and,O,O
timolol,B,B
gellan,O,O
reduced,O,O
the,O,O
mean,O,O
24,O,O
-,O,O
hour,O,O
heart,O,O
rate,O,O
compared,O,O
with,O,O
placebo,O,O
(,O,O
P,O,O
<,O,O
or,O,O
=,O,O
.,O,O
),O,O
",",O,O
and,O,O
this,O,O
reduction,O,O
was,O,O
most,O,O
pronounced,O,O
during,O,O
the,O,O
daytime,O,O
(,O,O
-,O,O
7,O,O
.,O,O
5,O,O
%,O,O
change,O,O
in,O,O
mean,O,O
heart,O,B
rate,O,I
",",O,O
-,O,O
5,O,O
.,O,O
7,O,O
beats,O,O
/,O,O
min,O,O
),O,O
.,O,O
Timolol,B,B
gellan,O,I
showed,O,O
a,O,O
numerically,O,O
but,O,O
not,O,O
significantly,O,O
smaller,O,O
reduction,O,O
in,O,O
24,O,O
-,O,O
hour,O,O
heart,O,B
rate,O,I
",",O,O
compared,O,O
with,O,O
timolol,B,B
solution,O,I
.,O,O
During,O,O
the,O,O
night,O,O
",",O,O
the,O,O
mean,O,O
12,O,O
-,O,O
hour,O,O
heart,O,B
rate,O,I
on,O,O
placebo,O,B
and,O,O
timolol,B,B
gellan,O,I
were,O,O
both,O,O
significantly,O,O
less,O,O
than,O,O
on,O,O
timolol,B,B
solution,O,I
;,O,O
the,O,O
difference,O,O
between,O,O
solution,O,I
and,O,O
gellan,O,I
treatments,O,O
was,O,O
statistically,O,O
significant,O,O
(,O,O
P,O,B
=,O,O
.,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Both,O,O
timolol,B,B
solution,O,O
and,O,O
timolol,B,B
gellan,O,O
decrease,O,O
the,O,O
mean,O,O
24,O,O
-,O,O
hour,O,O
heart,O,O
rate,O,O
compared,O,O
with,O,O
placebo,O,O
.,O,O
This,O,O
response,O,O
was,O,O
most,O,O
pronounced,O,O
during,O,O
the,O,O
active,O,O
daytime,O,O
period,O,O
.,O,O
These,O,O
data,O,O
quantify,O,O
the,O,O
modest,O,O
bradycardia,O,O
associated,O,O
with,O,O
ophthalmic,O,O
beta,O,B
-,O,O
blocker,O,O
therapy,O,O
in,O,O
a,O,O
typical,O,O
patient,O,O
population,O,O
on,O,O
therapy,O,O
for,O,O
glaucoma,O,O
.,O,O
Although,O,O
exercise,O,O
performance,O,O
was,O,O
not,O,O
assessed,O,O
in,O,O
this,O,O
trial,O,O
",",O,O
reductions,O,O
of,O,O
this,O,O
magnitude,O,O
should,O,O
not,O,O
have,O,O
substantial,O,O
clinical,O,O
consequences,O,O
.,O,O
Management,O,O
strategies,O,O
for,O,O
ribavirin,B,B
-,O,O
induced,O,O
hemolytic,O,O
anemia,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
hepatitis,O,O
C,O,O
:,O,O
clinical,O,O
and,O,O
economic,O,O
implications,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
Recently,O,O
published,O,O
studies,O,O
have,O,O
demonstrated,O,O
increased,O,O
efficacy,O,O
and,O,O
cost,O,O
-,O,O
effectiveness,O,O
of,O,O
combination,O,O
therapy,O,O
with,O,O
interferon,O,O
and,O,O
alpha,O,O
-,O,O
2b,O,O
/,O,O
ribavirin,B,B
compared,O,O
with,O,O
interferon,B,O
-,I,O
alpha,I,O
monotherapy,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
chronic,O,O
hepatitis,O,O
C,O,O
(,O,O
CHC,O,O
),O,O
.,O,O
Combination,O,O
therapy,O,O
is,O,O
associated,O,O
with,O,O
a,O,O
clinically,O,O
important,O,O
adverse,O,O
effect,O,O
:,O,O
ribavirin,B,B
-,O,O
induced,O,O
hemolytic,O,O
anemia,O,O
(,O,O
RIHA,O,B
),O,O
.,O,O
The,O,O
objective,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
evaluate,O,O
the,O,O
direct,O,O
health,O,O
-,O,O
care,O,O
costs,O,O
and,O,O
management,O,O
of,O,O
RIHA,O,B
during,O,O
treatment,O,O
of,O,O
CHC,O,O
in,O,O
a,O,O
clinical,O,O
trial,O,O
setting,O,O
.,O,O
METHODS,O,O
:,O,O
A,O,O
systematic,O,O
literature,O,O
review,O,O
was,O,O
conducted,O,O
to,O,O
synthesize,O,O
information,O,O
on,O,O
the,O,O
incidence,O,O
and,O,O
management,O,O
of,O,O
RIHA,O,B
.,O,O
Decision,O,O
-,O,O
analytic,O,O
techniques,O,O
were,O,O
used,O,O
to,O,O
estimate,O,O
the,O,O
cost,O,O
of,O,O
treating,O,O
RIHA,O,B
.,O,O
Uncertainty,O,O
was,O,O
evaluated,O,O
using,O,O
sensitivity,O,O
analyses,O,O
.,O,O
RESULTS,O,O
:,O,O
RIHA,O,B
",",O,O
defined,O,O
as,O,O
a,O,O
reduction,O,O
in,O,O
hemoglobin,O,B
to,O,O
less,O,O
than,O,O
100,O,O
g,O,O
/,O,O
L,O,O
",",O,O
occurs,O,O
in,O,O
approximately,O,O
7,O,O
%,O,O
to,O,O
9,O,O
%,O,O
of,O,O
patients,O,O
treated,O,O
with,O,O
combination,O,O
therapy,O,O
.,O,O
The,O,O
standard,O,O
of,O,O
care,O,O
for,O,O
management,O,O
of,O,O
RIHA,O,B
is,O,O
reduction,O,O
or,O,O
discontinuation,O,O
of,O,O
the,O,O
ribavirin,B,B
dosage,O,O
.,O,O
We,O,O
estimated,O,O
the,O,O
direct,O,O
cost,O,O
of,O,O
treating,O,O
clinically,O,O
significant,O,O
RIHA,O,O
to,O,O
be,O,O
170,O,O
per,O,O
patient,O,O
receiving,O,O
combination,O,O
therapy,O,O
per,O,O
48,O,O
-,O,O
week,O,O
treatment,O,O
course,O,O
(,O,O
range,O,O
68,O,O
-,O,O
692,O,O
),O,O
.,O,O
The,O,O
results,O,O
of,O,O
the,O,O
one,O,O
-,O,O
way,O,O
sensitivity,O,O
analyses,O,O
ranged,O,O
from,O,O
57,O,O
to,O,O
317,O,O
.,O,O
In,O,O
comparison,O,O
",",O,O
the,O,O
cost,O,O
of,O,O
48,O,O
weeks,O,O
of,O,O
combination,O,O
therapy,O,O
is,O,O
16,O,O
",",O,O
459,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
direct,O,O
cost,O,O
of,O,O
treating,O,O
clinically,O,O
significant,O,O
RIHA,O,B
is,O,O
1,O,O
%,O,O
(,O,O
170,O,O
/,O,O
16,O,O
",",O,O
459,O,O
),O,O
of,O,O
drug,O,O
treatment,O,O
costs,O,O
.,O,O
Questions,O,O
remain,O,O
about,O,O
the,O,O
optimal,O,O
dose,O,O
of,O,O
ribavirin,B,B
and,O,O
the,O,O
incidence,O,O
of,O,O
RIHA,O,B
in,O,O
a,O,O
real,O,O
-,O,O
world,O,O
population,O,O
.,O,O
Despite,O,O
these,O,O
uncertainties,O,O
",",O,O
this,O,O
initial,O,O
evaluation,O,O
of,O,O
the,O,O
direct,O,O
cost,O,O
of,O,O
treating,O,O
RIHA,O,B
provides,O,O
an,O,O
estimate,O,O
of,O,O
the,O,O
cost,O,O
and,O,O
management,O,O
implications,O,O
of,O,O
this,O,O
clinically,O,O
important,O,O
adverse,O,O
effect,O,O
.,O,O
Preliminary,O,O
efficacy,O,O
assessment,O,O
of,O,O
intrathecal,O,O
injection,O,O
of,O,O
an,O,O
American,O,O
formulation,O,O
of,O,O
adenosine,B,B
in,O,O
humans,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Preclinical,O,O
studies,O,O
of,O,O
intrathecal,O,O
adenosine,B,B
suggest,O,O
it,O,O
may,O,O
be,O,O
effective,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
acute,O,O
and,O,O
chronic,O,O
pain,O,O
in,O,O
humans,O,O
",",O,O
and,O,O
preliminary,O,O
studies,O,O
in,O,O
volunteers,O,O
and,O,O
patients,O,O
with,O,O
a,O,O
Swedish,O,O
formulation,O,O
of,O,O
adenosine,B,B
suggests,O,O
it,O,O
may,O,O
be,O,O
effective,O,O
in,O,O
hypersensitivity,O,O
states,O,O
but,O,O
not,O,O
with,O,O
acute,O,O
noxious,O,O
stimulation,O,O
.,O,O
The,O,O
purpose,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
screen,O,O
for,O,O
efficacy,O,O
of,O,O
a,O,O
different,O,O
formulation,O,O
of,O,O
adenosine,B,B
marketed,O,O
in,O,O
the,O,O
US,O,O
",",O,O
using,O,O
both,O,O
acute,O,O
noxious,O,O
stimulation,O,O
and,O,O
capsaicin,B,B
-,O,I
evoked,O,O
mechanical,O,O
hypersensitivity,O,O
.,O,O
METHODS,O,O
:,O,O
Following,O,O
Food,O,O
and,O,O
Drug,O,O
Administration,O,O
and,O,O
institutional,O,O
review,O,O
board,O,O
approval,O,O
and,O,O
written,O,O
informed,O,O
consent,O,O
",",O,O
65,O,O
volunteers,O,O
were,O,O
studied,O,O
in,O,O
two,O,O
trials,O,O
:,O,O
an,O,O
open,O,O
-,O,O
label,O,O
",",O,O
dose,O,O
-,O,O
escalating,O,O
trial,O,O
with,O,O
intrathecal,O,O
adenosine,B,B
doses,O,O
of,O,O
0,O,O
.,O,O
25,O,O
-,O,O
2,O,O
.,O,O
0,O,O
mg,O,O
and,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
of,O,O
adenosine,B,B
",",O,O
2,O,O
mg,O,O
.,O,O
Cerebrospinal,O,O
fluid,O,O
was,O,O
obtained,O,O
for,O,O
pharmacokinetic,O,O
analysis,O,O
",",O,O
and,O,O
pain,O,O
ratings,O,O
in,O,O
response,O,O
to,O,O
acute,O,O
heat,O,O
stimuli,O,O
and,O,O
areas,O,O
of,O,O
mechanical,O,O
hyperalgesia,O,O
and,O,O
allodynia,O,O
after,O,O
intradermal,O,O
capsaicin,B,B
injection,O,O
were,O,O
determined,O,O
.,O,O
RESULTS,O,O
:,O,O
Adenosine,B,B
produced,O,O
no,O,O
effect,O,O
on,O,O
pain,O,O
report,O,O
to,O,O
acute,O,O
noxious,O,O
thermal,O,O
or,O,O
chemical,O,B
stimulation,O,O
but,O,O
reduced,O,O
mechanical,O,O
hyperalgesia,O,O
and,O,O
allodynia,O,O
from,O,O
intradermal,O,O
capsaicin,B,B
injection,O,O
for,O,O
at,O,O
least,O,O
24,O,O
h,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
residence,O,O
time,O,O
of,O,O
adenosine,B,B
in,O,O
cerebrospinal,O,O
fluid,O,O
was,O,O
short,O,O
(,O,O
<,O,O
4,O,O
h,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
These,O,O
results,O,O
show,O,O
selective,O,O
inhibition,O,O
by,O,O
intrathecal,O,O
adenosine,B,B
of,O,O
hypersensitivity,O,O
",",O,O
presumed,O,O
to,O,O
reflect,O,O
central,O,O
sensitization,O,O
in,O,O
humans,O,O
after,O,O
peripheral,O,O
capsaicin,B,B
injection,O,O
.,O,O
The,O,O
long,O,O
-,O,O
lasting,O,O
effect,O,O
is,O,O
consistent,O,O
with,O,O
that,O,O
observed,O,O
in,O,O
preliminary,O,O
reports,O,O
of,O,O
patients,O,O
with,O,O
chronic,O,O
neuropathic,O,O
pain,O,O
and,O,O
is,O,O
not,O,O
due,O,O
to,O,O
prolonged,O,O
residence,O,O
of,O,O
adenosine,B,B
in,O,O
cerebrospinal,O,B
fluid,O,O
.,O,O
Delayed,O,O
-,O,O
onset,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
presents,O,O
5,O,O
to,O,O
12,O,O
days,O,O
after,O,O
heparin,B,B
exposure,O,O
",",O,O
with,O,O
or,O,O
without,O,O
arterial,O,O
or,O,O
venous,O,O
thromboemboli,O,O
.,O,O
Delayed,O,O
recognition,O,O
and,O,O
treatment,O,O
of,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
contribute,O,O
to,O,O
poor,O,O
patient,O,O
outcomes,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
describe,O,O
and,O,O
increase,O,O
awareness,O,O
of,O,O
a,O,O
clinical,O,O
scenario,O,O
in,O,O
which,O,O
the,O,O
onset,O,O
or,O,O
manifestations,O,O
of,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
are,O,O
delayed,O,O
.,O,O
DESIGN,O,O
:,O,O
Retrospective,O,O
case,O,O
series,O,O
.,O,O
SETTING,O,O
:,O,O
Three,O,O
large,O,O
urban,O,O
hospitals,O,O
(,O,O
with,O,O
active,O,O
cardiovascular,O,O
surgery,O,O
programs,O,O
),O,O
.,O,O
PATIENTS,O,O
:,O,O
14,O,O
patients,O,O
seen,O,O
over,O,O
a,O,O
3,O,O
-,O,O
year,O,O
period,O,O
in,O,O
whom,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
became,O,O
apparent,O,O
on,O,O
delayed,O,O
presentation,O,O
with,O,O
thromboembolic,O,O
complications,O,O
.,O,O
MEASUREMENTS,O,O
:,O,O
Platelet,O,B
counts,O,O
",",O,O
onset,O,O
of,O,O
objectively,O,O
determined,O,O
thromboembolism,O,O
",",O,O
results,O,O
of,O,O
heparin,B,B
-,O,O
induced,O,O
platelet,O,I
factor,O,I
4,O,I
antibody,O,I
tests,O,O
",",O,O
and,O,O
outcomes,O,O
.,O,O
RESULTS,O,O
:,O,O
Patients,O,O
went,O,O
home,O,O
after,O,O
hospitalizations,O,O
that,O,O
had,O,O
included,O,O
heparin,B,B
exposure,O,O
-,O,O
-,O,O
in,O,O
most,O,O
cases,O,O
",",O,O
with,O,O
no,O,O
thrombocytopenia,O,O
recognized,O,O
-,O,O
-,O,O
only,O,O
to,O,O
return,O,O
to,O,O
the,O,O
hospital,O,O
(,O,O
median,O,O
",",O,O
day,O,O
14,O,O
),O,O
with,O,O
thromboembolic,O,O
complications,O,O
.,O,O
Thromboemboli,O,O
were,O,O
venous,O,O
(,O,O
12,O,O
patients,O,O
",",O,O
7,O,O
with,O,O
pulmonary,O,O
emboli,O,O
),O,O
or,O,O
arterial,O,O
(,O,O
4,O,O
patients,O,O
),O,O
or,O,O
both,O,O
.,O,O
Platelet,O,B
counts,O,O
were,O,O
mildly,O,O
decreased,O,O
in,O,O
all,O,O
but,O,O
2,O,O
patients,O,O
on,O,O
second,O,O
presentation,O,O
.,O,O
On,O,O
readmission,O,O
",",O,O
11,O,O
patients,O,O
received,O,O
therapeutic,O,O
heparin,B,B
",",O,O
which,O,O
worsened,O,O
the,O,O
patients,O,O
',O,O
clinical,O,O
condition,O,O
and,O,O
",",O,O
in,O,O
all,O,O
11,O,O
cases,O,O
",",O,O
decreased,O,O
the,O,O
platelet,O,B
count,O,O
(,O,O
mean,O,O
at,O,O
readmission,O,O
",",O,O
143,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
cells,O,O
/,O,O
L,O,O
;,O,O
mean,O,O
nadir,O,O
after,O,O
heparin,B,B
re,O,O
-,O,O
exposure,O,O
",",O,O
39,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
cells,O,O
/,O,O
L,O,O
.,O,O
Results,O,O
of,O,O
serologic,O,O
tests,O,O
for,O,O
heparin,B,B
-,O,O
induced,O,O
antibodies,O,O
were,O,O
positive,O,O
in,O,O
all,O,O
patients,O,O
.,O,O
Subsequent,O,O
treatments,O,O
included,O,O
alternative,O,O
anticoagulants,O,O
(,O,O
11,O,O
patients,O,O
),O,O
",",O,O
thrombolytic,O,O
drugs,O,O
(,O,O
3,O,O
patients,O,O
),O,O
",",O,O
inferior,O,O
vena,O,O
cava,O,O
filters,O,O
(,O,O
3,O,O
patients,O,O
),O,O
and,O,O
",",O,O
eventually,O,O
",",O,O
warfarin,B,B
(,O,O
11,O,O
patients,O,O
),O,O
.,O,O
Three,O,O
patients,O,O
died,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Delayed,O,O
-,O,O
onset,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
is,O,O
increasingly,O,O
being,O,O
recognized,O,O
.,O,O
To,O,O
avoid,O,O
disastrous,O,O
outcomes,O,O
",",O,O
physicians,O,O
must,O,O
consider,O,O
heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
whenever,O,O
a,O,O
recently,O,O
hospitalized,O,O
patient,O,O
returns,O,O
with,O,O
thromboembolism,O,O
;,O,O
therapy,O,O
with,O,O
alternative,O,O
anticoagulants,O,O
",",O,O
not,O,O
heparin,B,B
",",O,O
should,O,O
be,O,O
initiated,O,O
.,O,O
Treatment,O,O
of,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,O
with,O,O
a,O,O
dopamine,B,B
agonist,O,O
in,O,O
children,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Risperidone,B,B
",",O,O
a,O,O
potent,O,O
antagonist,O,O
of,O,O
both,O,O
serotonergic,O,B
(,O,O
5HT2A,O,B
),O,O
and,O,O
dopaminergic,O,B
D2,O,I
receptors,O,O
is,O,O
associated,O,O
with,O,O
hyperprolactinemia,O,O
in,O,O
adults,O,O
and,O,O
children,O,O
.,O,O
Chronically,O,O
elevated,O,O
prolactin,O,B
levels,O,O
in,O,O
children,O,O
with,O,O
prolactinomas,O,O
may,O,O
be,O,O
associated,O,O
with,O,O
arrested,O,O
growth,O,O
and,O,O
development,O,O
resulting,O,O
in,O,O
either,O,O
delayed,O,O
puberty,O,O
or,O,O
short,O,O
stature,O,O
.,O,O
These,O,O
possibilities,O,O
stress,O,O
the,O,O
importance,O,O
of,O,O
developing,O,O
a,O,O
safe,O,O
and,O,O
effective,O,O
approach,O,O
to,O,O
drug,O,O
-,O,O
induced,O,O
hyperprolactinemia,O,O
in,O,O
youth,O,O
.,O,O
We,O,O
report,O,O
the,O,O
successful,O,O
treatment,O,O
of,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,O
with,O,O
cabergoline,B,B
in,O,O
youth,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
undertook,O,O
a,O,O
retrospective,O,O
case,O,O
review,O,O
of,O,O
four,O,O
children,O,O
with,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,O
treated,O,O
with,O,O
cabergoline,B,B
.,O,O
RESULTS,O,O
:,O,O
Four,O,O
males,O,O
(,O,O
age,O,O
6,O,O
-,O,O
11,O,O
years,O,O
),O,O
with,O,O
Diagnostic,O,O
and,O,O
Statistical,O,O
Manual,O,O
of,O,O
Mental,O,O
Disorders,O,O
(,O,O
fourth,O,O
edition,O,O
),O,O
bipolar,O,O
disorder,O,O
or,O,O
psychoses,O,O
",",O,O
with,O,O
risperidone,B,B
-,O,O
induced,O,O
elevations,O,O
in,O,O
serum,O,O
prolactin,O,B
levels,O,O
(,O,O
57,O,O
.,O,O
5,O,O
-,O,O
129,O,O
ng,O,O
/,O,O
mL,O,O
",",O,O
normal,O,O
5,O,O
-,O,O
15,O,O
ng,O,O
/,O,O
mL,O,O
),O,O
",",O,O
were,O,O
treated,O,O
with,O,O
cabergoline,B,B
(,O,O
mean,O,O
dose,O,O
2,O,O
.,O,O
13,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
mg,O,B
/,O,O
week,O,O
),O,O
.,O,O
When,O,O
serum,O,O
prolactin,O,B
levels,O,O
normalized,O,O
in,O,O
all,O,O
four,O,O
subjects,O,O
(,O,O
mean,O,O
11,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
10,O,O
9,O,O
ng,O,B
/,O,O
mL,O,O
),O,O
the,O,O
cabergoline,B,B
dose,O,O
was,O,O
reduced,O,O
to,O,O
1,O,O
mg,O,B
/,O,O
week,O,O
in,O,O
three,O,O
of,O,O
four,O,O
subjects,O,O
.,O,O
The,O,O
mean,O,O
duration,O,O
of,O,O
therapy,O,O
with,O,O
cabergoline,B,B
was,O,O
523,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
129,O,O
.,O,O
7,O,O
days,O,O
",",O,O
and,O,O
the,O,O
mean,O,O
duration,O,O
of,O,O
therapy,O,O
with,O,O
risperidone,B,B
was,O,O
788,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
162,O,O
.,O,O
5,O,O
days,O,O
.,O,O
Cabergoline,B,B
was,O,O
well,O,O
tolerated,O,O
without,O,O
adverse,O,O
effects,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Cabergoline,B,B
may,O,O
be,O,O
useful,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,O
in,O,O
youth,O,O
;,O,O
however,O,O
",",O,O
further,O,O
research,O,O
is,O,O
needed,O,O
.,O,O
Acute,O,O
cholestatic,O,O
hepatitis,O,O
after,O,O
exposure,O,O
to,O,O
isoflurane,B,B
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
report,O,O
a,O,O
case,O,O
of,O,O
acute,O,O
cholestatic,O,O
hepatitis,O,O
following,O,O
exposure,O,O
to,O,O
the,O,O
inhalational,O,O
anesthetic,O,O
isoflurane,B,B
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
70,O,O
-,O,O
year,O,O
-,O,O
old,O,O
healthy,O,O
woman,O,O
from,O,O
Iraq,O,O
developed,O,O
acute,O,O
cholestatic,O,B
hepatitis,O,I
3,O,O
weeks,O,O
following,O,O
repair,O,O
of,O,O
the,O,O
right,O,O
rotator,O,O
cuff,O,O
under,O,O
general,O,O
anesthesia,O,O
.,O,O
There,O,O
was,O,O
no,O,O
evidence,O,O
for,O,O
viral,O,O
",",O,O
autoimmune,O,O
",",O,O
or,O,O
metabolic,O,O
causes,O,O
of,O,O
hepatitis,O,O
.,O,O
No,O,O
other,O,O
medications,O,O
were,O,O
involved,O,O
except,O,O
for,O,O
dipyrone,B,B
for,O,O
analgesia,O,O
.,O,O
The,O,O
alanine,B,B
aminotransferase,O,I
was,O,O
elevated,O,O
to,O,O
a,O,O
peak,O,O
concentration,O,O
of,O,O
1533,O,O
U,O,O
/,O,O
L,O,O
and,O,O
the,O,O
serum,O,O
bilirubin,B,B
reached,O,O
a,O,O
peak,O,O
of,O,O
17,O,O
.,O,O
0,O,O
mg,O,O
/,O,O
dL,O,O
was,O,O
slow,O,O
improvement,O,O
over,O,O
4,O,O
months,O,O
.,O,O
Accidental,O,O
reexposure,O,O
by,O,O
the,O,O
patient,O,O
to,O,O
dipyrone,B,B
was,O,O
uneventful,O,O
.,O,O
DISCUSSION,O,O
:,O,O
The,O,O
clinical,O,O
and,O,O
histologic,O,O
picture,O,O
of,O,O
this,O,O
case,O,O
resembles,O,O
halothane,O,B
hepatitis,O,I
",",O,O
which,O,O
has,O,O
a,O,O
significant,O,O
mortality,O,O
rate,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Isoflurane,B,B
",",O,O
a,O,O
common,O,O
anesthetic,O,O
agent,O,O
",",O,O
can,O,O
cause,O,O
severe,O,O
cholestatic,O,O
hepatitis,O,O
.,O,O
Torsade,O,O
de,O,O
pointes,O,O
induced,O,O
by,O,O
metoclopramide,B,B
in,O,O
an,O,O
elderly,O,O
woman,O,O
with,O,O
preexisting,O,O
complete,O,O
left,O,O
bundle,O,O
branch,O,O
block,O,O
.,O,O
There,O,O
is,O,O
a,O,O
growing,O,O
list,O,O
of,O,O
drugs,O,O
implicated,O,O
in,O,O
acquired,O,O
long,O,O
QT,O,B
syndrome,O,O
and,O,O
torsade,O,O
de,O,O
pointes,O,O
.,O,O
However,O,O
",",O,O
the,O,O
torsadogenic,O,O
potential,O,O
of,O,O
metoclopramide,B,B
",",O,O
a,O,O
commonly,O,O
used,O,O
antiemetic,O,O
and,O,O
prokinetic,O,O
drug,O,O
",",O,O
has,O,O
not,O,O
been,O,O
reported,O,O
in,O,O
the,O,O
literature,O,O
",",O,O
despite,O,O
its,O,O
chemical,O,O
similarity,O,O
to,O,O
procainamide,B,B
.,O,O
We,O,O
report,O,O
on,O,O
a,O,O
92,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
preexisting,O,O
complete,O,O
left,O,O
bundle,O,O
branch,O,O
block,O,O
who,O,O
developed,O,O
torsade,O,O
de,O,O
pointes,O,O
after,O,O
intravenous,O,O
and,O,O
oral,O,O
administration,O,O
of,O,O
metoclopramide,B,B
.,O,O
This,O,O
patient,O,O
also,O,O
developed,O,O
torsade,O,O
de,O,O
pointes,O,O
when,O,O
cisapride,B,B
and,O,O
erythromycin,B,B
were,O,O
given,O,O
simultaneously,O,O
.,O,O
These,O,O
two,O,O
episodes,O,O
were,O,O
suppressed,O,O
successfully,O,O
after,O,O
discontinuing,O,O
the,O,O
offending,O,O
drugs,O,O
and,O,O
administering,O,O
class,O,O
IB,O,O
drugs,O,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
documentation,O,O
that,O,O
metoclopramide,B,B
provokes,O,O
torsade,O,O
de,O,O
pointes,O,O
clinically,O,O
.,O,O
Metoclopramide,B,B
should,O,O
be,O,O
used,O,O
cautiously,O,O
in,O,O
patients,O,O
with,O,O
a,O,O
risk,O,O
of,O,O
torsade,O,B
de,O,I
pointes,O,I
.,O,O
Dopamine,B,B
D2,O,I
receptor,O,I
signaling,O,O
controls,O,O
neuronal,O,O
cell,O,O
death,O,O
induced,O,O
by,O,O
muscarinic,O,B
and,O,O
glutamatergic,O,B
drugs,O,O
.,O,O
Dopamine,B,B
(,O,O
DA,B,B
),O,O
",",O,O
through,O,O
D1,O,B
/,O,I
D2,O,I
receptor,O,I
-,O,I
mediated,O,I
signaling,O,O
",",O,O
plays,O,O
a,O,O
major,O,O
role,O,O
in,O,O
the,O,O
control,O,O
of,O,O
epileptic,O,O
seizures,O,O
arising,O,O
in,O,O
the,O,O
limbic,O,O
system,O,O
.,O,O
Excitotoxicity,O,O
leading,O,O
to,O,O
neuronal,O,O
cell,O,O
death,O,O
in,O,O
the,O,O
affected,O,O
areas,O,O
is,O,O
a,O,O
major,O,O
consequence,O,O
of,O,O
seizures,O,O
at,O,O
the,O,O
cellular,O,O
level,O,O
.,O,O
In,O,O
this,O,O
respect,O,O
",",O,O
little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
role,O,O
of,O,O
DA,B,B
receptors,O,O
in,O,O
the,O,O
occurrence,O,O
of,O,O
epilepsy,O,O
-,O,O
induced,O,O
neuronal,O,O
cell,O,O
death,O,O
.,O,O
Here,O,O
we,O,O
analyze,O,O
the,O,O
occurrence,O,O
of,O,O
seizures,O,O
and,O,O
neurotoxicity,O,O
in,O,O
D2R,O,B
-,O,O
/,O,O
-,O,O
mice,O,O
treated,O,O
with,O,O
the,O,O
cholinergic,O,B
agonist,O,O
pilocarpine,B,B
.,O,O
We,O,O
compared,O,O
these,O,O
results,O,O
with,O,O
those,O,O
previously,O,O
obtained,O,O
with,O,O
kainic,B,B
acid,I,I
(,O,O
KA,B,B
),O,O
",",O,O
a,O,O
potent,O,O
glutamate,B,B
agonist,O,O
.,O,O
Importantly,O,O
",",O,O
D2R,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
develop,O,O
seizures,O,O
at,O,O
doses,O,O
of,O,O
both,O,O
drugs,O,O
that,O,O
are,O,O
not,O,O
epileptogenic,O,O
for,O,O
WT,O,O
littermates,O,O
and,O,O
show,O,O
greater,O,O
neurotoxicity,O,O
.,O,O
However,O,O
",",O,O
pilocarpine,B,B
-,O,O
induced,O,O
seizures,O,O
result,O,O
in,O,O
a,O,O
more,O,O
widespread,O,O
neuronal,O,O
death,O,O
in,O,O
both,O,O
WT,O,O
and,O,O
D2R,O,O
-,O,O
/,O,O
-,O,O
brains,O,O
in,O,O
comparison,O,O
to,O,O
KA,B,B
.,O,O
Thus,O,O
",",O,O
the,O,O
absence,O,O
of,O,O
D2R,O,B
lowers,O,O
the,O,O
threshold,O,O
for,O,O
seizures,O,O
induced,O,O
by,O,O
both,O,O
glutamate,B,B
and,O,O
acetylcholine,B,B
.,O,O
Moreover,O,O
",",O,O
the,O,O
dopaminergic,O,O
control,O,O
of,O,O
epilepsy,O,O
-,O,O
induced,O,O
neurodegeneration,O,O
seems,O,O
to,O,O
be,O,O
mediated,O,O
by,O,O
distinct,O,O
interactions,O,O
of,O,O
D2R,O,B
signaling,O,O
with,O,O
these,O,O
two,O,O
neurotransmitters,O,O
.,O,O
Steroid,B,B
structure,O,O
and,O,O
pharmacological,O,O
properties,O,O
determine,O,O
the,O,O
anti,O,O
-,O,O
amnesic,O,O
effects,O,O
of,O,O
pregnenolone,B,B
sulphate,I,I
in,O,O
the,O,O
passive,O,O
avoidance,O,O
task,O,O
in,O,O
rats,O,O
.,O,O
Pregnenolone,B,B
sulphate,I,I
(,O,O
PREGS,B,B
),O,O
has,O,O
generated,O,O
interest,O,O
as,O,O
one,O,O
of,O,O
the,O,O
most,O,O
potent,O,O
memory,O,O
-,O,O
enhancing,O,O
neurosteroids,O,O
to,O,O
be,O,O
examined,O,O
in,O,O
rodent,O,O
learning,O,O
studies,O,O
",",O,O
with,O,O
particular,O,O
importance,O,O
in,O,O
the,O,O
ageing,O,O
process,O,O
.,O,O
The,O,O
mechanism,O,O
by,O,O
which,O,O
this,O,O
endogenous,O,O
steroid,B,O
enhances,O,O
memory,O,O
formation,O,O
is,O,O
hypothesized,O,O
to,O,O
involve,O,O
actions,O,O
on,O,O
glutamatergic,O,B
and,O,O
GABAergic,O,B
systems,O,O
.,O,O
This,O,O
hypothesis,O,O
stems,O,O
from,O,O
findings,O,O
that,O,O
PREGS,B,B
is,O,O
a,O,O
potent,O,O
positive,O,O
modulator,O,O
of,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
d,I,I
-,I,I
aspartate,I,I
receptors,O,O
(,O,O
NMDARs,O,B
),O,O
and,O,O
a,O,O
negative,O,O
modulator,O,O
of,O,O
gamma,B,B
-,I,I
aminobutyric,I,I
acid,I,I
(,O,O
A,O,B
),O,O
receptors,O,O
(,O,O
GABA,B,B
(,O,O
A,O,I
),O,O
Rs,O,O
),O,O
.,O,O
Moreover,O,O
",",O,O
PREGS,B,B
is,O,O
able,O,O
to,O,O
reverse,O,O
the,O,O
amnesic,O,O
-,O,O
like,O,O
effects,O,O
of,O,O
NMDAR,O,B
and,O,O
GABA,B,B
(,O,O
A,O,I
),O,O
R,O,O
ligands,O,O
.,O,O
To,O,O
investigate,O,O
this,O,O
hypothesis,O,O
",",O,O
the,O,O
present,O,O
study,O,O
in,O,O
rats,O,O
examined,O,O
the,O,O
memory,O,O
-,O,O
altering,O,O
abilities,O,O
of,O,O
structural,O,O
analogs,O,O
of,O,O
PREGS,B,B
",",O,O
which,O,O
differ,O,O
in,O,O
their,O,O
modulation,O,O
of,O,O
NMDAR,O,B
and,O,O
/,O,O
or,O,O
GABA,B,B
(,O,O
A,O,O
),O,O
R,O,O
function,O,O
.,O,O
The,O,O
analogs,O,O
tested,O,O
were,O,O
:,O,O
11,B,B
-,I,I
ketopregnenolone,I,I
sulphate,I,I
(,O,O
an,O,O
agent,O,O
that,O,O
is,O,O
inactive,O,O
at,O,O
GABA,B,B
(,O,O
A,O,O
),O,O
Rs,O,O
and,O,O
NMDARs,O,O
),O,O
",",O,O
epipregnanolone,B,B
(,I,O
[,I,O
3beta,I,B
-,I,I
hydroxy,I,I
-,I,I
5beta,I,I
-,I,I
pregnan,I,I
-,I,I
20,I,I
-,I,I
one,I,I
],I,O
sulphate,I,I
",",O,O
an,O,O
inhibitor,O,O
of,O,O
both,O,O
GABA,B,B
(,O,O
A,O,O
),O,O
Rs,O,O
and,O,O
NMDARs,O,O
),O,O
",",O,O
and,O,O
a,O,O
newly,O,O
synthesized,O,O
(,O,O
-,O,O
),O,O
PREGS,B,B
enantiomer,O,O
(,O,O
which,O,O
is,O,O
identical,O,O
to,O,O
PREGS,B,B
in,O,O
effects,O,O
on,O,O
GABA,B,B
(,O,O
A,O,O
),O,O
Rs,O,O
and,O,O
NMDARs,O,O
),O,O
.,O,O
The,O,O
memory,O,O
-,O,O
enhancing,O,O
effects,O,O
of,O,O
PREGS,B,B
and,O,O
its,O,O
analogs,O,O
were,O,O
tested,O,O
in,O,O
the,O,O
passive,O,O
avoidance,O,O
task,O,O
using,O,O
the,O,O
model,O,O
of,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
.,O,O
Both,O,O
PREGS,B,B
and,O,O
its,O,O
(,O,O
-,O,O
),O,O
enantiomer,O,O
blocked,O,O
the,O,O
effects,O,O
of,O,O
scopolamine,B,B
.,O,O
The,O,O
results,O,O
show,O,O
that,O,O
",",O,O
unlike,O,O
PREGS,B,B
",",O,O
11,B,O
-,I,O
ketopregnenolone,I,B
sulphate,I,I
and,O,O
epipregnanolone,B,B
sulphate,I,I
failed,O,O
to,O,O
block,O,O
the,O,O
effect,O,O
of,O,O
scopolamine,B,B
",",O,O
suggesting,O,O
that,O,O
altering,O,O
the,O,O
modulation,O,O
of,O,O
NMDA,B,B
receptors,O,O
diminishes,O,O
the,O,O
memory,O,O
-,O,O
enhancing,O,O
effects,O,O
of,O,O
PREGS,B,B
.,O,O
Moreover,O,O
",",O,O
enantioselectivity,O,O
was,O,O
demonstrated,O,O
by,O,O
the,O,O
ability,O,O
of,O,O
natural,O,O
PREGS,B,B
to,O,O
be,O,O
an,O,O
order,O,O
of,O,O
magnitude,O,O
more,O,O
effective,O,O
than,O,O
its,O,O
synthetic,O,O
enantiomer,O,O
in,O,O
reversing,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
.,O,O
These,O,O
results,O,O
identify,O,O
a,O,O
novel,O,O
neuropharmacological,O,O
site,O,O
for,O,O
the,O,O
modulation,O,O
of,O,O
memory,O,O
processes,O,O
by,O,O
neuroactive,O,O
steroids,B,B
.,O,O
Activation,O,O
of,O,O
poly,B,B
(,I,O
ADP,I,B
-,I,I
ribose,I,I
),I,O
polymerase,O,O
contributes,O,O
to,O,O
development,O,O
of,O,O
doxorubicin,B,B
-,O,I
induced,O,I
heart,O,I
failure,O,I
.,O,O
Activation,O,O
of,O,O
the,O,O
nuclear,O,O
enzyme,O,O
poly,B,B
(,I,O
ADP,I,B
-,I,I
ribose,I,I
),I,O
polymerase,O,O
(,O,O
PARP,O,B
),O,O
by,O,O
oxidant,O,O
-,O,O
mediated,O,O
DNA,O,B
damage,O,I
is,O,O
an,O,O
important,O,O
pathway,O,O
of,O,O
cell,O,O
dysfunction,O,O
and,O,O
tissue,O,O
injury,O,O
in,O,O
conditions,O,O
associated,O,O
with,O,O
oxidative,O,O
stress,O,O
.,O,O
Increased,O,O
oxidative,O,O
stress,O,O
is,O,O
a,O,O
major,O,O
factor,O,O
implicated,O,O
in,O,O
the,O,O
cardiotoxicity,O,O
of,O,O
doxorubicin,B,B
(,O,O
DOX,B,B
),O,O
",",O,O
a,O,O
widely,O,O
used,O,O
antitumor,O,O
anthracycline,B,O
antibiotic,O,O
.,O,O
Thus,O,O
",",O,O
we,O,O
hypothesized,O,O
that,O,O
the,O,O
activation,O,O
of,O,O
PARP,O,B
may,O,O
contribute,O,O
to,O,O
the,O,O
DOX,B,B
-,O,O
induced,O,O
cardiotoxicity,O,O
.,O,O
Using,O,O
a,O,O
dual,O,O
approach,O,O
of,O,O
PARP,O,B
-,O,O
1,O,O
suppression,O,O
",",O,O
by,O,O
genetic,O,O
deletion,O,O
or,O,O
pharmacological,O,O
inhibition,O,O
with,O,O
the,O,O
phenanthridinone,O,O
PARP,O,B
inhibitor,O,O
PJ34,B,O
",",O,O
we,O,O
now,O,O
demonstrate,O,O
the,O,O
role,O,O
of,O,O
PARP,O,B
in,O,O
the,O,O
development,O,O
of,O,O
cardiac,O,O
dysfunction,O,O
induced,O,O
by,O,O
DOX,B,B
.,O,O
PARP,O,B
-,O,O
1,O,O
+,O,O
/,O,O
+,O,O
and,O,O
PARP,O,B
-,O,O
1,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
received,O,O
a,O,O
single,O,O
injection,O,O
of,O,O
DOX,B,B
(,O,O
25,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
),O,O
.,O,O
Five,O,O
days,O,O
after,O,O
DOX,B,B
administration,O,O
",",O,O
left,O,O
ventricular,O,O
performance,O,O
was,O,O
significantly,O,O
depressed,O,O
in,O,O
PARP,O,B
-,O,O
1,O,O
+,O,O
/,O,O
+,O,O
mice,O,O
",",O,O
but,O,O
only,O,O
to,O,O
a,O,O
smaller,O,O
extent,O,O
in,O,O
PARP,O,B
-,O,O
1,O,O
-,O,O
/,O,O
-,O,O
ones,O,O
.,O,O
Similar,O,O
experiments,O,O
were,O,O
conducted,O,O
in,O,O
BALB,O,B
/,O,O
c,O,O
mice,O,O
treated,O,O
with,O,O
PJ34,B,B
or,O,O
vehicle,O,O
.,O,O
Treatment,O,O
with,O,O
a,O,O
PJ34,B,B
significantly,O,O
improved,O,O
cardiac,O,O
dysfunction,O,O
and,O,O
increased,O,O
the,O,O
survival,O,O
of,O,O
the,O,O
animals,O,O
.,O,O
In,O,O
addition,O,O
PJ34,B,B
significantly,O,O
reduced,O,O
the,O,O
DOX,B,B
-,O,I
induced,O,I
increase,O,O
in,O,O
the,O,O
serum,O,O
lactate,B,B
dehydrogenase,O,I
and,O,O
creatine,B,B
kinase,O,I
activities,O,O
but,O,O
not,O,O
metalloproteinase,O,O
activation,O,O
in,O,O
the,O,O
heart,O,O
.,O,O
Thus,O,O
",",O,O
PARP,O,B
activation,O,O
contributes,O,O
to,O,O
the,O,O
cardiotoxicity,O,O
of,O,O
DOX,B,B
.,O,O
PARP,O,B
inhibitors,O,O
may,O,O
exert,O,O
protective,O,O
effects,O,O
against,O,O
the,O,O
development,O,O
of,O,O
severe,O,O
cardiac,O,O
complications,O,O
associated,O,O
with,O,O
the,O,O
DOX,B,B
treatment,O,O
.,O,O
Spironolactone,B,B
:,O,O
is,O,O
it,O,O
a,O,O
novel,O,O
drug,O,O
for,O,O
the,O,O
prevention,O,O
of,O,O
amphotericin,B,B
B,I,I
-,O,I
related,O,O
hypokalemia,O,O
in,O,O
cancer,O,O
patients,O,O
?,O,O
OBJECTIVE,O,O
:,O,O
Nephrotoxicity,O,O
is,O,O
the,O,O
major,O,O
adverse,O,O
effect,O,O
of,O,O
amphotericin,B,B
B,I,I
(,O,I
AmB,B,I
),O,I
",",O,O
often,O,O
limiting,O,O
administration,O,O
of,O,O
full,O,O
dosage,O,O
.,O,O
Selective,O,O
distal,O,O
tubular,O,O
epithelial,O,O
toxicity,O,O
seems,O,O
to,O,O
be,O,O
responsible,O,O
for,O,O
the,O,O
profound,O,O
potassium,B,B
wasting,O,O
that,O,O
is,O,O
a,O,O
major,O,O
clinical,O,O
side,O,O
effect,O,O
of,O,O
treatment,O,O
with,O,O
AmB,B,B
.,O,O
Potassium,B,B
depletion,O,O
also,O,O
potentiates,O,O
the,O,O
tubular,O,O
toxicity,O,O
of,O,O
AmB,B,B
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
assess,O,O
the,O,O
ability,O,O
of,O,O
spironolactone,B,O
to,O,O
reduce,O,O
potassium,B,B
requirements,O,O
and,O,O
to,O,O
prevent,O,O
hypokalemia,O,O
in,O,O
neutropenic,O,O
patients,O,O
on,O,O
AmB,B,B
treatment,O,O
.,O,O
METHODS,O,O
:,O,O
In,O,O
this,O,O
study,O,O
26,O,O
patients,O,O
with,O,O
various,O,O
hematological,O,O
disorders,O,O
were,O,O
randomized,O,O
to,O,O
receive,O,O
either,O,O
intravenous,O,O
AmB,B,B
alone,O,O
or,O,O
AmB,B,B
and,O,O
oral,O,O
spironolactone,B,B
100,O,O
mg,O,O
twice,O,O
daily,O,O
when,O,O
developing,O,O
a,O,O
proven,O,O
or,O,O
suspected,O,O
fungal,O,O
infection,O,O
.,O,O
RESULTS,O,O
:,O,O
Patients,O,O
receiving,O,O
concomitant,O,O
AmB,B,B
and,O,O
spironolactone,B,B
had,O,O
significantly,O,O
higher,O,O
plasma,O,O
potassium,B,B
levels,O,O
than,O,O
those,O,O
receiving,O,O
AmB,B,B
alone,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
Those,O,O
patients,O,O
receiving,O,O
AmB,B,B
and,O,O
spironolactone,B,B
required,O,O
significantly,O,O
less,O,O
potassium,B,O
supplementation,O,O
to,O,O
maintain,O,O
their,O,O
plasma,O,O
potassium,B,O
within,O,O
the,O,O
normal,O,O
range,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
Moreover,O,O
",",O,O
urinary,O,O
potassium,B,O
losses,O,O
were,O,O
significantly,O,O
less,O,O
in,O,O
patients,O,O
receiving,O,O
AmB,B,B
and,O,O
spironolactone,B,B
than,O,O
those,O,O
receiving,O,O
AmB,B,B
alone,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSION,O,O
:,O,O
This,O,O
study,O,O
showed,O,O
that,O,O
spironolactone,B,B
can,O,O
reduce,O,O
potassium,B,O
requirements,O,O
and,O,O
prevent,O,O
hypokalemia,O,O
by,O,O
reducing,O,O
urinary,O,O
potassium,B,O
loss,O,O
in,O,O
neutropenic,O,O
patients,O,O
on,O,O
AmB,B,B
treatment,O,O
.,O,O
Erectile,O,O
dysfunction,O,O
occurs,O,O
following,O,O
substantia,O,O
nigra,O,O
lesions,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Erectile,O,O
function,O,O
was,O,O
assessed,O,O
6,O,O
weeks,O,O
following,O,O
uni,O,O
-,O,O
and,O,O
bilateral,O,O
injections,O,O
of,O,O
6,B,B
-,I,I
hydroxydopamine,I,I
in,O,O
the,O,O
substantia,O,O
nigra,O,O
nucleus,O,O
of,O,O
the,O,O
brain,O,O
.,O,O
Behavioral,O,O
apomorphine,B,B
-,O,O
induced,O,O
penile,O,O
erections,O,O
were,O,O
reduced,O,O
(,O,O
5,O,O
/,O,O
8,O,O
),O,O
and,O,O
increased,O,O
(,O,O
3,O,O
/,O,O
8,O,O
),O,O
in,O,O
uni,O,O
-,O,O
and,O,O
bilateral,O,O
lesioned,O,O
animals,O,O
.,O,O
Intracavernous,O,O
pressures,O,O
",",O,O
following,O,O
electrical,O,O
stimulation,O,O
of,O,O
the,O,O
cavernous,O,O
nerve,O,O
",",O,O
decreased,O,O
in,O,O
lesioned,O,O
animals,O,O
.,O,O
Lesions,O,O
of,O,O
the,O,O
substantia,O,O
nigra,O,B
were,O,O
confirmed,O,O
by,O,O
histology,O,O
.,O,O
Concentration,O,O
of,O,O
dopamine,B,B
and,O,O
its,O,O
metabolites,O,O
were,O,O
decreased,O,O
in,O,O
the,O,O
striatum,O,O
of,O,O
substantia,O,B
nigra,O,I
lesioned,O,O
rats,O,O
.,O,O
Lesions,O,O
of,O,O
the,O,O
substantia,O,B
nigra,O,I
are,O,O
therefore,O,O
associated,O,O
with,O,O
erectile,O,O
dysfunction,O,O
in,O,O
rats,O,O
and,O,O
may,O,O
serve,O,O
as,O,O
a,O,O
model,O,O
to,O,O
study,O,O
erectile,O,O
dysfunction,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
.,O,O
Nicotine,B,B
potentiation,O,O
of,O,O
morphine,B,B
-,O,O
induced,O,O
catalepsy,O,O
in,O,O
mice,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
effects,O,O
of,O,O
nicotine,B,B
on,O,O
catalepsy,O,O
induced,O,O
by,O,O
morphine,B,B
in,O,O
mice,O,O
have,O,O
been,O,O
investigated,O,O
.,O,O
Morphine,B,B
but,O,O
not,O,O
nicotine,B,B
induced,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
catalepsy,O,O
.,O,O
The,O,O
response,O,O
of,O,O
morphine,B,B
was,O,O
potentiated,O,O
by,O,O
nicotine,B,B
.,O,O
Intraperitoneal,O,O
administration,O,O
of,O,O
atropine,B,B
",",O,O
naloxone,B,B
",",O,O
mecamylamine,B,B
",",O,O
and,O,O
hexamethonium,B,B
to,O,O
mice,O,O
reduced,O,O
catalepsy,O,O
induced,O,O
by,O,O
a,O,O
combination,O,O
of,O,O
morphine,B,B
with,O,O
nicotine,B,B
.,O,O
Intracerebroventricular,O,O
injection,O,O
of,O,O
atropine,B,B
",",O,O
hexamethonium,B,B
",",O,O
and,O,O
naloxone,B,B
also,O,O
decreased,O,O
catalepsy,O,O
induced,O,O
by,O,O
morphine,B,B
plus,O,O
nicotine,B,B
.,O,O
Intraperitoneal,O,O
administration,O,O
of,O,O
atropine,B,B
",",O,O
but,O,O
not,O,O
intraperitoneal,O,O
or,O,O
intracerebroventricular,O,O
injection,O,O
of,O,O
hexamethonium,B,B
",",O,O
decreased,O,O
the,O,O
effect,O,O
of,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
morphine,B,B
.,O,O
It,O,O
was,O,O
concluded,O,O
that,O,O
morphine,B,B
catalepsy,O,O
can,O,O
be,O,O
elicited,O,O
by,O,O
opioid,O,B
and,O,O
cholinergic,O,B
receptors,O,O
",",O,O
and,O,O
the,O,O
potentiation,O,O
of,O,O
morphine,B,B
induced,O,O
by,O,O
nicotine,B,B
may,O,O
also,O,O
be,O,O
mediated,O,O
through,O,O
cholinergic,O,B
receptor,O,O
mechanisms,O,O
.,O,O
Force,O,O
overflow,O,O
and,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
.,O,O
We,O,O
assessed,O,O
force,O,O
coordination,O,O
of,O,O
the,O,O
hand,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
and,O,O
its,O,O
relationship,O,O
to,O,O
motor,O,O
complications,O,O
of,O,O
levodopa,B,B
therapy,O,O
",",O,O
particularly,O,O
to,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
(,O,O
LID,O,O
),O,O
.,O,O
We,O,O
studied,O,O
two,O,O
groups,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
patients,O,O
with,O,O
(,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
+,O,O
LID,O,O
",",O,O
n,O,O
=,O,O
23,O,O
),O,O
and,O,O
without,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
(,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
-,O,O
LID,O,O
",",O,O
n,O,O
=,O,O
10,O,O
),O,O
",",O,O
and,O,O
age,O,O
-,O,O
matched,O,O
healthy,O,O
controls,O,O
.,O,O
The,O,O
motor,O,O
score,O,O
of,O,O
the,O,O
Unified,O,O
Parkinson,O,B
',O,I
s,O,I
Disease,O,I
Rating,O,I
Scale,O,I
",",O,O
a,O,O
dyskinesia,O,O
score,O,O
and,O,O
force,O,O
in,O,O
a,O,O
grip,O,O
-,O,O
lift,O,O
paradigm,O,O
were,O,O
assessed,O,O
ON,O,O
and,O,O
OFF,O,O
levodopa,B,B
.,O,O
A,O,O
pathological,O,O
increase,O,O
of,O,O
forces,O,O
was,O,O
seen,O,O
in,O,O
ON,O,B
-,O,O
state,O,O
in,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
+,O,O
LID,O,O
only,O,O
.,O,O
In,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
+,O,O
LID,O,O
",",O,O
the,O,O
force,O,O
involved,O,O
in,O,O
pressing,O,O
down,O,O
the,O,O
object,O,O
before,O,O
lifting,O,O
was,O,O
significantly,O,O
increased,O,O
by,O,O
levodopa,B,B
(,O,O
by,O,O
61,O,O
%,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
An,O,O
overshooting,O,O
of,O,O
peak,O,O
grip,O,O
force,O,O
by,O,O
51,O,O
%,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
of,O,O
static,O,O
grip,O,O
force,O,O
by,O,O
45,O,O
%,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
was,O,O
observed,O,O
in,O,O
the,O,O
ON,O,O
-,O,O
compared,O,O
with,O,O
the,O,O
OFF,O,O
-,O,O
drug,O,O
condition,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
no,O,O
excessive,O,O
force,O,O
was,O,O
found,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
-,O,O
LID,O,O
.,O,O
Peak,O,O
grip,O,O
force,O,O
in,O,O
ON,O,O
-,O,O
state,O,O
was,O,O
140,O,O
%,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
higher,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
+,O,O
LID,O,O
than,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
-,O,O
LID,O,O
",",O,O
while,O,O
static,O,O
grip,O,O
force,O,O
was,O,O
increased,O,O
by,O,O
138,O,O
%,O,O
(,O,O
P,O,O
<,O,O
0,O,O
between,O,O
groups,O,O
.,O,O
Severity,O,O
of,O,O
peak,O,O
-,O,O
dose,O,O
dyskinesias,O,O
was,O,O
strongly,O,O
correlated,O,O
with,O,O
grip,O,O
force,O,O
in,O,O
ON,O,O
-,O,O
state,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
79,O,O
with,O,O
peak,O,O
force,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
No,O,O
correlation,O,O
was,O,O
observed,O,O
between,O,O
forces,O,O
and,O,O
the,O,O
motor,O,O
score,O,O
as,O,O
well,O,O
as,O,O
with,O,O
the,O,O
daily,O,O
dose,O,O
of,O,O
dopaminergic,O,O
medication,O,O
.,O,O
Force,O,O
excess,O,O
was,O,O
only,O,O
observed,O,O
in,O,O
patients,O,O
with,O,O
LID,O,O
and,O,O
motor,O,O
fluctuations,O,O
.,O,O
A,O,O
close,O,O
relationship,O,O
was,O,O
seen,O,O
between,O,O
the,O,O
overshooting,O,O
of,O,O
forces,O,O
and,O,O
dyskinesias,O,O
in,O,O
the,O,O
ON,O,O
-,O,O
drug,O,O
condition,O,O
.,O,O
We,O,O
postulate,O,O
that,O,O
both,O,O
LID,O,B
and,O,O
grip,O,O
force,O,O
excess,O,O
share,O,O
common,O,O
pathophysiological,O,O
mechanisms,O,O
related,O,O
to,O,O
motor,O,O
fluctuations,O,O
.,O,O
Behavioral,O,O
effects,O,O
of,O,O
MK,B,B
-,I,I
801,I,I
on,O,O
reserpine,B,B
-,O,O
treated,O,O
mice,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
dizocilpine,B,B
(,O,O
MK,B,B
-,I,I
801,I,I
),O,O
",",O,O
a,O,O
noncompetitive,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
D,I,I
-,I,I
aspartate,I,I
(,O,O
NMDA,B,B
),O,O
receptor,O,O
antagonist,O,O
",",O,O
were,O,O
studied,O,O
on,O,O
dopamine,B,B
-,O,O
related,O,O
behaviors,O,O
induced,O,O
by,O,O
reserpine,B,B
treatments,O,O
.,O,O
This,O,O
study,O,O
focuses,O,O
on,O,O
behavioral,O,O
syndromes,O,O
that,O,O
may,O,O
used,O,O
as,O,O
models,O,O
for,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
",",O,O
or,O,O
tardive,O,O
dyskinesia,O,O
",",O,O
and,O,O
its,O,O
response,O,O
after,O,O
glutamatergic,O,O
blockage,O,O
.,O,O
Reserpine,B,B
(,O,O
1,O,B
mg,O,I
/,O,I
kg,O,I
),O,O
",",O,O
administered,O,O
once,O,O
every,O,O
other,O,O
day,O,O
for,O,O
4,O,O
days,O,O
",",O,O
produced,O,O
increases,O,O
in,O,O
orofacial,O,O
dyskinesia,O,O
",",O,O
tongue,O,O
protrusion,O,O
and,O,O
vacuous,O,O
chewing,O,O
in,O,O
mice,O,O
",",O,O
which,O,O
are,O,O
signs,O,O
indicative,O,O
of,O,O
tardive,O,O
dyskinesia,O,O
.,O,O
Reserpine,B,B
also,O,O
produced,O,O
tremor,O,B
and,O,O
catalepsy,O,B
",",O,O
which,O,O
are,O,O
signs,O,O
suggestive,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
.,O,O
MK,B,B
-,I,O
801,I,I
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
administered,O,O
30,O,O
min,O,O
before,O,O
the,O,O
observation,O,O
test,O,O
",",O,O
prevented,O,O
the,O,O
vacuous,O,O
chewing,O,O
movements,O,O
",",O,O
tongue,O,O
protrusions,O,O
and,O,O
catalepsy,O,B
induced,O,O
by,O,O
reserpine,B,B
.,O,O
However,O,O
",",O,O
MK,B,B
-,I,O
801,I,I
injection,O,O
produced,O,O
a,O,O
significant,O,O
increase,O,O
of,O,O
tremor,O,B
in,O,O
reserpine,B,B
-,O,O
treated,O,O
mice,O,O
.,O,O
Reserpine,B,B
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
administered,O,O
90,O,O
min,O,O
before,O,O
the,O,O
test,O,O
and,O,O
followed,O,O
by,O,O
apomophine,B,B
injection,O,O
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
5,O,O
min,O,O
before,O,O
the,O,O
test,O,O
",",O,O
did,O,O
not,O,O
produce,O,O
oral,O,O
dyskinesia,O,O
in,O,O
mice,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
reserpine,B,B
induced,O,O
increases,O,O
in,O,O
tremor,O,B
and,O,O
catalepsy,O,B
compared,O,O
to,O,O
control,O,O
mice,O,O
.,O,O
MK,B,B
-,I,I
801,I,I
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
administration,O,O
attenuated,O,O
the,O,O
catalepsy,O,B
and,O,O
tremor,O,B
induced,O,O
by,O,O
reserpine,B,B
.,O,O
Pretreatment,O,O
with,O,O
reserpine,B,B
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
24,O,O
h,O,O
before,O,O
the,O,O
observation,O,O
test,O,O
produced,O,O
increases,O,O
in,O,O
vacuous,O,O
chewing,O,O
movements,O,O
and,O,O
tongue,O,O
protrusion,O,O
",",O,O
as,O,O
well,O,O
as,O,O
increases,O,O
in,O,O
tremor,O,O
and,O,O
catalepsy,O,O
",",O,O
whereas,O,O
MK,B,B
-,I,O
801,I,I
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
injection,O,O
90,O,O
min,O,O
before,O,O
the,O,O
test,O,O
reversed,O,O
the,O,O
effects,O,O
of,O,O
reserpine,B,B
.,O,O
These,O,O
results,O,O
show,O,O
that,O,O
reserpine,B,B
produces,O,O
different,O,O
and,O,O
abnormal,O,O
movements,O,O
",",O,O
which,O,O
are,O,O
related,O,O
to,O,O
dose,O,O
and,O,O
schedule,O,O
employed,O,O
and,O,O
can,O,O
be,O,O
considered,O,O
as,O,O
parkinsonian,O,O
-,O,O
like,O,O
and,O,O
tardive,O,O
dsykinesia,O,O
signs,O,O
.,O,O
The,O,O
glutamatergic,O,O
blockage,O,O
produced,O,O
by,O,O
NMDA,B,B
can,O,O
restore,O,O
these,O,O
signs,O,O
",",O,O
such,O,O
as,O,O
vacuous,O,O
chewing,O,O
movements,O,O
",",O,O
tongue,O,O
protrusions,O,O
",",O,O
catalepsy,O,O
and,O,O
tremor,O,O
according,O,O
to,O,O
the,O,O
employed,O,O
model,O,O
.,O,O
Risperidone,B,B
-,O,I
associated,O,I
",",O,O
benign,O,O
transient,O,O
visual,O,O
disturbances,O,O
in,O,O
schizophrenic,O,O
patients,O,O
with,O,O
a,O,O
past,O,O
history,O,O
of,O,O
LSD,B,B
abuse,O,O
.,O,O
Two,O,O
schizophrenic,O,O
patients,O,O
",",O,O
who,O,O
had,O,O
a,O,O
prior,O,O
history,O,O
of,O,O
LSD,B,B
abuse,O,O
and,O,O
who,O,O
had,O,O
previously,O,O
developed,O,O
EPS,O,B
with,O,O
classic,O,O
antipsychotics,O,O
",",O,O
were,O,O
successfully,O,O
treated,O,O
with,O,O
risperidone,B,B
.,O,O
They,O,O
both,O,O
reported,O,O
short,O,O
episodes,O,O
of,O,O
transient,O,O
visual,O,O
disturbances,O,O
",",O,O
which,O,O
appeared,O,O
immediately,O,O
after,O,O
starting,O,O
treatment,O,O
with,O,O
risperidone,B,B
.,O,O
This,O,O
imagery,O,O
resembled,O,O
visual,O,O
disturbances,O,O
previously,O,O
experienced,O,O
as,O,O
related,O,O
to,O,O
prior,O,O
LSD,B,B
consumption,O,O
.,O,O
Risperidone,B,O
administration,O,O
was,O,O
continued,O,O
and,O,O
the,O,O
visual,O,O
disturbances,O,O
gradually,O,O
wore,O,O
off,O,O
.,O,O
During,O,O
a,O,O
six,O,O
-,O,O
month,O,O
follow,O,O
-,O,O
up,O,O
period,O,O
",",O,O
there,O,O
was,O,O
no,O,O
recurrence,O,O
of,O,O
visual,O,O
disturbances,O,O
.,O,O
This,O,O
phenomenon,O,O
may,O,O
be,O,O
interpreted,O,O
as,O,O
a,O,O
benign,O,O
",",O,O
short,O,O
-,O,O
term,O,O
and,O,O
self,O,O
-,O,O
limiting,O,O
side,O,O
effect,O,O
which,O,O
does,O,O
not,O,O
contraindicate,O,O
the,O,O
use,O,O
of,O,O
risperidone,B,O
or,O,O
interfere,O,O
with,O,O
treatment,O,O
.,O,O
Conclusions,O,O
based,O,O
on,O,O
two,O,O
case,O,O
reports,O,O
should,O,O
be,O,O
taken,O,O
with,O,O
appropriate,O,O
caution,O,O
.,O,O
Topiramate,B,B
-,O,O
induced,O,O
nephrolithiasis,O,O
.,O,O
Topiramate,B,B
is,O,O
a,O,O
recently,O,O
developed,O,O
antiepileptic,O,O
medication,O,O
that,O,O
is,O,O
becoming,O,O
more,O,O
widely,O,O
prescribed,O,O
because,O,O
of,O,O
its,O,O
efficacy,O,O
in,O,O
treating,O,O
refractory,O,O
seizures,O,O
.,O,O
Urologists,O,O
should,O,O
be,O,O
aware,O,O
that,O,O
this,O,O
medication,O,O
can,O,O
cause,O,O
metabolic,O,O
acidosis,O,O
in,O,O
patients,O,O
secondary,O,O
to,O,O
inhibition,O,O
of,O,O
carbonic,O,B
anhydrase,O,I
.,O,O
In,O,O
addition,O,O
",",O,O
a,O,O
distal,O,O
tubular,O,O
acidification,O,O
defect,O,O
may,O,O
result,O,O
",",O,O
thus,O,O
impairing,O,O
the,O,O
normal,O,O
compensatory,O,O
drop,O,O
in,O,O
urine,O,O
pH,O,O
.,O,O
These,O,O
factors,O,O
can,O,O
lead,O,O
to,O,O
the,O,O
development,O,O
of,O,O
calcium,B,B
phosphate,I,I
nephrolithiasis,O,I
.,O,O
We,O,O
report,O,O
the,O,O
first,O,O
two,O,O
cases,O,O
of,O,O
topiramate,B,B
-,O,I
induced,O,I
nephrolithiasis,O,I
in,O,O
the,O,O
urologic,O,O
literature,O,O
.,O,O
Ketamine,B,B
in,O,O
war,O,O
/,O,O
tropical,O,O
surgery,O,O
(,O,O
a,O,O
final,O,O
tribute,O,O
to,O,O
the,O,O
racemic,O,O
mixture,O,O
),O,O
.,O,O
A,O,O
technique,O,O
of,O,O
continuous,O,O
intravenous,O,O
anaesthesia,O,O
with,O,O
ketamine,B,B
was,O,O
used,O,O
successfully,O,O
during,O,O
the,O,O
Somalia,O,O
civil,O,O
war,O,O
in,O,O
1994,O,O
and,O,O
in,O,O
north,O,O
Uganda,O,O
in,O,O
1999,O,O
for,O,O
64,O,O
operations,O,O
in,O,O
62,O,O
patients,O,O
",",O,O
aged,O,O
from,O,O
6,O,O
weeks,O,O
to,O,O
70,O,O
years,O,O
",",O,O
undergoing,O,O
limb,O,O
and,O,O
abdominal,O,O
surgery,O,O
including,O,O
caesarian,O,O
sections,O,O
and,O,O
interventions,O,O
in,O,O
neonates,O,O
.,O,O
Operations,O,O
lasting,O,O
up,O,O
to,O,O
2h,O,O
could,O,O
be,O,O
performed,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
sophisticated,O,O
equipment,O,O
such,O,O
as,O,O
pulse,O,O
oximeters,O,O
or,O,O
ventilators,O,O
in,O,O
patients,O,O
on,O,O
spontaneous,O,O
ventilation,O,O
breathing,O,O
air,O,O
/,O,O
oxygen,B,B
only,O,O
.,O,O
After,O,O
premedication,O,O
with,O,O
diazepam,B,B
",",O,O
glycopyrrolate,B,B
and,O,O
local,O,O
anaesthesia,O,O
",",O,O
and,O,O
induction,O,O
with,O,O
standard,O,O
doses,O,O
of,O,O
ketamine,B,B
",",O,O
a,O,O
maintenance,O,O
dose,O,O
of,O,O
10,O,O
-,O,O
20,O,O
microg,O,O
/,O,O
kg,O,O
/,O,O
min,O,O
of,O,O
ketamine,B,B
proved,O,O
safe,O,O
and,O,O
effective,O,O
.,O,O
Emphasis,O,O
was,O,O
placed,O,O
on,O,O
bedside,O,O
clinical,O,O
monitoring,O,O
",",O,O
relying,O,O
heavily,O,O
on,O,O
the,O,O
heart,O,B
rate,O,I
.,O,O
Diazepam,B,B
",",O,O
unless,O,O
contraindicated,O,O
or,O,O
risky,O,O
",",O,O
remains,O,O
the,O,O
only,O,O
necessary,O,O
complementary,O,O
drug,O,O
to,O,O
ketamine,B,B
as,O,O
it,O,O
buffers,O,O
its,O,O
cardiovascular,O,O
response,O,O
and,O,O
decreases,O,O
the,O,O
duration,O,O
and,O,O
intensity,O,O
of,O,O
operative,O,O
and,O,O
postoperative,O,O
hallucinations,O,O
.,O,O
Local,O,O
anaesthetic,O,B
blocks,O,O
were,O,O
useful,O,O
in,O,O
decreasing,O,O
the,O,O
requirement,O,O
for,O,O
postoperative,O,O
analgesia,O,O
.,O,O
An,O,O
antisialogue,O,B
was,O,O
usually,O,O
unnecessary,O,O
in,O,O
operations,O,O
lasting,O,O
up,O,O
to,O,O
2,O,O
h,O,O
",",O,O
glycopyrrolate,B,B
being,O,O
the,O,O
best,O,O
choice,O,O
for,O,O
its,O,O
lowest,O,O
psychotropic,O,O
and,O,O
chronotropic,O,O
effects,O,O
",",O,O
especially,O,O
in,O,O
a,O,O
hot,O,O
climate,O,O
.,O,O
Experience,O,O
in,O,O
war,O,O
/,O,O
tropical,O,O
settings,O,O
suggests,O,O
this,O,O
technique,O,O
could,O,O
be,O,O
useful,O,O
in,O,O
civilian,O,O
contexts,O,O
such,O,O
as,O,O
outdoor,O,O
life,O,O
-,O,O
saving,O,O
emergency,O,O
surgery,O,O
or,O,O
in,O,O
mass,O,O
casualties,O,O
where,O,O
",",O,O
e,O,O
.,O,O
g,O,O
.,O,O
amputation,O,O
and,O,O
rapid,O,O
extrication,O,O
were,O,O
required,O,O
.,O,O
Intravenous,O,O
ribavirin,B,B
treatment,O,O
for,O,O
severe,O,O
adenovirus,O,B
disease,O,O
in,O,O
immunocompromised,O,O
children,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Adenovirus,O,B
is,O,O
an,O,O
important,O,O
cause,O,O
of,O,O
morbidity,O,O
and,O,O
mortality,O,O
in,O,O
the,O,O
immunocompromised,O,O
host,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
severe,O,O
adenovirus,O,B
disease,O,O
in,O,O
pediatrics,O,O
is,O,O
increasing,O,O
in,O,O
association,O,O
with,O,O
growing,O,O
numbers,O,O
of,O,O
immunocompromised,O,O
children,O,O
",",O,O
where,O,O
case,O,O
fatality,O,O
rates,O,O
as,O,O
high,O,O
as,O,O
50,O,O
%,O,O
to,O,O
80,O,O
%,O,O
have,O,O
been,O,O
reported,O,O
.,O,O
There,O,O
are,O,O
no,O,O
approved,O,O
antiviral,O,B
agents,O,O
with,O,O
proven,O,O
efficacy,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
severe,O,O
adenovirus,O,B
disease,O,O
",",O,O
nor,O,O
are,O,O
there,O,O
any,O,O
prospective,O,O
randomized,O,O
",",O,O
controlled,O,O
trials,O,O
of,O,O
potentially,O,O
useful,O,O
anti,O,B
-,O,I
adenovirus,O,I
therapies,O,O
.,O,O
Apparent,O,O
clinical,O,O
success,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
severe,O,O
adenovirus,O,B
disease,O,O
is,O,O
limited,O,O
to,O,O
a,O,O
few,O,O
case,O,O
reports,O,O
and,O,O
small,O,O
series,O,O
.,O,O
Experience,O,O
is,O,O
greatest,O,O
with,O,O
intravenous,O,O
ribavirin,B,B
and,O,O
cidofovir,B,B
.,O,O
Ribavirin,B,B
",",O,O
a,O,O
guanosine,B,B
analogue,O,O
",",O,O
has,O,O
broad,O,O
antiviral,O,O
activity,O,O
against,O,O
both,O,O
RNA,O,B
and,O,O
DNA,O,B
viruses,O,O
",",O,O
including,O,O
documented,O,O
activity,O,O
against,O,O
adenovirus,O,B
in,O,O
vitro,O,O
.,O,O
Ribavirin,B,B
is,O,O
licensed,O,O
in,O,O
aerosol,O,O
form,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
respiratory,O,O
syncytial,O,O
virus,O,O
infection,O,O
",",O,O
and,O,O
orally,O,O
in,O,O
combination,O,O
with,O,O
interferon,O,B
to,O,O
treat,O,O
hepatitis,O,B
C,O,I
.,O,O
Intravenous,O,O
ribavirin,B,B
is,O,O
the,O,O
treatment,O,O
of,O,O
choice,O,O
for,O,O
infection,O,O
with,O,O
hemorrhagic,O,O
fever,O,O
viruses,O,O
.,O,O
The,O,O
most,O,O
common,O,O
adverse,O,O
effect,O,O
of,O,O
intravenous,O,O
ribavirin,B,B
is,O,O
reversible,O,O
mild,O,O
anemia,O,O
.,O,O
The,O,O
use,O,O
of,O,O
cidofovir,B,B
in,O,O
severe,O,O
adenovirus,O,O
infection,O,O
has,O,O
been,O,O
limited,O,O
by,O,O
adverse,O,O
effects,O,O
",",O,O
the,O,O
most,O,O
significant,O,O
of,O,O
which,O,O
is,O,O
nephrotoxicity,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
We,O,O
report,O,O
our,O,O
experience,O,O
with,O,O
intravenous,O,O
ribavirin,B,B
therapy,O,O
for,O,O
severe,O,O
adenovirus,O,B
disease,O,O
in,O,O
a,O,O
series,O,O
of,O,O
immunocompromised,O,O
children,O,O
and,O,O
review,O,O
the,O,O
literature,O,O
.,O,O
DESIGN,O,O
/,O,O
METHODS,O,O
:,O,O
We,O,O
retrospectively,O,O
reviewed,O,O
the,O,O
medical,O,O
records,O,O
of,O,O
5,O,O
children,O,O
treated,O,O
with,O,O
intravenous,O,O
ribavirin,B,B
for,O,O
documented,O,O
severe,O,O
adenovirus,O,B
disease,O,O
.,O,O
Two,O,O
patients,O,O
developed,O,O
adenovirus,O,B
hemorrhagic,O,I
cystitis,O,I
after,O,O
cardiac,O,O
and,O,O
bone,O,O
marrow,O,O
transplants,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
bone,O,O
marrow,O,O
transplant,O,O
patient,O,O
also,O,O
received,O,O
intravenous,O,O
cidofovir,B,B
for,O,O
progressive,O,O
disseminated,O,O
disease,O,O
.,O,O
An,O,O
additional,O,O
3,O,O
children,O,O
developed,O,O
adenovirus,O,B
pneumonia,O,I
;,O,O
2,O,O
were,O,O
neonates,O,O
",",O,O
1,O,O
of,O,O
whom,O,O
had,O,O
partial,O,O
DiGeorge,O,B
syndrome,O,I
.,O,O
The,O,O
remaining,O,O
infant,O,O
had,O,O
recently,O,O
undergone,O,O
a,O,O
cardiac,O,O
transplant,O,O
.,O,O
Intravenous,O,O
ribavirin,B,B
was,O,O
administered,O,O
on,O,O
a,O,O
compassionate,O,O
-,O,O
use,O,O
protocol,O,O
.,O,O
RESULTS,O,O
:,O,O
Complete,O,O
clinical,O,O
recovery,O,O
followed,O,O
later,O,O
by,O,O
viral,O,O
clearance,O,O
was,O,O
observed,O,O
in,O,O
2,O,O
children,O,O
:,O,O
the,O,O
cardiac,O,O
transplant,O,O
recipient,O,O
with,O,O
adenovirus,O,B
hemorrhagic,O,I
cystitis,O,I
and,O,O
the,O,O
immunocompetent,O,O
neonate,O,O
with,O,O
adenovirus,O,B
pneumonia,O,I
.,O,O
The,O,O
remaining,O,O
3,O,O
children,O,O
died,O,O
of,O,O
adenovirus,O,B
disease,O,O
.,O,O
Intravenous,O,O
ribavirin,B,B
therapy,O,O
was,O,O
well,O,O
tolerated,O,O
.,O,O
Use,O,O
of,O,O
cidofovir,B,B
in,O,O
1,O,O
child,O,O
was,O,O
associated,O,O
with,O,O
progressive,O,O
renal,O,O
failure,O,O
and,O,O
neutropenia,O,O
.,O,O
DISCUSSION,O,O
:,O,O
Our,O,O
series,O,O
of,O,O
patients,O,O
is,O,O
representative,O,O
of,O,O
the,O,O
spectrum,O,O
of,O,O
immunocompromised,O,O
children,O,O
at,O,O
greatest,O,O
risk,O,O
for,O,O
severe,O,O
adenovirus,O,B
disease,O,O
",",O,O
namely,O,O
solid,O,O
-,O,O
organ,O,O
and,O,O
bone,O,O
marrow,O,O
transplant,O,O
recipients,O,O
",",O,O
neonates,O,O
",",O,O
and,O,O
children,O,O
with,O,O
immunodeficiency,O,O
.,O,O
Although,O,O
intravenous,O,O
ribavirin,B,B
was,O,O
not,O,O
effective,O,O
for,O,O
all,O,O
children,O,O
with,O,O
severe,O,O
adenovirus,O,B
disease,O,I
in,O,O
this,O,O
series,O,O
or,O,O
in,O,O
the,O,O
literature,O,O
",",O,O
therapy,O,O
is,O,O
unlikely,O,O
to,O,O
be,O,O
of,O,O
benefit,O,O
if,O,O
begun,O,O
late,O,O
in,O,O
the,O,O
course,O,O
of,O,O
the,O,O
infection,O,O
.,O,O
Early,O,O
identification,O,O
",",O,O
eg,O,O
by,O,O
polymerase,O,O
chain,O,O
reaction,O,O
of,O,O
those,O,O
patients,O,O
at,O,O
risk,O,O
of,O,O
disseminated,O,O
adenovirus,O,B
disease,O,I
may,O,O
permit,O,O
earlier,O,O
antiviral,O,O
treatment,O,O
and,O,O
better,O,O
evaluation,O,O
of,O,O
therapeutic,O,O
response,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Two,O,O
of,O,O
5,O,O
children,O,O
with,O,O
severe,O,O
adenovirus,O,B
disease,O,O
treated,O,O
with,O,O
intravenous,O,O
ribavirin,B,B
recovered,O,O
.,O,O
The,O,O
availability,O,O
of,O,O
newer,O,O
rapid,O,O
diagnostic,O,O
techniques,O,O
",",O,O
such,O,O
as,O,O
polymerase,O,O
chain,O,O
reaction,O,O
",",O,O
may,O,O
make,O,O
earlier,O,O
",",O,O
more,O,O
effective,O,O
treatment,O,O
of,O,O
adenovirus,O,B
infection,O,O
possible,O,O
.,O,O
Given,O,O
the,O,O
seriousness,O,O
and,O,O
increasing,O,O
prevalence,O,O
of,O,O
adenovirus,O,B
disease,O,O
in,O,O
certain,O,O
hosts,O,O
",",O,O
especially,O,O
children,O,O
",",O,O
a,O,O
large,O,O
",",O,O
multicenter,O,O
clinical,O,O
trial,O,O
of,O,O
potentially,O,O
useful,O,O
anti,O,O
-,O,O
adenoviral,O,O
therapies,O,O
",",O,O
such,O,O
as,O,O
intravenous,O,O
ribavirin,B,B
",",O,O
is,O,O
clearly,O,O
required,O,O
to,O,O
demonstrate,O,O
the,O,O
most,O,O
effective,O,O
and,O,O
least,O,O
toxic,O,O
therapy,O,O
.,O,O
Delayed,O,O
asystolic,O,O
cardiac,O,O
arrest,O,O
after,O,O
diltiazem,B,B
overdose,O,O
;,O,O
resuscitation,O,O
with,O,O
high,O,O
dose,O,O
intravenous,O,O
calcium,B,B
.,O,O
A,O,O
51,O,O
year,O,O
old,O,O
man,O,O
took,O,O
a,O,O
mixed,O,O
overdose,O,O
including,O,O
1,O,O
.,O,O
8,O,O
-,O,O
3,O,O
.,O,O
6,O,O
g,O,O
of,O,O
diltiazem,B,B
",",O,O
paracetamol,B,B
",",O,O
aspirin,B,B
",",O,O
isosorbide,B,B
nitrate,B,I
",",O,O
and,O,O
alcohol,B,B
.,O,O
He,O,O
initially,O,O
presented,O,O
to,O,O
hospital,O,O
after,O,O
six,O,O
hours,O,O
with,O,O
mild,O,O
hypotension,O,O
and,O,O
was,O,O
treated,O,O
with,O,O
activated,O,O
charcoal,O,B
and,O,O
intravenous,O,O
fluids,O,O
.,O,O
Eighteen,O,O
hours,O,O
after,O,O
the,O,O
overdose,O,O
he,O,O
had,O,O
two,O,O
generalised,O,O
tonic,O,O
-,O,O
clonic,O,O
seizures,O,O
.,O,O
The,O,O
patient,O,O
remained,O,O
unresponsive,O,O
with,O,O
junctional,O,O
bradycardia,O,O
",",O,O
unrecordable,O,O
blood,O,B
pressure,O,I
",",O,O
and,O,O
then,O,O
became,O,O
asystolic,O,O
.,O,O
He,O,O
was,O,O
resuscitated,O,O
with,O,O
high,O,O
dose,O,O
(,O,O
13,O,O
.,O,O
5,O,O
g,O,O
),O,O
intravenous,O,O
calcium,B,B
and,O,O
adrenaline,B,B
(,O,O
epinephrine,B,B
),O,O
.,O,O
He,O,O
required,O,O
inotropic,O,O
support,O,O
and,O,O
temporary,O,O
pacing,O,O
over,O,O
the,O,O
next,O,O
48,O,O
hours,O,O
.,O,O
This,O,O
case,O,O
suggests,O,O
there,O,O
is,O,O
a,O,O
role,O,O
for,O,O
aggressive,O,O
high,O,O
dose,O,O
intravenous,O,O
calcium,B,B
therapy,O,O
in,O,O
severe,O,O
diltiazem,B,O
overdose,O,O
",",O,O
particularly,O,O
with,O,O
the,O,O
onset,O,O
of,O,O
asystole,O,O
.,O,O
It,O,O
should,O,O
be,O,O
considered,O,O
early,O,O
in,O,O
cases,O,O
of,O,O
cardiac,O,O
arrest,O,O
after,O,O
diltiazem,B,O
overdose,O,O
.,O,O
The,O,O
case,O,O
also,O,O
highlights,O,O
the,O,O
problems,O,O
with,O,O
delayed,O,O
toxicity,O,O
when,O,O
whole,O,O
bowel,O,O
irrigation,O,O
is,O,O
not,O,O
administered,O,O
.,O,O
Low,B,B
-,I,I
molecular,I,I
-,I,I
weight,I,I
heparin,I,I
for,O,O
the,O,O
treatment,O,O
of,O,O
patients,O,O
with,O,O
mechanical,O,O
heart,O,O
valves,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
interruption,O,O
of,O,O
oral,O,O
anticoagulant,O,O
(,O,O
OAC,O,B
),O,O
administration,O,O
is,O,O
sometimes,O,O
indicated,O,O
in,O,O
patients,O,O
with,O,O
mechanical,O,O
heart,O,O
valves,O,O
",",O,O
mainly,O,O
before,O,O
noncardiac,O,O
surgery,O,O
",",O,O
non,O,O
-,O,O
surgical,O,O
interventions,O,O
",",O,O
and,O,O
pregnancy,O,O
.,O,O
Unfractionated,B,B
heparin,I,I
(,O,O
UH,B,B
),O,O
is,O,O
currently,O,O
the,O,O
substitute,O,O
for,O,O
selected,O,O
patients,O,O
.,O,O
Low,B,B
-,I,I
molecular,I,I
-,I,I
weight,I,I
heparin,I,I
(,O,O
LMWH,B,B
),O,O
offers,O,O
theoretical,O,O
advantages,O,O
over,O,O
UH,B,B
",",O,O
but,O,O
is,O,O
not,O,O
currently,O,O
considered,O,O
in,O,O
clinical,O,O
guidelines,O,O
as,O,O
an,O,O
alternative,O,O
to,O,O
UH,B,B
in,O,O
patients,O,O
with,O,O
prosthetic,O,O
valves,O,O
.,O,O
HYPOTHESIS,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
review,O,O
the,O,O
data,O,O
accumulated,O,O
so,O,O
far,O,O
on,O,O
the,O,O
use,O,O
of,O,O
LMWH,B,B
in,O,O
this,O,O
patient,O,O
population,O,O
and,O,O
to,O,O
discuss,O,O
its,O,O
applicability,O,O
in,O,O
common,O,O
practice,O,O
.,O,O
METHODS,O,O
:,O,O
For,O,O
this,O,O
paper,O,O
",",O,O
the,O,O
current,O,O
medical,O,O
literature,O,O
on,O,O
LMWH,B,B
in,O,O
patients,O,O
with,O,O
mechanical,O,O
heart,O,O
valves,O,O
was,O,O
extensively,O,O
reviewed,O,O
.,O,O
RESULTS,O,O
:,O,O
There,O,O
were,O,O
eight,O,O
series,O,O
and,O,O
six,O,O
case,O,O
reports,O,O
.,O,O
None,O,O
of,O,O
the,O,O
studies,O,O
was,O,O
randomized,O,O
",",O,O
and,O,O
only,O,O
one,O,O
was,O,O
prospective,O,O
.,O,O
Data,O,O
to,O,O
establish,O,O
the,O,O
thromboembolic,O,O
risk,O,O
were,O,O
incomplete,O,O
.,O,O
After,O,O
excluding,O,O
case,O,O
reports,O,O
",",O,O
the,O,O
following,O,O
groups,O,O
were,O,O
constructed,O,O
:,O,O
(,O,O
a,O,O
),O,O
short,O,O
-,O,O
term,O,O
administration,O,O
",",O,O
after,O,O
valve,O,O
insertion,O,O
(,O,O
n,O,O
=,O,O
212,O,O
),O,O
;,O,O
(,O,O
b,O,O
),O,O
short,O,O
-,O,O
term,O,O
",",O,O
perioperative,O,O
(,O,O
noncardiac,O,O
),O,O
/,O,O
periprocedural,O,O
(,O,O
n,O,O
=,O,O
114,O,O
),O,O
;,O,O
(,O,O
c,O,O
),O,O
long,O,O
-,O,O
term,O,O
",",O,O
due,O,O
to,O,O
intolerance,O,O
to,O,O
OAC,O,B
(,O,O
n,O,O
=,O,O
16,O,O
),O,O
;,O,O
(,O,O
d,O,O
),O,O
long,O,O
-,O,O
term,O,O
",",O,O
in,O,O
pregnancy,O,O
(,O,O
n,O,O
=,O,O
10,O,O
),O,O
.,O,O
The,O,O
incidence,O,O
rate,O,O
of,O,O
thromboembolism,O,B
was,O,O
0,O,O
.,O,O
9,O,O
%,O,O
for,O,O
all,O,O
the,O,O
studies,O,O
and,O,O
0,O,O
.,O,O
5,O,O
",",O,O
0,O,O
",",O,O
20,O,O
",",O,O
and,O,O
0,O,O
%,O,O
in,O,O
groups,O,O
a,O,O
",",O,O
b,O,O
",",O,O
c,O,O
",",O,O
and,O,O
d,O,O
",",O,O
respectively,O,O
;,O,O
for,O,O
hemorrhage,O,B
",",O,O
the,O,O
overall,O,O
rate,O,O
was,O,O
3,O,O
.,O,O
4,O,O
%,O,O
(,O,O
3,O,O
.,O,O
8,O,O
",",O,O
2,O,O
.,O,O
6,O,O
",",O,O
10,O,O
",",O,O
and,O,O
0,O,O
%,O,O
for,O,O
the,O,O
respective,O,O
groups,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
patients,O,O
with,O,O
mechanical,O,O
heart,O,O
valves,O,O
",",O,O
short,O,O
-,O,O
term,O,O
LMWH,B,B
therapy,O,O
compares,O,O
favorably,O,O
with,O,O
UH,B,B
.,O,O
Data,O,O
on,O,O
mid,O,B
-,O,I
and,O,I
long,O,I
-,O,I
term,O,I
LMWH,B,B
administration,O,O
in,O,O
these,O,O
patients,O,O
are,O,O
sparse,O,O
.,O,O
Further,O,O
randomized,O,O
studies,O,O
are,O,O
needed,O,O
to,O,O
confirm,O,O
the,O,O
safety,O,O
and,O,O
precise,O,O
indications,O,O
for,O,O
the,O,O
use,O,O
of,O,O
LMWH,B,B
in,O,O
patients,O,O
with,O,O
mechanical,O,O
heart,O,O
valves,O,O
.,O,O
Cardiac,O,O
arrest,O,O
after,O,O
intravenous,O,O
metoclopramide,B,B
-,O,I
a,O,O
case,O,O
of,O,O
five,O,O
repeated,O,O
injections,O,O
of,O,O
metoclopramide,B,B
causing,O,O
five,O,O
episodes,O,O
of,O,O
cardiac,O,O
arrest,O,O
.,O,O
We,O,O
describe,O,O
a,O,O
patient,O,O
where,O,O
intravenous,O,O
injection,O,O
of,O,O
metoclopramide,B,B
was,O,O
immediately,O,O
followed,O,O
by,O,O
asystole,O,O
repeatedly,O,O
.,O,O
The,O,O
patient,O,O
received,O,O
metoclopramide,B,B
10,O,O
mg,O,O
i,O,O
.,O,O
v,O,O
times,O,O
during,O,O
48,O,O
h,O,O
.,O,O
After,O,O
interviewing,O,O
the,O,O
attending,O,O
nurses,O,O
and,O,O
reviewing,O,O
the,O,O
written,O,O
documentation,O,O
",",O,O
it,O,O
is,O,O
clear,O,O
that,O,O
every,O,O
administration,O,O
of,O,O
metoclopramide,B,B
was,O,O
immediately,O,O
(,O,O
within,O,O
s,O,O
),O,O
followed,O,O
by,O,O
asystole,O,O
.,O,O
The,O,O
asystole,O,O
lasted,O,O
15,O,O
-,O,O
30,O,O
s,O,O
on,O,O
four,O,O
occasions,O,O
",",O,O
on,O,O
one,O,O
occasion,O,O
it,O,O
lasted,O,O
2,O,O
min,O,O
.,O,O
The,O,O
patient,O,O
received,O,O
atropine,B,B
0,O,O
.,O,O
5,O,O
-,O,O
1,O,O
mg,O,O
and,O,O
chest,O,O
compressions,O,O
",",O,O
before,O,O
sinus,O,O
rhythm,O,O
again,O,O
took,O,O
over,O,O
.,O,O
We,O,O
interpret,O,O
this,O,O
as,O,O
episodes,O,O
of,O,O
cardiac,O,O
arrest,O,O
caused,O,O
by,O,O
metoclopramide,B,B
.,O,O
The,O,O
rapid,O,O
injection,O,O
via,O,O
the,O,O
central,O,O
venous,O,O
route,O,O
and,O,O
the,O,O
concomitant,O,O
tapering,O,O
of,O,O
dopamine,B,O
infusion,O,O
might,O,O
have,O,O
contributed,O,O
in,O,O
precipitating,O,O
the,O,O
adverse,O,O
drug,O,O
reaction,O,O
.,O,O
Immunohistochemical,O,O
study,O,O
on,O,O
inducible,O,O
type,O,O
of,O,O
nitric,B,B
oxide,I,I
(,O,O
iNOS,O,B
),O,O
",",O,O
basic,O,B
fibroblast,O,I
growth,O,I
factor,O,I
(,O,O
bFGF,O,B
),O,O
and,O,O
tumor,O,B
growth,O,I
factor,O,I
-,O,I
beta1,O,I
(,O,O
TGF,O,B
-,O,I
beta1,O,I
),O,O
in,O,O
arteritis,O,O
induced,O,O
in,O,O
rats,O,O
by,O,O
fenoldopam,B,O
and,O,O
theophylline,B,O
",",O,O
vasodilators,O,O
.,O,O
Arteritis,O,O
induced,O,O
in,O,O
rats,O,O
by,O,O
vasodilators,O,O
",",O,O
fenoldopam,B,O
and,O,O
theophylline,B,O
",",O,O
was,O,O
examined,O,O
immunohistochemically,O,O
for,O,O
expressions,O,O
of,O,O
inducible,O,O
type,O,O
of,O,O
nitric,B,B
oxide,I,I
synthase,O,I
(,O,O
iNOS,O,B
),O,O
",",O,O
basic,O,B
fibroblast,O,I
growth,O,I
factor,O,I
(,O,O
bFGF,O,B
),O,O
and,O,O
tumor,O,B
growth,O,I
factor,O,I
-,O,I
beta1,O,I
(,O,O
TGF,O,B
-,O,I
beta1,O,I
),O,O
.,O,O
Rats,O,O
were,O,O
administered,O,O
fenoldopam,B,B
for,O,O
24,O,O
hours,O,O
by,O,O
intravenous,O,O
infusion,O,O
with,O,O
or,O,O
without,O,O
following,O,O
repeated,O,O
daily,O,O
oral,O,O
administrations,O,O
of,O,O
theophylline,B,B
.,O,O
Irrespective,O,O
of,O,O
theophylline,B,B
administration,O,O
",",O,O
iNOS,O,B
antigens,O,O
were,O,O
remarkably,O,O
abundant,O,O
in,O,O
ED,O,O
-,O,O
1,O,O
-,O,O
positive,O,O
cells,O,O
on,O,O
day,O,O
5,O,O
and,O,O
8,O,O
post,O,O
-,O,O
fenoldopam,B,B
-,O,O
infusion,O,O
(,O,O
DPI,O,O
),O,O
;,O,O
bFGF,O,B
antigens,O,O
were,O,O
remarkably,O,O
abundant,O,O
in,O,O
ED,O,O
-,O,O
1,O,O
-,O,O
positive,O,O
cells,O,O
on,O,O
1,O,O
and,O,O
3,O,O
DPI,O,O
;,O,O
TGF,O,B
-,O,O
beta1,O,I
antigens,O,O
were,O,O
observed,O,O
in,O,O
ED,O,O
-,O,O
1,O,O
-,O,O
positive,O,O
cells,O,O
on,O,O
and,O,O
after,O,O
5,O,O
DPI,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
peak,O,O
expression,O,O
of,O,O
iNOS,O,B
antigen,O,O
was,O,O
followed,O,O
by,O,O
that,O,O
of,O,O
bFGF,O,B
antigen,O,O
",",O,O
and,O,O
bFGF,O,B
may,O,O
have,O,O
a,O,O
suppressive,O,O
effect,O,O
on,O,O
iNOS,O,B
expression,O,O
in,O,O
these,O,O
rat,O,O
arteritis,O,O
models,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
TGF,O,B
-,O,O
beta1,O,I
was,O,O
not,O,O
considered,O,O
to,O,O
have,O,O
a,O,O
suppressive,O,O
effect,O,O
on,O,O
iNOS,O,B
expression,O,O
in,O,O
these,O,O
models,O,O
.,O,O
The,O,O
striatum,O,B
as,O,O
a,O,O
target,O,O
for,O,O
anti,O,O
-,O,O
rigor,O,O
effects,O,O
of,O,O
an,O,O
antagonist,O,O
of,O,O
mGluR1,O,B
",",O,O
but,O,O
not,O,O
an,O,O
agonist,O,O
of,O,O
group,O,O
II,O,O
metabotropic,O,O
glutamate,B,B
receptors,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
find,O,O
out,O,O
whether,O,O
the,O,O
metabotropic,O,O
receptor,O,O
1,O,O
(,O,O
mGluR1,O,B
),O,O
and,O,O
group,O,O
II,O,O
mGluRs,O,O
",",O,O
localized,O,O
in,O,O
the,O,O
striatum,O,B
",",O,O
are,O,O
involved,O,O
in,O,O
antiparkinsonian,O,O
-,O,O
like,O,O
effects,O,O
in,O,O
rats,O,O
.,O,O
Haloperidol,B,B
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
ip,O,O
),O,O
induced,O,O
parkinsonian,O,O
-,O,O
like,O,O
muscle,O,O
rigidity,O,O
",",O,O
measured,O,O
as,O,O
an,O,O
increased,O,O
resistance,O,O
of,O,O
a,O,O
rat,O,O
',O,O
s,O,O
hind,O,O
foot,O,O
to,O,O
passive,O,O
flexion,O,O
and,O,O
extension,O,O
at,O,O
the,O,O
ankle,O,O
joint,O,O
.,O,O
(,B,O
RS,I,B
),I,O
-,I,O
1,I,B
-,I,I
aminoindan,I,I
-,I,I
1,I,I
",",I,O
5,I,O
-,I,O
dicarboxylic,I,O
acid,I,O
(,O,O
AIDA,B,B
;,O,O
0,O,O
.,O,O
5,O,O
-,O,O
15,O,O
microg,O,O
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,O
),O,O
",",O,O
a,O,O
potent,O,O
and,O,O
selective,O,O
mGluR1,O,B
antagonist,O,O
",",O,O
or,O,O
(,B,O
2R,I,B
",",I,O
4R,I,I
),I,O
-,I,O
4,I,I
-,I,I
aminopyrrolidine,I,I
-,I,I
2,I,I
",",I,O
4,I,I
-,I,I
dicarboxylate,I,I
(,O,O
2R,B,I
",",I,O
4R,I,I
-,I,I
APDC,I,I
;,O,O
7,O,O
.,O,O
5,O,O
-,O,O
15,O,O
microg,O,B
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,B
),O,O
",",O,O
a,O,O
selective,O,O
group,O,O
II,O,O
agonist,O,O
",",O,O
was,O,O
injected,O,O
bilaterally,O,O
into,O,O
the,O,O
striatum,O,B
of,O,O
haloperidol,B,B
-,O,O
treated,O,O
animals,O,O
.,O,O
AIDA,B,B
in,O,O
doses,O,O
of,O,O
7,O,O
.,O,O
5,O,O
-,O,O
15,O,O
microg,O,B
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,B
diminished,O,O
the,O,O
haloperidol,B,B
-,O,O
induced,O,O
muscle,O,O
rigidity,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
2R,B,B
",",I,O
4R,I,B
-,I,O
APDC,I,B
injections,O,O
were,O,O
ineffective,O,O
.,O,O
The,O,O
present,O,O
results,O,O
may,O,O
suggest,O,O
that,O,O
the,O,O
blockade,O,O
of,O,O
striatal,O,O
mGluR1,O,B
",",O,O
but,O,O
not,O,O
the,O,O
stimulation,O,O
of,O,O
group,O,O
II,O,O
mGluRs,O,O
",",O,O
may,O,O
ameliorate,O,O
parkinsonian,O,O
muscle,O,O
rigidity,O,O
.,O,O
A,O,O
phase,O,O
II,O,O
study,O,O
of,O,O
thalidomide,B,B
in,O,O
advanced,O,O
metastatic,O,O
renal,O,O
cell,O,O
carcinoma,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
toxicity,O,O
and,O,O
activity,O,O
of,O,O
thalidomide,B,B
in,O,O
patients,O,O
with,O,O
advanced,O,O
metastatic,O,O
renal,O,O
cell,O,O
cancer,O,O
and,O,O
to,O,O
measure,O,O
changes,O,O
of,O,O
one,O,O
angiogenic,O,O
factor,O,O
",",O,O
vascular,O,O
endothelial,O,O
growth,O,O
factor,O,O
(,O,O
VEGF,O,B
),O,O
165,O,O
",",O,O
with,O,O
therapy,O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
29,O,O
patients,O,O
were,O,O
enrolled,O,O
on,O,O
a,O,O
study,O,O
of,O,O
thalidomide,B,B
using,O,O
an,O,O
intra,O,O
-,O,O
patient,O,O
dose,O,O
escalation,O,O
schedule,O,O
.,O,O
Patients,O,O
began,O,O
thalidomide,B,B
at,O,O
400,O,O
mg,O,O
/,O,O
d,O,O
and,O,O
escalated,O,O
as,O,O
tolerated,O,O
to,O,O
1200,O,O
mg,O,O
/,O,O
d,O,O
by,O,O
day,O,O
54,O,O
.,O,O
Fifty,O,O
-,O,O
nine,O,O
per,O,O
cent,O,O
of,O,O
patients,O,O
had,O,O
had,O,O
previous,O,O
therapy,O,O
with,O,O
IL,O,B
-,O,O
2,O,O
and,O,O
52,O,O
%,O,O
were,O,O
performance,O,O
status,O,O
2,O,O
or,O,O
3,O,O
.,O,O
Systemic,O,O
plasma,O,O
VEGF165,O,B
levels,O,O
were,O,O
measured,O,O
by,O,O
dual,O,O
monoclonal,O,O
ELISA,O,O
in,O,O
8,O,O
patients,O,O
.,O,O
RESULTS,O,O
:,O,O
24,O,O
patients,O,O
were,O,O
evaluable,O,O
for,O,O
response,O,O
with,O,O
one,O,O
partial,O,O
response,O,O
of,O,O
11,O,O
months,O,O
duration,O,O
of,O,O
a,O,O
patient,O,O
with,O,O
hepatic,O,O
and,O,O
pulmonary,O,O
metastases,O,O
(,O,O
4,O,O
%,O,O
),O,O
",",O,O
one,O,O
minor,O,O
response,O,O
",",O,O
and,O,O
2,O,O
patients,O,O
stable,O,O
for,O,O
over,O,O
6,O,O
months,O,O
.,O,O
Somnolence,O,O
and,O,O
constipation,O,O
were,O,O
prominent,O,O
toxicities,O,O
and,O,O
most,O,O
patients,O,O
could,O,O
not,O,O
tolerate,O,O
the,O,O
1200,O,O
mg,O,O
/,O,O
day,O,O
dose,O,O
level,O,O
.,O,O
Systemic,O,O
plasma,O,O
VEGF165,O,B
levels,O,O
did,O,O
not,O,O
change,O,O
with,O,O
therapy,O,O
.,O,O
CONCLUSION,O,O
:,O,O
These,O,O
results,O,O
are,O,O
consistent,O,O
with,O,O
a,O,O
low,O,O
level,O,O
of,O,O
activity,O,O
of,O,O
thalidomide,B,B
in,O,O
renal,O,O
cell,O,O
carcinoma,O,O
.,O,O
Administration,O,O
of,O,O
doses,O,O
over,O,O
800,O,O
mg,O,O
/,O,O
day,O,O
was,O,O
difficult,O,O
to,O,O
achieve,O,O
in,O,O
this,O,O
patient,O,O
population,O,O
",",O,O
however,O,O
lower,O,O
doses,O,O
were,O,O
practical,O,O
.,O,O
The,O,O
dose,O,O
-,O,O
response,O,O
relationship,O,O
",",O,O
if,O,O
any,O,O
",",O,O
of,O,O
thalidomide,B,B
for,O,O
renal,O,O
cell,O,O
carcinoma,O,O
is,O,O
unclear,O,O
.,O,O
Can,O,O
lidocaine,B,B
reduce,O,O
succinylcholine,B,B
induced,O,O
postoperative,O,O
myalgia,O,O
?,O,O
This,O,O
study,O,O
was,O,O
undertaken,O,O
to,O,O
determine,O,O
the,O,O
effect,O,O
of,O,O
lidocaine,B,B
pretreatment,O,O
on,O,O
reduction,O,O
of,O,O
succinylcholine,B,B
-,O,O
induced,O,O
myalgia,O,O
in,O,O
patients,O,O
undergoing,O,O
general,O,O
anesthesia,O,O
for,O,O
gynecological,O,O
surgery,O,O
.,O,O
One,O,O
hundred,O,O
and,O,O
thirty,O,O
-,O,O
five,O,O
patients,O,O
were,O,O
assigned,O,O
to,O,O
one,O,O
of,O,O
three,O,O
groups,O,O
in,O,O
a,O,O
prospective,O,O
",",O,O
double,O,O
blind,O,O
",",O,O
randomized,O,O
manner,O,O
.,O,O
Group,O,O
PS,O,O
",",O,O
the,O,O
control,O,O
group,O,O
",",O,O
received,O,O
normal,O,B
saline,O,I
and,O,O
succinylcholine,B,B
1,O,O
.,O,O
mg,O,O
x,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
;,O,O
Group,O,O
LS,O,O
",",O,O
lidocaine,B,B
1,O,O
.,O,O
mg,O,O
x,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
and,O,O
succinylcholine,B,B
1,O,O
.,O,O
mg,O,O
x,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
;,O,O
Group,O,O
PR,O,O
",",O,O
normal,O,B
saline,O,I
and,O,O
rocuronium,B,B
0,O,O
.,O,O
(,O,O
-,O,O
1,O,O
),O,O
iv,O,O
was,O,O
given,O,O
for,O,O
premedication,O,O
and,O,O
all,O,O
patients,O,O
were,O,O
monitored,O,O
with,O,O
a,O,O
noninvasive,O,O
blood,O,O
pressure,O,O
monitor,O,O
",",O,O
ECG,O,B
and,O,O
pulse,O,O
oximetry,O,O
.,O,O
Anesthesia,O,O
was,O,O
induced,O,O
with,O,O
5,O,O
mg,O,O
.,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
thiopental,B,B
iv,O,O
.,O,O
followed,O,O
by,O,O
succinylcholine,B,B
(,O,O
Group,O,O
PS,O,O
",",O,O
LS,O,O
),O,O
or,O,O
rocuronium,B,B
(,O,O
Group,O,O
PR,O,O
),O,O
for,O,O
tracheal,O,O
intubation,O,O
.,O,O
Following,O,O
administration,O,O
of,O,O
these,O,O
agents,O,O
",",O,O
the,O,O
presence,O,O
",",O,O
and,O,O
degree,O,O
of,O,O
fasciculation,O,O
were,O,O
assessed,O,O
visually,O,O
on,O,O
a,O,O
four,O,O
point,O,O
scale,O,O
by,O,O
one,O,O
investigator,O,O
who,O,O
was,O,O
blinded,O,O
to,O,O
the,O,O
drug,O,O
administered,O,O
.,O,O
The,O,O
blood,O,O
pressure,O,O
and,O,O
heart,O,O
rate,O,O
of,O,O
each,O,O
patient,O,O
were,O,O
monitored,O,O
on,O,O
nine,O,O
occasions,O,O
.,O,O
Twenty,O,O
-,O,O
four,O,O
hours,O,O
later,O,O
",",O,O
any,O,O
myalgia,O,O
experienced,O,O
was,O,O
assessed,O,O
according,O,O
to,O,O
a,O,O
structured,O,O
questionaire,O,O
and,O,O
graded,O,O
by,O,O
a,O,O
four,O,O
point,O,O
scale,O,O
by,O,O
one,O,O
investigator,O,O
blinded,O,O
to,O,O
the,O,O
intraoperative,O,O
management,O,O
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
muscle,O,O
fasciculation,O,O
was,O,O
not,O,O
found,O,O
in,O,O
Group,O,O
PR,O,O
while,O,O
the,O,O
patients,O,O
in,O,O
Group,O,O
LS,O,O
had,O,O
a,O,O
lower,O,O
incidence,O,O
of,O,O
muscle,O,O
fasciculation,O,O
than,O,O
those,O,O
in,O,O
Group,O,O
PS,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
At,O,O
24,O,O
h,O,O
",",O,O
the,O,O
incidence,O,O
of,O,O
myalgia,O,O
was,O,O
higher,O,O
in,O,O
Group,O,O
PS,O,O
than,O,O
in,O,O
Group,O,O
LS,O,O
and,O,O
PR,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
A,O,O
correlation,O,O
was,O,O
not,O,O
found,O,O
between,O,O
the,O,O
incidence,O,O
of,O,O
myalgia,O,O
and,O,O
the,O,O
occurrence,O,O
of,O,O
muscle,O,O
fasciculation,O,O
.,O,O
The,O,O
changes,O,O
in,O,O
systolic,O,O
and,O,O
diastolic,O,O
blood,O,B
pressure,O,I
and,O,O
heart,O,B
rate,O,I
were,O,O
not,O,O
significant,O,O
among,O,O
the,O,O
three,O,O
groups,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
where,O,O
succinylcholine,B,B
is,O,O
used,O,O
",",O,O
lidocaine,B,B
is,O,O
proven,O,O
to,O,O
be,O,O
the,O,O
useful,O,O
pretreatment,O,O
agent,O,O
for,O,O
the,O,O
reduction,O,O
of,O,O
postoperative,O,O
myalgia,O,O
.,O,O
Reduced,O,O
sodium,B,B
channel,O,I
density,O,I
",",O,O
altered,O,O
voltage,O,O
dependence,O,O
of,O,O
inactivation,O,O
",",O,O
and,O,O
increased,O,O
susceptibility,O,O
to,O,O
seizures,O,O
in,O,O
mice,O,O
lacking,O,O
sodium,B,B
channel,O,I
beta,O,I
2,O,I
-,O,I
subunits,O,I
.,O,O
Sodium,B,B
channel,O,I
beta,O,B
-,O,O
subunits,O,O
modulate,O,O
channel,O,O
gating,O,O
",",O,O
assembly,O,O
",",O,O
and,O,O
cell,O,O
surface,O,O
expression,O,O
in,O,O
heterologous,O,O
cell,O,O
systems,O,O
.,O,O
We,O,O
generated,O,O
beta2,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
to,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
beta2,O,B
in,O,O
control,O,O
of,O,O
sodium,B,B
channel,O,I
density,O,O
",",O,O
localization,O,O
",",O,O
and,O,O
function,O,O
in,O,O
neurons,O,O
in,O,O
vivo,O,O
.,O,O
Measurements,O,O
of,O,O
[,O,O
(,O,O
3,O,O
),O,O
H,O,O
],O,O
saxitoxin,B,B
(,O,O
STX,B,B
),O,O
binding,O,O
showed,O,O
a,O,O
significant,O,O
reduction,O,O
in,O,O
the,O,O
level,O,O
of,O,O
plasma,O,O
membrane,O,O
sodium,B,B
channels,O,I
in,O,O
beta2,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
neurons,O,O
.,O,O
The,O,O
loss,O,O
of,O,O
beta2,O,B
resulted,O,O
in,O,O
negative,O,O
shifts,O,O
in,O,O
the,O,O
voltage,O,O
dependence,O,O
of,O,O
inactivation,O,O
as,O,O
well,O,O
as,O,O
significant,O,O
decreases,O,O
in,O,O
sodium,B,B
current,O,I
density,O,I
in,O,O
acutely,O,O
dissociated,O,O
hippocampal,O,O
neurons,O,O
.,O,O
The,O,O
integral,O,O
of,O,O
the,O,O
compound,O,O
action,O,O
potential,O,O
in,O,O
optic,O,O
nerve,O,O
was,O,O
significantly,O,O
reduced,O,O
",",O,O
and,O,O
the,O,O
threshold,O,O
for,O,O
action,O,O
potential,O,O
generation,O,O
was,O,O
increased,O,O
",",O,O
indicating,O,O
a,O,O
reduction,O,O
in,O,O
the,O,O
level,O,O
of,O,O
functional,O,O
plasma,O,O
membrane,O,O
sodium,B,B
channels,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
conduction,O,O
velocity,O,O
",",O,O
the,O,O
number,O,O
and,O,O
size,O,O
of,O,O
axons,O,O
in,O,O
the,O,O
optic,O,B
nerve,O,I
",",O,O
and,O,O
the,O,O
specific,O,O
localization,O,O
of,O,O
Na,B,B
(,O,O
v,O,O
),O,O
1,O,O
.,O,O
6,O,O
channels,O,O
in,O,O
the,O,O
nodes,O,O
of,O,O
Ranvier,O,O
were,O,O
unchanged,O,O
.,O,O
beta2,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
displayed,O,O
increased,O,O
susceptibility,O,O
to,O,O
seizures,O,O
",",O,O
as,O,O
indicated,O,O
by,O,O
reduced,O,O
latency,O,O
and,O,O
threshold,O,O
for,O,O
pilocarpine,B,B
-,O,O
induced,O,O
seizures,O,O
",",O,O
but,O,O
seemed,O,O
normal,O,O
in,O,O
other,O,O
neurological,O,O
tests,O,O
.,O,O
Our,O,O
observations,O,O
show,O,O
that,O,O
beta2,O,B
-,O,O
subunits,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
sodium,B,B
channel,O,I
density,O,O
and,O,O
function,O,O
in,O,O
neurons,O,O
in,O,O
vivo,O,O
and,O,O
are,O,O
required,O,O
for,O,O
normal,O,O
action,O,O
potential,O,O
generation,O,O
and,O,O
control,O,O
of,O,O
excitability,O,O
.,O,O
Acute,O,O
liver,O,B
failure,O,I
with,O,O
concurrent,O,O
bupropion,B,B
and,O,O
carbimazole,B,B
therapy,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
report,O,O
a,O,O
case,O,O
of,O,O
fatal,O,O
liver,O,B
failure,O,I
possibly,O,O
associated,O,O
with,O,O
concurrent,O,O
use,O,O
of,O,O
bupropion,B,B
and,O,O
carbimazole,B,B
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
41,O,O
-,O,O
year,O,O
-,O,O
old,O,O
Chinese,O,O
man,O,O
with,O,O
a,O,O
history,O,O
of,O,O
hyperthyroidism,O,B
had,O,O
been,O,O
treated,O,O
with,O,O
carbimazole,B,B
and,O,O
propranolol,B,B
for,O,O
the,O,O
past,O,O
5,O,O
years,O,O
.,O,O
He,O,O
received,O,O
a,O,O
10,O,O
-,O,O
day,O,O
course,O,O
of,O,O
bupropion,B,B
as,O,O
an,O,O
aid,O,O
for,O,O
smoking,O,O
cessation,O,O
10,O,O
weeks,O,O
prior,O,O
to,O,O
presentation,O,O
.,O,O
He,O,O
developed,O,O
acute,O,O
liver,O,B
failure,O,O
with,O,O
rapid,O,O
deterioration,O,O
of,O,O
renal,O,B
function,O,O
.,O,O
Liver,O,B
biopsy,O,O
showed,O,O
evidence,O,O
of,O,O
nonspecific,O,O
drug,O,B
-,O,O
induced,O,O
acute,O,O
liver,O,O
injury,O,O
.,O,O
His,O,O
condition,O,O
was,O,O
further,O,O
complicated,O,O
by,O,O
sepsis,O,B
and,O,O
coagulopathy,O,O
.,O,O
Death,O,O
resulted,O,O
19,O,O
days,O,O
after,O,O
the,O,O
onset,O,O
of,O,O
symptoms,O,O
.,O,O
The,O,O
likelihood,O,O
that,O,O
bupropion,B,B
induced,O,O
hepatotoxicity,O,O
in,O,O
our,O,O
patient,O,O
was,O,O
possible,O,O
",",O,O
based,O,O
on,O,O
the,O,O
Naranjo,O,O
probability,O,O
scale,O,O
.,O,O
DISCUSSION,O,O
:,O,O
Although,O,O
there,O,O
is,O,O
increasing,O,O
evidence,O,O
of,O,O
hepatotoxicity,O,O
induced,O,O
by,O,O
bupropion,B,B
",",O,O
this,O,O
is,O,O
the,O,O
first,O,O
case,O,O
of,O,O
fatality,O,O
that,O,O
could,O,O
have,O,O
resulted,O,O
from,O,O
acute,O,O
liver,O,O
failure,O,O
in,O,O
a,O,O
patient,O,O
receiving,O,O
bupropion,B,B
while,O,O
on,O,O
concomitant,O,O
treatment,O,O
with,O,O
carbimazole,B,B
.,O,O
CONCLUSIONS,O,O
:,O,O
Clinicians,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
the,O,O
possibility,O,O
of,O,O
acute,O,O
liver,O,O
insult,O,O
induced,O,O
by,O,O
bupropion,B,B
given,O,O
concurrently,O,O
with,O,O
other,O,O
hepatotoxic,O,O
drugs,O,O
.,O,O
Pyeloureteral,O,B
filling,O,I
defects,O,I
associated,O,O
with,O,O
systemic,O,O
anticoagulation,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
The,O,O
etiology,O,O
of,O,O
pyeloureteritis,O,B
cystica,O,I
has,O,O
long,O,O
been,O,O
attributed,O,O
to,O,O
chronic,O,O
infection,O,O
and,O,O
inflammation,O,O
.,O,O
A,O,O
case,O,O
is,O,O
presented,O,O
that,O,O
is,O,O
unique,O,O
in,O,O
that,O,O
the,O,O
acute,O,O
onset,O,O
and,O,O
the,O,O
rapid,O,O
resolution,O,O
of,O,O
pyeloureteral,O,B
filling,O,I
defects,O,I
in,O,O
this,O,O
patient,O,O
were,O,O
documented,O,O
by,O,O
radiography,O,O
.,O,O
There,O,O
is,O,O
no,O,O
evidence,O,O
of,O,O
antecedent,O,O
or,O,O
concurrent,O,O
infection,O,O
in,O,O
this,O,O
patient,O,O
.,O,O
The,O,O
disease,O,O
occurred,O,O
subsequent,O,O
to,O,O
the,O,O
initiation,O,O
of,O,O
heparin,B,B
therapy,O,O
for,O,O
suspected,O,O
pelvic,O,O
thrombophlebitis,O,O
and,O,O
cleared,O,O
rapidly,O,O
subsequent,O,O
to,O,O
its,O,O
discontinuation,O,O
.,O,O
The,O,O
rate,O,O
of,O,O
resolution,O,O
of,O,O
the,O,O
radiographic,O,O
findings,O,O
may,O,O
be,O,O
helpful,O,O
in,O,O
distinguishing,O,O
between,O,O
pyeloureteritis,O,O
cystica,O,O
and,O,O
submucosal,O,O
hemorrhage,O,O
.,O,O
Nephrotoxic,O,O
effects,O,O
in,O,O
high,O,O
-,O,O
risk,O,O
patients,O,O
undergoing,O,O
angiography,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
use,O,O
of,O,O
iodinated,O,B
contrast,O,I
medium,O,I
can,O,O
result,O,O
in,O,O
nephropathy,O,O
.,O,O
Whether,O,O
iso,O,B
-,O,O
osmolar,O,I
contrast,O,I
medium,O,I
is,O,O
less,O,O
nephrotoxic,O,O
than,O,O
low,O,B
-,O,O
osmolar,O,I
contrast,O,I
medium,O,I
in,O,O
high,O,O
-,O,O
risk,O,O
patients,O,O
is,O,O
uncertain,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
conducted,O,O
a,O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
prospective,O,O
",",O,O
multicenter,O,O
study,O,O
comparing,O,O
the,O,O
nephrotoxic,O,O
effects,O,O
of,O,O
an,O,O
iso,O,B
-,O,O
osmolar,O,I
",",O,O
dimeric,O,O
",",O,O
nonionic,O,O
contrast,O,I
medium,O,I
",",O,O
iodixanol,B,B
",",O,O
with,O,O
those,O,O
of,O,O
a,O,O
low,O,B
-,O,O
osmolar,O,I
",",O,O
nonionic,O,O
",",O,O
monomeric,O,O
contrast,O,I
medium,O,I
",",O,O
iohexol,B,B
.,O,O
The,O,O
study,O,O
involved,O,O
129,O,O
patients,O,O
with,O,O
diabetes,O,O
with,O,O
serum,O,O
creatinine,B,B
concentrations,O,O
of,O,O
1,O,O
.,O,O
5,O,O
to,O,O
3,O,O
.,O,O
5,O,O
mg,O,O
per,O,O
deciliter,O,O
who,O,O
underwent,O,O
coronary,O,O
or,O,O
aortofemoral,O,O
angiography,O,O
.,O,O
The,O,O
primary,O,O
end,O,O
point,O,O
was,O,O
the,O,O
peak,O,O
increase,O,O
from,O,O
base,O,O
line,O,O
in,O,O
the,O,O
creatinine,B,B
concentration,O,O
during,O,O
the,O,O
three,O,O
days,O,O
after,O,O
angiography,O,O
.,O,O
Other,O,O
end,O,O
points,O,O
were,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
creatinine,B,B
concentration,O,O
of,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
per,O,O
deciliter,O,O
or,O,O
more,O,O
",",O,O
an,O,O
increase,O,O
of,O,O
1,O,O
.,O,O
0,O,O
mg,O,O
per,O,O
deciliter,O,O
or,O,O
more,O,O
",",O,O
and,O,O
a,O,O
change,O,O
in,O,O
the,O,O
creatinine,B,B
concentration,O,O
from,O,O
day,O,O
0,O,O
to,O,O
day,O,O
7,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
creatinine,B,B
concentration,O,O
increased,O,O
significantly,O,O
less,O,O
in,O,O
patients,O,O
who,O,O
received,O,O
iodixanol,B,B
.,O,O
From,O,O
day,O,O
0,O,O
to,O,O
day,O,O
3,O,O
",",O,O
the,O,O
mean,O,O
peak,O,O
increase,O,O
in,O,O
creatinine,B,B
was,O,O
0,O,O
.,O,O
13,O,O
mg,O,O
per,O,O
deciliter,O,O
in,O,O
the,O,O
iodixanol,B,B
group,O,O
and,O,O
0,O,O
.,O,O
55,O,O
mg,O,O
per,O,O
deciliter,O,O
in,O,O
the,O,O
iohexol,B,B
group,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
;,O,O
the,O,O
increase,O,O
with,O,O
iodixanol,B,B
minus,O,O
the,O,O
increase,O,O
with,O,O
iohexol,B,B
",",O,O
-,O,O
0,O,O
.,O,O
42,O,O
mg,O,O
per,O,O
deciliter,O,O
[,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
-,O,O
0,O,O
.,O,O
73,O,O
to,O,O
-,O,O
0,O,O
.,O,O
22,O,O
],O,O
),O,O
.,O,O
Two,O,O
of,O,O
the,O,O
64,O,O
patients,O,O
in,O,O
the,O,O
iodixanol,B,B
group,O,O
(,O,O
3,O,O
percent,O,O
),O,O
had,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
creatinine,B,B
concentration,O,O
of,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
per,O,O
deciliter,O,O
or,O,O
more,O,O
",",O,O
as,O,O
compared,O,O
with,O,O
17,O,O
of,O,O
the,O,O
65,O,O
patients,O,O
in,O,O
the,O,O
iohexol,B,B
group,O,O
(,O,O
26,O,O
percent,O,O
),O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
;,O,O
odds,O,O
ratio,O,O
for,O,O
such,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
iodixanol,B,B
group,O,O
",",O,O
0,O,O
.,O,O
[,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
0,O,O
.,O,O
to,O,O
0,O,O
.,O,O
41,O,O
],O,O
),O,O
.,O,O
No,O,O
patient,O,O
receiving,O,O
iodixanol,B,B
had,O,O
an,O,O
increase,O,O
of,O,O
1,O,O
.,O,O
0,O,O
mg,O,O
per,O,O
deciliter,O,O
or,O,O
more,O,O
",",O,O
but,O,O
10,O,O
patients,O,O
in,O,O
the,O,O
iohexol,B,B
group,O,O
(,O,O
15,O,O
percent,O,O
),O,O
did,O,O
.,O,O
The,O,O
mean,O,O
change,O,O
in,O,O
the,O,O
creatinine,B,B
concentration,O,O
from,O,O
day,O,O
0,O,O
to,O,O
day,O,O
7,O,O
was,O,O
0,O,O
.,O,O
mg,O,O
per,O,O
deciliter,O,O
in,O,O
the,O,O
iodixanol,B,B
group,O,O
and,O,O
0,O,O
.,O,O
24,O,O
mg,O,O
per,O,O
deciliter,O,O
in,O,O
the,O,O
iohexol,B,B
group,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
;,O,O
value,O,O
in,O,O
the,O,O
iodixanol,B,B
group,O,O
minus,O,O
the,O,O
value,O,O
in,O,O
the,O,O
iohexol,B,B
group,O,O
",",O,O
-,O,O
0,O,O
.,O,O
17,O,O
mg,O,O
per,O,O
deciliter,O,O
[,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
-,O,O
0,O,O
.,O,O
34,O,O
to,O,O
-,O,O
0,O,O
.,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Nephropathy,O,O
induced,O,O
by,O,O
contrast,O,O
medium,O,O
may,O,O
be,O,O
less,O,O
likely,O,O
to,O,O
develop,O,O
in,O,O
high,O,O
-,O,O
risk,O,O
patients,O,O
when,O,O
iodixanol,B,B
is,O,O
used,O,O
rather,O,O
than,O,O
a,O,O
low,O,O
-,O,O
osmolar,O,O
",",O,O
nonionic,O,O
contrast,O,O
medium,O,O
.,O,O
Protective,O,O
effect,O,O
of,O,O
edaravone,B,B
against,O,O
streptomycin,B,B
-,O,O
induced,O,O
vestibulotoxicity,O,O
in,O,O
the,O,O
guinea,O,O
pig,O,O
.,O,O
This,O,O
study,O,O
investigated,O,O
alleviation,O,O
of,O,O
streptomycin,B,B
-,O,O
induced,O,O
vestibulotoxicity,O,O
by,O,O
edaravone,B,B
in,O,O
guinea,O,O
pigs,O,O
.,O,O
Edaravone,B,B
",",O,O
a,O,O
free,O,O
radical,O,O
scavenger,O,O
",",O,O
has,O,O
potent,O,O
free,O,O
radical,O,O
quenching,O,O
action,O,O
and,O,O
is,O,O
used,O,O
in,O,O
clinical,O,O
practice,O,O
to,O,O
treat,O,O
cerebral,O,O
infarction,O,O
.,O,O
Streptomycin,B,B
was,O,O
administered,O,O
to,O,O
the,O,O
inner,O,O
ear,O,O
by,O,O
osmotic,O,O
pump,O,O
for,O,O
24,O,O
h,O,O
",",O,O
and,O,O
edaravone,B,B
(,O,O
n,O,O
=,O,O
8,O,O
),O,O
or,O,O
saline,O,B
(,O,O
n,O,O
=,O,O
6,O,O
),O,O
was,O,O
intraperitoneally,O,O
injected,O,O
once,O,O
a,O,O
day,O,O
for,O,O
7,O,O
days,O,O
.,O,O
We,O,O
observed,O,O
horizontal,O,O
vestibulo,O,O
-,O,O
ocular,O,O
reflex,O,O
as,O,O
a,O,O
marker,O,O
of,O,O
postoperative,O,O
vestibular,O,O
function,O,O
.,O,O
Animals,O,O
injected,O,O
with,O,O
saline,O,B
showed,O,O
statistically,O,O
smaller,O,O
gains,O,O
than,O,O
those,O,O
injected,O,O
with,O,O
edaravone,B,B
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
edaravone,B,B
suppresses,O,O
streptomycin,B,B
-,O,I
induced,O,O
vestibulotoxicity,O,O
.,O,O
Levodopa,B,B
-,O,I
induced,O,O
oromandibular,O,O
dystonia,O,O
in,O,O
progressive,O,O
supranuclear,O,O
palsy,O,O
.,O,O
Levodopa,B,B
-,O,I
induced,O,O
dyskinesias,O,O
have,O,O
been,O,O
reported,O,O
in,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
and,O,O
multiple,O,O
system,O,O
atrophy,O,O
.,O,O
Cranial,O,O
dystonias,O,O
are,O,O
rare,O,O
in,O,O
patients,O,O
with,O,O
progressive,O,O
supranuclear,O,O
palsy,O,O
(,O,O
PSP,O,O
),O,O
.,O,O
In,O,O
this,O,O
report,O,O
we,O,O
describe,O,O
an,O,O
unusual,O,O
case,O,O
of,O,O
reversible,O,O
levodopa,B,B
-,O,O
induced,O,O
Oromandibular,O,B
dystonia,O,I
(,O,O
OMD,O,B
),O,O
in,O,O
a,O,O
PSP,O,O
patient,O,O
to,O,O
highlight,O,O
the,O,O
importance,O,O
of,O,O
recognizing,O,O
this,O,O
drug,O,O
related,O,O
complication,O,O
in,O,O
the,O,O
management,O,O
of,O,O
PSP,O,O
",",O,O
and,O,O
discuss,O,O
the,O,O
possible,O,O
underlying,O,O
pathophysiology,O,O
.,O,O
Case,O,O
report,O,O
:,O,O
Dexatrim,B,B
(,O,O
Phenylpropanolamine,B,B
),O,O
as,O,O
a,O,O
cause,O,O
of,O,O
myocardial,O,O
infarction,O,O
.,O,O
Phenylpropanolamine,B,B
(,O,O
PPA,B,B
),O,O
is,O,O
a,O,O
sympathetic,O,O
amine,B,O
used,O,O
in,O,O
over,O,O
-,O,O
the,O,O
-,O,O
counter,O,O
cold,O,O
remedies,O,O
and,O,O
weight,O,O
-,O,O
control,O,O
preparations,O,O
worldwide,O,O
.,O,O
Its,O,O
use,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
hypertensive,O,O
episodes,O,O
and,O,O
hemorrhagic,O,O
strokes,O,O
in,O,O
younger,O,O
women,O,O
.,O,O
Several,O,O
reports,O,O
have,O,O
linked,O,O
the,O,O
abuse,O,O
of,O,O
PPA,B,B
with,O,O
myocardial,O,O
injury,O,O
",",O,O
especially,O,O
when,O,O
overdose,O,O
is,O,O
involved,O,O
.,O,O
We,O,O
report,O,O
here,O,O
the,O,O
first,O,O
case,O,O
of,O,O
Dexatrim,B,B
(,O,O
PPA,B,B
),O,O
-,O,O
induced,O,O
myocardial,O,O
injury,O,O
in,O,O
a,O,O
young,O,O
woman,O,O
who,O,O
was,O,O
using,O,O
it,O,O
at,O,O
recommended,O,O
doses,O,O
for,O,O
weight,O,O
control,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
we,O,O
review,O,O
the,O,O
7,O,O
other,O,O
cases,O,O
of,O,O
PPA,B,B
related,O,O
myocardial,O,O
injury,O,O
that,O,O
have,O,O
been,O,O
reported,O,O
so,O,O
far,O,O
.,O,O
Physicians,O,O
and,O,O
patients,O,O
should,O,O
be,O,O
alert,O,O
to,O,O
the,O,O
potential,O,O
cardiac,O,O
risk,O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
PPA,B,B
",",O,O
even,O,O
at,O,O
doses,O,O
generally,O,O
considered,O,O
to,O,O
be,O,O
safe,O,O
.,O,O
Differential,O,O
diagnosis,O,O
of,O,O
high,O,O
serum,O,O
creatine,B,B
kinase,O,I
levels,O,O
in,O,O
systemic,O,B
lupus,O,I
erythematosus,O,I
.,O,O
We,O,O
report,O,O
the,O,O
clinical,O,O
and,O,O
bioptic,O,O
findings,O,O
for,O,O
a,O,O
57,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
severe,O,O
chloroquine,B,B
-,O,I
induced,O,I
myopathy,O,I
.,O,O
Since,O,O
1989,O,O
",",O,O
she,O,O
had,O,O
been,O,O
suffering,O,O
from,O,O
systemic,O,B
lupus,O,I
erythematosus,O,I
(,O,O
SLE,O,B
),O,O
with,O,O
renal,O,O
involvement,O,O
and,O,O
undergone,O,O
periods,O,O
of,O,O
treatment,O,O
with,O,O
azathioprine,B,B
and,O,O
cyclophosphamide,B,B
.,O,O
Additional,O,O
therapy,O,O
with,O,O
chloroquine,B,B
(,O,O
CQ,B,B
),O,O
was,O,O
started,O,O
because,O,O
of,O,O
arthralgia,O,O
.,O,O
At,O,O
the,O,O
same,O,O
time,O,O
",",O,O
slightly,O,O
increased,O,O
creatine,B,B
kinase,O,I
(,O,O
CK,O,B
),O,O
levels,O,O
were,O,O
noted,O,O
.,O,O
Myositis,O,O
was,O,O
suspected,O,O
",",O,O
and,O,O
the,O,O
patient,O,O
was,O,O
treated,O,O
with,O,O
steroids,B,O
.,O,O
The,O,O
CK,O,B
increase,O,O
persisted,O,O
",",O,O
however,O,O
",",O,O
and,O,O
she,O,O
developed,O,O
progressive,O,O
muscular,O,O
weakness,O,O
and,O,O
muscular,O,O
atrophy,O,O
.,O,O
Routine,O,O
controls,O,O
revealed,O,O
markedly,O,O
elevated,O,O
CK,O,B
levels,O,O
of,O,O
1,O,O
",",O,O
700,O,O
U,O,O
/,O,O
l,O,O
.,O,O
The,O,O
neurological,O,O
and,O,O
electrophysiological,O,O
findings,O,O
were,O,O
not,O,O
typical,O,O
of,O,O
myositis,O,O
.,O,O
Thus,O,O
",",O,O
muscle,O,O
biopsy,O,O
of,O,O
the,O,O
deltoid,O,O
muscle,O,O
was,O,O
performed,O,O
in,O,O
order,O,O
to,O,O
exclude,O,O
polymyositis,O,O
or,O,O
toxic,O,O
myopathy,O,O
.,O,O
As,O,O
it,O,O
revealed,O,O
chloroquine,B,B
-,O,I
induced,O,I
myopathy,O,I
",",O,O
medication,O,O
was,O,O
stopped,O,O
.,O,O
Discriminating,O,O
between,O,O
primary,O,O
SLE,O,B
-,O,O
induced,O,O
affection,O,O
of,O,O
the,O,O
musculoskeletal,O,O
system,O,O
and,O,O
drug,O,O
-,O,O
induced,O,O
side,O,O
effects,O,O
is,O,O
important,O,O
for,O,O
appropriate,O,O
treatment,O,O
of,O,O
SLE,O,B
patients,O,O
.,O,O
Seizure,O,O
associated,O,O
with,O,O
sleep,O,O
deprivation,O,O
and,O,O
sustained,O,O
-,O,O
release,O,O
bupropion,B,B
.,O,O
This,O,O
case,O,O
report,O,O
describes,O,O
a,O,O
generalized,O,O
seizure,O,O
associated,O,O
with,O,O
sustained,O,O
-,O,O
release,O,O
bupropion,B,B
use,O,O
and,O,O
sleep,O,O
deprivation,O,O
.,O,O
The,O,O
subject,O,O
",",O,O
a,O,O
31,O,O
-,O,O
year,O,O
-,O,O
old,O,O
female,O,O
smoker,O,O
",",O,O
was,O,O
participating,O,O
in,O,O
a,O,O
clinical,O,O
trial,O,O
evaluating,O,O
an,O,O
investigational,O,O
medication,O,O
for,O,O
smoking,O,O
cessation,O,O
that,O,O
used,O,O
sustained,O,O
-,O,O
release,O,O
bupropion,B,B
as,O,O
an,O,O
active,O,O
control,O,O
.,O,O
After,O,O
5,O,O
weeks,O,O
of,O,O
bupropion,B,B
use,O,O
",",O,O
the,O,O
subject,O,O
experienced,O,O
a,O,O
generalized,O,O
tonic,O,O
clonic,O,O
seizure,O,O
after,O,O
staying,O,O
up,O,O
nearly,O,O
all,O,O
night,O,O
packing,O,O
and,O,O
moving,O,O
to,O,O
a,O,O
new,O,O
residence,O,O
.,O,O
The,O,O
patient,O,O
had,O,O
no,O,O
other,O,O
risk,O,O
factors,O,O
for,O,O
seizures,O,O
.,O,O
We,O,O
suggest,O,O
that,O,O
sleep,O,O
deprivation,O,O
may,O,O
add,O,O
to,O,O
the,O,O
risk,O,O
of,O,O
bupropion,B,B
-,O,O
associated,O,O
seizures,O,O
.,O,O
Postoperative,O,O
myalgia,O,O
after,O,O
succinylcholine,B,B
:,O,O
no,O,O
evidence,O,O
for,O,O
an,O,O
inflammatory,O,O
origin,O,O
.,O,O
A,O,O
common,O,O
side,O,O
effect,O,O
associated,O,O
with,O,O
succinylcholine,B,B
is,O,O
postoperative,O,O
myalgia,O,O
.,O,O
The,O,O
pathogenesis,O,O
of,O,O
this,O,O
myalgia,O,B
is,O,O
still,O,O
unclear,O,O
;,O,O
inflammation,O,O
has,O,O
been,O,O
suggested,O,O
but,O,O
without,O,O
convincing,O,O
evidence,O,O
.,O,O
We,O,O
designed,O,O
the,O,O
present,O,O
study,O,O
to,O,O
investigate,O,O
whether,O,O
an,O,O
inflammatory,O,O
reaction,O,O
contributes,O,O
to,O,O
this,O,O
myalgia,O,B
.,O,O
The,O,O
incidence,O,O
and,O,O
severity,O,O
of,O,O
succinylcholine,B,B
-,O,I
associated,O,I
myalgia,O,I
was,O,O
determined,O,O
in,O,O
64,O,O
patients,O,O
pretreated,O,O
with,O,O
saline,O,B
or,O,O
dexamethasone,B,B
before,O,O
succinylcholine,B,B
(,O,O
n,O,O
=,O,O
32,O,O
for,O,O
each,O,O
),O,O
.,O,O
Incidence,O,O
and,O,O
severity,O,O
of,O,O
myalgia,O,B
did,O,O
not,O,O
differ,O,O
significantly,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
:,O,O
15,O,O
patients,O,O
in,O,O
the,O,O
dexamethasone,B,B
group,O,O
complained,O,O
of,O,O
myalgia,O,B
compared,O,O
with,O,O
18,O,O
patients,O,O
in,O,O
the,O,O
saline,O,B
group,O,O
",",O,O
and,O,O
severe,O,O
myalgia,O,B
was,O,O
reported,O,O
by,O,O
five,O,O
patients,O,O
and,O,O
three,O,O
patients,O,O
",",O,O
respectively,O,O
(,O,O
not,O,O
significant,O,O
),O,O
.,O,O
At,O,O
48,O,O
h,O,O
after,O,O
surgery,O,O
",",O,O
12,O,O
patients,O,O
in,O,O
both,O,O
groups,O,O
still,O,O
suffered,O,O
from,O,O
myalgia,O,O
(,O,O
not,O,O
significant,O,O
),O,O
.,O,O
In,O,O
addition,O,O
",",O,O
interleukin,O,B
-,O,I
6,O,I
(,O,O
IL,O,B
-,O,I
6,O,I
),O,O
as,O,O
an,O,O
early,O,O
marker,O,O
of,O,O
inflammation,O,O
was,O,O
assessed,O,O
in,O,O
a,O,O
subgroup,O,O
of,O,O
10,O,O
patients,O,O
pretreated,O,O
with,O,O
saline,O,B
.,O,O
We,O,O
found,O,O
an,O,O
increase,O,O
of,O,O
IL,O,B
-,O,I
6,O,I
for,O,O
only,O,O
three,O,O
patients,O,O
",",O,O
but,O,O
only,O,O
one,O,O
patient,O,O
reported,O,O
myalgia,O,O
;,O,O
no,O,O
relationship,O,O
between,O,O
myalgia,O,O
and,O,O
the,O,O
increase,O,O
of,O,O
IL,O,B
-,O,I
6,O,I
was,O,O
found,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
there,O,O
is,O,O
no,O,O
evidence,O,O
for,O,O
an,O,O
inflammatory,O,O
origin,O,O
of,O,O
succinylcholine,B,B
-,O,O
associated,O,O
myalgia,O,O
.,O,O
IMPLICATIONS,O,O
:,O,O
Administration,O,O
of,O,O
dexamethasone,B,B
before,O,O
succinylcholine,B,B
was,O,O
not,O,O
effective,O,O
in,O,O
decreasing,O,O
the,O,O
incidence,O,O
or,O,O
the,O,O
severity,O,O
of,O,O
succinylcholine,B,B
-,O,O
induced,O,O
postoperative,O,O
myalgia,O,O
.,O,O
Furthermore,O,O
",",O,O
there,O,O
was,O,O
no,O,O
significant,O,O
relationship,O,O
between,O,O
postoperative,O,O
myalgia,O,O
and,O,O
time,O,O
course,O,O
of,O,O
interleukin,O,B
-,O,O
6,O,I
concentrations,O,O
",",O,O
a,O,O
marker,O,O
of,O,O
inflammation,O,O
.,O,O
Pretreatment,O,O
with,O,O
dexamethasone,B,B
is,O,O
not,O,O
justified,O,O
to,O,O
prevent,O,O
postoperative,O,O
myalgia,O,O
after,O,O
succinylcholine,B,B
.,O,O
Effect,O,O
of,O,O
lindane,B,B
on,O,O
hepatic,O,O
and,O,O
brain,O,O
cytochrome,O,B
P450s,O,I
and,O,O
influence,O,O
of,O,O
P450,O,B
modulation,O,O
in,O,O
lindane,B,B
induced,O,O
neurotoxicity,O,O
.,O,O
Oral,O,O
administration,O,O
of,O,O
lindane,B,B
(,O,O
2,O,O
.,O,O
5,O,O
",",O,O
5,O,O
",",O,O
10,O,O
and,O,O
15,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
body,O,O
weight,O,O
),O,O
for,O,O
5,O,O
days,O,O
was,O,O
found,O,O
to,O,O
produce,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
increase,O,O
in,O,O
the,O,O
activity,O,O
of,O,O
P450,O,B
dependent,O,O
7,O,O
-,O,O
ethoxyresorufin,O,B
-,O,O
O,O,I
-,O,O
deethylase,O,O
(,O,O
EROD,O,B
),O,O
",",O,O
7,O,O
-,O,O
pentoxyresorufin,O,B
-,O,O
O,O,I
-,O,O
dealkylase,O,O
(,O,O
PROD,O,B
),O,O
and,O,O
N,B,B
-,I,O
nitrosodimethylamine,I,I
demethylase,O,O
(,O,O
NDMA,B,B
-,O,O
d,O,I
),O,O
in,O,O
rat,O,O
brain,O,O
and,O,O
liver,O,O
.,O,O
A,O,O
significant,O,O
increase,O,O
in,O,O
the,O,O
hepatic,O,B
and,O,O
brain,O,B
P450,O,B
monooxygenases,O,I
was,O,O
also,O,O
observed,O,O
when,O,O
the,O,O
duration,O,O
of,O,O
exposure,O,O
of,O,O
low,O,O
dose,O,O
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
of,O,O
lindane,B,B
was,O,O
increased,O,O
from,O,O
5,O,O
days,O,O
to,O,O
15,O,O
or,O,O
21,O,O
days,O,O
.,O,O
As,O,O
observed,O,O
with,O,O
different,O,O
doses,O,O
",",O,O
the,O,O
magnitude,O,O
of,O,O
induction,O,O
in,O,O
the,O,O
activity,O,O
of,O,O
P450,O,B
monooxygenases,O,I
was,O,O
several,O,O
fold,O,O
higher,O,O
in,O,O
liver,O,B
microsomes,O,I
when,O,O
compared,O,O
with,O,O
the,O,O
brain,O,B
.,O,O
Western,O,O
blotting,O,O
studies,O,O
have,O,O
indicated,O,O
that,O,O
the,O,O
increase,O,O
in,O,O
the,O,O
P450,O,B
enzymes,O,O
could,O,O
be,O,O
due,O,O
to,O,O
the,O,O
increase,O,O
in,O,O
the,O,O
expression,O,O
of,O,O
P450,O,B
1A1,O,B
/,O,O
1A2,O,B
",",O,O
2B1,O,B
/,O,O
2B2,O,B
and,O,O
isoenzymes,O,O
.,O,O
In,O,O
vitro,O,O
studies,O,O
using,O,O
organic,O,O
inhibitors,O,O
specific,O,O
for,O,O
individual,O,O
P450,O,B
isoenzymes,O,O
and,O,O
antibody,O,O
inhibition,O,O
experiments,O,O
have,O,O
further,O,O
demonstrated,O,O
that,O,O
the,O,O
increase,O,O
in,O,O
the,O,O
activity,O,O
of,O,O
PROD,O,B
",",O,O
EROD,O,B
and,O,O
NDMA,B,B
-,O,O
d,O,O
are,O,O
due,O,O
to,O,O
the,O,O
increase,O,O
in,O,O
the,O,O
levels,O,O
of,O,O
P450,O,B
2B1,O,B
/,O,O
2B2,O,B
",",O,O
1A1,O,B
/,O,O
1A2,O,B
and,O,O
isoenzymes,O,O
",",O,O
respectively,O,O
.,O,O
Induction,O,O
studies,O,O
have,O,O
further,O,O
shown,O,O
that,O,O
while,O,O
pretreatment,O,O
of,O,O
3,B,B
-,I,I
methylcholanthrene,I,I
(,O,O
MC,B,B
),O,O
",",O,O
an,O,O
inducer,O,O
of,O,O
P4501A1,O,B
/,O,I
1A2,O,I
",",O,O
did,O,O
not,O,O
produce,O,O
any,O,O
significant,O,O
effect,O,O
in,O,O
the,O,O
incidence,O,O
of,O,O
lindane,B,B
induced,O,I
convulsions,O,I
",",O,O
pretreatment,O,O
with,O,O
phenobarbital,B,B
(,O,O
PB,O,B
),O,O
",",O,O
an,O,O
inducer,O,O
of,O,O
P450,O,B
2B1,O,I
/,O,I
2B2,O,I
or,O,O
ethanol,B,B
",",O,O
an,O,O
inducer,O,O
of,O,O
P450,O,B
catalysed,O,I
reactions,O,I
",",O,O
significantly,O,O
increased,O,O
the,O,O
incidence,O,O
of,O,O
lindane,B,B
induced,O,I
convulsions,O,I
.,O,O
Similarly,O,O
",",O,O
when,O,O
the,O,O
P450,O,B
-,O,O
mediated,O,O
metabolism,O,O
of,O,O
lindane,B,B
was,O,O
blocked,O,O
by,O,O
cobalt,B,B
chloride,I,I
incidence,O,O
of,O,O
convulsions,O,O
was,O,O
increased,O,O
in,O,O
animals,O,O
treated,O,O
with,O,O
lindane,B,B
indicating,O,O
that,O,O
lindane,B,B
per,O,O
se,O,O
or,O,O
its,O,O
metabolites,O,O
formed,O,O
by,O,O
PB,O,B
or,O,O
ethanol,B,B
inducible,O,O
P450,O,B
isoenzymes,O,I
are,O,O
involved,O,O
in,O,O
its,O,O
neurobehavioral,O,O
toxicity,O,O
.,O,O
Absolute,O,O
and,O,O
attributable,O,O
risk,O,O
of,O,O
venous,O,B
thromboembolism,O,I
in,O,O
women,O,O
on,O,O
combined,O,O
cyproterone,B,B
acetate,I,I
and,O,O
ethinylestradiol,B,B
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
achieve,O,O
absolute,O,O
risk,O,O
estimates,O,O
of,O,O
venous,O,B
thromboembolism,O,I
(,O,O
VTE,O,B
),O,O
among,O,O
women,O,O
on,O,O
cyproterone,B,B
acetate,I,I
plus,O,O
ethinylestradiol,B,B
(,O,O
CPA,B,B
/,O,O
EE,B,O
),O,O
",",O,O
and,O,O
among,O,O
women,O,O
on,O,O
combined,B,O
oral,I,O
contraceptives,I,O
(,O,O
COCs,B,B
),O,O
.,O,O
METHODS,O,O
:,O,O
From,O,O
the,O,O
Danish,O,O
National,O,O
Register,O,O
of,O,O
Patients,O,O
(,O,O
NRP,O,O
),O,O
",",O,O
1996,O,O
to,O,O
1998,O,O
",",O,O
the,O,O
records,O,O
of,O,O
1,O,O
.,O,O
1,O,O
million,O,O
Danish,O,O
women,O,O
",",O,O
ages,O,O
15,O,O
to,O,O
44,O,O
years,O,O
",",O,O
were,O,O
searched,O,O
for,O,O
evidence,O,O
of,O,O
VTE,O,B
.,O,O
COC,B,B
use,O,O
was,O,O
ascertained,O,O
through,O,O
mailed,O,O
questionnaires,O,O
.,O,O
Sales,O,O
statistics,O,O
of,O,O
COCs,B,B
and,O,O
CPA,B,B
/,O,I
EE,B,I
were,O,O
provided,O,O
through,O,O
Danish,O,O
Drug,O,O
Statistics,O,O
.,O,O
RESULTS,O,O
:,O,O
During,O,O
the,O,O
time,O,O
frame,O,O
of,O,O
the,O,O
study,O,O
",",O,O
330,O,O
women,O,O
were,O,O
found,O,O
to,O,O
have,O,O
had,O,O
VTE,O,B
while,O,O
on,O,O
COCs,B,B
.,O,O
Of,O,O
these,O,O
women,O,O
",",O,O
67,O,O
were,O,O
on,O,O
levonorgestrel,B,B
-,O,I
containing,O,I
COCs,B,I
.,O,O
Eleven,O,O
were,O,O
on,O,O
CPA,B,B
/,O,I
EE,B,I
.,O,O
The,O,O
corresponding,O,O
absolute,O,O
risk,O,O
of,O,O
VTE,O,B
was,O,O
3,O,O
.,O,O
4,O,O
(,O,O
range,O,O
",",O,O
3,O,O
.,O,O
1,O,O
-,O,O
3,O,O
.,O,O
8,O,O
),O,O
per,O,O
10,O,O
women,O,O
years,O,O
among,O,O
the,O,O
women,O,O
on,O,O
COCs,B,B
",",O,O
4,O,O
.,O,O
2,O,O
(,O,O
range,O,O
",",O,O
3,O,O
.,O,O
2,O,O
-,O,O
5,O,O
.,O,O
2,O,O
),O,O
per,O,O
10,O,O
women,O,O
years,O,O
among,O,O
women,O,O
on,O,O
levonorgestrel,B,B
-,O,I
containing,O,I
COCs,B,I
",",O,O
and,O,O
3,O,O
.,O,O
1,O,O
(,O,O
range,O,O
",",O,O
1,O,O
.,O,O
3,O,O
-,O,O
4,O,O
.,O,O
),O,O
per,O,O
10,O,O
women,O,O
years,O,O
among,O,O
the,O,O
women,O,O
on,O,O
CPA,B,B
/,O,I
EE,B,I
.,O,O
CONCLUSION,O,O
:,O,O
Our,O,O
results,O,O
suggest,O,O
the,O,O
absolute,O,O
risk,O,O
of,O,O
VTE,O,B
among,O,O
Danish,O,O
women,O,O
on,O,O
COCs,B,O
is,O,O
similar,O,O
to,O,O
that,O,O
among,O,O
women,O,O
taking,O,O
CPA,B,B
/,O,I
EE,B,I
.,O,O
Comparison,O,O
of,O,O
developmental,O,O
toxicology,O,O
of,O,O
aspirin,B,B
(,O,O
acetylsalicylic,B,B
acid,I,I
),O,O
in,O,O
rats,O,O
using,O,O
selected,O,O
dosing,O,O
paradigms,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Analysis,O,O
of,O,O
the,O,O
literature,O,O
for,O,O
nonsteroidal,O,O
anti,O,O
-,O,O
inflammatory,O,O
drugs,O,O
(,O,O
NSAIDs,O,B
),O,O
suggests,O,O
that,O,O
a,O,O
low,O,O
incidence,O,O
of,O,O
developmental,O,O
anomalies,O,O
occurs,O,O
in,O,O
rats,O,O
given,O,O
NSAIDs,O,B
on,O,O
specific,O,O
days,O,O
during,O,O
organogenesis,O,O
.,O,O
Aspirin,B,B
(,O,O
acetylsalicylic,B,B
acid,I,I
[,O,O
ASA,B,B
],O,O
),O,O
",",O,O
an,O,O
irreversible,O,O
cyclooxygenase,O,B
1,O,I
and,O,O
2,O,I
inhibitor,O,O
",",O,O
induces,O,O
developmental,O,O
anomalies,O,O
when,O,O
administered,O,O
to,O,O
Wistar,O,O
rats,O,O
on,O,O
gestational,O,O
day,O,O
(,O,O
GD,O,B
),O,O
9,O,O
",",O,O
10,O,O
",",O,O
or,O,O
11,O,O
(,O,O
Kimmel,O,O
CA,O,O
",",O,O
Wilson,O,O
JG,O,O
",",O,O
Schumacher,O,O
HJ,O,O
.,O,O
Teratology,O,O
4,O,O
:,O,O
15,O,O
-,O,O
24,O,O
",",O,O
1971,O,O
),O,O
.,O,O
There,O,O
are,O,O
no,O,O
published,O,O
ASA,B,B
studies,O,O
using,O,O
the,O,O
multiple,O,O
dosing,O,O
paradigm,O,O
of,O,O
GDs,O,B
6,O,O
to,O,O
17,O,O
.,O,O
Objectives,O,O
of,O,O
the,O,O
current,O,O
study,O,O
were,O,O
to,O,O
compare,O,O
results,O,O
between,O,O
Sprague,O,B
-,O,I
Dawley,O,I
(,O,O
SD,O,B
),O,O
and,O,O
Wistar,O,B
strains,O,O
when,O,O
ASA,B,B
is,O,O
administered,O,O
on,O,O
GD,O,O
9,O,O
",",O,O
10,O,O
",",O,O
or,O,O
11,O,O
;,O,O
to,O,O
compare,O,O
the,O,O
malformation,O,O
patterns,O,O
following,O,O
single,O,O
and,O,O
multiple,O,O
dosings,O,O
during,O,O
organogenesis,O,O
in,O,O
SD,O,B
rats,O,O
;,O,O
and,O,O
to,O,O
test,O,O
the,O,O
hypothesis,O,O
that,O,O
maternal,O,O
gastrointestinal,O,O
toxicity,O,O
confounds,O,O
the,O,O
detection,O,O
of,O,O
low,O,O
incidence,O,O
malformations,O,O
with,O,O
ASA,B,B
when,O,O
a,O,O
multiple,O,O
dosing,O,O
paradigm,O,O
is,O,O
used,O,O
.,O,O
METHODS,O,O
:,O,O
ASA,B,B
was,O,O
administered,O,O
as,O,O
a,O,O
single,O,O
dose,O,O
on,O,O
GD,O,O
9,O,O
(,O,O
0,O,O
",",O,O
250,O,B
",",O,O
500,O,B
",",O,O
or,O,O
625,O,B
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
10,O,O
(,O,O
0,O,O
",",O,O
500,O,B
",",O,O
625,O,B
",",O,O
or,O,O
750,O,B
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
or,O,O
11,O,O
(,O,O
0,O,O
",",O,O
500,O,B
",",O,O
750,O,B
",",O,O
or,O,O
1000,O,B
mg,O,O
/,O,O
kg,O,O
),O,O
and,O,O
from,O,O
GD,O,O
6,O,O
to,O,O
GD,O,O
17,O,O
(,O,O
0,O,O
",",O,O
50,O,B
",",O,O
125,O,B
",",O,O
or,O,O
250,O,B
mg,O,O
/,O,O
kg,O,O
a,O,O
day,O,O
),O,O
in,O,O
the,O,O
multiple,O,O
dose,O,O
study,O,O
to,O,O
SD,O,O
rats,O,O
.,O,O
Animals,O,O
were,O,O
killed,O,O
on,O,O
GD,O,O
21,O,O
",",O,O
and,O,O
fetuses,O,O
were,O,O
examined,O,O
viscerally,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
literature,O,O
evaluation,O,O
suggested,O,O
that,O,O
NSAIDs,O,B
induce,O,O
ventricular,O,O
septal,O,O
defects,O,O
(,O,O
VSDs,O,B
),O,O
and,O,O
midline,O,O
defects,O,O
(,O,O
MDs,O,B
),O,O
in,O,O
rats,O,O
and,O,O
diaphragmatic,O,O
hernia,O,O
(,O,O
DH,O,B
),O,O
",",O,O
MDs,O,B
",",O,O
and,O,O
VSDs,O,B
in,O,O
rabbits,O,O
(,O,O
Cook,O,O
JC,O,O
et,O,O
al,O,O
.,O,O
",",O,O
2003,O,O
),O,O
hence,O,O
",",O,O
the,O,O
present,O,O
study,O,O
focused,O,O
on,O,O
these,O,O
malformations,O,O
",",O,O
even,O,O
though,O,O
ASA,B,B
induces,O,O
several,O,O
other,O,O
low,O,O
-,O,O
incidence,O,O
malformations,O,O
.,O,O
In,O,O
single,O,O
dose,O,O
studies,O,O
",",O,O
DH,O,B
",",O,O
MD,O,B
",",O,O
and,O,O
VSD,O,B
were,O,O
induced,O,O
on,O,O
GDs,O,O
9,O,O
and,O,O
10,O,O
.,O,O
VSD,O,B
also,O,O
was,O,O
noted,O,O
following,O,O
treatment,O,O
on,O,O
GD,O,O
11,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
DH,O,B
and,O,O
MD,O,B
were,O,O
noted,O,O
in,O,O
the,O,O
multiple,O,O
dose,O,O
study,O,O
design,O,O
only,O,O
in,O,O
the,O,O
high,O,O
-,O,O
dose,O,O
group,O,O
",",O,O
and,O,O
VSD,O,B
was,O,O
noted,O,O
across,O,O
all,O,O
dose,O,O
groups,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
High,O,O
concordance,O,O
in,O,O
major,O,O
developmental,O,O
anomalies,O,O
between,O,O
Wistar,O,O
and,O,O
SD,O,O
rats,O,O
were,O,O
noted,O,O
with,O,O
the,O,O
exception,O,O
of,O,O
VSD,O,B
in,O,O
the,O,O
SD,O,O
rats,O,O
and,O,O
hydrocephalus,O,B
in,O,O
the,O,O
Wistar,O,O
rats,O,O
.,O,O
Variations,O,O
and,O,O
malformations,O,O
were,O,O
similar,O,O
when,O,O
ASA,B,B
was,O,O
administered,O,O
as,O,O
a,O,O
single,O,O
dose,O,O
or,O,O
during,O,O
the,O,O
period,O,O
of,O,O
organogenesis,O,O
(,O,O
GDs,O,B
6,O,I
to,O,I
17,O,I
),O,O
.,O,O
It,O,O
was,O,O
also,O,O
evident,O,O
that,O,O
",",O,O
by,O,O
titrating,O,O
the,O,O
dose,O,O
to,O,O
achieve,O,O
a,O,O
maximum,O,O
tolerated,O,O
dose,O,O
",",O,O
malformations,O,O
that,O,O
normally,O,O
occur,O,O
at,O,O
low,O,O
incidence,O,O
",",O,O
as,O,O
reported,O,O
from,O,O
previous,O,O
single,O,O
dose,O,O
studies,O,O
",",O,O
could,O,O
also,O,O
be,O,O
induced,O,O
with,O,O
ASA,B,B
given,O,O
at,O,O
multiple,O,O
doses,O,O
.,O,O
Reversal,O,O
of,O,O
central,O,O
benzodiazepine,B,B
effects,O,O
by,O,O
flumazenil,B,B
after,O,O
intravenous,O,O
conscious,O,O
sedation,O,O
with,O,O
diazepam,B,B
and,O,O
opioids,O,B
:,O,O
report,O,O
of,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
multicenter,O,O
study,O,O
.,O,O
The,O,O
Flumazenil,B,B
in,O,O
Intravenous,O,O
Conscious,O,O
Sedation,O,O
with,O,O
Diazepam,B,B
Multicenter,O,O
Study,O,O
Group,O,O
II,O,O
.,O,O
The,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
a,O,O
new,O,O
benzodiazepine,B,B
antagonist,O,O
",",O,O
flumazenil,B,B
",",O,O
were,O,O
assessed,O,O
in,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
multicenter,O,O
study,O,O
.,O,O
Flumazenil,B,B
(,O,O
mean,O,O
dose,O,O
",",O,O
0,O,O
.,O,O
76,O,O
mg,O,O
),O,O
or,O,O
placebo,O,B
(,O,O
mean,O,O
dose,O,O
",",O,O
8,O,O
.,O,O
9,O,O
ml,O,O
),O,O
was,O,O
administered,O,O
intravenously,O,O
to,O,O
130,O,O
and,O,O
67,O,O
patients,O,O
",",O,O
respectively,O,O
",",O,O
who,O,O
had,O,O
been,O,O
given,O,O
diazepam,B,B
in,O,O
conjunction,O,O
with,O,O
an,O,O
opioid,O,O
(,O,O
fentanyl,B,B
",",O,O
meperidine,B,B
",",O,O
or,O,O
morphine,B,B
),O,O
for,O,O
the,O,O
induction,O,O
and,O,O
maintenance,O,O
of,O,O
intravenous,O,O
conscious,O,O
sedation,O,O
for,O,O
diagnostic,O,O
or,O,O
therapeutic,O,O
surgical,O,O
procedures,O,O
.,O,O
The,O,O
group,O,O
assessable,O,O
for,O,O
efficacy,O,O
comprised,O,O
122,O,O
patients,O,O
treated,O,O
with,O,O
flumazenil,B,B
and,O,O
64,O,O
patients,O,O
given,O,O
placebo,O,B
.,O,O
After,O,O
5,O,O
minutes,O,O
",",O,O
80,O,O
/,O,O
115,O,O
(,O,O
70,O,O
%,O,O
),O,O
flumazenil,B,B
-,O,O
treated,O,O
patients,O,O
",",O,O
compared,O,O
with,O,O
21,O,O
/,O,O
63,O,O
(,O,O
33,O,O
%,O,O
),O,O
placebo,O,B
-,O,O
treated,O,O
patients,O,O
",",O,O
were,O,O
completely,O,O
awake,O,O
and,O,O
alert,O,O
",",O,O
as,O,O
indicated,O,O
by,O,O
a,O,O
score,O,O
of,O,O
5,O,O
on,O,O
the,O,O
Observer,O,O
',O,O
s,O,O
Assessment,O,O
of,O,O
Alertness,O,O
/,O,O
Sedation,O,O
Scale,O,O
.,O,O
Ninety,O,O
-,O,O
five,O,O
percent,O,O
of,O,O
patients,O,O
in,O,O
each,O,O
group,O,O
who,O,O
attained,O,O
a,O,O
score,O,O
of,O,O
5,O,O
at,O,O
the,O,O
5,O,O
-,O,O
minute,O,O
assessment,O,O
showed,O,O
no,O,O
loss,O,O
of,O,O
alertness,O,O
throughout,O,O
the,O,O
180,O,O
-,O,O
minute,O,O
assessment,O,O
period,O,O
.,O,O
Flumazenil,B,B
-,O,I
treated,O,I
patients,O,O
also,O,O
performed,O,O
significantly,O,O
better,O,O
on,O,O
the,O,O
Finger,O,B
-,O,I
to,O,I
-,O,I
Nose,O,I
Test,O,I
and,O,O
the,O,O
recall,O,O
of,O,O
pictures,O,O
shown,O,O
at,O,O
the,O,O
5,O,O
-,O,O
minute,O,O
assessment,O,O
.,O,O
Flumazenil,B,B
was,O,O
well,O,O
tolerated,O,O
",",O,O
with,O,O
no,O,O
serious,O,O
adverse,O,O
effects,O,O
reported,O,O
.,O,O
Thirty,O,O
-,O,O
nine,O,O
(,O,O
30,O,O
%,O,O
),O,O
of,O,O
flumazenil,B,B
-,O,O
treated,O,O
patients,O,O
",",O,O
compared,O,O
with,O,O
17,O,O
(,O,O
25,O,O
%,O,O
),O,O
of,O,O
placebo,O,B
-,O,O
treated,O,O
patients,O,O
had,O,O
one,O,O
or,O,O
more,O,O
drug,O,O
-,O,O
related,O,O
adverse,O,O
experiences,O,O
.,O,O
The,O,O
most,O,O
common,O,O
adverse,O,O
effects,O,O
were,O,O
nausea,O,B
and,O,O
vomiting,O,O
in,O,O
the,O,O
flumazenil,B,B
group,O,O
and,O,O
nausea,O,B
and,O,O
injection,O,B
-,O,I
site,O,I
pain,O,I
in,O,O
the,O,O
placebo,O,B
group,O,O
.,O,O
Flumazenil,B,B
was,O,O
found,O,O
to,O,O
promptly,O,O
reverse,O,O
sedation,O,O
induced,O,O
by,O,O
diazepam,B,B
in,O,O
the,O,O
presence,O,O
of,O,O
opioids,O,B
.,O,O
Methylphenidate,B,B
-,O,I
induced,O,O
obsessive,O,O
-,O,O
compulsive,O,O
symptoms,O,O
in,O,O
an,O,O
elderly,O,O
man,O,O
.,O,O
An,O,O
82,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
treatment,O,O
-,O,O
resistant,O,O
depression,O,O
and,O,O
early,O,O
Alzheimer,O,B
',O,I
s,O,I
disease,O,I
was,O,O
started,O,O
on,O,O
methylphenidate,B,B
.,O,O
Significant,O,O
obsessive,O,B
-,O,I
compulsive,O,I
behavior,O,O
ensued,O,O
but,O,O
diminished,O,O
over,O,O
several,O,O
weeks,O,O
when,O,O
methylphenidate,B,B
was,O,O
replaced,O,O
by,O,O
fluvoxamine,B,B
.,O,O
The,O,O
patient,O,O
had,O,O
no,O,O
prior,O,O
psychiatric,O,O
history,O,O
",",O,O
but,O,O
he,O,O
had,O,O
a,O,O
sister,O,O
with,O,O
obsessive,O,B
-,O,I
compulsive,O,I
disorder,O,O
.,O,O
It,O,O
appears,O,O
that,O,O
methylphenidate,B,B
precipitated,O,O
the,O,O
patient,O,O
',O,O
s,O,O
pathological,O,O
behavior,O,O
.,O,O
Ciprofloxacin,B,B
-,O,O
induced,O,O
acute,O,O
interstitial,O,B
nephritis,O,I
and,O,O
autoimmune,O,B
hemolytic,O,I
anemia,O,I
.,O,O
Ciprofloxacin,B,B
has,O,O
been,O,O
associated,O,O
with,O,O
several,O,O
side,O,O
effects,O,O
including,O,O
interstitial,O,B
nephritis,O,I
and,O,O
hemolytic,O,B
anemia,O,I
.,O,O
The,O,O
combination,O,O
of,O,O
both,O,O
side,O,O
effects,O,O
is,O,O
extremely,O,O
rare,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
describe,O,O
a,O,O
case,O,O
of,O,O
ciprofloxacin,B,B
-,O,O
induced,O,O
interstitial,O,B
nephritis,O,I
and,O,O
autoimmune,O,B
hemolytic,O,I
anemia,O,I
.,O,O
Hemolytic,O,B
anemia,O,I
improved,O,O
after,O,O
stopping,O,O
the,O,O
drug,O,O
and,O,O
initiation,O,O
of,O,O
steroid,B,B
therapy,O,I
.,O,O
Unfortunately,O,O
",",O,O
acute,O,B
interstitial,O,I
nephritis,O,I
was,O,O
irreversible,O,O
and,O,O
the,O,O
patient,O,O
developed,O,O
end,O,O
-,O,O
stage,O,O
renal,O,B
disease,O,I
.,O,O
Potential,O,O
deleterious,O,O
effect,O,O
of,O,O
furosemide,B,B
in,O,O
radiocontrast,O,B
nephropathy,O,I
.,O,O
The,O,O
purpose,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
the,O,O
efficacy,O,O
of,O,O
furosemide,B,B
in,O,O
addition,O,O
to,O,O
intravenous,O,B
fluids,O,I
in,O,O
the,O,O
prevention,O,O
of,O,O
radiocontrast,O,B
nephropathy,O,I
.,O,O
18,O,O
patients,O,O
",",O,O
referred,O,O
to,O,O
a,O,O
radiocontrast,O,B
study,O,I
",",O,O
considered,O,O
at,O,O
risk,O,O
because,O,O
of,O,O
preexisting,O,O
renal,O,B
insufficiency,O,I
",",O,O
were,O,O
enrolled,O,O
in,O,O
a,O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
controlled,O,O
trial,O,O
",",O,O
performed,O,O
at,O,O
the,O,O
secondary,O,O
care,O,O
center,O,O
of,O,O
a,O,O
1,O,O
",",O,O
100,O,O
-,O,O
bed,O,O
private,O,O
university,O,O
hospital,O,O
.,O,O
In,O,O
addition,O,O
to,O,O
fluids,O,O
",",O,O
the,O,O
treatment,O,O
group,O,O
received,O,O
furosemide,B,B
(,O,O
mean,O,O
dose,O,O
110,O,O
mg,O,O
),O,O
intravenously,O,O
30,O,O
min,O,O
prior,O,O
to,O,O
the,O,O
injection,O,O
of,O,O
contrast,O,B
material,O,I
.,O,O
The,O,O
control,O,O
group,O,O
received,O,O
fluids,O,O
(,O,O
mean,O,O
3,O,O
liters,O,O
),O,O
.,O,O
Radiological,O,O
studies,O,O
were,O,O
mostly,O,O
angiographies,O,O
performed,O,O
with,O,O
both,O,O
ionic,O,B
and,O,O
non,O,B
-,O,I
contrast,O,I
material,O,O
",",O,O
at,O,O
an,O,O
average,O,O
dose,O,O
of,O,O
245,O,O
ml,O,O
.,O,O
Renal,O,O
function,O,O
significantly,O,O
deteriorated,O,O
in,O,O
the,O,O
group,O,O
pretreated,O,O
with,O,O
furosemide,B,B
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
by,O,O
ANOVA,O,O
),O,O
",",O,O
with,O,O
a,O,O
rise,O,O
in,O,O
serum,O,O
creatinine,B,B
from,O,O
145,O,O
+,O,O
/,O,O
-,O,O
13,O,O
to,O,O
182,O,O
+,O,O
/,O,O
-,O,O
16,O,O
mumol,O,B
/,O,I
l,O,I
at,O,O
24,O,O
h,O,O
",",O,O
while,O,O
no,O,O
change,O,O
occurred,O,O
in,O,O
the,O,O
control,O,O
group,O,O
(,O,O
from,O,O
141,O,O
+,O,O
/,O,O
-,O,O
6,O,O
to,O,O
142,O,O
+,O,O
/,O,O
-,O,O
7,O,O
mumol,O,B
/,O,I
l,O,I
.,O,O
Renal,O,B
failure,O,I
was,O,O
associated,O,O
with,O,O
weight,O,O
loss,O,O
in,O,O
the,O,O
furosemide,B,B
-,O,I
treated,O,I
group,O,I
.,O,O
Furosemide,B,B
may,O,O
be,O,O
deleterious,O,O
in,O,O
the,O,O
prevention,O,O
of,O,O
radiocontrast,O,B
nephropathy,O,I
.,O,O
Progestational,O,B
agents,O,I
and,O,O
blood,O,B
coagulation,O,I
.,O,O
VII,O,O
.,O,O
Thromboembolic,O,B
and,O,I
other,O,I
complications,O,I
of,O,I
oral,B,I
contraceptive,I,I
therapy,O,I
in,O,I
relationship,O,I
to,O,I
pretreatment,O,I
levels,O,I
of,O,I
blood,O,I
coagulation,O,I
factors,O,I
:,O,O
summary,O,O
report,O,O
of,O,O
a,O,O
ten,O,O
-,O,O
year,O,O
study,O,O
.,O,O
During,O,O
a,O,O
ten,O,O
-,O,O
year,O,O
period,O,O
",",O,O
348,O,O
women,O,O
were,O,O
studied,O,O
for,O,O
a,O,O
total,O,O
of,O,O
5,O,O
",",O,O
877,O,O
patient,O,O
months,O,O
in,O,O
four,O,O
separate,O,O
studies,O,O
relating,O,O
oral,B,O
contraceptives,I,O
to,O,O
changes,O,O
in,O,O
hematologic,O,O
parameters,O,O
.,O,O
Significant,O,O
increases,O,O
in,O,O
certain,O,O
factors,O,O
of,O,O
the,O,O
blood,O,B
coagulation,O,I
and,O,O
fibrinolysin,O,B
systems,O,O
(,O,O
factors,O,O
I,O,B
",",O,O
II,O,B
",",O,O
VII,O,B
",",O,O
VIII,O,B
",",O,O
IX,O,B
",",O,O
and,O,O
X,O,B
and,O,O
plasminogen,O,B
),O,O
were,O,O
observed,O,O
in,O,O
the,O,O
treated,O,O
groups,O,O
.,O,O
Severe,O,O
complications,O,O
developed,O,O
in,O,O
four,O,O
patients,O,O
.,O,O
All,O,O
four,O,O
had,O,O
an,O,O
abnormal,O,O
blood,O,O
coagulation,O,O
profile,O,O
",",O,O
suggesting,O,O
before,O,O
initiation,O,O
of,O,O
therapy,O,O
.,O,O
Some,O,O
of,O,O
these,O,O
findings,O,O
represented,O,O
the,O,O
most,O,O
extreme,O,O
abnormalities,O,O
seen,O,O
in,O,O
the,O,O
entire,O,O
group,O,O
of,O,O
patients,O,O
;,O,O
some,O,O
increased,O,O
further,O,O
during,O,O
therapy,O,O
.,O,O
One,O,O
of,O,O
these,O,O
patients,O,O
developed,O,O
a,O,O
myocardial,O,B
infarction,O,I
before,O,O
receiving,O,O
any,O,O
medication,O,O
",",O,O
shortly,O,O
after,O,O
the,O,O
base,O,O
-,O,O
line,O,O
values,O,O
were,O,O
obtained,O,O
.,O,O
One,O,O
patient,O,O
developed,O,O
retinopathy,O,B
19,O,O
months,O,O
after,O,O
she,O,O
began,O,O
therapy,O,O
",",O,O
and,O,O
another,O,O
developed,O,O
thrombophlebitis,O,B
after,O,O
27,O,O
months,O,O
of,O,O
therapy,O,O
.,O,O
The,O,O
fourth,O,O
patient,O,O
developed,O,O
thrombophlebitis,O,B
14,O,O
days,O,O
after,O,O
initiation,O,O
of,O,O
contraceptive,O,O
therapy,O,O
.,O,O
All,O,O
four,O,O
patients,O,O
were,O,O
of,O,O
the,O,O
A,O,B
or,O,O
AB,O,B
blood,O,O
group,O,O
.,O,O
Previous,O,O
studies,O,O
suggested,O,O
the,O,O
possiblility,O,O
of,O,O
increased,O,O
propensity,O,O
for,O,O
thromboembolic,O,O
episodes,O,O
in,O,O
patients,O,O
possessing,O,O
the,O,O
A,O,B
antigen,O,O
.,O,O
It,O,O
appears,O,O
from,O,O
these,O,O
data,O,O
that,O,O
hematologic,O,O
work,O,O
-,O,O
ups,O,O
may,O,O
be,O,O
useful,O,O
in,O,O
women,O,O
who,O,O
are,O,O
about,O,O
to,O,O
start,O,O
long,O,O
-,O,O
term,O,O
oral,B,O
contraceptive,I,O
therapy,O,O
.,O,O
Orthostatic,O,O
hypotension,O,O
occurs,O,O
following,O,O
alpha,O,B
2,O,I
-,O,I
adrenoceptor,O,I
blockade,O,O
in,O,O
chronic,O,O
prazosin,B,O
-,O,O
pretreated,O,O
conscious,O,O
spontaneously,O,O
hypertensive,O,O
rats,O,O
.,O,O
1,O,O
.,O,O
Studies,O,O
were,O,O
performed,O,O
to,O,O
evaluate,O,O
whether,O,O
chronic,O,O
prazosin,B,O
treatment,O,O
alters,O,O
the,O,O
alpha,O,B
2,O,I
-,O,I
adrenoceptor,O,I
function,O,O
for,O,O
orthostatic,O,O
control,O,O
of,O,O
arterial,O,O
blood,O,O
pressure,O,O
in,O,O
conscious,O,O
spontaneously,O,O
hypertensive,O,O
rats,O,O
(,O,O
SHR,O,O
),O,O
.,O,O
2,O,O
.,O,O
Conscious,O,O
SHR,O,O
(,O,O
male,O,O
300,O,O
-,O,O
350,O,O
g,O,O
),O,O
were,O,O
subjected,O,O
to,O,O
90,O,O
degrees,O,O
head,O,O
-,O,O
up,O,O
tilts,O,O
for,O,O
60,O,O
s,O,O
following,O,O
acute,O,O
administration,O,O
of,O,O
prazosin,B,B
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
or,O,O
rauwolscine,B,B
(,O,O
3,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
.,O,O
Orthostatic,O,O
hypotension,O,O
was,O,O
determined,O,O
by,O,O
the,O,O
average,O,O
decrease,O,O
(,O,O
%,O,O
),O,O
in,O,O
mean,O,O
arterial,O,O
pressure,O,O
(,O,O
MAP,O,B
femoral,O,O
),O,O
over,O,O
the,O,O
60,O,O
-,O,O
s,O,O
tilt,O,O
period,O,O
.,O,O
The,O,O
basal,O,O
MAP,O,O
of,O,O
conscious,O,O
SHR,O,O
was,O,O
reduced,O,O
to,O,O
a,O,O
similar,O,O
extent,O,O
by,O,O
prazosin,B,B
(,O,O
-,O,O
23,O,O
%,O,O
(,O,O
-,O,O
),O,O
-,O,O
26,O,O
%,O,O
MAP,O,O
),O,O
and,O,O
rauwolscine,B,B
(,O,O
-,O,O
16,O,O
%,O,O
(,O,O
-,O,O
),O,O
-,O,O
33,O,O
%,O,O
MAP,O,O
),O,O
.,O,O
However,O,O
",",O,O
the,O,O
head,O,O
-,O,O
up,O,O
tilt,O,O
induced,O,O
orthostatic,O,O
hypotension,O,O
in,O,O
the,O,O
SHR,O,O
treated,O,O
with,O,O
prazosin,B,B
(,O,O
-,O,O
16,O,O
%,O,O
MAP,O,O
",",O,O
n,O,O
=,O,O
6,O,O
),O,O
",",O,O
but,O,O
not,O,O
in,O,O
the,O,O
SHR,O,O
treated,O,O
with,O,O
rauwolscine,B,B
(,O,O
less,O,O
than,O,O
+,O,O
2,O,O
%,O,O
MAP,O,O
",",O,O
n,O,O
=,O,O
6,O,O
),O,O
.,O,O
3,O,O
.,O,O
Conscious,O,O
SHR,O,O
were,O,O
treated,O,O
for,O,O
4,O,O
days,O,O
with,O,O
prazosin,B,B
at,O,O
2,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
day,O,O
-,O,O
1,O,O
i,O,O
.,O,O
p,O,O
.,O,O
for,O,O
chronic,O,O
alpha,O,B
1,O,I
-,O,I
adrenoceptor,O,I
blockade,O,I
.,O,O
MAP,O,O
in,O,O
conscious,O,O
SHR,O,O
after,O,O
chronic,O,O
prazosin,B,B
treatment,O,O
was,O,O
14,O,O
%,O,O
lower,O,O
than,O,O
in,O,O
the,O,O
untreated,O,O
SHR,O,O
(,O,O
n,O,O
=,O,O
8,O,O
),O,O
.,O,O
Head,O,O
-,O,O
up,O,O
tilts,O,O
in,O,O
these,O,O
rats,O,O
did,O,O
not,O,O
produce,O,O
orthostatic,O,O
hypotension,O,O
when,O,O
performed,O,O
either,O,O
prior,O,O
to,O,O
or,O,O
after,O,O
acute,O,O
dosing,O,O
of,O,O
prazosin,B,B
(,O,O
0,O,O
.,O,O
1,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
Conversely,O,O
",",O,O
administration,O,O
of,O,O
rauwolscine,B,B
(,O,O
3,O,B
mg,O,I
kg,O,I
-,O,I
1,O,I
i,O,I
.,O,I
v,O,I
.,O,I
),O,I
in,O,O
chronic,O,O
prazosin,B,B
treated,O,O
SHR,O,O
decreased,O,O
the,O,O
basal,O,O
MAP,O,B
by,O,O
12,O,O
-,O,O
31,O,O
%,O,O
(,O,O
n,O,O
=,O,O
4,O,O
),O,O
",",O,O
and,O,O
subsequent,O,O
tilts,O,O
induced,O,O
further,O,O
drops,O,O
of,O,O
MAP,O,B
by,O,O
19,O,O
-,O,O
23,O,O
%,O,O
in,O,O
these,O,O
rats,O,O
.,O,O
4,O,O
.,O,O
The,O,O
pressor,O,O
responses,O,O
and,O,O
bradycardia,O,O
to,O,O
the,O,O
alpha,O,O
1,O,O
-,O,O
agonist,O,O
cirazoline,B,B
(,O,O
0,O,B
.,O,I
6,O,O
and,O,O
2,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
",",O,O
the,O,O
alpha,O,B
2,O,I
-,O,I
agonist,O,I
Abbott,B,B
-,I,I
53693,I,I
(,O,O
1,O,O
and,O,O
3,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
",",O,O
and,O,O
noradrenaline,B,B
(,O,O
0,O,O
.,O,O
1,O,O
and,O,O
1,O,O
.,O,O
0,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
were,O,O
determined,O,O
in,O,O
conscious,O,O
SHR,O,O
with,O,O
and,O,O
without,O,O
chronic,O,O
prazosin,B,O
pretreatment,O,O
.,O,O
Both,O,O
the,O,O
pressor,O,O
and,O,O
bradycardia,O,O
effects,O,O
of,O,O
cirazoline,B,O
were,O,O
abolished,O,O
in,O,O
chronic,O,O
prazosin,B,O
treated,O,O
SHR,O,O
(,O,O
n,O,O
=,O,O
4,O,O
),O,O
as,O,O
compared,O,O
to,O,O
the,O,O
untreated,O,O
SHR,O,O
(,O,O
n,O,O
=,O,O
4,O,O
),O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
the,O,O
pressor,O,O
effects,O,O
of,O,O
Abbott,B,B
-,I,O
53693,I,I
were,O,O
similar,O,O
in,O,O
both,O,O
groups,O,O
of,O,O
SHR,O,O
",",O,O
but,O,O
the,O,O
accompanying,O,O
bradycardia,O,O
was,O,O
greater,O,O
in,O,O
SHR,O,O
with,O,O
chronic,O,O
prazosin,B,O
treatment,O,O
than,O,O
without,O,O
such,O,O
treatment,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
bradycardia,O,O
that,O,O
accompanied,O,O
the,O,O
noradrenaline,B,B
-,O,O
induced,O,O
pressor,O,O
effect,O,O
in,O,O
SHR,O,O
was,O,O
similar,O,O
with,O,O
and,O,O
without,O,O
chronic,O,O
prazosin,B,O
treatment,O,O
despite,O,O
a,O,O
47,O,O
-,O,O
71,O,O
%,O,O
reduction,O,O
of,O,O
the,O,O
pressor,O,O
effect,O,O
in,O,O
chronic,O,O
alpha,O,B
1,O,I
-,O,I
receptor,O,I
blocked,O,I
SHR,O,I
.,O,O
Hemolytic,O,B
-,O,I
uremic,O,I
syndrome,O,I
associated,O,O
with,O,O
ingestion,O,O
of,O,O
quinine,B,B
.,O,O
Hemolytic,O,B
-,O,I
uremic,O,I
syndrome,O,I
following,O,O
quinine,B,B
ingestion,O,O
is,O,O
a,O,O
newly,O,O
described,O,O
phenomenon,O,O
",",O,O
with,O,O
just,O,O
two,O,O
previous,O,O
descriptions,O,O
of,O,O
4,O,O
cases,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
We,O,O
describe,O,O
a,O,O
5th,O,O
case,O,O
.,O,O
The,O,O
reaction,O,O
may,O,O
be,O,O
mediated,O,O
by,O,O
the,O,O
presence,O,O
of,O,O
antibodies,O,O
reactive,O,O
against,O,O
platelets,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
quinine,B,B
.,O,O
Treatment,O,O
has,O,O
included,O,O
use,O,O
of,O,O
plasma,O,B
exchange,O,O
",",O,O
prednisone,B,B
",",O,O
aspirin,B,B
",",O,O
and,O,O
dipyridamole,B,B
.,O,O
The,O,O
patients,O,O
have,O,O
all,O,O
regained,O,O
some,O,O
degree,O,O
of,O,O
renal,O,O
function,O,O
.,O,O
However,O,O
",",O,O
it,O,O
is,O,O
unclear,O,O
whether,O,O
pharmacological,O,O
treatment,O,O
or,O,O
spontaneous,O,O
resolution,O,O
is,O,O
responsible,O,O
for,O,O
the,O,O
improvement,O,O
.,O,O
Quinine,B,B
-,O,O
associated,O,O
hemolytic,O,O
-,O,O
uremic,O,O
syndrome,O,O
probably,O,O
occurs,O,O
more,O,O
often,O,O
than,O,O
is,O,O
recognized,O,O
.,O,O
It,O,O
is,O,O
important,O,O
to,O,O
recognize,O,O
this,O,O
reaction,O,O
when,O,O
it,O,O
occurs,O,O
and,O,O
to,O,O
avoid,O,O
further,O,O
quinine,B,B
exposure,O,O
",",O,O
since,O,O
the,O,O
reaction,O,O
seems,O,O
to,O,O
be,O,O
recurrent,O,O
.,O,O
Amnestic,O,O
syndrome,O,O
associated,O,O
with,O,O
propranolol,B,B
toxicity,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
An,O,O
elderly,O,O
woman,O,O
developed,O,O
an,O,O
Alzheimer,O,B
-,O,I
like,O,I
subacute,O,I
dementia,O,I
as,O,O
a,O,O
result,O,O
of,O,O
propranolol,B,B
toxicity,O,O
.,O,O
Analysis,O,O
of,O,O
the,O,O
manifestations,O,O
showed,O,O
that,O,O
severe,O,O
impairment,O,O
of,O,O
memory,O,B
accounted,O,O
for,O,O
virtually,O,O
all,O,O
of,O,O
the,O,O
abnormalities,O,O
.,O,O
There,O,O
is,O,O
evidence,O,O
that,O,O
cerebral,O,O
reactions,O,O
to,O,O
drug,O,B
toxicity,O,O
can,O,O
exhibit,O,O
patterns,O,O
that,O,O
suggest,O,O
highly,O,O
selective,O,O
involvement,O,O
of,O,O
functional,O,O
subdivisions,O,O
of,O,O
the,O,O
brain,O,O
.,O,O
Cefotetan,B,B
-,O,I
induced,O,O
immune,O,B
hemolytic,O,I
anemia,O,I
.,O,O
Immune,O,O
hemolytic,O,O
anemia,O,O
due,O,O
to,O,O
a,O,O
drug,O,O
-,O,O
adsorption,O,O
mechanism,O,O
has,O,O
been,O,O
described,O,O
primarily,O,O
in,O,O
patients,O,O
receiving,O,O
penicillins,B,B
and,O,O
first,O,O
-,O,O
generation,O,O
cephalosporins,B,B
.,O,O
We,O,O
describe,O,O
a,O,O
patient,O,O
who,O,O
developed,O,O
anemia,O,O
while,O,O
receiving,O,O
intravenous,O,O
cefotetan,B,B
.,O,O
Cefotetan,B,B
-,O,O
dependent,O,O
antibodies,O,O
were,O,O
detected,O,O
in,O,O
the,O,O
patient,O,O
',O,O
s,O,O
serum,O,O
and,O,O
in,O,O
an,O,O
eluate,O,O
prepared,O,O
from,O,O
his,O,O
red,O,O
blood,O,O
cells,O,O
.,O,O
The,O,O
eluate,O,O
also,O,O
reacted,O,O
weakly,O,O
with,O,O
red,O,B
blood,O,I
cells,O,I
in,O,O
the,O,O
absence,O,O
of,O,O
cefotetan,B,B
",",O,O
suggesting,O,O
the,O,O
concomitant,O,O
formation,O,O
of,O,O
warm,O,B
-,O,I
reactive,O,I
autoantibodies,O,I
.,O,O
These,O,O
observations,O,O
",",O,O
in,O,O
conjunction,O,O
with,O,O
clinical,O,O
and,O,O
laboratory,O,O
evidence,O,O
of,O,O
extravascular,O,O
hemolysis,O,O
",",O,O
are,O,O
consistent,O,O
with,O,O
drug,O,B
-,O,I
induced,O,I
hemolytic,O,I
anemia,O,I
",",O,O
possibly,O,O
involving,O,O
both,O,O
drug,O,B
-,O,I
adsorption,O,I
and,O,O
autoantibody,O,B
formation,O,I
mechanisms,O,O
.,O,O
This,O,O
case,O,O
emphasizes,O,O
the,O,O
need,O,O
for,O,O
increased,O,O
awareness,O,O
of,O,O
hemolytic,O,O
reactions,O,O
to,O,O
all,O,O
cephalosporins,B,B
.,O,O
Use,O,O
of,O,O
dexamethasone,B,B
with,O,O
mesna,B,O
for,O,O
the,O,O
prevention,O,O
of,O,O
ifosfamide,B,B
-,O,O
induced,O,O
hemorrhagic,O,O
cystitis,O,O
.,O,O
AIM,O,O
:,O,O
Hemorrhagic,O,O
cystitis,O,O
(,O,O
HC,O,B
),O,O
is,O,O
a,O,O
limiting,O,O
side,O,O
-,O,O
effect,O,O
of,O,O
chemotherapy,O,O
with,O,O
ifosfamide,B,B
(,O,O
IFS,B,B
),O,O
.,O,O
In,O,O
the,O,O
study,O,O
presented,O,O
here,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
use,O,O
of,O,O
dexamethasone,B,B
in,O,O
combination,O,O
with,O,O
mesna,B,B
for,O,O
the,O,O
prevention,O,O
of,O,O
IFS,B,B
-,O,O
induced,O,O
HC,O,B
.,O,O
METHODS,O,O
:,O,O
Male,O,O
Wistar,O,O
rats,O,O
(,O,O
150,O,O
-,O,O
200,O,O
g,O,O
;,O,O
6,O,O
rats,O,O
per,O,O
group,O,O
),O,O
were,O,O
treated,O,O
with,O,O
saline,O,B
or,O,O
mesna,B,B
5,O,O
min,O,O
(,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
before,O,O
and,O,O
2,O,O
and,O,O
6,O,O
h,O,O
after,O,O
(,O,O
v,O,O
.,O,O
o,O,O
.,O,O
),O,O
administration,O,O
of,O,O
IFS,B,B
.,O,O
One,O,O
",",O,O
two,O,O
or,O,O
three,O,O
doses,O,O
of,O,O
mesna,B,B
were,O,O
replaced,O,O
with,O,O
dexamethasone,B,B
alone,O,O
or,O,O
with,O,O
dexamethasone,B,B
plus,O,O
mesna,B,B
.,O,O
Cystitis,O,O
was,O,O
evaluated,O,O
24,O,O
h,O,O
after,O,O
its,O,O
induction,O,O
by,O,O
the,O,O
changes,O,O
in,O,O
bladder,O,O
wet,O,O
weight,O,O
by,O,O
.,O,O
%,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
it,O,O
almost,O,O
abolished,O,O
the,O,O
macroscopic,O,O
and,O,O
microscopic,O,O
alterations,O,O
induced,O,O
by,O,O
IFS,B,B
.,O,O
Moreover,O,O
",",O,O
the,O,O
addition,O,O
of,O,O
dexamethasone,B,B
to,O,O
the,O,O
last,O,O
two,O,O
doses,O,O
of,O,O
mesna,B,B
was,O,O
more,O,O
efficient,O,O
than,O,O
three,O,O
doses,O,O
of,O,O
mesna,B,B
alone,O,O
when,O,O
evaluated,O,O
microscopically,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Dexamethasone,B,B
in,O,O
combination,O,O
with,O,O
mesna,B,B
was,O,O
efficient,O,O
in,O,O
blocking,O,O
IFS,B,B
-,O,O
induced,O,O
HC,O,O
.,O,O
However,O,O
",",O,O
the,O,O
replacement,O,O
of,O,O
last,O,O
two,O,O
doses,O,O
of,O,O
mesna,B,B
with,O,O
saline,O,B
or,O,O
all,O,O
of,O,O
the,O,O
mesna,B,B
doses,O,O
with,O,O
dexamethasone,B,B
did,O,O
not,O,O
prevent,O,O
HC,O,O
.,O,O
All,B,O
-,I,O
trans,I,B
-,I,I
retinoic,I,I
acid,I,I
-,O,I
induced,O,O
erythema,O,B
nodosum,O,I
in,O,O
patients,O,O
with,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
.,O,O
Erythema,O,B
nodosum,O,I
associated,O,O
with,O,O
all,B,O
-,I,O
trans,I,B
-,I,I
retinoic,I,I
acid,I,I
(,O,I
ATRA,B,I
),O,I
for,O,O
acute,O,O
promyelocytic,O,O
leukemia,O,O
(,O,O
APL,O,O
),O,O
is,O,O
very,O,O
rare,O,O
.,O,O
We,O,O
describe,O,O
four,O,O
patients,O,O
with,O,O
classic,O,O
APL,O,B
who,O,O
developed,O,O
erythema,O,B
nodosum,O,I
during,O,O
ATRA,B,O
therapy,O,O
.,O,O
Fever,O,O
and,O,O
subsequent,O,O
multiple,O,O
painful,O,O
erythematous,O,B
nodules,O,I
over,O,O
extremities,O,O
developed,O,O
on,O,O
D11,O,O
",",O,O
D16,O,O
",",O,O
D17,O,O
",",O,O
and,O,O
D19,O,O
",",O,O
respectively,O,O
",",O,O
after,O,O
ATRA,B,O
therapy,O,O
.,O,O
The,O,O
skin,O,O
biopsy,O,O
taken,O,O
from,O,O
each,O,O
patient,O,O
was,O,O
consistent,O,O
with,O,O
erythema,O,B
nodosum,O,I
.,O,O
All,O,O
patients,O,O
received,O,O
short,O,O
course,O,O
of,O,O
steroids,B,B
.,O,O
Fever,O,O
subsided,O,O
rapidly,O,O
and,O,O
the,O,O
skin,O,O
lesions,O,O
regressed,O,O
completely,O,O
.,O,O
All,O,O
patients,O,O
achieved,O,O
complete,O,O
remission,O,O
without,O,O
withdrawal,O,O
of,O,O
ATRA,B,B
.,O,O
ATRA,B,B
seemed,O,O
to,O,O
be,O,O
the,O,O
most,O,O
possible,O,O
etiology,O,O
of,O,O
erythema,O,O
nodosum,O,O
in,O,O
our,O,O
patients,O,O
.,O,O
Short,O,O
-,O,O
term,O,O
use,O,O
of,O,O
steroid,B,B
is,O,O
very,O,O
effective,O,O
in,O,O
ATRA,B,B
-,O,O
induced,O,O
erythema,O,O
nodosum,O,O
.,O,O
Effect,O,O
of,O,O
some,O,O
convulsants,O,O
on,O,O
the,O,O
protective,O,O
activity,O,O
of,O,O
loreclezole,B,B
and,O,O
its,O,O
combinations,O,O
with,O,O
valproate,B,B
or,O,O
clonazepam,B,B
in,O,O
amygdala,O,O
-,O,O
kindled,O,O
rats,O,O
.,O,O
Loreclezole,B,B
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
exerted,O,O
a,O,O
significant,O,O
protective,O,O
action,O,O
in,O,O
amygdala,O,O
-,O,O
kindled,O,O
rats,O,O
",",O,O
reducing,O,O
both,O,O
seizure,O,O
and,O,O
afterdischarge,O,O
durations,O,O
.,O,O
The,O,O
combinations,O,O
of,O,O
loreclezole,B,B
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
with,O,O
valproate,B,B
",",O,O
clonazepam,B,B
",",O,O
or,O,O
carbamazepine,B,B
(,O,O
applied,O,O
at,O,O
their,O,O
subprotective,O,O
doses,O,O
),O,O
also,O,O
exhibited,O,O
antiseizure,O,O
effect,O,O
in,O,O
this,O,O
test,O,O
.,O,O
However,O,O
",",O,O
only,O,O
two,O,O
first,O,O
combinations,O,O
occurred,O,O
to,O,O
be,O,O
of,O,O
pharmacodynamic,O,O
nature,O,O
.,O,O
Among,O,O
several,O,O
chemoconvulsants,O,O
",",O,O
bicuculline,B,B
",",O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
D,I,I
-,I,I
aspartic,I,I
acid,I,I
and,O,O
BAY,B,B
k,I,I
-,I,I
8644,I,I
(,O,O
the,O,O
opener,O,O
of,O,O
L,O,B
-,O,I
type,O,I
calcium,B,I
channels,O,I
),O,O
reversed,O,O
the,O,O
protective,O,O
activity,O,O
of,O,O
loreclezole,B,O
alone,O,O
and,O,O
its,O,O
combination,O,O
with,O,O
valproate,B,B
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
bicuculline,B,B
",",O,O
aminophylline,B,B
and,O,O
BAY,B,B
k,I,I
-,I,I
8644,I,I
inhibited,O,O
the,O,O
anticonvulsive,O,O
action,O,O
of,O,O
loreclezole,B,O
combined,O,O
with,O,O
clonazepam,B,O
.,O,O
The,O,O
results,O,O
support,O,O
the,O,O
hypothesis,O,O
that,O,O
the,O,O
protective,O,O
activity,O,O
of,O,O
loreclezole,B,O
and,O,O
its,O,O
combinations,O,O
with,O,O
other,O,O
antiepileptics,O,O
may,O,O
involve,O,O
potentiation,O,O
of,O,O
GABAergic,O,O
neurotransmission,O,O
and,O,O
blockade,O,O
of,O,O
L,O,B
-,O,I
type,O,I
of,O,I
calcium,B,I
channels,O,I
.,O,O
Mitochondrial,O,B
DNA,O,I
and,O,O
its,O,O
respiratory,O,O
chain,O,O
products,O,O
are,O,O
defective,O,O
in,O,O
doxorubicin,B,B
nephrosis,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Doxorubicin,B,B
induces,O,O
a,O,O
self,O,O
-,O,O
perpetuating,O,O
nephropathy,O,O
characterized,O,O
by,O,O
early,O,O
glomerular,O,O
and,O,O
late,O,O
-,O,O
onset,O,O
tubular,O,O
lesions,O,O
in,O,O
rats,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
potential,O,O
role,O,O
of,O,O
mitochondrial,O,B
injury,O,O
in,O,O
the,O,O
onset,O,O
of,O,O
these,O,O
lesions,O,O
.,O,O
METHODS,O,O
:,O,O
Rats,O,O
were,O,O
treated,O,O
with,O,O
intravenous,O,O
doxorubicin,B,B
(,O,O
1,O,O
mg,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
week,O,O
(,O,O
-,O,O
1,O,O
),O,O
for,O,O
7,O,O
weeks,O,O
and,O,O
were,O,O
sacrificed,O,O
either,O,O
1,O,O
week,O,O
(,O,O
',O,O
short,O,O
-,O,O
term,O,O
',O,O
),O,O
or,O,O
30,O,O
weeks,O,O
(,O,O
',O,O
long,O,O
-,O,O
term,O,O
',O,O
),O,O
following,O,O
the,O,O
last,O,O
dose,O,O
.,O,O
Additional,O,O
rats,O,O
received,O,O
a,O,O
single,O,O
dose,O,O
either,O,O
6,O,O
days,O,O
or,O,O
2,O,O
h,O,O
prior,O,O
to,O,O
euthanasia,O,O
.,O,O
All,O,O
rats,O,O
were,O,O
killed,O,O
at,O,O
48,O,O
weeks,O,O
of,O,O
age,O,O
.,O,O
Glomerular,O,B
and,O,O
tubular,O,B
injury,O,O
was,O,O
monitored,O,O
and,O,O
correlated,O,O
to,O,O
the,O,O
activity,O,O
or,O,O
expression,O,O
of,O,O
respiratory,O,O
chain,O,O
components,O,O
.,O,O
Finally,O,O
",",O,O
we,O,O
quantified,O,O
both,O,O
nuclear,O,B
and,O,O
mitochondrial,O,B
DNA,O,I
(,O,O
mtDNA,O,B
),O,O
as,O,O
well,O,O
as,O,O
superoxide,B,B
production,O,O
and,O,O
the,O,O
4834,O,O
base,O,O
pair,O,O
',O,O
common,O,O
',O,O
mtDNA,O,B
deletion,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
',O,O
long,O,O
-,O,O
term,O,O
',O,O
group,O,O
had,O,O
significant,O,O
glomerular,O,B
and,O,O
tubular,O,B
lesions,O,O
",",O,O
depressed,O,O
activities,O,O
of,O,O
mtDNA,O,B
-,O,O
encoded,O,O
NADH,O,B
dehydrogenase,O,I
and,O,O
cytochrome,O,B
-,O,O
c,O,I
oxidase,O,I
(,O,O
COX,O,B
),O,O
and,O,O
increased,O,O
citrate,B,B
synthase,O,I
activity,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
expression,O,O
of,O,O
the,O,O
mtDNA,O,B
-,O,O
encoded,O,O
COX,O,B
subunit,O,O
I,O,O
was,O,O
reduced,O,O
and,O,O
mtDNA,O,B
levels,O,O
were,O,O
decreased,O,O
.,O,O
In,O,O
',O,O
short,O,O
-,O,O
term,O,O
',O,O
rats,O,O
",",O,O
there,O,O
were,O,O
fewer,O,O
tubular,O,O
lesions,O,O
",",O,O
but,O,O
similar,O,O
numbers,O,O
of,O,O
glomerular,O,O
lesions,O,O
activity,O,O
.,O,O
Among,O,O
all,O,O
animals,O,O
",",O,O
glomerular,O,O
and,O,O
tubular,O,O
injury,O,O
were,O,O
inversely,O,O
correlated,O,O
with,O,O
mtDNA,O,B
levels,O,O
",",O,O
mtDNA,O,B
-,O,O
encoded,O,O
respiratory,O,O
chain,O,O
activities,O,O
and,O,O
with,O,O
the,O,O
expression,O,O
of,O,O
the,O,O
mtDNA,O,B
-,O,O
encoded,O,O
respiratory,O,O
chain,O,O
subunit,O,O
COX,O,B
-,O,O
I,O,O
.,O,O
Injury,O,O
was,O,O
positively,O,O
correlated,O,O
with,O,O
superoxide,B,B
production,O,O
and,O,O
the,O,O
activities,O,O
of,O,O
nucleus,O,O
-,O,O
encoded,O,O
mitochondrial,O,B
or,O,O
cytoplasmic,O,B
enzymes,O,O
.,O,O
Kidneys,O,O
from,O,O
the,O,O
',O,O
long,O,O
-,O,O
term,O,O
',O,O
group,O,O
showed,O,O
more,O,O
mtDNA,O,B
deletions,O,O
than,O,O
in,O,O
',O,O
short,O,O
-,O,O
term,O,O
',O,O
animals,O,O
and,O,O
these,O,O
were,O,O
not,O,O
observed,O,O
in,O,O
the,O,O
other,O,O
groups,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
These,O,O
results,O,O
suggest,O,O
an,O,O
important,O,O
role,O,O
for,O,O
quantitative,O,O
and,O,O
qualitative,O,O
mtDNA,O,B
alterations,O,O
through,O,O
the,O,O
reduction,O,O
of,O,O
mtDNA,O,B
-,O,O
encoded,O,O
respiratory,O,O
chain,O,O
function,O,O
and,O,O
induction,O,O
of,O,O
superoxide,B,B
in,O,O
doxorubicin,B,B
-,O,O
induced,O,O
renal,O,O
lesions,O,O
.,O,O
A,O,O
randomized,O,O
",",O,O
placebo,O,B
-,O,I
controlled,O,I
",",O,O
crossover,O,O
study,O,O
of,O,O
ephedrine,B,B
for,O,O
SSRI,O,B
-,O,I
induced,O,I
female,O,O
sexual,O,O
dysfunction,O,O
.,O,O
The,O,O
objective,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
whether,O,O
ephedrine,B,B
",",O,O
an,O,O
alpha,O,B
-,O,I
and,O,I
beta,O,I
-,O,I
adrenergic,O,I
agonist,O,I
previously,O,O
shown,O,O
to,O,O
enhance,O,O
genital,O,O
blood,O,O
flow,O,O
in,O,O
women,O,O
",",O,O
has,O,O
beneficial,O,O
effects,O,O
in,O,O
reversing,O,O
antidepressant,O,B
-,O,I
induced,O,I
sexual,O,O
dysfunction,O,O
.,O,O
Nineteen,O,O
sexually,O,O
dysfunctional,O,O
women,O,O
receiving,O,O
either,O,O
fluoxetine,B,B
",",O,O
sertraline,B,B
",",O,O
or,O,O
paroxetine,B,B
participated,O,O
in,O,O
an,O,O
eight,O,O
-,O,O
week,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
",",O,O
cross,O,O
-,O,O
over,O,O
study,O,O
of,O,O
the,O,O
effects,O,O
of,O,O
ephedrine,B,B
(,O,O
50,O,O
mg,O,O
),O,O
on,O,O
self,O,O
-,O,O
report,O,O
measures,O,O
of,O,O
sexual,O,O
desire,O,O
",",O,O
arousal,O,O
",",O,O
orgasm,O,O
",",O,O
and,O,O
sexual,O,O
satisfaction,O,O
.,O,O
Although,O,O
there,O,O
were,O,O
significant,O,O
improvements,O,O
relative,O,O
to,O,O
baseline,O,O
in,O,O
sexual,O,O
desire,O,O
and,O,O
orgasm,O,O
intensity,O,O
/,O,O
pleasure,O,O
on,O,O
50,O,B
mg,O,I
ephedrine,B,I
1,O,O
-,O,O
hr,O,O
prior,O,O
to,O,O
sexual,O,O
activity,O,O
",",O,O
significant,O,O
improvements,O,O
in,O,O
these,O,O
measures,O,O
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
sexual,O,O
arousal,O,O
and,O,O
orgasmic,O,O
ability,O,O
also,O,O
were,O,O
noted,O,O
with,O,O
placebo,O,B
.,O,O
These,O,O
findings,O,O
highlight,O,O
the,O,O
importance,O,O
of,O,O
conducting,O,O
placebo,O,B
-,O,O
controlled,O,O
trials,O,O
for,O,O
this,O,O
condition,O,O
.,O,O
Does,O,O
hormone,O,B
therapy,O,I
for,O,O
the,O,O
treatment,O,O
of,O,O
breast,O,B
cancer,O,I
have,O,O
a,O,O
detrimental,O,O
effect,O,O
on,O,O
memory,O,O
and,O,O
cognition,O,O
?,O,O
A,O,O
pilot,O,O
study,O,O
.,O,O
This,O,O
pilot,O,O
study,O,O
examines,O,O
whether,O,O
hormone,O,B
therapy,O,I
for,O,O
breast,O,B
cancer,O,I
affects,O,O
cognition,O,O
.,O,O
Patients,O,O
participating,O,O
in,O,O
a,O,O
randomised,O,O
trial,O,O
of,O,O
anastrozole,B,B
",",O,O
tamoxifen,B,B
alone,O,O
or,O,O
combined,O,O
(,O,O
ATAC,O,B
),O,O
(,O,O
n,O,O
=,O,O
94,O,O
),O,O
and,O,O
a,O,O
group,O,O
of,O,O
women,O,O
without,O,O
breast,O,B
cancer,O,I
(,O,O
n,O,O
=,O,O
35,O,O
),O,O
completed,O,O
a,O,O
battery,O,O
of,O,O
neuropsychological,O,O
measures,O,O
.,O,O
Compared,O,O
with,O,O
the,O,O
control,O,O
group,O,O
",",O,O
the,O,O
patients,O,O
were,O,O
impaired,O,O
on,O,O
a,O,O
processing,O,O
speed,O,O
task,O,O
(,O,O
p,O,B
=,O,O
0,O,O
.,O,O
),O,O
and,O,O
on,O,O
a,O,O
measure,O,O
of,O,O
immediate,O,O
verbal,O,O
memory,O,O
(,O,O
p,O,B
=,O,O
0,O,O
.,O,O
),O,O
after,O,O
controlling,O,O
for,O,O
the,O,O
use,O,O
of,O,O
hormone,O,B
replacement,O,I
therapy,O,I
in,O,O
both,O,O
groups,O,O
.,O,O
Patient,O,O
group,O,O
performance,O,O
was,O,O
not,O,O
significantly,O,O
related,O,O
to,O,O
length,O,O
of,O,O
treatment,O,O
or,O,O
measures,O,O
of,O,O
psychological,O,O
morbidity,O,O
.,O,O
The,O,O
results,O,O
showed,O,O
specific,O,O
impairments,O,O
in,O,O
processing,O,O
speed,O,O
and,O,O
verbal,O,O
memory,O,O
in,O,O
women,O,O
receiving,O,O
hormonal,O,O
therapy,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
breast,O,O
cancer,O,O
.,O,O
Verbal,O,O
memory,O,O
may,O,O
be,O,O
especially,O,O
sensitive,O,O
to,O,O
changes,O,O
in,O,O
oestrogen,B,B
levels,O,O
",",O,O
a,O,O
finding,O,O
commonly,O,O
reported,O,O
in,O,O
studies,O,O
of,O,O
hormone,O,O
replacement,O,O
therapy,O,O
in,O,O
healthy,O,O
women,O,O
.,O,O
In,O,O
view,O,O
of,O,O
the,O,O
increased,O,O
use,O,O
of,O,O
hormone,O,B
therapies,O,I
in,O,O
an,O,O
adjuvant,O,O
and,O,O
preventative,O,O
setting,O,O
their,O,O
impact,O,O
on,O,O
cognitive,O,O
functioning,O,O
should,O,O
be,O,O
investigated,O,O
more,O,O
thoroughly,O,O
.,O,O
Expression,O,O
of,O,O
p300,O,B
protects,O,O
cardiac,O,B
myocytes,O,I
from,O,O
apoptosis,O,O
in,O,O
vivo,O,O
.,O,O
Doxorubicin,B,B
is,O,O
an,O,O
anti,O,O
-,O,O
tumor,O,O
agent,O,O
that,O,O
represses,O,O
cardiac,O,B
-,O,O
specific,O,O
gene,O,O
expression,O,O
and,O,O
induces,O,O
myocardial,O,B
cell,O,I
apoptosis,O,O
.,O,O
Doxorubicin,B,B
depletes,O,O
cardiac,O,O
p300,O,B
",",O,O
a,O,O
transcriptional,O,O
coactivator,O,O
that,O,O
is,O,O
required,O,O
for,O,O
the,O,O
maintenance,O,O
of,O,O
the,O,O
differentiated,O,O
phenotype,O,O
of,O,O
cardiac,O,O
myocytes,O,O
.,O,O
However,O,O
",",O,O
the,O,O
role,O,O
of,O,O
p300,O,B
in,O,O
protection,O,O
against,O,O
doxorubicin,B,B
-,O,O
induced,O,O
apoptosis,O,O
is,O,O
unknown,O,O
.,O,O
Transgenic,O,O
mice,O,O
overexpressing,O,O
p300,O,B
in,O,O
the,O,O
heart,O,O
and,O,O
wild,O,O
-,O,O
type,O,O
mice,O,O
were,O,O
subjected,O,O
to,O,O
doxorubicin,B,B
treatment,O,O
.,O,O
Compared,O,O
with,O,O
wild,O,B
-,O,I
type,O,I
mice,O,I
",",O,O
transgenic,O,B
mice,O,I
exhibited,O,O
higher,O,O
survival,O,O
rate,O,O
as,O,O
well,O,O
as,O,O
more,O,O
preserved,O,O
left,O,O
ventricular,O,O
function,O,O
and,O,O
cardiac,O,O
expression,O,O
of,O,O
alpha,O,B
-,O,I
sarcomeric,O,I
actin,O,I
.,O,O
Doxorubicin,B,B
induced,O,O
myocardial,O,O
cell,O,O
apoptosis,O,O
in,O,O
wild,O,B
-,O,I
type,O,I
mice,O,I
but,O,O
not,O,O
in,O,O
transgenic,O,B
mice,O,I
.,O,O
Expression,O,O
of,O,O
p300,O,B
increased,O,O
the,O,O
cardiac,O,O
level,O,O
of,O,O
bcl,O,B
-,O,I
2,O,I
and,O,O
mdm,O,B
-,O,I
2,O,I
",",O,O
but,O,O
not,O,O
that,O,O
of,O,O
p53,O,B
or,O,O
other,O,O
members,O,O
of,O,O
the,O,O
bcl,O,B
-,O,I
2,O,I
family,O,I
.,O,O
These,O,O
findings,O,O
demonstrate,O,O
that,O,O
overexpression,O,O
of,O,O
p300,O,B
protects,O,O
cardiac,O,O
myocytes,O,O
from,O,O
doxorubicin,B,B
-,O,I
induced,O,I
apoptosis,O,I
and,O,O
reduces,O,O
the,O,O
extent,O,O
of,O,O
acute,O,O
heart,O,O
failure,O,O
in,O,O
adult,O,O
mice,O,O
in,O,O
vivo,O,O
.,O,O
Methimazole,B,B
-,O,I
induced,O,I
cholestatic,O,I
jaundice,O,I
.,O,O
Methimazole,B,B
is,O,O
a,O,O
widely,O,O
used,O,O
and,O,O
generally,O,O
well,O,O
-,O,O
tolerated,O,O
antithyroid,O,O
agent,O,O
.,O,O
A,O,O
43,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
had,O,O
severe,O,O
jaundice,O,B
and,O,O
itching,O,O
1,O,O
month,O,O
after,O,O
receiving,O,O
methimazole,B,B
(,O,O
10,O,O
mg,O,O
tid,O,O
),O,O
and,O,O
propranolol,B,B
(,O,O
20,O,O
mg,O,O
tid,O,O
),O,O
for,O,O
treatment,O,O
of,O,O
hyperthyroidism,O,O
.,O,O
The,O,O
patient,O,O
continued,O,O
treatment,O,O
for,O,O
another,O,O
4,O,O
days,O,O
after,O,O
the,O,O
appearance,O,O
of,O,O
jaundice,O,B
until,O,O
she,O,O
finished,O,O
both,O,O
medications,O,O
.,O,O
When,O,O
seen,O,O
at,O,O
the,O,O
emergency,O,O
department,O,O
2,O,O
weeks,O,O
later,O,O
",",O,O
she,O,O
still,O,O
had,O,O
severe,O,O
icterus,O,B
",",O,O
pruritus,O,B
",",O,O
and,O,O
hyperbilirubinemia,O,B
",",O,O
formed,O,O
mainly,O,O
of,O,O
the,O,O
conjugated,O,O
fraction,O,O
.,O,O
Methimazole,B,B
-,O,O
induced,O,O
cholestasis,O,O
was,O,O
diagnosed,O,O
",",O,O
and,O,O
propranolol,B,B
therapy,O,O
was,O,O
resumed,O,O
.,O,O
Over,O,O
the,O,O
following,O,O
9,O,O
days,O,O
",",O,O
the,O,O
symptoms,O,O
improved,O,O
and,O,O
plasma,O,O
bilirubin,B,B
levels,O,O
were,O,O
normal,O,O
after,O,O
12,O,O
weeks,O,O
without,O,O
methimazole,B,B
.,O,O
In,O,O
rare,O,O
cases,O,O
within,O,O
the,O,O
first,O,O
few,O,O
weeks,O,O
of,O,O
therapy,O,O
",",O,O
this,O,O
drug,O,O
can,O,O
cause,O,O
severe,O,O
and,O,O
reversible,O,O
cholestatic,O,O
jaundice,O,O
.,O,O
Physicians,O,O
and,O,O
patients,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
this,O,O
adverse,O,O
effect,O,O
so,O,O
that,O,O
",",O,O
upon,O,O
occurrence,O,O
",",O,O
they,O,O
can,O,O
discontinue,O,O
methimazole,B,B
therapy,O,O
and,O,O
avoid,O,O
unnecessary,O,O
invasive,O,O
procedures,O,O
.,O,O
Atrial,O,O
fibrillation,O,O
following,O,O
chemotherapy,O,O
for,O,O
stage,O,O
IIIE,O,O
diffuse,O,O
large,O,O
B,O,B
-,O,I
cell,O,I
gastric,O,I
lymphoma,O,I
in,O,O
a,O,O
patient,O,O
with,O,O
myotonic,O,O
dystrophy,O,O
(,O,O
Steinert,O,O
',O,O
s,O,O
disease,O,O
),O,O
.,O,O
The,O,O
authors,O,O
describe,O,O
the,O,O
unusual,O,O
association,O,O
between,O,O
diffuse,O,O
B,O,B
-,O,I
cell,O,I
gastric,O,I
lymphoma,O,I
and,O,O
myotonic,O,B
dystrophy,O,I
",",O,O
the,O,O
most,O,O
common,O,O
form,O,O
of,O,O
adult,O,O
muscular,O,O
dystrophy,O,O
",",O,O
and,O,O
sudden,O,O
atrial,O,B
fibrillation,O,I
following,O,O
one,O,O
cycle,O,O
of,O,O
doxorubicin,B,B
-,O,I
based,O,I
chemotherapy,O,I
in,O,O
the,O,O
same,O,O
patient,O,O
.,O,O
Atrial,O,B
fibrillation,O,I
or,O,O
other,O,O
cardiac,O,O
arrhythmias,O,O
are,O,O
unusual,O,O
complications,O,O
in,O,O
patients,O,O
treated,O,O
with,O,O
chemotherapy,O,O
.,O,O
The,O,O
cardiac,O,B
toxicity,O,I
intrinsically,O,O
associated,O,O
with,O,O
the,O,O
aggressive,O,O
chemotherapy,O,O
employed,O,O
could,O,O
function,O,O
as,O,O
a,O,O
triggering,O,O
factor,O,O
for,O,O
the,O,O
arrhythmia,O,O
in,O,O
the,O,O
predisposed,O,O
myocardium,O,O
of,O,O
this,O,O
patient,O,O
.,O,O
Hypersensitivity,O,B
immune,O,I
reaction,O,I
as,O,O
a,O,O
mechanism,O,O
for,O,O
dilevalol,B,B
-,O,I
associated,O,I
hepatitis,O,I
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
assess,O,O
lymphocyte,O,O
reactivity,O,O
to,O,O
dilevalol,B,B
and,O,O
to,O,O
serum,O,O
containing,O,O
putative,O,O
ex,O,O
vivo,O,O
dilevalol,B,I
antigens,O,I
or,O,O
metabolites,O,O
in,O,O
a,O,O
case,O,O
of,O,O
dilevalol,B,B
-,O,I
induced,O,I
liver,O,I
injury,O,I
.,O,O
PATIENT,O,O
:,O,O
A,O,O
58,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
a,O,O
clinical,O,O
diagnosis,O,O
of,O,O
dilevalol,B,B
-,O,I
induced,O,I
liver,O,I
injury,O,I
.,O,O
METHODS,O,O
:,O,O
Peripheral,O,O
blood,O,O
mononuclear,O,O
cells,O,O
collected,O,O
from,O,O
the,O,O
patient,O,O
were,O,O
cultured,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
solution,O,O
of,O,O
dilevalol,B,B
and,O,O
also,O,O
with,O,O
sera,O,O
collected,O,O
from,O,O
a,O,O
volunteer,O,O
before,O,O
and,O,O
after,O,O
dilevalol,B,B
intake,O,O
.,O,O
A,O,O
similar,O,O
protocol,O,O
was,O,O
performed,O,O
with,O,O
lymphocytes,O,O
from,O,O
a,O,O
healthy,O,O
subject,O,O
.,O,O
RESULTS,O,O
:,O,O
No,O,O
lymphocyte,O,O
proliferation,O,O
was,O,O
observed,O,O
either,O,O
in,O,O
the,O,O
patient,O,O
or,O,O
in,O,O
the,O,O
healthy,O,O
volunteer,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
dilevalol,B,B
solutions,O,O
.,O,O
A,O,O
significant,O,O
proliferative,O,O
response,O,O
to,O,O
serum,O,O
collected,O,O
after,O,O
dilevalol,B,B
intake,O,O
was,O,O
observed,O,O
in,O,O
the,O,O
case,O,O
of,O,O
the,O,O
patient,O,O
compared,O,O
with,O,O
the,O,O
proliferative,O,O
response,O,O
to,O,O
the,O,O
serum,O,O
collected,O,O
before,O,O
the,O,O
drug,O,O
intake,O,O
.,O,O
No,O,O
reactivity,O,O
was,O,O
found,O,O
when,O,O
lymphocytes,O,O
from,O,O
the,O,O
healthy,O,O
subject,O,O
were,O,O
tested,O,O
under,O,O
similar,O,O
conditions,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
methodology,O,O
used,O,O
allowed,O,O
the,O,O
detection,O,O
of,O,O
lymphocyte,O,O
sensitization,O,O
to,O,O
sera,O,O
containing,O,O
ex,O,O
vivo,O,O
-,O,O
prepared,O,O
dilevalol,B,B
antigens,O,O
",",O,O
suggesting,O,O
the,O,O
involvement,O,O
of,O,O
an,O,O
immunologic,O,O
mechanism,O,O
in,O,O
dilevalol,B,B
-,O,O
induced,O,O
liver,O,O
injury,O,O
.,O,O
Increased,O,O
expression,O,O
and,O,O
apical,O,O
targeting,O,O
of,O,O
renal,O,O
ENaC,O,B
subunits,O,O
in,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,I
nephrotic,O,I
syndrome,O,I
in,O,O
rats,O,O
.,O,O
Nephrotic,O,O
syndrome,O,O
is,O,O
often,O,O
accompanied,O,O
by,O,O
sodium,B,O
retention,O,O
and,O,O
generalized,O,O
edema,O,O
.,O,O
However,O,O
",",O,O
the,O,O
molecular,O,O
basis,O,O
for,O,O
the,O,O
decreased,O,O
renal,O,O
sodium,B,O
excretion,O,O
remains,O,O
undefined,O,O
.,O,O
We,O,O
hypothesized,O,O
that,O,O
epithelial,O,O
Na,B,B
channel,O,O
(,O,O
ENaC,O,B
),O,O
subunit,O,O
dysregulation,O,O
may,O,O
be,O,O
responsible,O,O
for,O,O
the,O,O
increased,O,O
sodium,B,B
retention,O,O
.,O,O
An,O,O
experimental,O,O
group,O,O
of,O,O
rats,O,O
was,O,O
treated,O,O
with,O,O
puromycin,B,B
aminonucleoside,I,I
(,O,O
PAN,B,B
;,O,O
180,O,O
mg,O,O
/,O,O
kg,O,O
iv,O,O
),O,O
",",O,O
whereas,O,O
the,O,O
control,O,O
group,O,O
received,O,O
only,O,O
vehicle,O,O
.,O,O
After,O,O
7,O,O
days,O,O
",",O,O
PAN,B,B
treatment,O,O
induced,O,O
significant,O,O
proteinuria,O,B
",",O,O
hypoalbuminemia,O,B
",",O,O
decreased,O,O
urinary,O,O
sodium,B,B
excretion,O,O
",",O,O
and,O,O
extensive,O,O
ascites,O,O
.,O,O
The,O,O
protein,O,O
abundance,O,O
of,O,O
alpha,O,B
-,O,O
ENaC,O,I
and,O,O
beta,O,B
-,O,O
ENaC,O,I
was,O,O
increased,O,O
in,O,O
the,O,O
inner,O,O
stripe,O,O
of,O,O
the,O,O
outer,O,O
medulla,O,O
(,O,O
ISOM,O,B
),O,O
and,O,O
in,O,O
the,O,O
inner,O,O
medulla,O,O
(,O,O
IM,O,B
),O,O
but,O,O
was,O,O
not,O,O
altered,O,O
in,O,O
the,O,O
cortex,O,O
.,O,O
gamma,O,B
-,O,O
ENaC,O,I
abundance,O,O
was,O,O
increased,O,O
in,O,O
the,O,O
cortex,O,O
",",O,O
ISOM,O,B
",",O,O
and,O,O
IM,O,B
.,O,O
Immunoperoxidase,O,O
brightfield,O,O
-,O,O
and,O,O
laser,O,O
-,O,O
scanning,O,O
confocal,O,O
fluorescence,O,O
microscopy,O,O
demonstrated,O,O
increased,O,O
targeting,O,O
of,O,O
alpha,O,B
-,O,O
ENaC,O,I
",",O,O
beta,O,B
-,O,O
ENaC,O,I
",",O,O
and,O,O
gamma,O,B
-,O,O
ENaC,O,I
subunits,O,O
to,O,O
the,O,O
apical,O,O
plasma,O,O
membrane,O,O
in,O,O
the,O,O
distal,O,O
convoluted,O,O
tubule,O,O
(,O,O
DCT2,O,B
),O,O
",",O,O
connecting,O,O
tubule,O,O
",",O,O
and,O,O
cortical,O,O
and,O,O
medullary,O,O
collecting,O,O
duct,O,O
segments,O,O
.,O,O
Immunoelectron,O,O
microscopy,O,O
further,O,O
revealed,O,O
an,O,O
increased,O,O
labeling,O,O
of,O,O
alpha,O,B
-,O,O
ENaC,O,I
in,O,O
the,O,O
apical,O,O
plasma,O,O
membrane,O,O
of,O,O
cortical,O,O
collecting,O,O
duct,O,O
principal,O,O
cells,O,O
of,O,O
PAN,B,O
-,O,O
treated,O,O
rats,O,O
",",O,O
indicating,O,O
enhanced,O,O
apical,O,O
targeting,O,O
of,O,O
alpha,O,B
-,O,O
ENaC,O,I
subunits,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
protein,O,O
abundances,O,O
of,O,O
Na,B,B
(,O,O
+,O,O
),O,O
H,B,B
(,O,I
+,O,I
),O,I
exchanger,O,O
type,O,O
3,O,O
(,O,O
NHE3,O,B
),O,O
",",O,O
Na,B,B
(,O,O
+,O,O
),O,O
(,O,O
+,O,O
),O,O
-,O,O
2Cl,B,I
(,O,O
-,O,O
),O,O
cotransporter,O,O
(,O,O
BSC,O,B
-,O,O
1,O,O
),O,O
",",O,O
and,O,O
thiazide,B,O
-,O,O
sensitive,O,O
Na,B,B
(,O,O
+,O,O
),O,O
-,O,O
Cl,B,I
(,O,O
-,O,O
),O,O
cotransporter,O,O
(,O,O
TSC,O,B
),O,O
were,O,O
decreased,O,O
.,O,O
Moreover,O,O
",",O,O
the,O,O
abundance,O,O
of,O,O
the,O,O
alpha,O,B
(,O,O
1,O,O
),O,O
-,O,O
subunit,O,O
of,O,O
the,O,O
Na,B,B
-,O,O
K,B,I
-,O,O
ATPase,O,I
was,O,O
decreased,O,O
in,O,O
the,O,O
cortex,O,O
and,O,O
ISOM,O,O
",",O,O
but,O,O
it,O,O
remained,O,O
unchanged,O,O
in,O,O
the,O,O
IM,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
the,O,O
increased,O,O
or,O,O
sustained,O,O
expression,O,O
of,O,O
ENaC,O,B
subunits,O,O
combined,O,O
with,O,O
increased,O,O
apical,O,O
targeting,O,O
in,O,O
the,O,O
DCT2,O,O
",",O,O
connecting,O,O
tubule,O,O
",",O,O
and,O,O
collecting,O,O
duct,O,O
are,O,O
likely,O,O
to,O,O
play,O,O
a,O,O
role,O,O
in,O,O
the,O,O
sodium,B,O
retention,O,O
associated,O,O
with,O,O
PAN,B,B
-,O,O
induced,O,O
nephrotic,O,O
syndrome,O,O
.,O,O
The,O,O
decreased,O,O
abundance,O,O
of,O,O
NHE3,O,B
",",O,O
BSC,O,B
-,O,I
1,O,I
",",O,O
TSC,O,B
",",O,O
and,O,O
Na,B,B
-,O,I
K,B,I
-,O,I
ATPase,O,I
may,O,O
play,O,O
a,O,O
compensatory,O,O
role,O,O
to,O,O
promote,O,O
sodium,B,O
excretion,O,O
.,O,O
Pallidal,O,B
stimulation,O,O
:,O,O
an,O,O
alternative,O,O
to,O,O
pallidotomy,O,O
?,O,O
A,O,O
resurgence,O,O
of,O,O
interest,O,O
in,O,O
the,O,O
surgical,O,O
treatment,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
(,O,O
PD,O,B
),O,I
came,O,O
with,O,O
the,O,O
rediscovery,O,O
of,O,O
posteroventral,O,O
pallidotomy,O,O
by,O,O
Laitinen,O,O
in,O,O
1985,O,O
.,O,O
Laitinen,O,O
',O,O
procedure,O,O
improved,O,O
most,O,O
symptoms,O,O
in,O,O
drug,O,B
-,O,I
resistant,O,I
PD,O,I
",",O,O
which,O,O
engendered,O,O
wide,O,O
interest,O,O
in,O,O
the,O,O
neurosurgical,O,O
community,O,O
.,O,O
Another,O,O
lesioning,O,O
procedure,O,O
",",O,O
ventrolateral,O,O
thalamotomy,O,O
",",O,O
has,O,O
become,O,O
a,O,O
powerful,O,O
alternative,O,O
to,O,O
stimulate,O,O
the,O,O
nucleus,O,O
ventralis,O,O
intermedius,O,O
",",O,O
producing,O,O
high,O,O
long,O,O
-,O,O
term,O,O
success,O,O
rates,O,O
and,O,O
low,O,O
morbidity,O,O
rates,O,O
.,O,O
Pallidal,O,B
stimulation,O,O
has,O,O
not,O,O
met,O,O
with,O,O
the,O,O
same,O,O
success,O,O
.,O,O
According,O,O
to,O,O
the,O,O
literature,O,O
pallidotomy,O,B
improves,O,O
the,O,O
symptoms,O,O
of,O,O
PD,O,B
",",O,O
such,O,O
as,O,O
dyskinesias,O,B
",",O,O
as,O,O
well,O,O
as,O,O
the,O,O
symptoms,O,O
",",O,O
such,O,O
as,O,O
rigidity,O,B
",",O,O
bradykinesia,O,B
",",O,O
and,O,O
on,O,O
-,O,O
off,O,O
fluctuations,O,O
.,O,O
Pallidal,O,B
stimulation,O,O
improves,O,O
bradykinesia,O,B
and,O,O
rigidity,O,B
to,O,O
a,O,O
minor,O,O
extent,O,O
;,O,O
however,O,O
",",O,O
its,O,O
strength,O,O
seems,O,O
to,O,O
be,O,O
in,O,O
improving,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,B
.,O,O
Stimulation,O,O
often,O,O
produces,O,O
an,O,O
improvement,O,O
in,O,O
the,O,O
hyper,O,B
-,O,O
or,O,O
dyskinetic,O,B
upper,O,I
limbs,O,O
",",O,O
but,O,O
increases,O,O
the,O,O
phenomenon,O,O
in,O,O
the,O,O
lower,O,B
limbs,O,O
at,O,O
the,O,O
same,O,O
time,O,O
.,O,O
Considering,O,O
the,O,O
small,O,O
increase,O,O
in,O,O
the,O,O
patient,O,O
',O,O
s,O,O
independence,O,O
",",O,O
the,O,O
high,O,O
costs,O,O
of,O,O
bilateral,O,O
implants,O,O
",",O,O
and,O,O
the,O,O
difficulty,O,O
most,O,O
patients,O,O
experience,O,O
in,O,O
handling,O,O
the,O,O
devices,O,O
",",O,O
the,O,O
question,O,O
arises,O,O
as,O,O
to,O,O
whether,O,O
bilateral,O,O
pallidal,O,B
stimulation,O,O
is,O,O
a,O,O
real,O,O
alternative,O,O
to,O,O
pallidotomy,O,O
.,O,O
Effects,O,O
of,O,O
the,O,O
cyclooxygenase,O,B
-,O,I
2,O,I
specific,O,I
inhibitor,O,I
valdecoxib,B,B
versus,O,O
nonsteroidal,O,B
antiinflammatory,O,I
agents,O,I
and,O,O
placebo,O,O
on,O,O
cardiovascular,O,O
thrombotic,O,O
events,O,O
in,O,O
patients,O,O
with,O,O
arthritis,O,O
.,O,O
There,O,O
have,O,O
been,O,O
concerns,O,O
that,O,O
the,O,O
risk,O,O
of,O,O
cardiovascular,O,O
thrombotic,O,O
events,O,O
may,O,O
be,O,O
higher,O,O
with,O,O
cyclooxygenase,O,B
(,O,I
COX,O,I
),O,I
-,O,I
2,O,I
-,O,I
specific,O,I
inhibitors,O,I
than,O,O
nonselective,O,B
nonsteroidal,O,I
antiinflammatory,O,I
drugs,O,I
(,O,I
NSAIDs,O,I
),O,I
.,O,O
We,O,O
evaluated,O,O
cardiovascular,O,O
event,O,O
data,O,O
for,O,O
valdecoxib,B,B
",",O,O
a,O,O
new,O,O
COX,O,B
-,O,I
2,O,I
-,O,I
specific,O,I
inhibitor,O,I
in,O,O
approximately,O,O
8000,O,O
patients,O,O
with,O,O
osteoarthritis,O,O
and,O,O
rheumatoid,O,O
arthritis,O,O
treated,O,O
with,O,O
this,O,O
agent,O,O
in,O,O
randomized,O,O
clinical,O,O
trials,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
cardiovascular,O,O
thrombotic,O,O
events,O,O
(,O,O
cardiac,O,O
",",O,O
cerebrovascular,O,O
and,O,O
peripheral,O,O
vascular,O,O
",",O,O
or,O,O
arterial,O,O
thrombotic,O,O
),O,O
was,O,O
determined,O,O
by,O,O
analyzing,O,O
pooled,O,O
valdecoxib,B,B
(,O,O
10,O,O
-,O,O
80,O,O
mg,O,O
daily,O,O
),O,O
",",O,O
nonselective,O,O
NSAID,O,B
(,O,O
diclofenac,B,B
75,O,O
mg,O,O
bid,O,O
",",O,O
ibuprofen,B,B
800,O,O
mg,O,O
tid,O,O
",",O,O
or,O,O
naproxen,B,B
500,O,O
mg,O,O
bid,O,O
),O,O
and,O,O
placebo,O,O
data,O,O
from,O,O
10,O,O
randomized,O,O
osteoarthritis,O,O
and,O,O
rheumatoid,O,O
arthritis,O,O
trials,O,O
that,O,O
were,O,O
6,O,O
-,O,O
52,O,O
weeks,O,O
in,O,O
duration,O,O
.,O,O
The,O,O
incidence,O,O
rates,O,O
of,O,O
events,O,O
were,O,O
determined,O,O
in,O,O
all,O,O
patients,O,O
(,O,O
n,O,O
=,O,O
7934,O,O
),O,O
and,O,O
in,O,O
users,O,O
of,O,O
low,O,O
-,O,O
dose,O,O
(,O,O
<,O,O
or,O,O
=,O,O
325,O,O
mg,O,O
daily,O,O
),O,O
aspirin,B,B
(,O,O
n,O,O
=,O,O
1051,O,O
),O,O
and,O,O
nonusers,O,O
of,O,O
aspirin,B,B
(,O,O
n,O,O
=,O,O
6883,O,O
),O,O
.,O,O
Crude,O,O
and,O,O
exposure,O,O
-,O,O
adjusted,O,O
incidences,O,O
of,O,O
thrombotic,O,B
events,O,O
were,O,O
similar,O,O
for,O,O
valdecoxib,B,B
",",O,O
NSAIDs,O,B
",",O,O
and,O,O
placebo,O,B
.,O,O
The,O,O
risk,O,O
of,O,O
serious,O,O
thrombotic,O,B
events,O,O
was,O,O
also,O,O
similar,O,O
for,O,O
each,O,O
valdecoxib,B,B
dose,O,O
.,O,O
Thrombotic,O,O
risk,O,O
was,O,O
consistently,O,O
higher,O,O
for,O,O
users,O,O
of,O,O
aspirin,B,B
users,O,O
than,O,O
nonusers,O,O
of,O,O
aspirin,B,O
(,O,O
placebo,O,O
",",O,O
1,O,O
.,O,O
4,O,O
%,O,O
vs,O,O
.,O,O
0,O,O
%,O,O
;,O,O
valdecoxib,B,B
",",O,O
1,O,O
.,O,O
7,O,O
%,O,O
vs,O,O
.,O,O
0,O,O
.,O,O
2,O,O
%,O,O
;,O,O
NSAIDs,O,B
",",O,O
1,O,O
.,O,O
9,O,O
%,O,O
vs,O,O
.,O,O
0,O,O
.,O,O
5,O,O
%,O,O
),O,O
The,O,O
rates,O,O
of,O,O
events,O,O
in,O,O
users,O,O
of,O,O
aspirin,B,B
were,O,O
similar,O,O
for,O,O
all,O,O
3,O,O
treatment,O,O
groups,O,O
and,O,O
across,O,O
valdecoxib,B,B
doses,O,O
.,O,O
Short,O,O
-,O,O
and,O,O
intermediate,O,O
-,O,O
term,O,O
treatment,O,O
with,O,O
therapeutic,O,O
(,O,O
10,O,O
or,O,O
20,O,O
mg,O,O
daily,O,O
),O,O
and,O,O
supratherapeutic,O,O
(,O,O
40,O,O
or,O,O
80,O,O
mg,O,O
daily,O,O
),O,O
valdecoxib,B,B
doses,O,O
was,O,O
not,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
incidence,O,O
of,O,O
thrombotic,O,O
events,O,O
relative,O,O
to,O,O
nonselective,O,O
NSAIDs,O,B
or,O,O
placebo,O,O
in,O,O
osteoarthritis,O,O
and,O,O
rheumatoid,O,O
arthritis,O,O
patients,O,O
in,O,O
controlled,O,O
clinical,O,O
trials,O,O
.,O,O
Hypersensitivity,O,B
myocarditis,O,I
complicating,O,O
hypertrophic,O,O
cardiomyopathy,O,O
heart,O,O
.,O,O
The,O,O
present,O,O
report,O,O
describes,O,O
a,O,O
case,O,O
of,O,O
eosinophilic,O,B
myocarditis,O,I
complicating,O,O
hypertrophic,O,O
cardiomyopathy,O,O
.,O,O
The,O,O
47,O,O
-,O,O
year,O,O
-,O,O
old,O,O
female,O,O
patient,O,O
",",O,O
known,O,O
to,O,O
have,O,O
hypertrophic,O,O
cardiomyopathy,O,O
",",O,O
was,O,O
admitted,O,O
with,O,O
biventricular,O,O
failure,O,O
and,O,O
managed,O,O
aggressively,O,O
with,O,O
dobutamine,B,B
infusion,O,O
and,O,O
other,O,O
drugs,O,O
while,O,O
being,O,O
assessed,O,O
for,O,O
heart,O,O
transplantation,O,O
.,O,O
On,O,O
transthoracic,O,O
echocardiogram,O,O
",",O,O
she,O,O
had,O,O
moderate,O,O
left,O,B
ventricular,O,I
dysfunction,O,I
with,O,O
regional,O,O
variability,O,O
and,O,O
moderate,O,O
mitral,O,B
regurgitation,O,I
.,O,O
The,O,O
recipient,O,O
',O,O
s,O,O
heart,O,O
showed,O,O
the,O,O
features,O,O
of,O,O
apical,O,B
hypertrophic,O,I
cardiomyopathy,O,I
and,O,O
myocarditis,O,B
with,O,O
abundant,O,O
eosinophils,O,B
.,O,O
Myocarditis,O,B
is,O,O
rare,O,O
and,O,O
eosinophilic,O,O
myocarditis,O,B
is,O,O
rarer,O,O
.,O,O
It,O,O
is,O,O
likely,O,O
that,O,O
the,O,O
hypersensitivity,O,O
(,O,O
eosinophilic,O,B
),O,O
myocarditis,O,O
was,O,O
related,O,O
to,O,O
dobutamine,B,B
infusion,O,O
therapy,O,O
.,O,O
Eosinophilic,O,B
myocarditis,O,O
has,O,O
been,O,O
reported,O,O
with,O,O
an,O,O
incidence,O,O
of,O,O
2,O,O
.,O,O
4,O,O
%,O,O
to,O,O
7,O,O
.,O,O
2,O,O
%,O,O
in,O,O
explanted,O,O
hearts,O,O
and,O,O
may,O,O
be,O,O
related,O,O
to,O,O
multidrug,O,O
therapy,O,O
.,O,O
Time,O,O
trends,O,O
in,O,O
warfarin,B,B
-,O,I
associated,O,I
hemorrhage,O,O
.,O,O
The,O,O
annual,O,O
incidence,O,O
of,O,O
warfarin,B,B
-,O,O
related,O,O
bleeding,O,O
at,O,O
Brigham,O,O
and,O,O
Women,O,O
',O,O
s,O,O
Hospital,O,O
increased,O,O
from,O,O
0,O,O
.,O,O
97,O,O
/,O,O
1,O,O
",",O,O
patient,O,O
admissions,O,O
in,O,O
the,O,O
first,O,O
time,O,O
period,O,O
(,O,O
January,O,O
1995,O,O
to,O,O
October,O,O
1998,O,O
),O,O
to,O,O
1,O,O
.,O,O
19,O,O
/,O,O
1,O,O
",",O,O
patient,O,O
admissions,O,O
in,O,O
the,O,O
second,O,O
time,O,O
period,O,O
(,O,O
November,O,O
1998,O,O
to,O,O
August,O,O
2002,O,O
),O,O
of,O,O
this,O,O
study,O,O
.,O,O
The,O,O
proportion,O,O
of,O,O
patients,O,O
with,O,O
major,O,O
and,O,O
intracranial,O,O
bleeding,O,O
increased,O,O
from,O,O
20,O,O
.,O,O
2,O,O
%,O,O
and,O,O
1,O,O
.,O,O
9,O,O
%,O,O
",",O,O
respectively,O,O
",",O,O
in,O,O
the,O,O
first,O,O
time,O,O
period,O,O
",",O,O
to,O,O
33,O,O
.,O,O
3,O,O
%,O,O
and,O,O
7,O,O
.,O,O
8,O,O
%,O,O
",",O,O
respectively,O,O
",",O,O
in,O,O
the,O,O
second,O,O
.,O,O
Yohimbine,B,B
treatment,O,O
of,O,O
sexual,O,O
side,O,O
effects,O,O
induced,O,O
by,O,O
serotonin,B,B
reuptake,O,I
blockers,O,I
.,O,O
BACKGROUND,O,O
:,O,O
Preclinical,O,O
and,O,O
clinical,O,O
studies,O,O
suggest,O,O
that,O,O
yohimbine,B,O
facilitates,O,O
sexual,O,O
behavior,O,O
and,O,O
may,O,O
be,O,O
helpful,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
male,O,O
impotence,O,O
.,O,O
A,O,O
single,O,O
case,O,O
report,O,O
suggests,O,O
that,O,O
yohimbine,B,B
may,O,O
be,O,O
used,O,O
to,O,O
treat,O,O
the,O,O
sexual,O,O
side,O,O
effects,O,O
of,O,O
clomipramine,B,B
.,O,O
This,O,O
study,O,O
evaluated,O,O
yohimbine,B,B
as,O,O
a,O,O
treatment,O,O
for,O,O
the,O,O
sexual,O,O
side,O,O
effects,O,O
caused,O,O
by,O,O
serotonin,B,B
reuptake,O,I
blockers,O,I
.,O,O
METHOD,O,O
:,O,O
Six,O,O
patients,O,O
with,O,O
either,O,O
obsessive,O,O
compulsive,O,O
disorder,O,O
",",O,O
trichotillomania,O,B
",",O,O
anxiety,O,O
",",O,O
or,O,O
affective,O,O
disorders,O,O
who,O,O
suffered,O,O
sexual,O,O
side,O,O
effects,O,O
after,O,O
treatment,O,O
with,O,O
serotonin,B,B
reuptake,O,I
blockers,O,I
were,O,O
given,O,O
yohimbine,B,B
on,O,O
a,O,O
p,O,O
.,O,O
r,O,O
.,O,O
n,O,O
.,O,O
basis,O,O
in,O,O
an,O,O
open,O,O
clinical,O,O
trial,O,O
.,O,O
Various,O,O
doses,O,O
of,O,O
yohimbine,B,B
were,O,O
used,O,O
to,O,O
determine,O,O
the,O,O
ideal,O,O
dose,O,O
for,O,O
each,O,O
patient,O,O
.,O,O
RESULTS,O,O
:,O,O
Five,O,O
of,O,O
the,O,O
six,O,O
patients,O,O
experienced,O,O
improved,O,O
sexual,O,O
functioning,O,O
after,O,O
taking,O,O
yohimbine,B,B
.,O,O
One,O,O
patient,O,O
who,O,O
failed,O,O
to,O,O
comply,O,O
with,O,O
yohimbine,B,B
treatment,O,O
had,O,O
no,O,O
therapeutic,O,O
effects,O,O
.,O,O
Side,O,O
effects,O,O
of,O,O
yohimbine,B,B
included,O,O
excessive,O,O
sweating,O,O
",",O,O
increased,O,O
anxiety,O,O
",",O,O
and,O,O
a,O,O
wound,O,O
-,O,O
up,O,O
feeling,O,O
in,O,O
some,O,O
patients,O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
results,O,O
of,O,O
this,O,O
study,O,O
indicate,O,O
that,O,O
yohimbine,B,B
may,O,O
be,O,O
an,O,O
effective,O,O
treatment,O,O
for,O,O
the,O,O
sexual,O,O
side,O,O
effects,O,O
caused,O,O
by,O,O
serotonin,B,B
reuptake,O,I
blockers,O,O
.,O,O
Future,O,O
controlled,O,O
studies,O,O
are,O,O
needed,O,O
to,O,O
further,O,O
investigate,O,O
the,O,O
effectiveness,O,O
and,O,O
safety,O,O
of,O,O
yohimbine,B,B
for,O,O
this,O,O
indication,O,O
.,O,O
Hemorrhagic,O,B
cystitis,O,I
complicating,O,O
bone,O,O
marrow,O,O
transplantation,O,O
.,O,O
Hemorrhagic,O,B
cystitis,O,I
is,O,O
a,O,O
potentially,O,O
serious,O,O
complication,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
cyclophosphamide,B,B
therapy,O,O
administered,O,O
before,O,O
bone,O,O
marrow,O,O
transplantation,O,O
.,O,O
As,O,O
standard,O,O
practice,O,O
at,O,O
our,O,O
institution,O,O
",",O,O
patients,O,O
who,O,O
are,O,O
scheduled,O,O
to,O,O
receive,O,O
a,O,O
bone,O,O
marrow,O,O
transplant,O,O
are,O,O
treated,O,O
prophylactically,O,O
with,O,O
forced,O,O
hydration,O,O
and,O,O
bladder,O,O
irrigation,O,O
.,O,O
In,O,O
an,O,O
attempt,O,O
to,O,O
obviate,O,O
the,O,O
inconvenience,O,O
of,O,O
bladder,O,O
irrigation,O,O
",",O,O
we,O,O
conducted,O,O
a,O,O
feasibility,O,O
trial,O,O
of,O,O
uroprophylaxis,O,O
with,O,O
mesna,B,B
",",O,O
which,O,O
neutralizes,O,O
the,O,O
hepatic,O,O
metabolite,O,O
of,O,O
cyclophosphamide,B,B
that,O,O
causes,O,O
hemorrhagic,O,O
cystitis,O,O
.,O,O
Of,O,O
97,O,O
patients,O,O
who,O,O
received,O,O
standard,O,O
prophylaxis,O,O
",",O,O
4,O,O
had,O,O
symptomatic,O,O
hemorrhagic,O,O
cystitis,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
two,O,O
of,O,O
four,O,O
consecutive,O,O
patients,O,O
who,O,O
received,O,O
mesna,B,B
uroprophylaxis,O,O
before,O,O
allogeneic,O,O
bone,O,O
marrow,O,O
transplantation,O,O
had,O,O
severe,O,O
hemorrhagic,O,O
cystitis,O,O
for,O,O
at,O,O
least,O,O
2,O,O
weeks,O,O
.,O,O
Because,O,O
of,O,O
this,O,O
suboptimal,O,O
result,O,O
",",O,O
we,O,O
resumed,O,O
the,O,O
use,O,O
of,O,O
bladder,O,O
irrigation,O,O
and,O,O
forced,O,O
hydration,O,O
to,O,O
minimize,O,O
the,O,O
risk,O,O
of,O,O
hemorrhagic,O,O
cystitis,O,O
.,O,O
Consensus,O,O
statement,O,O
concerning,O,O
cardiotoxicity,O,O
occurring,O,O
during,O,O
haematopoietic,O,B
stem,O,I
cell,O,I
transplantation,O,I
in,O,O
the,O,O
treatment,O,O
of,O,O
autoimmune,O,O
diseases,O,O
",",O,O
with,O,O
special,O,O
reference,O,O
to,O,O
systemic,O,O
sclerosis,O,O
and,O,O
multiple,O,O
sclerosis,O,O
.,O,O
Autologous,O,O
haematopoietic,O,B
stem,O,I
cell,O,I
transplantation,O,I
is,O,O
now,O,O
a,O,O
feasible,O,O
and,O,O
effective,O,O
treatment,O,O
for,O,O
selected,O,O
patients,O,O
with,O,O
severe,O,O
autoimmune,O,O
diseases,O,O
.,O,O
Worldwide,O,O
",",O,O
over,O,O
650,O,O
patients,O,O
have,O,O
been,O,O
transplanted,O,O
in,O,O
the,O,O
context,O,O
of,O,O
phase,O,O
I,O,O
and,O,O
II,O,O
clinical,O,O
trials,O,O
.,O,O
The,O,O
results,O,O
are,O,O
encouraging,O,O
enough,O,O
to,O,O
begin,O,O
randomised,O,O
phase,O,O
III,O,O
trials,O,O
.,O,O
However,O,O
",",O,O
as,O,O
predicted,O,O
",",O,O
significant,O,O
transplant,O,O
-,O,O
related,O,O
morbidity,O,O
and,O,O
mortality,O,O
have,O,O
been,O,O
observed,O,O
.,O,O
This,O,O
is,O,O
primarily,O,O
due,O,O
to,O,O
complications,O,O
related,O,O
to,O,O
either,O,O
the,O,O
stage,O,O
of,O,O
the,O,O
disease,O,O
at,O,O
transplant,O,O
or,O,O
due,O,O
to,O,O
infections,O,O
.,O,O
The,O,O
number,O,O
of,O,O
deaths,O,O
related,O,O
to,O,O
cardiac,O,B
toxicity,O,I
is,O,O
low,O,O
.,O,O
However,O,O
",",O,O
caution,O,O
is,O,O
required,O,O
when,O,O
cyclophosphamide,B,B
or,O,O
anthracyclines,B,B
such,O,O
as,O,O
mitoxantrone,B,B
are,O,O
used,O,O
in,O,O
patients,O,O
with,O,O
a,O,O
possible,O,O
underlying,O,O
heart,O,B
damage,O,I
",",O,O
for,O,O
example,O,O
",",O,O
systemic,O,O
sclerosis,O,O
patients,O,O
.,O,O
In,O,O
November,O,O
2002,O,O
",",O,O
a,O,O
meeting,O,O
was,O,O
held,O,O
in,O,O
Florence,O,O
",",O,O
bringing,O,O
together,O,O
a,O,O
number,O,O
of,O,O
experts,O,O
in,O,O
various,O,O
fields,O,O
",",O,O
including,O,O
rheumatology,O,B
",",O,O
cardiology,O,B
",",O,O
neurology,O,B
",",O,O
pharmacology,O,B
and,O,O
transplantation,O,B
medicine,O,I
.,O,O
The,O,O
object,O,O
of,O,O
the,O,O
meeting,O,O
was,O,O
to,O,O
analyse,O,O
existing,O,O
data,O,O
",",O,O
both,O,O
published,O,O
or,O,O
available,O,O
",",O,O
in,O,O
the,O,O
European,O,O
Group,O,O
for,O,O
Blood,O,B
and,O,I
Marrow,O,I
Transplantation,O,I
autoimmune,O,O
disease,O,O
database,O,O
",",O,O
and,O,O
to,O,O
propose,O,O
a,O,O
safe,O,O
approach,O,O
to,O,O
such,O,O
patients,O,O
.,O,O
A,O,O
full,O,O
cardiological,O,O
assessment,O,O
before,O,O
and,O,O
during,O,O
the,O,O
transplant,O,O
emerged,O,O
as,O,O
the,O,O
major,O,O
recommendation,O,O
.,O,O
Does,O,O
supplemental,O,O
vitamin,B,B
C,I,I
increase,O,O
cardiovascular,O,O
disease,O,O
risk,O,O
in,O,O
women,O,O
with,O,O
diabetes,O,O
?,O,O
BACKGROUND,O,O
:,O,O
Vitamin,B,B
C,I,I
acts,O,O
as,O,O
a,O,O
potent,O,O
antioxidant,O,O
;,O,O
however,O,O
",",O,O
it,O,O
can,O,O
also,O,O
be,O,O
a,O,O
prooxidant,O,O
and,O,O
glycate,O,O
protein,O,O
under,O,O
certain,O,O
circumstances,O,O
in,O,O
vitro,O,O
.,O,O
These,O,O
observations,O,O
led,O,O
us,O,O
to,O,O
hypothesize,O,O
that,O,O
a,O,O
high,O,O
intake,O,O
of,O,O
vitamin,B,B
C,I,I
in,O,O
diabetic,O,O
persons,O,O
might,O,O
promote,O,O
atherosclerosis,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
objective,O,O
was,O,O
to,O,O
examine,O,O
the,O,O
relation,O,O
between,O,O
vitamin,B,B
C,I,I
intake,O,O
and,O,O
mortality,O,O
from,O,O
cardiovascular,O,O
disease,O,O
.,O,O
DESIGN,O,O
:,O,O
We,O,O
studied,O,O
the,O,O
relation,O,O
between,O,O
vitamin,B,B
C,I,I
intake,O,O
and,O,O
mortality,O,O
from,O,O
total,O,O
cardiovascular,O,O
disease,O,O
(,O,O
n,O,O
=,O,O
281,O,O
),O,O
",",O,O
coronary,O,O
artery,O,O
disease,O,O
(,O,O
n,O,O
=,O,O
175,O,O
),O,O
",",O,O
and,O,O
stroke,O,O
(,O,O
n,O,O
=,O,O
57,O,O
),O,O
in,O,O
1923,O,O
postmenopausal,O,O
women,O,O
who,O,O
reported,O,O
being,O,O
diabetic,O,O
at,O,O
baseline,O,O
.,O,O
Diet,O,O
was,O,O
assessed,O,O
with,O,O
a,O,O
food,O,B
-,O,I
frequency,O,I
questionnaire,O,I
at,O,O
baseline,O,O
",",O,O
and,O,O
subjects,O,O
initially,O,O
free,O,O
of,O,O
coronary,O,B
artery,O,I
disease,O,I
were,O,O
prospectively,O,O
followed,O,O
for,O,O
15,O,O
y,O,O
.,O,O
RESULTS,O,O
:,O,O
After,O,O
adjustment,O,O
for,O,O
cardiovascular,O,B
disease,O,I
risk,O,I
factors,O,I
",",O,O
type,O,O
of,O,O
diabetes,O,B
medication,O,I
used,O,O
",",O,O
duration,O,O
of,O,O
diabetes,O,B
",",O,O
and,O,O
intakes,O,O
of,O,O
folate,B,B
",",O,O
vitamin,B,B
E,I,I
",",O,O
and,O,O
beta,B,B
-,I,I
carotene,I,I
",",O,O
the,O,O
adjusted,O,O
relative,O,O
risks,O,O
of,O,O
total,O,O
cardiovascular,O,B
disease,O,I
mortality,O,I
were,O,O
1,O,O
.,O,O
0,O,O
",",O,O
0,O,O
.,O,O
97,O,O
",",O,O
1,O,O
.,O,O
11,O,O
",",O,O
1,O,O
.,O,O
47,O,O
",",O,O
and,O,O
1,O,O
.,O,O
84,O,O
(,O,O
P,O,O
for,O,O
trend,O,O
<,O,O
0,O,O
.,O,O
),O,O
across,O,O
quintiles,O,O
of,O,O
total,O,O
vitamin,B,B
C,I,I
intake,O,I
from,O,I
food,O,I
and,O,I
supplements,O,I
.,O,O
Adjusted,O,O
relative,O,O
risks,O,O
of,O,O
coronary,O,O
artery,O,O
disease,O,O
were,O,O
1,O,O
.,O,O
0,O,O
",",O,O
0,O,O
.,O,O
81,O,O
",",O,O
0,O,O
.,O,O
99,O,O
",",O,O
1,O,O
.,O,O
26,O,O
",",O,O
and,O,O
1,O,O
.,O,O
91,O,O
(,O,O
P,O,O
for,O,O
trend,O,O
=,O,O
0,O,O
.,O,O
),O,O
and,O,O
of,O,O
stroke,O,O
were,O,O
1,O,O
.,O,O
0,O,O
",",O,O
0,O,O
.,O,O
52,O,O
",",O,O
1,O,O
.,O,O
23,O,O
",",O,O
2,O,O
.,O,O
22,O,O
",",O,O
and,O,O
2,O,O
.,O,O
57,O,O
(,O,O
P,O,O
for,O,O
trend,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
When,O,O
dietary,O,O
and,O,O
supplemental,O,O
vitamin,B,B
C,I,I
were,O,O
analyzed,O,O
separately,O,O
",",O,O
only,O,O
supplemental,O,O
vitamin,B,B
C,I,I
showed,O,O
a,O,O
positive,O,O
association,O,O
with,O,O
mortality,O,O
endpoints,O,O
.,O,O
Vitamin,B,B
C,I,I
intake,O,O
was,O,O
unrelated,O,O
to,O,O
mortality,O,O
from,O,O
cardiovascular,O,O
disease,O,O
in,O,O
the,O,O
nondiabetic,O,O
subjects,O,O
at,O,O
baseline,O,O
.,O,O
CONCLUSION,O,O
:,O,O
A,O,O
high,O,O
vitamin,B,B
C,I,I
intake,O,O
from,O,O
supplements,O,O
is,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
risk,O,O
of,O,O
cardiovascular,O,O
disease,O,O
mortality,O,O
in,O,O
postmenopausal,O,O
women,O,O
with,O,O
diabetes,O,O
.,O,O
Optical,O,O
coherence,O,O
tomography,O,O
can,O,O
measure,O,O
axonal,O,O
loss,O,O
in,O,O
patients,O,O
with,O,O
ethambutol,B,B
-,O,O
induced,O,O
optic,O,O
neuropathy,O,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
map,O,O
and,O,O
identify,O,O
the,O,O
pattern,O,O
",",O,O
in,O,O
vivo,O,O
",",O,O
of,O,O
axonal,O,O
degeneration,O,O
in,O,O
ethambutol,B,B
-,O,O
induced,O,O
optic,O,O
neuropathy,O,O
using,O,O
optical,O,O
coherence,O,O
tomography,O,O
(,O,O
OCT,O,B
),O,O
.,O,O
Ethambutol,B,B
is,O,O
an,O,O
antimycobacterial,O,O
agent,O,O
often,O,O
used,O,O
to,O,O
treat,O,O
tuberculosis,O,O
.,O,O
A,O,O
serious,O,O
complication,O,O
of,O,O
ethambutol,B,B
is,O,O
an,O,O
optic,O,B
neuropathy,O,I
that,O,O
impairs,O,O
visual,O,O
acuity,O,O
",",O,O
contrast,O,O
sensitivity,O,O
",",O,O
and,O,O
color,O,O
vision,O,O
.,O,O
However,O,O
",",O,O
early,O,O
on,O,O
",",O,O
when,O,O
the,O,O
toxic,O,O
optic,O,B
neuropathy,O,I
is,O,O
mild,O,O
and,O,O
partly,O,O
reversible,O,O
",",O,O
the,O,O
funduscopic,O,O
findings,O,O
are,O,O
often,O,O
subtle,O,O
and,O,O
easy,O,O
to,O,O
miss,O,O
.,O,O
METHODS,O,O
:,O,O
Three,O,O
subjects,O,O
with,O,O
a,O,O
history,O,O
of,O,O
ethambutol,B,B
(,O,O
EMB,B,B
),O,O
-,O,O
induced,O,O
optic,O,B
neuropathy,O,I
of,O,O
short,O,O
-,O,O
",",O,O
intermediate,O,O
-,O,O
",",O,O
and,O,O
long,O,O
-,O,O
term,O,O
visual,O,O
deficits,O,O
were,O,O
administered,O,O
a,O,O
full,O,O
neuro,O,O
-,O,O
ophthalmologic,O,O
examination,O,O
including,O,O
visual,O,O
acuity,O,O
",",O,O
color,O,O
vision,O,O
",",O,O
contrast,O,O
sensitivity,O,O
",",O,O
and,O,O
fundus,O,O
examination,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
OCT,O,B
(,O,O
OCT,O,B
3000,O,I
",",O,O
Humphrey,O,O
-,O,O
Zeiss,O,O
",",O,O
Dublin,O,O
",",O,O
CA,O,O
),O,O
was,O,O
performed,O,O
on,O,O
both,O,O
eyes,O,O
of,O,O
each,O,O
subject,O,O
using,O,O
the,O,O
retinal,O,B
nerve,O,I
fiber,O,I
layer,O,I
(,O,O
RNFL,O,B
),O,O
analysis,O,O
protocol,O,O
.,O,O
OCT,O,B
interpolates,O,O
data,O,O
from,O,O
100,O,O
points,O,O
around,O,O
the,O,O
optic,O,B
nerve,O,I
to,O,O
effectively,O,O
map,O,O
out,O,O
the,O,O
RNFL,O,B
.,O,O
RESULTS,O,O
:,O,O
The,O,O
results,O,O
were,O,O
compared,O,O
to,O,O
the,O,O
calculated,O,O
average,O,O
RNFL,O,B
of,O,O
normal,O,O
eyes,O,O
accumulated,O,O
from,O,O
four,O,O
prior,O,O
studies,O,O
using,O,O
OCT,O,B
",",O,O
n,O,O
=,O,O
661,O,O
.,O,O
In,O,O
all,O,O
subjects,O,O
with,O,O
history,O,O
of,O,O
EMB,B,B
-,O,O
induced,O,O
optic,O,B
neuropathy,O,I
",",O,O
there,O,O
was,O,O
a,O,O
mean,O,O
loss,O,O
of,O,O
72,O,O
%,O,O
nerve,O,B
fiber,O,I
layer,O,I
thickness,O,I
in,O,O
the,O,O
temporal,O,O
quadrant,O,O
(,O,O
patient,O,O
A,O,O
",",O,O
with,O,O
eventual,O,O
recovery,O,O
of,O,O
visual,O,O
acuity,O,O
and,O,O
fields,O,O
",",O,O
58,O,O
%,O,O
loss,O,O
;,O,O
patient,O,O
B,O,O
",",O,O
with,O,O
intermediate,O,O
visual,O,O
deficits,O,O
",",O,O
68,O,O
%,O,O
loss,O,O
;,O,O
patient,O,O
C,O,O
",",O,O
with,O,O
chronic,O,O
visual,O,O
deficits,O,O
",",O,O
90,O,O
%,O,O
loss,O,O
),O,O
",",O,O
with,O,O
an,O,O
average,O,O
mean,O,O
optic,O,B
nerve,O,I
thickness,O,I
of,O,O
26,O,O
+,O,O
/,O,O
-,O,O
16,O,O
microm,O,O
There,O,O
was,O,O
a,O,O
combined,O,O
mean,O,O
loss,O,O
of,O,O
46,O,O
%,O,O
of,O,O
fibers,O,O
from,O,O
the,O,O
superior,O,O
",",O,O
inferior,O,O
",",O,O
and,O,O
nasal,O,O
quadrants,O,O
in,O,O
the,O,O
(,O,O
six,O,O
),O,O
eyes,O,O
of,O,O
all,O,O
three,O,O
subjects,O,O
(,O,O
mean,O,O
average,O,O
thickness,O,O
of,O,O
55,O,O
+,O,O
/,O,O
-,O,O
29,O,O
microm,O,O
),O,O
.,O,O
In,O,O
both,O,O
sets,O,O
(,O,O
four,O,O
),O,O
of,O,O
eyes,O,O
of,O,O
the,O,O
subjects,O,O
with,O,O
persistent,O,O
visual,O,O
deficits,O,O
(,O,O
patients,O,O
B,O,O
and,O,O
C,O,O
),O,O
",",O,O
there,O,O
was,O,O
an,O,O
average,O,O
loss,O,O
of,O,O
79,O,O
%,O,O
of,O,O
nerve,O,O
fiber,O,O
thickness,O,O
in,O,O
the,O,O
temporal,O,O
quadrant,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
OCT,O,O
results,O,O
in,O,O
these,O,O
patients,O,O
with,O,O
EMB,B,B
-,O,O
induced,O,O
optic,O,O
neuropathy,O,O
show,O,O
considerable,O,O
loss,O,O
especially,O,O
of,O,O
the,O,O
temporal,O,O
fibers,O,O
.,O,O
This,O,O
is,O,O
consistent,O,O
with,O,O
prior,O,O
histopathological,O,O
studies,O,O
that,O,O
show,O,O
predominant,O,O
loss,O,O
of,O,O
parvo,O,B
-,O,O
cellular,O,O
axons,O,O
(,O,O
or,O,O
small,O,O
-,O,O
caliber,O,O
axons,O,O
),O,O
within,O,O
the,O,O
papillo,O,B
-,O,O
macular,O,O
bundle,O,O
in,O,O
toxic,O,O
or,O,O
hereditary,O,O
optic,O,O
neuropathies,O,O
.,O,O
OCT,O,B
can,O,O
be,O,O
a,O,O
valuable,O,O
tool,O,O
in,O,O
the,O,O
quantitative,O,O
analysis,O,O
of,O,O
optic,O,B
neuropathies,O,O
.,O,O
Additionally,O,O
",",O,O
in,O,O
terms,O,O
of,O,O
management,O,O
of,O,O
EMB,B,B
-,O,I
induced,O,I
optic,O,I
neuropathy,O,I
",",O,O
it,O,O
is,O,O
important,O,O
to,O,O
properly,O,O
manage,O,O
ethambutol,B,B
dosing,O,O
in,O,O
patients,O,O
with,O,O
renal,O,B
impairment,O,O
and,O,O
to,O,O
achieve,O,O
proper,O,O
transition,O,O
to,O,O
a,O,O
maintenance,O,O
dose,O,O
once,O,O
an,O,O
appropriate,O,O
loading,O,O
dose,O,O
has,O,O
been,O,O
reached,O,O
.,O,O
Hypoxia,O,B
in,O,O
renal,O,B
disease,O,I
with,O,O
proteinuria,O,B
and,O,O
/,O,O
or,O,O
glomerular,O,B
hypertension,O,I
.,O,O
Despite,O,O
the,O,O
increasing,O,O
need,O,O
to,O,O
identify,O,O
and,O,O
quantify,O,O
tissue,O,O
oxygenation,O,O
at,O,O
the,O,O
cellular,O,O
level,O,O
",",O,O
relatively,O,O
few,O,O
methods,O,O
have,O,O
been,O,O
available,O,O
.,O,O
In,O,O
this,O,O
study,O,O
",",O,O
we,O,O
developed,O,O
a,O,O
new,O,O
hypoxia,O,B
-,O,I
responsive,O,I
reporter,O,I
vector,O,I
using,O,O
a,O,O
hypoxia,O,B
-,O,I
responsive,O,I
element,O,I
of,O,O
the,O,O
5,O,O
',O,O
vascular,O,B
endothelial,O,I
growth,O,I
factor,O,I
untranslated,O,I
region,O,I
and,O,O
generated,O,O
a,O,O
novel,O,O
hypoxia,O,B
-,O,I
sensing,O,I
transgenic,O,I
rat,O,I
.,O,O
We,O,O
then,O,O
applied,O,O
this,O,O
animal,O,O
model,O,O
to,O,O
the,O,O
detection,O,O
of,O,O
tubulointerstitial,O,O
hypoxia,O,O
in,O,O
the,O,O
diseased,O,O
kidney,O,O
.,O,O
With,O,O
this,O,O
model,O,O
",",O,O
we,O,O
were,O,O
able,O,O
to,O,O
identify,O,O
diffuse,O,O
cortical,O,O
hypoxia,O,O
in,O,O
the,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,O
nephrotic,O,O
syndrome,O,O
and,O,O
focal,O,O
and,O,O
segmental,O,O
hypoxia,O,O
in,O,O
the,O,O
remnant,O,O
kidney,O,O
model,O,O
.,O,O
Expression,O,O
of,O,O
the,O,O
hypoxia,O,O
-,O,O
responsive,O,O
transgene,O,O
increased,O,O
throughout,O,O
the,O,O
observation,O,O
period,O,O
",",O,O
reaching,O,O
2,O,O
.,O,O
2,O,O
-,O,O
fold,O,O
at,O,O
2,O,O
weeks,O,O
in,O,O
the,O,O
puromycin,B,B
aminonucleoside,I,I
model,O,O
and,O,O
2,O,O
.,O,O
6,O,O
-,O,O
fold,O,O
at,O,O
4,O,O
weeks,O,O
in,O,O
the,O,O
remnant,O,B
kidney,O,I
model,O,O
",",O,O
whereas,O,O
that,O,O
of,O,O
vascular,O,B
endothelial,O,I
growth,O,I
factor,O,I
showed,O,O
a,O,O
mild,O,O
decrease,O,O
",",O,O
reflecting,O,O
distinct,O,O
behaviors,O,O
of,O,O
the,O,O
two,O,O
genes,O,O
.,O,O
The,O,O
degree,O,O
of,O,O
hypoxia,O,O
showed,O,O
a,O,O
positive,O,O
correlation,O,O
with,O,O
microscopic,O,O
tubulointerstitial,O,O
injury,O,O
in,O,O
both,O,O
models,O,O
.,O,O
Finally,O,O
",",O,O
we,O,O
identified,O,O
the,O,O
localization,O,O
of,O,O
proliferating,O,O
cell,O,O
nuclear,O,B
antigen,O,I
-,O,I
positive,O,O
",",O,O
ED,O,B
-,O,I
1,O,I
-,O,I
positive,O,O
",",O,O
and,O,O
terminal,O,O
dUTP,O,B
nick,O,I
-,O,I
end,O,I
labeled,O,I
-,O,I
positive,O,O
cells,O,O
in,O,O
the,O,O
hypoxic,O,O
cortical,O,O
area,O,O
in,O,O
the,O,O
remnant,O,O
kidney,O,O
model,O,O
.,O,O
We,O,O
propose,O,O
here,O,O
a,O,O
possible,O,O
pathological,O,O
tie,O,O
between,O,O
chronic,O,O
tubulointerstitial,O,O
hypoxia,O,O
and,O,O
progressive,O,O
glomerular,O,O
diseases,O,O
.,O,O
Adequate,O,O
timing,O,O
of,O,O
ribavirin,B,B
reduction,O,O
in,O,O
patients,O,O
with,O,O
hemolysis,O,O
during,O,O
combination,O,O
therapy,O,O
of,O,O
interferon,B,O
and,O,O
ribavirin,B,B
for,O,O
chronic,O,O
hepatitis,O,O
C,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Hemolytic,O,O
anemia,O,O
is,O,O
one,O,O
of,O,O
the,O,O
major,O,O
adverse,O,O
events,O,O
of,O,O
the,O,O
combination,O,O
therapy,O,O
of,O,O
interferon,B,O
and,O,O
ribavirin,B,B
.,O,O
Because,O,O
of,O,O
ribavirin,B,B
-,O,O
related,O,O
hemolytic,O,O
anemia,O,O
",",O,O
dose,O,O
reduction,O,O
is,O,O
a,O,O
common,O,O
event,O,O
in,O,O
this,O,O
therapy,O,O
.,O,O
In,O,O
this,O,O
clinical,O,O
retrospective,O,O
cohort,O,O
study,O,O
we,O,O
have,O,O
examined,O,O
the,O,O
suitable,O,O
timing,O,O
of,O,O
ribavirin,B,B
reduction,O,O
in,O,O
patients,O,O
with,O,O
hemolysis,O,O
during,O,O
combination,O,O
therapy,O,O
.,O,O
METHODS,O,O
:,O,O
Thirty,O,O
-,O,O
seven,O,O
of,O,O
160,O,O
patients,O,O
who,O,O
had,O,O
HCV,O,B
-,O,O
genotype,O,O
1b,O,O
",",O,O
had,O,O
high,O,O
virus,O,O
load,O,O
",",O,O
and,O,O
received,O,O
24,O,O
-,O,O
week,O,O
combination,O,O
therapy,O,O
developed,O,O
anemia,O,O
with,O,O
hemoglobin,O,B
level,O,O
<,O,O
10,O,O
g,O,O
/,O,O
dl,O,O
or,O,O
anemia,O,O
-,O,O
related,O,O
signs,O,O
during,O,O
therapy,O,O
.,O,O
After,O,O
that,O,O
",",O,O
these,O,O
37,O,O
patients,O,O
were,O,O
reduced,O,O
one,O,O
tablet,O,O
of,O,O
ribavirin,B,B
(,O,O
200,O,O
mg,O,O
),O,O
per,O,O
day,O,O
.,O,O
After,O,O
reduction,O,O
of,O,O
ribavirin,B,B
",",O,O
27,O,O
of,O,O
37,O,O
patients,O,O
could,O,O
continue,O,O
combination,O,O
therapy,O,O
for,O,O
a,O,O
total,O,O
of,O,O
24,O,O
weeks,O,O
(,O,O
group,O,O
A,O,O
),O,O
.,O,O
However,O,O
",",O,O
10,O,O
of,O,O
37,O,O
patients,O,O
with,O,O
reduction,O,O
of,O,O
ribavirin,B,B
could,O,O
not,O,O
continue,O,O
combination,O,O
therapy,O,O
because,O,O
their,O,O
<,O,O
8,O,O
.,O,O
5,O,O
g,O,O
/,O,O
dl,O,O
hemoglobin,O,B
values,O,O
decreased,O,O
to,O,O
or,O,O
anemia,O,B
-,O,I
related,O,I
severe,O,I
side,O,I
effects,O,I
occurred,O,O
(,O,O
group,O,O
B,O,O
),O,O
.,O,O
We,O,O
assessed,O,O
the,O,O
final,O,O
efficacy,O,O
and,O,O
safety,O,O
after,O,O
reduction,O,O
of,O,O
ribavirin,B,B
in,O,O
groups,O,O
A,O,O
and,O,O
B,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
sustained,O,O
virological,O,O
response,O,O
(,O,O
SVR,O,B
),O,O
was,O,O
29,O,O
.,O,O
6,O,O
%,O,O
(,O,O
8,O,O
/,O,O
27,O,O
),O,O
in,O,O
group,O,O
A,O,O
and,O,O
10,O,O
%,O,O
(,O,O
1,O,O
/,O,O
10,O,O
),O,O
in,O,O
group,O,O
B,O,O
",",O,O
respectively,O,O
.,O,O
A,O,O
34,O,O
.,O,O
4,O,B
%,O,O
(,O,O
12,O,O
/,O,O
27,O,O
),O,O
of,O,O
SVR,O,B
+,O,O
biological,O,O
response,O,O
in,O,O
group,O,O
A,O,O
was,O,O
higher,O,O
than,O,O
10,O,O
%,O,O
(,O,O
1,O,O
/,O,O
10,O,O
),O,O
in,O,O
group,O,O
B,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
with,O,O
slight,O,O
significance,O,O
.,O,O
With,O,O
respect,O,O
to,O,O
hemoglobin,O,B
level,O,O
at,O,O
the,O,O
time,O,O
of,O,O
ribavirin,B,B
reduction,O,O
",",O,O
a,O,O
rate,O,O
of,O,O
continuation,O,O
of,O,O
therapy,O,O
in,O,O
patients,O,O
with,O,O
>,O,O
or,O,O
=,O,O
10,O,O
g,O,O
/,O,O
dl,O,O
hemoglobin,O,B
was,O,O
higher,O,O
than,O,O
that,O,O
in,O,O
patients,O,O
with,O,O
<,O,O
10,O,O
g,O,O
/,O,O
dl,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Reduction,O,O
of,O,O
ribavirin,B,B
at,O,O
hemoglobin,O,B
level,O,O
>,O,O
or,O,O
=,O,O
10,O,O
g,O,O
/,O,O
dl,O,O
is,O,O
suitable,O,O
in,O,O
terms,O,O
of,O,O
efficacy,O,O
and,O,O
side,O,O
effects,O,O
.,O,O
Aging,O,O
process,O,O
of,O,O
epithelial,O,O
cells,O,O
of,O,O
the,O,O
rat,O,O
prostate,O,O
lateral,O,O
lobe,O,O
in,O,O
experimental,O,O
hyperprolactinemia,O,B
induced,O,O
by,O,O
haloperidol,B,B
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
examine,O,O
the,O,O
influence,O,O
of,O,O
hyperprolactinemia,O,B
",",O,O
induced,O,O
by,O,O
haloperidol,B,B
(,O,O
HAL,B,B
),O,O
on,O,O
age,O,O
related,O,O
morphology,O,O
and,O,O
function,O,O
changes,O,O
of,O,O
epithelial,O,O
cells,O,O
in,O,O
rat,O,O
prostate,O,O
lateral,O,O
lobe,O,O
.,O,O
The,O,O
study,O,O
was,O,O
performed,O,O
on,O,O
sexually,O,O
mature,O,O
male,O,O
rats,O,O
.,O,O
Serum,O,O
concentrations,O,O
of,O,O
prolactin,O,B
(,O,O
PRL,B,B
),O,O
and,O,O
testosterone,B,B
(,O,O
T,B,B
),O,O
were,O,O
measured,O,O
.,O,O
Tissue,O,O
sections,O,O
were,O,O
evaluated,O,O
with,O,O
light,O,O
and,O,O
electron,O,O
microscopy,O,O
.,O,O
Immunohistochemical,O,O
reactions,O,O
for,O,O
Anti,O,B
-,O,I
Proliferating,O,I
Cell,O,I
Nuclear,O,I
Antigen,O,I
(,O,O
PCNA,O,B
),O,O
were,O,O
performed,O,O
.,O,O
In,O,O
rats,O,O
of,O,O
the,O,O
experimental,O,O
group,O,O
",",O,O
the,O,O
mean,O,O
concentration,O,O
of,O,O
:,O,O
PRL,B,B
was,O,O
more,O,O
than,O,O
twice,O,O
higher,O,O
",",O,O
whereas,O,O
T,B,B
concentration,O,O
was,O,O
almost,O,O
twice,O,O
lower,O,O
than,O,O
that,O,O
in,O,O
the,O,O
control,O,O
group,O,O
.,O,O
Light,O,O
microscopy,O,O
visualized,O,O
the,O,O
following,O,O
:,O,O
hypertrophy,O,O
and,O,O
epithelium,O,O
hyperplasia,O,O
of,O,O
the,O,O
glandular,O,O
ducts,O,O
",",O,O
associated,O,O
with,O,O
increased,O,O
PCNA,O,B
expression,O,O
.,O,O
Electron,O,O
microscopy,O,O
revealed,O,O
changes,O,O
in,O,O
columnar,O,O
epithelial,O,O
cells,O,O
",",O,O
concerning,O,O
organelles,O,O
",",O,O
engaged,O,O
in,O,O
protein,O,B
synthesis,O,I
and,O,O
secretion,O,O
.,O,O
Relation,O,O
of,O,O
perfusion,O,O
defects,O,O
observed,O,O
with,O,O
myocardial,O,O
contrast,O,O
echocardiography,O,O
to,O,O
the,O,O
severity,O,O
of,O,O
coronary,O,O
stenosis,O,O
:,O,O
correlation,O,O
with,O,O
thallium,B,B
-,O,I
201,O,I
single,O,I
-,O,I
photon,O,I
emission,O,I
tomography,O,I
.,O,O
It,O,O
has,O,O
been,O,O
previously,O,O
shown,O,O
that,O,O
myocardial,O,B
contrast,O,I
echocardiography,O,I
is,O,O
a,O,O
valuable,O,O
technique,O,O
for,O,O
delineating,O,O
regions,O,O
of,O,O
myocardial,O,B
underperfusion,O,I
secondary,O,O
to,O,O
coronary,O,B
occlusion,O,I
and,O,O
to,O,O
critical,O,O
coronary,O,B
stenoses,O,I
in,O,O
the,O,O
presence,O,O
of,O,O
hyperemic,O,O
stimulation,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
whether,O,O
myocardial,O,B
contrast,O,I
echocardiography,O,I
performed,O,O
with,O,O
a,O,O
stable,O,O
solution,O,O
of,O,O
sonicated,O,O
albumin,O,B
could,O,O
detect,O,O
regions,O,O
of,O,O
myocardial,O,B
underperfusion,O,I
resulting,O,O
from,O,O
various,O,O
degrees,O,O
of,O,O
coronary,O,B
stenosis,O,I
.,O,O
The,O,O
perfusion,O,B
defect,O,I
produced,O,O
in,O,O
16,O,O
open,O,O
chest,O,O
dogs,O,O
was,O,O
compared,O,O
with,O,O
the,O,O
anatomic,O,O
area,O,O
at,O,O
risk,O,O
measured,O,O
by,O,O
the,O,O
postmortem,O,O
dual,O,O
-,O,O
perfusion,O,B
technique,O,O
and,O,O
with,O,O
thallium,B,B
-,O,O
201,O,O
single,O,O
-,O,O
photon,O,O
emission,O,O
tomography,O,O
(,O,O
SPECT,O,B
),O,O
.,O,O
During,O,O
a,O,O
transient,O,O
(,O,O
20,O,O
-,O,O
s,O,O
),O,O
coronary,O,O
occlusion,O,O
",",O,O
a,O,O
perfusion,O,B
defect,O,I
was,O,O
observed,O,O
with,O,O
contrast,O,O
echocardiography,O,O
in,O,O
14,O,O
of,O,O
the,O,O
15,O,O
dogs,O,O
in,O,O
which,O,O
the,O,O
occlusion,O,O
was,O,O
produced,O,O
.,O,O
The,O,O
perfusion,O,O
defect,O,O
correlated,O,O
significantly,O,O
with,O,O
the,O,O
anatomic,O,O
area,O,O
at,O,O
risk,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
74,O,O
;,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
During,O,O
dipyridamole,B,B
-,O,I
induced,O,I
hyperemia,O,I
",",O,O
12,O,O
of,O,O
the,O,O
16,O,O
dogs,O,O
with,O,O
a,O,O
partial,O,O
coronary,O,O
stenosis,O,O
had,O,O
a,O,O
visible,O,O
area,O,O
of,O,O
hypoperfusion,O,O
by,O,O
contrast,O,O
echocardiography,O,O
.,O,O
The,O,O
four,O,O
dogs,O,O
without,O,O
a,O,O
perfusion,O,O
defect,O,O
had,O,O
a,O,O
stenosis,O,O
that,O,O
resulted,O,O
in,O,O
a,O,O
mild,O,O
(,O,O
0,O,O
%,O,O
to,O,O
50,O,O
%,O,O
),O,O
reduction,O,O
in,O,O
dipyridamole,B,B
-,O,I
induced,O,I
hyperemia,O,I
.,O,O
The,O,O
size,O,O
of,O,O
the,O,O
perfusion,O,O
defect,O,O
during,O,O
stenosis,O,O
correlated,O,O
significantly,O,O
with,O,O
the,O,O
anatomic,O,O
area,O,O
at,O,O
risk,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
61,O,O
;,O,O
p,O,O
=,O,O
0,O,O
.,O,O
.,O,O
Thallium,B,B
-,O,I
201,O,I
SPECT,O,I
demonstrated,O,O
a,O,O
perfusion,O,O
defect,O,O
in,O,O
all,O,O
14,O,O
dogs,O,O
analyzed,O,O
during,O,O
dipyridamole,B,B
-,O,I
induced,O,I
hyperemia,O,I
;,O,O
the,O,O
size,O,O
of,O,O
the,O,O
perfusion,O,O
defect,O,O
correlated,O,O
with,O,O
the,O,O
anatomic,O,O
area,O,O
at,O,O
risk,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
58,O,O
;,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
and,O,O
with,O,O
the,O,O
perfusion,O,O
defect,O,O
by,O,O
contrast,O,O
echocardiography,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
58,O,O
;,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
Thus,O,O
",",O,O
myocardial,O,O
contrast,O,O
echocardiography,O,O
can,O,O
be,O,O
used,O,O
to,O,O
visualize,O,O
and,O,O
quantitate,O,O
the,O,O
amount,O,O
of,O,O
jeopardized,O,O
myocardium,O,O
during,O,O
moderate,O,O
to,O,O
severe,O,O
degrees,O,O
of,O,O
coronary,O,O
stenosis,O,O
.,O,O
The,O,O
results,O,O
obtained,O,O
show,O,O
a,O,O
correlation,O,O
with,O,O
the,O,O
anatomic,O,O
area,O,O
at,O,O
risk,O,O
similar,O,O
to,O,O
that,O,O
obtained,O,O
with,O,O
thallium,B,B
-,O,I
201,O,I
SPECT,O,I
.,O,O
The,O,O
activation,O,O
of,O,O
spinal,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
D,I,I
-,I,I
aspartate,I,I
receptors,O,O
may,O,O
contribute,O,O
to,O,O
degeneration,O,O
of,O,O
spinal,O,O
motor,O,O
neurons,O,O
induced,O,O
by,O,O
neuraxial,O,O
morphine,B,O
after,O,O
a,O,O
noninjurious,O,O
interval,O,O
of,O,O
spinal,O,O
cord,O,O
ischemia,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
relationship,O,O
between,O,O
the,O,O
degeneration,O,O
of,O,O
spinal,O,O
motor,O,O
neurons,O,O
and,O,O
activation,O,O
of,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
d,I,I
-,I,I
aspartate,I,I
(,O,O
NMDA,B,B
),O,O
receptors,O,O
after,O,O
neuraxial,O,O
morphine,B,O
following,O,O
a,O,O
noninjurious,O,O
interval,O,O
of,O,O
aortic,O,O
occlusion,O,O
in,O,O
rats,O,O
.,O,O
Spinal,O,O
cord,O,O
ischemia,O,O
was,O,O
induced,O,O
by,O,O
aortic,O,O
occlusion,O,O
for,O,O
6,O,O
min,O,O
with,O,O
a,O,O
balloon,O,O
catheter,O,O
.,O,O
In,O,O
a,O,O
microdialysis,O,O
study,O,O
",",O,O
10,O,O
muL,O,O
of,O,O
saline,O,B
(,O,O
group,O,O
C,O,O
;,O,O
n,O,O
=,O,O
8,O,O
),O,O
or,O,O
30,O,O
mug,O,O
of,O,O
morphine,B,B
(,O,O
group,O,O
M,O,O
;,O,O
n,O,O
=,O,O
8,O,O
),O,O
was,O,O
injected,O,O
intrathecally,O,O
(,O,O
IT,O,O
),O,O
0,O,O
.,O,O
5,O,O
h,O,O
after,O,O
reflow,O,O
",",O,O
and,O,O
30,O,O
mug,O,O
of,O,O
morphine,B,B
(,O,O
group,O,O
SM,O,O
;,O,O
n,O,O
=,O,O
8,O,O
),O,O
or,O,O
10,O,O
muL,O,O
of,O,O
saline,O,B
(,O,O
group,O,O
SC,O,O
;,O,O
n,O,O
=,O,O
8,O,O
),O,O
was,O,O
injected,O,O
IT,O,O
0,O,O
.,O,O
5,O,O
h,O,O
after,O,O
sham,O,O
operation,O,O
.,O,O
Microdialysis,O,O
samples,O,O
were,O,O
collected,O,O
preischemia,O,O
",",O,O
before,O,O
IT,O,O
injection,O,O
",",O,O
and,O,O
at,O,O
2,O,O
",",O,O
4,O,O
",",O,O
8,O,O
",",O,O
24,O,O
",",O,O
and,O,O
48,O,O
h,O,O
of,O,O
reperfusion,O,O
(,O,O
after,O,O
IT,O,O
injection,O,O
),O,O
.,O,O
Second,O,O
",",O,O
we,O,O
investigated,O,O
the,O,O
effect,O,O
of,O,O
IT,O,O
MK,B,B
-,I,I
801,I,I
(,O,O
30,O,O
mug,O,O
),O,O
on,O,O
the,O,O
histopathologic,O,O
changes,O,O
in,O,O
the,O,O
spinal,O,O
cord,O,O
after,O,O
morphine,B,B
-,O,O
induced,O,O
spastic,O,O
paraparesis,O,O
.,O,O
After,O,O
IT,O,O
morphine,B,B
",",O,O
the,O,O
cerebrospinal,O,O
fluid,O,O
(,O,O
CSF,O,B
),O,O
glutamate,B,B
concentration,O,O
was,O,O
increased,O,O
in,O,O
group,O,O
M,O,O
relative,O,O
to,O,O
both,O,O
baseline,O,O
and,O,O
group,O,O
C,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
This,O,O
increase,O,O
persisted,O,O
for,O,O
8,O,O
hrs,O,O
.,O,O
IT,O,O
MK,B,B
-,I,I
801,I,I
significantly,O,O
reduced,O,O
the,O,O
number,O,O
of,O,O
dark,O,O
-,O,O
stained,O,O
alpha,O,B
-,O,I
motoneurons,O,I
after,O,O
morphine,B,B
-,O,O
induced,O,O
spastic,O,O
paraparesis,O,O
compared,O,O
with,O,O
the,O,O
saline,O,O
group,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
IT,O,O
morphine,B,B
induces,O,O
spastic,O,O
paraparesis,O,O
with,O,O
a,O,O
concomitant,O,O
increase,O,O
in,O,O
CSF,O,B
glutamate,B,O
",",O,O
which,O,O
is,O,O
involved,O,O
in,O,O
NMDA,B,B
receptor,O,O
activation,O,O
.,O,O
We,O,O
suggest,O,O
that,O,O
opioids,O,O
may,O,O
be,O,O
neurotoxic,O,O
in,O,O
the,O,O
setting,O,O
of,O,O
spinal,O,O
cord,O,O
ischemia,O,O
via,O,O
NMDA,B,B
receptor,O,O
activation,O,O
.,O,O
Acute,O,O
low,O,O
back,O,O
pain,O,O
during,O,O
intravenous,O,O
administration,O,O
of,O,O
amiodarone,B,B
:,O,O
a,O,O
report,O,O
of,O,O
two,O,O
cases,O,O
.,O,O
Amiodarone,B,B
represents,O,O
an,O,O
effective,O,O
antiarrhythmic,O,O
drug,O,O
for,O,O
cardioversion,O,O
of,O,O
recent,O,O
-,O,O
onset,O,O
atrial,O,O
fibrillation,O,O
(,O,O
AF,O,B
),O,O
and,O,O
maintenance,O,O
of,O,O
sinus,O,O
rhythm,O,O
.,O,O
We,O,O
briefly,O,O
describe,O,O
two,O,O
patients,O,O
suffering,O,O
from,O,O
recent,O,O
-,O,O
onset,O,O
atrial,O,O
fibrillation,O,O
",",O,O
who,O,O
experienced,O,O
an,O,O
acute,O,O
devastating,O,O
low,O,O
back,O,O
pain,O,O
a,O,O
few,O,O
minutes,O,O
after,O,O
initiation,O,O
of,O,O
intravenous,O,O
amiodarone,B,B
loading,O,O
.,O,O
Notably,O,O
",",O,O
this,O,O
side,O,O
effect,O,O
has,O,O
not,O,O
been,O,O
ever,O,O
reported,O,O
in,O,O
the,O,O
medical,O,O
literature,O,O
.,O,O
Clinicians,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
this,O,O
reaction,O,O
since,O,O
prompt,O,O
termination,O,O
of,O,O
parenteral,O,O
administration,O,O
leads,O,O
to,O,O
complete,O,O
resolution,O,O
.,O,O
Quantitative,O,O
drug,O,O
levels,O,O
in,O,O
stimulant,O,O
psychosis,O,O
:,O,O
relationship,O,O
to,O,O
symptom,O,O
severity,O,O
",",O,O
catecholamines,B,B
and,O,O
hyperkinesia,O,O
.,O,O
To,O,O
examine,O,O
the,O,O
relationship,O,O
between,O,O
quantitative,O,O
stimulant,O,B
drug,O,I
levels,O,O
",",O,O
catecholamines,B,B
",",O,O
and,O,O
psychotic,O,O
symptoms,O,O
",",O,O
nineteen,O,O
patients,O,O
in,O,O
a,O,O
psychiatric,O,O
emergency,O,O
service,O,O
with,O,O
a,O,O
diagnosis,O,O
of,O,O
amphetamine,B,B
-,O,I
or,O,O
cocaine,B,B
-,O,I
induced,O,I
psychosis,O,I
were,O,O
interviewed,O,O
",",O,O
and,O,O
plasma,O,O
and,O,O
urine,O,O
were,O,O
collected,O,O
for,O,O
quantitative,O,O
assays,O,O
of,O,O
stimulant,O,B
drug,O,I
and,O,O
catecholamine,B,B
metabolite,O,I
levels,O,O
.,O,O
Methamphetamine,B,B
or,O,O
amphetamine,B,B
levels,O,O
were,O,O
related,O,O
to,O,O
several,O,O
psychopathology,O,O
scores,O,O
and,O,O
the,O,O
global,O,O
hyperkinesia,O,O
rating,O,O
.,O,O
HVA,O,B
levels,O,O
were,O,O
related,O,O
to,O,O
global,O,O
hyperkinesia,O,O
but,O,O
not,O,O
to,O,O
psychopathology,O,O
ratings,O,O
.,O,O
Although,O,O
many,O,O
other,O,O
factors,O,O
such,O,O
as,O,O
sensitization,O,O
may,O,O
play,O,O
a,O,O
role,O,O
",",O,O
intensity,O,O
of,O,O
stimulant,O,O
-,O,O
induced,O,O
psychotic,O,O
symptoms,O,O
and,O,O
stereotypies,O,O
appears,O,O
to,O,O
be,O,O
at,O,O
least,O,O
in,O,O
part,O,O
dose,O,O
-,O,O
related,O,O
.,O,O
Pheochromocytoma,O,B
unmasked,O,O
by,O,O
amisulpride,B,O
and,O,O
tiapride,B,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
describe,O,O
the,O,O
unmasking,O,O
of,O,O
pheochromocytoma,O,B
in,O,O
a,O,O
patient,O,O
treated,O,O
with,O,O
amisulpride,B,O
and,O,O
tiapride,B,O
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
42,O,O
-,O,O
year,O,O
-,O,O
old,O,O
white,O,O
man,O,O
developed,O,O
acute,O,O
hypertension,O,O
with,O,O
severe,O,O
headache,O,O
and,O,O
vomiting,O,O
2,O,O
hours,O,O
after,O,O
the,O,O
first,O,O
doses,O,O
of,O,O
amisulpride,B,O
100,O,O
mg,O,O
and,O,O
tiapride,B,O
100,O,O
mg,O,O
.,O,O
Both,O,O
drugs,O,O
were,O,O
immediately,O,O
discontinued,O,O
",",O,O
and,O,O
the,O,O
patient,O,O
recovered,O,O
after,O,O
subsequent,O,O
nicardipine,B,B
and,O,O
verapamil,B,B
treatment,O,O
.,O,O
Abdominal,O,O
ultrasound,O,O
showed,O,O
an,O,O
adrenal,O,O
mass,O,O
",",O,O
and,O,O
postoperative,O,O
histologic,O,O
examination,O,O
confirmed,O,O
the,O,O
diagnosis,O,O
of,O,O
pheochromocytoma,O,B
.,O,O
DISCUSSION,O,O
:,O,O
Drug,O,O
-,O,O
induced,O,O
symptoms,O,O
of,O,O
pheochromocytoma,O,B
are,O,O
often,O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
substituted,O,O
benzamide,B,B
drugs,O,O
",",O,O
but,O,O
the,O,O
underlying,O,O
mechanism,O,O
is,O,O
unknown,O,O
.,O,O
In,O,O
our,O,O
case,O,O
",",O,O
use,O,O
of,O,O
the,O,O
Naranjo,O,O
probability,O,O
scale,O,O
indicated,O,O
a,O,O
possible,O,O
relationship,O,O
between,O,O
the,O,O
hypertensive,O,O
crisis,O,O
and,O,O
amisulpride,B,B
and,O,O
tiapride,B,B
therapy,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
As,O,O
of,O,O
March,O,O
24,O,O
",",O,O
2005,O,O
",",O,O
this,O,O
is,O,O
the,O,O
first,O,O
reported,O,O
case,O,O
of,O,O
amisulpride,B,B
-,O,O
and,O,O
tiapride,B,B
-,O,O
induced,O,O
hypertensive,O,O
crisis,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
pheochromocytoma,O,B
.,O,O
Physicians,O,O
and,O,O
other,O,O
healthcare,O,O
professionals,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
this,O,O
potential,O,O
adverse,O,O
effect,O,O
of,O,O
tiapride,B,B
and,O,O
amisulpride,B,B
.,O,O
Minor,O,O
neurological,O,O
dysfunction,O,O
",",O,O
cognitive,O,O
development,O,O
",",O,O
and,O,O
somatic,O,O
development,O,O
at,O,O
the,O,O
age,O,O
of,O,O
3,O,O
to,O,O
7,O,O
years,O,O
after,O,O
dexamethasone,B,B
treatment,O,O
in,O,O
very,O,O
-,O,O
low,O,O
birth,O,O
-,O,O
weight,O,O
infants,O,O
.,O,O
The,O,O
objective,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
assess,O,O
minor,O,O
neurological,O,O
dysfunction,O,O
",",O,O
cognitive,O,O
development,O,O
",",O,O
and,O,O
somatic,O,O
development,O,O
after,O,O
dexamethasone,B,B
therapy,O,O
in,O,O
very,O,O
-,O,O
low,O,O
-,O,O
birthweight,O,O
infants,O,O
.,O,O
Thirty,O,O
-,O,O
three,O,O
children,O,O
after,O,O
dexamethasone,B,B
treatment,O,O
were,O,O
matched,O,O
to,O,O
33,O,O
children,O,O
without,O,O
dexamethasone,B,B
treatment,O,O
.,O,O
Data,O,O
were,O,O
assessed,O,O
at,O,O
the,O,O
age,O,O
of,O,O
3,O,O
-,O,O
7,O,O
years,O,O
.,O,O
Dexamethasone,B,B
was,O,O
started,O,O
between,O,O
the,O,O
7th,O,O
and,O,O
the,O,O
28th,O,O
day,O,O
of,O,O
life,O,O
over,O,O
7,O,O
days,O,O
with,O,O
a,O,O
total,O,O
dose,O,O
of,O,O
2,O,O
.,O,O
35,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
.,O,O
Exclusion,O,O
criteria,O,O
were,O,O
asphyxia,O,B
",",O,O
malformations,O,B
",",O,O
major,O,O
surgical,O,O
interventions,O,O
",",O,O
small,O,O
for,O,O
gestational,O,O
age,O,O
",",O,O
intraventricular,O,B
haemorrhage,O,I
grades,O,O
III,O,O
and,O,O
IV,O,O
",",O,O
periventricular,O,B
leukomalacia,O,I
",",O,O
and,O,O
severe,O,O
psychomotor,O,O
retardation,O,O
.,O,O
Each,O,O
child,O,O
was,O,O
examined,O,O
by,O,O
a,O,O
neuropediatrician,O,O
for,O,O
minor,O,O
neurological,O,O
dysfunctions,O,O
and,O,O
tested,O,O
by,O,O
a,O,O
psychologist,O,O
for,O,O
cognitive,O,O
development,O,O
with,O,O
a,O,O
Kaufman,O,B
Assessment,O,I
Battery,O,I
for,O,I
Children,O,I
and,O,O
a,O,O
Draw,O,B
-,O,I
a,O,I
-,O,I
Man,O,I
Test,O,I
.,O,O
There,O,O
were,O,O
no,O,O
differences,O,O
in,O,O
demographic,O,O
data,O,O
",",O,O
growth,O,O
",",O,O
and,O,O
socio,O,O
-,O,O
economic,O,O
status,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
.,O,O
Fine,O,O
motor,O,O
skills,O,O
and,O,O
gross,O,O
motor,O,O
function,O,O
were,O,O
significantly,O,O
better,O,O
in,O,O
the,O,O
control,O,O
group,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
Draw,O,O
-,O,O
a,O,O
-,O,O
Man,O,O
Test,O,O
",",O,O
the,O,O
control,O,O
group,O,O
showed,O,O
better,O,O
results,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
There,O,O
were,O,O
no,O,O
differences,O,O
in,O,O
development,O,O
of,O,O
speech,O,O
",",O,O
social,O,O
development,O,O
",",O,O
and,O,O
the,O,O
Kaufman,O,O
Assessment,O,O
Battery,O,O
for,O,O
Children,O,O
.,O,O
After,O,O
dexamethasone,B,B
treatment,O,O
",",O,O
children,O,O
showed,O,O
a,O,O
higher,O,O
rate,O,O
of,O,O
minor,O,O
neurological,O,O
dysfunctions,O,O
.,O,O
Neurological,O,O
development,O,O
was,O,O
affected,O,O
even,O,O
without,O,O
neurological,O,O
diagnosis,O,O
.,O,O
Further,O,O
long,O,O
-,O,O
term,O,O
follow,O,O
-,O,O
up,O,O
studies,O,O
will,O,O
be,O,O
necessary,O,O
to,O,O
fully,O,O
evaluate,O,O
the,O,O
impact,O,O
of,O,O
dexamethasone,B,B
on,O,O
neurological,O,O
and,O,O
cognitive,O,O
development,O,O
.,O,O
Valproic,B,B
acid,I,I
I,O,O
:,O,O
time,O,O
course,O,O
of,O,O
lipid,O,O
peroxidation,O,O
biomarkers,O,O
",",O,O
liver,O,O
toxicity,O,O
",",O,O
and,O,O
valproic,B,B
acid,I,I
metabolite,O,O
levels,O,O
in,O,O
rats,O,O
.,O,O
A,O,O
single,O,O
dose,O,O
of,O,O
valproic,B,B
acid,I,I
(,O,O
VPA,B,B
),O,O
",",O,O
which,O,O
is,O,O
a,O,O
widely,O,O
used,O,O
antiepileptic,O,O
drug,O,O
",",O,O
is,O,O
associated,O,O
with,O,O
oxidative,O,O
stress,O,O
in,O,O
rats,O,O
",",O,O
as,O,O
recently,O,O
demonstrated,O,O
by,O,O
elevated,O,O
levels,O,O
of,O,O
15,B,O
-,I,O
F,I,O
(,I,O
2t,I,O
),I,O
-,I,O
isoprostane,I,O
(,O,O
15,B,O
-,I,O
F,I,O
(,I,O
2t,I,O
),I,O
-,I,O
IsoP,I,O
.,O,O
To,O,O
determine,O,O
whether,O,O
there,O,O
was,O,O
a,O,O
temporal,O,O
relationship,O,O
between,O,O
VPA,B,B
-,O,O
associated,O,O
oxidative,O,O
stress,O,O
and,O,O
hepatotoxicity,O,O
",",O,O
adult,O,O
male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
treated,O,O
ip,O,O
with,O,O
VPA,B,B
(,O,O
500,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
or,O,O
0,O,O
.,O,O
9,O,O
%,O,O
saline,O,O
(,O,O
vehicle,O,O
),O,O
once,O,O
daily,O,O
for,O,O
2,O,O
",",O,O
4,O,O
",",O,O
7,O,O
",",O,O
10,O,O
",",O,O
or,O,O
14,O,O
days,O,O
.,O,O
Oxidative,O,O
stress,O,O
was,O,O
assessed,O,O
by,O,O
determining,O,O
plasma,O,O
and,O,O
liver,O,O
levels,O,O
of,O,O
15,B,B
-,I,I
F,I,I
(,I,I
2t,I,I
),I,I
-,I,I
IsoP,I,I
",",O,O
lipid,B,O
hydroperoxides,I,O
(,O,O
LPO,B,B
),O,O
",",O,O
and,O,O
thiobarbituric,B,O
acid,I,O
reactive,I,O
substances,I,O
(,O,O
TBARs,B,B
),O,O
.,O,O
Plasma,O,B
and,O,O
liver,O,B
15,B,O
-,I,O
F,I,O
(,I,O
2t,I,O
),I,O
-,I,O
IsoP,I,B
were,O,O
elevated,O,O
and,O,O
reached,O,O
a,O,O
plateau,O,O
after,O,O
day,O,O
2,O,O
of,O,O
VPA,B,B
treatment,O,O
compared,O,O
to,O,O
control,O,O
.,O,O
Liver,O,B
LPO,B,B
levels,O,O
were,O,O
not,O,O
elevated,O,O
until,O,O
day,O,O
7,O,O
of,O,O
treatment,O,O
(,O,O
1,O,O
.,O,O
8,O,O
-,O,O
fold,O,O
versus,O,O
control,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
.,O,O
Liver,O,B
and,O,O
plasma,O,B
TBARs,B,B
were,O,O
not,O,O
increased,O,O
until,O,O
14,O,O
days,O,O
(,O,O
2,O,O
-,O,O
fold,O,O
vs,O,O
.,O,O
control,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Liver,O,B
toxicity,O,O
was,O,O
evaluated,O,O
based,O,O
on,O,O
serum,O,O
levels,O,O
of,O,O
alpha,O,B
-,O,O
glutathione,B,I
S,O,I
-,O,I
transferase,O,I
(,O,O
alpha,O,B
-,O,I
GST,O,I
),O,O
and,O,O
by,O,O
histology,O,O
.,O,O
Serum,O,O
alpha,O,B
-,O,I
GST,O,I
levels,O,O
were,O,O
significantly,O,O
elevated,O,O
by,O,O
day,O,O
4,O,O
",",O,O
which,O,O
corresponded,O,O
to,O,O
hepatotoxicity,O,O
as,O,O
shown,O,O
by,O,O
the,O,O
increasing,O,O
incidence,O,O
of,O,O
inflammation,O,O
of,O,O
the,O,O
liver,O,B
capsule,O,O
",",O,O
necrosis,O,O
",",O,O
and,O,O
steatosis,O,O
throughout,O,O
the,O,O
study,O,O
.,O,O
The,O,O
liver,O,O
levels,O,O
of,O,O
beta,O,B
-,O,I
oxidation,O,I
metabolites,O,O
of,O,O
VPA,B,B
were,O,O
decreased,O,O
by,O,O
day,O,O
14,O,O
",",O,O
while,O,O
the,O,O
levels,O,O
of,O,O
4,B,B
-,I,I
ene,I,I
-,I,I
VPA,I,I
and,O,O
(,O,O
E,O,B
),O,I
",",I,O
4,I,B
-,I,I
diene,I,I
-,I,I
VPA,I,I
were,O,O
not,O,O
elevated,O,O
throughout,O,O
the,O,O
study,O,O
.,O,O
Overall,O,O
",",O,O
these,O,O
findings,O,O
indicate,O,O
that,O,O
VPA,B,B
treatment,O,O
results,O,O
in,O,O
oxidative,O,O
stress,O,O
",",O,O
as,O,O
measured,O,O
by,O,O
levels,O,O
of,O,O
15,B,B
-,I,I
F,I,I
(,I,I
2t,I,I
),I,I
-,I,I
IsoP,I,I
",",O,O
which,O,O
precedes,O,O
the,O,O
onset,O,O
of,O,O
necrosis,O,O
",",O,O
steatosis,O,O
",",O,O
and,O,O
elevated,O,O
levels,O,O
of,O,O
serum,O,O
alpha,O,B
-,O,I
GST,O,I
.,O,O
Assessment,O,O
of,O,O
perinatal,O,O
hepatitis,O,B
B,O,I
and,O,O
rubella,O,B
prevention,O,O
in,O,O
New,O,O
Hampshire,O,O
delivery,O,O
hospitals,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
evaluate,O,O
current,O,O
performance,O,O
on,O,O
recommended,O,O
perinatal,O,O
hepatitis,O,B
B,O,I
and,O,O
rubella,O,B
prevention,O,O
practices,O,O
in,O,O
New,O,O
Hampshire,O,O
.,O,O
METHODS,O,O
:,O,O
Data,O,O
were,O,O
extracted,O,O
from,O,O
2021,O,O
paired,O,O
mother,O,O
-,O,O
infant,O,O
records,O,O
for,O,O
the,O,O
year,O,O
2000,O,O
birth,O,O
cohort,O,O
in,O,O
New,O,O
Hampshire,O,O
',O,O
s,O,O
25,O,O
delivery,O,O
hospitals,O,O
.,O,O
Assessment,O,O
was,O,O
done,O,O
on,O,O
the,O,O
following,O,O
:,O,O
prenatal,O,O
screening,O,O
for,O,O
hepatitis,O,B
B,O,I
and,O,O
rubella,O,B
",",O,O
administration,O,O
of,O,O
the,O,O
hepatitis,O,B
B,O,I
vaccine,O,I
birth,O,I
dose,O,I
to,O,O
all,O,O
infants,O,O
",",O,O
administration,O,O
of,O,O
hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
to,O,O
infants,O,O
who,O,O
were,O,O
born,O,O
to,O,O
hepatitis,B,B
B,I,I
surface,I,I
antigen,I,I
-,O,I
positive,O,I
mothers,O,O
",",O,O
rubella,O,B
immunity,O,O
",",O,O
and,O,O
administration,O,O
of,O,O
in,O,O
-,O,O
hospital,O,O
postpartum,O,O
rubella,O,B
vaccine,O,I
to,O,O
rubella,O,B
nonimmune,O,I
women,O,O
.,O,O
RESULTS,O,O
:,O,O
Prenatal,O,O
screening,O,O
rates,O,O
for,O,O
hepatitis,O,B
B,O,I
(,O,O
98,O,O
.,O,O
8,O,O
%,O,O
),O,O
and,O,O
rubella,O,B
(,O,O
99,O,O
.,O,O
4,O,O
%,O,O
),O,O
were,O,O
high,O,O
.,O,O
Hepatitis,O,B
B,O,I
vaccine,O,O
birth,O,O
dose,O,O
was,O,O
administered,O,O
to,O,O
76,O,O
.,O,O
2,O,O
%,O,O
of,O,O
all,O,O
infants,O,O
.,O,O
All,O,O
infants,O,O
who,O,O
were,O,O
born,O,O
to,O,O
hepatitis,B,B
B,I,I
surface,I,I
antigen,I,I
-,O,I
positive,O,I
mothers,O,O
also,O,O
received,O,O
hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
.,O,O
Multivariate,O,O
logistic,O,O
regression,O,O
showed,O,O
that,O,O
the,O,O
month,O,O
of,O,O
delivery,O,O
and,O,O
infant,O,O
birth,O,O
weight,O,O
were,O,O
independent,O,O
predictors,O,O
of,O,O
hepatitis,O,B
B,O,I
vaccination,O,O
.,O,O
The,O,O
proportion,O,O
of,O,O
infants,O,O
who,O,O
were,O,O
vaccinated,O,O
in,O,O
January,O,O
and,O,O
February,O,O
2000,O,O
(,O,O
48,O,O
.,O,O
5,O,O
%,O,O
and,O,O
67,O,O
.,O,O
5,O,O
%,O,O
",",O,O
respectively,O,O
),O,O
was,O,O
less,O,O
than,O,O
any,O,O
other,O,O
months,O,O
",",O,O
whereas,O,O
the,O,O
proportion,O,O
who,O,O
were,O,O
vaccinated,O,O
in,O,O
December,O,O
2000,O,O
(,O,O
88,O,O
.,O,O
2,O,O
%,O,O
),O,O
was,O,O
the,O,O
highest,O,O
.,O,O
Women,O,O
who,O,O
were,O,O
born,O,O
between,O,O
1971,O,O
and,O,O
1975,O,O
had,O,O
the,O,O
highest,O,O
rate,O,O
of,O,O
rubella,O,B
nonimmunity,O,I
(,O,I
9,O,I
.,O,I
5,O,O
%,O,O
),O,O
.,O,O
In,O,O
-,O,O
hospital,O,O
postpartum,O,O
rubella,O,B
vaccine,O,O
administration,O,O
was,O,O
documented,O,O
for,O,O
75,O,O
.,O,O
6,O,O
%,O,O
of,O,O
nonimmune,O,O
women,O,O
.,O,O
CONCLUSION,O,O
:,O,O
This,O,O
study,O,O
documents,O,O
good,O,O
compliance,O,O
in,O,O
New,O,O
Hampshire,O,O
',O,O
s,O,O
birthing,O,O
hospitals,O,O
with,O,O
national,O,O
guidelines,O,O
for,O,O
perinatal,O,O
hepatitis,O,B
B,O,I
and,O,O
rubella,O,B
prevention,O,O
and,O,O
highlights,O,O
potential,O,O
areas,O,O
for,O,O
improvement,O,O
.,O,O
Succinylcholine,B,B
-,O,O
induced,O,O
masseter,O,B
muscle,O,I
rigidity,O,I
during,O,O
bronchoscopic,O,O
removal,O,O
of,O,O
a,O,O
tracheal,O,O
foreign,O,O
body,O,O
.,O,O
Masseter,O,B
muscle,O,I
rigidity,O,I
during,O,O
general,O,O
anesthesia,O,O
is,O,O
considered,O,O
an,O,O
early,O,O
warning,O,O
sign,O,O
of,O,O
a,O,O
possible,O,O
episode,O,O
of,O,O
malignant,O,O
hyperthermia,O,O
.,O,O
The,O,O
decision,O,O
whether,O,O
to,O,O
continue,O,O
or,O,O
discontinue,O,O
the,O,O
procedure,O,O
depends,O,O
on,O,O
the,O,O
urgency,O,O
of,O,O
the,O,O
surgery,O,O
and,O,O
severity,O,O
of,O,O
masseter,O,B
muscle,O,I
rigidity,O,I
.,O,O
Here,O,O
",",O,O
we,O,O
describe,O,O
a,O,O
case,O,O
of,O,O
severe,O,O
masseter,O,B
muscle,O,I
rigidity,O,I
(,O,O
jaw,O,B
of,O,I
steel,O,I
),O,O
after,O,O
succinylcholine,B,B
(,O,O
Sch,B,B
),O,O
administration,O,O
during,O,O
general,O,O
anesthetic,O,O
management,O,O
for,O,O
rigid,O,O
bronchoscopic,O,O
removal,O,O
of,O,O
a,O,O
tracheal,O,O
foreign,O,O
body,O,O
.,O,O
Anesthesia,O,O
was,O,O
continued,O,O
uneventfully,O,O
with,O,O
propofol,B,B
infusion,O,O
while,O,O
all,O,O
facilities,O,O
were,O,O
available,O,O
to,O,O
detect,O,O
and,O,O
treat,O,O
malignant,O,B
hyperthermia,O,I
.,O,O
Dexrazoxane,B,B
protects,O,O
against,O,O
myelosuppression,O,O
from,O,O
the,O,O
DNA,O,B
cleavage,O,I
-,O,I
enhancing,O,O
drugs,O,O
etoposide,B,B
and,O,O
daunorubicin,B,B
but,O,O
not,O,O
doxorubicin,B,B
.,O,O
PURPOSE,O,O
:,O,O
The,O,O
anthracyclines,B,O
daunorubicin,B,B
and,O,O
doxorubicin,B,B
and,O,O
the,O,O
epipodophyllotoxin,B,O
etoposide,B,B
are,O,O
potent,O,O
DNA,O,B
cleavage,O,I
-,O,I
enhancing,O,O
drugs,O,O
that,O,O
are,O,O
widely,O,O
used,O,O
in,O,O
clinical,O,O
oncology,O,O
;,O,O
however,O,O
",",O,O
myelosuppression,O,O
and,O,O
cardiac,O,O
toxicity,O,O
limit,O,O
their,O,O
use,O,O
.,O,O
Dexrazoxane,B,B
(,O,O
ICRF,B,B
-,I,I
187,I,I
),O,O
is,O,O
recommended,O,O
for,O,O
protection,O,O
against,O,O
anthracycline,B,B
-,O,O
induced,O,O
cardiotoxicity,O,O
.,O,O
EXPERIMENTAL,O,O
DESIGN,O,O
:,O,O
Because,O,O
of,O,O
their,O,O
widespread,O,O
use,O,O
",",O,O
the,O,O
hematologic,O,O
toxicity,O,O
following,O,O
coadministration,O,O
of,O,O
dexrazoxane,B,B
and,O,O
these,O,O
three,O,O
structurally,O,O
different,O,O
DNA,O,O
cleavage,O,O
enhancers,O,O
was,O,O
investigated,O,O
:,O,O
Sensitivity,O,O
of,O,O
human,O,O
and,O,O
murine,O,O
blood,O,O
progenitor,O,O
cells,O,O
to,O,O
etoposide,B,B
",",O,O
daunorubicin,B,B
",",O,O
and,O,O
doxorubicin,B,B
+,O,O
/,O,O
-,O,O
dexrazoxane,B,B
was,O,O
determined,O,O
in,O,O
granulocyte,O,O
-,O,O
macrophage,O,O
colony,O,O
forming,O,O
assays,O,O
.,O,O
Likewise,O,O
",",O,O
in,O,O
vivo,O,O
",",O,O
B6D2F1,O,O
mice,O,O
were,O,O
treated,O,O
with,O,O
etoposide,B,B
",",O,O
daunorubicin,B,B
",",O,O
and,O,O
doxorubicin,B,B
",",O,O
with,O,O
or,O,O
without,O,O
dexrazoxane,B,B
over,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
doses,O,O
:,O,O
posttreatment,O,O
",",O,O
a,O,O
full,O,O
hematologic,O,O
evaluation,O,O
was,O,O
done,O,O
.,O,O
RESULTS,O,O
:,O,O
Nontoxic,O,O
doses,O,O
of,O,O
dexrazoxane,B,B
reduced,O,O
myelosuppression,O,O
and,O,O
weight,O,O
loss,O,O
from,O,O
daunorubicin,B,B
and,O,O
etoposide,B,B
in,O,O
mice,O,O
and,O,O
antagonized,O,O
their,O,O
antiproliferative,O,O
effects,O,O
in,O,O
the,O,O
colony,O,O
assay,O,O
;,O,O
however,O,O
",",O,O
dexrazoxane,B,B
neither,O,O
reduced,O,O
myelosuppression,O,O
",",O,O
weight,O,O
loss,O,O
",",O,O
nor,O,O
the,O,O
in,O,O
vitro,O,O
cytotoxicity,O,O
from,O,O
doxorubicin,B,B
.,O,O
CONCLUSION,O,O
:,O,O
Although,O,O
our,O,O
findings,O,O
support,O,O
the,O,O
observation,O,O
that,O,O
dexrazoxane,B,B
reduces,O,O
neither,O,O
hematologic,O,O
activity,O,O
nor,O,O
antitumor,O,O
activity,O,O
from,O,O
doxorubicin,B,B
clinically,O,O
",",O,O
the,O,O
potent,O,O
antagonism,O,O
of,O,O
daunorubicin,B,B
activity,O,O
raises,O,O
concern,O,O
;,O,O
a,O,O
possible,O,O
interference,O,O
with,O,O
anticancer,O,O
efficacy,O,O
certainly,O,O
would,O,O
call,O,O
for,O,O
renewed,O,O
attention,O,O
.,O,O
Our,O,O
data,O,O
also,O,O
suggest,O,O
that,O,O
significant,O,O
etoposide,B,B
dose,O,O
escalation,O,O
is,O,O
perhaps,O,O
possible,O,O
by,O,O
the,O,O
use,O,O
of,O,O
dexrazoxane,B,B
.,O,O
Clinical,O,O
trials,O,O
in,O,O
patients,O,O
with,O,O
brain,O,O
metastases,O,O
combining,O,O
dexrazoxane,B,B
and,O,O
high,O,O
doses,O,O
of,O,O
etoposide,B,B
is,O,O
ongoing,O,O
with,O,O
the,O,O
aim,O,O
of,O,O
improving,O,O
efficacy,O,O
without,O,O
aggravating,O,O
hematologic,O,O
toxicity,O,O
.,O,O
If,O,O
successful,O,O
",",O,O
this,O,O
represents,O,O
an,O,O
exciting,O,O
mechanism,O,O
for,O,O
pharmacologic,O,O
regulation,O,O
of,O,O
side,O,O
effects,O,O
from,O,O
cytotoxic,O,O
chemotherapy,O,O
.,O,O
Assessment,O,O
of,O,O
the,O,O
onset,O,O
and,O,O
persistence,O,O
of,O,O
amnesia,O,O
during,O,O
procedural,O,O
sedation,O,O
with,O,O
propofol,B,B
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
assess,O,O
patients,O,O
',O,O
ability,O,O
to,O,O
repeat,O,O
and,O,O
recall,O,O
words,O,O
presented,O,O
to,O,O
them,O,O
while,O,O
undergoing,O,O
procedural,O,O
sedation,O,O
with,O,O
propofol,B,B
",",O,O
and,O,O
correlate,O,O
their,O,O
recall,O,O
with,O,O
their,O,O
level,O,O
of,O,O
awareness,O,O
as,O,O
measured,O,O
by,O,O
bispectral,O,O
index,O,O
(,O,O
BIS,O,B
),O,O
monitoring,O,O
.,O,O
METHODS,O,O
:,O,O
This,O,O
was,O,O
a,O,O
prospective,O,O
",",O,O
single,O,O
-,O,O
intervention,O,O
study,O,O
of,O,O
consenting,O,O
adult,O,O
patients,O,O
undergoing,O,O
procedural,O,O
sedation,O,O
with,O,O
propofol,B,B
between,O,O
December,O,O
28,O,O
",",O,O
2002,O,O
",",O,O
and,O,O
October,O,O
31,O,O
",",O,O
2003,O,O
.,O,O
BIS,O,O
monitoring,O,O
was,O,O
initiated,O,O
starting,O,O
3,O,O
minutes,O,O
before,O,O
the,O,O
procedure,O,O
and,O,O
continuing,O,O
until,O,O
the,O,O
patient,O,O
had,O,O
regained,O,O
baseline,O,O
mental,O,O
status,O,O
.,O,O
At,O,O
1,O,O
-,O,O
minute,O,O
intervals,O,O
during,O,O
the,O,O
procedural,O,O
sedation,O,O
",",O,O
until,O,O
the,O,O
patient,O,O
regained,O,O
baseline,O,O
mental,O,O
status,O,O
at,O,O
the,O,O
end,O,O
of,O,O
the,O,O
procedure,O,O
",",O,O
a,O,O
word,O,O
from,O,O
a,O,O
standardized,O,O
list,O,O
was,O,O
read,O,O
aloud,O,O
",",O,O
and,O,O
the,O,O
patient,O,O
was,O,O
asked,O,O
to,O,O
immediately,O,O
repeat,O,O
the,O,O
word,O,O
to,O,O
the,O,O
investigator,O,O
.,O,O
The,O,O
BIS,O,O
score,O,O
at,O,O
the,O,O
time,O,O
the,O,O
word,O,O
was,O,O
read,O,O
and,O,O
the,O,O
patient,O,O
',O,O
s,O,O
ability,O,O
to,O,O
repeat,O,O
the,O,O
word,O,O
were,O,O
recorded,O,O
.,O,O
After,O,O
the,O,O
procedure,O,O
",",O,O
the,O,O
patient,O,O
was,O,O
asked,O,O
to,O,O
state,O,O
all,O,O
of,O,O
the,O,O
words,O,O
from,O,O
the,O,O
list,O,O
that,O,O
he,O,O
or,O,O
she,O,O
could,O,O
recall,O,O
",",O,O
and,O,O
to,O,O
identify,O,O
the,O,O
last,O,O
word,O,O
recalled,O,O
from,O,O
prior,O,O
to,O,O
the,O,O
start,O,O
of,O,O
the,O,O
procedure,O,O
and,O,O
the,O,O
first,O,O
word,O,O
recalled,O,O
from,O,O
after,O,O
the,O,O
procedure,O,O
was,O,O
completed,O,O
.,O,O
RESULTS,O,O
:,O,O
Seventy,O,O
-,O,O
five,O,O
consenting,O,O
patients,O,O
were,O,O
enrolled,O,O
;,O,O
one,O,O
patient,O,O
was,O,O
excluded,O,O
from,O,O
data,O,O
analysis,O,O
for,O,O
a,O,O
protocol,O,O
violation,O,O
.,O,O
No,O,O
serious,O,O
adverse,O,O
events,O,O
were,O,O
noted,O,O
during,O,O
the,O,O
procedural,O,O
sedations,O,O
.,O,O
The,O,O
mean,O,O
(,O,O
+,O,O
/,O,O
-,O,O
standard,O,O
deviation,O,O
),O,O
time,O,O
of,O,O
data,O,O
collection,O,O
was,O,O
16,O,O
.,O,O
4,O,O
minutes,O,O
(,O,O
+,O,O
/,O,O
-,O,O
7,O,O
.,O,O
1,O,O
;,O,O
range,O,O
5,O,O
to,O,O
34,O,O
minutes,O,O
),O,O
.,O,O
The,O,O
mean,O,O
initial,O,O
(,O,O
preprocedure,O,O
),O,O
BIS,O,B
score,O,O
was,O,O
97,O,O
.,O,O
1,O,O
(,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
3,O,O
;,O,O
range,O,O
92,O,O
to,O,O
99,O,O
),O,O
.,O,O
The,O,O
mean,O,O
lowest,O,O
BIS,O,B
score,O,O
occurring,O,O
during,O,O
these,O,O
procedural,O,O
sedations,O,O
was,O,O
66,O,O
.,O,O
9,O,O
(,O,O
+,O,O
/,O,O
-,O,O
14,O,O
.,O,O
4,O,O
;,O,O
range,O,O
33,O,O
to,O,O
91,O,O
.,O,O
The,O,O
mean,O,O
lowest,O,O
BIS,O,O
score,O,O
corresponding,O,O
to,O,O
the,O,O
ability,O,O
of,O,O
the,O,O
patient,O,O
to,O,O
immediately,O,O
repeat,O,O
words,O,O
read,O,O
from,O,O
the,O,O
list,O,O
was,O,O
77,O,O
.,O,O
1,O,O
(,O,O
95,O,O
%,O,O
CI,O,O
=,O,O
74,O,O
.,O,O
3,O,O
to,O,O
80,O,O
.,O,O
0,O,O
),O,O
.,O,O
The,O,O
mean,O,O
highest,O,O
BIS,O,O
score,O,O
corresponding,O,O
to,O,O
the,O,O
inability,O,O
to,O,O
repeat,O,O
words,O,O
was,O,O
81,O,O
.,O,O
5,O,O
(,O,O
95,O,O
%,O,O
CI,O,O
=,O,O
78,O,O
.,O,O
1,O,O
to,O,O
84,O,O
),O,O
.,O,O
The,O,O
mean,O,O
BIS,O,B
score,O,O
corresponding,O,O
to,O,O
the,O,O
last,O,O
word,O,O
recalled,O,O
from,O,O
prior,O,O
to,O,O
the,O,O
initiation,O,O
of,O,O
the,O,O
sedation,O,O
was,O,O
96,O,O
.,O,O
(,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
4,O,O
;,O,O
range,O,O
84,O,O
to,O,O
98,O,O
),O,O
The,O,O
mean,O,O
BIS,O,B
score,O,O
corresponding,O,O
to,O,O
the,O,O
first,O,O
word,O,O
recalled,O,O
after,O,O
the,O,O
procedure,O,O
was,O,O
completed,O,O
was,O,O
91,O,O
.,O,O
(,O,O
95,O,O
%,O,O
CI,O,O
=,O,O
88,O,O
.,O,O
to,O,O
94,O,O
.,O,O
),O,O
All,O,O
patients,O,O
recalled,O,O
at,O,O
least,O,O
one,O,O
word,O,O
that,O,O
had,O,O
been,O,O
read,O,O
to,O,O
them,O,O
during,O,O
the,O,O
protocol,O,O
.,O,O
The,O,O
mean,O,O
lowest,O,O
BIS,O,B
score,O,O
for,O,O
any,O,O
recalled,O,O
word,O,O
was,O,O
91,O,O
.,O,O
5,O,O
(,O,O
+,O,O
/,O,O
-,O,O
11,O,O
.,O,O
1,O,O
;,O,O
range,O,O
79,O,O
to,O,O
98,O,O
",",O,O
and,O,O
no,O,O
words,O,O
were,O,O
recalled,O,O
when,O,O
the,O,O
corresponding,O,O
BIS,O,B
score,O,O
was,O,O
less,O,O
than,O,O
90,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
There,O,O
is,O,O
a,O,O
range,O,O
of,O,O
BIS,O,B
scores,O,O
during,O,O
which,O,O
sedated,O,O
patients,O,O
are,O,O
able,O,O
to,O,O
repeat,O,O
words,O,O
read,O,O
to,O,O
them,O,O
but,O,O
are,O,O
not,O,O
able,O,O
to,O,O
subsequently,O,O
recall,O,O
these,O,O
words,O,O
.,O,O
Furthermore,O,O
",",O,O
patients,O,O
had,O,O
no,O,O
recall,O,O
of,O,O
words,O,O
repeated,O,O
prior,O,O
to,O,O
procedural,O,O
sedation,O,O
in,O,O
BIS,O,O
ranges,O,O
associated,O,O
with,O,O
recall,O,O
after,O,O
procedural,O,O
sedation,O,O
",",O,O
suggestive,O,O
of,O,O
retrograde,O,O
amnesia,O,O
.,O,O
Amiodarone,B,B
pulmonary,O,O
toxicity,O,O
.,O,O
Amiodarone,B,B
is,O,O
an,O,O
effective,O,O
antiarrhythmic,O,O
agent,O,O
whose,O,O
utility,O,O
is,O,O
limited,O,O
by,O,O
many,O,O
side,O,O
-,O,O
effects,O,O
",",O,O
the,O,O
most,O,O
problematic,O,O
being,O,O
pneumonitis,O,B
.,O,O
The,O,O
pulmonary,O,O
toxicity,O,O
of,O,O
amiodarone,B,B
is,O,O
thought,O,O
to,O,O
result,O,O
from,O,O
direct,O,O
injury,O,O
related,O,O
to,O,O
the,O,O
intracellular,O,O
accumulation,O,O
of,O,O
phospholipid,O,B
and,O,O
T,O,B
cell,O,I
-,O,I
mediated,O,I
hypersensitivity,O,I
pneumonitis,O,I
.,O,O
The,O,O
clinical,O,O
and,O,O
radiographic,O,O
features,O,O
of,O,O
amiodarone,B,B
-,O,O
induced,O,O
pulmonary,O,O
toxicity,O,O
are,O,O
characteristic,O,O
but,O,O
nonspecific,O,O
.,O,O
The,O,O
diagnosis,O,O
depends,O,O
on,O,O
exclusion,O,O
of,O,O
other,O,O
entities,O,O
",",O,O
such,O,O
as,O,O
heart,O,B
failure,O,I
",",O,O
infection,O,B
",",O,O
and,O,O
malignancy,O,B
.,O,O
While,O,O
withdrawal,O,O
of,O,O
amiodarone,B,B
leads,O,O
to,O,O
clinical,O,O
improvement,O,O
in,O,O
majority,O,O
of,O,O
cases,O,O
",",O,O
this,O,O
is,O,O
not,O,O
always,O,O
possible,O,O
or,O,O
advisable,O,O
.,O,O
Dose,O,O
reduction,O,O
or,O,O
concomitant,O,O
steroid,B,O
therapy,O,O
may,O,O
have,O,O
a,O,O
role,O,O
in,O,O
selected,O,O
patients,O,O
.,O,O
Two,O,O
prodrugs,O,O
of,O,O
potent,O,O
and,O,O
selective,O,O
GluR5,O,B
kainate,B,I
receptor,O,I
antagonists,O,I
actives,O,O
in,O,O
three,O,O
animal,O,O
models,O,O
of,O,O
pain,O,O
.,O,O
Amino,O,O
acids,O,O
5,O,O
and,O,O
7,O,O
",",O,O
two,O,O
potent,O,O
and,O,O
selective,O,O
competitive,O,O
GluR5,O,B
KA,B,I
receptor,O,I
antagonists,O,I
",",O,O
exhibited,O,O
high,O,O
GluR5,O,B
receptor,O,I
affinity,O,O
over,O,O
other,O,O
glutamate,B,B
receptors,O,I
.,O,O
Their,O,O
ester,O,O
prodrugs,O,O
6,O,O
and,O,O
8,O,O
were,O,O
orally,O,O
active,O,O
in,O,O
three,O,O
models,O,O
of,O,O
pain,O,O
:,O,O
reversal,O,O
of,O,O
formalin,B,B
-,O,I
induced,O,I
paw,O,I
licking,O,I
",",O,O
carrageenan,B,B
-,O,I
induced,O,I
thermal,O,I
hyperalgesia,O,I
",",O,O
and,O,O
capsaicin,B,B
-,O,I
induced,O,I
mechanical,O,I
hyperalgesia,O,I
.,O,O
Possible,O,O
azithromycin,B,B
-,O,O
associated,O,O
hiccups,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
report,O,O
a,O,O
case,O,O
of,O,O
persistent,O,O
hiccups,O,O
associated,O,O
by,O,O
azithromycin,B,B
therapy,O,O
.,O,O
CASE,O,O
SUMMARY,O,O
:,O,O
A,O,O
76,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
presented,O,O
with,O,O
persistent,O,O
hiccups,O,O
after,O,O
beginning,O,O
azithromycin,B,B
for,O,O
the,O,O
treatment,O,O
of,O,O
pharyngitis,O,O
.,O,O
Hiccups,O,O
were,O,O
persistent,O,O
and,O,O
exhausting,O,O
.,O,O
Discontinuation,O,O
of,O,O
azithromycin,B,B
and,O,O
therapy,O,O
with,O,O
baclofen,B,B
finally,O,O
resolved,O,O
hiccups,O,O
.,O,O
No,O,O
organic,O,O
cause,O,O
of,O,O
hiccups,O,O
was,O,O
identified,O,O
despite,O,O
extensive,O,O
investigation,O,O
.,O,O
DISCUSSION,O,O
:,O,O
Pharmacotherapeutic,O,O
agents,O,O
have,O,O
been,O,O
uncommonly,O,O
associated,O,O
with,O,O
hiccups,O,O
.,O,O
Corticosteroids,O,B
(,O,O
dexamethasone,B,B
and,O,O
methylprednisolone,B,B
),O,O
",",O,O
benzodiazepines,B,B
(,O,O
midazolam,B,B
),O,O
and,O,O
general,O,O
anaesthesia,O,O
have,O,O
been,O,O
the,O,O
specific,O,O
agents,O,O
mentioned,O,O
most,O,O
frequently,O,O
in,O,O
the,O,O
literature,O,O
as,O,O
being,O,O
associated,O,O
with,O,O
the,O,O
development,O,O
of,O,O
hiccups,O,O
.,O,O
Few,O,O
cases,O,O
of,O,O
drug,O,B
-,O,O
induced,O,O
hiccups,O,O
have,O,O
been,O,O
reported,O,O
related,O,O
to,O,O
macrolide,B,B
antimicrobials,O,O
.,O,O
Using,O,O
the,O,O
Naranjo,O,O
adverse,O,O
effect,O,O
reaction,O,O
probability,O,O
scale,O,O
this,O,O
event,O,O
could,O,O
be,O,O
classified,O,O
as,O,O
possible,O,O
(,O,O
score,O,O
5,O,O
points,O,O
),O,O
",",O,O
mostly,O,O
because,O,O
of,O,O
the,O,O
close,O,O
temporal,O,O
sequence,O,O
",",O,O
previous,O,O
reports,O,O
on,O,O
this,O,O
reaction,O,O
with,O,O
other,O,O
macrolides,B,B
and,O,O
the,O,O
absence,O,O
of,O,O
any,O,O
alternative,O,O
explanation,O,O
for,O,O
hiccups,O,O
.,O,O
Our,O,O
hypothesis,O,O
is,O,O
that,O,O
a,O,O
vagal,O,O
mechanism,O,O
mediated,O,O
by,O,O
azithromycin,B,B
could,O,O
be,O,O
the,O,O
pathogenesis,O,O
of,O,O
hiccups,O,O
in,O,O
our,O,O
patient,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Diagnosis,O,O
of,O,O
drug,O,O
-,O,O
induced,O,O
hiccups,O,O
is,O,O
difficult,O,O
and,O,O
often,O,O
achieved,O,O
only,O,O
by,O,O
a,O,O
process,O,O
of,O,O
elimination,O,O
.,O,O
However,O,O
",",O,O
macrolide,B,B
antimicrobials,O,O
have,O,O
been,O,O
reported,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
hiccups,O,O
and,O,O
vagal,O,O
mechanism,O,O
could,O,O
explain,O,O
the,O,O
development,O,O
of,O,O
this,O,O
side,O,O
-,O,O
effect,O,O
.,O,O
Calcium,B,B
carbonate,I,I
toxicity,O,I
:,O,O
the,O,O
updated,O,O
milk,O,O
-,O,O
alkali,O,O
syndrome,O,O
;,O,O
report,O,O
of,O,O
3,O,O
cases,O,O
and,O,O
review,O,O
of,O,O
the,O,O
literature,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
describe,O,O
3,O,O
patients,O,O
with,O,O
calcium,B,B
carbonate,I,I
-,O,I
induced,O,I
hypercalcemia,O,I
and,O,O
gain,O,O
insights,O,O
into,O,O
the,O,O
cause,O,O
and,O,O
management,O,O
of,O,O
the,O,O
milk,O,O
-,O,O
alkali,O,O
syndrome,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
report,O,O
the,O,O
clinical,O,O
and,O,O
laboratory,O,O
data,O,O
in,O,O
3,O,O
patients,O,O
who,O,O
presented,O,O
with,O,O
severe,O,O
hypercalcemia,O,I
(,O,O
corrected,O,O
serum,O,O
calcium,B,B
>,O,O
or,O,O
=,O,O
14,O,O
mg,O,O
/,O,O
dL,O,O
and,O,O
review,O,O
the,O,O
pertinent,O,O
literature,O,O
on,O,O
milk,O,O
-,O,O
alkali,O,O
syndrome,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
3,O,O
patients,O,O
had,O,O
acute,O,O
renal,O,B
insufficiency,O,O
",",O,O
relative,O,O
metabolic,O,O
alkalosis,O,O
",",O,O
and,O,O
low,O,O
parathyroid,O,B
hormone,O,I
(,O,O
PTH,O,B
),O,O
",",O,O
PTH,O,B
-,O,O
related,O,O
peptide,O,O
",",O,O
and,O,O
1,B,O
",",I,O
25,I,O
-,I,O
dihydroxyvitamin,I,B
D,I,I
concentrations,O,O
.,O,O
No,O,O
malignant,O,O
lesion,O,O
was,O,O
found,O,O
.,O,O
Treatment,O,O
included,O,O
aggressive,O,O
hydration,O,O
and,O,O
varied,O,O
amounts,O,O
of,O,O
furosemide,B,B
.,O,O
The,O,O
2,O,O
patients,O,O
with,O,O
the,O,O
higher,O,O
serum,O,O
calcium,B,B
concentrations,O,O
received,O,O
pamidronate,B,B
intravenously,O,O
(,O,O
60,O,O
and,O,O
30,O,O
mg,O,O
",",O,O
respectively,O,O
),O,O
",",O,O
which,O,O
caused,O,O
severe,O,O
hypocalcemia,O,B
.,O,O
Of,O,O
the,O,O
3,O,O
patients,O,O
",",O,O
2,O,O
were,O,O
ingesting,O,O
acceptable,O,O
doses,O,O
of,O,O
elemental,O,O
calcium,B,B
(,O,O
1,O,O
g,O,O
and,O,O
2,O,O
g,O,O
daily,O,O
",",O,O
respectively,O,O
),O,O
in,O,O
the,O,O
form,O,O
of,O,O
calcium,B,B
carbonate,I,I
.,O,O
In,O,O
addition,O,O
to,O,O
our,O,O
highlighted,O,O
cases,O,O
",",O,O
we,O,O
review,O,O
the,O,O
history,O,O
",",O,O
classification,O,O
",",O,O
pathophysiologic,O,O
features,O,O
",",O,O
and,O,O
treatment,O,O
of,O,O
milk,O,B
-,O,I
alkali,O,I
syndrome,O,I
and,O,O
summarize,O,O
the,O,O
cases,O,O
reported,O,O
from,O,O
early,O,O
1995,O,O
to,O,O
November,O,O
2003,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Milk,O,B
-,O,I
alkali,O,I
syndrome,O,I
may,O,O
be,O,O
a,O,O
common,O,O
cause,O,O
of,O,O
unexplained,O,O
hypercalcemia,O,O
and,O,O
can,O,O
be,O,O
precipitated,O,O
by,O,O
small,O,O
amounts,O,O
of,O,O
orally,O,O
ingested,O,O
calcium,B,B
carbonate,I,I
in,O,O
susceptible,O,O
persons,O,O
.,O,O
Treatment,O,O
with,O,O
hydration,O,O
",",O,O
furosemide,B,B
",",O,O
and,O,O
discontinuation,O,O
of,O,O
the,O,O
calcium,B,B
and,O,O
vitamin,B,B
D,I,I
source,O,O
is,O,O
adequate,O,O
.,O,O
Pamidronate,B,B
treatment,O,O
is,O,O
associated,O,O
with,O,O
considerable,O,O
risk,O,O
for,O,O
hypocalcemia,O,O
",",O,O
even,O,O
in,O,O
cases,O,O
of,O,O
initially,O,O
severe,O,O
hypercalcemia,O,O
.,O,O
Warfarin,B,B
-,O,I
induced,O,I
leukocytoclastic,O,I
vasculitis,O,I
.,O,O
Skin,O,O
reactions,O,O
associated,O,O
with,O,O
oral,O,O
coumarin,B,B
-,O,I
derived,O,I
anticoagulants,O,I
are,O,O
an,O,O
uncommon,O,O
occurrence,O,O
.,O,O
Leukocytoclastic,O,B
vasculitis,O,I
(,O,O
LV,O,B
),O,O
is,O,O
primarily,O,O
a,O,O
cutaneous,O,O
small,O,O
vessel,O,O
vasculitis,O,O
",",O,O
though,O,O
systemic,O,O
involvement,O,O
may,O,O
be,O,O
encountered,O,O
.,O,O
We,O,O
report,O,O
4,O,O
patients,O,O
with,O,O
late,O,O
-,O,O
onset,O,O
LV,O,B
probably,O,O
due,O,O
to,O,O
warfarin,B,B
.,O,O
All,O,O
4,O,O
patients,O,O
presented,O,O
with,O,O
skin,O,O
eruptions,O,O
that,O,O
developed,O,O
after,O,O
receiving,O,O
warfarin,B,B
for,O,O
several,O,O
years,O,O
.,O,O
The,O,O
results,O,O
of,O,O
skin,O,O
lesion,O,O
biopsies,O,O
were,O,O
available,O,O
in,O,O
3,O,O
patients,O,O
",",O,O
confirming,O,O
LV,O,B
Cutaneous,O,I
lesions,O,I
resolved,O,O
in,O,O
all,O,O
patients,O,O
after,O,O
warfarin,B,B
was,O,O
discontinued,O,O
.,O,O
In,O,O
2,O,O
of,O,O
the,O,O
4,O,O
patients,O,O
",",O,O
rechallenge,O,O
with,O,O
warfarin,B,B
led,O,O
to,O,O
recurrence,O,O
of,O,O
the,O,O
lesions,O,O
.,O,O
LV,O,B
may,O,O
be,O,O
a,O,O
late,O,O
-,O,O
onset,O,O
adverse,O,O
reaction,O,O
associated,O,O
with,O,O
warfarin,B,B
therapy,O,O
.,O,O
Cocaine,B,B
-,O,O
induced,O,O
brainstem,O,O
seizures,O,O
and,O,O
behavior,O,O
.,O,O
A,O,O
variety,O,O
of,O,O
abnormal,O,O
sensory,O,O
/,O,O
motor,O,O
behaviors,O,O
associated,O,O
with,O,O
electrical,O,O
discharges,O,O
recorded,O,O
from,O,O
the,O,O
bilateral,O,O
brainstem,O,O
were,O,O
induced,O,O
in,O,O
adult,O,O
WKY,O,O
rats,O,O
by,O,O
mechanical,O,O
(,O,O
electrode,O,O
implants,O,O
),O,O
and,O,O
DC,O,O
electrical,O,O
current,O,O
stimulations,O,O
and,O,O
by,O,O
acute,O,O
and,O,O
chronic,O,O
administration,O,O
of,O,O
cocaine,B,B
.,O,O
The,O,O
electrode,O,O
implant,O,O
implicated,O,O
one,O,O
side,O,O
or,O,O
the,O,O
other,O,O
of,O,O
the,O,O
reticular,O,O
system,O,O
of,O,O
the,O,O
brainstem,O,O
but,O,O
subjects,O,O
were,O,O
not,O,O
incapacitated,O,O
by,O,O
the,O,O
stimulations,O,O
.,O,O
Cocaine,B,B
(,O,O
40,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
was,O,O
injected,O,O
subcutaneously,O,O
for,O,O
an,O,O
acute,O,O
experiment,O,O
and,O,O
subsequent,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
doses,O,O
twice,O,O
daily,O,O
for,O,O
3,O,O
days,O,O
in,O,O
a,O,O
chronic,O,O
study,O,O
.,O,O
Cocaine,B,B
generated,O,O
more,O,O
abnormal,O,O
behaviors,O,O
in,O,O
the,O,O
brainstem,O,B
perturbation,O,O
group,O,O
",",O,O
especially,O,O
the,O,O
electrically,O,O
perturbated,O,O
subjects,O,O
.,O,O
The,O,O
abnormal,O,O
behaviors,O,O
were,O,O
yawning,O,O
",",O,O
retrocollis,O,O
",",O,O
hyperactivity,O,O
",",O,O
hypersensitivity,O,O
",",O,O
behavior,O,O
",",O,O
squealing,O,O
",",O,O
head,O,O
bobbing,O,O
",",O,O
circling,O,O
",",O,O
sniffing,O,O
",",O,O
abnormal,O,O
posturing,O,O
",",O,O
and,O,O
facial,O,O
twitching,O,O
.,O,O
Shifts,O,O
in,O,O
the,O,O
power,O,O
frequency,O,O
spectra,O,O
of,O,O
the,O,O
discharge,O,O
patterns,O,O
were,O,O
noted,O,O
between,O,O
quiet,O,O
and,O,O
pacing,O,O
behavioral,O,O
states,O,O
.,O,O
Hypersensitivity,O,O
to,O,O
various,O,O
auditory,O,B
",",O,O
tactile,O,B
",",O,O
and,O,O
visual,O,B
stimulation,O,O
was,O,O
present,O,O
and,O,O
shifts,O,O
in,O,O
the,O,O
brainstem,O,B
ambient,O,I
power,O,I
spectral,O,I
frequency,O,I
occurred,O,O
in,O,O
response,O,O
to,O,O
tactile,O,B
stimulation,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
the,O,O
brainstem,O,O
generates,O,O
and,O,O
propagates,O,O
pathological,O,O
discharges,O,O
that,O,O
can,O,O
be,O,O
elicited,O,O
by,O,O
mechanical,O,O
and,O,O
DC,O,B
electrical,O,I
perturbation,O,I
.,O,O
Cocaine,B,B
was,O,O
found,O,O
to,O,O
activate,O,O
the,O,O
discharge,O,O
system,O,O
and,O,O
thus,O,O
induce,O,O
abnormal,O,O
behaviors,O,O
that,O,O
are,O,O
generated,O,O
at,O,O
the,O,O
discharge,O,O
site,O,O
and,O,O
at,O,O
distant,O,O
sites,O,O
to,O,O
which,O,O
the,O,O
discharge,O,O
propagates,O,O
.,O,O
Cognitive,O,O
functions,O,O
may,O,O
also,O,O
be,O,O
involved,O,O
since,O,O
dopaminergic,O,B
and,O,O
serotonergic,O,B
cellular,O,O
elements,O,O
at,O,O
the,O,O
brainstem,O,O
level,O,O
are,O,O
also,O,O
implicated,O,O
.,O,O
rTMS,O,O
of,O,O
supplementary,O,O
motor,O,O
area,O,O
modulates,O,O
therapy,O,O
-,O,O
induced,O,O
dyskinesias,O,O
in,O,O
Parkinson,O,O
disease,O,O
.,O,O
The,O,O
neural,O,O
mechanisms,O,O
and,O,O
circuitry,O,O
involved,O,O
in,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesia,O,O
are,O,O
unclear,O,O
.,O,O
Using,O,O
repetitive,O,O
transcranial,O,O
magnetic,O,O
stimulation,O,O
(,O,O
rTMS,O,B
),O,O
over,O,O
the,O,O
supplementary,O,O
motor,O,O
area,O,O
(,O,O
SMA,O,B
),O,O
in,O,O
a,O,O
group,O,O
of,O,O
patients,O,O
with,O,O
advanced,O,O
Parkinson,O,B
disease,O,I
",",O,O
the,O,O
authors,O,O
investigated,O,O
whether,O,O
modulation,O,O
of,O,O
SMA,O,B
excitability,O,O
may,O,O
result,O,O
in,O,O
a,O,O
modification,O,O
of,O,O
a,O,O
dyskinetic,O,O
state,O,O
induced,O,O
by,O,O
continuous,O,O
apomorphine,B,B
infusion,O,O
.,O,O
rTMS,O,O
at,O,O
1,O,O
Hz,O,O
was,O,O
observed,O,O
to,O,O
markedly,O,O
reduce,O,O
drug,O,B
-,O,O
induced,O,O
dyskinesias,O,O
",",O,O
whereas,O,O
5,O,B
-,O,I
Hz,O,I
rTMS,O,I
induced,O,O
a,O,O
slight,O,O
but,O,O
not,O,O
significant,O,O
increase,O,O
.,O,O
Intracavitary,O,O
chemotherapy,O,B
(,O,O
paclitaxel,B,B
/,O,O
carboplatin,B,B
liquid,O,O
crystalline,O,O
cubic,O,O
phases,O,O
),O,O
for,O,O
recurrent,O,O
glioblastoma,O,B
-,O,O
-,O,O
clinical,O,O
observations,O,O
.,O,O
Human,O,O
malignant,O,O
brain,O,O
tumors,O,O
have,O,O
a,O,O
poor,O,O
prognosis,O,O
in,O,O
spite,O,O
of,O,O
surgery,O,O
and,O,O
radiation,O,O
therapy,O,O
.,O,O
Cubic,O,B
phases,O,I
consist,O,O
of,O,O
curved,O,O
biocontinuous,O,O
lipid,O,B
bilayers,O,I
",",O,O
separating,O,O
two,O,O
congruent,O,O
networks,O,O
of,O,O
water,O,B
channels,O,I
.,O,O
Used,O,O
as,O,O
a,O,O
host,O,O
for,O,O
cytotoxic,O,O
drugs,O,O
",",O,O
the,O,O
gel,O,B
-,O,I
like,O,I
matrix,O,I
can,O,O
easily,O,O
be,O,O
applied,O,O
to,O,O
the,O,O
walls,O,O
of,O,O
a,O,O
surgical,O,O
resection,O,O
cavity,O,O
.,O,O
For,O,O
human,O,O
glioblastoma,O,B
recurrences,O,I
",",O,O
the,O,O
feasibility,O,O
",",O,O
safety,O,O
",",O,O
and,O,O
short,O,O
-,O,O
term,O,O
effects,O,O
of,O,O
a,O,O
surgical,O,O
intracavitary,O,O
application,O,O
of,O,O
paclitaxel,B,B
and,O,O
carboplatin,B,B
encapsulated,O,O
by,O,O
liquid,O,B
crystalline,O,I
cubic,O,I
phases,O,I
are,O,O
examined,O,O
in,O,O
a,O,O
pilot,O,O
study,O,O
.,O,O
A,O,O
total,O,O
of,O,O
12,O,O
patients,O,O
with,O,O
a,O,O
recurrence,O,O
of,O,O
a,O,O
glioblastoma,O,B
multiforme,O,I
underwent,O,O
re,O,O
-,O,O
resection,O,O
and,O,O
received,O,O
an,O,O
intracavitary,O,O
application,O,O
of,O,O
paclitaxel,B,B
and,O,O
carboplatin,B,B
cubic,O,O
phases,O,O
in,O,O
different,O,O
dosages,O,O
.,O,O
Six,O,O
of,O,O
the,O,O
patients,O,O
received,O,O
more,O,O
than,O,O
15,O,O
mg,O,O
paclitaxel,B,B
and,O,O
suffered,O,O
from,O,O
moderate,O,O
to,O,O
severe,O,O
brain,O,O
edema,O,O
",",O,O
while,O,O
the,O,O
remaining,O,O
patients,O,O
received,O,O
only,O,O
a,O,O
total,O,O
of,O,O
15,O,O
mg,O,O
paclitaxel,B,B
.,O,O
In,O,O
the,O,O
latter,O,O
group,O,O
",",O,O
brain,O,B
edema,O,I
was,O,O
markedly,O,O
reduced,O,O
and,O,O
dealt,O,O
medically,O,O
.,O,O
Intracavitary,O,O
chemotherapy,O,O
in,O,O
recurrent,O,O
glioblastoma,O,B
using,O,O
cubic,O,O
phases,O,O
is,O,O
feasible,O,O
and,O,O
safe,O,O
",",O,O
yet,O,O
the,O,O
clinical,O,O
benefit,O,O
remains,O,O
to,O,O
be,O,O
examined,O,O
in,O,O
a,O,O
clinical,O,O
phase,O,O
II,O,O
study,O,O
.,O,O
Lamotrigine,B,B
associated,O,O
with,O,O
exacerbation,O,O
or,O,O
de,O,O
novo,O,O
myoclonus,O,O
in,O,O
idiopathic,O,O
generalized,O,O
epilepsies,O,O
.,O,O
Five,O,O
patients,O,O
with,O,O
idiopathic,O,B
generalized,O,I
epilepsies,O,I
(,O,O
IGE,O,B
),O,O
treated,O,O
with,O,O
lamotrigine,B,B
(,O,O
LTG,B,B
),O,O
experienced,O,O
exacerbation,O,O
or,O,O
de,O,O
novo,O,O
appearance,O,O
of,O,O
myoclonic,O,B
jerks,O,I
(,O,O
MJ,O,B
),O,O
.,O,O
In,O,O
three,O,O
patients,O,O
",",O,O
LTG,B,B
exacerbated,O,O
MJ,O,B
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
with,O,O
early,O,O
aggravation,O,O
during,O,O
titration,O,O
.,O,O
MJ,O,B
disappeared,O,O
when,O,O
LTG,B,B
dose,O,O
was,O,O
decreased,O,O
by,O,O
25,O,O
to,O,O
50,O,O
%,O,O
.,O,O
In,O,O
two,O,O
patients,O,O
",",O,O
LTG,B,B
exacerbated,O,O
MJ,O,B
in,O,O
a,O,O
delayed,O,O
but,O,O
more,O,O
severe,O,O
manner,O,O
",",O,O
with,O,O
myoclonic,O,B
status,O,O
that,O,O
only,O,O
ceased,O,O
after,O,O
LTG,B,B
withdrawal,O,O
.,O,O
Absence,O,O
of,O,O
acute,O,O
cerebral,O,O
vasoconstriction,O,O
after,O,O
cocaine,B,B
-,O,O
associated,O,O
subarachnoid,O,O
hemorrhage,O,O
.,O,O
INTRODUCTION,O,O
:,O,O
Cocaine,B,B
use,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
neurovascular,O,O
complications,O,O
",",O,O
including,O,O
arterial,O,O
vasoconstriction,O,O
and,O,O
vasculitis,O,O
.,O,O
However,O,O
",",O,O
there,O,O
are,O,O
few,O,O
studies,O,O
of,O,O
angiographic,O,O
effects,O,O
of,O,O
cocaine,B,B
on,O,O
human,O,O
cerebral,O,O
arteries,O,O
.,O,O
Information,O,O
on,O,O
these,O,O
effects,O,O
could,O,O
be,O,O
obtained,O,O
from,O,O
angiograms,O,O
of,O,O
patients,O,O
with,O,O
cocaine,B,B
-,O,O
associated,O,O
subarachnoid,O,O
hemorrhage,O,O
(,O,O
SAH,O,O
),O,O
who,O,O
underwent,O,O
angiography,O,O
shortly,O,O
after,O,O
cocaine,B,B
use,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
screened,O,O
patients,O,O
with,O,O
SAH,O,O
retrospectively,O,O
and,O,O
identified,O,O
those,O,O
with,O,O
positive,O,O
urine,O,O
toxicology,O,O
for,O,O
cocaine,B,B
or,O,O
its,O,O
metabolites,O,O
.,O,O
Quantitative,O,O
arterial,O,B
diameter,O,I
measurements,O,O
from,O,O
angiograms,O,O
of,O,O
these,O,O
patients,O,O
were,O,O
compared,O,O
to,O,O
measurements,O,O
from,O,O
control,O,O
patients,O,O
with,O,O
SAH,O,O
who,O,O
were,O,O
matched,O,O
for,O,O
factors,O,O
known,O,O
to,O,O
influence,O,O
arterial,O,B
diameter,O,I
.,O,O
Qualitative,O,O
comparisons,O,O
of,O,O
small,O,O
artery,O,B
changes,O,O
also,O,O
were,O,O
made,O,O
.,O,O
RESULTS,O,O
:,O,O
Thirteen,O,O
patients,O,O
with,O,O
positive,O,O
cocaine,B,B
toxicology,O,I
were,O,O
compared,O,O
to,O,O
26,O,O
controls,O,O
.,O,O
There,O,O
were,O,O
no,O,O
significant,O,O
differences,O,O
between,O,O
groups,O,O
in,O,O
the,O,O
mean,O,O
diameters,O,O
of,O,O
the,O,O
intradural,O,O
internal,O,B
carotid,O,I
",",O,O
sphenoidal,O,O
segment,O,O
of,O,O
the,O,O
middle,O,B
cerebral,O,I
",",O,O
precommunicating,O,O
segment,O,O
of,O,O
the,O,O
anterior,O,B
cerebral,O,I
",",O,O
or,O,O
basilar,O,B
arteries,O,I
(,O,O
p,O,O
greater,O,O
than,O,O
0,O,O
.,O,O
for,O,O
all,O,O
comparisons,O,O
",",O,O
unpaired,O,O
t,O,O
-,O,O
tests,O,O
.,O,O
There,O,O
also,O,O
were,O,O
no,O,O
significant,O,O
differences,O,O
between,O,O
groups,O,O
when,O,O
expressing,O,O
diameters,O,O
as,O,O
the,O,O
sum,O,O
of,O,O
the,O,O
precommunicating,O,O
segment,O,O
of,O,O
the,O,O
anterior,O,B
cerebral,O,I
+,O,O
sphenoidal,O,O
segment,O,O
of,O,O
the,O,O
middle,O,B
cerebral,O,I
+,O,O
supraclinoid,O,O
internal,O,B
carotid,O,I
artery,O,I
+,O,O
basilar,O,B
artery,O,I
divided,O,O
by,O,O
the,O,O
diameter,O,O
of,O,O
the,O,O
petrous,O,O
internal,O,B
carotid,O,I
artery,O,I
(,O,O
p,O,O
greater,O,O
than,O,O
0,O,O
unpaired,O,O
t,O,O
-,O,O
tests,O,O
.,O,O
Qualitative,O,O
assessments,O,O
showed,O,O
two,O,O
arterial,O,O
irregularities,O,O
in,O,O
the,O,O
distal,O,O
vasculature,O,O
in,O,O
each,O,O
group,O,O
.,O,O
CONCLUSION,O,O
:,O,O
No,O,O
quantitative,O,O
evidence,O,O
for,O,O
narrowing,O,O
of,O,O
large,O,O
cerebral,O,O
arteries,O,O
or,O,O
qualitative,O,O
angiographic,O,O
evidence,O,O
for,O,O
distal,O,O
narrowing,O,O
or,O,O
vasculitis,O,O
could,O,O
be,O,O
found,O,O
in,O,O
patients,O,O
who,O,O
underwent,O,O
angiography,O,O
after,O,O
aneurysmal,O,O
SAH,O,O
associated,O,O
with,O,O
cocaine,B,B
use,O,O
.,O,O
Methamphetamine,B,B
causes,O,O
alterations,O,O
in,O,O
the,O,O
MAP,O,B
kinase,O,I
-,O,I
related,O,I
pathways,O,I
in,O,O
the,O,O
brains,O,O
of,O,O
mice,O,O
that,O,O
display,O,O
increased,O,O
aggressiveness,O,O
.,O,O
Aggressive,O,O
behaviors,O,O
have,O,O
been,O,O
reported,O,O
in,O,O
patients,O,O
who,O,O
suffer,O,O
from,O,O
some,O,O
psychiatric,O,O
disorders,O,O
",",O,O
and,O,O
are,O,O
common,O,O
in,O,O
methamphetamine,B,B
(,O,O
METH,B,B
),O,O
abusers,O,O
.,O,O
Herein,O,O
",",O,O
we,O,O
report,O,O
that,O,O
multiple,O,O
(,O,O
but,O,O
not,O,O
single,O,O
),O,O
injections,O,O
of,O,O
METH,B,B
significantly,O,O
increased,O,O
aggressiveness,O,O
in,O,O
male,O,O
CD,O,O
-,O,O
1,O,O
mice,O,O
.,O,O
This,O,O
increase,O,O
in,O,O
aggressiveness,O,O
was,O,O
not,O,O
secondary,O,O
to,O,O
METH,B,B
-,O,O
induced,O,O
hyperactivity,O,O
.,O,O
Analysis,O,O
of,O,O
protein,O,O
expression,O,O
using,O,O
antibody,O,O
microarrays,O,O
and,O,O
Western,O,O
blotting,O,O
revealed,O,O
differential,O,O
changes,O,O
in,O,O
MAP,O,B
kinase,O,I
-,O,I
related,O,I
pathways,O,I
after,O,O
multiple,O,O
and,O,O
single,O,O
METH,B,B
injections,O,O
.,O,O
There,O,O
were,O,O
statistically,O,O
significant,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
decreases,O,O
in,O,O
MEK1,O,B
",",O,O
Erk2p,O,B
",",O,O
GSK3alpha,O,B
",",O,O
14,O,B
-,O,I
3,O,I
-,O,I
3e,O,I
",",O,O
and,O,O
MEK7,O,B
in,O,O
the,O,O
striata,O,O
of,O,O
mice,O,O
after,O,O
multiple,O,O
injections,O,O
of,O,O
METH,B,B
.,O,O
MEK1,O,B
was,O,O
significantly,O,O
decreased,O,O
also,O,O
after,O,O
a,O,O
single,O,O
injection,O,O
of,O,O
METH,B,B
",",O,O
but,O,O
to,O,O
a,O,O
much,O,O
lesser,O,O
degree,O,O
than,O,O
after,O,O
multiple,O,O
injections,O,O
of,O,O
METH,B,B
.,O,O
In,O,O
the,O,O
frontal,O,O
cortex,O,O
",",O,O
there,O,O
was,O,O
a,O,O
statistically,O,O
significant,O,O
decrease,O,O
in,O,O
GSK3alpha,O,B
after,O,O
multiple,O,O
(,O,O
but,O,O
not,O,O
single,O,O
),O,O
injections,O,O
of,O,O
METH,B,B
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
alterations,O,O
in,O,O
MAP,O,B
kinase,O,I
-,O,I
related,O,I
pathways,O,I
in,O,O
the,O,O
prefronto,O,B
-,O,I
striatal,O,I
circuitries,O,I
might,O,O
be,O,O
involved,O,O
in,O,O
the,O,O
manifestation,O,O
of,O,O
aggressive,O,O
behaviors,O,O
in,O,O
mice,O,O
.,O,O
Amisulpride,B,B
related,O,O
tic,O,B
-,O,I
like,O,I
symptoms,O,I
in,O,O
an,O,O
adolescent,O,O
schizophrenic,O,O
.,O,O
Tic,O,B
disorders,O,I
can,O,O
be,O,O
effectively,O,O
treated,O,O
by,O,O
atypical,O,B
antipsychotics,O,I
such,O,O
as,O,O
risperidone,B,B
",",O,O
olanzapine,B,B
and,O,O
ziprasidone,B,B
.,O,O
However,O,O
",",O,O
there,O,O
are,O,O
two,O,O
case,O,O
reports,O,O
that,O,O
show,O,O
tic,O,B
-,O,I
like,O,I
symptoms,O,O
",",O,O
including,O,O
motor,O,O
and,O,O
phonic,O,O
variants,O,O
",",O,O
occurring,O,O
during,O,O
treatment,O,O
with,O,O
quetiapine,B,B
or,O,O
clozapine,B,B
.,O,O
We,O,O
present,O,O
a,O,O
15,O,O
-,O,O
year,O,O
-,O,O
old,O,O
girl,O,O
schizophrenic,O,O
who,O,O
developed,O,O
frequent,O,O
involuntary,O,O
eye,O,O
-,O,O
blinking,O,O
movements,O,O
after,O,O
5,O,O
months,O,O
of,O,O
amisulpride,B,B
treatment,O,O
(,O,O
1000,O,O
mg,O,O
per,O,O
day,O,O
),O,O
.,O,O
The,O,O
tic,O,O
-,O,O
like,O,O
symptoms,O,O
resolved,O,O
completely,O,O
after,O,O
we,O,O
reduced,O,O
the,O,O
dose,O,O
of,O,O
amisulpride,B,B
down,O,O
to,O,O
800,O,O
mg,O,O
per,O,O
day,O,O
.,O,O
However,O,O
",",O,O
her,O,O
psychosis,O,O
recurred,O,O
after,O,O
the,O,O
dose,O,O
reduction,O,O
.,O,O
We,O,O
then,O,O
placed,O,O
her,O,O
on,O,O
an,O,O
additional,O,O
100,O,O
mg,O,O
per,O,O
day,O,O
of,O,O
quetiapine,B,B
.,O,O
She,O,O
has,O,O
been,O,O
in,O,O
complete,O,O
remission,O,O
under,O,O
the,O,O
combined,O,O
medications,O,O
for,O,O
more,O,O
than,O,O
one,O,O
year,O,O
and,O,O
maintains,O,O
a,O,O
fair,O,O
role,O,O
function,O,O
.,O,O
No,O,O
more,O,O
tic,O,O
-,O,O
like,O,O
symptoms,O,O
or,O,O
other,O,O
side,O,O
effects,O,O
have,O,O
been,O,O
reported,O,O
.,O,O
Together,O,O
with,O,O
previously,O,O
reported,O,O
cases,O,O
",",O,O
our,O,O
patient,O,O
suggests,O,O
that,O,O
tic,O,O
-,O,O
like,O,O
symptoms,O,O
might,O,O
occur,O,O
in,O,O
certain,O,O
vulnerable,O,O
individuals,O,O
during,O,O
treatment,O,O
with,O,O
atypical,O,O
antipsychotics,O,O
such,O,O
as,O,O
quetiapine,B,B
",",O,O
clozapine,B,B
",",O,O
or,O,O
amisulpride,B,B
.,O,O
Chloroquine,B,B
related,O,O
complete,O,O
heart,O,O
block,O,O
with,O,O
blindness,O,O
:,O,O
case,O,O
report,O,O
.,O,O
A,O,O
27,O,O
-,O,O
year,O,O
old,O,O
African,O,O
woman,O,O
with,O,O
history,O,O
of,O,O
regular,O,O
chloroquine,B,B
ingestion,O,O
presented,O,O
with,O,O
progressive,O,O
deterioration,O,O
of,O,O
vision,O,O
",",O,O
easy,O,O
fatiguability,O,O
",",O,O
dyspnoea,O,O
",",O,O
dizziness,O,O
progressing,O,O
to,O,O
syncopal,O,O
attacks,O,O
.,O,O
Ophthalmological,O,O
assessment,O,O
revealed,O,O
features,O,O
of,O,O
chloroquine,B,B
retinopathy,O,O
",",O,O
cardiac,O,O
assessment,O,O
revealed,O,O
features,O,O
of,O,O
heart,O,O
failure,O,O
and,O,O
a,O,O
complete,O,O
heart,O,O
block,O,O
with,O,O
right,O,O
bundle,O,O
branch,O,O
block,O,O
pattern,O,O
.,O,O
The,O,O
heart,O,B
block,O,I
was,O,O
treated,O,O
by,O,O
pacemaker,O,O
insertion,O,O
and,O,O
the,O,O
heart,O,B
failure,O,I
resolved,O,O
spontaneously,O,O
following,O,O
chloroquine,B,B
discontinuation,O,O
.,O,O
She,O,O
however,O,O
remains,O,O
blind,O,O
.,O,O
Effects,O,O
of,O,O
suprofen,B,B
on,O,O
the,O,O
isolated,O,O
perfused,O,O
rat,O,O
kidney,O,O
.,O,O
Although,O,O
suprofen,B,B
has,O,O
been,O,O
associated,O,O
with,O,O
the,O,O
development,O,O
of,O,O
acute,O,O
renal,O,B
failure,O,I
in,O,O
greater,O,O
than,O,O
100,O,O
subjects,O,O
",",O,O
the,O,O
mechanism,O,O
of,O,O
damage,O,O
remains,O,O
unclear,O,O
.,O,O
The,O,O
direct,O,O
nephrotoxic,O,O
effects,O,O
of,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
15,O,O
mg,O,O
of,O,O
suprofen,B,B
were,O,O
compared,O,O
in,O,O
the,O,O
recirculating,O,O
isolated,O,O
rat,O,O
kidney,O,O
perfused,O,O
with,O,O
cell,O,O
-,O,O
free,O,O
buffer,O,O
with,O,O
or,O,O
without,O,O
the,O,O
addition,O,O
of,O,O
5,O,O
mg,O,O
/,O,O
dL,O,O
of,O,O
uric,B,B
acid,I,I
.,O,O
There,O,O
were,O,O
no,O,O
significant,O,O
differences,O,O
in,O,O
renal,O,O
sodium,B,O
excretion,O,O
",",O,O
oxygen,B,O
consumption,O,O
",",O,O
or,O,O
urinary,O,O
flow,O,O
rates,O,O
in,O,O
kidneys,O,O
perfused,O,O
with,O,O
suprofen,B,B
compared,O,O
with,O,O
the,O,O
drug,O,O
-,O,O
free,O,O
control,O,O
groups,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
significant,O,O
decline,O,O
in,O,O
glomerular,O,B
filtration,O,I
rate,O,I
was,O,O
found,O,O
after,O,O
the,O,O
introduction,O,O
of,O,O
suprofen,B,B
to,O,O
the,O,O
kidney,O,B
perfused,O,O
with,O,O
uric,B,B
acid,I,I
;,O,O
no,O,O
changes,O,O
were,O,O
found,O,O
with,O,O
suprofen,B,B
in,O,O
the,O,O
absence,O,O
of,O,O
uric,B,B
acid,I,I
.,O,O
A,O,O
significant,O,O
decrease,O,O
in,O,O
the,O,O
baseline,O,O
excretion,O,O
rate,O,O
of,O,O
uric,B,B
acid,I,I
was,O,O
found,O,O
in,O,O
rats,O,O
given,O,O
suprofen,B,B
",",O,O
compared,O,O
with,O,O
drug,O,O
-,O,O
free,O,O
controls,O,O
.,O,O
However,O,O
",",O,O
the,O,O
fractional,O,O
excretion,O,O
of,O,O
uric,B,B
acid,I,I
was,O,O
unchanged,O,O
between,O,O
the,O,O
groups,O,O
over,O,O
the,O,O
experimental,O,O
period,O,O
.,O,O
In,O,O
summary,O,O
",",O,O
suprofen,B,O
causes,O,O
acute,O,O
declines,O,O
in,O,O
renal,O,O
function,O,O
",",O,O
most,O,O
likely,O,O
by,O,O
directly,O,O
altering,O,O
the,O,O
intrarenal,O,O
distribution,O,O
of,O,O
uric,B,B
acid,I,I
.,O,O
Microinjection,O,O
of,O,O
ritanserin,B,O
into,O,O
the,O,O
CA1,O,O
region,O,O
of,O,O
hippocampus,O,O
improves,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
in,O,O
adult,O,O
male,O,O
rats,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
ritanserin,B,B
(,O,O
5,O,O
-,O,O
HT2,O,B
antagonist,O,O
),O,O
on,O,O
scopolamine,B,B
(,O,O
muscarinic,O,B
cholinergic,O,I
antagonist,O,O
),O,O
-,O,O
induced,O,O
amnesia,O,O
in,O,O
Morris,O,O
water,O,O
maze,O,O
(,O,O
MWM,O,O
),O,O
was,O,O
investigated,O,O
.,O,O
Rats,O,O
were,O,O
divided,O,O
into,O,O
eight,O,O
groups,O,O
and,O,O
bilaterally,O,O
cannulated,O,O
into,O,O
CA1,O,O
region,O,O
of,O,O
the,O,O
hippocampus,O,O
.,O,O
One,O,O
week,O,O
later,O,O
",",O,O
they,O,O
received,O,O
repeatedly,O,O
vehicles,O,O
(,O,O
saline,O,B
",",O,O
DMSO,B,B
",",O,O
saline,O,B
+,O,O
DMSO,B,B
),O,O
",",O,O
scopolamine,B,B
(,O,O
2,O,O
microg,O,O
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,O
saline,O,B
/,O,O
side,O,O
;,O,O
30,O,O
min,O,O
before,O,O
training,O,O
),O,O
",",O,O
ritanserin,B,B
(,O,O
2,O,O
",",O,O
4,O,O
and,O,O
8,O,O
microg,O,O
/,O,O
0,O,O
.,O,O
5,O,O
DMSO,B,B
20,O,O
min,O,B
0,O,O
ritanserin,B,O
injection,O,O
+,O,O
4,O,O
DMSO,B,B
through,O,O
cannulae,O,O
each,O,O
day,O,O
Animals,O,O
were,O,O
tested,O,O
for,O,O
four,O,O
consecutive,O,O
days,O,O
(,O,O
4,O,O
trial,O,O
/,O,O
day,O,O
),O,O
in,O,O
MWM,O,O
during,O,O
which,O,O
the,O,O
position,O,O
of,O,O
hidden,O,O
platform,O,O
was,O,O
unchanged,O,O
In,O,O
the,O,O
fifth,O,O
day,O,O
",",O,O
the,O,O
platform,O,O
was,O,O
elevated,O,O
above,O,O
the,O,O
water,O,O
surface,O,O
in,O,O
another,O,O
position,O,O
to,O,O
evaluate,O,O
the,O,O
function,O,O
of,O,O
motor,O,O
",",O,O
motivational,O,O
and,O,O
visual,O,O
systems,O,O
.,O,O
The,O,O
results,O,O
showed,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
escape,O,O
latencies,O,O
and,O,O
traveled,O,O
distances,O,O
to,O,O
find,O,O
platform,O,O
in,O,O
scopolamine,B,B
-,O,I
treated,O,I
group,O,O
as,O,O
compared,O,O
to,O,O
saline,O,B
group,O,O
.,O,O
Ritanserin,B,B
-,O,O
treated,O,O
rats,O,O
(,O,O
4,O,B
microg,O,I
/,O,I
0,O,I
.,O,I
5,O,I
microl,O,I
/,O,I
side,O,I
),O,O
showed,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
the,O,O
mentioned,O,O
parameters,O,O
as,O,O
compared,O,O
to,O,O
DMSO,B,B
-,O,O
treated,O,O
group,O,O
.,O,O
However,O,O
",",O,O
scopolamine,B,B
and,O,O
ritanserin,B,B
co,O,O
-,O,O
administration,O,O
resulted,O,O
in,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
escape,O,O
latencies,O,O
and,O,O
traveled,O,O
distances,O,O
as,O,O
compared,O,O
to,O,O
the,O,O
scopolamine,B,B
-,O,O
treated,O,O
rats,O,O
.,O,O
Our,O,O
findings,O,O
show,O,O
that,O,O
microinjection,O,O
of,O,O
ritanserin,B,B
into,O,O
the,O,O
CA1,O,B
region,O,O
of,O,O
the,O,O
hippocampus,O,O
improves,O,O
the,O,O
scopolamine,B,B
-,O,I
induced,O,I
amnesia,O,I
.,O,O
PTU,B,B
-,O,I
associated,O,I
vasculitis,O,I
in,O,O
a,O,O
girl,O,O
with,O,O
Turner,O,B
Syndrome,O,I
and,O,O
Graves,O,B
',O,I
disease,O,I
.,O,O
Palpable,O,O
purpura,O,O
is,O,O
a,O,O
concerning,O,O
clinical,O,O
finding,O,O
in,O,O
pediatric,O,O
patients,O,O
and,O,O
can,O,O
have,O,O
many,O,O
causes,O,O
",",O,O
including,O,O
infectious,O,O
and,O,O
autoimmune,O,O
processes,O,O
.,O,O
A,O,O
rare,O,O
cause,O,O
",",O,O
drug,O,B
-,O,O
induced,O,O
vasculitis,O,O
",",O,O
may,O,O
result,O,O
from,O,O
the,O,O
production,O,O
of,O,O
antineutrophil,O,B
cytoplasmic,O,I
antibodies,O,I
(,O,O
ANCAs,O,B
),O,O
in,O,O
response,O,O
to,O,O
a,O,O
medication,O,O
.,O,O
We,O,O
report,O,O
a,O,O
girl,O,O
with,O,O
Turner,O,O
syndrome,O,O
and,O,O
Graves,O,O
',O,O
disease,O,O
who,O,O
presented,O,O
with,O,O
palpable,O,O
purpuric,O,O
lesions,O,O
.,O,O
The,O,O
diagnosis,O,O
of,O,O
propylthiouracil,B,B
(,O,O
PTU,B,B
),O,O
-,O,O
associated,O,O
vasculitis,O,O
was,O,O
made,O,O
by,O,O
observation,O,O
of,O,O
consistent,O,O
clinical,O,O
features,O,O
",",O,O
the,O,O
detection,O,O
of,O,O
elevated,O,O
ANA,O,B
and,O,O
ANCA,O,B
in,O,O
the,O,O
blood,O,O
",",O,O
and,O,O
the,O,O
observed,O,O
clinical,O,O
resolution,O,O
of,O,O
symptoms,O,O
following,O,O
withdrawal,O,O
of,O,O
PTU,B,B
.,O,O
Subsequent,O,O
treatment,O,O
of,O,O
persistent,O,O
hyperthyroidism,O,B
with,O,O
radioablation,O,O
did,O,O
not,O,O
result,O,O
in,O,O
an,O,O
exacerbation,O,O
of,O,O
the,O,O
vasculitis,O,B
",",O,O
a,O,O
complication,O,O
described,O,O
in,O,O
prior,O,O
case,O,O
reports,O,O
.,O,O
Daidzein,B,B
activates,O,O
choline,B,B
acetyltransferase,O,I
from,O,O
MC,O,B
-,O,I
IXC,O,I
cells,O,O
and,O,O
improves,O,O
drug,O,O
-,O,O
induced,O,O
amnesia,O,O
.,O,O
The,O,O
choline,B,B
acetyltransferase,O,I
(,O,O
ChAT,O,B
),O,O
activator,O,O
",",O,O
which,O,O
enhances,O,O
cholinergic,O,O
transmission,O,O
via,O,O
an,O,O
augmentation,O,O
of,O,O
the,O,O
enzymatic,O,O
production,O,O
of,O,O
acetylcholine,B,B
(,O,O
ACh,B,B
),O,O
",",O,O
is,O,O
an,O,O
important,O,O
factor,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
Alzheimer,O,B
',O,O
s,O,O
disease,O,O
(,O,O
AD,O,B
),O,O
.,O,O
Methanolic,O,B
extracts,O,O
from,O,O
Pueraria,O,B
thunbergiana,O,I
exhibited,O,O
an,O,O
activation,O,O
effect,O,O
(,O,O
46,O,O
%,O,O
),O,O
on,O,O
ChAT,O,B
in,O,O
vitro,O,O
.,O,O
Via,O,O
the,O,O
sequential,O,O
isolation,O,O
of,O,O
Pueraria,O,B
thunbergiana,O,I
",",O,O
the,O,O
active,O,O
component,O,O
was,O,O
ultimately,O,O
identified,O,O
as,O,O
daidzein,B,B
(,O,O
4,B,O
',I,O
",",I,O
7,I,O
-,I,O
dihydroxy,I,O
-,I,O
isoflavone,I,O
),O,O
.,O,O
In,O,O
order,O,O
to,O,O
investigate,O,O
the,O,O
effects,O,O
of,O,O
daidzein,B,B
from,O,O
Pueraria,O,B
thunbergiana,O,I
on,O,O
scopolamine,B,B
-,O,O
induced,O,O
impairments,O,O
of,O,O
learning,O,O
and,O,O
memory,O,O
",",O,O
we,O,O
conducted,O,O
a,O,O
series,O,O
of,O,O
in,O,O
vivo,O,O
tests,O,O
.,O,O
Administration,O,O
of,O,O
daidzein,B,B
(,O,O
4,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
),O,O
to,O,O
mice,O,O
was,O,O
shown,O,O
significantly,O,O
to,O,O
reverse,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
",",O,O
according,O,O
to,O,O
the,O,O
results,O,O
of,O,O
a,O,O
Y,O,O
-,O,O
maze,O,O
test,O,O
.,O,O
Injections,O,O
of,O,O
scopolamine,B,B
into,O,O
mice,O,O
resulted,O,O
in,O,O
impaired,O,O
performance,O,O
on,O,O
Y,O,O
-,O,O
maze,O,O
tests,O,O
(,O,O
a,O,O
37,O,O
%,O,O
decreases,O,O
in,O,O
alternation,O,O
behavior,O,O
),O,O
.,O,O
By,O,O
way,O,O
of,O,O
contrast,O,O
",",O,O
mice,O,O
treated,O,O
with,O,O
daidzein,B,B
prior,O,O
to,O,O
the,O,O
scopolamine,B,B
injections,O,O
were,O,O
noticeably,O,O
protected,O,O
from,O,O
this,O,O
performance,O,O
impairment,O,O
(,O,O
an,O,O
approximately,O,O
12,O,O
%,O,O
-,O,O
21,O,O
%,O,O
decrease,O,O
in,O,O
alternation,O,O
behavior,O,O
),O,O
.,O,O
These,O,O
results,O,O
indicate,O,O
that,O,O
daidzein,B,B
might,O,O
play,O,O
a,O,O
role,O,O
in,O,O
acetylcholine,B,B
biosynthesis,O,O
as,O,O
a,O,O
ChAT,O,B
activator,O,O
",",O,O
and,O,O
that,O,O
it,O,O
also,O,O
ameliorates,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
.,O,O
Urinary,O,O
symptoms,O,O
and,O,O
quality,O,O
of,O,O
life,O,O
changes,O,O
in,O,O
Thai,O,O
women,O,O
with,O,O
overactive,O,O
bladder,O,O
after,O,O
tolterodine,B,B
treatment,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
study,O,O
the,O,O
urinary,O,O
symptoms,O,O
and,O,O
quality,O,O
of,O,O
life,O,O
changes,O,O
in,O,O
Thai,O,O
women,O,O
with,O,O
overactive,O,O
bladder,O,O
(,O,O
OAB,O,B
),O,O
after,O,O
tolterodine,B,B
treatment,O,O
.,O,O
MATERIAL,O,O
AND,O,O
METHOD,O,O
:,O,O
Thirty,O,O
women,O,O
(,O,O
aged,O,O
30,O,O
-,O,O
77,O,O
years,O,O
),O,O
diagnosed,O,O
as,O,O
having,O,O
OAB,O,B
at,O,O
the,O,O
Gynecology,O,O
Clinic,O,O
",",O,O
King,O,O
Chulalongkorn,O,O
Memorial,O,O
Hospital,O,O
from,O,O
January,O,O
to,O,O
April,O,O
2004,O,O
were,O,O
included,O,O
in,O,O
the,O,O
present,O,O
study,O,O
.,O,O
Tolterodine,B,B
2,O,O
mg,O,O
",",O,O
twice,O,O
daily,O,O
was,O,O
given,O,O
.,O,O
After,O,O
8,O,O
weeks,O,O
treatment,O,O
",",O,O
changes,O,O
in,O,O
micturition,O,O
diary,O,O
variables,O,O
and,O,O
tolerability,O,O
were,O,O
determined,O,O
.,O,O
Short,O,O
form,O,O
36,O,O
(,O,O
SF36,O,B
),O,O
questionaires,O,O
(,O,O
Thai,O,O
version,O,O
),O,O
were,O,O
given,O,O
before,O,O
and,O,O
after,O,O
8,O,O
weeks,O,O
of,O,O
treatment,O,O
.,O,O
RESULTS,O,O
:,O,O
At,O,O
8,O,O
weeks,O,O
",",O,O
all,O,O
micturition,O,O
per,O,O
day,O,O
decreased,O,O
from,O,O
16,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
5,O,O
.,O,O
3,O,O
to,O,O
6,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
4,O,O
times,O,O
per,O,O
day,O,O
.,O,O
The,O,O
number,O,O
of,O,O
nocturia,O,O
episodes,O,O
decreased,O,O
from,O,O
5,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
2,O,O
to,O,O
1,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
0,O,O
times,O,O
per,O,O
night,O,O
.,O,O
The,O,O
most,O,O
common,O,O
side,O,O
effect,O,O
was,O,O
dry,O,B
month,O,I
in,O,O
5,O,O
cases,O,O
(,O,O
16,O,O
.,O,O
7,O,O
%,O,O
),O,O
with,O,O
2,O,O
cases,O,O
reporting,O,O
a,O,O
moderate,O,O
degree,O,O
and,O,O
1,O,O
case,O,O
with,O,O
severe,O,O
degree,O,O
.,O,O
Only,O,O
one,O,O
case,O,O
(,O,O
3,O,O
.,O,O
3,O,O
%,O,O
),O,O
withdrew,O,O
from,O,O
the,O,O
present,O,O
study,O,O
due,O,O
to,O,O
a,O,O
severe,O,O
dry,O,O
mouth,O,O
.,O,O
The,O,O
SF,O,O
-,O,O
36,O,O
scores,O,O
changed,O,O
significantly,O,O
in,O,O
the,O,O
domains,O,O
of,O,O
physical,O,O
functioning,O,O
",",O,O
role,O,O
function,O,O
emotional,O,O
",",O,O
social,O,O
function,O,O
and,O,O
mental,O,O
heath,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Tolterodine,B,B
was,O,O
well,O,O
tolerated,O,O
and,O,O
its,O,O
effects,O,O
improved,O,O
the,O,O
quality,O,O
of,O,O
life,O,O
in,O,O
Thai,O,O
women,O,O
with,O,O
OAB,O,B
.,O,O
Remifentanil,B,B
pretreatment,O,O
reduces,O,O
myoclonus,O,O
after,O,O
etomidate,B,B
.,O,O
STUDY,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
compare,O,O
the,O,O
effect,O,O
of,O,O
pretreatment,O,O
with,O,O
remifentanil,B,B
1,O,O
microg,O,O
/,O,O
kg,O,O
and,O,O
the,O,O
effect,O,O
of,O,O
gender,O,O
on,O,O
the,O,O
incidence,O,O
of,O,O
myoclonus,O,O
after,O,O
anesthesia,O,O
induction,O,O
with,O,O
etomidate,B,B
.,O,O
DESIGN,O,O
:,O,O
This,O,O
was,O,O
a,O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
study,O,O
.,O,O
SETTING,O,O
:,O,O
The,O,O
study,O,O
was,O,O
conducted,O,O
at,O,O
a,O,O
university,O,O
hospital,O,O
.,O,O
PATIENTS,O,O
:,O,O
Sixty,O,O
patients,O,O
were,O,O
pretreated,O,O
in,O,O
a,O,O
randomized,O,O
double,O,O
-,O,O
blinded,O,O
fashion,O,O
with,O,O
remifentanil,B,B
1,O,O
microg,O,O
/,O,O
kg,O,O
or,O,O
placebo,O,B
.,O,O
Two,O,O
minutes,O,O
after,O,O
remifentanil,B,B
or,O,O
placebo,O,B
injection,O,O
",",O,O
etomidate,B,B
0,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
was,O,O
given,O,O
.,O,O
MEASUREMENTS,O,O
:,O,O
Myoclonus,O,O
was,O,O
recorded,O,O
with,O,O
a,O,O
scale,O,O
of,O,O
0,O,O
to,O,O
3,O,O
.,O,O
The,O,O
grade,O,O
of,O,O
sedation,O,O
(,O,O
none,O,O
",",O,O
mild,O,O
",",O,O
moderate,O,O
",",O,O
severe,O,O
),O,O
",",O,O
nausea,O,O
",",O,O
pruritus,O,O
",",O,O
and,O,O
apnea,O,O
were,O,O
recorded,O,O
after,O,O
injection,O,O
of,O,O
both,O,O
drugs,O,O
.,O,O
MAIN,O,O
RESULTS,O,O
:,O,O
The,O,O
incidence,O,O
of,O,O
myoclonus,O,O
was,O,O
significantly,O,O
lower,O,O
in,O,O
the,O,O
remifentanil,B,B
group,O,O
(,O,O
6,O,O
.,O,O
7,O,O
%,O,O
),O,O
than,O,O
in,O,O
the,O,O
placebo,O,B
group,O,O
(,O,O
70,O,O
%,O,O
),O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
None,O,O
of,O,O
the,O,O
patients,O,O
experienced,O,O
sedation,O,O
",",O,O
apnea,O,O
",",O,O
nausea,O,O
",",O,O
or,O,O
pruritus,O,O
after,O,O
injection,O,O
of,O,O
both,O,O
drugs,O,O
.,O,O
In,O,O
the,O,O
placebo,O,O
group,O,O
",",O,O
male,O,O
patients,O,O
were,O,O
associated,O,O
with,O,O
significantly,O,O
increased,O,O
incidence,O,O
of,O,O
myoclonus,O,B
after,O,O
etomidate,B,O
administration,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Pretreatment,O,O
with,O,O
remifentanil,B,B
1,O,O
microg,O,O
/,O,O
kg,O,O
reduced,O,O
myoclonus,O,B
after,O,O
etomidate,B,O
induction,O,O
without,O,O
side,O,O
effects,O,O
such,O,O
as,O,O
sedation,O,O
",",O,O
apnea,O,B
",",O,O
nausea,O,B
",",O,O
or,O,O
pruritus,O,B
.,O,O
Men,O,O
experience,O,O
increased,O,O
incidence,O,O
of,O,O
myoclonus,O,B
than,O,O
women,O,O
after,O,O
etomidate,B,O
administration,O,O
.,O,O
Memory,O,O
function,O,O
and,O,O
serotonin,B,B
transporter,O,O
promoter,O,O
gene,O,O
polymorphism,O,O
in,O,O
ecstasy,B,B
(,O,O
MDMA,B,I
),O,O
users,O,O
.,O,O
Although,O,O
3,B,O
",",I,O
4,I,B
-,I,I
methylenedioxymethamphetamine,I,I
(,O,O
MDMA,B,I
or,O,O
ecstasy,B,I
),O,O
has,O,O
been,O,O
shown,O,O
to,O,O
damage,O,O
brain,O,O
serotonin,B,B
(,O,O
5,B,B
-,I,I
HT,I,I
),O,O
neurons,O,O
in,O,O
animals,O,O
and,O,O
possibly,O,O
humans,O,O
",",O,O
little,O,O
is,O,O
known,O,O
about,O,O
the,O,O
long,O,O
-,O,O
term,O,O
consequences,O,O
of,O,O
MDMA,B,B
-,O,O
induced,O,O
5,B,B
-,I,I
HT,I,I
neurotoxic,O,I
lesions,O,O
on,O,O
functions,O,O
in,O,O
which,O,O
5,B,B
-,I,I
HT,I,I
is,O,O
involved,O,O
",",O,O
such,O,O
as,O,O
cognitive,O,O
function,O,O
.,O,O
Because,O,O
5,B,B
-,I,I
HT,I,I
transporters,O,O
play,O,O
a,O,O
key,O,O
element,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
synaptic,O,O
5,B,B
-,I,I
HT,I,I
transmission,O,O
it,O,O
may,O,O
be,O,O
important,O,O
to,O,O
control,O,O
for,O,O
the,O,O
potential,O,O
covariance,O,O
effect,O,O
of,O,O
a,O,O
polymorphism,O,O
in,O,O
the,O,O
5,B,B
-,I,I
HT,I,I
transporter,O,O
promoter,O,O
gene,O,O
region,O,O
(,O,O
5,O,B
-,O,I
HTTLPR,O,I
),O,O
when,O,O
studying,O,O
the,O,O
effects,O,O
of,O,O
MDMA,B,B
as,O,O
well,O,O
as,O,O
cognitive,O,O
functioning,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
investigate,O,O
the,O,O
effects,O,O
of,O,O
moderate,O,O
and,O,O
heavy,O,O
MDMA,B,B
use,O,O
on,O,O
cognitive,O,O
function,O,O
",",O,O
as,O,O
well,O,O
as,O,O
the,O,O
effects,O,O
of,O,O
long,O,O
-,O,O
term,O,O
abstention,O,O
from,O,O
MDMA,B,B
",",O,O
in,O,O
subjects,O,O
genotyped,O,O
for,O,O
5,O,O
-,O,O
HTTLPR,O,B
.,O,O
A,O,O
second,O,O
aim,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
whether,O,O
these,O,O
effects,O,O
differ,O,O
for,O,O
females,O,O
and,O,O
males,O,O
.,O,O
Fifteen,O,O
moderate,O,O
MDMA,B,B
users,O,O
(,O,O
<,O,O
55,O,O
lifetime,O,O
tablets,O,O
),O,O
",",O,O
22,O,O
heavy,O,O
MDMA,B,B
+,O,O
users,O,O
(,O,O
>,O,O
55,O,O
lifetime,O,O
tablets,O,O
),O,O
",",O,O
16,O,O
ex,O,O
-,O,O
MDMA,B,B
+,O,O
users,O,O
(,O,O
last,O,O
tablet,O,O
>,O,O
1,O,O
year,O,O
ago,O,O
),O,O
and,O,O
13,O,O
controls,O,O
were,O,O
compared,O,O
on,O,O
a,O,O
battery,O,O
of,O,O
neuropsychological,O,O
tests,O,O
.,O,O
DNA,O,B
from,O,O
peripheral,O,O
nuclear,O,O
blood,O,O
cells,O,O
was,O,O
genotyped,O,O
for,O,O
5,O,B
-,O,I
HTTLPR,O,I
using,O,O
standard,O,O
polymerase,O,O
chain,O,O
reaction,O,O
methods,O,O
.,O,O
A,O,O
significant,O,O
group,O,O
effect,O,O
was,O,O
observed,O,O
only,O,O
on,O,O
memory,O,B
function,O,I
tasks,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
but,O,O
not,O,O
on,O,O
reaction,O,O
times,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
61,O,O
),O,O
or,O,O
attention,O,O
/,O,O
executive,O,O
functioning,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
59,O,O
),O,O
.,O,O
Heavy,O,O
and,O,O
ex,O,B
-,O,I
MDMA,B,I
+,O,I
users,O,O
performed,O,O
significantly,O,O
poorer,O,O
on,O,O
memory,O,B
tasks,O,O
than,O,O
controls,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
no,O,O
evidence,O,O
of,O,O
memory,O,B
impairment,O,I
was,O,O
observed,O,O
in,O,O
moderate,O,O
MDMA,B,B
users,O,O
.,O,O
No,O,O
significant,O,O
effect,O,O
of,O,O
5,O,B
-,O,I
HTTLPR,O,I
or,O,O
gender,O,O
was,O,O
observed,O,O
.,O,O
While,O,O
the,O,O
use,O,O
of,O,O
MDMA,B,B
in,O,O
quantities,O,O
that,O,O
may,O,O
be,O,O
considered,O,O
is,O,O
not,O,O
associated,O,O
with,O,O
impaired,O,O
memory,O,O
functioning,O,O
",",O,O
heavy,O,O
use,O,O
of,O,O
MDMA,B,B
use,O,O
may,O,O
lead,O,O
to,O,O
long,O,O
lasting,O,O
memory,O,O
impairments,O,O
.,O,O
No,O,O
effect,O,O
of,O,O
5,O,B
-,O,I
HTTLPR,O,I
or,O,O
gender,O,O
on,O,O
memory,O,O
function,O,O
or,O,O
MDMA,B,B
use,O,O
was,O,O
observed,O,O
.,O,O
Role,O,O
of,O,O
mangiferin,B,B
on,O,O
biochemical,O,O
alterations,O,O
and,O,O
antioxidant,O,O
status,O,O
in,O,O
isoproterenol,B,B
-,O,O
induced,O,O
myocardial,O,O
infarction,O,O
in,O,O
rats,O,O
.,O,O
The,O,O
current,O,O
study,O,O
dealt,O,O
with,O,O
the,O,O
protective,O,O
role,O,O
of,O,O
mangiferin,B,B
",",O,O
a,O,O
polyphenol,B,O
from,O,O
Mangifera,O,B
indica,O,I
Linn,O,I
.,O,O
(,O,O
Anacardiaceae,O,B
),O,O
",",O,O
on,O,O
isoproterenol,B,B
(,O,O
ISPH,B,B
),O,O
-,O,O
induced,O,O
myocardial,O,O
infarction,O,O
(,O,O
MI,O,B
),O,O
in,O,O
rats,O,O
through,O,O
its,O,O
antioxidative,O,O
mechanism,O,O
.,O,O
Subcutaneous,O,O
injection,O,O
of,O,O
ISPH,B,B
(,O,O
200,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
in,O,O
1,O,O
ml,O,O
saline,O,O
),O,O
to,O,O
rats,O,O
for,O,O
2,O,O
consecutive,O,O
days,O,O
caused,O,O
myocardial,O,O
damage,O,O
in,O,O
rat,O,O
heart,O,O
",",O,O
which,O,O
was,O,O
determined,O,O
by,O,O
the,O,O
increased,O,O
activity,O,O
of,O,O
serum,O,O
lactate,B,B
dehydrogenase,O,I
(,O,O
LDH,O,B
),O,O
and,O,O
creatine,B,B
phosphokinase,O,I
isoenzymes,O,I
(,O,O
CK,O,B
-,O,I
MB,O,I
),O,O
",",O,O
increased,O,O
uric,B,B
acid,I,I
level,O,I
and,O,O
reduced,O,O
plasma,O,O
iron,B,B
binding,O,I
capacity,O,I
.,O,O
The,O,O
protective,O,O
role,O,O
of,O,O
mangiferin,B,B
was,O,O
analyzed,O,O
by,O,O
triphenyl,B,B
tetrazolium,I,I
chloride,I,I
(,O,O
TTC,B,B
),O,O
test,O,O
used,O,O
for,O,O
macroscopic,O,O
enzyme,O,O
mapping,O,O
assay,O,O
of,O,O
the,O,O
ischemic,O,O
myocardium,O,O
.,O,O
The,O,O
heart,O,O
tissue,O,O
antioxidant,O,O
enzymes,O,O
such,O,O
as,O,O
superoxide,B,B
dismutase,O,I
",",O,O
catalase,O,B
",",O,O
glutathione,B,B
peroxidase,O,I
",",O,O
glutathione,B,B
transferase,O,I
and,O,O
glutathione,B,B
reductase,O,I
activities,O,O
",",O,O
non,O,O
-,O,O
enzymic,O,O
antioxidants,O,O
such,O,O
as,O,O
cerruloplasmin,O,B
",",O,O
Vitamin,B,B
C,I,I
",",O,O
Vitamin,B,B
E,I,I
and,O,O
glutathione,B,B
levels,O,O
were,O,O
altered,O,O
in,O,O
MI,O,O
rats,O,O
.,O,O
Upon,O,O
pretreatment,O,O
with,O,O
mangiferin,B,B
(,O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
suspended,O,O
in,O,O
2,O,O
ml,O,O
of,O,O
dimethyl,B,B
sulphoxide,I,I
),O,O
given,O,O
intraperitoneally,O,O
for,O,O
28,O,O
days,O,O
to,O,O
MI,O,O
rats,O,O
protected,O,O
the,O,O
above,O,O
-,O,O
mentioned,O,O
parameters,O,O
to,O,O
fall,O,O
from,O,O
the,O,O
normal,O,O
levels,O,O
.,O,O
Activities,O,O
of,O,O
heart,O,O
tissue,O,O
enzymic,O,O
antioxidants,O,O
and,O,O
serum,O,O
non,O,O
-,O,O
enzymic,O,O
antioxidants,O,O
levels,O,O
rose,O,O
significantly,O,O
upon,O,O
mangiferin,B,B
administration,O,O
as,O,O
compared,O,O
to,O,O
ISPH,B,O
-,O,O
induced,O,O
MI,O,O
rats,O,O
.,O,O
From,O,O
the,O,O
present,O,O
study,O,O
it,O,O
is,O,O
concluded,O,O
that,O,O
mangiferin,B,B
exerts,O,O
a,O,O
beneficial,O,O
effect,O,O
against,O,O
ISPH,B,B
-,O,O
induced,O,O
MI,O,O
due,O,O
to,O,O
its,O,O
antioxidant,O,O
potential,O,O
",",O,O
which,O,O
regulated,O,O
the,O,O
tissues,O,O
defense,O,O
system,O,O
against,O,O
cardiac,O,O
damage,O,O
.,O,O
Cardiovascular,O,O
risk,O,O
with,O,O
cyclooxygenase,B,B
inhibitors,I,O
:,O,O
general,O,O
problem,O,O
with,O,O
substance,O,O
specific,O,O
differences,O,O
?,O,O
Randomised,O,O
clinical,O,O
trials,O,O
and,O,O
observational,O,O
studies,O,O
have,O,O
shown,O,O
an,O,O
increased,O,O
risk,O,O
of,O,O
myocardial,O,O
infarction,O,O
",",O,O
stroke,O,O
",",O,O
hypertension,O,O
and,O,O
heart,O,O
failure,O,O
during,O,O
treatment,O,O
with,O,O
cyclooxygenase,B,B
inhibitors,I,O
.,O,O
Adverse,O,O
cardiovascular,O,B
effects,O,I
occurred,O,O
mainly,O,O
",",O,O
but,O,O
not,O,O
exclusively,O,O
",",O,O
in,O,O
patients,O,O
with,O,O
concomitant,O,O
risk,O,O
factors,O,O
.,O,O
Cyclooxygenase,B,B
inhibitors,I,I
cause,O,O
complex,O,O
changes,O,O
in,O,O
renal,O,B
",",O,O
vascular,O,B
and,O,O
cardiac,O,B
prostanoid,O,I
profiles,O,I
thereby,O,O
increasing,O,O
vascular,O,B
resistance,O,I
and,O,O
fluid,O,O
retention,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
cardiovascular,O,B
adverse,O,I
events,O,I
tends,O,O
to,O,O
increase,O,O
with,O,O
the,O,O
daily,O,O
dose,O,O
and,O,O
total,O,O
exposure,O,O
time,O,O
.,O,O
A,O,O
comparison,O,O
of,O,O
individual,O,O
selective,O,O
and,O,O
unselective,O,O
cyclooxygenase,B,B
inhibitors,I,O
suggests,O,O
substance,O,O
-,O,O
specific,O,O
differences,O,O
",",O,O
which,O,O
may,O,O
depend,O,O
on,O,O
differences,O,O
in,O,O
pharmacokinetic,O,O
parameters,O,O
or,O,O
inhibitory,O,O
potency,O,O
and,O,O
may,O,O
be,O,O
contributed,O,O
by,O,O
prostaglandin,B,B
-,O,I
independent,O,I
effects,O,O
.,O,O
Diagnostic,O,O
markers,O,O
such,O,O
as,O,O
N,B,B
-,I,I
terminal,I,I
pro,I,I
brain,I,I
natriuretic,I,I
peptide,I,I
(,O,I
NT,B,I
-,I,I
proBNP,I,I
),O,I
or,O,O
high,O,O
-,O,O
sensitive,O,O
C,O,B
-,O,I
reactive,O,I
protein,O,I
might,O,O
help,O,O
in,O,O
the,O,O
early,O,O
identification,O,O
of,O,O
patients,O,O
at,O,O
risk,O,O
",",O,O
thus,O,O
avoiding,O,O
the,O,O
occurrence,O,O
of,O,O
serious,O,O
cardiovascular,O,O
toxicity,O,O
.,O,O
Pilocarpine,B,B
seizures,O,O
cause,O,O
age,O,O
-,O,O
dependent,O,O
impairment,O,O
in,O,O
auditory,O,O
location,O,O
discrimination,O,O
.,O,O
Children,O,O
who,O,O
have,O,O
status,O,O
epilepticus,O,O
have,O,O
continuous,O,O
or,O,O
rapidly,O,O
repeating,O,O
seizures,O,O
that,O,O
may,O,O
be,O,O
life,O,O
-,O,O
threatening,O,O
and,O,O
may,O,O
cause,O,O
life,O,O
-,O,O
long,O,O
changes,O,O
in,O,O
brain,O,O
and,O,O
behavior,O,O
.,O,O
The,O,O
extent,O,O
to,O,O
which,O,O
status,O,O
epilepticus,O,O
causes,O,O
deficits,O,O
in,O,O
auditory,O,O
discrimination,O,O
is,O,O
unknown,O,O
.,O,O
A,O,O
naturalistic,O,O
auditory,O,O
location,O,O
discrimination,O,O
method,O,O
was,O,O
used,O,O
to,O,O
evaluate,O,O
this,O,O
question,O,O
using,O,O
an,O,O
animal,O,O
model,O,O
of,O,O
status,O,O
epilepticus,O,O
.,O,O
Male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
injected,O,O
with,O,O
saline,O,B
on,O,O
postnatal,O,O
day,O,O
(,O,O
P,O,B
),O,O
20,O,O
",",O,O
or,O,O
a,O,O
convulsant,O,O
dose,O,O
of,O,O
pilocarpine,B,B
on,O,O
P20,O,O
or,O,O
P45,O,O
.,O,O
Pilocarpine,B,B
on,O,O
either,O,O
day,O,O
induced,O,O
status,O,O
epilepticus,O,O
;,O,O
status,O,O
epilepticus,O,O
at,O,O
P45,O,O
resulted,O,O
in,O,O
CA3,O,B
cell,O,O
loss,O,O
and,O,O
spontaneous,O,O
seizures,O,O
",",O,O
whereas,O,O
P20,O,O
rats,O,O
had,O,O
no,O,O
cell,O,O
loss,O,O
or,O,O
spontaneous,O,O
seizures,O,O
.,O,O
Mature,O,O
rats,O,O
were,O,O
trained,O,O
with,O,O
sound,O,B
-,O,O
source,O,I
location,O,I
and,O,O
sound,O,B
-,O,O
silence,O,I
discriminations,O,O
.,O,O
Control,O,O
(,O,O
saline,O,B
P20,O,I
),O,O
rats,O,O
acquired,O,O
both,O,O
discriminations,O,O
immediately,O,O
.,O,O
In,O,O
status,O,O
epilepticus,O,O
(,O,O
P20,O,I
),O,O
rats,O,O
",",O,O
acquisition,O,O
of,O,O
the,O,O
sound,O,B
-,O,O
source,O,I
location,O,I
discrimination,O,O
was,O,O
moderately,O,O
impaired,O,O
.,O,O
Status,O,O
epilepticus,O,O
(,O,O
P45,O,I
),O,O
rats,O,O
failed,O,O
to,O,O
acquire,O,O
either,O,O
sound,O,B
-,O,O
source,O,I
location,O,I
or,O,O
sound,O,B
-,O,O
silence,O,I
discriminations,O,O
.,O,O
Status,O,O
epilepticus,O,O
in,O,O
rat,O,O
causes,O,O
an,O,O
age,O,O
-,O,O
dependent,O,O
",",O,O
long,O,O
-,O,O
term,O,O
impairment,O,O
in,O,O
auditory,O,O
discrimination,O,O
.,O,O
This,O,O
impairment,O,O
may,O,O
explain,O,O
one,O,O
cause,O,O
of,O,O
impaired,O,O
auditory,O,O
location,O,O
discrimination,O,O
in,O,O
humans,O,O
.,O,O
Nerve,O,B
growth,O,I
factor,O,I
and,O,O
prostaglandins,B,B
in,O,O
the,O,O
urine,O,O
of,O,O
female,O,O
patients,O,O
with,O,O
overactive,O,O
bladder,O,O
.,O,O
PURPOSE,O,O
:,O,O
NGF,O,B
and,O,O
PGs,B,B
in,O,O
the,O,O
bladder,O,O
can,O,O
be,O,O
affected,O,O
by,O,O
pathological,O,O
changes,O,O
in,O,O
the,O,O
bladder,O,O
and,O,O
these,O,O
changes,O,O
can,O,O
be,O,O
detected,O,O
in,O,O
urine,O,O
.,O,O
We,O,O
investigated,O,O
changes,O,O
in,O,O
urinary,O,O
NGF,O,B
and,O,O
PGs,B,B
in,O,O
women,O,O
with,O,O
OAB,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
The,O,O
study,O,O
groups,O,O
included,O,O
65,O,O
women,O,O
with,O,O
OAB,O,O
and,O,O
20,O,O
without,O,O
bladder,O,O
symptoms,O,O
who,O,O
served,O,O
as,O,O
controls,O,O
.,O,O
Evaluation,O,O
included,O,O
patient,O,O
history,O,O
",",O,O
urinalysis,O,O
",",O,O
a,O,O
voiding,O,O
diary,O,O
and,O,O
urodynamic,O,O
studies,O,O
.,O,O
Urine,O,O
samples,O,O
were,O,O
collected,O,O
.,O,O
NGF,O,B
",",O,O
PGE2,B,B
",",O,O
PGF2alpha,B,B
and,O,O
PGI2,B,B
were,O,O
measured,O,O
using,O,O
enzyme,O,O
-,O,O
linked,O,O
immunosorbent,O,O
assay,O,O
and,O,O
compared,O,O
between,O,O
the,O,O
groups,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
correlations,O,O
between,O,O
urinary,O,O
NGF,O,B
and,O,O
PG,B,B
",",O,O
and,O,O
urodynamic,O,O
parameters,O,O
in,O,O
patients,O,O
with,O,O
OAB,O,O
were,O,O
examined,O,O
.,O,O
RESULTS,O,O
:,O,O
Urinary,O,O
NGF,O,B
",",O,O
PGE2,B,B
and,O,O
PGF2alpha,B,B
were,O,O
significantly,O,O
increased,O,O
in,O,O
patients,O,O
with,O,O
OAB,O,O
compared,O,O
with,O,O
controls,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
However,O,O
",",O,O
urinary,O,O
PGI2,B,B
was,O,O
not,O,O
different,O,O
between,O,O
controls,O,O
and,O,O
patients,O,O
with,O,O
OAB,O,O
.,O,O
In,O,O
patients,O,O
with,O,O
OAB,O,O
urinary,O,O
PGE2,B,B
positively,O,O
correlated,O,O
with,O,O
volume,O,O
at,O,O
first,O,O
desire,O,O
to,O,O
void,O,O
and,O,O
maximum,O,O
cystometric,O,O
capacity,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Urinary,O,O
NGF,O,B
",",O,O
PGF2alpha,B,B
and,O,O
PGI2,B,B
did,O,O
not,O,O
correlate,O,O
with,O,O
urodynamic,O,O
parameters,O,O
in,O,O
patients,O,O
with,O,O
OAB,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
NGF,O,B
and,O,O
PGs,B,B
have,O,O
important,O,O
roles,O,O
in,O,O
the,O,O
development,O,O
of,O,O
OAB,O,O
symptoms,O,O
in,O,O
female,O,O
patients,O,O
.,O,O
Urinary,O,O
levels,O,O
of,O,O
these,O,O
factors,O,O
may,O,O
be,O,O
used,O,O
as,O,O
markers,O,O
to,O,O
evaluate,O,O
OAB,O,O
symptoms,O,O
.,O,O
Definition,O,O
and,O,O
management,O,O
of,O,O
anemia,O,O
in,O,O
patients,O,O
infected,O,O
with,O,O
hepatitis,O,B
C,O,I
virus,O,I
.,O,O
Chronic,O,O
infection,O,O
with,O,O
hepatitis,O,B
C,O,I
virus,O,I
(,O,O
HCV,O,B
),O,I
can,O,O
progress,O,O
to,O,O
cirrhosis,O,O
",",O,O
hepatocellular,O,O
carcinoma,O,O
",",O,O
and,O,O
end,O,O
-,O,O
stage,O,O
liver,O,O
disease,O,O
.,O,O
The,O,O
current,O,O
best,O,O
treatment,O,O
for,O,O
HCV,O,B
infection,O,O
is,O,O
combination,O,O
therapy,O,O
with,O,O
pegylated,O,O
interferon,B,B
and,O,O
ribavirin,B,B
.,O,O
Although,O,O
this,O,O
regimen,O,O
produces,O,O
sustained,O,O
virologic,O,O
responses,O,O
(,O,O
SVRs,O,O
),O,O
in,O,O
approximately,O,O
50,O,O
%,O,O
of,O,O
patients,O,O
",",O,O
it,O,O
can,O,O
be,O,O
associated,O,O
with,O,O
a,O,O
potentially,O,O
dose,O,O
-,O,O
limiting,O,O
hemolytic,O,O
anemia,O,O
.,O,O
Hemoglobin,O,B
concentrations,O,O
decrease,O,O
mainly,O,O
as,O,O
a,O,O
result,O,O
of,O,O
ribavirin,B,B
-,O,O
induced,O,O
hemolysis,O,O
",",O,O
and,O,O
this,O,O
anemia,O,O
can,O,O
be,O,O
problematic,O,O
in,O,O
patients,O,O
with,O,O
HCV,O,B
infection,O,O
",",O,O
especially,O,O
those,O,O
who,O,O
have,O,O
comorbid,O,O
renal,O,O
or,O,O
cardiovascular,O,O
disorders,O,O
.,O,O
In,O,O
general,O,O
",",O,O
anemia,O,B
can,O,O
increase,O,O
the,O,O
risk,O,O
of,O,O
morbidity,O,O
and,O,O
mortality,O,O
",",O,O
and,O,O
may,O,O
have,O,O
negative,O,O
effects,O,O
on,O,O
cerebral,O,O
function,O,O
and,O,O
quality,O,O
of,O,O
life,O,O
.,O,O
Although,O,O
ribavirin,B,B
-,O,O
associated,O,O
anemia,O,B
can,O,O
be,O,O
reversed,O,O
by,O,O
dose,O,O
reduction,O,O
or,O,O
discontinuation,O,O
",",O,O
this,O,O
approach,O,O
compromises,O,O
outcomes,O,O
by,O,O
significantly,O,O
decreasing,O,O
SVR,O,O
rates,O,O
.,O,O
Recombinant,O,B
human,O,I
erythropoietin,O,I
has,O,O
been,O,O
used,O,O
to,O,O
manage,O,O
ribavirin,B,B
-,O,O
associated,O,O
anemia,O,O
but,O,O
has,O,O
other,O,O
potential,O,O
disadvantages,O,O
.,O,O
Viramidine,B,B
",",O,O
a,O,O
liver,O,B
-,O,O
targeting,O,O
prodrug,O,O
of,O,O
ribavirin,B,B
",",O,O
has,O,O
the,O,O
potential,O,O
to,O,O
maintain,O,O
the,O,O
virologic,O,O
efficacy,O,O
of,O,O
ribavirin,B,B
while,O,O
decreasing,O,O
the,O,O
risk,O,O
of,O,O
hemolytic,O,O
anemia,O,O
in,O,O
patients,O,O
with,O,O
chronic,O,O
hepatitis,O,B
C,O,I
.,O,O
Impact,O,O
of,O,O
alcohol,B,B
exposure,O,O
after,O,O
pregnancy,O,O
recognition,O,O
on,O,O
ultrasonographic,O,O
fetal,O,O
growth,O,O
measures,O,O
.,O,O
BACKGROUND,O,O
:,O,O
More,O,O
than,O,O
3,O,O
decades,O,O
after,O,O
Jones,O,O
and,O,O
Smith,O,O
(,O,O
1973,O,O
),O,O
reported,O,O
on,O,O
the,O,O
devastation,O,O
caused,O,O
by,O,O
alcohol,B,B
exposure,O,O
on,O,O
fetal,O,O
development,O,O
",",O,O
the,O,O
rates,O,O
of,O,O
heavy,O,O
drinking,O,O
during,O,O
pregnancy,O,O
remain,O,O
relatively,O,O
unchanged,O,O
.,O,O
Early,O,O
identification,O,O
of,O,O
fetal,O,B
alcohol,B,I
exposure,O,I
and,O,O
maternal,O,O
abstinence,O,O
led,O,O
to,O,O
better,O,O
infant,O,O
outcomes,O,O
.,O,O
This,O,O
study,O,O
examined,O,O
the,O,O
utility,O,O
of,O,O
biometry,O,O
for,O,O
detecting,O,O
alcohol,B,B
-,O,I
related,O,I
fetal,O,I
growth,O,I
impairment,O,I
.,O,O
METHODS,O,O
:,O,O
We,O,O
obtained,O,O
fetal,O,B
ultrasound,O,I
measures,O,O
from,O,O
routine,O,O
ultrasound,O,I
examinations,O,O
for,O,O
167,O,O
pregnant,O,O
hazardous,O,O
drinkers,O,O
who,O,O
were,O,O
enrolled,O,O
in,O,O
a,O,O
brief,O,O
alcohol,B,B
intervention,O,I
study,O,O
.,O,O
The,O,O
fetal,O,O
measures,O,O
for,O,O
women,O,O
who,O,O
quit,O,O
after,O,O
learning,O,O
of,O,O
their,O,O
pregnancies,O,O
were,O,O
compared,O,O
with,O,O
measures,O,O
for,O,O
women,O,O
who,O,O
continued,O,O
some,O,O
drinking,O,O
throughout,O,O
the,O,O
course,O,O
of,O,O
their,O,O
pregnancies,O,O
.,O,O
Because,O,O
intensity,O,O
of,O,O
alcohol,B,B
consumption,O,O
is,O,O
associated,O,O
with,O,O
poorer,O,O
fetal,O,O
outcomes,O,O
",",O,O
separate,O,O
analyses,O,O
were,O,O
conducted,O,O
for,O,O
the,O,O
heavy,O,O
(,O,O
average,O,O
of,O,O
>,O,O
or,O,O
=,O,O
5,O,O
drinks,O,O
per,O,O
drinking,O,O
day,O,O
),O,O
alcohol,B,B
consumers,O,O
.,O,O
Fetal,O,O
measures,O,O
from,O,O
the,O,O
heavy,O,O
-,O,O
exposed,O,O
fetuses,O,O
were,O,O
also,O,O
compared,O,O
with,O,O
measures,O,O
from,O,O
a,O,O
nondrinking,O,O
group,O,O
that,O,O
was,O,O
representative,O,O
of,O,O
normal,O,O
",",O,O
uncomplicated,O,O
pregnancies,O,O
from,O,O
our,O,O
clinics,O,O
.,O,O
Analyses,O,O
of,O,O
covariance,O,O
were,O,O
used,O,O
to,O,O
determine,O,O
whether,O,O
there,O,O
were,O,O
differences,O,O
between,O,O
groups,O,O
after,O,O
controlling,O,O
for,O,O
influences,O,O
of,O,O
gestational,O,O
age,O,O
and,O,O
drug,O,O
abuse,O,O
.,O,O
RESULTS,O,O
:,O,O
Nearly,O,O
half,O,O
of,O,O
the,O,O
pregnant,O,O
drinkers,O,O
abstained,O,O
after,O,O
learning,O,O
of,O,O
their,O,O
pregnancies,O,O
.,O,O
When,O,O
women,O,O
reportedly,O,O
quit,O,O
drinking,O,O
early,O,O
in,O,O
their,O,O
pregnancies,O,O
",",O,O
fetal,O,O
growth,O,O
measures,O,O
were,O,O
not,O,O
significantly,O,O
different,O,O
from,O,O
a,O,O
non,O,O
-,O,O
alcohol,B,B
-,O,I
exposed,O,I
group,O,O
",",O,O
regardless,O,O
of,O,O
prior,O,O
drinking,O,O
patterns,O,O
.,O,O
Any,O,O
alcohol,B,B
consumption,O,O
postpregnancy,O,O
recognition,O,O
among,O,O
the,O,O
heavy,O,O
drinkers,O,O
resulted,O,O
in,O,O
reduced,O,O
cerebellar,O,B
growth,O,O
as,O,O
well,O,O
as,O,O
decreased,O,O
cranial,O,B
to,O,I
body,O,I
growth,O,O
in,O,O
comparison,O,O
with,O,O
women,O,O
who,O,O
either,O,O
quit,O,O
drinking,O,O
or,O,O
who,O,O
were,O,O
nondrinkers,O,O
.,O,O
Amphetamine,B,B
abuse,O,O
was,O,O
predictive,O,O
of,O,O
larger,O,O
cranial,O,B
to,O,O
body,O,O
growth,O,O
ratios,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Alterations,O,O
in,O,O
fetal,O,O
biometric,O,O
measurements,O,O
were,O,O
observed,O,O
among,O,O
the,O,O
heavy,O,O
drinkers,O,O
only,O,O
when,O,O
they,O,O
continued,O,O
drinking,O,O
after,O,O
becoming,O,O
aware,O,O
of,O,O
their,O,O
pregnancies,O,O
.,O,O
Although,O,O
the,O,O
reliance,O,O
on,O,O
self,O,O
-,O,O
reported,O,O
drinking,O,O
is,O,O
a,O,O
limitation,O,O
in,O,O
this,O,O
study,O,O
",",O,O
these,O,O
findings,O,O
support,O,O
the,O,O
benefits,O,O
of,O,O
early,O,O
abstinence,O,O
and,O,O
the,O,O
potential,O,O
for,O,O
ultrasound,O,O
examinations,O,O
in,O,O
the,O,O
detection,O,O
of,O,O
fetal,O,O
alcohol,B,B
effects,O,O
.,O,O
Ethambutol,B,B
-,O,O
associated,O,O
optic,O,B
neuropathy,O,I
.,O,O
INTRODUCTION,O,O
:,O,O
Ethambutol,B,B
is,O,O
used,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
tuberculosis,O,O
",",O,O
which,O,O
is,O,O
still,O,O
prevalent,O,O
in,O,O
Southeast,O,O
Asia,O,O
",",O,O
and,O,O
can,O,O
be,O,O
associated,O,O
with,O,O
permanent,O,O
visual,O,O
loss,O,O
.,O,O
We,O,O
report,O,O
3,O,O
cases,O,O
which,O,O
presented,O,O
with,O,O
bitemporal,O,O
hemianopia,O,O
.,O,O
CLINICAL,O,O
PICTURE,O,O
:,O,O
Three,O,O
patients,O,O
with,O,O
ethambutol,B,B
-,O,O
associated,O,O
toxic,O,B
optic,O,I
neuropathy,O,I
are,O,O
described,O,O
.,O,O
All,O,O
3,O,O
patients,O,O
had,O,O
loss,O,O
of,O,O
central,O,O
visual,O,O
acuity,O,O
",",O,O
colour,O,O
vision,O,O
(,O,O
Ishihara,O,O
),O,O
and,O,O
visual,O,O
field,O,O
.,O,O
The,O,O
visual,O,O
field,O,O
loss,O,O
had,O,O
a,O,O
bitemporal,O,O
flavour,O,O
",",O,O
suggesting,O,O
involvement,O,O
of,O,O
the,O,O
optic,O,O
chiasm,O,O
.,O,O
TREATMENT,O,O
:,O,O
Despite,O,O
stopping,O,O
ethambutol,B,B
on,O,O
diagnosis,O,O
",",O,O
visual,O,O
function,O,O
continued,O,O
to,O,O
deteriorate,O,O
for,O,O
a,O,O
few,O,O
months,O,O
.,O,O
Subsequent,O,O
improvement,O,O
was,O,O
mild,O,O
in,O,O
2,O,O
cases,O,O
.,O,O
In,O,O
the,O,O
third,O,O
case,O,O
",",O,O
visual,O,O
acuity,O,O
and,O,O
colour,O,O
vision,O,O
normalised,O,O
but,O,O
the,O,O
optic,O,B
discs,O,I
were,O,O
pale,O,O
.,O,O
OUTCOME,O,O
:,O,O
All,O,O
3,O,O
patients,O,O
had,O,O
some,O,O
permanent,O,O
loss,O,O
of,O,O
visual,O,O
function,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Ethambutol,B,B
usage,O,O
is,O,O
associated,O,O
with,O,O
permanent,O,O
visual,O,O
loss,O,O
and,O,O
should,O,O
be,O,O
avoided,O,O
if,O,O
possible,O,O
or,O,O
used,O,O
with,O,O
caution,O,O
and,O,O
proper,O,O
ophthalmological,O,O
follow,O,O
-,O,O
up,O,O
.,O,O
The,O,O
author,O,O
postulates,O,O
that,O,O
in,O,O
cases,O,O
of,O,O
ethambutol,B,B
associated,O,O
chiasmopathy,O,O
",",O,O
ethambutol,B,B
may,O,O
initially,O,O
affect,O,O
the,O,O
optic,O,O
nerves,O,O
and,O,O
subsequently,O,O
progress,O,O
to,O,O
involve,O,O
the,O,O
optic,O,O
chiasm,O,O
.,O,O
Possible,O,O
neuroleptic,O,O
malignant,O,O
syndrome,O,O
related,O,O
to,O,O
concomitant,O,O
treatment,O,O
with,O,O
paroxetine,B,B
and,O,O
alprazolam,B,B
.,O,O
A,O,O
74,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
depressive,O,O
symptoms,O,O
was,O,O
admitted,O,O
to,O,O
a,O,O
psychiatric,O,O
hospital,O,O
due,O,O
to,O,O
insomnia,O,O
",",O,O
loss,O,O
of,O,O
appetite,O,O
",",O,O
exhaustion,O,O
",",O,O
and,O,O
agitation,O,O
.,O,O
Medical,O,O
treatment,O,O
was,O,O
initiated,O,O
at,O,O
a,O,O
daily,O,O
dose,O,O
of,O,O
20,O,O
mg,O,O
paroxetine,B,B
and,O,O
1,O,O
.,O,O
2,O,O
mg,O,O
alprazolam,B,B
.,O,O
On,O,O
the,O,O
10th,O,O
day,O,O
of,O,O
paroxetine,B,B
and,O,O
alprazolam,B,B
treatment,O,O
",",O,O
the,O,O
patient,O,O
exhibited,O,O
marked,O,O
psychomotor,O,O
retardation,O,O
",",O,O
disorientation,O,O
",",O,O
and,O,O
severe,O,O
muscle,O,O
rigidity,O,O
with,O,O
tremors,O,O
.,O,O
The,O,O
patient,O,O
had,O,O
a,O,O
fever,O,O
(,O,O
38,O,O
.,O,O
2,O,O
degrees,O,O
C,O,O
),O,O
",",O,O
fluctuating,O,O
blood,O,O
pressure,O,O
(,O,O
between,O,O
165,O,O
/,O,O
90,O,O
and,O,O
130,O,O
/,O,O
70,O,O
mg,O,O
mm,O,O
Hg,O,O
),O,O
",",O,O
and,O,O
severe,O,O
extrapyramidal,O,O
symptoms,O,O
.,O,O
Laboratory,O,O
tests,O,O
showed,O,O
an,O,O
elevation,O,O
of,O,O
creatine,B,B
phosphokinase,O,I
(,O,O
2218,O,O
IU,O,O
/,O,O
L,O,O
),O,O
",",O,O
aspartate,B,B
aminotransferase,O,I
(,O,O
134,O,O
IU,O,O
/,O,O
L,O,O
),O,O
",",O,O
alanine,B,B
aminotransferase,O,I
(,O,O
78,O,O
IU,O,O
/,O,O
L,O,O
),O,O
",",O,O
and,O,O
BUN,O,B
(,O,O
27,O,O
.,O,O
9,O,O
mg,O,O
/,O,O
ml,O,O
),O,O
levels,O,O
.,O,O
The,O,O
patient,O,O
received,O,O
bromocriptine,B,B
and,O,O
diazepam,B,B
to,O,O
treat,O,O
his,O,O
symptoms,O,O
.,O,O
7,O,O
days,O,O
later,O,O
",",O,O
the,O,O
fever,O,O
disappeared,O,O
and,O,O
the,O,O
patient,O,O
',O,O
s,O,O
serum,O,O
CPK,O,B
levels,O,O
were,O,O
normalized,O,O
(,O,O
175,O,O
IU,O,O
/,O,O
L,O,O
),O,O
.,O,O
This,O,O
patient,O,O
presented,O,O
with,O,O
symptoms,O,O
of,O,O
neuroleptic,O,B
malignant,O,I
syndrome,O,I
(,O,O
NMS,O,B
),O,O
",",O,O
thus,O,O
demonstrating,O,O
that,O,O
NMS,O,B
-,O,O
like,O,O
symptoms,O,O
can,O,O
occur,O,O
after,O,O
combined,O,O
paroxetine,B,B
and,O,O
alprazolam,B,B
treatment,O,O
.,O,O
The,O,O
adverse,O,O
drug,O,O
reaction,O,O
score,O,O
obtained,O,O
by,O,O
the,O,O
Naranjo,O,O
algorithm,O,O
was,O,O
6,O,O
in,O,O
our,O,O
case,O,O
",",O,O
indicating,O,O
a,O,O
probable,O,O
relationship,O,O
between,O,O
the,O,O
patient,O,O
',O,O
s,O,O
NMS,O,B
-,O,O
like,O,O
adverse,O,O
symptoms,O,O
and,O,O
the,O,O
combined,O,O
treatment,O,O
used,O,O
in,O,O
this,O,O
case,O,O
.,O,O
The,O,O
involvement,O,O
of,O,O
physiologic,O,O
and,O,O
environmental,O,O
aspects,O,O
specific,O,O
to,O,O
this,O,O
patient,O,O
was,O,O
suspected,O,O
.,O,O
Several,O,O
risk,O,O
factors,O,O
for,O,O
NMS,O,B
should,O,O
be,O,O
noted,O,O
in,O,O
elderly,O,O
depressive,O,O
patients,O,O
whose,O,O
symptoms,O,O
often,O,O
include,O,O
dehydration,O,B
",",O,O
agitation,O,B
",",O,O
malnutrition,O,B
",",O,O
and,O,O
exhaustion,O,B
.,O,O
Careful,O,O
therapeutic,O,O
intervention,O,O
is,O,O
necessary,O,O
in,O,O
cases,O,O
involving,O,O
elderly,O,O
patients,O,O
who,O,O
suffer,O,O
from,O,O
depression,O,O
.,O,O
Down,O,O
-,O,O
regulation,O,O
of,O,O
norepinephrine,B,B
transporter,O,O
function,O,O
induced,O,O
by,O,O
chronic,O,O
administration,O,O
of,O,O
desipramine,B,B
linking,O,O
to,O,O
the,O,O
alteration,O,O
of,O,O
sensitivity,O,O
of,O,O
local,O,O
-,O,O
anesthetics,O,O
-,O,O
induced,O,O
convulsions,O,O
and,O,O
the,O,O
counteraction,O,O
by,O,O
co,O,O
-,O,O
administration,O,O
with,O,O
local,O,O
anesthetics,O,O
.,O,O
Alterations,O,O
of,O,O
norepinephrine,B,B
transporter,O,O
(,O,O
NET,O,B
),O,O
function,O,O
by,O,O
chronic,O,O
inhibition,O,O
of,O,O
NET,O,B
in,O,O
relation,O,O
to,O,O
sensitization,O,O
to,O,O
seizures,O,O
induce,O,O
by,O,O
cocaine,B,B
and,O,O
local,O,O
anesthetics,O,O
were,O,O
studied,O,O
in,O,O
mice,O,O
.,O,O
Daily,O,O
administration,O,O
of,O,O
desipramine,B,B
",",O,O
an,O,O
inhibitor,O,O
of,O,O
the,O,O
NET,O,B
",",O,O
for,O,O
5,O,O
days,O,O
decreased,O,O
[,O,O
(,O,O
3,O,O
),O,O
H,O,O
],O,O
norepinephrine,B,B
uptake,O,O
in,O,O
the,O,O
P2,O,O
fractions,O,O
of,O,O
hippocampus,O,O
but,O,O
not,O,O
cortex,O,O
",",O,O
striatum,O,O
or,O,O
amygdalae,O,O
.,O,O
Co,O,O
-,O,O
administration,O,O
of,O,O
lidocaine,B,B
",",O,O
bupivacaine,B,B
or,O,O
tricaine,B,B
with,O,O
desipramine,B,B
reversed,O,O
this,O,O
effect,O,O
.,O,O
Daily,O,O
treatment,O,O
of,O,O
cocaine,B,B
increased,O,O
[,O,O
(,O,O
3,O,O
),O,O
H,O,O
],O,O
norepinephrine,B,B
uptake,O,O
into,O,O
the,O,O
hippocampus,O,O
.,O,O
Daily,O,O
administration,O,O
of,O,O
desipramine,B,B
increased,O,O
the,O,O
incidence,O,O
of,O,O
appearance,O,O
of,O,O
lidocaine,B,B
-,O,O
induced,O,O
convulsions,O,O
and,O,O
decreased,O,O
that,O,O
of,O,O
cocaine,B,B
-,O,O
induced,O,O
convulsions,O,O
.,O,O
Co,O,O
-,O,O
administration,O,O
of,O,O
lidocaine,B,B
with,O,O
desipramine,B,B
reversed,O,O
the,O,O
changes,O,O
of,O,O
convulsive,O,O
activity,O,O
of,O,O
lidocaine,B,B
and,O,O
cocaine,B,B
induced,O,O
by,O,O
repeated,O,O
administration,O,O
of,O,O
desipramine,B,B
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
hippocampal,O,O
NET,O,B
induced,O,O
by,O,O
chronic,O,O
administration,O,O
of,O,O
desipramine,B,B
may,O,O
be,O,O
relevant,O,O
to,O,O
desipramine,B,B
-,O,O
induced,O,O
sensitization,O,O
of,O,O
lidocaine,B,B
convulsions,O,O
.,O,O
Inhibition,O,O
of,O,O
Na,B,B
(,O,O
+,O,O
),O,O
channels,O,O
by,O,O
local,O,O
anesthetics,O,B
may,O,O
regulate,O,O
desipramine,B,B
-,O,O
induced,O,O
down,O,O
-,O,O
regulation,O,O
of,O,O
NET,O,B
function,O,O
.,O,O
Repeated,O,O
administration,O,O
of,O,O
cocaine,B,B
induces,O,O
up,O,O
-,O,O
regulation,O,O
of,O,O
hippocampal,O,O
NET,O,B
function,O,O
.,O,O
Desipramine,B,B
-,O,O
induced,O,O
sensitization,O,O
of,O,O
lidocaine,B,B
seizures,O,O
may,O,O
have,O,O
a,O,O
mechanism,O,O
distinct,O,O
from,O,O
kindling,O,O
resulting,O,O
from,O,O
repeated,O,O
administration,O,O
of,O,O
cocaine,B,B
.,O,O
Atorvastatin,B,B
prevented,O,O
and,O,O
reversed,O,O
dexamethasone,B,B
-,O,O
induced,O,O
hypertension,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
To,O,O
assess,O,O
the,O,O
antioxidant,O,O
effects,O,O
of,O,O
atorvastatin,B,B
(,O,O
atorva,B,B
),O,O
on,O,O
dexamethasone,B,B
(,O,O
dex,B,B
),O,O
-,O,O
induced,O,O
hypertension,O,O
",",O,O
60,O,O
male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
treated,O,O
with,O,O
atorva,B,B
30,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
or,O,O
tap,O,O
water,O,O
for,O,O
15,O,O
days,O,O
.,O,O
Dex,B,B
increased,O,O
systolic,O,O
blood,O,O
pressure,O,O
(,O,O
SBP,O,B
),O,O
from,O,O
109,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
8,O,O
to,O,O
135,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
mmHg,O,O
and,O,O
plasma,O,O
superoxide,B,O
(,O,O
5711,O,B
+,O,O
/,O,O
-,O,O
284,O,O
.,O,O
9,O,O
saline,O,B
",",O,O
7931,O,O
+,O,O
/,O,O
-,O,O
392,O,O
.,O,O
U,O,B
/,O,O
ml,O,O
dex,B,B
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
In,O,O
this,O,O
prevention,O,O
study,O,O
",",O,O
SBP,O,B
in,O,O
the,O,O
atorva,B,B
+,O,O
dex,B,B
group,O,O
was,O,O
increased,O,O
from,O,O
115,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
to,O,O
124,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
mmHg,O,O
",",O,O
but,O,O
this,O,O
was,O,O
significantly,O,O
lower,O,O
than,O,O
in,O,O
the,O,O
dex,B,B
-,O,O
only,O,O
group,O,O
(,O,O
P,O,O
',O,O
<,O,O
0,O,O
.,O,O
),O,O
Atorva,B,B
reversed,O,O
dex,B,B
-,O,O
induced,O,O
hypertension,O,O
(,O,O
129,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
mmHg,O,B
",",O,O
vs,O,O
.,O,O
135,O,B
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
mmHg,O,B
P,O,O
',O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
decreased,O,O
plasma,O,O
superoxide,B,B
(,O,O
7931,O,B
+,O,O
/,O,O
-,O,O
392,O,B
.,O,O
8,O,O
dex,B,B
",",O,O
1187,O,B
dex,B,B
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Plasma,O,O
nitrate,B,B
/,O,O
nitrite,B,B
(,O,O
NOx,O,B
),O,O
was,O,O
decreased,O,O
in,O,O
dex,B,B
-,O,O
treated,O,O
rats,O,O
compared,O,O
to,O,O
saline,O,B
-,O,O
treated,O,O
rats,O,O
(,O,O
11,O,B
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
3,O,O
1,O,O
",",O,O
respectively,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
.,O,O
affected,O,O
neither,O,O
plasma,O,B
NOx,O,I
nor,O,O
thymus,O,B
weight,O,I
.,O,O
Thus,O,O
",",O,O
atorvastatin,B,B
prevented,O,O
and,O,O
reversed,O,O
dexamethasone,B,B
-,O,I
induced,O,I
hypertension,O,I
in,O,O
the,O,O
rat,O,O
.,O,O
Peripheral,O,O
neuropathy,O,B
caused,O,O
by,O,O
high,O,O
-,O,O
dose,O,O
cytosine,B,B
arabinoside,I,I
treatment,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
acute,O,O
myeloid,O,O
leukemia,O,O
.,O,O
The,O,O
central,O,O
nervous,O,O
system,O,O
toxicity,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
cytosine,B,B
arabinoside,I,I
is,O,O
well,O,O
recognized,O,O
",",O,O
but,O,O
the,O,O
toxicity,O,O
of,O,O
cytosine,B,B
arabinoside,I,I
in,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
has,O,O
been,O,O
infrequently,O,O
reported,O,O
.,O,O
A,O,O
49,O,O
-,O,O
year,O,O
-,O,O
old,O,O
Japanese,O,O
man,O,O
was,O,O
diagnosed,O,O
with,O,O
acute,O,O
myeloid,O,O
leukemia,O,O
.,O,O
After,O,O
he,O,O
achieved,O,O
complete,O,O
remission,O,O
",",O,O
he,O,O
received,O,O
high,O,O
-,O,O
dose,O,O
cytosine,B,B
arabinoside,I,I
treatment,O,O
(,O,O
2,O,O
g,O,O
/,O,O
m2,O,O
twice,O,O
a,O,O
day,O,O
for,O,O
5,O,O
days,O,O
;,O,O
total,O,O
",",O,O
20,O,O
g,O,O
/,O,O
m2,O,O
),O,O
as,O,O
consolidation,O,O
therapy,O,O
.,O,O
The,O,O
first,O,O
course,O,O
of,O,O
high,O,B
-,O,I
dose,O,I
cytosine,B,B
arabinoside,I,I
resulted,O,O
in,O,O
no,O,O
unusual,O,O
symptoms,O,O
",",O,O
but,O,O
on,O,O
day,O,O
21,O,O
of,O,O
the,O,O
second,O,O
course,O,O
of,O,O
treatment,O,O
",",O,O
the,O,O
patient,O,O
complained,O,O
of,O,O
numbness,O,O
in,O,O
his,O,O
right,O,O
foot,O,O
.,O,O
Electromyogram,O,O
and,O,O
nerve,O,O
-,O,O
conduction,O,O
studies,O,O
showed,O,O
peripheral,O,O
neuropathy,O,O
in,O,O
both,O,O
peroneal,O,O
nerves,O,O
.,O,O
This,O,O
neuropathy,O,O
was,O,O
gradually,O,O
resolving,O,O
;,O,O
however,O,O
",",O,O
after,O,O
the,O,O
patient,O,O
received,O,O
allogeneic,O,O
bone,O,O
marrow,O,O
transplantation,O,O
",",O,O
the,O,O
symptoms,O,O
worsened,O,O
",",O,O
with,O,O
the,O,O
development,O,O
of,O,O
graft,O,B
-,O,I
versus,O,I
-,O,I
host,O,I
disease,O,I
",",O,O
and,O,O
the,O,O
symptoms,O,O
subsequently,O,O
responded,O,O
to,O,O
methylprednisolone,B,B
.,O,O
Although,O,O
the,O,O
mechanisms,O,O
of,O,O
peripheral,O,O
neuropathy,O,O
are,O,O
still,O,O
unclear,O,O
",",O,O
high,O,O
-,O,O
dose,O,O
cytosine,B,B
arabinoside,I,I
is,O,O
a,O,O
therapy,O,O
that,O,O
is,O,O
potentially,O,O
toxic,O,O
to,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
",",O,O
and,O,O
auto,O,O
/,O,O
alloimmunity,O,O
may,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
these,O,O
mechanisms,O,O
.,O,O
Effect,O,O
of,O,O
alpha,B,B
-,I,O
tocopherol,I,I
and,O,O
deferoxamine,B,B
on,O,O
methamphetamine,B,B
-,O,O
induced,O,O
neurotoxicity,O,O
.,O,O
Methamphetamine,B,B
(,O,O
MA,B,B
),O,O
induced,O,O
dopaminergic,O,O
neurotoxicity,O,O
is,O,O
believed,O,O
to,O,O
be,O,O
associated,O,O
with,O,O
the,O,O
increased,O,O
formation,O,O
of,O,O
free,O,O
radicals,O,O
.,O,O
This,O,O
study,O,O
examined,O,O
the,O,O
effect,O,O
of,O,O
alpha,B,B
-,I,I
tocopherol,I,I
(,O,O
alpha,B,B
-,I,I
TC,I,I
),O,O
",",O,O
a,O,O
scavenger,O,O
of,O,O
reactive,O,O
oxygen,B,B
species,O,O
",",O,O
and,O,O
deferoxamine,B,B
(,O,O
DFO,B,B
),O,O
",",O,O
an,O,O
iron,B,O
chelator,O,O
",",O,O
on,O,O
the,O,O
MA,B,B
-,O,O
induced,O,O
neurotoxicity,O,O
.,O,O
Male,O,O
rats,O,O
were,O,O
treated,O,O
with,O,O
MA,B,B
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
every,O,O
2,O,O
h,O,O
for,O,O
four,O,O
injections,O,O
),O,O
.,O,O
The,O,O
rat,O,O
received,O,O
either,O,O
alpha,B,B
-,I,I
TC,I,I
(,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
intraperitoneally,O,O
for,O,O
3,O,O
days,O,O
and,O,O
30,O,O
min,O,O
prior,O,O
to,O,O
MA,B,B
administration,O,O
or,O,O
DFO,B,B
(,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
subcutaneously,O,O
30,O,O
min,O,O
before,O,O
MA,B,B
administration,O,O
.,O,O
The,O,O
concentrations,O,O
of,O,O
dopamine,B,B
(,O,O
DA,B,B
),O,O
",",O,O
serotonin,B,B
and,O,O
their,O,O
metabolites,O,O
decreased,O,O
significantly,O,O
after,O,O
MA,B,B
administration,O,O
",",O,O
which,O,O
was,O,O
inhibited,O,O
by,O,O
the,O,O
alpha,B,B
-,I,I
TC,I,I
and,O,O
DFO,B,B
pretreatment,O,O
.,O,O
alpha,B,B
-,I,O
TC,I,O
and,O,O
DFO,B,B
attenuated,O,O
the,O,O
MA,B,B
-,O,O
induced,O,O
hyperthermia,O,O
as,O,O
well,O,O
as,O,O
the,O,O
alterations,O,O
in,O,O
the,O,O
locomotor,O,O
activity,O,O
.,O,O
The,O,O
level,O,O
of,O,O
lipid,O,B
peroxidation,O,I
was,O,O
higher,O,O
and,O,O
the,O,O
reduced,O,B
glutathione,B,I
concentration,O,I
was,O,O
lower,O,O
in,O,O
the,O,O
MA,B,B
-,O,O
treated,O,O
rats,O,O
.,O,O
These,O,O
changes,O,O
were,O,O
significantly,O,O
attenuated,O,O
by,O,O
alpha,B,B
-,I,O
TC,I,O
and,O,O
DFO,B,B
.,O,O
This,O,O
suggests,O,O
that,O,O
alpha,B,B
-,I,I
TC,I,I
and,O,O
DFO,B,B
ameliorate,O,O
the,O,O
MA,B,B
-,O,I
induced,O,I
neuronal,O,I
damage,O,I
by,O,O
decreasing,O,O
the,O,O
level,O,O
of,O,O
oxidative,O,B
stress,O,I
.,O,O
Blockade,O,O
of,O,O
both,O,O
D,O,B
-,O,I
1,O,I
and,O,O
D,O,B
-,O,I
2,O,I
dopamine,B,I
receptors,O,I
may,O,O
induce,O,O
catalepsy,O,O
in,O,O
mice,O,O
.,O,O
1,O,O
.,O,O
The,O,O
catalepsy,O,O
induced,O,O
by,O,O
dopamine,B,B
antagonists,O,I
has,O,O
been,O,O
tested,O,O
and,O,O
the,O,O
possible,O,O
dopamine,B,B
subtypes,O,I
involved,O,O
in,O,O
catalepsy,O,O
was,O,O
determined,O,O
.,O,O
2,O,O
Dopamine,B,B
antagonist,O,O
fluphenazine,B,B
",",O,O
D,O,B
-,O,I
1,O,I
antagonist,O,O
SCH,B,B
23390,I,I
or,O,O
D,O,B
-,O,I
2,O,I
antagonist,O,O
sulpiride,B,B
induced,O,O
catalepsy,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
fluphenazine,B,B
and,O,O
sulpiride,B,B
was,O,O
dose,O,O
-,O,O
dependent,O,O
.,O,O
Combination,O,O
of,O,O
SCH,B,B
23390,I,I
with,O,O
sulpiride,B,B
did,O,O
not,O,O
induce,O,O
catalepsy,O,O
potentiation,O,O
.,O,O
3,O,O
D,O,B
-,O,I
1,O,I
agonist,O,O
SKF,B,B
38393,I,I
or,O,O
D,O,B
-,O,I
2,O,I
agonist,O,O
quinpirole,B,B
decreased,O,O
the,O,O
catalepsy,O,O
induced,O,O
by,O,O
fluphenazine,B,B
",",O,O
SCH,B,B
23390,I,I
or,O,O
sulpiride,B,B
.,O,O
4,O,O
Combination,O,O
of,O,O
SKF,B,B
38393,I,I
with,O,O
quinpirole,B,B
did,O,O
not,O,O
cause,O,O
potentiated,O,O
inhibitory,O,O
effect,O,O
on,O,O
catalepsy,O,O
induced,O,O
by,O,O
dopamine,B,B
antagonists,O,I
.,O,O
5,O,O
The,O,O
data,O,O
may,O,O
indicate,O,O
that,O,O
although,O,O
D,O,B
-,O,I
2,O,I
receptor,O,I
blockade,O,O
is,O,O
involved,O,O
in,O,O
catalepsy,O,O
",",O,O
the,O,O
D,O,B
-,O,I
1,O,I
receptor,O,I
may,O,O
plan,O,O
a,O,O
role,O,O
.,O,O
Sustained,O,O
clinical,O,O
improvement,O,O
of,O,O
a,O,O
patient,O,O
with,O,O
decompensated,O,O
hepatitis,O,B
B,O,I
virus,O,I
-,O,I
related,O,I
cirrhosis,O,I
after,O,O
treatment,O,O
with,O,O
lamivudine,B,B
monotherapy,O,O
.,O,O
Hepatitis,O,B
B,O,I
virus,O,I
(,O,O
HBV,O,B
),O,O
infection,O,O
",",O,O
which,O,O
causes,O,O
liver,O,B
cirrhosis,O,I
and,O,O
hepatocellular,O,B
carcinoma,O,I
",",O,O
remains,O,O
a,O,O
major,O,O
health,O,O
problem,O,O
in,O,O
Asian,O,O
countries,O,O
.,O,O
Recent,O,O
development,O,O
of,O,O
vaccine,O,B
for,O,O
prevention,O,O
is,O,O
reported,O,O
to,O,O
be,O,O
successful,O,O
in,O,O
reducing,O,O
the,O,O
size,O,O
of,O,O
chronically,O,O
infected,O,O
carriers,O,O
",",O,O
although,O,O
the,O,O
standard,O,O
medical,O,O
therapies,O,O
have,O,O
not,O,O
been,O,O
established,O,O
up,O,O
to,O,O
now,O,O
.,O,O
In,O,O
this,O,O
report,O,O
",",O,O
we,O,O
encountered,O,O
a,O,O
patient,O,O
with,O,O
decompensated,O,O
HBV,O,B
-,O,O
related,O,O
cirrhosis,O,O
who,O,O
exhibited,O,O
the,O,O
dramatic,O,O
improvements,O,O
after,O,O
antiviral,O,B
therapy,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
a,O,O
50,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
.,O,O
Previous,O,O
conventional,O,O
medical,O,O
treatments,O,O
were,O,O
not,O,O
effective,O,O
for,O,O
this,O,O
patient,O,O
",",O,O
thus,O,O
this,O,O
patient,O,O
had,O,O
been,O,O
referred,O,O
to,O,O
our,O,O
hospital,O,O
.,O,O
However,O,O
",",O,O
the,O,O
administration,O,O
of,O,O
lamivudine,B,B
",",O,O
a,O,O
reverse,O,O
transcriptase,O,O
inhibitor,O,O
",",O,O
for,O,O
23,O,O
months,O,O
dramatically,O,O
improved,O,O
her,O,O
liver,O,O
severity,O,O
.,O,O
During,O,O
this,O,O
period,O,O
",",O,O
no,O,O
drug,O,O
resistant,O,O
mutant,O,O
HBV,O,B
emerged,O,O
",",O,O
and,O,O
the,O,O
serum,O,O
HBV,O,B
-,O,O
DNA,O,I
level,O,O
was,O,O
continuously,O,O
suppressed,O,O
.,O,O
These,O,O
virological,O,O
responses,O,O
were,O,O
also,O,O
maintained,O,O
even,O,O
after,O,O
the,O,O
antiviral,O,O
therapy,O,O
was,O,O
discontinued,O,O
.,O,O
Moreover,O,O
",",O,O
both,O,O
hepatitis,B,B
B,I,I
surface,I,I
antigen,I,I
and,I,O
e,I,B
antigen,I,I
were,O,O
observed,O,O
to,O,O
have,O,O
disappeared,O,O
in,O,O
this,O,O
patient,O,O
.,O,O
The,O,O
administration,O,O
of,O,O
lamivudine,B,B
to,O,O
patients,O,O
with,O,O
HBV,O,B
-,O,I
related,O,I
cirrhosis,O,I
",",O,O
like,O,O
our,O,O
present,O,O
case,O,O
",",O,O
should,O,O
be,O,O
considered,O,O
as,O,O
an,O,O
initial,O,O
medical,O,O
therapeutic,O,O
option,O,O
",",O,O
especially,O,O
in,O,O
countries,O,O
where,O,O
liver,O,O
transplantation,O,O
is,O,O
not,O,O
reliably,O,O
available,O,O
.,O,O
Antiarrhythmic,O,O
effects,O,O
of,O,O
optical,O,O
isomers,O,O
of,O,O
cibenzoline,B,B
on,O,O
canine,O,O
ventricular,O,O
arrhythmias,O,O
.,O,O
Antiarrhythmic,O,O
effects,O,O
of,O,O
(,O,O
+,O,O
),O,O
(,O,O
-,O,O
),O,O
cibenzoline,B,B
were,O,O
examined,O,O
using,O,O
two,O,O
canine,O,O
ventricular,O,O
arrhythmia,O,O
models,O,O
.,O,O
Digitalis,B,O
arrhythmia,O,O
",",O,O
which,O,O
is,O,O
suppressed,O,O
by,O,O
Na,B,B
channel,O,O
blockers,O,O
",",O,O
was,O,O
induced,O,O
by,O,O
intermittent,O,O
intravenous,O,O
(,O,O
i,O,O
.,O,O
v,O,O
.,O,O
injection,O,O
of,O,O
ouabain,B,B
in,O,O
pentobarbital,B,O
-,O,O
anesthetized,O,O
dogs,O,O
.,O,O
Adrenaline,O,B
arrhythmia,O,O
",",O,O
which,O,O
is,O,O
suppressed,O,O
by,O,O
Ca,B,B
channel,O,I
blockers,O,I
",",O,O
was,O,O
induced,O,O
by,O,O
adrenaline,B,B
infusion,O,O
in,O,O
halothane,B,O
-,O,O
anesthetized,O,O
dogs,O,O
.,O,O
Ten,O,O
and,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
(,O,O
+,O,O
),O,O
suppressed,O,O
digitalis,B,B
-,O,O
and,O,O
adrenaline,B,B
-,O,O
induced,O,O
arrhythmias,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
minimum,O,O
effective,O,O
plasma,O,O
concentrations,O,O
of,O,O
(,O,O
+,O,O
),O,O
for,O,O
digitalis,B,B
-,O,O
and,O,O
adrenaline,B,B
-,O,O
induced,O,O
arrhythmias,O,O
were,O,O
1,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
4,O,O
and,O,O
2,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
6,O,O
micrograms,O,O
/,O,O
ml,O,O
",",O,O
respectively,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SD,O,O
",",O,O
n,O,O
=,O,O
6,O,O
),O,O
.,O,O
A,O,O
lower,O,O
dose,O,O
of,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
of,O,O
(,O,O
-,O,O
),O,O
suppressed,O,O
the,O,O
digitalis,B,B
-,O,O
induced,O,O
arrhythmia,O,O
",",O,O
whereas,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
was,O,O
needed,O,O
to,O,O
suppress,O,O
adrenaline,B,B
-,O,O
induced,O,O
arrhythmias,O,O
.,O,O
The,O,O
minimum,O,O
effective,O,O
plasma,O,O
concentrations,O,O
of,O,O
(,O,O
-,O,O
),O,O
-,O,O
cibenzoline,B,B
for,O,O
digitalis,B,B
-,O,O
and,O,O
adrenaline,B,B
-,O,O
induced,O,O
arrhythmia,O,O
were,O,O
0,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
and,O,O
0,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
micrograms,O,O
/,O,O
ml,O,O
",",O,O
respectively,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SD,O,O
",",O,O
n,O,O
=,O,O
6,O,O
),O,O
.,O,O
The,O,O
stronger,O,O
antiarrhythmic,O,O
effect,O,O
of,O,O
(,O,O
-,O,O
),O,O
-,O,O
cibenzoline,B,B
indicates,O,O
that,O,O
(,O,O
-,O,O
),O,O
-,O,O
isomer,O,O
may,O,O
have,O,O
an,O,O
effect,O,O
nearly,O,O
5,O,O
-,O,O
20,O,O
times,O,O
stronger,O,O
in,O,O
suppressing,O,O
Na,B,B
channels,O,O
",",O,O
but,O,O
effects,O,O
of,O,O
both,O,O
drugs,O,O
on,O,O
Ca,B,B
channels,O,O
may,O,O
be,O,O
almost,O,O
equipotent,O,O
.,O,O
Passage,O,O
of,O,O
mannitol,B,B
into,O,O
the,O,O
brain,O,O
around,O,O
gliomas,O,O
:,O,O
a,O,O
potential,O,O
cause,O,O
of,O,O
rebound,O,O
phenomenon,O,O
.,O,O
A,O,O
study,O,O
on,O,O
21,O,O
patients,O,O
.,O,O
AIM,O,O
:,O,O
Widespread,O,O
use,O,O
of,O,O
mannitol,B,B
to,O,O
reduce,O,O
brain,O,O
edema,O,O
and,O,O
lower,O,O
elevated,O,O
ICP,O,O
in,O,O
brain,O,O
tumor,O,O
patients,O,O
continues,O,O
to,O,O
be,O,O
afflicted,O,O
by,O,O
the,O,O
so,O,O
-,O,O
called,O,O
rebound,O,O
phenomenon,O,O
.,O,O
Leakage,O,O
of,O,O
mannitol,B,B
into,O,O
the,O,O
brain,O,O
parenchyma,O,O
through,O,O
an,O,O
altered,O,O
BBB,O,O
and,O,O
secondary,O,O
reversal,O,O
of,O,O
osmotic,O,O
gradient,O,O
is,O,O
considered,O,O
the,O,O
major,O,O
cause,O,O
of,O,O
rebound,O,O
.,O,O
This,O,O
has,O,O
only,O,O
been,O,O
demonstrated,O,O
experimentally,O,O
in,O,O
animals,O,O
.,O,O
As,O,O
a,O,O
contribution,O,O
to,O,O
this,O,O
issue,O,O
we,O,O
decided,O,O
to,O,O
research,O,O
the,O,O
possible,O,O
passage,O,O
of,O,O
mannitol,B,B
into,O,O
the,O,O
brain,O,O
after,O,O
administration,O,O
to,O,O
21,O,O
brain,O,O
tumor,O,O
patients,O,O
.,O,O
METHODS,O,O
:,O,O
Mannitol,B,B
(,O,O
18,O,O
%,O,O
solution,O,O
;,O,O
1,O,O
g,O,O
/,O,O
kg,O,O
),O,O
was,O,O
administered,O,O
as,O,O
a,O,O
bolus,O,O
to,O,O
patients,O,O
(,O,O
ten,O,O
had,O,O
malignant,O,O
glioma,O,O
",",O,O
seven,O,O
brain,O,O
metastases,O,O
and,O,O
four,O,O
meningioma,O,O
),O,O
about,O,O
30,O,O
minutes,O,O
before,O,O
craniotomy,O,O
.,O,O
During,O,O
resection,O,O
",",O,O
a,O,O
sample,O,O
of,O,O
the,O,O
surrounding,O,O
edematous,O,O
white,O,B
matter,O,I
was,O,O
taken,O,O
at,O,O
the,O,O
same,O,O
time,O,O
as,O,O
a,O,O
10,O,O
ml,O,O
venous,O,O
blood,O,O
sample,O,O
.,O,O
Mannitol,B,B
concentrations,O,O
were,O,O
measured,O,O
in,O,O
plasma,O,O
and,O,O
white,O,B
matter,O,I
by,O,O
a,O,O
modified,O,O
version,O,O
of,O,O
the,O,O
enzyme,O,O
assay,O,O
of,O,O
Blonquist,O,O
et,O,O
al,O,O
.,O,O
RESULTS,O,O
:,O,O
In,O,O
most,O,O
glioma,O,O
patients,O,O
",",O,O
mannitol,B,B
concentrations,O,O
in,O,O
white,O,B
matter,O,I
were,O,O
2,O,O
to,O,O
6,O,O
times,O,O
higher,O,O
than,O,O
in,O,O
plasma,O,O
(,O,O
mean,O,O
3,O,O
.,O,O
5,O,O
times,O,O
),O,O
.,O,O
In,O,O
meningioma,O,B
and,O,O
metastases,O,B
patients,O,O
plasma,O,O
concentrations,O,O
of,O,O
mannitol,B,B
were,O,O
higher,O,O
than,O,O
white,O,O
matter,O,O
concentrations,O,O
except,O,O
in,O,O
three,O,O
cases,O,O
with,O,O
infiltration,O,O
by,O,O
neoplastic,O,B
cells,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
results,O,O
of,O,O
our,O,O
study,O,O
show,O,O
that,O,O
even,O,O
after,O,O
a,O,O
single,O,O
bolus,O,O
",",O,O
mannitol,B,B
may,O,O
leak,O,O
through,O,O
the,O,O
altered,O,O
BBB,O,O
near,O,O
gliomas,O,B
",",O,O
reversing,O,O
the,O,O
initial,O,O
plasma,O,O
-,O,O
to,O,O
-,O,O
blood,O,O
osmotic,O,O
gradient,O,O
",",O,O
aggravating,O,O
peritumoral,O,O
edema,O,O
and,O,O
promoting,O,O
rebound,O,O
of,O,O
ICP,O,O
.,O,O
Placebo,O,B
-,O,O
level,O,O
incidence,O,O
of,O,O
extrapyramidal,O,B
symptoms,O,I
(,O,O
EPS,O,B
),O,O
with,O,O
quetiapine,B,O
in,O,O
controlled,O,O
studies,O,O
of,O,O
patients,O,O
with,O,O
bipolar,O,O
mania,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
evaluate,O,O
extrapyramidal,O,B
symptoms,O,I
(,O,O
EPS,O,B
),O,O
",",O,O
including,O,O
akathisia,O,O
",",O,O
with,O,O
quetiapine,B,O
in,O,O
patients,O,O
with,O,O
bipolar,O,O
mania,O,O
.,O,O
METHODS,O,O
:,O,O
Data,O,O
were,O,O
analyzed,O,O
from,O,O
four,O,O
similarly,O,O
designed,O,O
",",O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
3,O,O
-,O,O
to,O,O
12,O,O
-,O,O
week,O,O
studies,O,O
.,O,O
Two,O,O
studies,O,O
evaluated,O,O
quetiapine,B,B
monotherapy,O,O
(,O,O
up,O,O
to,O,O
800,O,O
mg,O,O
/,O,O
day,O,O
),O,O
(,O,O
n,O,O
=,O,O
209,O,O
),O,O
versus,O,O
placebo,O,O
(,O,O
n,O,O
=,O,O
198,O,O
),O,O
",",O,O
with,O,O
lithium,B,B
or,O,O
haloperidol,B,B
monotherapy,O,O
as,O,O
respective,O,O
active,O,O
controls,O,O
.,O,O
Two,O,O
studies,O,O
evaluated,O,O
quetiapine,B,B
(,O,O
up,O,O
to,O,O
800,O,O
mg,O,O
/,O,O
day,O,O
),O,O
in,O,O
combination,O,O
with,O,O
a,O,O
mood,O,O
stabilizer,O,O
(,O,O
lithium,B,B
or,O,O
divalproex,B,B
",",O,O
QTP,B,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
),O,O
(,O,O
n,O,O
=,O,O
196,O,O
),O,O
compared,O,O
to,O,O
placebo,O,O
and,O,O
mood,O,O
stabilizer,O,O
(,O,O
PBO,O,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
),O,O
(,O,O
n,O,O
=,O,O
203,O,O
),O,O
.,O,O
Extrapyramidal,O,B
symptoms,O,O
were,O,O
evaluated,O,O
using,O,O
the,O,O
Simpson,O,B
-,O,I
Angus,O,I
Scale,O,I
(,O,O
SAS,O,B
),O,O
",",O,O
the,O,O
Barnes,O,B
Akathisia,O,I
Rating,O,I
Scale,O,I
(,O,O
BARS,O,B
),O,O
",",O,O
adverse,O,O
event,O,O
reports,O,O
and,O,O
anticholinergic,O,B
drug,O,I
usage,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
incidence,O,O
of,O,O
EPS,O,B
-,O,I
related,O,I
adverse,O,I
events,O,I
",",O,O
including,O,O
akathisia,O,B
",",O,O
was,O,O
no,O,O
different,O,O
with,O,O
quetiapine,B,B
monotherapy,O,O
(,O,O
12,O,O
.,O,O
9,O,O
%,O,O
),O,O
than,O,O
with,O,O
placebo,O,B
(,O,O
13,O,O
.,O,O
1,O,O
%,O,O
),O,O
.,O,O
Similarly,O,O
",",O,O
EPS,O,B
-,O,O
related,O,O
adverse,O,O
events,O,O
with,O,O
QTP,B,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
(,O,O
21,O,O
.,O,O
4,O,O
%,O,O
),O,O
were,O,O
no,O,O
different,O,O
than,O,O
with,O,O
PBO,O,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
(,O,O
19,O,O
.,O,O
2,O,O
%,O,O
),O,O
.,O,O
Adverse,O,O
events,O,O
related,O,O
to,O,O
EPS,O,B
occurred,O,O
in,O,O
59,O,O
.,O,O
6,O,O
%,O,O
of,O,O
patients,O,O
treated,O,O
with,O,O
haloperidol,B,B
(,O,O
n,O,O
=,O,O
99,O,O
),O,O
monotherapy,O,O
",",O,O
whereas,O,O
26,O,O
.,O,O
5,O,O
%,O,O
of,O,O
patients,O,O
treated,O,O
with,O,O
lithium,B,B
(,O,O
n,O,O
=,O,O
98,O,O
),O,O
monotherapy,O,O
experienced,O,O
adverse,O,O
events,O,O
related,O,O
to,O,O
EPS,O,B
.,O,O
The,O,O
incidence,O,O
of,O,O
akathisia,O,O
was,O,O
low,O,O
and,O,O
similar,O,O
with,O,O
quetiapine,B,B
monotherapy,O,O
(,O,O
3,O,O
.,O,O
3,O,O
%,O,O
),O,O
and,O,O
placebo,O,O
(,O,O
6,O,O
.,O,O
1,O,O
%,O,O
),O,O
",",O,O
and,O,O
with,O,O
QTP,B,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
(,O,O
3,O,O
.,O,O
6,O,O
%,O,O
),O,O
and,O,O
PBO,O,B
+,O,O
Li,B,B
/,O,O
DVP,B,B
(,O,O
4,O,O
.,O,O
9,O,O
%,O,O
),O,O
.,O,O
Lithium,B,B
was,O,O
associated,O,O
with,O,O
a,O,O
significantly,O,O
higher,O,O
incidence,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
of,O,O
tremor,O,B
(,O,O
18,O,O
.,O,O
4,O,O
%,O,O
),O,O
than,O,O
quetiapine,B,B
(,O,O
5,O,O
.,O,O
6,O,O
%,O,O
),O,O
;,O,O
cerebellar,O,B
tremor,O,I
",",O,O
which,O,O
is,O,O
a,O,O
known,O,O
adverse,O,O
effect,O,O
of,O,O
lithium,B,B
",",O,O
may,O,O
have,O,O
contributed,O,O
to,O,O
the,O,O
elevated,O,O
rate,O,O
of,O,O
tremor,O,B
in,O,O
patients,O,O
receiving,O,O
lithium,B,B
therapy,O,O
.,O,O
Haloperidol,B,B
induced,O,O
a,O,O
significantly,O,O
higher,O,O
incidence,O,O
(,O,O
p,O,B
<,O,O
0,O,O
.,O,O
),O,O
of,O,O
akathisia,O,B
(,O,O
33,O,O
.,O,O
3,O,O
%,O,O
versus,O,O
5,O,O
.,O,O
9,O,O
%,O,O
),O,O
",",O,O
tremor,O,B
(,O,O
30,O,O
.,O,O
3,O,O
%,O,O
versus,O,O
7,O,O
.,O,O
8,O,O
%,O,O
),O,O
",",O,O
and,O,O
extrapyramidal,O,B
syndrome,O,I
(,O,O
35,O,O
.,O,O
4,O,O
%,O,O
versus,O,O
5,O,O
.,O,O
9,O,O
%,O,O
),O,O
than,O,O
quetiapine,B,B
.,O,O
No,O,O
significant,O,O
differences,O,O
were,O,O
observed,O,O
between,O,O
quetiapine,B,B
and,O,O
placebo,O,B
on,O,O
SAS,O,B
and,O,O
BARS,O,B
scores,O,O
.,O,O
Anticholinergic,O,B
use,O,O
was,O,O
low,O,O
and,O,O
similar,O,O
with,O,O
quetiapine,B,B
or,O,O
placebo,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
bipolar,O,O
mania,O,O
",",O,O
the,O,O
incidence,O,O
of,O,O
EPS,O,B
",",O,O
including,O,O
akathisia,O,B
",",O,O
with,O,O
quetiapine,B,B
therapy,O,O
is,O,O
similar,O,O
to,O,O
that,O,O
with,O,O
placebo,O,O
.,O,O
Is,O,O
phenytoin,B,B
administration,O,O
safe,O,O
in,O,O
a,O,O
hypothermic,O,O
child,O,O
?,O,O
A,O,O
male,O,O
neonate,O,O
with,O,O
a,O,O
Chiari,O,B
malformation,O,O
and,O,O
a,O,O
leaking,O,O
myelomeningocoele,O,B
underwent,O,O
ventriculoperitoneal,O,O
shunt,O,O
insertion,O,O
followed,O,O
by,O,O
repair,O,O
of,O,O
myelomeningocoele,O,B
.,O,O
During,O,O
anaesthesia,O,O
and,O,O
surgery,O,O
",",O,O
he,O,O
inadvertently,O,O
became,O,O
moderately,O,O
hypothermic,O,O
.,O,O
Intravenous,O,O
phenytoin,B,B
was,O,O
administered,O,O
during,O,O
the,O,O
later,O,O
part,O,O
of,O,O
the,O,O
surgery,O,O
for,O,O
seizure,O,O
prophylaxis,O,O
.,O,O
Following,O,O
phenytoin,B,B
administration,O,O
",",O,O
the,O,O
patient,O,O
developed,O,O
acute,O,O
severe,O,O
bradycardia,O,O
",",O,O
refractory,O,O
to,O,O
atropine,B,B
and,O,O
adrenaline,B,B
.,O,O
The,O,O
cardiac,O,O
depressant,O,O
actions,O,O
of,O,O
phenytoin,B,B
and,O,O
hypothermia,O,B
can,O,O
be,O,O
additive,O,O
.,O,O
Administration,O,O
of,O,O
phenytoin,B,B
in,O,O
the,O,O
presence,O,O
of,O,O
hypothermia,O,B
may,O,O
lead,O,O
to,O,O
an,O,O
adverse,O,O
cardiac,O,O
event,O,O
in,O,O
children,O,O
.,O,O
As,O,O
phenytoin,B,B
is,O,O
a,O,O
commonly,O,O
used,O,O
drug,O,O
",",O,O
clinicians,O,O
need,O,O
to,O,O
be,O,O
aware,O,O
of,O,O
this,O,O
interaction,O,O
.,O,O
Valproate,B,B
-,O,I
induced,O,I
chorea,O,I
and,O,O
encephalopathy,O,O
in,O,O
atypical,O,O
nonketotic,O,O
hyperglycinemia,O,B
.,O,O
Nonketotic,O,O
hyperglycinemia,O,B
is,O,O
a,O,O
disorder,O,O
of,O,O
amino,O,B
acid,O,I
metabolism,O,I
in,O,O
which,O,O
a,O,O
defect,O,O
in,O,O
the,O,O
glycine,B,B
cleavage,O,I
system,O,I
leads,O,O
to,O,O
an,O,O
accumulation,O,O
of,O,O
glycine,B,B
in,O,O
the,O,O
brain,O,O
and,O,O
other,O,O
body,O,O
compartments,O,O
.,O,O
In,O,O
the,O,O
classical,O,O
form,O,O
it,O,O
presents,O,O
as,O,O
neonatal,O,O
apnea,O,O
",",O,O
intractable,O,O
seizures,O,O
",",O,O
and,O,O
hypotonia,O,O
",",O,O
followed,O,O
by,O,O
significant,O,O
psychomotor,O,O
retardation,O,O
.,O,O
An,O,O
important,O,O
subset,O,O
of,O,O
children,O,O
with,O,O
nonketotic,O,B
hyperglycinemia,O,I
are,O,O
atypical,O,O
variants,O,O
who,O,O
present,O,O
in,O,O
a,O,O
heterogeneous,O,O
manner,O,O
.,O,O
This,O,O
report,O,O
describes,O,O
a,O,O
patient,O,O
with,O,O
mild,O,O
language,O,O
delay,O,O
and,O,O
mental,O,O
retardation,O,O
",",O,O
who,O,O
was,O,O
found,O,O
to,O,O
have,O,O
nonketotic,O,B
hyperglycinemia,O,I
following,O,O
her,O,O
presentation,O,O
with,O,O
acute,O,O
encephalopathy,O,O
and,O,O
chorea,O,O
shortly,O,O
after,O,O
initiation,O,O
of,O,O
valproate,B,B
therapy,O,O
.,O,O
Delayed,O,O
institution,O,O
of,O,O
hypertension,O,B
during,O,O
focal,O,O
cerebral,O,O
ischemia,O,O
:,O,O
effect,O,O
on,O,O
brain,O,O
edema,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
induced,O,O
hypertension,O,B
instituted,O,O
after,O,O
a,O,O
2,O,O
-,O,O
h,O,O
delay,O,O
following,O,O
middle,O,O
cerebral,O,O
artery,O,O
occlusion,O,O
(,O,O
MCAO,O,B
),O,O
on,O,O
brain,O,O
edema,O,O
formation,O,O
and,O,O
histochemical,O,O
injury,O,O
was,O,O
studied,O,O
.,O,O
Under,O,O
isoflurane,B,B
anesthesia,O,O
",",O,O
the,O,O
MCA,O,B
of,O,O
14,O,O
spontaneously,O,O
hypertensive,O,B
rats,O,O
was,O,O
occluded,O,O
.,O,O
In,O,O
the,O,O
control,O,O
group,O,O
(,O,O
n,O,O
=,O,O
7,O,O
),O,O
",",O,O
the,O,O
mean,O,O
arterial,O,O
pressure,O,O
(,O,O
MAP,O,B
),O,O
was,O,O
not,O,O
manipulated,O,O
.,O,O
In,O,O
the,O,O
hypertensive,O,O
group,O,O
(,O,O
n,O,O
=,O,O
7,O,O
),O,O
",",O,O
the,O,O
MAP,O,B
was,O,O
elevated,O,O
by,O,O
25,O,O
-,O,O
30,O,O
mm,O,O
Hg,O,O
beginning,O,O
2,O,O
h,O,O
after,O,O
MCAO,O,O
.,O,O
Four,O,O
hours,O,O
after,O,O
MCAO,O,O
",",O,O
the,O,O
rats,O,O
were,O,O
killed,O,O
and,O,O
the,O,O
brains,O,O
harvested,O,O
.,O,O
The,O,O
brains,O,O
were,O,O
sectioned,O,O
along,O,O
coronal,O,O
planes,O,O
spanning,O,O
the,O,O
distribution,O,O
of,O,O
ischemia,O,O
produced,O,O
by,O,O
MCAO,O,O
.,O,O
Specific,O,O
gravity,O,O
(,O,O
SG,O,B
),O,O
was,O,O
determined,O,O
in,O,O
the,O,O
subcortex,O,O
and,O,O
in,O,O
two,O,O
sites,O,O
in,O,O
the,O,O
cortex,O,O
(,O,O
core,O,O
and,O,O
periphery,O,O
of,O,O
the,O,O
ischemic,O,O
territory,O,O
),O,O
.,O,O
The,O,O
extent,O,O
of,O,O
neuronal,O,O
injury,O,O
was,O,O
determined,O,O
by,O,O
2,B,O
",",I,O
3,I,O
",",I,O
5,I,O
-,I,O
triphenyltetrazolium,I,B
staining,O,O
.,O,O
In,O,O
the,O,O
ischemic,O,O
core,O,O
",",O,O
there,O,O
was,O,O
no,O,O
difference,O,O
in,O,O
SG,O,B
in,O,O
the,O,O
subcortex,O,O
and,O,O
cortex,O,O
in,O,O
the,O,O
two,O,O
groups,O,O
.,O,O
In,O,O
the,O,O
periphery,O,O
of,O,O
the,O,O
ischemic,O,B
territory,O,I
",",O,O
SG,O,O
in,O,O
the,O,O
cortex,O,O
was,O,O
greater,O,O
(,O,O
less,O,O
edema,O,B
accumulation,O,O
),O,O
in,O,O
the,O,O
hypertensive,O,O
group,O,O
(,O,O
1,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
vs,O,O
1,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
",",O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
area,O,O
of,O,O
histochemical,O,B
injury,O,I
(,O,O
as,O,O
a,O,O
percent,O,O
of,O,O
the,O,O
cross,O,O
-,O,O
sectional,O,O
area,O,O
of,O,O
the,O,O
hemisphere,O,O
),O,O
was,O,O
less,O,O
in,O,O
the,O,O
hypertensive,O,O
group,O,O
(,O,O
33,O,B
+,O,O
/,O,O
-,O,O
3,O,O
%,O,O
vs,O,O
21,O,B
+,O,O
/,O,O
-,O,O
2,O,O
%,O,O
",",O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
data,O,O
indicate,O,O
that,O,O
phenylephrine,B,B
-,O,O
induced,O,O
hypertension,O,O
instituted,O,O
2,O,O
h,O,O
after,O,O
MCAO,O,O
does,O,O
not,O,O
aggravate,O,O
edema,O,O
in,O,O
the,O,O
ischemic,O,O
core,O,O
",",O,O
that,O,O
it,O,O
improves,O,O
edema,O,O
in,O,O
the,O,O
periphery,O,O
of,O,O
the,O,O
ischemic,O,O
territory,O,O
",",O,O
and,O,O
that,O,O
it,O,O
reduces,O,O
the,O,O
area,O,O
of,O,O
histochemical,O,O
neuronal,O,O
dysfunction,O,O
.,O,O
Behavioral,O,O
effects,O,O
of,O,O
pubertal,O,O
anabolic,O,O
androgenic,O,O
steroid,B,B
exposure,O,O
in,O,O
male,O,O
rats,O,O
with,O,O
low,O,O
serotonin,B,B
.,O,O
The,O,O
goal,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
assess,O,O
the,O,O
interactive,O,O
effects,O,O
of,O,O
chronic,O,O
anabolic,O,B
androgenic,O,I
steroid,B,I
(,O,O
AAS,O,B
),O,O
exposure,O,O
and,O,O
brain,O,O
serotonin,B,B
(,O,O
5,B,B
-,I,I
hydroxytryptamine,I,I
",",O,O
5,B,B
-,I,I
HT,I,I
),O,O
depletion,O,O
on,O,O
behavior,O,O
of,O,O
pubertal,O,O
male,O,O
rats,O,O
.,O,O
Serotonin,B,B
was,O,O
depleted,O,O
beginning,O,O
on,O,O
postnatal,O,O
day,O,O
26,O,O
with,O,O
parachlorophenylalanine,B,B
(,O,O
PCPA,B,B
100,O,I
mg,O,I
/,O,I
kg,O,I
",",O,O
every,O,O
other,O,O
day,O,O
),O,O
;,O,O
controls,O,O
received,O,O
saline,O,B
.,O,O
At,O,O
puberty,O,O
(,O,O
P40,O,O
),O,O
",",O,O
half,O,O
the,O,O
PCPA,B,B
-,O,O
treated,O,O
rats,O,O
and,O,O
half,O,O
the,O,O
saline,O,B
-,O,O
treated,O,O
rats,O,O
began,O,O
treatment,O,O
with,O,O
testosterone,B,B
(,O,O
T,B,B
",",O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
5,O,O
days,O,O
/,O,O
week,O,O
),O,O
.,O,O
Behavioral,O,O
measures,O,O
included,O,O
locomotion,O,O
",",O,O
irritability,O,O
",",O,O
copulation,O,O
",",O,O
partner,O,O
preference,O,O
",",O,O
and,O,O
aggression,O,O
.,O,O
Animals,O,O
were,O,O
tested,O,O
for,O,O
aggression,O,O
in,O,O
their,O,O
home,O,O
cage,O,O
",",O,O
both,O,O
with,O,O
and,O,O
without,O,O
physical,O,O
provocation,O,O
(,O,O
mild,O,O
tail,O,O
pinch,O,O
),O,O
.,O,O
Brain,O,O
levels,O,O
of,O,O
5,B,B
-,I,I
HT,I,I
and,O,O
its,O,O
metabolite,O,O
",",O,O
5,B,B
-,I,I
hydroxyindoleacetic,I,I
acid,I,I
(,O,O
5,B,B
-,I,I
HIAA,I,I
),O,O
",",O,O
were,O,O
determined,O,O
using,O,O
HPLC,O,O
.,O,O
PCPA,B,O
significantly,O,O
and,O,O
substantially,O,O
depleted,O,O
5,B,B
-,I,I
HT,I,I
and,O,O
5,B,B
-,I,I
HIAA,I,I
in,O,O
all,O,O
brain,O,O
regions,O,O
examined,O,O
.,O,O
Chronic,O,O
T,B,O
treatment,O,O
significantly,O,O
decreased,O,O
5,B,B
-,I,I
HT,I,I
and,O,O
5,B,B
-,I,I
HIAA,I,I
in,O,O
certain,O,O
brain,O,O
areas,O,O
",",O,O
but,O,O
to,O,O
a,O,O
much,O,O
lesser,O,O
extent,O,O
than,O,O
PCPA,B,O
.,O,O
Chronic,O,O
exposure,O,O
to,O,O
PCPA,B,B
alone,O,O
significantly,O,O
decreased,O,O
locomotor,O,O
activity,O,O
and,O,O
increased,O,O
irritability,O,O
but,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
sexual,O,O
behavior,O,O
",",O,O
partner,O,O
preference,O,O
",",O,O
or,O,O
aggression,O,O
.,O,O
T,B,O
alone,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
locomotion,O,O
",",O,O
irritability,O,O
",",O,O
or,O,O
sexual,O,O
behavior,O,O
but,O,O
increased,O,O
partner,O,O
preference,O,O
and,O,O
aggression,O,O
.,O,O
The,O,O
most,O,O
striking,O,O
effect,O,O
of,O,O
combining,O,O
T,B,O
+,O,O
PCPA,B,B
was,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
attack,O,O
frequency,O,O
as,O,O
well,O,O
as,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
the,O,O
latency,O,O
to,O,O
attack,O,O
",",O,O
particularly,O,O
following,O,O
physical,O,O
provocation,O,O
.,O,O
Based,O,O
on,O,O
these,O,O
data,O,O
",",O,O
it,O,O
can,O,O
be,O,O
speculated,O,O
that,O,O
pubertal,O,O
AAS,O,B
users,O,O
with,O,O
low,O,O
central,O,O
5,B,B
-,I,I
HT,I,I
may,O,O
be,O,O
especially,O,O
prone,O,O
to,O,O
exhibit,O,O
aggressive,O,O
behavior,O,O
.,O,O
Effects,O,O
of,O,O
UMB24,B,B
and,O,O
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
-,O,O
SM,B,B
21,I,I
",",O,O
putative,O,O
sigma2,O,B
-,O,I
preferring,O,I
antagonists,O,O
",",O,O
on,O,O
behavioral,O,O
toxic,O,O
and,O,O
stimulant,O,O
effects,O,O
of,O,O
cocaine,B,B
in,O,O
mice,O,O
.,O,O
Earlier,O,O
studies,O,O
have,O,O
demonstrated,O,O
that,O,O
antagonism,O,O
of,O,O
sigma1,O,B
receptors,O,O
attenuates,O,O
the,O,O
convulsive,O,O
",",O,O
lethal,O,O
",",O,O
locomotor,O,O
stimulatory,O,O
and,O,O
rewarding,O,O
actions,O,O
of,O,O
cocaine,B,B
in,O,O
mice,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
contribution,O,O
of,O,O
sigma2,O,B
receptors,O,O
is,O,O
unclear,O,O
because,O,O
experimental,O,O
tools,O,O
to,O,O
selectively,O,O
target,O,O
this,O,O
subtype,O,O
are,O,O
unavailable,O,O
.,O,O
To,O,O
begin,O,O
addressing,O,O
this,O,O
need,O,O
",",O,O
we,O,O
characterized,O,O
UMB24,B,B
(,O,O
1,B,O
-,I,O
(,I,O
2,I,O
-,I,O
phenethyl,I,B
),I,O
-,I,O
4,I,B
-,I,I
(,I,O
2,I,O
-,I,O
pyridyl,I,B
),I,O
-,I,O
piperazine,I,B
),O,O
and,O,O
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
-,O,O
SM,B,B
21,I,I
(,O,O
3alpha,B,B
-,I,I
tropanyl,I,I
-,I,I
2,I,I
-,I,I
(,I,O
4,I,B
-,I,I
chorophenoxy,I,I
),I,O
butyrate,I,B
),O,O
in,O,O
receptor,O,O
binding,O,O
and,O,O
behavioral,O,O
studies,O,O
.,O,O
Receptor,O,O
binding,O,O
studies,O,O
confirmed,O,O
that,O,O
UMB24,B,B
and,O,O
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
-,O,O
SM,B,B
21,I,I
display,O,O
preferential,O,O
affinity,O,O
for,O,O
sigma2,O,B
over,O,O
sigma1,O,B
receptors,O,O
.,O,O
In,O,O
behavioral,O,O
studies,O,O
",",O,O
pretreatment,O,O
of,O,O
Swiss,O,O
Webster,O,O
mice,O,O
with,O,O
UMB24,B,B
or,O,O
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
-,O,O
SM,B,B
21,I,I
significantly,O,O
attenuated,O,O
cocaine,B,B
-,O,O
induced,O,O
convulsions,O,O
and,O,O
locomotor,O,O
activity,O,O
",",O,O
but,O,O
not,O,O
lethality,O,O
.,O,O
When,O,O
administered,O,O
alone,O,O
",",O,O
(,O,O
+,O,O
/,O,O
-,O,O
),O,O
-,O,O
SM,B,B
21,I,I
produced,O,O
no,O,O
significant,O,O
effects,O,O
compared,O,O
to,O,O
control,O,O
injections,O,O
of,O,O
saline,O,B
",",O,O
but,O,O
UMB24,B,B
had,O,O
locomotor,O,O
depressant,O,O
actions,O,O
.,O,O
Together,O,O
",",O,O
the,O,O
data,O,O
suggest,O,O
that,O,O
sigma2,O,B
receptor,O,O
antagonists,O,O
have,O,O
the,O,O
potential,O,O
to,O,O
attenuate,O,O
some,O,O
of,O,O
the,O,O
behavioral,O,O
effects,O,O
of,O,O
cocaine,B,B
",",O,O
and,O,O
further,O,O
development,O,O
of,O,O
more,O,O
selective,O,O
",",O,O
high,O,O
affinity,O,O
ligands,O,O
are,O,O
warranted,O,O
.,O,O
Cardiac,O,O
arrest,O,O
in,O,O
a,O,O
child,O,O
with,O,O
cerebral,O,B
palsy,O,I
undergoing,O,O
sevoflurane,B,B
induction,O,O
of,O,O
anesthesia,O,O
after,O,O
preoperative,O,O
clonidine,B,B
.,O,O
Clonidine,B,O
is,O,O
a,O,O
frequently,O,O
administered,O,O
alpha2,O,B
-,O,I
adrenergic,O,I
agonist,O,I
which,O,O
can,O,O
decrease,O,O
heart,O,O
rate,O,O
and,O,O
blood,O,O
pressure,O,O
.,O,O
We,O,O
present,O,O
a,O,O
case,O,O
of,O,O
a,O,O
5,O,O
-,O,O
year,O,O
-,O,O
old,O,O
child,O,O
with,O,O
cerebral,O,B
palsy,O,I
and,O,O
seizure,O,O
disorder,O,O
",",O,O
receiving,O,O
clonidine,B,B
for,O,O
restlessness,O,O
",",O,O
who,O,O
presented,O,O
for,O,O
placement,O,O
of,O,O
a,O,O
baclofen,B,B
pump,O,O
.,O,O
Without,O,O
the,O,O
knowledge,O,O
of,O,O
the,O,O
medical,O,O
personnel,O,O
",",O,O
the,O,O
patient,O,O
',O,O
s,O,O
mother,O,O
administered,O,O
three,O,O
doses,O,O
of,O,O
clonidine,B,B
during,O,O
the,O,O
evening,O,O
before,O,O
and,O,O
morning,O,O
of,O,O
surgery,O,O
to,O,O
reduce,O,O
anxiety,O,O
.,O,O
During,O,O
induction,O,O
of,O,O
anesthesia,O,O
",",O,O
the,O,O
patient,O,O
developed,O,O
bradycardia,O,O
and,O,O
hypotension,O,O
requiring,O,O
cardiac,O,O
resuscitation,O,O
.,O,O
There,O,O
are,O,O
no,O,O
previous,O,O
reports,O,O
of,O,O
clonidine,B,B
-,O,O
associated,O,O
cardiac,O,O
arrest,O,O
in,O,O
a,O,O
child,O,O
undergoing,O,O
induction,O,O
of,O,O
anesthesia,O,O
.,O,O
Angiotensin,O,B
-,O,O
converting,O,O
enzyme,O,O
(,O,O
ACE,O,B
),O,O
inhibitor,O,O
-,O,O
associated,O,O
angioedema,O,O
of,O,O
the,O,O
stomach,O,O
and,O,O
small,O,O
intestine,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
This,O,O
is,O,O
a,O,O
case,O,O
report,O,O
on,O,O
a,O,O
45,O,O
-,O,O
year,O,O
old,O,O
African,O,O
-,O,O
American,O,O
female,O,O
with,O,O
newly,O,O
diagnosed,O,O
hypertension,O,O
",",O,O
who,O,O
was,O,O
started,O,O
on,O,O
a,O,O
combination,O,O
pill,O,O
of,O,O
amlodipine,B,B
/,O,O
benazapril,B,B
10,O,O
/,O,O
5,O,O
mg,O,O
.,O,O
The,O,O
very,O,O
next,O,O
day,O,O
",",O,O
she,O,O
presented,O,O
at,O,O
the,O,O
emergency,O,O
room,O,O
(,O,O
ER,O,B
),O,O
with,O,O
abdominal,O,O
pain,O,O
",",O,O
nausea,O,O
and,O,O
vomiting,O,O
.,O,O
Physical,O,O
exam,O,O
",",O,O
complete,O,O
metabolic,O,O
panel,O,O
",",O,O
and,O,O
hemogram,O,O
were,O,O
in,O,O
the,O,O
normal,O,O
range,O,O
.,O,O
She,O,O
was,O,O
discharged,O,O
from,O,O
the,O,O
ER,O,B
after,O,O
a,O,O
few,O,O
hours,O,O
of,O,O
treatment,O,O
with,O,O
fluid,O,O
and,O,O
analgesics,O,O
.,O,O
However,O,O
",",O,O
she,O,O
returned,O,O
to,O,O
the,O,O
ER,O,B
the,O,O
next,O,O
day,O,O
with,O,O
the,O,O
same,O,O
complaints,O,O
.,O,O
This,O,O
time,O,O
the,O,O
physical,O,O
exam,O,O
was,O,O
significant,O,O
for,O,O
a,O,O
distended,O,O
abdomen,O,O
with,O,O
dullness,O,O
to,O,O
percussion,O,O
.,O,O
CT,O,O
scan,O,O
of,O,O
the,O,O
abdomen,O,O
revealed,O,O
markedly,O,O
thickened,O,O
antrum,O,O
of,O,O
the,O,O
stomach,O,O
",",O,O
duodenum,O,O
and,O,O
jejunum,O,O
",",O,O
along,O,O
with,O,O
fluid,O,O
in,O,O
the,O,O
abdominal,O,O
and,O,O
pelvic,O,O
cavity,O,O
.,O,O
Angiotensin,O,B
-,O,I
converting,O,I
enzyme,O,I
inhibitor,O,I
(,O,I
ACEI,O,I
),O,I
-,O,I
induced,O,I
angioedema,O,I
was,O,O
suspected,O,O
",",O,O
and,O,O
anti,O,O
-,O,O
hypertensive,O,O
medications,O,O
were,O,O
discontinued,O,O
.,O,O
Her,O,O
symptoms,O,O
improved,O,O
within,O,O
the,O,O
next,O,O
24,O,O
hours,O,O
",",O,O
and,O,O
repeat,O,O
CT,O,O
after,O,O
72,O,O
hours,O,O
revealed,O,O
marked,O,O
improvement,O,O
in,O,O
stomach,O,B
and,O,O
small,O,B
bowel,O,I
thickening,O,O
and,O,O
resolution,O,O
of,O,O
ascites,O,B
.,O,O
The,O,O
recognition,O,O
of,O,O
angiotensin,B,B
-,O,I
converting,O,I
enzyme,O,I
(,O,I
ACE,O,I
),O,I
and,O,O
angiotensin,B,B
receptor,O,I
blocker,O,I
(,O,I
ARB,O,I
),O,I
intestinal,O,I
angioedema,O,I
constitutes,O,O
a,O,O
challenge,O,O
to,O,O
primary,O,O
care,O,O
physicians,O,O
",",O,O
internists,O,O
",",O,O
emergency,O,O
room,O,O
personal,O,O
and,O,O
surgeons,O,O
.,O,O
Carbamazepine,B,B
-,O,O
induced,O,O
cardiac,O,O
dysfunction,O,O
.,O,O
Characterization,O,O
of,O,O
two,O,O
distinct,O,O
clinical,O,O
syndromes,O,O
.,O,O
A,O,O
patient,O,O
with,O,O
sinus,O,O
bradycardia,O,O
and,O,O
atrioventricular,O,O
block,O,O
",",O,O
induced,O,O
by,O,O
carbamazepine,B,B
",",O,O
prompted,O,O
an,O,O
extensive,O,O
literature,O,O
review,O,O
of,O,O
all,O,O
previously,O,O
reported,O,O
cases,O,O
.,O,O
From,O,O
the,O,O
analysis,O,O
of,O,O
these,O,O
cases,O,O
",",O,O
two,O,O
distinct,O,O
forms,O,O
of,O,O
carbamazepine,B,B
-,O,O
associated,O,O
cardiac,O,O
dysfunction,O,O
emerged,O,O
.,O,O
One,O,O
patient,O,O
group,O,O
developed,O,O
sinus,O,B
tachycardias,O,O
in,O,O
the,O,O
setting,O,O
of,O,O
a,O,O
massive,O,O
carbamazepine,B,B
overdose,O,O
.,O,O
The,O,O
second,O,O
group,O,O
consisted,O,O
almost,O,O
exclusively,O,O
of,O,O
elderly,O,O
women,O,O
who,O,O
developed,O,O
potentially,O,O
life,O,O
-,O,O
threatening,O,O
bradyarrhythmias,O,B
or,O,O
atrioventricular,O,B
conduction,O,O
delay,O,O
",",O,O
associated,O,O
with,O,O
either,O,O
therapeutic,O,O
or,O,O
modestly,O,O
elevated,O,O
carbamazepine,B,B
serum,O,O
levels,O,O
.,O,O
Because,O,O
carbamazepine,B,B
is,O,O
widely,O,O
used,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
many,O,O
neurologic,O,O
and,O,O
psychiatric,O,O
conditions,O,O
",",O,O
the,O,O
recognition,O,O
of,O,O
the,O,O
latter,O,O
syndrome,O,O
has,O,O
important,O,O
implications,O,O
for,O,O
the,O,O
use,O,O
of,O,O
this,O,O
drug,O,O
in,O,O
elderly,O,O
patients,O,O
.,O,O
Detection,O,O
of,O,O
abnormal,O,O
cardiac,O,O
adrenergic,O,O
neuron,O,O
activity,O,O
in,O,O
adriamycin,B,B
-,O,I
induced,O,I
cardiomyopathy,O,I
with,O,O
iodine,B,B
-,I,I
125,I,I
-,I,I
metaiodobenzylguanidine,I,I
.,O,O
Radiolabeled,B,O
metaiodobenzylguanidine,I,B
(,O,O
MIBG,B,B
),O,O
",",O,O
an,O,O
analog,O,O
of,O,O
norepinephrine,B,B
(,O,O
NE,B,B
),O,O
",",O,O
serves,O,O
as,O,O
an,O,O
index,O,O
of,O,O
adrenergic,O,O
neuron,O,O
integrity,O,O
and,O,O
function,O,O
.,O,O
Using,O,O
a,O,O
rat,O,O
model,O,O
of,O,O
adriamycin,B,B
-,O,O
induced,O,O
cardiomyopathy,O,O
",",O,O
we,O,O
tested,O,O
the,O,O
hypothesis,O,O
that,O,O
abnormal,O,O
cardiac,O,O
adrenergic,O,O
neuron,O,O
activity,O,O
may,O,O
appear,O,O
and,O,O
be,O,O
exacerbated,O,O
dose,O,O
-,O,O
dependently,O,O
in,O,O
adriamycin,B,B
cardiomyopathy,O,O
.,O,O
The,O,O
degree,O,O
of,O,O
vacuolar,O,O
degeneration,O,O
of,O,O
myocardial,O,O
cells,O,O
was,O,O
analyzed,O,O
in,O,O
relation,O,O
to,O,O
the,O,O
duration,O,O
of,O,O
adriamycin,B,B
treatment,O,O
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
once,O,O
a,O,O
week,O,O
),O,O
.,O,O
There,O,O
were,O,O
no,O,O
abnormalities,O,O
or,O,O
only,O,O
isolated,O,O
degeneration,O,O
in,O,O
the,O,O
1,O,O
-,O,O
or,O,O
2,O,O
-,O,O
wk,O,O
treatment,O,O
groups,O,O
",",O,O
isolated,O,O
or,O,O
scattered,O,O
degeneration,O,O
in,O,O
half,O,O
of,O,O
the,O,O
3,O,O
-,O,O
wk,O,O
group,O,O
",",O,O
frequent,O,O
scattered,O,O
degeneration,O,O
in,O,O
the,O,O
4,O,O
-,O,O
wk,O,O
group,O,O
",",O,O
scattered,O,O
or,O,O
focal,O,O
degeneration,O,O
in,O,O
the,O,O
5,O,O
-,O,O
wk,O,O
group,O,O
",",O,O
and,O,O
extensive,O,O
degeneration,O,O
in,O,O
the,O,O
8,O,O
-,O,O
wk,O,O
group,O,O
.,O,O
Myocardial,O,O
accumulation,O,O
of,O,O
[,O,O
125I,O,B
],O,O
MIBG,B,B
4,O,O
hr,O,O
after,O,O
intravenous,O,O
injection,O,O
did,O,O
not,O,O
differ,O,O
between,O,O
the,O,O
controls,O,O
and,O,O
the,O,O
groups,O,O
treated,O,O
3,O,O
wk,O,O
or,O,O
less,O,O
.,O,O
However,O,O
",",O,O
the,O,O
4,O,O
-,O,O
wk,O,O
group,O,O
had,O,O
a,O,O
slightly,O,O
lower,O,O
accumulation,O,O
in,O,O
the,O,O
right,O,O
ventricular,O,O
wall,O,O
(,O,O
82,O,O
%,O,O
of,O,O
the,O,O
control,O,O
),O,O
and,O,O
significantly,O,O
lower,O,O
accumulation,O,O
in,O,O
the,O,O
left,O,O
ventricular,O,O
wall,O,O
(,O,O
about,O,O
66,O,O
%,O,O
of,O,O
the,O,O
control,O,O
:,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
5,O,O
-,O,O
wk,O,O
group,O,O
",",O,O
MIBG,B,B
accumulation,O,O
in,O,O
the,O,O
right,O,O
and,O,O
left,O,O
ventricular,O,O
wall,O,O
was,O,O
35,O,O
%,O,O
and,O,O
27,O,O
%,O,O
of,O,O
that,O,O
in,O,O
controls,O,O
",",O,O
respectively,O,O
(,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
8,O,O
-,O,O
wk,O,O
group,O,O
",",O,O
MIBG,B,B
accumulation,O,O
in,O,O
the,O,O
right,O,O
and,O,O
left,O,O
ventricular,O,O
wall,O,O
was,O,O
18,O,O
%,O,O
and,O,O
14,O,O
%,O,O
of,O,O
that,O,O
in,O,O
controls,O,O
",",O,O
respectively,O,O
(,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
Thus,O,O
",",O,O
MIBG,B,B
accumulation,O,O
in,O,O
the,O,O
myocardium,O,O
decreased,O,O
in,O,O
an,O,O
adriamycin,B,B
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
The,O,O
appearance,O,O
of,O,O
impaired,O,O
cardiac,O,O
adrenergic,O,O
neuron,O,O
activity,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
slight,O,O
myocardial,O,O
impairment,O,O
(,O,O
scattered,O,O
or,O,O
focal,O,O
vacuolar,O,O
degeneration,O,O
),O,O
indicates,O,O
that,O,O
MIBG,B,B
scintigraphy,O,O
may,O,O
be,O,O
a,O,O
useful,O,O
method,O,O
for,O,O
detection,O,O
of,O,O
adriamycin,B,B
-,O,O
induced,O,O
cardiomyopathy,O,O
.,O,O
Syncope,O,O
and,O,O
QT,O,B
prolongation,O,I
among,O,O
patients,O,O
treated,O,O
with,O,O
methadone,B,B
for,O,O
heroin,B,O
dependence,O,O
in,O,O
the,O,O
city,O,O
of,O,O
Copenhagen,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Methadone,B,B
is,O,O
prescribed,O,O
to,O,O
heroin,B,O
addicts,O,O
to,O,O
decrease,O,O
illicit,O,O
opioid,O,O
use,O,O
.,O,O
Prolongation,O,O
of,O,O
the,O,O
QT,O,B
interval,O,I
in,O,O
the,O,O
ECG,O,O
of,O,O
patients,O,O
with,O,O
torsade,O,O
de,O,O
pointes,O,O
(,O,O
TdP,O,O
),O,O
has,O,O
been,O,O
reported,O,O
in,O,O
methadone,B,B
users,O,O
.,O,O
As,O,O
heroin,B,B
addicts,O,O
sometimes,O,O
faint,O,O
while,O,O
using,O,O
illicit,O,O
drugs,O,O
",",O,O
doctors,O,O
might,O,O
attribute,O,O
too,O,O
many,O,O
episodes,O,O
of,O,O
syncope,O,O
to,O,O
illicit,O,O
drug,O,O
use,O,O
and,O,O
thereby,O,O
underestimate,O,O
the,O,O
incidence,O,O
of,O,O
TdP,O,B
in,O,O
this,O,O
special,O,O
population,O,O
",",O,O
and,O,O
the,O,O
high,O,O
mortality,O,O
in,O,O
this,O,O
population,O,O
may,O,O
",",O,O
in,O,O
part,O,O
",",O,O
be,O,O
caused,O,O
by,O,O
the,O,O
proarrhythmic,O,O
effect,O,O
of,O,O
methadone,B,B
.,O,O
METHODS,O,O
:,O,O
In,O,O
this,O,O
cross,O,O
-,O,O
sectional,O,O
study,O,O
interview,O,O
",",O,O
ECGs,O,O
and,O,O
blood,O,O
samples,O,O
were,O,O
collected,O,O
in,O,O
a,O,O
population,O,O
of,O,O
adult,O,O
heroin,B,B
addicts,O,O
treated,O,O
with,O,O
methadone,B,B
or,O,O
buprenorphine,B,B
on,O,O
a,O,O
daily,O,O
basis,O,O
.,O,O
Of,O,O
the,O,O
patients,O,O
at,O,O
the,O,O
Drug,O,B
Addiction,O,I
Service,O,I
in,O,O
the,O,O
municipal,O,O
of,O,O
Copenhagen,O,O
",",O,O
450,O,O
(,O,O
approximately,O,O
52,O,O
%,O,O
),O,O
were,O,O
included,O,O
.,O,O
The,O,O
QT,O,B
interval,O,I
was,O,O
estimated,O,O
from,O,O
12,O,O
lead,O,O
ECGs,O,O
.,O,O
All,O,O
participants,O,O
were,O,O
interviewed,O,O
about,O,O
any,O,O
experience,O,O
of,O,O
syncope,O,O
.,O,O
The,O,O
association,O,O
between,O,O
opioid,O,B
dose,O,O
and,O,O
QT,O,B
",",O,O
and,O,O
methadone,B,B
dose,O,O
and,O,O
reporting,O,O
of,O,O
syncope,O,O
was,O,O
assessed,O,O
using,O,O
multivariate,O,O
linear,O,O
regression,O,O
and,O,O
logistic,O,O
regression,O,O
",",O,O
respectively,O,O
.,O,O
RESULTS,O,O
:,O,O
Methadone,B,B
dose,O,O
was,O,O
associated,O,O
with,O,O
longer,O,O
QT,O,B
interval,O,I
of,O,O
0,O,O
.,O,O
140,O,O
ms,O,O
/,O,O
mg,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
No,O,O
association,O,O
between,O,O
buprenorphine,B,B
and,O,O
QTc,O,B
was,O,O
found,O,O
.,O,O
Among,O,O
the,O,O
subjects,O,O
treated,O,O
with,O,O
methadone,B,B
",",O,O
28,O,O
%,O,O
men,O,O
and,O,O
32,O,O
%,O,O
women,O,O
had,O,O
prolonged,O,O
QTc,O,B
interval,O,O
.,O,O
None,O,O
of,O,O
the,O,O
subjects,O,O
treated,O,O
with,O,O
buprenorphine,B,B
had,O,O
QTc,O,B
interval,O,O
>,O,O
0,O,O
.,O,O
440,O,O
s,O,O
(,O,O
(,O,O
1,O,O
/,O,O
2,O,O
),O,O
),O,O
.,O,O
A,O,O
50,O,O
mg,O,O
higher,O,O
methadone,B,B
dose,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
1,O,O
.,O,O
2,O,O
(,O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
1,O,O
to,O,O
1,O,O
.,O,O
4,O,O
),O,O
times,O,O
higher,O,O
odds,O,O
for,O,O
syncope,O,B
.,O,O
CONCLUSIONS,O,O
:,O,O
Methadone,B,B
is,O,O
associated,O,O
with,O,O
QT,O,B
prolongation,O,O
and,O,O
higher,O,O
reporting,O,O
of,O,O
syncope,O,B
in,O,O
a,O,O
population,O,O
of,O,O
heroin,B,B
addicts,O,O
.,O,O
Neuroleptic,O,B
malignant,O,I
syndrome,O,I
induced,O,O
by,O,O
ziprasidone,B,B
on,O,O
the,O,O
second,O,O
day,O,O
of,O,O
treatment,O,O
.,O,O
Neuroleptic,O,B
malignant,O,I
syndrome,O,I
(,O,O
NMS,O,B
),O,O
is,O,O
the,O,O
rarest,O,O
and,O,O
most,O,O
serious,O,O
of,O,O
the,O,O
neuroleptic,O,O
-,O,O
induced,O,O
movement,O,O
disorders,O,O
.,O,O
We,O,O
describe,O,O
a,O,O
case,O,O
of,O,O
neuroleptic,O,B
malignant,O,I
syndrome,O,I
(,O,O
NMS,O,B
),O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
ziprasidone,B,B
.,O,O
Although,O,O
conventional,O,O
neuroleptics,O,B
are,O,O
more,O,O
frequently,O,O
associated,O,O
with,O,O
NMS,O,B
",",O,O
atypical,O,O
antipsychotic,O,O
drugs,O,O
like,O,O
ziprasidone,B,B
may,O,O
also,O,O
be,O,O
a,O,O
cause,O,O
.,O,O
The,O,O
patient,O,O
is,O,O
a,O,O
24,O,O
-,O,O
year,O,O
-,O,O
old,O,O
male,O,O
with,O,O
a,O,O
history,O,O
of,O,O
schizophrenia,O,B
who,O,O
developed,O,O
signs,O,O
and,O,O
symptoms,O,O
of,O,O
NMS,O,B
after,O,O
2,O,O
days,O,O
of,O,O
treatment,O,O
with,O,O
an,O,O
80,O,O
-,O,O
mg,O,O
/,O,O
day,O,O
dose,O,O
of,O,O
orally,O,O
administrated,O,O
ziprasidone,B,B
.,O,O
This,O,O
case,O,O
is,O,O
the,O,O
earliest,O,O
(,O,O
second,O,O
day,O,O
of,O,O
treatment,O,O
),O,O
NMS,O,O
due,O,O
to,O,O
ziprasidone,B,B
reported,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
Peripheral,O,O
iron,B,B
dextran,I,I
induced,O,O
degeneration,O,O
of,O,O
dopaminergic,O,O
neurons,O,O
in,O,O
rat,O,O
substantia,O,O
nigra,O,O
.,O,O
Iron,B,B
accumulation,O,O
is,O,O
considered,O,O
to,O,O
be,O,O
involved,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
.,O,O
To,O,O
demonstrate,O,O
the,O,O
relationship,O,O
between,O,O
peripheral,O,O
iron,B,B
overload,O,O
and,O,O
dopaminergic,O,O
neuron,O,O
loss,O,O
in,O,O
rat,O,O
substantia,O,O
nigra,O,O
(,O,O
SN,O,O
),O,O
",",O,O
in,O,O
the,O,O
present,O,O
study,O,O
we,O,O
used,O,O
fast,O,O
cyclic,O,O
voltammetry,O,O
",",O,O
tyrosine,B,O
hydroxylase,O,O
(,O,O
TH,O,O
),O,O
immunohistochemistry,O,O
",",O,O
Perls,O,O
',O,O
iron,B,B
staining,O,O
",",O,O
and,O,O
high,O,O
performance,O,O
liquid,O,O
chromatography,O,O
-,O,O
electrochemical,O,O
detection,O,O
to,O,O
study,O,O
the,O,O
degeneration,O,O
of,O,O
dopaminergic,O,O
neurons,O,O
and,O,O
increased,O,O
iron,B,B
content,O,O
in,O,O
the,O,O
SN,O,O
of,O,O
iron,B,B
dextran,I,I
overloaded,O,O
animals,O,O
.,O,O
The,O,O
findings,O,O
showed,O,O
that,O,O
peripheral,O,O
iron,B,B
dextran,I,I
overload,O,O
increased,O,O
the,O,O
iron,B,B
staining,O,O
positive,O,O
cells,O,O
and,O,O
reduced,O,O
the,O,O
number,O,O
of,O,O
TH,O,B
-,O,O
immunoreactive,O,O
neurons,O,O
in,O,O
the,O,O
SN,O,O
.,O,O
As,O,O
a,O,O
result,O,O
",",O,O
dopamine,B,B
release,O,O
and,O,O
content,O,O
",",O,O
as,O,O
well,O,O
as,O,O
its,O,O
metabolites,O,O
contents,O,O
were,O,O
decreased,O,O
in,O,O
caudate,O,O
putamen,O,O
.,O,O
Even,O,O
more,O,O
dramatic,O,O
changes,O,O
were,O,O
found,O,O
in,O,O
chronic,O,O
overload,O,O
group,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
peripheral,O,O
iron,B,B
dextran,I,I
can,O,O
increase,O,O
the,O,O
iron,B,B
level,O,O
in,O,O
the,O,O
SN,O,O
",",O,O
where,O,O
excessive,O,O
iron,B,B
causes,O,O
the,O,O
degeneration,O,O
of,O,O
dopaminergic,O,O
neurons,O,O
.,O,O
The,O,O
chronic,O,O
iron,B,B
overload,O,O
may,O,O
be,O,O
more,O,O
destructive,O,O
to,O,O
dopaminergic,O,O
neurons,O,O
than,O,O
the,O,O
acute,O,O
iron,B,B
overload,O,O
.,O,O
Attenuated,O,O
disruption,O,O
of,O,O
prepulse,O,O
inhibition,O,O
by,O,O
dopaminergic,O,O
stimulation,O,O
after,O,O
maternal,O,O
deprivation,O,O
and,O,O
adolescent,O,O
corticosterone,B,O
treatment,O,O
in,O,O
rats,O,O
.,O,O
The,O,O
development,O,O
of,O,O
schizophrenia,O,B
may,O,O
include,O,O
an,O,O
early,O,O
neurodevelopmental,O,O
stress,O,O
component,O,O
which,O,O
increases,O,O
vulnerability,O,O
to,O,O
later,O,O
stressful,O,O
life,O,O
events,O,O
",",O,O
in,O,O
combination,O,O
leading,O,O
to,O,O
overt,O,O
disease,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
effect,O,O
of,O,O
an,O,O
early,O,O
stress,O,O
",",O,O
in,O,O
the,O,O
form,O,O
of,O,O
maternal,O,O
deprivation,O,O
",",O,O
combined,O,O
with,O,O
a,O,O
later,O,O
stress,O,O
",",O,O
simulated,O,O
by,O,O
chronic,O,O
periadolescent,O,O
corticosterone,B,B
treatment,O,O
",",O,O
on,O,O
behaviour,O,O
in,O,O
rats,O,O
.,O,O
Acute,O,O
treatment,O,O
with,O,O
apomorphine,B,B
caused,O,O
disruption,O,O
of,O,O
prepulse,O,O
inhibition,O,O
(,O,O
PPI,O,B
),O,O
in,O,O
controls,O,O
and,O,O
in,O,O
rats,O,O
that,O,O
had,O,O
undergone,O,O
either,O,O
maternal,O,O
deprivation,O,O
or,O,O
corticosterone,B,B
treatment,O,O
",",O,O
but,O,O
was,O,O
surprisingly,O,O
absent,O,O
in,O,O
rats,O,O
that,O,O
had,O,O
undergone,O,O
the,O,O
combined,O,O
early,O,O
and,O,O
late,O,O
stress,O,O
.,O,O
Amphetamine,B,B
treatment,O,O
significantly,O,O
disrupted,O,O
PPI,O,B
in,O,O
both,O,O
non,O,O
-,O,O
deprived,O,O
groups,O,O
",",O,O
but,O,O
was,O,O
absent,O,O
in,O,O
both,O,O
maternally,O,O
deprived,O,O
groups,O,O
.,O,O
The,O,O
serotonin,B,B
-,O,O
1A,O,O
receptor,O,O
agonist,O,O
",",O,O
8,B,B
-,I,I
OH,I,I
-,I,I
DPAT,I,I
",",O,O
induced,O,O
a,O,O
significant,O,O
disruption,O,O
of,O,O
PPI,O,B
in,O,O
all,O,O
groups,O,O
.,O,O
Amphetamine,B,B
-,O,O
induced,O,O
locomotor,O,O
hyperactivity,O,O
was,O,O
similar,O,O
in,O,O
all,O,O
groups,O,O
.,O,O
These,O,O
results,O,O
show,O,O
an,O,O
inhibitory,O,O
interaction,O,O
of,O,O
early,O,O
stress,O,O
",",O,O
caused,O,O
by,O,O
maternal,O,O
deprivation,O,O
",",O,O
combined,O,O
with,O,O
',O,O
adolescent,O,O
',O,O
stress,O,O
",",O,O
simulated,O,O
by,O,O
corticosterone,B,B
treatment,O,O
",",O,O
on,O,O
dopaminergic,O,O
regulation,O,O
of,O,O
PPI,O,B
.,O,O
The,O,O
altered,O,O
effects,O,O
of,O,O
apomorphine,B,B
and,O,O
amphetamine,B,B
could,O,O
indicate,O,O
differential,O,O
changes,O,O
in,O,O
dopamine,B,B
receptor,O,O
signalling,O,O
leading,O,O
to,O,O
functional,O,O
desensitisation,O,O
",",O,O
or,O,O
altered,O,O
modulation,O,O
of,O,O
sensory,O,O
gating,O,O
in,O,O
the,O,O
nucleus,O,O
accumbens,O,B
by,O,O
limbic,O,O
structures,O,O
such,O,O
as,O,O
the,O,O
hippocampus,O,B
.,O,O
An,O,O
extremely,O,O
rare,O,O
case,O,O
of,O,O
delusional,O,O
parasitosis,O,B
in,O,O
a,O,O
chronic,O,O
hepatitis,O,B
C,O,I
patient,O,O
during,O,O
pegylated,B,B
interferon,I,I
alpha,I,I
-,I,I
2b,I,I
and,O,O
ribavirin,B,B
treatment,O,O
.,O,O
During,O,O
treatment,O,O
of,O,O
chronic,O,O
hepatitis,O,B
C,O,I
patients,O,O
with,O,O
interferon,O,B
and,O,O
ribavirin,B,B
",",O,O
a,O,O
lot,O,O
of,O,O
side,O,O
effects,O,O
are,O,O
described,O,O
.,O,O
Twenty,O,O
-,O,O
three,O,O
percent,O,O
to,O,O
44,O,O
%,O,O
of,O,O
patients,O,O
develop,O,O
depression,O,B
.,O,O
A,O,O
minority,O,O
of,O,O
patients,O,O
evolve,O,O
to,O,O
psychosis,O,B
.,O,O
To,O,O
the,O,O
best,O,O
of,O,O
our,O,O
knowledge,O,O
",",O,O
no,O,O
cases,O,O
of,O,O
psychogenic,O,B
parasitosis,O,I
occurring,O,O
during,O,O
interferon,O,B
therapy,O,O
have,O,O
been,O,O
described,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
We,O,O
present,O,O
a,O,O
49,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
who,O,O
developed,O,O
a,O,O
delusional,O,O
parasitosis,O,O
during,O,O
treatment,O,O
with,O,O
pegylated,B,B
interferon,I,I
alpha,I,I
-,I,I
2b,I,I
weekly,O,O
and,O,O
ribavirin,B,B
.,O,O
She,O,O
complained,O,O
of,O,O
seeing,O,O
parasites,O,B
and,O,O
the,O,O
larvae,O,O
of,O,O
fleas,O,B
in,O,O
her,O,O
stools,O,O
.,O,O
This,O,O
could,O,O
not,O,O
be,O,O
confirmed,O,O
by,O,O
any,O,O
technical,O,O
examination,O,O
.,O,O
All,O,O
the,O,O
complaints,O,O
disappeared,O,O
after,O,O
stopping,O,O
pegylated,B,B
interferon,I,I
alpha,I,I
-,I,I
2b,I,I
and,O,O
reappeared,O,O
after,O,O
restarting,O,O
it,O,O
.,O,O
She,O,O
had,O,O
a,O,O
complete,O,O
sustained,O,O
viral,O,O
response,O,O
.,O,O
Hepatonecrosis,O,B
and,O,O
cholangitis,O,B
related,O,O
to,O,O
long,O,O
-,O,O
term,O,O
phenobarbital,B,B
therapy,O,O
:,O,O
an,O,O
autopsy,O,O
report,O,O
of,O,O
two,O,O
patients,O,O
.,O,O
Phenobarbital,B,B
(,O,O
PB,B,I
),O,O
has,O,O
a,O,O
reputation,O,O
for,O,O
safety,O,O
",",O,O
and,O,O
it,O,O
is,O,O
commonly,O,O
believed,O,O
that,O,O
PB,B,B
-,O,O
related,O,O
increases,O,O
in,O,O
serum,O,O
aminotransferase,O,B
levels,O,O
do,O,O
not,O,O
indicate,O,O
or,O,O
predict,O,O
the,O,O
development,O,O
of,O,O
significant,O,O
chronic,O,O
liver,O,O
disease,O,O
.,O,O
Here,O,O
we,O,O
report,O,O
of,O,O
two,O,O
adult,O,O
patients,O,O
with,O,O
a,O,O
long,O,O
history,O,O
of,O,O
epilepsy,O,B
treated,O,O
with,O,O
PB,B,B
who,O,O
died,O,O
suddenly,O,O
:,O,O
one,O,O
as,O,O
consequence,O,O
of,O,O
cardiac,O,B
arrest,O,I
",",O,O
the,O,O
other,O,O
of,O,O
acute,O,O
bronchopneumonia,O,B
.,O,O
At,O,O
autopsy,O,O
",",O,O
analysis,O,O
of,O,O
liver,O,B
parenchyma,O,I
revealed,O,O
rich,O,O
portal,O,O
inflammatory,O,O
infiltrate,O,O
",",O,O
which,O,O
consisted,O,O
of,O,O
mixed,O,O
eosinophil,O,B
and,O,O
monocyte,O,B
cells,O,O
",",O,O
associated,O,O
with,O,O
several,O,O
foci,O,O
of,O,O
necrosis,O,B
surrounded,O,O
by,O,O
a,O,O
hard,O,O
ring,O,O
of,O,O
non,O,O
-,O,O
specific,O,O
granulomatous,O,O
tissue,O,O
.,O,O
Inflammatory,O,B
reactions,O,O
of,O,O
internal,O,O
and,O,O
external,O,O
hepatic,O,B
biliary,O,I
ducts,O,I
were,O,O
also,O,O
seen,O,O
.,O,O
Our,O,O
findings,O,O
illustrate,O,O
that,O,O
PB,B,B
may,O,O
be,O,O
associated,O,O
with,O,O
chronic,O,O
liver,O,B
damage,O,O
",",O,O
which,O,O
may,O,O
lead,O,O
to,O,O
more,O,O
serious,O,O
and,O,O
deleterious,O,O
consequences,O,O
.,O,O
For,O,O
this,O,O
reason,O,O
",",O,O
each,O,O
clinician,O,O
should,O,O
recognize,O,O
this,O,O
entity,O,O
in,O,O
the,O,O
differential,O,O
diagnosis,O,O
of,O,O
PB,B,B
-,O,O
related,O,O
asymptomatic,O,O
chronic,O,O
hepatic,O,B
enzyme,O,I
dysfunction,O,I
.,O,O
Delayed,O,O
leukoencephalopathy,O,B
with,O,O
stroke,O,O
-,O,O
like,O,O
presentation,O,O
in,O,O
chemotherapy,O,O
recipients,O,O
.,O,O
BACKGROUND,O,O
:,O,O
A,O,O
transient,O,O
leukoencephalopathy,O,B
mimicking,O,O
cerebrovascular,O,O
accident,O,O
has,O,O
been,O,O
described,O,O
as,O,O
a,O,O
complication,O,O
of,O,O
chemotherapy,O,O
",",O,O
most,O,O
commonly,O,O
in,O,O
recipients,O,O
of,O,O
intrathecal,O,O
methotrexate,B,B
for,O,O
childhood,O,O
leukaemia,O,O
.,O,O
Recently,O,O
published,O,O
neuroimaging,O,O
data,O,O
suggest,O,O
a,O,O
common,O,O
pathophysiology,O,O
associated,O,O
with,O,O
a,O,O
variety,O,O
of,O,O
chemotherapy,O,B
agents,O,O
and,O,O
modes,O,O
of,O,O
administration,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
reviewed,O,O
the,O,O
medical,O,O
literature,O,O
for,O,O
single,O,O
reports,O,O
and,O,O
case,O,O
series,O,O
of,O,O
patients,O,O
presenting,O,O
with,O,O
stroke,O,O
-,O,O
like,O,O
episodes,O,O
while,O,O
receiving,O,O
systemic,O,O
or,O,O
intrathecal,O,O
chemotherapy,O,B
.,O,O
We,O,O
only,O,O
included,O,O
studies,O,O
providing,O,O
detailed,O,O
neuroimaging,O,O
data,O,O
.,O,O
Patients,O,O
with,O,O
cerebrovascular,O,O
accidents,O,O
were,O,O
excluded,O,O
.,O,O
RESULTS,O,O
:,O,O
We,O,O
identified,O,O
27,O,O
reports,O,O
of,O,O
toxic,O,O
leukoencephalopathy,O,O
in,O,O
patients,O,O
treated,O,O
with,O,O
methotrexate,B,B
(,O,O
intrathecal,O,B
",",O,O
systemic,O,B
),O,O
",",O,O
5,B,O
-,I,O
fluorouracil,I,B
and,O,O
its,O,O
derivative,O,O
carmofur,B,B
",",O,O
and,O,O
capecitabine,B,B
.,O,O
Diffusion,O,B
weighted,O,I
imaging,O,I
(,O,O
DWI,O,B
),O,O
of,O,O
all,O,O
patients,O,O
revealed,O,O
well,O,O
demarcated,O,O
hyperintense,O,O
lesions,O,O
within,O,O
the,O,O
subcortical,O,O
white,O,B
matter,O,I
of,O,O
the,O,O
cerebral,O,B
hemispheres,O,I
and,O,O
the,O,O
corpus,O,B
callosum,O,I
",",O,O
corresponding,O,O
to,O,O
areas,O,O
of,O,O
decreased,O,O
proton,O,B
diffusion,O,I
on,O,O
apparent,O,B
diffusion,O,I
coefficient,O,I
(,O,O
ADC,O,B
),O,O
maps,O,O
(,O,O
available,O,O
in,O,O
21,O,O
/,O,O
27,O,O
patients,O,O
),O,O
.,O,O
Lesions,O,O
exceeded,O,O
the,O,O
confines,O,O
of,O,O
adjacent,O,O
vascular,O,O
territories,O,O
.,O,O
Complete,O,O
resolution,O,O
of,O,O
symptoms,O,O
within,O,O
1,O,O
-,O,O
4,O,O
days,O,O
was,O,O
accompanied,O,O
by,O,O
normalisation,O,O
of,O,O
ADC,O,B
abnormalities,O,O
.,O,O
However,O,O
",",O,O
fluid,O,O
attenuated,O,O
inversion,O,O
recovery,O,O
(,O,O
FLAIR,O,B
),O,O
sequences,O,O
frequently,O,O
revealed,O,O
persistent,O,O
white,O,O
matter,O,O
abnormalities,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Several,O,O
pathophysiological,O,O
models,O,O
of,O,O
delayed,O,O
leukoencephalopathy,O,O
after,O,O
exposure,O,O
to,O,O
intrathecal,O,B
or,O,O
systemic,O,O
chemotherapy,O,B
have,O,O
been,O,O
proposed,O,O
.,O,O
DWI,O,O
findings,O,O
in,O,O
this,O,O
cohort,O,O
are,O,O
indicative,O,O
of,O,O
cytotoxic,O,O
oedema,O,O
within,O,O
cerebral,O,O
white,O,O
matter,O,O
and,O,O
lend,O,O
support,O,O
to,O,O
an,O,O
at,O,O
least,O,O
partially,O,O
reversible,O,O
metabolic,O,O
derangement,O,O
as,O,O
the,O,O
basis,O,O
for,O,O
this,O,O
syndrome,O,O
.,O,O
Prenatal,O,O
exposure,O,O
to,O,O
fluoxetine,B,B
induces,O,O
fetal,O,O
pulmonary,O,O
hypertension,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
RATIONALE,O,O
:,O,O
Fluoxetine,B,B
is,O,O
a,O,O
selective,O,O
serotonin,B,B
reuptake,O,I
inhibitor,O,I
antidepressant,O,O
widely,O,O
used,O,O
by,O,O
pregnant,O,O
women,O,O
.,O,O
Epidemiological,O,O
data,O,O
suggest,O,O
that,O,O
fluoxetine,B,B
exposure,O,O
prenatally,O,O
increases,O,O
the,O,O
prevalence,O,O
of,O,O
persistent,O,O
pulmonary,O,B
hypertension,O,I
syndrome,O,I
of,O,I
the,O,I
newborn,O,I
.,O,O
The,O,O
mechanism,O,O
responsible,O,O
for,O,O
this,O,O
effect,O,O
is,O,O
unclear,O,O
and,O,O
paradoxical,O,O
",",O,O
considering,O,O
the,O,O
current,O,O
evidence,O,O
of,O,O
a,O,O
pulmonary,O,B
hypertension,O,I
protective,O,I
fluoxetine,B,I
effect,O,I
in,O,I
adult,O,I
rodents,O,I
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
fluoxetine,B,B
effect,O,O
on,O,O
fetal,O,O
rat,O,O
pulmonary,O,O
vascular,O,O
smooth,O,O
muscle,O,O
mechanical,O,O
properties,O,O
and,O,O
cell,O,O
proliferation,O,O
rate,O,O
.,O,O
METHODS,O,O
:,O,O
Pregnant,O,O
rats,O,O
were,O,O
treated,O,O
with,O,O
fluoxetine,B,B
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
from,O,O
Day,O,O
11,O,O
through,O,O
Day,O,O
21,O,O
of,O,O
gestation,O,O
.,O,O
MEASUREMENTS,O,O
AND,O,O
MAIN,O,O
RESULTS,O,O
:,O,O
Fetuses,O,O
were,O,O
delivered,O,O
by,O,O
cesarean,O,O
section,O,O
.,O,O
As,O,O
compared,O,O
with,O,O
controls,O,O
",",O,O
fluoxetine,B,B
exposure,O,O
resulted,O,O
in,O,O
fetal,O,O
pulmonary,O,B
hypertension,O,I
as,O,O
evidenced,O,O
by,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
weight,O,O
ratio,O,O
of,O,O
the,O,O
right,O,O
ventricle,O,O
to,O,O
the,O,O
left,O,O
ventricle,O,O
plus,O,O
septum,O,O
(,O,O
P,O,B
=,O,O
0,O,O
.,O,O
),O,O
and,O,O
by,O,O
an,O,O
increase,O,O
in,O,O
pulmonary,O,B
arterial,O,I
medial,O,I
thickness,O,I
(,O,O
P,O,B
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Postnatal,O,O
mortality,O,O
was,O,O
increased,O,O
among,O,O
experimental,O,O
animals,O,O
",",O,O
and,O,O
arterial,O,B
oxygen,B,I
saturation,O,I
was,O,O
96,O,O
+,O,O
/,O,O
-,O,O
1,O,O
%,O,O
in,O,O
1,O,O
-,O,O
day,O,O
-,O,O
old,O,O
control,O,O
animals,O,O
and,O,O
significantly,O,O
lower,O,O
(,O,O
P,O,B
<,O,O
0,O,O
.,O,O
),O,O
in,O,O
fluoxetine,B,B
-,O,O
exposed,O,O
pups,O,O
(,O,O
79,O,O
+,O,O
/,O,O
-,O,O
2,O,O
%,O,O
),O,O
.,O,O
In,O,O
vitro,O,O
",",O,O
fluoxetine,B,B
induced,O,O
pulmonary,O,O
arterial,O,O
muscle,O,O
contraction,O,O
in,O,O
fetal,O,O
",",O,O
but,O,O
not,O,O
adult,O,O
",",O,O
animals,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
reduced,O,O
serotonin,B,B
-,O,O
induced,O,O
contraction,O,O
at,O,O
both,O,O
ages,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
After,O,O
in,O,O
utero,O,O
exposure,O,O
to,O,O
a,O,O
low,O,O
fluoxetine,B,B
concentration,O,O
the,O,O
pulmonary,O,O
arterial,O,O
smooth,O,O
muscle,O,O
cell,O,O
proliferation,O,O
rate,O,O
was,O,O
significantly,O,O
increased,O,O
in,O,O
fetal,O,O
",",O,O
but,O,O
not,O,O
adult,O,O
",",O,O
cells,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
contrast,O,O
to,O,O
the,O,O
adult,O,O
",",O,O
fluoxetine,B,B
exposure,O,O
in,O,O
utero,O,O
induces,O,O
pulmonary,O,O
hypertension,O,O
in,O,O
the,O,O
fetal,O,O
rat,O,O
as,O,O
a,O,O
result,O,O
of,O,O
a,O,O
developmentally,O,O
regulated,O,O
increase,O,O
in,O,O
pulmonary,O,O
vascular,O,O
smooth,O,O
muscle,O,O
proliferation,O,O
.,O,O
Disulfiram,B,B
-,O,I
induced,O,O
transient,O,O
optic,O,O
and,O,O
peripheral,O,O
neuropathy,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
AIM,O,O
:,O,O
To,O,O
report,O,O
a,O,O
case,O,O
of,O,O
optic,O,B
and,O,O
peripheral,O,B
neuropathy,O,I
after,O,O
chronic,O,O
use,O,O
of,O,O
disulfiram,B,B
for,O,O
alcohol,O,O
dependence,O,O
management,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
A,O,O
case,O,O
report,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
57,O,O
-,O,O
year,O,O
-,O,O
old,O,O
male,O,O
presented,O,O
with,O,O
gradual,O,O
loss,O,O
of,O,O
vision,O,O
in,O,O
both,O,O
eyes,O,O
with,O,O
intermittent,O,O
headaches,O,O
for,O,O
2,O,O
months,O,O
.,O,O
He,O,O
also,O,O
complained,O,O
of,O,O
paraesthesia,O,B
with,O,O
numbness,O,B
in,O,O
both,O,O
feet,O,O
.,O,O
His,O,O
vision,O,O
was,O,O
6,O,O
/,O,O
15,O,O
and,O,O
2,O,O
/,O,O
60,O,O
in,O,O
the,O,O
right,O,O
and,O,O
left,O,O
eyes,O,O
",",O,O
respectively,O,O
.,O,O
Fundoscopy,O,O
revealed,O,O
bilaterally,O,O
swollen,O,O
optic,O,B
nerve,O,I
heads,O,I
.,O,O
Visual,O,O
field,O,O
testing,O,O
confirmed,O,O
bilateral,O,O
central,O,O
-,O,O
caecal,O,O
scotomata,O,O
.,O,O
He,O,O
had,O,O
been,O,O
taking,O,O
disulfiram,B,B
for,O,O
alcohol,O,O
dependence,O,O
for,O,O
the,O,O
preceding,O,O
3,O,O
years,O,O
.,O,O
Disulfiram,B,B
discontinuation,O,O
lead,O,O
to,O,O
an,O,O
immediate,O,O
symptomatic,O,O
improvement,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Physicians,O,O
initiating,O,O
long,O,O
-,O,O
term,O,O
disulfiram,B,B
therapy,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
these,O,O
adverse,O,O
effects,O,O
.,O,O
They,O,O
should,O,O
recommend,O,O
annual,O,O
ophthalmic,O,O
reviews,O,O
with,O,O
visual,O,O
field,O,O
testing,O,O
.,O,O
Patients,O,O
should,O,O
be,O,O
reassured,O,O
with,O,O
respect,O,O
to,O,O
the,O,O
reversibility,O,O
of,O,O
these,O,O
adverse,O,O
effects,O,O
.,O,O
Intraocular,O,O
pressure,O,O
in,O,O
patients,O,O
with,O,O
uveitis,O,O
treated,O,O
with,O,O
fluocinolone,B,B
acetonide,I,I
implants,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
report,O,O
the,O,O
incidence,O,O
and,O,O
management,O,O
of,O,O
elevated,O,O
intraocular,O,B
pressure,O,I
(,O,O
IOP,O,B
),O,O
in,O,O
patients,O,O
with,O,O
uveitis,O,O
treated,O,O
with,O,O
the,O,O
fluocinolone,B,B
acetonide,I,I
(,O,O
FA,B,B
),O,O
intravitreal,O,O
implant,O,O
.,O,O
DESIGN,O,O
:,O,O
Pooled,O,O
data,O,O
from,O,O
3,O,O
multicenter,O,O
",",O,O
double,O,O
-,O,O
masked,O,O
",",O,O
randomized,O,O
",",O,O
controlled,O,O
",",O,O
phase,O,O
2b,O,O
/,O,O
3,O,O
clinical,O,O
trials,O,O
evaluating,O,O
the,O,O
safety,O,O
and,O,O
efficacy,O,O
of,O,O
the,O,O
0,O,O
.,O,O
59,O,O
-,O,O
mg,O,O
or,O,O
2,O,O
.,O,O
1,O,O
-,O,O
mg,O,O
FA,B,B
intravitreal,O,O
implant,O,O
or,O,O
standard,O,O
therapy,O,O
were,O,O
analyzed,O,O
.,O,O
RESULTS,O,O
:,O,O
During,O,O
the,O,O
3,O,O
-,O,O
year,O,O
follow,O,O
-,O,O
up,O,O
",",O,O
71,O,O
.,O,O
0,O,O
%,O,O
of,O,O
implanted,O,O
eyes,O,O
had,O,O
an,O,O
IOP,O,O
increase,O,O
of,O,O
10,O,O
mm,O,O
Hg,O,O
or,O,O
more,O,O
than,O,O
baseline,O,O
and,O,O
55,O,O
.,O,O
1,O,O
%,O,O
",",O,O
24,O,O
.,O,O
7,O,O
%,O,O
",",O,O
and,O,O
6,O,O
.,O,O
2,O,O
%,O,O
of,O,O
eyes,O,O
reached,O,O
an,O,O
IOP,O,O
of,O,O
30,O,O
mm,O,O
Hg,O,O
or,O,O
more,O,O
",",O,O
40,O,O
mm,O,O
Hg,O,O
or,O,O
more,O,O
",",O,O
and,O,O
50,O,O
mm,O,O
Hg,O,O
or,O,O
more,O,O
",",O,O
respectively,O,O
.,O,O
Topical,O,O
IOP,O,B
-,O,O
lowering,O,O
medication,O,O
was,O,O
administered,O,O
in,O,O
74,O,O
.,O,O
8,O,O
%,O,O
of,O,O
implanted,O,O
eyes,O,O
",",O,O
and,O,O
IOP,O,B
-,O,O
lowering,O,O
surgeries,O,O
",",O,O
most,O,O
of,O,O
which,O,O
were,O,O
trabeculectomies,O,O
(,O,O
76,O,O
.,O,O
2,O,O
%,O,O
),O,O
",",O,O
were,O,O
performed,O,O
on,O,O
36,O,O
.,O,O
6,O,O
%,O,O
of,O,O
implanted,O,O
eyes,O,O
.,O,O
Intraocular,O,O
pressure,O,O
-,O,O
lowering,O,O
surgeries,O,O
were,O,O
considered,O,O
a,O,O
success,O,O
(,O,O
postoperative,O,O
IOP,O,B
of,O,O
6,O,O
-,O,O
21,O,O
mm,O,O
Hg,O,O
with,O,O
or,O,O
without,O,O
additional,O,O
IOP,O,B
-,O,O
lowering,O,O
medication,O,O
),O,O
in,O,O
85,O,O
.,O,O
1,O,O
%,O,O
of,O,O
eyes,O,O
at,O,O
1,O,O
year,O,O
.,O,O
The,O,O
rate,O,O
of,O,O
hypotony,O,O
(,O,O
IOP,O,B
<,O,O
/,O,O
=,O,O
5,O,O
mm,O,O
Hg,O,O
),O,O
following,O,O
IOP,O,B
-,O,O
lowering,O,O
surgery,O,O
(,O,O
42,O,O
.,O,O
5,O,O
%,O,O
),O,O
was,O,O
not,O,O
different,O,O
from,O,O
that,O,O
of,O,O
implanted,O,O
eyes,O,O
not,O,O
subjected,O,O
to,O,O
surgery,O,O
(,O,O
35,O,O
.,O,O
4,O,O
%,O,O
),O,O
(,O,O
P,O,O
=,O,O
.,O,O
),O,O
.,O,O
CONCLUSION,O,O
:,O,O
Elevated,O,O
IOP,O,B
is,O,O
a,O,O
significant,O,O
complication,O,O
with,O,O
the,O,O
FA,O,O
intravitreal,O,O
implant,O,O
but,O,O
may,O,O
be,O,O
controlled,O,O
with,O,O
medication,O,O
and,O,O
surgery,O,O
.,O,O
Myocardial,O,B
Fas,O,B
ligand,O,I
expression,O,O
increases,O,O
susceptibility,O,O
to,O,O
AZT,B,B
-,O,I
induced,O,I
cardiomyopathy,O,I
.,O,O
BACKGROUND,O,O
:,O,O
Dilated,O,B
cardiomyopathy,O,I
(,O,O
DCM,O,B
),O,O
and,O,O
myocarditis,O,B
occur,O,O
in,O,O
many,O,O
HIV,O,B
-,O,I
infected,O,I
individuals,O,O
",",O,O
resulting,O,O
in,O,O
symptomatic,O,O
heart,O,O
failure,O,O
in,O,O
up,O,O
to,O,O
5,O,O
%,O,O
of,O,O
patients,O,O
.,O,O
Highly,O,O
active,O,O
antiretroviral,O,O
therapy,O,O
(,O,O
HAART,O,B
),O,O
has,O,O
significantly,O,O
reduced,O,O
morbidity,O,O
and,O,O
mortality,O,O
of,O,O
acquired,O,O
immunodeficiency,O,O
syndrome,O,O
(,O,O
AIDS,O,B
),O,O
",",O,O
but,O,O
has,O,O
resulted,O,O
in,O,O
an,O,O
increase,O,O
in,O,O
cardiac,O,B
and,O,O
skeletal,O,O
myopathies,O,O
.,O,O
METHODS,O,O
AND,O,O
RESULTS,O,O
:,O,O
In,O,O
order,O,O
to,O,O
investigate,O,O
whether,O,O
the,O,O
HAART,O,B
component,O,O
zidovudine,B,B
(,O,O
3,B,B
',I,I
-,I,I
azido,I,I
-,I,I
2,I,I
',I,I
",",I,O
3,I,B
',I,I
-,I,I
deoxythymidine,I,I
;,O,O
AZT,B,B
),O,O
triggers,O,O
the,O,O
Fas,O,B
-,O,O
dependent,O,O
cell,O,O
-,O,O
death,O,O
pathway,O,O
and,O,O
cause,O,O
cytoskeletal,O,O
disruption,O,O
in,O,O
a,O,O
murine,O,O
model,O,O
of,O,O
DCM,O,B
",",O,O
8,O,O
-,O,O
week,O,O
-,O,O
old,O,O
transgenic,O,O
(,O,O
expressing,O,O
Fas,O,B
ligand,O,O
in,O,O
the,O,O
myocardium,O,O
:,O,O
FasL,O,B
Tg,O,I
),O,O
and,O,O
non,O,O
-,O,O
transgenic,O,O
(,O,O
NTg,O,B
),O,O
mice,O,O
received,O,O
water,O,O
ad,O,O
libitum,O,O
containing,O,O
different,O,O
concentrations,O,O
of,O,O
AZT,B,B
(,O,O
0,O,O
",",O,O
0,O,O
.,O,O
",",O,O
0,O,O
.,O,O
2,O,O
",",O,O
and,O,O
0,O,O
.,O,O
7,O,O
mg,O,O
/,O,O
ml,O,O
.,O,O
After,O,O
6,O,O
weeks,O,O
",",O,O
cardiac,O,O
function,O,O
was,O,O
assessed,O,O
by,O,O
echocardiography,O,O
and,O,O
morphology,O,O
was,O,O
assessed,O,O
by,O,O
histopathologic,O,O
and,O,O
immunohistochemical,O,O
methods,O,O
.,O,O
NTg,O,O
and,O,O
untreated,O,O
FasL,O,O
Tg,O,O
mice,O,O
showed,O,O
little,O,O
or,O,O
no,O,O
change,O,O
in,O,O
cardiac,O,O
structure,O,O
or,O,O
function,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
AZT,B,B
-,O,I
treated,O,O
FasL,O,O
Tg,O,O
mice,O,O
developed,O,O
cardiac,O,O
dilation,O,O
and,O,O
depressed,O,O
cardiac,O,O
function,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
with,O,O
concomitant,O,O
inflammatory,O,O
infiltration,O,O
of,O,O
both,O,O
ventricles,O,O
.,O,O
These,O,O
changes,O,O
were,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
sarcolemmal,O,O
expression,O,O
of,O,O
Fas,O,B
and,O,O
FasL,O,B
",",O,O
as,O,O
well,O,O
as,O,O
increased,O,O
activation,O,O
of,O,O
caspase,O,B
3,O,I
",",O,O
translocation,O,O
of,O,O
calpain,O,B
1,O,I
to,O,O
the,O,O
sarcolemma,O,O
and,O,O
sarcomere,O,O
",",O,O
and,O,O
increased,O,O
numbers,O,O
of,O,O
cells,O,O
undergoing,O,O
apoptosis,O,O
.,O,O
These,O,O
were,O,O
associated,O,O
with,O,O
changes,O,O
in,O,O
dystrophin,O,B
and,O,O
cardiac,O,B
troponin,O,I
I,O,I
localization,O,O
",",O,O
as,O,O
well,O,O
as,O,O
loss,O,O
of,O,O
sarcolemmal,O,O
integrity,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
expression,O,O
of,O,O
Fas,O,B
ligand,O,I
in,O,O
the,O,O
myocardium,O,O
",",O,O
as,O,O
identified,O,O
in,O,O
HIV,O,B
-,O,O
positive,O,O
patients,O,O
",",O,O
might,O,O
increase,O,O
the,O,O
susceptibility,O,O
to,O,O
HAART,O,B
-,O,O
induced,O,O
cardiomyopathy,O,O
due,O,O
to,O,O
activation,O,O
of,O,O
apoptotic,O,O
pathways,O,O
",",O,O
resulting,O,O
in,O,O
cardiac,O,O
dilation,O,O
and,O,O
dysfunction,O,O
.,O,O
Gastrointestinal,O,O
tolerability,O,O
of,O,O
etoricoxib,B,B
in,O,O
rheumatoid,O,O
arthritis,O,O
patients,O,O
:,O,O
results,O,O
of,O,O
the,O,O
etoricoxib,B,B
vs,O,O
diclofenac,B,B
sodium,I,I
gastrointestinal,O,O
tolerability,O,O
and,O,O
effectiveness,O,O
trial,O,O
(,O,O
EDGE,O,O
-,O,O
II,O,O
),O,O
.,O,O
OBJECTIVE,O,O
:,O,O
A,O,O
randomised,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
study,O,O
to,O,O
compare,O,O
the,O,O
gastrointestinal,O,B
(,O,O
GI,O,I
),O,O
tolerability,O,O
",",O,O
safety,O,O
and,O,O
efficacy,O,O
of,O,O
etoricoxib,B,B
and,O,O
diclofenac,B,B
in,O,O
patients,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
(,O,O
RA,O,B
),O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
A,O,O
total,O,O
of,O,O
4086,O,O
patients,O,O
(,O,O
mean,O,O
age,O,O
60,O,O
.,O,O
8,O,O
years,O,O
),O,O
diagnosed,O,O
with,O,O
RA,O,B
were,O,O
enrolled,O,O
and,O,O
received,O,O
etoricoxib,B,B
90,O,O
mg,O,O
daily,O,O
(,O,O
n,O,O
=,O,O
2032,O,O
),O,O
or,O,O
diclofenac,B,B
75,O,O
mg,O,O
twice,O,O
daily,O,O
(,O,O
n,O,O
=,O,O
2054,O,O
),O,O
.,O,O
Use,O,O
of,O,O
gastroprotective,O,B
agents,O,I
and,O,O
low,O,O
-,O,O
dose,O,O
aspirin,B,B
was,O,O
allowed,O,O
.,O,O
The,O,O
prespecified,O,O
primary,O,O
end,O,O
point,O,O
consisted,O,O
of,O,O
the,O,O
cumulative,O,O
rate,O,O
of,O,O
patient,O,O
discontinuations,O,O
due,O,O
to,O,O
clinical,O,O
and,O,O
laboratory,O,O
GI,O,B
adverse,O,I
experiences,O,I
(,O,O
AEs,O,B
),O,O
.,O,O
General,O,O
safety,O,O
was,O,O
also,O,O
assessed,O,O
",",O,O
including,O,O
adjudicated,O,O
thrombotic,O,O
cardiovascular,O,O
event,O,O
data,O,O
.,O,O
Efficacy,O,O
was,O,O
evaluated,O,O
using,O,O
the,O,O
Patient,O,O
Global,O,O
Assessment,O,O
of,O,O
Disease,O,O
Status,O,O
(,O,O
PGADS,O,B
;,O,O
0,O,O
-,O,O
4,O,O
point,O,O
scale,O,O
),O,O
.,O,O
RESULTS,O,O
:,O,O
Mean,O,O
(,O,O
SD,O,B
;,O,O
maximum,O,O
),O,O
duration,O,O
of,O,O
treatment,O,O
was,O,O
19,O,O
.,O,O
3,O,O
(,O,O
10,O,O
.,O,O
3,O,O
;,O,O
32,O,O
.,O,O
9,O,O
),O,O
and,O,O
19,O,O
.,O,O
1,O,O
(,O,O
10,O,O
.,O,O
4,O,O
;,O,O
33,O,O
.,O,O
1,O,O
),O,O
months,O,O
in,O,O
the,O,O
etoricoxib,B,B
and,O,O
diclofenac,B,B
groups,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
cumulative,O,O
discontinuation,O,O
rate,O,O
due,O,O
to,O,O
GI,O,B
AEs,O,I
was,O,O
significantly,O,O
lower,O,O
with,O,O
etoricoxib,B,B
than,O,O
diclofenac,B,B
(,O,O
5,O,O
.,O,O
2,O,O
vs,O,O
8,O,O
.,O,O
5,O,O
events,O,O
per,O,O
100,O,O
patient,O,O
-,O,O
years,O,O
",",O,O
respectively,O,O
;,O,O
hazard,O,O
ratio,O,O
0,O,O
.,O,O
62,O,O
(,O,O
95,O,O
%,O,O
CI,O,O
:,O,O
0,O,O
.,O,O
47,O,O
",",O,O
0,O,O
.,O,O
81,O,O
;,O,O
p,O,O
<,O,O
or,O,O
=,O,O
0,O,O
.,O,O
),O,O
),O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
discontinuations,O,O
for,O,O
hypertension,O,B
-,O,O
related,O,O
and,O,O
oedema,O,B
-,O,O
related,O,O
AEs,O,O
were,O,O
significantly,O,O
higher,O,O
with,O,O
etoricoxib,B,B
(,O,O
2,O,O
.,O,O
5,O,O
%,O,O
and,O,O
1,O,O
.,O,O
1,O,O
%,O,O
respectively,O,O
),O,O
compared,O,O
with,O,O
diclofenac,B,B
(,O,O
1,O,O
.,O,O
5,O,O
%,O,O
and,O,O
0,O,O
.,O,O
4,O,O
%,O,O
respectively,O,O
;,O,O
p,O,O
<,O,O
0,O,O
.,O,O
for,O,O
hypertension,O,B
and,O,O
p,O,O
<,O,O
0,O,O
.,O,O
for,O,O
oedema,O,B
),O,O
.,O,O
Etoricoxib,B,B
and,O,O
diclofenac,B,B
treatment,O,O
resulted,O,O
in,O,O
similar,O,O
efficacy,O,O
(,O,O
PGADS,O,O
mean,O,O
changes,O,O
from,O,O
baseline,O,O
-,O,O
0,O,O
.,O,O
62,O,O
vs,O,O
-,O,O
0,O,O
.,O,O
58,O,O
",",O,O
respectively,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Etoricoxib,B,B
90,O,O
mg,O,O
demonstrated,O,O
a,O,O
significantly,O,O
lower,O,O
risk,O,O
for,O,O
discontinuing,O,O
treatment,O,O
due,O,O
to,O,O
GI,O,B
AEs,O,I
compared,O,O
with,O,O
diclofenac,B,B
150,O,O
mg,O,O
.,O,O
Discontinuations,O,O
from,O,O
renovascular,O,B
AEs,O,O
",",O,O
although,O,O
less,O,O
common,O,O
than,O,O
discontinuations,O,O
from,O,O
GI,O,B
AEs,O,O
",",O,O
were,O,O
significantly,O,O
higher,O,O
with,O,O
etoricoxib,B,B
.,O,O
Anxiogenic,O,O
potential,O,O
of,O,O
ciprofloxacin,B,B
and,O,O
norfloxacin,B,B
in,O,O
rats,O,O
.,O,O
INTRODUCTION,O,O
:,O,O
The,O,O
possible,O,O
anxiogenic,O,O
effects,O,O
of,O,O
fluoroquinolones,B,B
",",O,O
namely,O,O
ciprofloxacin,B,B
and,O,O
norfloxacin,B,B
",",O,O
were,O,O
investigated,O,O
in,O,O
adult,O,O
Charles,O,O
Foster,O,O
albino,O,O
rats,O,O
of,O,O
either,O,O
sex,O,O
",",O,O
weighing,O,O
150,O,O
-,O,O
200,O,O
g,O,O
.,O,O
METHODS,O,O
:,O,O
The,O,O
drugs,O,O
were,O,O
given,O,O
orally,O,O
",",O,O
in,O,O
doses,O,O
of,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
five,O,O
consecutive,O,O
days,O,O
and,O,O
the,O,O
experiments,O,O
were,O,O
performed,O,O
on,O,O
the,O,O
fifth,O,O
day,O,O
.,O,O
The,O,O
tests,O,O
included,O,O
open,O,O
-,O,O
field,O,O
exploratory,O,O
behaviour,O,O
",",O,O
elevated,O,O
plus,O,O
maze,O,O
and,O,O
elevated,O,O
zero,O,O
maze,O,O
",",O,O
social,O,O
interaction,O,O
and,O,O
novelty,O,O
-,O,O
suppressed,O,O
feeding,O,O
latency,O,O
behaviour,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
ciprofloxacin,B,B
-,O,O
and,O,O
norfloxacin,B,B
-,O,O
treated,O,O
rats,O,O
showed,O,O
anxious,O,O
behaviour,O,O
in,O,O
comparison,O,O
to,O,O
control,O,O
rats,O,O
in,O,O
all,O,O
the,O,O
parameters,O,O
studied,O,O
.,O,O
However,O,O
",",O,O
ciprofloxacin,B,B
-,O,O
and,O,O
norfloxacin,B,B
-,O,O
treated,O,O
rats,O,O
did,O,O
not,O,O
differ,O,O
significantly,O,O
from,O,O
each,O,O
other,O,O
in,O,O
various,O,O
behavioural,O,O
parameters,O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
present,O,O
experimental,O,O
findings,O,O
substantiate,O,O
the,O,O
clinically,O,O
observed,O,O
anxiogenic,O,O
potential,O,O
of,O,O
ciprofloxacin,B,B
and,O,O
norfloxacin,B,B
.,O,O
Reduction,O,O
of,O,O
pain,O,O
during,O,O
induction,O,O
with,O,O
target,O,O
-,O,O
controlled,O,O
propofol,B,B
and,O,O
remifentanil,B,B
.,O,O
BACKGROUND,O,O
:,O,O
Pain,O,O
on,O,O
injection,O,O
of,O,O
propofol,B,B
is,O,O
unpleasant,O,O
.,O,O
We,O,O
hypothesized,O,O
that,O,O
propofol,B,B
infusion,O,O
pain,O,O
might,O,O
be,O,O
prevented,O,O
by,O,O
infusing,O,O
remifentanil,B,B
before,O,O
starting,O,O
the,O,O
propofol,B,B
infusion,O,O
in,O,O
a,O,O
clinical,O,O
setting,O,O
where,O,O
target,O,O
-,O,O
controlled,O,O
infusions,O,O
(,O,O
TCI,O,O
),O,O
of,O,O
both,O,O
drugs,O,O
were,O,O
used,O,O
.,O,O
A,O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
was,O,O
performed,O,O
to,O,O
determine,O,O
the,O,O
effect,O,O
-,O,O
site,O,O
concentration,O,O
(,O,O
Ce,O,B
),O,O
of,O,O
remifentanil,B,B
to,O,O
prevent,O,O
the,O,O
pain,O,O
without,O,O
producing,O,O
complications,O,O
.,O,O
METHODS,O,O
:,O,O
A,O,O
total,O,O
of,O,O
128,O,O
patients,O,O
undergoing,O,O
general,O,O
surgery,O,O
were,O,O
randomly,O,O
allocated,O,O
to,O,O
receive,O,O
normal,O,O
saline,O,B
(,O,O
control,O,O
),O,O
or,O,O
remifentanil,B,B
to,O,O
a,O,O
target,O,O
Ce,O,B
of,O,O
2,O,O
ng,O,O
ml,O,O
(,O,O
-,O,O
1,O,O
),O,O
(,O,O
R2,O,B
),O,O
",",O,O
4,O,O
ng,O,O
ml,O,O
(,O,O
-,O,O
1,O,O
),O,O
(,O,O
R4,O,B
),O,O
",",O,O
or,O,O
6,O,O
ng,O,O
ml,O,O
(,O,O
-,O,O
1,O,O
),O,O
(,O,O
R6,O,B
),O,O
administered,O,O
via,O,O
TCI,O,O
.,O,O
After,O,O
the,O,O
target,O,O
Ce,O,B
was,O,O
achieved,O,O
",",O,O
the,O,O
infusion,O,O
of,O,O
propofol,B,B
was,O,O
started,O,O
.,O,O
Remifentanil,B,B
-,O,O
related,O,O
complications,O,O
were,O,O
assessed,O,O
during,O,O
the,O,O
remifentanil,B,B
infusion,O,O
",",O,O
and,O,O
pain,O,O
caused,O,O
by,O,O
propofol,B,B
was,O,O
evaluated,O,O
using,O,O
a,O,O
four,O,O
-,O,O
point,O,O
scale,O,O
during,O,O
the,O,O
propofol,B,B
infusion,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
incidence,O,O
of,O,O
pain,O,O
was,O,O
significantly,O,O
lower,O,O
in,O,O
Groups,O,O
R4,O,O
and,O,O
R6,O,O
than,O,O
in,O,O
the,O,O
control,O,O
and,O,O
R2,O,O
groups,O,O
(,O,O
12,O,O
/,O,O
32,O,O
and,O,O
6,O,O
/,O,O
31,O,O
vs,O,O
26,O,O
/,O,O
31,O,O
and,O,O
25,O,O
/,O,O
32,O,O
",",O,O
respectively,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Pain,O,O
was,O,O
less,O,O
severe,O,O
in,O,O
Groups,O,O
R4,O,O
and,O,O
R6,O,O
than,O,O
in,O,O
the,O,O
control,O,O
and,O,O
R2,O,O
groups,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
However,O,O
",",O,O
both,O,O
incidence,O,O
and,O,O
severity,O,O
of,O,O
pain,O,O
were,O,O
not,O,O
different,O,O
between,O,O
Groups,O,O
R4,O,O
and,O,O
R6,O,O
.,O,O
No,O,O
significant,O,O
complications,O,O
were,O,O
observed,O,O
during,O,O
the,O,O
study,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
During,O,O
induction,O,O
of,O,O
anaesthesia,O,O
with,O,O
TCI,O,O
of,O,O
propofol,B,B
and,O,O
remifentanil,B,B
",",O,O
a,O,O
significant,O,O
reduction,O,O
in,O,O
propofol,B,B
infusion,O,O
pain,O,O
was,O,O
achieved,O,O
without,O,O
significant,O,O
complications,O,O
by,O,O
prior,O,O
administration,O,O
of,O,O
remifentanil,B,B
at,O,O
a,O,O
target,O,O
Ce,O,O
of,O,O
4,O,O
ng,O,O
ml,O,O
(,O,O
-,O,O
1,O,O
),O,O
.,O,O
Dexmedetomidine,B,B
and,O,O
cardiac,O,O
protection,O,O
for,O,O
non,O,O
-,O,O
cardiac,O,O
surgery,O,O
:,O,O
a,O,O
meta,O,O
-,O,O
analysis,O,O
of,O,O
randomised,O,O
controlled,O,O
trials,O,O
.,O,O
We,O,O
conducted,O,O
a,O,O
systematic,O,O
review,O,O
of,O,O
the,O,O
effects,O,O
of,O,O
dexmedetomidine,B,B
on,O,O
cardiac,O,O
outcomes,O,O
following,O,O
non,O,O
-,O,O
cardiac,O,O
surgery,O,O
.,O,O
We,O,O
included,O,O
prospective,O,O
",",O,O
randomised,O,O
peri,O,O
-,O,O
operative,O,O
studies,O,O
of,O,O
dexmedetomidine,B,B
that,O,O
reported,O,O
mortality,O,O
",",O,O
cardiac,O,O
morbidity,O,O
or,O,O
adverse,O,O
drug,O,O
events,O,O
.,O,O
A,O,O
PubMed,O,O
Central,O,O
and,O,O
EMBASE,O,O
search,O,O
was,O,O
conducted,O,O
up,O,O
to,O,O
July,O,O
2007,O,O
.,O,O
The,O,O
reference,O,O
lists,O,O
of,O,O
identified,O,O
papers,O,O
were,O,O
examined,O,O
for,O,O
further,O,O
trials,O,O
.,O,O
Of,O,O
425,O,O
studies,O,O
identified,O,O
",",O,O
20,O,O
were,O,O
included,O,O
in,O,O
the,O,O
meta,O,O
-,O,O
analysis,O,O
(,O,O
840,O,O
patients,O,O
),O,O
.,O,O
Dexmedetomidine,B,B
was,O,O
associated,O,O
with,O,O
a,O,O
trend,O,O
towards,O,O
improved,O,O
cardiac,O,O
outcomes,O,O
;,O,O
all,O,O
-,O,O
cause,O,O
mortality,O,O
(,O,O
OR,O,O
0,O,O
.,O,O
27,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
.,O,O
-,O,O
7,O,O
.,O,O
13,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
44,O,O
),O,O
",",O,O
non,O,O
-,O,O
fatal,O,O
myocardial,O,B
infarction,O,I
(,O,O
OR,O,O
0,O,O
.,O,O
26,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
.,O,O
-,O,O
1,O,O
.,O,O
60,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
14,O,O
",",O,O
and,O,O
myocardial,O,B
ischaemia,O,I
(,O,O
OR,O,O
0,O,O
.,O,O
65,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
0,O,O
.,O,O
26,O,O
-,O,O
1,O,O
.,O,O
63,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
36,O,O
),O,O
.,O,O
Peri,O,O
-,O,O
operative,O,O
hypotension,O,O
(,O,O
26,O,O
%,O,O
",",O,O
OR,O,O
3,O,O
.,O,O
80,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
91,O,O
-,O,O
7,O,O
.,O,O
54,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
and,O,O
bradycardia,O,O
(,O,O
17,O,O
%,O,O
",",O,O
OR,O,O
5,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
2,O,O
.,O,O
98,O,O
-,O,O
9,O,O
.,O,O
95,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
were,O,O
significantly,O,O
increased,O,O
.,O,O
An,O,O
anticholinergic,O,O
did,O,O
not,O,O
reduce,O,O
the,O,O
incidence,O,O
of,O,O
bradycardia,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
43,O,O
),O,O
.,O,O
A,O,O
randomised,O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
of,O,O
dexmedetomidine,B,O
is,O,O
warranted,O,O
.,O,O
Myocardial,O,O
infarction,O,O
in,O,O
pregnancy,O,O
associated,O,O
with,O,O
clomiphene,B,B
citrate,I,I
for,O,O
ovulation,O,O
induction,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Clomiphene,B,B
citrate,I,I
(,O,O
CC,B,B
),O,O
is,O,O
commonly,O,O
prescribed,O,O
for,O,O
ovulation,O,O
induction,O,O
.,O,O
It,O,O
is,O,O
considered,O,O
safe,O,O
",",O,O
with,O,O
minimal,O,O
side,O,O
effects,O,O
.,O,O
Thromboembolism,O,O
is,O,O
a,O,O
rare,O,O
but,O,O
life,O,O
-,O,O
threatening,O,O
complication,O,O
that,O,O
has,O,O
been,O,O
reported,O,O
after,O,O
ovulation,O,O
induction,O,O
with,O,O
CC,B,B
.,O,O
Spontaneous,O,O
coronary,O,B
thrombosis,O,I
or,O,O
thromboembolism,O,O
with,O,O
subsequent,O,O
clot,O,O
lysis,O,O
has,O,O
been,O,O
suggested,O,O
as,O,O
one,O,O
of,O,O
the,O,O
most,O,O
common,O,O
causes,O,O
of,O,O
myocardial,O,B
infarction,O,I
(,O,O
MI,O,B
),O,O
during,O,O
pregnancy,O,O
",",O,O
with,O,O
a,O,O
subsequently,O,O
normal,O,O
coronary,O,B
angiogram,O,I
.,O,O
CASE,O,O
:,O,O
A,O,O
33,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
a,O,O
5,O,O
-,O,O
week,O,O
gestation,O,O
had,O,O
recently,O,O
received,O,O
CC,B,B
for,O,O
ovulation,O,O
induction,O,O
and,O,O
presented,O,O
with,O,O
chest,O,O
pain,O,O
.,O,O
An,O,O
electrocardiogram,O,O
showed,O,O
a,O,O
lateral,O,O
and,O,O
anterior,O,O
wall,O,O
myocardial,O,O
infarction,O,O
.,O,O
Cardiac,O,O
enzymes,O,O
showed,O,O
a,O,O
peak,O,O
rise,O,O
in,O,O
troponin,O,B
I,O,I
to,O,O
9,O,O
.,O,O
10,O,O
ng,O,O
/,O,O
mL,O,O
.,O,O
An,O,O
initial,O,O
exercise,O,O
stress,O,O
test,O,O
was,O,O
normal,O,O
.,O,O
At,O,O
the,O,O
time,O,O
of,O,O
admission,O,O
",",O,O
the,O,O
patient,O,O
was,O,O
at,O,O
high,O,O
risk,O,O
of,O,O
radiation,O,B
injury,O,O
to,O,O
the,O,O
fetus,O,O
",",O,O
so,O,O
a,O,O
coronary,O,B
angiogram,O,I
was,O,O
postponed,O,O
until,O,O
the,O,O
second,O,O
trimester,O,O
.,O,O
It,O,O
showed,O,O
normal,O,O
coronary,O,B
vessels,O,O
.,O,O
CONCLUSION,O,O
:,O,O
This,O,O
appears,O,O
to,O,O
be,O,O
the,O,O
first,O,O
reported,O,O
case,O,O
documenting,O,O
a,O,O
possible,O,O
association,O,O
between,O,O
CC,B,B
and,O,O
myocardial,O,B
infarction,O,O
.,O,O
Thrombosis,O,B
might,O,O
be,O,O
a,O,O
rare,O,O
but,O,O
hazardous,O,O
complication,O,O
of,O,O
CC,B,B
.,O,O
Given,O,O
this,O,O
life,O,O
-,O,O
threatening,O,O
complication,O,O
",",O,O
appropriate,O,O
prophylactic,O,O
measures,O,O
should,O,O
be,O,O
used,O,O
in,O,O
high,O,O
-,O,O
risk,O,O
woman,O,O
undergoing,O,O
ovarian,O,O
stimulation,O,O
.,O,O
Reverse,O,O
or,O,O
inverted,O,O
left,O,O
ventricular,O,O
apical,O,O
ballooning,O,O
syndrome,O,O
(,O,O
reverse,O,O
Takotsubo,O,B
cardiomyopathy,O,I
),O,O
in,O,O
a,O,O
young,O,O
woman,O,O
in,O,O
the,O,O
setting,O,O
of,O,O
amphetamine,B,B
use,O,O
.,O,O
Transient,O,O
left,O,O
ventricular,O,O
apical,O,O
ballooning,O,O
syndrome,O,O
was,O,O
first,O,O
described,O,O
in,O,O
Japan,O,O
as,O,O
syndrome,O,O
has,O,O
been,O,O
identified,O,O
in,O,O
many,O,O
other,O,O
countries,O,O
.,O,O
Many,O,O
variations,O,O
of,O,O
this,O,O
syndrome,O,O
have,O,O
been,O,O
recently,O,O
described,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
One,O,O
of,O,O
the,O,O
rarest,O,O
is,O,O
the,O,O
reverse,O,O
type,O,O
of,O,O
this,O,O
syndrome,O,O
",",O,O
with,O,O
hyperdynamic,O,O
apex,O,O
and,O,O
complete,O,O
akinesia,O,O
of,O,O
the,O,O
base,O,O
(,O,O
as,O,O
opposed,O,O
to,O,O
the,O,O
classic,O,O
apical,O,O
ballooning,O,O
),O,O
.,O,O
In,O,O
this,O,O
article,O,O
",",O,O
we,O,O
report,O,O
an,O,O
interesting,O,O
case,O,O
of,O,O
a,O,O
young,O,O
woman,O,O
who,O,O
presented,O,O
with,O,O
this,O,O
rare,O,O
type,O,O
of,O,O
reverse,O,O
apical,O,O
ballooning,O,O
syndrome,O,O
occurring,O,O
after,O,O
amphetamine,B,B
use,O,O
.,O,O
This,O,O
report,O,O
is,O,O
followed,O,O
by,O,O
review,O,O
of,O,O
the,O,O
literature,O,O
.,O,O
Results,O,O
of,O,O
a,O,O
comparative,O,O
",",O,O
phase,O,O
III,O,O
",",O,O
12,O,O
-,O,O
week,O,O
",",O,O
multicenter,O,O
",",O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
assessment,O,O
of,O,O
the,O,O
efficacy,O,O
and,O,O
tolerability,O,O
of,O,O
a,O,O
fixed,O,O
-,O,O
dose,O,O
combination,O,O
of,O,O
telmisartan,B,B
and,O,O
amlodipine,B,B
versus,O,O
amlodipine,B,B
monotherapy,O,O
in,O,O
Indian,O,O
adults,O,O
with,O,O
stage,O,O
II,O,O
hypertension,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
evaluate,O,O
the,O,O
efficacy,O,O
and,O,O
tolerability,O,O
of,O,O
a,O,O
new,O,O
fixed,O,O
-,O,O
dose,O,O
combination,O,O
(,O,O
FDC,O,O
),O,O
of,O,O
telmisartan,B,B
40,O,O
mg,O,O
+,O,O
amlodipine,B,B
5,O,O
mg,O,O
(,O,O
T,O,O
+,O,O
A,O,O
),O,O
compared,O,O
with,O,O
amlodipine,B,B
5,O,O
-,O,O
mg,O,O
monotherapy,O,O
(,O,O
A,O,O
),O,O
in,O,O
adult,O,O
Indian,O,O
patients,O,O
with,O,O
stage,O,O
II,O,O
hypertension,O,O
.,O,O
METHODS,O,O
:,O,O
This,O,O
comparative,O,O
",",O,O
Phase,O,O
III,O,O
",",O,O
12,O,O
-,O,O
week,O,O
",",O,O
multicenter,O,O
",",O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
study,O,O
was,O,O
conducted,O,O
in,O,O
Indian,O,O
patients,O,O
aged,O,O
18,O,O
to,O,O
65,O,O
years,O,O
with,O,O
established,O,O
stage,O,O
II,O,O
hypertension,O,O
.,O,O
Patients,O,O
were,O,O
treated,O,O
with,O,O
oral,O,O
FDC,O,B
of,O,O
T,O,B
+,O,O
A,O,B
or,O,O
A,O,B
QD,O,O
before,O,O
breakfast,O,O
for,O,O
12,O,O
weeks,O,O
;,O,O
blood,O,O
pressure,O,O
(,O,O
BP,O,B
),O,O
and,O,O
heart,O,O
rate,O,O
were,O,O
measured,O,O
in,O,O
the,O,O
sitting,O,O
position,O,O
.,O,O
Primary,O,O
efficacy,O,O
end,O,O
points,O,O
were,O,O
reduction,O,O
in,O,O
clinical,O,O
systolic,O,B
BP,O,I
(,O,O
SBP,O,B
),O,O
/,O,O
diastolic,O,B
BP,O,I
(,O,O
DBP,O,B
),O,O
from,O,O
baseline,O,O
to,O,O
study,O,O
end,O,O
and,O,O
number,O,O
of,O,O
responders,O,O
(,O,O
ie,O,O
",",O,O
patients,O,O
who,O,O
achieved,O,O
target,O,O
SBP,O,B
/,O,O
DBP,O,B
<,O,O
130,O,O
/,O,O
<,O,O
80,O,O
mm,O,O
Hg,O,O
),O,O
at,O,O
end,O,O
of,O,O
study,O,O
.,O,O
Tolerability,O,O
was,O,O
assessed,O,O
by,O,O
treatment,O,O
-,O,O
emergent,O,O
adverse,O,O
events,O,O
",",O,O
identified,O,O
using,O,O
physical,O,O
examination,O,O
",",O,O
laboratory,O,O
analysis,O,O
",",O,O
and,O,O
electrocardiography,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
total,O,O
of,O,O
210,O,O
patients,O,O
were,O,O
enrolled,O,O
in,O,O
the,O,O
study,O,O
;,O,O
203,O,O
patients,O,O
(,O,O
143,O,O
men,O,O
",",O,O
60,O,O
women,O,O
),O,O
completed,O,O
the,O,O
study,O,O
while,O,O
7,O,O
were,O,O
lost,O,O
to,O,O
follow,O,O
-,O,O
up,O,O
(,O,O
4,O,O
patients,O,O
in,O,O
the,O,O
T,O,B
+,O,I
A,O,I
group,O,I
and,O,O
3,O,O
in,O,O
the,O,O
A,O,B
group,O,I
),O,O
and,O,O
considered,O,O
with,O,O
-,O,O
drawn,O,O
.,O,O
At,O,O
study,O,O
end,O,O
",",O,O
statistically,O,O
significant,O,O
percentage,O,O
reductions,O,O
from,O,O
baseline,O,O
within,O,O
groups,O,O
and,O,O
between,O,O
groups,O,O
were,O,O
observed,O,O
in,O,O
SBP,O,B
(,O,O
T,O,B
+,O,I
A,O,I
[,O,O
-,O,O
27,O,O
.,O,O
4,O,O
%,O,O
],O,O
;,O,O
A,O,B
[,O,O
-,O,O
16,O,O
.,O,O
6,O,O
%,O,O
],O,O
and,O,O
DBP,O,B
(,O,O
T,O,B
+,O,I
A,O,I
[,O,O
-,O,O
20,O,O
.,O,O
1,O,O
%,O,O
],O,O
;,O,O
A,O,B
[,O,O
-,O,O
13,O,O
.,O,O
3,O,O
%,O,O
],O,O
all,O,O
",",O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Response,O,O
rates,O,O
were,O,O
87,O,O
.,O,O
3,O,O
%,O,O
(,O,O
89,O,O
/,O,O
102,O,O
),O,O
in,O,O
the,O,O
T,O,B
+,O,I
A,O,I
group,O,O
and,O,O
69,O,O
.,O,O
3,O,O
%,O,O
(,O,O
70,O,O
/,O,O
101,O,O
),O,O
in,O,O
the,O,O
A,O,B
group,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
prevalences,O,O
of,O,O
adverse,O,O
events,O,O
were,O,O
not,O,O
significantly,O,O
different,O,O
between,O,O
the,O,O
2,O,O
treatment,O,O
groups,O,O
(,O,O
T,O,B
+,O,O
A,O,O
",",O,O
16,O,O
.,O,O
0,O,O
%,O,O
[,O,O
17,O,O
/,O,O
106,O,O
],O,O
;,O,O
A,O,B
",",O,O
15,O,O
.,O,O
4,O,O
%,O,O
[,O,O
16,O,O
/,O,O
104,O,O
],O,O
),O,O
.,O,O
Peripheral,O,O
edema,O,O
was,O,O
reported,O,O
in,O,O
8,O,O
.,O,O
5,O,O
%,O,O
patients,O,O
(,O,O
9,O,O
/,O,O
106,O,O
),O,O
in,O,O
the,O,O
T,O,B
+,O,O
A,O,O
group,O,O
compared,O,O
with,O,O
13,O,O
.,O,O
5,O,O
%,O,O
(,O,O
14,O,O
/,O,O
104,O,O
),O,O
in,O,O
the,O,O
A,O,O
group,O,O
",",O,O
and,O,O
cough,O,O
was,O,O
reported,O,O
in,O,O
3,O,O
.,O,O
8,O,O
%,O,O
patients,O,O
(,O,O
4,O,O
/,O,O
106,O,O
),O,O
in,O,O
the,O,O
T,O,O
+,O,O
A,O,O
group,O,O
and,O,O
1,O,O
.,O,O
0,O,O
%,O,O
(,O,O
1,O,O
/,O,O
104,O,O
),O,O
patients,O,O
in,O,O
the,O,O
A,O,O
group,O,O
;,O,O
these,O,O
differences,O,O
did,O,O
not,O,O
reach,O,O
statistical,O,O
significance,O,O
.,O,O
The,O,O
incidences,O,O
of,O,O
headache,O,O
",",O,O
dizziness,O,O
",",O,O
and,O,O
diarrhea,O,O
were,O,O
similar,O,O
between,O,O
the,O,O
2,O,O
groups,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Among,O,O
these,O,O
Indian,O,O
patients,O,O
with,O,O
stage,O,O
II,O,O
hypertension,O,O
",",O,O
the,O,O
FDC,O,B
of,O,O
T,O,B
+,O,O
A,O,B
was,O,O
found,O,O
to,O,O
be,O,O
significantly,O,O
more,O,O
effective,O,O
",",O,O
with,O,O
regard,O,O
to,O,O
BP,O,O
reductions,O,O
",",O,O
than,O,O
A,O,B
",",O,O
and,O,O
both,O,O
treatments,O,O
were,O,O
well,O,O
tolerated,O,O
.,O,O
Increased,O,O
mental,O,O
slowing,O,O
associated,O,O
with,O,O
the,O,O
APOE,O,B
epsilon4,O,I
allele,O,O
after,O,O
trihexyphenidyl,B,B
oral,O,O
anticholinergic,O,O
challenge,O,O
in,O,O
healthy,O,O
elderly,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
The,O,O
objectives,O,O
of,O,O
this,O,O
study,O,O
were,O,O
to,O,O
examine,O,O
the,O,O
relationship,O,O
between,O,O
APOE,O,B
epsilon4,O,I
and,O,O
subjective,O,O
effects,O,O
of,O,O
trihexyphenidyl,B,B
on,O,O
measures,O,O
reflecting,O,O
sedation,O,O
and,O,O
confusion,O,O
and,O,O
to,O,O
investigate,O,O
the,O,O
relationship,O,O
between,O,O
trihexyphenidyl,B,B
-,O,O
induced,O,O
subjective,O,O
effects,O,O
and,O,O
objective,O,O
memory,O,O
performance,O,O
.,O,O
METHODS,O,O
:,O,O
This,O,O
study,O,O
comprised,O,O
24,O,O
cognitively,O,O
intact,O,O
",",O,O
health,O,O
elderly,O,O
adults,O,O
(,O,O
12,O,O
APOE,O,B
epsilon4,O,I
carriers,O,O
),O,O
at,O,O
an,O,O
outpatient,O,O
geriatric,O,O
psychiatry,O,O
research,O,O
clinic,O,O
.,O,O
This,O,O
was,O,O
a,O,O
randomized,O,O
",",O,O
double,O,O
blind,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
",",O,O
three,O,O
-,O,O
way,O,O
",",O,O
crossover,O,O
experimental,O,O
design,O,O
.,O,O
All,O,O
participants,O,O
received,O,O
1,O,O
.,O,O
0,O,O
mg,O,O
or,O,O
2,O,O
.,O,O
0,O,O
mg,O,O
trihexyphenidyl,B,B
or,O,O
placebo,O,O
administered,O,O
in,O,O
counterbalanced,O,O
sequences,O,O
over,O,O
a,O,O
period,O,O
of,O,O
three,O,O
consecutive,O,O
weeks,O,O
.,O,O
Bond,O,O
and,O,O
Lader,O,O
',O,O
s,O,O
visual,O,O
analog,O,O
scales,O,O
and,O,O
alternate,O,O
versions,O,O
of,O,O
the,O,O
Buschke,O,O
Selective,O,O
Reminding,O,O
Test,O,O
were,O,O
administered,O,O
in,O,O
a,O,O
repeated,O,O
measures,O,O
design,O,O
at,O,O
baseline,O,O
",",O,O
1,O,O
",",O,O
2,O,O
.,O,O
5,O,O
",",O,O
and,O,O
5,O,O
hours,O,O
postdrug,O,O
administration,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
2,O,O
.,O,O
0,O,O
-,O,O
mg,O,O
oral,O,O
dose,O,O
of,O,O
trihexyphenidyl,B,B
resulted,O,O
in,O,O
increased,O,O
subjective,O,O
ratings,O,O
of,O,O
mental,O,O
slowness,O,O
in,O,O
carriers,O,O
of,O,O
the,O,O
APOE,O,B
epsilon4,O,I
allele,O,I
only,O,O
.,O,O
Drug,O,O
effects,O,O
as,O,O
determined,O,O
by,O,O
difference,O,O
scores,O,O
between,O,O
2,O,O
.,O,O
0,O,O
mg,O,O
trihexyphenidyl,B,B
and,O,O
placebo,O,O
on,O,O
ratings,O,O
of,O,O
mental,O,O
slowness,O,O
significantly,O,O
correlated,O,O
with,O,O
total,O,O
and,O,O
delayed,O,O
recall,O,O
on,O,O
the,O,O
Buschke,O,O
Selective,O,O
Reminding,O,O
Test,O,O
in,O,O
carriers,O,O
of,O,O
the,O,O
APOE,O,B
epsilon4,O,I
allele,O,I
only,O,O
.,O,O
However,O,O
",",O,O
no,O,O
significant,O,O
effects,O,O
were,O,O
found,O,O
with,O,O
other,O,O
visual,O,O
analog,O,O
scales,O,O
reflecting,O,O
subjective,O,O
sedation,O,O
and,O,O
clear,O,O
-,O,O
headedness,O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
epsilon4,O,B
allele,O,O
in,O,O
healthy,O,O
elderly,O,O
was,O,O
associated,O,O
with,O,O
increased,O,O
subjective,O,O
mental,O,O
slowing,O,O
after,O,O
trihexyphenidyl,B,B
anticholinergic,O,O
challenge,O,O
.,O,O
An,O,O
evaluation,O,O
of,O,O
amikacin,B,B
nephrotoxicity,O,O
in,O,O
the,O,O
hematology,O,O
/,O,O
oncology,O,O
population,O,O
.,O,O
Amikacin,B,B
is,O,O
an,O,O
aminoglycoside,B,B
commonly,O,O
used,O,O
to,O,O
provide,O,O
empirical,O,O
double,O,O
gram,O,O
-,O,O
negative,O,O
treatment,O,O
for,O,O
febrile,O,O
neutropenia,O,O
and,O,O
other,O,O
suspected,O,O
infections,O,O
.,O,O
Strategies,O,O
of,O,O
extended,O,O
-,O,O
interval,O,O
and,O,O
conventional,O,O
dosing,O,O
have,O,O
been,O,O
utilized,O,O
extensively,O,O
in,O,O
the,O,O
general,O,O
medical,O,O
population,O,O
;,O,O
however,O,O
",",O,O
data,O,O
are,O,O
lacking,O,O
to,O,O
support,O,O
a,O,O
dosing,O,O
strategy,O,O
in,O,O
the,O,O
hematology,O,O
/,O,O
oncology,O,O
population,O,O
.,O,O
To,O,O
evaluate,O,O
amikacin,B,B
-,O,O
associated,O,O
nephrotoxicity,O,O
in,O,O
an,O,O
adult,O,O
hematology,O,O
/,O,O
oncology,O,O
population,O,O
",",O,O
a,O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
open,O,O
-,O,O
label,O,O
trial,O,O
was,O,O
conducted,O,O
at,O,O
a,O,O
university,O,O
-,O,O
affiliated,O,O
medical,O,O
center,O,O
.,O,O
Forty,O,O
patients,O,O
with,O,O
a,O,O
diagnosis,O,O
consistent,O,O
with,O,O
a,O,O
hematologic,O,O
/,O,O
oncologic,O,O
disorder,O,O
that,O,O
required,O,O
treatment,O,O
with,O,O
an,O,O
aminoglycoside,B,O
were,O,O
randomized,O,O
to,O,O
either,O,O
conventional,O,O
or,O,O
extended,O,O
-,O,O
interval,O,O
amikacin,B,B
.,O,O
The,O,O
occurrence,O,O
of,O,O
nephrotoxicity,O,O
by,O,O
means,O,O
of,O,O
an,O,O
increase,O,O
in,O,O
serum,O,O
creatinine,B,B
and,O,O
evaluation,O,O
of,O,O
efficacy,O,O
via,O,O
amikacin,B,B
serum,O,O
concentrations,O,O
with,O,O
respective,O,O
pathogens,O,O
were,O,O
assessed,O,O
.,O,O
The,O,O
occurrence,O,O
of,O,O
nephrotoxicity,O,O
was,O,O
similar,O,O
between,O,O
the,O,O
conventional,O,O
and,O,O
extended,O,O
-,O,O
interval,O,O
groups,O,O
",",O,O
at,O,O
10,O,O
%,O,O
and,O,O
5,O,O
%,O,O
",",O,O
respectively,O,O
(,O,O
P,O,O
=,O,O
1,O,O
.,O,O
),O,O
.,O,O
Six,O,O
patients,O,O
in,O,O
the,O,O
conventional,O,O
group,O,O
had,O,O
a,O,O
positive,O,O
culture,O,O
",",O,O
compared,O,O
with,O,O
none,O,O
in,O,O
the,O,O
extended,O,O
-,O,O
interval,O,O
group,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
occurrence,O,O
of,O,O
nephrotoxicity,O,O
was,O,O
similar,O,O
between,O,O
the,O,O
two,O,O
dosing,O,O
regimens,O,O
",",O,O
but,O,O
the,O,O
distribution,O,O
of,O,O
risk,O,O
factors,O,O
was,O,O
variable,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
.,O,O
Efficacy,O,O
could,O,O
not,O,O
be,O,O
assessed,O,O
.,O,O
High,O,O
dose,O,O
dexmedetomidine,B,B
as,O,O
the,O,O
sole,O,O
sedative,O,O
for,O,O
pediatric,O,O
MRI,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
This,O,O
large,O,O
-,O,O
scale,O,O
retrospective,O,O
review,O,O
evaluates,O,O
the,O,O
sedation,O,O
profile,O,O
of,O,O
dexmedetomidine,B,B
.,O,O
AIM,O,O
:,O,O
To,O,O
determine,O,O
the,O,O
hemodynamic,O,O
responses,O,O
",",O,O
efficacy,O,O
and,O,O
adverse,O,O
events,O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
high,O,O
dose,O,O
dexmedetomidine,B,B
as,O,O
the,O,O
sole,O,O
sedative,O,O
for,O,O
magnetic,O,O
resonance,O,O
imaging,O,O
(,O,O
MRI,O,O
),O,O
studies,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Dexmedetomidine,B,B
has,O,O
been,O,O
used,O,O
at,O,O
our,O,O
institution,O,O
since,O,O
2005,O,O
to,O,O
provide,O,O
sedation,O,O
for,O,O
pediatric,O,O
radiological,O,O
imaging,O,O
studies,O,O
.,O,O
Over,O,O
time,O,O
",",O,O
an,O,O
effective,O,O
protocol,O,O
utilizing,O,O
high,O,O
dose,O,O
dexmedetomidine,B,B
as,O,O
the,O,O
sole,O,O
sedative,O,O
agent,O,O
has,O,O
evolved,O,O
.,O,O
METHODS,O,O
/,O,O
MATERIALS,O,O
:,O,O
As,O,O
part,O,O
of,O,O
the,O,O
ongoing,O,O
Quality,O,O
Assurance,O,O
process,O,O
",",O,O
data,O,O
on,O,O
all,O,O
sedations,O,O
are,O,O
reviewed,O,O
monthly,O,O
and,O,O
protocols,O,O
modified,O,O
as,O,O
needed,O,O
.,O,O
Data,O,O
were,O,O
analyzed,O,O
from,O,O
all,O,O
747,O,O
consecutive,O,O
patients,O,O
who,O,O
received,O,O
dexmedetomidine,B,B
for,O,O
MRI,O,O
sedation,O,O
from,O,O
April,O,O
2005,O,O
to,O,O
April,O,O
2007,O,O
.,O,O
RESULTS,O,O
:,O,O
Since,O,O
2005,O,O
",",O,O
the,O,O
10,O,O
-,O,O
min,O,O
loading,O,O
dose,O,O
of,O,O
our,O,O
dexmedetomidine,B,B
protocol,O,O
increased,O,O
from,O,O
2,O,O
to,O,O
3,O,O
microg,O,B
.,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
",",O,O
and,O,O
the,O,O
infusion,O,O
rate,O,O
increased,O,O
from,O,O
1,O,O
to,O,O
1,O,O
.,O,O
5,O,O
to,O,O
2,O,O
microg,O,B
.,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
.,O,O
h,O,O
(,O,O
-,O,O
1,O,O
),O,O
.,O,O
The,O,O
current,O,O
sedation,O,O
protocol,O,O
progressively,O,O
increased,O,O
the,O,O
rate,O,O
of,O,O
successful,O,O
sedation,O,O
(,O,O
able,O,O
to,O,O
complete,O,O
the,O,O
imaging,O,O
study,O,O
),O,O
when,O,O
using,O,O
dexmedetomidine,B,B
alone,O,O
from,O,O
91,O,O
.,O,O
8,O,O
%,O,O
to,O,O
97,O,O
.,O,O
6,O,O
%,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
reducing,O,O
the,O,O
requirement,O,O
for,O,O
adjuvant,O,O
pentobarbital,B,B
in,O,O
the,O,O
event,O,O
of,O,O
sedation,O,O
failure,O,O
with,O,O
dexmedetomidine,B,B
alone,O,O
and,O,O
decreased,O,O
the,O,O
mean,O,O
recovery,O,O
time,O,O
by,O,O
10,O,O
min,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Although,O,O
dexmedetomidine,B,B
sedation,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
16,O,O
%,O,O
incidence,O,O
of,O,O
bradycardia,O,O
",",O,O
all,O,O
concomitant,O,O
mean,O,O
arterial,O,O
blood,O,O
pressures,O,O
were,O,O
within,O,O
20,O,O
%,O,O
of,O,O
age,O,O
-,O,O
adjusted,O,O
normal,O,O
range,O,O
and,O,O
oxygen,B,B
saturations,O,O
were,O,O
95,O,O
%,O,O
or,O,O
higher,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Dexmedetomidine,B,B
in,O,O
high,O,O
doses,O,O
provides,O,O
adequate,O,O
sedation,O,O
for,O,O
pediatric,O,O
MRI,O,O
studies,O,O
.,O,O
While,O,O
use,O,O
of,O,O
high,O,O
dose,O,O
dexmedetomidine,B,B
is,O,O
associated,O,O
with,O,O
decreases,O,O
in,O,O
heart,O,B
rate,O,I
and,O,O
blood,O,B
pressure,O,I
outside,O,O
the,O,O
established,O,O
',O,O
awake,O,O
',O,O
norms,O,O
",",O,O
this,O,O
deviation,O,O
is,O,O
generally,O,O
within,O,O
20,O,O
%,O,O
of,O,O
norms,O,O
",",O,O
and,O,O
is,O,O
not,O,O
associated,O,O
with,O,O
adverse,O,O
sequelae,O,O
.,O,O
Dexmedetomidine,B,B
is,O,O
useful,O,O
as,O,O
the,O,O
sole,O,O
sedative,O,O
for,O,O
pediatric,O,O
MRI,O,O
.,O,O
Hepatotoxicity,O,O
associated,O,O
with,O,O
sulfasalazine,B,B
in,O,O
inflammatory,O,O
arthritis,O,O
:,O,O
A,O,O
case,O,O
series,O,O
from,O,O
a,O,O
local,O,O
surveillance,O,O
of,O,O
serious,O,O
adverse,O,O
events,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Spontaneous,O,O
reporting,O,O
systems,O,O
for,O,O
adverse,O,O
drug,O,O
reactions,O,O
(,O,O
),O,O
are,O,O
handicapped,O,O
by,O,O
under,O,O
-,O,O
reporting,O,O
and,O,O
limited,O,O
detail,O,O
on,O,O
individual,O,O
cases,O,O
.,O,O
We,O,O
report,O,O
an,O,O
investigation,O,O
from,O,O
a,O,O
local,O,O
surveillance,O,O
for,O,O
serious,O,O
adverse,O,O
drug,O,O
reactions,O,O
associated,O,O
with,O,O
disease,O,O
modifying,O,O
anti,O,O
-,O,O
rheumatic,O,O
drugs,O,O
that,O,O
was,O,O
triggered,O,O
by,O,O
the,O,O
occurrence,O,O
of,O,O
liver,O,O
failure,O,O
in,O,O
two,O,O
of,O,O
our,O,O
patients,O,O
.,O,O
METHODS,O,O
:,O,O
Serious,O,O
ADR,O,O
reports,O,O
have,O,O
been,O,O
solicited,O,O
from,O,O
local,O,O
clinicians,O,O
by,O,O
regular,O,O
postcards,O,O
over,O,O
the,O,O
past,O,O
seven,O,O
years,O,O
.,O,O
Patients,O,O
',O,O
",",O,O
who,O,O
had,O,O
hepatotoxicity,O,B
on,O,O
sulfasalazine,B,B
and,O,O
met,O,O
a,O,O
definition,O,O
of,O,O
a,O,O
serious,O,O
ADR,O,O
",",O,O
were,O,O
identified,O,O
.,O,O
Two,O,O
clinicians,O,O
reviewed,O,O
structured,O,O
case,O,O
reports,O,O
and,O,O
assessed,O,O
causality,O,O
by,O,O
consensus,O,O
and,O,O
by,O,O
using,O,O
a,O,O
causality,O,O
assessment,O,O
instrument,O,O
.,O,O
The,O,O
likely,O,O
frequency,O,O
of,O,O
hepatotoxicity,O,B
with,O,O
sulfasalazine,B,B
was,O,O
estimated,O,O
by,O,O
making,O,O
a,O,O
series,O,O
of,O,O
conservative,O,O
assumptions,O,O
.,O,O
RESULTS,O,O
:,O,O
Ten,O,O
cases,O,O
were,O,O
identified,O,O
:,O,O
eight,O,O
occurred,O,O
during,O,O
surveillance,O,O
.,O,O
Eight,O,O
patients,O,O
were,O,O
hospitalised,O,O
",",O,O
two,O,O
in,O,O
hepatic,O,O
failure,O,O
-,O,O
one,O,O
died,O,O
after,O,O
a,O,O
liver,O,O
transplant,O,O
.,O,O
All,O,O
but,O,O
one,O,O
event,O,O
occurred,O,O
within,O,O
6,O,O
weeks,O,O
of,O,O
treatment,O,O
.,O,O
Seven,O,O
patients,O,O
had,O,O
a,O,O
skin,O,B
rash,O,I
",",O,O
three,O,O
eosinophilia,O,B
and,O,O
one,O,O
interstitial,O,B
nephritis,O,I
.,O,O
Five,O,O
patients,O,O
were,O,O
of,O,O
Black,O,B
British,O,I
of,O,I
African,O,I
or,O,I
Caribbean,O,I
descent,O,I
.,O,O
Liver,O,B
enzymes,O,I
showed,O,O
a,O,O
hepatocellular,O,B
pattern,O,I
in,O,O
four,O,O
cases,O,O
and,O,O
a,O,O
mixed,O,B
pattern,O,I
in,O,O
six,O,O
.,O,O
Drug,O,B
-,O,I
related,O,I
hepatotoxicity,O,I
was,O,O
judged,O,O
probable,O,O
or,O,O
highly,O,O
probable,O,O
in,O,O
8,O,O
patients,O,O
.,O,O
The,O,O
likely,O,O
frequency,O,O
of,O,O
serious,O,O
hepatotoxicity,O,O
with,O,O
sulfasalazine,B,B
was,O,O
estimated,O,O
at,O,O
0,O,O
.,O,O
4,O,O
%,O,O
of,O,O
treated,O,O
patients,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Serious,O,O
hepatotoxicity,O,O
associated,O,O
with,O,O
sulfasalazine,B,B
appears,O,O
to,O,O
be,O,O
under,O,O
-,O,O
appreciated,O,O
and,O,O
intensive,O,O
monitoring,O,O
and,O,O
vigilance,O,O
in,O,O
the,O,O
first,O,O
6,O,O
weeks,O,O
of,O,O
treatment,O,O
is,O,O
especially,O,O
important,O,O
.,O,O
Complete,O,O
atrioventricular,O,B
block,O,I
secondary,O,O
to,O,O
lithium,B,B
therapy,O,O
.,O,O
Sinus,O,O
node,O,O
dysfunction,O,O
has,O,O
been,O,O
reported,O,O
most,O,O
frequently,O,O
among,O,O
the,O,O
adverse,O,O
cardiovascular,O,O
effects,O,O
of,O,O
lithium,B,B
.,O,O
In,O,O
the,O,O
present,O,O
case,O,O
",",O,O
complete,O,O
atrioventricular,O,B
(,O,O
AV,O,O
),O,O
block,O,I
with,O,O
syncopal,O,O
attacks,O,O
developed,O,O
secondary,O,O
to,O,O
lithium,B,B
therapy,O,O
",",O,O
necessitating,O,O
permanent,O,O
pacemaker,O,O
implantation,O,O
.,O,O
Serum,O,O
lithium,B,B
levels,O,O
remained,O,O
under,O,O
or,O,O
within,O,O
the,O,O
therapeutic,O,O
range,O,O
during,O,O
the,O,O
syncopal,O,O
attacks,O,O
.,O,O
Lithium,B,B
should,O,O
be,O,O
used,O,O
with,O,O
extreme,O,O
caution,O,O
",",O,O
especially,O,O
in,O,O
patients,O,O
with,O,O
mild,O,O
disturbance,O,O
of,O,O
AV,O,O
conduction,O,O
.,O,O
Exaggerated,O,O
expression,O,O
of,O,O
inflammatory,O,O
mediators,O,O
in,O,O
vasoactive,O,O
intestinal,O,O
polypeptide,O,O
knockout,O,O
(,O,O
VIP,O,B
-,O,I
/,O,I
-,O,I
),O,I
mice,O,O
with,O,O
cyclophosphamide,B,B
(,O,O
CYP,B,B
),O,O
-,O,O
induced,O,O
cystitis,O,O
.,O,O
Vasoactive,O,B
intestinal,O,I
polypeptide,O,I
(,O,O
VIP,O,B
),O,O
is,O,O
an,O,O
immunomodulatory,O,O
neuropeptide,O,O
distributed,O,O
in,O,O
micturition,O,O
pathways,O,O
.,O,O
VIP,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
exhibit,O,O
altered,O,O
bladder,O,O
function,O,O
and,O,O
neurochemical,O,O
properties,O,O
in,O,O
micturition,O,O
pathways,O,O
after,O,O
cyclophosphamide,B,B
(,O,O
CYP,B,B
),O,O
-,O,O
induced,O,O
cystitis,O,O
.,O,O
Given,O,O
VIP,O,B
',O,O
s,O,O
role,O,O
as,O,O
an,O,O
anti,O,O
-,O,O
inflammatory,O,O
mediator,O,O
",",O,O
we,O,O
hypothesized,O,O
that,O,O
VIP,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
would,O,O
exhibit,O,O
enhanced,O,O
inflammatory,O,O
mediator,O,O
expression,O,O
after,O,O
cystitis,O,O
.,O,O
A,O,O
mouse,O,O
inflammatory,O,O
cytokine,O,B
and,O,O
receptor,O,O
RT2,O,B
profiler,O,O
array,O,O
was,O,O
used,O,O
to,O,O
determine,O,O
regulated,O,O
transcripts,O,O
in,O,O
the,O,O
urinary,O,O
bladder,O,O
of,O,O
wild,O,O
type,O,O
(,O,O
WT,O,O
),O,O
and,O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
with,O,O
or,O,O
without,O,O
CYP,B,B
-,O,O
induced,O,O
cystitis,O,O
(,O,O
150,O,O
mg,O,O
/,O,O
kg,O,O
;,O,O
i,O,O
.,O,O
p,O,O
48,O,O
h,O,O
),O,O
.,O,O
Four,O,O
binary,O,O
comparisons,O,O
were,O,O
made,O,O
:,O,O
WT,O,O
control,O,O
versus,O,O
CYP,B,B
treatment,O,O
(,O,O
48,O,O
h,O,O
),O,O
",",O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
control,O,O
versus,O,O
CYP,B,B
treatment,O,O
(,O,O
48,O,O
h,O,O
),O,O
",",O,O
WT,O,O
control,O,O
versus,O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,control_94
",",O,O
and,O,O
WT,O,O
with,O,O
CYP,B,B
treatment,O,O
(,O,O
48,O,O
h,O,O
),O,O
versus,O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,with_112
CYP,B,B
treatment,O,O
(,O,O
48,O,O
h,O,O
),O,O
The,O,O
genes,O,O
presented,O,O
represent,O,O
(,O,O
1,O,O
),O,O
greater,O,O
than,O,O
1,O,O
.,O,O
5,O,O
-,O,O
fold,O,O
change,O,O
in,O,O
either,O,O
direction,O,O
and,O,O
(,O,O
2,O,O
),O,O
the,O,O
p,O,O
value,O,O
is,O,O
less,O,O
than,O,O
0,O,O
.,O,O
for,O,O
the,O,O
comparison,O,O
being,O,O
made,O,O
.,O,O
Several,O,O
regulated,O,O
genes,O,O
were,O,O
validated,O,O
using,O,O
enzyme,O,O
-,O,O
linked,O,O
immunoassays,O,O
including,O,O
IL,O,B
-,O,O
1beta,O,I
and,O,O
CXCL1,O,B
.,O,O
CYP,B,B
treatment,O,O
significantly,O,O
(,O,O
p,O,O
<,O,O
or,O,O
=,O,O
0,O,O
.,O,O
),O,O
increased,O,O
expression,O,O
of,O,O
CXCL1,O,B
and,O,O
IL,O,B
-,O,I
1beta,O,I
in,O,O
the,O,O
urinary,O,O
bladder,O,O
of,O,O
WT,O,O
and,O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
",",O,O
but,O,O
expression,O,O
in,O,O
VIP,O,O
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
with,O,O
CYP,B,O
treatment,O,O
was,O,O
significantly,O,O
(,O,O
p,O,O
<,O,O
or,O,O
=,O,O
0,O,O
.,O,O
),O,O
greater,O,O
(,O,O
4,O,O
.,O,O
2,O,O
-,O,O
to,O,O
13,O,O
-,O,O
fold,O,O
increase,O,O
),O,O
than,O,O
that,O,O
observed,O,O
in,O,O
WT,O,O
urinary,O,O
bladder,O,O
(,O,O
3,O,O
.,O,O
6,O,O
-,O,O
to,O,O
5,O,O
-,O,O
fold,O,O
increase,O,O
),O,O
.,O,O
The,O,O
data,O,O
suggest,O,O
that,O,O
in,O,O
VIP,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
with,O,O
bladder,O,O
inflammation,O,O
",",O,O
inflammatory,O,O
mediators,O,O
are,O,O
increased,O,O
above,O,O
that,O,O
observed,O,O
in,O,O
WT,O,O
with,O,O
CYP,B,B
.,O,O
This,O,O
shift,O,O
in,O,O
balance,O,O
may,O,O
contribute,O,O
to,O,O
increased,O,O
bladder,O,O
dysfunction,O,O
in,O,O
VIP,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
with,O,O
bladder,O,O
inflammation,O,O
and,O,O
altered,O,O
neurochemical,O,O
expression,O,O
in,O,O
micturition,O,O
pathways,O,O
.,O,O
Debrisoquine,B,B
phenotype,O,O
and,O,O
the,O,O
pharmacokinetics,O,O
and,O,O
beta,O,B
-,O,I
2,O,I
receptor,O,I
pharmacodynamics,O,O
of,O,O
metoprolol,B,B
and,O,O
its,O,O
enantiomers,O,O
.,O,O
The,O,O
metabolism,O,O
of,O,O
the,O,O
cardioselective,O,O
beta,O,B
-,O,I
blocker,O,I
metoprolol,B,B
is,O,O
under,O,O
genetic,O,O
control,O,O
of,O,O
the,O,O
debrisoquine,B,B
/,O,I
sparteine,B,I
type,O,I
.,O,O
The,O,O
two,O,O
metabolic,O,O
phenotypes,O,O
",",O,O
extensive,O,O
(,O,O
EM,O,B
),O,O
and,O,O
poor,O,O
metabolizers,O,O
(,O,O
PM,O,B
),O,O
",",O,O
show,O,O
different,O,O
stereoselective,O,O
metabolism,O,O
",",O,O
resulting,O,O
in,O,O
apparently,O,O
higher,O,O
beta,O,B
-,O,I
1,O,I
adrenoceptor,O,I
antagonistic,O,I
potency,O,I
of,O,O
racemic,O,O
metoprolol,B,B
in,O,O
EMs,O,O
.,O,O
We,O,O
investigated,O,O
if,O,O
the,O,O
latter,O,O
also,O,O
applies,O,O
to,O,O
the,O,O
beta,O,B
-,O,I
2,O,I
adrenoceptor,O,I
antagonism,O,O
by,O,O
metoprolol,B,B
.,O,O
The,O,O
drug,O,O
effect,O,O
studied,O,O
was,O,O
the,O,O
antagonism,O,O
by,O,O
metoprolol,B,B
of,O,O
terbutaline,B,B
-,O,I
induced,O,O
hypokalemia,O,O
.,O,O
By,O,O
using,O,O
pharmacokinetic,O,O
pharmacodynamic,O,O
modeling,O,O
the,O,O
pharmacodynamics,O,O
of,O,O
racemic,O,B
metoprolol,B,I
and,O,O
the,O,O
active,O,O
S,O,B
-,O,I
isomer,O,I
",",O,O
were,O,O
quantitated,O,O
in,O,O
EMs,O,O
and,O,O
PMs,O,O
in,O,O
terms,O,O
of,O,O
IC50,O,O
values,O,O
",",O,O
representing,O,O
metoprolol,B,B
plasma,O,O
concentrations,O,O
resulting,O,O
in,O,O
half,O,O
-,O,O
maximum,O,O
receptor,O,O
occupancy,O,O
.,O,O
Six,O,O
EMs,O,O
received,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
of,O,O
terbutaline,B,B
s,O,O
.,O,O
c,O,O
.,O,O
on,O,O
two,O,O
different,O,O
occasions,O,O
:,O,O
1,O,O
),O,O
1,O,O
hr,O,O
after,O,O
administration,O,O
of,O,O
a,O,O
placebo,O,O
and,O,O
2,O,O
),O,O
1,O,O
hr,O,O
after,O,O
150,O,O
mg,O,O
of,O,O
metoprolol,B,B
p,O,O
.,O,O
o,O,O
.,O,O
Five,O,O
PMs,O,O
were,O,O
studied,O,O
according,O,O
to,O,O
the,O,O
same,O,O
protocol,O,O
",",O,O
except,O,O
for,O,O
a,O,O
higher,O,O
terbutaline,B,B
dose,O,O
(,O,O
0,O,O
.,O,O
75,O,O
mg,O,O
),O,O
on,O,O
day,O,O
2,O,O
.,O,O
Blood,O,O
samples,O,O
for,O,O
the,O,O
analysis,O,O
of,O,O
plasma,O,O
potassium,B,B
",",O,O
terbutaline,B,B
",",O,O
metoprolol,B,B
(,O,O
racemic,O,O
",",O,O
R,O,O
-,O,O
and,O,O
S,O,O
-,O,O
isomer,O,O
),O,O
",",O,O
and,O,O
alpha,B,O
-,I,O
hydroxymetoprolol,I,B
concentrations,O,O
were,O,O
taken,O,O
at,O,O
regular,O,O
time,O,O
intervals,O,O
",",O,O
during,O,O
8,O,O
hr,O,O
after,O,O
metoprolol,B,B
.,O,O
In,O,O
PMs,O,O
",",O,O
metoprolol,B,B
increased,O,O
the,O,O
terbutaline,B,B
area,O,I
under,O,I
the,O,I
plasma,O,I
concentration,O,I
vs,O,I
.,O,O
time,O,O
curve,O,O
(,O,O
+,O,O
67,O,O
%,O,O
),O,O
.,O,O
Higher,O,O
metoprolol,B,B
/,O,O
alpha,B,B
-,I,I
hydroxymetoprolol,I,I
ratios,O,O
in,O,O
PMs,O,O
were,O,O
predictive,O,O
for,O,O
higher,O,O
R,O,B
-,O,I
/,O,I
S,O,I
-,O,I
isomer,O,I
ratios,O,O
of,O,O
unchanged,O,O
drug,O,O
.,O,O
There,O,O
was,O,O
a,O,O
difference,O,O
in,O,O
metoprolol,B,B
potency,O,O
with,O,O
higher,O,O
racemic,O,B
metoprolol,B,I
IC50,O,O
values,O,O
in,O,O
PMs,O,O
(,O,O
72,O,O
+,O,O
/,O,O
-,O,O
7,O,O
ng,O,O
.,O,O
ml,O,O
-,O,O
1,O,O
),O,O
than,O,O
EMs,O,O
(,O,O
42,O,B
+,O,O
/,O,O
-,O,O
8,O,O
ng,O,O
.,O,O
ml,O,O
-,O,O
1,O,O
",",O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
The,O,O
hemodynamics,O,O
of,O,O
oxytocin,B,B
and,O,O
other,O,O
vasoactive,O,O
agents,O,O
during,O,O
neuraxial,O,O
anesthesia,O,O
for,O,O
cesarean,O,O
delivery,O,O
:,O,O
findings,O,O
in,O,O
six,O,O
cases,O,O
.,O,O
Oxytocin,B,B
is,O,O
a,O,O
commonly,O,O
used,O,O
uterotonic,O,O
that,O,O
can,O,O
cause,O,O
significant,O,O
and,O,O
even,O,O
fatal,O,O
hypotension,O,O
",",O,O
particularly,O,O
when,O,O
given,O,O
as,O,O
a,O,O
bolus,O,O
.,O,O
The,O,O
resulting,O,O
hypotension,O,O
can,O,O
be,O,O
produced,O,O
by,O,O
a,O,O
decrease,O,O
in,O,O
systemic,O,O
vascular,O,O
resistance,O,O
or,O,O
cardiac,O,O
output,O,O
through,O,O
a,O,O
decrease,O,O
in,O,O
venous,O,O
return,O,O
.,O,O
Parturients,O,O
with,O,O
normal,O,O
volume,O,O
status,O,O
",",O,O
heart,O,O
valves,O,O
and,O,O
pulmonary,O,O
vasculature,O,O
most,O,O
often,O,O
respond,O,O
to,O,O
this,O,O
hypotension,O,O
with,O,O
a,O,O
compensatory,O,O
increase,O,O
in,O,O
heart,O,O
rate,O,O
and,O,O
stroke,O,O
volume,O,O
.,O,O
Oxytocin,B,B
-,O,O
induced,O,O
hypotension,O,O
at,O,O
cesarean,O,O
delivery,O,O
may,O,O
be,O,O
incorrectly,O,O
attributed,O,O
to,O,O
blood,O,O
loss,O,O
.,O,O
Pulse,O,O
power,O,O
analysis,O,O
(,O,O
also,O,O
called,O,O
),O,O
of,O,O
an,O,O
arterial,O,O
pressure,O,O
wave,O,O
form,O,O
allows,O,O
continuous,O,O
evaluation,O,O
of,O,O
systemic,O,O
vascular,O,O
resistance,O,O
and,O,O
cardiac,O,O
output,O,O
in,O,O
real,O,O
time,O,O
",",O,O
thereby,O,O
elucidating,O,O
the,O,O
causative,O,O
factors,O,O
behind,O,O
changes,O,O
in,O,O
blood,O,O
pressure,O,O
.,O,O
Pulse,O,O
power,O,O
analysis,O,O
was,O,O
conducted,O,O
in,O,O
six,O,O
cases,O,O
of,O,O
cesarean,O,B
delivery,O,I
performed,O,O
under,O,O
neuraxial,O,O
anesthesia,O,O
.,O,O
Hypotension,O,O
in,O,O
response,O,O
to,O,O
oxytocin,B,B
was,O,O
associated,O,O
with,O,O
a,O,O
decrease,O,O
in,O,O
systemic,O,O
vascular,O,O
resistance,O,O
and,O,O
a,O,O
compensatory,O,O
increase,O,O
in,O,O
stroke,O,O
volume,O,O
",",O,O
heart,O,O
rate,O,O
and,O,O
cardiac,O,O
output,O,O
.,O,O
Pulse,O,O
power,O,O
analysis,O,O
may,O,O
be,O,O
helpful,O,O
in,O,O
determining,O,O
the,O,O
etiology,O,O
of,O,O
and,O,O
treating,O,O
hypotension,O,O
during,O,O
cesarean,O,B
delivery,O,I
under,O,O
neuraxial,O,O
anesthesia,O,O
.,O,O
Protective,O,O
effects,O,O
of,O,O
antithrombin,O,B
on,O,O
puromycin,B,B
aminonucleoside,I,I
nephrosis,O,I
in,O,O
rats,O,O
.,O,O
We,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
antithrombin,O,B
",",O,O
a,O,O
plasma,O,O
inhibitor,O,O
of,O,O
coagulation,O,O
factors,O,O
",",O,O
in,O,O
rats,O,O
with,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,I
nephrosis,O,I
",",O,O
which,O,O
is,O,O
an,O,O
experimental,O,O
model,O,O
of,O,O
human,O,O
nephrotic,O,O
syndrome,O,O
.,O,O
Antithrombin,O,B
(,O,O
50,O,O
or,O,O
500,O,O
IU,O,O
/,O,O
kg,O,O
/,O,O
i,O,O
.,O,O
v,O,O
.,O,O
was,O,O
administered,O,O
to,O,O
rats,O,O
once,O,O
a,O,O
day,O,O
for,O,O
10,O,O
days,O,O
immediately,O,O
after,O,O
the,O,O
injection,O,O
of,O,O
puromycin,B,B
aminonucleoside,I,I
(,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
i,O,O
.,O,O
.,O,O
Treatment,O,O
with,O,O
antithrombin,O,O
attenuated,O,O
the,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,O
induced,O,O
hematological,O,O
abnormalities,O,O
.,O,O
Puromycin,B,B
aminonucleoside,I,I
-,O,O
induced,O,O
renal,O,O
dysfunction,O,O
and,O,O
hyperlipidemia,O,O
were,O,O
also,O,O
suppressed,O,O
.,O,O
Histopathological,O,O
examination,O,O
revealed,O,O
severe,O,O
renal,O,B
damage,O,O
such,O,O
as,O,O
proteinaceous,O,O
casts,O,O
in,O,O
tubuli,O,B
and,O,O
tubular,O,O
expansion,O,O
in,O,O
the,O,O
kidney,O,B
of,O,O
control,O,O
rats,O,O
",",O,O
while,O,O
an,O,O
improvement,O,O
of,O,O
the,O,O
damage,O,O
was,O,O
seen,O,O
in,O,O
antithrombin,O,B
-,O,O
treated,O,O
rats,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
antithrombin,O,B
treatment,O,O
markedly,O,O
suppressed,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,O
apoptosis,O,O
of,O,O
renal,O,B
tubular,O,O
epithelial,O,O
cells,O,O
.,O,O
Furthermore,O,O
",",O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,O
increases,O,O
in,O,O
renal,O,O
cytokine,O,O
content,O,O
were,O,O
also,O,O
decreased,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
thrombin,O,B
plays,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
puromycin,B,B
aminonucleoside,I,I
-,O,I
induced,O,O
nephrotic,O,O
syndrome,O,O
.,O,O
Treatment,O,O
with,O,O
antithrombin,O,B
may,O,O
be,O,O
clinically,O,O
effective,O,O
in,O,O
patients,O,O
with,O,O
nephrotic,O,O
syndrome,O,O
.,O,O
Heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
after,O,O
liver,O,O
transplantation,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Unfractionated,B,B
heparin,I,O
sodium,I,O
(,O,O
UFH,B,B
),O,O
or,O,O
low,B,B
-,I,I
molecular,I,I
weight,I,I
heparin,I,I
(,O,O
LMWH,O,B
),O,O
is,O,O
used,O,O
in,O,O
anticoagulant,O,O
protocols,O,O
at,O,O
several,O,O
institutions,O,O
to,O,O
prevent,O,O
thrombosis,O,O
after,O,O
liver,O,O
transplantation,O,O
.,O,O
Heparin,B,B
-,O,O
induced,O,O
thrombocytopenia,O,O
(,O,O
HIT,O,B
),O,O
is,O,O
an,O,O
adverse,O,O
immune,O,O
-,O,O
mediated,O,O
reaction,O,O
to,O,O
heparin,B,O
",",O,O
resulting,O,O
in,O,O
platelet,O,O
count,O,O
decreases,O,O
of,O,O
more,O,O
than,O,O
50,O,O
%,O,O
.,O,O
The,O,O
frequencies,O,O
of,O,O
HIT,O,B
after,O,O
liver,O,O
transplantation,O,O
and,O,O
platelet,O,O
factor,O,O
4,O,B
/,O,I
heparin,B,I
-,O,I
reactive,O,I
antibody,O,I
(,O,O
HIT,O,B
antibody,O,I
),O,O
positivity,O,O
in,O,O
liver,O,O
transplantation,O,O
patients,O,O
",",O,O
however,O,O
",",O,O
are,O,O
unknown,O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
The,O,O
32,O,O
men,O,O
and,O,O
20,O,O
women,O,O
underwent,O,O
living,O,O
donor,O,O
liver,O,O
transplantation,O,O
.,O,O
We,O,O
started,O,O
LMWH,O,B
(,O,O
25,O,O
IU,O,O
/,O,O
kg,O,O
/,O,O
h,O,O
),O,O
on,O,O
postoperative,O,O
day,O,O
(,O,O
POD,O,O
),O,O
1,O,O
",",O,O
switching,O,O
to,O,O
UFH,B,B
(,O,O
5000,O,O
U,O,O
/,O,O
d,O,O
),O,O
on,O,O
POD,O,O
2,O,O
or,O,O
3,O,O
.,O,O
The,O,O
dose,O,O
of,O,O
UFH,B,B
was,O,O
changed,O,O
according,O,O
to,O,O
the,O,O
activated,O,O
clotting,O,O
time,O,O
level,O,O
.,O,O
HIT,O,B
antibody,O,I
levels,O,O
were,O,O
measured,O,O
the,O,O
day,O,O
before,O,O
surgery,O,O
and,O,O
on,O,O
POD,O,O
7,O,O
and,O,O
14,O,O
.,O,O
Platelet,O,B
count,O,O
was,O,O
measured,O,O
daily,O,O
for,O,O
3,O,O
weeks,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
average,O,O
platelet,O,B
counts,O,O
preoperatively,O,O
",",O,O
and,O,O
on,O,O
POD,O,O
7,O,O
",",O,O
14,O,O
",",O,O
and,O,O
21,O,O
were,O,O
65,O,O
",",O,O
88,O,O
",",O,O
149,O,O
",",O,O
and,O,O
169,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
L,O,O
",",O,O
respectively,O,O
.,O,O
Two,O,O
patients,O,O
developed,O,O
hepatic,O,B
artery,O,I
thrombosis,O,I
on,O,O
POD,O,O
11,O,O
and,O,O
19,O,O
",",O,O
respectively,O,O
",",O,O
although,O,O
they,O,O
were,O,O
HIT,O,B
antibody,O,I
-,O,I
negative,O,I
and,O,O
their,O,O
platelet,O,O
counts,O,O
were,O,O
stable,O,O
.,O,O
In,O,O
2,O,O
other,O,O
patients,O,O
",",O,O
the,O,O
platelet,O,O
count,O,O
decreased,O,O
suddenly,O,O
from,O,O
107,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
L,O,O
on,O,O
POD,O,O
4,O,O
to,O,O
65,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
L,O,O
on,O,O
POD,O,O
6,O,O
and,O,O
from,O,O
76,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
L,O,O
on,O,O
POD,O,O
7,O,O
to,O,O
33,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
L,O,O
on,O,O
POD,O,O
9,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
heparin,B,B
-,O,O
induced,O,O
platelet,O,O
aggregation,O,O
test,O,O
was,O,O
negative,O,O
in,O,O
these,O,O
patients,O,O
.,O,O
The,O,O
percentage,O,O
of,O,O
HIT,O,B
antibody,O,I
-,O,I
positive,O,O
patients,O,O
was,O,O
0,O,O
.,O,O
5,O,O
%,O,O
preoperatively,O,O
",",O,O
5,O,O
.,O,O
6,O,O
%,O,O
on,O,O
POD,O,O
7,O,O
",",O,O
and,O,O
5,O,O
.,O,O
6,O,O
%,O,O
on,O,O
POD,O,O
14,O,O
.,O,O
None,O,O
of,O,O
the,O,O
subjects,O,O
/,O,O
patients,O,O
developed,O,O
UFH,B,B
-,O,I
related,O,I
HIT,O,I
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
our,O,O
series,O,O
",",O,O
the,O,O
occurrence,O,O
of,O,O
HIT,O,B
after,O,O
liver,O,O
transplantation,O,O
was,O,O
uncommon,O,O
.,O,O
Doxorubicin,B,B
cardiomyopathy,O,O
-,O,O
induced,O,O
inflammation,O,O
and,O,O
apoptosis,O,O
are,O,O
attenuated,O,O
by,O,O
gene,O,O
deletion,O,O
of,O,O
the,O,O
kinin,O,B
B1,O,I
receptor,O,I
.,O,O
Clinical,O,O
use,O,O
of,O,O
the,O,O
anthracycline,B,B
doxorubicin,B,I
(,O,O
DOX,B,B
),O,O
is,O,O
limited,O,O
by,O,O
its,O,O
cardiotoxic,O,O
effects,O,O
",",O,O
which,O,O
are,O,O
attributed,O,O
to,O,O
the,O,O
induction,O,O
of,O,O
apoptosis,O,O
.,O,O
To,O,O
elucidate,O,O
the,O,O
possible,O,O
role,O,O
of,O,O
the,O,O
kinin,O,B
B1,O,I
receptor,O,I
(,O,O
B1R,O,B
),O,O
during,O,O
the,O,O
development,O,O
of,O,O
DOX,B,B
cardiomyopathy,O,O
",",O,O
we,O,O
studied,O,O
B1R,O,B
knockout,O,O
mice,O,O
(,O,O
B1R,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
),O,O
by,O,O
investigating,O,O
cardiac,O,O
inflammation,O,O
and,O,O
apoptosis,O,O
after,O,O
induction,O,O
of,O,O
DOX,B,B
-,O,O
induced,O,O
cardiomyopathy,O,O
.,O,O
DOX,B,B
control,O,O
mice,O,O
showed,O,O
cardiac,O,O
dysfunction,O,O
measured,O,O
by,O,O
pressure,O,O
-,O,O
volume,O,O
loops,O,O
in,O,O
vivo,O,O
.,O,O
This,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
reduced,O,O
activation,O,O
state,O,O
of,O,O
AKT,O,B
",",O,O
as,O,O
well,O,O
as,O,O
an,O,O
increased,O,O
bax,O,B
/,O,I
bcl2,O,I
ratio,O,O
in,O,O
Western,O,O
blots,O,O
",",O,O
indicating,O,O
cardiac,O,O
apoptosis,O,O
.,O,O
Furthermore,O,O
",",O,O
mRNA,O,O
levels,O,O
of,O,O
the,O,O
proinflammatory,O,O
cytokine,O,O
interleukin,O,B
6,O,I
were,O,O
increased,O,O
in,O,O
the,O,O
cardiac,O,O
tissue,O,O
.,O,O
In,O,O
DOX,B,B
B1R,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
",",O,O
cardiac,O,O
dysfunction,O,O
was,O,O
improved,O,O
compared,O,O
to,O,O
DOX,B,B
control,O,O
mice,O,O
",",O,O
which,O,O
was,O,O
associated,O,O
with,O,O
normalization,O,O
of,O,O
the,O,O
bax,O,B
/,O,I
bcl,O,I
-,O,I
2,O,I
ratio,O,O
and,O,O
interleukin,O,B
6,O,I
",",O,O
as,O,O
well,O,O
as,O,O
AKT,O,B
activation,O,O
state,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
B1R,O,B
is,O,O
detrimental,O,O
in,O,O
DOX,B,B
cardiomyopathy,O,O
in,O,O
that,O,O
it,O,O
mediates,O,O
the,O,O
inflammatory,O,O
response,O,O
and,O,O
apoptosis,O,O
.,O,O
These,O,O
insights,O,O
might,O,O
have,O,O
useful,O,O
implications,O,O
for,O,O
future,O,O
studies,O,O
utilizing,O,O
B1R,O,B
antagonists,O,O
for,O,O
treatment,O,O
of,O,O
human,O,O
DOX,B,B
cardiomyopathy,O,O
.,O,O
Detailed,O,O
spectral,O,O
profile,O,O
analysis,O,O
of,O,O
penicillin,B,B
-,O,O
induced,O,O
epileptiform,O,O
activity,O,O
in,O,O
anesthetized,O,O
rats,O,O
.,O,O
Penicillin,B,B
model,O,O
is,O,O
a,O,O
widely,O,O
used,O,O
experimental,O,O
model,O,O
for,O,O
epilepsy,O,O
research,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
we,O,O
aimed,O,O
to,O,O
portray,O,O
a,O,O
detailed,O,O
spectral,O,O
analysis,O,O
of,O,O
penicillin,B,B
-,O,O
induced,O,O
epileptiform,O,O
activity,O,O
in,O,O
comparison,O,O
with,O,O
basal,O,O
brain,O,O
activity,O,O
in,O,O
anesthetized,O,O
Wistar,O,O
rats,O,O
.,O,O
Male,O,O
Wistar,O,O
rats,O,O
were,O,O
anesthetized,O,O
with,O,O
i,O,O
.,O,O
p,O,O
.,O,O
urethane,B,B
and,O,O
connected,O,O
to,O,O
an,O,O
electrocorticogram,O,O
setup,O,O
.,O,O
After,O,O
a,O,O
short,O,O
period,O,O
of,O,O
basal,O,O
activity,O,O
recording,O,O
epileptic,O,O
focus,O,O
was,O,O
induced,O,O
by,O,O
injecting,O,O
400IU,O,O
/,O,O
2,O,O
microl,O,O
penicillin,B,B
-,I,O
G,I,I
potassium,I,I
into,O,O
the,O,O
left,O,O
lateral,O,O
ventricle,O,O
while,O,O
the,O,O
cortical,O,O
activity,O,O
was,O,O
continuously,O,O
recorded,O,O
.,O,O
Basal,O,O
activity,O,O
",",O,O
latent,O,O
period,O,O
and,O,O
the,O,O
penicillin,B,B
-,O,O
induced,O,O
epileptiform,O,O
activity,O,O
periods,O,O
were,O,O
then,O,O
analyzed,O,O
using,O,O
both,O,O
conventional,O,O
methods,O,O
and,O,O
spectral,O,O
analysis,O,O
.,O,O
Spectral,O,O
analyses,O,O
were,O,O
conducted,O,O
by,O,O
dividing,O,O
the,O,O
whole,O,O
spectrum,O,O
into,O,O
different,O,O
frequency,O,O
bands,O,O
including,O,O
delta,O,B
",",O,O
theta,O,B
(,O,O
slow,O,I
and,O,I
fast,O,I
),O,O
",",O,O
alpha,O,B
-,O,O
sigma,O,I
",",O,O
beta,O,B
(,O,O
1,O,I
and,O,I
2,O,I
),O,O
and,O,O
gamma,O,B
(,O,O
1,O,I
and,O,I
2,O,I
),O,O
bands,O,O
.,O,O
Our,O,O
results,O,O
show,O,O
that,O,O
the,O,O
most,O,O
affected,O,O
frequency,O,O
bands,O,O
were,O,O
delta,O,B
",",O,O
theta,O,B
",",O,O
beta,O,B
-,O,I
2,O,I
and,O,O
gamma,O,B
-,O,I
2,O,I
bands,O,O
during,O,O
the,O,O
epileptiform,O,O
activity,O,O
and,O,O
there,O,O
were,O,O
marked,O,O
differences,O,O
in,O,O
terms,O,O
of,O,O
spectral,O,O
densities,O,O
between,O,O
three,O,O
investigated,O,O
episodes,O,O
(,O,O
basal,O,O
activity,O,O
",",O,O
latent,O,O
period,O,O
and,O,O
epileptiform,O,O
activity,O,O
),O,O
.,O,O
Our,O,O
results,O,O
may,O,O
help,O,O
to,O,O
analyze,O,O
novel,O,O
data,O,O
obtained,O,O
using,O,O
similar,O,O
experimental,O,O
models,O,O
and,O,O
the,O,O
simple,O,O
analysis,O,O
method,O,O
described,O,O
here,O,O
can,O,O
be,O,O
used,O,O
in,O,O
similar,O,O
studies,O,O
to,O,O
investigate,O,O
the,O,O
basic,O,O
neuronal,O,O
mechanism,O,O
of,O,O
this,O,O
or,O,O
other,O,O
types,O,O
of,O,O
experimental,O,O
epilepsies,O,O
.,O,O
High,O,O
fat,B,O
diet,O,O
-,O,O
fed,O,O
obese,O,O
rats,O,O
are,O,O
highly,O,O
sensitive,O,O
to,O,O
doxorubicin,B,B
-,O,I
induced,O,I
cardiotoxicity,O,I
.,O,O
Often,O,O
",",O,O
chemotherapy,O,O
by,O,O
doxorubicin,B,B
(,O,O
Adriamycin,B,B
),O,O
is,O,O
limited,O,O
due,O,O
to,O,O
life,O,O
threatening,O,O
cardiotoxicity,O,O
in,O,O
patients,O,O
during,O,O
and,O,O
posttherapy,O,O
.,O,O
Recently,O,O
",",O,O
we,O,O
have,O,O
shown,O,O
that,O,O
moderate,O,O
diet,O,O
restriction,O,O
remarkably,O,O
protects,O,O
against,O,O
doxorubicin,B,B
-,O,O
induced,O,O
cardiotoxicity,O,O
.,O,O
This,O,O
cardioprotection,O,O
is,O,O
accompanied,O,O
by,O,O
decreased,O,O
cardiac,O,O
oxidative,O,O
stress,O,O
and,O,O
triglycerides,B,B
and,O,O
increased,O,O
cardiac,O,O
fatty,O,O
-,O,O
acid,O,O
oxidation,O,O
",",O,O
ATP,B,B
synthesis,O,O
",",O,O
and,O,O
upregulated,O,O
JAK,O,B
/,O,I
STAT3,O,I
pathway,O,O
.,O,O
In,O,O
the,O,O
current,O,O
study,O,O
",",O,O
we,O,O
investigated,O,O
whether,O,O
a,O,O
physiological,O,O
intervention,O,O
by,O,O
feeding,O,O
40,O,O
%,O,O
high,O,O
fat,B,O
diet,O,O
(,O,O
HFD,O,B
),O,O
",",O,O
which,O,O
induces,O,O
obesity,O,O
in,O,O
male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
(,O,O
250,O,O
-,O,O
275,O,O
g,O,O
),O,O
",",O,O
sensitizes,O,O
to,O,O
doxorubicin,B,B
-,O,I
induced,O,I
cardiotoxicity,O,I
.,O,O
LD,O,O
(,O,O
10,O,O
),O,O
dose,O,O
(,O,O
8,O,O
mg,O,O
doxorubicin,B,B
/,O,O
kg,O,O
",",O,O
ip,O,O
),O,O
administered,O,O
on,O,O
day,O,O
43,O,O
of,O,O
the,O,O
HFD,O,B
feeding,O,O
regimen,O,O
led,O,O
to,O,O
higher,O,O
cardiotoxicity,O,O
",",O,O
cardiac,O,O
dysfunction,O,O
",",O,O
lipid,O,O
peroxidation,O,O
",",O,O
and,O,O
80,O,O
%,O,O
mortality,O,O
in,O,O
the,O,O
obese,O,O
(,O,O
OB,O,B
),O,O
rats,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
any,O,O
significant,O,O
renal,O,O
or,O,O
hepatic,O,O
toxicity,O,O
.,O,O
Doxorubicin,B,B
toxicokinetics,O,O
studies,O,O
revealed,O,O
no,O,O
change,O,O
in,O,O
accumulation,O,O
of,O,O
doxorubicin,B,B
and,O,O
doxorubicinol,B,B
(,O,O
toxic,O,I
metabolite,O,I
),O,O
in,O,O
the,O,O
normal,O,O
diet,O,O
-,O,O
fed,O,O
(,O,O
ND,O,O
),O,O
and,O,O
OB,O,O
hearts,O,O
.,O,O
Mechanistic,O,O
studies,O,O
revealed,O,O
that,O,O
OB,O,O
rats,O,O
are,O,O
sensitized,O,O
due,O,O
to,O,O
:,O,O
(,O,O
1,O,O
),O,O
higher,O,O
oxyradical,O,O
stress,O,O
leading,O,O
to,O,O
upregulation,O,O
of,O,O
uncoupling,O,O
proteins,O,O
2,O,O
and,O,O
3,O,O
",",O,O
(,O,O
2,O,O
),O,O
downregulation,O,O
of,O,O
cardiac,O,O
peroxisome,O,O
proliferators,O,O
activated,O,O
receptor,O,O
-,O,O
alpha,O,O
",",O,O
(,O,O
3,O,O
),O,O
decreased,O,O
plasma,O,O
adiponectin,O,B
levels,O,O
",",O,O
(,O,O
4,O,O
),O,O
decreased,O,O
cardiac,O,O
fatty,O,O
-,O,O
acid,O,O
oxidation,O,O
(,O,O
666,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
14,O,B
.,O,O
0,O,O
nmol,O,O
/,O,O
min,O,O
/,O,O
g,O,O
heart,O,O
in,O,O
ND,O,O
versus,O,O
400,O,B
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
11,O,B
.,O,O
8,O,O
nmol,O,O
/,O,O
min,O,O
/,O,O
g,O,O
heart,O,O
in,O,O
OB,O,O
),O,O
",",O,O
(,O,O
5,O,O
),O,O
decreased,O,O
mitochondrial,O,O
AMP,B,B
-,O,O
alpha2,O,B
protein,O,O
kinase,O,O
",",O,O
and,O,O
(,O,O
6,O,O
),O,O
86,O,O
%,O,O
drop,O,O
in,O,O
cardiac,O,O
ATP,B,B
levels,O,O
accompanied,O,O
by,O,O
decreased,O,O
ATP,B,B
/,O,O
ADP,B,B
ratio,O,O
after,O,O
doxorubicin,B,O
administration,O,O
.,O,O
Decreased,O,O
cardiac,O,O
erythropoietin,O,O
and,O,O
increased,O,O
SOCS3,O,O
further,O,O
downregulated,O,O
the,O,O
cardioprotective,O,O
JAK,O,B
/,O,O
STAT3,O,B
pathway,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
HFD,O,B
-,O,O
induced,O,O
obese,O,O
rats,O,O
are,O,O
highly,O,O
sensitized,O,O
to,O,O
doxorubicin,B,B
-,O,O
induced,O,O
cardiotoxicity,O,O
by,O,O
substantially,O,O
downregulating,O,O
cardiac,O,O
mitochondrial,O,O
ATP,B,B
generation,O,O
",",O,O
increasing,O,O
oxidative,O,O
stress,O,O
and,O,O
downregulating,O,O
the,O,O
JAK,O,B
/,O,I
STAT3,O,I
pathway,O,O
.,O,O
Isoproterenol,B,B
induces,O,O
primary,O,O
loss,O,O
of,O,O
dystrophin,O,B
in,O,O
rat,O,O
hearts,O,O
:,O,O
correlation,O,O
with,O,O
myocardial,O,O
injury,O,O
.,O,O
The,O,O
mechanism,O,O
of,O,O
isoproterenol,B,B
-,O,O
induced,O,O
myocardial,O,O
damage,O,O
is,O,O
unknown,O,O
",",O,O
but,O,O
a,O,O
mismatch,O,O
of,O,O
oxygen,B,O
supply,O,O
vs,O,O
.,O,O
demand,O,O
following,O,O
coronary,O,O
hypotension,O,O
and,O,O
myocardial,O,O
hyperactivity,O,O
is,O,O
the,O,O
best,O,O
explanation,O,O
for,O,O
the,O,O
complex,O,O
morphological,O,O
alterations,O,O
observed,O,O
.,O,O
Severe,O,O
alterations,O,O
in,O,O
the,O,O
structural,O,O
integrity,O,O
of,O,O
the,O,O
sarcolemma,O,O
of,O,O
cardiomyocytes,O,O
have,O,O
been,O,O
demonstrated,O,O
to,O,O
be,O,O
caused,O,O
by,O,O
isoproterenol,B,B
.,O,O
Taking,O,O
into,O,O
account,O,O
that,O,O
the,O,O
sarcolemmal,O,O
integrity,O,O
is,O,O
stabilized,O,O
by,O,O
the,O,O
dystrophin,O,B
-,O,I
glycoprotein,O,I
complex,O,I
(,O,O
DGC,O,B
),O,O
that,O,O
connects,O,O
actin,O,B
and,O,O
laminin,O,B
in,O,O
contractile,O,O
machinery,O,O
and,O,O
extracellular,O,O
matrix,O,O
and,O,O
by,O,O
integrins,O,B
",",O,O
this,O,O
study,O,O
tests,O,O
the,O,O
hypothesis,O,O
that,O,O
isoproterenol,B,B
affects,O,O
sarcolemmal,O,O
stability,O,O
through,O,O
changes,O,O
in,O,O
the,O,O
DGC,O,B
and,O,O
integrins,O,B
.,O,O
We,O,O
found,O,O
different,O,O
sensitivity,O,O
of,O,O
the,O,O
DGC,O,B
and,O,O
integrin,O,B
to,O,O
isoproterenol,B,B
subcutaneous,O,O
administration,O,O
.,O,O
Immunofluorescent,O,O
staining,O,O
revealed,O,O
that,O,O
dystrophin,O,B
is,O,O
the,O,O
most,O,O
sensitive,O,O
among,O,O
the,O,O
structures,O,O
connecting,O,O
the,O,O
actin,O,B
in,O,O
the,O,O
cardiomyocyte,O,O
cytoskeleton,O,O
and,O,O
the,O,O
extracellular,O,O
matrix,O,O
.,O,O
The,O,O
sarcomeric,O,O
actin,O,B
dissolution,O,O
occurred,O,O
after,O,O
the,O,O
reduction,O,O
or,O,O
loss,O,O
of,O,O
dystrophin,O,B
.,O,O
Subsequently,O,O
",",O,O
after,O,O
lysis,O,O
of,O,O
myofilaments,O,O
",",O,O
gamma,O,B
-,O,O
sarcoglycan,O,I
",",O,O
beta,O,B
-,O,O
dystroglycan,O,I
",",O,O
beta1,O,B
-,O,O
integrin,O,I
",",O,O
and,O,O
laminin,O,B
alpha,O,I
-,O,O
2,O,I
expressions,O,O
were,O,O
reduced,O,O
followed,O,O
by,O,O
their,O,O
breakdown,O,O
",",O,O
as,O,O
epiphenomena,O,O
of,O,O
the,O,O
myocytolytic,O,O
process,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
administration,O,O
of,O,O
isoproterenol,B,B
to,O,O
rats,O,O
results,O,O
in,O,O
primary,O,O
loss,O,O
of,O,O
dystrophin,O,B
",",O,O
the,O,O
most,O,O
sensitive,O,O
among,O,O
the,O,O
structural,O,O
proteins,O,O
that,O,O
form,O,O
the,O,O
DGC,O,O
that,O,O
connects,O,O
the,O,O
extracellular,O,O
matrix,O,O
and,O,O
the,O,O
cytoskeleton,O,O
in,O,O
cardiomyocyte,O,O
.,O,O
These,O,O
changes,O,O
",",O,O
related,O,O
to,O,O
ischaemic,O,O
injury,O,O
",",O,O
explain,O,O
the,O,O
severe,O,O
alterations,O,O
in,O,O
the,O,O
structural,O,O
integrity,O,O
of,O,O
the,O,O
sarcolemma,O,B
of,O,O
cardiomyocytes,O,O
and,O,O
hence,O,O
severe,O,O
and,O,O
irreversible,O,O
injury,O,O
induced,O,O
by,O,O
isoproterenol,B,B
.,O,O
Etiologic,O,O
factors,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
liver,O,B
tumors,O,O
associated,O,O
with,O,O
oral,B,O
contraceptives,I,O
.,O,O
Within,O,O
the,O,O
last,O,O
several,O,O
years,O,O
",",O,O
previously,O,O
rare,O,O
liver,O,B
tumors,O,O
have,O,O
been,O,O
seen,O,O
in,O,O
young,O,O
women,O,O
using,O,O
oral,B,O
contraceptive,I,O
steroids,B,O
.,O,O
The,O,O
Registry,O,O
for,O,O
Liver,O,B
Tumors,O,I
Associated,O,O
with,O,O
Oral,B,B
Contraceptives,I,I
at,O,O
the,O,O
University,O,O
of,O,O
California,O,O
",",O,O
Irvine,O,O
",",O,O
has,O,O
clearly,O,O
identified,O,O
27,O,O
cases,O,O
.,O,O
The,O,O
recent,O,O
literature,O,O
contains,O,O
44,O,O
case,O,O
reports,O,O
.,O,O
Common,O,O
to,O,O
these,O,O
71,O,O
cases,O,O
has,O,O
been,O,O
a,O,O
histopathologic,O,O
diagnosis,O,O
of,O,O
focal,O,O
nodular,O,O
hyperplasia,O,B
",",O,O
adenoma,O,B
",",O,O
hamartoma,O,B
",",O,O
and,O,O
hepatoma,O,B
.,O,O
Significant,O,O
statistical,O,O
etiologic,O,O
factors,O,O
include,O,O
prolonged,O,O
uninterrupted,O,O
usage,O,O
of,O,O
oral,B,B
contraceptive,I,I
steroids,B,I
.,O,O
Eight,O,O
deaths,O,O
and,O,O
liver,O,B
rupture,O,O
in,O,O
18,O,O
patients,O,O
attest,O,O
to,O,O
the,O,O
seriousness,O,O
of,O,O
this,O,O
new,O,O
potentially,O,O
lethal,O,O
adverse,O,O
phenomenon,O,O
.,O,O
Ifosfamide,B,B
continuous,O,O
infusion,O,O
without,O,O
mesna,B,B
.,O,O
A,O,O
phase,O,O
I,O,O
trial,O,O
of,O,O
a,O,O
14,O,O
-,O,O
day,O,O
cycle,O,O
.,O,O
Twenty,O,O
patients,O,O
received,O,O
27,O,O
courses,O,O
of,O,O
ifosfamide,B,B
administered,O,O
as,O,O
a,O,O
24,O,O
-,O,O
hour,O,O
continuous,O,O
infusion,O,O
for,O,O
14,O,O
days,O,O
without,O,O
Mesna,B,O
.,O,O
The,O,O
goal,O,O
of,O,O
the,O,O
study,O,O
was,O,O
to,O,O
deliver,O,O
a,O,O
dose,O,O
rate,O,O
and,O,O
total,O,O
cumulative,O,O
dose,O,O
of,O,O
ifosfamide,B,B
that,O,O
would,O,O
be,O,O
comparable,O,O
to,O,O
standard,O,O
bolus,O,O
or,O,O
short,O,O
-,O,O
term,O,O
infusions,O,O
administered,O,O
with,O,O
Mesna,B,O
.,O,O
Dose,O,O
escalations,O,O
proceeded,O,O
from,O,O
200,O,O
to,O,O
300,O,O
",",O,O
400,O,O
",",O,O
450,O,O
",",O,O
500,O,O
",",O,O
and,O,O
550,O,O
mg,O,O
/,O,O
m2,O,O
/,O,O
d,O,O
.,O,O
Four,O,O
patients,O,O
developed,O,O
transient,O,O
microscopic,O,O
hematuria,O,O
at,O,O
400,O,O
",",O,O
450,O,O
",",O,O
and,O,O
500,O,O
mg,O,O
/,O,O
m2,O,O
/,O,O
d,O,O
.,O,O
There,O,O
were,O,O
no,O,O
instances,O,O
of,O,O
macroscopic,O,O
hematuria,O,O
.,O,O
At,O,O
550,O,O
mg,O,O
/,O,O
m2,O,O
/,O,O
d,O,O
",",O,O
three,O,O
patients,O,O
experienced,O,O
nonurologic,O,O
toxicity,O,O
;,O,O
confusion,O,B
(,O,O
1,O,O
),O,O
",",O,O
nausea,O,B
(,O,O
1,O,O
),O,O
",",O,O
and,O,O
Grade,O,O
2,O,O
leukopenia,O,B
(,O,O
1,O,O
),O,O
.,O,O
The,O,O
recommended,O,O
dose,O,O
of,O,O
500,O,B
mg,O,I
/,O,I
m2,O,I
/,O,I
d,O,I
delivers,O,O
a,O,O
total,O,O
dose,O,O
of,O,O
7,O,B
g,O,I
/,O,I
m2,O,I
per,O,O
cycle,O,O
",",O,O
which,O,O
is,O,O
comparable,O,O
to,O,O
that,O,O
delivered,O,O
in,O,O
clinical,O,O
practice,O,O
for,O,O
bolus,O,O
or,O,O
short,O,O
-,O,O
term,O,O
infusion,O,O
.,O,O
Because,O,O
few,O,O
patients,O,O
received,O,O
multiple,O,O
courses,O,O
over,O,O
time,O,O
",",O,O
the,O,O
cumulative,O,O
effects,O,O
are,O,O
indeterminate,O,O
in,O,O
the,O,O
present,O,O
trial,O,O
.,O,O
The,O,O
frequency,O,O
and,O,O
predictability,O,O
of,O,O
hematuria,O,B
are,O,O
not,O,O
precise,O,O
",",O,O
and,O,O
at,O,O
least,O,O
daily,O,O
monitoring,O,O
by,O,O
urine,O,O
Hematest,O,O
is,O,O
essential,O,O
",",O,O
adding,O,O
Mesna,B,B
to,O,O
the,O,O
infusate,O,O
in,O,O
patients,O,O
with,O,O
persistent,O,O
hematuria,O,B
.,O,O
The,O,O
protracted,O,O
infusion,O,O
schedule,O,O
for,O,O
ifosfamide,B,B
permits,O,O
convenient,O,O
outpatient,O,O
administration,O,O
without,O,O
Mesna,B,B
and,O,O
reduces,O,O
the,O,O
drug,O,O
cost,O,O
of,O,O
clinical,O,O
usage,O,O
of,O,O
this,O,O
agent,O,O
by,O,O
up,O,O
to,O,O
890,O,O
per,O,O
cycle,O,O
.,O,O
Clinical,O,O
activity,O,O
was,O,O
demonstrated,O,O
in,O,O
a,O,O
single,O,O
patient,O,O
",",O,O
but,O,O
a,O,O
comparative,O,O
trial,O,O
of,O,O
standard,O,O
bolus,O,O
schedules,O,O
with,O,O
the,O,O
protracted,O,O
infusion,O,O
schedule,O,O
will,O,O
be,O,O
necessary,O,O
to,O,O
determine,O,O
if,O,O
the,O,O
clinical,O,O
effectiveness,O,O
of,O,O
the,O,O
drug,O,O
is,O,O
maintained,O,O
.,O,O
A,O,O
case,O,O
of,O,O
ventricular,O,O
tachycardia,O,O
related,O,O
to,O,O
caffeine,B,B
pretreatment,O,O
.,O,O
Suboptimal,O,O
seizure,O,O
duration,O,O
is,O,O
commonly,O,O
encountered,O,O
in,O,O
electroconvulsive,O,O
therapy,O,O
practice,O,O
",",O,O
especially,O,O
in,O,O
older,O,O
patients,O,O
with,O,O
higher,O,O
seizure,O,O
thresholds,O,O
.,O,O
Intravenous,O,O
caffeine,B,B
is,O,O
commonly,O,O
used,O,O
to,O,O
improve,O,O
seizure,O,O
duration,O,O
and,O,O
quality,O,O
in,O,O
such,O,O
patients,O,O
and,O,O
is,O,O
generally,O,O
well,O,O
tolerated,O,O
aside,O,O
from,O,O
occasional,O,O
reports,O,O
of,O,O
relatively,O,O
benign,O,O
ventricular,O,O
ectopy,O,O
.,O,O
We,O,O
describe,O,O
a,O,O
patient,O,O
with,O,O
no,O,O
previous,O,O
history,O,O
of,O,O
cardiac,O,B
disease,O,I
or,O,O
arrhythmia,O,B
who,O,O
developed,O,O
sustained,O,O
bigeminy,O,O
and,O,O
2,O,O
brief,O,O
runs,O,O
of,O,O
ventricular,O,B
tachycardia,O,I
after,O,O
caffeine,B,B
administration,O,O
.,O,O
Although,O,O
intravenous,O,O
caffeine,B,B
is,O,O
generally,O,O
well,O,O
tolerated,O,O
",",O,O
the,O,O
clinician,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
the,O,O
potential,O,O
for,O,O
unpredictable,O,O
and,O,O
serious,O,O
ventricular,O,B
arrhythmias,O,I
.,O,O
Fatal,O,O
haemopericardium,O,O
and,O,O
gastrointestinal,O,O
haemorrhage,O,O
due,O,O
to,O,O
possible,O,O
interaction,O,O
of,O,O
cranberry,O,B
juice,O,I
with,O,O
warfarin,B,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
fatal,O,O
internal,O,O
haemorrhage,O,O
in,O,O
an,O,O
elderly,O,O
man,O,O
who,O,O
consumed,O,O
only,O,O
cranberry,O,B
juice,O,I
for,O,O
two,O,O
weeks,O,O
while,O,O
maintaining,O,O
his,O,O
usual,O,O
dosage,O,O
of,O,O
warfarin,B,O
.,O,O
We,O,O
propose,O,O
that,O,O
naturally,O,O
occurring,O,O
compounds,O,O
such,O,O
as,O,O
flavonoids,B,B
",",O,O
which,O,O
are,O,O
present,O,O
in,O,O
fruit,O,O
juices,O,O
",",O,O
may,O,O
increase,O,O
the,O,O
potency,O,O
of,O,O
warfarin,B,O
by,O,O
competing,O,O
for,O,O
the,O,O
enzymes,O,O
that,O,O
normally,O,O
inactivate,O,O
warfarin,B,O
.,O,O
While,O,O
traditionally,O,O
regarded,O,O
as,O,O
foodstuffs,O,O
",",O,O
consumption,O,O
of,O,O
fruit,O,B
juices,O,I
should,O,O
be,O,O
considered,O,O
when,O,O
patients,O,O
develop,O,O
adverse,O,O
drug,O,B
reactions,O,O
.,O,O
Effect,O,O
of,O,O
increasing,O,O
intraperitoneal,O,O
infusion,O,O
rates,O,O
on,O,O
bupropion,B,B
hydrochloride,I,I
-,O,I
induced,O,O
seizures,O,O
in,O,O
mice,O,O
.,O,O
BACKGROUND,O,O
:,O,O
It,O,O
is,O,O
not,O,O
known,O,O
if,O,O
there,O,O
is,O,O
a,O,O
relationship,O,O
between,O,O
input,O,O
rate,O,O
and,O,O
incidence,O,O
of,O,O
bupropion,B,B
-,O,I
induced,O,O
seizures,O,O
.,O,O
This,O,O
is,O,O
important,O,O
",",O,O
since,O,O
different,O,O
controlled,O,O
release,O,O
formulations,O,O
of,O,O
bupropion,B,B
release,O,O
the,O,O
active,O,O
drug,O,O
at,O,O
different,O,O
rates,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
investigated,O,O
the,O,O
effect,O,O
of,O,O
varying,O,O
the,O,O
intraperitoneal,O,O
infusion,O,O
rates,O,O
of,O,O
bupropion,B,B
HCl,I,I
120,O,I
mg,O,I
/,O,I
kg,O,I
",",O,O
a,O,O
known,O,O
convulsive,O,O
dose,O,O
50,O,O
(,O,O
CD50,O,O
),O,O
",",O,O
on,O,O
the,O,O
incidence,O,O
and,O,O
severity,O,O
of,O,O
bupropion,B,B
-,O,O
induced,O,O
convulsions,O,O
in,O,O
the,O,O
Swiss,O,O
albino,O,O
mice,O,O
.,O,O
A,O,O
total,O,O
of,O,O
69,O,O
mice,O,O
",",O,O
approximately,O,O
7,O,O
weeks,O,O
of,O,O
age,O,O
",",O,O
and,O,O
weighing,O,O
21,O,O
.,O,O
0,O,O
to,O,O
29,O,O
.,O,O
1,O,O
g,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
bupropion,B,B
HCl,I,I
120,O,O
mg,O,O
/,O,O
kg,O,O
treatment,O,O
by,O,O
intraperitoneal,O,O
(,O,O
IP,O,B
),O,O
administration,O,O
in,O,O
7,O,O
groups,O,O
(,O,O
9,O,O
to,O,O
10,O,O
animals,O,O
per,O,O
group,O,O
),O,O
.,O,O
Bupropion,B,B
HCl,I,I
was,O,O
infused,O,O
through,O,O
a,O,O
surgically,O,O
implanted,O,O
IP,O,B
dosing,O,O
catheter,O,O
with,O,O
infusions,O,O
in,O,O
each,O,O
group,O,O
of,O,O
0,O,O
min,O,O
",",O,O
15,O,O
min,O,O
",",O,O
30,O,O
min,O,O
",",O,O
60,O,O
min,O,O
",",O,O
90,O,O
min,O,O
",",O,O
120,O,O
min,O,O
",",O,O
and,O,O
240,O,O
min,O,O
.,O,O
The,O,O
number,O,O
",",O,O
time,O,O
of,O,O
onset,O,O
",",O,O
duration,O,O
and,O,O
the,O,O
intensity,O,O
of,O,O
the,O,O
convulsions,O,O
or,O,O
absence,O,O
of,O,O
convulsions,O,O
were,O,O
recorded,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
results,O,O
showed,O,O
that,O,O
IP,O,O
administration,O,O
of,O,O
bupropion,B,B
HCl,I,I
120,O,O
mg,O,O
/,O,O
kg,O,O
by,O,O
bolus,O,O
injection,O,O
induced,O,O
convulsions,O,O
in,O,O
6,O,O
out,O,O
of,O,O
10,O,O
mice,O,O
(,O,O
60,O,O
%,O,O
of,O,O
convulsing,O,O
mice,O,O
),O,O
in,O,O
group,O,O
1,O,O
.,O,O
Logistic,O,O
regression,O,O
analysis,O,O
revealed,O,O
that,O,O
infusion,O,O
time,O,O
was,O,O
significant,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
;,O,O
odds,O,O
ratio,O,O
=,O,O
0,O,O
.,O,O
974,O,B
),O,O
and,O,O
increasing,O,O
the,O,O
IP,O,O
infusion,O,O
time,O,O
of,O,O
bupropion,B,B
HCl,I,I
120,O,I
mg,O,I
/,O,I
kg,O,I
was,O,O
associated,O,O
with,O,O
a,O,O
91,O,B
%,O,I
reduced,O,I
odds,O,I
of,O,I
convulsions,O,I
at,O,I
infusion,O,I
times,O,I
of,O,I
15,O,I
to,O,I
90,O,I
min,O,I
compared,O,I
to,O,I
bolus,O,I
injection,O,I
.,O,O
Further,O,O
increase,O,O
in,O,O
infusion,O,O
time,O,O
resulted,O,O
in,O,O
further,O,O
reduction,O,O
in,O,O
the,O,O
odds,O,O
of,O,O
convulsions,O,O
to,O,O
99,O,B
.,O,O
8,O,O
%,O,O
reduction,O,O
at,O,O
240,O,O
min,O,O
.,O,O
CONCLUSION,O,O
:,O,O
In,O,O
conclusion,O,O
",",O,O
the,O,O
demonstration,O,O
of,O,O
an,O,O
inverse,O,O
relationship,O,O
between,O,O
infusion,O,O
time,O,O
of,O,O
a,O,O
fixed,O,O
and,O,O
convulsive,O,O
dose,O,O
of,O,O
bupropion,B,B
and,O,O
the,O,O
risk,O,O
of,O,O
convulsions,O,O
in,O,O
a,O,O
prospective,O,O
study,O,O
is,O,O
novel,O,O
.,O,O
Graft,O,O
-,O,O
versus,O,O
-,O,O
host,O,O
disease,O,O
prophylaxis,O,O
with,O,O
everolimus,B,B
and,O,O
tacrolimus,B,B
is,O,O
associated,O,O
with,O,O
a,O,O
high,O,O
incidence,O,O
of,O,O
sinusoidal,O,B
obstruction,O,I
syndrome,O,I
and,O,O
microangiopathy,O,O
:,O,O
results,O,O
of,O,O
the,O,O
EVTAC,O,O
trial,O,O
.,O,O
A,O,O
calcineurin,O,B
inhibitor,O,I
combined,O,O
with,O,O
methotrexate,B,B
is,O,O
the,O,O
standard,O,O
prophylaxis,O,O
for,O,O
graft,O,O
-,O,O
versus,O,O
-,O,O
host,O,O
disease,O,O
(,O,O
GVHD,O,B
),O,O
after,O,O
allogeneic,O,O
hematopoietic,O,O
stem,O,O
cell,O,O
transplantation,O,O
(,O,O
HSCT,O,B
),O,O
.,O,O
Everolimus,B,B
",",O,O
a,O,O
derivative,O,O
of,O,O
sirolimus,B,B
",",O,O
seems,O,O
to,O,O
mediate,O,O
antileukemia,O,O
effects,O,O
.,O,O
We,O,O
report,O,O
on,O,O
a,O,O
combination,O,O
of,O,O
everolimus,B,B
and,O,O
tacrolimus,B,B
in,O,O
24,O,O
patients,O,O
(,O,O
median,O,O
age,O,O
",",O,O
62,O,O
years,O,O
),O,O
with,O,O
either,O,O
myelodysplastic,O,B
syndrome,O,I
(,O,O
MDS,O,B
;,O,O
n,O,O
=,O,O
17,O,O
),O,O
or,O,O
acute,O,B
myeloid,O,I
leukemia,O,I
(,O,O
AML,O,B
;,O,O
n,O,O
=,O,O
7,O,O
),O,O
undergoing,O,O
intensive,O,O
conditioning,O,O
followed,O,O
by,O,O
HSCT,O,B
from,O,O
related,O,O
(,O,O
n,O,O
=,O,O
4,O,O
),O,O
or,O,O
unrelated,O,O
(,O,O
n,O,O
=,O,O
20,O,O
),O,O
donors,O,O
.,O,O
All,O,O
patients,O,O
engrafted,O,O
",",O,O
and,O,O
only,O,O
1,O,O
patient,O,O
experienced,O,O
grade,O,O
IV,O,O
mucositis,O,B
.,O,O
Nine,O,O
patients,O,O
(,O,O
37,O,O
%,O,O
),O,O
developed,O,O
acute,O,O
grade,O,O
II,O,O
-,O,O
IV,O,O
GVHD,O,B
",",O,O
and,O,O
11,O,O
of,O,O
17,O,O
evaluable,O,O
patients,O,O
(,O,O
64,O,O
%,O,O
),O,O
developed,O,O
chronic,O,O
extensive,O,O
GVHD,O,B
.,O,O
Transplantation,O,O
-,O,O
associated,O,O
microangiopathy,O,B
(,O,O
TMA,O,B
),O,O
occurred,O,O
in,O,O
7,O,O
patients,O,O
(,O,O
29,O,O
%,O,O
),O,O
",",O,O
with,O,O
2,O,O
cases,O,O
of,O,O
acute,O,O
renal,O,O
failure,O,O
.,O,O
The,O,O
study,O,O
was,O,O
terminated,O,O
prematurely,O,O
because,O,O
an,O,O
additional,O,O
6,O,O
patients,O,O
(,O,O
25,O,O
%,O,O
),O,O
developed,O,O
sinusoidal,O,B
obstruction,O,I
syndrome,O,I
(,O,O
SOS,O,B
),O,O
",",O,O
which,O,O
was,O,O
fatal,O,O
in,O,O
2,O,O
cases,O,O
.,O,O
With,O,O
a,O,O
median,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
26,O,O
months,O,O
",",O,O
the,O,O
2,O,O
-,O,O
year,O,O
overall,O,O
survival,O,O
rate,O,O
was,O,O
47,O,O
%,O,O
.,O,O
Although,O,O
this,O,O
new,O,O
combination,O,O
appears,O,O
to,O,O
be,O,O
effective,O,O
as,O,O
a,O,O
prophylactic,O,O
regimen,O,O
for,O,O
acute,O,O
GVHD,O,O
",",O,O
the,O,O
incidence,O,O
of,O,O
TMA,O,B
and,O,O
SOS,O,B
is,O,O
considerably,O,O
higher,O,O
than,O,O
seen,O,O
with,O,O
other,O,O
regimens,O,O
.,O,O
Longitudinal,O,O
assessment,O,O
of,O,O
air,O,O
conduction,O,O
audiograms,O,O
in,O,O
a,O,O
phase,O,O
III,O,O
clinical,O,O
trial,O,O
of,O,O
difluoromethylornithine,B,B
and,O,O
sulindac,B,B
for,O,O
prevention,O,O
of,O,O
sporadic,O,O
colorectal,O,O
adenomas,O,O
.,O,O
A,O,O
phase,O,O
III,O,O
clinical,O,O
trial,O,O
assessed,O,O
the,O,O
recurrence,O,O
of,O,O
adenomatous,O,O
polyps,O,O
after,O,O
treatment,O,O
for,O,O
36,O,O
months,O,O
with,O,O
difluoromethylornithine,B,B
(,O,O
DFMO,B,I
),O,O
plus,O,O
sulindac,B,B
or,O,O
matched,O,O
placebos,O,O
.,O,O
Temporary,O,O
hearing,O,O
loss,O,O
is,O,O
a,O,O
known,O,O
toxicity,O,O
of,O,O
treatment,O,O
with,O,O
DFMO,B,B
",",O,O
thus,O,O
a,O,O
comprehensive,O,O
approach,O,O
was,O,O
developed,O,O
to,O,O
analyze,O,O
serial,O,O
air,O,O
conduction,O,O
audiograms,O,O
.,O,O
The,O,O
generalized,O,O
estimating,O,O
equation,O,O
method,O,O
estimated,O,O
the,O,O
mean,O,O
difference,O,O
between,O,O
treatment,O,O
arms,O,O
with,O,O
regard,O,O
to,O,O
change,O,O
in,O,O
air,O,O
conduction,O,O
pure,O,O
tone,O,O
thresholds,O,O
while,O,O
accounting,O,O
for,O,O
within,O,O
-,O,O
subject,O,O
correlation,O,O
due,O,O
to,O,O
repeated,O,O
measurements,O,O
at,O,O
frequencies,O,O
.,O,O
Based,O,O
on,O,O
290,O,O
subjects,O,O
",",O,O
there,O,O
was,O,O
an,O,O
average,O,O
difference,O,O
of,O,O
0,O,O
.,O,O
50,O,O
dB,O,O
between,O,O
subjects,O,O
treated,O,O
with,O,O
DFMO,B,B
plus,O,O
sulindac,B,B
compared,O,O
with,O,O
those,O,O
treated,O,O
with,O,O
placebo,O,B
(,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
-,O,O
0,O,O
.,O,O
64,O,O
to,O,O
1,O,O
.,O,O
63,O,O
dB,O,O
;,O,O
P,O,O
=,O,O
0,O,O
.,O,O
39,O,O
),O,O
",",O,O
adjusted,O,O
for,O,O
baseline,O,O
values,O,O
",",O,O
age,O,O
",",O,O
and,O,O
frequencies,O,O
.,O,O
In,O,O
the,O,O
normal,O,O
speech,O,O
range,O,O
of,O,O
500,O,O
to,O,O
3,O,O
",",O,O
Hz,O,O
",",O,O
an,O,O
estimated,O,O
difference,O,O
of,O,O
0,O,O
.,O,O
99,O,O
dB,O,O
(,O,O
-,O,O
0,O,O
.,O,O
17,O,O
to,O,O
2,O,O
.,O,O
14,O,O
dB,O,O
;,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
was,O,O
detected,O,O
.,O,O
Dose,O,O
intensity,O,O
did,O,O
not,O,O
add,O,O
information,O,O
to,O,O
models,O,O
.,O,O
There,O,O
were,O,O
14,O,O
of,O,O
151,O,O
(,O,O
9,O,O
.,O,O
3,O,O
%,O,O
),O,O
in,O,O
the,O,O
DFMO,B,O
plus,O,O
sulindac,B,O
group,O,O
and,O,O
4,O,O
of,O,O
139,O,O
(,O,O
2,O,O
.,O,O
9,O,O
%,O,O
),O,O
in,O,O
the,O,O
placebo,O,O
group,O,O
who,O,O
experienced,O,O
at,O,O
least,O,O
15,O,O
dB,O,O
hearing,O,O
reduction,O,O
from,O,O
baseline,O,O
in,O,O
2,O,O
or,O,O
more,O,O
consecutive,O,O
frequencies,O,O
across,O,O
the,O,O
entire,O,O
range,O,O
tested,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
Follow,O,O
-,O,O
up,O,O
air,O,O
conduction,O,O
done,O,O
at,O,O
least,O,O
6,O,O
months,O,O
after,O,O
end,O,O
of,O,O
treatment,O,O
showed,O,O
an,O,O
adjusted,O,O
mean,O,O
difference,O,O
in,O,O
hearing,O,O
thresholds,O,O
of,O,O
1,O,O
.,O,O
dB,O,O
(,O,O
-,O,O
0,O,O
.,O,O
81,O,O
to,O,O
2,O,O
.,O,O
96,O,O
dB,O,O
;,O,O
P,O,O
=,O,O
0,O,O
.,O,O
26,O,O
),O,O
between,O,O
treatment,O,O
arms,O,O
.,O,O
There,O,O
was,O,O
no,O,O
significant,O,O
difference,O,O
in,O,O
the,O,O
proportion,O,O
of,O,O
subjects,O,O
in,O,O
the,O,O
DFMO,B,B
plus,O,O
sulindac,B,B
group,O,O
who,O,O
experienced,O,O
clinically,O,O
significant,O,O
hearing,O,O
loss,O,O
compared,O,O
with,O,O
the,O,O
placebo,O,B
group,O,O
.,O,O
The,O,O
estimated,O,O
attributable,O,O
risk,O,O
of,O,O
ototoxicity,O,B
from,O,O
exposure,O,O
to,O,O
the,O,O
drug,O,O
is,O,O
8,O,O
.,O,O
4,O,O
%,O,O
(,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
-,O,O
2,O,O
.,O,O
0,O,O
%,O,O
to,O,O
18,O,O
.,O,O
8,O,O
%,O,O
;,O,O
P,O,O
=,O,O
0,O,O
.,O,O
12,O,O
.,O,O
There,O,O
is,O,O
a,O,O
<,O,O
2,O,O
dB,O,O
difference,O,O
in,O,O
mean,O,O
threshold,O,O
for,O,O
patients,O,O
treated,O,O
with,O,O
DFMO,B,B
plus,O,O
sulindac,B,B
compared,O,O
with,O,O
those,O,O
treated,O,O
with,O,O
placebo,O,O
.,O,O
Proteinase,O,B
3,O,I
-,O,I
antineutrophil,O,I
cytoplasmic,O,I
antibody,O,I
-,O,I
(,O,I
PR3,O,I
-,O,I
ANCA,O,I
),O,I
positive,O,O
necrotizing,O,O
glomerulonephritis,O,O
after,O,O
restarting,O,O
sulphasalazine,B,B
treatment,O,O
.,O,O
A,O,O
59,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
ulcerative,O,B
colitis,O,I
developed,O,O
red,O,O
eyes,O,O
",",O,O
pleural,O,O
effusion,O,O
",",O,O
eosinophilia,O,O
and,O,O
urinary,O,O
abnormalities,O,O
after,O,O
restarting,O,O
of,O,O
sulphasalazine,B,B
treatment,O,O
.,O,O
Light,O,O
microscopy,O,O
of,O,O
a,O,O
kidney,O,O
biopsy,O,O
revealed,O,O
segmental,O,O
necrotizing,O,O
glomerulonephritis,O,O
without,O,O
deposition,O,O
of,O,O
immunoglobulin,O,O
or,O,O
complement,O,O
.,O,O
Proteinase,O,B
3,O,I
-,O,O
antineutrophil,O,O
cytoplasmic,O,O
antibody,O,O
(,O,O
PR3,O,B
-,O,O
ANCA,O,O
),O,O
titer,O,O
was,O,O
elevated,O,O
at,O,O
183,O,O
ELISA,O,O
units,O,O
(,O,O
EU,O,B
),O,O
in,O,O
sera,O,O
(,O,O
normal,O,O
range,O,O
less,O,O
than,O,O
10,O,O
EU,O,B
),O,O
",",O,O
myeloperoxidase,O,O
-,O,O
ANCA,O,O
was,O,O
negative,O,O
.,O,O
PR3,O,B
-,O,O
ANCA,O,O
titer,O,O
was,O,O
250,O,O
and,O,O
1,O,O
",",O,O
EU,O,B
in,O,O
pleural,O,O
effusions,O,O
on,O,O
right,O,O
and,O,O
left,O,O
side,O,O
",",O,O
respectively,O,O
.,O,O
Although,O,O
cessation,O,O
of,O,O
sulphasalazine,B,B
treatment,O,O
resulted,O,O
in,O,O
improvements,O,O
in,O,O
fever,O,O
",",O,O
red,O,O
eyes,O,O
",",O,O
chest,O,O
pain,O,O
",",O,O
titer,O,O
of,O,O
C,O,B
-,O,I
reactive,O,I
protein,O,I
and,O,O
volume,O,O
of,O,O
the,O,O
pleural,O,O
effusions,O,O
",",O,O
we,O,O
initiated,O,O
steroid,B,O
therapy,O,O
",",O,O
because,O,O
PR3,O,B
-,O,O
ANCA,O,O
titer,O,O
rose,O,O
to,O,O
320,O,O
EU,O,B
",",O,O
eosinophil,O,O
count,O,O
increased,O,O
to,O,O
1,O,O
",",O,O
100,O,O
cells,O,O
/,O,O
microl,O,O
",",O,O
and,O,O
the,O,O
pleural,O,O
effusion,O,O
remained,O,O
.,O,O
One,O,O
month,O,O
after,O,O
steroid,B,B
therapy,O,O
",",O,O
the,O,O
pleural,O,B
effusion,O,I
disappeared,O,O
",",O,O
and,O,O
PR3,O,B
-,O,O
ANCA,O,I
titer,O,O
normalized,O,O
3,O,O
months,O,O
later,O,O
.,O,O
This,O,O
case,O,O
suggests,O,O
that,O,O
sulphasalazine,B,B
can,O,O
induce,O,O
PR3,O,B
-,O,O
ANCA,O,I
-,O,O
positive,O,O
necrotizing,O,O
glomerulonephritis,O,O
.,O,O
Comparison,O,O
of,O,O
unilateral,O,O
pallidotomy,O,O
and,O,O
subthalamotomy,O,O
findings,O,O
in,O,O
advanced,O,O
idiopathic,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
.,O,O
A,O,O
prospective,O,O
",",O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
pilot,O,O
study,O,O
to,O,O
compare,O,O
the,O,O
results,O,O
of,O,O
stereotactic,O,O
unilateral,O,O
pallidotomy,O,B
and,O,O
subthalamotomy,O,B
in,O,O
advanced,O,O
idiopathic,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
(,O,O
PD,O,B
),O,O
refractory,O,O
to,O,O
medical,O,O
treatment,O,O
was,O,O
designed,O,O
.,O,O
Ten,O,O
consecutive,O,O
patients,O,O
(,O,O
mean,O,O
age,O,O
",",O,O
58,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
6,O,O
years,O,O
;,O,O
7,O,O
men,O,O
",",O,O
3,O,O
women,O,O
),O,O
with,O,O
similar,O,O
characteristics,O,O
at,O,O
the,O,O
duration,O,O
of,O,O
disease,O,O
(,O,O
mean,O,O
disease,O,O
time,O,O
",",O,O
8,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
5,O,O
years,O,O
),O,O
",",O,O
disabling,O,O
motor,O,O
fluctuations,O,O
(,O,O
Hoehn,O,B
Yahr,O,I
stage,O,O
3,O,O
-,O,O
5,O,O
in,O,O
off,O,O
-,O,O
drug,O,O
phases,O,O
),O,O
and,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
were,O,O
selected,O,O
.,O,O
All,O,O
patients,O,O
had,O,O
bilateral,O,O
symptoms,O,O
and,O,O
their,O,O
levodopa,B,B
equivalent,O,O
dosing,O,O
were,O,O
analysed,O,O
.,O,O
Six,O,O
patients,O,O
were,O,O
operated,O,O
on,O,O
in,O,O
the,O,O
globus,O,B
pallidus,O,I
interna,O,I
(,O,O
GPi,O,B
),O,O
and,O,O
four,O,O
in,O,O
the,O,O
subthalamic,O,B
nucleus,O,I
(,O,O
STN,O,B
),O,O
.,O,O
Clinical,O,O
evaluation,O,O
included,O,O
the,O,O
use,O,O
of,O,O
the,O,O
Unified,O,B
Parkinson,O,I
',O,I
s,O,I
Disease,O,I
Rating,O,I
Scale,O,I
(,O,O
UPDRS,O,B
),O,O
",",O,O
Hoehn,O,B
Yahr,O,I
score,O,O
and,O,O
Schwab,O,B
England,O,I
activities,O,I
of,O,I
daily,O,I
living,O,I
(,O,O
ADL,O,B
),O,O
score,O,O
in,O,O
',O,O
on,O,O
',O,O
-,O,O
and,O,O
',O,O
off,O,O
',O,O
-,O,O
drug,O,O
conditions,O,O
before,O,O
surgery,O,O
and,O,O
6,O,O
months,O,O
after,O,O
surgery,O,O
.,O,O
There,O,O
was,O,O
statistically,O,O
significant,O,O
improvement,O,O
in,O,O
all,O,O
contralateral,O,O
major,O,O
parkinsonian,O,O
motor,O,O
signs,O,O
in,O,O
all,O,O
patients,O,O
followed,O,O
for,O,O
6,O,O
months,O,O
.,O,O
Levodopa,B,B
equivalent,O,O
daily,O,O
intake,O,O
was,O,O
significantly,O,O
reduced,O,O
in,O,O
the,O,O
STN,O,B
group,O,O
.,O,O
Changes,O,O
in,O,O
UPDRS,O,B
",",O,O
Hoehn,O,B
Yahr,O,I
and,O,O
Schwab,O,B
England,O,I
ADL,O,I
scores,O,O
were,O,O
similar,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
Cognitive,O,O
functions,O,O
were,O,O
unchanged,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
Complications,O,O
were,O,O
observed,O,O
in,O,O
two,O,O
patients,O,O
:,O,O
one,O,O
had,O,O
a,O,O
left,O,O
homonymous,O,O
hemianopsia,O,B
after,O,O
pallidotomy,O,B
and,O,O
another,O,O
one,O,O
developed,O,O
left,O,O
hemiballistic,O,B
movements,O,I
3,O,I
days,O,I
after,O,I
subthalamotomy,O,I
which,O,O
partly,O,O
improved,O,O
within,O,O
1,O,O
month,O,O
with,O,O
Valproate,B,B
1000,O,I
mg,O,I
/,O,I
day,O,I
.,O,O
The,O,O
findings,O,O
of,O,O
this,O,O
study,O,O
suggest,O,O
that,O,O
lesions,O,O
of,O,O
the,O,O
unilateral,O,O
STN,O,B
and,O,O
GPi,O,B
are,O,O
equally,O,O
effective,O,O
treatment,O,O
for,O,O
patients,O,O
with,O,O
advanced,O,O
PD,O,B
refractory,O,O
to,O,O
medical,O,O
treatment,O,O
.,O,O
DSMM,O,O
XI,O,O
study,O,O
:,O,O
dose,O,O
definition,O,O
for,O,O
intravenous,O,O
cyclophosphamide,B,B
in,O,O
combination,O,O
with,O,O
bortezomib,B,B
/,O,O
dexamethasone,B,B
for,O,O
remission,O,O
induction,O,O
in,O,O
patients,O,O
with,O,O
newly,O,O
diagnosed,O,O
myeloma,O,B
.,O,O
A,O,O
clinical,O,O
trial,O,O
was,O,O
initiated,O,O
to,O,O
evaluate,O,O
the,O,O
recommended,O,O
dose,O,O
of,O,O
cyclophosphamide,B,B
in,O,O
combination,O,O
with,O,O
bortezomib,B,B
and,O,O
dexamethasone,B,B
as,O,O
induction,O,O
treatment,O,O
before,O,O
stem,O,O
cell,O,O
transplantation,O,O
for,O,O
younger,O,O
patients,O,O
with,O,O
newly,O,O
diagnosed,O,O
multiple,O,O
myeloma,O,O
(,O,O
MM,O,B
),O,O
.,O,O
Thirty,O,O
patients,O,O
were,O,O
treated,O,O
with,O,O
three,O,O
21,O,O
-,O,O
day,O,O
cycles,O,O
of,O,O
bortezomib,B,B
1,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
on,O,O
days,O,O
1,O,O
",",O,O
4,O,O
",",O,O
8,O,O
",",O,O
and,O,O
11,O,O
plus,O,O
dexamethasone,B,B
40,O,O
mg,O,O
on,O,O
the,O,O
day,O,O
of,O,O
bortezomib,B,B
injection,O,O
and,O,O
the,O,O
day,O,O
after,O,O
plus,O,O
cyclophosphamide,B,B
at,O,O
900,O,O
",",O,O
1,O,O
",",O,O
200,O,O
",",O,O
or,O,O
1,O,O
",",O,O
500,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
on,O,O
day,O,O
1,O,O
.,O,O
The,O,O
maximum,O,O
tolerated,O,O
dose,O,O
of,O,O
cyclophosphamide,B,B
was,O,O
defined,O,O
as,O,O
900,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
.,O,O
At,O,O
this,O,O
dose,O,O
level,O,O
",",O,O
92,O,O
%,O,O
of,O,O
patients,O,O
achieved,O,O
at,O,O
least,O,O
a,O,O
partial,O,O
response,O,O
.,O,O
The,O,O
overall,O,O
response,O,O
rate,O,O
[,O,O
complete,O,O
response,O,O
(,O,O
CR,O,B
),O,O
plus,O,O
partial,O,O
response,O,O
(,O,O
PR,O,B
),O,O
],O,O
across,O,O
all,O,O
dose,O,O
levels,O,O
was,O,O
77,O,O
%,O,O
",",O,O
with,O,O
a,O,O
10,O,O
%,O,O
CR,O,B
rate,O,O
.,O,O
No,O,O
patient,O,O
experienced,O,O
progressive,O,O
disease,O,O
.,O,O
The,O,O
most,O,O
frequent,O,O
adverse,O,O
events,O,O
were,O,O
hematological,O,B
and,O,O
gastrointestinal,O,B
toxicities,O,O
as,O,O
well,O,O
as,O,O
neuropathy,O,B
.,O,O
The,O,O
results,O,O
suggest,O,O
that,O,O
bortezomib,B,B
in,O,O
combination,O,O
with,O,O
cyclophosphamide,B,B
at,O,O
900,O,O
mg,O,O
/,O,O
m,O,O
(,O,O
2,O,O
),O,O
and,O,O
dexamethasone,B,B
is,O,O
an,O,O
effective,O,O
induction,O,O
treatment,O,O
for,O,O
patients,O,O
with,O,O
newly,O,O
diagnosed,O,O
MM,O,B
that,O,O
warrants,O,O
further,O,O
investigation,O,O
.,O,O
Naloxone,B,B
reversal,O,O
of,O,O
hypotension,O,O
due,O,O
to,O,O
captopril,B,B
overdose,O,O
.,O,O
The,O,O
hemodynamic,O,O
effects,O,O
of,O,O
captopril,B,B
and,O,O
other,O,O
angiotensin,B,O
-,I,O
converting,I,O
enzyme,I,O
inhibitors,I,O
may,O,O
be,O,O
mediated,O,O
by,O,O
the,O,O
endogenous,O,O
opioid,O,O
system,O,O
.,O,O
The,O,O
opioid,O,O
antagonist,O,O
naloxone,B,B
has,O,O
been,O,O
shown,O,O
to,O,O
block,O,O
or,O,O
reverse,O,O
the,O,O
hypotensive,O,O
actions,O,O
of,O,O
captopril,B,B
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
an,O,O
intentional,O,O
captopril,B,B
overdose,O,O
",",O,O
manifested,O,O
by,O,O
marked,O,O
hypotension,O,O
",",O,O
that,O,O
resolved,O,O
promptly,O,O
with,O,O
the,O,O
administration,O,O
of,O,O
naloxone,B,B
.,O,O
To,O,O
our,O,O
knowledge,O,O
",",O,O
this,O,O
is,O,O
the,O,O
first,O,O
reported,O,O
case,O,O
of,O,O
captopril,B,B
-,O,O
induced,O,O
hypotension,O,O
treated,O,O
with,O,O
naloxone,B,B
.,O,O
experience,O,O
demonstrates,O,O
a,O,O
possible,O,O
role,O,O
of,O,O
naloxone,B,B
in,O,O
the,O,O
reversal,O,O
of,O,O
hypotension,O,O
resulting,O,O
from,O,O
captopril,B,B
.,O,O
Identification,O,O
of,O,O
a,O,O
simple,O,O
and,O,O
sensitive,O,O
microplate,O,O
method,O,O
for,O,O
the,O,O
detection,O,O
of,O,O
oversulfated,O,B
chondroitin,B,I
sulfate,I,I
in,O,O
heparin,B,B
products,O,O
.,O,O
Heparin,B,B
is,O,O
a,O,O
commonly,O,O
implemented,O,O
anticoagulant,O,O
used,O,O
to,O,O
treat,O,O
critically,O,O
ill,O,O
patients,O,O
.,O,O
Recently,O,O
",",O,O
a,O,O
number,O,O
of,O,O
commercial,O,O
lots,O,O
of,O,O
heparin,B,B
products,O,O
were,O,O
found,O,O
to,O,O
be,O,O
contaminated,O,O
with,O,O
an,O,O
oversulfated,O,B
chondroitin,B,I
sulfate,I,I
(,O,I
OSCS,O,I
),O,I
derivative,O,O
that,O,O
could,O,O
elicit,O,O
a,O,O
hypotensive,O,O
response,O,O
in,O,O
pigs,O,O
following,O,O
a,O,O
single,O,O
high,O,O
-,O,O
dose,O,O
infusion,O,O
.,O,O
Using,O,O
both,O,O
contaminated,O,O
heparin,B,B
products,O,O
and,O,O
the,O,O
synthetically,O,O
produced,O,O
derivative,O,O
",",O,O
we,O,O
showed,O,O
that,O,O
the,O,O
OSCS,O,B
produces,O,O
dose,O,O
-,O,O
dependent,O,O
hypotension,O,O
in,O,O
pigs,O,O
.,O,O
The,O,O
no,O,O
observed,O,O
effect,O,O
level,O,O
(,O,O
NOEL,O,B
),O,O
for,O,O
this,O,O
contaminant,O,O
appears,O,O
to,O,O
be,O,O
approximately,O,O
1mg,O,O
/,O,O
kg,O,O
",",O,O
corresponding,O,O
to,O,O
a,O,O
contamination,O,O
level,O,O
of,O,O
approximately,O,O
3,O,O
%,O,O
.,O,O
We,O,O
also,O,O
demonstrated,O,O
that,O,O
OSCS,O,B
can,O,O
be,O,O
identified,O,O
in,O,O
heparin,B,O
products,O,O
using,O,O
a,O,O
simple,O,O
",",O,O
inexpensive,O,O
",",O,O
commercially,O,O
available,O,O
heparin,B,O
enzyme,O,O
immunoassay,O,O
(,O,O
EIA,O,B
),O,O
kit,O,O
that,O,O
has,O,O
a,O,O
limit,O,O
of,O,O
detection,O,O
of,O,O
approximately,O,O
0,O,O
.,O,O
1,O,O
%,O,O
",",O,O
well,O,O
below,O,O
the,O,O
NOEL,O,O
.,O,O
This,O,O
kit,O,O
may,O,O
provide,O,O
a,O,O
useful,O,O
method,O,O
to,O,O
test,O,O
heparin,B,O
products,O,O
for,O,O
contamination,O,O
with,O,O
oversulfated,O,B
GAG,O,I
derivatives,O,I
.,O,O
5,B,O
flourouracil,I,B
-,O,I
induced,O,O
apical,O,B
ballooning,O,I
syndrome,O,I
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
The,O,O
apical,O,B
ballooning,O,I
syndrome,O,I
(,O,O
ABS,O,B
),O,O
is,O,O
a,O,O
recently,O,O
described,O,O
stress,O,O
-,O,O
mediated,O,O
acute,O,O
cardiac,O,O
syndrome,O,O
characterized,O,O
by,O,O
transient,O,O
wall,O,O
-,O,O
motion,O,O
abnormalities,O,O
involving,O,O
the,O,O
apex,O,O
and,O,O
midventricle,O,O
with,O,O
hyperkinesis,O,O
of,O,O
the,O,O
basal,O,O
left,O,O
ventricular,O,O
(,O,O
LV,O,B
),O,O
segments,O,O
without,O,O
obstructive,O,O
epicardial,O,O
coronary,O,O
disease,O,O
.,O,O
Cardiotoxicity,O,O
is,O,O
not,O,O
an,O,O
uncommon,O,O
adverse,O,O
effect,O,O
of,O,O
chemotherapeutic,O,O
agents,O,O
.,O,O
However,O,O
",",O,O
there,O,O
are,O,O
no,O,O
reports,O,O
of,O,O
ABS,O,O
secondary,O,O
to,O,O
chemotherapeutic,O,O
agents,O,O
.,O,O
We,O,O
describe,O,O
the,O,O
case,O,O
of,O,O
a,O,O
woman,O,O
who,O,O
developed,O,O
the,O,O
syndrome,O,O
after,O,O
chemotherapy,O,O
for,O,O
metastatic,O,O
cancer,O,O
.,O,O
A,O,O
79,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
presented,O,O
with,O,O
typical,O,O
ischemic,O,O
chest,O,O
pain,O,O
",",O,O
elevated,O,O
cardiac,O,O
enzymes,O,O
with,O,O
significant,O,O
ST,O,O
-,O,O
segment,O,O
abnormalities,O,O
on,O,O
her,O,O
electrocardiogram,O,O
.,O,O
She,O,O
underwent,O,O
recent,O,O
chemotherapy,O,B
with,O,O
fluorouracil,B,B
for,O,O
metastatic,O,O
colorectal,O,O
cancer,O,O
.,O,O
Echocardiography,O,O
revealed,O,O
a,O,O
wall,O,O
-,O,O
motion,O,O
abnormality,O,O
involving,O,O
the,O,O
apical,O,O
and,O,O
periapical,O,O
segments,O,O
which,O,O
appeared,O,O
akinetic,O,O
.,O,O
Coronary,O,O
angiography,O,O
revealed,O,O
no,O,O
obstructive,O,O
coronary,O,O
lesions,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
stabilized,O,O
with,O,O
medical,O,O
therapy,O,O
.,O,O
Four,O,O
weeks,O,O
later,O,O
she,O,O
remained,O,O
completely,O,O
asymptomatic,O,O
.,O,O
Echocardiogram,O,O
revealed,O,O
a,O,O
normal,O,O
ejection,O,O
fraction,O,O
and,O,O
a,O,O
resolution,O,O
of,O,O
the,O,O
apical,O,O
akinesis,O,O
.,O,O
Pathogenetic,O,O
mechanisms,O,O
of,O,O
cardiac,O,O
complications,O,O
in,O,O
cancer,O,O
patients,O,O
undergoing,O,O
chemotherapy,O,O
include,O,O
coronary,O,B
vasospasm,O,O
",",O,O
endothelial,O,B
damage,O,O
and,O,O
consequent,O,O
thrombus,O,B
formation,O,O
.,O,O
In,O,O
our,O,O
patient,O,O
",",O,O
both,O,O
supraphysiologic,O,O
levels,O,O
of,O,O
plasma,O,O
catecholamines,B,B
and,O,O
stress,O,O
related,O,O
neuropeptides,O,B
caused,O,O
by,O,O
cancer,O,O
diagnosis,O,O
as,O,O
well,O,O
as,O,O
chemotherapy,O,O
may,O,O
have,O,O
contributed,O,O
the,O,O
development,O,O
of,O,O
ABS,O,O
.,O,O
Rapid,O,O
reversal,O,O
of,O,O
anticoagulation,O,O
reduces,O,O
hemorrhage,O,O
volume,O,O
in,O,O
a,O,O
mouse,O,O
model,O,O
of,O,O
warfarin,B,B
-,O,O
associated,O,O
intracerebral,O,O
hemorrhage,O,O
.,O,O
Warfarin,B,B
-,O,O
associated,O,O
intracerebral,O,B
hemorrhage,O,I
(,O,O
W,O,B
-,O,I
ICH,O,I
),O,O
is,O,O
a,O,O
severe,O,O
type,O,O
of,O,O
stroke,O,O
.,O,O
There,O,O
is,O,O
no,O,O
consensus,O,O
on,O,O
the,O,O
optimal,O,O
treatment,O,O
for,O,O
W,O,B
-,O,I
ICH,O,I
.,O,O
Using,O,O
a,O,O
mouse,O,O
model,O,O
",",O,O
we,O,O
tested,O,O
whether,O,O
the,O,O
rapid,O,O
reversal,O,O
of,O,O
anticoagulation,O,O
using,O,O
human,O,O
prothrombin,B,B
complex,I,I
concentrate,I,I
(,O,O
PCC,B,B
),O,O
can,O,O
reduce,O,O
hemorrhagic,O,O
blood,O,O
volume,O,O
.,O,O
Male,O,O
CD,O,B
-,O,I
1,O,I
mice,O,O
were,O,O
treated,O,O
with,O,O
warfarin,B,B
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
over,O,O
24,O,O
h,O,O
),O,O
",",O,O
resulting,O,O
in,O,O
a,O,O
mean,O,O
(,O,O
+,O,O
/,O,O
-,O,O
s,O,O
.,O,O
d,O,O
.,O,O
),O,O
International,O,O
Normalized,O,O
Ratio,O,O
of,O,O
3,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
.,O,O
First,O,O
",",O,O
we,O,O
showed,O,O
that,O,O
an,O,O
intravenous,O,O
administration,O,O
of,O,O
human,O,O
PCC,B,B
rapidly,O,O
reversed,O,O
anticoagulation,O,O
in,O,O
mice,O,O
.,O,O
Second,O,O
",",O,O
a,O,O
stereotactic,O,O
injection,O,O
of,O,O
collagenase,O,B
was,O,O
administered,O,O
to,O,O
induce,O,O
hemorrhage,O,O
in,O,O
the,O,O
right,O,O
striatum,O,O
.,O,O
Forty,O,O
-,O,O
five,O,O
minutes,O,O
later,O,O
",",O,O
the,O,O
animals,O,O
were,O,O
randomly,O,O
treated,O,O
with,O,O
PCC,B,B
(,O,O
100,O,O
U,O,O
/,O,O
kg,O,O
),O,O
or,O,O
saline,O,B
i,O,O
.,O,O
.,O,O
(,O,O
n,O,O
=,O,O
12,O,O
per,O,O
group,O,O
),O,O
.,O,O
Twenty,O,O
-,O,O
four,O,O
hours,O,O
after,O,O
hemorrhage,O,O
induction,O,O
",",O,O
hemorrhagic,O,O
blood,O,O
volume,O,O
was,O,O
quantified,O,O
using,O,O
a,O,O
photometric,O,O
hemoglobin,O,B
assay,O,O
.,O,O
The,O,O
mean,O,O
hemorrhagic,O,O
blood,O,O
volume,O,O
was,O,O
reduced,O,O
in,O,O
PCC,B,B
-,O,O
treated,O,O
animals,O,O
(,O,O
6,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
1,O,O
microL,O,B
),O,O
compared,O,O
with,O,O
saline,O,O
controls,O,O
(,O,O
15,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
11,O,O
.,O,O
2,O,O
microL,O,B
",",O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
the,O,O
saline,O,O
group,O,O
",",O,O
45,O,O
%,O,O
of,O,O
the,O,O
mice,O,O
developed,O,O
large,O,O
hematomas,O,O
(,O,O
i,O,O
.,O,O
e,O,O
.,O,O
",",O,O
>,O,O
15,O,O
microL,O,B
),O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
such,O,O
extensive,O,O
lesions,O,O
were,O,O
never,O,O
found,O,O
in,O,O
the,O,O
PCC,B,O
group,O,O
.,O,O
We,O,O
provide,O,O
experimental,O,O
data,O,O
suggesting,O,O
PCC,B,O
to,O,O
be,O,O
an,O,O
effective,O,O
acute,O,O
treatment,O,O
for,O,O
W,O,O
-,O,O
ICH,O,O
in,O,O
terms,O,O
of,O,O
reducing,O,O
hemorrhagic,O,O
blood,O,O
volume,O,O
.,O,O
Future,O,O
studies,O,O
are,O,O
needed,O,O
to,O,O
assess,O,O
the,O,O
therapeutic,O,O
potential,O,O
emerging,O,O
from,O,O
our,O,O
finding,O,O
for,O,O
human,O,O
W,O,B
-,O,O
ICH,O,O
.,O,O
Long,O,O
term,O,O
hormone,O,O
therapy,O,O
for,O,O
perimenopausal,O,O
and,O,O
postmenopausal,O,O
women,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Hormone,O,B
therapy,O,O
(,O,O
HT,O,B
),O,O
is,O,O
widely,O,O
used,O,O
for,O,O
controlling,O,O
menopausal,O,O
symptoms,O,O
and,O,O
has,O,O
also,O,O
been,O,O
used,O,O
for,O,O
the,O,O
management,O,O
and,O,O
prevention,O,O
of,O,O
cardiovascular,O,O
disease,O,O
",",O,O
osteoporosis,O,B
and,O,O
dementia,O,O
in,O,O
older,O,O
women,O,O
.,O,O
This,O,O
is,O,O
an,O,O
updated,O,O
version,O,O
of,O,O
the,O,O
original,O,O
Cochrane,O,O
review,O,O
first,O,O
published,O,O
in,O,O
2005,O,O
.,O,O
OBJECTIVES,O,O
:,O,O
To,O,O
assess,O,O
the,O,O
effect,O,O
of,O,O
long,O,O
-,O,O
term,O,O
HT,O,O
on,O,O
mortality,O,O
",",O,O
cardiovascular,O,O
outcomes,O,O
",",O,O
cancer,O,B
",",O,O
gallbladder,O,B
disease,O,I
",",O,O
cognition,O,O
",",O,O
fractures,O,O
and,O,O
quality,O,O
of,O,O
life,O,O
.,O,O
SEARCH,O,O
STRATEGY,O,O
:,O,O
We,O,O
searched,O,O
the,O,O
following,O,O
databases,O,O
to,O,O
November,O,O
2007,O,O
:,O,O
Trials,O,O
Register,O,O
of,O,O
the,O,O
Cochrane,O,O
Menstrual,O,O
Disorders,O,O
and,O,O
Subfertility,O,O
Group,O,O
",",O,O
Cochrane,O,O
Central,O,O
Register,O,O
of,O,O
Controlled,O,O
Trials,O,O
",",O,O
MEDLINE,O,O
",",O,O
EMBASE,O,O
",",O,O
Biological,O,O
Abstracts,O,O
.,O,O
Also,O,O
relevant,O,O
non,O,O
-,O,O
indexed,O,O
journals,O,O
and,O,O
conference,O,O
abstracts,O,O
.,O,O
SELECTION,O,O
CRITERIA,O,O
:,O,O
Randomised,O,O
double,O,O
-,O,O
blind,O,O
trials,O,O
of,O,O
HT,O,O
versus,O,O
placebo,O,O
",",O,O
taken,O,O
for,O,O
at,O,O
least,O,O
one,O,O
year,O,O
by,O,O
perimenopausal,O,O
or,O,O
postmenopausal,O,O
women,O,O
.,O,O
HT,O,O
included,O,O
oestrogens,B,B
",",O,O
with,O,O
or,O,O
without,O,O
progestogens,B,B
",",O,O
via,O,O
oral,O,O
",",O,O
transdermal,O,O
",",O,O
subcutaneous,O,O
or,O,O
transnasal,O,O
routes,O,O
.,O,O
DATA,O,O
COLLECTION,O,O
AND,O,O
ANALYSIS,O,O
:,O,O
Two,O,O
authors,O,O
independently,O,O
assessed,O,O
trial,O,O
quality,O,O
and,O,O
extracted,O,O
data,O,O
.,O,O
MAIN,O,O
RESULTS,O,O
:,O,O
Nineteen,O,O
trials,O,O
involving,O,O
41,O,O
",",O,O
904,O,O
women,O,O
were,O,O
included,O,O
.,O,O
In,O,O
relatively,O,O
healthy,O,O
women,O,O
",",O,O
combined,O,O
continuous,O,O
HT,O,O
significantly,O,O
increased,O,O
the,O,O
risk,O,O
of,O,O
venous,O,B
thrombo,O,I
-,O,I
embolism,O,I
or,O,O
coronary,O,B
event,O,I
(,O,I
after,O,O
one,O,O
year,O,O
',O,O
s,O,O
use,O,O
),O,O
",",O,O
stroke,O,B
(,O,O
after,O,O
three,O,O
years,O,O
),O,O
",",O,O
breast,O,B
cancer,O,I
and,O,O
gallbladder,O,B
disease,O,I
.,O,O
Long,O,O
-,O,O
term,O,O
oestrogen,B,B
-,O,O
only,O,O
HT,O,O
significantly,O,O
increased,O,O
the,O,O
risk,O,O
of,O,O
venous,O,B
thrombo,O,I
-,O,I
embolism,O,I
",",O,O
stroke,O,B
and,O,O
gallbladder,O,B
disease,O,I
(,O,O
after,O,O
one,O,O
to,O,O
two,O,O
years,O,O
",",O,O
three,O,O
years,O,O
and,O,O
seven,O,O
years,O,O
',O,O
use,O,O
respectively,O,O
),O,O
",",O,O
but,O,O
did,O,O
not,O,O
significantly,O,O
increase,O,O
the,O,O
risk,O,O
of,O,O
breast,O,B
cancer,O,I
.,O,O
The,O,O
only,O,O
statistically,O,O
significant,O,O
benefits,O,O
of,O,O
HT,O,O
were,O,O
a,O,O
decreased,O,O
incidence,O,O
of,O,O
fractures,O,B
and,O,O
(,O,O
for,O,O
combined,O,O
HT,O,O
),O,O
colon,O,B
cancer,O,I
",",O,O
with,O,O
long,O,O
-,O,O
term,O,O
use,O,O
.,O,O
Among,O,O
women,O,O
aged,O,O
over,O,O
65,O,O
who,O,O
were,O,O
relatively,O,O
healthy,O,O
(,O,O
i,O,O
.,O,O
e,O,O
.,O,O
generally,O,O
fit,O,O
",",O,O
without,O,O
overt,O,O
disease,O,O
),O,O
and,O,O
taking,O,O
continuous,O,O
combined,O,O
HT,O,B
",",O,O
there,O,O
was,O,O
a,O,O
statistically,O,O
significant,O,O
increase,O,O
in,O,O
the,O,O
incidence,O,O
of,O,O
dementia,O,B
.,O,O
Among,O,O
women,O,O
with,O,O
cardiovascular,O,B
disease,O,I
",",O,O
long,O,O
-,O,O
term,O,O
use,O,O
of,O,O
combined,O,O
continuous,O,O
HT,O,B
significantly,O,O
increased,O,O
the,O,O
risk,O,O
of,O,O
venous,O,B
thrombo,O,I
-,O,I
embolism,O,I
.,O,O
One,O,O
trial,O,O
analysed,O,O
subgroups,O,O
of,O,O
2839,O,O
relatively,O,O
healthy,O,O
50,O,O
to,O,O
59,O,O
year,O,O
old,O,O
women,O,O
taking,O,O
combined,O,O
continuous,O,O
HT,O,B
and,O,O
1637,O,O
taking,O,O
oestrogen,B,B
-,O,O
only,O,O
HT,O,B
",",O,O
versus,O,O
similar,O,O
-,O,O
sized,O,O
placebo,O,O
groups,O,O
.,O,O
The,O,O
only,O,O
significantly,O,O
increased,O,O
risk,O,O
reported,O,O
was,O,O
for,O,O
venous,O,B
thrombo,O,I
-,O,I
embolism,O,I
in,O,O
women,O,O
taking,O,O
combined,O,O
continuous,O,O
HT,O,B
:,O,O
their,O,O
absolute,O,O
risk,O,O
remained,O,O
low,O,O
",",O,O
at,O,O
less,O,O
than,O,O
1,O,O
/,O,O
500,O,O
.,O,O
However,O,O
",",O,O
this,O,O
study,O,O
was,O,O
not,O,O
powered,O,O
to,O,O
detect,O,O
differences,O,O
between,O,O
groups,O,O
of,O,O
younger,O,O
women,O,O
.,O,O
AUTHORS,O,O
',O,O
CONCLUSIONS,O,O
:,O,O
HT,O,O
is,O,O
not,O,O
indicated,O,O
for,O,O
the,O,O
routine,O,O
management,O,O
of,O,O
chronic,O,O
disease,O,O
.,O,O
We,O,O
need,O,O
more,O,O
evidence,O,O
on,O,O
the,O,O
safety,O,O
of,O,O
HT,O,O
for,O,O
menopausal,O,O
symptom,O,O
control,O,O
",",O,O
though,O,O
short,O,O
-,O,O
term,O,O
use,O,O
appears,O,O
to,O,O
be,O,O
relatively,O,O
safe,O,O
for,O,O
healthy,O,O
younger,O,O
women,O,O
.,O,O
Acute,O,O
renal,O,B
failure,O,I
in,O,O
patients,O,O
with,O,O
AIDS,O,O
on,O,O
tenofovir,B,B
while,O,O
receiving,O,O
prolonged,O,O
vancomycin,B,B
course,O,O
for,O,O
osteomyelitis,O,O
.,O,O
Renal,O,B
failure,O,I
developed,O,O
after,O,O
a,O,O
prolonged,O,O
course,O,O
of,O,O
vancomycin,B,B
therapy,O,O
in,O,O
2,O,O
patients,O,O
who,O,O
were,O,O
receiving,O,O
tenofovir,B,B
disoproxil,I,I
fumarate,I,I
as,O,O
part,O,O
of,O,O
an,O,O
antiretroviral,O,O
regimen,O,O
.,O,O
Tenofovir,B,B
has,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
development,O,O
of,O,O
Fanconi,O,B
syndrome,O,I
and,O,O
renal,O,B
insufficiency,O,I
because,O,O
of,O,O
its,O,O
effects,O,O
on,O,O
the,O,O
proximal,O,O
renal,O,B
tubule,O,I
.,O,O
Vancomycin,B,B
nephrotoxicity,O,O
is,O,O
infrequent,O,O
but,O,O
may,O,O
result,O,O
from,O,O
coadministration,O,O
with,O,O
a,O,O
nephrotoxic,O,O
agent,O,O
.,O,O
Clinicians,O,O
should,O,O
be,O,O
aware,O,O
that,O,O
tenofovir,B,B
may,O,O
raise,O,O
the,O,O
risk,O,O
of,O,O
renal,O,O
failure,O,O
during,O,O
prolonged,O,O
administration,O,O
of,O,O
vancomycin,B,B
.,O,O
Recurrent,O,O
dysosmia,O,O
induced,O,O
by,O,O
pyrazinamide,B,B
.,O,O
Pyrazinamide,B,B
can,O,O
have,O,O
adverse,O,O
effects,O,O
such,O,O
as,O,O
hepatic,O,O
toxicity,O,O
",",O,O
hyperuricemia,O,O
or,O,O
digestive,O,O
disorders,O,O
.,O,O
In,O,O
rare,O,O
cases,O,O
",",O,O
alterations,O,O
in,O,O
taste,O,B
and,O,O
smell,O,B
function,O,O
have,O,O
been,O,O
reported,O,O
for,O,O
pyrazinamide,B,B
when,O,O
combined,O,O
with,O,O
other,O,O
drugs,O,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
reversible,O,O
olfactory,O,B
disorder,O,O
related,O,O
to,O,O
pyrazinamide,B,B
in,O,O
a,O,O
woman,O,O
",",O,O
with,O,O
a,O,O
positive,O,O
rechallenge,O,O
.,O,O
The,O,O
patient,O,O
presented,O,O
every,O,O
day,O,O
a,O,O
sensation,O,O
of,O,O
smelling,O,O
something,O,O
burning,O,O
15,O,O
min,O,O
after,O,O
drug,O,O
intake,O,O
.,O,O
Dysosmia,O,B
disappeared,O,O
completely,O,O
after,O,O
pyrazinamide,B,B
withdrawal,O,O
and,O,O
recurred,O,O
after,O,O
its,O,O
rechallenge,O,O
.,O,O
The,O,O
case,O,O
was,O,O
reported,O,O
to,O,O
the,O,O
Tunisian,O,O
Centre,O,O
of,O,O
Pharmacovigilance,O,O
.,O,O
Mice,O,O
lacking,O,O
mPGES,O,B
-,O,I
1,O,I
are,O,O
resistant,O,O
to,O,O
lithium,B,B
-,O,O
induced,O,O
polyuria,O,O
.,O,O
Cyclooxygenase,O,B
-,O,I
2,O,I
activity,O,O
is,O,O
required,O,O
for,O,O
the,O,O
development,O,O
of,O,O
lithium,B,B
-,O,O
induced,O,O
polyuria,O,O
.,O,O
However,O,O
",",O,O
the,O,O
involvement,O,O
of,O,O
a,O,O
specific,O,O
",",O,O
terminal,O,O
prostaglandin,B,B
(,O,O
PG,B,B
),O,O
isomerase,O,O
has,O,O
not,O,O
been,O,O
evaluated,O,O
.,O,O
The,O,O
present,O,O
study,O,O
was,O,O
undertaken,O,O
to,O,O
assess,O,O
lithium,B,B
-,O,O
induced,O,O
polyuria,O,O
in,O,O
mice,O,O
deficient,O,O
in,O,O
microsomal,O,O
prostaglandin,B,B
E,I,I
synthase,O,I
-,O,I
1,O,I
(,O,O
mPGES,O,B
-,O,I
1,O,I
),O,O
.,O,O
A,O,O
2,O,O
-,O,O
wk,O,O
administration,O,O
of,O,O
LiCl,B,B
(,O,O
4,O,O
mmol,O,O
.,O,O
kg,O,O
(,O,O
-,O,O
1,O,O
),O,O
.,O,O
day,O,O
(,O,O
-,O,O
1,O,O
),O,O
ip,O,O
),O,O
in,O,O
mPGES,O,B
-,O,O
1,O,O
+,O,O
/,O,O
+,O,O
mice,O,O
led,O,O
to,O,O
a,O,O
marked,O,O
polyuria,O,O
with,O,O
hyposmotic,O,O
urine,O,O
.,O,O
This,O,O
was,O,O
associated,O,O
with,O,O
elevated,O,O
renal,O,O
mPGES,O,B
-,O,O
1,O,O
protein,O,O
expression,O,O
and,O,O
increased,O,O
urine,O,O
PGE,B,B
(,I,O
2,I,O
),I,O
excretion,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
mPGES,O,B
-,O,O
1,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
were,O,O
largely,O,O
resistant,O,O
to,O,O
lithium,B,B
-,O,O
induced,O,O
polyuria,O,O
and,O,O
a,O,O
urine,O,O
concentrating,O,O
defect,O,O
",",O,O
accompanied,O,O
by,O,O
nearly,O,O
complete,O,O
blockade,O,O
of,O,O
high,O,O
urine,O,O
PGE,B,B
(,I,O
2,I,O
),I,O
and,O,O
cAMP,O,B
output,O,O
.,O,O
Immunoblotting,O,O
",",O,O
immunohistochemistry,O,O
",",O,O
and,O,O
quantitative,O,O
(,O,O
q,O,O
),O,O
RT,O,O
-,O,O
PCR,O,O
consistently,O,O
detected,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
aquaporin,O,B
-,O,O
2,O,I
(,O,O
AQP2,O,B
),O,O
protein,O,O
expression,O,O
in,O,O
both,O,O
the,O,O
renal,O,O
cortex,O,O
and,O,O
medulla,O,O
of,O,O
lithium,B,B
-,O,O
treated,O,O
+,O,O
/,O,O
+,O,O
mice,O,O
.,O,O
This,O,O
decrease,O,O
was,O,O
significantly,O,O
attenuated,O,O
in,O,O
the,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
.,O,O
qRT,O,O
-,O,O
PCR,O,O
detected,O,O
similar,O,O
patterns,O,O
of,O,O
changes,O,O
in,O,O
AQP2,O,B
mRNA,O,O
in,O,O
the,O,O
medulla,O,O
but,O,O
not,O,O
in,O,O
the,O,O
cortex,O,O
.,O,O
Similarly,O,O
",",O,O
the,O,O
total,O,O
protein,O,O
abundance,O,O
of,O,O
the,O,O
Na,B,B
-,O,I
K,B,I
-,O,I
2Cl,B,I
cotransporter,O,I
(,O,O
NKCC2,O,B
),O,O
in,O,O
the,O,O
medulla,O,O
but,O,O
not,O,O
in,O,O
the,O,O
cortex,O,O
of,O,O
the,O,O
+,O,O
/,O,O
+,O,O
mice,O,O
was,O,O
significantly,O,O
reduced,O,O
by,O,O
lithium,B,B
treatment,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
dowregulation,O,O
of,O,O
renal,O,O
medullary,O,O
NKCC2,O,B
expression,O,O
was,O,O
significantly,O,O
attenuated,O,O
in,O,O
the,O,O
-,O,O
/,O,O
-,O,O
mice,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
mPGES,O,B
-,O,I
1,O,I
-,O,I
derived,O,O
PGE,B,B
(,I,O
2,I,O
),I,O
mediates,O,O
lithium,B,B
-,O,O
induced,O,O
polyuria,O,O
likely,O,O
via,O,O
inhibition,O,O
of,O,O
AQP2,O,B
and,O,O
NKCC2,O,B
expression,O,O
.,O,O
Preservation,O,O
of,O,O
renal,O,O
blood,O,O
flow,O,O
during,O,O
hypotension,O,O
induced,O,O
with,O,O
fenoldopam,B,B
in,O,O
dogs,O,O
.,O,O
The,O,O
introduction,O,O
of,O,O
drugs,O,O
that,O,O
could,O,O
induce,O,O
hypotension,O,O
with,O,O
different,O,O
pharmacological,O,O
actions,O,O
would,O,O
be,O,O
advantageous,O,O
because,O,O
side,O,O
effects,O,O
unique,O,O
to,O,O
a,O,O
specific,O,O
drug,O,O
could,O,O
be,O,O
minimized,O,O
by,O,O
selecting,O,O
appropriate,O,O
therapy,O,O
.,O,O
Specific,O,O
dopamine,B,B
-,O,I
1,O,I
",",O,O
(,O,O
DA1,B,B
),O,O
and,O,O
dopamine,B,B
-,O,I
2,O,I
(,O,O
DA2,B,B
),O,O
receptor,O,O
agonists,O,O
are,O,O
now,O,O
under,O,O
clinical,O,O
investigation,O,O
.,O,O
Fenoldopam,B,B
mesylate,I,O
is,O,O
a,O,O
specific,O,O
DA1,O,B
receptor,O,O
agonist,O,O
that,O,O
lowers,O,O
blood,O,O
pressure,O,O
by,O,O
vasodilatation,O,O
.,O,O
The,O,O
hypothesis,O,O
that,O,O
fenoldopam,B,B
could,O,O
be,O,O
used,O,O
to,O,O
induce,O,O
hypotension,O,O
and,O,O
preserve,O,O
blood,O,O
flow,O,O
to,O,O
the,O,O
kidney,O,O
was,O,O
tested,O,O
.,O,O
Systemic,O,O
aortic,O,O
blood,O,O
pressure,O,O
and,O,O
renal,O,O
blood,O,O
flow,O,O
were,O,O
measured,O,O
continuously,O,O
with,O,O
a,O,O
carotid,O,O
arterial,O,O
catheter,O,O
and,O,O
an,O,O
electromagnetic,O,O
flow,O,O
probe,O,O
respectively,O,O
",",O,O
in,O,O
order,O,O
to,O,O
compare,O,O
the,O,O
cardiovascular,O,O
and,O,O
renal,O,O
vascular,O,O
effects,O,O
of,O,O
fenoldopam,B,B
and,O,O
sodium,B,B
nitroprusside,B,I
in,O,O
ten,O,O
dogs,O,O
under,O,O
halothane,B,O
general,O,O
anaesthesia,O,O
.,O,O
Mean,O,O
arterial,O,O
pressure,O,O
was,O,O
decreased,O,O
30,O,O
+,O,O
/,O,O
-,O,O
8,O,O
per,O,O
cent,O,O
from,O,O
control,O,O
with,O,O
infusion,O,O
of,O,O
fenoldopam,B,B
(,O,O
3,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
kg,O,O
-,O,O
1,O,O
.,O,O
min,O,O
-,O,O
1,O,O
),O,O
and,O,O
34,O,O
+,O,O
/,O,O
-,O,O
4,O,O
per,O,O
cent,O,O
with,O,O
infusion,O,O
of,O,O
sodium,B,B
nitroprusside,B,I
(,O,O
5,O,O
.,O,O
9,O,O
micrograms,O,B
.,O,O
kg,O,O
-,O,O
1,O,O
.,O,O
min,O,O
-,O,O
1,O,O
),O,O
(,O,O
NS,O,B
),O,O
.,O,O
Renal,O,O
blood,O,O
flow,O,O
(,O,O
RBF,O,B
),O,O
increased,O,O
during,O,O
fenoldopam,B,B
-,O,O
induced,O,O
hypotension,O,O
11,O,O
+,O,O
/,O,O
-,O,O
7,O,O
per,O,O
cent,O,O
and,O,O
decreased,O,O
21,O,O
+,O,O
/,O,O
-,O,O
8,O,O
per,O,O
cent,O,O
during,O,O
sodium,B,B
nitroprusside,B,I
-,O,O
induced,O,O
hypotension,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
Sodium,O,B
nitroprusside,B,I
is,O,O
a,O,O
non,O,O
-,O,O
selective,O,O
arteriolar,O,O
and,O,O
venous,O,O
vasodilator,O,O
that,O,O
can,O,O
produce,O,O
redistribution,O,O
of,O,O
blood,O,O
flow,O,O
away,O,O
from,O,O
the,O,O
kidney,O,O
during,O,O
induced,O,O
hypotension,O,O
.,O,O
Fenoldopam,O,B
is,O,O
a,O,O
selective,O,O
dopamine,B,B
-,O,O
1,O,O
(,O,O
DA1,O,O
),O,O
receptor,O,O
agonist,O,O
that,O,O
causes,O,O
vasodilatation,O,O
to,O,O
the,O,O
kidney,O,O
and,O,O
other,O,O
organs,O,O
with,O,O
DA1,O,O
receptors,O,O
and,O,O
preserves,O,O
blood,O,O
flow,O,O
to,O,O
the,O,O
kidney,O,O
during,O,O
induced,O,O
hypotension,O,O
.,O,O
Seizures,O,O
associated,O,O
with,O,O
levofloxacin,B,B
:,O,O
case,O,O
presentation,O,O
and,O,O
literature,O,O
review,O,O
.,O,O
PURPOSE,O,O
:,O,O
We,O,O
present,O,O
a,O,O
case,O,O
of,O,O
a,O,O
patient,O,O
who,O,O
developed,O,O
seizures,O,O
shortly,O,O
after,O,O
initiating,O,O
treatment,O,O
with,O,O
levofloxacin,B,B
and,O,O
to,O,O
discuss,O,O
the,O,O
potential,O,O
drug,O,O
-,O,O
drug,O,O
interactions,O,O
related,O,O
to,O,O
the,O,O
inhibition,O,O
of,O,O
cytochrome,O,B
P450,O,I
(,O,I
CYP,O,I
),O,I
1A2,O,I
in,O,O
this,O,O
case,O,O
",",O,O
as,O,O
well,O,O
as,O,O
in,O,O
other,O,O
cases,O,O
",",O,O
of,O,O
levofloxacin,B,B
-,O,O
induced,O,O
seizures,O,O
.,O,O
METHODS,O,O
:,O,O
Several,O,O
biomedical,O,O
databases,O,O
were,O,O
searched,O,O
including,O,O
MEDLINE,O,B
",",O,O
Cochrane,O,B
and,O,O
Ovid,O,B
.,O,O
The,O,O
main,O,O
search,O,O
terms,O,O
utilized,O,O
were,O,O
case,O,O
report,O,O
and,O,O
levofloxacin,B,B
.,O,O
The,O,O
search,O,O
was,O,O
limited,O,O
to,O,O
studies,O,O
published,O,O
in,O,O
English,O,O
.,O,O
RESULTS,O,O
:,O,O
Six,O,O
cases,O,O
of,O,O
levofloxacin,B,B
-,O,O
induced,O,O
seizures,O,O
have,O,O
been,O,O
reported,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
Drug,O,B
-,O,O
drug,O,O
interactions,O,O
related,O,O
to,O,O
the,O,O
inhibition,O,O
of,O,O
CYP1A2,O,B
by,O,O
levofloxacin,B,O
are,O,O
likely,O,O
involved,O,O
in,O,O
the,O,O
clinical,O,O
outcome,O,O
of,O,O
these,O,O
cases,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Clinicians,O,O
are,O,O
exhorted,O,O
to,O,O
pay,O,O
close,O,O
attention,O,O
when,O,O
initiating,O,O
levofloxacin,B,O
therapy,O,O
in,O,O
patients,O,O
taking,O,O
medications,O,O
with,O,O
epileptogenic,O,O
properties,O,O
that,O,O
are,O,O
CYP1A2,O,B
substrates,O,O
.,O,O
Dextran,B,B
-,O,O
etodolac,B,B
conjugates,O,O
:,O,O
synthesis,O,O
",",O,O
in,O,O
vitro,O,O
and,O,O
in,O,O
vivo,O,O
evaluation,O,O
.,O,O
Etodolac,B,B
(,O,O
E,B,O
),O,O
",",O,O
is,O,O
a,O,O
non,O,O
-,O,O
narcotic,O,O
analgesic,O,O
and,O,O
antiinflammatory,O,O
drug,O,O
.,O,O
A,O,O
biodegradable,O,O
polymer,O,O
dextran,B,B
has,O,O
been,O,O
utilized,O,O
as,O,O
a,O,O
carrier,O,O
for,O,O
synthesis,O,O
of,O,O
etodolac,B,B
-,O,O
dextran,B,B
conjugates,O,O
(,O,O
ED,O,O
),O,O
to,O,O
improve,O,O
its,O,O
aqueous,O,O
solubility,O,O
and,O,O
reduce,O,O
gastrointestinal,O,O
side,O,O
effects,O,O
.,O,O
An,O,O
activated,O,O
moiety,O,O
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
N,B,B
-,I,O
acylimidazole,I,I
derivative,O,I
of,O,O
etodolac,B,B
(,O,O
EAI,B,B
),O,O
",",O,O
was,O,O
condensed,O,O
with,O,O
the,O,O
polysaccharide,O,O
polymer,O,O
dextran,B,B
of,O,O
different,O,O
molecular,O,O
weights,O,O
(,O,O
40000,O,O
",",O,O
60000,O,O
",",O,O
110000,O,O
and,O,O
200000,O,O
),O,O
.,O,O
IR,O,B
spectral,O,I
data,O,I
confirmed,O,O
formation,O,O
of,O,O
ester,O,O
bonding,O,O
in,O,O
the,O,O
conjugates,O,O
.,O,O
Etodolac,B,B
contents,O,O
were,O,O
evaluated,O,O
by,O,O
UV,O,B
-,O,O
spectrophotometric,O,I
analysis,O,I
.,O,O
The,O,O
molecular,O,O
weights,O,O
were,O,O
determined,O,O
by,O,O
measuring,O,O
viscosity,O,O
using,O,O
the,O,O
Mark,O,B
-,O,I
Howink,O,I
-,O,I
Sakurada,O,I
equation,O,O
.,O,O
In,O,O
vitro,O,O
hydrolysis,O,O
of,O,O
ED,O,B
was,O,O
done,O,O
in,O,O
aqueous,O,O
buffers,O,O
(,O,O
pH,O,O
1,O,B
.,O,I
2,O,I
",",O,O
7,O,B
.,O,I
4,O,I
",",O,O
9,O,B
),O,I
and,O,O
in,O,O
80,O,B
%,O,I
(,O,O
v,O,O
/,O,O
v,O,O
),O,O
human,O,O
plasma,O,O
(,O,O
pH,O,O
7,O,B
.,O,I
4,O,I
),O,I
.,O,O
At,O,O
pH,O,O
9,O,B
",",O,O
a,O,O
higher,O,O
rate,O,O
of,O,O
etodolac,B,B
release,O,O
from,O,O
ED,O,B
was,O,O
observed,O,O
as,O,O
compared,O,O
to,O,O
aqueous,O,O
buffer,O,O
of,O,O
pH,O,O
7,O,B
.,O,I
4,O,O
and,O,O
80,O,O
%,O,O
human,O,O
plasma,O,O
(,O,O
pH,O,O
7,O,O
.,O,O
4,O,O
),O,O
",",O,O
following,O,O
first,O,O
-,O,O
order,O,O
kinetics,O,O
.,O,O
In,O,O
vivo,O,O
investigations,O,O
were,O,O
performed,O,O
in,O,O
animals,O,O
.,O,O
Acute,O,O
analgesic,O,O
and,O,O
antiinflammatory,O,O
activities,O,O
were,O,O
ascertained,O,O
using,O,O
acetic,B,B
acid,I,I
induced,O,I
writhing,O,I
model,O,I
(,O,O
mice,O,O
),O,O
and,O,O
carrageenan,B,B
-,O,I
induced,O,I
rat,O,I
paw,O,I
edema,O,I
model,O,I
",",O,O
respectively,O,O
.,O,O
In,O,O
comparison,O,O
to,O,O
control,O,O
",",O,O
E,B,O
and,O,O
ED1,O,O
-,O,O
ED4,O,O
showed,O,O
highly,O,O
significant,O,O
analgesic,O,O
and,O,O
antiinflammatory,O,O
activities,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Biological,O,O
evaluation,O,O
suggested,O,O
that,O,O
conjugates,O,O
(,O,O
ED1,O,B
-,O,I
ED4,O,I
),O,O
retained,O,O
comparable,O,O
analgesic,O,O
and,O,O
antiinflammatory,O,O
activities,O,O
with,O,O
remarkably,O,O
reduced,O,O
ulcerogenicity,O,O
as,O,O
compared,O,O
to,O,O
their,O,O
parent,O,O
drug,O,O
-,O,O
-,O,O
etodolac,B,B
.,O,O
The,O,O
antiarrhythmic,O,O
effect,O,O
and,O,O
possible,O,O
ionic,O,O
mechanisms,O,O
of,O,O
pilocarpine,B,B
on,O,O
animal,O,O
models,O,O
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
evaluate,O,O
the,O,O
effects,O,O
of,O,O
pilocarpine,B,B
and,O,O
explore,O,O
the,O,O
underlying,O,O
ionic,O,O
mechanism,O,O
",",O,O
using,O,O
both,O,O
aconitine,B,B
-,O,I
induced,O,I
rat,O,O
and,O,O
ouabain,B,B
-,O,I
induced,O,I
guinea,O,I
pig,O,I
arrhythmia,O,I
models,O,O
.,O,O
Confocal,O,O
microscopy,O,O
was,O,O
used,O,O
to,O,O
measure,O,O
intracellular,O,O
free,O,O
-,O,O
calcium,B,B
concentrations,O,O
(,O,O
[,O,O
Ca,B,B
(,O,O
2,O,O
+,O,O
),O,O
],O,O
(,O,O
i,O,O
),O,O
in,O,O
isolated,O,O
myocytes,O,O
.,O,O
The,O,O
current,O,O
data,O,O
showed,O,O
that,O,O
pilocarpine,B,B
significantly,O,O
delayed,O,O
onset,O,O
of,O,O
arrhythmias,O,O
",",O,O
decreased,O,O
the,O,O
time,O,O
course,O,O
of,O,O
ventricular,O,O
tachycardia,O,O
and,O,O
fibrillation,O,O
",",O,O
reduced,O,O
arrhythmia,O,O
score,O,O
",",O,O
and,O,O
increased,O,O
the,O,O
survival,O,O
time,O,O
of,O,O
arrhythmic,O,O
rats,O,O
and,O,O
guinea,O,O
pigs,O,O
.,O,O
[,O,O
Ca,B,B
(,O,O
2,O,O
+,O,O
),O,O
],O,O
(,O,O
i,O,O
),O,O
overload,O,O
induced,O,O
by,O,O
aconitine,B,B
or,O,O
ouabain,B,B
was,O,O
reduced,O,O
in,O,O
isolated,O,O
myocytes,O,O
pretreated,O,O
with,O,O
pilocarpine,B,B
.,O,O
Moreover,O,O
",",O,O
M,O,B
(,O,O
3,O,O
),O,O
-,O,O
muscarinic,O,B
acetylcholine,B,I
receptor,O,I
(,O,O
mAChR,O,B
),O,O
antagonist,O,O
4,B,B
-,I,I
DAMP,I,I
(,O,O
4,B,B
-,I,I
diphenylacetoxy,I,I
-,I,I
N,I,I
-,I,I
methylpiperidine,I,I
-,I,I
methiodide,I,I
),O,O
partially,O,O
abolished,O,O
the,O,O
beneficial,O,O
effects,O,O
of,O,O
pilocarpine,B,B
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
pilocarpine,B,B
produced,O,O
antiarrhythmic,O,O
actions,O,O
on,O,O
arrhythmic,O,O
rat,O,O
and,O,O
guinea,O,O
pig,O,O
models,O,O
induced,O,O
by,O,O
aconitine,B,B
or,O,O
ouabain,B,B
via,O,O
stimulating,O,O
the,O,O
cardiac,O,O
M,O,B
(,O,O
3,O,O
),O,O
-,O,O
mAChR,O,B
.,O,O
The,O,O
mechanism,O,O
may,O,O
be,O,O
related,O,O
to,O,O
the,O,O
improvement,O,O
of,O,O
Ca,B,B
(,O,O
2,O,O
+,O,O
),O,O
handling,O,O
.,O,O
Effect,O,O
of,O,O
Hibiscus,B,B
rosa,I,I
sinensis,I,I
on,O,O
reserpine,B,B
-,O,O
induced,O,O
neurobehavioral,O,O
and,O,O
biochemical,O,O
alterations,O,O
in,O,O
rats,O,O
.,O,O
Effect,O,O
of,O,O
methanolic,O,B
extract,O,O
of,O,O
Hibiscus,B,B
rosa,I,I
sinensis,I,I
(,O,O
100,O,O
-,O,O
300,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
was,O,O
studied,O,O
on,O,O
reserpine,B,B
-,O,O
induced,O,O
orofacial,O,O
dyskinesia,O,O
and,O,O
neurochemical,O,O
alterations,O,O
.,O,O
The,O,O
rats,O,O
were,O,O
treated,O,O
with,O,O
intraperitoneal,O,O
reserpine,B,B
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
ip,O,O
),O,O
for,O,O
3,O,O
days,O,O
every,O,O
other,O,O
day,O,O
.,O,O
On,O,O
day,O,O
5,O,O
",",O,O
vacuous,O,O
chewing,O,O
movements,O,O
and,O,O
tongue,O,O
protrusions,O,O
were,O,O
counted,O,O
for,O,O
5,O,O
min,O,O
.,O,O
Reserpine,B,B
treated,O,O
rats,O,O
significantly,O,O
developed,O,O
vacuous,O,O
chewing,O,O
movements,O,O
and,O,O
tongue,O,O
protrusions,O,O
however,O,O
",",O,O
coadministration,O,O
of,O,O
Hibiscus,B,B
rosa,I,I
sinensis,I,I
roots,O,I
extract,O,I
(,O,O
100,O,O
",",O,O
200,O,O
and,O,O
300,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
per,O,O
orally,O,O
),O,O
attenuated,O,O
the,O,O
effects,O,O
.,O,O
Biochemical,O,O
analysis,O,O
of,O,O
brain,O,O
revealed,O,O
that,O,O
the,O,O
reserpine,B,B
treatment,O,O
significantly,O,O
increased,O,O
lipid,O,B
peroxidation,O,I
and,O,O
decreased,O,O
levels,O,O
of,O,O
superoxide,B,B
dismutase,O,I
(,O,O
SOD,O,B
),O,O
",",O,O
catalase,O,B
(,O,O
CAT,O,B
),O,O
and,O,O
glutathione,B,B
reductase,O,I
(,O,O
GSH,O,B
),O,O
",",O,O
an,O,O
index,O,O
of,O,O
oxidative,O,O
stress,O,O
process,O,O
.,O,O
Coadministration,O,O
of,O,O
extract,O,O
significantly,O,O
reduced,O,O
the,O,O
lipid,O,B
peroxidation,O,I
and,O,O
reversed,O,O
the,O,O
decrease,O,O
in,O,O
brain,O,O
SOD,O,B
",",O,O
CAT,O,B
and,O,O
GSH,O,B
levels,O,O
.,O,O
The,O,O
results,O,O
of,O,O
the,O,O
present,O,O
study,O,O
suggested,O,O
that,O,O
Hibiscus,B,B
rosa,I,I
sinensis,I,I
had,O,O
a,O,O
protective,O,O
role,O,O
against,O,O
reserpine,B,B
-,O,I
induced,O,I
orofacial,O,I
dyskinesia,O,I
and,O,O
oxidative,O,O
stress,O,O
.,O,O
Dynamic,O,O
response,O,O
of,O,O
blood,O,O
vessel,O,O
in,O,O
acute,O,O
renal,O,O
failure,O,O
.,O,O
In,O,O
this,O,O
study,O,O
we,O,O
postulated,O,O
that,O,O
during,O,O
acute,O,O
renal,O,O
failure,O,O
induced,O,O
by,O,O
gentamicin,B,B
the,O,O
transient,O,O
or,O,O
dynamic,O,O
response,O,O
of,O,O
blood,O,O
vessels,O,O
could,O,O
be,O,O
affected,O,O
",",O,O
and,O,O
that,O,O
antioxidants,O,O
can,O,O
prevent,O,O
the,O,O
changes,O,O
in,O,O
dynamic,O,O
responses,O,O
of,O,O
blood,O,O
vessels,O,O
.,O,O
The,O,O
new,O,O
approach,O,O
to,O,O
ex,O,O
vivo,O,O
blood,O,B
vessel,O,I
experiments,O,O
in,O,O
which,O,O
not,O,O
only,O,O
the,O,O
end,O,O
points,O,O
of,O,O
vessels,O,O
response,O,O
within,O,O
the,O,O
time,O,O
interval,O,O
is,O,O
considered,O,O
",",O,O
but,O,O
also,O,O
dynamics,O,O
of,O,O
this,O,O
response,O,O
",",O,O
was,O,O
used,O,O
in,O,O
this,O,O
paper,O,O
.,O,O
Our,O,O
results,O,O
confirm,O,O
the,O,O
alteration,O,O
in,O,O
dynamic,O,O
response,O,O
of,O,O
blood,O,B
vessels,O,I
during,O,O
the,O,O
change,O,O
of,O,O
pressure,O,O
in,O,O
gentamicin,B,B
-,O,O
treated,O,O
animals,O,O
.,O,O
The,O,O
beneficial,O,O
effects,O,O
of,O,O
vitamin,B,B
C,I,I
administration,O,O
to,O,O
gentamicin,B,B
-,O,I
treated,O,I
animals,O,O
are,O,O
also,O,O
confirmed,O,O
through,O,O
:,O,O
lower,O,O
level,O,O
of,O,O
blood,O,O
urea,B,B
and,O,O
creatinine,B,B
and,O,O
higher,O,O
level,O,O
of,O,O
potassium,B,B
.,O,O
The,O,O
pressure,O,O
dynamic,O,O
responses,O,O
of,O,O
isolated,O,O
blood,O,O
vessels,O,O
show,O,O
a,O,O
faster,O,O
pressure,O,O
change,O,O
in,O,O
gentamicin,B,B
-,O,I
treated,O,I
animals,O,O
(,O,O
8,O,O
.,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
7,O,O
s,O,O
vs,O,O
.,O,O
5,O,O
.,O,O
64,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
18,O,O
s,O,O
),O,O
.,O,O
Vitamin,B,B
C,I,I
administration,O,O
induced,O,O
slowdown,O,O
of,O,O
pressure,O,O
change,O,O
back,O,O
to,O,O
the,O,O
control,O,O
values,O,O
.,O,O
The,O,O
pressure,O,O
dynamic,O,O
properties,O,O
",",O,O
quantitatively,O,O
defined,O,O
by,O,O
comparative,O,O
pressure,O,O
dynamic,O,O
and,O,O
total,O,O
pressure,O,O
dynamic,O,O
",",O,O
confirm,O,O
the,O,O
alteration,O,O
in,O,O
dynamic,O,O
response,O,O
of,O,O
blood,O,O
vessels,O,O
during,O,O
the,O,O
change,O,O
of,O,O
pressure,O,O
in,O,O
gentamicin,B,B
-,O,I
treated,O,I
animals,O,O
and,O,O
beneficial,O,O
effects,O,O
of,O,O
vitamin,B,B
C,I,I
administration,O,O
.,O,O
Reversible,O,O
myocardial,O,B
hypertrophy,O,I
induced,O,O
by,O,O
tacrolimus,B,B
in,O,O
a,O,O
pediatric,O,O
heart,O,O
transplant,O,O
recipient,O,O
:,O,O
case,O,O
report,O,O
.,O,O
Tacrolimus,B,B
is,O,O
a,O,O
potent,O,O
immunosuppressant,O,O
that,O,O
is,O,O
frequently,O,O
used,O,O
in,O,O
organ,O,O
transplantation,O,O
.,O,O
However,O,O
",",O,O
adverse,O,O
effects,O,O
include,O,O
cardiac,O,O
toxicity,O,O
.,O,O
Herein,O,O
we,O,O
describe,O,O
transient,O,O
myocardial,O,B
hypertrophy,O,I
induced,O,O
by,O,O
tacrolimus,B,B
after,O,O
heart,O,O
transplantation,O,O
.,O,O
The,O,O
hypertrophy,O,O
caused,O,O
no,O,O
clinical,O,O
symptoms,O,O
but,O,O
was,O,O
noted,O,O
because,O,O
of,O,O
elevation,O,O
of,O,O
plasma,O,O
brain,O,B
natriuretic,O,I
peptide,O,I
concentration,O,O
and,O,O
confirmed,O,O
at,O,O
echocardiography,O,O
.,O,O
Initially,O,O
",",O,O
allograft,O,O
rejection,O,O
was,O,O
feared,O,O
;,O,O
however,O,O
",",O,O
myocardial,O,O
biopsy,O,O
samples,O,O
revealed,O,O
only,O,O
interstitial,O,O
edema,O,O
and,O,O
mild,O,O
myocardial,O,O
hypertrophy,O,O
;,O,O
neither,O,O
cellular,O,O
nor,O,O
humoral,O,O
rejection,O,O
was,O,O
detected,O,O
.,O,O
The,O,O
blood,O,O
tacrolimus,B,B
concentration,O,O
was,O,O
higher,O,O
than,O,O
usual,O,O
at,O,O
that,O,O
time,O,O
;,O,O
thus,O,O
",",O,O
tacrolimus,B,B
dosage,O,O
was,O,O
reduced,O,O
.,O,O
Myocardial,O,O
hypertrophy,O,O
completely,O,O
resolved,O,O
upon,O,O
reducing,O,O
the,O,O
target,O,O
concentration,O,O
of,O,O
tacrolimus,B,B
and,O,O
did,O,O
not,O,O
recur,O,O
",",O,O
as,O,O
confirmed,O,O
at,O,O
echocardiography,O,O
and,O,O
myocardial,O,O
biopsy,O,O
.,O,O
Thus,O,O
",",O,O
we,O,O
conclude,O,O
that,O,O
tacrolimus,B,B
induces,O,O
reversible,O,O
myocardial,O,O
hypertrophy,O,O
.,O,O
In,O,O
patients,O,O
receiving,O,O
tacrolimus,B,B
therapy,O,O
",",O,O
blood,O,O
concentration,O,O
should,O,O
be,O,O
carefully,O,O
controlled,O,O
and,O,O
extreme,O,O
attention,O,O
paid,O,O
to,O,O
cardiac,O,O
involvement,O,O
.,O,O
Nimodipine,B,B
prevents,O,O
memory,O,O
impairment,O,O
caused,O,O
by,O,O
nitroglycerin,B,B
-,O,I
induced,O,I
hypotension,O,I
in,O,O
adult,O,O
mice,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Hypotension,O,O
and,O,O
a,O,O
resultant,O,O
decrease,O,O
in,O,O
cerebral,O,O
blood,O,O
flow,O,O
have,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
development,O,O
of,O,O
cognitive,O,O
dysfunction,O,O
.,O,O
We,O,O
tested,O,O
the,O,O
hypothesis,O,O
that,O,O
nimodipine,B,B
(,O,O
NIMO,B,B
),O,O
administered,O,O
at,O,O
the,O,O
onset,O,O
of,O,O
nitroglycerin,B,B
(,O,O
NTG,B,B
),O,O
-,O,O
induced,O,O
hypotension,O,O
would,O,O
preserve,O,O
long,O,O
-,O,O
term,O,O
associative,O,O
memory,O,O
.,O,O
METHODS,O,O
:,O,O
The,O,O
passive,O,O
avoidance,O,O
(,O,O
PA,O,B
),O,O
paradigm,O,O
was,O,O
used,O,O
to,O,O
assess,O,O
memory,O,O
retention,O,O
.,O,O
For,O,O
PA,O,B
training,O,O
",",O,O
latencies,O,O
(,O,O
seconds,O,O
),O,O
were,O,O
recorded,O,O
for,O,O
entry,O,O
from,O,O
a,O,O
suspended,O,O
platform,O,O
into,O,O
a,O,O
Plexiglas,O,O
tube,O,O
where,O,O
a,O,O
shock,O,O
was,O,O
automatically,O,O
delivered,O,O
.,O,O
Latencies,O,O
were,O,O
recorded,O,O
48,O,O
h,O,O
later,O,O
for,O,O
a,O,O
testing,O,O
trial,O,O
.,O,O
Ninety,O,O
-,O,O
six,O,O
Swiss,O,O
-,O,O
Webster,O,O
mice,O,O
(,O,O
30,O,O
-,O,O
35,O,O
g,O,O
",",O,O
6,O,O
-,O,O
8,O,O
wk,O,O
),O,O
",",O,O
were,O,O
randomized,O,O
into,O,O
6,O,O
groups,O,O
1,O,O
),O,O
saline,O,B
(,O,O
control,O,O
),O,O
",",O,O
2,O,O
),O,O
NTG,B,B
immediately,O,O
after,O,O
learning,O,O
",",O,O
3,O,O
),O,O
NTG,B,B
3,O,O
h,O,O
after,O,O
learning,O,O
",",O,O
4,O,O
),O,O
NTG,B,B
and,O,O
NIMO,B,B
",",O,O
5,O,O
),O,O
vehicle,O,B
",",O,O
and,O,O
6,O,O
),O,O
NIMO,B,B
alone,O,O
.,O,O
The,O,O
extent,O,O
of,O,O
hypotension,O,B
and,O,O
changes,O,O
in,O,O
brain,O,O
tissue,O,O
oxygenation,O,O
(,O,O
PbtO,O,B
(,O,O
2,O,O
),O,O
and,O,O
in,O,O
cerebral,O,O
blood,O,O
flow,O,O
were,O,O
studied,O,O
in,O,O
a,O,O
separate,O,O
group,O,O
of,O,O
animals,O,O
.,O,O
RESULTS,O,O
:,O,O
All,O,O
groups,O,O
exhibited,O,O
similar,O,O
training,O,O
latencies,O,O
(,O,O
17,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
6,O,O
s,O,O
),O,O
.,O,O
Mice,O,O
subjected,O,O
to,O,O
hypotensive,O,O
episodes,O,O
showed,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
latency,O,O
time,O,O
(,O,O
178,O,O
+,O,O
/,O,O
-,O,O
156,O,O
s,O,O
),O,O
compared,O,O
with,O,O
those,O,O
injected,O,O
with,O,O
saline,O,B
",",O,O
NTG,B,B
+,O,O
NIMO,B,B
",",O,O
or,O,O
delayed,O,O
NTG,B,B
(,O,O
580,O,O
+,O,O
/,O,O
-,O,O
81,O,O
s,O,O
",",O,O
557,O,O
+,O,O
/,O,O
-,O,O
67,O,O
s,O,O
",",O,O
and,O,O
493,O,O
+,O,O
/,O,O
-,O,O
146,O,O
s,O,O
",",O,O
respectively,O,O
.,O,O
A,O,O
Kruskal,O,B
-,O,I
Wallis,O,I
1,O,O
-,O,O
way,O,O
analysis,O,O
of,O,O
variance,O,O
indicated,O,O
a,O,O
significant,O,O
difference,O,O
among,O,O
the,O,O
4,O,O
treatment,O,O
groups,O,O
(,O,O
H,O,B
=,O,O
15,O,O
.,O,O
34,O,O
;,O,O
P,O,B
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
a,O,O
separate,O,O
group,O,O
of,O,O
mice,O,O
not,O,O
subjected,O,O
to,O,O
behavioral,O,O
studies,O,O
",",O,O
the,O,O
same,O,O
dose,O,O
of,O,O
NTG,B,B
(,O,O
n,O,O
=,O,O
3,O,O
),O,O
and,O,O
NTG,B,B
+,O,O
NIMO,B,B
(,O,O
n,O,O
=,O,O
3,O,O
),O,O
caused,O,O
mean,O,O
arterial,O,O
blood,O,O
pressure,O,O
to,O,O
decrease,O,O
from,O,O
85,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
8,O,O
mm,O,O
Hg,O,B
sem,O,O
to,O,O
31,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
8,O,O
mm,O,O
Hg,O,B
sem,O,O
and,O,O
from,O,O
86,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
7,O,O
mm,O,O
Hg,O,B
sem,O,O
to,O,O
32,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
mm,O,O
Hg,O,B
sem,O,O
",",O,O
respectively,O,O
.,O,O
Mean,O,O
arterial,O,O
blood,O,O
pressure,O,O
in,O,O
mice,O,O
treated,O,O
with,O,O
NIMO,B,B
alone,O,O
decreased,O,O
from,O,O
88,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
8,O,O
mm,O,O
Hg,O,B
to,O,O
80,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
9,O,O
mm,O,O
Hg,O,B
.,O,O
The,O,O
intergroup,O,O
difference,O,O
was,O,O
statistically,O,O
significant,O,O
(,O,O
P,O,B
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
PbtO,O,B
(,O,O
2,O,O
),O,O
decreased,O,O
from,O,O
51,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
5,O,O
mm,O,O
Hg,O,O
sem,O,O
to,O,O
33,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
5,O,O
mm,O,O
Hg,O,O
sem,O,O
in,O,O
the,O,O
NTG,B,B
group,O,O
and,O,O
from,O,O
38,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
6,O,O
Hg,O,O
sem,O,O
to,O,O
25,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
2,O,O
mm,O,O
Hg,O,O
sem,O,O
in,O,O
the,O,O
NTG,B,B
+,O,I
NIMO,B,I
groups,O,O
",",O,O
respectively,O,O
.,O,O
There,O,O
were,O,O
no,O,O
significant,O,O
differences,O,O
among,O,O
groups,O,O
.,O,O
CONCLUSION,O,O
:,O,O
In,O,O
a,O,O
PA,O,B
retention,O,O
paradigm,O,O
",",O,O
the,O,O
injection,O,O
of,O,O
NTG,B,B
immediately,O,O
after,O,O
learning,O,O
produced,O,O
a,O,O
significant,O,O
impairment,O,O
of,O,O
long,O,O
-,O,O
term,O,O
associative,O,O
memory,O,O
in,O,O
mice,O,O
",",O,O
whereas,O,O
delayed,O,O
induced,O,O
hypotension,O,O
had,O,O
no,O,O
effect,O,O
.,O,O
NIMO,B,B
attenuated,O,O
the,O,O
disruption,O,O
in,O,O
consolidation,O,O
of,O,O
long,O,O
-,O,O
term,O,O
memory,O,O
caused,O,O
by,O,O
NTG,B,B
but,O,O
did,O,O
not,O,O
improve,O,O
latency,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
hypotension,O,O
.,O,O
The,O,O
observed,O,O
effect,O,O
of,O,O
NIMO,B,B
may,O,O
have,O,O
been,O,O
attributable,O,O
to,O,O
the,O,O
preservation,O,O
of,O,O
calcium,B,B
homeostasis,O,O
during,O,O
hypotension,O,O
",",O,O
because,O,O
there,O,O
were,O,O
no,O,O
differences,O,O
in,O,O
the,O,O
PbtO,O,B
(,O,O
2,O,O
),O,O
indices,O,O
among,O,O
groups,O,O
.,O,O
Metabotropic,O,B
glutamate,B,I
7,O,I
receptor,O,I
subtype,O,I
modulates,O,O
motor,O,O
symptoms,O,O
in,O,O
rodent,O,O
models,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
.,O,O
Metabotropic,O,B
glutamate,B,I
(,O,I
mGlu,O,I
),O,I
receptors,O,I
modulate,O,O
synaptic,O,O
transmission,O,O
in,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
and,O,O
represent,O,O
promising,O,O
therapeutic,O,O
targets,O,O
for,O,O
symptomatic,O,O
treatment,O,O
of,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
(,O,I
PD,O,I
),O,I
.,O,O
Among,O,O
the,O,O
eight,O,O
mGlu,O,B
receptor,O,O
subtypes,O,O
",",O,O
mGlu7,O,B
receptor,O,O
is,O,O
prominently,O,O
expressed,O,O
in,O,O
the,O,O
basal,O,O
ganglia,O,O
",",O,O
but,O,O
its,O,O
role,O,O
in,O,O
restoring,O,O
motor,O,O
function,O,O
in,O,O
animal,O,O
models,O,O
of,O,O
PD,O,B
is,O,O
not,O,O
known,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
N,B,B
",",I,O
N,I,B
',I,I
-,I,I
dibenzhydrylethane,I,I
-,I,I
1,I,I
",",I,I
2,I,I
-,I,I
diamine,I,I
dihydrochloride,I,I
(,O,I
AMN082,B,B
),O,I
",",O,O
the,O,O
first,O,O
selective,O,O
allosteric,O,O
activator,O,O
of,O,O
mGlu7,O,B
receptors,O,O
",",O,O
were,O,O
thus,O,O
tested,O,O
in,O,O
different,O,O
rodent,O,O
models,O,O
of,O,O
PD,O,B
.,O,O
Here,O,O
",",O,O
we,O,O
show,O,O
that,O,O
oral,O,O
(,O,O
5,O,B
mg,O,I
/,O,I
kg,O,I
),O,O
or,O,O
intrastriatal,O,O
administration,O,O
(,O,O
0,O,B
.,O,I
1,O,I
and,O,I
0,O,I
.,O,I
5,O,I
nmol,O,I
),O,O
of,O,O
AMN082,B,B
reverses,O,O
haloperidol,B,B
-,O,I
induced,O,I
catalepsy,O,I
in,O,O
rats,O,O
.,O,O
AMN082,B,B
(,O,O
2,O,B
.,O,I
5,O,I
and,O,I
5,O,I
mg,O,I
/,O,I
kg,O,I
),O,O
reduces,O,O
apomorphine,B,B
-,O,I
induced,O,I
rotations,O,I
in,O,O
unilateral,O,O
6,B,B
-,I,I
hydroxydopamine,I,I
(,O,I
6,B,I
-,I,I
OHDA,I,I
),O,I
-,O,I
lesioned,O,I
rats,O,O
.,O,O
In,O,O
a,O,O
more,O,O
complex,O,O
task,O,O
commonly,O,O
used,O,O
to,O,O
evaluate,O,O
major,O,O
akinetic,O,O
symptoms,O,O
of,O,O
PD,O,O
patients,O,O
",",O,O
5,O,B
mg,O,I
/,O,I
kg,O,I
AMN082,B,B
reverses,O,O
the,O,O
increased,O,O
reaction,O,O
time,O,O
to,O,O
respond,O,O
a,O,O
cue,O,O
of,O,O
bilateral,O,O
6,B,B
-,I,I
OHDA,I,I
-,O,I
lesioned,O,I
rats,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
AMN082,B,B
reduces,O,O
the,O,O
duration,O,O
of,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
in,O,O
a,O,O
mGlu7,O,B
receptor,O,O
-,O,O
dependent,O,O
manner,O,O
in,O,O
wild,O,O
-,O,O
type,O,O
but,O,O
not,O,O
mGlu7,O,B
receptor,O,O
knockout,O,O
mice,O,O
.,O,O
Higher,O,O
doses,O,O
of,O,O
AMN082,B,B
(,O,O
10,O,O
and,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
.,O,O
),O,O
have,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
same,O,O
models,O,O
of,O,O
PD,O,B
.,O,O
Overall,O,O
these,O,O
findings,O,O
suggest,O,O
that,O,O
mGlu7,O,B
receptor,O,O
activation,O,O
can,O,O
reverse,O,O
motor,O,O
dysfunction,O,O
associated,O,O
with,O,O
reduced,O,O
dopamine,B,B
activity,O,O
.,O,O
Selective,O,O
ligands,O,O
of,O,O
mGlu7,O,B
receptor,O,I
subtypes,O,I
may,O,O
thus,O,O
be,O,O
considered,O,O
as,O,O
promising,O,O
compounds,O,O
for,O,O
the,O,O
development,O,O
of,O,O
antiparkinsonian,O,O
therapeutic,O,O
strategies,O,O
.,O,O
Sorafenib,B,B
-,O,I
induced,O,I
acute,O,I
myocardial,O,I
infarction,O,I
due,O,O
to,O,O
coronary,O,B
artery,O,I
spasm,O,I
.,O,O
A,O,O
65,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
advanced,O,O
renal,O,B
cell,O,I
carcinoma,O,I
was,O,O
admitted,O,O
due,O,O
to,O,O
continuing,O,O
chest,O,O
pain,O,O
at,O,O
rest,O,O
.,O,O
Two,O,O
weeks,O,O
before,O,O
his,O,O
admission,O,O
",",O,O
sorafenib,B,B
had,O,O
been,O,O
started,O,O
.,O,O
He,O,O
was,O,O
diagnosed,O,O
with,O,O
non,O,B
-,O,I
ST,O,I
-,O,I
elevation,O,I
myocardial,O,I
infarction,O,I
by,O,O
laboratory,O,O
data,O,O
and,O,O
electrocardiogram,O,O
.,O,O
Enhanced,O,O
heart,O,O
magnetic,O,O
resonance,O,O
imaging,O,O
also,O,O
showed,O,O
subendocardial,O,O
infarction,O,O
.,O,O
However,O,O
",",O,O
there,O,O
was,O,O
no,O,O
stenosis,O,O
in,O,O
coronary,O,O
arteries,O,O
on,O,O
angiography,O,O
.,O,O
Coronary,O,B
artery,O,I
spasm,O,I
was,O,O
induced,O,O
by,O,O
a,O,O
provocative,O,O
test,O,O
.,O,O
Cessation,O,O
of,O,O
sorafenib,B,B
and,O,O
administration,O,O
of,O,O
Ca,B,B
-,O,I
channel,O,I
blocker,O,I
and,O,O
nitrates,B,B
ameliorated,O,O
his,O,O
symptoms,O,O
",",O,O
but,O,O
relapse,O,O
occurred,O,O
after,O,O
resumption,O,O
of,O,O
sorafenib,B,B
.,O,O
Addition,O,O
of,O,O
oral,O,O
nicorandil,B,B
reduced,O,O
his,O,O
symptoms,O,O
and,O,O
maintained,O,O
stable,O,O
angina,O,O
status,O,O
.,O,O
We,O,O
report,O,O
the,O,O
first,O,O
case,O,O
of,O,O
sorafenib,B,B
-,O,I
induced,O,O
coronary,O,B
artery,O,I
spasm,O,I
.,O,O
Sorafenib,B,B
is,O,O
a,O,O
multikinase,O,O
inhibitor,O,O
that,O,O
targets,O,O
signaling,O,O
pathways,O,O
necessary,O,O
for,O,O
cellular,O,O
proliferation,O,O
and,O,O
survival,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
the,O,O
Rho,O,O
/,O,O
ROCK,O,O
pathway,O,O
has,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
coronary,O,B
artery,O,I
spasm,O,I
.,O,O
Our,O,O
report,O,O
may,O,O
show,O,O
an,O,O
adverse,O,O
effect,O,O
on,O,O
the,O,O
Rho,O,B
/,O,I
ROCK,O,I
pathway,O,O
by,O,O
sorafenib,B,B
use,O,O
.,O,O
A,O,O
novel,O,O
animal,O,O
model,O,O
to,O,O
evaluate,O,O
the,O,O
ability,O,O
of,O,O
a,O,O
drug,O,O
delivery,O,O
system,O,O
to,O,O
promote,O,O
the,O,O
passage,O,O
through,O,O
the,O,O
BBB,O,B
.,O,O
The,O,O
purpose,O,O
of,O,O
this,O,O
investigation,O,O
was,O,O
to,O,O
explore,O,O
the,O,O
potentiality,O,O
of,O,O
a,O,O
novel,O,O
animal,O,O
model,O,O
to,O,O
be,O,O
used,O,O
for,O,O
the,O,O
in,O,O
vivo,O,O
evaluation,O,O
of,O,O
the,O,O
ability,O,O
of,O,O
a,O,O
drug,O,O
delivery,O,O
system,O,O
to,O,O
promote,O,O
the,O,O
passage,O,O
through,O,O
the,O,O
blood,O,O
-,O,O
brain,O,O
barrier,O,O
(,O,O
BBB,O,I
),O,O
and,O,O
/,O,O
or,O,O
to,O,O
improve,O,O
the,O,O
brain,O,O
localization,O,O
of,O,O
a,O,O
bioactive,O,O
compound,O,O
.,O,O
A,O,O
Tween,O,B
80,O,I
-,O,I
coated,O,O
poly,B,B
-,I,I
L,I,I
-,I,I
lactid,I,I
acid,I,I
nanoparticles,O,O
was,O,O
used,O,O
as,O,O
a,O,O
model,O,O
of,O,O
colloidal,O,O
drug,O,O
delivery,O,O
system,O,O
",",O,O
able,O,O
to,O,O
trespass,O,O
the,O,O
BBB,O,B
.,O,O
Tacrine,B,B
",",O,O
administered,O,O
in,O,O
LiCl,B,B
pre,O,O
-,O,O
treated,O,O
rats,O,O
",",O,O
induces,O,O
electrocorticographic,O,O
seizures,O,O
and,O,O
delayed,O,O
hippocampal,O,O
damage,O,O
.,O,O
The,O,O
toxic,O,O
effects,O,O
of,O,O
tacrine,B,B
-,O,O
loaded,O,O
poly,B,B
-,I,I
L,I,I
-,I,I
lactid,I,I
acid,I,I
nanoparticles,O,O
(,O,O
5mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
a,O,O
saline,O,O
solution,O,O
of,O,O
tacrine,B,B
(,O,O
5mg,O,O
/,O,O
kg,O,O
),O,O
and,O,O
an,O,O
empty,O,O
colloidal,O,O
nanoparticle,O,O
suspension,O,O
were,O,O
compared,O,O
following,O,O
i,O,O
.,O,O
p,O,O
.,O,O
administration,O,O
in,O,O
LiCl,B,B
-,O,O
pre,O,O
-,O,O
treated,O,O
Wistar,O,O
rats,O,O
.,O,O
All,O,O
the,O,O
animals,O,O
treated,O,O
with,O,O
tacrine,B,B
-,O,O
loaded,O,O
nanoparticles,O,O
showed,O,O
an,O,O
earlier,O,O
outcome,O,O
of,O,O
CNS,O,O
adverse,O,O
symptoms,O,O
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
epileptic,O,O
onset,O,O
",",O,O
with,O,O
respect,O,O
to,O,O
those,O,O
animals,O,O
treated,O,O
with,O,O
the,O,O
free,O,O
compound,O,O
(,O,O
10,O,O
min,O,O
vs,O,O
.,O,O
22,O,O
min,O,O
respectively,O,O
),O,O
.,O,O
In,O,O
addition,O,O
",",O,O
tacrine,B,B
-,O,O
loaded,O,O
nanoparticles,O,O
administration,O,O
induced,O,O
damage,O,O
of,O,O
neuronal,O,O
cells,O,O
in,O,O
CA1,O,B
field,O,O
of,O,O
the,O,O
hippocampus,O,O
in,O,O
all,O,O
treated,O,O
animals,O,O
",",O,O
while,O,O
the,O,O
saline,O,B
solution,O,O
of,O,O
tacrine,B,B
only,O,O
in,O,O
60,O,O
%,O,O
of,O,O
animals,O,O
.,O,O
Empty,O,O
nanoparticles,O,B
provided,O,O
similar,O,O
results,O,O
to,O,O
control,O,O
(,O,O
saline,O,B
-,O,I
treated,O,I
),O,O
group,O,O
of,O,O
animals,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
the,O,O
evaluation,O,O
of,O,O
time,O,O
-,O,O
to,O,O
-,O,O
onset,O,O
of,O,O
symptoms,O,O
and,O,O
the,O,O
severity,O,O
of,O,O
neurodegenerative,O,O
processes,O,O
induced,O,O
by,O,O
the,O,O
tacrine,B,B
-,O,I
lithium,B,I
model,O,O
of,O,O
epilepsy,O,O
in,O,O
the,O,O
rat,O,O
",",O,O
could,O,O
be,O,O
used,O,O
to,O,O
evaluate,O,O
preliminarily,O,O
the,O,O
capability,O,O
of,O,O
a,O,O
drug,O,O
delivery,O,O
system,O,O
to,O,O
trespass,O,O
(,O,O
or,O,O
not,O,O
),O,O
the,O,O
BBB,O,B
in,O,O
vivo,O,O
.,O,O
High,O,O
-,O,O
dose,O,O
tranexamic,B,B
Acid,I,I
is,O,O
associated,O,O
with,O,O
nonischemic,O,O
clinical,O,O
seizures,O,O
in,O,O
cardiac,O,O
surgical,O,O
patients,O,O
.,O,O
BACKGROUND,O,O
:,O,O
In,O,O
2,O,O
separate,O,O
centers,O,O
",",O,O
we,O,O
observed,O,O
a,O,O
notable,O,O
increase,O,O
in,O,O
the,O,O
incidence,O,O
of,O,O
postoperative,O,O
convulsive,O,O
seizures,O,O
from,O,O
1,O,O
.,O,O
3,O,O
%,O,O
to,O,O
3,O,O
.,O,O
8,O,O
%,O,O
in,O,O
patients,O,O
having,O,O
undergone,O,O
major,O,O
cardiac,O,O
surgical,O,O
procedures,O,O
.,O,O
These,O,O
events,O,O
were,O,O
temporally,O,O
coincident,O,O
with,O,O
the,O,O
initial,O,O
use,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
tranexamic,B,B
acid,I,I
(,O,O
TXA,B,B
),O,O
therapy,O,O
after,O,O
withdrawal,O,O
of,O,O
aprotinin,O,O
from,O,O
general,O,O
clinical,O,O
usage,O,O
.,O,O
The,O,O
purpose,O,O
of,O,O
this,O,O
review,O,O
was,O,O
to,O,O
perform,O,O
a,O,O
retrospective,O,O
analysis,O,O
to,O,O
examine,O,O
whether,O,O
there,O,O
was,O,O
a,O,O
relation,O,O
between,O,O
TXA,B,B
usage,O,O
and,O,O
seizures,O,O
after,O,O
cardiac,O,O
surgery,O,O
.,O,O
METHODS,O,O
:,O,O
An,O,O
in,O,O
-,O,O
depth,O,O
chart,O,O
review,O,O
was,O,O
undertaken,O,O
in,O,O
all,O,O
24,O,O
patients,O,O
who,O,O
developed,O,O
perioperative,O,O
seizures,O,O
.,O,O
Electroencephalographic,O,O
activity,O,O
was,O,O
recorded,O,O
in,O,O
11,O,O
of,O,O
these,O,O
patients,O,O
",",O,O
and,O,O
all,O,O
patients,O,O
had,O,O
a,O,O
formal,O,O
neurological,O,O
evaluation,O,O
and,O,O
brain,O,O
imaging,O,O
studies,O,O
.,O,O
RESULTS,O,O
:,O,O
Twenty,O,O
-,O,O
one,O,O
of,O,O
the,O,O
24,O,O
patients,O,O
did,O,O
not,O,O
have,O,O
evidence,O,O
of,O,O
new,O,O
cerebral,O,O
ischemic,O,O
injury,O,O
",",O,O
but,O,O
seizures,O,O
were,O,O
likely,O,O
due,O,O
to,O,O
ischemic,O,O
brain,O,O
injury,O,O
in,O,O
3,O,O
patients,O,O
.,O,O
All,O,O
patients,O,O
with,O,O
seizures,O,O
did,O,O
not,O,O
have,O,O
permanent,O,O
neurological,O,O
abnormalities,O,O
.,O,O
All,O,O
24,O,O
patients,O,O
with,O,O
seizures,O,O
received,O,O
high,O,O
doses,O,O
of,O,O
TXA,B,B
intraoperatively,O,O
ranging,O,O
from,O,O
61,O,O
to,O,O
259,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
had,O,O
a,O,O
mean,O,O
age,O,O
of,O,O
69,O,O
.,O,O
9,O,O
years,O,O
",",O,O
and,O,O
21,O,O
of,O,O
24,O,O
had,O,O
undergone,O,O
open,O,O
chamber,O,O
rather,O,O
than,O,O
coronary,O,O
bypass,O,O
procedures,O,O
.,O,O
All,O,O
but,O,O
one,O,O
patient,O,O
were,O,O
managed,O,O
using,O,O
cardiopulmonary,O,O
bypass,O,O
.,O,O
No,O,O
evidence,O,O
of,O,O
brain,O,B
ischemic,O,I
",",O,O
metabolic,O,B
",",O,O
or,O,O
hyperthermia,O,B
-,O,I
induced,O,I
causes,O,O
for,O,O
their,O,O
seizures,O,O
was,O,O
apparent,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
use,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
TXA,B,B
in,O,O
older,O,O
patients,O,O
in,O,O
conjunction,O,O
with,O,O
cardiopulmonary,O,O
bypass,O,O
and,O,O
open,O,O
-,O,O
chamber,O,O
cardiac,O,O
surgery,O,O
is,O,O
associated,O,O
with,O,O
clinical,O,O
seizures,O,O
in,O,O
susceptible,O,O
patients,O,O
.,O,O
Electrocardiographic,O,O
changes,O,O
and,O,O
cardiac,O,O
arrhythmias,O,O
in,O,O
patients,O,O
receiving,O,O
psychotropic,O,O
drugs,O,O
.,O,O
Eight,O,O
patients,O,O
had,O,O
cardiac,O,O
manifestations,O,O
that,O,O
were,O,O
life,O,O
-,O,O
threatening,O,O
in,O,O
five,O,O
while,O,O
taking,O,O
psychotropic,O,O
drugs,O,O
",",O,O
either,O,O
phenothiazines,B,B
or,O,O
tricyclic,O,B
antidepressants,O,I
.,O,O
Although,O,O
most,O,O
patients,O,O
were,O,O
receiving,O,O
several,O,O
drugs,O,O
",",O,O
Mellaril,B,B
(,O,O
thioridazine,B,I
),O,O
appeared,O,O
to,O,O
be,O,O
responsible,O,O
for,O,O
five,O,O
cases,O,O
of,O,O
ventricular,O,O
tachycardia,O,O
",",O,O
one,O,O
of,O,O
which,O,O
was,O,O
fatal,O,O
in,O,O
a,O,O
35,O,O
year,O,O
old,O,O
woman,O,O
.,O,O
Supraventricular,O,O
tachycardia,O,O
developed,O,O
in,O,O
one,O,O
patient,O,O
receiving,O,O
Thorazine,B,B
(,O,O
chlorpromazine,B,B
),O,O
.,O,O
Aventyl,B,B
(,O,O
nortriptyline,B,B
),O,O
and,O,O
Elavil,B,B
(,O,O
amitriptyline,B,B
),O,O
each,O,O
produced,O,O
left,O,O
bundle,O,O
branch,O,O
block,O,O
in,O,O
a,O,O
73,O,O
year,O,O
old,O,O
woman,O,O
.,O,O
Electrocardiographic,O,O
T,O,B
and,O,O
U,O,B
wave,O,I
abnormalities,O,O
were,O,O
present,O,O
in,O,O
most,O,O
patients,O,O
.,O,O
The,O,O
ventricular,O,B
arrhythmias,O,I
responded,O,O
to,O,O
intravenous,O,O
administration,O,O
of,O,O
lidocaine,B,B
and,O,O
to,O,O
direct,O,O
current,O,O
electric,O,O
shock,O,O
;,O,O
ventricular,O,B
pacing,O,I
was,O,O
required,O,O
in,O,O
some,O,O
instances,O,O
and,O,O
intravenous,O,O
administration,O,O
of,O,O
propranolol,B,B
combined,O,O
with,O,O
ventricular,O,B
pacing,O,I
in,O,O
one,O,O
.,O,O
The,O,O
tachyarrhythmias,O,O
generally,O,O
subsided,O,O
within,O,O
48,O,O
hours,O,O
after,O,O
administration,O,O
of,O,O
the,O,O
drugs,O,O
was,O,O
stopped,O,O
.,O,O
Five,O,O
of,O,O
the,O,O
eight,O,O
patients,O,O
were,O,O
50,O,O
years,O,O
of,O,O
age,O,O
or,O,O
younger,O,O
;,O,O
only,O,O
one,O,O
clearly,O,O
had,O,O
antecedent,O,O
heart,O,O
disease,O,O
.,O,O
Major,O,O
cardiac,O,O
arrhythmias,O,O
are,O,O
a,O,O
potential,O,O
hazard,O,O
in,O,O
patients,O,O
without,O,O
heart,O,O
disease,O,O
who,O,O
are,O,O
receiving,O,O
customary,O,O
therapeutic,O,O
doses,O,O
of,O,O
psychotropic,O,O
drugs,O,O
.,O,O
A,O,O
prospective,O,O
clinical,O,O
trial,O,O
is,O,O
suggested,O,O
to,O,O
quantify,O,O
the,O,O
risk,O,O
of,O,O
cardiac,O,O
complications,O,O
to,O,O
patients,O,O
receiving,O,O
phenothiazines,B,B
or,O,O
tricyclic,O,B
antidepressant,O,I
drugs,O,O
.,O,O
Sensitivity,O,O
of,O,O
erythroid,O,O
progenitor,O,O
colonies,O,O
to,O,O
erythropoietin,O,B
in,O,O
azidothymidine,B,B
treated,O,O
immunodeficient,O,O
mice,O,O
.,O,O
The,O,O
anaemia,O,O
induced,O,O
by,O,O
3,B,B
',I,I
-,I,I
azido,I,I
-,I,I
3,I,I
',I,I
dideoxythymidine,I,I
(,O,I
AZT,B,I
),O,I
is,O,O
poorly,O,O
understood,O,O
.,O,O
We,O,O
have,O,O
used,O,O
a,O,O
murine,O,O
model,O,O
of,O,O
AIDS,O,O
",",O,O
infection,O,O
of,O,O
female,O,O
C57BL,O,O
/,O,O
6,O,O
mice,O,O
with,O,O
LP,O,B
-,O,I
BM5,O,I
murine,O,I
leukaemia,O,I
(,O,O
MuLV,O,B
),O,O
virus,O,O
",",O,O
to,O,O
determine,O,O
if,O,O
AZT,B,B
-,O,O
induced,O,O
anaemia,O,O
is,O,O
due,O,O
",",O,O
in,O,O
part,O,O
",",O,O
to,O,O
decreased,O,O
responsiveness,O,O
of,O,O
erythropoietic,O,O
precursors,O,O
(,O,O
BFU,O,B
-,O,I
e,O,I
),O,O
to,O,O
erythropoietin,O,B
(,O,O
EPO,O,B
),O,O
.,O,O
Mice,O,O
in,O,O
the,O,O
early,O,O
stage,O,O
of,O,O
LP,O,B
-,O,I
BM5,O,I
MuLV,O,I
disease,O,I
were,O,O
given,O,O
AZT,B,B
in,O,O
their,O,O
drinking,O,O
water,O,O
at,O,O
1,O,O
.,O,O
0,O,O
and,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
ml,O,O
.,O,O
AZT,B,B
produced,O,O
anaemia,O,O
in,O,O
both,O,O
groups,O,O
",",O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
fashion,O,O
.,O,O
Despite,O,O
the,O,O
anaemia,O,O
",",O,O
the,O,O
number,O,O
of,O,O
splenic,O,O
and,O,O
bone,O,O
marrow,O,O
BFU,O,O
-,O,O
e,O,O
in,O,O
AZT,B,B
treated,O,O
mice,O,O
increased,O,O
up,O,O
to,O,O
five,O,O
-,O,O
fold,O,O
over,O,O
levels,O,O
observed,O,O
in,O,O
infected,O,O
untreated,O,O
animals,O,O
after,O,O
15,O,O
d,O,O
of,O,O
treatment,O,O
.,O,O
Colony,O,O
formation,O,O
by,O,O
splenic,O,O
and,O,O
bone,O,O
marrow,O,O
BFUe,O,O
was,O,O
stimulated,O,O
at,O,O
lower,O,O
concentrations,O,O
of,O,O
EPO,O,B
in,O,O
mice,O,O
receiving,O,O
AZT,B,B
for,O,O
15,O,O
d,O,O
than,O,O
for,O,O
infected,O,O
",",O,O
untreated,O,O
mice,O,O
.,O,O
By,O,O
day,O,O
30,O,O
",",O,O
sensitivity,O,O
of,O,O
both,O,O
splenic,O,B
and,O,O
bone,O,B
marrow,O,I
BFU,O,I
-,O,I
e,O,I
of,O,O
treated,O,O
animals,O,O
returned,O,O
to,O,O
that,O,O
observed,O,O
from,O,O
cells,O,O
of,O,O
infected,O,O
untreated,O,O
animals,O,O
.,O,O
The,O,O
mean,O,O
plasma,O,O
levels,O,O
of,O,O
EPO,O,B
observed,O,O
in,O,O
AZT,B,B
treated,O,O
mice,O,O
were,O,O
appropriate,O,O
for,O,O
the,O,O
degree,O,O
of,O,O
anaemia,O,O
observed,O,O
when,O,O
compared,O,O
with,O,O
phenylhydrazine,B,B
(,O,I
PHZ,B,I
),O,I
treated,O,O
mice,O,O
.,O,O
The,O,O
numbers,O,O
of,O,O
BFU,O,B
-,O,I
e,O,I
and,O,O
the,O,O
percentage,O,O
of,O,O
bone,O,O
marrow,O,O
erythroblasts,O,B
observed,O,O
were,O,O
comparable,O,O
in,O,O
AZT,B,B
and,O,O
PHZ,B,B
treated,O,O
mice,O,O
with,O,O
similar,O,O
degrees,O,O
of,O,O
anaemia,O,O
.,O,O
However,O,O
",",O,O
reticulocytosis,O,O
was,O,O
inappropriate,O,O
for,O,O
the,O,O
degree,O,O
of,O,O
anaemia,O,O
observed,O,O
in,O,O
AZT,B,B
treated,O,O
infected,O,O
mice,O,O
.,O,O
AZT,B,B
-,O,O
induced,O,O
peripheral,O,O
anaemia,O,O
in,O,O
the,O,O
face,O,O
of,O,O
increased,O,O
numbers,O,O
of,O,O
BFU,O,B
-,O,I
e,O,I
and,O,O
increased,O,O
levels,O,O
of,O,O
plasma,O,O
EPO,O,B
suggest,O,O
a,O,O
lesion,O,O
in,O,O
terminal,O,O
differentiation,O,O
.,O,O
Sedation,O,O
depth,O,O
during,O,O
spinal,O,O
anesthesia,O,O
and,O,O
the,O,O
development,O,O
of,O,O
postoperative,O,O
delirium,O,O
in,O,O
elderly,O,O
patients,O,O
undergoing,O,O
hip,O,O
fracture,O,O
repair,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
determine,O,O
whether,O,O
limiting,O,O
intraoperative,O,O
sedation,O,O
depth,O,O
during,O,O
spinal,O,O
anesthesia,O,O
for,O,O
hip,O,O
fracture,O,O
repair,O,O
in,O,O
elderly,O,O
patients,O,O
can,O,O
decrease,O,O
the,O,O
prevalence,O,O
of,O,O
postoperative,O,O
delirium,O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
We,O,O
performed,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
",",O,O
randomized,O,O
controlled,O,O
trial,O,O
at,O,O
an,O,O
academic,O,O
medical,O,O
center,O,O
of,O,O
elderly,O,O
patients,O,O
(,O,O
>,O,O
or,O,O
=,O,O
65,O,O
years,O,O
),O,O
without,O,O
preoperative,O,O
delirium,O,O
or,O,O
severe,O,O
dementia,O,O
who,O,O
underwent,O,O
hip,O,O
fracture,O,O
repair,O,O
under,O,O
spinal,O,O
anesthesia,O,O
with,O,O
propofol,B,B
sedation,O,O
.,O,O
Sedation,O,O
depth,O,O
was,O,O
titrated,O,O
using,O,O
processed,O,O
electroencephalography,O,O
with,O,O
the,O,O
bispectral,O,O
index,O,O
(,O,O
BIS,O,B
),O,O
",",O,O
and,O,O
patients,O,O
were,O,O
randomized,O,O
to,O,O
receive,O,O
either,O,O
deep,O,O
(,O,O
BIS,O,B
",",O,O
approximately,O,O
50,O,O
),O,O
or,O,O
light,O,O
(,O,O
BIS,O,B
",",O,O
>,O,O
or,O,O
=,O,O
80,O,O
),O,O
sedation,O,O
.,O,O
Postoperative,O,O
delirium,O,O
was,O,O
assessed,O,O
as,O,O
defined,O,O
by,O,O
Diagnostic,O,B
and,O,I
Statistical,O,I
Manual,O,I
of,O,I
Mental,O,I
Disorders,O,I
(,O,I
Third,O,I
Edition,O,I
Revised,O,I
),O,I
criteria,O,O
using,O,O
the,O,O
Confusion,O,B
Assessment,O,I
Method,O,I
beginning,O,O
at,O,O
any,O,O
time,O,O
from,O,O
the,O,O
second,O,O
day,O,O
after,O,O
surgery,O,O
.,O,O
RESULTS,O,O
:,O,O
From,O,O
April,O,O
2,O,O
",",O,O
2005,O,O
",",O,O
through,O,O
October,O,O
30,O,O
",",O,O
2008,O,O
",",O,O
a,O,O
total,O,O
of,O,O
114,O,O
patients,O,O
were,O,O
randomized,O,O
.,O,O
The,O,O
prevalence,O,O
of,O,O
postoperative,O,O
delirium,O,O
was,O,O
significantly,O,O
lower,O,O
in,O,O
the,O,O
light,O,O
sedation,O,O
group,O,O
(,O,O
11,O,O
/,O,O
57,O,O
[,O,O
19,O,O
%,O,O
],O,O
vs,O,O
23,O,O
/,O,O
57,O,O
[,O,O
40,O,O
%,O,O
],O,O
in,O,O
the,O,O
deep,O,O
sedation,O,O
group,O,O
;,O,O
P,O,O
=,O,O
.,O,O
),O,O
",",O,O
indicating,O,O
that,O,O
1,O,O
incident,O,O
of,O,O
delirium,O,O
will,O,O
be,O,O
prevented,O,O
for,O,O
every,O,O
4,O,O
.,O,O
7,O,O
patients,O,O
treated,O,O
with,O,O
light,O,O
sedation,O,O
.,O,O
The,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SD,O,O
number,O,O
of,O,O
days,O,O
of,O,O
delirium,O,O
during,O,O
hospitalization,O,O
was,O,O
lower,O,O
in,O,O
the,O,O
light,O,O
sedation,O,O
group,O,O
than,O,O
in,O,O
the,O,O
deep,O,O
sedation,O,O
group,O,O
(,O,O
0,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
5,O,O
days,O,O
vs,O,O
1,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
4,O,O
.,O,O
0,O,O
days,O,O
;,O,O
P,O,O
=,O,O
.,O,O
),O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
use,O,O
of,O,O
light,O,O
propofol,B,B
sedation,O,O
decreased,O,O
the,O,O
prevalence,O,O
of,O,O
postoperative,O,O
delirium,O,O
by,O,O
50,O,O
%,O,O
compared,O,O
with,O,O
deep,O,O
sedation,O,O
.,O,O
Limiting,O,O
depth,O,O
of,O,O
sedation,O,O
during,O,O
spinal,O,O
anesthesia,O,O
is,O,O
a,O,O
simple,O,O
",",O,O
safe,O,O
",",O,O
and,O,O
cost,O,O
-,O,O
effective,O,O
intervention,O,O
for,O,O
preventing,O,O
postoperative,O,O
delirium,O,O
in,O,O
elderly,O,O
patients,O,O
that,O,O
could,O,O
be,O,O
widely,O,O
and,O,O
readily,O,O
adopted,O,O
.,O,O
The,O,O
protective,O,O
role,O,O
of,O,O
Nrf2,O,B
in,O,O
streptozotocin,B,B
-,O,I
induced,O,I
diabetic,O,I
nephropathy,O,I
.,O,O
OBJECTIVE,O,O
:,O,O
Diabetic,O,O
nephropathy,O,O
is,O,O
one,O,O
of,O,O
the,O,O
major,O,O
causes,O,O
of,O,O
renal,O,O
failure,O,O
",",O,O
which,O,O
is,O,O
accompanied,O,O
by,O,O
the,O,O
production,O,O
of,O,O
reactive,O,O
oxygen,B,O
species,O,O
(,O,O
ROS,O,B
),O,O
.,O,O
Nrf2,O,B
is,O,O
the,O,O
primary,O,O
transcription,O,O
factor,O,O
that,O,O
controls,O,O
the,O,O
antioxidant,O,O
response,O,O
essential,O,O
for,O,O
maintaining,O,O
cellular,O,O
redox,O,O
homeostasis,O,O
.,O,O
Here,O,O
",",O,O
we,O,O
report,O,O
our,O,O
findings,O,O
demonstrating,O,O
a,O,O
protective,O,O
role,O,O
of,O,O
Nrf2,O,B
against,O,O
diabetic,O,O
nephropathy,O,O
.,O,O
RESEARCH,O,O
DESIGN,O,O
AND,O,O
METHODS,O,O
:,O,O
We,O,O
explore,O,O
the,O,O
protective,O,O
role,O,O
of,O,O
Nrf2,O,B
against,O,O
diabetic,O,O
nephropathy,O,O
using,O,O
human,O,O
kidney,O,O
biopsy,O,O
tissues,O,O
from,O,O
diabetic,O,O
nephropathy,O,O
patients,O,O
",",O,O
a,O,O
streptozotocin,B,B
-,O,I
induced,O,O
diabetic,O,O
nephropathy,O,O
model,O,O
in,O,O
Nrf2,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
",",O,O
and,O,O
cultured,O,O
human,O,O
mesangial,O,O
cells,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
glomeruli,O,O
of,O,O
human,O,O
diabetic,O,B
nephropathy,O,I
patients,O,O
were,O,O
under,O,O
oxidative,O,O
stress,O,O
and,O,O
had,O,O
elevated,O,O
Nrf2,O,B
levels,O,O
.,O,O
In,O,O
the,O,O
animal,O,O
study,O,O
",",O,O
Nrf2,O,B
was,O,O
demonstrated,O,O
to,O,O
be,O,O
crucial,O,O
in,O,O
ameliorating,O,O
streptozotocin,B,B
-,O,I
induced,O,I
renal,O,I
damage,O,O
.,O,O
This,O,O
is,O,O
evident,O,O
by,O,O
Nrf2,O,B
(,O,O
-,O,O
/,O,O
-,O,O
),O,O
mice,O,O
having,O,O
higher,O,O
ROS,O,B
production,O,O
and,O,O
suffering,O,O
from,O,O
greater,O,O
oxidative,O,O
DNA,O,B
damage,O,O
and,O,O
renal,O,I
injury,O,O
compared,O,O
with,O,O
Nrf2,O,B
(,O,O
+,O,O
/,O,O
+,O,O
),O,O
mice,O,O
.,O,O
Mechanistic,O,O
studies,O,O
in,O,O
both,O,O
in,O,O
vivo,O,O
and,O,O
in,O,O
vitro,O,O
systems,O,O
showed,O,O
that,O,O
the,O,O
Nrf2,O,B
-,O,O
mediated,O,O
protection,O,O
against,O,O
diabetic,O,O
nephropathy,O,O
is,O,O
",",O,O
at,O,O
least,O,O
",",O,O
partially,O,O
through,O,O
inhibition,O,O
of,O,O
transforming,O,B
growth,O,I
factor,O,I
-,O,I
beta1,O,I
(,O,O
TGF,O,B
-,O,I
beta1,O,I
),O,O
and,O,O
reduction,O,O
of,O,O
extracellular,O,O
matrix,O,O
production,O,O
.,O,O
In,O,O
human,O,O
renal,O,O
mesangial,O,O
cells,O,O
",",O,O
high,O,O
glucose,B,B
induced,O,O
ROS,O,B
production,O,O
and,O,O
activated,O,O
expression,O,O
of,O,O
Nrf2,O,B
and,O,O
its,O,O
downstream,O,O
genes,O,O
.,O,O
Furthermore,O,O
",",O,O
activation,O,O
or,O,O
overexpression,O,O
of,O,O
Nrf2,O,B
inhibited,O,O
the,O,O
promoter,O,O
activity,O,O
of,O,O
TGF,O,B
-,O,O
beta1,O,I
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
whereas,O,O
knockdown,O,O
of,O,O
Nrf2,O,B
by,O,O
siRNA,O,B
enhanced,O,O
TGF,O,B
-,O,O
beta1,O,I
transcription,O,O
and,O,O
fibronectin,O,B
production,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
This,O,O
work,O,O
clearly,O,O
indicates,O,O
a,O,O
protective,O,O
role,O,O
of,O,O
Nrf2,O,B
in,O,O
diabetic,O,O
nephropathy,O,O
",",O,O
suggesting,O,O
that,O,O
dietary,O,O
or,O,O
therapeutic,O,O
activation,O,O
of,O,O
Nrf2,O,B
could,O,O
be,O,O
used,O,O
as,O,O
a,O,O
strategy,O,O
to,O,O
prevent,O,O
or,O,O
slow,O,O
down,O,O
the,O,O
progression,O,O
of,O,O
diabetic,O,O
nephropathy,O,O
.,O,O
Metformin,B,B
prevents,O,O
experimental,O,O
gentamicin,B,B
-,O,O
induced,O,O
nephropathy,O,O
by,O,O
a,O,O
mitochondria,O,B
-,O,O
dependent,O,O
pathway,O,O
.,O,O
The,O,O
antidiabetic,O,O
drug,O,O
metformin,B,B
can,O,O
diminish,O,O
apoptosis,O,O
induced,O,O
by,O,O
oxidative,O,O
stress,O,O
in,O,O
endothelial,O,O
cells,O,O
and,O,O
prevent,O,O
vascular,O,O
dysfunction,O,O
even,O,O
in,O,O
nondiabetic,O,O
patients,O,O
.,O,O
Here,O,O
we,O,O
tested,O,O
whether,O,O
it,O,O
has,O,O
a,O,O
beneficial,O,O
effect,O,O
in,O,O
a,O,O
rat,O,O
model,O,O
of,O,O
gentamicin,B,B
toxicity,O,O
.,O,O
Mitochondrial,O,B
analysis,O,O
",",O,O
respiration,O,O
intensity,O,O
",",O,O
levels,O,O
of,O,O
reactive,O,B
oxygen,B,I
species,O,I
",",O,O
permeability,O,O
transition,O,O
",",O,O
and,O,O
cytochrome,O,B
c,O,I
release,O,O
were,O,O
assessed,O,O
3,O,O
and,O,O
6,O,O
days,O,O
after,O,O
gentamicin,B,B
administration,O,O
.,O,O
Metformin,B,B
treatment,O,O
fully,O,O
blocked,O,O
gentamicin,B,B
-,O,O
mediated,O,O
acute,O,O
renal,O,O
failure,O,O
.,O,O
This,O,O
was,O,O
accompanied,O,O
by,O,O
a,O,O
lower,O,O
activity,O,O
of,O,O
N,O,B
-,O,O
acetyl,O,I
-,O,I
beta,O,I
-,O,I
D,O,I
-,O,I
glucosaminidase,O,I
",",O,O
together,O,O
with,O,O
a,O,O
decrease,O,O
of,O,O
lipid,O,B
peroxidation,O,I
and,O,O
increase,O,O
of,O,O
antioxidant,O,B
systems,O,I
.,O,O
Metformin,B,B
also,O,O
protected,O,O
the,O,O
kidney,O,O
from,O,O
histological,O,O
damage,O,O
6,O,O
days,O,O
after,O,O
gentamicin,B,O
administration,O,O
.,O,O
These,O,O
in,O,O
vivo,O,O
markers,O,O
of,O,O
kidney,O,O
dysfunction,O,O
and,O,O
their,O,O
correction,O,O
by,O,O
metformin,B,B
were,O,O
complemented,O,O
by,O,O
in,O,O
vitro,O,O
studies,O,O
of,O,O
mitochondrial,O,O
function,O,O
.,O,O
We,O,O
found,O,O
that,O,O
gentamicin,B,O
treatment,O,O
depleted,O,O
respiratory,O,O
components,O,O
(,O,O
cytochrome,O,B
c,O,I
",",O,O
NADH,O,B
),O,O
",",O,O
probably,O,O
due,O,O
to,O,O
the,O,O
opening,O,O
of,O,O
mitochondrial,O,O
transition,O,O
pores,O,O
.,O,O
These,O,O
injuries,O,O
",",O,O
partly,O,O
mediated,O,O
by,O,O
a,O,O
rise,O,O
in,O,O
reactive,O,B
oxygen,B,I
species,O,I
from,O,O
the,O,O
electron,O,O
transfer,O,O
chain,O,O
",",O,O
were,O,O
significantly,O,O
decreased,O,O
by,O,O
metformin,B,B
.,O,O
Thus,O,O
",",O,O
our,O,O
study,O,O
suggests,O,O
that,O,O
pleiotropic,O,O
effects,O,O
of,O,O
metformin,B,B
can,O,O
lessen,O,O
gentamicin,B,O
nephrotoxicity,O,O
and,O,O
improve,O,O
mitochondrial,O,O
homeostasis,O,O
.,O,O
Risk,O,O
of,O,O
nephropathy,O,O
after,O,O
consumption,O,O
of,O,O
nonionic,O,B
contrast,B,I
media,I,I
by,O,O
children,O,O
undergoing,O,O
cardiac,O,O
angiography,O,O
:,O,O
a,O,O
prospective,O,O
study,O,O
.,O,O
Despite,O,O
increasing,O,O
reports,O,O
on,O,O
nonionic,O,B
contrast,B,I
media,I,I
-,O,I
induced,O,O
nephropathy,O,O
(,O,O
CIN,O,B
),O,O
in,O,O
hospitalized,O,O
adult,O,O
patients,O,O
during,O,O
cardiac,O,O
procedures,O,O
",",O,O
the,O,O
studies,O,O
in,O,O
pediatrics,O,O
are,O,O
limited,O,O
",",O,O
with,O,O
even,O,O
less,O,O
focus,O,O
on,O,O
possible,O,O
predisposing,O,O
factors,O,O
and,O,O
preventive,O,O
measures,O,O
for,O,O
patients,O,O
undergoing,O,O
cardiac,O,O
angiography,O,O
.,O,O
This,O,O
prospective,O,O
study,O,O
determined,O,O
the,O,O
incidence,O,O
of,O,O
CIN,O,B
for,O,O
two,O,O
nonionic,O,O
contrast,B,O
media,I,O
(,O,O
CM,B,B
),O,O
",",O,O
iopromide,B,B
and,O,O
iohexol,B,B
",",O,O
among,O,O
80,O,O
patients,O,O
younger,O,O
than,O,O
18,O,O
years,O,O
and,O,O
compared,O,O
the,O,O
rates,O,O
for,O,O
this,O,O
complication,O,O
in,O,O
relation,O,O
to,O,O
the,O,O
type,O,O
and,O,O
dosage,O,O
of,O,O
CM,B,B
and,O,O
the,O,O
presence,O,O
of,O,O
cyanosis,O,O
.,O,O
The,O,O
80,O,O
patients,O,O
in,O,O
the,O,O
study,O,O
consecutively,O,O
received,O,O
either,O,O
iopromide,B,B
(,O,O
group,O,O
A,O,O
",",O,O
n,O,O
=,O,O
40,O,O
),O,O
or,O,O
iohexol,B,B
(,O,O
group,O,O
B,O,O
",",O,O
n,O,O
=,O,O
40,O,O
),O,O
.,O,O
Serum,O,O
sodium,B,B
(,O,O
Na,B,B
),O,O
",",O,O
potassium,B,B
(,O,O
K,B,B
),O,O
",",O,O
and,O,O
creatinine,B,B
(,O,O
Cr,B,B
),O,O
were,O,O
measured,O,O
24,O,O
h,O,O
before,O,O
angiography,O,O
as,O,O
baseline,O,O
values,O,O
",",O,O
then,O,O
measured,O,O
again,O,O
at,O,O
12,O,O
-,O,O
",",O,O
24,O,O
-,O,O
",",O,O
and,O,O
48,O,O
-,O,O
h,O,O
intervals,O,O
after,O,O
CM,B,O
use,O,O
.,O,O
Urine,O,O
samples,O,O
for,O,O
Na,B,B
and,O,O
Cr,B,B
also,O,O
were,O,O
checked,O,O
at,O,O
the,O,O
same,O,O
intervals,O,O
.,O,O
Risk,O,O
of,O,O
renal,O,O
failure,O,O
",",O,O
Injury,O,O
to,O,O
the,O,O
kidney,O,O
",",O,O
Failure,O,O
of,O,O
kidney,O,O
function,O,O
",",O,O
Loss,O,O
of,O,O
kidney,O,O
function,O,O
",",O,O
and,O,O
End,O,O
-,O,O
stage,O,O
renal,O,O
damage,O,O
(,O,O
RIFLE,O,O
criteria,O,O
),O,O
were,O,O
used,O,O
to,O,O
define,O,O
CIN,O,O
and,O,O
its,O,O
incidence,O,O
in,O,O
the,O,O
study,O,O
population,O,O
.,O,O
Accordingly,O,O
",",O,O
among,O,O
the,O,O
15,O,O
CIN,O,B
patients,O,O
(,O,O
18,O,O
.,O,O
75,O,O
%,O,O
),O,O
",",O,O
7,O,O
.,O,O
5,O,O
%,O,O
of,O,O
the,O,O
patients,O,O
in,O,O
group,O,O
A,O,O
had,O,O
increased,O,O
risk,O,O
and,O,O
3,O,O
.,O,O
75,O,O
%,O,O
had,O,O
renal,O,O
injury,O,O
",",O,O
whereas,O,O
5,O,O
%,O,O
of,O,O
group,O,O
B,O,O
had,O,O
increased,O,O
risk,O,O
and,O,O
2,O,O
.,O,O
5,O,O
%,O,O
had,O,O
renal,O,O
injury,O,O
.,O,O
Whereas,O,O
33,O,O
.,O,O
3,O,O
%,O,O
of,O,O
the,O,O
patients,O,O
with,O,O
CIN,O,B
were,O,O
among,O,O
those,O,O
who,O,O
received,O,O
the,O,O
proper,O,O
dosage,O,O
of,O,O
CM,B,B
",",O,O
the,O,O
percentage,O,O
increased,O,O
to,O,O
66,O,O
.,O,O
6,O,O
%,O,O
among,O,O
those,O,O
who,O,O
received,O,O
larger,O,O
doses,O,O
",",O,O
with,O,O
a,O,O
significant,O,O
difference,O,O
in,O,O
the,O,O
incidence,O,O
of,O,O
CIN,O,B
related,O,O
to,O,O
the,O,O
different,O,O
dosages,O,O
of,O,O
CM,B,B
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
Among,O,O
the,O,O
15,O,O
patients,O,O
with,O,O
CIN,O,B
",",O,O
6,O,O
had,O,O
cyanotic,O,O
congenital,O,O
heart,O,O
diseases,O,O
",",O,O
but,O,O
the,O,O
incidence,O,O
did,O,O
not,O,O
differ,O,O
significantly,O,O
from,O,O
that,O,O
for,O,O
the,O,O
noncyanotic,O,O
patients,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
243,O,O
),O,O
.,O,O
Although,O,O
clinically,O,O
silent,O,O
",",O,O
CIN,O,B
is,O,O
not,O,O
rare,O,O
in,O,O
pediatrics,O,O
.,O,O
The,O,O
incidence,O,O
depends,O,O
on,O,O
dosage,O,O
but,O,O
not,O,O
on,O,O
the,O,O
type,O,O
of,O,O
consumed,O,O
nonionic,O,B
CM,B,I
",",O,O
nor,O,O
on,O,O
the,O,O
presence,O,O
of,O,O
cyanosis,O,O
",",O,O
and,O,O
although,O,O
CIN,O,B
usually,O,O
is,O,O
reversible,O,O
",",O,O
more,O,O
concern,O,O
is,O,O
needed,O,O
for,O,O
the,O,O
prevention,O,O
of,O,O
such,O,O
a,O,O
complication,O,O
in,O,O
children,O,O
.,O,O
Renal,O,B
function,O,O
and,O,O
hemodynamics,O,O
during,O,O
prolonged,O,O
isoflurane,B,B
-,O,O
induced,O,O
hypotension,O,O
in,O,O
humans,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
isoflurane,B,B
-,O,O
induced,O,O
hypotension,O,O
on,O,O
glomerular,O,O
function,O,O
and,O,O
renal,O,O
blood,O,O
flow,O,O
was,O,O
investigated,O,O
in,O,O
20,O,O
human,O,O
subjects,O,O
.,O,O
Glomerular,O,O
filtration,O,O
rate,O,O
(,O,O
GFR,O,B
),O,O
and,O,O
effective,O,O
renal,O,O
plasma,O,O
flow,O,O
(,O,O
ERPF,O,B
),O,O
were,O,O
measured,O,O
by,O,O
inulin,O,B
and,O,O
para,B,B
-,I,I
aminohippurate,I,I
(,O,O
PAH,B,B
),O,O
clearance,O,O
",",O,O
respectively,O,O
.,O,O
Anesthesia,O,O
was,O,O
maintained,O,O
with,O,O
fentanyl,B,B
",",O,O
nitrous,B,B
oxide,I,I
",",O,O
oxygen,B,B
",",O,O
and,O,O
isoflurane,B,B
.,O,O
Hypotension,O,O
was,O,O
induced,O,O
for,O,O
236,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
15,O,O
.,O,O
1,O,O
min,O,O
by,O,O
increasing,O,O
the,O,O
isoflurane,B,B
inspired,O,I
concentration,O,I
to,O,O
maintain,O,O
a,O,O
mean,O,O
arterial,O,O
pressure,O,O
of,O,O
59,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
4,O,O
mmHg,O,O
.,O,O
GFR,O,B
and,O,O
ERPF,O,B
decreased,O,O
with,O,O
the,O,O
induction,O,O
of,O,O
anesthesia,O,O
but,O,O
not,O,O
significantly,O,O
more,O,O
during,O,O
hypotension,O,O
.,O,O
Postoperatively,O,O
",",O,O
ERPF,O,B
returned,O,O
to,O,O
preoperative,O,O
values,O,O
",",O,O
whereas,O,O
GFR,O,B
was,O,O
higher,O,O
than,O,O
preoperative,O,O
values,O,O
.,O,O
Renal,O,B
vascular,O,I
resistance,O,I
increased,O,O
during,O,O
anesthesia,O,O
but,O,O
decreased,O,O
when,O,O
hypotension,O,B
was,O,O
induced,O,O
",",O,O
allowing,O,O
the,O,O
maintenance,O,O
of,O,O
renal,O,B
blood,O,I
flow,O,I
.,O,O
We,O,O
conclude,O,O
that,O,O
renal,O,B
compensatory,O,I
mechanisms,O,I
are,O,O
preserved,O,O
during,O,O
isoflurane,B,B
-,O,I
induced,O,I
hypotension,O,I
and,O,O
that,O,O
renal,O,B
function,O,I
and,O,I
hemodynamics,O,I
quickly,O,O
return,O,O
to,O,O
normal,O,O
when,O,O
normotension,O,B
is,O,O
resumed,O,O
.,O,O
Brainstem,O,B
dysgenesis,O,O
in,O,O
an,O,O
infant,O,O
prenatally,O,O
exposed,O,O
to,O,O
cocaine,B,B
.,O,O
Many,O,O
authors,O,O
described,O,O
the,O,O
effects,O,O
on,O,O
the,O,O
fetus,O,O
of,O,O
maternal,O,O
cocaine,O,B
abuse,O,O
during,O,O
pregnancy,O,O
.,O,O
Vasoconstriction,O,O
appears,O,O
to,O,O
be,O,O
the,O,O
common,O,O
mechanism,O,O
of,O,O
action,O,O
leading,O,O
to,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
fetal,O,O
anomalies,O,O
.,O,O
We,O,O
report,O,O
on,O,O
an,O,O
infant,O,O
with,O,O
multiple,O,O
cranial,O,O
-,O,O
nerve,O,O
involvement,O,O
attributable,O,O
to,O,O
brainstem,O,B
dysgenesis,O,O
",",O,O
born,O,O
to,O,O
a,O,O
cocaine,O,B
-,O,O
addicted,O,O
mother,O,O
.,O,O
A,O,O
cross,O,O
-,O,O
sectional,O,O
evaluation,O,O
of,O,O
the,O,O
effect,O,O
of,O,O
risperidone,B,B
and,O,O
selective,O,O
serotonin,B,B
reuptake,O,I
inhibitors,O,I
on,O,O
bone,O,B
mineral,O,I
density,O,I
in,O,O
boys,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
investigate,O,O
the,O,O
effect,O,O
of,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,O
on,O,O
trabecular,O,O
bone,O,B
mineral,O,I
density,O,I
(,O,O
BMD,O,O
),O,O
in,O,O
children,O,O
and,O,O
adolescents,O,O
.,O,O
METHOD,O,O
:,O,O
Medically,O,O
healthy,O,O
7,O,O
-,O,O
to,O,O
17,O,O
-,O,O
year,O,O
-,O,O
old,O,O
males,O,O
chronically,O,O
treated,O,O
",",O,O
in,O,O
a,O,O
naturalistic,O,O
setting,O,O
",",O,O
with,O,O
risperidone,B,B
were,O,O
recruited,O,O
for,O,O
this,O,O
cross,O,O
-,O,O
sectional,O,O
study,O,O
through,O,O
child,O,O
psychiatry,O,O
outpatient,O,O
clinics,O,O
between,O,O
November,O,O
2005,O,O
and,O,O
June,O,O
2007,O,O
.,O,O
Anthropometric,O,O
measurements,O,O
and,O,O
laboratory,O,O
testing,O,O
were,O,O
conducted,O,O
.,O,O
The,O,O
clinical,O,O
diagnoses,O,O
were,O,O
based,O,O
on,O,O
chart,O,O
review,O,O
",",O,O
and,O,O
developmental,O,O
and,O,O
treatment,O,O
history,O,O
was,O,O
obtained,O,O
from,O,O
the,O,O
medical,O,O
record,O,O
.,O,O
Volumetric,O,O
BMD,O,B
of,O,O
the,O,O
ultradistal,O,O
radius,O,O
was,O,O
measured,O,O
using,O,O
peripheral,O,O
quantitative,O,O
computed,O,O
tomography,O,O
",",O,O
and,O,O
areal,O,O
BMD,O,B
of,O,O
the,O,O
lumbar,O,O
spine,O,O
was,O,O
estimated,O,O
using,O,O
dual,O,O
-,O,O
energy,O,O
x,O,O
-,O,O
ray,O,O
absorptiometry,O,O
.,O,O
RESULTS,O,O
:,O,O
Hyperprolactinemia,O,B
was,O,O
present,O,O
in,O,O
49,O,O
%,O,O
of,O,O
83,O,O
boys,O,O
(,O,O
n,O,O
=,O,O
41,O,O
),O,O
treated,O,O
with,O,O
risperidone,B,B
for,O,O
a,O,O
mean,O,O
of,O,O
2,O,O
.,O,O
9,O,O
years,O,O
.,O,O
Serum,O,O
testosterone,B,B
concentration,O,O
increased,O,O
with,O,O
pubertal,O,O
status,O,O
but,O,O
was,O,O
not,O,O
affected,O,O
by,O,O
hyperprolactinemia,O,B
.,O,O
As,O,O
expected,O,O
",",O,O
bone,O,O
mineral,O,O
content,O,O
and,O,O
BMD,O,B
increased,O,O
with,O,O
sexual,O,O
maturity,O,O
.,O,O
After,O,O
adjusting,O,O
for,O,O
the,O,O
stage,O,O
of,O,O
sexual,O,O
development,O,O
and,O,O
height,O,O
and,O,O
BMI,O,O
z,O,O
scores,O,O
",",O,O
serum,O,O
prolactin,O,B
was,O,O
negatively,O,O
associated,O,O
with,O,O
trabecular,O,O
volumetric,O,O
BMD,O,B
at,O,O
the,O,O
ultradistal,O,O
radius,O,O
(,O,O
P,O,O
<,O,O
.,O,O
),O,O
.,O,O
Controlling,O,O
for,O,O
relevant,O,O
covariates,O,O
",",O,O
we,O,O
also,O,O
found,O,O
treatment,O,O
with,O,O
selective,O,O
serotonin,B,B
reuptake,O,I
inhibitors,O,I
(,O,O
SSRIs,O,B
),O,O
to,O,O
be,O,O
associated,O,O
with,O,O
lower,O,O
trabecular,O,O
BMD,O,B
at,O,O
the,O,O
radius,O,O
(,O,O
P,O,O
=,O,O
.,O,O
),O,O
and,O,O
BMD,O,B
z,O,I
score,O,I
at,O,O
the,O,O
lumbar,O,O
spine,O,O
(,O,O
P,O,O
<,O,O
.,O,O
),O,O
.,O,O
These,O,O
findings,O,O
became,O,O
more,O,O
marked,O,O
when,O,O
the,O,O
analysis,O,O
was,O,O
restricted,O,O
to,O,O
non,O,O
-,O,O
Hispanic,O,O
white,O,O
patients,O,O
.,O,O
Of,O,O
13,O,O
documented,O,O
fractures,O,O
",",O,O
3,O,O
occurred,O,O
after,O,O
risperidone,B,B
and,O,O
SSRIs,O,B
were,O,O
started,O,O
",",O,O
and,O,O
none,O,O
occurred,O,O
in,O,O
patients,O,O
with,O,O
hyperprolactinemia,O,B
.,O,O
CONCLUSIONS,O,O
:,O,O
This,O,O
is,O,O
the,O,O
first,O,O
study,O,O
to,O,O
link,O,O
risperidone,B,B
-,O,O
induced,O,O
hyperprolactinemia,O,I
and,O,O
SSRI,O,B
treatment,O,O
to,O,O
lower,O,O
BMD,O,B
in,O,O
children,O,O
and,O,O
adolescents,O,O
.,O,O
Future,O,O
research,O,O
should,O,O
evaluate,O,O
the,O,O
longitudinal,O,O
course,O,O
of,O,O
this,O,O
adverse,O,O
event,O,O
to,O,O
determine,O,O
its,O,O
temporal,O,O
stability,O,O
and,O,O
whether,O,O
a,O,O
higher,O,O
fracture,O,O
rate,O,O
ensues,O,O
.,O,O
Fear,O,O
-,O,O
potentiated,O,O
startle,O,O
",",O,O
but,O,O
not,O,O
light,O,O
-,O,O
enhanced,O,O
startle,O,O
",",O,O
is,O,O
enhanced,O,O
by,O,O
anxiogenic,O,O
drugs,O,O
.,O,O
RATIONALE,O,O
AND,O,O
OBJECTIVES,O,O
:,O,O
The,O,O
light,O,O
-,O,O
enhanced,O,O
startle,O,O
paradigm,O,O
(,O,O
LES,O,B
),O,O
is,O,O
suggested,O,O
to,O,O
model,O,O
anxiety,O,O
",",O,O
because,O,O
of,O,O
the,O,O
non,O,O
-,O,O
specific,O,O
cue,O,O
and,O,O
the,O,O
long,O,O
-,O,O
term,O,O
effect,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
fear,O,B
-,O,I
potentiated,O,I
startle,O,I
(,O,O
FPS,O,B
),O,O
is,O,O
suggested,O,O
to,O,O
model,O,O
conditioned,O,O
fear,O,O
.,O,O
However,O,O
",",O,O
the,O,O
pharmacological,O,O
profiles,O,O
of,O,O
these,O,O
two,O,O
paradigms,O,O
are,O,O
very,O,O
similar,O,O
.,O,O
The,O,O
present,O,O
study,O,O
investigated,O,O
the,O,O
effects,O,O
of,O,O
putative,O,O
anxiogenic,O,O
drugs,O,O
on,O,O
LES,O,B
and,O,O
FPS,O,B
and,O,O
aimed,O,O
at,O,O
determining,O,O
the,O,O
sensitivity,O,O
of,O,O
LES,O,B
for,O,O
anxiogenic,O,O
drugs,O,O
and,O,O
to,O,O
potentially,O,O
showing,O,O
a,O,O
pharmacological,O,O
differentiation,O,O
between,O,O
these,O,O
two,O,O
paradigms,O,O
.,O,O
METHODS,O,O
:,O,O
Male,O,O
Wistar,O,O
rats,O,O
received,O,O
each,O,O
dose,O,O
of,O,O
the,O,O
alpha,O,B
(,O,O
2,O,O
),O,O
antagonist,O,O
yohimbine,B,B
(,O,O
0,O,O
.,O,O
25,O,O
-,O,O
1,O,O
.,O,O
0mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
the,O,O
5,B,B
-,I,I
HT,I,I
(,O,O
2C,O,O
),O,O
receptor,O,O
agonist,O,O
m,B,B
-,I,I
chlorophenylpiperazine,I,I
(,O,O
mCPP,B,B
",",O,O
0,O,O
.,O,O
5,O,O
-,O,O
2,O,O
.,O,O
0mg,O,O
/,O,O
kg,O,O
),O,O
or,O,O
the,O,O
GABA,B,B
(,O,O
A,O,O
),O,O
inverse,O,O
receptor,O,O
agonist,O,O
pentylenetetrazole,B,B
(,O,O
PTZ,B,B
",",O,O
3,O,O
-,O,O
30mg,O,O
/,O,O
kg,O,O
),O,O
and,O,O
were,O,O
subsequently,O,O
tested,O,O
in,O,O
either,O,O
LES,O,O
or,O,O
FPS,O,O
.,O,O
RESULTS,O,O
:,O,O
None,O,O
of,O,O
the,O,O
drugs,O,O
enhanced,O,O
LES,O,O
",",O,O
whereas,O,O
mCPP,B,O
increased,O,O
percentage,O,O
FPS,O,O
and,O,O
yohimbine,B,O
increased,O,O
absolute,O,O
FPS,O,O
values,O,O
.,O,O
Furthermore,O,O
",",O,O
yohimbine,B,O
increased,O,O
baseline,O,O
startle,O,O
amplitude,O,O
in,O,O
the,O,O
LES,O,O
",",O,O
while,O,O
mCPP,B,O
suppressed,O,O
baseline,O,O
startle,O,O
in,O,O
both,O,O
the,O,O
LES,O,O
and,O,O
FPS,O,O
and,O,O
PTZ,B,O
suppressed,O,O
baseline,O,O
startle,O,O
in,O,O
the,O,O
FPS,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
contrast,O,O
to,O,O
findings,O,O
in,O,O
the,O,O
FPS,O,O
paradigm,O,O
",",O,O
none,O,O
of,O,O
the,O,O
drugs,O,O
were,O,O
able,O,O
to,O,O
exacerbate,O,O
the,O,O
LES,O,O
response,O,O
.,O,O
Thus,O,O
",",O,O
a,O,O
clear,O,O
pharmacological,O,O
differentiation,O,O
was,O,O
found,O,O
between,O,O
LES,O,O
and,O,O
FPS,O,O
.,O,O
Rosaceiform,O,O
dermatitis,O,O
associated,O,O
with,O,O
topical,O,O
tacrolimus,B,B
treatment,O,O
.,O,O
We,O,O
describe,O,O
herein,O,O
3,O,O
patients,O,O
who,O,O
developed,O,O
rosacea,O,B
-,O,I
like,O,I
dermatitis,O,I
eruptions,O,O
while,O,O
using,O,O
0,O,O
.,O,O
%,O,O
or,O,O
0,O,O
.,O,O
1,O,O
%,O,O
tacrolimus,B,B
ointment,O,O
for,O,O
facial,O,O
dermatitis,O,O
.,O,O
Skin,O,O
biopsy,O,O
specimens,O,O
showed,O,O
telangiectasia,O,O
and,O,O
noncaseating,O,O
epithelioid,O,O
granulomatous,O,O
tissue,O,O
formation,O,O
in,O,O
the,O,O
papillary,O,O
to,O,O
mid,O,O
dermis,O,O
.,O,O
Continuous,O,O
topical,O,O
use,O,O
of,O,O
immunomodulators,O,O
such,O,O
as,O,O
tacrolimus,B,B
or,O,O
pimecrolimus,B,B
should,O,O
be,O,O
regarded,O,O
as,O,O
a,O,O
potential,O,O
cause,O,O
of,O,O
rosaceiform,O,O
dermatitis,O,O
",",O,O
although,O,O
many,O,O
cases,O,O
have,O,O
not,O,O
been,O,O
reported,O,O
.,O,O
Coenzyme,B,B
Q10,I,I
treatment,O,O
ameliorates,O,O
acute,O,O
cisplatin,B,B
nephrotoxicity,O,O
in,O,O
mice,O,O
.,O,O
The,O,O
nephroprotective,O,O
effect,O,O
of,O,O
coenzyme,B,B
Q10,I,I
was,O,O
investigated,O,O
in,O,O
mice,O,O
with,O,O
acute,O,O
renal,O,O
injury,O,O
induced,O,O
by,O,O
a,O,O
single,O,O
i,O,O
.,O,O
p,O,O
of,O,O
cisplatin,B,B
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
.,O,O
Coenzyme,B,B
Q10,I,I
treatment,O,O
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
was,O,O
applied,O,O
for,O,O
6,O,O
consecutive,O,O
days,O,O
",",O,O
starting,O,O
1,O,O
day,O,O
before,O,O
cisplatin,B,O
administration,O,O
.,O,O
Coenzyme,B,B
Q10,I,I
significantly,O,O
reduced,O,O
blood,B,O
urea,I,B
nitrogen,I,I
and,O,O
serum,O,O
creatinine,B,B
levels,O,O
which,O,O
were,O,O
increased,O,O
by,O,O
cisplatin,B,B
.,O,O
Coenzyme,B,B
Q10,I,I
significantly,O,O
compensated,O,O
deficits,O,O
in,O,O
the,O,O
antioxidant,O,O
defense,O,O
mechanisms,O,O
(,O,O
reduced,B,O
glutathione,I,B
level,O,O
and,O,O
superoxide,B,B
dismutase,O,I
activity,O,O
),O,O
",",O,O
suppressed,O,O
lipid,O,O
peroxidation,O,O
",",O,O
decreased,O,O
the,O,O
elevations,O,O
of,O,O
tumor,O,O
necrosis,O,O
factor,O,O
-,O,O
alpha,O,O
",",O,O
nitric,B,B
oxide,I,I
and,O,O
platinum,B,B
ion,O,I
concentration,O,O
",",O,O
and,O,O
attenuated,O,O
the,O,O
reductions,O,O
of,O,O
selenium,B,B
and,O,O
zinc,B,B
ions,O,I
in,O,O
renal,O,O
tissue,O,O
resulted,O,O
from,O,O
cisplatin,B,B
administration,O,O
.,O,O
Also,O,O
",",O,O
histopathological,O,O
renal,O,B
tissue,O,I
damage,O,O
mediated,O,O
by,O,O
cisplatin,B,B
was,O,O
ameliorated,O,O
by,O,O
coenzyme,B,B
Q10,I,I
treatment,O,O
.,O,O
Immunohistochemical,O,O
analysis,O,O
revealed,O,O
that,O,O
coenzyme,B,B
Q10,I,I
significantly,O,O
decreased,O,O
the,O,O
cisplatin,B,B
-,O,O
induced,O,O
overexpression,O,O
of,O,O
inducible,O,B
nitric,B,I
oxide,I,I
synthase,O,I
",",O,O
nuclear,O,B
factor,O,I
-,O,I
kappaB,O,I
",",O,O
caspase,O,B
-,O,I
3,O,I
and,O,O
p53,O,B
in,O,O
renal,O,B
tissue,O,I
.,O,O
It,O,O
was,O,O
concluded,O,O
that,O,O
coenzyme,B,B
Q10,I,I
represents,O,O
a,O,O
potential,O,O
therapeutic,O,O
option,O,O
to,O,O
protect,O,O
against,O,O
acute,O,O
cisplatin,B,B
nephrotoxicity,O,O
commonly,O,O
encountered,O,O
in,O,O
clinical,O,O
practice,O,O
.,O,O
Reversible,O,O
cholestasis,O,O
with,O,O
bile,O,O
duct,O,O
injury,O,O
following,O,O
azathioprine,B,B
therapy,O,O
.,O,O
A,O,O
case,O,O
report,O,O
.,O,O
A,O,O
67,O,O
-,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
",",O,O
with,O,O
primary,O,O
polymyositis,O,O
and,O,O
without,O,O
previous,O,O
evidence,O,O
of,O,O
liver,O,O
disease,O,O
",",O,O
developed,O,O
clinical,O,O
and,O,O
biochemical,O,O
features,O,O
of,O,O
severe,O,O
cholestasis,O,O
3,O,O
months,O,O
after,O,O
initiation,O,O
of,O,O
azathioprine,B,B
therapy,O,O
.,O,O
Liver,O,B
biopsy,O,O
showed,O,O
cholestasis,O,B
with,O,O
both,O,O
cytological,O,O
and,O,O
architectural,O,O
alterations,O,O
of,O,O
interlobular,O,O
bile,O,B
ducts,O,O
.,O,O
Azathioprine,B,B
withdrawal,O,O
resulted,O,O
after,O,O
7,O,O
weeks,O,O
in,O,O
the,O,O
resolution,O,O
of,O,O
clinical,O,O
and,O,O
biochemical,O,O
abnormalities,O,O
.,O,O
It,O,O
is,O,O
believed,O,O
that,O,O
this,O,O
is,O,O
the,O,O
first,O,O
reported,O,O
case,O,O
of,O,O
reversible,O,O
azathioprine,B,B
-,O,I
induced,O,O
cholestasis,O,B
associated,O,O
with,O,O
histological,O,O
evidence,O,O
of,O,O
bile,O,B
duct,O,I
injury,O,O
.,O,O
Dopamine,B,B
is,O,O
not,O,O
essential,O,O
for,O,O
the,O,O
development,O,O
of,O,O
methamphetamine,B,B
-,O,O
induced,O,O
neurotoxicity,O,O
.,O,O
It,O,O
is,O,O
widely,O,O
believed,O,O
that,O,O
dopamine,B,B
(,O,O
DA,B,B
),O,O
mediates,O,O
methamphetamine,B,B
(,O,O
METH,B,B
),O,O
-,O,O
induced,O,O
toxicity,O,O
to,O,O
brain,O,O
dopaminergic,O,O
neurons,O,O
",",O,O
because,O,O
drugs,O,O
that,O,O
interfere,O,O
with,O,O
DA,B,B
neurotransmission,O,O
decrease,O,O
toxicity,O,O
",",O,O
whereas,O,O
drugs,O,O
that,O,O
increase,O,O
DA,B,B
neurotransmission,O,O
enhance,O,O
toxicity,O,O
.,O,O
However,O,O
",",O,O
temperature,O,O
effects,O,O
of,O,O
drugs,O,O
that,O,O
have,O,O
been,O,O
used,O,O
to,O,O
manipulate,O,O
brain,O,O
DA,B,B
neurotransmission,O,O
confound,O,O
interpretation,O,O
of,O,O
the,O,O
data,O,O
.,O,O
Here,O,O
we,O,O
show,O,O
that,O,O
the,O,O
recently,O,O
reported,O,O
ability,O,O
of,O,O
L,B,B
-,I,I
dihydroxyphenylalanine,I,I
to,O,O
reverse,O,O
the,O,O
protective,O,O
effect,O,O
of,O,O
alpha,B,B
-,I,I
methyl,I,I
-,I,I
para,I,I
-,I,I
tyrosine,I,I
on,O,O
METH,B,B
-,O,I
induced,O,I
DA,B,I
neurotoxicity,O,O
is,O,O
also,O,O
confounded,O,O
by,O,O
drug,O,O
effects,O,O
on,O,O
body,O,O
temperature,O,O
.,O,O
Further,O,O
",",O,O
we,O,O
show,O,O
that,O,O
mice,O,O
genetically,O,O
engineered,O,O
to,O,O
be,O,O
deficient,O,O
in,O,O
brain,O,O
DA,B,B
develop,O,O
METH,B,B
neurotoxicity,O,O
",",O,O
as,O,O
long,O,O
as,O,O
the,O,O
thermic,O,O
effects,O,O
of,O,O
METH,B,B
are,O,O
preserved,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
we,O,O
demonstrate,O,O
that,O,O
mice,O,O
genetically,O,O
engineered,O,O
to,O,O
have,O,O
unilateral,O,O
brain,O,O
DA,B,B
deficits,O,O
develop,O,O
METH,B,B
-,O,O
induced,O,O
dopaminergic,O,O
deficits,O,O
that,O,O
are,O,O
of,O,O
comparable,O,O
magnitude,O,O
on,O,O
both,O,O
sides,O,O
of,O,O
the,O,O
brain,O,O
.,O,O
Taken,O,O
together,O,O
",",O,O
these,O,O
findings,O,O
demonstrate,O,O
that,O,O
DA,B,B
is,O,O
not,O,O
essential,O,O
for,O,O
the,O,O
development,O,O
of,O,O
METH,B,B
-,O,I
induced,O,I
dopaminergic,O,I
neurotoxicity,O,I
and,O,O
suggest,O,O
that,O,O
mechanisms,O,O
independent,O,O
of,O,O
DA,B,B
warrant,O,O
more,O,O
intense,O,O
investigation,O,O
.,O,O
Swallowing,O,O
-,O,O
induced,O,O
atrial,O,O
tachyarrhythmia,O,O
triggered,O,O
by,O,O
salbutamol,B,B
:,O,O
case,O,O
report,O,O
and,O,O
review,O,O
of,O,O
the,O,O
literature,O,O
.,O,O
CASE,O,O
:,O,O
A,O,O
49,O,O
-,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
experienced,O,O
chest,O,O
discomfort,O,O
while,O,O
swallowing,O,O
.,O,O
On,O,O
electrocardiogram,O,O
",",O,O
episodes,O,O
of,O,O
atrial,O,O
tachyarrhythmia,O,O
were,O,O
recorded,O,O
immediately,O,O
after,O,O
swallowing,O,O
;,O,O
24,O,O
-,O,O
hour,O,O
Holter,O,O
monitoring,O,O
recorded,O,O
several,O,O
events,O,O
.,O,O
The,O,O
arrhythmia,O,O
resolved,O,O
after,O,O
therapy,O,O
with,O,O
atenolol,B,B
",",O,O
but,O,O
recurred,O,O
a,O,O
year,O,O
later,O,O
.,O,O
The,O,O
patient,O,O
noticed,O,O
that,O,O
before,O,O
these,O,O
episodes,O,O
he,O,O
had,O,O
been,O,O
using,O,O
an,O,O
inhalator,O,O
of,O,O
salbutamol,B,B
.,O,O
After,O,O
stopping,O,O
the,O,O
beta,O,B
-,O,I
agonist,O,I
",",O,O
and,O,O
after,O,O
a,O,O
week,O,O
with,O,O
the,O,O
atenolol,B,B
",",O,O
the,O,O
arrhythmia,O,O
disappeared,O,O
.,O,O
DISCUSSION,O,O
:,O,O
Swallowing,O,O
-,O,O
induced,O,O
atrial,O,O
tachyarrhythmia,O,O
(,O,O
SIAT,O,B
),O,O
is,O,O
a,O,O
rare,O,O
phenomenon,O,O
.,O,O
Fewer,O,O
than,O,O
50,O,O
cases,O,O
of,O,O
SIAT,O,B
have,O,O
been,O,O
described,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
This,O,O
article,O,O
summarizes,O,O
all,O,O
the,O,O
cases,O,O
published,O,O
",",O,O
creating,O,O
a,O,O
comprehensive,O,O
review,O,O
of,O,O
the,O,O
current,O,O
knowledge,O,O
and,O,O
approach,O,O
to,O,O
SIAT,O,B
.,O,O
It,O,O
discusses,O,O
demographics,O,O
",",O,O
clinical,O,O
characteristics,O,O
and,O,O
types,O,O
of,O,O
arrhythmia,O,O
",",O,O
postulated,O,O
mechanisms,O,O
of,O,O
SIAT,O,B
",",O,O
and,O,O
different,O,O
treatment,O,O
possibilities,O,O
such,O,O
as,O,O
medications,O,B
",",O,O
surgery,O,O
",",O,O
and,O,O
radiofrequency,O,B
catheter,O,I
ablation,O,I
(,O,I
RFCA,O,I
),O,I
.,O,O
CONCLUSION,O,O
:,O,O
Salbutamol,B,B
is,O,O
presented,O,O
here,O,O
as,O,O
a,O,O
possible,O,O
trigger,O,O
for,O,O
SIAT,O,O
.,O,O
Although,O,O
it,O,O
is,O,O
difficult,O,O
to,O,O
define,O,O
causality,O,O
in,O,O
a,O,O
case,O,O
report,O,O
",",O,O
it,O,O
is,O,O
logical,O,O
to,O,O
think,O,O
that,O,O
a,O,O
beta,O,O
-,O,O
agonist,O,O
like,O,O
salbutamol,B,B
(,O,O
known,O,O
to,O,O
induce,O,O
tachycardia,O,O
),O,O
may,O,O
be,O,O
the,O,O
trigger,O,O
of,O,O
adrenergic,O,O
reflexes,O,O
originating,O,O
in,O,O
the,O,O
esophagus,O,O
while,O,O
swallowing,O,O
and,O,O
that,O,O
a,O,O
beta,O,O
-,O,O
blocker,O,O
such,O,O
as,O,O
atenolol,B,B
(,O,O
that,O,O
blocks,O,O
the,O,O
adrenergic,O,O
activity,O,O
),O,O
may,O,O
relieve,O,O
it,O,O
.,O,O
The,O,O
ability,O,O
of,O,O
insulin,O,B
treatment,O,O
to,O,O
reverse,O,O
or,O,O
prevent,O,O
the,O,O
changes,O,O
in,O,O
urinary,O,O
bladder,O,O
function,O,O
caused,O,O
by,O,O
streptozotocin,B,B
-,O,O
induced,O,O
diabetes,O,O
mellitus,O,O
.,O,O
1,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
insulin,O,B
treatment,O,O
on,O,O
in,O,O
vivo,O,O
and,O,O
in,O,O
vitro,O,O
urinary,O,O
bladder,O,O
function,O,O
in,O,O
streptozotocin,B,B
-,O,O
diabetic,O,O
rats,O,O
were,O,O
investigated,O,O
.,O,O
2,O,O
.,O,O
Diabetes,O,O
of,O,O
2,O,O
months,O,O
duration,O,O
resulted,O,O
in,O,O
decreases,O,O
in,O,O
body,O,O
weight,O,O
and,O,O
increases,O,O
in,O,O
fluid,O,O
consumption,O,O
",",O,O
urine,O,O
volume,O,O
",",O,O
frequency,O,O
of,O,O
micturition,O,O
",",O,O
and,O,O
average,O,O
volume,O,O
per,O,O
micturition,O,O
;,O,O
effects,O,O
which,O,O
were,O,O
prevented,O,O
by,O,O
insulin,O,B
treatment,O,O
.,O,O
3,O,O
Insulin,O,B
treatment,O,O
also,O,O
prevented,O,O
the,O,O
increases,O,O
in,O,O
contractile,O,O
responses,O,O
of,O,O
bladder,O,O
body,O,O
strips,O,O
from,O,O
diabetic,O,O
rats,O,O
to,O,O
nerve,O,O
stimulation,O,O
",",O,O
ATP,B,B
",",O,O
and,O,O
bethanechol,B,B
.,O,O
4,O,O
Diabetes,O,O
of,O,O
4,O,O
months,O,O
duration,O,O
also,O,O
resulted,O,O
in,O,O
decreases,O,O
in,O,O
body,O,O
weight,O,O
",",O,O
and,O,O
increases,O,O
in,O,O
fluid,O,O
consumption,O,O
",",O,O
urine,O,O
volume,O,O
",",O,O
frequency,O,O
of,O,O
micturition,O,O
",",O,O
and,O,O
average,O,O
volume,O,O
per,O,O
micturition,O,O
",",O,O
effects,O,O
which,O,O
were,O,O
reversed,O,O
by,O,O
insulin,O,B
treatment,O,O
for,O,O
the,O,O
final,O,O
2,O,O
months,O,O
of,O,O
the,O,O
study,O,O
.,O,O
5,O,O
Insulin,O,B
treatment,O,O
reversed,O,O
the,O,O
increases,O,O
in,O,O
contractile,O,O
responses,O,O
of,O,O
bladder,O,O
body,O,O
strips,O,O
from,O,O
diabetic,O,O
rats,O,O
to,O,O
nerve,O,O
stimulation,O,O
",",O,O
ATP,B,B
",",O,O
and,O,O
bethanechol,B,B
.,O,O
6,O,O
The,O,O
data,O,O
indicate,O,O
that,O,O
the,O,O
effects,O,O
of,O,O
streptozotocin,B,B
-,O,I
induced,O,I
diabetes,O,I
on,O,O
urinary,O,O
bladder,O,O
function,O,O
are,O,O
both,O,O
prevented,O,O
and,O,O
reversed,O,O
by,O,O
insulin,O,B
treatment,O,O
.,O,O
Glutamatergic,O,B
neurotransmission,O,O
mediated,O,O
by,O,O
NMDA,B,B
receptors,O,O
in,O,O
the,O,O
inferior,O,O
colliculus,O,O
can,O,O
modulate,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
.,O,O
The,O,O
inferior,O,O
colliculus,O,O
(,O,O
IC,O,B
),O,O
is,O,O
primarily,O,O
involved,O,O
in,O,O
the,O,O
processing,O,O
of,O,O
auditory,O,O
information,O,O
",",O,O
but,O,O
it,O,O
is,O,O
distinguished,O,O
from,O,O
other,O,O
auditory,O,O
nuclei,O,O
in,O,O
the,O,O
brainstem,O,O
by,O,O
its,O,O
connections,O,O
with,O,O
structures,O,O
of,O,O
the,O,O
motor,O,O
system,O,O
.,O,O
Functional,O,O
evidence,O,O
relating,O,O
the,O,O
IC,O,B
to,O,O
motor,O,O
behavior,O,O
derives,O,O
from,O,O
experiments,O,O
showing,O,O
that,O,O
activation,O,O
of,O,O
the,O,O
IC,O,B
by,O,O
electrical,O,O
stimulation,O,O
or,O,O
excitatory,O,B
amino,B,I
acid,I,I
microinjection,O,I
causes,O,O
freezing,O,O
",",O,O
escape,O,O
-,O,O
like,O,O
behavior,O,O
",",O,O
and,O,O
immobility,O,O
.,O,O
However,O,O
",",O,O
the,O,O
nature,O,O
of,O,O
this,O,O
immobility,O,O
is,O,O
still,O,O
unclear,O,O
.,O,O
The,O,O
present,O,O
study,O,O
examined,O,O
the,O,O
influence,O,O
of,O,O
excitatory,O,B
amino,B,I
acid,I,I
-,O,I
mediated,O,I
mechanisms,O,I
in,O,O
the,O,O
IC,O,B
on,O,O
the,O,O
catalepsy,O,O
induced,O,O
by,O,O
the,O,O
dopamine,B,B
receptor,O,I
blocker,O,I
haloperidol,B,I
administered,O,O
systemically,O,O
(,O,O
1,O,O
or,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
in,O,O
rats,O,O
.,O,O
Haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
was,O,O
challenged,O,O
with,O,O
prior,O,O
intracollicular,O,O
microinjections,O,O
of,O,O
glutamate,B,B
NMDA,B,B
receptor,O,O
antagonists,O,O
",",O,O
MK,B,B
-,I,O
801,I,I
(,O,O
15,O,O
or,O,O
30,O,O
mmol,O,O
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,O
),O,O
and,O,O
AP7,B,B
(,O,O
10,O,O
or,O,O
20,O,O
nmol,O,O
/,O,O
0,O,O
.,O,O
NMDA,B,B
receptor,O,O
agonist,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
d,I,I
-,I,I
aspartate,I,I
(,O,I
NMDA,B,I
",",O,I
20,O,I
or,O,I
30,O,I
nmol,O,I
/,O,I
0,O,I
.,O,I
5,O,O
microl,O,O
),O,O
.,O,O
The,O,O
results,O,O
showed,O,O
that,O,O
intracollicular,O,O
microinjection,O,O
of,O,O
MK,B,B
-,I,O
801,I,B
and,O,O
AP7,B,B
previous,O,O
to,O,O
systemic,O,O
injections,O,O
of,O,O
haloperidol,B,B
significantly,O,O
attenuated,O,O
the,O,O
catalepsy,O,O
",",O,O
as,O,O
indicated,O,O
by,O,O
a,O,O
reduced,O,O
latency,O,O
to,O,O
step,O,O
down,O,O
from,O,O
a,O,O
horizontal,O,O
bar,O,O
.,O,O
Accordingly,O,O
",",O,O
intracollicular,O,O
microinjection,O,O
of,O,O
NMDA,B,B
increased,O,O
the,O,O
latency,O,O
to,O,O
step,O,O
down,O,O
the,O,O
bar,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
glutamate,B,B
-,O,O
mediated,O,O
mechanisms,O,O
in,O,O
the,O,O
neural,O,O
circuits,O,O
at,O,O
the,O,O
IC,O,O
level,O,O
influence,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
and,O,O
participate,O,O
in,O,O
the,O,O
regulation,O,O
of,O,O
motor,O,O
activity,O,O
.,O,O
Severe,O,O
congestive,O,O
heart,O,O
failure,O,O
patient,O,O
on,O,O
amiodarone,B,B
presenting,O,O
with,O,O
myxedemic,O,O
coma,O,O
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
This,O,O
is,O,O
a,O,O
case,O,O
report,O,O
of,O,O
myxedema,O,O
coma,O,O
secondary,O,O
to,O,O
amiodarone,B,B
-,O,O
induced,O,O
hypothyroidism,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
severe,O,O
congestive,O,O
heart,O,O
failure,O,O
(,O,O
CHF,O,O
),O,O
.,O,O
To,O,O
our,O,O
knowledge,O,O
and,O,O
after,O,O
reviewing,O,O
the,O,O
literature,O,O
there,O,O
is,O,O
one,O,O
case,O,O
report,O,O
of,O,O
myxedema,O,B
coma,O,I
during,O,O
long,O,O
term,O,O
amiodarone,B,B
therapy,O,O
.,O,O
Myxedema,O,B
coma,O,I
is,O,O
a,O,O
life,O,O
threatening,O,O
condition,O,O
that,O,O
carries,O,O
a,O,O
mortality,O,O
reaching,O,O
as,O,O
high,O,O
as,O,O
20,O,O
%,O,O
with,O,O
treatment,O,O
.,O,O
The,O,O
condition,O,O
is,O,O
treated,O,O
with,O,O
intravenous,O,O
thyroxine,B,B
(,O,O
T4,B,B
),O,O
or,O,O
intravenous,O,O
tri,B,B
-,I,I
iodo,I,I
-,I,I
thyronine,I,I
(,O,O
T3,B,B
),O,O
.,O,O
Patients,O,O
with,O,O
CHF,O,O
on,O,O
amiodarone,B,B
may,O,O
suffer,O,O
serious,O,O
morbidity,O,O
and,O,O
mortality,O,O
from,O,O
hypothyroidism,O,O
",",O,O
and,O,O
thus,O,O
may,O,O
deserve,O,O
closer,O,O
follow,O,O
up,O,O
for,O,O
thyroid,O,O
stimulating,O,O
hormone,O,O
(,O,O
TSH,O,B
),O,O
levels,O,O
.,O,O
This,O,O
case,O,O
report,O,O
carries,O,O
an,O,O
important,O,O
clinical,O,O
application,O,O
given,O,O
the,O,O
frequent,O,O
usage,O,O
of,O,O
amiodarone,B,B
among,O,O
CHF,O,O
patients,O,O
.,O,O
The,O,O
myriad,O,O
clinical,O,O
presentation,O,O
of,O,O
myxedema,O,B
coma,O,I
and,O,O
its,O,O
serious,O,O
morbidity,O,O
and,O,O
mortality,O,O
stresses,O,O
the,O,O
need,O,O
to,O,O
suspect,O,O
this,O,O
clinical,O,O
syndrome,O,O
among,O,O
CHF,O,B
patients,O,O
presenting,O,O
with,O,O
hypotension,O,O
",",O,O
weakness,O,O
or,O,O
other,O,O
unexplained,O,O
symptoms,O,O
.,O,O
Effects,O,O
of,O,O
active,O,O
constituents,O,O
of,O,O
Crocus,O,B
sativus,O,I
L,O,I
.,O,O
",",O,O
crocin,B,B
on,O,O
streptozocin,B,B
-,O,I
induced,O,I
model,O,I
of,O,I
sporadic,O,I
Alzheimer,O,B
',O,I
s,O,I
disease,O,I
in,O,O
male,O,O
rats,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
involvement,O,O
of,O,O
water,O,B
-,O,I
soluble,O,I
carotenoids,B,I
",",O,O
crocins,B,B
",",O,O
as,O,O
the,O,O
main,O,O
and,O,O
active,O,O
components,O,O
of,O,O
Crocus,O,B
sativus,O,I
L,O,I
.,O,O
extract,O,O
in,O,O
learning,O,O
and,O,O
memory,O,O
processes,O,O
has,O,O
been,O,O
proposed,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
the,O,O
effect,O,O
of,O,O
crocins,B,B
on,O,O
sporadic,O,O
Alzheimer,O,B
',O,I
s,O,I
disease,O,I
induced,O,O
by,O,O
intracerebroventricular,O,O
(,O,O
icv,O,B
),O,I
streptozocin,B,I
(,O,I
STZ,B,I
),O,I
in,O,O
male,O,O
rats,O,O
was,O,O
investigated,O,O
.,O,O
METHODS,O,O
:,O,O
Male,O,O
adult,O,O
Wistar,O,O
rats,O,O
(,O,O
n,O,O
=,O,O
90,O,O
and,O,O
260,O,O
-,O,O
290,O,O
g,O,O
),O,O
were,O,O
divided,O,O
into,O,O
1,O,O
",",O,O
control,O,O
;,O,O
2,O,O
and,O,O
3,O,O
",",O,O
crocins,B,B
(,O,O
15,O,O
and,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
;,O,O
4,O,O
",",O,O
STZ,B,B
;,O,O
5,O,O
and,O,O
6,O,O
",",O,O
STZ,B,B
+,O,O
crocins,B,B
(,O,O
15,O,O
and,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
groups,O,O
.,O,O
In,O,O
Alzheimer,O,B
',O,O
s,O,O
disease,O,O
groups,O,O
",",O,O
rats,O,O
were,O,O
injected,O,O
with,O,O
STZ,B,B
-,O,O
icv,O,O
bilaterally,O,O
(,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
in,O,O
first,O,O
day,O,O
and,O,O
3,O,O
days,O,O
later,O,O
",",O,O
a,O,O
similar,O,O
STZ,B,B
-,O,O
icv,O,O
application,O,O
was,O,O
repeated,O,O
.,O,O
In,O,O
STZ,B,B
+,O,O
crocin,B,B
animal,O,O
groups,O,O
",",O,O
crocin,B,B
was,O,O
applied,O,O
in,O,O
doses,O,O
of,O,O
15,O,O
and,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
",",O,O
one,O,O
day,O,O
pre,O,O
-,O,O
surgery,O,O
and,O,O
continued,O,O
for,O,O
three,O,O
weeks,O,O
.,O,O
Prescription,O,O
of,O,O
crocin,B,B
in,O,O
each,O,O
dose,O,O
was,O,O
repeated,O,O
once,O,O
for,O,O
two,O,O
days,O,O
.,O,O
However,O,O
",",O,O
the,O,O
learning,O,O
and,O,O
memory,O,O
performance,O,O
was,O,O
assessed,O,O
using,O,O
passive,O,O
avoidance,O,O
paradigm,O,O
",",O,O
and,O,O
for,O,O
spatial,O,O
cognition,O,O
evaluation,O,O
",",O,O
Y,O,O
-,O,O
maze,O,O
task,O,O
was,O,O
used,O,O
.,O,O
RESULTS,O,O
:,O,O
It,O,O
was,O,O
found,O,O
out,O,O
that,O,O
crocin,B,B
(,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
STZ,B,B
-,O,O
injected,O,O
rats,O,O
show,O,O
higher,O,O
correct,O,O
choices,O,O
and,O,O
lower,O,O
errors,O,O
in,O,O
Y,O,O
-,O,O
maze,O,O
than,O,O
vehicle,O,O
-,O,O
treated,O,O
STZ,B,B
-,O,O
injected,O,O
rats,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
crocin,B,B
in,O,O
the,O,O
mentioned,O,O
dose,O,O
could,O,O
significantly,O,O
attenuated,O,O
learning,O,O
and,O,O
memory,O,O
impairment,O,O
in,O,O
treated,O,O
STZ,B,B
-,O,O
injected,O,O
group,O,O
in,O,O
passive,O,O
avoidance,O,O
test,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Therefore,O,O
",",O,O
these,O,O
results,O,O
demonstrate,O,O
the,O,O
effectiveness,O,O
of,O,O
crocin,B,B
(,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
in,O,O
antagonizing,O,O
the,O,O
cognitive,O,O
deficits,O,O
caused,O,O
by,O,O
STZ,B,B
-,O,O
icv,O,O
in,O,O
rats,O,O
and,O,O
its,O,O
potential,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
neurodegenerative,O,O
diseases,O,O
such,O,O
as,O,O
Alzheimer,O,B
',O,O
s,O,O
disease,O,O
.,O,O
Serotonin,B,B
6,O,I
receptor,O,I
gene,O,I
is,O,O
associated,O,O
with,O,O
methamphetamine,B,B
-,O,O
induced,O,O
psychosis,O,O
in,O,O
a,O,O
Japanese,O,O
population,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Altered,O,O
serotonergic,O,O
neural,O,O
transmission,O,O
is,O,O
hypothesized,O,O
to,O,O
be,O,O
a,O,O
susceptibility,O,O
factor,O,O
for,O,O
psychotic,O,O
disorders,O,O
such,O,O
as,O,O
schizophrenia,O,O
.,O,O
The,O,O
serotonin,B,B
6,O,I
(,O,I
5,B,I
-,I,I
HT6,I,I
),O,I
receptor,O,O
is,O,O
therapeutically,O,O
targeted,O,O
by,O,O
several,O,O
second,O,O
generation,O,O
antipsychotics,O,O
",",O,O
such,O,O
as,O,O
clozapine,B,B
and,O,O
olanzapine,B,B
",",O,O
and,O,O
d,B,B
-,I,I
amphetamine,I,I
-,O,I
induced,O,I
hyperactivity,O,O
in,O,O
rats,O,O
is,O,O
corrected,O,O
with,O,O
the,O,O
use,O,O
of,O,O
a,O,O
selective,O,O
5,B,B
-,I,I
HT6,I,I
receptor,O,O
antagonist,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
the,O,O
disrupted,O,O
prepulse,O,O
inhibition,O,O
induced,O,O
by,O,O
d,B,B
-,I,I
amphetamine,I,I
or,O,O
phencyclidine,B,B
was,O,O
restored,O,O
by,O,O
5,B,B
-,I,I
HT6,I,I
receptor,O,I
antagonist,O,I
in,O,O
an,O,O
animal,O,O
study,O,O
using,O,O
rats,O,O
.,O,O
These,O,O
animal,O,O
models,O,O
were,O,O
considered,O,O
to,O,O
reflect,O,O
the,O,O
positive,O,O
symptoms,O,O
of,O,O
schizophrenia,O,B
",",O,O
and,O,O
the,O,O
above,O,O
evidence,O,O
suggests,O,O
that,O,O
altered,O,O
5,B,B
-,I,I
HT6,I,I
receptors,O,I
are,O,O
involved,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
psychotic,O,O
disorders,O,O
.,O,O
The,O,O
symptoms,O,O
of,O,O
methamphetamine,B,B
(,O,O
METH,B,B
),O,O
-,O,O
induced,O,O
psychosis,O,O
are,O,O
similar,O,O
to,O,O
those,O,O
of,O,O
paranoid,O,O
type,O,O
schizophrenia,O,O
.,O,O
Therefore,O,O
",",O,O
we,O,O
conducted,O,O
an,O,O
analysis,O,O
of,O,O
the,O,O
association,O,O
of,O,O
the,O,O
5,B,O
-,I,O
HT6,I,B
gene,O,O
(,O,O
HTR6,O,B
),O,O
with,O,O
METH,B,B
-,O,O
induced,O,O
psychosis,O,O
.,O,O
METHOD,O,O
:,O,O
Using,O,O
five,O,O
tagging,O,O
SNPs,O,O
(,O,O
rs6693503,O,B
",",O,O
rs1805054,O,B
",",O,O
rs4912138,O,B
",",O,O
rs3790757,O,B
and,O,O
rs9659997,O,B
),O,O
",",O,O
we,O,O
conducted,O,O
a,O,O
genetic,O,O
association,O,O
analysis,O,O
of,O,O
case,O,O
-,O,O
control,O,O
samples,O,O
(,O,O
197,O,O
METH,B,B
-,O,O
induced,O,O
psychosis,O,O
patients,O,O
and,O,O
337,O,O
controls,O,O
),O,O
in,O,O
the,O,O
Japanese,O,O
population,O,O
.,O,O
The,O,O
age,O,O
and,O,O
sex,O,O
of,O,O
the,O,O
control,O,O
subjects,O,O
did,O,O
not,O,O
differ,O,O
from,O,O
those,O,O
of,O,O
the,O,O
methamphetamine,B,B
dependence,O,I
patients,O,I
.,O,O
RESULTS,O,O
:,O,O
rs6693503,O,O
was,O,O
associated,O,O
with,O,O
METH,B,B
-,O,I
induced,O,I
psychosis,O,I
patients,O,I
in,O,O
the,O,O
allele,O,O
/,O,O
genotype,O,O
-,O,O
wise,O,O
analysis,O,O
.,O,O
Moreover,O,O
",",O,O
this,O,O
association,O,O
remained,O,O
significant,O,O
after,O,O
Bonferroni,O,O
correction,O,O
.,O,O
In,O,O
the,O,O
haplotype,O,O
-,O,O
wise,O,O
analysis,O,O
",",O,O
we,O,O
detected,O,O
an,O,O
association,O,O
between,O,O
two,O,O
markers,O,O
(,O,O
rs6693503,O,B
and,O,O
rs1805054,O,B
),O,O
and,O,O
three,O,O
markers,O,O
(,O,O
rs6693503,O,B
",",O,O
rs1805054,O,B
and,O,O
rs4912138,O,B
),O,O
in,O,O
HTR6,O,B
and,O,O
METH,B,B
-,O,O
induced,O,O
psychosis,O,O
patients,O,O
",",O,O
respectively,O,O
.,O,O
CONCLUSION,O,O
:,O,O
HTR6,O,B
may,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
METH,B,B
-,O,O
induced,O,O
psychosis,O,O
in,O,O
the,O,O
Japanese,O,O
population,O,O
.,O,O
Neural,O,O
correlates,O,O
of,O,O
S,B,B
-,I,I
ketamine,I,I
induced,O,O
psychosis,O,O
during,O,O
overt,O,O
continuous,O,O
verbal,O,O
fluency,O,O
.,O,O
The,O,O
glutamatergic,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
D,I,I
-,I,I
aspartate,I,I
(,O,O
NMDA,B,B
),O,O
receptor,O,O
has,O,O
been,O,O
implicated,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
schizophrenia,O,O
.,O,O
Administered,O,O
to,O,O
healthy,O,O
volunteers,O,O
",",O,O
a,O,O
subanesthetic,O,O
dose,O,O
of,O,O
the,O,O
non,O,O
-,O,O
competitive,O,O
NMDA,B,B
receptor,O,O
antagonist,O,O
ketamine,B,I
leads,O,O
to,O,O
psychopathological,O,O
symptoms,O,O
similar,O,O
to,O,O
those,O,O
observed,O,O
in,O,O
schizophrenia,O,O
.,O,O
In,O,O
patients,O,O
with,O,O
schizophrenia,O,B
",",O,O
ketamine,B,B
exacerbates,O,O
the,O,O
core,O,O
symptoms,O,O
of,O,O
illness,O,O
",",O,O
supporting,O,O
the,O,O
hypothesis,O,O
of,O,O
a,O,O
glutamatergic,O,O
dysfunction,O,O
.,O,O
In,O,O
a,O,O
counterbalanced,O,O
",",O,O
placebo,O,O
-,O,O
controlled,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
study,O,O
design,O,O
",",O,O
healthy,O,O
subjects,O,O
were,O,O
administered,O,O
a,O,O
continuous,O,O
subanesthetic,O,O
S,B,B
-,I,O
ketamine,I,B
infusion,O,O
while,O,O
differences,O,O
in,O,O
BOLD,O,B
responses,O,O
measured,O,O
with,O,O
fMRI,O,B
were,O,O
detected,O,O
.,O,O
During,O,O
the,O,O
scanning,O,O
period,O,O
",",O,O
subjects,O,O
performed,O,O
continuous,O,O
overt,O,O
verbal,O,O
fluency,O,O
tasks,O,O
(,O,O
phonological,O,B
",",O,O
lexical,O,B
and,O,O
semantic,O,B
),O,O
.,O,O
Ketamine,B,B
-,O,O
induced,O,O
psychopathological,O,O
symptoms,O,O
were,O,O
assessed,O,O
with,O,O
the,O,O
Positive,O,B
and,O,I
Negative,O,I
Syndrome,O,I
Scale,O,I
(,O,O
PANSS,O,B
),O,O
.,O,O
Ketamine,B,B
elicited,O,O
psychosis,O,O
like,O,O
psychopathology,O,O
.,O,O
Post,O,O
-,O,O
hoc,O,O
t,O,O
-,O,O
tests,O,O
revealed,O,O
significant,O,O
differences,O,O
between,O,O
placebo,O,O
and,O,O
ketamine,B,B
for,O,O
the,O,O
amounts,O,O
of,O,O
words,O,O
generated,O,O
during,O,O
lexical,O,B
and,O,O
semantic,O,B
verbal,O,O
fluency,O,O
",",O,O
while,O,O
the,O,O
phonological,O,B
domain,O,O
remained,O,O
unaffected,O,O
.,O,O
Ketamine,B,B
led,O,O
to,O,O
enhanced,O,O
cortical,O,O
activations,O,O
in,O,O
supramarginal,O,B
and,O,O
frontal,O,B
brain,O,O
regions,O,O
for,O,O
phonological,O,B
and,O,O
lexical,O,O
verbal,O,O
fluency,O,O
",",O,O
but,O,O
not,O,O
for,O,O
semantic,O,B
verbal,O,O
fluency,O,O
.,O,O
Ketamine,B,B
induces,O,O
activation,O,O
changes,O,O
in,O,O
healthy,O,O
subjects,O,O
similar,O,O
to,O,O
those,O,O
observed,O,O
in,O,O
patients,O,O
with,O,O
schizophrenia,O,B
",",O,O
particularly,O,O
in,O,O
frontal,O,B
and,O,O
temporal,O,B
brain,O,O
regions,O,O
.,O,O
Our,O,O
results,O,O
provide,O,O
further,O,O
support,O,O
for,O,O
the,O,O
hypothesis,O,O
of,O,O
an,O,O
NMDA,B,B
receptor,O,I
dysfunction,O,O
in,O,O
the,O,O
pathophysiology,O,O
of,O,O
schizophrenia,O,O
.,O,O
Long,O,O
-,O,O
term,O,O
prognosis,O,O
for,O,O
transplant,O,O
-,O,O
free,O,O
survivors,O,O
of,O,O
paracetamol,B,B
-,O,I
induced,O,I
acute,O,I
liver,O,I
failure,O,I
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
prognosis,O,O
for,O,O
transplant,O,O
-,O,O
free,O,O
survivors,O,O
of,O,O
paracetamol,B,B
-,O,I
induced,O,I
acute,O,I
liver,O,I
failure,O,I
remains,O,O
unknown,O,O
.,O,O
AIM,O,O
:,O,O
To,O,O
examine,O,O
whether,O,O
paracetamol,B,B
-,O,O
induced,O,O
acute,O,O
liver,O,O
failure,O,O
increases,O,O
long,O,O
-,O,O
term,O,O
mortality,O,O
.,O,O
METHODS,O,O
:,O,O
We,O,O
followed,O,O
up,O,O
all,O,O
transplant,O,O
-,O,O
free,O,O
survivors,O,O
of,O,O
paracetamol,B,B
-,O,O
induced,O,O
acute,O,O
liver,O,O
injury,O,O
",",O,O
hospitalized,O,O
in,O,O
a,O,O
Danish,O,O
national,O,O
referral,O,O
centre,O,O
during,O,O
1984,O,O
-,O,O
2004,O,O
.,O,O
We,O,O
compared,O,O
age,O,O
-,O,O
specific,O,O
mortality,O,O
rates,O,O
from,O,O
1,O,O
year,O,O
post,O,O
-,O,O
discharge,O,O
through,O,O
2008,O,O
between,O,O
those,O,O
in,O,O
whom,O,O
the,O,O
liver,O,O
injury,O,O
led,O,O
to,O,O
an,O,O
acute,O,O
liver,O,O
failure,O,O
and,O,O
those,O,O
in,O,O
whom,O,O
it,O,O
did,O,O
not,O,O
.,O,O
RESULTS,O,O
:,O,O
We,O,O
included,O,O
641,O,O
patients,O,O
.,O,O
On,O,O
average,O,O
",",O,O
age,O,O
-,O,O
specific,O,O
mortality,O,O
rates,O,O
were,O,O
slightly,O,O
higher,O,O
for,O,O
the,O,O
101,O,O
patients,O,O
whose,O,O
paracetamol,B,B
-,O,O
induced,O,O
liver,O,B
injury,O,O
had,O,O
caused,O,O
an,O,O
acute,O,O
liver,O,B
failure,O,I
(,O,O
adjusted,O,O
mortality,O,O
rate,O,O
ratio,O,O
=,O,O
1,O,O
.,O,O
70,O,O
",",O,O
95,O,O
%,O,O
CI,O,O
1,O,O
.,O,O
-,O,O
2,O,O
.,O,O
85,O,O
),O,O
",",O,O
but,O,O
the,O,O
association,O,O
was,O,O
age,O,O
-,O,O
dependent,O,O
",",O,O
and,O,O
no,O,O
survivors,O,O
of,O,O
acute,O,O
liver,O,B
failure,O,I
died,O,O
of,O,O
liver,O,B
disease,O,I
",",O,O
whereas,O,O
suicides,O,O
were,O,O
frequent,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
These,O,O
observations,O,O
speak,O,O
against,O,O
long,O,O
-,O,O
term,O,O
effects,O,O
of,O,O
acute,O,O
liver,O,B
failure,O,I
.,O,O
More,O,O
likely,O,O
",",O,O
the,O,O
elevated,O,O
mortality,O,O
rate,O,O
ratio,O,O
resulted,O,O
from,O,O
incomplete,O,O
adjustment,O,O
for,O,O
the,O,O
greater,O,O
prevalence,O,O
of,O,O
substance,O,O
abuse,O,O
among,O,O
survivors,O,O
of,O,O
acute,O,O
liver,O,B
failure,O,I
.,O,O
CONCLUSIONS,O,O
:,O,O
Paracetamol,B,B
-,O,I
induced,O,I
acute,O,I
liver,O,I
failure,O,I
did,O,O
not,O,O
affect,O,O
long,O,O
-,O,O
term,O,O
mortality,O,O
.,O,O
Clinical,O,O
follow,O,O
-,O,O
up,O,O
may,O,O
be,O,O
justified,O,O
by,O,O
the,O,O
cause,O,O
of,O,O
the,O,O
liver,O,B
failure,O,I
",",O,O
but,O,O
not,O,O
by,O,O
the,O,O
liver,O,B
failure,O,I
itself,O,O
.,O,O
In,O,O
vivo,O,O
characterization,O,O
of,O,O
a,O,O
dual,O,O
adenosine,B,B
A2A,I,I
/,I,O
A1,I,I
receptor,I,I
antagonist,I,I
in,O,O
animal,O,O
models,O,O
of,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,I
.,O,O
The,O,O
in,O,O
vivo,O,O
characterization,O,O
of,O,O
a,O,O
dual,O,O
adenosine,B,B
A,I,I
(,I,O
2A,I,I
),I,O
/,I,O
A,I,I
(,I,O
1,I,I
),I,O
receptor,I,I
antagonist,I,I
in,O,O
several,O,O
animal,O,O
models,O,O
of,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,I
is,O,O
described,O,O
.,O,O
Discovery,O,O
and,O,O
scale,O,O
-,O,O
up,O,O
syntheses,O,O
of,O,O
compound,O,O
1,O,B
are,O,O
described,O,O
in,O,O
detail,O,O
",",O,O
highlighting,O,O
optimization,O,O
steps,O,O
that,O,O
increased,O,O
the,O,O
overall,O,O
yield,O,O
of,O,O
1,O,B
from,O,O
10,O,O
.,O,O
0,O,O
%,O,O
to,O,O
30,O,O
.,O,O
5,O,O
%,O,O
.,O,O
Compound,O,O
1,O,B
is,O,O
a,O,O
potent,O,O
A,O,B
(,O,O
2A,O,O
),O,O
/,O,O
A,O,B
(,O,O
1,O,O
),O,O
receptor,O,O
antagonist,O,O
in,O,O
vitro,O,O
(,O,O
A,O,B
(,O,O
2A,O,O
),O,O
K,O,B
(,O,O
i,O,O
),O,O
=,O,O
4,O,O
.,O,O
1,O,O
nM,O,O
;,O,O
A,O,B
(,O,O
1,O,O
),O,O
K,O,B
(,O,O
i,O,O
),O,O
=,O,O
17,O,O
.,O,O
0,O,O
nM,O,O
),O,O
that,O,O
has,O,O
excellent,O,O
activity,O,O
",",O,O
after,O,O
oral,O,O
administration,O,O
",",O,O
across,O,O
a,O,O
number,O,O
of,O,O
animal,O,O
models,O,O
of,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
including,O,O
mouse,O,O
and,O,O
rat,O,O
models,O,O
of,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
",",O,O
mouse,O,O
model,O,O
of,O,O
reserpine,B,B
-,O,O
induced,O,O
akinesia,O,O
",",O,O
rat,O,O
6,B,O
-,I,O
hydroxydopamine,I,B
(,O,O
6,B,O
-,I,O
OHDA,I,O
),O,O
lesion,O,O
model,O,O
of,O,O
drug,O,O
-,O,O
induced,O,O
rotation,O,O
",",O,O
and,O,O
MPTP,B,B
-,O,O
treated,O,O
non,O,O
-,O,O
human,O,O
primate,O,O
model,O,O
.,O,O
Effects,O,O
of,O,O
the,O,O
hippocampal,O,B
deep,O,I
brain,O,I
stimulation,O,I
on,O,O
cortical,O,B
epileptic,O,I
discharges,O,I
in,O,O
penicillin,B,B
-,O,I
induced,O,I
epilepsy,O,I
model,O,I
in,O,I
rats,O,I
.,O,O
AIM,O,O
:,O,O
Experimental,O,O
and,O,O
clinical,O,O
studies,O,O
have,O,O
revealed,O,O
that,O,O
hippocampal,O,B
DBS,O,I
can,O,O
control,O,O
epileptic,O,I
activity,O,I
",",O,O
but,O,O
the,O,O
mechanism,O,O
of,O,O
action,O,O
is,O,O
obscure,O,O
and,O,O
optimal,O,O
stimulation,O,O
parameters,O,O
are,O,O
not,O,O
clearly,O,O
defined,O,O
.,O,O
The,O,O
aim,O,O
was,O,O
to,O,O
evaluate,O,O
the,O,O
effects,O,O
of,O,O
high,O,O
frequency,O,O
hippocampal,O,O
stimulation,O,O
on,O,O
cortical,O,O
epileptic,O,O
activity,O,O
in,O,O
penicillin,B,B
-,O,I
induced,O,I
epilepsy,O,I
model,O,O
.,O,O
MATERIAL,O,O
AND,O,O
METHODS,O,O
:,O,O
Twenty,O,O
-,O,O
five,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
implanted,O,O
DBS,O,O
electrodes,O,O
.,O,O
In,O,O
group,O,O
-,O,O
1,O,O
(,O,O
n,O,O
=,O,O
10,O,O
),O,O
hippocampal,O,O
DBS,O,O
was,O,O
off,O,O
and,O,O
in,O,O
the,O,O
group,O,O
-,O,O
2,O,O
(,O,O
n,O,O
=,O,O
10,O,O
),O,O
hippocampal,O,O
DBS,O,O
was,O,O
on,O,O
(,O,O
185,O,O
Hz,O,O
",",O,O
0,O,O
.,O,O
5V,O,B
",",O,O
1V,O,B
",",O,O
2V,O,B
",",O,O
and,O,O
5V,O,B
for,O,O
60,O,O
sec,O,O
),O,O
following,O,O
penicillin,B,B
G,I,I
injection,O,O
intracortically,O,O
.,O,O
In,O,O
the,O,O
control,O,O
group,O,O
hippocampal,O,O
DBS,O,O
was,O,O
on,O,O
following,O,O
8,O,O
l,O,O
saline,O,B
injection,O,O
intracortically,O,O
.,O,O
EEG,O,O
recordings,O,O
were,O,O
obtained,O,O
before,O,O
and,O,O
15,O,O
minutes,O,O
following,O,O
penicillin,B,B
-,I,I
G,I,I
injection,O,O
",",O,O
and,O,O
at,O,O
10th,O,O
minutes,O,O
following,O,O
each,O,O
stimulus,O,O
for,O,O
analysis,O,O
in,O,O
terms,O,O
of,O,O
frequency,O,O
",",O,O
amplitude,O,O
",",O,O
and,O,O
power,O,O
spectrum,O,O
.,O,O
RESULTS,O,O
:,O,O
High,O,O
frequency,O,O
hippocampal,O,O
DBS,O,O
suppressed,O,O
the,O,O
acute,O,O
penicillin,B,B
-,O,O
induced,O,O
cortical,O,O
epileptic,O,O
activity,O,O
independent,O,O
from,O,O
stimulus,O,O
intensity,O,O
.,O,O
In,O,O
the,O,O
control,O,O
group,O,O
",",O,O
hippocampal,O,O
stimulation,O,O
alone,O,O
lead,O,O
only,O,O
to,O,O
diffuse,O,O
slowing,O,O
of,O,O
cerebral,O,O
bioelectrical,O,O
activity,O,O
at,O,O
5V,O,O
stimulation,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Our,O,O
results,O,O
revealed,O,O
that,O,O
continuous,O,O
high,O,O
frequency,O,O
stimulation,O,O
of,O,O
the,O,O
suppressed,O,O
acute,O,O
cortical,O,O
epileptic,O,O
activity,O,O
effectively,O,O
without,O,O
causing,O,O
secondary,O,O
epileptic,O,O
discharges,O,O
.,O,O
These,O,O
results,O,O
are,O,O
important,O,O
in,O,O
terms,O,O
of,O,O
defining,O,O
the,O,O
optimal,O,O
parameters,O,O
of,O,O
hippocampal,O,O
DBS,O,O
in,O,O
patients,O,O
with,O,O
epilepsy,O,O
.,O,O
CCNU,B,B
(,O,O
lomustine,B,I
),O,O
toxicity,O,O
in,O,O
dogs,O,O
:,O,O
a,O,O
retrospective,O,O
study,O,O
(,O,O
2002,O,O
-,O,O
),O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
describe,O,O
the,O,O
incidence,O,O
of,O,O
haematological,O,O
",",O,O
renal,O,O
",",O,O
hepatic,O,O
and,O,O
gastrointestinal,O,O
toxicities,O,O
in,O,O
tumour,O,O
-,O,O
bearing,O,O
dogs,O,O
receiving,O,O
1,B,O
-,I,O
(,I,O
2,I,O
-,I,O
chloroethyl,I,B
),I,O
-,I,O
3,I,O
-,I,O
cyclohexyl,I,B
-,I,O
1,I,O
-,I,O
nitrosourea,I,I
(,O,O
CCNU,B,B
),O,O
.,O,O
DESIGN,O,O
:,O,O
The,O,O
medical,O,O
records,O,O
of,O,O
206,O,O
dogs,O,O
that,O,O
were,O,O
treated,O,O
with,O,O
CCNU,B,B
at,O,O
the,O,O
Melbourne,O,O
Veterinary,O,O
Specialist,O,O
Centre,O,O
between,O,O
February,O,O
2002,O,O
and,O,O
December,O,O
2007,O,O
were,O,O
retrospectively,O,O
evaluated,O,O
.,O,O
RESULTS,O,O
:,O,O
Of,O,O
the,O,O
206,O,O
dogs,O,O
treated,O,O
with,O,O
CCNU,B,B
",",O,O
185,O,O
met,O,O
the,O,O
inclusion,O,O
criteria,O,O
for,O,O
at,O,O
least,O,O
one,O,O
class,O,O
of,O,O
toxicity,O,O
.,O,O
CCNU,B,B
was,O,O
used,O,O
most,O,O
commonly,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
lymphoma,O,B
",",O,O
mast,O,B
cell,O,I
tumour,O,I
",",O,O
brain,O,B
tumour,O,I
",",O,O
histiocytic,O,B
tumours,O,I
and,O,O
epitheliotropic,O,B
lymphoma,O,I
.,O,O
Throughout,O,O
treatment,O,O
",",O,O
56,O,O
.,O,O
9,O,O
%,O,O
of,O,O
dogs,O,O
experienced,O,O
neutropenia,O,B
",",O,O
34,O,O
.,O,O
2,O,O
%,O,O
experienced,O,O
anaemia,O,B
and,O,O
14,O,O
.,O,O
2,O,O
%,O,O
experienced,O,O
thrombocytopenia,O,B
.,O,O
Gastrointestinal,O,B
toxicosis,O,I
was,O,O
detected,O,O
in,O,O
37,O,O
.,O,O
8,O,O
%,O,O
of,O,O
dogs,O,O
",",O,O
the,O,O
most,O,O
common,O,O
sign,O,O
of,O,O
which,O,O
was,O,O
vomiting,O,B
(,O,O
24,O,O
.,O,O
3,O,O
%,O,O
),O,O
.,O,O
Potential,O,O
renal,O,B
toxicity,O,I
and,O,O
elevated,O,O
alanine,B,B
transaminase,O,I
(,O,O
ALT,O,B
),O,O
concentration,O,O
were,O,O
reported,O,O
in,O,O
12,O,O
.,O,O
2,O,O
%,O,O
and,O,O
48,O,O
.,O,O
8,O,O
%,O,O
of,O,O
dogs,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
hepatic,O,B
failure,O,I
was,O,O
1,O,O
.,O,O
2,O,O
%,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
CCNU,B,B
-,O,I
associated,O,I
toxicity,O,I
in,O,O
dogs,O,O
is,O,O
common,O,O
",",O,O
but,O,O
is,O,O
usually,O,O
not,O,O
life,O,O
threatening,O,O
.,O,O
Central,O,B
vein,O,I
thrombosis,O,I
and,O,O
topical,O,O
dipivalyl,B,B
epinephrine,I,I
.,O,O
A,O,O
report,O,O
is,O,O
given,O,O
on,O,O
an,O,O
83,O,O
-,O,O
year,O,O
-,O,O
old,O,O
female,O,O
who,O,O
acquired,O,O
central,O,B
vein,O,I
thrombosis,O,I
in,O,O
her,O,O
seeing,O,O
eye,O,O
one,O,O
day,O,O
after,O,O
having,O,O
started,O,O
topical,O,O
medication,O,O
with,O,O
dipivalyl,B,B
epinephrine,I,I
for,O,O
advanced,O,O
glaucoma,O,O
discovered,O,O
in,O,O
the,O,O
other,O,O
eye,O,O
.,O,O
From,O,O
present,O,O
knowledge,O,O
about,O,O
the,O,O
effects,O,O
of,O,O
adrenergic,O,O
eye,O,O
drops,O,O
on,O,O
ocular,O,O
blood,O,O
circulation,O,O
",",O,O
it,O,O
is,O,O
difficult,O,O
to,O,O
suggest,O,O
an,O,O
association,O,O
between,O,O
the,O,O
two,O,O
events,O,O
",",O,O
which,O,O
may,O,O
be,O,O
coincidental,O,O
only,O,O
.,O,O
Benzylacyclouridine,B,B
reverses,O,O
azidothymidine,B,B
-,O,I
induced,O,O
marrow,O,O
suppression,O,O
without,O,O
impairment,O,O
of,O,O
anti,O,O
-,O,O
human,O,O
immunodeficiency,O,O
virus,O,O
activity,O,O
.,O,O
Increased,O,O
extracellular,O,O
concentrations,O,O
of,O,O
uridine,B,B
(,O,O
Urd,B,B
),O,O
have,O,O
been,O,O
reported,O,O
to,O,O
reduce,O,O
",",O,O
in,O,O
vitro,O,O
",",O,O
azidothymidine,B,B
(,O,O
AZT,B,B
),O,O
-,O,O
induced,O,O
inhibition,O,O
of,O,O
human,O,O
granulocyte,O,O
-,O,O
macrophage,O,O
progenitor,O,O
cells,O,O
without,O,O
impairment,O,O
of,O,O
its,O,O
antihuman,O,O
immunodeficiency,O,O
virus,O,O
(,O,O
HIV,O,B
),O,O
activity,O,O
.,O,O
Because,O,O
of,O,O
the,O,O
clinical,O,O
toxicities,O,O
associated,O,O
with,O,O
chronic,O,O
Urd,B,B
administration,O,O
",",O,O
the,O,O
ability,O,O
of,O,O
benzylacyclouridine,B,B
(,O,O
BAU,B,B
),O,O
to,O,O
effect,O,O
",",O,O
in,O,O
vivo,O,O
",",O,O
AZT,B,B
-,O,O
induced,O,O
anemia,O,O
and,O,O
leukopenia,O,O
was,O,O
assessed,O,O
.,O,O
This,O,O
agent,O,O
inhibits,O,O
Urd,B,B
catabolism,O,O
and,O,O
",",O,O
in,O,O
vivo,O,O
",",O,O
increases,O,O
the,O,O
plasma,O,O
concentration,O,O
of,O,O
Urd,B,B
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
",",O,O
without,O,O
Urd,B,B
-,O,O
related,O,O
toxicity,O,O
.,O,O
In,O,O
mice,O,O
rendered,O,O
anemic,O,O
and,O,O
leukopenic,O,O
by,O,O
the,O,O
administration,O,O
of,O,O
AZT,B,B
for,O,O
28,O,O
days,O,O
in,O,O
drinking,O,O
water,O,O
(,O,O
1,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
mL,O,O
),O,O
",",O,O
the,O,O
continued,O,O
administration,O,O
of,O,O
AZT,B,B
plus,O,O
daily,O,O
BAU,B,B
(,O,O
300,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
orally,O,O
),O,O
partially,O,O
reversed,O,O
AZT,B,B
-,O,O
induced,O,O
anemia,O,O
and,O,O
leukopenia,O,O
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
",",O,O
increased,O,O
peripheral,O,O
reticulocytes,O,O
(,O,O
to,O,O
4,O,O
.,O,O
9,O,O
%,O,O
",",O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
",",O,O
increased,O,O
cellularity,O,O
in,O,O
the,O,O
marrow,O,O
",",O,O
and,O,O
improved,O,O
megaloblastosis,O,O
.,O,O
When,O,O
coadministered,O,O
with,O,O
AZT,B,B
from,O,O
the,O,O
onset,O,O
of,O,O
drug,O,O
administration,O,O
",",O,O
BAU,B,B
reduced,O,O
AZT,B,B
-,O,O
induced,O,O
marrow,O,O
toxicity,O,O
.,O,O
In,O,O
vitro,O,O
",",O,O
at,O,O
a,O,O
concentration,O,O
of,O,O
100,O,O
mumol,O,O
/,O,O
L,O,O
",",O,O
BAU,B,B
possesses,O,O
minimal,O,O
anti,O,O
-,O,O
HIV,O,B
activity,O,O
and,O,O
has,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
ability,O,O
of,O,O
AZT,B,B
to,O,O
reverse,O,O
the,O,O
HIV,O,B
-,O,O
induced,O,O
cytopathic,O,O
effect,O,O
in,O,O
MT4,O,O
cells,O,O
.,O,O
The,O,O
clinical,O,O
and,O,O
biochemical,O,O
implications,O,O
of,O,O
these,O,O
findings,O,O
are,O,O
discussed,O,O
.,O,O
Lethal,O,O
anuria,O,B
complicating,O,O
high,O,O
dose,O,O
ifosfamide,B,B
chemotherapy,O,O
in,O,O
a,O,O
breast,O,O
cancer,O,O
patient,O,O
with,O,O
an,O,O
impaired,O,O
renal,O,O
function,O,O
.,O,O
A,O,O
sixty,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
advanced,O,O
breast,O,O
cancer,O,O
",",O,O
previously,O,O
treated,O,O
with,O,O
cisplatin,B,B
",",O,O
developed,O,O
an,O,O
irreversible,O,O
lethal,O,O
renal,O,O
failure,O,O
with,O,O
anuria,O,B
",",O,O
the,O,O
day,O,O
after,O,O
5,O,O
g,O,O
/,O,O
m2,O,O
bolus,O,O
ifosfamide,B,B
.,O,O
Postrenal,O,O
failure,O,O
was,O,O
excluded,O,O
by,O,O
echography,O,O
.,O,O
A,O,O
prerenal,O,O
component,O,O
could,O,O
have,O,O
contributed,O,O
to,O,O
renal,O,O
failure,O,O
because,O,O
of,O,O
a,O,O
transient,O,O
hypotension,O,O
",",O,O
due,O,O
to,O,O
an,O,O
increasing,O,O
ascitis,O,O
",",O,O
occurring,O,O
just,O,O
before,O,O
anuria,O,O
.,O,O
However,O,O
",",O,O
correction,O,O
of,O,O
the,O,O
hemodynamic,O,O
parameters,O,O
did,O,O
not,O,O
improve,O,O
renal,O,O
function,O,O
.,O,O
Ifosfamide,B,B
is,O,O
a,O,O
known,O,O
nephrotoxic,O,O
drug,O,O
with,O,O
demonstrated,O,O
tubulopathies,O,O
.,O,O
We,O,O
strongly,O,O
suspect,O,O
that,O,O
this,O,O
lethal,O,O
anuria,O,O
was,O,O
mainly,O,O
due,O,O
to,O,O
ifosfamide,B,B
",",O,O
occurring,O,O
in,O,O
a,O,O
patient,O,O
having,O,O
received,O,O
previous,O,O
cisplatin,B,B
chemotherapy,O,O
and,O,O
with,O,O
poor,O,O
kidney,O,O
perfusion,O,O
due,O,O
to,O,O
transient,O,O
hypotension,O,O
.,O,O
We,O,O
recommend,O,O
careful,O,O
use,O,O
of,O,O
ifosfamide,B,B
in,O,O
patients,O,O
pretreated,O,O
with,O,O
nephrotoxic,O,O
chemotherapy,O,O
and,O,O
inadequate,O,O
renal,O,O
perfusion,O,O
.,O,O
Nociceptive,O,O
effects,O,O
induced,O,O
by,O,O
intrathecal,O,O
administration,O,O
of,O,O
prostaglandin,B,B
D2,I,I
",",I,O
E2,I,B
",",I,O
or,I,O
F2,I,B
alpha,I,I
to,O,O
conscious,O,O
mice,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
intrathecal,O,O
administration,O,O
of,O,O
prostaglandins,B,B
on,O,O
pain,O,O
responses,O,O
in,O,O
conscious,O,O
mice,O,O
were,O,O
evaluated,O,O
by,O,O
using,O,O
hot,O,O
plate,O,O
and,O,O
acetic,B,O
acid,I,O
writhing,O,O
tests,O,O
.,O,O
Prostaglandin,B,B
D2,I,I
(,O,O
0,O,O
.,O,O
5,O,O
-,O,O
3,O,O
ng,O,O
/,O,O
mouse,O,O
),O,O
had,O,O
a,O,O
hyperalgesic,O,O
action,O,O
on,O,O
the,O,O
response,O,O
to,O,O
a,O,O
hot,O,O
plate,O,O
during,O,O
a,O,O
3,O,O
-,O,O
60,O,O
min,O,O
period,O,O
after,O,O
injection,O,O
.,O,O
Prostaglandin,B,B
E2,I,I
showed,O,O
a,O,O
hyperalgesic,O,O
effect,O,O
at,O,O
doses,O,O
of,O,O
1,O,O
pg,B,O
to,O,O
10,O,O
ng,O,O
/,O,O
mouse,O,O
",",O,O
but,O,O
the,O,O
effect,O,O
lasted,O,O
shorter,O,O
(,O,O
3,O,O
-,O,O
30,O,O
min,O,O
),O,O
than,O,O
that,O,O
of,O,O
prostaglandin,B,B
D2,I,I
.,O,O
Similar,O,O
results,O,O
were,O,O
obtained,O,O
by,O,O
acetic,B,B
acid,I,I
writhing,O,I
tests,O,I
.,O,O
The,O,O
hyperalgesic,O,O
effect,O,O
of,O,O
prostaglandin,B,B
D2,I,I
was,O,O
blocked,O,O
by,O,O
simultaneous,O,O
injection,O,O
of,O,O
a,O,O
substance,O,O
P,O,O
antagonist,O,O
(,O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
100,O,O
ng,O,O
),O,O
but,O,O
not,O,O
by,O,O
AH6809,B,B
",",O,O
a,O,O
prostanoid,O,O
EP1,O,O
-,O,O
receptor,O,O
antagonist,O,O
.,O,O
Conversely,O,O
",",O,O
prostaglandin,B,B
E2,I,I
-,O,I
induced,O,O
hyperalgesia,O,O
was,O,O
blocked,O,O
by,O,O
AH6809,B,B
(,O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
500,O,O
ng,O,O
),O,O
but,O,O
not,O,O
by,O,O
the,O,O
substance,O,O
P,O,O
antagonist,O,O
.,O,O
Prostaglandin,B,B
F2,I,I
alpha,I,I
had,O,O
little,O,O
effect,O,O
on,O,O
pain,O,O
responses,O,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
that,O,O
both,O,O
prostaglandin,B,B
D2,I,I
and,O,O
prostaglandin,B,B
E2,I,I
exert,O,O
hyperalgesia,O,O
in,O,O
the,O,O
spinal,O,O
cord,O,O
",",O,O
but,O,O
in,O,O
different,O,O
ways,O,O
.,O,O
D,B,B
-,I,I
penicillamine,I,I
in,O,O
the,O,O
treatment,O,O
of,O,O
localized,O,O
scleroderma,O,O
.,O,O
Localized,O,B
scleroderma,O,I
has,O,O
no,O,O
recognized,O,O
internal,O,O
organ,O,O
involvement,O,O
but,O,O
may,O,O
be,O,O
disfiguring,O,O
and,O,O
disabling,O,O
when,O,O
the,O,O
cutaneous,O,O
lesions,O,O
are,O,O
extensive,O,O
or,O,O
affect,O,O
children,O,O
.,O,O
There,O,O
is,O,O
no,O,O
accepted,O,O
or,O,O
proven,O,O
treatment,O,O
for,O,O
localized,O,B
scleroderma,O,I
.,O,O
Case,O,O
reports,O,O
of,O,O
11,O,O
patients,O,O
with,O,O
severe,O,O
",",O,O
extensive,O,B
localized,O,I
scleroderma,O,I
who,O,O
were,O,O
treated,O,O
with,O,O
D,B,B
-,I,I
penicillamine,I,I
are,O,O
summarized,O,O
in,O,O
this,O,O
article,O,O
.,O,O
This,O,O
drug,O,O
was,O,O
judged,O,O
to,O,O
have,O,O
a,O,O
favorable,O,O
effect,O,O
on,O,O
the,O,O
disease,O,O
course,O,O
in,O,O
7,O,O
(,O,O
64,O,O
%,O,O
),O,O
of,O,O
11,O,O
patients,O,O
.,O,O
Improvement,O,O
began,O,O
within,O,O
3,O,O
to,O,O
6,O,O
months,O,O
and,O,O
consisted,O,O
of,O,O
cessation,O,O
of,O,O
active,O,O
cutaneous,O,O
lesions,O,O
in,O,O
all,O,O
7,O,O
patients,O,O
",",O,O
skin,O,O
softening,O,O
in,O,O
5,O,O
",",O,O
and,O,O
more,O,O
normal,O,O
growth,O,O
of,O,O
the,O,O
affected,O,O
limb,O,O
in,O,O
2,O,O
of,O,O
3,O,O
children,O,O
.,O,O
Joint,O,O
stiffness,O,O
and,O,O
contractures,O,O
also,O,O
improved,O,O
.,O,O
The,O,O
dose,O,O
of,O,O
D,B,B
-,I,I
penicillamine,I,I
associated,O,O
with,O,O
a,O,O
favorable,O,O
response,O,O
was,O,O
as,O,O
low,O,O
as,O,O
2,O,O
to,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
per,O,O
day,O,O
given,O,O
over,O,O
a,O,O
period,O,O
ranging,O,O
from,O,O
15,O,O
to,O,O
53,O,O
months,O,O
.,O,O
D,B,B
-,I,I
Penicillamine,I,I
caused,O,O
nephrotic,O,O
syndrome,O,O
in,O,O
1,O,O
patient,O,O
and,O,O
milder,O,O
reversible,O,O
proteinuria,O,O
in,O,O
3,O,O
other,O,O
patients,O,O
;,O,O
none,O,O
developed,O,O
renal,O,O
insufficiency,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
D,B,B
-,I,I
penicillamine,I,I
may,O,O
be,O,O
effective,O,O
in,O,O
severe,O,O
cases,O,O
of,O,O
localized,O,O
scleroderma,O,O
.,O,O
Cerebral,O,B
sinus,O,I
thrombosis,O,I
as,O,O
a,O,O
potential,O,O
hazard,O,O
of,O,O
antifibrinolytic,O,O
treatment,O,O
in,O,O
menorrhagia,O,O
.,O,O
We,O,O
describe,O,O
a,O,O
42,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
who,O,O
developed,O,O
superior,O,B
sagittal,O,I
and,O,O
left,O,B
transverse,O,I
sinus,O,I
thrombosis,O,I
associated,O,O
with,O,O
prolonged,O,O
epsilon,B,B
-,I,I
aminocaproic,I,I
acid,I,I
therapy,O,O
for,O,O
menorrhagia,O,O
.,O,O
This,O,O
antifibrinolytic,O,O
agent,O,O
has,O,O
been,O,O
used,O,O
in,O,O
women,O,O
with,O,O
menorrhagia,O,O
to,O,O
promote,O,O
clotting,O,O
and,O,O
reduce,O,O
blood,O,O
loss,O,O
.,O,O
Although,O,O
increased,O,O
risk,O,O
of,O,O
thromboembolic,O,O
disease,O,O
has,O,O
been,O,O
reported,O,O
during,O,O
treatment,O,O
with,O,O
epsilon,B,B
-,I,I
aminocaproic,I,I
acid,I,I
",",O,O
cerebral,O,B
sinus,O,I
thrombosis,O,I
has,O,O
not,O,O
been,O,O
previously,O,O
described,O,O
.,O,O
Careful,O,O
use,O,O
of,O,O
epsilon,B,B
-,I,I
aminocaproic,I,I
acid,I,I
therapy,O,O
is,O,O
recommended,O,O
.,O,O
Seizure,O,O
activity,O,O
with,O,O
imipenem,B,B
therapy,O,O
:,O,O
incidence,O,O
and,O,O
risk,O,O
factors,O,O
.,O,O
Two,O,O
elderly,O,O
patients,O,O
with,O,O
a,O,O
history,O,O
of,O,O
either,O,O
cerebral,O,O
vascular,O,O
accident,O,O
(,O,O
CVA,O,B
),O,O
or,O,O
head,O,O
trauma,O,O
and,O,O
no,O,O
evidence,O,O
of,O,O
renal,O,O
disease,O,O
developed,O,O
seizures,O,O
while,O,O
receiving,O,O
maximum,O,O
doses,O,O
of,O,O
imipenem,B,B
/,I,O
cilastatin,I,B
.,O,O
Neither,O,O
patient,O,O
had,O,O
reported,O,O
previous,O,O
seizures,O,O
or,O,O
seizure,O,O
-,O,O
like,O,O
activity,O,O
nor,O,O
was,O,O
receiving,O,O
anticonvulsant,O,O
agents,O,O
.,O,O
All,O,O
seizures,O,O
were,O,O
controlled,O,O
with,O,O
therapeutic,O,O
doses,O,O
of,O,O
phenytoin,B,B
.,O,O
Both,O,O
patients,O,O
had,O,O
received,O,O
maximum,O,O
doses,O,O
of,O,O
other,O,O
beta,B,O
-,I,O
lactam,I,O
antibiotics,O,O
without,O,O
evidence,O,O
of,O,O
seizure,O,O
activity,O,O
.,O,O
Midline,O,O
B3,O,O
serotonin,B,O
nerves,O,O
in,O,O
rat,O,O
medulla,O,O
are,O,O
involved,O,O
in,O,O
hypotensive,O,O
effect,O,O
of,O,O
methyldopa,B,B
.,O,O
Previous,O,O
experiments,O,O
in,O,O
this,O,O
laboratory,O,O
have,O,O
shown,O,O
that,O,O
microinjection,O,O
of,O,O
methyldopa,B,B
onto,O,O
the,O,O
ventrolateral,O,O
cells,O,O
of,O,O
the,O,O
B3,O,O
serotonin,B,B
neurons,O,O
in,O,O
the,O,O
medulla,O,O
elicits,O,O
a,O,O
hypotensive,O,O
response,O,O
mediated,O,O
by,O,O
a,O,O
projection,O,O
descending,O,O
into,O,O
the,O,O
spinal,O,B
cord,O,I
.,O,O
The,O,O
present,O,O
experiments,O,O
were,O,O
designed,O,O
to,O,O
investigate,O,O
the,O,O
role,O,O
of,O,O
the,O,O
midline,O,O
cells,O,O
of,O,O
the,O,O
B3,O,O
serotonin,B,B
neurons,O,O
in,O,O
the,O,O
medulla,O,O
",",O,O
coinciding,O,O
with,O,O
the,O,O
raphe,O,O
magnus,O,O
.,O,O
In,O,O
spontaneously,O,O
hypertensive,O,O
",",O,O
stroke,O,O
-,O,O
prone,O,O
rats,O,O
",",O,O
microinjection,O,O
of,O,O
methyldopa,B,B
into,O,O
the,O,O
area,O,O
of,O,O
the,O,O
midline,O,O
B3,O,O
serotonin,B,O
cell,O,O
group,O,O
in,O,O
the,O,O
ventral,O,O
medulla,O,O
caused,O,O
a,O,O
potent,O,O
hypotension,O,O
of,O,O
30,O,O
-,O,O
40,O,O
mm,O,O
Hg,O,O
",",O,O
which,O,O
was,O,O
maximal,O,O
2,O,O
-,O,O
3,O,O
h,O,O
after,O,O
administration,O,O
and,O,O
was,O,O
abolished,O,O
by,O,O
the,O,O
serotonin,B,O
neurotoxin,O,O
5,B,B
",",I,O
7,I,I
-,I,I
dihydroxytryptamine,I,I
(,O,I
5,B,I
",",I,I
7,I,I
-,I,I
DHT,I,I
),O,I
injected,O,O
intracerebroventricularly,O,O
.,O,O
However,O,O
",",O,O
intraspinal,O,O
injection,O,O
of,O,O
5,B,B
",",I,O
7,I,I
-,I,I
DHT,I,I
to,O,O
produce,O,O
a,O,O
more,O,O
selective,O,O
lesion,O,O
of,O,O
only,O,O
descending,O,O
serotonin,B,B
projections,O,O
in,O,O
the,O,O
spinal,O,O
cord,O,O
did,O,O
not,O,O
affect,O,O
this,O,O
hypotension,O,O
.,O,O
Further,O,O
",",O,O
5,B,B
",",I,O
7,I,I
-,I,I
DHT,I,I
lesion,O,O
of,O,O
serotonin,B,B
nerves,O,O
travelling,O,O
in,O,O
the,O,O
median,O,O
forebrain,O,O
bundle,O,O
",",O,O
one,O,O
of,O,O
the,O,O
main,O,O
ascending,O,O
pathways,O,O
from,O,O
the,O,O
B3,O,O
serotonin,B,B
cells,O,O
",",O,O
did,O,O
not,O,O
affect,O,O
the,O,O
fall,O,O
in,O,O
blood,O,O
pressure,O,O
associated,O,O
with,O,O
a,O,O
midline,O,O
B3,O,O
serotonin,B,B
methyldopa,B,O
injection,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
therefore,O,O
that,O,O
",",O,O
unlike,O,O
the,O,O
ventrolateral,O,O
B3,O,O
cells,O,O
which,O,O
mediate,O,O
a,O,O
methyldopa,B,B
-,O,O
induced,O,O
hypotension,O,O
via,O,O
descending,O,O
projections,O,O
",",O,O
the,O,O
midline,O,O
serotonin,B,B
B3,O,O
cells,O,O
in,O,O
the,O,O
medulla,O,O
contribute,O,O
to,O,O
the,O,O
hypotensive,O,O
action,O,O
of,O,O
methyldopa,B,B
",",O,O
either,O,O
by,O,O
way,O,O
of,O,O
an,O,O
ascending,O,O
projection,O,O
which,O,O
does,O,O
not,O,O
pass,O,O
through,O,O
the,O,O
median,O,O
forebrain,O,O
bundle,O,O
",",O,O
or,O,O
through,O,O
a,O,O
projection,O,O
restricted,O,O
to,O,O
the,O,O
caudal,O,O
brainstem,O,O
.,O,O
Antiarrhythmic,O,O
plasma,O,O
concentrations,O,O
of,O,O
cibenzoline,B,B
on,O,O
canine,O,O
ventricular,O,O
arrhythmias,O,O
.,O,O
Using,O,O
two,O,O
-,O,O
stage,O,O
coronary,O,O
ligation,O,O
-,O,O
",",O,O
digitalis,B,B
-,O,O
",",O,O
and,O,O
adrenaline,B,B
-,O,O
induced,O,O
canine,O,O
ventricular,O,O
arrhythmias,O,O
",",O,O
antiarrhythmic,O,O
effects,O,O
of,O,O
cibenzoline,B,B
were,O,O
examined,O,O
and,O,O
the,O,O
minimum,O,O
effective,O,O
plasma,O,O
concentration,O,O
for,O,O
each,O,O
arrhythmia,O,O
model,O,O
was,O,O
determined,O,O
.,O,O
Cibenzoline,B,B
suppressed,O,O
all,O,O
the,O,O
arrhythmias,O,O
",",O,O
and,O,O
the,O,O
minimum,O,O
effective,O,O
plasma,O,O
concentrations,O,O
for,O,O
arrhythmias,O,O
induced,O,O
by,O,O
24,O,O
-,O,O
h,O,O
coronary,O,O
ligation,O,O
",",O,O
48,O,O
-,O,O
h,O,O
coronary,O,O
ligation,O,O
",",O,O
digitalis,B,B
",",O,O
and,O,O
adrenaline,B,B
were,O,O
1,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
(,O,O
by,O,O
8,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
",",O,O
1,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
(,O,O
by,O,O
8,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
",",O,O
0,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
by,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
",",O,O
and,O,O
3,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
3,O,O
(,O,O
by,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
micrograms,O,O
/,O,O
ml,O,O
",",O,O
respectively,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SDM,O,O
",",O,O
n,O,O
=,O,O
6,O,O
-,O,O
7,O,O
),O,O
.,O,O
The,O,O
concentration,O,O
for,O,O
adrenaline,B,B
-,O,O
induced,O,O
arrhythmia,O,O
was,O,O
significantly,O,O
higher,O,O
than,O,O
those,O,O
for,O,O
the,O,O
other,O,O
types,O,O
of,O,O
arrhythmias,O,O
.,O,O
This,O,O
pharmacological,O,O
profile,O,O
is,O,O
similar,O,O
to,O,O
those,O,O
of,O,O
mexiletine,B,B
and,O,O
tocainide,B,B
",",O,O
and,O,O
all,O,O
three,O,O
drugs,O,O
have,O,O
central,O,O
nervous,O,O
system,O,O
(,O,O
CNS,O,B
),O,O
stimulant,O,O
action,O,O
.,O,O
Because,O,O
cibenzoline,B,B
had,O,O
only,O,O
weak,O,O
hypotensive,O,O
and,O,O
sinus,O,B
node,O,I
depressive,O,I
effects,O,O
and,O,O
was,O,O
found,O,O
to,O,O
be,O,O
orally,O,O
active,O,O
when,O,O
given,O,O
to,O,O
coronary,O,O
ligation,O,O
arrhythmia,O,O
dogs,O,O
",",O,O
its,O,O
clinical,O,O
usefulness,O,O
is,O,O
expected,O,O
.,O,O
Continuous,O,O
ambulatory,O,O
ECG,O,B
monitoring,O,O
during,O,O
fluorouracil,B,B
therapy,O,O
:,O,O
a,O,O
prospective,O,O
study,O,O
.,O,O
Although,O,O
there,O,O
have,O,O
been,O,O
anecdotal,O,O
reports,O,O
of,O,O
cardiac,O,O
toxicity,O,O
associated,O,O
with,O,O
fluorouracil,B,B
(,O,I
5,B,I
-,I,I
FU,I,I
),O,I
therapy,O,O
",",O,O
this,O,O
phenomenon,O,O
has,O,O
not,O,O
been,O,O
studied,O,O
in,O,O
a,O,O
systematic,O,O
fashion,O,O
.,O,O
We,O,O
prospectively,O,O
performed,O,O
continuous,O,O
ambulatory,O,O
ECG,O,O
monitoring,O,O
on,O,O
25,O,O
patients,O,O
undergoing,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
for,O,O
treatment,O,O
of,O,O
solid,O,O
tumors,O,O
in,O,O
order,O,O
to,O,O
assess,O,O
the,O,O
incidence,O,O
of,O,O
ischemic,O,O
ST,O,O
changes,O,O
.,O,O
Patients,O,O
were,O,O
monitored,O,O
for,O,O
23,O,O
+,O,O
/,O,O
-,O,O
4,O,O
hours,O,O
before,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
",",O,O
and,O,O
98,O,O
+,O,O
/,O,O
-,O,O
9,O,O
hours,O,O
during,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
.,O,O
Anginal,O,B
episodes,O,O
were,O,O
rare,O,O
:,O,O
only,O,O
one,O,O
patient,O,O
had,O,O
angina,O,B
(,O,O
during,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
),O,O
.,O,O
However,O,O
",",O,O
asymptomatic,O,O
ST,O,B
changes,O,O
(,O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
1,O,O
mm,O,O
ST,O,B
deviation,O,O
),O,O
were,O,O
common,O,O
:,O,O
six,O,O
of,O,O
25,O,O
patients,O,O
(,O,O
24,O,O
%,O,O
),O,O
had,O,O
ST,O,B
changes,O,O
before,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
v,O,O
17,O,O
(,O,O
68,O,O
%,O,O
),O,O
during,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,I
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
ischemic,O,B
episodes,O,O
per,O,O
patient,O,O
per,O,O
hour,O,O
was,O,O
0,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
prior,O,O
to,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,O
v,O,O
0,O,O
.,O,O
13,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
during,O,O
5,B,B
-,I,I
FU,I,I
infusion,O,O
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
;,O,O
the,O,O
duration,O,O
of,O,O
ECG,O,B
changes,O,O
was,O,O
0,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
minutes,O,O
per,O,O
patient,O,O
per,O,O
hour,O,O
before,O,O
5,B,B
-,I,I
FU,I,I
v,O,O
1,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
minutes,O,O
per,O,O
patient,O,O
per,O,O
hour,O,O
during,O,O
5,B,B
-,I,I
FU,I,I
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
.,O,O
ECG,O,O
changes,O,O
were,O,O
more,O,O
common,O,O
among,O,O
patients,O,O
with,O,O
known,O,O
coronary,O,B
artery,O,I
disease,O,I
.,O,O
There,O,O
were,O,O
two,O,O
cases,O,O
of,O,O
sudden,O,O
death,O,O
",",O,O
both,O,O
of,O,O
which,O,O
occurred,O,O
at,O,O
the,O,O
end,O,O
of,O,O
the,O,O
chemotherapy,O,O
course,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
5,B,O
-,I,O
FU,I,B
infusion,O,O
is,O,O
associated,O,O
with,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
silent,O,O
ST,O,B
segment,O,I
deviation,O,I
suggestive,O,O
of,O,O
ischemia,O,O
",",O,O
particularly,O,O
among,O,O
patients,O,O
with,O,O
coronary,O,B
artery,O,I
disease,O,I
.,O,O
The,O,O
mechanism,O,O
and,O,O
clinical,O,O
significance,O,O
of,O,O
these,O,O
ECG,O,O
changes,O,O
remain,O,O
to,O,O
be,O,O
determined,O,O
.,O,O
Nature,O,O
",",O,O
time,O,O
course,O,O
and,O,O
dose,O,O
dependence,O,O
of,O,O
zidovudine,B,B
-,O,O
related,O,O
side,O,O
effects,O,O
:,O,O
results,O,O
from,O,O
the,O,O
Multicenter,O,O
Canadian,O,O
Azidothymidine,B,B
Trial,O,O
.,O,O
To,O,O
characterize,O,O
the,O,O
nature,O,O
",",O,O
time,O,O
course,O,O
and,O,O
dose,O,O
dependency,O,O
of,O,O
zidovudine,B,B
-,O,O
related,O,O
side,O,O
effects,O,O
",",O,O
we,O,O
undertook,O,O
a,O,O
multicenter,O,O
",",O,O
prospective,O,O
",",O,O
dose,O,O
-,O,O
range,O,O
finding,O,O
study,O,O
.,O,O
Our,O,O
study,O,O
group,O,O
consisted,O,O
of,O,O
74,O,O
HIV,O,B
-,O,O
positive,O,O
homosexual,O,O
men,O,O
belonging,O,O
to,O,O
groups,O,O
II,O,O
B,O,O
",",O,O
III,O,O
and,O,O
IV,O,O
C2,O,O
from,O,O
the,O,O
Centers,O,O
for,O,O
Disease,O,O
Control,O,O
(,O,O
CDC,O,B
),O,O
classification,O,O
of,O,O
HIV,O,B
disease,O,O
.,O,O
Following,O,O
a,O,O
3,O,O
-,O,O
week,O,O
observation,O,O
period,O,O
",",O,O
volunteers,O,O
were,O,O
treated,O,O
with,O,O
zidovudine,B,B
600,O,O
mg,O,O
/,O,O
day,O,O
for,O,O
18,O,O
weeks,O,O
",",O,O
900,O,O
mg,O,O
/,O,O
day,O,O
for,O,O
9,O,O
weeks,O,O
and,O,O
1200,O,O
mg,O,O
/,O,O
day,O,O
for,O,O
9,O,O
weeks,O,O
",",O,O
followed,O,O
by,O,O
a,O,O
washout,O,O
period,O,O
of,O,O
6,O,O
weeks,O,O
after,O,O
which,O,O
they,O,O
were,O,O
re,O,O
-,O,O
started,O,O
on,O,O
1200,O,O
mg,O,O
/,O,O
day,O,O
or,O,O
the,O,O
highest,O,O
tolerated,O,O
dose,O,O
at,O,O
8,O,O
-,O,O
hourly,O,O
intervals,O,O
.,O,O
Subjects,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
4,O,O
-,O,O
hourly,O,O
or,O,O
8,O,O
-,O,O
hourly,O,O
regimens,O,O
within,O,O
CDC,O,B
groups,O,O
while,O,O
taking,O,O
600,O,B
and,O,O
1200,O,B
mg,O,I
/,O,I
day,O,I
.,O,O
Clinical,O,O
and,O,O
laboratory,O,O
evaluations,O,O
were,O,O
performed,O,O
at,O,O
3,O,O
-,O,O
week,O,O
intervals,O,O
.,O,O
Symptomatic,O,O
adverse,O,O
effects,O,O
were,O,O
present,O,O
in,O,O
96,O,B
%,O,I
of,O,O
subjects,O,O
",",O,O
most,O,O
commonly,O,O
nausea,O,B
(,O,O
64,O,B
%,O,I
),O,I
",",O,O
fatigue,O,B
(,O,O
55,O,B
%,O,I
),O,I
and,O,O
headache,O,B
(,O,O
49,O,B
%,O,I
),O,I
.,O,O
These,O,O
were,O,O
generally,O,O
self,O,O
-,O,O
limited,O,O
",",O,O
reappearing,O,O
briefly,O,O
at,O,O
each,O,O
dose,O,O
increment,O,O
.,O,O
A,O,O
decrease,O,O
in,O,O
hemoglobin,O,B
occurred,O,O
shortly,O,O
after,O,O
initiation,O,O
of,O,O
therapy,O,O
.,O,O
This,O,O
was,O,O
not,O,O
dose,O,O
dependent,O,O
and,O,O
reversed,O,O
rapidly,O,O
upon,O,O
discontinuation,O,O
of,O,O
treatment,O,O
.,O,O
A,O,O
red,O,B
blood,O,I
cell,O,I
count,O,I
decrease,O,O
",",O,O
a,O,O
mean,O,O
cell,O,O
volume,O,O
increase,O,O
and,O,O
a,O,O
granulocyte,O,B
count,O,I
decrease,O,O
developed,O,O
early,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
independent,O,O
fashion,O,O
",",O,O
reverting,O,O
at,O,O
least,O,O
partially,O,O
during,O,O
the,O,O
washout,O,O
phase,O,O
.,O,O
The,O,O
decrease,O,O
in,O,O
reticulocyte,O,B
count,O,O
was,O,O
dose,O,O
related,O,O
between,O,O
600,O,O
and,O,O
900,O,O
mg,O,O
/,O,O
day,O,O
with,O,O
no,O,O
further,O,O
change,O,O
when,O,O
the,O,O
dose,O,O
was,O,O
escalated,O,O
to,O,O
1200,O,O
mg,O,O
/,O,O
day,O,O
.,O,O
Bone,O,B
marrow,O,I
changes,O,O
occurred,O,O
rapidly,O,O
as,O,O
demonstrated,O,O
by,O,O
megaloblastosis,O,B
in,O,O
95,O,O
%,O,O
of,O,O
65,O,O
specimens,O,O
at,O,O
week,O,O
18,O,O
.,O,O
(,O,O
ABSTRACT,O,B
TRUNCATED,O,I
AT,O,I
250,O,I
WORDS,O,I
),O,O
National,O,B
project,O,I
on,O,I
the,O,I
prevention,O,I
of,O,I
mother,O,I
-,O,I
to,O,I
-,O,I
infant,O,I
infection,O,I
by,O,I
hepatitis,O,B
B,O,I
virus,O,I
in,O,I
Japan,O,I
.,O,O
In,O,O
Japan,O,O
",",O,O
a,O,O
nationwide,O,O
prevention,O,O
program,O,O
against,O,O
mother,O,O
-,O,O
to,O,O
-,O,O
infant,O,O
infection,O,O
by,O,O
hepatitis,O,B
B,O,I
virus,O,I
(,O,O
HBV,O,B
),O,O
started,O,O
in,O,O
1985,O,O
.,O,O
This,O,O
program,O,O
consists,O,O
of,O,O
double,O,O
screenings,O,O
of,O,O
pregnant,O,O
women,O,O
and,O,O
prophylactic,O,O
treatment,O,O
to,O,O
the,O,O
infants,O,O
born,O,O
to,O,O
both,O,O
hepatitis,B,B
B,I,I
surface,I,I
antigen,I,I
(,O,O
HBsAg,B,B
),O,O
and,O,O
hepatitis,B,B
B,I,I
e,I,I
antigen,I,I
(,O,O
HBeAg,B,B
),O,O
positive,O,O
mothers,O,O
.,O,O
These,O,O
infants,O,O
are,O,O
treated,O,O
with,O,O
two,O,O
injections,O,O
of,O,O
hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
(,O,O
HBIG,O,B
),O,O
and,O,O
at,O,O
least,O,O
three,O,O
injections,O,O
of,O,O
plasma,O,B
derived,O,I
hepatitis,B,B
B,I,I
vaccine,I,I
.,O,O
We,O,O
sent,O,O
questionnaires,O,O
about,O,O
the,O,O
numbers,O,O
of,O,O
each,O,O
procedure,O,O
or,O,O
examination,O,O
during,O,O
nine,O,O
months,O,O
of,O,O
investigation,O,O
period,O,O
to,O,O
each,O,O
local,O,O
government,O,O
in,O,O
1986,O,O
and,O,O
1987,O,O
.,O,O
93,O,O
.,O,O
4,O,O
%,O,O
pregnant,O,O
women,O,O
had,O,O
the,O,O
chance,O,O
to,O,O
be,O,O
examined,O,O
for,O,O
HBsAg,B,B
",",O,O
and,O,O
the,O,O
positive,O,O
rate,O,O
was,O,O
1,O,O
.,O,O
4,O,O
to,O,O
1,O,O
.,O,O
5,O,O
%,O,O
.,O,O
The,O,O
HBeAg,B,B
positive,O,O
rate,O,O
in,O,O
HBsAg,B,B
positive,O,O
was,O,O
23,O,O
to,O,O
26,O,O
%,O,O
.,O,O
The,O,O
HBsAg,B,B
positive,O,O
rate,O,O
in,O,O
neonates,O,O
and,O,O
in,O,O
infants,O,O
before,O,O
two,O,O
months,O,O
were,O,O
3,O,O
%,O,O
and,O,O
2,O,O
%,O,O
respectively,O,O
.,O,O
Some,O,O
problems,O,O
may,O,O
arise,O,O
",",O,O
because,O,O
27,O,O
to,O,O
30,O,O
%,O,O
of,O,O
infants,O,O
need,O,O
the,O,O
fourth,O,O
vaccination,O,O
in,O,O
some,O,O
restricted,O,O
areas,O,O
.,O,O
Involvement,O,O
of,O,O
the,O,O
mu,O,B
-,O,O
opiate,O,O
receptor,O,O
in,O,O
peripheral,O,O
analgesia,O,O
.,O,O
The,O,O
intradermal,O,O
injection,O,O
of,O,O
mu,O,B
(,O,O
morphine,B,B
",",O,O
Tyr,B,B
-,I,O
D,I,I
-,I,I
Ala,I,I
-,I,I
Gly,I,I
-,I,I
NMe,I,I
-,I,I
Phe,I,I
-,I,I
Gly,I,I
-,I,I
ol,I,I
and,O,O
morphiceptin,B,B
),O,O
",",O,O
kappa,O,B
(,O,O
trans,B,B
-,I,I
3,I,I
",",I,I
4,I,I
-,I,I
dichloro,I,I
-,I,I
N,I,I
-,I,I
methyl,I,I
-,I,I
N,I,I
[,I,I
2,I,I
-,I,I
(,I,I
1,I,I
-,I,I
pyrrolidinyl,I,I
),I,I
cyclohexyl,I,I
],I,I
benzeneactemide,I,I
),O,O
and,O,O
delta,O,B
(,O,O
[,B,O
D,I,I
-,I,I
Pen2,I,I
.,I,I
5,I,O
],I,O
-,I,O
enkephalin,I,B
and,O,O
[,B,O
D,I,B
-,I,I
Ser2,I,I
],I,I
-,I,I
[,I,I
Leu,I,I
],I,I
enkephalin,I,I
-,I,O
Thr,I,O
selective,O,O
opioid,O,O
-,O,O
agonists,O,O
",",O,O
by,O,O
themselves,O,O
",",O,O
did,O,O
not,O,O
significantly,O,O
affect,O,O
the,O,O
mechanical,O,O
nociceptive,O,O
threshold,O,O
in,O,O
the,O,O
hindpaw,O,O
of,O,O
the,O,O
rat,O,O
.,O,O
Intradermal,O,O
injection,O,O
of,O,O
mu,O,B
",",O,O
but,O,O
not,O,O
delta,O,B
or,O,O
kappa,O,B
opioid,O,I
-,O,I
agonists,O,I
",",O,O
however,O,O
",",O,O
produced,O,O
dose,O,O
-,O,O
dependent,O,O
inhibition,O,O
of,O,O
prostaglandin,B,B
E2,I,I
-,O,I
induced,O,I
hyperalgesia,O,I
.,O,O
The,O,O
analgesic,O,O
effect,O,O
of,O,O
the,O,O
mu,O,B
-,O,O
agonist,O,O
morphine,B,B
was,O,O
dose,O,O
-,O,O
dependently,O,O
antagonized,O,O
by,O,O
naloxone,B,B
and,O,O
prevented,O,O
by,O,O
co,O,O
-,O,O
injection,O,O
of,O,O
pertussis,O,B
toxin,O,I
.,O,O
Morphine,B,B
did,O,O
not,O,O
",",O,O
however,O,O
",",O,O
alter,O,O
the,O,O
hyperalgesia,O,O
induced,O,O
by,O,O
8,B,O
-,I,O
bromo,I,B
cyclic,I,I
adenosine,I,I
monophosphate,I,I
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
analgesic,O,O
action,O,O
of,O,O
opioids,O,B
on,O,O
the,O,O
peripheral,O,O
terminals,O,O
of,O,O
primary,O,O
afferents,O,O
is,O,O
via,O,O
a,O,O
binding,O,O
site,O,O
with,O,O
characteristics,O,O
of,O,O
the,O,O
mu,O,B
-,O,O
opioid,O,I
receptor,O,I
and,O,O
that,O,O
this,O,O
action,O,O
is,O,O
mediated,O,O
by,O,O
inhibition,O,O
of,O,O
the,O,O
cyclic,B,B
adenosine,I,I
monophosphate,I,I
second,O,I
messenger,O,I
system,O,I
.,O,O
Involvement,O,O
of,O,O
locus,O,B
coeruleus,O,I
and,O,O
noradrenergic,O,B
neurotransmission,O,I
in,O,O
fentanyl,B,B
-,O,O
induced,O,O
muscular,O,O
rigidity,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Whereas,O,O
muscular,O,O
rigidity,O,O
is,O,O
a,O,O
well,O,O
-,O,O
known,O,O
side,O,O
effect,O,O
that,O,O
is,O,O
associated,O,O
with,O,O
high,O,O
-,O,O
dose,O,O
fentanyl,B,B
anesthesia,O,O
",",O,O
a,O,O
paucity,O,O
of,O,O
information,O,O
exists,O,O
with,O,O
regard,O,O
to,O,O
its,O,O
underlying,O,O
mechanism,O,O
(,O,O
s,O,O
),O,O
.,O,O
We,O,O
investigated,O,O
in,O,O
this,O,O
study,O,O
the,O,O
possible,O,O
engagement,O,O
of,O,O
locus,O,B
coeruleus,O,I
of,O,I
the,O,I
pons,O,I
in,O,O
this,O,O
phenomenon,O,O
",",O,O
using,O,O
male,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
anesthetized,O,O
with,O,O
ketamine,B,B
.,O,O
Under,O,O
proper,O,O
control,O,O
of,O,O
respiration,O,O
",",O,O
body,O,O
temperature,O,O
and,O,O
end,O,O
-,O,O
tidal,O,O
CO2,B,B
",",O,O
intravenous,O,O
administration,O,O
of,O,O
fentanyl,B,B
(,O,O
50,O,O
or,O,O
100,O,O
micrograms,O,O
/,O,O
kg,O,O
),O,O
consistently,O,O
promoted,O,O
an,O,O
increase,O,O
in,O,O
electromyographic,O,O
activity,O,O
recorded,O,O
from,O,O
the,O,O
gastrocnemius,O,B
and,O,O
abdominal,O,B
rectus,O,I
muscles,O,O
.,O,O
Such,O,O
an,O,O
induced,O,O
muscular,O,O
rigidity,O,O
by,O,O
the,O,O
narcotic,O,B
agent,O,O
was,O,O
significantly,O,O
antagonized,O,O
or,O,O
even,O,O
reduced,O,O
by,O,O
prior,O,O
electrolytic,O,O
lesions,O,O
of,O,O
the,O,O
locus,O,O
coeruleus,O,O
or,O,O
pretreatment,O,O
with,O,O
the,O,O
alpha,O,B
-,O,I
adrenoceptor,O,I
blocker,O,O
",",O,O
prazosin,B,B
.,O,O
Microinjection,O,O
of,O,O
fentanyl,B,B
(,O,O
2,O,O
.,O,O
5,O,O
micrograms,O,O
/,O,O
50,O,O
nl,O,O
),O,O
directly,O,O
into,O,O
this,O,O
pontine,O,O
nucleus,O,O
",",O,O
on,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
elicited,O,O
discernible,O,O
electromyographic,O,O
excitation,O,O
.,O,O
It,O,O
is,O,O
speculated,O,O
that,O,O
the,O,O
induction,O,O
of,O,O
muscular,O,O
rigidity,O,O
by,O,O
fentanyl,B,B
may,O,O
involve,O,O
the,O,O
coerulospinal,O,O
noradrenergic,O,O
fibers,O,O
to,O,O
the,O,O
spinal,O,O
motoneurons,O,O
.,O,O
Dexmedetomidine,B,B
",",O,O
acting,O,O
through,O,O
central,O,O
alpha,O,B
-,O,I
2,O,I
adrenoceptors,O,I
",",O,O
prevents,O,O
opiate,O,O
-,O,O
induced,O,O
muscle,O,O
rigidity,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
The,O,O
highly,O,O
-,O,O
selective,O,O
alpha,O,B
-,O,I
2,O,I
adrenergic,O,I
agonist,O,O
dexmedetomidine,B,B
(,O,O
D,B,B
-,I,I
MED,I,I
),O,O
is,O,O
capable,O,O
of,O,O
inducing,O,O
muscle,O,O
flaccidity,O,O
and,O,O
anesthesia,O,O
in,O,O
rats,O,O
and,O,O
dogs,O,O
.,O,O
Intense,O,O
generalized,O,O
muscle,O,O
rigidity,O,O
is,O,O
an,O,O
undesirable,O,O
side,O,O
effect,O,O
of,O,O
potent,O,O
opiate,O,B
agonists,O,O
.,O,O
Although,O,O
the,O,O
neurochemistry,O,O
of,O,O
opiate,O,B
-,O,O
induced,O,O
rigidity,O,O
has,O,O
yet,O,O
to,O,O
be,O,O
fully,O,O
elucidated,O,O
",",O,O
recent,O,O
work,O,O
suggests,O,O
a,O,O
role,O,O
for,O,O
a,O,O
central,O,O
adrenergic,O,B
mechanism,O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
the,O,O
authors,O,O
determined,O,O
if,O,O
treatment,O,O
with,O,O
D,B,B
-,I,I
MED,I,I
prevents,O,O
the,O,O
muscle,O,O
rigidity,O,O
caused,O,O
by,O,O
high,O,O
-,O,O
dose,O,O
alfentanil,B,B
anesthesia,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Animals,O,O
(,O,O
n,O,O
=,O,O
42,O,O
),O,O
were,O,O
treated,O,O
intraperitoneally,O,O
with,O,O
one,O,O
of,O,O
the,O,O
following,O,O
six,O,O
regimens,O,O
:,O,O
1,O,O
),O,O
L,O,B
-,O,I
MED,O,I
(,O,O
the,O,O
inactive,O,O
L,O,B
-,O,I
isomer,O,I
of,O,O
medetomidine,B,B
),O,O
",",O,O
30,O,O
micrograms,O,O
/,O,O
kg,O,O
;,O,O
2,O,O
),O,O
D,B,B
-,I,I
MED,I,I
",",O,O
10,O,O
micrograms,O,O
/,O,O
kg,O,O
;,O,O
3,O,O
),O,O
D,B,B
-,I,I
MED,I,I
",",O,O
30,O,O
micrograms,O,O
/,O,O
kg,O,O
;,O,O
4,O,O
),O,O
D,B,B
-,I,I
MED,I,I
[,O,O
30,O,O
micrograms,O,O
/,O,O
kg,O,O
],O,O
and,O,O
the,O,O
central,O,O
-,O,O
acting,O,O
alpha,O,B
-,O,I
2,O,I
antagonist,O,I
",",O,O
idazoxan,B,B
[,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
],O,O
;,O,O
5,O,O
),O,O
D,B,B
-,I,I
MED,I,I
[,O,O
30,O,O
micrograms,O,O
/,O,O
kg,O,O
],O,O
and,O,O
the,O,O
peripheral,O,O
-,O,O
acting,O,O
alpha,O,B
-,O,I
2,O,I
antagonist,O,I
DG,B,B
-,I,I
5128,I,I
[,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
],O,O
",",O,O
or,O,O
;,O,O
6,O,O
),O,O
saline,O,B
Baseline,O,O
electromyographic,O,O
activity,O,O
was,O,O
recorded,O,O
from,O,O
the,O,O
gastrocnemius,O,B
muscle,O,I
before,O,O
and,O,O
after,O,O
drug,O,O
treatment,O,O
.,O,O
Each,O,O
rat,O,O
was,O,O
then,O,O
injected,O,O
with,O,O
alfentanil,B,B
(,O,O
ALF,B,B
",",O,O
0,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
sc,O,O
),O,O
.,O,O
ALF,B,B
injection,O,O
resulted,O,O
in,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
hindlimb,O,O
EMG,O,B
activity,O,O
in,O,O
the,O,O
L,O,O
-,O,O
MED,O,O
treatment,O,O
group,O,O
which,O,O
was,O,O
indistinguishable,O,O
from,O,O
that,O,O
seen,O,O
in,O,O
animals,O,O
treated,O,O
with,O,O
saline,O,B
.,O,O
In,O,O
contrast,O,O
",",O,O
D,B,B
-,I,I
MED,I,I
prevented,O,O
alfentanil,B,B
-,O,O
induced,O,O
muscle,O,O
rigidity,O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
fashion,O,O
.,O,O
The,O,O
small,O,O
EMG,O,B
values,O,O
obtained,O,O
in,O,O
the,O,O
high,O,O
-,O,O
dose,O,O
D,B,B
-,I,I
MED,I,I
group,O,O
were,O,O
comparable,O,O
with,O,O
those,O,O
recorded,O,O
in,O,O
earlier,O,O
studies,O,O
from,O,O
control,O,O
animals,O,O
not,O,O
given,O,O
any,O,O
opiate,O,O
.,O,O
The,O,O
high,O,O
-,O,O
dose,O,O
D,B,B
-,I,I
MED,I,I
animals,O,O
were,O,O
flaccid,O,O
",",O,O
akinetic,O,O
",",O,O
and,O,O
lacked,O,O
a,O,O
startle,O,O
response,O,O
during,O,O
the,O,O
entire,O,O
experimental,O,O
period,O,O
.,O,O
Some,O,O
central,O,O
effects,O,O
of,O,O
repeated,O,O
treatment,O,O
with,O,O
fluvoxamine,B,B
.,O,O
We,O,O
investigated,O,O
the,O,O
effect,O,O
of,O,O
repeated,O,O
treatment,O,O
with,O,O
fluvoxamine,B,B
",",O,O
a,O,O
selective,O,O
serotonin,B,B
uptake,O,I
inhibitor,O,I
",",O,O
on,O,O
behavioral,O,O
effects,O,O
of,O,O
dopaminomimetics,O,B
and,O,O
methoxamine,B,B
and,O,O
on,O,O
the,O,O
animal,O,O
behavior,O,O
in,O,O
the,O,O
test,O,O
.,O,O
A,O,O
repeated,O,O
treatment,O,O
with,O,O
fluvoxamine,B,B
(,O,O
twice,O,O
daily,O,O
for,O,O
14,O,O
days,O,O
),O,O
potentiated,O,O
in,O,O
mice,O,O
and,O,O
in,O,O
rats,O,O
(,O,O
weaker,O,O
),O,O
the,O,O
amphetamine,B,B
-,O,O
induced,O,O
hyperactivity,O,O
.,O,O
The,O,O
hyperactivity,O,O
induced,O,O
by,O,O
nomifensine,B,B
in,O,O
mice,O,O
remained,O,O
unaffected,O,O
by,O,O
fluvoxamine,B,B
.,O,O
The,O,O
stimulation,O,O
of,O,O
locomotor,O,O
activity,O,O
by,O,O
intracerebroventricularly,O,O
administered,O,O
methoxamine,B,B
was,O,O
not,O,O
affected,O,O
by,O,O
repeated,O,O
treatment,O,O
with,O,O
fluvoxamine,B,B
.,O,O
Given,O,O
three,O,O
times,O,O
fluvoxamine,B,B
had,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
immobilization,O,O
time,O,O
in,O,O
the,O,O
test,O,O
in,O,O
rats,O,O
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
fluvoxamine,B,B
given,O,O
repeatedly,O,O
acts,O,O
differently,O,O
than,O,O
citalopram,B,B
",",O,O
another,O,O
selective,O,O
serotonin,B,B
uptake,O,I
inhibitor,O,I
",",O,O
and,O,O
differs,O,O
also,O,O
from,O,O
other,O,O
antidepressant,O,B
drugs,O,O
.,O,O
Protective,O,O
effect,O,O
of,O,O
a,O,O
specific,O,O
platelet,O,B
-,O,I
activating,O,I
factor,O,I
antagonist,O,O
",",O,O
BN,B,B
52021,I,I
",",O,O
on,O,O
bupivacaine,B,B
-,O,I
induced,O,I
cardiovascular,O,I
impairments,O,I
in,O,O
rats,O,O
.,O,O
Administration,O,O
of,O,O
the,O,O
local,O,O
anaesthetic,O,O
bupivacaine,B,B
(,O,O
1,O,O
.,O,O
5,O,O
or,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
to,O,O
rats,O,O
elicited,O,O
a,O,O
marked,O,O
decrease,O,O
of,O,O
mean,O,O
arterial,O,O
blood,O,O
pressure,O,O
(,O,O
MBP,O,B
),O,O
and,O,O
heart,O,O
rate,O,O
(,O,O
HR,O,B
),O,O
leading,O,O
to,O,O
death,O,O
(,O,O
in,O,O
67,O,O
%,O,O
or,O,O
90,O,O
%,O,O
of,O,O
animals,O,O
respectively,O,O
.,O,O
Intravenous,O,O
injection,O,O
of,O,O
the,O,O
specific,O,O
platelet,O,O
-,O,O
activating,O,O
factor,O,O
(,O,O
PAF,O,B
),O,O
antagonist,O,O
BN,B,B
52021,I,I
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
30,O,O
min,O,O
before,O,O
bupivacaine,B,O
administration,O,O
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
suppressed,O,O
both,O,O
the,O,O
decrease,O,O
of,O,O
MBP,O,B
and,O,O
HR,O,B
.,O,O
In,O,O
contrast,O,O
",",O,O
doses,O,O
of,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
BN,B,B
52021,I,I
given,O,O
30,O,O
min,O,O
before,O,O
or,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
administered,O,O
5,O,O
min,O,O
before,O,O
i,O,O
.,O,O
v,O,O
of,O,O
bupivacaine,B,B
were,O,O
ineffective,O,O
.,O,O
When,O,O
BN,B,B
52021,I,I
(,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
was,O,O
injected,O,O
immediately,O,O
after,O,O
bupivacaine,B,B
(,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
a,O,O
partial,O,O
reversion,O,O
of,O,O
the,O,O
decrease,O,O
of,O,O
MBP,O,B
and,O,O
HR,O,B
was,O,O
observed,O,O
",",O,O
whereas,O,O
the,O,O
dose,O,O
of,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
was,O,O
ineffective,O,O
.,O,O
A,O,O
partial,O,O
recovery,O,O
of,O,O
bupivacaine,B,B
-,O,O
induced,O,O
ECG,O,B
alterations,O,O
was,O,O
observed,O,O
after,O,O
pretreatment,O,O
of,O,O
the,O,O
rats,O,O
with,O,O
BN,B,B
52021,I,I
.,O,O
Since,O,O
the,O,O
administration,O,O
of,O,O
BN,B,B
52021,I,I
",",O,O
at,O,O
all,O,O
doses,O,O
studied,O,O
",",O,O
did,O,O
not,O,O
alter,O,O
MBP,O,B
and,O,O
HR,O,B
at,O,O
the,O,O
doses,O,O
used,O,O
",",O,O
the,O,O
bulk,O,O
of,O,O
these,O,O
results,O,O
clearly,O,O
demonstrate,O,O
a,O,O
protective,O,O
action,O,O
of,O,O
BN,B,B
52021,I,I
",",O,O
a,O,O
specific,O,O
antagonist,O,O
of,O,O
PAF,O,B
",",O,O
against,O,O
bupivacaine,B,O
-,O,O
induced,O,O
cardiovascular,O,O
toxicity,O,O
.,O,O
Thus,O,O
",",O,O
consistent,O,O
with,O,O
its,O,O
direct,O,O
effect,O,O
on,O,O
heart,O,O
",",O,O
PAF,O,B
appears,O,O
to,O,O
be,O,O
implicated,O,O
in,O,O
bupivacaine,B,O
-,O,O
induced,O,O
cardiovascular,O,O
alterations,O,O
.,O,O
The,O,O
epidemiology,O,O
of,O,O
the,O,O
acute,O,O
flank,O,O
pain,O,O
syndrome,O,O
from,O,O
suprofen,B,B
.,O,O
Suprofen,B,B
",",O,O
a,O,O
new,O,O
nonsteroidal,O,O
anti,O,O
-,O,O
inflammatory,O,O
drug,O,O
",",O,O
was,O,O
marketed,O,O
in,O,O
early,O,O
1986,O,O
as,O,O
an,O,O
analgesic,O,O
agent,O,O
.,O,O
Until,O,O
physicians,O,O
began,O,O
reporting,O,O
an,O,O
unusual,O,O
acute,O,O
flank,O,O
pain,O,O
syndrome,O,O
to,O,O
the,O,O
spontaneous,O,O
reporting,O,O
system,O,O
",",O,O
700,O,O
",",O,O
persons,O,O
used,O,O
the,O,O
drug,O,O
in,O,O
the,O,O
United,O,O
States,O,O
.,O,O
Through,O,O
August,O,O
1986,O,O
",",O,O
a,O,O
total,O,O
of,O,O
163,O,O
cases,O,O
of,O,O
this,O,O
syndrome,O,O
were,O,O
reported,O,O
.,O,O
To,O,O
elucidate,O,O
the,O,O
epidemiology,O,O
of,O,O
the,O,O
syndrome,O,O
",",O,O
a,O,O
case,O,O
-,O,O
control,O,O
study,O,O
was,O,O
performed,O,O
",",O,O
comparing,O,O
62,O,O
of,O,O
the,O,O
case,O,O
patients,O,O
who,O,O
had,O,O
been,O,O
reported,O,O
to,O,O
the,O,O
spontaneous,O,O
reporting,O,O
system,O,O
to,O,O
185,O,O
suprofen,B,B
-,O,I
exposed,O,O
control,O,O
subjects,O,O
who,O,O
did,O,O
not,O,O
have,O,O
the,O,O
syndrome,O,O
.,O,O
Case,O,O
patients,O,O
were,O,O
more,O,O
likely,O,O
to,O,O
be,O,O
men,O,O
(,O,O
odds,O,O
ratio,O,O
",",O,O
3,O,O
.,O,O
8,O,O
;,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
1,O,O
.,O,O
2,O,O
-,O,O
12,O,O
.,O,O
1,O,O
),O,O
",",O,O
suffer,O,O
from,O,O
hay,O,B
fever,O,I
and,O,O
asthma,O,B
(,O,O
odds,O,O
ratio,O,O
",",O,O
3,O,O
.,O,O
4,O,O
;,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
1,O,O
.,O,O
0,O,O
-,O,O
11,O,O
.,O,O
9,O,O
),O,O
;,O,O
to,O,O
participate,O,O
in,O,O
regular,O,O
exercise,O,O
(,O,O
odds,O,O
ratio,O,O
",",O,O
5,O,O
.,O,O
9,O,O
;,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
1,O,O
.,O,O
1,O,O
-,O,O
30,O,O
.,O,O
7,O,O
),O,O
",",O,O
especially,O,O
in,O,O
the,O,O
use,O,O
of,O,O
Nautilus,O,B
equipment,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
;,O,O
and,O,O
to,O,O
use,O,O
alcohol,B,B
(,O,O
odds,O,O
ratio,O,O
",",O,O
4,O,B
.,O,O
4,O,O
;,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
1,O,O
.,O,O
-,O,O
17,O,O
.,O,O
5,O,O
),O,O
.,O,O
Possible,O,O
risk,O,O
factors,O,O
included,O,O
young,O,O
age,O,O
",",O,O
concurrent,O,O
use,O,O
of,O,O
other,O,O
analgesic,O,O
agents,O,O
(,O,O
especially,O,O
ibuprofen,B,B
),O,O
",",O,O
preexisting,O,O
renal,O,O
disease,O,O
",",O,O
a,O,O
history,O,O
of,O,O
kidney,O,O
stones,O,O
",",O,O
a,O,O
history,O,O
of,O,O
gout,O,B
",",O,O
a,O,O
recent,O,O
increase,O,O
in,O,O
activity,O,O
",",O,O
a,O,O
recent,O,O
increase,O,O
in,O,O
sun,O,O
exposure,O,O
",",O,O
and,O,O
residence,O,O
in,O,O
the,O,O
Sunbelt,O,B
.,O,O
These,O,O
were,O,O
findings,O,O
that,O,O
were,O,O
suggestive,O,O
but,O,O
did,O,O
not,O,O
reach,O,O
conventional,O,O
statistical,O,O
significance,O,O
.,O,O
These,O,O
findings,O,O
are,O,O
consistent,O,O
with,O,O
the,O,O
postulated,O,O
mechanism,O,O
for,O,O
this,O,O
unusual,O,O
syndrome,O,O
:,O,O
acute,O,O
diffuse,O,O
crystallization,O,O
of,O,O
uric,B,B
acid,I,I
in,O,O
renal,O,O
tubules,O,O
.,O,O
Phlorizin,B,B
-,O,I
induced,O,I
glycosuria,O,I
does,O,O
not,O,O
prevent,O,O
gentamicin,B,B
nephrotoxicity,O,I
in,O,O
rats,O,O
.,O,O
Because,O,O
rats,O,O
with,O,O
streptozotocin,B,B
-,O,I
induced,O,I
diabetes,O,I
mellitus,O,I
(,O,O
DM,O,B
),O,O
have,O,O
a,O,O
high,O,O
solute,O,O
diuresis,O,O
(,O,O
glycosuria,O,B
of,O,O
10,O,O
to,O,O
12,O,O
g,O,O
/,O,O
day,O,O
),O,O
",",O,O
we,O,O
have,O,O
suggested,O,O
that,O,O
this,O,O
may,O,O
in,O,O
part,O,O
be,O,O
responsible,O,O
for,O,O
their,O,O
resistance,O,O
to,O,O
gentamicin,B,B
-,O,I
induced,O,I
acute,O,I
renal,O,I
failure,O,I
(,O,O
ARF,O,B
),O,O
.,O,O
The,O,O
protection,O,O
from,O,O
gentamicin,B,B
nephrotoxicity,O,I
was,O,O
studied,O,O
in,O,O
non,O,O
-,O,O
diabetic,O,O
rats,O,O
with,O,O
chronic,O,O
solute,O,O
diuresis,O,O
induced,O,O
by,O,O
blockage,O,O
of,O,O
tubular,O,O
glucose,B,B
reabsorption,O,I
with,O,O
phlorizin,B,B
(,O,O
P,B,B
),O,O
.,O,O
DM,O,B
rats,O,O
with,O,O
mild,O,O
glycosuria,O,O
(,O,O
similar,O,O
in,O,O
degree,O,O
to,O,O
that,O,O
of,O,O
the,O,O
P,B,B
treated,O,O
animals,O,O
),O,O
were,O,O
also,O,O
studied,O,O
.,O,O
Unanesthetized,O,O
adult,O,O
female,O,O
",",O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
divided,O,O
in,O,O
four,O,O
groups,O,O
and,O,O
studied,O,O
for,O,O
15,O,O
days,O,O
.,O,O
Group,O,O
1,O,O
(,O,O
P,B,B
alone,O,O
),O,O
received,O,O
P,B,B
",",O,O
360,O,O
mg,O,O
/,O,O
day,O,O
",",O,O
for,O,O
15,O,O
days,O,O
;,O,O
Group,O,O
II,O,O
(,O,O
P,B,B
+,O,O
gentamicin,B,B
),O,O
;,O,O
Group,O,O
III,O,O
(,O,O
gentamicin,B,B
alone,O,O
),O,O
and,O,O
Group,O,O
IV,O,O
(,O,O
mild,O,O
DM,O,B
+,O,O
gentamicin,B,B
),O,O
.,O,O
Nephrotoxic,O,O
doses,O,O
(,O,O
40,O,O
mg,O,B
/,O,O
kg,O,O
body,O,O
wt,O,O
/,O,O
day,O,O
),O,O
of,O,O
gentamicin,B,B
were,O,O
injected,O,O
during,O,O
the,O,O
last,O,O
nine,O,O
days,O,O
of,O,O
study,O,O
to,O,O
the,O,O
animals,O,O
of,O,O
groups,O,O
II,O,O
to,O,O
IV,O,O
.,O,O
In,O,O
Group,O,O
I,O,O
",",O,O
P,B,O
induced,O,O
a,O,O
moderate,O,O
and,O,O
stable,O,O
glycosuria,O,O
(,O,O
3,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
g,O,O
/,O,O
day,O,O
",",O,O
SE,O,O
),O,O
",",O,O
and,O,O
no,O,O
functional,O,O
or,O,O
morphologic,O,O
evidence,O,O
of,O,O
renal,O,O
dysfunction,O,O
(,O,O
baseline,O,O
CCr,O,B
2,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
ml,O,O
/,O,O
min,O,O
",",O,O
undetectable,O,O
lysozymuria,O,O
),O,O
or,O,O
damage,O,O
(,O,O
tubular,O,O
necrosis,O,O
score,O,O
[,O,O
maximum,O,O
4,O,O
],O,O
",",O,O
zero,O,O
),O,O
In,O,O
Group,O,O
II,O,O
",",O,O
P,B,O
did,O,O
not,O,O
prevent,O,O
gentamicin,B,B
-,O,O
ARF,O,O
(,O,O
maximal,O,O
decrease,O,O
in,O,O
CCr,O,O
at,O,O
day,O,O
9,O,O
.,O,O
89,O,O
%,O,O
",",O,O
less,O,O
than,O,O
0,O,O
.,O,O
;,O,O
peak,O,O
lysozymuria,O,O
",",O,O
1863,O,O
+,O,O
/,O,O
-,O,O
321,O,O
micrograms,O,O
/,O,O
day,O,O
;,O,O
and,O,O
tubular,O,O
necrosis,O,O
score,O,O
",",O,O
3,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
.,O,O
These,O,O
values,O,O
were,O,O
not,O,O
different,O,O
from,O,O
those,O,O
of,O,O
Group,O,O
III,O,O
:,O,O
maximal,O,O
decrease,O,O
in,O,O
CCr,O,B
73,O,O
%,O,O
(,O,O
P,B,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
;,O,O
lysozymuria,O,B
",",O,O
2147,O,O
+,O,O
/,O,O
-,O,O
701,O,O
micrograms,O,O
/,O,O
day,O,O
;,O,O
tubular,O,O
necrosis,O,O
score,O,O
",",O,O
3,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
Catalepsy,O,O
induced,O,O
by,O,O
combinations,O,O
of,O,O
ketamine,B,B
and,O,O
morphine,B,B
:,O,O
potentiation,O,O
",",O,O
antagonism,O,O
",",O,O
tolerance,O,O
and,O,O
cross,O,O
-,O,O
tolerance,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Previous,O,O
studies,O,O
demonstrated,O,O
that,O,O
both,O,O
ketamine,B,B
and,O,O
morphine,B,B
induced,O,O
analgesia,O,O
and,O,O
catalepsy,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Pre,O,O
-,O,O
treatment,O,O
with,O,O
ketamine,B,B
produced,O,O
cross,O,O
-,O,O
tolerance,O,O
to,O,O
morphine,B,B
",",O,O
whereas,O,O
pretreatment,O,O
with,O,O
morphine,B,B
did,O,O
not,O,O
induce,O,O
cross,O,O
-,O,O
tolerance,O,O
to,O,O
ketamine,B,B
but,O,O
rather,O,O
augmented,O,O
the,O,O
cataleptic,O,O
response,O,O
;,O,O
this,O,O
augmentation,O,O
was,O,O
attributed,O,O
to,O,O
residual,O,O
morphine,B,B
in,O,O
the,O,O
brain,O,O
.,O,O
The,O,O
present,O,O
studies,O,O
explored,O,O
the,O,O
duration,O,O
of,O,O
the,O,O
loss,O,O
of,O,O
righting,O,O
reflex,O,O
induced,O,O
by,O,O
sub,O,O
-,O,O
effective,O,O
doses,O,O
of,O,O
ketamine,B,B
and,O,O
morphine,B,B
",",O,O
administered,O,O
simultaneously,O,O
.,O,O
There,O,O
was,O,O
mutual,O,O
potentiation,O,O
between,O,O
sub,O,O
-,O,O
effective,O,O
doses,O,O
of,O,O
ketamine,B,B
and,O,O
morphine,B,B
",",O,O
but,O,O
sub,O,O
-,O,O
effective,O,O
doses,O,O
of,O,O
ketamine,B,B
partly,O,O
antagonized,O,O
fully,O,O
-,O,O
effective,O,O
doses,O,O
of,O,O
morphine,B,B
.,O,O
Latency,O,O
to,O,O
the,O,O
loss,O,O
of,O,O
righting,O,O
reflex,O,O
",",O,O
rigidity,O,O
and,O,O
behavior,O,O
on,O,O
recovery,O,O
",",O,O
reflected,O,O
the,O,O
relative,O,O
predominance,O,O
of,O,O
ketamine,B,B
or,O,O
morphine,B,B
in,O,O
each,O,O
combination,O,O
.,O,O
Naloxone,B,B
inhibited,O,O
the,O,O
induced,O,O
cataleptic,O,O
effects,O,O
.,O,O
The,O,O
degree,O,O
and,O,O
time,O,O
course,O,O
of,O,O
development,O,O
of,O,O
tolerance,O,O
to,O,O
daily,O,O
administration,O,O
of,O,O
sub,O,O
-,O,O
effective,O,O
dose,O,O
combinations,O,O
of,O,O
ketamine,B,B
and,O,O
morphine,B,B
were,O,O
similar,O,O
.,O,O
Rats,O,O
",",O,O
tolerant,O,O
to,O,O
ketamine,B,B
-,O,O
dominant,O,O
combinations,O,O
",",O,O
were,O,O
cross,O,O
-,O,O
tolerant,O,O
to,O,O
both,O,O
drugs,O,O
",",O,O
while,O,O
those,O,O
tolerant,O,O
to,O,O
morphine,B,B
-,O,O
dominant,O,O
combinations,O,O
were,O,O
cross,O,O
-,O,O
tolerant,O,O
to,O,O
morphine,B,B
but,O,O
showed,O,O
either,O,O
no,O,O
cross,O,O
-,O,O
tolerance,O,O
or,O,O
an,O,O
augmented,O,O
response,O,O
to,O,O
ketamine,B,B
.,O,O
While,O,O
the,O,O
mutual,O,O
potentiation,O,O
",",O,O
antagonism,O,O
and,O,O
tolerance,O,O
suggest,O,O
common,O,O
mechanisms,O,O
for,O,O
the,O,O
induced,O,O
catalepsy,O,O
",",O,O
differences,O,O
in,O,O
latency,O,O
",",O,O
rigidity,O,O
and,O,O
behavior,O,O
",",O,O
asymmetry,O,O
of,O,O
cross,O,O
-,O,O
tolerance,O,O
and,O,O
a,O,O
widely,O,O
-,O,O
different,O,O
ID50,O,O
for,O,O
naloxone,B,B
would,O,O
argue,O,O
against,O,O
an,O,O
action,O,O
at,O,O
a,O,O
single,O,O
opioid,O,O
site,O,O
.,O,O
Hydrocortisone,B,B
-,O,O
induced,O,O
hypertension,O,O
in,O,O
humans,O,O
:,O,O
pressor,O,O
responsiveness,O,O
and,O,O
sympathetic,O,O
function,O,O
.,O,O
Oral,O,O
hydrocortisone,B,B
increases,O,O
blood,O,O
pressure,O,O
and,O,O
enhances,O,O
pressor,O,O
responsiveness,O,O
in,O,O
normal,O,O
human,O,O
subjects,O,O
.,O,O
We,O,O
studied,O,O
the,O,O
effects,O,O
of,O,O
1,O,O
week,O,O
of,O,O
oral,O,O
hydrocortisone,B,B
(,O,O
200,O,O
mg,O,O
/,O,O
day,O,O
),O,O
on,O,O
blood,O,O
pressure,O,O
",",O,O
cardiac,O,O
output,O,O
",",O,O
total,O,O
peripheral,O,O
resistance,O,O
",",O,O
forearm,O,O
vascular,O,O
resistance,O,O
",",O,O
and,O,O
norepinephrine,B,B
spillover,O,O
to,O,O
plasma,O,O
in,O,O
eight,O,O
healthy,O,O
male,O,O
volunteers,O,O
.,O,O
Although,O,O
diastolic,O,O
blood,O,O
pressure,O,O
remained,O,O
unchanged,O,O
",",O,O
systolic,O,O
blood,O,O
pressure,O,O
increased,O,O
from,O,O
119,O,O
to,O,O
135,O,O
mm,O,O
Hg,O,O
(,O,O
SED,O,B
+,O,I
/,O,I
-,O,I
3,O,I
.,O,O
4,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
cardiac,O,O
output,O,O
(,O,O
5,O,O
.,O,O
85,O,O
-,O,O
7,O,O
.,O,O
73,O,O
l,O,O
/,O,O
min,O,O
",",O,O
SED,O,B
+,O,I
/,O,I
-,O,I
0,O,I
.,O,O
46,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
peripheral,O,O
vascular,O,O
resistance,O,O
fell,O,O
from,O,O
15,O,O
.,O,O
1,O,O
to,O,O
12,O,O
.,O,O
2,O,O
mm,O,B
Hg,O,I
/,O,I
l,O,I
/,O,I
min,O,O
(,O,O
SED,O,B
+,O,I
/,O,I
-,O,I
1,O,I
.,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
.,O,O
Resting,O,O
forearm,O,O
vascular,O,O
resistance,O,O
remained,O,O
unchanged,O,O
",",O,O
but,O,O
the,O,O
reflex,O,O
response,O,O
to,O,O
the,O,O
cold,O,O
pressor,O,O
test,O,O
was,O,O
accentuated,O,O
",",O,O
the,O,O
rise,O,O
in,O,O
resistance,O,O
increasing,O,O
from,O,O
10,O,O
.,O,O
5,O,O
mm,O,B
Hg,O,I
/,O,I
ml,O,I
/,O,I
100,O,I
ml,O,I
/,O,I
min,O,O
(,O,O
R,O,O
units,O,O
),O,O
before,O,O
treatment,O,O
to,O,O
32,O,O
.,O,O
6,O,O
R,O,O
units,O,O
after,O,O
treatment,O,O
(,O,O
SED,O,B
+,O,I
/,O,I
-,O,I
6,O,I
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
rise,O,O
in,O,O
forearm,O,O
vascular,O,O
resistance,O,O
accompanying,O,O
intra,O,O
-,O,O
arterial,O,O
norepinephrine,B,B
(,O,O
25,O,O
",",O,O
50,O,O
",",O,O
and,O,O
100,O,O
ng,O,O
/,O,O
min,O,O
),O,O
was,O,O
also,O,O
significantly,O,O
greater,O,O
after,O,O
hydrocortisone,B,B
",",O,O
increasing,O,O
from,O,O
an,O,O
average,O,O
of,O,O
14,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
2,O,O
units,O,O
before,O,O
treatment,O,O
to,O,O
35,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
5,O,O
R,O,O
units,O,O
after,O,O
hydrocortisone,B,B
(,O,O
SED,O,O
+,O,O
/,O,O
-,O,O
6,O,O
.,O,O
0,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
A,O,O
shift,O,O
to,O,O
the,O,O
left,O,O
in,O,O
the,O,O
dose,O,O
-,O,O
response,O,O
relation,O,O
and,O,O
fall,O,O
in,O,O
threshold,O,O
suggested,O,O
increased,O,O
sensitivity,O,O
to,O,O
norepinephrine,B,B
after,O,O
treatment,O,O
.,O,O
Measurement,O,O
of,O,O
resting,O,O
norepinephrine,B,B
spillover,O,O
rate,O,O
to,O,O
plasma,O,O
and,O,O
norepinephrine,B,B
uptake,O,O
indicated,O,O
that,O,O
overall,O,O
resting,O,O
sympathetic,O,O
nervous,O,O
system,O,O
activity,O,O
was,O,O
not,O,O
increased,O,O
.,O,O
The,O,O
rise,O,O
in,O,O
resting,O,O
blood,O,B
pressure,O,I
with,O,O
hydrocortisone,B,B
is,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
cardiac,O,O
output,O,O
(,O,O
presumably,O,O
due,O,O
to,O,O
increased,O,O
blood,O,B
volume,O,I
),O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
Neuromuscular,O,O
blockade,O,O
with,O,O
magnesium,B,B
sulfate,I,I
and,O,O
nifedipine,B,B
.,O,O
A,O,O
patient,O,O
who,O,O
received,O,O
tocolysis,O,O
with,O,O
nifedipine,B,B
developed,O,O
neuromuscular,O,O
blockade,O,O
after,O,O
500,O,O
mg,O,O
of,O,O
magnesium,B,B
sulfate,I,I
was,O,O
administered,O,O
.,O,O
This,O,O
reaction,O,O
demonstrates,O,O
that,O,O
nifedipine,B,B
can,O,O
seriously,O,O
potentiate,O,O
the,O,O
toxicity,O,O
of,O,O
magnesium,B,B
.,O,O
Caution,O,O
should,O,O
be,O,O
exercised,O,O
when,O,O
these,O,O
two,O,O
tocolytics,O,O
are,O,O
combined,O,O
.,O,O
Chronic,O,O
carbamazepine,B,B
inhibits,O,O
the,O,O
development,O,O
of,O,O
local,O,O
anesthetic,O,O
seizures,O,O
kindled,O,O
by,O,O
cocaine,B,B
and,O,O
lidocaine,B,B
.,O,O
The,O,O
effects,O,O
of,O,O
carbamazepine,B,B
(,O,O
CBZ,B,O
),O,O
treatment,O,O
on,O,O
local,O,O
anesthetic,O,O
-,O,O
kindled,O,O
seizures,O,O
and,O,O
lethality,O,O
were,O,O
evaluated,O,O
in,O,O
different,O,O
stages,O,O
of,O,O
the,O,O
kindling,O,O
process,O,O
and,O,O
under,O,O
different,O,O
methods,O,O
of,O,O
CBZ,B,O
administration,O,O
.,O,O
Chronic,O,O
oral,O,O
CBZ,B,B
inhibited,O,O
the,O,O
development,O,O
of,O,O
both,O,O
lidocaine,B,B
-,O,O
and,O,O
cocaine,B,B
-,O,O
induced,O,O
seizures,O,O
",",O,O
but,O,O
had,O,O
little,O,O
effect,O,O
on,O,O
the,O,O
fully,O,O
developed,O,O
local,O,O
anesthetic,O,O
seizures,O,O
.,O,O
Chronic,O,O
CBZ,B,B
also,O,O
decreased,O,O
the,O,O
incidence,O,O
of,O,O
seizure,O,O
-,O,O
related,O,O
mortality,O,O
in,O,O
the,O,O
cocaine,B,B
-,O,O
injected,O,O
rats,O,O
.,O,O
Acute,O,O
CBZ,B,B
over,O,O
a,O,O
range,O,O
of,O,O
doses,O,O
(,O,O
15,O,O
-,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
had,O,O
no,O,O
effect,O,O
on,O,O
completed,O,O
lidocaine,B,B
-,O,O
kindled,O,O
or,O,O
acute,O,O
cocaine,B,B
-,O,O
induced,O,O
seizures,O,O
.,O,O
Repeated,O,O
i,O,O
.,O,O
p,O,O
.,O,O
injection,O,O
of,O,O
CBZ,B,B
(,O,O
15,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
also,O,O
was,O,O
without,O,O
effect,O,O
on,O,O
the,O,O
development,O,O
of,O,O
lidocaine,B,B
-,O,O
or,O,O
cocaine,B,B
-,O,O
kindled,O,O
seizures,O,O
.,O,O
The,O,O
differential,O,O
effects,O,O
of,O,O
CBZ,B,B
depending,O,O
upon,O,O
stage,O,O
of,O,O
seizure,O,O
development,O,O
suggest,O,O
that,O,O
distinct,O,O
mechanisms,O,O
underlie,O,O
the,O,O
development,O,O
versus,O,O
maintenance,O,O
of,O,O
local,O,O
anesthetic,O,O
-,O,O
kindled,O,O
seizures,O,O
.,O,O
The,O,O
effectiveness,O,O
of,O,O
chronic,O,O
but,O,O
not,O,O
repeated,O,O
",",O,O
intermittent,O,O
injections,O,O
of,O,O
CBZ,B,B
suggests,O,O
that,O,O
different,O,O
biochemical,O,O
consequences,O,O
result,O,O
from,O,O
the,O,O
different,O,O
treatment,O,O
regimens,O,O
.,O,O
The,O,O
possible,O,O
utility,O,O
of,O,O
chronic,O,O
CBZ,B,B
in,O,O
preventing,O,O
the,O,O
development,O,O
of,O,O
toxic,O,O
side,O,O
effects,O,O
in,O,O
human,O,O
cocaine,B,B
users,O,O
is,O,O
suggested,O,O
by,O,O
these,O,O
data,O,O
",",O,O
but,O,O
remains,O,O
to,O,O
be,O,O
directly,O,O
evaluated,O,O
.,O,O
Magnetic,O,O
resonance,O,O
imaging,O,O
of,O,O
cerebral,O,O
venous,O,O
thrombosis,O,O
secondary,O,O
to,O,O
birth,O,O
control,O,O
pills,O,O
.,O,O
The,O,O
clinical,O,O
and,O,O
radiographic,O,O
features,O,O
of,O,O
cerebral,O,O
deep,O,O
venous,O,O
thrombosis,O,O
in,O,O
a,O,O
21,O,O
-,O,O
year,O,O
-,O,O
old,O,O
white,O,O
woman,O,O
are,O,O
presented,O,O
.,O,O
This,O,O
nulliparous,O,O
patient,O,O
presented,O,O
with,O,O
relatively,O,O
mild,O,O
clinical,O,O
symptoms,O,O
and,O,O
progressing,O,O
mental,O,O
status,O,O
changes,O,O
.,O,O
The,O,O
only,O,O
known,O,O
risk,O,O
factor,O,O
was,O,O
oral,B,O
contraceptive,I,O
pills,O,O
.,O,O
The,O,O
magnetic,O,O
resonance,O,O
image,O,O
(,O,O
MRI,O,B
),O,O
showed,O,O
increased,O,O
signal,O,O
intensity,O,O
from,O,O
the,O,O
internal,O,O
cerebral,O,O
veins,O,O
",",O,O
vein,O,O
of,O,O
Galen,O,B
",",O,O
and,O,O
straight,O,O
sinus,O,O
.,O,O
The,O,O
diagnosis,O,O
was,O,O
confirmed,O,O
by,O,O
arterial,O,O
angiography,O,O
.,O,O
Beta,O,B
-,O,I
2,O,I
-,O,I
adrenoceptor,O,I
-,O,I
mediated,O,I
hypokalemia,O,I
and,O,O
its,O,O
abolishment,O,O
by,O,O
oxprenolol,B,B
.,O,O
The,O,O
time,O,O
course,O,O
and,O,O
concentration,O,O
-,O,O
effect,O,O
relationship,O,O
of,O,O
terbutaline,B,B
-,O,O
induced,O,O
hypokalemia,O,O
was,O,O
studied,O,O
",",O,O
using,O,O
computer,O,O
-,O,O
aided,O,O
pharmacokinetic,O,O
-,O,O
dynamic,O,O
modeling,O,O
.,O,O
Subsequently,O,O
we,O,O
investigated,O,O
the,O,O
efficacy,O,O
of,O,O
oxprenolol,B,B
in,O,O
antagonizing,O,O
such,O,O
hypokalemia,O,O
",",O,O
together,O,O
with,O,O
the,O,O
pharmacokinetic,O,O
interaction,O,O
between,O,O
both,O,O
drugs,O,O
.,O,O
Six,O,O
healthy,O,O
subjects,O,O
were,O,O
given,O,O
a,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
subcutaneous,O,O
dose,O,O
of,O,O
terbutaline,B,B
on,O,O
two,O,O
occasions,O,O
:,O,O
1,O,O
hour,O,O
after,O,O
oral,O,O
administration,O,O
of,O,O
a,O,O
placebo,O,B
and,O,O
1,O,O
hour,O,O
after,O,O
80,O,O
mg,O,O
oxprenolol,B,B
orally,O,O
.,O,O
In,O,O
the,O,O
7,O,O
-,O,O
hour,O,O
period,O,O
after,O,O
terbutaline,B,B
administration,O,O
",",O,O
plasma,O,O
samples,O,O
were,O,O
taken,O,O
for,O,O
determination,O,O
of,O,O
plasma,O,O
potassium,B,B
levels,O,O
and,O,O
drug,O,O
concentrations,O,O
.,O,O
The,O,O
sigmoid,O,O
Emax,O,O
model,O,O
offered,O,O
a,O,O
good,O,O
description,O,O
of,O,O
the,O,O
relation,O,O
between,O,O
terbutaline,B,B
concentrations,O,O
and,O,O
potassium,B,B
effects,O,O
.,O,O
Oxprenolol,B,B
caused,O,O
decreases,O,O
of,O,O
65,O,O
%,O,O
and,O,O
56,O,O
%,O,O
of,O,O
terbutaline,B,B
volume,O,O
of,O,O
distribution,O,O
and,O,O
clearance,O,O
",",O,O
respectively,O,O
",",O,O
and,O,O
an,O,O
increase,O,O
of,O,O
130,O,O
%,O,O
of,O,O
its,O,O
AUC,O,O
.,O,O
In,O,O
spite,O,O
of,O,O
higher,O,O
terbutaline,B,B
concentrations,O,O
after,O,O
oxprenolol,B,B
pretreatment,O,O
",",O,O
the,O,O
hypokalemia,O,O
was,O,O
almost,O,O
completely,O,O
antagonized,O,O
by,O,O
the,O,O
beta,O,O
2,O,O
-,O,O
blocking,O,O
action,O,O
.,O,O
A,O,O
dystonia,O,B
-,O,O
like,O,O
syndrome,O,O
after,O,O
neuropeptide,O,B
(,O,O
MSH,B,B
/,O,O
ACTH,B,B
),O,O
stimulation,O,O
of,O,O
the,O,O
rat,O,O
locus,O,O
ceruleus,O,O
.,O,O
The,O,O
movement,O,O
disorder,O,O
investigated,O,O
in,O,O
these,O,O
studies,O,O
has,O,O
some,O,O
features,O,O
in,O,O
common,O,O
with,O,O
human,O,O
idiopathic,O,O
dystonia,O,B
",",O,O
and,O,O
information,O,O
obtained,O,O
in,O,O
these,O,O
studies,O,O
may,O,O
be,O,O
of,O,O
potential,O,O
clinical,O,O
benefit,O,O
.,O,O
The,O,O
present,O,O
experimental,O,O
results,O,O
indicated,O,O
that,O,O
peptidergic,O,B
stimulation,O,O
of,O,O
the,O,O
LC,O,O
resulted,O,O
in,O,O
a,O,O
NE,O,B
-,O,O
mediated,O,O
inhibition,O,O
of,O,O
cerebellar,O,O
Purkinje,O,B
cells,O,O
located,O,O
at,O,O
terminals,O,O
of,O,O
the,O,O
ceruleo,O,O
-,O,O
cerebellar,O,O
pathway,O,O
.,O,O
However,O,O
",",O,O
it,O,O
is,O,O
not,O,O
certain,O,O
as,O,O
to,O,O
the,O,O
following,O,O
:,O,O
(,O,O
a,O,O
),O,O
what,O,O
receptors,O,O
were,O,O
stimulated,O,O
by,O,O
the,O,O
ACTH,B,B
N,O,I
-,O,I
terminal,O,I
fragments,O,I
at,O,O
the,O,O
LC,O,B
that,O,O
resulted,O,O
in,O,O
this,O,O
disorder,O,O
;,O,O
(,O,O
b,O,O
),O,O
whether,O,O
NE,O,B
",",O,O
released,O,O
onto,O,O
Purkinje,O,B
cell,O,I
synapses,O,I
located,O,O
at,O,O
terminals,O,O
of,O,O
the,O,O
ceruleo,O,B
-,O,I
cerebellar,O,I
pathway,O,I
",",O,O
did,O,O
indeed,O,O
cause,O,O
the,O,O
long,O,O
-,O,O
term,O,O
depression,O,O
at,O,O
Purkinje,O,B
cell,O,I
synapses,O,I
(,O,O
previously,O,O
described,O,O
by,O,O
others,O,O
),O,O
that,O,O
resulted,O,O
in,O,O
the,O,O
long,O,O
duration,O,O
of,O,O
the,O,O
movement,O,O
disorder,O,O
;,O,O
(,O,O
c,O,O
),O,O
whether,O,O
the,O,O
inhibition,O,O
of,O,O
inhibitory,O,O
Purkinje,O,B
cells,O,I
resulted,O,O
in,O,O
disinhibition,O,O
or,O,O
increased,O,O
excitability,O,O
of,O,O
the,O,O
unilateral,O,O
cerebellar,O,O
fastigial,O,O
or,O,O
interpositus,O,O
nuclei,O,O
",",O,O
the,O,O
output,O,O
targets,O,O
of,O,O
the,O,O
Purkinje,O,B
cell,O,I
axons,O,I
",",O,O
that,O,O
may,O,O
have,O,O
been,O,O
an,O,O
important,O,O
contributing,O,O
factor,O,O
to,O,O
this,O,O
disorder,O,O
.,O,O
These,O,O
questions,O,O
are,O,O
currently,O,O
being,O,O
investigated,O,O
.,O,O
Enhanced,O,O
stimulus,O,O
-,O,O
induced,O,O
neurotransmitter,O,O
overflow,O,O
in,O,O
epinephrine,B,B
-,O,O
induced,O,O
hypertensive,O,O
rats,O,O
is,O,O
not,O,O
mediated,O,O
by,O,O
prejunctional,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
activation,O,O
.,O,O
The,O,O
present,O,O
study,O,O
examines,O,O
the,O,O
effect,O,O
of,O,O
6,O,O
-,O,O
day,O,O
epinephrine,B,B
treatment,O,O
(,O,O
100,O,O
micrograms,O,O
/,O,O
kg,O,O
per,O,O
h,O,O
",",O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
on,O,O
stimulus,O,O
-,O,O
induced,O,O
(,O,O
1,O,O
Hz,O,O
),O,O
endogenous,O,O
neurotransmitter,O,O
overflow,O,O
from,O,O
the,O,O
isolated,O,O
perfused,O,O
kidney,O,O
of,O,O
vehicle,O,O
-,O,O
and,O,O
epinephrine,B,B
-,O,O
treated,O,O
rats,O,O
.,O,O
Renal,O,O
catecholamine,B,O
stores,O,O
and,O,O
stimulus,O,O
-,O,O
induced,O,O
overflow,O,O
in,O,O
the,O,O
vehicle,O,O
-,O,O
treated,O,O
group,O,O
consisted,O,O
of,O,O
norepinephrine,B,B
only,O,O
.,O,O
However,O,O
",",O,O
epinephrine,B,B
treatment,O,O
resulted,O,O
in,O,O
the,O,O
incorporation,O,O
of,O,O
epinephrine,B,B
into,O,O
renal,O,O
catecholamine,B,O
stores,O,O
such,O,O
that,O,O
approximately,O,O
40,O,O
%,O,O
of,O,O
the,O,O
catecholamine,B,O
present,O,O
was,O,O
epinephrine,B,B
while,O,O
the,O,O
norepinephrine,B,B
content,O,O
was,O,O
reduced,O,O
by,O,O
a,O,O
similar,O,O
degree,O,O
.,O,O
Total,O,O
tissue,O,O
catecholamine,B,B
content,O,O
of,O,O
the,O,O
kidney,O,O
on,O,O
a,O,O
molar,O,O
basis,O,O
was,O,O
unchanged,O,O
.,O,O
Stimulus,O,O
-,O,O
induced,O,O
fractional,O,O
overflow,O,O
of,O,O
neurotransmitter,O,O
from,O,O
the,O,O
epinephrine,B,B
-,O,O
treated,O,O
kidneys,O,O
was,O,O
approximately,O,O
twice,O,O
normal,O,O
and,O,O
consisted,O,O
of,O,O
both,O,O
norepinephrine,B,B
and,O,O
epinephrine,B,B
in,O,O
proportions,O,O
similar,O,O
to,O,O
those,O,O
found,O,O
in,O,O
the,O,O
kidney,O,O
.,O,O
This,O,O
difference,O,O
in,O,O
fractional,O,O
overflow,O,O
between,O,O
groups,O,O
was,O,O
not,O,O
affected,O,O
by,O,O
neuronal,O,O
and,O,O
extraneuronal,O,O
uptake,O,O
blockade,O,O
.,O,O
Propranolol,B,O
had,O,O
no,O,O
effect,O,O
on,O,O
stimulus,O,O
-,O,O
induced,O,O
overflow,O,O
in,O,O
either,O,O
group,O,O
.,O,O
Phentolamine,B,O
increased,O,O
stimulus,O,O
-,O,O
induced,O,O
overflow,O,O
in,O,O
both,O,O
groups,O,O
although,O,O
the,O,O
increment,O,O
in,O,O
overflow,O,O
was,O,O
greater,O,O
in,O,O
the,O,O
epinephrine,B,B
-,O,I
treated,O,O
group,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
chronic,O,O
epinephrine,B,B
treatment,O,O
results,O,O
in,O,O
enhanced,O,O
fractional,O,O
neurotransmitter,O,O
overflow,O,O
.,O,O
However,O,O
",",O,O
neither,O,O
alterations,O,O
in,O,O
prejunctional,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
influences,O,O
nor,O,O
alterations,O,O
in,O,O
neuronal,O,O
and,O,O
extraneuronal,O,O
uptake,O,O
mechanisms,O,O
appear,O,O
to,O,O
be,O,O
responsible,O,O
for,O,O
this,O,O
alteration,O,O
.,O,O
Furthermore,O,O
",",O,O
data,O,O
obtained,O,O
with,O,O
phentolamine,B,B
alone,O,O
do,O,O
not,O,O
suggest,O,O
alpha,O,B
-,O,I
adrenoceptor,O,I
desensitization,O,O
as,O,O
the,O,O
cause,O,O
of,O,O
the,O,O
enhanced,O,O
neurotransmitter,O,O
overflow,O,O
after,O,O
epinephrine,B,B
treatment,O,O
.,O,O
GABA,B,B
involvement,O,O
in,O,O
naloxone,B,B
induced,O,O
reversal,O,O
of,O,O
respiratory,O,O
paralysis,O,O
produced,O,O
by,O,O
thiopental,B,B
.,O,O
No,O,O
agent,O,O
is,O,O
yet,O,O
available,O,O
to,O,O
reverse,O,O
respiratory,O,O
paralysis,O,O
produced,O,O
by,O,O
CNS,O,B
depressants,O,O
",",O,O
such,O,O
as,O,O
general,O,O
anesthetics,O,O
.,O,O
In,O,O
this,O,O
study,O,O
naloxone,B,B
reversed,O,O
respiratory,O,O
paralysis,O,O
induced,O,O
by,O,O
thiopental,B,B
in,O,O
rats,O,O
.,O,O
25,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
v,O,O
.,O,O
thiopental,B,B
produced,O,O
anesthesia,O,O
without,O,O
altering,O,O
respiratory,O,O
rate,O,O
",",O,O
increased,O,O
GABA,B,B
",",O,O
decreased,O,O
glutamate,B,B
",",O,O
and,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
aspartate,B,B
or,O,O
glycine,B,B
levels,O,O
compared,O,O
to,O,O
controls,O,O
in,O,O
rat,O,O
cortex,O,O
and,O,O
brain,O,O
stem,O,O
.,O,O
Pretreatment,O,O
of,O,O
rats,O,O
with,O,O
thiosemicarbazide,B,B
for,O,O
30,O,O
minutes,O,O
abolished,O,O
the,O,O
anesthetic,O,O
action,O,O
as,O,O
well,O,O
as,O,O
the,O,O
respiratory,O,O
depressant,O,O
action,O,O
of,O,O
thiopental,B,B
.,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
v,O,O
.,O,O
thiopental,B,B
produced,O,O
respiratory,O,O
arrest,O,O
with,O,O
further,O,O
increase,O,O
in,O,O
GABA,B,B
and,O,O
decrease,O,O
in,O,O
glutamate,B,B
again,O,O
in,O,O
cortex,O,O
and,O,O
brain,O,O
stem,O,O
without,O,O
affecting,O,O
any,O,O
of,O,O
the,O,O
amino,B,O
acids,I,O
studied,O,O
in,O,O
four,O,O
regions,O,O
of,O,O
rat,O,O
brain,O,O
.,O,O
Naloxone,B,B
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
v,O,O
.,O,O
),O,O
reversed,O,O
respiratory,O,O
paralysis,O,O
",",O,O
glutamate,B,B
and,O,O
GABA,B,B
levels,O,O
to,O,O
control,O,O
values,O,O
in,O,O
brain,O,O
stem,O,O
and,O,O
cortex,O,O
with,O,O
no,O,O
changes,O,O
in,O,O
caudate,O,O
or,O,O
cerebellum,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
naloxone,B,B
reverses,O,O
respiratory,O,O
paralysis,O,O
produced,O,O
by,O,O
thiopental,B,B
and,O,O
involves,O,O
GABA,B,B
in,O,O
its,O,O
action,O,O
.,O,O
Diazepam,B,B
facilitates,O,O
reflex,O,O
bradycardia,O,O
in,O,O
conscious,O,O
rats,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
diazepam,B,B
on,O,O
cardiovascular,O,O
function,O,O
were,O,O
assessed,O,O
in,O,O
conscious,O,O
rats,O,O
.,O,O
Intravenous,O,O
administration,O,O
of,O,O
diazepam,B,B
(,O,O
1,O,O
-,O,O
30,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
),O,O
produced,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
decrease,O,O
in,O,O
both,O,O
the,O,O
mean,O,O
arterial,O,O
pressure,O,O
and,O,O
the,O,O
heart,O,O
rate,O,O
.,O,O
Also,O,O
",",O,O
reflex,O,O
bradycardia,O,O
was,O,O
produced,O,O
in,O,O
rats,O,O
by,O,O
intravenous,O,O
infusion,O,O
of,O,O
adrenaline,B,B
(,O,O
1,O,O
.,O,O
25,O,O
-,O,O
2,O,O
.,O,O
5,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
),O,O
.,O,O
Intravenous,O,O
pretreatment,O,O
of,O,O
the,O,O
rats,O,O
with,O,O
diazepam,B,B
",",O,O
although,O,O
causing,O,O
no,O,O
change,O,O
in,O,O
the,O,O
adrenaline,B,B
-,O,O
induced,O,O
pressor,O,O
effect,O,O
",",O,O
did,O,O
enhance,O,O
the,O,O
adrenaline,B,B
-,O,O
induced,O,O
reflex,O,O
bradycardia,O,O
.,O,O
However,O,O
",",O,O
the,O,O
diazepam,B,B
enhancement,O,O
of,O,O
adrenaline,B,B
-,O,O
induced,O,O
reflex,O,O
bradycardia,O,O
was,O,O
antagonized,O,O
by,O,O
pretreatment,O,O
of,O,O
rats,O,O
with,O,O
an,O,O
intravenous,O,O
dose,O,O
of,O,O
picrotoxin,B,B
(,O,O
an,O,O
agent,O,O
blocks,O,O
chloride,B,B
channels,O,O
by,O,O
binding,O,O
to,O,O
sites,O,O
associated,O,O
with,O,O
the,O,O
benzodiazepine,B,B
-,O,I
GABA,B,I
-,O,I
chloride,B,I
channel,O,I
macromolecular,O,I
complex,O,I
),O,O
.,O,O
The,O,O
data,O,O
indicate,O,O
that,O,O
diazepam,B,B
acts,O,O
through,O,O
the,O,O
benzodiazepine,B,B
-,O,I
GABA,B,B
-,O,I
chloride,B,I
channel,O,I
macromolecular,O,I
complex,O,I
within,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
to,O,O
facilitate,O,O
reflex,O,O
bradycardia,O,O
mediated,O,O
through,O,O
baroreceptor,O,O
reflexes,O,O
in,O,O
response,O,O
to,O,O
an,O,O
acute,O,O
increase,O,O
in,O,O
arterial,O,O
pressure,O,O
.,O,O
Initial,O,O
potassium,B,B
loss,O,O
and,O,O
hypokalaemia,O,O
during,O,O
chlorthalidone,B,B
administration,O,O
in,O,O
patients,O,O
with,O,O
essential,O,O
hypertension,O,O
:,O,O
the,O,O
influence,O,O
of,O,O
dietary,O,O
sodium,B,O
restriction,O,O
.,O,O
To,O,O
investigate,O,O
the,O,O
initial,O,O
potassium,B,B
loss,O,O
and,O,O
development,O,O
of,O,O
hypokalaemia,O,O
during,O,O
the,O,O
administration,O,O
of,O,O
an,O,O
oral,O,O
diuretic,O,O
",",O,O
metabolic,O,O
balance,O,O
studies,O,O
were,O,O
performed,O,O
in,O,O
ten,O,O
patients,O,O
with,O,O
essential,O,O
hypertension,O,O
who,O,O
had,O,O
shown,O,O
hypokalaemia,O,O
under,O,O
prior,O,O
oral,O,O
diuretic,O,O
treatment,O,O
.,O,O
Chlorthalidone,B,B
(,O,O
50,O,O
mg,O,O
daily,O,O
),O,O
was,O,O
given,O,O
for,O,O
14,O,O
days,O,O
.,O,O
Six,O,O
patients,O,O
received,O,O
a,O,O
normal,O,O
-,O,O
sodium,B,B
diet,O,O
and,O,O
four,O,O
a,O,O
low,O,O
-,O,O
sodium,B,B
(,O,O
17,O,O
mmol,O,O
/,O,O
day,O,O
),O,O
diet,O,O
.,O,O
All,O,O
patients,O,O
had,O,O
a,O,O
normal,O,O
initial,O,O
total,O,O
body,O,O
potassium,B,B
(,O,O
40K,O,O
),O,O
.,O,O
The,O,O
electrolyte,O,O
balances,O,O
",",O,O
weight,O,O
",",O,O
bromide,O,B
space,O,O
",",O,O
plasma,O,O
renin,O,O
activity,O,O
",",O,O
and,O,O
aldosterone,B,B
secretion,O,O
rate,O,O
were,O,O
measured,O,O
.,O,O
In,O,O
both,O,O
groups,O,O
a,O,O
potassium,B,B
deficit,O,O
developed,O,O
",",O,O
with,O,O
proportionally,O,O
larger,O,O
losses,O,O
from,O,O
the,O,O
extracellular,O,O
than,O,O
from,O,O
the,O,O
intracellular,O,O
compartment,O,O
.,O,O
In,O,O
the,O,O
normal,O,O
-,O,O
sodium,B,B
group,O,O
the,O,O
highest,O,O
mean,O,O
potassium,B,B
deficit,O,O
was,O,O
176,O,O
mmol,O,O
on,O,O
day,O,O
9,O,O
",",O,O
after,O,O
which,O,O
some,O,O
potassium,B,B
was,O,O
regained,O,O
;,O,O
in,O,O
the,O,O
low,O,O
-,O,O
sodium,B,B
group,O,O
the,O,O
highest,O,O
deficit,O,O
was,O,O
276,O,O
mmol,O,O
on,O,O
day,O,O
13,O,O
.,O,O
The,O,O
normal,O,O
-,O,O
sodium,B,B
group,O,O
showed,O,O
an,O,O
immediate,O,O
but,O,O
temporary,O,O
rise,O,O
of,O,O
the,O,O
renin,O,B
and,O,O
aldosterone,B,B
levels,O,O
;,O,O
in,O,O
the,O,O
low,O,O
-,O,O
sodium,B,B
group,O,O
renin,O,B
and,O,O
aldosterone,B,B
increased,O,O
more,O,O
slowly,O,O
but,O,O
remained,O,O
elevated,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
dietary,O,O
sodium,B,B
restriction,O,O
increases,O,O
diuretic,O,O
-,O,O
induced,O,O
potassium,B,B
loss,O,O
",",O,O
presumably,O,O
by,O,O
an,O,O
increased,O,O
activity,O,O
of,O,O
the,O,O
renin,O,B
-,O,I
angiotensin,B,I
-,O,I
aldosterone,B,I
system,O,O
",",O,O
while,O,O
sodium,B,B
delivery,O,O
to,O,O
the,O,O
distal,O,O
renal,O,O
tubules,O,O
remains,O,O
sufficiently,O,O
high,O,O
to,O,O
allow,O,O
increased,O,O
potassium,B,B
secretion,O,O
.,O,O
Reversal,O,O
of,O,O
neuroleptic,O,O
-,O,O
induced,O,O
catalepsy,O,O
by,O,O
novel,O,O
aryl,B,B
-,I,I
piperazine,I,I
anxiolytic,O,I
drugs,O,O
.,O,O
The,O,O
novel,O,O
anxiolytic,O,O
drug,O,O
",",O,O
buspirone,B,B
",",O,O
reverses,O,O
catalepsy,O,O
induced,O,O
by,O,O
haloperidol,B,O
.,O,O
A,O,O
series,O,O
of,O,O
aryl,B,O
-,I,O
piperazine,I,O
analogues,O,O
of,O,O
buspirone,B,O
and,O,O
other,O,O
5,B,B
-,I,I
hydroxytryptaminergic,I,I
agonists,I,O
were,O,O
tested,O,O
for,O,O
their,O,O
ability,O,O
to,O,O
reverse,O,O
haloperidol,B,O
induced,O,O
catalepsy,O,O
.,O,O
Those,O,O
drugs,O,O
with,O,O
strong,O,O
affinity,O,O
for,O,O
5,B,B
-,I,I
hydroxytryptamine1a,I,I
receptors,O,O
were,O,O
able,O,O
to,O,O
reverse,O,O
catalepsy,O,O
.,O,O
Drugs,O,O
with,O,O
affinity,O,O
for,O,O
other,O,O
5,B,B
-,I,I
HT,I,I
receptors,O,O
or,O,O
weak,O,O
affinity,O,O
were,O,O
ineffective,O,O
.,O,O
However,O,O
",",O,O
inhibition,O,O
of,O,O
postsynaptic,O,O
5,B,B
-,I,I
HT,I,I
receptors,O,O
neither,O,O
inhibited,O,O
nor,O,O
potentiated,O,O
reversal,O,O
of,O,O
catalepsy,O,O
and,O,O
leaves,O,O
open,O,O
the,O,O
question,O,O
as,O,O
to,O,O
the,O,O
site,O,O
or,O,O
mechanism,O,O
for,O,O
this,O,O
effect,O,O
.,O,O
Glycopyrronium,B,B
requirements,O,O
for,O,O
antagonism,O,O
of,O,O
the,O,O
muscarinic,O,O
side,O,O
effects,O,O
of,O,O
edrophonium,B,B
.,O,O
We,O,O
have,O,O
compared,O,O
",",O,O
in,O,O
60,O,O
adult,O,O
patients,O,O
",",O,O
the,O,O
cardiovascular,O,O
effects,O,O
of,O,O
glycopyrronium,B,B
5,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
and,O,O
10,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
given,O,O
either,O,O
simultaneously,O,O
or,O,O
1,O,O
min,O,O
before,O,O
edrophonium,B,B
1,O,O
mg,O,O
kg,O,O
-,O,O
1,O,O
.,O,O
Significant,O,O
differences,O,O
between,O,O
the,O,O
four,O,O
groups,O,O
were,O,O
detected,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
Both,O,O
groups,O,O
receiving,O,O
10,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
showed,O,O
increases,O,O
in,O,O
heart,O,O
rate,O,O
of,O,O
up,O,O
to,O,O
30,O,O
beat,O,O
min,O,O
-,O,O
1,O,O
(,O,O
95,O,O
%,O,O
confidence,O,O
limits,O,O
28,O,O
-,O,O
32,O,O
beat,O,O
min,O,O
-,O,O
1,O,O
.,O,O
Use,O,O
of,O,O
glycopyrronium,B,B
5,O,O
micrograms,O,O
kg,O,O
-,O,O
1,O,O
provided,O,O
greater,O,O
cardiovascular,O,O
stability,O,O
and,O,O
",",O,O
given,O,O
1,O,O
min,O,O
before,O,O
the,O,O
edrophonium,B,O
",",O,O
was,O,O
sufficient,O,O
to,O,O
minimize,O,O
early,O,O
",",O,O
edrophonium,B,O
-,O,O
induced,O,O
bradycardias,O,O
.,O,O
This,O,O
low,O,O
dose,O,O
of,O,O
glycopyrronium,B,B
provided,O,O
good,O,O
control,O,O
of,O,O
oropharyngeal,O,O
secretions,O,O
.,O,O
Selective,O,O
injection,O,O
of,O,O
iopentol,B,B
",",O,O
iohexol,B,B
and,O,O
metrizoate,B,B
into,O,O
the,O,O
left,O,O
coronary,O,O
artery,O,O
of,O,O
the,O,O
dog,O,O
.,O,O
Induction,O,O
of,O,O
ventricular,O,O
fibrillation,O,O
and,O,O
decrease,O,O
of,O,O
aortic,O,O
pressure,O,O
.,O,O
In,O,O
twenty,O,O
beagle,O,O
dogs,O,O
selective,O,O
injections,O,O
were,O,O
made,O,O
into,O,O
the,O,O
left,O,O
coronary,O,O
artery,O,O
with,O,O
iopentol,B,B
",",O,O
iohexol,B,B
and,O,O
metrizoate,B,B
in,O,O
doses,O,O
of,O,O
4,O,O
ml,O,O
",",O,O
8,O,O
ml,O,O
and,O,O
16,O,O
ml,O,O
.,O,O
Thirty,O,O
-,O,O
six,O,O
iopentol,B,B
injections,O,O
",",O,O
35,O,O
iohexol,B,B
injections,O,O
and,O,O
37,O,O
metrizoate,B,B
injections,O,O
were,O,O
made,O,O
.,O,O
Frequencies,O,O
of,O,O
ventricular,O,O
fibrillation,O,O
were,O,O
significantly,O,O
lower,O,O
(,O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
after,O,O
iopentol,B,B
(,O,O
0,O,O
%,O,O
),O,O
and,O,O
iohexol,B,B
(,O,O
3,O,O
%,O,O
),O,O
than,O,O
after,O,O
metrizoate,B,B
(,O,O
22,O,O
%,O,O
),O,O
.,O,O
Iopentol,B,B
and,O,O
iohexol,B,B
also,O,O
produced,O,O
significantly,O,O
less,O,O
decrease,O,O
in,O,O
aortic,O,O
blood,O,O
pressure,O,O
than,O,O
metrizoate,B,B
at,O,O
the,O,O
different,O,O
doses,O,O
.,O,O
Thyroid,O,B
function,O,O
and,O,O
urine,O,O
-,O,O
concentrating,O,O
ability,O,O
during,O,O
lithium,B,B
treatment,O,O
.,O,O
It,O,O
has,O,O
been,O,O
suggested,O,O
that,O,O
adenylate,O,B
cyclase,O,I
inhibition,O,O
may,O,O
be,O,O
important,O,O
in,O,O
the,O,O
development,O,O
of,O,O
both,O,O
nephrogenic,O,B
diabetes,O,I
insipidus,O,I
and,O,O
hypothyroidism,O,B
during,O,O
lithium,B,O
treatment,O,O
.,O,O
We,O,O
measured,O,O
serum,O,O
thyroxine,B,B
and,O,O
urine,O,O
-,O,O
concentrating,O,O
ability,O,O
(,O,O
Umax,O,B
),O,O
in,O,O
response,O,O
to,O,O
desmopressin,O,B
(,O,O
DDAVP,O,B
),O,O
in,O,O
85,O,O
patients,O,O
receiving,O,O
lithium,B,O
.,O,O
Hypothyroidism,O,B
developed,O,O
in,O,O
eight,O,O
patients,O,O
while,O,O
they,O,O
were,O,O
taking,O,O
lithium,B,B
.,O,O
Impaired,O,O
Umax,O,O
was,O,O
found,O,O
in,O,O
both,O,O
euthyroid,O,O
and,O,O
hypothyroid,O,B
patients,O,O
while,O,O
some,O,O
hypothyroid,O,B
patients,O,O
concentrated,O,O
their,O,O
urine,O,O
well,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
the,O,O
dominant,O,O
mechanisms,O,O
by,O,O
which,O,O
lithium,B,B
exerts,O,O
these,O,O
two,O,O
effects,O,O
are,O,O
different,O,O
.,O,O
Remodelling,O,O
of,O,O
nerve,O,O
structure,O,O
in,O,O
experimental,O,O
isoniazid,B,B
neuropathy,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
The,O,O
neuropathy,O,O
caused,O,O
by,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
isoniazid,B,B
in,O,O
rats,O,O
was,O,O
studied,O,O
with,O,O
a,O,O
computer,O,O
-,O,O
assisted,O,O
morphometric,O,O
method,O,O
.,O,O
Scatter,O,O
diagrams,O,O
of,O,O
the,O,O
g,O,O
ratio,O,O
(,O,O
quotient,O,O
fibre,O,O
diameter,O,O
/,O,O
axon,O,O
diameter,O,O
),O,O
define,O,O
regenerating,O,O
fibres,O,O
as,O,O
a,O,O
distinct,O,O
population,O,O
",",O,O
distinguishable,O,O
from,O,O
the,O,O
surviving,O,O
fibres,O,O
by,O,O
reduced,O,O
sheath,O,O
thickness,O,O
and,O,O
reduced,O,O
axon,O,O
calibre,O,O
.,O,O
There,O,O
was,O,O
also,O,O
evidence,O,O
of,O,O
a,O,O
subtle,O,O
direct,O,O
toxic,O,O
effect,O,O
on,O,O
the,O,O
entire,O,O
fibre,O,O
population,O,O
",",O,O
causing,O,O
axon,O,O
shrinkage,O,O
masked,O,O
by,O,O
readjustment,O,O
of,O,O
the,O,O
myelin,O,B
sheath,O,I
.,O,O
Multicenter,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
multiple,O,O
-,O,O
dose,O,O
",",O,O
parallel,O,O
-,O,O
groups,O,O
efficacy,O,O
and,O,O
safety,O,O
trial,O,O
of,O,O
azelastine,B,B
",",O,O
chlorpheniramine,B,B
",",O,O
and,O,O
placebo,O,B
in,O,O
the,O,O
treatment,O,O
of,O,O
spring,O,O
allergic,O,O
rhinitis,O,O
.,O,O
Azelastine,B,B
",",O,O
a,O,O
novel,O,O
antiallergic,O,O
medication,O,O
",",O,O
was,O,O
compared,O,O
with,O,O
chlorpheniramine,B,B
maleate,I,I
and,O,O
placebo,O,O
for,O,O
efficacy,O,O
and,O,O
safety,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
spring,O,O
allergic,O,O
rhinitis,O,O
in,O,O
a,O,O
multicenter,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
multiple,O,O
-,O,O
dose,O,O
",",O,O
parallel,O,O
-,O,O
groups,O,O
study,O,O
.,O,O
One,O,O
hundred,O,O
fifty,O,O
-,O,O
five,O,O
subjects,O,O
participated,O,O
.,O,O
Subjects,O,O
ranged,O,O
in,O,O
age,O,O
from,O,O
18,O,O
to,O,O
60,O,O
years,O,O
of,O,O
age,O,O
and,O,O
had,O,O
at,O,O
least,O,O
a,O,O
2,O,O
-,O,O
year,O,O
history,O,O
of,O,O
spring,O,O
allergic,O,O
rhinitis,O,O
",",O,O
confirmed,O,O
by,O,O
positive,O,O
skin,O,O
test,O,O
to,O,O
spring,O,O
aeroallergens,O,O
.,O,O
Medications,O,O
were,O,O
given,O,O
four,O,O
times,O,O
daily,O,O
;,O,O
the,O,O
azelastine,B,B
groups,O,O
received,O,O
0,O,O
.,O,O
5,O,O
",",O,O
1,O,O
.,O,O
0,O,O
",",O,O
or,O,O
2,O,O
.,O,O
0,O,O
mg,O,O
in,O,O
the,O,O
morning,O,O
and,O,O
evening,O,O
with,O,O
placebo,O,O
late,O,O
afternoon,O,O
;,O,O
the,O,O
chlorpheniramine,B,B
group,O,O
received,O,O
4,O,O
.,O,O
0,O,O
mg,O,O
four,O,O
times,O,O
daily,O,O
.,O,O
Daily,O,O
subject,O,O
symptom,O,O
cards,O,O
were,O,O
completed,O,O
during,O,O
a,O,O
screening,O,O
period,O,O
to,O,O
assess,O,O
pretreatment,O,O
symptoms,O,O
and,O,O
during,O,O
a,O,O
4,O,O
-,O,O
week,O,O
treatment,O,O
period,O,O
while,O,O
subjects,O,O
received,O,O
study,O,O
medications,O,O
.,O,O
Individual,O,O
symptoms,O,O
",",O,O
total,O,O
symptoms,O,O
",",O,O
and,O,O
major,O,O
symptoms,O,O
were,O,O
compared,O,O
to,O,O
determine,O,O
efficacy,O,O
of,O,O
medication,O,O
.,O,O
Elicited,O,O
",",O,O
volunteered,O,O
",",O,O
and,O,O
observed,O,O
adverse,O,O
experiences,O,O
were,O,O
recorded,O,O
for,O,O
each,O,O
subject,O,O
and,O,O
compared,O,O
among,O,O
groups,O,O
.,O,O
Vital,O,O
signs,O,O
",",O,O
body,O,O
weights,O,O
",",O,O
serum,O,B
chemistry,O,I
values,O,I
",",O,O
complete,O,O
blood,O,O
cell,O,O
counts,O,O
",",O,O
urine,O,O
studies,O,O
",",O,O
and,O,O
electrocardiograms,O,O
were,O,O
obtained,O,O
for,O,O
each,O,O
subject,O,O
and,O,O
compared,O,O
among,O,O
groups,O,O
.,O,O
Symptoms,O,O
relief,O,O
in,O,O
the,O,O
group,O,O
receiving,O,O
the,O,O
highest,O,O
concentration,O,O
of,O,O
azelastine,B,B
(,O,O
2,O,O
.,O,O
0,O,O
mg,O,O
twice,O,O
daily,O,O
),O,O
was,O,O
statistically,O,O
greater,O,O
than,O,O
in,O,O
the,O,O
placebo,O,O
group,O,O
during,O,O
all,O,O
weeks,O,O
of,O,O
the,O,O
study,O,O
.,O,O
Lower,O,O
doses,O,O
of,O,O
azelastine,B,B
were,O,O
statistically,O,O
more,O,O
effective,O,O
than,O,O
placebo,O,O
only,O,O
during,O,O
portions,O,O
of,O,O
the,O,O
first,O,O
3,O,O
weeks,O,O
of,O,O
the,O,O
study,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
although,O,O
the,O,O
chlorpheniramine,B,B
group,O,O
did,O,O
have,O,O
fewer,O,O
symptoms,O,O
than,O,O
the,O,O
placebo,O,B
group,O,O
during,O,O
the,O,O
study,O,O
",",O,O
the,O,O
difference,O,O
never,O,O
reached,O,O
statistical,O,O
significance,O,O
during,O,O
any,O,O
week,O,O
of,O,O
the,O,O
study,O,O
.,O,O
There,O,O
were,O,O
no,O,O
serious,O,O
side,O,O
effects,O,O
in,O,O
any,O,O
of,O,O
the,O,O
treatment,O,O
groups,O,O
.,O,O
Drowsiness,O,O
and,O,O
altered,O,O
taste,O,O
perception,O,O
were,O,O
increased,O,O
significantly,O,O
over,O,O
placebo,O,B
only,O,O
in,O,O
the,O,O
high,O,O
-,O,O
dose,O,O
azelastine,B,B
group,O,O
.,O,O
Azelastine,B,B
appears,O,O
to,O,O
be,O,O
a,O,O
safe,O,O
",",O,O
efficacious,O,O
medication,O,O
for,O,O
seasonal,O,O
allergic,O,O
rhinitis,O,O
.,O,O
Toxicity,O,B
due,O,O
to,O,O
remission,O,O
inducing,O,O
drugs,O,O
in,O,O
rheumatoid,O,O
arthritis,O,O
.,O,O
Association,O,O
with,O,O
HLA,O,B
-,O,I
B35,O,I
and,O,O
Cw4,O,B
antigens,O,O
.,O,O
Twenty,O,O
-,O,O
five,O,O
patients,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
(,O,O
RA,O,O
),O,O
who,O,O
developed,O,O
toxicity,O,B
while,O,O
taking,O,O
remission,O,O
inducing,O,O
drugs,O,O
and,O,O
30,O,O
without,O,O
toxicity,O,B
were,O,O
studied,O,O
for,O,O
possible,O,O
associations,O,O
with,O,O
class,O,O
I,O,O
and,O,O
II,O,O
HLA,O,B
antigens,O,O
.,O,O
A,O,O
strong,O,O
association,O,O
has,O,O
been,O,O
found,O,O
between,O,O
nephritis,O,B
and,O,O
dermatitis,O,B
due,O,O
to,O,O
Tiopronin,B,B
(,O,O
a,O,O
D,B,B
-,I,I
Penicillamine,I,I
like,O,I
compound,O,I
),O,O
and,O,O
class,O,O
I,O,O
antigens,O,O
B35,O,B
-,O,I
Cw4,O,I
",",O,O
and,O,O
between,O,O
dermatitis,O,B
due,O,O
to,O,O
gold,B,B
thiosulphate,B,I
and,O,O
B35,O,B
.,O,O
Compared,O,O
to,O,O
healthy,O,O
controls,O,O
a,O,O
lower,O,O
DR5,O,B
frequency,O,O
was,O,O
observed,O,O
in,O,O
patients,O,O
with,O,O
RA,O,O
except,O,O
for,O,O
the,O,O
Tiopronin,B,B
related,O,I
nephritis,O,I
group,O,I
.,O,O
Transient,O,O
contralateral,O,O
rotation,O,O
following,O,O
unilateral,O,O
substantia,O,B
nigra,O,I
lesion,O,O
reflects,O,O
susceptibility,O,O
of,O,O
the,O,O
nigrostriatal,O,B
system,O,O
to,O,O
exhaustion,O,O
by,O,O
amphetamine,B,B
.,O,O
Following,O,O
unilateral,O,O
6,B,O
-,I,O
OHDA,I,B
induced,O,O
SN,O,B
lesion,O,O
",",O,O
a,O,O
transient,O,O
period,O,O
of,O,O
contralateral,O,O
rotation,O,O
has,O,O
been,O,O
reported,O,O
to,O,O
precede,O,O
the,O,O
predominant,O,O
ipsilateral,O,O
circling,O,O
.,O,O
In,O,O
order,O,O
to,O,O
clarify,O,O
the,O,O
nature,O,O
of,O,O
this,O,O
initial,O,O
contralateral,O,O
rotation,O,O
we,O,O
examined,O,O
the,O,O
effect,O,O
of,O,O
the,O,O
duration,O,O
of,O,O
recovery,O,O
period,O,O
after,O,O
the,O,O
lesion,O,O
",",O,O
on,O,O
amphetamine,B,B
-,O,I
induced,O,I
rotational,O,I
behavior,O,I
.,O,O
Three,O,O
days,O,O
post,O,O
lesion,O,O
",",O,O
most,O,O
rats,O,O
circled,O,O
predominantly,O,O
contralaterally,O,O
to,O,O
the,O,O
lesion,O,O
.,O,O
Such,O,O
contralateral,O,O
rotation,O,O
may,O,O
result,O,O
from,O,O
either,O,O
degeneration,O,O
-,O,O
induced,O,O
breakdown,O,O
of,O,O
the,O,O
DA,O,B
pool,O,I
",",O,O
or,O,O
lesion,O,O
-,O,O
induced,O,O
increase,O,O
of,O,O
DA,O,B
turnover,O,I
in,O,O
the,O,O
spared,O,O
neurons,O,O
.,O,O
A,O,O
substantial,O,O
degree,O,O
of,O,O
contralateral,O,O
preference,O,O
was,O,O
still,O,O
evident,O,O
when,O,O
amphetamine,B,B
was,O,O
administered,O,O
for,O,O
the,O,O
first,O,O
time,O,O
24,O,O
days,O,O
after,O,O
lesioning,O,O
",",O,O
indicating,O,O
involvement,O,O
of,O,O
spared,O,O
cells,O,O
in,O,O
the,O,O
contralateral,O,O
rotation,O,O
.,O,O
However,O,O
",",O,O
regardless,O,O
of,O,O
the,O,O
duration,O,O
of,O,O
recovery,O,O
(,O,O
and,O,O
irrespective,O,O
of,O,O
either,O,O
lesion,O,O
volume,O,O
",",O,O
amphetamine,B,B
dose,O,O
",",O,O
or,O,O
post,O,O
-,O,O
lesion,O,O
motor,O,O
exercise,O,O
),O,O
",",O,O
amphetamine,B,B
-,O,O
induced,O,O
rotation,O,O
tended,O,O
to,O,O
become,O,O
gradually,O,O
more,O,O
ipsilateral,O,O
as,O,O
the,O,O
observation,O,O
session,O,O
progressed,O,O
",",O,O
and,O,O
all,O,O
rats,O,O
circled,O,O
ipsilaterally,O,O
to,O,O
the,O,O
lesion,O,O
in,O,O
response,O,O
to,O,O
further,O,O
amphetamine,B,B
injections,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
amphetamine,B,B
has,O,O
an,O,O
irreversible,O,O
effect,O,O
on,O,O
the,O,O
post,O,O
-,O,O
lesion,O,O
DA,O,B
pool,O,O
contributing,O,O
to,O,O
contralateral,O,O
rotation,O,O
.,O,O
Mitomycin,B,B
C,I,I
associated,O,O
hemolytic,O,O
uremic,O,O
syndrome,O,O
.,O,O
Mitomycin,B,B
C,I,I
associated,O,O
Hemolytic,O,B
Uremic,O,I
Syndrome,O,I
(,O,O
HUS,O,I
),O,O
is,O,O
a,O,O
potentially,O,O
fatal,O,O
but,O,O
uncommon,O,O
condition,O,O
that,O,O
is,O,O
not,O,O
yet,O,O
widely,O,O
recognised,O,O
.,O,O
It,O,O
consists,O,O
of,O,O
microangiopathic,O,B
hemolytic,O,I
anemia,O,I
",",O,O
thrombocytopenia,O,B
and,O,O
progressive,O,O
renal,O,B
failure,O,I
associated,O,O
with,O,O
mitomycin,B,B
C,I,I
treatment,O,O
and,O,O
affects,O,O
about,O,O
10,O,O
%,O,O
of,O,O
patients,O,O
treated,O,O
with,O,O
this,O,O
agent,O,O
.,O,O
The,O,O
renal,O,B
failure,O,I
usually,O,O
develops,O,O
about,O,O
8,O,O
-,O,O
10,O,O
mth,O,O
after,O,O
start,O,O
of,O,O
mitomycin,B,B
C,I,I
treatment,O,O
and,O,O
the,O,O
mortality,O,O
is,O,O
approximately,O,O
60,O,O
%,O,O
from,O,O
renal,O,B
failure,O,I
or,O,O
pulmonary,O,B
edema,O,I
.,O,O
Renal,O,O
lesions,O,O
are,O,O
similar,O,O
to,O,O
those,O,O
seen,O,O
in,O,O
idiopathic,O,O
HUS,O,O
and,O,O
include,O,O
arteriolar,O,O
fibrin,O,B
thrombi,O,O
",",O,O
expanded,O,O
subendothelial,O,O
zones,O,O
in,O,O
glomerular,O,O
capillary,O,O
walls,O,O
",",O,O
ischemic,O,O
wrinkling,O,O
of,O,O
glomerular,O,O
basement,O,O
membranes,O,O
and,O,O
mesangiolysis,O,O
.,O,O
The,O,O
mechanism,O,O
of,O,O
action,O,O
is,O,O
postulated,O,O
as,O,O
mitomycin,B,B
C,I,I
-,O,I
induced,O,O
endothelial,O,O
cell,O,O
damage,O,O
.,O,O
We,O,O
describe,O,O
the,O,O
clinical,O,O
course,O,O
and,O,O
pathological,O,O
findings,O,O
in,O,O
a,O,O
65,O,O
yr,O,O
-,O,O
old,O,O
man,O,O
with,O,O
gastric,O,B
adenocarcinoma,O,I
who,O,O
developed,O,O
renal,O,B
failure,O,I
and,O,O
thrombocytopenia,O,B
while,O,O
on,O,O
treatment,O,O
with,O,O
mitomycin,B,B
C,I,I
and,O,O
died,O,O
in,O,O
pulmonary,O,B
edema,O,I
.,O,O
Ketanserin,B,B
pretreatment,O,O
reverses,O,O
alfentanil,B,B
-,O,O
induced,O,O
muscle,O,O
rigidity,O,O
.,O,O
Systemic,O,O
pretreatment,O,O
with,O,O
ketanserin,B,B
",",O,O
a,O,O
relatively,O,O
specific,O,O
type,O,O
-,O,O
2,O,O
serotonin,B,O
receptor,O,O
antagonist,O,O
",",O,O
significantly,O,O
attenuated,O,O
the,O,O
muscle,O,O
rigidity,O,O
produced,O,O
in,O,O
rats,O,O
by,O,O
the,O,O
potent,O,O
short,O,O
-,O,O
acting,O,O
opiate,O,O
agonist,O,O
alfentanil,B,B
.,O,O
Following,O,O
placement,O,O
of,O,O
subcutaneous,O,O
electrodes,O,O
in,O,O
each,O,O
animal,O,O
',O,O
s,O,O
left,O,O
gastrocnemius,O,O
muscle,O,O
",",O,O
rigidity,O,O
was,O,O
assessed,O,O
by,O,O
analyzing,O,O
root,O,O
-,O,O
mean,O,O
-,O,O
square,O,O
electromyographic,O,O
activity,O,O
.,O,O
Intraperitoneal,O,O
ketanserin,B,B
administration,O,O
at,O,O
doses,O,O
of,O,O
0,O,O
.,O,O
63,O,O
and,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
prevented,O,O
the,O,O
alfentanil,B,B
-,O,O
induced,O,O
increase,O,O
in,O,O
electromyographic,O,O
activity,O,O
compared,O,O
with,O,O
animals,O,O
pretreated,O,O
saline,O,B
.,O,O
Chlordiazepoxide,B,B
at,O,O
doses,O,O
up,O,O
to,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
failed,O,O
to,O,O
significantly,O,O
influence,O,O
the,O,O
rigidity,O,O
produced,O,O
by,O,O
alfentanil,B,O
.,O,O
Despite,O,O
the,O,O
absence,O,O
of,O,O
rigidity,O,O
",",O,O
animals,O,O
that,O,O
received,O,O
ketanserin,B,B
(,O,O
greater,O,O
than,O,O
0,O,O
.,O,O
31,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
followed,O,O
by,O,O
alfentanil,B,O
were,O,O
motionless,O,O
",",O,O
flaccid,O,O
",",O,O
and,O,O
less,O,O
responsive,O,O
to,O,O
external,O,O
stimuli,O,O
than,O,O
were,O,O
animals,O,O
receiving,O,O
alfentanil,B,O
alone,O,O
.,O,O
Rats,O,O
that,O,O
received,O,O
ketanserin,B,B
and,O,O
alfentanil,B,B
exhibited,O,O
less,O,O
rearing,O,O
and,O,O
exploratory,O,O
behavior,O,O
at,O,O
the,O,O
end,O,O
of,O,O
the,O,O
60,O,O
-,O,O
min,O,O
recording,O,O
period,O,O
than,O,O
did,O,O
animals,O,O
that,O,O
received,O,O
ketanserin,B,B
alone,O,O
.,O,O
These,O,O
results,O,O
",",O,O
in,O,O
combination,O,O
with,O,O
previous,O,O
work,O,O
",",O,O
suggest,O,O
that,O,O
muscle,O,O
rigidity,O,O
",",O,O
a,O,O
clinically,O,O
relevant,O,O
side,O,O
-,O,O
effect,O,O
of,O,O
parenteral,O,O
narcotic,O,O
administration,O,O
",",O,O
may,O,O
be,O,O
partly,O,O
mediated,O,O
via,O,O
serotonergic,O,O
pathways,O,O
.,O,O
Pretreatment,O,O
with,O,O
type,O,B
-,O,I
2,O,I
serotonin,B,I
antagonists,O,I
may,O,O
be,O,O
clinically,O,O
useful,O,O
in,O,O
attenuating,O,O
opiate,O,B
-,O,I
induced,O,I
rigidity,O,I
",",O,O
although,O,O
further,O,O
studies,O,O
will,O,O
be,O,O
necessary,O,O
to,O,O
assess,O,O
the,O,O
interaction,O,O
of,O,O
possibly,O,O
enhanced,O,O
CNS,O,B
",",O,O
cardiovascular,O,B
",",O,O
and,O,O
respiratory,O,B
depression,O,I
.,O,O
Antagonism,O,O
of,O,O
diazepam,B,B
-,O,I
induced,O,I
sedative,O,I
effects,O,I
by,O,O
Ro15,B,B
-,I,I
1788,I,I
in,O,O
patients,O,O
after,O,O
surgery,O,O
under,O,O
lumbar,O,O
epidural,O,O
block,O,O
.,O,O
A,O,O
double,O,O
-,O,O
blind,O,O
placebo,O,B
-,O,O
controlled,O,O
investigation,O,O
of,O,O
efficacy,O,O
and,O,O
safety,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
assess,O,O
the,O,O
efficacy,O,O
of,O,O
Ro15,B,B
-,I,I
1788,I,I
and,O,O
a,O,O
placebo,O,B
in,O,O
reversing,O,O
diazepam,B,B
-,O,O
induced,O,O
effects,O,O
after,O,O
surgery,O,O
under,O,O
epidural,O,O
block,O,O
",",O,O
and,O,O
to,O,O
evaluate,O,O
the,O,O
local,O,O
tolerance,O,O
and,O,O
general,O,O
safety,O,O
of,O,O
Ro15,B,B
-,I,I
1788,I,I
.,O,O
Fifty,O,O
-,O,O
seven,O,O
patients,O,O
were,O,O
sedated,O,O
with,O,O
diazepam,B,B
for,O,O
surgery,O,O
under,O,O
epidural,O,O
anaesthesia,O,O
.,O,O
Antagonism,O,O
of,O,O
diazepam,B,B
-,O,O
induced,O,O
effects,O,O
by,O,O
Ro15,B,B
-,I,O
1788,I,I
was,O,O
investigated,O,O
postoperatively,O,O
in,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
.,O,O
The,O,O
patient,O,O
',O,O
s,O,O
subjective,O,O
assessment,O,O
of,O,O
mood,O,O
rating,O,O
",",O,O
an,O,O
objective,O,O
test,O,O
of,O,O
performance,O,O
",",O,O
a,O,O
test,O,O
for,O,O
amnesia,O,O
",",O,O
and,O,O
vital,O,O
signs,O,O
were,O,O
recorded,O,O
for,O,O
up,O,O
to,O,O
300,O,O
min,O,O
after,O,O
administration,O,O
of,O,O
the,O,O
trial,O,O
drug,O,O
.,O,O
No,O,O
significant,O,O
differences,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
were,O,O
observed,O,O
for,O,O
mood,O,O
rating,O,O
",",O,O
amnesia,O,O
",",O,O
or,O,O
vital,O,O
signs,O,O
.,O,O
The,O,O
Ro15,B,B
-,I,I
1788,I,I
group,O,O
showed,O,O
a,O,O
significant,O,O
improvement,O,O
in,O,O
the,O,O
performance,O,O
test,O,O
up,O,O
to,O,O
120,O,O
min,O,O
after,O,O
administration,O,O
of,O,O
the,O,O
drug,O,O
.,O,O
There,O,O
was,O,O
no,O,O
evidence,O,O
of,O,O
reaction,O,O
at,O,O
the,O,O
injection,O,O
site,O,O
.,O,O
Chorea,O,B
associated,O,O
with,O,O
oral,B,O
contraception,I,O
.,O,O
Three,O,O
patients,O,O
developed,O,O
chorea,O,O
while,O,O
receiving,O,O
oral,B,B
contraceptives,I,I
.,O,O
Two,O,O
were,O,O
young,O,O
patients,O,O
whose,O,O
chorea,O,O
developed,O,O
long,O,O
after,O,O
treatment,O,O
had,O,O
been,O,O
started,O,O
and,O,O
disappeared,O,O
soon,O,O
after,O,O
it,O,O
had,O,O
been,O,O
discontinued,O,O
.,O,O
The,O,O
third,O,O
patient,O,O
had,O,O
acute,O,O
amphetamine,B,B
-,O,I
induced,O,I
chorea,O,O
after,O,O
prolonged,O,O
oral,B,B
contraception,I,I
.,O,O
Prolonged,O,O
administration,O,O
of,O,O
female,O,B
sex,O,I
hormones,O,I
is,O,O
a,O,O
possible,O,O
cause,O,O
of,O,O
chorea,O,O
in,O,O
women,O,O
who,O,O
have,O,O
not,O,O
previously,O,O
had,O,O
chorea,O,O
or,O,O
rheumatic,O,O
fever,O,O
.,O,O
Co,O,O
-,O,O
carcinogenic,O,O
effect,O,O
of,O,O
retinyl,B,B
acetate,I,I
on,O,O
forestomach,O,O
carcinogenesis,O,O
of,O,O
male,O,B
F344,O,I
rats,O,I
induced,O,O
with,O,O
butylated,B,B
hydroxyanisole,I,I
.,O,O
The,O,O
potential,O,O
modifying,O,O
effect,O,O
of,O,O
retinyl,B,B
acetate,I,I
(,O,O
RA,B,B
),O,O
on,O,O
butylated,B,B
hydroxyanisole,I,I
(,O,O
BHA,B,B
),O,O
-,O,O
induced,O,O
rat,O,B
forestomach,O,I
tumorigenesis,O,I
was,O,O
examined,O,O
.,O,O
Male,O,O
F344,O,O
rats,O,O
",",O,O
5,O,O
weeks,O,O
of,O,O
age,O,O
",",O,O
were,O,O
maintained,O,O
on,O,O
diet,O,O
containing,O,O
1,O,O
%,O,O
or,O,O
2,O,O
%,O,O
BHA,B,B
by,O,O
weight,O,O
and,O,O
simultaneously,O,O
on,O,O
drinking,O,O
water,O,O
supplemented,O,O
with,O,O
RA,B,B
at,O,O
various,O,O
concentrations,O,O
(,O,O
w,O,O
/,O,O
v,O,O
),O,O
for,O,O
52,O,O
weeks,O,O
.,O,O
In,O,O
groups,O,O
given,O,O
2,O,O
%,O,O
BHA,B,B
",",O,O
although,O,O
marked,O,O
hyperplastic,O,O
changes,O,O
of,O,O
the,O,O
forestomach,O,O
epithelium,O,O
were,O,O
observed,O,O
in,O,O
all,O,O
animals,O,O
",",O,O
co,O,O
-,O,O
administration,O,O
of,O,O
0,O,O
.,O,O
25,O,O
%,O,O
RA,B,B
significantly,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
increased,O,O
the,O,O
incidence,O,O
of,O,O
forestomach,O,B
tumors,O,O
(,O,O
squamous,O,B
cell,O,I
papilloma,O,I
and,O,O
carcinoma,O,I
),O,O
to,O,O
60,O,O
%,O,O
(,O,O
9,O,O
/,O,O
15,O,O
",",O,O
2,O,O
rats,O,O
with,O,O
carcinoma,O,I
),O,O
from,O,O
15,O,O
%,O,O
(,O,O
3,O,O
/,O,O
20,O,O
",",O,O
one,O,O
rat,O,O
with,O,O
carcinoma,O,I
),O,O
in,O,O
the,O,O
group,O,O
given,O,O
RA,B,B
-,O,O
free,O,O
water,O,O
.,O,O
In,O,O
rats,O,O
given,O,O
1,O,O
%,O,O
BHA,B,B
",",O,O
RA,B,B
co,O,O
-,O,O
administered,O,O
at,O,O
a,O,O
dose,O,O
of,O,O
0,O,O
.,O,O
",",O,O
0,O,O
.,O,O
1,O,O
",",O,O
0,O,O
.,O,O
2,O,O
or,O,O
0,O,O
.,O,O
25,O,O
%,O,O
showed,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
enhancing,O,O
effect,O,O
on,O,O
the,O,O
development,O,O
of,O,O
the,O,O
BHA,B,B
-,O,O
induced,O,O
epithelial,O,O
hyperplasia,O,O
.,O,O
Tumors,O,O
",",O,O
all,O,O
papillomas,O,O
",",O,O
were,O,O
induced,O,O
in,O,O
3,O,O
rats,O,O
(,O,O
17,O,O
%,O,O
),O,O
with,O,O
0,O,O
.,O,O
25,O,O
%,O,O
RA,B,B
and,O,O
in,O,O
one,O,O
rat,O,O
(,O,O
10,O,O
%,O,O
),O,O
with,O,O
0,O,O
.,O,O
%,O,O
RA,B,B
co,O,O
-,O,O
administration,O,O
.,O,O
RA,B,B
alone,O,O
did,O,O
not,O,O
induce,O,O
hyperplastic,O,O
changes,O,O
in,O,O
the,O,O
forestomach,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
RA,B,B
acted,O,O
as,O,O
a,O,O
co,O,O
-,O,O
carcinogen,O,O
in,O,O
the,O,O
BHA,B,B
forestomach,O,O
carcinogenesis,O,O
of,O,O
the,O,O
rat,O,O
.,O,O
A,O,O
prospective,O,O
study,O,O
on,O,O
the,O,O
dose,O,O
dependency,O,O
of,O,O
cardiotoxicity,O,O
induced,O,O
by,O,O
mitomycin,B,B
C,I,I
.,O,O
Since,O,O
1975,O,O
mitomycin,B,B
C,I,I
(,O,O
MMC,B,B
),O,O
has,O,O
been,O,O
suggested,O,O
to,O,O
be,O,O
cardiotoxic,O,O
",",O,O
especially,O,O
when,O,O
combined,O,O
with,O,O
or,O,O
given,O,O
following,O,O
doxorubicin,B,B
.,O,O
Data,O,O
on,O,O
dose,O,O
dependency,O,O
or,O,O
incidence,O,O
concerning,O,O
this,O,O
side,O,O
effect,O,O
were,O,O
not,O,O
known,O,O
.,O,O
We,O,O
have,O,O
initiated,O,O
a,O,O
prospective,O,O
study,O,O
to,O,O
obtain,O,O
some,O,O
more,O,O
data,O,O
on,O,O
these,O,O
subjects,O,O
.,O,O
Forty,O,O
-,O,O
four,O,O
MMC,B,B
-,O,O
treated,O,O
patients,O,O
were,O,O
studied,O,O
",",O,O
37,O,O
of,O,O
them,O,O
could,O,O
be,O,O
evaluated,O,O
.,O,O
All,O,O
patients,O,O
were,O,O
studied,O,O
by,O,O
repeated,O,O
physical,O,O
examinations,O,O
",",O,O
chest,O,O
X,O,B
-,O,I
rays,O,I
",",O,O
electro,O,B
-,O,I
and,O,I
echocardiography,O,I
and,O,I
radionuclide,O,B
left,O,I
ventricular,O,I
ejection,O,I
fraction,O,I
(,O,I
EF,O,I
),O,I
determinations,O,I
.,O,O
The,O,O
results,O,O
were,O,O
evaluated,O,O
per,O,O
cumulative,O,O
dose,O,O
level,O,O
.,O,O
One,O,O
of,O,O
the,O,O
patients,O,O
developed,O,O
cardiac,O,B
failure,O,I
after,O,O
30,O,O
mg,O,O
m,O,O
-,O,O
2,O,O
MMC,B,B
and,O,O
only,O,O
150,O,O
mg,O,O
m,O,O
-,O,O
2,O,O
doxorubicin,B,B
.,O,O
The,O,O
cardiac,O,B
failure,O,I
was,O,O
predicted,O,O
by,O,O
a,O,O
drop,O,O
in,O,O
EF,O,B
determined,O,O
during,O,O
a,O,O
cold,O,O
pressor,O,O
test,O,O
.,O,O
None,O,O
of,O,O
the,O,O
other,O,O
patients,O,O
developed,O,O
clinical,O,O
cardiotoxicity,O,B
",",O,O
nor,O,O
did,O,O
the,O,O
studied,O,O
parameters,O,O
change,O,O
.,O,O
The,O,O
literature,O,O
on,O,O
this,O,O
subject,O,O
was,O,O
also,O,O
reviewed,O,O
.,O,O
Based,O,O
on,O,O
the,O,O
combined,O,O
data,O,O
from,O,O
the,O,O
present,O,O
study,O,O
and,O,O
the,O,O
literature,O,O
",",O,O
we,O,O
suggest,O,O
that,O,O
MMC,B,B
-,O,O
related,O,O
cardiotoxicity,O,O
is,O,O
dose,O,O
dependent,O,O
",",O,O
occurring,O,O
at,O,O
cumulative,O,O
dose,O,O
levels,O,O
of,O,O
30,O,O
mg,O,O
m,O,O
-,O,O
2,O,O
or,O,O
more,O,O
",",O,O
mainly,O,O
in,O,O
patients,O,O
also,O,O
(,O,O
previously,O,O
or,O,O
simultaneously,O,O
),O,O
treated,O,O
with,O,O
doxorubicin,B,B
.,O,O
The,O,O
incidence,O,O
is,O,O
likely,O,O
to,O,O
be,O,O
less,O,O
than,O,O
10,O,O
%,O,O
even,O,O
for,O,O
this,O,O
risk,O,O
group,O,O
.,O,O
Reversible,O,O
cerebral,O,O
lesions,O,O
associated,O,O
with,O,O
tiazofurin,B,B
usage,O,O
:,O,O
MR,O,O
demonstration,O,O
.,O,O
Tiazofurin,B,B
is,O,O
an,O,O
experimental,O,O
chemotherapeutic,O,O
agent,O,O
currently,O,O
undergoing,O,O
clinical,O,O
evaluation,O,O
.,O,O
We,O,O
report,O,O
our,O,O
results,O,O
with,O,O
magnetic,O,O
resonance,O,O
(,O,O
MR,O,O
),O,O
in,O,O
demonstrating,O,O
reversible,O,O
cerebral,O,O
abnormalities,O,O
concurrent,O,O
with,O,O
the,O,O
use,O,O
of,O,O
this,O,O
drug,O,O
.,O,O
The,O,O
abnormalities,O,O
on,O,O
MR,O,B
were,O,O
correlated,O,O
with,O,O
findings,O,O
on,O,O
CT,O,B
as,O,O
well,O,O
as,O,O
with,O,O
cerebral,O,B
angiography,O,I
.,O,O
The,O,O
utility,O,O
of,O,O
MR,O,B
in,O,O
the,O,O
evaluation,O,O
of,O,O
patients,O,O
receiving,O,O
this,O,O
new,O,O
agent,O,O
is,O,O
illustrated,O,O
.,O,O
Receptor,O,O
mechanisms,O,O
of,O,O
nicotine,B,B
-,O,O
induced,O,O
locomotor,O,O
hyperactivity,O,O
in,O,O
chronic,O,O
nicotine,B,B
-,O,O
treated,O,O
rats,O,O
.,O,O
Rats,O,O
were,O,O
pretreated,O,O
with,O,O
saline,O,B
or,O,O
nicotine,B,B
(,O,O
1,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
per,O,O
day,O,O
),O,O
by,O,O
subcutaneously,O,O
implanting,O,O
each,O,O
animal,O,O
with,O,O
an,O,O
Alzet,O,B
osmotic,O,I
mini,O,I
-,O,I
pump,O,I
which,O,O
continuously,O,O
released,O,O
saline,O,B
or,O,O
nicotine,B,B
for,O,O
1,O,O
",",O,O
5,O,O
and,O,O
14,O,O
days,O,O
.,O,O
At,O,O
the,O,O
end,O,O
of,O,O
each,O,O
pretreatment,O,O
period,O,O
",",O,O
animals,O,O
were,O,O
used,O,O
for,O,O
(,O,O
i,O,O
),O,O
determining,O,O
their,O,O
locomotor,O,O
response,O,O
to,O,O
acutely,O,O
injected,O,O
nicotine,B,B
(,O,O
0,O,O
.,O,O
2,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
and,O,O
(,O,O
ii,O,O
),O,O
measuring,O,O
the,O,O
density,O,O
of,O,O
L,O,B
-,O,O
[,O,O
3H,O,B
],O,O
nicotine,B,B
and,O,O
[,O,O
3H,O,B
],O,O
spiperone,B,B
binding,O,O
sites,O,O
in,O,O
the,O,O
striatum,O,O
.,O,O
We,O,O
observed,O,O
no,O,O
changes,O,O
in,O,O
nicotine,B,B
-,O,O
induced,O,O
locomotor,O,O
response,O,O
",",O,O
striatal,O,O
L,O,B
-,O,O
[,O,O
3H,O,B
],O,O
nicotine,B,B
and,O,O
[,O,O
3H,O,B
],O,O
spiperone,B,B
binding,O,O
in,O,O
the,O,O
animals,O,O
pretreated,O,O
with,O,O
nicotine,B,B
for,O,O
1,O,O
day,O,O
.,O,O
In,O,O
rats,O,O
which,O,O
were,O,O
pretreated,O,O
with,O,O
nicotine,B,B
for,O,O
5,O,O
days,O,O
",",O,O
there,O,O
was,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
the,O,O
nicotine,B,B
-,O,O
stimulated,O,O
locomotor,O,O
response,O,O
which,O,O
was,O,O
associated,O,O
with,O,O
an,O,O
increase,O,O
in,O,O
the,O,O
number,O,O
of,O,O
L,O,B
-,O,I
[,O,O
3H,O,B
],O,O
nicotine,B,B
binding,O,O
sites,O,O
and,O,O
also,O,O
with,O,O
an,O,O
elevated,O,O
dopamine,B,B
(,O,O
DA,B,I
),O,O
level,O,O
in,O,O
the,O,O
striatum,O,O
.,O,O
The,O,O
number,O,O
of,O,O
striatal,O,O
[,O,O
3H,O,B
],O,O
spiperone,B,I
binding,O,O
sites,O,O
was,O,O
not,O,O
affected,O,O
.,O,O
In,O,O
animals,O,O
pretreated,O,O
with,O,O
nicotine,B,B
for,O,O
14,O,O
days,O,O
",",O,O
the,O,O
nicotine,B,B
-,O,O
induced,O,O
locomotor,O,O
response,O,O
remained,O,O
to,O,O
be,O,O
potentiated,O,O
.,O,O
However,O,O
",",O,O
this,O,O
response,O,O
was,O,O
correlated,O,O
with,O,O
an,O,O
elevated,O,O
number,O,O
of,O,O
striatal,O,O
[,O,O
3H,O,B
],O,O
spiperone,B,I
binding,O,O
sites,O,O
",",O,O
whereas,O,O
the,O,O
number,O,O
of,O,O
striatal,O,O
L,O,B
-,O,O
[,O,O
3H,O,B
],O,O
nicotine,B,I
binding,O,O
sites,O,O
and,O,O
the,O,O
striatal,O,O
DA,B,B
level,O,O
were,O,O
normal,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
chronic,O,O
nicotine,B,B
-,O,O
treated,O,O
rats,O,O
develop,O,O
locomotor,O,O
hyperactivity,O,O
in,O,O
response,O,O
to,O,O
nicotine,B,B
initially,O,O
due,O,O
to,O,O
increases,O,O
of,O,O
both,O,O
the,O,O
density,O,O
of,O,O
nicotinic,O,B
receptors,O,O
and,O,O
DA,B,B
concentration,O,O
",",O,O
followed,O,O
by,O,O
inducing,O,O
DA,B,B
receptor,O,O
supersensitivity,O,O
in,O,O
the,O,O
striatum,O,O
.,O,O
Amelioration,O,O
of,O,O
bendrofluazide,B,B
-,O,O
induced,O,O
hypokalemia,O,O
by,O,O
timolol,B,B
.,O,O
The,O,O
beta,O,B
adrenergic,O,I
blocking,O,I
drug,O,I
",",O,O
timolol,B,B
",",O,O
tended,O,O
to,O,O
correct,O,O
the,O,O
hypokalemia,O,O
of,O,O
short,O,O
-,O,O
term,O,O
bendrofluazide,B,O
treatment,O,O
in,O,O
6,O,O
healthy,O,O
male,O,O
subjects,O,O
and,O,O
although,O,O
the,O,O
effect,O,O
was,O,O
small,O,O
it,O,O
was,O,O
significant,O,O
.,O,O
Timolol,B,B
also,O,O
reduced,O,O
the,O,O
rise,O,O
in,O,O
plasma,O,O
aldosterone,B,B
and,O,O
urine,O,O
potassium,B,B
excretion,O,O
following,O,O
bendrofluazide,B,O
and,O,O
increased,O,O
the,O,O
urine,O,O
sodium,B,B
/,O,O
potassium,B,B
ratio,O,O
.,O,O
There,O,O
was,O,O
no,O,O
evidence,O,O
of,O,O
a,O,O
shift,O,O
of,O,O
potassium,B,B
from,O,O
the,O,O
intracellular,O,O
to,O,O
the,O,O
extracellular,O,O
space,O,O
.,O,O
St,O,O
.,O,O
Anthony,O,O
',O,O
s,O,O
fire,O,O
",",O,O
then,O,O
and,O,O
now,O,O
:,O,O
a,O,O
case,O,O
report,O,O
and,O,O
historical,O,O
review,O,O
.,O,O
A,O,O
rare,O,O
case,O,O
of,O,O
morbid,O,O
vasospasm,O,O
",",O,O
together,O,O
with,O,O
striking,O,O
angiographic,O,O
findings,O,O
",",O,O
is,O,O
described,O,O
secondary,O,O
to,O,O
the,O,O
ingestion,O,O
of,O,O
methysergide,B,B
by,O,O
a,O,O
48,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
.,O,O
A,O,O
brief,O,O
review,O,O
of,O,O
the,O,O
literature,O,O
on,O,O
similar,O,O
cases,O,O
is,O,O
presented,O,O
.,O,O
A,O,O
discussion,O,O
of,O,O
the,O,O
history,O,O
of,O,O
ergot,B,B
includes,O,O
its,O,O
original,O,O
discovery,O,O
",",O,O
the,O,O
epidemics,O,O
of,O,O
gangrene,O,O
that,O,O
it,O,O
has,O,O
caused,O,O
through,O,O
the,O,O
ages,O,O
and,O,O
its,O,O
past,O,O
and,O,O
present,O,O
role,O,O
in,O,O
the,O,O
management,O,O
of,O,O
migraine,O,O
headache,O,O
.,O,O
Despite,O,O
the,O,O
advent,O,O
of,O,O
calcium,B,B
channel,O,I
blockers,O,I
and,O,O
beta,O,B
-,O,I
adrenergic,O,I
antagonists,O,I
",",O,O
ergot,B,B
preparations,O,O
continue,O,O
to,O,O
play,O,O
a,O,O
major,O,O
role,O,O
in,O,O
migraine,O,O
therapy,O,O
",",O,O
so,O,O
that,O,O
the,O,O
danger,O,O
of,O,O
St,O,O
.,O,O
Anthony,O,O
',O,O
s,O,O
fire,O,O
persists,O,O
.,O,O
Cardiac,O,O
transplantation,O,O
:,O,O
improved,O,O
quality,O,O
of,O,O
survival,O,O
with,O,O
a,O,O
modified,O,O
immunosuppressive,O,O
protocol,O,O
.,O,O
The,O,O
effects,O,O
on,O,O
renal,O,O
function,O,O
on,O,O
two,O,O
different,O,O
immunosuppressive,O,O
protocols,O,O
were,O,O
evaluated,O,O
retrospectively,O,O
in,O,O
two,O,O
subsequent,O,O
groups,O,O
of,O,O
heart,O,O
transplant,O,O
recipients,O,O
.,O,O
In,O,O
group,O,O
I,O,O
",",O,O
cyclosporine,B,B
was,O,O
given,O,O
before,O,O
the,O,O
procedure,O,O
at,O,O
a,O,O
loading,O,O
dose,O,O
of,O,O
17,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
and,O,O
then,O,O
continued,O,O
after,O,O
the,O,O
procedure,O,O
to,O,O
keep,O,O
a,O,O
whole,O,O
blood,O,O
level,O,O
about,O,O
1000,O,O
ng,O,O
/,O,O
ml,O,O
.,O,O
In,O,O
group,O,O
II,O,O
",",O,O
cyclosporine,B,B
was,O,O
started,O,O
only,O,O
after,O,O
the,O,O
procedure,O,O
at,O,O
a,O,O
lower,O,O
dosage,O,O
and,O,O
was,O,O
complemented,O,O
by,O,O
azathioprine,B,B
",",O,O
which,O,O
was,O,O
used,O,O
for,O,O
the,O,O
first,O,O
postoperative,O,O
week,O,O
.,O,O
Group,O,O
II,O,O
showed,O,O
a,O,O
better,O,O
perioperative,O,O
renal,O,O
function,O,O
as,O,O
determined,O,O
by,O,O
serum,O,O
blood,O,O
urea,B,B
nitrogen,I,I
and,O,O
serum,O,O
creatinine,B,B
levels,O,O
.,O,O
Group,O,O
II,O,O
also,O,O
showed,O,O
a,O,O
significant,O,O
decrease,O,O
of,O,O
chronic,O,O
nephrotoxicity,O,O
secondary,O,O
to,O,O
long,O,O
-,O,O
term,O,O
therapy,O,O
with,O,O
cyclosporine,B,B
.,O,O
Despite,O,O
this,O,O
improvement,O,O
in,O,O
late,O,O
renal,O,O
function,O,O
",",O,O
group,O,O
II,O,O
still,O,O
shows,O,O
a,O,O
slow,O,O
rise,O,O
in,O,O
serum,O,O
creatinine,B,B
.,O,O
We,O,O
think,O,O
that,O,O
even,O,O
these,O,O
lower,O,O
dosages,O,O
of,O,O
cyclosporine,B,B
can,O,O
cause,O,O
chronic,O,O
nephrotoxicity,O,O
and,O,O
that,O,O
further,O,O
modification,O,O
of,O,O
the,O,O
immunosuppressive,O,O
regimen,O,O
is,O,O
required,O,O
to,O,O
completely,O,O
abolish,O,O
this,O,O
toxic,O,O
side,O,O
effect,O,O
.,O,O
Ethopropazine,B,B
and,O,O
benztropine,B,B
in,O,O
neuroleptic,O,O
-,O,O
induced,O,O
parkinsonism,O,O
.,O,O
In,O,O
a,O,O
12,O,O
-,O,O
week,O,O
controlled,O,O
study,O,O
ethopropazine,B,B
was,O,O
compared,O,O
to,O,O
benztropine,B,B
in,O,O
the,O,O
treatment,O,O
of,O,O
parkinsonism,O,O
induced,O,O
by,O,O
fluphenazine,B,O
enanthate,I,O
in,O,O
60,O,O
schizophrenic,O,O
outpatients,O,O
.,O,O
Ethopropazine,B,B
and,O,O
benztropine,B,B
were,O,O
found,O,O
to,O,O
be,O,O
equally,O,O
effective,O,O
in,O,O
controlling,O,O
parkinsonian,O,O
symptoms,O,O
and,O,O
were,O,O
as,O,O
efficacious,O,O
as,O,O
procyclidine,B,O
",",O,O
their,O,O
previous,O,O
antiparkinsonian,O,O
drug,O,O
.,O,O
However,O,O
",",O,O
benztropine,B,B
treated,O,O
patients,O,O
had,O,O
a,O,O
significant,O,O
increase,O,O
in,O,O
tardive,O,B
dyskinesia,O,I
compared,O,O
to,O,O
their,O,O
condition,O,O
during,O,O
procyclindine,B,B
treatment,O,O
",",O,O
and,O,O
significantly,O,O
more,O,O
anxiety,O,O
and,O,O
depression,O,O
than,O,O
ethopropazine,B,B
treated,O,O
patients,O,O
.,O,O
This,O,O
suggests,O,O
that,O,O
benztropine,B,B
is,O,O
not,O,O
the,O,O
anticholinergic,O,O
drug,O,O
of,O,O
choice,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
neuroleptic,O,O
-,O,O
induced,O,O
parkinsonian,O,O
symptoms,O,O
",",O,O
because,O,O
of,O,O
its,O,O
more,O,O
toxic,O,O
central,O,O
and,O,O
peripheral,O,O
atropinic,O,O
effect,O,O
.,O,O
Quinidine,B,B
phenylethylbarbiturate,I,I
-,O,I
induced,O,O
fulminant,O,O
hepatitis,O,O
in,O,O
a,O,O
pregnant,O,O
woman,O,O
.,O,O
A,O,O
case,O,O
report,O,O
.,O,O
We,O,O
report,O,O
the,O,O
case,O,O
of,O,O
a,O,O
19,O,O
-,O,O
year,O,O
-,O,O
old,O,O
Laotian,O,O
patient,O,O
affected,O,O
by,O,O
fulminant,O,O
hepatitis,O,O
during,O,O
the,O,O
third,O,O
trimester,O,O
of,O,O
her,O,O
pregnancy,O,O
after,O,O
a,O,O
1,O,O
-,O,O
month,O,O
administration,O,O
of,O,O
quinidine,B,B
phenylethylbarbiturate,I,I
.,O,O
After,O,O
delivery,O,O
",",O,O
the,O,O
patient,O,O
underwent,O,O
orthotopic,O,O
liver,O,B
transplantation,O,I
.,O,O
The,O,O
patient,O,O
was,O,O
in,O,O
good,O,O
condition,O,O
16,O,O
months,O,O
after,O,O
liver,O,B
transplantation,O,I
.,O,O
Quinidine,B,B
itself,O,O
or,O,O
phenylethylbarbiturate,B,B
may,O,O
be,O,O
responsible,O,O
for,O,O
fulminant,O,O
hepatitis,O,O
in,O,O
this,O,O
patient,O,O
.,O,O
Mechanisms,O,O
of,O,O
myocardial,O,O
ischemia,O,O
induced,O,O
by,O,O
epinephrine,B,B
:,O,O
comparison,O,O
with,O,O
exercise,O,O
-,O,O
induced,O,O
ischemia,O,O
.,O,O
The,O,O
role,O,O
of,O,O
epinephrine,B,B
in,O,O
eliciting,O,O
myocardial,O,O
ischemia,O,O
was,O,O
examined,O,O
in,O,O
patients,O,O
with,O,O
coronary,O,O
artery,O,O
disease,O,O
.,O,O
Objective,O,O
signs,O,O
of,O,O
ischemia,O,O
and,O,O
factors,O,O
increasing,O,O
myocardial,O,O
oxygen,B,O
consumption,O,O
were,O,O
compared,O,O
during,O,O
epinephrine,B,B
infusion,O,O
and,O,O
supine,O,O
bicycle,O,O
exercise,O,O
.,O,O
Both,O,O
epinephrine,B,B
and,O,O
exercise,O,O
produced,O,O
myocardial,O,O
ischemia,O,O
as,O,O
evidenced,O,O
by,O,O
ST,O,B
segment,O,I
depression,O,I
and,O,O
angina,O,O
.,O,O
However,O,O
",",O,O
the,O,O
mechanisms,O,O
of,O,O
myocardial,O,O
ischemia,O,O
induced,O,O
by,O,O
epinephrine,B,B
were,O,O
significantly,O,O
different,O,O
from,O,O
those,O,O
of,O,O
exercise,O,O
.,O,O
Exercise,O,O
-,O,O
induced,O,O
myocardial,O,O
ischemia,O,O
was,O,O
marked,O,O
predominantly,O,O
by,O,O
increased,O,O
heart,O,O
rate,O,O
and,O,O
rate,O,O
-,O,O
pressure,O,O
product,O,O
with,O,O
a,O,O
minor,O,O
contribution,O,O
of,O,O
end,O,O
-,O,O
diastolic,O,O
volume,O,O
",",O,O
while,O,O
epinephrine,B,B
-,O,O
induced,O,O
ischemia,O,O
was,O,O
characterized,O,O
by,O,O
a,O,O
marked,O,O
increase,O,O
in,O,O
contractility,O,O
and,O,O
a,O,O
less,O,O
pronounced,O,O
increase,O,O
in,O,O
heart,O,O
rate,O,O
and,O,O
rate,O,O
-,O,O
pressure,O,O
product,O,O
.,O,O
These,O,O
findings,O,O
indicate,O,O
that,O,O
ischemia,O,O
produced,O,O
by,O,O
epinephrine,B,B
",",O,O
as,O,O
may,O,O
occur,O,O
during,O,O
states,O,O
of,O,O
emotional,O,O
distress,O,O
",",O,O
has,O,O
a,O,O
mechanism,O,O
distinct,O,O
from,O,O
that,O,O
due,O,O
to,O,O
physical,O,O
exertion,O,O
.,O,O
Recent,O,O
preclinical,O,O
and,O,O
clinical,O,O
studies,O,O
with,O,O
the,O,O
thymidylate,O,B
synthase,O,I
inhibitor,O,O
N10,B,B
-,I,I
propargyl,I,I
-,I,I
5,I,I
",",I,I
8,I,I
-,I,I
dideazafolic,I,I
acid,I,I
(,O,I
CB,B,I
3717,I,I
),O,I
.,O,O
CB,B,B
3717,I,I
",",O,O
N10,B,B
-,I,I
propargyl,I,I
-,I,I
5,I,I
",",I,O
8,I,I
-,I,I
dideazafolic,I,I
acid,I,I
",",O,O
is,O,O
a,O,O
tight,O,O
-,O,O
binding,O,O
inhibitor,O,O
of,O,O
thymidylate,O,B
synthase,O,I
(,O,I
TS,O,I
),O,O
whose,O,O
cytotoxicity,O,O
is,O,O
mediated,O,O
solely,O,O
through,O,O
the,O,O
inhibition,O,O
of,O,O
this,O,O
enzyme,O,O
.,O,O
Recent,O,O
preclinical,O,O
studies,O,O
have,O,O
focused,O,O
on,O,O
the,O,O
intracellular,O,O
formation,O,O
of,O,O
CB,B,B
3717,I,I
polyglutamates,O,I
.,O,O
Following,O,O
a,O,O
12,O,O
-,O,O
hour,O,O
exposure,O,O
of,O,O
L1210,O,O
cells,O,O
to,O,O
50,O,O
microM,O,O
[,O,O
3H,O,O
],O,O
CB,B,B
3717,I,I
",",O,O
30,O,O
%,O,O
of,O,O
the,O,O
extractable,O,O
radioactivity,O,O
could,O,O
be,O,O
accounted,O,O
for,O,O
as,O,O
CB,B,B
3717,I,I
tetra,O,I
-,O,I
and,O,I
pentaglutamate,O,I
",",O,O
as,O,O
determined,O,O
by,O,O
high,O,O
-,O,O
pressure,O,O
liquid,O,O
chromatography,O,O
(,O,O
HPLC,O,O
),O,O
analyses,O,O
.,O,O
As,O,O
inhibitors,O,O
of,O,O
isolated,O,O
L1210,O,B
TS,O,O
",",O,O
CB,O,B
3717,O,I
di,O,O
-,O,O
",",O,O
tri,O,O
-,O,O
",",O,O
tetra,O,O
-,O,O
pentaglutamate,O,O
are,O,O
26,O,O
-,O,O
",",O,O
87,O,O
-,O,O
",",O,O
119,O,O
-,O,O
114,O,O
-,O,O
fold,O,O
more,O,O
potent,O,O
than,O,O
CB,B,B
3717,I,I
",",O,O
respectively,O,O
",",O,O
and,O,O
their,O,O
formation,O,O
may,O,O
",",O,O
therefore,O,O
",",O,O
be,O,O
an,O,O
important,O,O
determinant,O,O
of,O,O
CB,B,B
3717,I,I
cytotoxicity,O,O
.,O,O
In,O,O
early,O,O
clinical,O,O
studies,O,O
with,O,O
CB,B,B
3717,I,I
",",O,O
activity,O,O
has,O,O
been,O,O
seen,O,O
in,O,O
breast,O,O
cancer,O,O
",",O,O
ovarian,O,O
cancer,O,O
",",O,O
hepatoma,O,O
",",O,O
and,O,O
mesothelioma,O,O
.,O,O
Toxicities,O,O
included,O,O
hepatotoxicity,O,B
",",O,O
malaise,O,O
",",O,O
and,O,O
dose,O,O
-,O,O
limiting,O,O
nephrotoxicity,O,B
.,O,O
This,O,O
latter,O,O
effect,O,O
is,O,O
thought,O,O
to,O,O
be,O,O
due,O,O
to,O,O
drug,O,O
precipitation,O,O
within,O,O
the,O,O
renal,O,O
tubule,O,O
as,O,O
a,O,O
result,O,O
of,O,O
the,O,O
poor,O,O
solubility,O,O
of,O,O
CB,B,B
3717,I,I
under,O,O
acidic,O,O
conditions,O,O
.,O,O
In,O,O
an,O,O
attempt,O,O
to,O,O
overcome,O,O
this,O,O
problem,O,O
",",O,O
a,O,O
clinical,O,O
trial,O,O
of,O,O
CB,B,B
3717,I,I
administered,O,O
with,O,O
alkaline,O,O
diuresis,O,O
is,O,O
under,O,O
way,O,O
.,O,O
Preliminary,O,O
results,O,O
at,O,O
400,O,B
and,O,O
500,O,B
mg,O,I
/,O,I
m2,O,I
suggest,O,O
that,O,O
a,O,O
reduction,O,O
in,O,O
nephrotoxicity,O,B
may,O,O
have,O,O
been,O,O
achieved,O,O
with,O,O
only,O,O
1,O,O
instance,O,O
of,O,O
renal,O,B
toxicity,O,I
in,O,O
10,O,O
patients,O,O
.,O,O
Hepatotoxicity,O,B
and,O,O
malaise,O,O
are,O,O
again,O,O
the,O,O
most,O,O
frequent,O,O
side,O,O
effects,O,O
.,O,O
Evidence,O,O
of,O,O
antitumor,O,B
activity,O,I
has,O,O
been,O,O
seen,O,O
in,O,O
3,O,O
patients,O,O
.,O,O
Pharmacokinetic,O,B
investigations,O,I
have,O,O
shown,O,O
that,O,O
alkaline,O,B
diuresis,O,I
does,O,O
not,O,O
alter,O,O
CB,B,B
3717,I,I
plasma,O,I
levels,O,I
or,O,O
urinary,O,B
excretion,O,I
and,O,O
that,O,O
satisfactory,O,O
urinary,O,B
alkalinization,O,I
can,O,O
be,O,O
readily,O,O
achieved,O,O
.,O,O
Type,O,O
B,O,O
hepatitis,O,B
after,O,O
needle,O,O
-,O,O
stick,O,O
exposure,O,O
:,O,O
prevention,O,O
with,O,O
hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
.,O,O
Final,O,O
report,O,O
of,O,O
the,O,O
Veterans,O,O
Administration,O,O
Cooperative,O,O
Study,O,O
.,O,O
Hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
(,O,O
HBIG,O,B
),O,O
and,O,O
immune,O,O
serum,O,O
globulin,O,O
(,O,O
ISG,O,B
),O,O
were,O,O
examined,O,O
in,O,O
a,O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
trial,O,O
to,O,O
assess,O,O
their,O,O
relative,O,O
efficacies,O,O
in,O,O
preventing,O,O
type,O,O
B,O,I
hepatitis,O,I
after,O,O
needle,O,O
-,O,O
stick,O,O
exposure,O,O
to,O,O
hepatitis,B,B
B,I,I
surface,I,I
antigen,I,I
(,O,O
HBsAG,B,B
),O,O
-,O,O
positive,O,O
donors,O,O
.,O,O
Clinical,O,O
hepatitis,O,B
developed,O,O
in,O,O
1,O,O
.,O,O
4,O,O
%,O,O
of,O,O
HBIG,O,O
and,O,O
in,O,O
5,O,O
.,O,O
9,O,O
%,O,O
of,O,O
ISG,O,O
recipients,O,O
(,O,O
P,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
and,O,O
seroconversion,O,O
(,O,O
anti,O,B
-,O,I
HBs,O,I
),O,O
occurred,O,O
in,O,O
5,O,O
.,O,O
6,O,O
%,O,O
and,O,O
20,O,O
.,O,O
7,O,O
%,O,O
of,O,O
them,O,O
respectively,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
.,O,O
Mild,O,O
and,O,O
transient,O,O
side,O,O
-,O,O
effects,O,O
were,O,O
noted,O,O
in,O,O
3,O,O
.,O,O
0,O,O
%,O,O
of,O,O
ISG,O,O
and,O,O
in,O,O
3,O,O
.,O,O
2,O,O
%,O,O
of,O,O
HBIG,O,O
recipients,O,O
.,O,O
Available,O,O
donor,O,O
sera,O,O
were,O,O
examined,O,O
for,O,O
DNA,O,B
polymerase,O,I
(,O,O
DNAP,O,B
),O,O
and,O,O
e,O,O
antigen,O,O
and,O,O
antibody,O,O
(,O,O
HBeAg,B,B
;,O,O
anti,O,O
-,O,O
HBE,O,O
),O,O
.,O,O
Both,O,O
DNAP,O,B
and,O,O
HBeAg,B,B
showed,O,O
a,O,O
highly,O,O
statistically,O,O
significant,O,O
correlation,O,O
with,O,O
the,O,O
infectivity,O,O
of,O,O
HBsAg,B,B
-,O,O
positive,O,O
donors,O,O
.,O,O
Hepatitis,O,B
B,O,I
immune,O,I
globulin,O,I
remained,O,O
significantly,O,O
superior,O,O
to,O,O
ISG,O,B
in,O,O
preventing,O,O
type,O,O
B,O,I
hepatitis,O,I
even,O,O
when,O,O
the,O,O
analysis,O,O
was,O,O
confined,O,O
to,O,O
these,O,O
two,O,O
high,O,O
-,O,O
risk,O,O
subgroups,O,O
.,O,O
The,O,O
efficacy,O,O
of,O,O
ISG,O,B
in,O,O
preventing,O,O
type,O,O
B,O,O
hepatitis,O,O
cannot,O,O
be,O,O
ascertained,O,O
because,O,O
a,O,O
placebo,O,O
group,O,O
was,O,O
not,O,O
included,O,O
.,O,O
Production,O,O
of,O,O
autochthonous,O,O
prostate,O,B
cancer,O,I
in,O,O
Lobund,O,O
-,O,O
Wistar,O,O
rats,O,O
by,O,O
treatments,O,O
with,O,O
N,B,B
-,I,I
nitroso,I,I
-,I,I
N,I,I
-,I,I
methylurea,I,I
and,O,O
testosterone,B,O
.,O,O
More,O,O
than,O,O
50,O,O
%,O,O
of,O,O
Lobund,O,O
-,O,O
Wistar,O,O
(,O,O
L,O,O
-,O,O
W,O,O
),O,O
strain,O,O
rats,O,O
developed,O,O
large,O,O
",",O,O
palpable,O,O
prostate,O,B
adenocarcinomas,O,I
(,O,O
PAs,O,B
),O,O
following,O,O
treatments,O,O
with,O,O
N,B,B
-,I,I
nitroso,I,I
-,I,I
N,I,I
-,I,I
methylurea,I,I
(,O,O
CAS,O,O
:,O,O
684,O,O
-,O,O
93,O,O
-,O,O
5,O,O
),O,O
and,O,O
testosterone,B,O
propionate,I,O
[,O,O
(,O,O
TP,B,B
),O,O
CAS,O,O
:,O,O
57,O,O
-,O,O
85,O,O
-,O,O
2,O,O
],O,O
",",O,O
and,O,O
most,O,O
of,O,O
the,O,O
tumor,O,O
-,O,O
bearing,O,O
rats,O,O
manifested,O,O
metastatic,O,O
lesions,O,O
.,O,O
The,O,O
incubation,O,O
periods,O,O
averaged,O,O
10,O,O
.,O,O
6,O,O
months,O,O
.,O,O
Within,O,O
the,O,O
same,O,O
timeframe,O,O
",",O,O
no,O,O
L,O,O
-,O,O
W,O,O
rat,O,O
developed,O,O
a,O,O
similar,O,O
palpable,O,O
PA,O,O
when,O,O
treated,O,O
only,O,O
with,O,O
TP,B,B
.,O,O
In,O,O
L,O,O
-,O,O
W,O,O
rats,O,O
",",O,O
TP,B,B
acted,O,O
as,O,O
a,O,O
tumor,O,O
enhancement,O,O
agent,O,O
",",O,O
with,O,O
primary,O,O
emphasis,O,O
on,O,O
the,O,O
development,O,O
of,O,O
prostate,O,B
cancer,O,I
.,O,O
Relative,O,O
efficacy,O,O
and,O,O
toxicity,O,O
of,O,O
netilmicin,B,B
and,O,O
tobramycin,B,B
in,O,O
oncology,O,O
patients,O,O
.,O,O
We,O,O
prospectively,O,O
compared,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
netilmicin,B,B
sulfate,I,I
or,O,O
tobramycin,B,B
sulfate,I,I
in,O,O
conjunction,O,O
with,O,O
piperacillin,B,O
sodium,I,O
in,O,O
118,O,O
immunocompromised,O,O
patients,O,O
with,O,O
presumed,O,O
severe,O,O
infections,O,O
.,O,O
The,O,O
two,O,O
treatment,O,O
regimens,O,O
were,O,O
equally,O,O
efficacious,O,O
.,O,O
Nephrotoxicity,O,O
occurred,O,O
in,O,O
a,O,O
similar,O,O
proportion,O,O
in,O,O
patients,O,O
treated,O,O
with,O,O
netilmicin,B,B
and,O,O
tobramycin,B,B
(,O,O
17,O,O
%,O,O
vs,O,O
11,O,O
%,O,O
),O,O
.,O,O
Ototoxicity,O,O
occurred,O,O
in,O,O
four,O,O
(,O,O
9,O,O
.,O,O
5,O,O
%,O,O
),O,O
of,O,O
42,O,O
netilmicin,B,B
and,O,O
piperacillin,B,B
and,O,O
in,O,O
12,O,O
(,O,O
22,O,O
%,O,O
),O,O
of,O,O
54,O,O
tobramycin,B,B
and,O,O
piperacillin,B,B
-,O,O
treated,O,O
patients,O,O
.,O,O
Of,O,O
those,O,O
evaluated,O,O
with,O,O
posttherapy,O,O
audiograms,O,O
",",O,O
three,O,O
of,O,O
four,O,O
netilmicin,B,B
and,O,O
piperacillin,B,B
-,O,O
treated,O,O
patients,O,O
had,O,O
auditory,O,O
thresholds,O,O
return,O,O
to,O,O
baseline,O,O
compared,O,O
with,O,O
one,O,O
of,O,O
nine,O,O
tobramycin,B,B
and,O,O
piperacillin,B,B
-,O,O
treated,O,O
patients,O,O
.,O,O
The,O,O
number,O,O
of,O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
15,O,O
-,O,O
dB,O,O
increases,O,O
in,O,O
auditory,O,O
threshold,O,O
as,O,O
a,O,O
proportion,O,O
of,O,O
total,O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
15,O,O
-,O,O
dB,O,O
changes,O,O
(,O,O
increases,O,O
and,O,O
decreases,O,O
),O,O
was,O,O
significantly,O,O
lower,O,O
in,O,O
netilmicin,B,B
and,O,O
piperacillin,B,B
-,O,O
vs,O,O
tobramycin,B,B
and,O,O
piperacillin,B,B
-,O,O
treated,O,O
patients,O,O
(,O,O
18,O,O
of,O,O
78,O,O
vs,O,O
67,O,O
of,O,O
115,O,O
),O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
aminoglycoside,B,B
-,O,I
associated,O,O
ototoxicity,O,O
was,O,O
less,O,O
severe,O,O
and,O,O
more,O,O
often,O,O
reversible,O,O
with,O,O
netilmicin,B,B
than,O,O
with,O,O
tobramycin,B,B
.,O,O
Urinary,O,O
enzymes,O,O
and,O,O
protein,O,O
patterns,O,O
as,O,O
indicators,O,O
of,O,O
injury,O,O
to,O,O
different,O,O
regions,O,O
of,O,O
the,O,O
kidney,O,O
.,O,O
Acute,O,O
experimental,O,O
models,O,O
of,O,O
renal,O,O
damage,O,O
to,O,O
the,O,O
proximal,O,O
tubular,O,O
",",O,O
glomerular,O,O
",",O,O
and,O,O
papillary,O,O
regions,O,O
of,O,O
the,O,O
rat,O,O
were,O,O
produced,O,O
by,O,O
administration,O,O
of,O,O
hexachloro,B,B
-,I,I
1,I,I
:,I,I
3,I,I
-,I,I
butadiene,I,I
(,O,I
HCBD,B,I
),O,I
",",O,O
puromycin,B,B
aminonucleoside,I,I
(,O,I
PAN,B,I
),O,I
",",O,O
and,O,O
2,B,B
-,I,I
bromoethylamine,I,I
(,O,I
BEA,B,I
),O,I
",",O,O
respectively,O,O
.,O,O
Several,O,O
routine,O,O
indicators,O,O
of,O,O
nephrotoxicity,O,O
",",O,O
the,O,O
enzymes,O,O
alkaline,O,B
phosphatase,O,I
and,O,O
N,O,B
-,O,I
acetyl,O,I
-,O,I
beta,O,I
-,O,I
glucosaminidase,O,I
",",O,O
and,O,O
the,O,O
molecular,O,O
weight,O,O
of,O,O
protein,O,O
excretion,O,O
were,O,O
determined,O,O
on,O,O
urine,O,O
samples,O,O
.,O,O
Tubular,O,O
damage,O,O
produced,O,O
by,O,O
HCBD,B,B
or,O,O
BEA,B,B
was,O,O
discriminated,O,O
both,O,O
quantitatively,O,O
and,O,O
qualitatively,O,O
from,O,O
glomerular,O,O
damage,O,O
produced,O,O
by,O,O
PAN,B,B
.,O,O
The,O,O
latter,O,O
was,O,O
characterized,O,O
by,O,O
a,O,O
pronounced,O,O
increase,O,O
in,O,O
protein,O,B
excretion,O,O
",",O,O
especially,O,O
proteins,O,O
with,O,O
molecular,O,O
weight,O,O
greater,O,O
than,O,O
40,O,O
",",O,O
Da,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
protein,O,B
excretion,O,O
in,O,O
tubular,O,O
damage,O,O
was,O,O
raised,O,O
only,O,O
slightly,O,O
and,O,O
characterized,O,O
by,O,O
excretion,O,O
of,O,O
proteins,O,O
of,O,O
a,O,O
wide,O,O
range,O,O
of,O,O
molecular,O,O
weights,O,O
.,O,O
Proximal,O,O
tubular,O,O
damage,O,O
caused,O,O
by,O,O
HCBD,B,B
and,O,O
papillary,O,O
damage,O,O
caused,O,O
by,O,O
BEA,B,B
were,O,O
distinguished,O,O
both,O,O
by,O,O
conventional,O,O
urinalysis,O,O
(,O,O
volume,O,O
and,O,O
specific,O,O
gravity,O,O
),O,O
and,O,O
by,O,O
measurement,O,O
of,O,O
the,O,O
two,O,O
urinary,O,O
enzymes,O,O
.,O,O
Alkaline,O,B
phosphatase,O,I
and,O,O
glucose,B,B
were,O,O
markedly,O,O
and,O,O
transiently,O,O
elevated,O,O
in,O,O
proximal,O,O
tubular,O,O
damage,O,O
and,O,O
N,O,B
-,O,I
acetyl,O,I
-,O,I
beta,O,I
-,O,I
glucosaminidase,O,I
showed,O,O
a,O,O
sustained,O,O
elevation,O,O
in,O,O
papillary,O,O
damage,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
both,O,O
selective,O,O
urinary,O,O
enzymes,O,O
and,O,O
the,O,O
molecular,O,O
weight,O,O
pattern,O,O
of,O,O
urinary,O,O
proteins,O,O
can,O,O
be,O,O
used,O,O
to,O,O
provide,O,O
diagnostic,O,O
information,O,O
about,O,O
the,O,O
possible,O,O
site,O,O
of,O,O
renal,O,O
damage,O,O
.,O,O
A,O,O
catch,O,O
in,O,O
the,O,O
Reye,O,B
.,O,O
Twenty,O,O
-,O,O
six,O,O
cases,O,O
of,O,O
Reye,O,B
syndrome,O,O
from,O,O
The,O,O
Children,O,O
',O,O
s,O,O
Hospital,O,O
",",O,O
Camperdown,O,O
",",O,O
Australia,O,O
",",O,O
occurring,O,O
between,O,O
1973,O,O
and,O,O
1982,O,O
were,O,O
reviewed,O,O
.,O,O
Of,O,O
these,O,O
",",O,O
20,O,O
cases,O,O
met,O,O
the,O,O
US,O,O
Public,O,O
Health,O,O
Service,O,O
Centers,O,O
for,O,O
Disease,O,O
Control,O,O
criteria,O,O
for,O,O
the,O,O
diagnosis,O,O
of,O,O
Reye,O,B
syndrome,O,I
.,O,O
Aspirin,B,B
or,O,O
salicylate,B,B
ingestion,O,O
had,O,O
occurred,O,O
in,O,O
only,O,O
one,O,O
of,O,O
the,O,O
20,O,O
cases,O,O
(,O,O
5,O,O
%,O,O
),O,O
",",O,O
and,O,O
paracetamol,B,B
(,O,O
acetaminophen,B,I
),O,O
had,O,O
been,O,O
administered,O,O
in,O,O
only,O,O
six,O,O
of,O,O
the,O,O
cases,O,O
(,O,O
30,O,O
%,O,O
),O,O
.,O,O
Pathologic,O,O
confirmation,O,O
of,O,O
the,O,O
diagnosis,O,O
of,O,O
Reye,O,B
syndrome,O,I
was,O,O
accomplished,O,O
in,O,O
90,O,O
%,O,O
of,O,O
the,O,O
cases,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
Reye,O,B
syndrome,O,I
in,O,O
New,O,O
South,O,O
Wales,O,O
",",O,O
Australia,O,O
",",O,O
is,O,O
estimated,O,O
from,O,O
this,O,O
study,O,O
to,O,O
be,O,O
approximately,O,O
nine,O,O
cases,O,O
per,O,O
1,O,O
million,O,O
children,O,O
compared,O,O
with,O,O
recent,O,O
US,O,O
data,O,O
of,O,O
ten,O,O
to,O,O
20,O,O
cases,O,O
per,O,O
1,O,O
million,O,O
children,O,O
and,O,O
three,O,O
to,O,O
seven,O,O
cases,O,O
per,O,O
1,O,O
million,O,O
children,O,O
in,O,O
Great,O,O
Britain,O,O
.,O,O
The,O,O
mortality,O,O
for,O,O
these,O,O
Reye,O,B
syndrome,O,I
cases,O,O
in,O,O
Australia,O,O
was,O,O
45,O,O
%,O,O
as,O,O
compared,O,O
with,O,O
a,O,O
32,O,O
%,O,O
case,O,O
-,O,O
fatality,O,O
rate,O,O
in,O,O
the,O,O
United,O,O
States,O,O
.,O,O
In,O,O
Australia,O,O
",",O,O
the,O,O
pediatric,O,O
usage,O,O
of,O,O
aspirin,B,B
has,O,O
been,O,O
extremely,O,O
low,O,O
for,O,O
the,O,O
past,O,O
25,O,O
years,O,O
(,O,O
less,O,O
than,O,O
1,O,O
%,O,O
of,O,O
total,O,O
dosage,O,O
units,O,O
sold,O,O
),O,O
",",O,O
with,O,O
paracetamol,B,B
(,O,O
acetaminophen,B,I
),O,O
dominating,O,O
the,O,O
pediatric,O,O
analgesic,O,O
and,O,O
antipyretic,O,O
market,O,O
.,O,O
Reye,O,B
syndrome,O,I
may,O,O
be,O,O
disappearing,O,O
from,O,O
Australia,O,O
despite,O,O
a,O,O
total,O,O
lack,O,O
of,O,O
association,O,O
with,O,O
salicylates,B,B
or,O,O
aspirin,B,B
ingestion,O,O
",",O,O
since,O,O
there,O,O
were,O,O
no,O,O
cases,O,O
found,O,O
at,O,O
The,O,O
Children,O,O
',O,O
s,O,O
Hospital,O,O
in,O,O
1983,O,O
",",O,O
1984,O,O
",",O,O
or,O,O
1985,O,O
.,O,O
Postpartum,O,O
psychosis,O,O
induced,O,O
by,O,O
bromocriptine,B,B
.,O,O
Two,O,O
multigravida,O,O
patients,O,O
with,O,O
no,O,O
prior,O,O
psychiatric,O,O
history,O,O
were,O,O
seen,O,O
with,O,O
postpartum,O,O
psychosis,O,O
",",O,O
having,O,O
received,O,O
bromocriptine,B,B
for,O,O
inhibition,O,O
of,O,O
lactation,O,O
.,O,O
Bromocriptine,B,B
given,O,O
in,O,O
high,O,O
doses,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
psychosis,O,O
in,O,O
patients,O,O
receiving,O,O
the,O,O
drug,O,O
for,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
.,O,O
These,O,O
cases,O,O
demonstrate,O,O
that,O,O
bromocriptine,B,B
may,O,O
cause,O,O
psychosis,O,O
even,O,O
when,O,O
given,O,O
in,O,O
low,O,O
doses,O,O
.,O,O
Hyperglycemic,O,B
acidotic,O,I
coma,O,I
and,O,I
death,O,I
in,O,I
Kearns,O,I
-,O,I
Sayre,O,I
syndrome,O,I
.,O,O
This,O,O
paper,O,O
presents,O,O
the,O,O
clinical,O,O
and,O,O
metabolic,O,O
findings,O,O
in,O,O
two,O,O
young,O,O
boys,O,O
with,O,O
long,O,O
-,O,O
standing,O,O
Kearns,O,B
-,O,I
Sayre,O,I
syndrome,O,I
.,O,O
Following,O,O
short,O,O
exposure,O,O
to,O,O
oral,O,O
prednisone,B,B
",",O,O
both,O,O
boys,O,O
developed,O,O
lethargy,O,O
",",O,O
increasing,O,O
somnolence,O,O
",",O,O
polydipsia,O,O
",",O,O
polyphagia,O,O
",",O,O
and,O,O
polyuria,O,O
.,O,O
Both,O,O
presented,O,O
in,O,O
the,O,O
emergency,O,O
room,O,O
with,O,O
profound,O,O
coma,O,O
",",O,O
hypotension,O,O
",",O,O
severe,O,O
hyperglycemia,O,B
",",O,O
and,O,O
acidosis,O,B
.,O,O
Nonketotic,O,O
lactic,O,B
acidosis,O,I
was,O,O
present,O,O
in,O,O
one,O,O
and,O,O
ketosis,O,B
without,O,O
a,O,O
known,O,O
serum,O,O
lactate,B,O
level,O,O
was,O,O
present,O,O
in,O,O
the,O,O
other,O,O
.,O,O
Respiratory,O,O
failure,O,O
rapidly,O,O
ensued,O,O
and,O,O
both,O,O
patients,O,O
expired,O,O
in,O,O
spite,O,O
of,O,O
efforts,O,O
at,O,O
resuscitation,O,O
.,O,O
We,O,O
believe,O,O
these,O,O
two,O,O
cases,O,O
represent,O,O
a,O,O
newly,O,O
described,O,O
and,O,O
catastrophic,O,O
metabolic,O,B
-,O,I
endocrine,O,I
failure,O,O
in,O,O
the,O,O
Kearns,O,O
-,O,O
Sayre,O,O
syndrome,O,O
.,O,O
Experimental,O,O
cyclosporine,B,B
nephrotoxicity,O,O
:,O,O
risk,O,O
of,O,O
concomitant,O,O
chemotherapy,O,O
.,O,O
The,O,O
role,O,O
of,O,O
cyclosporine,B,B
(,O,O
CSA,B,B
),O,O
alone,O,O
or,O,O
in,O,O
combination,O,O
with,O,O
various,O,O
chemotherapeutics,O,O
in,O,O
the,O,O
development,O,O
of,O,O
renal,O,O
toxicity,O,O
was,O,O
evaluated,O,O
in,O,O
rats,O,O
.,O,O
Administration,O,O
of,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
CSA,B,B
for,O,O
4,O,O
weeks,O,O
caused,O,O
renal,O,O
functional,O,O
and,O,O
structural,O,O
changes,O,O
similar,O,O
to,O,O
those,O,O
reported,O,O
in,O,O
man,O,O
.,O,O
The,O,O
combined,O,O
administration,O,O
of,O,O
CSA,B,B
and,O,O
various,O,O
chemotherapeutic,O,O
drugs,O,O
with,O,O
a,O,O
nephrotoxic,O,O
potential,O,O
",",O,O
such,O,O
as,O,O
gentamicin,B,B
(,O,O
at,O,O
therapeutic,O,O
doses,O,O
),O,O
",",O,O
amphothericin,B,B
B,I,I
and,O,O
ketoconazole,B,B
",",O,O
which,O,O
are,O,O
frequently,O,O
used,O,O
in,O,O
immunosuppressed,O,O
patients,O,O
",",O,O
did,O,O
not,O,O
aggravate,O,O
the,O,O
CSA,B,B
induced,O,O
toxicity,O,O
in,O,O
the,O,O
rat,O,O
model,O,O
.,O,O
Gentamicin,B,B
at,O,O
toxic,O,O
doses,O,O
",",O,O
however,O,O
",",O,O
increased,O,O
CSA,B,B
nephrotoxicity,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
nephrotoxicity,O,O
induced,O,O
by,O,O
CSA,B,B
has,O,O
a,O,O
different,O,O
pathogenetic,O,O
mechanism,O,O
.,O,O
Diuretics,O,B
",",O,O
potassium,B,B
and,O,O
arrhythmias,O,O
in,O,O
hypertensive,O,O
coronary,O,O
disease,O,O
.,O,O
It,O,O
has,O,O
been,O,O
proposed,O,O
that,O,O
modest,O,O
changes,O,O
in,O,O
plasma,O,O
potassium,B,B
can,O,O
alter,O,O
the,O,O
tendency,O,O
towards,O,O
cardiac,O,O
arrhythmias,O,O
.,O,O
If,O,O
this,O,O
were,O,O
so,O,O
",",O,O
patients,O,O
with,O,O
coronary,O,B
artery,O,I
disease,O,I
might,O,O
be,O,O
especially,O,O
susceptible,O,O
.,O,O
Thus,O,O
",",O,O
myocardial,O,O
electrical,O,O
excitability,O,O
was,O,O
measured,O,O
in,O,O
patients,O,O
with,O,O
mild,O,O
essential,O,O
hypertension,O,O
and,O,O
known,O,O
coronary,O,B
artery,O,I
disease,O,I
after,O,O
8,O,O
weeks,O,O
of,O,O
treatment,O,O
with,O,O
a,O,O
potassium,B,B
-,O,I
conserving,O,I
diuretic,O,I
(,O,O
amiloride,B,B
),O,O
and,O,O
a,O,O
similar,O,O
period,O,O
on,O,O
a,O,O
potassium,B,B
-,O,I
losing,O,I
diuretic,O,I
(,O,O
chlorthalidone,B,B
),O,O
in,O,O
a,O,O
randomised,O,O
study,O,O
.,O,O
Plasma,O,B
potassium,B,B
concentrations,O,O
were,O,O
on,O,O
average,O,O
1,O,O
mmol,O,O
/,O,O
L,O,O
lower,O,O
during,O,O
the,O,O
chlorthalidone,B,B
phase,O,O
compared,O,O
to,O,O
amiloride,B,B
therapy,O,O
.,O,O
Blood,O,B
pressure,O,O
and,O,O
volume,O,O
states,O,O
as,O,O
assessed,O,O
by,O,O
bodyweight,O,O
",",O,O
plasma,O,B
renin,O,B
and,O,O
noradrenaline,B,B
(,O,O
norepinephrine,B,O
),O,O
concentrations,O,O
were,O,O
similar,O,O
on,O,O
the,O,O
2,O,O
regimens,O,O
.,O,O
Compared,O,O
to,O,O
amiloride,B,B
treatment,O,O
",",O,O
the,O,O
chlorthalidone,B,B
phase,O,O
was,O,O
associated,O,O
with,O,O
an,O,O
increased,O,O
frequency,O,O
of,O,O
ventricular,O,B
ectopic,O,I
beats,O,O
(,O,O
24,O,O
-,O,O
hour,O,O
Holter,O,O
monitoring,O,O
),O,O
and,O,O
a,O,O
higher,O,O
Lown,O,B
grading,O,O
",",O,O
increased,O,O
upslope,O,O
and,O,O
duration,O,O
of,O,O
the,O,O
monophasic,O,O
action,O,O
potential,O,O
",",O,O
prolonged,O,O
ventricular,O,B
effective,O,I
refractory,O,I
period,O,O
",",O,O
and,O,O
increased,O,O
electrical,O,O
instability,O,O
during,O,O
programmed,O,O
ventricular,O,B
stimulation,O,O
.,O,O
The,O,O
above,O,O
results,O,O
indicate,O,O
that,O,O
because,O,O
potassium,B,B
-,O,O
losing,O,O
diuretic,O,O
therapy,O,O
can,O,O
increase,O,O
myocardial,O,O
electrical,O,O
excitability,O,O
in,O,O
patients,O,O
with,O,O
ischaemic,O,O
heart,O,O
disease,O,O
",",O,O
even,O,O
minor,O,O
falls,O,O
in,O,O
plasma,O,O
potassium,B,B
concentrations,O,O
are,O,O
probably,O,O
best,O,O
avoided,O,O
in,O,O
such,O,O
patients,O,O
.,O,O
Transketolase,O,O
abnormality,O,O
in,O,O
tolazamide,B,B
-,O,O
induced,O,O
Wernicke,O,B
',O,O
s,O,O
encephalopathy,O,O
.,O,O
We,O,O
studied,O,O
a,O,O
thiamine,B,B
-,O,O
dependent,O,O
enzyme,O,O
",",O,O
transketolase,O,O
",",O,O
from,O,O
fibroblasts,O,O
of,O,O
a,O,O
diabetic,O,O
patient,O,O
who,O,O
developed,O,O
Wernicke,O,O
',O,O
s,O,O
encephalopathy,O,O
when,O,O
treated,O,O
with,O,O
tolazamide,B,O
",",O,O
in,O,O
order,O,O
to,O,O
delineate,O,O
if,O,O
this,O,O
patient,O,O
also,O,O
had,O,O
transketolase,O,O
abnormality,O,O
[,O,O
high,O,O
Km,O,O
for,O,O
thiamine,B,B
pyrophosphate,I,I
(,O,I
TPP,B,I
),O,I
],O,O
as,O,O
previously,O,O
reported,O,O
in,O,O
postalcoholic,O,O
Wernicke,O,O
-,O,O
Korsakoff,O,O
syndrome,O,O
.,O,O
In,O,O
addition,O,O
to,O,O
this,O,O
patient,O,O
",",O,O
we,O,O
also,O,O
studied,O,O
this,O,O
enzyme,O,O
from,O,O
three,O,O
diabetic,O,O
kindreds,O,O
without,O,O
any,O,O
history,O,O
of,O,O
Wernicke,O,O
',O,O
s,O,O
encephalopathy,O,O
and,O,O
from,O,O
four,O,O
normal,O,O
controls,O,O
.,O,O
We,O,O
found,O,O
that,O,O
the,O,O
above,O,O
-,O,O
mentioned,O,O
patient,O,O
and,O,O
one,O,O
of,O,O
the,O,O
diabetic,O,O
kindreds,O,O
with,O,O
no,O,O
history,O,O
of,O,O
Wernicke,O,O
',O,O
s,O,O
encephalopathy,O,O
had,O,O
abnormal,O,O
transketolase,O,O
as,O,O
determined,O,O
by,O,O
its,O,O
Km,O,O
for,O,O
TPP,B,B
.,O,O
These,O,O
data,O,O
suggest,O,O
a,O,O
similarity,O,O
between,O,O
postalcoholic,O,O
Wernicke,O,B
-,O,I
Korsakoff,O,I
syndrome,O,I
and,O,O
the,O,O
patient,O,O
with,O,O
tolazamide,B,B
-,O,I
induced,O,I
Wernicke,O,I
',O,I
s,O,I
encephalopathy,O,I
from,O,O
the,O,O
standpoint,O,O
of,O,O
transketolase,O,O
abnormality,O,O
.,O,O
Bradycardia,O,O
due,O,O
to,O,O
trihexyphenidyl,B,B
hydrochloride,I,I
.,O,O
A,O,O
chronic,O,O
schizophrenic,O,O
patient,O,O
was,O,O
treated,O,O
with,O,O
an,O,O
anticholinergic,O,O
drug,O,O
",",O,O
trihexyphenidyl,B,B
hydrochloride,I,I
.,O,O
The,O,O
patient,O,O
developed,O,O
",",O,O
paradoxically,O,O
",",O,O
sinus,O,O
bradycardia,O,O
.,O,O
The,O,O
reaction,O,O
was,O,O
specific,O,O
to,O,O
trihexyphenidyl,B,B
and,O,O
not,O,O
to,O,O
other,O,O
anticholinergic,O,O
drugs,O,O
.,O,O
This,O,O
antidyskinetic,O,O
drug,O,O
is,O,O
widely,O,O
used,O,O
in,O,O
clinical,O,O
psychiatric,O,O
practice,O,O
and,O,O
physicians,O,O
should,O,O
be,O,O
aware,O,O
of,O,O
this,O,O
side,O,O
effect,O,O
.,O,O
Post,O,O
-,O,O
operative,O,O
rigidity,O,O
after,O,O
fentanyl,B,B
administration,O,O
.,O,O
A,O,O
case,O,O
of,O,O
thoraco,O,B
-,O,I
abdominal,O,I
rigidity,O,I
leading,O,O
to,O,O
respiratory,O,O
failure,O,O
is,O,O
described,O,O
in,O,O
the,O,O
post,O,O
-,O,O
operative,O,O
period,O,O
in,O,O
an,O,O
elderly,O,O
patient,O,O
who,O,O
received,O,O
a,O,O
moderate,O,O
dose,O,O
of,O,O
fentanyl,B,B
.,O,O
This,O,O
was,O,O
successfully,O,O
reversed,O,O
by,O,O
naloxone,B,B
.,O,O
The,O,O
mechanisms,O,O
possibly,O,O
implicated,O,O
in,O,O
this,O,O
accident,O,O
are,O,O
discussed,O,O
.,O,O
Anti,O,O
-,O,O
carcinogenic,O,O
action,O,O
of,O,O
phenobarbital,B,B
given,O,O
simultaneously,O,O
with,O,O
diethylnitrosamine,B,B
in,O,O
the,O,O
rat,O,O
.,O,O
The,O,O
present,O,O
work,O,O
has,O,O
been,O,O
planned,O,O
in,O,O
order,O,O
to,O,O
elucidate,O,O
the,O,O
effect,O,O
of,O,O
phenobarbital,B,B
(,O,O
PB,B,B
:,O,O
15,O,O
mg,O,O
per,O,O
rat,O,O
of,O,O
ingested,O,O
dose,O,O
),O,O
on,O,O
carcinogenesis,O,O
when,O,O
it,O,O
is,O,O
administered,O,O
simultaneously,O,O
with,O,O
diethylnitrosamine,B,B
(,O,O
DEN,B,B
:,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
),O,O
.,O,O
Wistar,O,O
rats,O,O
(,O,O
180,O,O
g,O,O
),O,O
were,O,O
treated,O,O
by,O,O
DEN,B,B
alone,O,O
or,O,O
by,O,O
DEN,B,B
+,O,O
PB,B,B
during,O,O
2,O,O
",",O,O
4,O,O
and,O,O
6,O,O
weeks,O,O
according,O,O
to,O,O
our,O,O
schedule,O,O
for,O,O
hepatocarcinogenesis,O,O
.,O,O
After,O,O
the,O,O
end,O,O
of,O,O
the,O,O
treatment,O,O
",",O,O
the,O,O
number,O,O
and,O,O
the,O,O
size,O,O
of,O,O
induced,O,O
PAS,O,B
positive,O,O
preneoplastic,O,O
foci,O,O
was,O,O
significantly,O,O
reduced,O,O
when,O,O
PB,B,B
was,O,O
given,O,O
simultaneously,O,O
with,O,O
DEN,B,B
for,O,O
4,O,O
and,O,O
6,O,O
weeks,O,O
.,O,O
The,O,O
mitotic,O,O
inhibition,O,O
and,O,O
the,O,O
production,O,O
of,O,O
micronuclei,O,O
normally,O,O
observed,O,O
after,O,O
partial,O,O
hepatectomy,O,O
in,O,O
DEN,B,B
treated,O,O
rats,O,O
were,O,O
also,O,O
significantly,O,O
decreased,O,O
in,O,O
DEN,B,B
+,O,O
PB,B,B
treated,O,O
rats,O,O
.,O,O
When,O,O
the,O,O
treatment,O,O
last,O,O
only,O,O
2,O,O
weeks,O,O
",",O,O
the,O,O
presence,O,O
of,O,O
PB,B,B
did,O,O
not,O,O
change,O,O
significantly,O,O
the,O,O
last,O,O
parameters,O,O
.,O,O
In,O,O
DEN,B,B
+,O,O
PB,B,B
treated,O,O
rats,O,O
",",O,O
the,O,O
survival,O,O
was,O,O
prolonged,O,O
and,O,O
the,O,O
tumor,O,O
incidence,O,O
decreased,O,O
as,O,O
compared,O,O
with,O,O
the,O,O
results,O,O
obtained,O,O
by,O,O
DEN,B,B
alone,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
PB,B,B
",",O,O
which,O,O
promotes,O,O
carcinogenesis,O,O
when,O,O
administered,O,O
after,O,O
the,O,O
DEN,B,B
treatment,O,O
",",O,O
reduces,O,O
the,O,O
carcinogen,O,O
effect,O,O
when,O,O
given,O,O
simultaneously,O,O
with,O,O
DEN,B,B
.,O,O
This,O,O
',O,O
anti,O,B
-,O,I
carcinogen,O,I
',O,O
effect,O,O
acts,O,O
on,O,O
the,O,O
initiation,O,O
as,O,O
well,O,O
as,O,O
on,O,O
the,O,O
promotion,O,O
of,O,O
the,O,O
precancerous,O,O
lesions,O,O
.,O,O
Biochemical,O,O
investigations,O,O
are,O,O
in,O,O
progress,O,O
to,O,O
obtain,O,O
more,O,O
information,O,O
about,O,O
this,O,O
',O,O
paradoxical,O,O
',O,O
PB,B,B
effect,O,O
.,O,O
Bilateral,O,O
optic,O,B
neuropathy,O,I
due,O,O
to,O,O
combined,O,O
ethambutol,B,B
and,O,O
isoniazid,B,B
treatment,O,O
.,O,O
The,O,O
case,O,O
of,O,O
a,O,O
40,O,O
-,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
who,O,O
underwent,O,O
an,O,O
unsuccessful,O,O
cadaver,O,O
kidney,O,B
transplantation,O,O
and,O,O
was,O,O
treated,O,O
with,O,O
ethambutol,B,B
and,O,O
isoniazid,B,B
is,O,O
reported,O,O
.,O,O
A,O,O
bilateral,O,O
retrobulbar,O,O
neuropathy,O,O
with,O,O
an,O,O
unusual,O,O
central,O,O
bitemporal,O,O
hemianopic,O,O
scotoma,O,O
was,O,O
found,O,O
.,O,O
Ethambutol,B,B
was,O,O
stopped,O,O
and,O,O
only,O,O
small,O,O
improvement,O,O
of,O,O
the,O,O
visual,O,O
acuity,O,O
followed,O,O
.,O,O
Isoniazid,B,B
was,O,O
discontinued,O,O
later,O,O
",",O,O
followed,O,O
by,O,O
a,O,O
dramatic,O,O
improvement,O,O
in,O,O
the,O,O
visual,O,O
acuity,O,O
.,O,O
The,O,O
hazards,O,O
of,O,O
optic,O,O
nerve,O,O
toxicity,O,O
due,O,O
to,O,O
ethambutol,B,B
are,O,O
known,O,O
.,O,O
We,O,O
emphasize,O,O
the,O,O
potential,O,O
danger,O,O
in,O,O
the,O,O
use,O,O
of,O,O
ethambutol,B,B
and,O,O
isoniazid,B,B
.,O,O
A,O,O
prospective,O,O
study,O,O
of,O,O
adverse,O,O
reactions,O,O
associated,O,O
with,O,O
vancomycin,B,B
therapy,O,O
.,O,O
A,O,O
prospective,O,O
evaluation,O,O
of,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
vancomycin,B,B
was,O,O
conducted,O,O
in,O,O
54,O,O
consecutive,O,O
patients,O,O
over,O,O
a,O,O
16,O,O
-,O,O
month,O,O
period,O,O
.,O,O
Vancomycin,B,B
was,O,O
curative,O,O
in,O,O
95,O,O
%,O,O
of,O,O
43,O,O
patients,O,O
with,O,O
proven,O,O
infection,O,O
.,O,O
Drugs,O,O
were,O,O
ceased,O,O
in,O,O
six,O,O
patients,O,O
because,O,O
of,O,O
adverse,O,O
reactions,O,O
;,O,O
in,O,O
three,O,O
of,O,O
these,O,O
vancomycin,B,B
was,O,O
considered,O,O
the,O,O
likely,O,O
cause,O,O
.,O,O
Reactions,O,O
included,O,O
thrombophlebitis,O,B
(,O,O
20,O,O
of,O,O
54,O,O
patients,O,O
),O,O
",",O,O
rash,O,B
(,O,O
4,O,O
of,O,O
54,O,O
),O,O
",",O,O
nephrotoxicity,O,B
(,O,O
4,O,O
of,O,O
50,O,O
),O,O
",",O,O
proteinuria,O,B
(,O,O
1,O,O
of,O,O
50,O,O
),O,O
and,O,O
ototoxicity,O,B
(,O,O
1,O,O
of,O,O
11,O,O
patients,O,O
tested,O,O
by,O,O
audiometry,O,O
),O,O
.,O,O
Thrombophlebitis,O,B
occurred,O,O
only,O,O
with,O,O
infusion,O,O
through,O,O
peripheral,O,O
cannulae,O,O
;,O,O
nephrotoxicity,O,B
and,O,O
ototoxicity,O,B
were,O,O
confined,O,O
to,O,O
patients,O,O
receiving,O,O
an,O,O
aminoglycoside,B,B
plus,O,O
vancomycin,B,B
.,O,O
We,O,O
conclude,O,O
that,O,O
vancomycin,B,B
",",O,O
administered,O,O
appropriately,O,O
",",O,O
constitutes,O,O
safe,O,O
",",O,O
effective,O,O
therapy,O,O
for,O,O
infections,O,O
caused,O,O
by,O,O
susceptible,O,O
bacteria,O,O
.,O,O
Factors,O,O
associated,O,O
with,O,O
nephrotoxicity,O,O
and,O,O
clinical,O,O
outcome,O,O
in,O,O
patients,O,O
receiving,O,O
amikacin,B,B
.,O,O
Data,O,O
from,O,O
60,O,O
patients,O,O
treated,O,O
with,O,O
amikacin,B,B
were,O,O
analyzed,O,O
for,O,O
factors,O,O
associated,O,O
with,O,O
nephrotoxicity,O,O
.,O,O
In,O,O
42,O,O
of,O,O
these,O,O
patients,O,O
",",O,O
data,O,O
were,O,O
examined,O,O
for,O,O
factors,O,O
associated,O,O
with,O,O
clinical,O,O
outcome,O,O
.,O,O
Variables,O,O
evaluated,O,O
included,O,O
patient,O,O
weight,O,O
",",O,O
age,O,O
",",O,O
sex,O,O
",",O,O
serum,O,B
creatinine,B,I
level,O,I
",",O,O
creatinine,B,B
clearance,O,I
",",O,O
duration,O,O
of,O,O
therapy,O,O
",",O,O
total,O,O
dose,O,O
",",O,O
mean,O,O
daily,O,O
dose,O,O
",",O,O
organism,O,O
minimum,O,O
inhibitory,O,O
concentration,O,O
(,O,O
MIC,O,B
),O,O
",",O,O
mean,O,O
peak,O,O
levels,O,O
",",O,O
mean,O,O
trough,O,O
levels,O,O
",",O,O
mean,O,O
area,O,O
under,O,O
the,O,O
serum,O,B
concentration,O,I
-,O,I
time,O,I
curve,O,I
(,O,I
AUC,O,I
),O,O
",",O,O
total,O,O
AUC,O,O
",",O,O
mean,O,O
AUC,O,O
greater,O,O
than,O,O
MIC,O,O
",",O,O
total,O,O
AUC,O,O
greater,O,O
than,O,O
MIC,O,O
",",O,O
mean,O,O
Schumacher,O,O
',O,O
s,O,O
intensity,O,O
factor,O,O
(,O,O
IF,O,B
),O,O
",",O,O
total,O,O
IF,O,O
",",O,O
In,O,O
(,O,O
mean,O,O
maximum,O,O
concentration,O,O
[,O,O
Cmax,O,O
],O,O
/,O,O
MIC,O,O
),O,O
.,O,O
Model,O,B
-,O,O
dependent,O,O
pharmacokinetic,O,O
parameters,O,O
were,O,O
calculated,O,O
by,O,O
computer,O,O
based,O,O
on,O,O
a,O,O
one,O,O
-,O,O
compartment,O,O
model,O,O
.,O,O
When,O,O
the,O,O
parameters,O,O
were,O,O
examined,O,O
individually,O,O
",",O,O
duration,O,O
of,O,O
therapy,O,O
and,O,O
total,O,O
AUC,O,B
correlated,O,O
significantly,O,O
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
with,O,O
nephrotoxicity,O,B
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
stepwise,O,O
discriminant,O,O
function,O,O
analysis,O,O
identified,O,O
only,O,O
duration,O,O
of,O,O
therapy,O,O
(,O,O
P,O,O
less,O,O
than,O,O
as,O,O
an,O,O
important,O,O
factor,O,O
.,O,O
Based,O,O
on,O,O
this,O,O
model,O,O
and,O,O
on,O,O
Bayes,O,O
',O,O
theorem,O,O
",",O,O
the,O,O
predictive,O,O
accuracy,O,O
of,O,O
identifying,O,O
patients,O,O
increased,O,O
from,O,O
0,O,O
.,O,O
17,O,O
to,O,O
0,O,O
.,O,O
39,O,O
.,O,O
When,O,O
examined,O,O
individually,O,O
",",O,O
mean,O,O
IF,O,O
",",O,O
MIC,O,B
",",O,O
total,O,O
dose,O,O
",",O,O
mean,O,O
daily,O,O
dose,O,O
",",O,O
and,O,O
ln,O,O
(,O,O
mean,O,O
Cmax,O,O
/,O,O
MIC,O,B
),O,O
correlated,O,O
significantly,O,O
(,O,O
P,O,O
less,O,O
than,O,O
.,O,O
),O,O
with,O,O
cure,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
a,O,O
simultaneous,O,O
multivariable,O,O
analysis,O,O
identified,O,O
IF,O,B
",",O,O
MIC,O,B
",",O,O
and,O,O
total,O,O
dose,O,O
according,O,O
to,O,O
one,O,O
model,O,O
and,O,O
ln,O,O
(,O,O
mean,O,O
Cmax,O,B
/,O,O
MIC,O,B
),O,O
according,O,O
to,O,O
a,O,O
second,O,O
statistical,O,O
model,O,O
of,O,O
parameters,O,O
selected,O,O
to,O,O
have,O,O
the,O,O
greatest,O,O
prospective,O,O
value,O,O
.,O,O
Based,O,O
on,O,O
Bayes,O,B
',O,O
theorem,O,O
and,O,O
the,O,O
first,O,O
model,O,O
",",O,O
the,O,O
predictive,O,O
accuracy,O,O
of,O,O
identifying,O,O
patients,O,O
not,O,O
cured,O,O
increased,O,O
from,O,O
0,O,O
.,O,O
19,O,O
to,O,O
0,O,O
.,O,O
83,O,O
.,O,O
For,O,O
the,O,O
second,O,O
model,O,O
",",O,O
the,O,O
predictive,O,O
accuracy,O,O
increased,O,O
from,O,O
0,O,O
.,O,O
19,O,O
to,O,O
0,O,O
.,O,O
50,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
Cardiac,O,O
toxicity,O,O
of,O,O
5,B,B
-,I,I
fluorouracil,I,I
.,O,O
Report,O,O
of,O,O
a,O,O
case,O,O
of,O,O
spontaneous,O,O
angina,O,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
a,O,O
patient,O,O
with,O,O
colon,O,O
carcinoma,O,O
and,O,O
liver,O,O
metastasis,O,O
who,O,O
presented,O,O
chest,O,O
pain,O,O
after,O,O
5,B,B
-,I,I
fluorouracil,I,I
(,O,O
5,B,B
-,I,I
FU,I,I
),O,O
administration,O,O
.,O,O
Clinical,O,O
electrocardiographic,O,O
evolution,O,O
was,O,O
similar,O,O
to,O,O
that,O,O
observed,O,O
in,O,O
Prinzmetal,O,O
',O,O
s,O,O
angina,O,O
",",O,O
and,O,O
chest,O,O
pain,O,O
promptly,O,O
resolved,O,O
with,O,O
nifedipine,B,B
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
coronary,O,O
spasm,O,O
may,O,O
be,O,O
the,O,O
cause,O,O
of,O,O
cardiotoxicity,O,O
due,O,O
to,O,O
5,B,B
-,I,I
FU,I,I
",",O,O
and,O,O
that,O,O
calcium,B,B
antagonists,O,O
may,O,O
probably,O,O
be,O,O
used,O,O
in,O,O
the,O,O
prevention,O,O
or,O,O
treatment,O,O
of,O,O
5,B,B
-,I,I
FU,I,I
cardiotoxicity,O,O
.,O,O
Dose,O,O
-,O,O
related,O,O
beneficial,O,O
and,O,O
adverse,O,O
effects,O,O
of,O,O
dietary,O,O
corticosterone,B,B
on,O,O
organophosphorus,B,O
-,O,O
induced,O,O
delayed,O,O
neuropathy,O,O
in,O,O
chickens,O,O
.,O,O
Tri,B,O
-,I,O
ortho,I,B
-,I,I
tolyl,I,I
phosphate,I,I
(,O,O
TOTP,B,B
),O,O
",",O,O
360,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
po,O,O
",",O,O
and,O,O
0,B,O
",",I,O
0,I,O
',I,O
-,I,O
diisopropyl,I,B
phosphorofluoridate,I,I
(,O,O
DFP,B,B
),O,O
",",O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
sc,O,O
",",O,O
were,O,O
administered,O,O
to,O,O
adult,O,O
White,O,O
Leghorn,O,O
chickens,O,O
24,O,O
hr,O,O
after,O,O
they,O,O
were,O,O
placed,O,O
on,O,O
diets,O,O
containing,O,O
0,O,O
to,O,O
300,O,O
ppm,O,O
corticosterone,B,B
.,O,O
Supplemented,O,O
diets,O,O
were,O,O
continued,O,O
until,O,O
clinical,O,O
signs,O,O
and,O,O
lesions,O,O
of,O,O
delayed,O,O
neuropathy,O,O
appeared,O,O
.,O,O
Although,O,O
low,O,O
concentrations,O,O
(,O,O
less,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
50,O,O
ppm,O,O
),O,O
of,O,O
corticosterone,B,B
had,O,O
beneficial,O,O
effects,O,O
on,O,O
TOTP,B,B
-,O,O
induced,O,O
neuropathy,O,O
",",O,O
greater,O,O
than,O,O
or,O,O
equal,O,O
to,O,O
200,O,O
ppm,O,O
exacerbated,O,O
clinical,O,O
signs,O,O
in,O,O
chickens,O,O
given,O,O
either,O,O
TOTP,B,B
or,O,O
DFP,B,B
.,O,O
Neurotoxic,O,B
esterase,O,I
activities,O,O
24,O,O
hr,O,O
after,O,O
TOTP,B,B
or,O,O
DFP,B,B
were,O,O
less,O,O
than,O,O
20,O,O
%,O,O
of,O,O
values,O,O
measured,O,O
in,O,O
chickens,O,O
not,O,O
given,O,O
organophosphorous,B,O
compounds,O,O
.,O,O
Chickens,O,O
given,O,O
200,O,O
ppm,O,O
corticosterone,B,B
without,O,O
TOTP,B,B
or,O,O
DFP,B,B
had,O,O
significantly,O,O
elevated,O,O
activity,O,O
of,O,O
plasma,O,O
cholinesterase,O,B
and,O,O
significantly,O,O
inhibited,O,O
activity,O,O
of,O,O
liver,O,O
carboxylesterase,O,B
.,O,O
Degenerating,O,O
myelinated,O,O
fibers,O,O
were,O,O
also,O,O
evident,O,O
in,O,O
distal,O,O
levels,O,O
of,O,O
the,O,O
peripheral,O,O
nerves,O,O
of,O,O
chickens,O,O
given,O,O
TOTP,B,B
or,O,O
DFP,B,B
.,O,O
Hepatotoxicity,O,O
of,O,O
amiodarone,B,B
.,O,O
Amiodarone,B,B
has,O,O
proved,O,O
very,O,O
effective,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
otherwise,O,O
resistant,O,O
cardiac,O,O
tachyarrhythmias,O,O
.,O,O
The,O,O
use,O,O
of,O,O
amiodarone,B,B
has,O,O
",",O,O
however,O,O
",",O,O
been,O,O
limited,O,O
due,O,O
to,O,O
its,O,O
serious,O,O
side,O,O
-,O,O
effects,O,O
.,O,O
A,O,O
patient,O,O
with,O,O
cholestatic,O,B
hepatitis,O,I
due,O,O
to,O,O
amiodarone,B,B
treatment,O,O
is,O,O
presented,O,O
below,O,O
and,O,O
a,O,O
review,O,O
of,O,O
the,O,O
hepatotoxicity,O,O
of,O,O
amiodarone,B,B
is,O,O
given,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
solid,O,O
evidence,O,O
exists,O,O
of,O,O
hepatic,O,O
injury,O,O
due,O,O
to,O,O
amiodarone,B,B
treatment,O,O
",",O,O
including,O,O
steatosis,O,O
",",O,O
alterations,O,O
resembling,O,O
alcoholic,O,O
hepatitis,O,O
",",O,O
cholestatic,O,B
hepatitis,O,I
and,O,O
micronodular,O,O
cirrhosis,O,O
of,O,O
the,O,O
liver,O,O
.,O,O
Patients,O,O
receiving,O,O
amiodarone,B,B
should,O,O
be,O,O
regularly,O,O
screened,O,O
with,O,O
respect,O,O
to,O,O
hepatic,O,O
enzyme,O,O
levels,O,O
.,O,O
Therapy,O,O
should,O,O
be,O,O
discontinued,O,O
on,O,O
the,O,O
suspicion,O,O
of,O,O
cholestatic,O,O
injury,O,O
or,O,O
hepatomegaly,O,O
.,O,O
Promotional,O,O
effects,O,O
of,O,O
testosterone,B,B
and,O,O
dietary,O,O
fat,O,O
on,O,O
prostate,O,O
carcinogenesis,O,O
in,O,O
genetically,O,O
susceptible,O,O
rats,O,O
.,O,O
Germfree,O,O
(,O,O
GF,O,O
),O,O
Lobund,O,O
strain,O,O
Wistar,O,O
(,O,O
LW,O,O
),O,O
rats,O,O
",",O,O
fed,O,O
vegetable,O,O
diet,O,O
L,O,O
-,O,O
485,O,O
",",O,O
have,O,O
developed,O,O
prostate,O,O
adenocarcinomas,O,O
spontaneously,O,O
(,O,O
10,O,O
%,O,O
incidence,O,O
),O,O
at,O,O
average,O,O
age,O,O
34,O,O
months,O,O
.,O,O
Conventional,O,O
LW,O,O
rats,O,O
",",O,O
implanted,O,O
with,O,O
testosterone,B,B
at,O,O
age,O,O
4,O,O
months,O,O
",",O,O
developed,O,O
a,O,O
higher,O,O
incidence,O,O
of,O,O
prostate,O,B
cancer,O,I
after,O,O
an,O,O
average,O,O
interval,O,O
of,O,O
14,O,O
months,O,O
:,O,O
24,O,O
%,O,O
had,O,O
developed,O,O
gross,O,O
tumors,O,O
",",O,O
and,O,O
40,O,O
%,O,O
when,O,O
it,O,O
included,O,O
microscopic,O,O
tumors,O,O
.,O,O
Preliminary,O,O
results,O,O
indicate,O,O
that,O,O
testosterone,B,B
-,O,O
treated,O,O
LW,O,O
rats,O,O
that,O,O
were,O,O
fed,O,O
the,O,O
same,O,O
diet,O,O
",",O,O
which,O,O
was,O,O
supplemented,O,O
with,O,O
corn,O,B
oil,O,I
up,O,O
to,O,O
20,O,O
%,O,O
fat,O,O
",",O,O
developed,O,O
prostate,O,B
cancer,O,I
after,O,O
intervals,O,O
of,O,O
6,O,O
-,O,O
12,O,O
months,O,O
.,O,O
Aged,O,O
GF,O,O
Sprague,O,B
-,O,I
Dawley,O,I
(,O,O
SD,O,I
),O,O
rats,O,O
have,O,O
not,O,O
developed,O,O
prostate,O,B
cancer,O,I
spontaneously,O,O
.,O,O
Conventional,O,O
SD,O,I
rats,O,O
fed,O,O
diet,O,O
L,O,B
-,O,I
485,O,I
and,O,O
treated,O,O
with,O,O
testosterone,B,B
developed,O,O
only,O,O
prostatitis,O,B
.,O,O
Experimental,O,O
designs,O,O
should,O,O
consider,O,O
genetic,O,O
susceptibility,O,O
as,O,O
a,O,O
basic,O,O
prerequisite,O,O
for,O,O
studies,O,O
on,O,O
experimental,O,O
prostate,O,B
cancer,O,I
.,O,O
Time,O,O
course,O,O
alterations,O,O
of,O,O
QTC,O,B
interval,O,O
due,O,O
to,O,O
hypaque,B,B
76,I,O
.,O,O
Sequential,O,O
measurement,O,O
of,O,O
QT,O,B
interval,O,O
during,O,O
left,O,O
ventricular,O,O
angiography,O,O
was,O,O
made,O,O
30,O,O
seconds,O,O
and,O,O
one,O,O
",",O,O
three,O,O
",",O,O
five,O,O
and,O,O
ten,O,O
minutes,O,O
after,O,O
injection,O,O
of,O,O
hypaque,B,B
76,I,O
.,O,O
The,O,O
subjects,O,O
were,O,O
ten,O,O
patients,O,O
found,O,O
to,O,O
have,O,O
normal,O,O
left,O,O
ventricles,O,O
and,O,O
coronary,O,O
arteries,O,O
.,O,O
Significant,O,O
QTC,O,B
prolongation,O,O
occurred,O,O
in,O,O
30,O,O
seconds,O,O
to,O,O
one,O,O
minute,O,O
in,O,O
association,O,O
with,O,O
marked,O,O
hypotension,O,O
and,O,O
elevation,O,O
of,O,O
cardiac,O,O
output,O,O
.,O,O
Rat,O,O
extraocular,O,O
muscle,O,O
regeneration,O,O
.,O,O
Repair,O,O
of,O,O
local,O,O
anesthetic,O,O
-,O,O
induced,O,O
damage,O,O
.,O,O
Local,O,O
anesthetics,O,O
that,O,O
are,O,O
commonly,O,O
used,O,O
in,O,O
ophthalmic,O,O
surgery,O,O
(,O,O
0,O,O
.,O,O
75,O,O
%,O,O
bupivacaine,B,B
hydrochloride,I,I
",",O,O
2,O,O
.,O,O
0,O,O
mepivacaine,B,B
hydrochloride,I,I
",",O,O
and,O,O
2,O,O
.,O,O
0,O,O
lidocaine,B,B
hydrochloride,I,I
plus,O,O
1,O,O
:,O,O
100,O,O
",",O,O
epinephrine,B,B
),O,O
were,O,O
injected,O,O
into,O,O
the,O,O
retrobulbar,O,O
area,O,O
of,O,O
rat,O,O
eyes,O,O
.,O,O
Controls,O,O
were,O,O
injected,O,O
with,O,O
physiological,O,O
saline,O,B
.,O,O
All,O,O
three,O,O
anesthetics,O,O
produced,O,O
massive,O,O
degeneration,O,O
of,O,O
the,O,O
extraocular,O,O
muscles,O,O
.,O,O
Muscle,O,O
degeneration,O,O
is,O,O
followed,O,O
by,O,O
regeneration,O,O
of,O,O
the,O,O
damaged,O,O
muscle,O,O
fibers,O,O
.,O,O
In,O,O
addition,O,O
to,O,O
muscle,O,B
damage,O,I
",",O,O
severe,O,O
damage,O,B
was,O,O
also,O,O
seen,O,O
in,O,O
harderian,O,B
glands,O,I
",",O,O
especially,O,O
after,O,O
exposure,O,O
to,O,O
mepivacaine,B,B
and,O,O
lidocaine,B,B
plus,O,O
epinephrine,B,B
.,O,O
With,O,O
these,O,O
findings,O,O
in,O,O
rats,O,O
",",O,O
it,O,O
is,O,O
hypothesized,O,O
that,O,O
the,O,O
temporary,O,O
diplopia,O,O
sometimes,O,O
seen,O,O
in,O,O
patients,O,O
after,O,O
ophthalmic,O,O
surgery,O,O
might,O,O
be,O,O
due,O,O
to,O,O
anesthetic,O,B
-,O,I
induced,O,I
damage,O,I
to,O,O
the,O,O
extraocular,O,B
muscles,O,I
.,O,O
Gentamicin,B,B
nephropathy,O,O
in,O,O
a,O,O
neonate,O,O
.,O,O
The,O,O
clinical,O,O
and,O,O
autopsy,O,O
findings,O,O
in,O,O
a,O,O
premature,O,O
baby,O,O
who,O,O
died,O,O
of,O,O
acute,O,O
renal,O,O
failure,O,O
after,O,O
therapy,O,O
with,O,O
gentamicin,B,B
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
),O,O
and,O,O
penicillin,B,O
are,O,O
presented,O,O
.,O,O
The,O,O
serum,O,O
gentamicin,B,B
concentration,O,O
had,O,O
reached,O,O
toxic,O,O
levels,O,O
when,O,O
anuria,O,O
developed,O,O
.,O,O
Numerous,O,O
periodic,B,O
acid,I,B
Schiff,O,I
(,O,O
PAS,O,B
),O,O
positive,O,O
",",O,O
diastase,O,B
resistant,O,O
cytoplasmic,O,O
inclusion,O,O
bodies,O,O
which,O,O
appeared,O,O
as,O,O
myelin,O,O
figures,O,O
in,O,O
cytosegresomes,O,O
under,O,O
the,O,O
electron,O,O
microscope,O,O
were,O,O
identified,O,O
in,O,O
the,O,O
proximal,O,O
convoluted,O,O
tubules,O,O
.,O,O
The,O,O
pathological,O,O
changes,O,O
induced,O,O
by,O,O
gentamicin,B,B
in,O,O
the,O,O
human,O,O
neonatal,O,O
kidneys,O,O
have,O,O
not,O,O
been,O,O
previously,O,O
reported,O,O
.,O,O
Induction,O,O
by,O,O
paracetamol,B,B
of,O,O
bladder,O,B
and,O,O
liver,O,B
tumours,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Effects,O,O
on,O,O
hepatocyte,O,O
fine,O,O
structure,O,O
.,O,O
Groups,O,O
of,O,O
male,O,O
and,O,O
female,O,O
inbred,O,O
Leeds,O,O
strain,O,O
rats,O,O
were,O,O
fed,O,O
diets,O,O
containing,O,O
either,O,O
0,O,O
.,O,O
5,O,O
%,O,O
or,O,O
1,O,O
.,O,O
0,O,O
%,O,O
paracetamol,B,B
by,O,O
weight,O,O
for,O,O
up,O,O
to,O,O
18,O,O
months,O,O
.,O,O
At,O,O
the,O,O
1,O,O
.,O,O
0,O,O
%,O,O
dosage,O,O
level,O,O
",",O,O
20,O,O
%,O,O
of,O,O
rats,O,O
of,O,O
both,O,O
sexes,O,O
developed,O,O
neoplastic,O,B
nodules,O,O
of,O,O
the,O,O
liver,O,B
",",O,O
a,O,O
statistically,O,O
significant,O,O
incidence,O,O
.,O,O
These,O,O
rats,O,O
also,O,O
showed,O,O
gross,O,O
enlargement,O,O
of,O,O
their,O,O
livers,O,O
and,O,O
an,O,O
increase,O,O
in,O,O
foci,O,O
of,O,O
cellular,O,O
alteration,O,O
",",O,O
the,O,O
latter,O,O
also,O,O
being,O,O
observed,O,O
in,O,O
the,O,O
low,O,O
dosage,O,O
male,O,O
rats,O,O
.,O,O
Papillomas,O,B
of,O,O
the,O,O
transitional,O,O
epithelium,O,O
of,O,O
the,O,O
bladder,O,B
developed,O,O
in,O,O
all,O,O
paracetamol,B,B
-,O,O
treated,O,O
groups,O,O
",",O,O
and,O,O
three,O,O
rats,O,O
bore,O,O
bladder,O,B
carcinomas,O,O
.,O,O
However,O,O
",",O,O
significant,O,O
yields,O,O
of,O,O
bladder,O,B
tumours,O,O
were,O,O
only,O,O
obtained,O,O
from,O,O
low,O,O
dosage,O,O
females,O,O
and,O,O
high,O,O
dosage,O,O
males,O,O
.,O,O
Additionally,O,O
",",O,O
20,O,O
to,O,O
25,O,O
%,O,O
of,O,O
paracetamol,B,B
-,O,O
treated,O,O
rats,O,O
developed,O,O
hyperplasia,O,O
of,O,O
the,O,O
bladder,O,B
epithelium,O,O
",",O,O
which,O,O
was,O,O
not,O,O
coincident,O,O
with,O,O
the,O,O
presence,O,O
of,O,O
bladder,O,B
calculi,O,O
.,O,O
A,O,O
low,O,O
yield,O,O
of,O,O
tumours,O,O
at,O,O
various,O,O
other,O,O
sites,O,O
also,O,O
arose,O,O
following,O,O
paracetamol,B,B
feeding,O,O
.,O,O
An,O,O
electron,O,O
microscope,O,O
study,O,O
of,O,O
the,O,O
livers,O,O
of,O,O
paracetamol,B,B
-,O,O
treated,O,O
rats,O,O
revealed,O,O
ultrastructural,O,O
changes,O,O
in,O,O
the,O,O
hepatocytes,O,O
that,O,O
resemble,O,O
those,O,O
that,O,O
result,O,O
from,O,O
exposure,O,O
to,O,O
a,O,O
variety,O,O
of,O,O
known,O,O
hepatocarcinogens,O,B
.,O,O
Transient,O,O
hemiparesis,O,O
:,O,O
a,O,O
rare,O,O
manifestation,O,O
of,O,O
diphenylhydantoin,B,B
toxicity,O,O
.,O,O
Report,O,O
of,O,O
two,O,O
cases,O,O
.,O,O
Among,O,O
the,O,O
common,O,O
side,O,O
effects,O,O
of,O,O
diphenylhydantoin,B,B
(,O,O
DPH,B,B
),O,O
overdose,O,O
",",O,O
the,O,O
most,O,O
frequently,O,O
encountered,O,O
neurological,O,O
signs,O,O
are,O,O
those,O,O
of,O,O
cerebellar,O,O
dysfunction,O,O
.,O,O
Very,O,O
rarely,O,O
",",O,O
the,O,O
toxic,O,O
neurological,O,O
manifestations,O,O
of,O,O
this,O,O
drug,O,O
are,O,O
of,O,O
cerebral,O,O
origin,O,O
.,O,O
Two,O,O
patients,O,O
are,O,O
presented,O,O
who,O,O
suffered,O,O
progressive,O,O
hemiparesis,O,O
due,O,O
to,O,O
DPH,B,B
overdose,O,O
.,O,O
Both,O,O
had,O,O
brain,O,O
surgery,O,O
before,O,O
DPH,B,B
treatment,O,O
.,O,O
It,O,O
is,O,O
assumed,O,O
that,O,O
patients,O,O
with,O,O
some,O,O
cerebral,O,O
damage,O,O
are,O,O
liable,O,O
to,O,O
manifest,O,O
DPH,B,B
toxicity,O,O
as,O,O
focal,O,O
neurological,O,O
signs,O,O
.,O,O
Tiapride,B,B
in,O,O
levodopa,B,B
-,O,O
induced,O,O
involuntary,O,O
movements,O,O
.,O,O
Tiapride,B,B
",",O,O
a,O,O
substituted,O,O
benzamide,B,B
derivative,O,O
closely,O,O
related,O,O
to,O,O
metoclopramide,B,B
",",O,O
reduced,O,O
levodopa,B,B
-,O,O
induced,O,O
peak,O,O
dose,O,O
involuntary,O,O
movements,O,O
in,O,O
16,O,O
patients,O,O
with,O,O
idiopathic,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
.,O,O
However,O,O
",",O,O
an,O,O
unacceptable,O,O
increase,O,O
in,O,O
disability,O,O
from,O,O
Parkinsonism,O,B
with,O,O
aggravation,O,O
of,O,O
end,O,O
-,O,O
of,O,O
-,O,O
dose,O,O
akinesia,O,O
led,O,O
to,O,O
its,O,O
cessation,O,O
in,O,O
14,O,O
patients,O,O
.,O,O
Tiapride,B,B
had,O,O
no,O,O
effect,O,O
on,O,O
levodopa,B,B
-,O,O
induced,O,O
early,O,O
morning,O,O
of,O,O
segmental,O,O
dystonia,O,O
.,O,O
These,O,O
results,O,O
fail,O,O
to,O,O
support,O,O
the,O,O
notion,O,O
that,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
are,O,O
caused,O,O
by,O,O
overstimulation,O,O
of,O,O
a,O,O
separate,O,O
group,O,O
of,O,O
dopamine,B,B
receptors,O,O
.,O,O
Quinidine,B,B
hepatitis,O,O
.,O,O
Long,O,O
-,O,O
term,O,O
administration,O,O
of,O,O
quinidine,B,B
was,O,O
associated,O,O
with,O,O
persistent,O,O
elevation,O,O
of,O,O
serum,O,O
concentrations,O,O
of,O,O
SGOT,O,B
",",O,O
lactic,B,B
acid,I,I
dehydrogenase,O,I
",",O,O
and,O,O
alkaline,O,B
phosphatase,O,I
.,O,O
Liver,O,B
biopsy,O,I
showed,O,O
active,O,O
hepatitis,O,O
.,O,O
Discontinuance,O,O
of,O,O
quinidine,B,B
therapy,O,O
led,O,O
to,O,O
normalization,O,O
of,O,O
liver,O,B
function,O,I
tests,O,I
.,O,O
A,O,O
challenge,O,O
dose,O,O
of,O,O
quinidine,B,B
caused,O,O
clinical,O,O
symptoms,O,O
and,O,O
abrupt,O,O
elevation,O,O
of,O,O
SGOT,O,B
",",O,O
alkaline,O,B
phosphatase,O,I
",",O,O
and,O,O
lactic,B,B
acid,I,I
dehydrogenase,O,I
values,O,I
.,O,O
We,O,O
concluded,O,O
that,O,O
this,O,O
patient,O,O
had,O,O
quinidine,B,B
hepatotoxicity,O,O
and,O,O
believe,O,O
that,O,O
this,O,O
is,O,O
the,O,O
first,O,O
case,O,O
reported,O,O
with,O,O
liver,O,B
biopsy,O,I
documentation,O,I
.,O,O
This,O,O
report,O,O
also,O,O
suggests,O,O
that,O,O
",",O,O
even,O,O
after,O,O
long,O,O
-,O,O
term,O,O
administration,O,O
",",O,O
the,O,O
hepatic,O,B
toxicity,O,I
is,O,O
reversible,O,O
.,O,O
Arterial,O,B
thromboembolism,O,I
in,O,O
patients,O,O
receiving,O,O
systemic,O,B
heparin,B,I
therapy,O,I
:,O,O
a,O,O
complication,O,O
associated,O,O
with,O,O
heparin,B,B
-,O,I
induced,O,I
thrombocytopenia,O,I
.,O,O
Arterial,O,B
thromboembolism,O,I
is,O,O
a,O,O
recognized,O,O
complication,O,O
of,O,O
systemic,O,B
heparin,B,I
therapy,O,I
.,O,O
Characteristic,O,O
of,O,O
the,O,O
entity,O,O
is,O,O
arterial,O,O
occlusion,O,O
by,O,O
platelet,O,B
-,O,O
fibrin,O,B
thrombi,O,O
with,O,O
distal,O,O
ischemia,O,O
occurring,O,O
four,O,O
to,O,O
twenty,O,O
days,O,O
after,O,O
the,O,O
initiation,O,O
of,O,O
heparin,B,B
therapy,O,O
",",O,O
preceded,O,O
by,O,O
profound,O,O
thrombocytopenia,O,O
with,O,O
platelet,O,B
counts,O,O
in,O,O
the,O,O
range,O,O
of,O,O
30,O,O
",",O,O
to,O,O
40,O,O
",",O,O
per,O,O
cubic,O,O
millimeter,O,O
.,O,O
The,O,O
clinically,O,O
apparent,O,O
occlusion,O,O
may,O,O
be,O,O
preceded,O,O
by,O,O
gastrointestinal,O,O
and,O,O
musculoskeletal,O,O
symptoms,O,O
that,O,O
appear,O,O
to,O,O
be,O,O
ischemic,O,O
in,O,O
origin,O,O
",",O,O
and,O,O
might,O,O
serve,O,O
to,O,O
warn,O,O
the,O,O
clinician,O,O
of,O,O
these,O,O
complications,O,O
.,O,O
Previous,O,O
reports,O,O
of,O,O
these,O,O
phenomena,O,O
as,O,O
well,O,O
as,O,O
recent,O,O
studies,O,O
of,O,O
the,O,O
effect,O,O
of,O,O
heparin,B,B
are,O,O
reviewed,O,O
.,O,O
The,O,O
common,O,O
factor,O,O
relating,O,O
thromboembolism,O,O
and,O,O
thrombocytopenia,O,O
is,O,O
heparin,B,B
-,O,O
induced,O,O
platelet,O,O
aggregation,O,O
.,O,O
Appropriate,O,O
treatment,O,O
consists,O,O
of,O,O
discontinuation,O,O
of,O,O
heparin,B,B
",",O,O
and,O,O
anticoagulation,O,O
with,O,O
sodium,B,O
warfarin,I,O
if,O,O
necessary,O,O
.,O,O
Vascular,O,O
procedures,O,O
are,O,O
performed,O,O
as,O,O
indicated,O,O
.,O,O
Pharmacology,O,O
of,O,O
GYKI,B,B
-,I,I
41,I,I
(,O,O
chlorpropanol,B,B
",",O,O
Tobanum,B,B
),O,O
a,O,O
new,O,O
potent,O,O
beta,O,O
-,O,O
adrenergic,O,O
antagonist,O,O
.,O,O
The,O,O
compound,O,O
GYKI,B,B
-,I,I
41,I,I
",",O,O
as,O,O
a,O,O
beta,O,O
-,O,O
adrenergic,O,O
antagonist,O,O
",",O,O
is,O,O
3,O,O
-,O,O
8,O,O
times,O,O
more,O,O
potent,O,O
than,O,O
propranolol,B,B
in,O,O
vitro,O,O
and,O,O
in,O,O
vivo,O,O
.,O,O
Its,O,O
antiarrhythmic,O,O
effectiveness,O,O
surpasses,O,O
that,O,O
of,O,O
propranolol,B,B
and,O,O
pindolol,B,B
inhibiting,O,O
the,O,O
ouabain,B,B
arrhythmia,O,O
in,O,O
dogs,O,O
and,O,O
cats,O,O
.,O,O
GYKI,B,B
-,I,O
41,I,I
900,I,I
has,O,O
a,O,O
negligible,O,O
cardiodepressant,O,O
activity,O,O
;,O,O
it,O,O
is,O,O
not,O,O
cardioselective,O,O
.,O,O
The,O,O
compound,O,O
shows,O,O
a,O,O
rapid,O,O
and,O,O
long,O,O
lasting,O,O
effect,O,O
.,O,O
There,O,O
was,O,O
a,O,O
prolonged,O,O
elimination,O,O
of,O,O
the,O,O
radioactivity,O,O
after,O,O
the,O,O
injection,O,O
of,O,O
14C,B,B
-,I,I
41,I,I
to,O,O
rats,O,O
and,O,O
dogs,O,O
.,O,O
The,O,O
half,O,O
life,O,O
of,O,O
the,O,O
unlabeled,O,O
substance,O,O
in,O,O
humans,O,O
was,O,O
more,O,O
than,O,O
10,O,O
hours,O,O
.,O,O
Adverse,O,O
reactions,O,O
to,O,O
bendrofluazide,B,B
and,O,O
propranolol,B,B
for,O,O
the,O,O
treatment,O,O
of,O,O
mild,O,O
hypertension,O,O
.,O,O
Report,O,O
of,O,O
Medical,O,O
Research,O,O
Council,O,O
Working,O,O
Party,O,O
on,O,O
Mild,O,O
to,O,O
Moderate,O,O
Hypertension,O,O
.,O,O
Participants,O,O
in,O,O
the,O,O
Medical,O,O
Research,O,O
Council,O,O
treatment,O,O
trial,O,O
for,O,O
mild,O,O
hypertension,O,O
are,O,O
randomly,O,O
allocated,O,O
to,O,O
one,O,O
of,O,O
four,O,O
treatment,O,O
groups,O,O
:,O,O
bendrofluazide,B,B
",",O,O
propranolol,B,B
",",O,O
or,O,O
a,O,O
placebo,O,O
for,O,O
either,O,O
of,O,O
these,O,O
drugs,O,O
.,O,O
The,O,O
trial,O,O
is,O,O
single,O,O
-,O,O
blind,O,O
.,O,O
23,O,O
582,O,O
patient,O,O
-,O,O
years,O,O
of,O,O
observation,O,O
have,O,O
been,O,O
completed,O,O
so,O,O
far,O,O
",",O,O
10,O,O
684,O,O
on,O,O
active,O,O
drugs,O,O
and,O,O
12,O,O
898,O,O
on,O,O
placebos,O,O
.,O,O
The,O,O
results,O,O
show,O,O
an,O,O
association,O,O
between,O,O
bendrofluazide,B,B
treatment,O,O
and,O,O
impotence,O,B
",",O,O
and,O,O
impotence,O,B
also,O,O
occurred,O,O
more,O,O
frequently,O,O
in,O,O
patients,O,O
taking,O,O
propranolol,B,B
than,O,O
in,O,O
those,O,O
taking,O,O
placebos,O,O
.,O,O
Other,O,O
adverse,O,O
reactions,O,O
significantly,O,O
linked,O,O
with,O,O
active,O,O
drugs,O,O
include,O,O
impaired,O,O
glucose,O,B
tolerance,O,I
in,O,O
men,O,O
and,O,O
women,O,O
and,O,O
gout,O,B
in,O,O
men,O,O
",",O,O
associated,O,O
with,O,O
bendrofluazide,B,B
treatment,O,O
",",O,O
and,O,O
Raynaud,O,B
',O,I
s,O,I
phenomenon,O,I
and,O,O
dyspnoea,O,B
in,O,O
men,O,O
and,O,O
women,O,O
taking,O,O
propranolol,B,B
.,O,O
No,O,O
corneal,O,O
disease,O,O
is,O,O
known,O,O
to,O,O
have,O,O
occurred,O,O
in,O,O
the,O,O
propranolol,B,B
group,O,O
.,O,O
Mean,O,O
serum,O,O
potassium,B,B
level,O,O
fell,O,O
",",O,O
and,O,O
urea,B,B
and,O,O
uric,B,B
acid,I,I
levels,O,O
rose,O,O
",",O,O
in,O,O
men,O,O
and,O,O
women,O,O
taking,O,O
bendrofluazide,B,O
.,O,O
In,O,O
the,O,O
propranolol,B,O
group,O,O
",",O,O
serum,O,O
potassium,B,B
and,O,O
uric,B,B
acid,I,I
levels,O,O
rose,O,O
in,O,O
both,O,O
sexes,O,O
",",O,O
but,O,O
the,O,O
urea,B,B
level,O,O
rose,O,O
significantly,O,O
in,O,O
women,O,O
only,O,O
.,O,O
Serotonergic,O,O
drugs,O,O
",",O,O
benzodiazepines,B,O
and,O,O
baclofen,B,O
block,O,O
muscimol,B,B
-,O,O
induced,O,O
myoclonic,O,O
jerks,O,O
in,O,O
a,O,O
strain,O,O
of,O,O
mice,O,O
.,O,O
In,O,O
male,O,O
Swiss,O,O
mice,O,O
",",O,O
muscimol,B,B
produced,O,O
myoclonic,O,O
jerks,O,O
.,O,O
A,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
(,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
dose,O,O
induced,O,O
this,O,O
response,O,O
in,O,O
all,O,O
of,O,O
the,O,O
mice,O,O
tested,O,O
and,O,O
the,O,O
peak,O,O
response,O,O
of,O,O
73,O,O
jerks,O,O
per,O,O
min,O,O
was,O,O
observed,O,O
between,O,O
27,O,O
and,O,O
45,O,O
min,O,O
.,O,O
Increasing,O,O
the,O,O
brain,O,O
serotonin,B,B
levels,O,O
by,O,O
the,O,O
administration,O,O
of,O,O
5,B,O
-,I,O
hydroxytryptophan,I,B
(,O,O
80,O,O
-,O,O
160,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
in,O,O
combination,O,O
with,O,O
a,O,O
peripheral,O,O
decarboxylase,O,O
inhibitor,O,O
resulted,O,O
in,O,O
an,O,O
inhibition,O,O
of,O,O
the,O,O
muscimol,B,B
effect,O,O
.,O,O
However,O,O
",",O,O
in,O,O
a,O,O
similar,O,O
experiment,O,O
l,B,B
-,I,I
dopa,I,I
(,O,O
80,O,O
-,O,O
160,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
was,O,O
without,O,O
effect,O,O
.,O,O
In,O,O
doses,O,O
of,O,O
3,O,O
-,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
the,O,O
serotonin,B,B
receptor,O,I
agonist,O,I
MK,B,B
-,I,I
212,I,I
caused,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
blockade,O,O
of,O,O
the,O,O
response,O,O
of,O,O
muscimol,B,B
.,O,O
Of,O,O
the,O,O
benzodiazepines,B,B
",",O,O
clonazepam,B,B
(,O,O
0,O,O
.,O,O
1,O,O
-,O,O
0,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
was,O,O
found,O,O
to,O,O
be,O,O
several,O,O
fold,O,O
more,O,O
potent,O,O
than,O,O
diazepam,B,B
(,O,O
0,O,O
.,O,O
3,O,O
-,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
in,O,O
blocking,O,O
the,O,O
myoclonic,O,O
jerks,O,O
.,O,O
While,O,O
(,O,O
-,O,O
),O,O
-,O,O
baclofen,B,B
(,O,O
1,O,B
-,O,I
3,O,I
mg,O,I
/,O,I
kg,O,I
),O,O
proved,O,O
to,O,O
be,O,O
an,O,O
effective,O,O
antagonist,O,O
of,O,O
muscimol,B,B
",",O,O
its,O,O
(,O,O
+,O,O
),O,O
-,O,O
isomer,O,O
(,O,O
5,O,B
-,O,I
20,O,I
mg,O,I
/,O,I
kg,O,I
),O,O
lacked,O,O
this,O,O
property,O,O
.,O,O
Considering,O,O
the,O,O
fact,O,O
that,O,O
5,B,B
-,I,I
HTP,I,I
and,O,O
the,O,O
benzodiazepines,B,B
have,O,O
been,O,O
found,O,O
to,O,O
be,O,O
beneficial,O,O
in,O,O
the,O,O
management,O,O
of,O,O
clinical,O,O
myoclonus,O,O
",",O,O
the,O,O
muscimol,B,B
-,O,O
induced,O,O
myoclonus,O,O
seems,O,O
to,O,O
be,O,O
a,O,O
satisfactory,O,O
animal,O,O
model,O,O
that,O,O
may,O,O
prove,O,O
useful,O,O
for,O,O
the,O,O
development,O,O
of,O,O
new,O,O
drug,O,O
treatments,O,O
for,O,O
this,O,O
condition,O,O
.,O,O
Our,O,O
present,O,O
study,O,O
indicated,O,O
the,O,O
possible,O,O
value,O,O
of,O,O
MK,B,B
-,I,O
212,I,I
and,O,O
(,O,O
-,O,O
),O,O
-,O,O
baclofen,B,B
in,O,O
the,O,O
management,O,O
of,O,O
clinical,O,O
myoclonus,O,O
.,O,O
Adverse,O,O
interaction,O,O
between,O,O
beta,B,B
-,I,O
adrenergic,I,I
blocking,I,I
drugs,I,I
and,O,O
verapamil,B,B
-,O,O
-,O,O
report,O,O
of,O,O
three,O,O
cases,O,O
.,O,O
Three,O,O
patients,O,O
with,O,O
ischaemic,O,O
heart,O,O
disease,O,O
developed,O,O
profound,O,O
cardiac,O,O
failure,O,O
",",O,O
hypotension,O,O
and,O,O
bradycardia,O,O
during,O,O
combined,O,O
therapy,O,O
with,O,O
verapamil,B,B
and,O,O
beta,B,B
-,I,O
adrenergic,I,I
blocking,I,I
drugs,I,I
.,O,O
This,O,O
clinical,O,O
picture,O,O
resolved,O,O
completely,O,O
with,O,O
cessation,O,O
of,O,O
the,O,O
combined,O,O
therapy,O,O
.,O,O
Baseline,O,O
left,O,O
ventricular,O,O
function,O,O
",",O,O
assessed,O,O
by,O,O
cardiac,O,O
catheterisation,O,O
or,O,O
nuclear,O,O
angiography,O,O
",",O,O
was,O,O
normal,O,O
in,O,O
two,O,O
patients,O,O
and,O,O
only,O,O
mildly,O,O
reduced,O,O
in,O,O
the,O,O
other,O,O
.,O,O
Simultaneously,O,O
administration,O,O
of,O,O
beta,B,B
-,I,I
adrenergic,I,I
blocking,I,I
drugs,I,I
and,O,O
verapamil,B,B
may,O,O
result,O,O
in,O,O
profound,O,O
adverse,O,O
interactions,O,O
and,O,O
should,O,O
only,O,O
be,O,O
administered,O,O
with,O,O
great,O,O
caution,O,O
.,O,O
Comparison,O,O
of,O,O
the,O,O
effectiveness,O,O
of,O,O
ranitidine,B,B
and,O,O
cimetidine,B,B
in,O,O
inhibiting,O,O
acid,O,B
secretion,O,O
in,O,O
patients,O,O
with,O,O
gastric,O,O
hypersecretory,O,O
states,O,O
.,O,O
The,O,O
H2,O,O
-,O,O
histamine,B,B
receptor,O,O
antagonists,O,O
ranitidine,B,B
and,O,O
cimetidine,B,B
were,O,O
compared,O,O
for,O,O
their,O,O
abilities,O,O
to,O,O
control,O,O
gastric,O,O
acid,O,B
hypersecretion,O,O
on,O,O
a,O,O
short,O,O
-,O,O
and,O,O
long,O,O
-,O,O
term,O,O
basis,O,O
in,O,O
22,O,O
patients,O,O
with,O,O
gastric,O,O
acid,O,B
hypersecretory,O,O
states,O,O
.,O,O
Nineteen,O,O
patients,O,O
had,O,O
Zollinger,O,B
-,O,I
Ellison,O,I
syndrome,O,I
",",O,O
one,O,O
patient,O,O
had,O,O
systemic,O,B
mastocytosis,O,I
",",O,O
and,O,O
two,O,O
patients,O,O
had,O,O
idiopathic,O,B
hypersecretion,O,I
.,O,O
The,O,O
rates,O,O
of,O,O
onset,O,O
of,O,O
the,O,O
action,O,O
of,O,O
cimetidine,B,B
and,O,O
ranitidine,B,B
were,O,O
the,O,O
same,O,O
.,O,O
The,O,O
actions,O,O
of,O,O
both,O,O
drugs,O,O
were,O,O
increased,O,O
by,O,O
anticholinergic,O,B
agents,O,I
",",O,O
and,O,O
there,O,O
was,O,O
a,O,O
close,O,O
correlation,O,O
between,O,O
the,O,O
daily,O,O
maintenance,O,O
dose,O,O
of,O,O
each,O,O
drug,O,O
needed,O,O
to,O,O
control,O,O
acid,O,O
secretion,O,O
.,O,O
However,O,O
",",O,O
ranitidine,B,B
was,O,O
threefold,O,O
more,O,O
potent,O,O
than,O,O
cimetidine,B,B
both,O,O
in,O,O
acute,O,O
inhibition,O,O
studies,O,O
and,O,O
in,O,O
the,O,O
median,O,O
maintenance,O,O
dose,O,O
needed,O,O
(,O,O
1,O,O
.,O,O
2,O,O
g,O,O
per,O,O
day,O,O
for,O,O
ranitidine,B,B
and,O,O
3,O,O
.,O,O
6,O,O
g,O,O
per,O,O
day,O,O
for,O,O
cimetidine,B,B
.,O,O
Sixty,O,O
percent,O,O
of,O,O
the,O,O
males,O,O
developed,O,O
breast,O,O
changes,O,O
or,O,O
impotence,O,O
while,O,O
taking,O,O
cimetidine,B,B
and,O,O
in,O,O
all,O,O
cases,O,O
these,O,O
changes,O,O
disappeared,O,O
when,O,O
cimetidine,B,B
was,O,O
replaced,O,O
by,O,O
ranitidine,B,B
.,O,O
Treatment,O,O
with,O,O
high,O,O
doses,O,O
of,O,O
cimetidine,B,B
(,O,O
one,O,O
to,O,O
60,O,O
months,O,O
;,O,O
median,O,O
",",O,O
11,O,O
months,O,O
),O,O
or,O,O
ranitidine,B,B
(,O,O
two,O,O
to,O,O
31,O,O
months,O,O
;,O,O
median,O,O
",",O,O
14,O,O
months,O,O
),O,O
was,O,O
not,O,O
associated,O,O
with,O,O
hepatic,O,O
or,O,O
hematologic,O,O
toxicity,O,O
or,O,O
alterations,O,O
of,O,O
serum,O,O
gastrin,O,B
concentrations,O,O
",",O,O
but,O,O
ranitidine,B,B
therapy,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
significantly,O,O
lower,O,O
serum,O,O
creatinine,B,B
level,O,O
than,O,O
seen,O,O
with,O,O
cimetidine,B,B
therapy,O,O
.,O,O
The,O,O
results,O,O
show,O,O
that,O,O
both,O,O
drugs,O,O
can,O,O
adequately,O,O
inhibit,O,O
acid,O,B
secretion,O,O
in,O,O
patients,O,O
with,O,O
gastric,O,O
hypersecretory,O,O
states,O,O
.,O,O
Both,O,O
are,O,O
safe,O,O
at,O,O
high,O,O
doses,O,O
",",O,O
but,O,O
ranitidine,B,B
is,O,O
threefold,O,O
more,O,O
potent,O,O
and,O,O
does,O,O
not,O,O
cause,O,O
the,O,O
antiandrogen,O,O
side,O,O
effects,O,O
frequently,O,O
seen,O,O
with,O,O
high,O,O
doses,O,O
of,O,O
cimetidine,B,B
.,O,O
Epileptogenic,O,O
properties,O,O
of,O,O
enflurane,B,B
and,O,O
their,O,O
clinical,O,O
interpretation,O,O
.,O,O
Three,O,O
cases,O,O
of,O,O
EEG,O,O
changes,O,O
induced,O,O
by,O,O
single,O,O
exposure,O,O
to,O,O
enflurane,B,B
anesthesia,O,O
are,O,O
reported,O,O
.,O,O
In,O,O
one,O,O
patient,O,O
",",O,O
enflurane,B,B
administered,O,O
during,O,O
a,O,O
donor,O,O
nephrectomy,O,O
resulted,O,O
in,O,O
unexpected,O,O
partial,O,O
motor,O,O
seizures,O,O
.,O,O
Until,O,O
the,O,O
cause,O,O
of,O,O
the,O,O
seizures,O,O
was,O,O
correctly,O,O
identified,O,O
",",O,O
the,O,O
patient,O,O
was,O,O
inappropriately,O,O
treated,O,O
with,O,O
anticonvulsants,O,B
.,O,O
Two,O,O
other,O,O
patients,O,O
suffered,O,O
from,O,O
partial,O,O
",",O,O
complex,O,O
and,O,O
generalized,O,O
seizures,O,O
uncontrolled,O,O
by,O,O
medication,O,O
.,O,O
Epileptic,O,O
foci,O,O
delineated,O,O
and,O,O
activated,O,O
by,O,O
enflurane,B,B
were,O,O
surgically,O,O
ablated,O,O
and,O,O
the,O,O
patients,O,O
are,O,O
now,O,O
seizure,O,O
-,O,O
free,O,O
.,O,O
Previous,O,O
exposures,O,O
to,O,O
enflurane,B,B
have,O,O
to,O,O
be,O,O
disclosed,O,O
to,O,O
avoid,O,O
mistakes,O,O
in,O,O
clinical,O,O
interpretation,O,O
of,O,O
the,O,O
EEG,O,O
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
enflurane,B,B
may,O,O
prove,O,O
to,O,O
be,O,O
a,O,O
safe,O,O
fast,O,O
acting,O,O
activator,O,O
of,O,O
epileptic,O,O
foci,O,O
during,O,O
corticography,O,O
or,O,O
depth,O,O
electrode,O,O
intraoperative,O,O
recordings,O,O
.,O,O
Development,O,O
of,O,O
isoproterenol,B,B
-,O,I
induced,O,O
cardiac,O,O
hypertrophy,O,O
.,O,O
The,O,O
development,O,O
of,O,O
cardiac,O,O
hypertrophy,O,O
was,O,O
studied,O,O
in,O,O
adult,O,O
female,O,O
Wistar,O,O
rats,O,O
following,O,O
daily,O,O
subcutaneous,O,O
injections,O,O
of,O,O
isoproterenol,B,B
(,O,O
ISO,B,B
),O,O
(,O,O
0,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
),O,O
.,O,O
A,O,O
time,O,O
course,O,O
was,O,O
established,O,O
for,O,O
the,O,O
change,O,O
in,O,O
tissue,O,O
mass,O,O
",",O,O
RNA,O,B
and,O,O
DNA,O,B
content,O,O
",",O,O
as,O,O
well,O,O
as,O,O
hydroxyproline,B,B
content,O,O
.,O,O
Heart,O,O
weight,O,O
increased,O,O
44,O,O
%,O,O
after,O,O
8,O,O
days,O,O
of,O,O
treatment,O,O
with,O,O
a,O,O
half,O,O
time,O,O
of,O,O
3,O,O
.,O,O
4,O,O
days,O,O
.,O,O
Ventricular,O,O
RNA,O,B
content,O,O
was,O,O
elevated,O,O
26,O,O
%,O,O
after,O,O
24,O,O
h,O,O
of,O,O
a,O,O
single,O,O
injection,O,O
and,O,O
reached,O,O
a,O,O
maximal,O,O
level,O,O
following,O,O
8,O,O
days,O,O
of,O,O
therapy,O,O
.,O,O
The,O,O
half,O,O
time,O,O
for,O,O
RNA,O,B
accumulation,O,O
was,O,O
2,O,O
.,O,O
0,O,O
days,O,O
.,O,O
The,O,O
total,O,O
content,O,O
of,O,O
hydroxyproline,B,B
remained,O,O
stable,O,O
during,O,O
the,O,O
first,O,O
2,O,O
days,O,O
of,O,O
treatment,O,O
but,O,O
increased,O,O
46,O,O
%,O,O
after,O,O
4,O,O
days,O,O
of,O,O
therapy,O,O
.,O,O
Ventricular,O,O
DNA,O,B
content,O,O
was,O,O
unchanged,O,O
during,O,O
the,O,O
early,O,O
stage,O,O
(,O,O
1,O,O
-,O,O
4,O,O
days,O,O
),O,O
of,O,O
hypertrophic,O,O
growth,O,O
but,O,O
increased,O,O
to,O,O
a,O,O
new,O,O
steady,O,O
-,O,O
state,O,O
level,O,O
19,O,O
%,O,O
above,O,O
the,O,O
controls,O,O
after,O,O
8,O,O
days,O,O
of,O,O
treatment,O,O
.,O,O
Intraventricular,O,O
pressures,O,O
and,O,O
coronary,O,O
flow,O,O
measures,O,O
were,O,O
similar,O,O
for,O,O
control,O,O
and,O,O
experimental,O,O
animals,O,O
following,O,O
4,O,O
days,O,O
of,O,O
developed,O,O
hypertrophy,O,O
.,O,O
However,O,O
",",O,O
dP,O,O
/,O,O
dt,O,O
in,O,O
the,O,O
ISO,B,B
-,O,O
treated,O,O
hearts,O,O
was,O,O
slightly,O,O
but,O,O
significantly,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
elevated,O,O
.,O,O
These,O,O
data,O,O
indicate,O,O
that,O,O
the,O,O
adaptive,O,O
response,O,O
to,O,O
ISO,B,B
shows,O,O
an,O,O
early,O,O
hypertrophic,O,O
phase,O,O
(,O,O
1,O,O
-,O,O
4,O,O
days,O,O
),O,O
characterized,O,O
by,O,O
a,O,O
substantial,O,O
increase,O,O
in,O,O
RNA,O,B
content,O,O
and,O,O
cardiac,O,O
mass,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
changes,O,O
in,O,O
DNA,O,B
.,O,O
However,O,O
",",O,O
prolonged,O,O
stimulation,O,O
(,O,O
8,O,O
-,O,O
12,O,O
days,O,O
),O,O
appears,O,O
to,O,O
represent,O,O
a,O,O
complex,O,O
integration,O,O
of,O,O
both,O,O
cellular,O,O
hypertrophy,O,O
and,O,O
hyperplasia,O,O
within,O,O
the,O,O
heart,O,O
.,O,O
Multiple,O,O
side,O,O
effects,O,O
of,O,O
penicillamine,B,B
therapy,O,O
in,O,O
one,O,O
patient,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
.,O,O
Skin,O,O
rashes,O,O
",",O,O
proteinuria,O,O
",",O,O
systemic,O,O
lupus,O,O
erythematosus,O,O
",",O,O
polymyositis,O,O
and,O,O
myasthenia,O,O
gravis,O,O
have,O,O
all,O,O
been,O,O
recorded,O,O
as,O,O
complications,O,O
of,O,O
penicillamine,B,B
therapy,O,O
in,O,O
patients,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
.,O,O
A,O,O
patient,O,O
who,O,O
had,O,O
developed,O,O
all,O,O
5,O,O
is,O,O
now,O,O
described,O,O
.,O,O
The,O,O
skin,O,O
lesion,O,O
resembled,O,O
elastosis,O,B
perforans,O,I
serpiginosa,O,I
",",O,O
which,O,O
has,O,O
been,O,O
reported,O,O
as,O,O
a,O,O
rare,O,O
side,O,O
effect,O,O
in,O,O
patients,O,O
with,O,O
Wilson,O,B
',O,O
s,O,O
disease,O,O
but,O,O
not,O,O
in,O,O
patients,O,O
with,O,O
rheumatoid,O,B
arthritis,O,I
treated,O,O
with,O,O
penicillamine,B,B
.,O,O
Obsolete,O,O
but,O,O
dangerous,O,O
antacid,O,B
preparations,O,O
.,O,O
One,O,O
case,O,O
of,O,O
acute,O,O
hypercalcaemia,O,B
and,O,O
two,O,O
of,O,O
recurrent,O,O
nephrolithiasis,O,B
are,O,O
reported,O,O
in,O,O
patients,O,O
who,O,O
had,O,O
regularly,O,O
consumed,O,O
large,O,O
amounts,O,O
of,O,O
calcium,B,B
carbon,I,I
-,I,I
ate,I,I
-,O,I
sodium,B,I
bicarbonate,I,I
powders,O,O
for,O,O
more,O,O
than,O,O
20,O,O
years,O,O
.,O,O
The,O,O
powders,O,O
had,O,O
been,O,O
obtained,O,O
from,O,O
pharmacists,O,O
unknown,O,O
to,O,O
the,O,O
patients,O,O
',O,O
medical,O,O
practitioners,O,O
.,O,O
It,O,O
is,O,O
suggested,O,O
that,O,O
these,O,O
preparations,O,O
were,O,O
responsible,O,O
for,O,O
the,O,O
patient,O,O
',O,O
s,O,O
problems,O,O
",",O,O
and,O,O
that,O,O
such,O,O
powders,O,O
should,O,O
no,O,O
longer,O,O
be,O,O
freely,O,O
obtainable,O,O
.,O,O
Doxorubicin,B,B
cardiomyopathy,O,O
in,O,O
children,O,O
with,O,O
left,O,O
-,O,O
sided,O,O
Wilms,O,O
tumor,O,O
.,O,O
Two,O,O
children,O,O
with,O,O
Wilms,O,O
tumor,O,O
of,O,O
the,O,O
left,O,O
kidney,O,O
experienced,O,O
severe,O,O
anthracycline,B,B
cardiomyopathy,O,O
after,O,O
irradiation,O,O
to,O,O
the,O,O
tumor,O,O
bed,O,O
and,O,O
conventional,O,O
dosage,O,O
of,O,O
doxorubicin,B,B
.,O,O
The,O,O
cardiomyopathy,O,B
is,O,O
attributed,O,O
1,O,O
),O,O
to,O,O
the,O,O
fact,O,O
that,O,O
radiation,O,O
fields,O,O
for,O,O
left,O,O
Wilms,O,B
tumor,O,I
include,O,O
the,O,O
lower,O,O
portion,O,O
of,O,O
the,O,O
heart,O,B
and,O,O
2,O,O
),O,O
to,O,O
the,O,O
interaction,O,O
of,O,O
doxorubicin,B,B
and,O,O
irradiation,O,O
on,O,O
cardiac,O,B
muscle,O,I
.,O,O
It,O,O
is,O,O
recommended,O,O
that,O,O
doxorubicin,B,B
dosage,O,O
be,O,O
sharply,O,O
restricted,O,O
in,O,O
children,O,O
with,O,O
Wilms,O,B
tumor,O,I
of,O,O
the,O,O
left,O,O
kidney,O,B
who,O,O
receive,O,O
postoperative,O,O
irradiation,O,O
.,O,O
Effects,O,O
of,O,O
calcitonin,O,B
on,O,O
rat,O,O
extrapyramidal,O,O
motor,O,O
system,O,O
:,O,O
behavioral,O,O
and,O,O
biochemical,O,O
data,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
i,O,O
.,O,O
v,O,O
.,O,O
c,O,O
.,O,O
injection,O,O
of,O,O
human,O,O
and,O,O
salmon,O,B
calcitonin,O,I
on,O,O
biochemical,O,O
and,O,O
behavioral,O,O
parameters,O,O
related,O,O
to,O,O
the,O,O
extrapyramidal,O,O
motor,O,O
system,O,O
",",O,O
were,O,O
investigated,O,O
in,O,O
male,O,O
rats,O,O
.,O,O
Calcitonin,O,B
injection,O,O
resulted,O,O
in,O,O
a,O,O
potentiation,O,O
of,O,O
haloperidol,B,O
-,O,O
induced,O,O
catalepsy,O,O
and,O,O
a,O,O
partial,O,O
prevention,O,O
of,O,O
apomorphine,B,O
-,O,O
induced,O,O
hyperactivity,O,O
.,O,O
Moreover,O,O
calcitonin,O,B
induced,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
nigral,O,O
GAD,O,B
activity,O,O
but,O,O
no,O,O
change,O,O
in,O,O
striatal,O,O
DA,B,B
and,O,O
DOPAC,B,B
concentration,O,O
or,O,O
GAD,O,B
activity,O,O
.,O,O
The,O,O
results,O,O
are,O,O
discussed,O,O
in,O,O
view,O,O
of,O,O
a,O,O
primary,O,O
action,O,O
of,O,O
calcitonin,O,B
on,O,O
the,O,O
striatonigral,O,O
GABAergic,O,O
pathway,O,O
mediating,O,O
the,O,O
DA,B,B
-,O,O
related,O,O
behavioral,O,O
messages,O,O
of,O,O
striatal,O,O
origin,O,O
.,O,O
Naloxazone,B,B
pretreatment,O,O
modifies,O,O
cardiorespiratory,O,O
",",O,O
temperature,O,O
",",O,O
and,O,O
behavioral,O,O
effects,O,O
of,O,O
morphine,B,B
.,O,O
Behavioral,O,O
and,O,O
cardiorespiratory,O,O
responses,O,O
to,O,O
a,O,O
lethal,O,O
dose,O,O
of,O,O
morphine,B,B
were,O,O
evaluated,O,O
in,O,O
rats,O,O
pretreated,O,O
with,O,O
saline,O,B
or,O,O
naloxazone,B,B
",",O,O
an,O,O
antagonist,O,O
of,O,O
high,O,O
-,O,O
affinity,O,O
mu,O,O
1,O,O
opioid,O,O
receptors,O,O
.,O,O
Pretreatment,O,O
with,O,O
naloxazone,B,B
significantly,O,O
blocked,O,O
morphine,B,B
analgesia,O,O
",",O,O
catalepsy,O,O
and,O,O
hypothermia,O,O
at,O,O
a,O,O
dose,O,O
which,O,O
completely,O,O
eliminated,O,O
high,O,O
-,O,O
affinity,O,O
binding,O,O
in,O,O
brain,O,O
membranes,O,O
.,O,O
Moreover,O,O
",",O,O
naloxazone,B,B
significantly,O,O
attenuated,O,O
the,O,O
morphine,B,B
-,O,O
induced,O,O
hypotension,O,O
and,O,O
respiratory,O,O
depression,O,O
",",O,O
whereas,O,O
morphine,B,B
-,O,O
induced,O,O
bradycardia,O,O
was,O,O
less,O,O
affected,O,O
.,O,O
Results,O,O
indicate,O,O
that,O,O
subpopulations,O,O
of,O,O
mu,O,O
receptors,O,O
may,O,O
mediate,O,O
selective,O,O
behavioral,O,O
and,O,O
cardiorespiratory,O,O
responses,O,O
to,O,O
morphine,B,B
.,O,O
Modification,O,O
of,O,O
drug,O,O
action,O,O
by,O,O
hyperammonemia,O,B
.,O,O
Pretreatment,O,O
with,O,O
ammonium,B,B
acetate,I,I
(,O,O
NH4Ac,B,B
),O,O
(,O,O
6,O,O
mmol,O,O
/,O,O
kg,O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
approximately,O,O
doubled,O,O
the,O,O
time,O,O
morphine,B,B
-,O,O
treated,O,O
mice,O,O
remained,O,O
on,O,O
a,O,O
hot,O,O
surface,O,O
and,O,O
similarly,O,O
increased,O,O
muscular,O,O
incoordination,O,O
by,O,O
diazepam,B,B
",",O,O
but,O,O
NH4Ac,B,B
treatment,O,O
alone,O,O
had,O,O
no,O,O
effect,O,O
.,O,O
Thus,O,O
",",O,O
hyperammonemia,O,B
is,O,O
capable,O,O
of,O,O
altering,O,O
drug,O,O
action,O,O
and,O,O
must,O,O
be,O,O
considered,O,O
along,O,O
with,O,O
impaired,O,O
drug,O,O
metabolism,O,O
in,O,O
enhanced,O,O
drug,O,O
responses,O,O
associated,O,O
with,O,O
liver,O,O
disease,O,O
.,O,O
Experiments,O,O
in,O,O
vitro,O,O
showed,O,O
that,O,O
acetylcholine,B,B
-,O,O
induced,O,O
catecholamine,B,B
release,O,O
from,O,O
bovine,O,O
adrenal,O,O
medulla,O,O
is,O,O
depressed,O,O
as,O,O
much,O,O
as,O,O
50,O,O
%,O,O
by,O,O
0,O,O
.,O,O
3,O,O
mM,O,O
NH4Ac,B,B
and,O,O
KCl,B,B
-,O,O
induced,O,O
contractions,O,O
of,O,O
guinea,O,O
-,O,O
pig,O,O
ileum,O,O
were,O,O
inhibited,O,O
20,O,O
%,O,O
by,O,O
5,O,O
mM,O,O
NH4Ac,B,B
.,O,O
Addition,O,O
of,O,O
excess,O,O
calcium,B,B
reversed,O,O
the,O,O
depression,O,O
in,O,O
both,O,O
tissues,O,O
",",O,O
but,O,O
calcium,B,B
-,O,O
independent,O,O
catecholamine,B,B
release,O,O
by,O,O
acetaldehyde,B,B
was,O,O
not,O,O
blocked,O,O
by,O,O
NH4Ac,B,B
.,O,O
These,O,O
results,O,O
suggested,O,O
that,O,O
ammonia,B,B
blocks,O,O
calcium,B,B
channels,O,O
.,O,O
Parallels,O,O
in,O,O
the,O,O
actions,O,O
of,O,O
NH4Ac,B,B
and,O,O
the,O,O
calcium,B,B
channel,O,O
blocker,O,O
verapamil,B,B
support,O,O
this,O,O
concept,O,O
.,O,O
Both,O,O
verapamil,B,B
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
and,O,O
NH4Ac,B,B
pretreatment,O,O
enhanced,O,O
morphine,B,B
analgesia,O,O
-,O,O
and,O,O
diazepam,B,B
-,O,O
induced,O,O
muscular,O,O
incoordination,O,O
and,O,O
antagonized,O,O
amphetamine,B,B
-,O,O
induced,O,O
motor,O,O
activity,O,O
",",O,O
and,O,O
neither,O,O
verapamil,B,B
nor,O,O
NH4Ac,B,B
affected,O,O
the,O,O
convulsant,O,O
action,O,O
of,O,O
metrazol,B,B
.,O,O
The,O,O
data,O,O
suggest,O,O
that,O,O
hyperammonemia,O,O
exerts,O,O
a,O,O
calcium,B,B
channel,O,I
blocking,O,I
action,O,I
which,O,O
enhances,O,O
the,O,O
effects,O,O
of,O,O
central,O,O
nervous,O,O
system,O,O
depressants,O,O
and,O,O
certain,O,O
opioid,O,B
analgesics,O,I
.,O,O
Levodopa,B,O
-,O,O
induced,O,O
dyskinesia,O,O
and,O,O
thalamotomy,O,O
.,O,O
Levodopa,B,O
-,O,O
induced,O,O
dyskinesia,O,O
of,O,O
the,O,O
limbs,O,O
in,O,O
thirteen,O,O
cases,O,O
of,O,O
Parkinsonism,O,O
",",O,O
which,O,O
was,O,O
choreic,O,O
",",O,O
ballistic,O,O
or,O,O
dystonic,O,O
in,O,O
type,O,O
",",O,O
was,O,O
alleviated,O,O
almost,O,O
completely,O,O
by,O,O
stereotaxic,O,O
surgery,O,O
using,O,O
a,O,O
microelectrode,O,O
technique,O,O
for,O,O
the,O,O
ventralis,O,O
oralis,O,O
anterior,O,O
and,O,O
posterior,O,O
nuclei,O,O
of,O,O
the,O,O
thalamus,O,O
",",O,O
but,O,O
much,O,O
less,O,O
by,O,O
the,O,O
ventralis,O,O
intermedius,O,O
nucleus,O,O
.,O,O
Control,O,O
of,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
by,O,O
thalamic,O,O
lesions,O,O
in,O,O
the,O,O
course,O,O
of,O,O
routine,O,O
treatment,O,O
of,O,O
Parkinsonism,O,O
is,O,O
discussed,O,O
.,O,O
Treatment,O,O
of,O,O
ifosfamide,B,B
-,O,O
induced,O,O
urothelial,O,O
toxicity,O,O
by,O,O
oral,O,O
administration,O,O
of,O,O
sodium,B,B
2,I,I
-,I,I
mercaptoethane,I,I
sulphonate,I,I
(,O,I
MESNA,B,I
),O,I
to,O,O
patients,O,O
with,O,O
inoperable,O,O
lung,O,O
cancer,O,O
.,O,O
The,O,O
protective,O,O
effect,O,O
of,O,O
oral,O,O
administration,O,O
of,O,O
the,O,O
thiol,B,O
compound,O,O
sodium,B,B
2,I,I
-,I,I
mercaptoethane,I,I
sulphonate,I,I
(,O,I
MESNA,B,I
),O,I
against,O,O
urothelial,O,O
toxicity,O,O
induced,O,O
by,O,O
ifosfamide,B,B
(,O,O
IF,B,O
),O,O
was,O,O
tested,O,O
in,O,O
a,O,O
group,O,O
of,O,O
45,O,O
patients,O,O
with,O,O
inoperable,O,O
lung,O,O
cancer,O,O
under,O,O
treatment,O,O
with,O,O
IF,B,O
(,O,O
2250,O,O
mg,O,O
/,O,O
m2,O,O
on,O,O
days,O,O
2,O,O
-,O,O
5,O,O
),O,O
as,O,O
part,O,O
of,O,O
a,O,O
polychemotherapy,O,O
regimen,O,O
repeated,O,O
in,O,O
a,O,O
4,O,O
-,O,O
week,O,O
cycle,O,O
.,O,O
MESNA,B,B
was,O,O
given,O,O
orally,O,O
on,O,O
the,O,O
days,O,O
of,O,O
treatment,O,O
with,O,O
IF,B,B
in,O,O
3,O,O
doses,O,O
of,O,O
840,O,B
mg,O,I
/,O,I
m2,O,I
",",O,O
each,O,O
administered,O,O
at,O,O
0,O,O
hr,O,O
(,O,O
=,O,O
injection,O,O
of,O,O
IF,B,B
),O,O
",",O,O
4,O,O
hr,O,O
and,O,O
8,O,O
hr,O,O
p,O,O
.,O,O
i,O,O
.,O,O
Out,O,O
of,O,O
a,O,O
total,O,O
of,O,O
88,O,O
courses,O,O
of,O,O
this,O,O
treatment,O,O
we,O,O
observed,O,O
10,O,O
episodes,O,O
of,O,O
asymptomatic,O,O
microscopic,O,O
haematuria,O,O
and,O,O
no,O,O
episodes,O,O
of,O,O
gross,O,O
haematuria,O,O
.,O,O
In,O,O
this,O,O
group,O,O
of,O,O
45,O,O
patients,O,O
under,O,O
protection,O,O
with,O,O
MESNA,B,B
there,O,O
were,O,O
5,O,O
complete,O,O
remissions,O,O
and,O,O
9,O,O
partial,O,O
remissions,O,O
(,O,O
total,O,O
31,O,O
%,O,O
),O,O
.,O,O
A,O,O
further,O,O
group,O,O
of,O,O
25,O,O
patients,O,O
under,O,O
polychemotherapy,O,O
with,O,O
IF,B,B
were,O,O
treated,O,O
by,O,O
conventional,O,O
prophylactic,O,O
measures,O,O
(,O,O
raised,O,O
fluid,O,B
intake,O,O
and,O,O
forced,O,O
diuresis,O,O
),O,O
.,O,O
In,O,O
this,O,O
group,O,O
there,O,O
were,O,O
1,O,O
complete,O,O
and,O,O
5,O,O
partial,O,O
remissions,O,O
(,O,O
total,O,O
24,O,O
%,O,O
),O,O
",",O,O
but,O,O
nearly,O,O
all,O,O
patients,O,O
developed,O,O
either,O,O
gross,O,O
haematuria,O,B
and,O,O
/,O,O
or,O,O
symptoms,O,O
of,O,O
bladder,O,B
irritation,O,O
(,O,O
cystitis,O,B
and,O,O
pollakisuria,O,B
),O,O
.,O,O
There,O,O
were,O,O
no,O,O
appreciable,O,O
differences,O,O
between,O,O
the,O,O
MESNA,B,B
series,O,O
and,O,O
the,O,O
conventional,O,O
prophylaxis,O,O
series,O,O
with,O,O
respect,O,O
to,O,O
either,O,O
haematological,O,O
or,O,O
systemic,O,O
toxicity,O,O
of,O,O
the,O,O
cytostatic,O,O
treatment,O,O
.,O,O
Our,O,O
results,O,O
support,O,O
the,O,O
view,O,O
that,O,O
MESNA,B,B
",",O,O
given,O,O
orally,O,O
in,O,O
conjunction,O,O
with,O,O
combined,O,O
cytostatic,O,O
regimens,O,O
which,O,O
include,O,O
IF,B,O
",",O,O
simplifies,O,O
the,O,O
treatment,O,O
and,O,O
provides,O,O
optimum,O,O
protection,O,O
for,O,O
the,O,O
urinary,O,O
epithelium,O,O
.,O,O
Protection,O,O
with,O,O
oral,O,O
MESNA,B,B
is,O,O
particularly,O,O
suitable,O,O
for,O,O
outpatients,O,O
.,O,O
Myoclonic,O,B
",",O,O
atonic,O,B
",",O,O
and,O,O
absence,O,B
seizures,O,O
following,O,O
institution,O,O
of,O,O
carbamazepine,B,B
therapy,O,O
in,O,O
children,O,O
.,O,O
Five,O,O
children,O,O
",",O,O
aged,O,O
3,O,O
to,O,O
11,O,O
years,O,O
",",O,O
treated,O,O
with,O,O
carbamazepine,B,B
for,O,O
epilepsy,O,O
",",O,O
had,O,O
an,O,O
acute,O,O
aberrant,O,O
reaction,O,O
characterized,O,O
by,O,O
the,O,O
onset,O,O
of,O,O
myoclonic,O,B
",",O,O
atypical,O,O
absence,O,B
and,O,O
/,O,O
or,O,O
atonic,O,B
(,O,O
minor,O,O
motor,O,O
),O,O
seizures,O,O
within,O,O
a,O,O
few,O,O
days,O,O
.,O,O
When,O,O
the,O,O
carbamazepine,B,B
was,O,O
discontinued,O,O
",",O,O
two,O,O
of,O,O
the,O,O
children,O,O
returned,O,O
to,O,O
their,O,O
former,O,O
state,O,O
very,O,O
quickly,O,O
",",O,O
two,O,O
had,O,O
the,O,O
minor,O,O
motor,O,O
seizures,O,O
resolve,O,O
in,O,O
3,O,O
and,O,O
6,O,O
months,O,O
",",O,O
and,O,O
one,O,O
had,O,O
the,O,O
seizures,O,O
persist,O,O
.,O,O
The,O,O
child,O,O
in,O,O
whom,O,O
the,O,O
seizures,O,O
persisted,O,O
was,O,O
later,O,O
found,O,O
to,O,O
have,O,O
ceroid,O,B
lipofuscinosis,O,I
.,O,O
The,O,O
other,O,O
children,O,O
are,O,O
doing,O,O
well,O,O
on,O,O
other,O,O
anticonvulsants,O,O
.,O,O
Effect,O,O
of,O,O
prostaglandin,B,B
synthetase,O,I
inhibitors,O,I
on,O,O
experimentally,O,O
induced,O,O
convulsions,O,O
in,O,O
rats,O,O
.,O,O
To,O,O
investigate,O,O
the,O,O
relationship,O,O
of,O,O
prostaglandins,B,B
(,O,O
PGs,B,I
),O,O
to,O,O
seizure,O,O
induction,O,O
",",O,O
the,O,O
effects,O,O
of,O,O
six,O,O
PG,O,B
synthetase,O,I
inhibitors,O,I
on,O,O
convulsions,O,O
induced,O,O
by,O,O
flurothyl,B,O
",",O,O
picrotoxin,B,O
",",O,O
pentetrazol,B,O
(,O,O
PTZ,B,B
),O,O
",",O,O
electroshock,O,O
or,O,O
bicuculline,B,O
were,O,O
evaluated,O,O
.,O,O
Ibuprofen,B,B
",",O,O
sulindac,B,B
",",O,O
mefenamic,B,B
acid,I,I
",",O,O
and,O,O
low,O,O
dose,O,O
meclofenamic,B,B
acid,I,I
increased,O,O
the,O,O
latency,O,O
-,O,O
to,O,O
-,O,O
onset,O,O
in,O,O
the,O,O
flurothyl,B,B
and,O,O
/,O,O
or,O,O
PTZ,B,B
models,O,O
;,O,O
the,O,O
electroshock,O,B
",",O,O
picrotoxin,B,B
and,O,O
bicuculline,B,B
models,O,O
were,O,O
not,O,O
significantly,O,O
affected,O,O
by,O,O
any,O,O
of,O,O
the,O,O
pretreatment,O,O
agents,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
PGs,B,B
are,O,O
involved,O,O
in,O,O
the,O,O
mechanism,O,O
(,O,O
s,O,O
),O,O
underlying,O,O
fluorthyl,B,B
-,O,O
and,O,O
PTZ,B,B
-,O,O
induced,O,O
convulsions,O,O
",",O,O
but,O,O
not,O,O
picrotoxin,B,B
-,O,O
",",O,O
electroshock,O,B
-,O,O
",",O,O
or,O,O
bicuculline,B,B
-,O,O
induced,O,O
convulsions,O,O
.,O,O
Acute,O,O
changes,O,O
of,O,O
blood,O,O
ammonia,B,B
may,O,O
predict,O,O
short,O,O
-,O,O
term,O,O
adverse,O,O
effects,O,O
of,O,O
valproic,B,B
acid,I,I
.,O,O
Valproic,B,B
acid,I,I
(,O,O
VPA,B,B
),O,O
was,O,O
given,O,O
to,O,O
24,O,O
epileptic,O,O
patients,O,O
who,O,O
were,O,O
already,O,O
being,O,O
treated,O,O
with,O,O
other,O,O
antiepileptic,O,O
drugs,O,O
.,O,O
A,O,O
standardized,O,O
loading,O,O
dose,O,O
of,O,O
VPA,B,B
was,O,O
administered,O,O
",",O,O
and,O,O
venous,O,O
blood,O,O
was,O,O
sampled,O,O
at,O,O
0,O,O
",",O,O
1,O,O
",",O,O
2,O,O
",",O,O
3,O,O
",",O,O
and,O,O
4,O,O
hours,O,O
.,O,O
Ammonia,B,B
(,O,O
NH3,B,B
),O,O
was,O,O
higher,O,O
in,O,O
patients,O,O
who,O,O
",",O,O
during,O,O
continuous,O,O
therapy,O,O
",",O,O
complained,O,O
of,O,O
drowsiness,O,O
(,O,O
7,O,O
patients,O,O
),O,O
than,O,O
in,O,O
those,O,O
who,O,O
were,O,O
symptom,O,O
-,O,O
free,O,O
(,O,O
17,O,O
patients,O,O
),O,O
",",O,O
although,O,O
VPA,B,O
plasma,O,O
levels,O,O
were,O,O
similar,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
By,O,O
measuring,O,O
VPA,B,O
-,O,O
induced,O,O
changes,O,O
of,O,O
blood,O,O
NH3,B,B
content,O,O
",",O,O
it,O,O
may,O,O
be,O,O
possible,O,O
to,O,O
identify,O,O
patients,O,O
at,O,O
higher,O,O
risk,O,O
of,O,O
obtundation,O,O
when,O,O
VPA,B,O
is,O,O
given,O,O
chronically,O,O
.,O,O
Effect,O,O
of,O,O
captopril,B,B
on,O,O
pre,O,O
-,O,O
existing,O,O
and,O,O
aminonucleoside,B,B
-,O,I
induced,O,I
proteinuria,O,O
in,O,O
spontaneously,O,O
hypertensive,O,O
rats,O,O
.,O,O
Proteinuria,O,O
is,O,O
a,O,O
side,O,O
effect,O,O
of,O,O
captopril,B,B
treatment,O,O
in,O,O
hypertensive,O,O
patients,O,O
.,O,O
The,O,O
possibility,O,O
of,O,O
reproducing,O,O
the,O,O
same,O,O
renal,O,O
abnormality,O,O
with,O,O
captopril,B,B
was,O,O
examined,O,O
in,O,O
SHR,O,O
.,O,O
Oral,O,O
administration,O,O
of,O,O
captopril,B,B
at,O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
14,O,O
days,O,O
failed,O,O
to,O,O
aggravate,O,O
proteinuria,O,O
pre,O,O
-,O,O
existing,O,O
in,O,O
SHR,O,O
.,O,O
Also,O,O
",",O,O
captopril,B,B
treatment,O,O
failed,O,O
to,O,O
potentiate,O,O
or,O,O
facilitate,O,O
development,O,O
of,O,O
massive,O,O
proteinuria,O,O
invoked,O,O
by,O,O
puromycin,B,B
aminonucleoside,I,I
in,O,O
SHR,O,O
.,O,O
Captopril,B,B
had,O,O
little,O,O
or,O,O
no,O,O
demonstrable,O,O
effects,O,O
on,O,O
serum,O,O
electrolyte,O,O
concentrations,O,O
",",O,O
excretion,O,O
of,O,O
urine,O,O
",",O,O
sodium,B,B
and,O,O
potassium,B,B
",",O,O
endogenous,O,O
creatinine,B,B
clearance,O,I
",",O,O
body,O,O
weight,O,O
",",O,O
and,O,O
food,O,O
and,O,O
water,O,O
consumption,O,O
.,O,O
However,O,O
",",O,O
ketone,B,B
bodies,O,I
were,O,O
consistently,O,O
present,O,O
in,O,O
urine,O,O
and,O,O
several,O,O
lethalities,O,O
occurred,O,O
during,O,O
multiple,O,O
dosing,O,O
of,O,O
captopril,B,B
in,O,O
SHR,O,O
.,O,O
Complete,O,O
heart,O,O
block,O,O
following,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
trazodone,B,B
.,O,O
Forty,O,O
minutes,O,O
after,O,O
receiving,O,O
a,O,O
single,O,O
starting,O,O
dose,O,O
of,O,O
trazodone,B,B
",",O,O
a,O,O
patient,O,O
developed,O,O
complete,O,O
heart,O,O
block,O,O
.,O,O
The,O,O
case,O,O
illustrates,O,O
that,O,O
",",O,O
despite,O,O
the,O,O
results,O,O
of,O,O
earlier,O,O
studies,O,O
",",O,O
trazodone,B,B
',O,O
s,O,O
effect,O,O
on,O,O
cardiac,O,O
conduction,O,O
may,O,O
be,O,O
severe,O,O
in,O,O
individuals,O,O
at,O,O
risk,O,O
for,O,O
conduction,O,O
delay,O,O
.,O,O
Phenobarbital,B,B
-,O,I
induced,O,O
dyskinesia,O,O
in,O,O
a,O,O
neurologically,O,O
-,O,O
impaired,O,O
child,O,O
.,O,O
A,O,O
2,O,O
-,O,O
year,O,O
-,O,O
old,O,O
child,O,O
with,O,O
known,O,O
neurologic,O,O
impairment,O,O
developed,O,O
a,O,O
dyskinesia,O,O
soon,O,O
after,O,O
starting,O,O
phenobarbital,B,B
therapy,O,O
for,O,O
seizures,O,O
.,O,O
Known,O,O
causes,O,O
of,O,O
movement,O,O
disorders,O,O
were,O,O
eliminated,O,O
after,O,O
evaluation,O,O
.,O,O
On,O,O
repeat,O,O
challenge,O,O
with,O,O
phenobarbital,B,B
",",O,O
the,O,O
dyskinesia,O,O
recurred,O,O
.,O,O
Phenobarbital,B,B
should,O,O
be,O,O
added,O,O
to,O,O
the,O,O
list,O,O
of,O,O
anticonvulsant,O,O
drugs,O,O
that,O,O
can,O,O
cause,O,O
movement,O,O
disorders,O,O
.,O,O
Effects,O,O
of,O,O
amine,B,B
pretreatment,O,O
on,O,O
ketamine,B,B
catatonia,O,O
in,O,O
pinealectomized,O,O
or,O,O
hypophysectomized,O,O
animals,O,O
.,O,O
The,O,O
present,O,O
studies,O,O
were,O,O
designed,O,O
to,O,O
clarify,O,O
the,O,O
role,O,O
of,O,O
catecholamines,B,B
and,O,O
pineal,O,B
idolamines,O,I
on,O,O
ketamine,B,B
-,O,O
induced,O,O
catatonia,O,O
in,O,O
the,O,O
intact,O,O
",",O,O
pinealectomized,O,O
or,O,O
hypophysectomized,O,O
chick,O,O
and,O,O
rat,O,O
.,O,O
In,O,O
the,O,O
pinealectomized,O,O
chick,O,O
",",O,O
pretreatment,O,O
with,O,O
dopamine,B,B
increased,O,O
the,O,O
duration,O,O
of,O,O
catatonia,O,O
(,O,O
DOC,O,O
),O,O
after,O,O
ketamine,B,B
",",O,O
but,O,O
pretreatment,O,O
with,O,O
norepinephrine,B,B
did,O,O
not,O,O
.,O,O
The,O,O
pineal,O,B
indolamines,O,O
exhibited,O,O
mixed,O,O
actions,O,O
.,O,O
Serotonin,B,B
and,O,O
N,B,B
-,I,I
acetyl,I,I
serotonin,I,I
which,O,O
augmented,O,O
ketamine,B,B
DOC,O,I
",",O,O
did,O,O
not,O,O
do,O,O
so,O,O
in,O,O
the,O,O
absence,O,O
of,O,O
the,O,O
pineal,O,B
gland,O,I
",",O,O
whereas,O,O
melatonin,B,B
potentiated,O,O
the,O,O
ketamine,B,B
DOC,O,I
in,O,O
both,O,O
the,O,O
intact,O,O
and,O,O
pinealectomized,O,O
chick,O,O
.,O,O
Ketamine,B,B
was,O,O
more,O,O
potent,O,O
in,O,O
the,O,O
hypophysectomized,O,O
chick,O,O
and,O,O
the,O,O
circadian,O,O
rhythm,O,O
noted,O,O
in,O,O
the,O,O
intact,O,O
chick,O,O
was,O,O
absent,O,O
;,O,O
furthermore,O,O
",",O,O
melatonin,B,B
did,O,O
not,O,O
augment,O,O
the,O,O
ketamine,B,B
DOC,O,I
whereas,O,O
dopamine,B,B
continued,O,O
to,O,O
do,O,O
so,O,O
.,O,O
This,O,O
study,O,O
did,O,O
not,O,O
demonstrate,O,O
a,O,O
species,O,O
difference,O,O
regarding,O,O
the,O,O
role,O,O
of,O,O
the,O,O
amines,B,B
on,O,O
the,O,O
pineal,O,O
in,O,O
spite,O,O
of,O,O
the,O,O
immature,O,O
blood,O,O
-,O,O
brain,O,O
barrier,O,O
in,O,O
the,O,O
young,O,O
chick,O,O
and,O,O
the,O,O
intact,O,O
barrier,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
these,O,O
data,O,O
indicate,O,O
a,O,O
direct,O,O
role,O,O
of,O,O
the,O,O
pituitary,O,O
in,O,O
the,O,O
augmentation,O,O
of,O,O
ketamine,B,B
DOC,O,O
induced,O,O
by,O,O
melatonin,B,B
.,O,O
Furthermore,O,O
",",O,O
dopamine,B,B
appeared,O,O
to,O,O
act,O,O
on,O,O
systems,O,O
more,O,O
closely,O,O
involved,O,O
with,O,O
the,O,O
induction,O,O
of,O,O
ketamine,B,B
catatonia,O,I
rather,O,O
than,O,O
directly,O,O
on,O,O
the,O,O
pituitary,O,O
.,O,O
Heparin,B,B
-,O,I
induced,O,I
thrombocytopenia,O,I
",",O,O
thrombosis,O,B
",",O,O
and,O,O
hemorrhage,O,B
.,O,O
Sixty,O,O
-,O,O
two,O,O
patients,O,O
with,O,O
a,O,O
heparin,B,B
-,O,I
induced,O,I
thrombocytopenia,O,I
are,O,O
reported,O,O
.,O,O
Clinical,O,O
manifestations,O,O
of,O,O
this,O,O
disorder,O,O
include,O,O
hemorrhage,O,B
or,O,O
",",O,O
more,O,O
frequently,O,O
",",O,O
thromboembolic,O,B
events,O,I
in,O,O
patients,O,O
receiving,O,O
heparin,B,B
.,O,O
Laboratory,O,O
testing,O,O
has,O,O
revealed,O,O
a,O,O
falling,O,O
platelet,O,B
count,O,O
",",O,O
increased,O,O
resistance,O,O
to,O,O
heparin,B,B
",",O,O
and,O,O
aggregation,O,O
of,O,O
platelets,O,B
by,O,O
the,O,O
patient,O,O
',O,O
s,O,O
plasma,O,O
when,O,O
heparin,B,B
is,O,O
added,O,O
.,O,O
Immunologic,O,O
testing,O,O
has,O,O
demonstrated,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
heparin,B,B
-,O,O
dependent,O,O
platelet,O,B
membrane,O,O
antibody,O,O
.,O,O
The,O,O
20,O,O
deaths,O,O
",",O,O
52,O,O
hemorrhagic,O,O
and,O,O
thromboembolic,O,O
complications,O,O
",",O,O
and,O,O
21,O,O
surgical,O,O
procedures,O,O
to,O,O
manage,O,O
the,O,O
complications,O,O
confirm,O,O
the,O,O
seriousness,O,O
of,O,O
the,O,O
disorder,O,O
.,O,O
Specific,O,O
risk,O,O
factors,O,O
have,O,O
not,O,O
been,O,O
identified,O,O
;,O,O
therefore,O,O
",",O,O
all,O,O
patients,O,O
receiving,O,O
heparin,B,B
should,O,O
be,O,O
monitored,O,O
.,O,O
If,O,O
the,O,O
platelet,O,B
count,O,O
falls,O,O
to,O,O
less,O,O
than,O,O
100,O,O
",",O,O
/,O,O
mm3,O,O
",",O,O
while,O,O
the,O,O
patient,O,O
is,O,O
receiving,O,O
heparin,B,B
",",O,O
platelet,O,B
aggregation,O,O
testing,O,O
",",O,O
using,O,O
the,O,O
patient,O,O
',O,O
s,O,O
plasma,O,O
",",O,O
is,O,O
indicated,O,O
.,O,O
Management,O,O
consists,O,O
of,O,O
cessation,O,O
of,O,O
heparin,B,B
",",O,O
platelet,O,B
anti,O,O
-,O,O
aggregating,O,O
agents,O,O
",",O,O
and,O,O
alternate,O,O
forms,O,O
of,O,O
anticoagulation,O,O
when,O,O
indicated,O,O
.,O,O
Ventricular,O,O
fibrillation,O,O
from,O,O
diatrizoate,B,B
with,O,O
and,O,O
without,O,O
chelating,O,O
agents,O,O
.,O,O
The,O,O
toxicity,O,O
of,O,O
Renografin,B,B
76,I,O
%,I,O
was,O,O
compared,O,O
with,O,O
that,O,O
of,O,O
Hypaque,B,B
76,I,O
%,I,O
by,O,O
selective,O,O
injection,O,O
of,O,O
each,O,O
into,O,O
the,O,O
right,O,O
coronary,O,O
artery,O,O
of,O,O
dogs,O,O
.,O,O
Renografin,B,B
contains,O,O
the,O,O
chelating,O,O
agents,O,O
sodium,B,B
citrate,I,I
and,O,O
disodium,B,B
edetate,I,I
",",O,O
while,O,O
Hypaque,B,B
contains,O,O
calcium,B,B
disodium,I,I
edetate,I,I
and,O,O
no,O,O
sodium,B,B
citrate,I,I
.,O,O
Ventricular,O,B
fibrillation,O,I
occurred,O,O
significantly,O,O
more,O,O
often,O,O
with,O,O
Renografin,B,B
",",O,O
suggesting,O,O
that,O,O
chelating,O,O
agents,O,O
contribute,O,O
to,O,O
toxicity,O,O
in,O,O
coronary,O,O
angiography,O,O
.,O,O
Long,O,O
-,O,O
term,O,O
efficacy,O,O
and,O,O
toxicity,O,O
of,O,O
high,O,O
-,O,O
dose,O,O
amiodarone,B,B
therapy,O,O
for,O,O
ventricular,O,O
tachycardia,O,O
or,O,O
ventricular,O,O
fibrillation,O,I
.,O,O
Amiodarone,B,B
was,O,O
administered,O,O
to,O,O
154,O,O
patients,O,O
who,O,O
had,O,O
sustained,O,O
",",O,O
symptomatic,O,O
ventricular,O,O
tachycardia,O,O
(,O,O
VT,O,B
),O,O
(,O,O
n,O,O
=,O,O
118,O,O
),O,O
or,O,O
a,O,O
cardiac,O,O
arrest,O,O
(,O,O
n,O,O
=,O,O
36,O,O
),O,O
and,O,O
who,O,O
were,O,O
refractory,O,O
to,O,O
conventional,O,O
antiarrhythmic,O,O
drugs,O,O
.,O,O
The,O,O
loading,O,O
dose,O,O
was,O,O
800,O,B
mg,O,I
/,O,I
day,O,O
for,O,O
6,O,O
weeks,O,O
and,O,O
the,O,O
maintenance,O,O
dose,O,O
was,O,O
600,O,B
mg,O,I
/,O,I
day,O,O
.,O,O
Sixty,O,O
-,O,O
nine,O,O
percent,O,O
of,O,O
patients,O,O
continued,O,O
treatment,O,O
with,O,O
amiodarone,B,B
and,O,O
had,O,O
no,O,O
recurrence,O,O
of,O,O
symptomatic,O,O
VT,O,B
or,O,O
ventricular,O,O
fibrillation,O,O
(,O,O
VF,O,B
),O,O
over,O,O
a,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
6,O,O
to,O,O
52,O,O
months,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
standard,O,O
deviation,O,O
14,O,O
.,O,O
2,O,O
+,O,O
/,O,O
-,O,O
8,O,O
.,O,O
2,O,O
),O,O
.,O,O
Six,O,O
percent,O,O
of,O,O
the,O,O
patients,O,O
had,O,O
a,O,O
nonfatal,O,O
recurrence,O,O
of,O,O
VT,O,B
and,O,O
were,O,O
successfully,O,O
managed,O,O
by,O,O
continuing,O,O
amiodarone,B,B
at,O,O
a,O,O
higher,O,O
dose,O,O
or,O,O
by,O,O
the,O,O
addition,O,O
of,O,O
a,O,O
conventional,O,O
antiarrhythmic,O,O
drug,O,O
.,O,O
One,O,O
or,O,O
more,O,O
adverse,O,O
drug,O,O
reactions,O,O
occurred,O,O
in,O,O
51,O,O
%,O,O
of,O,O
patients,O,O
.,O,O
Adverse,O,O
effects,O,O
forced,O,O
a,O,O
reduction,O,O
in,O,O
the,O,O
dose,O,O
of,O,O
amiodarone,B,B
in,O,O
41,O,O
%,O,O
and,O,O
discontinuation,O,O
of,O,O
amiodarone,B,B
in,O,O
10,O,O
%,O,O
of,O,O
patients,O,O
.,O,O
The,O,O
most,O,O
common,O,O
symptomatic,O,O
adverse,O,O
reactions,O,O
were,O,O
tremor,O,B
or,O,O
ataxia,O,B
(,O,O
35,O,O
%,O,O
),O,O
",",O,O
nausea,O,B
and,O,O
anorexia,O,B
(,O,O
8,O,O
%,O,O
),O,O
",",O,O
visual,O,O
halos,O,B
or,O,O
blurring,O,B
(,O,O
6,O,O
%,O,O
),O,O
",",O,O
thyroid,O,B
function,O,I
abnormalities,O,I
(,O,O
6,O,O
%,O,O
),O,O
and,O,O
pulmonary,O,B
interstitial,O,I
infiltrates,O,I
(,O,O
5,O,O
%,O,O
),O,O
.,O,O
Although,O,O
large,O,O
-,O,O
dose,O,O
amiodarone,B,B
is,O,O
highly,O,O
effective,O,O
in,O,O
the,O,O
long,O,O
-,O,O
term,O,O
treatment,O,O
of,O,O
VT,O,B
or,O,O
VF,O,B
refractory,O,O
to,O,O
conventional,O,O
antiarrhythmic,O,O
drugs,O,O
",",O,O
it,O,O
causes,O,O
significant,O,O
toxicity,O,O
in,O,O
approximately,O,O
50,O,O
%,O,O
of,O,O
patients,O,O
.,O,O
However,O,O
",",O,O
when,O,O
the,O,O
dose,O,O
is,O,O
adjusted,O,O
based,O,O
on,O,O
clinical,O,O
response,O,O
or,O,O
the,O,O
development,O,O
of,O,O
adverse,O,O
effects,O,O
",",O,O
75,O,O
%,O,O
of,O,O
patients,O,O
with,O,O
VT,O,O
or,O,O
VF,O,O
can,O,O
be,O,O
successfully,O,O
managed,O,O
with,O,O
amiodarone,B,B
.,O,O
Why,O,O
may,O,O
epsilon,B,B
-,I,I
aminocaproic,I,I
acid,I,I
(,O,O
EACA,B,B
),O,O
induce,O,O
myopathy,O,O
in,O,O
man,O,O
?,O,O
Report,O,O
of,O,O
a,O,O
case,O,O
and,O,O
literature,O,O
review,O,O
.,O,O
A,O,O
case,O,O
of,O,O
necrotizing,O,O
myopathy,O,O
due,O,O
to,O,O
a,O,O
short,O,O
epsilon,B,B
-,I,I
aminocaproic,I,I
acid,I,I
(,O,O
EACA,B,B
),O,O
treatment,O,O
in,O,O
a,O,O
72,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
with,O,O
subarachnoid,O,O
haemorrhage,O,O
(,O,O
SAH,O,O
),O,O
is,O,O
described,O,O
.,O,O
Pathogenetic,O,O
hypotheses,O,O
are,O,O
discussed,O,O
.,O,O
Cerebral,O,O
hemorrhage,O,O
associated,O,O
with,O,O
phenylpropanolamine,B,B
in,O,O
combination,O,O
with,O,O
caffeine,B,B
.,O,O
Phenylpropanolamine,B,B
(,O,O
PPA,B,O
),O,O
is,O,O
a,O,O
drug,O,O
that,O,O
has,O,O
been,O,O
associated,O,O
with,O,O
serious,O,O
side,O,O
effects,O,O
including,O,O
stroke,O,O
.,O,O
It,O,O
is,O,O
often,O,O
combined,O,O
with,O,O
caffeine,B,B
in,O,O
diet,O,O
preparations,O,O
and,O,O
pills,O,O
.,O,O
In,O,O
order,O,O
to,O,O
determine,O,O
if,O,O
PPA,B,B
/,O,O
caffeine,B,B
can,O,O
lead,O,O
to,O,O
stroke,O,O
in,O,O
normotensive,O,O
and,O,O
/,O,O
or,O,O
hypertensive,O,O
rats,O,O
",",O,O
we,O,O
administered,O,O
the,O,O
combination,O,O
in,O,O
six,O,O
times,O,O
the,O,O
allowed,O,O
human,O,O
dose,O,O
calculated,O,O
on,O,O
a,O,O
per,O,O
weight,O,O
basis,O,O
for,O,O
the,O,O
rats,O,O
two,O,O
times,O,O
per,O,O
day,O,O
for,O,O
five,O,O
days,O,O
.,O,O
Subarachnoid,O,B
and,O,O
cerebral,O,B
hemorrhage,O,O
was,O,O
noted,O,O
in,O,O
18,O,O
%,O,O
of,O,O
the,O,O
hypertensive,O,O
rats,O,O
.,O,O
A,O,O
single,O,O
PPA,B,B
/,O,O
caffeine,B,B
administration,O,O
(,O,O
same,O,O
dose,O,O
),O,O
lead,O,O
to,O,O
acute,O,O
hypertension,O,O
in,O,O
both,O,O
the,O,O
normotensive,O,O
and,O,O
hypertensive,O,O
animals,O,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
PPA,B,B
/,O,O
caffeine,B,B
can,O,O
lead,O,O
to,O,O
cerebral,O,O
hemorrhage,O,O
in,O,O
previously,O,O
hypertensive,O,O
animals,O,O
when,O,O
administered,O,O
in,O,O
greater,O,O
than,O,O
the,O,O
allowed,O,O
dosage,O,O
.,O,O
An,O,O
acute,O,O
elevation,O,O
in,O,O
blood,O,O
pressure,O,O
may,O,O
be,O,O
a,O,O
contributing,O,O
factor,O,O
.,O,O
Renal,O,B
papillary,O,I
necrosis,O,I
due,O,O
to,O,O
naproxen,B,B
.,O,O
A,O,O
31,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
",",O,O
who,O,O
had,O,O
previously,O,O
been,O,O
treated,O,O
with,O,O
sulindac,B,B
",",O,O
fenoprofen,B,B
calcium,I,I
",",O,O
high,O,O
dose,O,O
salicylates,B,B
and,O,O
gold,B,B
salts,O,I
",",O,O
developed,O,O
renal,O,B
papillary,O,I
necrosis,O,I
(,O,O
RPN,O,B
),O,O
4,O,O
months,O,O
after,O,O
institution,O,O
of,O,O
naproxen,B,B
therapy,O,O
.,O,O
No,O,O
other,O,O
factor,O,O
predisposing,O,O
to,O,O
RPN,O,B
could,O,O
be,O,O
discovered,O,O
.,O,O
Sulindac,B,B
was,O,O
substituted,O,O
for,O,O
naproxen,B,B
and,O,O
no,O,O
further,O,O
adverse,O,O
renal,O,O
effects,O,O
occurred,O,O
over,O,O
the,O,O
next,O,O
12,O,O
months,O,O
.,O,O
We,O,O
review,O,O
previous,O,O
reports,O,O
linking,O,O
RPN,O,O
to,O,O
antiinflammatory,O,O
drug,O,O
use,O,O
and,O,O
discuss,O,O
possible,O,O
advantages,O,O
of,O,O
sulindac,B,B
in,O,O
patients,O,O
who,O,O
have,O,O
experienced,O,O
renal,O,O
toxicity,O,O
from,O,O
other,O,O
antiinflammatory,O,O
agents,O,O
.,O,O
Nephrotoxic,O,O
effects,O,O
of,O,O
aminoglycoside,B,B
treatment,O,O
on,O,O
renal,O,O
protein,O,O
reabsorption,O,O
and,O,O
accumulation,O,O
.,O,O
To,O,O
quantify,O,O
the,O,O
effects,O,O
of,O,O
gentamicin,B,B
",",O,O
kanamycin,B,B
and,O,O
netilmicin,B,B
on,O,O
renal,O,O
protein,O,O
reabsorption,O,O
and,O,O
accumulation,O,O
",",O,O
these,O,O
drugs,O,O
were,O,O
administered,O,O
to,O,O
rats,O,O
intraperitoneally,O,O
(,O,O
30,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
),O,O
for,O,O
7,O,O
",",O,O
14,O,O
or,O,O
21,O,O
days,O,O
.,O,O
Scanning,O,O
electron,O,O
microscopy,O,O
of,O,O
the,O,O
glomerular,O,O
endothelia,O,O
",",O,O
urinary,O,O
measurements,O,O
of,O,O
sodium,B,B
",",O,O
potassium,B,B
",",O,O
endogenous,O,O
lysozyme,O,B
",",O,O
N,O,B
-,O,I
acetyl,O,I
-,O,I
beta,O,I
-,O,I
D,O,I
-,O,I
glucosaminidase,O,I
(,O,O
NAG,O,B
),O,O
as,O,O
well,O,O
as,O,O
clearance,O,O
and,O,O
accumulation,O,O
experiments,O,O
after,O,O
i,O,O
.,O,O
v,O,O
.,O,O
administration,O,O
of,O,O
egg,O,B
-,O,I
white,O,I
lysozyme,O,I
and,O,O
measurements,O,O
of,O,O
inulin,O,B
clearance,O,O
(,O,O
GFR,O,B
),O,O
were,O,O
done,O,O
in,O,O
each,O,O
treatment,O,O
group,O,O
.,O,O
Gentamicin,B,B
administration,O,O
decreased,O,O
diameter,O,O
",",O,O
density,O,O
and,O,O
shape,O,O
of,O,O
endothelial,O,B
fenestrae,O,O
.,O,O
Kanamycin,B,B
and,O,O
netilmicin,B,B
appeared,O,O
to,O,O
have,O,O
no,O,O
effect,O,O
at,O,O
the,O,O
dose,O,O
used,O,O
.,O,O
All,O,O
three,O,O
aminoglycosides,B,B
decreased,O,O
GFR,O,B
and,O,O
increased,O,O
urinary,O,B
excretion,O,O
of,O,O
sodium,B,B
and,O,O
potassium,B,B
.,O,O
While,O,O
gentamicin,B,B
and,O,O
kanamycin,B,B
decreased,O,O
the,O,O
percentage,O,O
reabsorption,O,O
and,O,O
accumulation,O,O
of,O,O
lysozyme,O,B
after,O,O
i,O,O
.,O,O
v,O,O
administration,O,O
of,O,O
egg,O,B
-,O,I
white,O,I
lysozyme,O,B
netilmicin,B,B
had,O,O
no,O,O
effect,O,O
.,O,O
Daily,O,O
excretion,O,O
of,O,O
total,O,O
protein,O,B
",",O,O
endogenous,O,O
lysozyme,O,B
and,O,O
NAG,O,B
increased,O,O
only,O,O
after,O,O
treatment,O,O
with,O,O
kanamycin,B,B
and,O,O
gentamicin,B,B
.,O,O
Thus,O,O
",",O,O
aminoglycosides,B,B
may,O,O
act,O,O
as,O,O
nephrotoxicants,O,O
at,O,O
glomerular,O,O
and,O,O
/,O,O
or,O,O
tubular,O,O
level,O,O
inducing,O,O
impairment,O,O
of,O,O
renal,O,O
reabsorption,O,O
and,O,O
accumulation,O,O
of,O,O
proteins,O,B
.,O,O
Induction,O,O
of,O,O
the,O,O
obstructive,O,O
sleep,O,O
apnea,O,O
syndrome,O,O
in,O,O
a,O,O
woman,O,O
by,O,O
exogenous,O,O
androgen,B,B
administration,O,O
.,O,O
We,O,O
documented,O,O
airway,O,O
occlusion,O,O
during,O,O
sleep,O,O
and,O,O
an,O,O
abnormally,O,O
high,O,O
supraglottic,O,O
resistance,O,O
while,O,O
awake,O,O
in,O,O
a,O,O
54,O,O
-,O,O
yr,O,O
-,O,O
old,O,O
woman,O,O
who,O,O
had,O,O
developed,O,O
physical,O,O
changes,O,O
and,O,O
the,O,O
syndrome,O,O
of,O,O
obstructive,O,O
sleep,O,O
apnea,O,O
while,O,O
being,O,O
administered,O,O
exogenous,O,O
androgens,B,B
.,O,O
When,O,O
the,O,O
androgens,B,B
were,O,O
withdrawn,O,O
",",O,O
the,O,O
patient,O,O
',O,O
s,O,O
physical,O,O
changes,O,O
",",O,O
symptoms,O,O
",",O,O
sleep,O,O
study,O,O
",",O,O
and,O,O
supraglottic,O,O
resistance,O,O
all,O,O
returned,O,O
to,O,O
normal,O,O
.,O,O
A,O,O
rechallenge,O,O
with,O,O
androgen,B,B
produced,O,O
symptoms,O,O
of,O,O
obstructive,O,O
sleep,O,O
apnea,O,O
that,O,O
abated,O,O
upon,O,O
withdrawal,O,O
of,O,O
the,O,O
hormone,O,O
.,O,O
Previous,O,O
reports,O,O
have,O,O
favored,O,O
a,O,O
role,O,O
of,O,O
androgens,B,B
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
sleep,O,O
apnea,O,O
.,O,O
Our,O,O
report,O,O
provides,O,O
direct,O,O
evidence,O,O
for,O,O
this,O,O
role,O,O
.,O,O
Structural,O,O
and,O,O
functional,O,O
measurements,O,O
indicate,O,O
that,O,O
androgens,B,B
exert,O,O
a,O,O
permissive,O,O
or,O,O
necessary,O,O
action,O,O
on,O,O
the,O,O
structural,O,O
configuration,O,O
of,O,O
the,O,O
oropharynx,O,O
that,O,O
predisposes,O,O
to,O,O
obstruction,O,O
during,O,O
sleep,O,O
.,O,O
Development,O,O
of,O,O
the,O,O
obstructive,O,O
sleep,O,O
apnea,O,O
syndrome,O,O
must,O,O
be,O,O
considered,O,O
a,O,O
possible,O,O
side,O,O
effect,O,O
of,O,O
androgen,B,B
therapy,O,O
.,O,O
Cardiotoxic,O,B
and,O,O
possible,O,O
leukemogenic,O,O
effects,O,O
of,O,O
adriamycin,B,B
in,O,O
nonhuman,O,O
primates,O,O
.,O,O
10,O,O
monkeys,O,O
(,O,O
macaques,O,O
),O,O
received,O,O
adriamycin,B,B
by,O,O
monthly,O,O
intravenous,O,O
injections,O,O
at,O,O
12,O,O
mg,O,O
/,O,O
m2,O,O
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
.,O,O
8,O,O
of,O,O
the,O,O
10,O,O
monkeys,O,O
developed,O,O
congestive,O,O
heart,O,O
failure,O,O
at,O,O
an,O,O
average,O,O
cumulative,O,O
adriamycin,B,B
dose,O,O
(,O,O
310,O,O
mg,O,O
/,O,O
m2,O,O
),O,O
well,O,O
below,O,O
that,O,O
considered,O,O
the,O,O
safe,O,O
upper,O,O
limit,O,O
(,O,O
550,O,O
mg,O,O
/,O,O
m2,O,O
),O,O
in,O,O
man,O,O
.,O,O
Histologically,O,O
",",O,O
the,O,O
myocardial,O,O
lesions,O,O
resembled,O,O
those,O,O
found,O,O
in,O,O
human,O,O
anthracycline,B,B
-,O,I
induced,O,I
cardiomyopathy,O,I
.,O,O
1,O,O
of,O,O
the,O,O
10,O,O
monkeys,O,O
developed,O,O
acute,O,O
myeloblastic,O,O
leukemia,O,B
after,O,O
receiving,O,O
324,O,O
mg,O,O
/,O,O
m2,O,O
of,O,O
adriamycin,B,B
;,O,O
the,O,O
10th,O,O
monkey,O,O
is,O,O
alive,O,O
and,O,O
well,O,O
26,O,O
months,O,O
after,O,O
the,O,O
last,O,O
dose,O,O
of,O,O
drug,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
that,O,O
adriamycin,B,B
is,O,O
a,O,O
more,O,O
potent,O,O
cardiotoxin,O,O
in,O,O
monkeys,O,O
than,O,O
in,O,O
man,O,O
",",O,O
and,O,O
that,O,O
leukemia,O,O
may,O,O
be,O,O
a,O,O
consequence,O,O
of,O,O
prolonged,O,O
treatment,O,O
with,O,O
this,O,O
drug,O,O
.,O,O
Tricuspid,O,B
valve,O,I
regurgitation,O,I
and,O,O
lithium,B,B
carbonate,I,I
toxicity,O,I
in,O,O
a,O,O
newborn,O,O
infant,O,O
.,O,O
A,O,O
newborn,O,O
with,O,O
massive,O,O
tricuspid,O,B
regurgitation,O,I
",",O,O
atrial,O,B
flutter,O,I
",",O,O
congestive,O,O
heart,O,O
failure,O,O
",",O,O
and,O,O
a,O,O
high,O,O
serum,O,O
lithium,B,B
level,O,I
is,O,O
described,O,O
.,O,O
This,O,O
is,O,O
the,O,O
first,O,O
patient,O,O
to,O,O
initially,O,O
manifest,O,O
tricuspid,O,B
regurgitation,O,I
and,O,O
atrial,O,B
flutter,O,I
",",O,O
and,O,O
the,O,O
11th,O,O
described,O,O
patient,O,O
with,O,O
cardiac,O,O
disease,O,O
among,O,O
infants,O,O
exposed,O,O
to,O,O
lithium,B,B
compounds,O,I
in,O,O
the,O,O
first,O,O
trimester,O,O
of,O,O
pregnancy,O,O
.,O,O
Sixty,O,O
-,O,O
three,O,O
percent,O,O
of,O,O
these,O,O
infants,O,O
had,O,O
tricuspid,O,B
valve,O,I
involvement,O,O
.,O,O
Lithium,B,B
carbonate,I,I
may,O,O
be,O,O
a,O,O
factor,O,O
in,O,O
the,O,O
increasing,O,O
incidence,O,O
of,O,O
congenital,O,B
heart,O,I
disease,O,I
when,O,O
taken,O,O
during,O,O
early,O,O
pregnancy,O,O
.,O,O
It,O,O
also,O,O
causes,O,O
neurologic,O,O
depression,O,O
",",O,O
cyanosis,O,B
",",O,O
and,O,O
cardiac,O,B
arrhythmia,O,I
when,O,O
consumed,O,O
prior,O,O
to,O,O
delivery,O,O
.,O,O
Effects,O,O
of,O,O
the,O,O
novel,O,O
compound,O,O
aniracetam,B,B
(,O,O
Ro,B,B
13,I,I
-,I,I
5057,I,I
),O,O
upon,O,O
impaired,O,O
learning,O,O
and,O,O
memory,O,O
in,O,O
rodents,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
aniracetam,B,B
(,O,O
Ro,B,B
13,I,I
-,I,I
5057,I,I
",",O,O
1,B,O
-,I,O
anisoyl,I,B
-,I,I
2,I,I
-,I,I
pyrrolidinone,I,I
),O,O
was,O,O
studied,O,O
on,O,O
various,O,O
forms,O,O
of,O,O
experimentally,O,O
impaired,O,O
cognitive,O,O
functions,O,O
(,O,O
learning,O,O
and,O,O
memory,O,O
),O,O
in,O,O
rodents,O,O
and,O,O
produced,O,O
the,O,O
following,O,O
effects,O,O
:,O,O
(,O,O
1,O,O
),O,O
almost,O,O
complete,O,O
prevention,O,O
of,O,O
the,O,O
incapacity,O,O
to,O,O
learn,O,O
a,O,O
discrete,O,O
escape,O,O
response,O,O
in,O,O
rats,O,O
exposed,O,O
to,O,O
sublethal,O,O
hypercapnia,O,B
immediately,O,O
before,O,O
the,O,O
acquisition,O,O
session,O,O
;,O,O
(,O,O
2,O,O
),O,O
partial,O,O
(,O,O
rats,O,O
),O,O
or,O,O
complete,O,O
(,O,O
mice,O,O
),O,O
prevention,O,O
of,O,O
the,O,O
scopolamine,B,B
-,O,I
induced,O,O
short,O,O
-,O,O
term,O,O
amnesia,O,O
for,O,O
a,O,O
passive,O,O
avoidance,O,O
task,O,O
;,O,O
(,O,O
3,O,O
),O,O
complete,O,O
protection,O,O
against,O,O
amnesia,O,O
for,O,O
a,O,O
passive,O,O
avoidance,O,O
task,O,O
in,O,O
rats,O,O
submitted,O,O
to,O,O
electroconvulsive,O,O
shock,O,O
immediately,O,O
after,O,O
avoidance,O,O
acquisition,O,O
;,O,O
(,O,O
4,O,O
),O,O
prevention,O,O
of,O,O
the,O,O
long,O,O
-,O,O
term,O,O
retention,O,O
-,O,O
or,O,O
retrieval,O,O
-,O,O
deficit,O,O
for,O,O
a,O,O
passive,O,O
avoidance,O,O
task,O,O
induced,O,O
in,O,O
rats,O,O
and,O,O
mice,O,O
by,O,O
chloramphenicol,B,B
or,O,O
cycloheximide,B,B
administered,O,O
immediately,O,O
after,O,O
acquisition,O,O
;,O,O
(,O,O
5,O,O
),O,O
reversal,O,O
",",O,O
when,O,O
administered,O,O
as,O,O
late,O,O
as,O,O
1,O,O
h,O,O
before,O,O
the,O,O
retention,O,O
test,O,O
",",O,O
of,O,O
the,O,O
deficit,O,O
in,O,O
retention,O,O
or,O,O
retrieval,O,O
of,O,O
a,O,O
passive,O,O
avoidance,O,O
task,O,O
induced,O,O
by,O,O
cycloheximide,B,B
injected,O,O
2,O,O
days,O,O
previously,O,O
;,O,O
(,O,O
6,O,O
),O,O
prevention,O,O
of,O,O
the,O,O
deficit,O,O
in,O,O
the,O,O
retrieval,O,O
of,O,O
an,O,O
active,O,O
avoidance,O,O
task,O,O
induced,O,O
in,O,O
mice,O,O
by,O,O
subconvulsant,O,O
electroshock,O,O
or,O,O
hypercapnia,O,B
applied,O,O
immediately,O,O
before,O,O
retrieval,O,O
testing,O,O
(,O,O
24,O,O
h,O,O
after,O,O
acquisition,O,O
),O,O
.,O,O
These,O,O
improvements,O,O
or,O,O
normalizations,O,O
of,O,O
impaired,O,O
cognitive,O,O
functions,O,O
were,O,O
seen,O,O
at,O,O
oral,O,O
aniracetam,B,B
doses,O,O
of,O,O
10,O,O
-,O,O
100,O,O
mg,O,O
/,O,O
kg,O,O
.,O,O
Generally,O,O
",",O,O
the,O,O
dose,O,O
-,O,O
response,O,O
curves,O,O
were,O,O
bell,O,O
-,O,O
shaped,O,O
.,O,O
The,O,O
mechanisms,O,O
underlying,O,O
the,O,O
activity,O,O
of,O,O
aniracetam,B,B
and,O,O
its,O,O
',O,O
therapeutic,O,O
window,O,O
',O,O
are,O,O
unknown,O,O
.,O,O
Piracetam,B,B
",",O,O
another,O,O
pyrrolidinone,B,B
derivative,O,O
was,O,O
used,O,O
for,O,O
comparison,O,O
.,O,O
It,O,O
was,O,O
active,O,O
only,O,O
in,O,O
six,O,O
of,O,O
nine,O,O
tests,O,O
and,O,O
had,O,O
about,O,O
one,O,O
-,O,O
tenth,O,O
the,O,O
potency,O,O
of,O,O
aniracetam,B,B
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
aniracetam,B,B
improves,O,O
cognitive,O,O
functions,O,O
which,O,O
are,O,O
impaired,O,O
by,O,O
different,O,O
procedure,O,O
and,O,O
in,O,O
different,O,O
phases,O,O
of,O,O
the,O,O
learning,O,O
and,O,O
memory,O,O
process,O,O
.,O,O
Effect,O,O
of,O,O
calcium,B,B
chloride,I,I
on,O,O
gross,O,O
behavioural,O,O
changes,O,O
produced,O,O
by,O,O
carbachol,B,B
and,O,O
eserine,B,B
in,O,O
cats,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
calcium,B,B
chloride,I,I
injected,O,O
into,O,O
the,O,O
cerebral,O,O
ventricles,O,O
of,O,O
group,O,O
-,O,O
housed,O,O
unanaesthetized,O,O
cats,O,O
upon,O,O
vocalization,O,O
(,O,O
rage,O,O
",",O,O
hissing,O,O
and,O,O
snarling,O,O
),O,O
",",O,O
fighting,O,O
(,O,O
attack,O,O
with,O,O
paws,O,O
and,O,O
claws,O,O
",",O,O
defense,O,O
with,O,O
paws,O,O
and,O,O
claws,O,O
and,O,O
biting,O,O
),O,O
",",O,O
mydriasis,O,O
",",O,O
tremor,O,O
and,O,O
clonic,O,O
-,O,O
tonic,O,O
convulsions,O,O
produced,O,O
by,O,O
carbachol,B,B
and,O,O
eserine,B,B
injected,O,O
similarly,O,O
was,O,O
investigated,O,O
.,O,O
Calcium,B,B
chloride,I,I
depressed,O,O
or,O,O
almost,O,O
completely,O,O
abolished,O,O
the,O,O
vocalization,O,O
and,O,O
fighting,O,O
due,O,O
to,O,O
carbachol,B,B
and,O,O
eserine,B,B
.,O,O
On,O,O
the,O,O
other,O,O
hand,O,O
",",O,O
mydriasis,O,O
",",O,O
tremor,O,O
and,O,O
clonic,O,O
-,O,O
tonic,O,O
convulsions,O,O
evoked,O,O
by,O,O
carbachol,B,B
and,O,O
eserine,B,B
were,O,O
not,O,O
significantly,O,O
changed,O,O
by,O,O
calcium,B,B
chloride,I,I
.,O,O
It,O,O
is,O,O
apparent,O,O
that,O,O
calcium,B,B
chloride,I,I
can,O,O
vocalization,O,O
and,O,O
fighting,O,O
from,O,O
autonomic,O,O
and,O,O
motor,O,O
phenomena,O,O
such,O,O
as,O,O
mydriasis,O,O
",",O,O
tremor,O,O
and,O,O
clonic,O,O
-,O,O
tonic,O,O
convulsions,O,O
caused,O,O
by,O,O
carbachol,B,B
and,O,O
eserine,B,B
.,O,O
Calcium,B,B
chloride,I,I
inhibited,O,O
the,O,O
vocalization,O,O
and,O,O
fighting,O,O
produced,O,O
by,O,O
carbachol,B,B
and,O,O
eserine,B,B
most,O,O
probably,O,O
by,O,O
a,O,O
nonspecific,O,O
stabilizing,O,O
action,O,O
on,O,O
central,O,O
muscarinic,O,O
cholinoceptive,O,O
sites,O,O
.,O,O
These,O,O
results,O,O
further,O,O
support,O,O
the,O,O
view,O,O
that,O,O
calcium,B,B
ions,O,I
in,O,O
excess,O,O
have,O,O
an,O,O
atropine,B,O
-,O,O
like,O,O
action,O,O
also,O,O
in,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
.,O,O
Thiazide,B,B
diuretics,O,I
",",O,O
hypokalemia,O,B
and,O,O
cardiac,O,O
arrhythmias,O,O
.,O,O
Thiazide,B,B
diuretics,O,I
are,O,O
widely,O,O
accepted,O,O
as,O,O
the,O,O
cornerstone,O,O
of,O,O
antihypertensive,O,O
treatment,O,O
programs,O,O
.,O,O
Hypokalemia,O,B
is,O,O
a,O,O
commonly,O,O
encountered,O,O
metabolic,O,O
consequence,O,O
of,O,O
chronic,O,O
thiazide,B,B
therapy,O,O
.,O,O
We,O,O
treated,O,O
38,O,O
patients,O,O
(,O,O
22,O,O
low,O,O
renin,O,O
",",O,O
16,O,O
normal,O,O
renin,O,O
),O,O
with,O,O
moderate,O,O
diastolic,O,O
hypertension,O,O
with,O,O
hydrochlorothiazide,B,B
(,O,O
HCTC,B,B
),O,O
administered,O,O
on,O,O
a,O,O
twice,O,O
daily,O,O
schedule,O,O
.,O,O
Initial,O,O
dose,O,O
was,O,O
50,O,O
mg,O,O
and,O,O
the,O,O
dose,O,O
was,O,O
increased,O,O
at,O,O
monthly,O,O
intervals,O,O
to,O,O
100,O,O
mg,O,O
",",O,O
150,O,O
mg,O,O
and,O,O
200,O,O
mg,O,O
daily,O,O
until,O,O
blood,O,O
pressure,O,O
normalized,O,O
.,O,O
The,O,O
serum,O,O
K,B,B
during,O,O
the,O,O
control,O,O
period,O,O
was,O,O
4,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
mEq,O,O
/,O,O
l,O,O
an,O,O
on,O,O
50,O,O
",",O,O
100,O,O
",",O,O
150,O,O
and,O,O
200,O,O
mg,O,O
HCTZ,B,B
daily,O,O
3,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
3,O,O
",",O,O
3,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
",",O,O
2,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
",",O,O
+,O,O
/,O,O
-,O,O
",",O,O
+,O,O
/,O,O
-,O,O
",",O,O
+,O,O
/,O,O
-,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
13,O,O
patients,O,O
we,O,O
observed,O,O
the,O,O
effects,O,O
of,O,O
HCTZ,B,B
therapy,O,O
(,O,O
100,O,O
mg,O,O
daily,O,O
),O,O
on,O,O
the,O,O
occurrence,O,O
of,O,O
PVC,O,B
',O,O
s,O,O
during,O,O
rest,O,O
as,O,O
well,O,O
as,O,O
during,O,O
static,O,O
and,O,O
dynamic,O,O
exercise,O,O
.,O,O
During,O,O
rest,O,O
we,O,O
observed,O,O
0,O,O
.,O,O
6,O,B
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
PVC,O,B
beats,O,O
/,O,O
min,O,O
+,O,O
/,O,O
-,O,O
SEM,O,O
and,O,O
during,O,O
static,O,O
and,O,O
dynamic,O,O
exercise,O,O
0,O,O
.,O,O
6,O,B
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
and,O,O
0,O,O
.,O,O
8,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
15,O,O
",",O,O
respectively,O,O
.,O,O
Corresponding,O,O
figures,O,O
during,O,O
HCTZ,B,B
therapy,O,O
100,O,O
mg,O,O
daily,O,O
were,O,O
1,O,O
.,O,O
4,O,B
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
1,O,O
",",O,O
3,O,O
.,O,O
6,O,B
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
7,O,O
and,O,O
5,O,B
.,O,O
7,O,I
4,O,I
/,O,I
-,O,I
0,O,I
.,O,I
8,O,I
",",O,O
respectively,O,O
.,O,O
The,O,O
occurrence,O,O
of,O,O
PVC,O,B
',O,O
s,O,O
correlated,O,O
significantly,O,O
with,O,O
the,O,O
fall,O,O
in,O,O
serum,O,O
K,B,B
+,O,O
observed,O,O
r,O,O
=,O,O
0,O,O
.,O,O
72,O,O
",",O,O
p,O,O
less,O,O
than,O,O
0,O,O
.,O,O
.,O,O
In,O,O
conclusion,O,O
we,O,O
found,O,O
that,O,O
thiazide,B,B
diuretics,O,I
cause,O,O
hypokalemia,O,O
and,O,O
depletion,O,O
of,O,O
body,O,O
potassium,B,O
.,O,O
The,O,O
more,O,O
profound,O,O
hypokalemia,O,O
",",O,O
the,O,O
greater,O,O
the,O,O
propensity,O,O
for,O,O
the,O,O
occurrence,O,O
of,O,O
PVC,O,B
',O,O
s,O,O
.,O,O
Circulating,O,O
lysosomal,O,O
enzymes,O,O
and,O,O
acute,O,O
hepatic,O,O
necrosis,O,O
.,O,O
The,O,O
activities,O,O
of,O,O
the,O,O
lysosomal,O,O
enzymes,O,O
acid,O,B
and,O,O
neutral,O,O
protease,O,O
",",O,O
N,O,B
-,O,I
acetylglucosaminidase,O,I
",",O,O
and,O,O
acid,O,B
phosphatase,O,I
were,O,O
measured,O,O
in,O,O
the,O,O
serum,O,O
of,O,O
patients,O,O
with,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
.,O,O
Acid,O,B
protease,O,I
(,O,O
cathepsin,O,B
D,O,I
),O,O
activity,O,O
was,O,O
increased,O,O
about,O,O
tenfold,O,O
in,O,O
patients,O,O
who,O,O
died,O,O
and,O,O
nearly,O,O
fourfold,O,O
in,O,O
those,O,O
who,O,O
survived,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
after,O,O
paracetamol,B,B
overdose,O,I
",",O,O
whereas,O,O
activities,O,O
were,O,O
increased,O,O
equally,O,O
in,O,O
patients,O,O
with,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
due,O,O
to,O,O
viral,O,B
hepatitis,O,I
whether,O,O
or,O,O
not,O,O
they,O,O
survived,O,O
.,O,O
A,O,O
correlation,O,O
was,O,O
found,O,O
between,O,O
serum,O,O
acid,O,B
protease,O,I
activity,O,I
and,O,O
prothrombin,O,O
time,O,O
",",O,O
and,O,O
the,O,O
increase,O,O
in,O,O
cathepsin,O,B
D,O,I
activity,O,I
was,O,O
sustained,O,O
over,O,O
several,O,O
days,O,O
compared,O,O
with,O,O
aspartate,B,B
aminotransferase,O,I
",",O,O
which,O,O
showed,O,O
a,O,O
sharp,O,O
early,O,O
peak,O,O
and,O,O
then,O,O
a,O,O
fall,O,O
.,O,O
Circulating,O,O
lysosomal,O,B
proteases,O,I
can,O,O
damage,O,O
other,O,O
organs,O,O
",",O,O
and,O,O
measurement,O,O
of,O,O
their,O,O
activity,O,O
may,O,O
therefore,O,O
be,O,O
of,O,O
added,O,O
value,O,O
in,O,O
assessing,O,O
prognosis,O,O
in,O,O
this,O,O
condition,O,O
.,O,O
Hepatic,O,B
veno,O,I
-,O,I
occlusive,O,I
disease,O,I
caused,O,O
by,O,O
6,B,B
-,I,I
thioguanine,I,I
.,O,O
Clinically,O,O
reversible,O,O
veno,O,B
-,O,I
occlusive,O,I
disease,O,I
of,O,O
the,O,O
liver,O,B
developed,O,O
in,O,O
a,O,O
23,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
acute,O,O
lymphocytic,O,O
leukemia,O,O
after,O,O
10,O,O
months,O,O
of,O,O
maintenance,O,O
therapy,O,O
with,O,O
6,B,B
-,I,I
thioguanine,I,I
.,O,O
Serial,O,O
liver,O,B
biopsies,O,O
showed,O,O
the,O,O
development,O,O
and,O,O
resolution,O,O
of,O,O
intense,O,O
sinusoidal,O,O
engorgement,O,O
.,O,O
Although,O,O
this,O,O
disease,O,O
was,O,O
clinically,O,O
reversible,O,O
",",O,O
some,O,O
subintimal,O,O
fibrosis,O,O
about,O,O
the,O,O
terminal,O,O
hepatic,O,O
veins,O,O
persisted,O,O
.,O,O
This,O,O
case,O,O
presented,O,O
a,O,O
unique,O,O
opportunity,O,O
to,O,O
observe,O,O
the,O,O
histologic,O,O
features,O,O
of,O,O
clinically,O,O
reversible,O,O
hepatic,O,O
veno,O,B
-,O,I
occlusive,O,I
disease,O,I
over,O,O
time,O,O
",",O,O
and,O,O
may,O,O
be,O,O
the,O,O
first,O,O
case,O,O
of,O,O
veno,O,B
-,O,I
occlusive,O,I
related,O,O
solely,O,O
to,O,O
6,B,B
-,I,I
thioguanine,I,I
.,O,O
Chlorpropamide,B,B
-,O,O
induced,O,O
optic,O,B
neuropathy,O,I
.,O,O
A,O,O
65,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
adult,O,O
-,O,O
onset,O,O
diabetes,O,O
treated,O,O
with,O,O
chlorpropamide,B,B
(,O,O
Diabenese,B,B
),O,O
had,O,O
a,O,O
toxic,O,O
optic,O,B
neuropathy,O,I
that,O,O
resolved,O,O
with,O,O
discontinuation,O,O
of,O,O
chlorpropamide,B,B
therapy,O,O
.,O,O
Visual,O,O
loss,O,O
occurs,O,O
in,O,O
diabetics,O,O
for,O,O
a,O,O
variety,O,O
of,O,O
reasons,O,O
",",O,O
and,O,O
accurate,O,O
diagnosis,O,O
is,O,O
necessary,O,O
to,O,O
institute,O,O
appropriate,O,O
therapy,O,O
.,O,O
The,O,O
possibility,O,O
of,O,O
a,O,O
drug,O,B
-,O,O
induced,O,O
optic,O,O
neuropathy,O,O
should,O,O
be,O,O
considered,O,O
in,O,O
the,O,O
differential,O,O
diagnosis,O,O
of,O,O
visual,O,O
loss,O,O
in,O,O
diabetics,O,O
.,O,O
Plasma,O,O
and,O,O
urinary,O,O
lipids,O,B
and,O,O
lipoproteins,O,O
during,O,O
the,O,O
development,O,O
of,O,O
nephrotic,O,O
syndrome,O,O
induced,O,O
in,O,O
the,O,O
rat,O,O
by,O,O
puromycin,B,B
aminonucleoside,I,I
.,O,O
This,O,O
study,O,O
was,O,O
undertaken,O,O
to,O,O
ascertain,O,O
whether,O,O
the,O,O
alterations,O,O
of,O,O
plasma,O,O
lipoproteins,O,O
found,O,O
in,O,O
nephrotic,O,O
syndrome,O,O
induced,O,O
by,O,O
puromycin,B,B
aminonucleoside,I,I
were,O,O
due,O,O
to,O,O
nephrotic,O,O
syndrome,O,O
per,O,O
se,O,O
",",O,O
or,O,O
",",O,O
at,O,O
least,O,O
in,O,O
part,O,O
",",O,O
to,O,O
the,O,O
aminonucleoside,B,O
.,O,O
The,O,O
purpose,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
investigate,O,O
the,O,O
changes,O,O
in,O,O
plasma,O,B
and,O,O
urinary,O,B
lipoproteins,O,O
during,O,O
the,O,O
administration,O,O
of,O,O
puromycin,B,B
aminonucleoside,I,I
(,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
7,O,O
days,O,O
),O,O
and,O,O
the,O,O
subsequent,O,O
development,O,O
of,O,O
nephrotic,O,B
syndrome,O,O
.,O,O
Since,O,O
massive,O,O
albuminuria,O,B
occurred,O,O
after,O,O
6,O,O
days,O,O
of,O,O
treatment,O,O
",",O,O
the,O,O
time,O,O
-,O,O
course,O,O
study,O,O
was,O,O
divided,O,O
into,O,O
two,O,O
stages,O,O
:,O,O
pre,O,O
-,O,O
nephrotic,O,B
stage,O,O
(,O,O
day,O,O
1,O,O
-,O,O
5,O,O
),O,O
and,O,O
nephrotic,O,B
stage,O,O
(,O,O
day,O,O
6,O,O
-,O,O
11,O,O
),O,O
.,O,O
In,O,O
pre,O,O
-,O,O
nephrotic,O,O
stage,O,O
the,O,O
plasma,O,O
level,O,O
of,O,O
fatty,B,B
acids,I,I
",",O,O
triacylglycerol,B,B
and,O,O
VLDL,O,B
decreased,O,O
while,O,O
that,O,O
of,O,O
phospholipid,O,B
",",O,O
cholesteryl,B,B
esters,I,I
and,O,O
HDL,O,B
remained,O,O
constant,O,O
.,O,O
Plasma,O,O
apolipoprotein,O,B
A,O,I
-,O,I
I,O,I
tended,O,O
to,O,O
increase,O,O
(,O,O
40,O,O
%,O,O
increase,O,O
at,O,O
day,O,O
5,O,O
),O,O
.,O,O
At,O,O
the,O,O
beginning,O,O
of,O,O
nephrotic,O,O
stage,O,O
(,O,O
day,O,O
6,O,O
),O,O
the,O,O
concentration,O,O
of,O,O
plasma,O,O
albumin,O,B
dropped,O,O
to,O,O
a,O,O
very,O,O
low,O,O
level,O,O
",",O,O
while,O,O
that,O,O
of,O,O
apolipoprotein,O,B
A,O,I
-,O,I
I,O,I
increased,O,O
abruptly,O,O
(,O,O
4,O,O
-,O,O
fold,O,O
increase,O,O
),O,O
and,O,O
continued,O,O
to,O,O
rise,O,O
",",O,O
although,O,O
less,O,O
steeply,O,O
",",O,O
in,O,O
the,O,O
following,O,O
days,O,O
.,O,O
The,O,O
plasma,O,O
concentration,O,O
of,O,O
HDL,O,B
followed,O,O
the,O,O
same,O,O
pattern,O,O
.,O,O
Plasma,O,O
VLDL,O,B
and,O,O
LDL,O,B
increased,O,O
at,O,O
a,O,O
later,O,O
stage,O,O
(,O,O
day,O,O
9,O,O
),O,O
.,O,O
Plasma,O,O
apolipoprotein,O,O
A,O,O
-,O,O
I,O,O
was,O,O
found,O,O
not,O,O
only,O,O
in,O,O
HDL,O,B
(,O,O
1,O,O
.,O,O
-,O,O
1,O,O
.,O,O
210,O,O
g,O,O
/,O,O
ml,O,O
),O,O
but,O,O
also,O,O
in,O,O
the,O,O
LDL,O,B
density,O,O
class,O,O
(,O,O
1,O,O
.,O,O
-,O,O
1,O,O
.,O,O
g,O,O
/,O,O
ml,O,O
),O,O
.,O,O
In,O,O
the,O,O
pre,O,O
-,O,O
nephrotic,O,O
stage,O,O
lipoproteinuria,O,O
was,O,O
negligible,O,O
",",O,O
while,O,O
in,O,O
the,O,O
early,O,O
nephrotic,O,O
stage,O,O
the,O,O
urinary,O,O
loss,O,O
of,O,O
plasma,O,O
lipoproteins,O,O
consisted,O,O
mainly,O,O
of,O,O
HDL,O,B
.,O,O
These,O,O
observations,O,O
indicate,O,O
that,O,O
puromycin,B,B
aminonucleoside,I,I
alters,O,O
plasma,O,O
lipoproteins,O,O
by,O,O
lowering,O,O
VLDL,O,B
and,O,O
increasing,O,O
HDL,O,B
.,O,O
It,O,O
is,O,O
likely,O,O
that,O,O
the,O,O
early,O,O
and,O,O
striking,O,O
increase,O,O
of,O,O
plasma,O,O
HDL,O,B
found,O,O
in,O,O
nephrotic,O,O
rats,O,O
is,O,O
related,O,O
to,O,O
a,O,O
direct,O,O
effect,O,O
of,O,O
the,O,O
drug,O,O
on,O,O
HDL,O,B
metabolism,O,O
.,O,O
Fatal,O,O
aplastic,O,O
anemia,O,O
following,O,O
topical,O,O
administration,O,O
of,O,O
ophthalmic,O,O
chloramphenicol,B,B
.,O,O
A,O,O
73,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
died,O,O
of,O,O
aplastic,O,B
anemia,O,I
less,O,O
than,O,O
two,O,O
months,O,O
after,O,O
undergoing,O,O
cataract,O,O
extraction,O,O
and,O,O
beginning,O,O
topical,O,O
therapy,O,O
with,O,O
chloramphenicol,B,B
.,O,O
The,O,O
first,O,O
signs,O,O
of,O,O
pancytopenia,O,B
began,O,O
within,O,O
one,O,O
month,O,O
of,O,O
the,O,O
surgery,O,O
.,O,O
The,O,O
pattern,O,O
of,O,O
the,O,O
aplastic,O,B
anemia,O,I
was,O,O
associated,O,O
with,O,O
an,O,O
idiosyncratic,O,O
response,O,O
to,O,O
chloramphenicol,B,B
.,O,O
This,O,O
was,O,O
the,O,O
second,O,O
report,O,O
of,O,O
fatal,O,O
aplastic,O,O
anemia,O,O
after,O,O
topical,O,O
treatment,O,O
with,O,O
chloramphenicol,B,B
for,O,O
ocular,O,O
conditions,O,O
",",O,O
although,O,O
two,O,O
cases,O,O
of,O,O
reversible,O,O
bone,O,O
marrow,O,O
hypoplasia,O,O
have,O,O
also,O,O
been,O,O
reported,O,O
.,O,O
Any,O,O
other,O,O
suspected,O,O
cases,O,O
of,O,O
ocular,O,O
toxicity,O,O
associated,O,O
with,O,O
topically,O,O
applied,O,O
chloramphenicol,B,B
should,O,O
be,O,O
reported,O,O
to,O,O
the,O,O
National,O,O
Registry,O,O
of,O,O
Drug,O,O
-,O,O
Induced,O,O
Ocular,O,O
Side,O,O
Effects,O,O
",",O,O
Oregon,O,O
Health,O,O
Sciences,O,O
University,O,O
",",O,O
Portland,O,O
",",O,O
OR,O,O
97201,O,O
.,O,O
Midazolam,B,B
compared,O,O
with,O,O
thiopentone,B,B
as,O,O
an,O,O
induction,O,O
agent,O,O
.,O,O
In,O,O
patients,O,O
premedicated,O,O
with,O,O
scopolamine,B,B
+,O,O
morphine,B,B
(,O,O
+,O,O
5,O,O
mg,O,O
nitrazepam,B,B
the,O,O
evening,O,O
before,O,O
surgery,O,O
),O,O
",",O,O
the,O,O
sleep,O,O
-,O,O
inducing,O,O
effect,O,O
of,O,O
midazolam,B,B
0,O,O
.,O,O
15,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
was,O,O
clearly,O,O
slower,O,O
in,O,O
onset,O,O
than,O,O
that,O,O
of,O,O
thiopentone,B,B
4,O,O
.,O,O
67,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
v,O,O
.,O,O
Somewhat,O,O
fewer,O,O
cardiovascular,O,O
and,O,O
local,O,O
sequelae,O,O
were,O,O
found,O,O
in,O,O
the,O,O
midazolam,B,B
group,O,O
",",O,O
but,O,O
",",O,O
although,O,O
apnoea,O,O
occurred,O,O
less,O,O
often,O,O
in,O,O
the,O,O
midazolam,B,B
group,O,O
it,O,O
lasted,O,O
longer,O,O
.,O,O
On,O,O
the,O,O
whole,O,O
",",O,O
the,O,O
differences,O,O
between,O,O
midazolam,B,B
and,O,O
thiopentone,B,B
had,O,O
no,O,O
apparent,O,O
clinical,O,O
consequences,O,O
.,O,O
Midazolam,B,B
is,O,O
a,O,O
new,O,O
alternative,O,O
agent,O,O
for,O,O
induction,O,O
in,O,O
combination,O,O
anaesthesia,O,O
.,O,O
Extrapyramidal,O,B
side,O,I
effects,O,I
and,O,O
oral,O,O
haloperidol,B,B
:,O,O
an,O,O
analysis,O,O
of,O,O
explanatory,O,O
patient,O,O
and,O,O
treatment,O,O
characteristics,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
extrapyramidal,O,B
side,O,I
effects,O,I
(,O,O
EPS,O,B
),O,O
was,O,O
evaluated,O,O
in,O,O
98,O,O
patients,O,O
treated,O,O
with,O,O
haloperidol,B,B
.,O,O
The,O,O
incidence,O,O
of,O,O
parkinsonism,O,B
was,O,O
higher,O,O
at,O,O
higher,O,O
doses,O,O
of,O,O
haloperidol,B,B
and,O,O
in,O,O
younger,O,O
patients,O,O
.,O,O
Prophylactic,O,O
antiparkinsonian,O,B
medication,O,O
was,O,O
effective,O,O
in,O,O
younger,O,O
but,O,O
not,O,O
in,O,O
older,O,O
patients,O,O
.,O,O
However,O,O
",",O,O
these,O,O
medications,O,O
were,O,O
more,O,O
effective,O,O
in,O,O
both,O,O
young,O,O
and,O,O
old,O,O
patients,O,O
when,O,O
given,O,O
after,O,O
parkinsonism,O,B
developed,O,O
.,O,O
Akathisia,O,O
was,O,O
controlled,O,O
by,O,O
the,O,O
benzodiazepine,B,B
lorazepam,B,I
in,O,O
14,O,O
out,O,O
of,O,O
16,O,O
patients,O,O
",",O,O
while,O,O
prophylactic,O,O
antiparkinsonians,O,O
were,O,O
ineffective,O,O
.,O,O
The,O,O
present,O,O
study,O,O
points,O,O
to,O,O
patient,O,O
characteristics,O,O
that,O,O
may,O,O
be,O,O
of,O,O
significance,O,O
in,O,O
the,O,O
development,O,O
of,O,O
EPS,O,O
due,O,O
to,O,O
haloperidol,B,B
.,O,O
Deaths,O,O
from,O,O
local,O,O
anesthetic,O,B
-,O,I
induced,O,I
convulsions,O,I
in,O,O
mice,O,O
.,O,O
Median,O,O
convulsant,O,O
(,O,O
CD50,O,B
),O,O
and,O,O
median,O,O
lethal,O,O
(,O,O
LD50,O,B
),O,O
doses,O,O
of,O,O
three,O,O
representative,O,O
local,O,O
anesthetics,O,O
were,O,O
determined,O,O
in,O,O
adult,O,O
mice,O,O
to,O,O
evaluate,O,O
the,O,O
threat,O,O
to,O,O
life,O,O
of,O,O
local,O,O
anesthetic,O,O
-,O,O
induced,O,O
convulsions,O,O
.,O,O
The,O,O
CD50,O,B
and,O,O
LD50,O,B
",",O,O
respectively,O,O
",",O,O
were,O,O
57,O,O
.,O,O
7,O,O
and,O,O
58,O,O
.,O,O
7,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
bupivacaine,B,B
",",O,O
111,O,O
.,O,O
0,O,O
and,O,O
133,O,O
.,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
lidocaine,B,B
",",O,O
and,O,O
243,O,O
.,O,O
4,O,O
and,O,O
266,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
for,O,O
chloroprocaine,B,B
.,O,O
When,O,O
given,O,O
intraperitoneally,O,O
",",O,O
bupivacaine,B,B
thus,O,O
was,O,O
only,O,O
about,O,O
twice,O,O
as,O,O
toxic,O,O
as,O,O
lidocaine,B,B
and,O,O
four,O,O
times,O,O
as,O,O
toxic,O,O
as,O,O
chloroprocaine,B,B
.,O,O
Convulsions,O,O
always,O,O
preceded,O,O
death,O,O
",",O,O
except,O,O
after,O,O
precipitous,O,O
cardiopulmonary,O,O
arrest,O,O
from,O,O
extreme,O,O
doses,O,O
.,O,O
A,O,O
CD50,O,O
dose,O,O
of,O,O
local,O,B
anesthetic,O,I
(,O,O
causing,O,O
convulsions,O,O
in,O,O
50,O,O
%,O,O
of,O,O
mice,O,O
),O,O
was,O,O
fatal,O,O
in,O,O
90,O,O
%,O,O
of,O,O
bupivacaine,B,B
-,O,O
induced,O,O
seizures,O,O
",",O,O
in,O,O
57,O,O
%,O,O
of,O,O
the,O,O
chloroprocaine,B,B
group,O,O
",",O,O
and,O,O
in,O,O
6,O,O
%,O,O
of,O,O
the,O,O
lidocaine,B,B
group,O,O
.,O,O
The,O,O
narrow,O,O
gap,O,O
between,O,O
convulsant,O,O
and,O,O
lethal,O,O
doses,O,O
of,O,O
local,O,B
anesthetics,O,I
indicates,O,O
that,O,O
untreated,O,O
convulsions,O,O
present,O,O
much,O,O
more,O,O
of,O,O
a,O,O
threat,O,O
to,O,O
life,O,O
than,O,O
heretofore,O,O
appreciated,O,O
.,O,O
REM,O,B
sleep,O,I
deprivation,O,I
changes,O,O
behavioral,O,O
response,O,O
to,O,O
catecholaminergic,O,B
and,O,O
serotonergic,O,B
receptor,O,I
activation,O,I
in,O,O
rats,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
REM,O,B
sleep,O,I
deprivation,O,I
(,O,O
REMD,O,B
),O,O
on,O,O
apomorphine,B,B
-,O,O
induced,O,O
aggressiveness,O,O
and,O,O
quipazine,B,B
-,O,O
induced,O,O
head,O,O
twitches,O,O
in,O,O
rats,O,O
were,O,O
determined,O,O
.,O,O
Forty,O,O
-,O,O
eight,O,O
hr,O,O
of,O,O
REMD,O,B
increased,O,O
apomorphine,B,B
-,O,O
induced,O,O
aggressiveness,O,O
",",O,O
and,O,O
reduced,O,O
(,O,O
immediately,O,O
after,O,O
completing,O,O
of,O,O
REMD,O,B
),O,O
or,O,O
increased,O,O
(,O,O
96,O,O
hr,O,O
after,O,O
completing,O,O
of,O,O
REMD,O,B
),O,O
quipazine,B,B
-,O,O
induced,O,O
head,O,O
twitches,O,O
.,O,O
Results,O,O
are,O,O
discussed,O,O
in,O,O
terms,O,O
of,O,O
similarity,O,O
to,O,O
pharmacological,O,O
effects,O,O
of,O,O
other,O,O
antidepressive,O,O
treatments,O,O
.,O,O
Fatal,O,O
aplastic,O,O
anemia,O,O
due,O,O
to,O,O
indomethacin,B,B
-,O,O
-,O,O
lymphocyte,O,O
transformation,O,O
tests,O,O
in,O,O
vitro,O,O
.,O,O
Although,O,O
indomethacin,B,B
has,O,O
been,O,O
implicated,O,O
as,O,O
a,O,O
possible,O,O
cause,O,O
of,O,O
aplastic,O,O
anemia,O,O
on,O,O
the,O,O
basis,O,O
of,O,O
a,O,O
few,O,O
clinical,O,O
observations,O,O
",",O,O
its,O,O
role,O,O
has,O,O
not,O,O
been,O,O
definitely,O,O
established,O,O
.,O,O
A,O,O
case,O,O
of,O,O
fatal,O,O
aplastic,O,B
anemia,O,I
is,O,O
described,O,O
in,O,O
which,O,O
no,O,O
drugs,O,O
other,O,O
than,O,O
allopurinol,B,B
and,O,O
indomethacin,B,B
were,O,O
given,O,O
.,O,O
Indomethacin,B,B
was,O,O
first,O,O
given,O,O
four,O,O
weeks,O,O
prior,O,O
to,O,O
the,O,O
onset,O,O
of,O,O
symptoms,O,O
.,O,O
A,O,O
positive,O,O
lymphocyte,O,O
transformation,O,O
test,O,O
with,O,O
indomethacin,B,B
in,O,O
vitro,O,O
further,O,O
substantiates,O,O
the,O,O
potential,O,O
role,O,O
of,O,O
this,O,O
drug,O,O
in,O,O
causing,O,O
aplastic,O,B
anemia,O,I
in,O,O
a,O,O
susceptible,O,O
patient,O,O
.,O,O
Fortunately,O,O
",",O,O
this,O,O
seems,O,O
to,O,O
be,O,O
a,O,O
very,O,O
rare,O,O
complication,O,O
.,O,O
Dose,O,O
-,O,O
effect,O,O
and,O,O
structure,O,O
-,O,O
function,O,O
relationships,O,O
in,O,O
doxorubicin,B,B
cardiomyopathy,O,O
.,O,O
The,O,O
cardiomyopathy,O,O
(,O,O
CM,O,O
),O,O
produced,O,O
by,O,O
the,O,O
anticancer,O,O
drug,O,O
doxorubicin,B,B
(,O,O
DXR,B,O
),O,O
(,O,O
Adriamycin,B,O
),O,O
provides,O,O
a,O,O
unique,O,O
opportunity,O,O
to,O,O
analyze,O,O
dose,O,O
-,O,O
effect,O,O
and,O,O
structure,O,O
-,O,O
function,O,O
relationships,O,O
during,O,O
development,O,O
of,O,O
myocardial,O,O
disease,O,O
.,O,O
We,O,O
measured,O,O
the,O,O
degree,O,O
of,O,O
morphologic,O,O
damage,O,O
by,O,O
ultrastructural,O,O
examination,O,O
of,O,O
endomyocardial,O,O
biopsy,O,O
and,O,O
the,O,O
degree,O,O
of,O,O
performance,O,O
abnormally,O,O
by,O,O
right,O,O
heart,O,O
catheterization,O,O
in,O,O
patients,O,O
receiving,O,O
DXR,B,B
.,O,O
Morphologic,O,O
damage,O,O
was,O,O
variable,O,O
but,O,O
was,O,O
proportional,O,O
to,O,O
the,O,O
total,O,O
cumulative,O,O
DXR,B,B
dose,O,O
between,O,O
100,O,O
and,O,O
600,O,O
mg,O,O
/,O,O
m2,O,O
.,O,O
Performance,O,O
abnormalities,O,O
correlated,O,O
weakly,O,O
with,O,O
dose,O,O
",",O,O
exhibited,O,O
a,O,O
curvilinear,O,O
relationship,O,O
",",O,O
and,O,O
had,O,O
a,O,O
for,O,O
expression,O,O
.,O,O
Catheterization,O,O
abnormalities,O,O
correlated,O,O
well,O,O
with,O,O
morphologic,O,B
damage,O,O
(,O,O
r,O,O
=,O,O
0,O,O
.,O,O
57,O,O
to,O,O
0,O,O
.,O,O
78,O,O
),O,O
in,O,O
a,O,O
subgroup,O,O
of,O,O
patients,O,O
in,O,O
whom,O,O
exercise,O,O
hemodynamics,O,O
were,O,O
measured,O,O
",",O,O
and,O,O
this,O,O
relationship,O,O
also,O,O
exhibited,O,O
a,O,O
curvilinear,O,O
",",O,O
threshold,O,B
configuration,O,O
.,O,O
In,O,O
DXR,B,B
-,O,O
CM,O,O
myocardial,O,O
damage,O,O
is,O,O
proportional,O,O
to,O,O
the,O,O
degree,O,O
of,O,O
cytotoxic,O,O
insult,O,O
(,O,O
DXR,B,B
dose,O,O
),O,O
while,O,O
myocardial,O,O
function,O,O
is,O,O
preserved,O,O
until,O,O
a,O,O
critical,O,O
dose,O,O
or,O,O
degree,O,O
of,O,O
damage,O,O
is,O,O
reached,O,O
",",O,O
after,O,O
which,O,O
myocardial,O,O
performance,O,O
deteriorates,O,O
rapidly,O,O
.,O,O
Massive,O,O
cerebral,O,O
edema,O,O
associated,O,O
with,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
in,O,O
acetaminophen,B,B
overdose,O,O
:,O,O
possible,O,O
role,O,O
of,O,O
cranial,O,O
decompression,O,O
.,O,O
Cerebral,O,B
edema,O,I
may,O,O
complicate,O,O
the,O,O
course,O,O
of,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
.,O,O
Response,O,O
to,O,O
conventional,O,O
therapy,O,O
has,O,O
been,O,O
disappointing,O,O
.,O,O
We,O,O
present,O,O
a,O,O
patient,O,O
with,O,O
fatal,O,O
acetaminophen,B,B
-,O,I
induced,O,O
fulminant,O,O
hepatic,O,O
failure,O,O
",",O,O
with,O,O
signs,O,O
and,O,O
symptoms,O,O
of,O,O
cerebral,O,B
edema,O,I
",",O,O
unresponsive,O,O
to,O,O
conventional,O,O
medical,O,O
therapy,O,O
.,O,O
Cranial,O,O
decompression,O,O
was,O,O
carried,O,O
out,O,O
.,O,O
A,O,O
justification,O,O
of,O,O
the,O,O
need,O,O
for,O,O
further,O,O
evaluation,O,O
of,O,O
cranial,O,O
decompression,O,O
in,O,O
such,O,O
patients,O,O
is,O,O
presented,O,O
.,O,O
Subjective,O,O
assessment,O,O
of,O,O
sexual,O,O
dysfunction,O,O
of,O,O
patients,O,O
on,O,O
long,O,O
-,O,O
term,O,O
administration,O,O
of,O,O
digoxin,B,B
.,O,O
Various,O,O
data,O,O
suggest,O,O
that,O,O
male,O,O
patients,O,O
who,O,O
have,O,O
received,O,O
digoxin,B,B
on,O,O
a,O,O
longterm,O,O
basis,O,O
have,O,O
increased,O,O
levels,O,O
of,O,O
serum,O,O
estrogen,B,B
and,O,O
decreased,O,O
levels,O,O
of,O,O
plasma,O,O
testosterone,B,B
and,O,O
luteinizing,O,B
hormone,O,I
(,O,I
LH,O,I
),O,I
.,O,O
This,O,O
study,O,O
was,O,O
undertaken,O,O
to,O,O
investigate,O,O
the,O,O
links,O,O
between,O,O
the,O,O
long,O,O
-,O,O
term,O,O
administration,O,O
of,O,O
digoxin,B,B
therapy,O,O
and,O,O
sexual,O,O
behavior,O,O
",",O,O
and,O,O
the,O,O
effect,O,O
of,O,O
digoxin,B,B
on,O,O
plasma,O,O
levels,O,O
of,O,O
estradiol,B,B
",",O,O
testosterone,B,B
",",O,O
and,O,O
LH,O,B
.,O,O
The,O,O
patients,O,O
of,O,O
the,O,O
study,O,O
and,O,O
control,O,O
group,O,O
(,O,O
without,O,O
digoxin,B,B
),O,O
were,O,O
of,O,O
similar,O,O
cardiac,O,O
functional,O,O
capacity,O,O
and,O,O
age,O,O
(,O,O
25,O,O
-,O,O
40,O,O
years,O,O
),O,O
and,O,O
were,O,O
randomly,O,O
selected,O,O
from,O,O
the,O,O
rheumatic,O,O
heart,O,O
disease,O,O
patients,O,O
.,O,O
A,O,O
subjective,O,O
assessment,O,O
of,O,O
sexual,O,O
behavior,O,O
in,O,O
the,O,O
study,O,O
and,O,O
control,O,O
groups,O,O
was,O,O
carried,O,O
out,O,O
",",O,O
using,O,O
parameters,O,O
such,O,O
as,O,O
sexual,O,O
desire,O,O
",",O,O
sexual,O,O
excitement,O,O
",",O,O
and,O,O
frequency,O,O
of,O,O
sexual,O,O
relations,O,O
.,O,O
interviews,O,O
and,O,O
a,O,O
questionnaire,O,O
were,O,O
also,O,O
used,O,O
for,O,O
the,O,O
evaluation,O,O
of,O,O
sexual,O,O
behavior,O,O
.,O,O
findings,O,O
support,O,O
the,O,O
reports,O,O
concerning,O,O
digoxin,B,B
effect,O,O
on,O,O
plasma,O,O
estradiol,B,B
",",O,O
testosterone,B,B
",",O,O
and,O,O
LH,O,B
.,O,O
The,O,O
differences,O,O
in,O,O
the,O,O
means,O,O
were,O,O
significant,O,O
.,O,O
Tests,O,O
used,O,O
to,O,O
evaluate,O,O
the,O,O
changes,O,O
in,O,O
sexual,O,O
behavior,O,O
showed,O,O
a,O,O
significant,O,O
decrease,O,O
in,O,O
sexual,O,O
desire,O,O
",",O,O
sexual,O,O
excitement,O,O
phase,O,O
(,O,O
erection,O,O
),O,O
",",O,O
and,O,O
frequency,O,O
of,O,O
sexual,O,O
relations,O,O
in,O,O
the,O,O
study,O,O
group,O,O
.,O,O
Endometrial,O,B
carcinoma,O,I
after,O,O
Hodgkin,O,B
disease,O,I
in,O,O
childhood,O,O
.,O,O
A,O,O
34,O,O
-,O,O
year,O,O
-,O,O
old,O,O
patient,O,O
developed,O,O
metastic,O,B
endometrial,O,I
carcinoma,O,I
after,O,O
Hodgkin,O,O
disease,O,O
in,O,O
childhood,O,O
.,O,O
She,O,O
had,O,O
ovarian,O,B
failure,O,I
after,O,O
abdominal,O,O
irradiation,O,O
and,O,O
chemotherapy,O,O
for,O,O
Hodgkin,O,O
disease,O,O
",",O,O
and,O,O
received,O,O
exogenous,O,O
estrogens,B,B
",",O,O
a,O,O
treatment,O,O
implicated,O,O
in,O,O
the,O,O
development,O,O
of,O,O
endometrial,O,B
cancer,O,I
in,O,O
menopausal,O,O
women,O,O
.,O,O
Young,O,O
women,O,O
on,O,O
replacement,O,O
estrogens,B,B
for,O,O
ovarian,O,O
failure,O,O
after,O,O
cancer,O,O
therapy,O,O
may,O,O
also,O,O
have,O,O
increased,O,O
risk,O,O
of,O,O
endometrial,O,B
carcinoma,O,I
and,O,O
should,O,O
be,O,O
examined,O,O
periodically,O,O
.,O,O
Long,O,O
-,O,O
term,O,O
lithium,B,B
treatment,O,O
and,O,O
the,O,O
kidney,O,O
.,O,O
Interim,O,O
report,O,O
on,O,O
fifty,O,O
patients,O,O
.,O,O
This,O,O
is,O,O
a,O,O
report,O,O
on,O,O
the,O,O
first,O,O
part,O,O
of,O,O
our,O,O
study,O,O
of,O,O
the,O,O
effects,O,O
of,O,O
long,O,O
-,O,O
term,O,O
lithium,B,B
treatment,O,O
on,O,O
the,O,O
kidney,O,O
.,O,O
Creatinine,B,B
clearance,O,I
",",O,O
maximum,O,O
urinary,O,O
osmolality,O,O
and,O,O
24,O,O
hour,O,O
urine,O,O
volume,O,O
have,O,O
been,O,O
tested,O,O
in,O,O
50,O,O
affectively,O,O
ill,O,O
patients,O,O
who,O,O
have,O,O
been,O,O
on,O,O
long,O,O
-,O,O
term,O,O
lithium,B,B
for,O,O
more,O,O
than,O,O
one,O,O
year,O,O
.,O,O
These,O,O
findings,O,O
have,O,O
been,O,O
compared,O,O
with,O,O
norms,O,O
and,O,O
with,O,O
values,O,O
of,O,O
the,O,O
same,O,O
tests,O,O
from,O,O
screening,O,O
prior,O,O
to,O,O
lithium,B,B
",",O,O
available,O,O
for,O,O
most,O,O
of,O,O
our,O,O
patients,O,O
.,O,O
No,O,O
evidence,O,O
was,O,O
found,O,O
for,O,O
any,O,O
reduction,O,O
of,O,O
glomerular,O,B
filtration,O,I
during,O,O
lithium,B,B
treatment,O,O
.,O,O
Low,O,O
clearance,O,O
values,O,O
found,O,O
in,O,O
several,O,O
patients,O,O
could,O,O
be,O,O
accounted,O,O
for,O,O
by,O,O
their,O,O
age,O,O
and,O,O
their,O,O
pre,O,O
-,O,O
lithium,B,B
values,O,O
.,O,O
Urinary,O,B
concentration,O,I
defect,O,I
appeared,O,O
frequent,O,O
but,O,O
the,O,O
extent,O,O
of,O,O
the,O,O
impairment,O,O
is,O,O
difficult,O,O
to,O,O
assess,O,O
because,O,O
of,O,O
the,O,O
uncertainty,O,O
about,O,O
the,O,O
norms,O,O
applicable,O,O
to,O,O
this,O,O
group,O,O
of,O,O
patients,O,O
.,O,O
The,O,O
concentration,O,O
defect,O,O
appeared,O,O
reversible,O,O
",",O,O
at,O,O
least,O,O
in,O,O
part,O,O
.,O,O
Polyuria,O,O
above,O,O
3,O,O
litres,O,O
/,O,O
24,O,O
hours,O,O
was,O,O
found,O,O
in,O,O
10,O,O
%,O,O
of,O,O
patients,O,O
.,O,O
An,O,O
attempt,O,O
is,O,O
made,O,O
to,O,O
draw,O,O
practical,O,O
conclusions,O,O
from,O,O
the,O,O
preliminary,O,O
findings,O,O
.,O,O
Nephrotoxicity,O,O
of,O,O
cyclosporin,B,B
A,I,I
and,O,O
FK506,B,B
:,O,O
inhibition,O,O
of,O,O
calcineurin,O,B
phosphatase,O,I
.,O,O
Cyclosporin,B,B
A,I,I
(,O,O
CsA,B,B
;,O,O
50,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
and,O,O
Fujimycine,B,B
(,O,O
FK506,B,B
;,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
but,O,O
not,O,O
the,O,O
related,O,O
macrolide,B,O
immunosuppressant,O,O
rapamycin,B,B
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
",",O,O
caused,O,O
a,O,O
reduction,O,O
of,O,O
glomerular,O,O
filtration,O,O
rate,O,O
",",O,O
degenerative,O,O
changes,O,O
of,O,O
proximal,O,O
tubular,O,O
epithelium,O,O
",",O,O
and,O,O
hypertrophy,O,O
of,O,O
the,O,O
juxtaglomerular,O,O
apparatus,O,O
in,O,O
male,O,O
Wistar,O,O
rats,O,O
when,O,O
given,O,O
for,O,O
10,O,O
days,O,O
.,O,O
The,O,O
molecular,O,O
mechanisms,O,O
of,O,O
CsA,B,B
and,O,O
FK506,B,B
toxicity,O,O
were,O,O
investigated,O,O
.,O,O
Cyclophilin,O,B
A,O,I
and,O,O
FK506,B,B
-,O,O
binding,O,O
protein,O,O
",",O,O
the,O,O
main,O,O
intracytoplasmic,O,O
receptors,O,O
for,O,O
CsA,B,B
and,O,O
FK506,B,B
",",O,O
respectively,O,O
",",O,O
were,O,O
each,O,O
detected,O,O
in,O,O
renal,O,O
tissue,O,O
extract,O,O
.,O,O
In,O,O
the,O,O
kidney,O,O
",",O,O
high,O,O
levels,O,O
of,O,O
immunoreactive,O,O
and,O,O
enzymatically,O,O
active,O,O
calcineurin,O,B
were,O,O
found,O,O
which,O,O
were,O,O
inhibited,O,O
by,O,O
the,O,O
immunosuppressants,O,O
CsA,B,B
and,O,O
FK506,B,B
",",O,O
but,O,O
not,O,O
by,O,O
rapamycin,B,B
.,O,O
Finally,O,O
",",O,O
specific,O,O
immunophilin,O,B
-,O,I
drug,O,O
-,O,O
calcineurin,O,B
complexes,O,O
formed,O,O
only,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
CsA,B,B
and,O,O
FK506,B,B
",",O,O
but,O,O
not,O,O
rapamycin,B,O
.,O,O
These,O,O
results,O,O
suggest,O,O
that,O,O
the,O,O
nephrotoxic,O,O
effects,O,O
of,O,O
CsA,B,B
and,O,O
FK506,B,B
is,O,O
likely,O,O
mediated,O,O
through,O,O
binding,O,O
to,O,O
renal,O,O
immunophilin,O,B
and,O,O
inhibiting,O,O
calcineurin,O,B
phosphatase,O,O
.,O,O
Acute,O,O
renal,O,O
failure,O,O
in,O,O
high,O,O
dose,O,O
carboplatin,B,B
chemotherapy,O,O
.,O,O
Carboplatin,B,B
has,O,O
been,O,O
reported,O,O
to,O,O
cause,O,O
acute,O,O
renal,O,O
failure,O,O
when,O,O
administered,O,O
in,O,O
high,O,O
doses,O,O
to,O,O
adult,O,O
patients,O,O
.,O,O
We,O,O
report,O,O
a,O,O
4,O,O
1,O,O
/,O,O
2,O,O
-,O,O
year,O,O
-,O,O
old,O,O
girl,O,O
who,O,O
was,O,O
treated,O,O
with,O,O
high,O,O
-,O,O
dose,O,O
carboplatin,B,B
for,O,O
metastatic,O,O
parameningeal,O,O
embryonal,O,O
rhabdomyosarcoma,O,O
.,O,O
Acute,O,O
renal,O,O
failure,O,O
developed,O,O
followed,O,O
by,O,O
a,O,O
slow,O,O
partial,O,O
recovery,O,O
of,O,O
renal,O,O
function,O,O
.,O,O
Possible,O,O
contributing,O,O
factors,O,O
are,O,O
discussed,O,O
.,O,O
Clinical,O,O
evaluation,O,O
on,O,O
combined,O,O
administration,O,O
of,O,O
oral,O,O
prostacyclin,B,B
analogue,O,O
beraprost,B,B
and,O,O
phosphodiesterase,O,B
inhibitor,O,O
cilostazol,B,B
.,O,O
Among,O,O
various,O,O
oral,O,O
antiplatelets,O,O
",",O,O
a,O,O
combination,O,O
of,O,O
a,O,O
novel,O,O
prostacyclin,B,B
analogue,O,O
beraprost,B,B
(,O,O
BPT,B,B
),O,O
and,O,O
a,O,O
potent,O,O
phosphodiesterase,O,B
inhibitor,O,O
cilostazol,B,B
(,O,O
CLZ,B,B
),O,O
may,O,O
result,O,O
in,O,O
untoward,O,O
clinical,O,O
effects,O,O
due,O,O
to,O,O
possible,O,O
synergistic,O,O
elevation,O,O
of,O,O
intracellular,O,O
cAMP,B,B
(,O,O
cyclic,B,B
adenosine,I,I
3,I,I
',I,I
",",I,I
5,I,I
',I,I
-,I,I
monophosphate,I,I
),O,O
.,O,O
Thereby,O,O
",",O,O
a,O,O
clinical,O,O
study,O,O
of,O,O
the,O,O
combined,O,O
administration,O,O
of,O,O
the,O,O
two,O,O
agents,O,O
was,O,O
attempted,O,O
.,O,O
Twelve,O,O
healthy,O,O
volunteers,O,O
were,O,O
assigned,O,O
to,O,O
take,O,O
BPT,B,B
/,O,O
CLZ,B,B
in,O,O
the,O,O
following,O,O
schedule,O,O
;,O,O
BPT,B,B
:,O,O
40,O,O
micrograms,O,O
at,O,O
day,O,O
1,O,O
and,O,O
120,O,O
micrograms,O,O
t,O,O
.,O,O
i,O,O
.,O,O
d,O,O
.,O,O
from,O,O
day,O,O
7,O,O
to,O,O
14,O,O
",",O,O
CLZ,B,B
:,O,O
200,O,O
mg,O,O
t,O,O
.,O,O
i,O,O
.,O,O
d,O,O
.,O,O
from,O,O
day,O,O
3,O,O
to,O,O
14,O,O
.,O,O
At,O,O
various,O,O
time,O,O
intervals,O,O
",",O,O
physical,O,O
examination,O,O
and,O,O
blood,O,O
collection,O,O
for,O,O
ex,O,O
vivo,O,O
platelet,O,O
aggregation,O,O
and,O,O
determination,O,O
of,O,O
intraplatelet,O,O
cAMP,B,B
were,O,O
performed,O,O
.,O,O
Throughout,O,O
the,O,O
observation,O,O
period,O,O
",",O,O
no,O,O
significant,O,O
alteration,O,O
in,O,O
vital,O,O
signs,O,O
was,O,O
observed,O,O
.,O,O
Seven,O,O
out,O,O
of,O,O
12,O,O
subjects,O,O
experienced,O,O
headache,O,O
of,O,O
a,O,O
short,O,O
duration,O,O
accompanying,O,O
facial,O,O
flush,O,O
in,O,O
one,O,O
and,O,O
nausea,O,O
in,O,O
one,O,O
",",O,O
especially,O,O
after,O,O
ingestion,O,O
of,O,O
CLZ,B,B
.,O,O
All,O,O
of,O,O
these,O,O
symptoms,O,O
",",O,O
probably,O,O
caused,O,O
by,O,O
the,O,O
vasodilating,O,O
effect,O,O
of,O,O
the,O,O
two,O,O
agents,O,O
",",O,O
were,O,O
of,O,O
mild,O,O
degree,O,O
and,O,O
no,O,O
special,O,O
treatment,O,O
was,O,O
required,O,O
.,O,O
Intraplatelet,O,O
cAMP,B,B
content,O,O
was,O,O
gradually,O,O
but,O,O
significantly,O,O
increased,O,O
to,O,O
9,O,O
.,O,O
84,O,O
+,O,O
/,O,O
-,O,O
4,O,O
59,O,O
pmol,O,O
per,O,O
10,O,O
(,O,O
9,O,O
),O,O
platelets,O,O
at,O,O
day,O,O
14,O,O
in,O,O
comparison,O,O
with,O,O
the,O,O
initial,O,O
value,O,O
(,O,O
6,O,O
.,O,O
87,O,O
+,O,O
/,O,O
-,O,O
2,O,O
pmol,O,O
.,O,O
The,O,O
platelet,O,O
aggregability,O,O
was,O,O
significantly,O,O
suppressed,O,O
at,O,O
various,O,O
time,O,O
intervals,O,O
but,O,O
no,O,O
additive,O,O
or,O,O
synergistic,O,O
inhibitory,O,O
effect,O,O
by,O,O
the,O,O
combined,O,O
administration,O,O
was,O,O
noted,O,O
.,O,O
In,O,O
conclusion,O,O
",",O,O
the,O,O
combined,O,O
administration,O,O
of,O,O
BPT,B,B
/,O,I
CLZ,B,I
is,O,O
safe,O,O
at,O,O
doses,O,O
used,O,O
in,O,O
the,O,O
study,O,O
",",O,O
though,O,O
the,O,O
beneficial,O,O
clinical,O,O
effect,O,O
of,O,O
the,O,O
combined,O,O
administration,O,O
has,O,O
yet,O,O
to,O,O
be,O,O
elucidated,O,O
.,O,O
Pravastatin,B,B
-,O,I
associated,O,I
myopathy,O,I
.,O,O
Report,O,O
of,O,O
a,O,O
case,O,O
.,O,O
A,O,O
case,O,O
of,O,O
acute,O,O
inflammatory,O,O
myopathy,O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
pravastatin,B,B
",",O,O
a,O,O
new,O,O
hydrophilic,O,O
3,O,O
-,O,O
hydroxy,O,O
-,O,O
3,O,O
methylglutaril,O,O
coenzyme,O,O
A,O,O
reductase,O,O
inhibitor,O,O
",",O,O
is,O,O
reported,O,O
.,O,O
The,O,O
patient,O,O
",",O,O
a,O,O
69,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
was,O,O
affected,O,O
by,O,O
non,O,O
-,O,O
insulin,O,B
-,O,I
dependent,O,I
diabetes,O,I
mellitus,O,I
and,O,O
hypertension,O,O
.,O,O
He,O,O
assumed,O,O
pravastatin,B,B
(,O,O
20,O,O
mg,O,O
/,O,O
day,O,O
),O,O
because,O,O
of,O,O
hypercholesterolemia,O,O
.,O,O
He,O,O
was,O,O
admitted,O,O
with,O,O
acute,O,O
myopathy,O,O
of,O,O
the,O,O
lower,O,O
limbs,O,O
which,O,O
resolved,O,O
in,O,O
a,O,O
few,O,O
days,O,O
after,O,O
pravastatin,B,B
discontinuation,O,O
.,O,O
A,O,O
previously,O,O
unknown,O,O
hypothyroidism,O,B
",",O,O
probably,O,O
due,O,O
to,O,O
chronic,O,O
autoimmune,O,O
thyroiditis,O,B
",",O,O
was,O,O
evidenced,O,O
.,O,O
Muscle,O,O
biopsy,O,O
(,O,O
left,O,O
gastrocnemius,O,O
),O,O
revealed,O,O
a,O,O
perimysial,O,O
and,O,O
endomysial,O,O
inflammatory,O,O
infiltrate,O,O
with,O,O
a,O,O
prevalence,O,O
of,O,O
CD4,O,B
+,O,O
lymphocytes,O,O
.,O,O
While,O,O
lovastatin,B,B
and,O,O
simvastatin,B,B
have,O,O
been,O,O
associated,O,O
with,O,O
toxic,O,O
myopathy,O,O
",",O,O
pravastatin,B,B
-,O,O
associated,O,O
myopathy,O,O
could,O,O
represent,O,O
a,O,O
distinct,O,O
",",O,O
inflammatory,O,O
entity,O,O
.,O,O
Reversal,O,O
of,O,O
ammonia,B,B
coma,O,I
in,O,O
rats,O,O
by,O,O
L,B,B
-,I,I
dopa,I,I
:,O,O
a,O,O
peripheral,O,O
effect,O,O
.,O,O
Ammonia,B,B
coma,O,I
was,O,O
produced,O,O
in,O,O
rats,O,O
within,O,O
10,O,O
to,O,O
15,O,O
minutes,O,O
of,O,O
an,O,O
intraperitonealinjection,O,O
of,O,O
1,O,O
.,O,O
7,O,O
mmol,O,O
NH4CL,B,B
.,O,O
This,O,O
coma,O,I
was,O,O
prevented,O,O
with,O,O
1,O,O
.,O,O
68,O,O
mmol,O,O
L,B,B
-,I,I
dopa,I,I
given,O,O
by,O,O
gastric,O,O
intubation,O,O
15,O,O
minutes,O,O
before,O,O
the,O,O
ammonium,B,B
salt,I,I
injection,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
L,B,B
-,I,I
dopa,I,I
was,O,O
correlated,O,O
with,O,O
a,O,O
decrease,O,O
in,O,O
blood,O,B
and,O,O
brain,O,B
ammonia,B,I
",",O,O
an,O,O
increase,O,O
in,O,O
brain,O,B
dopamine,B,I
",",O,O
and,O,O
an,O,O
increase,O,O
in,O,O
renal,O,B
excretion,O,I
of,O,I
ammonia,B,I
and,O,O
urea,B,B
.,O,O
Intraventricular,O,O
infusion,O,O
of,O,O
dopamine,B,B
sufficient,O,O
to,O,O
raise,O,O
the,O,O
brain,O,B
dopamine,B,I
to,O,O
the,O,O
same,O,O
extent,O,O
did,O,O
not,O,O
prevent,O,O
the,O,O
ammonia,B,B
coma,O,I
nor,O,O
affect,O,O
the,O,O
blood,O,B
and,O,O
brain,O,B
ammonia,B,I
concentrations,O,I
.,O,O
Bilateral,O,O
nephrectomy,O,O
eliminated,O,O
the,O,O
beneficial,O,O
effect,O,O
of,O,O
L,B,B
-,I,O
dopa,I,I
on,O,O
blood,O,B
and,O,O
brain,O,B
ammonia,B,I
and,O,O
the,O,O
ammonia,B,B
coma,O,I
was,O,O
not,O,O
prevented,O,O
.,O,O
Thus,O,O
",",O,O
the,O,O
reduction,O,O
in,O,O
blood,O,B
and,O,O
brain,O,B
ammonia,B,I
and,O,O
the,O,O
prevention,O,O
of,O,O
ammonia,B,B
coma,O,I
after,O,O
L,B,B
-,I,O
dopa,I,I
",",O,O
can,O,O
be,O,O
accounted,O,O
for,O,O
by,O,O
the,O,O
peripheral,O,O
effect,O,O
of,O,O
dopamine,B,B
on,O,O
renal,O,O
function,O,O
rather,O,O
than,O,O
its,O,O
central,O,O
action,O,O
.,O,O
These,O,O
results,O,O
provide,O,O
a,O,O
reasonable,O,O
explanation,O,O
for,O,O
the,O,O
beneficial,O,O
effects,O,O
observed,O,O
in,O,O
some,O,O
encephalopathic,O,O
patients,O,O
receiving,O,O
L,B,B
-,I,I
dopa,I,I
.,O,O
Etoposide,B,B
-,O,I
related,O,I
myocardial,O,I
infarction,O,I
.,O,O
The,O,O
occurrence,O,O
of,O,O
a,O,O
myocardial,O,I
infarction,O,I
is,O,O
reported,O,O
after,O,O
chemotherapy,O,O
containing,O,O
etoposide,B,B
",",O,O
in,O,O
a,O,O
man,O,O
with,O,O
no,O,O
risk,O,O
factors,O,O
for,O,O
coronary,O,O
heart,O,O
disease,O,O
.,O,O
Possible,O,O
causal,O,O
mechanisms,O,O
are,O,O
discussed,O,O
.,O,O
Halogenated,O,B
anesthetics,O,I
form,O,O
liver,O,O
adducts,O,O
and,O,O
antigens,O,O
that,O,O
cross,O,O
-,O,O
react,O,O
with,O,O
halothane,B,B
-,O,O
induced,O,O
antibodies,O,O
.,O,O
Two,O,O
halogenated,O,B
anesthetics,O,I
",",O,O
enflurane,B,B
and,O,O
isoflurane,B,B
",",O,O
have,O,O
been,O,O
associated,O,O
with,O,O
an,O,O
allergic,O,O
-,O,O
type,O,O
hepatic,O,O
injury,O,O
both,O,O
alone,O,O
and,O,O
following,O,O
previous,O,O
exposure,O,O
to,O,O
halothane,B,B
.,O,O
Halothane,B,B
hepatitis,O,I
appears,O,O
to,O,O
involve,O,O
an,O,O
aberrant,O,O
immune,O,O
response,O,O
.,O,O
An,O,O
antibody,O,O
response,O,O
to,O,O
a,O,O
protein,O,O
-,O,O
bound,O,O
biotransformation,O,O
product,O,O
(,O,O
trifluoroacetyl,B,B
adduct,O,I
),O,O
has,O,O
been,O,O
detected,O,O
on,O,O
halothane,B,B
hepatitis,O,I
patients,O,O
.,O,O
This,O,O
study,O,O
was,O,O
performed,O,O
to,O,O
determine,O,O
cross,O,O
-,O,O
reactivity,O,O
between,O,O
enflurane,B,B
and,O,O
isoflurane,B,B
with,O,O
the,O,O
hypersensitivity,O,O
induced,O,O
by,O,O
halothane,B,B
.,O,O
The,O,O
subcellular,O,O
and,O,O
lobular,O,O
production,O,O
of,O,O
hepatic,O,O
neoantigens,O,B
recognized,O,O
by,O,O
halothane,B,O
-,O,O
induced,O,O
antibodies,O,O
following,O,O
enflurane,B,O
and,O,O
isoflurane,B,O
",",O,O
and,O,O
the,O,O
biochemical,O,O
nature,O,O
of,O,O
these,O,O
neoantigens,O,B
was,O,O
investigated,O,O
in,O,O
two,O,O
animal,O,O
models,O,O
.,O,O
Enflurane,B,O
administration,O,O
resulted,O,O
in,O,O
neoantigens,O,B
detected,O,O
in,O,O
both,O,O
the,O,O
microsomal,O,O
and,O,O
cytosolic,O,O
fraction,O,O
of,O,O
liver,O,O
homogenates,O,O
and,O,O
in,O,O
the,O,O
centrilobular,O,O
region,O,O
of,O,O
the,O,O
liver,O,O
.,O,O
In,O,O
the,O,O
same,O,O
liver,O,B
",",O,O
biochemical,O,O
analysis,O,O
detected,O,O
fluorinated,O,B
liver,O,I
adducts,O,I
that,O,O
were,O,O
up,O,O
to,O,O
20,O,O
-,O,O
fold,O,O
greater,O,O
in,O,O
guinea,O,O
pigs,O,O
than,O,O
in,O,O
rats,O,O
.,O,O
This,O,O
supports,O,O
and,O,O
extends,O,O
previous,O,O
evidence,O,O
for,O,O
a,O,O
mechanism,O,O
by,O,O
which,O,O
enflurane,B,B
and,O,O
/,O,O
or,O,O
isoflurane,B,B
could,O,O
produce,O,O
a,O,O
hypersensitivity,O,O
condition,O,O
similar,O,O
to,O,O
that,O,O
of,O,O
halothane,B,B
hepatitis,O,I
either,O,O
alone,O,O
or,O,O
subsequent,O,O
to,O,O
halothane,B,B
administration,O,O
.,O,O
The,O,O
guinea,O,B
pig,O,I
would,O,O
appear,O,O
to,O,O
be,O,O
a,O,O
useful,O,O
model,O,O
for,O,O
further,O,O
investigations,O,O
of,O,O
the,O,O
immunological,O,O
response,O,O
to,O,O
these,O,O
antigens,O,B
.,O,O
Cholinergic,O,B
toxicity,O,O
resulting,O,O
from,O,O
ocular,O,O
instillation,O,O
of,O,O
echothiophate,B,B
iodide,I,I
eye,O,I
drops,O,I
.,O,O
A,O,O
patient,O,O
developed,O,O
a,O,O
severe,O,O
cholinergic,O,B
syndrome,O,O
from,O,O
the,O,O
use,O,O
of,O,O
echothiophate,B,B
iodide,I,I
ophthalmic,O,I
drops,O,I
",",O,O
presented,O,O
with,O,O
profound,O,O
muscle,O,O
weakness,O,O
and,O,O
was,O,O
initially,O,O
given,O,O
the,O,O
diagnosis,O,O
of,O,O
myasthenia,O,B
gravis,O,I
.,O,O
Red,O,O
blood,O,O
cell,O,O
and,O,O
serum,O,O
cholinesterase,O,B
levels,O,O
were,O,O
severely,O,O
depressed,O,O
and,O,O
symptoms,O,O
resolved,O,O
spontaneously,O,O
following,O,O
discontinuation,O,O
of,O,O
the,O,O
eye,O,O
drops,O,O
.,O,O
Seizure,O,O
after,O,O
flumazenil,B,B
administration,O,O
in,O,O
a,O,O
pediatric,O,O
patient,O,O
.,O,O
Flumazenil,B,B
is,O,O
a,O,O
benzodiazepine,B,B
receptor,O,O
antagonist,O,O
used,O,O
to,O,O
reverse,O,O
sedation,O,O
and,O,O
respiratory,O,O
depression,O,O
induced,O,O
by,O,O
benzodiazepines,B,O
.,O,O
Seizures,O,O
and,O,O
cardiac,O,O
arrhythmias,O,O
have,O,O
complicated,O,O
its,O,O
use,O,O
in,O,O
adult,O,O
patients,O,O
.,O,O
Overdose,O,O
patients,O,O
who,O,O
have,O,O
coingested,O,O
tricyclic,O,B
antidepressants,O,I
have,O,O
a,O,O
higher,O,O
risk,O,O
of,O,O
these,O,O
complications,O,O
.,O,O
Little,O,O
information,O,O
exists,O,O
concerning,O,O
adverse,O,O
effects,O,O
of,O,O
flumazenil,B,B
in,O,O
children,O,O
.,O,O
We,O,O
report,O,O
the,O,O
occurrence,O,O
of,O,O
a,O,O
generalized,O,O
tonic,O,O
-,O,O
clonic,O,O
seizure,O,O
in,O,O
a,O,O
pediatric,O,O
patient,O,O
following,O,O
the,O,O
administration,O,O
of,O,O
flumazenil,B,B
.,O,O
Phase,O,O
I,O,O
trial,O,O
of,O,O
13,B,B
-,I,I
cis,I,I
-,I,I
retinoic,I,I
acid,I,I
in,O,O
children,O,O
with,O,O
neuroblastoma,O,O
following,O,O
bone,O,O
marrow,O,O
transplantation,O,O
.,O,O
PURPOSE,O,O
:,O,O
Treatment,O,O
of,O,O
neuroblastoma,O,O
cell,O,O
lines,O,O
with,O,O
13,B,B
-,I,I
cis,I,I
-,I,I
retinoic,I,I
acid,I,I
(,O,O
cis,B,B
-,I,I
RA,I,I
),O,O
can,O,O
cause,O,O
sustained,O,O
inhibition,O,O
of,O,O
proliferation,O,O
.,O,O
Since,O,O
cis,B,B
-,I,I
RA,I,I
has,O,O
demonstrated,O,O
clinical,O,O
responses,O,O
in,O,O
neuroblastoma,O,O
patients,O,O
",",O,O
it,O,O
may,O,O
be,O,O
effective,O,O
in,O,O
preventing,O,O
relapse,O,O
after,O,O
cytotoxic,O,O
therapy,O,O
.,O,O
This,O,O
phase,O,O
I,O,O
trial,O,O
was,O,O
designed,O,O
to,O,O
determine,O,O
the,O,O
maximal,O,O
-,O,O
tolerated,O,O
dosage,O,O
(,O,O
MTD,O,B
),O,O
",",O,O
toxicities,O,O
",",O,O
and,O,O
pharmacokinetics,O,O
of,O,O
cis,B,B
-,I,O
RA,I,I
administered,O,O
on,O,O
an,O,O
intermittent,O,O
schedule,O,O
in,O,O
children,O,O
with,O,O
neuroblastoma,O,O
following,O,O
bone,O,O
marrow,O,O
transplantation,O,O
(,O,O
BMT,O,B
),O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
Fifty,O,O
-,O,O
one,O,O
assessable,O,O
patients,O,O
",",O,O
2,O,O
to,O,O
12,O,O
years,O,O
of,O,O
age,O,O
",",O,O
were,O,O
treated,O,O
with,O,O
oral,O,O
cis,B,B
-,I,O
RA,I,I
administered,O,O
in,O,O
two,O,O
equally,O,O
divided,O,O
doses,O,O
daily,O,O
for,O,O
2,O,O
weeks,O,O
",",O,O
followed,O,O
by,O,O
a,O,O
2,O,O
-,O,O
week,O,O
rest,O,O
period,O,O
",",O,O
for,O,O
up,O,O
to,O,O
12,O,O
courses,O,O
.,O,O
The,O,O
dose,O,O
was,O,O
escalated,O,O
from,O,O
100,O,O
to,O,O
200,O,B
mg,O,I
/,O,I
m2,O,I
/,O,I
d,O,I
until,O,O
dose,O,O
-,O,O
limiting,O,O
toxicity,O,O
(,O,O
DLT,O,O
),O,O
was,O,O
observed,O,O
.,O,O
A,O,O
single,O,O
intrapatient,O,O
dose,O,O
escalation,O,O
was,O,O
permitted,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
MTD,O,O
of,O,O
cis,B,B
-,I,I
RA,I,I
was,O,O
160,O,B
mg,O,I
/,O,I
m2,O,I
/,O,I
d,O,I
.,O,O
Dose,O,O
-,O,O
limiting,O,O
toxicities,O,O
in,O,O
six,O,O
of,O,O
nine,O,O
patients,O,O
at,O,O
200,O,B
mg,O,I
/,O,I
m2,O,I
/,O,I
d,O,I
included,O,O
hypercalcemia,O,B
(,O,O
n,O,O
=,O,O
3,O,O
),O,O
",",O,O
rash,O,B
(,O,O
n,O,O
=,O,O
2,O,O
),O,O
",",O,O
and,O,O
anemia,O,B
/,O,I
thrombocytopenia,O,I
/,O,I
emesis,O,I
/,O,I
rash,O,I
(,O,O
n,O,O
=,O,O
1,O,O
),O,O
.,O,O
All,O,O
toxicities,O,O
resolved,O,O
after,O,O
cis,B,B
-,I,I
RA,I,I
was,O,O
discontinued,O,O
.,O,O
Three,O,O
complete,O,O
responses,O,O
were,O,O
observed,O,O
in,O,O
marrow,O,O
metastases,O,O
.,O,O
Serum,O,O
levels,O,O
of,O,O
7,O,O
.,O,O
4,O,B
+,O,O
/,O,O
-,O,O
3,O,I
.,O,O
0,O,I
mumol,O,I
/,O,I
L,O,I
(,O,O
peak,O,O
),O,O
and,O,O
4,O,B
.,O,O
0,O,I
+,O,O
/,O,O
-,O,O
2,O,I
.,O,O
8,O,I
mumol,O,I
/,O,I
L,O,I
(,O,O
trough,O,O
),O,O
at,O,O
the,O,O
MTD,O,O
were,O,O
maintained,O,O
during,O,O
14,O,O
days,O,O
of,O,O
therapy,O,O
.,O,O
The,O,O
DLT,O,O
correlated,O,O
with,O,O
serum,O,O
levels,O,O
>,O,O
or,O,O
=,O,O
10,O,O
mumol,O,I
/,O,I
L,O,I
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
MTD,O,O
of,O,O
cis,B,B
-,I,I
RA,I,I
given,O,O
on,O,O
this,O,O
intermittent,O,O
schedule,O,O
was,O,O
160,O,O
mg,O,O
/,O,O
m2,O,O
/,O,O
d,O,O
.,O,O
Serum,O,O
levels,O,O
known,O,O
to,O,O
be,O,O
effective,O,O
against,O,O
neuroblastoma,O,O
in,O,O
vitro,O,O
were,O,O
achieved,O,O
at,O,O
this,O,O
dose,O,O
.,O,O
The,O,O
DLT,O,O
included,O,O
hypercalcemia,O,B
",",O,O
and,O,O
may,O,O
be,O,O
predicted,O,O
by,O,O
serum,O,O
cis,B,B
-,I,I
RA,I,I
levels,O,O
.,O,O
Monitoring,O,O
of,O,O
serum,O,O
calcium,B,B
and,O,O
cis,B,B
-,I,I
RA,I,I
levels,O,O
is,O,O
indicated,O,O
in,O,O
future,O,O
trials,O,O
.,O,O
Time,O,O
dependence,O,O
of,O,O
plasma,O,O
malondialdehyde,B,B
",",O,O
oxypurines,B,B
",",O,O
and,O,O
nucleosides,B,B
during,O,O
incomplete,O,O
cerebral,O,O
ischemia,O,O
in,O,O
the,O,O
rat,O,O
.,O,O
Incomplete,O,O
cerebral,O,O
ischemia,O,O
(,O,O
30,O,O
min,O,O
),O,O
was,O,O
induced,O,O
in,O,O
the,O,O
rat,O,O
by,O,O
bilaterally,O,O
clamping,O,O
the,O,O
common,O,O
carotid,O,O
arteries,O,O
.,O,O
Peripheral,O,O
venous,O,O
blood,O,O
samples,O,O
were,O,O
withdrawn,O,O
from,O,O
the,O,O
femoral,O,O
vein,O,O
four,O,O
times,O,O
(,O,O
once,O,O
every,O,O
5,O,O
min,O,O
),O,O
before,O,O
ischemia,O,O
(,O,O
0,O,O
time,O,O
),O,O
and,O,O
5,O,O
",",O,O
15,O,O
",",O,O
and,O,O
30,O,O
min,O,O
after,O,O
ischemia,O,O
.,O,O
Plasma,O,B
extracts,O,O
were,O,O
analyzed,O,O
by,O,O
a,O,O
highly,O,O
sensitive,O,O
high,O,O
-,O,O
performance,O,O
liquid,O,O
chromatographic,O,O
method,O,O
for,O,O
the,O,O
direct,O,O
determination,O,O
of,O,O
malondialdehyde,B,B
",",O,O
oxypurines,B,B
",",O,O
and,O,O
nucleosides,B,B
.,O,O
During,O,O
ischemia,O,O
",",O,O
a,O,O
time,O,O
-,O,O
dependent,O,O
increase,O,O
of,O,O
plasma,O,B
oxypurines,B,B
and,O,O
nucleosides,B,B
was,O,O
observed,O,O
.,O,O
Plasma,O,B
malondialdehyde,B,B
",",O,O
which,O,O
was,O,O
present,O,O
in,O,O
minimal,O,O
amount,O,O
at,O,O
zero,O,O
time,O,O
(,O,O
0,O,O
.,O,O
mumol,O,B
/,O,I
liter,O,I
plasma,O,I
;,O,O
SD,O,O
0,O,O
.,O,O
),O,O
",",O,O
increased,O,O
after,O,O
5,O,O
min,O,O
of,O,O
ischemia,O,B
",",O,O
resulting,O,O
in,O,O
a,O,O
fivefold,O,O
increase,O,O
after,O,O
30,O,O
min,O,O
of,O,O
carotid,O,O
occlusion,O,O
(,O,O
0,O,O
.,O,O
298,O,O
mumol,O,B
/,O,I
liter,O,I
plasma,O,I
;,O,O
SD,O,O
0,O,O
.,O,O
),O,O
.,O,O
Increased,O,O
plasma,O,I
malondialdehyde,B,B
was,O,O
also,O,O
recorded,O,O
in,O,O
two,O,O
other,O,O
groups,O,O
of,O,O
animals,O,O
subjected,O,O
to,O,O
the,O,O
same,O,O
experimental,O,O
model,O,O
",",O,O
one,O,O
receiving,O,O
20,O,O
mg,O,O
/,O,O
kg,O,O
b,O,O
.,O,O
w,O,O
.,O,O
of,O,O
the,O,O
cyclooxygenase,O,B
inhibitor,O,O
acetylsalicylate,B,B
intravenously,O,O
immediately,O,O
before,O,O
ischemia,O,O
",",O,O
the,O,O
other,O,O
receiving,O,O
650,O,O
micrograms,O,O
/,O,O
kg,O,O
b,O,O
.,O,O
w,O,O
.,O,O
of,O,O
the,O,O
hypotensive,O,O
drug,O,O
nitroprusside,B,B
at,O,O
a,O,O
flow,O,O
rate,O,O
of,O,O
103,O,O
microliters,O,O
/,O,O
min,O,O
intravenously,O,O
during,O,O
ischemia,O,O
",",O,O
although,O,O
in,O,O
this,O,O
latter,O,O
group,O,O
malondialdehyde,B,B
was,O,O
significantly,O,O
higher,O,O
.,O,O
The,O,O
present,O,O
data,O,O
indicate,O,O
that,O,O
the,O,O
determination,O,O
of,O,O
malondialdehyde,B,B
",",O,O
oxypurines,B,B
",",O,O
and,O,O
nucleosides,B,B
in,O,O
peripheral,O,O
blood,O,O
",",O,O
may,O,O
be,O,O
used,O,O
to,O,O
monitor,O,O
the,O,O
metabolic,O,O
alterations,O,O
of,O,O
tissues,O,O
occurring,O,O
during,O,O
ischemic,O,O
phenomena,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
Acute,O,O
renal,O,O
toxicity,O,O
of,O,O
doxorubicin,B,B
(,O,O
adriamycin,B,I
),O,O
-,O,O
loaded,O,O
cyanoacrylate,B,B
nanoparticles,O,O
.,O,O
Acute,O,O
doxorubicin,B,B
-,O,O
loaded,O,O
nanoparticle,O,O
(,O,O
DXNP,O,B
),O,O
renal,O,O
toxicity,O,O
was,O,O
explored,O,O
in,O,O
both,O,O
normal,O,O
rats,O,O
and,O,O
rats,O,O
with,O,O
experimental,O,O
glomerulonephritis,O,O
.,O,O
In,O,O
normal,O,O
rats,O,O
",",O,O
2,O,O
/,O,O
6,O,O
rats,O,O
given,O,O
free,O,O
doxorubicin,B,B
(,O,O
DX,B,B
),O,O
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
died,O,O
within,O,O
one,O,O
week,O,O
",",O,O
whereas,O,O
all,O,O
control,O,O
animals,O,O
and,O,O
all,O,O
rats,O,O
having,O,O
received,O,O
free,O,O
NP,O,B
or,O,O
DXNP,O,B
survived,O,O
.,O,O
A,O,O
3,O,O
times,O,O
higher,O,O
proteinuria,O,O
appeared,O,O
in,O,O
animals,O,O
treated,O,O
with,O,O
DXNP,O,B
than,O,O
in,O,O
those,O,O
treated,O,O
with,O,O
DX,B,B
.,O,O
Free,O,O
NP,O,B
did,O,O
not,O,O
provoke,O,O
any,O,O
proteinuria,O,O
.,O,O
Two,O,O
hr,O,O
post,O,O
-,O,O
injection,O,O
",",O,O
DXNP,O,B
was,O,O
2,O,O
.,O,O
7,O,O
times,O,O
more,O,O
concentrated,O,O
in,O,O
kidneys,O,O
than,O,O
free,O,O
DX,B,B
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
In,O,O
rats,O,O
with,O,O
immune,O,O
experimental,O,O
glomerulonephritis,O,O
",",O,O
5,O,O
/,O,O
6,O,O
rats,O,O
given,O,O
DX,B,B
died,O,O
within,O,O
7,O,O
days,O,O
",",O,O
in,O,O
contrast,O,O
to,O,O
animals,O,O
treated,O,O
by,O,O
DXNP,O,B
",",O,O
NP,O,B
",",O,O
or,O,O
untreated,O,O
",",O,O
which,O,O
all,O,O
survived,O,O
.,O,O
Proteinuria,O,O
appeared,O,O
in,O,O
all,O,O
series,O,O
",",O,O
but,O,O
was,O,O
2,O,O
-,O,O
5,O,O
times,O,O
more,O,O
intense,O,O
(,O,O
p,O,O
>,O,O
0,O,O
.,O,O
),O,O
and,O,O
prolonged,O,O
after,O,O
doxorubicin,B,B
treatment,O,O
(,O,O
400,O,O
-,O,O
700,O,O
mg,O,O
/,O,O
day,O,O
),O,O
",",O,O
without,O,O
significant,O,O
difference,O,O
between,O,O
DXNP,O,B
and,O,O
DX,B,B
.,O,O
Rats,O,O
treated,O,O
by,O,O
unloaded,O,O
NP,O,B
behaved,O,O
as,O,O
controls,O,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
that,O,O
",",O,O
in,O,O
these,O,O
experimental,O,O
conditions,O,O
",",O,O
DXNP,O,B
killed,O,O
less,O,O
animals,O,O
than,O,O
free,O,O
DX,B,B
",",O,O
despite,O,O
of,O,O
an,O,O
enhanced,O,O
renal,O,O
toxicity,O,O
of,O,O
the,O,O
former,O,O
.,O,O
Both,O,O
effects,O,O
(,O,O
better,O,O
survival,O,O
and,O,O
nephrosis,O,O
),O,O
are,O,O
most,O,O
probably,O,O
related,O,O
to,O,O
an,O,O
enhanced,O,O
capture,O,O
of,O,O
DXNP,O,B
by,O,O
cells,O,O
of,O,O
the,O,O
mononuclear,O,O
phagocyte,O,O
system,O,O
",",O,O
including,O,O
mesangial,O,O
cells,O,O
.,O,O
Prostaglandin,B,B
E2,I,I
-,O,I
induced,O,I
bladder,O,I
hyperactivity,O,I
in,O,O
normal,O,O
",",O,O
conscious,O,O
rats,O,O
:,O,O
involvement,O,O
of,O,O
tachykinins,B,O
?,O,O
In,O,O
normal,O,O
conscious,O,O
rats,O,O
investigated,O,O
by,O,O
continuous,O,O
cystometry,O,O
",",O,O
intravesically,O,O
instilled,O,O
prostaglandin,B,B
(,I,I
PG,I,I
),I,I
E2,I,I
facilitated,O,I
micturition,O,I
and,O,I
increased,O,I
basal,O,I
intravesical,O,I
pressure,O,I
.,O,O
The,O,O
effect,O,O
was,O,O
attenuated,O,O
by,O,O
both,O,O
the,O,O
NK1,O,B
receptor,O,O
selective,O,O
antagonist,O,O
RP,B,B
67,I,I
",",I,O
580,I,I
and,O,O
the,O,O
NK2,O,B
receptor,O,O
selective,O,O
antagonist,O,O
SR,B,B
48,I,I
",",I,O
968,I,I
",",O,O
given,O,O
intra,O,O
-,O,O
arterially,O,O
",",O,O
suggesting,O,O
that,O,O
it,O,O
was,O,O
mediated,O,O
by,O,O
stimulation,O,O
of,O,O
both,O,O
NK1,O,B
and,O,O
NK2,O,B
receptors,O,O
.,O,O
Intra,O,O
-,O,O
arterially,O,O
given,O,O
PGE2,B,B
produced,O,O
a,O,O
distinct,O,O
increase,O,O
in,O,O
bladder,O,O
pressure,O,O
before,O,O
initiating,O,O
a,O,O
micturition,O,O
reflex,O,O
",",O,O
indicating,O,O
that,O,O
the,O,O
PG,B,B
had,O,O
a,O,O
direct,O,O
contractant,O,O
effect,O,O
on,O,O
the,O,O
detrusor,O,O
smooth,O,O
muscle,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
intra,O,O
-,O,O
arterial,O,O
PGE2,B,B
could,O,O
not,O,O
be,O,O
blocked,O,O
by,O,O
intra,O,O
-,O,O
arterial,O,O
RP,B,B
67,I,I
",",I,O
580,I,I
or,O,O
SR,B,B
48,I,I
",",I,O
968,I,I
",",O,O
which,O,O
opens,O,O
the,O,O
possibility,O,O
that,O,O
the,O,O
micturition,O,O
reflex,O,O
elicited,O,O
by,O,O
intra,O,O
-,O,O
arterial,O,O
PGE2,B,B
was,O,O
mediated,O,O
by,O,O
pathways,O,O
other,O,O
than,O,O
the,O,O
reflex,O,O
initiated,O,O
when,O,O
the,O,O
PG,B,B
was,O,O
given,O,O
intravesically,O,O
.,O,O
The,O,O
present,O,O
results,O,O
thus,O,O
suggest,O,O
that,O,O
intra,O,O
-,O,O
arterial,O,O
PGE2,B,B
",",O,O
given,O,O
near,O,O
the,O,O
bladder,O,O
",",O,O
may,O,O
initiate,O,O
micturition,O,O
in,O,O
the,O,O
normal,O,O
rat,O,O
chiefly,O,O
by,O,O
directly,O,O
contracting,O,O
the,O,O
smooth,O,O
muscle,O,O
of,O,O
the,O,O
detrusor,O,O
.,O,O
However,O,O
",",O,O
when,O,O
given,O,O
intravesically,O,O
",",O,O
PGE2,B,B
may,O,O
stimulate,O,O
micturition,O,O
by,O,O
releasing,O,O
tachykinins,B,B
from,O,O
nerves,O,O
in,O,O
and,O,O
/,O,O
or,O,O
immediately,O,O
below,O,O
the,O,O
urothelium,O,O
.,O,O
These,O,O
tachykinins,B,B
",",O,O
in,O,O
turn,O,O
",",O,O
initiate,O,O
a,O,O
micturition,O,O
reflex,O,O
by,O,O
stimulating,O,O
NK1,O,B
and,O,O
NK2,O,B
receptors,O,O
.,O,O
Prostanoids,B,B
may,O,O
",",O,O
via,O,O
release,O,O
of,O,O
tachykinins,B,B
",",O,O
contribute,O,O
to,O,O
both,O,O
urge,O,O
and,O,O
bladder,O,O
hyperactivity,O,O
seen,O,O
in,O,O
inflammatory,O,O
conditions,O,O
of,O,O
the,O,O
lower,O,O
urinary,O,O
tract,O,O
.,O,O
Refractory,O,O
cardiogenic,O,O
shock,O,O
and,O,O
complete,O,O
heart,O,O
block,O,O
after,O,O
verapamil,B,B
SR,O,I
and,O,O
metoprolol,B,B
treatment,O,O
.,O,O
A,O,O
case,O,O
report,O,O
.,O,O
A,O,O
seventy,O,O
-,O,O
eight,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
presented,O,O
with,O,O
complete,O,O
heart,O,O
block,O,O
and,O,O
refractory,O,O
hypotension,O,O
two,O,O
days,O,O
after,O,O
a,O,O
therapeutic,O,O
dose,O,O
of,O,O
sustained,O,O
-,O,O
release,O,O
verapamil,B,B
with,O,O
concomitant,O,O
use,O,O
of,O,O
metoprolol,B,B
.,O,O
The,O,O
patient,O,O
continued,O,O
to,O,O
remain,O,O
hypotensive,O,O
with,O,O
complete,O,O
heart,O,O
block,O,O
",",O,O
even,O,O
with,O,O
multiple,O,O
uses,O,O
of,O,O
intravenous,O,O
atropine,B,B
as,O,O
well,O,O
as,O,O
high,O,O
doses,O,O
of,O,O
pressor,O,O
agents,O,O
such,O,O
as,O,O
dopamine,B,B
and,O,O
dobutamine,B,B
.,O,O
However,O,O
",",O,O
shortly,O,O
after,O,O
the,O,O
use,O,O
of,O,O
intravenous,O,O
calcium,B,B
chloride,I,I
",",O,O
the,O,O
refractory,O,O
hypotension,O,O
and,O,O
complete,O,O
heart,O,O
block,O,O
resolved,O,O
.,O,O
Protective,O,O
effect,O,O
of,O,O
misoprostol,B,B
on,O,O
indomethacin,B,B
induced,O,O
renal,O,O
dysfunction,O,O
in,O,O
elderly,O,O
patients,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
possible,O,O
protective,O,O
effects,O,O
of,O,O
misoprostol,B,B
on,O,O
renal,O,O
function,O,O
in,O,O
hospitalized,O,O
elderly,O,O
patients,O,O
treated,O,O
with,O,O
indomethacin,B,B
.,O,O
METHODS,O,O
:,O,O
Forty,O,O
-,O,O
five,O,O
hospitalized,O,O
elderly,O,O
patients,O,O
(,O,O
>,O,O
65,O,O
years,O,O
old,O,O
),O,O
who,O,O
required,O,O
therapy,O,O
with,O,O
nonsteroidal,O,O
antiinflammatory,O,O
drugs,O,O
(,O,O
NSAID,O,B
),O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
receive,O,O
either,O,O
indomethacin,B,B
",",O,O
150,O,O
mg,O,O
/,O,O
day,O,O
(,O,O
Group,O,O
A,O,O
),O,O
",",O,O
or,O,O
indomethacin,B,B
150,O,O
mg,O,O
/,O,O
day,O,O
plus,O,O
misoprostol,B,B
at,O,O
0,O,O
.,O,O
6,O,O
mg,O,O
/,O,O
day,O,O
(,O,O
Group,O,O
B,O,O
),O,O
.,O,O
Laboratory,O,O
variables,O,O
of,O,O
renal,O,O
function,O,O
[,O,O
serum,O,B
creatinine,B,I
",",O,O
blood,B,B
urea,I,I
nitrogen,I,I
(,O,O
BUN,B,B
),O,O
and,O,O
electrolytes,O,B
],O,O
were,O,O
evaluated,O,O
before,O,O
initiation,O,O
of,O,O
therapy,O,O
and,O,O
every,O,O
2,O,O
days,O,O
",",O,O
until,O,O
termination,O,O
of,O,O
the,O,O
study,O,O
(,O,O
a,O,O
period,O,O
of,O,O
at,O,O
least,O,O
6,O,O
days,O,O
),O,O
.,O,O
Response,O,O
to,O,O
treatment,O,O
was,O,O
estimated,O,O
by,O,O
the,O,O
visual,O,O
analog,O,O
scale,O,O
for,O,O
severity,O,O
of,O,O
pain,O,O
.,O,O
RESULTS,O,O
:,O,O
Forty,O,O
-,O,O
two,O,O
patients,O,O
completed,O,O
the,O,O
study,O,O
",",O,O
22,O,O
in,O,O
Group,O,O
A,O,O
and,O,O
20,O,O
in,O,O
Group,O,O
B,O,O
.,O,O
BUN,B,B
and,O,O
creatinine,B,B
increased,O,O
by,O,O
>,O,O
50,O,O
%,O,O
of,O,O
baseline,O,O
levels,O,O
in,O,O
54,O,O
and,O,O
45,O,O
%,O,O
of,O,O
Group,O,O
A,O,O
patients,O,O
",",O,O
respectively,O,O
",",O,O
compared,O,O
to,O,O
only,O,O
20,O,O
and,O,O
10,O,O
%,O,O
of,O,O
Group,O,O
B,O,O
patients,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Potassium,B,B
(,O,O
K,B,B
),O,O
increment,O,O
of,O,O
0,O,O
.,O,O
6,O,O
mEq,O,O
/,O,O
l,O,O
or,O,O
more,O,O
was,O,O
observed,O,O
in,O,O
50,O,O
%,O,O
of,O,O
Group,O,O
A,O,O
",",O,O
but,O,O
in,O,O
only,O,O
15,O,O
%,O,O
of,O,O
Group,O,O
B,O,O
patients,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
mean,O,O
increments,O,O
in,O,O
BUN,B,B
",",O,O
creatinine,B,B
",",O,O
and,O,O
K,B,B
were,O,O
reduced,O,O
by,O,O
63,O,O
",",O,O
80,O,O
",",O,O
and,O,O
42,O,O
%,O,O
",",O,O
respectively,O,O
",",O,O
in,O,O
Group,O,O
B,O,O
patients,O,O
compared,O,O
to,O,O
Group,O,O
A,O,O
.,O,O
Response,O,O
to,O,O
treatment,O,O
did,O,O
not,O,O
differ,O,O
significantly,O,O
between,O,O
the,O,O
2,O,O
groups,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Hospitalized,O,O
elderly,O,O
patients,O,O
are,O,O
at,O,O
risk,O,O
for,O,O
developing,O,O
indomethacin,B,B
related,O,O
renal,O,B
dysfunction,O,O
.,O,O
Addition,O,O
of,O,O
misoprostol,B,B
can,O,O
minimize,O,O
this,O,O
renal,O,O
impairment,O,O
without,O,O
affecting,O,O
pain,O,O
control,O,O
.,O,O
Cognitive,O,O
deterioration,O,O
from,O,O
long,O,O
-,O,O
term,O,O
abuse,O,O
of,O,O
dextromethorphan,B,B
:,O,O
a,O,O
case,O,O
report,O,O
.,O,O
Dextromethorphan,B,B
(,O,O
DM,B,B
),O,O
",",O,O
the,O,O
dextrorotatory,O,O
isomer,O,O
of,O,O
3,B,O
-,I,O
hydroxy,I,B
-,I,I
N,I,I
-,I,I
methylmorphinan,I,I
",",O,O
is,O,O
the,O,O
main,O,O
ingredient,O,O
in,O,O
a,O,O
number,O,O
of,O,O
widely,O,O
available,O,O
",",O,O
over,O,O
-,O,O
the,O,O
-,O,O
counter,O,O
antitussives,O,O
.,O,O
Initial,O,O
studies,O,O
(,O,O
Bornstein,O,B
1968,O,O
),O,O
showed,O,O
that,O,O
it,O,O
possessed,O,O
no,O,O
respiratory,O,O
suppressant,O,O
effects,O,O
and,O,O
no,O,O
addiction,O,O
liability,O,O
.,O,O
Subsequently,O,O
",",O,O
however,O,O
",",O,O
several,O,O
articles,O,O
reporting,O,O
abuse,O,O
of,O,O
this,O,O
drug,O,B
have,O,O
appeared,O,O
in,O,O
the,O,O
literature,O,O
.,O,O
The,O,O
drug,O,B
is,O,O
known,O,O
to,O,O
cause,O,O
a,O,O
variety,O,O
of,O,O
acute,O,O
toxic,O,O
effects,O,O
",",O,O
ranging,O,O
from,O,O
nausea,O,B
",",O,O
restlessness,O,B
",",O,O
insomnia,O,B
",",O,O
ataxia,O,B
",",O,O
slurred,O,B
speech,O,I
and,O,O
nystagmus,O,B
to,O,O
mood,O,B
changes,O,I
",",O,O
perceptual,O,B
alterations,O,I
",",O,O
inattention,O,B
",",O,O
disorientation,O,B
and,O,O
aggressive,O,B
behavior,O,I
(,O,O
Rammer,O,B
et,O,I
al,O,I
1988,O,O
;,O,O
Katona,O,B
and,O,I
Watson,O,I
1986,O,O
;,O,O
Isbell,O,B
and,O,I
Fraser,O,I
1953,O,O
;,O,O
Devlin,O,B
et,O,I
al,O,I
1985,O,O
;,O,O
McCarthy,O,B
1971,O,O
;,O,O
Dodds,O,B
and,O,I
Revai,O,I
1967,O,O
;,O,O
Degkwitz,O,B
1964,O,O
;,O,O
Hildebrand,O,B
et,O,I
al,O,I
1989,O,O
),O,O
.,O,O
There,O,O
have,O,O
also,O,O
been,O,O
two,O,O
reported,O,O
fatalities,O,O
from,O,O
DM,B,B
overdoses,O,O
(,O,O
Fleming,O,O
1986,O,O
),O,O
.,O,O
However,O,O
",",O,O
there,O,O
are,O,O
no,O,O
reports,O,O
describing,O,O
the,O,O
effects,O,O
of,O,O
chronic,O,O
abuse,O,O
.,O,O
This,O,O
report,O,O
describes,O,O
a,O,O
case,O,O
of,O,O
cognitive,O,O
deterioration,O,O
resulting,O,O
from,O,O
prolonged,O,O
use,O,O
of,O,O
DM,B,B
.,O,O
Effects,O,O
of,O,O
ouabain,B,B
on,O,O
myocardial,O,O
oxygen,B,O
supply,O,O
and,O,O
demand,O,O
in,O,O
patients,O,O
with,O,O
chronic,O,O
coronary,O,O
artery,O,O
disease,O,O
.,O,O
A,O,O
hemodynamic,O,O
",",O,O
volumetric,O,O
",",O,O
and,O,O
metabolic,O,O
study,O,O
in,O,O
patients,O,O
without,O,O
heart,O,O
failure,O,O
.,O,O
The,O,O
effects,O,O
of,O,O
digitalis,B,B
glycosides,I,I
on,O,O
myocardial,O,O
oxygen,B,O
supply,O,O
and,O,O
demand,O,O
are,O,O
of,O,O
particular,O,O
interest,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
obstructive,O,O
coronary,O,O
artery,O,O
disease,O,O
",",O,O
but,O,O
have,O,O
not,O,O
been,O,O
measured,O,O
previously,O,O
in,O,O
man,O,O
.,O,O
We,O,O
assessed,O,O
the,O,O
effects,O,O
of,O,O
ouabain,B,B
(,O,O
0,O,O
.,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
),O,O
on,O,O
hemodynamic,O,O
",",O,O
volumetric,O,O
",",O,O
and,O,O
metabolic,O,O
parameters,O,O
in,O,O
11,O,O
patients,O,O
with,O,O
severe,O,O
chronic,O,O
coronary,O,O
artery,O,O
disease,O,O
without,O,O
clinical,O,O
congestive,O,O
heart,O,O
failure,O,O
.,O,O
Because,O,O
the,O,O
protocol,O,O
was,O,O
long,O,O
and,O,O
involved,O,O
interventions,O,O
which,O,O
might,O,O
affect,O,O
the,O,O
determinations,O,O
",",O,O
we,O,O
also,O,O
studied,O,O
in,O,O
nine,O,O
patients,O,O
using,O,O
an,O,O
identical,O,O
protocol,O,O
except,O,O
that,O,O
ouabain,B,B
administration,O,O
was,O,O
omitted,O,O
.,O,O
Left,O,O
ventricular,O,O
end,O,O
-,O,O
diastolic,O,O
pressure,O,O
and,O,O
left,O,O
ventricular,O,O
end,O,O
-,O,O
diastolic,O,O
volume,O,O
fell,O,O
in,O,O
each,O,O
patient,O,O
given,O,O
ouabain,B,B
",",O,O
even,O,O
though,O,O
they,O,O
were,O,O
initially,O,O
elevated,O,O
in,O,O
only,O,O
two,O,O
patients,O,O
.,O,O
Left,O,O
ventricular,O,O
end,O,O
-,O,O
diastolic,O,O
pressure,O,O
fell,O,O
from,O,O
11,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
4,O,O
(,O,O
mean,O,O
+,O,O
/,O,O
-,O,O
SE,O,O
),O,O
to,O,O
5,O,O
.,O,O
6,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
9,O,O
mm,O,O
Hg,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
and,O,O
left,O,O
ventricular,O,O
end,O,O
-,O,O
diastolic,O,O
volume,O,O
fell,O,O
from,O,O
100,O,O
+,O,O
/,O,O
-,O,O
17,O,O
to,O,O
82,O,O
+,O,O
/,O,O
-,O,O
12,O,O
ml,O,O
/,O,O
m2,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
),O,O
1,O,O
h,O,O
after,O,O
ouabain,B,B
infusion,O,O
was,O,O
completed,O,O
.,O,O
The,O,O
maximum,O,O
velocity,O,O
of,O,O
contractile,O,O
element,O,O
shortening,O,O
increased,O,O
from,O,O
1,O,O
.,O,O
68,O,O
+,O,O
/,O,O
-,O,O
0,O,O
ml,O,O
/,O,O
s,O,O
to,O,O
2,O,O
.,O,O
18,O,O
+,O,O
/,O,O
-,O,O
0,O,O
21,O,O
muscle,O,O
-,O,O
lengths,O,O
/,O,O
s,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
),O,O
and,O,O
is,O,O
consistent,O,O
with,O,O
an,O,O
increase,O,O
in,O,O
contractility,O,O
.,O,O
No,O,O
significant,O,O
change,O,O
in,O,O
these,O,O
parameters,O,O
occurred,O,O
in,O,O
the,O,O
control,O,O
patients,O,O
.,O,O
No,O,O
significant,O,O
change,O,O
in,O,O
myocardial,O,O
oxygen,B,O
consumption,O,O
occurred,O,O
after,O,O
ouabain,B,B
administration,O,O
but,O,O
this,O,O
may,O,O
be,O,O
related,O,O
to,O,O
a,O,O
greater,O,O
decrease,O,O
in,O,O
mean,O,O
arterial,O,O
pressure,O,O
in,O,O
the,O,O
ouabain,B,B
patients,O,O
than,O,O
in,O,O
the,O,O
control,O,O
patients,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
in,O,O
patients,O,O
with,O,O
chronic,O,O
coronary,O,B
artery,O,I
disease,O,I
who,O,O
are,O,O
not,O,O
in,O,O
clinical,O,O
congestive,O,O
heart,O,O
failure,O,O
left,O,O
ventricular,O,O
end,O,O
-,O,O
diastolic,O,O
volume,O,O
falls,O,O
after,O,O
ouabain,B,B
administration,O,O
even,O,O
when,O,O
it,O,O
is,O,O
initially,O,O
normal,O,O
.,O,O
Though,O,O
this,O,O
fall,O,O
would,O,O
be,O,O
associated,O,O
with,O,O
a,O,O
decrease,O,O
in,O,O
wall,O,O
tension,O,O
",",O,O
and,O,O
",",O,O
therefore,O,O
",",O,O
of,O,O
myocardial,O,O
oxygen,B,O
consumption,O,O
",",O,O
it,O,O
may,O,O
not,O,O
be,O,O
of,O,O
sufficient,O,O
magnitude,O,O
to,O,O
prevent,O,O
a,O,O
net,O,O
increase,O,O
in,O,O
myocardial,O,O
oxygen,B,O
consumption,O,O
.,O,O
Nevertheless,O,O
",",O,O
compensatory,O,O
mechanisms,O,O
prevent,O,O
a,O,O
deterioration,O,O
of,O,O
resting,O,O
myocardial,O,O
metabolism,O,O
.,O,O
Dexamethasone,B,B
-,O,O
induced,O,O
ocular,O,B
hypertension,O,I
in,O,O
perfusion,O,O
-,O,O
cultured,O,O
human,O,O
eyes,O,O
.,O,O
PURPOSE,O,O
:,O,O
Glucocorticoid,O,B
administration,O,O
can,O,O
lead,O,O
to,O,O
the,O,O
development,O,O
of,O,O
ocular,O,B
hypertension,O,I
and,O,O
corticosteroid,O,B
glaucoma,O,I
in,O,O
a,O,O
subset,O,O
of,O,O
the,O,O
population,O,O
through,O,O
a,O,O
decrease,O,O
in,O,O
the,O,O
aqueous,O,B
humor,O,I
outflow,O,I
facility,O,I
.,O,O
The,O,O
purpose,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
determine,O,O
whether,O,O
glucocorticoid,O,B
treatment,O,O
can,O,O
directly,O,O
affect,O,O
the,O,O
outflow,O,O
facility,O,O
of,O,O
isolated,O,O
",",O,O
perfusion,O,O
-,O,O
cultured,O,O
human,O,O
eyes,O,O
.,O,O
METHODS,O,O
:,O,O
The,O,O
anterior,O,O
segments,O,O
of,O,O
human,O,O
donor,O,O
eyes,O,O
from,O,O
regional,O,O
eye,O,O
banks,O,O
were,O,O
placed,O,O
in,O,O
a,O,O
constant,O,O
flow,O,O
",",O,O
variable,O,O
pressure,O,O
perfusion,O,O
culture,O,O
system,O,O
.,O,O
Paired,O,O
eyes,O,O
were,O,O
perfused,O,O
in,O,O
serum,O,B
-,O,I
free,O,I
media,O,I
with,O,O
or,O,O
without,O,O
10,O,B
(,O,O
-,O,O
7,O,O
),O,O
M,O,O
dexamethasone,B,B
for,O,O
12,O,O
days,O,O
.,O,O
Intraocular,O,O
pressure,O,O
was,O,O
monitored,O,O
daily,O,O
.,O,O
After,O,O
incubation,O,O
",",O,O
the,O,O
eyes,O,O
were,O,O
morphologically,O,O
characterized,O,O
by,O,O
light,O,O
microscopy,O,O
",",O,O
transmission,O,O
and,O,O
scanning,O,O
electron,O,O
microscopy,O,O
",",O,O
and,O,O
scanning,O,O
laser,O,O
confocal,O,O
microscopy,O,O
.,O,O
RESULTS,O,O
:,O,O
A,O,O
significant,O,O
increase,O,O
in,O,O
intraocular,O,O
pressure,O,O
developed,O,O
in,O,O
13,O,O
of,O,O
the,O,O
44,O,O
pairs,O,O
of,O,O
eyes,O,O
perfused,O,O
with,O,O
dexamethasone,B,B
with,O,O
an,O,O
average,O,O
pressure,O,O
rise,O,O
of,O,O
17,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
8,O,O
mm,O,O
Hg,O,O
after,O,O
12,O,O
days,O,O
of,O,O
dexamethasone,B,B
exposure,O,O
The,O,O
contralateral,O,O
control,O,O
eyes,O,O
",",O,O
which,O,O
did,O,O
not,O,O
receive,O,O
dexamethasone,B,O
",",O,O
maintained,O,O
a,O,O
stable,O,O
intraocular,O,O
pressure,O,O
during,O,O
the,O,O
same,O,O
period,O,O
.,O,O
The,O,O
outflow,O,O
pathway,O,O
of,O,O
the,O,O
untreated,O,O
eyes,O,O
appeared,O,O
morphologically,O,O
normal,O,O
.,O,O
In,O,O
contrast,O,O
",",O,O
the,O,O
dexamethasone,B,B
-,O,I
treated,O,O
hypertensive,O,O
eyes,O,O
had,O,O
thickened,O,O
trabecular,O,O
beams,O,O
",",O,O
decreased,O,O
intertrabecular,O,O
spaces,O,O
",",O,O
thickened,O,O
juxtacanalicular,O,O
tissue,O,O
",",O,O
activated,O,O
trabecular,O,O
meshwork,O,O
cells,O,O
",",O,O
and,O,O
increased,O,O
amounts,O,O
of,O,O
amorphogranular,O,O
extracellular,O,O
material,O,O
",",O,O
especially,O,O
in,O,O
the,O,O
juxtacanalicular,O,O
tissue,O,O
and,O,O
beneath,O,O
the,O,O
endothelial,O,O
lining,O,O
of,O,O
the,O,O
canal,O,O
of,O,O
Schlemm,O,B
.,O,O
The,O,O
dexamethasone,B,B
-,O,O
treated,O,O
nonresponder,O,O
eyes,O,O
appeared,O,O
to,O,O
be,O,O
morphologically,O,O
similar,O,O
to,O,O
the,O,O
untreated,O,O
eyes,O,O
",",O,O
although,O,O
several,O,O
subtle,O,O
dexamethasone,B,B
-,O,O
induced,O,O
morphologic,O,O
changes,O,O
were,O,O
evident,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Dexamethasone,B,B
treatment,O,O
of,O,O
isolated,O,O
",",O,O
perfusion,O,O
-,O,O
cultured,O,O
human,O,O
eyes,O,O
led,O,O
to,O,O
the,O,O
generation,O,O
of,O,O
ocular,O,O
hypertension,O,O
in,O,O
approximately,O,O
30,O,O
%,O,O
of,O,O
the,O,O
dexamethasone,B,B
-,O,O
treated,O,O
eyes,O,O
.,O,O
Steroid,B,B
treatment,O,O
resulted,O,O
in,O,O
morphologic,O,O
changes,O,O
in,O,O
the,O,O
trabecular,O,B
meshwork,O,I
similar,O,O
to,O,O
those,O,O
reported,O,O
for,O,O
corticosteroid,O,B
glaucoma,O,I
and,O,O
open,O,B
angle,O,I
glaucoma,O,I
.,O,O
This,O,O
system,O,O
may,O,O
provide,O,O
an,O,O
acute,O,O
model,O,O
in,O,O
which,O,O
to,O,O
study,O,O
the,O,O
pathogenic,O,O
mechanisms,O,O
involved,O,O
in,O,O
steroid,O,B
glaucoma,O,I
and,O,O
primary,O,B
open,O,I
angle,O,I
glaucoma,O,I
.,O,O
Auditory,O,O
disturbance,O,O
associated,O,O
with,O,O
interscalene,O,B
brachial,O,I
plexus,O,I
block,O,I
.,O,O
We,O,O
performed,O,O
an,O,O
audiometric,O,O
study,O,O
in,O,O
20,O,O
patients,O,O
who,O,O
underwent,O,O
surgery,O,O
of,O,O
the,O,O
shoulder,O,O
region,O,O
under,O,O
an,O,O
interscalene,O,B
brachial,O,I
plexus,O,I
block,O,I
(,O,O
IBPB,O,O
),O,O
.,O,O
Bupivacaine,B,B
0,O,O
.,O,O
75,O,O
%,O,O
with,O,O
adrenaline,B,B
was,O,O
given,O,O
followed,O,O
by,O,O
a,O,O
24,O,O
-,O,O
hr,O,O
continuous,O,O
infusion,O,O
of,O,O
0,O,O
.,O,O
25,O,O
%,O,O
bupivacaine,B,B
.,O,O
Three,O,O
audiometric,O,O
threshold,O,O
measurements,O,O
(,O,O
0,O,O
.,O,O
25,O,O
-,O,O
18,O,O
kHz,O,O
),O,O
were,O,O
made,O,O
:,O,O
the,O,O
first,O,O
before,O,O
IBPB,O,O
",",O,O
the,O,O
second,O,O
2,O,O
-,O,O
6,O,O
h,O,O
after,O,O
surgery,O,O
and,O,O
the,O,O
third,O,O
on,O,O
the,O,O
first,O,O
day,O,O
after,O,O
operation,O,O
.,O,O
In,O,O
four,O,O
patients,O,O
hearing,O,O
impairment,O,O
on,O,O
the,O,O
side,O,O
of,O,O
the,O,O
block,O,O
was,O,O
demonstrated,O,O
after,O,O
operation,O,O
",",O,O
in,O,O
three,O,O
measurements,O,O
on,O,O
the,O,O
day,O,O
of,O,O
surgery,O,O
and,O,O
in,O,O
one,O,O
on,O,O
the,O,O
following,O,O
day,O,O
.,O,O
The,O,O
frequencies,O,O
at,O,O
which,O,O
the,O,O
impairment,O,O
occurred,O,O
varied,O,O
between,O,O
patients,O,O
;,O,O
in,O,O
one,O,O
only,O,O
low,O,O
frequencies,O,O
(,O,O
0,O,B
.,O,I
25,O,I
-,O,I
0,O,I
.,O,I
5,O,I
kHz,O,I
),O,O
were,O,O
involved,O,O
.,O,O
maximum,O,O
change,O,O
in,O,O
threshold,O,O
was,O,O
35,O,B
dB,O,I
at,O,O
6,O,B
kHz,O,I
measured,O,O
at,O,O
the,O,O
end,O,O
of,O,O
the,O,O
continuous,O,O
infusion,O,O
of,O,O
bupivacaine,B,B
.,O,O
patient,O,O
had,O,O
hearing,O,O
threshold,O,O
changes,O,O
(,O,O
15,O,B
-,O,I
20,O,I
dB,O,I
),O,O
at,O,O
6,O,B
-,O,I
10,O,I
kHz,O,I
on,O,O
the,O,O
opposite,O,O
side,O,O
also,O,O
.,O,O
IBPB,O,O
may,O,O
cause,O,O
transient,O,O
auditory,O,O
dysfunction,O,O
in,O,O
the,O,O
ipsilateral,O,O
ear,O,O
",",O,O
possibly,O,O
via,O,O
an,O,O
effect,O,O
on,O,O
sympathetic,O,O
innervation,O,O
.,O,O
The,O,O
safety,O,O
and,O,O
efficacy,O,O
of,O,O
combination,O,O
N,B,B
-,I,I
butyl,I,I
-,I,I
deoxynojirimycin,I,I
(,O,O
SC,B,B
-,I,I
48334,I,I
),O,O
and,O,O
zidovudine,B,B
in,O,O
patients,O,O
with,O,O
HIV,O,B
-,O,I
1,O,I
infection,O,O
and,O,O
200,O,O
-,O,O
500,O,O
CD4,O,B
cells,O,O
/,O,O
mm3,O,O
.,O,O
We,O,O
conducted,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
",",O,O
randomized,O,O
phase,O,O
II,O,O
study,O,O
to,O,O
evaluate,O,O
the,O,O
safety,O,O
and,O,O
activity,O,O
of,O,O
combination,O,O
therapy,O,O
with,O,O
N,B,B
-,I,I
butyl,I,I
-,I,I
deoxynojirimycin,I,I
(,O,O
SC,B,B
-,I,I
48334,I,I
),O,O
(,O,O
an,O,O
alpha,O,O
-,O,O
glucosidase,O,O
I,O,O
inhibitor,O,O
),O,O
and,O,O
zidovudine,B,B
versus,O,O
zidovudine,B,B
alone,O,O
.,O,O
Patients,O,O
with,O,O
200,O,B
to,O,O
500,O,I
CD4,O,I
cells,O,I
/,O,O
mm3,O,O
who,O,O
tolerated,O,O
<,O,O
or,O,O
=,O,O
12,O,O
weeks,O,O
of,O,O
prior,O,O
zidovudine,B,B
therapy,O,O
received,O,O
SC,B,B
-,I,I
48334,I,I
(,O,O
1000,O,B
mg,O,I
every,O,I
8,O,I
h,O,I
),O,O
and,O,O
zidovudine,B,B
(,O,O
100,O,B
mg,O,I
every,O,I
8,O,I
h,O,I
),O,O
or,O,O
zidovudine,B,B
and,O,O
placebo,O,B
.,O,O
Sixty,O,O
patients,O,O
received,O,O
combination,O,O
therapy,O,O
and,O,O
58,O,O
",",O,O
zidovudine,B,B
and,O,O
placebo,O,B
.,O,O
Twenty,O,O
-,O,O
three,O,O
patients,O,O
(,O,O
38,O,O
%,O,O
),O,O
and,O,O
15,O,O
(,O,O
26,O,O
%,O,O
),O,O
",",O,O
in,O,O
the,O,O
combination,O,O
and,O,O
zidovudine,B,B
groups,O,O
",",O,O
respectively,O,O
",",O,O
discontinued,O,O
therapy,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
15,O,O
),O,O
.,O,O
The,O,O
mean,O,O
SC,B,B
-,I,I
48334,I,I
steady,O,O
-,O,O
state,O,O
trough,O,O
level,O,O
(,O,O
4,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
99,O,O
micrograms,O,O
/,O,O
ml,O,O
),O,O
was,O,O
below,O,O
the,O,O
in,O,O
vitro,O,O
inhibitory,O,O
concentration,O,O
for,O,O
human,O,O
immunodeficiency,O,B
virus,O,I
(,O,I
HIV,O,I
.,O,O
The,O,O
mean,O,O
increase,O,O
in,O,O
CD4,O,B
cells,O,I
at,O,O
week,O,O
4,O,O
was,O,O
73,O,O
.,O,O
8,O,O
cells,O,O
/,O,O
mm3,O,O
and,O,O
52,O,O
.,O,O
4,O,O
cells,O,O
/,O,O
mm3,O,O
for,O,O
the,O,O
combination,O,O
and,O,O
zidovudine,B,B
groups,O,O
",",O,O
respectively,O,O
(,O,O
p,O,O
>,O,O
0,O,O
.,O,O
36,O,O
),O,O
.,O,O
For,O,O
patients,O,O
with,O,O
prior,O,O
zidovudine,B,B
therapy,O,O
",",O,O
the,O,O
mean,O,O
change,O,O
in,O,O
CD4,O,B
cells,O,O
in,O,O
the,O,O
combination,O,O
and,O,O
zidovudine,B,B
groups,O,O
was,O,O
63,O,O
.,O,O
cells,O,O
/,O,O
mm3,O,O
and,O,O
4,O,O
.,O,O
cells,O,O
/,O,O
mm3,O,O
at,O,O
week,O,O
8,O,O
and,O,O
6,O,O
.,O,O
cells,O,O
/,O,O
mm3,O,O
and,O,O
-,O,O
45,O,O
.,O,O
cells,O,O
/,O,O
mm3,O,O
at,O,O
week,O,O
16,O,O
",",O,O
respectively,O,O
.,O,O
The,O,O
number,O,O
of,O,O
patients,O,O
with,O,O
suppression,O,O
of,O,O
HIV,O,B
p24,O,I
antigenemia,O,I
in,O,O
the,O,O
combination,O,O
and,O,O
zidovudine,B,B
groups,O,O
was,O,O
six,O,O
(,O,O
40,O,O
%,O,O
),O,O
and,O,O
two,O,O
(,O,O
11,O,O
%,O,O
),O,O
at,O,O
week,O,O
4,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
10,O,O
),O,O
and,O,O
five,O,O
(,O,O
45,O,O
%,O,O
),O,O
and,O,O
two,O,O
(,O,O
14,O,O
%,O,O
),O,O
at,O,O
week,O,O
24,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
respectively,O,O
.,O,O
Diarrhea,O,B
",",O,O
flatulence,O,B
",",O,O
abdominal,O,B
pain,O,I
",",O,O
and,O,O
weight,O,B
loss,O,I
were,O,O
common,O,O
for,O,O
combination,O,O
recipients,O,O
.,O,O
(,O,O
ABSTRACT,O,O
TRUNCATED,O,O
AT,O,O
250,O,O
WORDS,O,O
),O,O
Prolonged,O,O
paralysis,O,O
due,O,O
to,O,O
nondepolarizing,B,O
neuromuscular,I,O
blocking,I,O
agents,I,O
and,O,O
corticosteroids,B,O
.,O,O
The,O,O
long,O,O
-,O,O
term,O,O
use,O,O
of,O,O
nondepolarizing,B,O
neuromuscular,I,O
blocking,I,O
agents,I,O
(,O,O
ND,B,B
-,I,I
NMBA,I,I
),O,O
has,O,O
recently,O,O
been,O,O
implicated,O,O
as,O,O
a,O,O
cause,O,O
of,O,O
prolonged,O,O
muscle,O,O
weakness,O,O
",",O,O
although,O,O
the,O,O
site,O,O
of,O,O
the,O,O
lesion,O,O
and,O,O
the,O,O
predisposing,O,O
factors,O,O
have,O,O
been,O,O
unclear,O,O
.,O,O
We,O,O
report,O,O
3,O,O
patients,O,O
(,O,O
age,O,O
37,O,O
-,O,O
52,O,O
years,O,O
),O,O
with,O,O
acute,O,O
respiratory,O,O
insufficiency,O,O
who,O,O
developed,O,O
prolonged,O,O
weakness,O,O
following,O,O
the,O,O
discontinuation,O,O
of,O,O
ND,B,B
-,I,I
NMBAs,I,I
.,O,O
Two,O,O
patients,O,O
also,O,O
received,O,O
intravenous,O,O
corticosteroids,B,B
.,O,O
Renal,O,O
function,O,O
was,O,O
normal,O,O
but,O,O
hepatic,O,O
function,O,O
was,O,O
impaired,O,O
in,O,O
all,O,O
patients,O,O
",",O,O
and,O,O
all,O,O
had,O,O
acidosis,O,B
.,O,O
Electrophysiologic,O,O
studies,O,O
revealed,O,O
low,O,O
amplitude,O,O
compound,O,O
motor,O,O
action,O,O
potentials,O,O
",",O,O
normal,O,O
sensory,O,O
studies,O,O
",",O,O
and,O,O
fibrillations,O,O
.,O,O
Repetitive,O,O
stimulation,O,O
at,O,O
2,O,O
Hz,O,O
showed,O,O
a,O,O
decremental,O,O
response,O,O
in,O,O
2,O,O
patients,O,O
.,O,O
The,O,O
serum,O,O
vecuronium,B,B
level,O,O
measured,O,O
in,O,O
1,O,O
patient,O,O
14,O,O
days,O,O
after,O,O
the,O,O
drug,O,O
had,O,O
been,O,O
discontinued,O,O
was,O,O
172,O,O
ng,O,O
/,O,O
mL,O,O
.,O,O
A,O,O
muscle,O,O
biopsy,O,O
in,O,O
this,O,O
patient,O,O
showed,O,O
loss,O,O
of,O,O
thick,O,O
",",O,O
myosin,O,B
filaments,O,O
.,O,O
The,O,O
weakness,O,O
in,O,O
these,O,O
patients,O,O
is,O,O
due,O,O
to,O,O
pathology,O,O
at,O,O
both,O,O
the,O,O
neuromuscular,O,O
junction,O,O
(,O,O
most,O,O
likely,O,O
due,O,O
to,O,O
ND,B,B
-,I,O
NMBA,I,B
),O,O
and,O,O
muscle,O,O
(,O,O
most,O,O
likely,O,O
due,O,O
to,O,O
corticosteroids,B,B
),O,O
.,O,O
Hepatic,O,B
dysfunction,O,I
and,O,O
acidosis,O,B
are,O,O
contributing,O,O
risk,O,O
factors,O,O
.,O,O
Failure,O,O
of,O,O
ancrod,O,B
in,O,O
the,O,O
treatment,O,O
of,O,O
heparin,B,B
-,O,I
induced,O,I
arterial,O,I
thrombosis,O,I
.,O,O
The,O,O
morbidity,O,O
and,O,O
mortality,O,O
associated,O,O
with,O,O
heparin,B,B
-,O,I
induced,O,I
thrombosis,O,I
remain,O,O
high,O,O
despite,O,O
numerous,O,O
empirical,O,O
therapies,O,O
.,O,O
Ancrod,O,B
has,O,O
been,O,O
used,O,O
successfully,O,O
for,O,O
prophylaxis,O,O
against,O,O
development,O,O
of,O,O
thrombosis,O,O
in,O,O
patients,O,O
with,O,O
heparin,B,B
induced,O,I
platelet,O,I
aggregation,O,I
who,O,O
require,O,O
brief,O,O
reexposure,O,O
to,O,O
heparin,B,B
",",O,O
but,O,O
its,O,O
success,O,O
in,O,O
patients,O,O
who,O,O
have,O,O
developed,O,O
the,O,O
thrombosis,O,O
syndrome,O,O
is,O,O
not,O,O
well,O,O
defined,O,O
.,O,O
The,O,O
authors,O,O
present,O,O
a,O,O
case,O,O
of,O,O
failure,O,O
of,O,O
ancrod,O,B
treatment,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
heparin,B,B
-,O,O
induced,O,O
thrombosis,O,O
.,O,O
Water,O,B
intoxication,O,O
associated,O,O
with,O,O
oxytocin,B,B
administration,O,O
during,O,O
saline,O,B
-,O,O
induced,O,O
abortion,O,O
.,O,O
Four,O,O
cases,O,O
of,O,O
water,O,B
intoxication,O,O
in,O,O
connection,O,O
with,O,O
oxytocin,B,B
administration,O,O
during,O,O
saline,O,B
-,O,O
induced,O,O
abortions,O,O
are,O,O
described,O,O
.,O,O
The,O,O
mechanism,O,O
of,O,O
water,O,B
intoxication,O,I
is,O,O
discussed,O,O
in,O,O
regard,O,O
to,O,O
these,O,O
cases,O,O
.,O,O
Oxytocin,B,B
administration,O,O
during,O,O
midtrimester,O,O
-,O,O
induced,O,O
abortions,O,O
is,O,O
advocated,O,O
only,O,O
if,O,O
it,O,O
can,O,O
be,O,O
carried,O,O
out,O,O
under,O,O
careful,O,O
observations,O,O
of,O,O
an,O,O
alert,O,O
nursing,O,O
staff,O,O
",",O,O
aware,O,O
of,O,O
the,O,O
symptoms,O,O
of,O,O
water,O,B
intoxication,O,I
and,O,O
instructed,O,O
to,O,O
watch,O,O
the,O,O
diuresis,O,O
and,O,O
report,O,O
such,O,O
early,O,O
signs,O,O
of,O,O
the,O,O
syndrome,O,O
as,O,O
asthenia,O,O
",",O,O
muscular,O,O
irritability,O,O
",",O,O
or,O,O
headaches,O,O
.,O,O
The,O,O
oxytocin,B,B
should,O,O
be,O,O
given,O,O
only,O,O
in,O,O
Ringers,O,B
lactate,B,I
or,O,O
",",O,O
alternately,O,O
",",O,O
in,O,O
Ringers,O,B
lactate,B,I
and,O,O
a,O,O
5,O,O
per,O,O
cent,O,O
dextrose,B,B
and,O,O
water,O,O
solutions,O,O
.,O,O
The,O,O
urinary,O,O
output,O,O
should,O,O
be,O,O
monitored,O,O
and,O,O
the,O,O
oxytocin,B,B
administration,O,O
discontinued,O,O
and,O,O
the,O,O
serum,O,O
electrolytes,O,O
checked,O,O
if,O,O
the,O,O
urinary,O,O
output,O,O
decreases,O,O
.,O,O
The,O,O
oxytocin,B,B
should,O,O
not,O,O
be,O,O
administered,O,O
in,O,O
excess,O,O
of,O,O
36,O,O
hours,O,O
.,O,O
If,O,O
the,O,O
patient,O,O
has,O,O
not,O,O
aborted,O,O
by,O,O
then,O,O
the,O,O
oxytocin,B,B
should,O,O
be,O,O
discontinued,O,O
for,O,O
10,O,O
to,O,O
12,O,O
hours,O,O
in,O,O
order,O,O
to,O,O
perform,O,O
electrolyte,O,B
determinations,O,O
and,O,O
correct,O,O
any,O,O
electrolyte,O,B
imbalance,O,O
.,O,O
Light,O,O
chain,O,B
proteinuria,O,I
and,O,O
cellular,O,O
mediated,O,O
immunity,O,O
in,O,O
rifampin,B,B
treated,O,O
patients,O,O
with,O,O
tuberculosis,O,O
.,O,O
Light,O,O
chain,O,B
proteinuria,O,I
was,O,O
found,O,O
in,O,O
9,O,O
of,O,O
17,O,O
tuberculosis,O,O
patients,O,O
treated,O,O
with,O,O
rifampin,B,B
.,O,O
Concomitant,O,O
assay,O,O
of,O,O
cellular,O,O
mediated,O,O
immunity,O,O
in,O,O
these,O,O
patients,O,O
using,O,O
skin,O,B
test,O,I
antigen,O,I
and,O,O
a,O,O
lymphokine,O,O
in,O,O
vitro,O,O
test,O,O
provided,O,O
results,O,O
that,O,O
were,O,O
different,O,O
.,O,O
Response,O,O
to,O,O
Varidase,O,B
skin,O,I
test,O,I
antigen,O,I
was,O,O
negative,O,O
for,O,O
all,O,O
eight,O,O
tuberculosis,O,O
patients,O,O
tested,O,O
",",O,O
but,O,O
there,O,O
occurred,O,O
a,O,O
hyper,O,O
-,O,O
responsiveness,O,O
of,O,O
the,O,O
lymphocytes,O,O
of,O,O
these,O,O
eight,O,O
patients,O,O
to,O,O
phytomitogen,O,B
(,O,O
PHA,O,I
-,O,I
P,O,I
),O,I
.,O,O
as,O,O
well,O,O
as,O,O
of,O,O
those,O,O
of,O,O
seven,O,O
other,O,O
tuberculous,O,B
patients,O,O
.,O,O
This,O,O
last,O,O
finding,O,O
may,O,O
be,O,O
related,O,O
to,O,O
time,O,O
of,O,O
testing,O,O
and,O,O
/,O,O
or,O,O
endogenous,O,O
serum,O,O
binding,O,O
of,O,O
rifampin,B,B
which,O,O
could,O,O
have,O,O
inhibited,O,O
mitogen,O,O
activity,O,O
for,O,O
the,O,O
lymphocyte,O,O
.,O,O
KF17837,B,B
:,O,O
a,O,O
novel,O,O
selective,O,O
adenosine,B,B
A2A,O,I
receptor,O,I
antagonist,O,O
with,O,O
anticataleptic,O,O
activity,O,O
.,O,O
KF17837,B,B
is,O,O
a,O,O
novel,O,O
selective,O,O
adenosine,B,B
A2A,O,I
receptor,O,I
antagonist,O,O
.,O,O
Oral,O,O
administration,O,O
of,O,O
KF17837,B,B
(,O,O
2,O,O
.,O,O
5,O,O
",",O,O
10,O,O
.,O,O
0,O,O
and,O,O
30,O,O
.,O,O
0,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
significantly,O,O
ameliorated,O,O
the,O,O
cataleptic,O,O
responses,O,O
induced,O,O
by,O,O
intracerebroventricular,O,O
administration,O,O
of,O,O
an,O,O
adenosine,B,B
A2A,O,I
receptor,O,I
agonist,O,O
",",O,O
CGS,B,B
21680,I,I
(,O,O
10,O,O
micrograms,O,O
),O,O
",",O,O
in,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
manner,O,O
.,O,O
KF17837,B,B
also,O,O
reduced,O,O
the,O,O
catalepsy,O,O
induced,O,O
by,O,O
haloperidol,B,B
(,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
and,O,O
by,O,O
reserpine,B,B
(,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
These,O,O
anticataleptic,O,O
effects,O,O
were,O,O
exhibited,O,O
dose,O,O
dependently,O,O
at,O,O
doses,O,O
from,O,O
0,O,O
.,O,O
625,O,O
and,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
.,O,O
",",O,O
respectively,O,O
.,O,O
Moreover,O,O
",",O,O
KF17837,B,B
(,O,O
0,O,O
.,O,O
625,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
.,O,O
),O,O
potentiated,O,O
the,O,O
anticataleptic,O,O
effects,O,O
of,O,O
a,O,O
subthreshold,O,O
dose,O,O
of,O,O
L,B,B
-,I,I
3,I,I
",",I,I
4,I,I
-,I,I
dihydroxyphenylalanine,I,I
(,O,I
L,B,I
-,I,I
DOPA,I,I
;,O,I
25,O,I
mg,O,I
/,O,I
kg,O,I
i,O,I
.,O,O
),O,O
plus,O,O
benserazide,B,B
(,O,O
6,O,O
.,O,O
25,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
These,O,O
results,O,O
suggested,O,O
that,O,O
KF17837,B,B
is,O,O
a,O,O
centrally,O,O
active,O,O
adenosine,B,B
A2A,O,I
receptor,O,I
antagonist,O,I
and,O,O
that,O,O
the,O,O
dopaminergic,O,O
function,O,O
of,O,O
the,O,O
nigrostriatal,O,O
pathway,O,O
is,O,O
potentiated,O,O
by,O,O
adenosine,B,B
A2A,O,I
receptor,O,I
antagonists,O,I
.,O,O
Furthermore,O,O
",",O,O
KF17837,B,B
may,O,O
be,O,O
a,O,O
useful,O,O
drug,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
parkinsonism,O,O
.,O,O
Effect,O,O
of,O,O
nondopaminergic,O,B
drugs,O,I
on,O,O
L,B,B
-,I,I
dopa,I,I
-,O,I
induced,O,I
dyskinesias,O,I
in,O,O
MPTP,B,B
-,O,I
treated,O,I
monkeys,O,I
.,O,O
A,O,O
group,O,O
of,O,O
four,O,O
monkeys,O,O
was,O,O
rendered,O,O
parkinsonian,O,O
with,O,O
the,O,O
toxin,O,B
MPTP,B,I
.,O,O
They,O,O
were,O,O
then,O,O
treated,O,O
chronically,O,O
with,O,O
L,B,B
-,I,I
DOPA,I,I
/,I,I
benserazide,I,I
50,O,I
/,O,I
12,O,I
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
given,O,O
orally,O,O
daily,O,O
for,O,O
2,O,O
months,O,O
.,O,O
This,O,O
dose,O,O
produced,O,O
a,O,O
striking,O,O
antiparkinsonian,O,O
effect,O,O
",",O,O
but,O,O
all,O,O
animals,O,O
manifested,O,O
dyskinesia,O,O
.,O,O
A,O,O
series,O,O
of,O,O
agents,O,O
acting,O,O
primarily,O,O
on,O,O
neurotransmitters,O,O
other,O,O
than,O,O
dopamine,B,B
were,O,O
then,O,O
tested,O,O
in,O,O
combination,O,O
with,O,O
L,B,B
-,I,I
DOPA,I,I
to,O,O
see,O,O
if,O,O
the,O,O
dyskinetic,O,O
movements,O,O
would,O,O
be,O,O
modified,O,O
.,O,O
Several,O,O
drugs,O,O
",",O,O
including,O,O
clonidine,B,B
",",O,O
physostigmine,B,B
",",O,O
methysergide,B,B
",",O,O
5,B,B
-,I,I
MDOT,I,I
",",O,O
propranolol,B,B
",",O,O
and,O,O
MK,B,B
-,I,I
801,I,I
",",O,O
markedly,O,O
reduced,O,O
the,O,O
dyskinetic,O,O
movements,O,O
but,O,O
at,O,O
the,O,O
cost,O,O
of,O,O
a,O,O
return,O,O
of,O,O
parkinsonian,O,O
symptomatology,O,O
.,O,O
However,O,O
",",O,O
yohimbine,B,B
and,O,O
meperidine,B,B
reduced,O,O
predominantly,O,O
the,O,O
dyskinetic,O,O
movements,O,O
.,O,O
Baclofen,B,B
was,O,O
also,O,O
useful,O,O
in,O,O
one,O,O
monkey,O,O
against,O,O
a,O,O
more,O,O
dystonic,O,O
form,O,O
of,O,O
dyskinesia,O,O
.,O,O
Atropine,B,B
converted,O,O
the,O,O
dystonic,O,O
movements,O,O
into,O,O
chorea,O,O
.,O,O
Hallucinations,O,B
and,O,O
ifosfamide,B,B
-,O,O
induced,O,O
neurotoxicity,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Hallucinations,O,B
as,O,O
a,O,O
symptom,O,O
of,O,O
central,O,O
neurotoxicity,O,O
are,O,O
a,O,O
known,O,O
but,O,O
poorly,O,O
described,O,O
side,O,O
effect,O,O
of,O,O
ifosfamide,B,B
.,O,O
Most,O,O
cases,O,O
of,O,O
ifosfamide,B,B
-,O,O
induced,O,O
hallucinations,O,O
have,O,O
been,O,O
reported,O,O
with,O,O
other,O,O
mental,O,O
status,O,O
changes,O,O
.,O,O
METHODS,O,O
:,O,O
The,O,O
authors,O,O
interviewed,O,O
six,O,O
persons,O,O
with,O,O
ifosfamide,B,B
-,O,O
induced,O,O
hallucinations,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
a,O,O
clear,O,O
sensorium,O,O
.,O,O
All,O,O
patients,O,O
were,O,O
receiving,O,O
high,O,O
-,O,O
dose,O,O
ifosfamide,B,B
as,O,O
part,O,O
of,O,O
their,O,O
bone,O,O
marrow,O,O
transplant,O,O
procedure,O,O
.,O,O
RESULTS,O,O
:,O,O
Hallucinations,O,B
occurred,O,O
only,O,O
when,O,O
the,O,O
patient,O,O
',O,O
s,O,O
eyes,O,O
were,O,O
closed,O,O
and,O,O
",",O,O
in,O,O
all,O,O
but,O,O
one,O,O
case,O,O
",",O,O
were,O,O
reported,O,O
as,O,O
disturbing,O,O
or,O,O
frightening,O,O
.,O,O
Underreporting,O,O
of,O,O
these,O,O
hallucinations,O,B
by,O,O
patients,O,O
is,O,O
likely,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Hallucinations,O,B
may,O,O
be,O,O
the,O,O
sole,O,O
or,O,O
first,O,O
manifestation,O,O
of,O,O
neurotoxicity,O,B
.,O,O
The,O,O
incidence,O,O
may,O,O
be,O,O
dose,O,O
and,O,O
infusion,O,O
-,O,O
time,O,O
related,O,O
.,O,O
The,O,O
clinician,O,O
should,O,O
be,O,O
alerted,O,O
for,O,O
possible,O,O
ifosfamide,B,B
-,O,O
induced,O,O
hallucinations,O,O
",",O,O
which,O,O
may,O,O
occur,O,O
without,O,O
other,O,O
signs,O,O
of,O,O
neurotoxicity,O,O
.,O,O
hallucinatory,O,O
experiences,O,O
appear,O,O
to,O,O
be,O,O
an,O,O
unusual,O,O
feature,O,O
of,O,O
this,O,O
presentation,O,O
.,O,O
Patients,O,O
anxious,O,O
about,O,O
this,O,O
experience,O,O
respond,O,O
well,O,O
to,O,O
support,O,O
and,O,O
education,O,O
about,O,O
this,O,O
occurrence,O,O
.,O,O
Optimal,O,O
pharmacologic,O,O
management,O,O
of,O,O
disturbed,O,O
patients,O,O
is,O,O
unclear,O,O
.,O,O
If,O,O
agitation,O,O
becomes,O,O
marked,O,O
",",O,O
high,O,O
-,O,O
potency,O,O
neuroleptics,O,O
(,O,O
i,O,O
.,O,O
e,O,O
.,O,O
",",O,O
haloperidol,B,B
),O,O
may,O,O
be,O,O
effective,O,O
.,O,O
Photodistributed,O,O
nifedipine,B,B
-,O,O
induced,O,O
facial,O,O
telangiectasia,O,O
.,O,O
Five,O,O
months,O,O
after,O,O
starting,O,O
nifedipine,B,B
(,O,O
Adalat,B,B
),O,O
",",O,O
two,O,O
patients,O,O
developed,O,O
photodistributed,O,O
facial,O,O
telangiectasia,O,O
",",O,O
which,O,O
became,O,O
more,O,O
noticeable,O,O
with,O,O
time,O,O
.,O,O
Neither,O,O
patient,O,O
complained,O,O
of,O,O
photosensitivity,O,B
or,O,O
flushing,O,B
.,O,O
Both,O,O
patients,O,O
reported,O,O
a,O,O
significant,O,O
cosmetic,O,O
improvement,O,O
after,O,O
discontinuing,O,O
the,O,O
drug,O,O
.,O,O
One,O,O
commenced,O,O
the,O,O
closely,O,O
related,O,O
drug,O,O
amlodipine,B,B
3,O,O
years,O,O
later,O,O
",",O,O
with,O,O
recurrence,O,O
of,O,O
telangiectasia,O,B
.,O,O
The,O,O
photodistribution,O,O
of,O,O
the,O,O
telangiectasia,O,B
suggests,O,O
a,O,O
significant,O,O
drug,O,O
/,O,O
light,O,O
interaction,O,O
.,O,O
Penicillamine,B,B
-,O,O
induced,O,O
rapidly,O,O
progressive,O,O
glomerulonephritis,O,B
in,O,O
a,O,O
patient,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
.,O,O
A,O,O
67,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
presented,O,O
rapidly,O,O
progressive,O,O
glomerulonephritis,O,B
(,O,O
RPGN,O,B
),O,O
after,O,O
5,O,O
months,O,O
of,O,O
D,B,B
-,I,O
penicillamine,I,I
(,O,O
250,O,O
mg,O,O
/,O,O
day,O,O
),O,O
treatment,O,O
.,O,O
Light,O,O
microscopy,O,O
study,O,O
showed,O,O
severe,O,O
glomerulonephritis,O,B
with,O,O
crescent,O,O
formation,O,O
in,O,O
60,O,O
%,O,O
of,O,O
the,O,O
glomeruli,O,O
and,O,O
infiltration,O,O
of,O,O
inflammatory,O,O
cells,O,O
in,O,O
the,O,O
wall,O,O
of,O,O
an,O,O
arteriole,O,O
.,O,O
Immunofluorescence,O,O
revealed,O,O
scanty,O,O
granular,O,O
IgG,O,B
",",O,O
IgA,O,B
and,O,O
C3,O,B
deposits,O,O
along,O,O
the,O,O
capillary,O,O
walls,O,O
and,O,O
mesangium,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
treated,O,O
with,O,O
steroid,B,O
pulse,O,O
",",O,O
plasmapheresis,O,O
",",O,O
cyclophosphamide,B,B
and,O,O
antiplatelet,B,O
agents,I,O
.,O,O
A,O,O
complete,O,O
recovery,O,O
of,O,O
renal,O,O
function,O,O
was,O,O
achieved,O,O
in,O,O
a,O,O
few,O,O
weeks,O,O
.,O,O
This,O,O
new,O,O
case,O,O
of,O,O
RPGN,O,O
in,O,O
the,O,O
course,O,O
of,O,O
D,B,O
-,I,O
penicillamine,I,B
treatment,O,O
emphasizes,O,O
the,O,O
need,O,O
for,O,O
frequent,O,O
monitoring,O,O
of,O,O
renal,O,O
function,O,O
and,O,O
evaluation,O,O
of,O,O
urinary,O,O
sediment,O,O
and,O,O
proteinuria,O,O
in,O,O
these,O,O
patients,O,O
.,O,O
The,O,O
prompt,O,O
discontinuation,O,O
of,O,O
D,B,B
-,I,I
penicillamine,I,I
and,O,O
vigorous,O,O
treatment,O,O
measures,O,O
could,O,O
allow,O,O
for,O,O
a,O,O
good,O,O
prognosis,O,O
as,O,O
in,O,O
this,O,O
case,O,O
.,O,O
A,O,O
case,O,O
of,O,O
polymyositis,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
primary,O,O
biliary,O,O
cirrhosis,O,O
treated,O,O
with,O,O
D,B,B
-,I,I
penicillamine,I,I
.,O,O
Although,O,O
D,B,B
-,I,I
penicillamine,I,I
has,O,O
been,O,O
used,O,O
for,O,O
many,O,O
rheumatologic,O,O
diseases,O,O
",",O,O
toxicity,O,O
limits,O,O
its,O,O
usefulness,O,O
in,O,O
many,O,O
patients,O,O
.,O,O
Polymyositis,O,B
/,O,I
dermatomyositis,O,I
can,O,O
develop,O,O
as,O,O
one,O,O
of,O,O
the,O,O
autoimmune,O,O
complications,O,O
of,O,O
D,B,B
-,I,I
penicillamine,I,I
treatment,O,O
",",O,O
but,O,O
its,O,O
exact,O,O
pathogenesis,O,O
remains,O,O
unclear,O,O
.,O,O
We,O,O
report,O,O
a,O,O
patient,O,O
with,O,O
primary,O,O
biliary,O,O
cirrhosis,O,O
",",O,O
who,O,O
developed,O,O
polymyositis,O,B
while,O,O
receiving,O,O
D,B,B
-,I,I
penicillamine,I,I
therapy,O,O
.,O,O
We,O,O
described,O,O
the,O,O
special,O,O
clinical,O,O
course,O,O
of,O,O
the,O,O
patient,O,O
.,O,O
Patients,O,O
receiving,O,O
D,B,B
-,I,I
penicillamine,I,I
therapy,O,O
should,O,O
be,O,O
followed,O,O
carefully,O,O
for,O,O
the,O,O
development,O,O
of,O,O
autoimmune,O,O
complications,O,O
like,O,O
polymyositis,O,B
/,O,I
dermatomyositis,O,I
.,O,O
Hyperalgesia,O,O
and,O,O
myoclonus,O,O
in,O,O
terminal,O,O
cancer,O,O
patients,O,O
treated,O,O
with,O,O
continuous,O,O
intravenous,O,O
morphine,B,B
.,O,O
Eight,O,O
cancer,O,O
patients,O,O
in,O,O
the,O,O
terminal,O,O
stages,O,O
of,O,O
the,O,O
disease,O,O
treated,O,O
with,O,O
high,O,O
doses,O,O
of,O,O
intravenous,O,O
morphine,B,B
developed,O,O
hyperalgesia,O,O
.,O,O
All,O,O
cases,O,O
were,O,O
retrospectively,O,O
sampled,O,O
from,O,O
three,O,O
different,O,O
hospitals,O,O
in,O,O
Copenhagen,O,O
.,O,O
Five,O,O
patients,O,O
developed,O,O
universal,O,O
hyperalgesia,O,B
and,O,O
hyperesthesia,O,B
which,O,O
in,O,O
2,O,O
cases,O,O
were,O,O
accompanied,O,O
by,O,O
myoclonus,O,B
.,O,O
In,O,O
3,O,O
patients,O,O
a,O,O
pre,O,O
-,O,O
existing,O,O
neuralgia,O,B
increased,O,O
to,O,O
excruciating,O,O
intensity,O,O
and,O,O
in,O,O
2,O,O
of,O,O
these,O,O
cases,O,O
myoclonus,O,B
occurred,O,O
simultaneously,O,O
.,O,O
Although,O,O
only,O,O
few,O,O
clinical,O,O
descriptions,O,O
of,O,O
the,O,O
relationship,O,O
between,O,O
hyperalgesia,O,B
/,O,I
myoclonus,O,B
and,O,O
high,O,O
doses,O,O
of,O,O
morphine,B,B
are,O,O
available,O,O
",",O,O
experimental,O,O
support,O,O
from,O,O
animal,O,O
studies,O,O
indicates,O,O
that,O,O
morphine,B,B
",",O,O
or,O,O
its,O,O
metabolites,O,O
",",O,O
plays,O,O
a,O,O
causative,O,O
role,O,O
for,O,O
the,O,O
observed,O,O
behavioural,O,O
syndrome,O,O
.,O,O
The,O,O
possible,O,O
mechanisms,O,O
are,O,O
discussed,O,O
and,O,O
treatment,O,O
proposals,O,O
given,O,O
suggesting,O,O
the,O,O
use,O,O
of,O,O
more,O,O
efficacious,O,O
opioids,O,B
with,O,O
less,O,O
excitatory,O,O
potency,O,O
in,O,O
these,O,O
situations,O,O
.,O,O
Liposomal,O,B
daunorubicin,B,B
in,O,O
advanced,O,O
Kaposi,O,B
',O,I
s,O,I
sarcoma,O,I
:,O,O
a,O,O
phase,O,O
II,O,O
study,O,O
.,O,O
We,O,O
report,O,O
a,O,O
non,O,O
-,O,O
randomized,O,O
Phase,O,O
II,O,O
clinical,O,O
trial,O,O
to,O,O
assess,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
liposomal,O,B
daunorubicin,B,B
(,O,O
DaunoXome,O,B
),O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
AIDS,O,B
related,O,O
Kaposi,O,B
',O,I
s,O,I
sarcoma,O,I
.,O,O
Eleven,O,O
homosexual,O,O
men,O,O
with,O,O
advanced,O,O
Kaposi,O,B
',O,I
s,O,I
sarcoma,O,I
were,O,O
entered,O,O
in,O,O
the,O,O
trial,O,O
.,O,O
Changes,O,O
in,O,O
size,O,O
",",O,O
colour,O,O
and,O,O
associated,O,O
oedema,O,O
of,O,O
selected,O,O
',O,O
target,O,O
',O,O
lesions,O,O
were,O,O
measured,O,O
.,O,O
Clinical,O,O
",",O,O
biochemical,O,O
and,O,O
haematological,O,O
toxicities,O,O
were,O,O
assessed,O,O
.,O,O
Ten,O,O
subjects,O,O
were,O,O
evaluated,O,O
.,O,O
A,O,O
partial,O,O
response,O,O
was,O,O
achieved,O,O
in,O,O
four,O,O
",",O,O
of,O,O
whom,O,O
two,O,O
subsequently,O,O
relapsed,O,O
.,O,O
Stabilization,O,O
of,O,O
Kaposi,O,B
',O,O
s,O,O
sarcoma,O,O
occurred,O,O
in,O,O
the,O,O
remaining,O,O
six,O,O
",",O,O
maintained,O,O
until,O,O
the,O,O
end,O,O
of,O,O
the,O,O
trial,O,O
period,O,O
in,O,O
four,O,O
.,O,O
The,O,O
drug,O,O
was,O,O
generally,O,O
well,O,O
tolerated,O,O
",",O,O
with,O,O
few,O,O
mild,O,O
symptoms,O,O
of,O,O
toxicity,O,O
.,O,O
The,O,O
main,O,O
problem,O,O
encountered,O,O
was,O,O
haematological,O,B
toxicity,O,I
",",O,O
with,O,O
three,O,O
subjects,O,O
experiencing,O,O
severe,O,O
neutropenia,O,B
(,O,O
neutrophil,O,B
count,O,I
<,O,O
0,O,O
.,O,O
5,O,O
x,O,O
10,O,O
(,O,O
9,O,O
),O,O
/,O,O
l,O,O
.,O,O
There,O,O
was,O,O
no,O,O
evidence,O,O
of,O,O
cardiotoxicity,O,B
.,O,O
In,O,O
this,O,O
small,O,O
patient,O,O
sample,O,O
",",O,O
liposomal,O,B
daunorubicin,B,I
was,O,O
an,O,O
effective,O,O
and,O,O
well,O,O
tolerated,O,O
agent,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
Kaposi,O,O
',O,O
s,O,O
sarcoma,O,O
.,O,O
Long,O,O
-,O,O
term,O,O
effects,O,O
of,O,O
vincristine,B,B
on,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
.,O,O
Forty,O,O
patients,O,O
with,O,O
Non,O,B
-,O,I
Hodgkin,O,I
',O,I
s,O,I
Lymphoma,O,I
treated,O,O
with,O,O
vincristine,B,B
between,O,O
1984,O,O
and,O,O
1990,O,O
(,O,O
cumulative,O,O
dose,O,O
12,O,O
mg,O,O
in,O,O
18,O,O
-,O,O
24,O,O
weeks,O,O
),O,O
were,O,O
investigated,O,O
in,O,O
order,O,O
to,O,O
evaluate,O,O
the,O,O
long,O,O
term,O,O
effects,O,O
of,O,O
vincristine,B,B
on,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
.,O,O
The,O,O
patients,O,O
were,O,O
interviewed,O,O
with,O,O
emphasis,O,O
on,O,O
neuropathic,O,O
symptoms,O,O
.,O,O
Physical,O,O
and,O,O
quantitative,O,O
sensory,O,O
examination,O,O
with,O,O
determination,O,O
of,O,O
vibratory,O,O
perception,O,O
and,O,O
thermal,O,O
discrimination,O,O
thresholds,O,O
were,O,O
performed,O,O
",",O,O
four,O,O
to,O,O
77,O,O
months,O,O
(,O,O
median,O,O
34,O,O
months,O,O
),O,O
after,O,O
vincristine,B,B
treatment,O,O
.,O,O
Twenty,O,O
-,O,O
seven,O,O
patients,O,O
reported,O,O
neuropathic,O,O
symptoms,O,O
.,O,O
In,O,O
13,O,O
of,O,O
these,O,O
27,O,O
patients,O,O
symptoms,O,O
were,O,O
still,O,O
present,O,O
at,O,O
the,O,O
time,O,O
of,O,O
examination,O,O
.,O,O
In,O,O
these,O,O
patients,O,O
sensory,O,O
signs,O,O
and,O,O
symptoms,O,O
predominated,O,O
.,O,O
In,O,O
the,O,O
other,O,O
14,O,O
patients,O,O
symptoms,O,O
had,O,O
been,O,O
present,O,O
in,O,O
the,O,O
past,O,O
.,O,O
Symptoms,O,O
persisted,O,O
maximally,O,O
40,O,O
months,O,O
since,O,O
cessation,O,O
of,O,O
therapy,O,O
.,O,O
There,O,O
was,O,O
no,O,O
age,O,O
difference,O,O
between,O,O
patients,O,O
with,O,O
and,O,O
without,O,O
complaints,O,O
at,O,O
the,O,O
time,O,O
of,O,O
examination,O,O
.,O,O
Normal,O,O
reflexes,O,O
were,O,O
found,O,O
in,O,O
two,O,O
third,O,O
of,O,O
patients,O,O
.,O,O
Neuropathic,O,O
complaints,O,O
were,O,O
not,O,O
very,O,O
troublesome,O,O
on,O,O
the,O,O
long,O,O
term,O,O
.,O,O
It,O,O
is,O,O
concluded,O,O
that,O,O
with,O,O
the,O,O
above,O,O
mentioned,O,O
vincristine,B,B
dose,O,O
schedule,O,O
signs,O,O
and,O,O
symptoms,O,O
of,O,O
vincristine,B,B
neuropathy,O,O
are,O,O
reversible,O,O
for,O,O
a,O,O
great,O,O
deal,O,O
and,O,O
prognosis,O,O
is,O,O
fairly,O,O
good,O,O
.,O,O
Hepatic,O,B
adenomas,O,I
and,O,O
focal,O,B
nodular,O,I
hyperplasia,O,I
of,O,I
the,O,I
liver,O,I
in,O,I
young,O,I
women,O,I
on,O,I
oral,B,I
contraceptives,I,I
:,O,O
case,O,O
reports,O,O
.,O,O
Two,O,O
cases,O,O
of,O,O
hepatic,O,B
adenoma,O,I
and,O,O
one,O,O
of,O,O
focal,O,B
nodular,O,I
hyperplasia,O,I
presumably,O,O
associated,O,O
with,O,O
the,O,O
use,O,O
of,O,O
oral,B,B
contraceptives,I,I
",",O,O
are,O,O
reported,O,O
.,O,O
Special,O,O
reference,O,O
is,O,O
made,O,O
to,O,O
their,O,O
clinical,O,O
presentation,O,O
",",O,O
which,O,O
may,O,O
be,O,O
totally,O,O
asymptomatic,O,O
.,O,O
Liver,O,B
-,O,I
function,O,I
tests,O,I
are,O,O
of,O,O
little,O,O
diagnostic,O,O
value,O,O
",",O,O
but,O,O
valuable,O,O
information,O,O
may,O,O
be,O,O
obtained,O,O
from,O,O
both,O,O
liver,O,B
scanning,O,I
and,O,O
hepatic,O,B
angiography,O,I
.,O,O
Histologic,O,O
differences,O,O
and,O,O
clinical,O,O
similarities,O,O
between,O,O
hepatic,O,B
adenoma,O,I
and,O,O
focal,O,B
nodular,O,I
hyperplasia,O,I
of,O,O
the,O,O
liver,O,B
are,O,O
discussed,O,O
.,O,O
Loss,O,O
of,O,O
glutamate,B,B
decarboxylase,O,I
mRNA,O,I
-,O,O
containing,O,O
neurons,O,O
in,O,O
the,O,O
rat,O,O
dentate,O,O
gyrus,O,O
following,O,O
pilocarpine,B,B
-,O,O
induced,O,O
seizures,O,O
.,O,O
In,O,O
situ,O,O
hybridization,O,O
methods,O,O
were,O,O
used,O,O
to,O,O
determine,O,O
if,O,O
glutamic,B,B
acid,I,I
decarboxylase,O,I
(,O,O
GAD,O,B
),O,O
mRNA,O,I
-,O,O
containing,O,O
neurons,O,O
within,O,O
the,O,O
hilus,O,O
of,O,O
the,O,O
dentate,O,O
gyrus,O,O
are,O,O
vulnerable,O,O
to,O,O
seizure,O,O
-,O,O
induced,O,O
damage,O,O
in,O,O
a,O,O
model,O,O
of,O,O
chronic,O,O
seizures,O,O
.,O,O
Sprague,O,O
-,O,O
Dawley,O,O
rats,O,O
were,O,O
injected,O,O
intraperitoneally,O,O
with,O,O
pilocarpine,B,B
",",O,O
and,O,O
the,O,O
hippocampal,O,O
formation,O,O
was,O,O
studied,O,O
histologically,O,O
at,O,O
1,O,O
",",O,O
2,O,O
",",O,O
4,O,O
",",O,O
and,O,O
8,O,O
week,O,O
intervals,O,O
after,O,O
pilocarpine,B,O
-,O,O
induced,O,O
seizures,O,O
.,O,O
In,O,O
situ,O,O
hybridization,O,O
histochemistry,O,O
",",O,O
using,O,O
a,O,O
digoxigenin,B,B
-,O,O
labeled,O,O
GAD,O,B
cRNA,O,I
probe,O,O
",",O,O
demonstrated,O,O
a,O,O
substantial,O,O
decrease,O,O
in,O,O
the,O,O
number,O,O
of,O,O
GAD,O,B
mRNA,O,I
-,O,I
containing,O,I
neurons,O,O
in,O,O
the,O,O
hilus,O,O
of,O,O
the,O,O
dentate,O,O
gyrus,O,O
in,O,O
the,O,O
pilocarpine,B,O
-,O,O
treated,O,O
rats,O,O
as,O,O
compared,O,O
to,O,O
controls,O,O
at,O,O
all,O,O
time,O,O
intervals,O,O
.,O,O
Additional,O,O
neuronanatomical,O,O
studies,O,O
",",O,O
including,O,O
cresyl,B,B
violet,I,I
staining,O,O
",",O,O
neuronal,O,O
degeneration,O,O
methods,O,O
",",O,O
and,O,O
histochemical,O,O
localization,O,O
of,O,O
glial,O,B
fibrillary,O,I
acidic,O,I
protein,O,I
",",O,O
suggested,O,O
that,O,O
the,O,O
decrease,O,O
in,O,O
the,O,O
number,O,O
of,O,O
GAD,O,B
mRNA,O,I
-,O,I
containing,O,I
neurons,O,I
was,O,O
related,O,O
to,O,O
neuronal,O,O
loss,O,O
rather,O,O
than,O,O
to,O,O
a,O,O
decrease,O,O
in,O,O
GAD,O,B
mRNA,O,I
levels,O,I
.,O,O
The,O,O
loss,O,O
of,O,O
GAD,O,B
mRNA,O,I
-,O,I
containing,O,I
neurons,O,O
in,O,O
the,O,O
hilus,O,O
contrasted,O,O
with,O,O
the,O,O
relative,O,O
preservation,O,O
of,O,O
labeled,O,O
putative,O,O
basket,O,O
cells,O,O
along,O,O
the,O,O
inner,O,O
margin,O,O
of,O,O
the,O,O
granule,O,O
cell,O,O
layer,O,O
.,O,O
Quantitative,O,O
analyses,O,O
of,O,O
labeled,O,O
neurons,O,O
in,O,O
three,O,O
regions,O,O
of,O,O
the,O,O
dentate,O,O
gyrus,O,O
in,O,O
the,O,O
1,O,O
and,O,O
2,O,O
week,O,O
groups,O,O
showed,O,O
statistically,O,O
significant,O,O
decreases,O,O
in,O,O
the,O,O
mean,O,O
number,O,O
of,O,O
GAD,O,B
mRNA,O,I
-,O,I
containing,O,I
neurons,O,O
in,O,O
the,O,O
hilus,O,O
of,O,O
both,O,O
groups,O,O
of,O,O
experimental,O,O
animals,O,O
.,O,O
No,O,O
significant,O,O
differences,O,O
were,O,O
found,O,O
in,O,O
the,O,O
molecular,O,O
layer,O,O
or,O,O
the,O,O
granule,O,O
cell,O,O
layer,O,O
",",O,O
which,O,O
included,O,O
labeled,O,O
neurons,O,O
along,O,O
the,O,O
lower,O,O
margin,O,O
of,O,O
the,O,O
granule,O,O
cell,O,O
layer,O,O
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
",",O,O
in,O,O
this,O,O
model,O,O
",",O,O
a,O,O
subpopulation,O,O
of,O,O
GAD,O,B
mRNA,O,I
-,O,I
containing,O,I
neurons,O,O
within,O,O
the,O,O
dentate,O,O
gyrus,O,O
is,O,O
selectively,O,O
vulnerable,O,O
to,O,O
seizure,O,O
-,O,O
induced,O,O
damage,O,O
.,O,O
Such,O,O
differential,O,O
vulnerability,O,O
appears,O,O
to,O,O
be,O,O
another,O,O
indication,O,O
of,O,O
the,O,O
heterogeneity,O,O
of,O,O
GABA,B,B
neurons,O,O
.,O,O
Effects,O,O
of,O,O
deliberate,O,O
hypotension,O,O
induced,O,O
by,O,O
labetalol,B,B
with,O,O
isoflurane,B,B
on,O,O
neuropsychological,O,O
function,O,O
.,O,O
The,O,O
effect,O,O
of,O,O
deliberate,O,O
hypotension,O,O
on,O,O
brain,O,O
function,O,O
measured,O,O
by,O,O
neuropsychological,O,O
tests,O,O
was,O,O
studied,O,O
in,O,O
41,O,O
adult,O,O
patients,O,O
.,O,O
Twenty,O,O
-,O,O
four,O,O
patients,O,O
were,O,O
anaesthetized,O,O
for,O,O
middle,O,O
-,O,O
ear,O,O
surgery,O,O
with,O,O
deliberate,O,O
hypotension,O,O
induced,O,O
by,O,O
labetalol,B,B
with,O,O
isoflurane,B,B
(,O,O
hypotensive,O,O
group,O,O
),O,O
.,O,O
Seventeen,O,O
patients,O,O
without,O,O
hypotension,O,O
served,O,O
as,O,O
a,O,O
control,O,O
group,O,O
.,O,O
The,O,O
mean,O,O
arterial,O,O
pressure,O,O
was,O,O
77,O,O
+,O,O
/,O,O
-,O,O
2,O,O
mmHg,O,B
(,O,O
10,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
0,O,O
kPa,O,B
),O,O
before,O,O
hypotension,O,O
and,O,O
50,O,O
+,O,O
/,O,O
-,O,O
0,O,O
mmHg,O,B
(,O,O
6,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
kPa,O,B
),O,O
during,O,O
hypotension,O,O
in,O,O
the,O,O
hypotensive,O,O
group,O,O
",",O,O
and,O,O
86,O,O
+,O,O
/,O,O
-,O,O
2,O,O
mmHg,O,B
(,O,O
11,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
kPa,O,B
),O,O
during,O,O
anaesthesia,O,O
in,O,O
the,O,O
control,O,O
group,O,O
.,O,O
The,O,O
following,O,O
psychological,O,O
tests,O,O
were,O,O
performed,O,O
:,O,O
four,O,O
subtests,O,O
of,O,O
the,O,O
Wechsler,O,O
Adult,O,O
Intelligence,O,O
Scale,O,O
(,O,O
similarities,O,O
",",O,O
digit,O,O
span,O,O
",",O,O
vocabulary,O,O
and,O,O
digit,O,O
symbol,O,O
),O,O
",",O,O
Trail,O,O
-,O,O
Making,O,O
tests,O,O
A,O,O
and,O,O
B,O,O
",",O,O
Zung,O,O
tests,O,O
(,O,O
self,O,O
-,O,O
rating,O,O
anxiety,O,O
scale,O,O
and,O,O
self,O,O
-,O,O
rating,O,O
depression,O,O
scale,O,O
),O,O
and,O,O
two,O,O
-,O,O
part,O,O
memory,O,O
test,O,O
battery,O,O
with,O,O
immediate,O,O
and,O,O
delayed,O,O
recall,O,O
.,O,O
The,O,O
tests,O,O
were,O,O
performed,O,O
preoperatively,O,O
and,O,O
2,O,O
days,O,O
postoperatively,O,O
.,O,O
There,O,O
were,O,O
no,O,O
statistically,O,O
significant,O,O
differences,O,O
between,O,O
the,O,O
groups,O,O
in,O,O
any,O,O
of,O,O
the,O,O
tests,O,O
in,O,O
the,O,O
changes,O,O
from,O,O
preoperative,O,O
value,O,O
to,O,O
postoperative,O,O
value,O,O
.,O,O
The,O,O
results,O,O
indicate,O,O
that,O,O
hypotension,O,O
induced,O,O
by,O,O
labetalol,B,B
with,O,O
isoflurane,B,B
has,O,O
no,O,O
significant,O,O
harmful,O,O
effects,O,O
on,O,O
mental,O,O
functions,O,O
compared,O,O
to,O,O
normotensive,O,O
anaesthesia,O,O
.,O,O
Apparent,O,O
cure,O,O
of,O,O
rheumatoid,O,B
arthritis,O,I
by,O,O
bone,O,B
marrow,O,I
transplantation,O,I
.,O,O
We,O,O
describe,O,O
the,O,O
induction,O,O
of,O,O
sustained,O,O
remissions,O,O
and,O,O
possible,O,O
cure,O,O
of,O,O
severe,O,O
erosive,O,O
rheumatoid,O,B
arthritis,O,I
(,O,O
RA,O,B
),O,O
by,O,O
bone,O,B
marrow,O,I
transplantation,O,I
(,O,O
BMT,O,B
),O,O
in,O,O
2,O,O
patients,O,O
.,O,O
BMT,O,B
was,O,O
used,O,O
to,O,O
treat,O,O
severe,O,O
aplastic,O,O
anemia,O,O
which,O,O
was,O,O
caused,O,O
by,O,O
gold,B,B
in,O,O
one,O,O
case,O,O
and,O,O
D,B,B
-,I,I
penicillamine,I,I
in,O,O
the,O,O
other,O,O
.,O,O
In,O,O
the,O,O
8,O,O
and,O,O
6,O,O
years,O,O
since,O,O
the,O,O
transplants,O,O
(,O,O
representing,O,O
8,O,O
and,O,O
4,O,O
years,O,O
since,O,O
cessation,O,O
of,O,O
all,O,O
immunosuppressive,O,O
therapy,O,O
",",O,O
respectively,O,O
),O,O
",",O,O
the,O,O
RA,O,O
in,O,O
each,O,O
case,O,O
has,O,O
been,O,O
completely,O,O
quiescent,O,O
.,O,O
Although,O,O
short,O,O
term,O,O
remission,O,O
of,O,O
severe,O,O
RA,O,O
following,O,O
BMT,O,O
has,O,O
been,O,O
reported,O,O
",",O,O
these,O,O
are,O,O
the,O,O
first,O,O
cases,O,O
for,O,O
which,O,O
prolonged,O,O
followup,O,O
has,O,O
been,O,O
available,O,O
.,O,O
This,O,O
experience,O,O
raises,O,O
the,O,O
question,O,O
of,O,O
the,O,O
role,O,O
of,O,O
BMT,O,B
itself,O,O
as,O,O
a,O,O
therapeutic,O,O
option,O,O
for,O,O
patients,O,O
with,O,O
uncontrolled,O,O
destructive,O,O
synovitis,O,O
.,O,O
Seizures,O,O
induced,O,O
by,O,O
combined,O,O
levomepromazine,B,B
-,O,O
fluvoxamine,B,B
treatment,O,O
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
combined,O,O
levomepromazine,B,B
-,O,O
fluvoxamine,B,B
treatment,O,O
-,O,O
induced,O,O
seizures,O,O
.,O,O
It,O,O
seems,O,O
that,O,O
combined,O,O
treatment,O,O
of,O,O
fluvoxamine,B,B
with,O,O
phenothiazines,B,B
may,O,O
possess,O,O
proconvulsive,O,O
activity,O,O
.,O,O
Case,O,O
report,O,O
:,O,O
pentamidine,B,B
and,O,O
polymorphic,O,O
ventricular,O,O
tachycardia,O,O
revisited,O,O
.,O,O
Pentamidine,B,B
isethionate,I,O
has,O,O
been,O,O
associated,O,O
with,O,O
ventricular,O,O
tachyarrhythmias,O,O
",",O,O
including,O,O
torsade,O,O
de,O,O
pointes,O,O
.,O,O
This,O,O
article,O,O
reports,O,O
two,O,O
cases,O,O
of,O,O
this,O,O
complication,O,O
and,O,O
reviews,O,O
all,O,O
reported,O,O
cases,O,O
to,O,O
date,O,O
.,O,O
Pentamidine,B,B
-,O,O
induced,O,O
torsade,O,O
de,O,O
pointes,O,O
may,O,O
be,O,O
related,O,O
to,O,O
serum,O,O
magnesium,B,B
levels,O,O
and,O,O
hypomagnesemia,O,O
may,O,O
synergistically,O,O
induce,O,O
torsade,O,O
.,O,O
Torsade,O,B
de,O,I
pointes,O,I
occurred,O,O
after,O,O
an,O,O
average,O,O
of,O,O
10,O,O
days,O,O
of,O,O
treatment,O,O
with,O,O
pentamidine,B,B
.,O,O
In,O,O
these,O,O
patients,O,O
",",O,O
no,O,O
other,O,O
acute,O,O
side,O,O
effects,O,O
of,O,O
pentamidine,B,B
were,O,O
observed,O,O
.,O,O
Torsade,O,B
de,O,I
pointes,O,I
can,O,O
be,O,O
treated,O,O
when,O,O
recognized,O,O
early,O,O
",",O,O
possibly,O,O
without,O,O
discontinuation,O,O
of,O,O
pentamidine,B,B
.,O,O
When,O,O
QTc,O,B
interval,O,I
prolongation,O,I
is,O,O
observed,O,O
",",O,O
early,O,O
magnesium,B,B
supplementation,O,I
is,O,O
advocated,O,O
.,O,O
Efficacy,O,O
and,O,O
tolerability,O,O
of,O,O
lovastatin,B,B
in,O,O
3390,O,O
women,O,O
with,O,O
moderate,O,O
hypercholesterolemia,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
lovastatin,B,B
in,O,O
women,O,O
with,O,O
moderate,O,O
hypercholesterolemia,O,O
.,O,O
DESIGN,O,O
:,O,O
The,O,O
Expanded,O,O
Clinical,O,O
Evaluation,O,O
of,O,O
Lovastatin,B,B
(,O,O
EXCEL,O,O
),O,O
Study,O,O
",",O,O
a,O,O
multicenter,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
diet,O,O
-,O,O
and,O,O
placebo,O,O
-,O,O
controlled,O,O
trial,O,O
",",O,O
in,O,O
which,O,O
participants,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
receive,O,O
placebo,O,O
or,O,O
lovastatin,B,B
at,O,O
doses,O,O
of,O,O
20,O,O
or,O,O
40,O,O
mg,O,O
once,O,O
daily,O,O
",",O,O
or,O,O
20,O,O
or,O,O
40,O,O
mg,O,O
twice,O,O
daily,O,O
for,O,O
48,O,O
weeks,O,O
.,O,O
SETTING,O,O
:,O,O
Ambulatory,O,O
patients,O,O
recruited,O,O
by,O,O
362,O,O
participating,O,O
centers,O,O
throughout,O,O
the,O,O
United,O,O
States,O,O
.,O,O
PATIENTS,O,O
:,O,O
Women,O,O
(,O,O
n,O,O
=,O,O
3390,O,O
),O,O
from,O,O
the,O,O
total,O,O
cohort,O,O
of,O,O
8245,O,O
volunteers,O,O
.,O,O
MEASUREMENTS,O,O
:,O,O
Plasma,O,B
total,O,O
",",O,O
low,O,B
-,O,I
density,O,I
lipoprotein,O,I
(,O,O
LDL,O,B
),O,O
",",O,O
and,O,O
high,O,B
-,O,I
density,O,I
lipoprotein,O,I
(,O,O
HDL,O,B
),O,O
cholesterol,B,O
",",O,O
and,O,O
triglycerides,B,B
;,O,O
and,O,O
laboratory,O,O
and,O,O
clinical,O,O
evidence,O,O
of,O,O
adverse,O,O
events,O,O
monitored,O,O
periodically,O,O
throughout,O,O
the,O,O
study,O,O
.,O,O
RESULTS,O,O
:,O,O
Among,O,O
women,O,O
",",O,O
lovastatin,B,B
(,O,O
20,O,O
to,O,O
80,O,O
mg,O,O
/,O,O
d,O,O
),O,O
produced,O,O
sustained,O,O
(,O,O
12,O,O
-,O,O
to,O,O
48,O,O
-,O,O
week,O,O
),O,O
",",O,O
dose,O,O
-,O,O
related,O,O
changes,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
:,O,O
decreases,O,O
in,O,O
LDL,O,B
cholesterol,B,I
(,O,O
24,O,O
%,O,O
to,O,O
40,O,O
%,O,O
),O,O
and,O,O
triglycerides,B,B
(,O,O
9,O,O
%,O,O
to,O,O
18,O,O
%,O,O
),O,O
",",O,O
and,O,O
increases,O,O
in,O,O
HDL,O,B
cholesterol,B,I
(,O,O
6,O,O
.,O,O
7,O,O
%,O,O
to,O,O
8,O,O
.,O,O
6,O,O
%,O,O
),O,O
.,O,O
Depending,O,O
on,O,O
the,O,O
dose,O,O
",",O,O
from,O,O
82,O,O
%,O,O
to,O,O
95,O,O
%,O,O
of,O,O
lovastatin,B,B
-,O,O
treated,O,O
women,O,O
achieved,O,O
the,O,O
National,O,O
Cholesterol,B,O
Education,O,O
Program,O,O
goal,O,O
of,O,O
LDL,O,B
cholesterol,B,I
levels,O,O
less,O,O
than,O,O
4,O,O
.,O,O
14,O,O
mmol,O,B
/,O,O
L,O,O
(,O,O
160,O,B
mg,O,I
/,O,I
dL,O,I
),O,O
",",O,O
and,O,O
40,O,O
%,O,O
to,O,O
87,O,O
%,O,O
achieved,O,O
the,O,O
goal,O,O
of,O,O
3,O,O
.,O,O
36,O,B
mmol,O,I
/,O,I
L,O,I
(,O,O
130,O,B
mg,O,I
/,O,I
dL,O,I
),O,O
.,O,O
Successive,O,O
transaminase,O,O
elevations,O,O
greater,O,O
than,O,O
three,O,O
times,O,O
the,O,O
upper,O,O
limit,O,O
of,O,O
normal,O,O
occurred,O,O
in,O,O
0,O,O
.,O,O
1,O,O
%,O,O
of,O,O
women,O,O
and,O,O
were,O,O
dose,O,O
dependent,O,O
above,O,O
the,O,O
20,O,O
-,O,O
mg,O,O
dose,O,O
.,O,O
Myopathy,O,O
",",O,O
defined,O,O
as,O,O
muscle,O,O
symptoms,O,O
with,O,O
creatine,B,B
kinase,O,I
elevations,O,I
greater,O,I
than,O,I
10,O,I
times,O,I
the,O,I
upper,O,I
limit,O,I
of,O,I
normal,O,I
",",O,O
was,O,O
rare,O,O
and,O,O
associated,O,O
with,O,O
the,O,O
highest,O,O
recommended,O,O
daily,O,O
dose,O,O
of,O,O
lovastatin,B,B
(,O,O
80,O,B
mg,O,I
),O,O
.,O,O
Estrogen,O,B
-,O,O
replacement,O,O
therapy,O,O
appeared,O,O
to,O,O
have,O,O
no,O,O
effect,O,O
on,O,O
either,O,O
the,O,O
efficacy,O,O
or,O,O
safety,O,O
profile,O,O
of,O,O
lovastatin,B,B
.,O,O
CONCLUSION,O,O
:,O,O
Lovastatin,B,B
is,O,O
highly,O,O
effective,O,O
and,O,O
generally,O,O
well,O,O
tolerated,O,O
as,O,O
therapy,O,O
for,O,O
primary,O,O
hypercholesterolemia,O,O
in,O,O
women,O,O
.,O,O
Tetany,O,O
and,O,O
rhabdomyolysis,O,O
due,O,O
to,O,O
surreptitious,O,O
furosemide,B,B
-,O,O
-,O,O
importance,O,O
of,O,O
magnesium,B,B
supplementation,O,O
.,O,O
Diuretics,O,B
may,O,O
induce,O,O
hypokalemia,O,B
",",O,O
hypocalcemia,O,B
and,O,O
hypomagnesemia,O,B
.,O,O
While,O,O
severe,O,O
hypokalemia,O,B
may,O,O
cause,O,O
muscle,O,O
weakness,O,O
",",O,O
severe,O,O
hypomagnesemia,O,B
is,O,O
associated,O,O
with,O,O
muscle,O,O
spasms,O,O
and,O,O
tetany,O,O
which,O,O
cannot,O,O
be,O,O
corrected,O,O
by,O,O
potassium,B,B
and,O,O
calcium,B,B
supplementation,O,O
alone,O,O
(,O,O
1,O,O
",",O,O
2,O,O
),O,O
.,O,O
Surreptitious,O,O
diuretic,O,B
ingestion,O,O
has,O,O
been,O,O
described,O,O
",",O,O
mainly,O,O
in,O,O
women,O,O
who,O,O
are,O,O
concerned,O,O
that,O,O
they,O,O
are,O,O
obese,O,O
or,O,O
edematous,O,O
.,O,O
Symptomatic,O,O
hypokalemia,O,B
has,O,O
been,O,O
reported,O,O
in,O,O
such,O,O
patients,O,O
(,O,O
3,O,O
-,O,O
7,O,O
),O,O
and,O,O
in,O,O
one,O,O
case,O,O
hypocalcemia,O,B
was,O,O
observed,O,O
(,O,O
8,O,O
),O,O
",",O,O
but,O,O
the,O,O
effects,O,O
of,O,O
magnesium,B,B
depletion,O,O
were,O,O
not,O,O
noted,O,O
in,O,O
these,O,O
patients,O,O
.,O,O
Ciprofloxacin,B,B
-,O,O
induced,O,O
nephrotoxicity,O,O
in,O,O
patients,O,O
with,O,O
cancer,O,O
.,O,O
Nephrotoxicity,O,O
associated,O,O
with,O,O
ciprofloxacin,B,B
is,O,O
uncommon,O,O
.,O,O
Five,O,O
patients,O,O
with,O,O
cancer,O,B
who,O,O
developed,O,O
acute,O,O
renal,O,O
failure,O,O
that,O,O
followed,O,O
treatment,O,O
with,O,O
ciprofloxacin,B,B
are,O,O
described,O,O
and,O,O
an,O,O
additional,O,O
15,O,O
cases,O,O
reported,O,O
in,O,O
the,O,O
literature,O,O
are,O,O
reviewed,O,O
.,O,O
Other,O,O
than,O,O
elevation,O,O
of,O,O
serum,O,O
creatinine,B,B
levels,O,O
",",O,O
characteristic,O,O
clinical,O,O
manifestations,O,O
and,O,O
abnormal,O,O
laboratory,O,O
findings,O,O
are,O,O
not,O,O
frequently,O,O
present,O,O
.,O,O
Allergic,O,B
interstitial,O,I
nephritis,O,I
is,O,O
believed,O,O
to,O,O
be,O,O
the,O,O
underlying,O,O
pathological,O,O
-,O,O
process,O,O
.,O,O
Definitive,O,O
diagnosis,O,O
requires,O,O
performance,O,O
of,O,O
renal,O,B
biopsy,O,I
",",O,O
although,O,O
this,O,O
is,O,O
not,O,O
always,O,O
feasible,O,O
.,O,O
An,O,O
improvement,O,O
in,O,O
renal,O,B
function,O,I
that,O,O
followed,O,O
the,O,O
discontinuation,O,O
of,O,O
the,O,O
offending,O,O
antibiotic,O,B
supports,O,O
the,O,O
presumptive,O,O
diagnosis,O,O
of,O,O
ciprofloxacin,B,B
-,O,I
induced,O,I
acute,O,I
renal,O,I
failure,O,I
.,O,O
Venous,O,O
complications,O,O
of,O,O
midazolam,B,B
versus,O,O
diazepam,B,B
.,O,O
Although,O,O
some,O,O
studies,O,O
have,O,O
suggested,O,O
fewer,O,O
venous,O,O
complications,O,O
are,O,O
associated,O,O
with,O,O
midazolam,B,B
than,O,O
with,O,O
diazepam,B,B
for,O,O
endoscopic,O,O
procedures,O,O
",",O,O
this,O,O
variable,O,O
has,O,O
not,O,O
been,O,O
well,O,O
documented,O,O
.,O,O
We,O,O
prospectively,O,O
evaluated,O,O
the,O,O
incidence,O,O
of,O,O
venous,O,O
complications,O,O
after,O,O
intravenous,O,O
injection,O,O
of,O,O
diazepam,B,B
or,O,O
midazolam,B,B
in,O,O
122,O,O
consecutive,O,O
patients,O,O
undergoing,O,O
colonoscopy,O,O
and,O,O
esophagogastroduodenoscopy,O,O
.,O,O
Overall,O,O
",",O,O
venous,O,O
complications,O,O
were,O,O
more,O,O
frequent,O,O
with,O,O
diazepam,B,B
(,O,O
22,O,O
of,O,O
62,O,O
patients,O,O
),O,O
than,O,O
with,O,O
midazolam,B,B
(,O,O
4,O,O
of,O,O
60,O,O
patients,O,O
),O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
A,O,O
palpable,O,O
venous,O,O
cord,O,O
was,O,O
present,O,O
in,O,O
23,O,O
%,O,O
(,O,O
14,O,O
of,O,O
62,O,O
),O,O
of,O,O
patients,O,O
in,O,O
the,O,O
diazepam,B,B
group,O,O
",",O,O
compared,O,O
with,O,O
2,O,O
%,O,O
(,O,O
1,O,O
of,O,O
60,O,O
patients,O,O
),O,O
in,O,O
the,O,O
midazolam,B,B
group,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Pain,O,O
at,O,O
the,O,O
injection,O,O
site,O,O
occurred,O,O
in,O,O
35,O,O
%,O,O
(,O,O
22,O,O
of,O,O
62,O,O
),O,O
of,O,O
patients,O,O
in,O,O
the,O,O
diazepam,B,B
group,O,O
compared,O,O
with,O,O
7,O,O
%,O,O
(,O,O
4,O,O
of,O,O
60,O,O
patients,O,O
),O,O
in,O,O
the,O,O
midazolam,B,B
group,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Swelling,O,O
and,O,O
warmth,O,O
at,O,O
the,O,O
injection,O,O
site,O,O
were,O,O
not,O,O
significantly,O,O
different,O,O
between,O,O
the,O,O
two,O,O
groups,O,O
.,O,O
Smoking,O,O
",",O,O
nonsteroidal,O,O
anti,O,O
-,O,O
inflammatory,O,O
drug,O,O
use,O,O
",",O,O
intravenous,O,O
catheter,O,O
site,O,O
",",O,O
dwell,O,O
time,O,O
of,O,O
the,O,O
needle,O,O
",",O,O
alcohol,B,O
use,O,O
",",O,O
and,O,O
pain,O,O
during,O,O
the,O,O
injection,O,O
had,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
incidence,O,O
of,O,O
venous,O,O
complications,O,O
.,O,O
Clarithromycin,B,B
-,O,O
associated,O,O
visual,O,O
hallucinations,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
chronic,O,O
renal,O,O
failure,O,O
on,O,O
continuous,O,O
ambulatory,O,O
peritoneal,O,O
dialysis,O,O
.,O,O
Visual,O,O
hallucinations,O,O
are,O,O
a,O,O
rare,O,O
event,O,O
in,O,O
chronic,O,O
renal,O,O
failure,O,O
and,O,O
not,O,O
related,O,O
to,O,O
uremia,O,O
per,O,O
se,O,O
.,O,O
Unreported,O,O
in,O,O
the,O,O
literature,O,O
is,O,O
visual,O,O
hallucinations,O,O
occurring,O,O
in,O,O
association,O,O
with,O,O
the,O,O
new,O,O
macrolide,B,B
antibiotic,O,O
",",O,O
clarithromycin,B,B
.,O,O
We,O,O
describe,O,O
such,O,O
a,O,O
case,O,O
in,O,O
a,O,O
patient,O,O
with,O,O
end,O,B
-,O,I
stage,O,I
renal,O,I
disease,O,I
(,O,O
ESRD,O,B
),O,O
maintained,O,O
on,O,O
continuous,O,O
ambulatory,O,O
peritoneal,O,O
dialysis,O,O
(,O,O
CAPD,O,B
),O,O
.,O,O
The,O,O
combination,O,O
of,O,O
a,O,O
relatively,O,O
high,O,O
dose,O,O
of,O,O
clarithromycin,B,B
in,O,O
face,O,O
of,O,O
chronic,O,O
renal,O,B
failure,O,I
in,O,O
a,O,O
functionally,O,O
anephric,O,O
patient,O,O
",",O,O
with,O,O
underlying,O,O
aluminum,B,B
intoxication,O,I
",",O,O
may,O,O
have,O,O
facilitated,O,O
the,O,O
appearance,O,O
of,O,O
this,O,O
neurotoxic,O,O
side,O,O
effect,O,O
.,O,O
It,O,O
is,O,O
important,O,O
to,O,O
understand,O,O
the,O,O
pharmacokinetics,O,O
of,O,O
medications,O,O
in,O,O
face,O,O
of,O,O
chronic,O,O
renal,O,O
failure,O,O
",",O,O
the,O,O
possibility,O,O
of,O,O
drug,O,O
interactions,O,O
",",O,O
and,O,O
how,O,O
these,O,O
factors,O,O
should,O,O
help,O,O
guide,O,O
medication,O,O
therapy,O,O
in,O,O
the,O,O
ESRD,O,O
patient,O,O
.,O,O
Changes,O,O
in,O,O
peroxisomes,O,O
in,O,O
preneoplastic,O,O
liver,O,O
and,O,O
hepatoma,O,O
of,O,O
mice,O,O
induced,O,O
by,O,O
alpha,B,B
-,I,I
benzene,I,I
hexachloride,I,I
.,O,O
Peroxisomes,O,B
in,O,O
hepatomas,O,O
and,O,O
hyperplastic,O,O
preneoplastic,O,O
liver,O,O
lesions,O,O
induced,O,O
in,O,O
mice,O,O
by,O,O
500,O,O
ppm,O,O
alpha,B,B
-,I,I
benzene,I,I
hexachloride,I,I
were,O,O
examined,O,O
histochemically,O,O
and,O,O
electron,O,O
microscopically,O,O
.,O,O
Although,O,O
most,O,O
of,O,O
the,O,O
hepatomas,O,O
were,O,O
well,O,O
-,O,O
differentiated,O,O
tumors,O,O
and,O,O
contained,O,O
a,O,O
considerable,O,O
number,O,O
of,O,O
peroxisomes,O,B
",",O,O
the,O,O
tumor,O,O
cells,O,O
did,O,O
not,O,O
respond,O,O
to,O,O
ethyl,B,B
-,I,I
alpha,I,I
-,I,I
p,I,I
-,I,I
chlorophenoxyisobutyrate,I,I
with,O,O
proliferation,O,O
of,O,O
peroxisomes,O,B
.,O,O
At,O,O
the,O,O
16th,O,O
week,O,O
of,O,O
carcinogen,O,B
feeding,O,O
",",O,O
hyperplastic,O,O
nodules,O,O
appeared,O,O
and,O,O
advanced,O,O
to,O,O
further,O,O
stages,O,O
.,O,O
A,O,O
majority,O,O
of,O,O
the,O,O
nodules,O,O
showed,O,O
a,O,O
considerable,O,O
number,O,O
of,O,O
peroxisomes,O,B
and,O,O
the,O,O
inductive,O,O
proliferation,O,O
of,O,O
peroxisomes,O,B
.,O,O
Within,O,O
the,O,O
nodules,O,O
",",O,O
foci,O,O
of,O,O
proliferation,O,O
of,O,O
the,O,O
cells,O,O
that,O,O
showed,O,O
no,O,O
inducibility,O,O
of,O,O
proliferation,O,O
of,O,O
peroxisomes,O,B
appeared,O,O
.,O,O
These,O,O
cells,O,O
proliferated,O,O
further,O,O
",",O,O
replacing,O,O
the,O,O
most,O,O
part,O,O
of,O,O
the,O,O
nodules,O,O
",",O,O
and,O,O
with,O,O
this,O,O
process,O,O
hepatomas,O,B
appeared,O,O
to,O,O
have,O,O
been,O,O
formed,O,O
.,O,O
No,O,O
abnormal,O,O
matrical,O,O
inclusions,O,O
of,O,O
peroxisomes,O,B
were,O,O
formed,O,O
in,O,O
the,O,O
cells,O,O
of,O,O
hyperplastic,O,O
nodules,O,O
by,O,O
ethyl,B,B
-,I,I
alpha,I,I
-,I,I
p,I,I
-,I,I
chlorophenoxyisobutyrate,I,I
unlike,O,O
in,O,O
the,O,O
case,O,O
of,O,O
rats,O,O
.,O,O
Contribution,O,O
of,O,O
the,O,O
sympathetic,O,O
nervous,O,O
system,O,O
to,O,O
salt,O,B
-,O,O
sensitivity,O,O
in,O,O
lifetime,O,O
captopril,B,B
-,O,O
treated,O,O
spontaneously,O,O
hypertensive,O,O
rats,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
test,O,O
the,O,O
hypothesis,O,O
that,O,O
",",O,O
in,O,O
lifetime,O,O
captopril,B,B
-,O,O
treated,O,O
spontaneously,O,O
hypertensive,O,O
rats,O,O
(,O,O
SHR,O,O
),O,O
",",O,O
the,O,O
sympathetic,O,O
nervous,O,O
system,O,O
contributes,O,O
importantly,O,O
to,O,O
the,O,O
hypertensive,O,O
effect,O,O
of,O,O
dietary,B,O
sodium,I,B
chloride,I,I
supplementation,O,O
.,O,O
METHODS,O,O
:,O,O
Male,O,O
SHR,O,O
(,O,O
aged,O,O
6,O,O
weeks,O,O
),O,O
that,O,O
had,O,O
been,O,O
treated,O,O
from,O,O
conception,O,O
onward,O,O
with,O,O
either,O,O
captopril,B,B
or,O,O
vehicle,O,O
remained,O,O
on,O,O
a,O,O
basal,O,O
sodium,B,B
chloride,I,I
diet,O,O
or,O,O
were,O,O
fed,O,O
a,O,O
high,O,O
sodium,B,B
chloride,I,I
diet,O,O
.,O,O
After,O,O
2,O,O
weeks,O,O
",",O,O
the,O,O
rats,O,O
were,O,O
subjected,O,O
to,O,O
ganglionic,O,O
blockade,O,O
and,O,O
2,O,O
days,O,O
later,O,O
",",O,O
an,O,O
infusion,O,O
of,O,O
clonidine,B,B
.,O,O
RESULTS,O,O
:,O,O
Lifetime,O,O
captopril,B,B
treatment,O,O
significantly,O,O
lowered,O,O
mean,O,O
arterial,O,O
pressure,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
Intravenous,O,O
infusion,O,O
of,O,O
the,O,O
ganglionic,O,O
blocker,O,O
hexamethonium,B,B
resulted,O,O
in,O,O
a,O,O
rapid,O,O
decline,O,O
in,O,O
MAP,O,O
that,O,O
eliminated,O,O
the,O,O
dietary,B,O
sodium,I,B
chloride,I,I
-,O,I
induced,O,O
increase,O,O
in,O,O
MAP,O,O
in,O,O
both,O,O
groups,O,O
.,O,O
Infusion,O,O
of,O,O
the,O,O
central,O,O
nervous,O,O
system,O,O
alpha2,B,B
-,I,I
adrenergic,I,I
receptor,I,I
agonist,I,I
clonidine,B,B
also,O,O
resulted,O,O
in,O,O
a,O,O
greater,O,O
reduction,O,O
in,O,O
MAP,O,O
in,O,O
both,O,O
groups,O,O
of,O,O
SHR,O,O
that,O,O
were,O,O
fed,O,O
the,O,O
high,O,O
(,O,O
compared,O,O
with,O,O
the,O,O
basal,O,O
),O,O
sodium,B,B
chloride,I,I
diet,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
both,O,O
lifetime,O,O
captopril,B,B
-,O,I
treated,O,O
and,O,O
control,O,O
SHR,O,O
",",O,O
the,O,O
sympathetic,O,O
nervous,O,O
system,O,O
contributes,O,O
to,O,O
the,O,O
pressor,O,O
effects,O,O
of,O,O
a,O,O
high,O,O
sodium,B,B
chloride,I,I
diet,O,O
.,O,O
Angioedema,O,B
associated,O,O
with,O,O
droperidol,B,B
administration,O,O
.,O,O
Angioedema,O,B
",",O,O
also,O,O
known,O,O
as,O,O
angioneurotic,O,O
edema,O,O
or,O,O
Quincke,O,B
',O,O
s,O,O
disease,O,O
",",O,O
is,O,O
a,O,O
well,O,O
-,O,O
demarcated,O,O
",",O,O
localized,O,O
edema,O,O
involving,O,O
the,O,O
subcutaneous,O,O
tissues,O,O
that,O,O
may,O,O
cause,O,O
upper,O,O
-,O,O
airway,O,O
obstruction,O,O
.,O,O
We,O,O
report,O,O
the,O,O
case,O,O
of,O,O
a,O,O
previously,O,O
healthy,O,O
19,O,O
-,O,O
year,O,O
-,O,O
old,O,O
man,O,O
with,O,O
no,O,O
known,O,O
drug,O,O
allergies,O,O
in,O,O
whom,O,O
angioedema,O,O
with,O,O
significant,O,O
tongue,O,O
swelling,O,O
and,O,O
protrusion,O,O
developed,O,O
within,O,O
10,O,O
minutes,O,O
of,O,O
the,O,O
administration,O,O
of,O,O
a,O,O
single,O,O
IV,O,O
dose,O,O
of,O,O
droperidol,B,B
.,O,O
Late,O,O
cardiotoxicity,O,O
after,O,O
treatment,O,O
for,O,O
a,O,O
malignant,O,O
bone,O,O
tumor,O,O
.,O,O
Cardiac,O,O
function,O,O
was,O,O
assessed,O,O
in,O,O
long,O,O
-,O,O
term,O,O
survivors,O,O
of,O,O
malignant,O,O
bone,O,O
tumors,O,O
who,O,O
were,O,O
treated,O,O
according,O,O
to,O,O
Rosen,B,O
',I,O
s,I,O
T5,I,O
or,I,O
T10,I,O
protocol,I,O
",",O,O
both,O,O
including,O,O
doxorubicin,B,B
.,O,O
Thirty,O,O
-,O,O
one,O,O
patients,O,O
",",O,O
age,O,O
10,O,O
-,O,O
45,O,O
years,O,O
(,O,O
median,O,O
age,O,O
17,O,O
.,O,O
8,O,O
years,O,O
),O,O
were,O,O
evaluated,O,O
2,O,O
.,O,O
3,O,O
-,O,O
14,O,O
.,O,O
1,O,O
years,O,O
(,O,O
median,O,O
8,O,O
.,O,O
9,O,O
years,O,O
),O,O
following,O,O
completion,O,O
of,O,O
treatment,O,O
.,O,O
Cumulative,O,O
doses,O,O
of,O,O
doxorubicin,B,B
were,O,O
225,O,O
-,O,O
550,O,O
mg,O,O
/,O,O
m2,O,O
(,O,O
median,O,O
dose,O,O
360,O,O
),O,O
.,O,O
The,O,O
evaluation,O,O
consisted,O,O
of,O,O
a,O,O
history,O,O
",",O,O
physical,O,O
examination,O,O
",",O,O
electrocardiogram,O,B
(,O,O
ECG,O,B
),O,O
",",O,O
signal,O,O
averaged,O,O
ECG,O,B
",",O,O
24,O,O
-,O,O
hour,O,O
ambulatory,O,O
ECG,O,B
",",O,O
echocardiography,O,B
and,O,O
radionuclide,O,B
angiography,O,I
.,O,O
Eighteen,O,O
of,O,O
31,O,O
(,O,O
58,O,O
%,O,O
),O,O
patients,O,O
showed,O,O
cardiac,O,O
toxicity,O,O
",",O,O
defined,O,O
as,O,O
having,O,O
one,O,O
or,O,O
more,O,O
of,O,O
the,O,O
following,O,O
abnormalities,O,O
:,O,O
late,O,O
potentials,O,O
",",O,O
complex,O,O
ventricular,O,O
arrhythmias,O,O
",",O,O
left,O,O
ventricular,O,O
dilation,O,O
",",O,O
decreased,O,O
shortening,O,O
fraction,O,O
",",O,O
or,O,O
decreased,O,O
ejection,O,O
fraction,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
cardiac,O,B
abnormalities,O,I
increased,O,O
with,O,O
length,O,O
of,O,O
follow,O,O
-,O,O
up,O,O
(,O,O
P,O,B
<,O,O
or,O,O
=,O,O
.,O,O
.,O,O
No,O,O
correlation,O,O
could,O,O
be,O,O
demonstrated,O,O
between,O,O
cumulative,O,O
dose,O,O
of,O,O
doxorubicin,B,B
and,O,O
cardiac,O,B
status,O,O
",",O,O
except,O,O
for,O,O
heart,O,O
rate,O,O
variability,O,O
.,O,O
When,O,O
adjusted,O,O
to,O,O
body,O,O
surface,O,O
area,O,O
",",O,O
the,O,O
left,O,O
ventricular,O,O
posterior,O,O
wall,O,O
thickness,O,O
(,O,O
LVPW,O,B
index,O,I
),O,O
was,O,O
decreased,O,O
in,O,O
all,O,O
patients,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
doxorubicin,B,B
-,O,O
induced,O,O
cardiotoxicity,O,O
is,O,O
high,O,O
and,O,O
increases,O,O
with,O,O
follow,O,O
-,O,O
up,O,O
",",O,O
irrespective,O,O
of,O,O
cumulative,O,O
dose,O,O
.,O,O
Life,O,O
-,O,O
long,O,O
cardiac,O,O
follow,O,O
-,O,O
up,O,O
in,O,O
these,O,O
patients,O,O
is,O,O
warranted,O,O
.,O,O
The,O,O
results,O,O
of,O,O
our,O,O
study,O,O
suggest,O,O
that,O,O
heart,O,O
rate,O,O
variability,O,O
and,O,O
LVPW,O,B
index,O,O
could,O,O
be,O,O
sensitive,O,O
indicators,O,O
for,O,O
cardiotoxicity,O,O
.,O,O
Acute,O,O
blood,O,O
pressure,O,O
elevations,O,O
with,O,O
caffeine,B,B
in,O,O
men,O,O
with,O,O
borderline,O,O
systemic,O,O
hypertension,O,O
.,O,O
Whether,O,O
the,O,O
vasoconstrictive,O,O
actions,O,O
of,O,O
caffeine,B,B
are,O,O
enhanced,O,O
in,O,O
hypertensive,O,O
persons,O,O
has,O,O
not,O,O
been,O,O
demonstrated,O,O
.,O,O
Thus,O,O
",",O,O
caffeine,B,B
(,O,O
3,O,O
.,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
versus,O,O
placebo,O,O
was,O,O
tested,O,O
in,O,O
48,O,O
healthy,O,O
men,O,O
(,O,O
aged,O,O
20,O,O
to,O,O
35,O,O
years,O,O
),O,O
selected,O,O
after,O,O
screening,O,O
on,O,O
2,O,O
separate,O,O
occasions,O,O
.,O,O
Borderline,O,O
hypertensive,O,O
men,O,O
(,O,O
n,O,O
=,O,O
24,O,O
),O,O
were,O,O
selected,O,O
with,O,O
screening,O,O
systolic,O,B
blood,O,I
pressure,O,I
(,O,O
BP,O,O
),O,O
of,O,O
140,O,O
to,O,O
160,O,O
mm,O,O
Hg,O,O
and,O,O
/,O,O
or,O,O
diastolic,O,B
BP,O,I
90,O,O
to,O,O
99,O,O
mm,O,O
Hg,O,O
.,O,O
Low,O,O
-,O,O
risk,O,O
controls,O,O
(,O,O
n,O,O
=,O,O
24,O,O
),O,O
reported,O,O
no,O,O
parental,O,O
history,O,O
of,O,O
hypertension,O,O
and,O,O
had,O,O
screening,O,O
BP,O,O
<,O,O
130,O,O
/,O,O
85,O,O
mm,O,O
Hg,O,O
.,O,O
Participants,O,O
were,O,O
then,O,O
tested,O,O
on,O,O
2,O,O
occasions,O,O
after,O,O
12,O,O
-,O,O
hour,O,O
abstinence,O,O
from,O,O
caffeine,B,B
in,O,O
each,O,O
of,O,O
2,O,O
protocols,O,O
;,O,O
this,O,O
required,O,O
a,O,O
total,O,O
of,O,O
4,O,O
laboratory,O,O
visits,O,O
.,O,O
Caffeine,B,B
-,O,O
induced,O,O
changes,O,O
in,O,O
diastolic,O,O
BP,O,O
were,O,O
2,O,O
to,O,O
3,O,O
times,O,O
larger,O,O
in,O,O
borderline,O,O
subjects,O,O
than,O,O
in,O,O
controls,O,O
(,O,O
+,O,O
8,O,O
.,O,O
4,O,O
vs,O,O
+,O,O
3,O,O
.,O,O
8,O,O
mm,O,O
Hg,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
and,O,O
were,O,O
attributable,O,O
to,O,O
larger,O,O
changes,O,O
in,O,O
impedance,O,B
-,O,I
derived,O,I
measures,O,O
of,O,O
systemic,O,O
vascular,O,O
resistance,O,O
(,O,O
+,O,O
135,O,O
vs,O,O
+,O,O
45,O,O
dynes,O,O
.,O,O
s,O,O
.,O,O
cm,O,O
-,O,O
5,O,O
",",O,O
p,O,O
<,O,O
0,O,O
.,O,O
.,O,O
These,O,O
findings,O,O
were,O,O
consistent,O,O
and,O,O
reached,O,O
significance,O,O
in,O,O
both,O,O
protocols,O,O
.,O,O
The,O,O
percentage,O,O
of,O,O
borderline,O,O
subjects,O,O
in,O,O
whom,O,O
diastolic,O,O
BP,O,O
changes,O,O
exceeded,O,O
the,O,O
median,O,O
control,O,O
response,O,O
was,O,O
96,O,O
%,O,O
.,O,O
Consequently,O,O
",",O,O
whereas,O,O
all,O,O
participants,O,O
exhibited,O,O
normotensive,O,O
levels,O,O
during,O,O
the,O,O
resting,O,O
predrug,O,O
baseline,O,O
",",O,O
33,O,O
%,O,O
of,O,O
borderline,O,O
subjects,O,O
achieved,O,O
hypertensive,O,O
BP,O,O
levels,O,O
after,O,O
caffeine,B,B
ingestion,O,O
.,O,O
Thus,O,O
",",O,O
in,O,O
borderline,O,O
hypertensive,O,O
men,O,O
",",O,O
exaggerated,O,O
responses,O,O
to,O,O
caffeine,B,B
were,O,O
:,O,O
selective,O,O
for,O,O
diastolic,O,B
BP,O,I
",",O,O
consistent,O,O
with,O,O
greater,O,O
vasoconstriction,O,O
",",O,O
replicated,O,O
in,O,O
2,O,O
protocols,O,O
",",O,O
and,O,O
representative,O,O
of,O,O
nearly,O,O
all,O,O
borderline,O,O
hypertensives,O,O
.,O,O
We,O,O
suspect,O,O
that,O,O
the,O,O
potential,O,O
for,O,O
caffeine,B,B
to,O,O
stabilize,O,O
high,O,O
resistance,O,O
states,O,O
in,O,O
susceptible,O,O
persons,O,O
suggests,O,O
that,O,O
its,O,O
use,O,O
may,O,O
facilitate,O,O
their,O,O
disease,O,O
progression,O,O
",",O,O
as,O,O
well,O,O
as,O,O
hinder,O,O
accurate,O,O
diagnosis,O,O
and,O,O
treatment,O,O
.,O,O
Absence,O,O
of,O,O
effect,O,O
of,O,O
sertraline,B,B
on,O,O
time,O,O
-,O,O
based,O,O
sensitization,O,O
of,O,O
cognitive,O,O
impairment,O,O
with,O,O
haloperidol,B,B
.,O,O
This,O,O
double,O,O
-,O,O
blind,O,O
",",O,O
randomized,O,O
",",O,O
placebo,O,B
-,O,I
controlled,O,I
study,O,O
evaluated,O,O
the,O,O
effects,O,O
of,O,O
haloperidol,B,B
alone,O,O
and,O,O
haloperidol,B,B
plus,O,O
sertraline,B,B
on,O,O
cognitive,O,O
and,O,O
psychomotor,O,O
function,O,O
in,O,O
24,O,O
healthy,O,O
male,O,O
subjects,O,O
.,O,O
METHOD,O,O
:,O,O
All,O,O
subjects,O,O
received,O,O
placebo,O,B
on,O,O
Day,O,O
1,O,O
and,O,O
haloperidol,B,B
2,O,O
mg,O,O
on,O,O
Days,O,O
2,O,O
and,O,O
25,O,O
.,O,O
From,O,O
Days,O,O
9,O,O
to,O,O
25,O,O
",",O,O
subjects,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
either,O,O
sertraline,B,B
(,O,O
12,O,O
subjects,O,O
),O,O
or,O,O
placebo,O,B
(,O,O
12,O,O
subjects,O,O
),O,O
;,O,O
the,O,O
sertraline,B,B
dose,O,O
was,O,O
titrated,O,O
from,O,O
50,O,O
to,O,O
200,O,O
mg,O,O
/,O,O
day,O,O
from,O,O
Days,O,O
9,O,O
to,O,O
16,O,O
",",O,O
and,O,O
remained,O,O
at,O,O
200,O,O
mg,O,O
/,O,O
day,O,O
for,O,O
the,O,O
final,O,O
10,O,O
days,O,O
of,O,O
the,O,O
drug,O,O
administration,O,O
period,O,O
.,O,O
Cognitive,O,O
function,O,O
testing,O,O
was,O,O
performed,O,O
before,O,O
dosing,O,O
and,O,O
over,O,O
a,O,O
24,O,O
-,O,O
hour,O,O
period,O,O
after,O,O
dosing,O,O
on,O,O
Days,O,O
1,O,O
",",O,O
2,O,O
",",O,O
and,O,O
25,O,O
.,O,O
RESULTS,O,O
:,O,O
Impairment,O,O
of,O,O
cognitive,O,O
function,O,O
was,O,O
observed,O,O
6,O,O
to,O,O
8,O,O
hours,O,O
after,O,O
administration,O,O
of,O,O
haloperidol,B,B
on,O,O
Day,O,O
2,O,O
but,O,O
was,O,O
not,O,O
evident,O,O
23,O,O
hours,O,O
after,O,O
dosing,O,O
.,O,O
When,O,O
single,O,O
-,O,O
dose,O,O
haloperidol,B,B
was,O,O
given,O,O
again,O,O
25,O,O
days,O,O
later,O,O
",",O,O
greater,O,O
impairment,O,O
with,O,O
earlier,O,O
onset,O,O
was,O,O
noted,O,O
in,O,O
several,O,O
tests,O,O
in,O,O
both,O,O
treatment,O,O
groups,O,O
",",O,O
suggesting,O,O
enhancement,O,O
of,O,O
this,O,O
effect,O,O
.,O,O
There,O,O
was,O,O
no,O,O
indication,O,O
that,O,O
sertraline,B,B
exacerbated,O,O
the,O,O
impairment,O,O
produced,O,O
by,O,O
haloperidol,B,B
since,O,O
an,O,O
equivalent,O,O
effect,O,O
also,O,O
occurred,O,O
in,O,O
the,O,O
placebo,O,B
group,O,O
.,O,O
Three,O,O
subjects,O,O
(,O,O
2,O,O
on,O,O
sertraline,B,B
and,O,O
1,O,O
on,O,O
placebo,O,B
),O,O
withdrew,O,O
from,O,O
the,O,O
study,O,O
because,O,O
of,O,O
side,O,O
effects,O,O
.,O,O
Ten,O,O
subjects,O,O
in,O,O
each,O,O
group,O,O
reported,O,O
side,O,O
effects,O,O
related,O,O
to,O,O
treatment,O,O
.,O,O
The,O,O
side,O,O
effect,O,O
profiles,O,O
of,O,O
sertraline,B,B
and,O,O
of,O,O
placebo,O,B
were,O,O
similar,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Haloperidol,B,B
produced,O,O
a,O,O
clear,O,O
profile,O,O
of,O,O
cognitive,O,O
impairment,O,O
that,O,O
was,O,O
not,O,O
worsened,O,O
by,O,O
concomitant,O,O
sertraline,B,B
administration,O,O
.,O,O
Coexistence,O,O
of,O,O
cerebral,O,O
venous,O,O
sinus,O,O
and,O,O
internal,O,O
carotid,O,O
artery,O,O
thrombosis,O,O
associated,O,O
with,O,O
exogenous,O,O
sex,O,O
hormones,O,O
.,O,O
A,O,O
case,O,O
report,O,O
.,O,O
A,O,O
forty,O,O
-,O,O
six,O,O
year,O,O
-,O,O
old,O,O
premenopausal,O,O
woman,O,O
developed,O,O
headache,O,O
",",O,O
nausea,O,O
and,O,O
vomiting,O,O
",",O,O
left,O,O
hemiparesis,O,O
and,O,O
seizure,O,O
two,O,O
days,O,O
after,O,O
parenteral,O,O
use,O,O
of,O,O
progesterone,B,B
and,O,O
estradiol,B,B
.,O,O
Diabetes,O,B
mellitus,O,I
(,O,I
DM,O,I
),O,I
was,O,O
found,O,O
during,O,O
admission,O,O
.,O,O
Computed,O,O
tomography,O,O
showed,O,O
a,O,O
hemorrhagic,O,O
infarct,O,O
in,O,O
the,O,O
right,O,O
frontal,O,O
lobe,O,O
and,O,O
increased,O,O
density,O,O
in,O,O
the,O,O
superior,O,O
sagittal,O,O
sinus,O,O
(,O,O
SSS,O,O
),O,O
.,O,O
Left,O,O
carotid,O,O
angiography,O,O
found,O,O
occlusion,O,O
of,O,O
the,O,O
left,O,O
internal,O,O
carotid,O,O
artery,O,B
(,O,O
ICA,O,B
),O,O
.,O,O
Right,O,O
carotid,O,O
angiograms,O,O
failed,O,O
to,O,O
show,O,O
the,O,O
SSS,O,O
and,O,O
inferior,O,O
sagittal,O,O
sinus,O,O
",",O,O
suggestive,O,O
of,O,O
venous,O,O
sinus,O,O
thrombosis,O,O
.,O,O
Coexistence,O,O
of,O,O
the,O,O
cerebral,O,O
artery,O,B
and,O,O
the,O,O
venous,O,O
sinus,O,O
occlusion,O,O
has,O,O
been,O,O
described,O,O
infrequently,O,O
.,O,O
In,O,O
this,O,O
case,O,O
",",O,O
the,O,O
authors,O,O
postulate,O,O
that,O,O
the,O,O
use,O,O
of,O,O
estradiol,B,B
and,O,O
progesterone,B,B
and,O,O
the,O,O
underlying,O,O
DM,O,O
increased,O,O
vascular,O,O
thrombogenicity,O,O
",",O,O
which,O,O
provided,O,O
a,O,O
common,O,O
denominator,O,O
for,O,O
thrombosis,O,O
of,O,O
both,O,O
the,O,O
ICA,O,B
and,O,O
the,O,O
venous,O,O
sinus,O,O
.,O,O
Chemotherapy,O,O
of,O,O
advanced,O,O
inoperable,O,O
non,O,O
-,O,O
small,O,O
cell,O,O
lung,O,O
cancer,O,O
with,O,O
paclitaxel,B,B
:,O,O
a,O,O
phase,O,O
II,O,O
trial,O,O
.,O,O
Paclitaxel,B,B
(,O,O
Taxol,B,B
;,O,O
Bristol,O,B
-,O,I
Myers,O,I
Squibb,O,I
Company,O,I
",",O,O
Princeton,O,B
",",O,O
NJ,O,B
),O,O
has,O,O
demonstrated,O,O
significant,O,O
antineoplastic,O,O
activity,O,O
against,O,O
different,O,O
tumor,O,O
types,O,O
",",O,O
notably,O,O
ovarian,O,B
and,O,O
breast,O,B
carcinoma,O,I
.,O,O
Two,O,O
phase,O,O
II,O,O
trials,O,O
of,O,O
24,O,O
-,O,O
hour,O,O
paclitaxel,B,B
infusions,O,O
in,O,O
chemotherapy,O,O
-,O,O
naive,O,O
patients,O,O
with,O,O
stage,O,O
IIIB,O,O
or,O,O
IV,O,O
non,O,O
-,O,O
small,O,O
cell,O,O
lung,O,O
cancer,O,O
(,O,O
NSCLC,O,B
),O,O
reported,O,O
response,O,O
rates,O,O
of,O,O
21,O,O
%,O,O
and,O,O
24,O,O
%,O,O
.,O,O
Leukopenia,O,B
was,O,O
dose,O,O
limiting,O,O
:,O,O
as,O,O
many,O,O
as,O,O
62,O,O
.,O,O
5,O,O
%,O,O
of,O,O
patients,O,O
experienced,O,O
grade,O,O
4,O,O
leukopenia,O,B
.,O,O
We,O,O
investigated,O,O
the,O,O
efficacy,O,O
and,O,O
toxicity,O,O
of,O,O
a,O,O
3,O,O
-,O,O
hour,O,O
paclitaxel,B,B
infusion,O,O
in,O,O
a,O,O
phase,O,O
II,O,O
trial,O,O
in,O,O
patients,O,O
with,O,O
inoperable,O,O
stage,O,O
IIIB,O,O
or,O,O
IV,O,O
NSCLC,O,O
.,O,O
The,O,O
58,O,O
patients,O,O
treated,O,O
(,O,O
41,O,O
men,O,O
and,O,O
17,O,O
women,O,O
),O,O
had,O,O
a,O,O
median,O,O
age,O,O
of,O,O
59,O,O
years,O,O
(,O,O
age,O,O
range,O,O
",",O,O
25,O,O
to,O,O
75,O,O
),O,O
and,O,O
a,O,O
performance,O,O
status,O,O
of,O,O
0,O,O
through,O,O
2,O,O
.,O,O
Most,O,O
patients,O,O
(,O,O
72,O,O
.,O,O
4,O,O
%,O,O
),O,O
had,O,O
stage,O,O
IV,O,O
NSCLC,O,B
.,O,O
Paclitaxel,B,B
225,O,O
mg,O,O
/,O,O
m2,O,O
was,O,O
infused,O,O
over,O,O
3,O,O
hours,O,O
every,O,O
3,O,O
weeks,O,O
with,O,O
standard,O,O
prophylactic,O,O
premedication,O,O
.,O,O
Of,O,O
50,O,O
patients,O,O
evaluable,O,O
for,O,O
response,O,O
",",O,O
12,O,O
(,O,O
24,O,O
%,O,O
),O,O
had,O,O
partial,O,O
remission,O,O
",",O,O
26,O,O
(,O,O
52,O,O
%,O,O
),O,O
had,O,O
no,O,O
change,O,O
",",O,O
and,O,O
12,O,O
had,O,O
disease,O,O
progression,O,O
(,O,O
24,O,O
%,O,O
),O,O
.,O,O
Hematologic,O,O
toxicities,O,O
were,O,O
mild,O,O
:,O,O
only,O,O
one,O,O
patient,O,O
(,O,O
2,O,O
%,O,O
),O,O
developed,O,O
grade,O,O
3,O,O
or,O,O
4,O,O
neutropenia,O,B
",",O,O
while,O,O
29,O,O
%,O,O
had,O,O
grade,O,O
1,O,O
or,O,O
2,O,O
.,O,O
Grade,O,O
1,O,O
or,O,O
2,O,O
polyneuropathy,O,B
affected,O,O
56,O,O
%,O,O
of,O,O
patients,O,O
while,O,O
only,O,O
one,O,O
(,O,O
2,O,O
%,O,O
),O,O
experienced,O,O
severe,O,B
polyneuropathy,O,I
.,O,O
Similarly,O,O
",",O,O
grade,O,O
1,O,O
or,O,O
2,O,O
myalgia,O,B
/,O,I
arthralgia,O,I
was,O,O
observed,O,O
in,O,O
63,O,O
.,O,O
%,O,O
of,O,O
patients,O,O
",",O,O
but,O,O
only,O,O
14,O,O
.,O,O
experienced,O,O
grade,O,O
3,O,O
or,O,O
4,O,O
.,O,O
Nausea,O,B
and,O,I
vomiting,O,I
were,O,O
infrequent,O,O
",",O,O
with,O,O
14,O,O
%,O,O
of,O,O
patients,O,O
experiencing,O,O
grade,O,O
1,O,O
or,O,O
2,O,O
and,O,O
only,O,O
2,O,O
%,O,O
experiencing,O,O
grade,O,O
3,O,O
or,O,O
4,O,O
.,O,O
Paclitaxel,B,B
is,O,O
thus,O,O
an,O,O
active,O,O
single,O,O
agent,O,O
in,O,O
this,O,O
patient,O,O
population,O,O
",",O,O
with,O,O
a,O,O
3,O,O
-,O,O
hour,O,O
infusion,O,O
proving,O,O
comparably,O,O
effective,O,O
to,O,O
a,O,O
24,O,O
-,O,O
hour,O,O
infusion,O,O
and,O,O
superior,O,O
in,O,O
terms,O,O
of,O,O
the,O,O
incidence,O,O
of,O,O
hematologic,O,B
and,O,O
nonhematologic,O,B
toxicity,O,O
.,O,O
Further,O,O
phase,O,O
II,O,O
studies,O,O
with,O,O
paclitaxel,B,B
combined,O,O
with,O,O
other,O,O
drugs,O,O
active,O,O
against,O,O
NSCLC,O,B
are,O,O
indicated,O,O
",",O,O
and,O,O
phase,O,O
III,O,O
studies,O,O
comparing,O,O
paclitaxel,B,B
with,O,O
standard,O,O
chemotherapy,O,O
remain,O,O
to,O,O
be,O,O
completed,O,O
.,O,O
Paclitaxel,B,B
combined,O,O
with,O,O
carboplatin,B,B
in,O,O
the,O,O
first,O,O
-,O,O
line,O,O
treatment,O,O
of,O,O
advanced,O,O
ovarian,O,O
cancer,O,O
.,O,O
In,O,O
a,O,O
phase,O,O
I,O,O
study,O,O
to,O,O
determine,O,O
the,O,O
maximum,O,O
tolerated,O,O
dose,O,O
of,O,O
paclitaxel,B,B
(,O,O
Taxol,B,B
;,O,O
Bristol,O,B
-,O,O
Myers,O,I
Squibb,O,I
Company,O,I
",",O,O
Princeton,O,B
",",O,O
NJ,O,B
),O,O
given,O,O
as,O,O
a,O,O
3,O,O
-,O,O
hour,O,O
infusion,O,O
in,O,O
combination,O,O
with,O,O
carboplatin,B,B
administered,O,O
every,O,O
21,O,O
days,O,O
to,O,O
women,O,O
with,O,O
advanced,O,O
ovarian,O,O
cancer,O,O
",",O,O
paclitaxel,B,B
doses,O,O
were,O,O
escalated,O,O
as,O,O
follows,O,O
:,O,O
level,O,O
1,O,O
",",O,O
135,O,O
mg,O,O
/,O,O
m2,O,O
;,O,O
level,O,O
2,O,O
",",O,O
160,O,O
mg,O,O
/,O,O
m2,O,O
;,O,O
level,O,O
3,O,O
",",O,O
185,O,O
mg,O,O
/,O,O
m2,O,O
;,O,O
and,O,O
level,O,O
4,O,O
",",O,O
210,O,O
mg,O,O
/,O,O
m2,O,O
.,O,O
The,O,O
fixed,O,O
dose,O,O
of,O,O
carboplatin,B,B
at,O,O
levels,O,O
1,O,O
through,O,O
4,O,O
was,O,O
given,O,O
to,O,O
achieve,O,O
an,O,O
area,O,O
under,O,O
the,O,O
concentration,O,O
-,O,O
time,O,O
curve,O,O
(,O,O
AUC,O,B
),O,O
of,O,O
5,O,O
using,O,O
the,O,O
Calvert,O,O
formula,O,O
.,O,O
In,O,O
levels,O,O
5,O,O
and,O,O
6,O,O
the,O,O
carboplatin,B,B
dose,O,O
was,O,O
targeted,O,O
at,O,O
AUCs,O,O
of,O,O
6,O,O
and,O,O
7,O,O
.,O,O
5,O,O
",",O,O
respectively,O,O
",",O,O
combined,O,O
with,O,O
a,O,O
fixed,O,O
paclitaxel,B,B
dose,O,O
of,O,O
185,O,O
mg,O,O
/,O,O
m2,O,O
.,O,O
To,O,O
date,O,O
",",O,O
30,O,O
previously,O,O
untreated,O,O
patients,O,O
",",O,O
all,O,O
with,O,O
a,O,O
good,O,O
performance,O,O
status,O,O
(,O,O
Eastern,O,O
Cooperative,O,O
Oncology,O,O
Group,O,O
0,O,O
to,O,O
2,O,O
),O,O
have,O,O
been,O,O
entered,O,O
into,O,O
this,O,O
ongoing,O,O
study,O,O
.,O,O
The,O,O
dose,O,O
-,O,O
limiting,O,O
toxicity,O,O
of,O,O
the,O,O
combination,O,O
was,O,O
myelosuppression,O,B
(,O,O
leukopenia,O,B
",",O,O
granulocytopenia,O,B
",",O,O
and,O,O
thrombocytopenia,O,B
),O,O
.,O,O
Neurotoxicity,O,O
was,O,O
largely,O,O
moderate,O,O
.,O,O
So,O,O
far,O,O
",",O,O
14,O,O
patients,O,O
are,O,O
evaluable,O,O
for,O,O
response,O,O
;,O,O
of,O,O
these,O,O
",",O,O
eight,O,O
(,O,O
57,O,O
%,O,O
),O,O
showed,O,O
objective,O,O
(,O,O
complete,O,O
or,O,O
partial,O,O
),O,O
response,O,O
and,O,O
disease,O,O
stabilized,O,O
in,O,O
six,O,O
patients,O,O
.,O,O
No,O,O
patient,O,O
had,O,O
disease,O,O
progression,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
the,O,O
combination,O,O
of,O,O
paclitaxel,B,B
185,O,O
mg,O,O
/,O,O
m2,O,O
administered,O,O
as,O,O
a,O,O
3,O,O
-,O,O
hour,O,O
infusion,O,O
followed,O,O
immediately,O,O
by,O,O
a,O,O
1,O,O
-,O,O
hour,O,O
infusion,O,O
of,O,O
carboplatin,B,B
at,O,O
an,O,O
AUC,O,B
of,O,O
6,O,O
can,O,O
be,O,O
administered,O,O
safely,O,O
in,O,O
a,O,O
21,O,O
-,O,O
day,O,O
schedule,O,O
in,O,O
the,O,O
outpatient,O,O
setting,O,O
.,O,O
The,O,O
recommended,O,O
dose,O,O
for,O,O
phase,O,O
III,O,O
studies,O,O
is,O,O
paclitaxel,B,B
185,O,O
mg,O,O
/,O,O
m2,O,O
and,O,O
carboplatin,B,B
AUC,O,O
6,O,O
.,O,O
Effects,O,O
of,O,O
acute,O,O
steroid,B,B
administration,O,O
on,O,O
ventilatory,O,O
and,O,O
peripheral,O,O
muscles,O,O
in,O,O
rats,O,O
.,O,O
Occasional,O,O
case,O,O
reports,O,O
have,O,O
shown,O,O
that,O,O
acute,O,O
myopathy,O,O
may,O,O
occur,O,O
in,O,O
patients,O,O
treated,O,O
with,O,O
massive,O,O
doses,O,O
of,O,O
corticosteroids,B,B
.,O,O
The,O,O
mechanism,O,O
of,O,O
this,O,O
myopathy,O,O
is,O,O
poorly,O,O
understood,O,O
.,O,O
Therefore,O,O
",",O,O
60,O,O
male,O,O
rats,O,O
were,O,O
randomly,O,O
assigned,O,O
to,O,O
receive,O,O
daily,O,O
injection,O,O
of,O,O
saline,O,B
(,O,O
C,O,B
),O,O
",",O,O
methylprednisolone,B,B
(,O,O
M,B,B
),O,O
",",O,O
or,O,O
triamcinolone,B,B
(,O,O
T,B,B
),O,O
80,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
d,O,O
for,O,O
5,O,O
d,O,O
.,O,O
Nutritional,O,O
intake,O,O
",",O,O
measured,O,O
daily,O,O
in,O,O
15,O,O
animals,O,O
",",O,O
showed,O,O
a,O,O
significant,O,O
reduction,O,O
of,O,O
food,O,O
intake,O,O
in,O,O
the,O,O
steroid,B,O
-,O,O
treated,O,O
groups,O,O
(,O,O
-,O,O
50,O,O
and,O,O
-,O,O
79,O,O
%,O,O
in,O,O
M,B,B
and,O,O
T,B,B
",",O,O
respectively,O,O
.,O,O
This,O,O
was,O,O
associated,O,O
with,O,O
a,O,O
similar,O,O
loss,O,O
in,O,O
body,O,O
weight,O,O
.,O,O
In,O,O
the,O,O
45,O,O
remaining,O,O
animals,O,O
",",O,O
diaphragm,O,O
contractility,O,O
and,O,O
histopathologic,O,O
features,O,O
of,O,O
several,O,O
muscles,O,O
were,O,O
studied,O,O
.,O,O
Weights,O,O
of,O,O
respiratory,O,O
and,O,O
peripheral,O,O
muscles,O,O
were,O,O
similarly,O,O
decreased,O,O
after,O,O
steroid,B,O
treatment,O,O
.,O,O
Maximal,O,O
twitches,O,O
of,O,O
the,O,O
diaphragm,O,O
were,O,O
lower,O,O
in,O,O
the,O,O
C,O,O
group,O,O
(,O,O
653,O,O
+,O,O
/,O,O
-,O,O
174,O,O
g,O,O
/,O,O
cm,O,O
(,O,O
2,O,O
),O,O
than,O,O
in,O,O
the,O,O
M,B,O
group,O,O
(,O,O
837,O,O
+,O,O
/,O,O
-,O,O
171,O,O
g,O,O
/,O,O
cm,O,O
(,O,O
2,O,O
),O,O
;,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
the,O,O
T,B,B
group,O,O
(,O,O
765,O,O
+,O,O
/,O,O
-,O,O
145,O,O
g,O,O
/,O,O
cm,O,O
(,O,O
2,O,O
),O,O
",",O,O
NS,O,B
.,O,O
Half,O,O
-,O,O
relaxation,O,O
time,O,O
was,O,O
prolonged,O,O
in,O,O
both,O,O
steroid,B,B
groups,O,O
",",O,O
and,O,O
time,O,O
to,O,O
peak,O,O
tension,O,O
was,O,O
longer,O,O
with,O,O
M,B,B
",",O,O
whereas,O,O
tetanic,O,O
tensions,O,O
were,O,O
similar,O,O
.,O,O
Steroid,B,B
treatment,O,O
also,O,O
induced,O,O
a,O,O
leftward,O,O
shift,O,O
of,O,O
the,O,O
force,O,O
-,O,O
frequency,O,O
curve,O,O
at,O,O
25,O,O
and,O,O
50,O,O
Hz,O,B
when,O,O
compared,O,O
with,O,O
saline,O,B
treatment,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
ATPase,O,B
staining,O,O
of,O,O
the,O,O
diaphragm,O,O
",",O,O
scalenus,O,O
medius,O,O
",",O,O
and,O,O
gastrocnemius,O,O
showed,O,O
type,O,O
IIb,O,O
fiber,O,O
atrophy,O,O
in,O,O
the,O,O
steroid,B,O
groups,O,O
and,O,O
also,O,O
diaphragmatic,O,O
type,O,O
IIa,O,O
atrophy,O,O
with,O,O
T,B,B
",",O,O
whereas,O,O
histologic,O,O
examinations,O,O
revealed,O,O
a,O,O
normal,O,O
muscular,O,O
pattern,O,O
with,O,O
absence,O,O
of,O,O
necrosis,O,O
.,O,O
Finally,O,O
",",O,O
a,O,O
pair,O,O
-,O,O
fed,O,O
(,O,O
PF,O,B
),O,O
study,O,O
",",O,O
performed,O,O
in,O,O
18,O,O
rats,O,O
(,O,O
C,O,B
",",O,O
T,B,B
",",O,O
and,O,O
PF,O,B
),O,O
",",O,O
showed,O,O
that,O,O
muscle,O,O
atrophy,O,O
was,O,O
considerably,O,O
less,O,O
pronounced,O,O
in,O,O
PF,O,B
animals,O,O
than,O,O
in,O,O
T,B,B
-,O,O
treated,O,O
animals,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
(,O,O
1,O,O
),O,O
short,O,O
-,O,O
term,O,O
treatment,O,O
with,O,O
massive,O,O
doses,O,O
of,O,O
steroids,B,B
induced,O,O
severe,O,O
respiratory,O,O
and,O,O
limb,O,O
muscle,O,O
wasting,O,O
;,O,O
(,O,O
2,O,O
),O,O
both,O,O
types,O,O
of,O,O
steroids,B,B
induced,O,O
predominantly,O,O
type,O,O
IIb,O,O
atrophy,O,O
",",O,O
resulting,O,O
in,O,O
the,O,O
expected,O,O
alterations,O,O
in,O,O
diaphragm,O,O
contractile,O,O
properties,O,O
;,O,O
(,O,O
3,O,O
),O,O
neither,O,O
steroid,B,B
caused,O,O
muscle,O,O
necrosis,O,O
;,O,O
(,O,O
4,O,O
),O,O
type,O,O
IIb,O,O
atrophy,O,O
was,O,O
not,O,O
caused,O,O
by,O,O
acute,O,O
nutritional,O,O
deprivation,O,O
alone,O,O
.,O,O
Continuous,O,O
subcutaneous,O,O
administration,O,O
of,O,O
mesna,B,B
to,O,O
prevent,O,O
ifosfamide,B,B
-,O,O
induced,O,O
hemorrhagic,O,O
cystitis,O,O
.,O,O
Hemorrhagic,O,O
cystitis,O,O
is,O,O
a,O,O
major,O,O
potential,O,O
toxicity,O,O
of,O,O
ifosfamide,B,B
that,O,O
can,O,O
be,O,O
prevented,O,O
by,O,O
administering,O,O
mesna,B,B
along,O,O
with,O,O
the,O,O
cytotoxic,O,O
agent,O,O
.,O,O
Mesna,B,B
is,O,O
generally,O,O
administered,O,O
by,O,O
the,O,O
intravenous,O,O
route,O,O
",",O,O
although,O,O
experience,O,O
with,O,O
oral,O,O
delivery,O,O
of,O,O
the,O,O
drug,O,O
has,O,O
increased,O,O
.,O,O
The,O,O
continuous,O,O
subcutaneous,O,O
administration,O,O
of,O,O
mesna,B,B
has,O,O
the,O,O
advantage,O,O
of,O,O
not,O,O
requiring,O,O
intravenous,O,O
access,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
subcutaneous,O,O
delivery,O,O
of,O,O
the,O,O
neutralizing,O,O
agent,O,O
will,O,O
not,O,O
be,O,O
associated,O,O
with,O,O
the,O,O
risk,O,O
of,O,O
inadequate,O,O
urinary,O,O
mesna,B,B
concentrations,O,O
",",O,O
such,O,O
as,O,O
in,O,O
a,O,O
patient,O,O
taking,O,O
oral,O,O
mesna,B,B
who,O,O
experiences,O,O
severe,O,O
ifosfamide,B,B
-,O,I
induced,O,O
emesis,O,O
and,O,O
is,O,O
unable,O,O
to,O,O
absorb,O,O
the,O,O
drug,O,O
.,O,O
Limited,O,O
clinical,O,O
experience,O,O
with,O,O
continuous,O,O
subcutaneous,O,O
mesna,B,B
administration,O,O
suggests,O,O
it,O,O
is,O,O
a,O,O
safe,O,O
",",O,O
practical,O,O
",",O,O
and,O,O
economic,O,O
method,O,O
of,O,O
drug,O,O
delivery,O,O
that,O,O
permits,O,O
ifosfamide,B,B
to,O,O
be,O,O
administered,O,O
successfully,O,O
in,O,O
the,O,O
outpatient,O,O
setting,O,O
.,O,O
Leg,O,O
and,O,O
back,O,O
pain,O,O
after,O,O
spinal,O,O
anaesthesia,O,O
involving,O,O
hyperbaric,O,O
5,O,O
%,O,O
lignocaine,B,B
.,O,O
Fifty,O,O
-,O,O
four,O,O
patients,O,O
",",O,O
aged,O,O
27,O,O
-,O,O
90,O,O
years,O,O
",",O,O
who,O,O
were,O,O
given,O,O
lignocaine,B,B
5,O,O
%,O,O
in,O,O
6,O,O
.,O,O
8,O,O
%,O,O
glucose,B,B
solution,O,O
for,O,O
spinal,O,O
anaesthesia,O,O
were,O,O
studied,O,O
.,O,O
Thirteen,O,O
of,O,O
these,O,O
patients,O,O
experienced,O,O
pain,O,O
in,O,O
the,O,O
legs,O,O
and,O,O
/,O,O
or,O,O
back,O,O
after,O,O
recovery,O,O
from,O,O
anaesthesia,O,O
.,O,O
The,O,O
patients,O,O
affected,O,O
were,O,O
younger,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
the,O,O
site,O,O
of,O,O
the,O,O
dural,O,O
puncture,O,O
was,O,O
higher,O,O
(,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
than,O,O
those,O,O
individuals,O,O
without,O,O
pain,O,O
.,O,O
Five,O,O
of,O,O
the,O,O
13,O,O
patients,O,O
(,O,O
38,O,O
%,O,O
),O,O
with,O,O
pain,O,O
and,O,O
seven,O,O
of,O,O
the,O,O
41,O,O
patients,O,O
(,O,O
17,O,O
%,O,O
),O,O
without,O,O
pain,O,O
admitted,O,O
to,O,O
a,O,O
high,O,O
alcohol,B,O
intake,O,O
",",O,O
which,O,O
might,O,O
be,O,O
a,O,O
contributing,O,O
factor,O,O
.,O,O
Leg,O,O
and,O,O
/,O,O
or,O,O
back,O,O
pain,O,O
is,O,O
associated,O,O
with,O,O
the,O,O
intrathecal,O,O
use,O,O
of,O,O
hyperbaric,O,O
5,O,B
%,O,I
lignocaine,B,I
.,O,O
The,O,O
use,O,O
of,O,O
serum,O,B
cholinesterase,O,I
in,O,O
succinylcholine,B,B
apnoea,O,O
.,O,O
Fifteen,O,O
patients,O,O
demonstrating,O,O
unexpected,O,O
prolonged,O,O
apnoea,O,O
lasting,O,O
several,O,O
hours,O,O
after,O,O
succinylcholine,B,B
have,O,O
been,O,O
treated,O,O
by,O,O
a,O,O
new,O,O
preparation,O,O
of,O,O
human,O,B
serum,O,I
cholinesterase,O,I
.,O,O
Adequate,O,O
spontaneous,O,O
respiration,O,O
was,O,O
re,O,O
-,O,O
established,O,O
in,O,O
an,O,O
average,O,O
period,O,O
of,O,O
ten,O,O
minutes,O,O
after,O,O
the,O,O
injection,O,O
.,O,O
In,O,O
12,O,O
patients,O,O
biochemical,O,O
genetic,O,O
examinations,O,O
confirmed,O,O
the,O,O
presence,O,O
of,O,O
an,O,O
atypical,O,B
serum,O,I
cholinesterase,O,I
.,O,O
In,O,O
three,O,O
patients,O,O
none,O,O
of,O,O
the,O,O
usual,O,O
variants,O,O
were,O,O
found,O,O
.,O,O
It,O,O
is,O,O
therefore,O,O
supposed,O,O
that,O,O
other,O,O
unknown,O,O
variants,O,O
of,O,O
serum,O,B
cholinesterase,O,I
exist,O,O
which,O,O
cannot,O,O
hydrolyze,O,O
succinylcholine,B,O
.,O,O
The,O,O
use,O,O
of,O,O
serum,O,B
cholinesterase,O,I
in,O,O
succinylcholine,B,O
apnoea,O,O
provided,O,O
considerable,O,O
relief,O,O
to,O,O
both,O,O
patient,O,O
and,O,O
anaesthetist,O,O
.,O,O
Increased,O,O
sulfation,O,B
and,O,O
decreased,O,O
7alpha,O,B
-,O,I
hydroxylation,O,I
of,O,O
deoxycholic,B,B
acid,I,I
in,O,O
ethinyl,B,B
estradiol,I,I
-,O,I
induced,O,I
cholestasis,O,I
in,O,I
rats,O,I
.,O,O
Deoxycholic,B,B
acid,I,I
conjugation,O,I
",",O,O
transport,O,B
capacity,O,I
",",O,O
and,O,O
metabolism,O,B
were,O,O
compared,O,O
in,O,O
control,O,B
and,O,O
ethinyl,B,B
estradiol,I,I
-,O,I
treated,O,I
rats,O,I
.,O,O
Control,O,B
rats,O,I
were,O,O
found,O,O
to,O,O
have,O,O
a,O,O
lower,O,O
capacity,O,I
to,O,O
transport,O,B
deoxycholic,B,B
acid,I,I
than,O,O
taurodeoxycholic,B,B
acid,I,I
",",O,O
and,O,O
both,O,O
were,O,O
decreased,O,O
by,O,O
ethinyl,B,B
estradiol,I,I
treatment,O,I
.,O,O
During,O,O
[,O,O
24,O,B
-,O,I
14C,O,I
],O,O
sodium,B,B
deoxycholate,I,I
infusion,O,O
",",O,O
[,O,O
14C,O,B
],O,O
biliary,O,O
bile,B,O
acid,I,O
secretion,O,O
increased,O,O
",",O,O
but,O,O
bile,O,O
flow,O,O
did,O,O
not,O,O
change,O,O
significantly,O,O
in,O,O
either,O,O
control,O,O
or,O,O
ethinyl,B,B
estradiol,I,I
-,O,I
treated,O,I
rats,O,O
.,O,O
Ethinyl,B,B
estradiol,I,I
-,O,I
treated,O,I
animals,O,O
excreted,O,O
significantly,O,O
less,O,O
14C,O,B
as,O,O
taurocholic,B,B
acid,I,I
than,O,O
did,O,O
control,O,O
animals,O,O
",",O,O
consistent,O,O
with,O,O
an,O,O
impairment,O,O
of,O,O
7alpha,O,B
-,O,I
hydroxylation,O,I
of,O,O
taurodeoxycholic,B,B
acid,I,I
.,O,O
Ethinyl,B,B
estradiol,I,I
treatment,O,O
did,O,O
not,O,O
impair,O,O
conjugation,O,O
of,O,O
deoxycholic,B,B
acid,I,I
",",O,O
but,O,O
did,O,O
result,O,O
in,O,O
an,O,O
increase,O,O
in,O,O
sulfation,O,O
of,O,O
taurodeoxycholic,B,B
acid,I,I
from,O,O
1,O,O
.,O,O
5,O,O
%,O,O
in,O,O
controls,O,O
to,O,O
nearly,O,O
4,O,O
.,O,O
0,O,O
%,O,O
(,O,O
P,O,O
less,O,O
than,O,O
0,O,O
.,O,O
.,O,O
These,O,O
results,O,O
are,O,O
consistent,O,O
with,O,O
the,O,O
hypothesis,O,O
that,O,O
the,O,O
rat,O,O
has,O,O
a,O,O
poorer,O,O
tolerance,O,O
for,O,O
deoxycholic,B,B
acid,I,I
than,O,O
do,O,O
certain,O,O
other,O,O
species,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
rat,O,O
converts,O,O
deoxycholic,B,B
acid,I,I
",",O,O
a,O,O
poor,O,O
choleretic,O,O
",",O,O
to,O,O
taurocholic,B,B
acid,I,I
",",O,O
a,O,O
good,O,O
choleretic,O,O
.,O,O
When,O,O
this,O,O
conversion,O,O
is,O,O
impaired,O,O
with,O,O
ethinyl,B,B
estradiol,I,I
treatment,O,O
",",O,O
sulfation,O,O
may,O,O
be,O,O
an,O,O
important,O,O
alternate,O,O
pathway,O,O
for,O,O
excretion,O,O
of,O,O
this,O,O
potentially,O,O
harmful,O,O
bile,B,B
acid,I,I
.,O,O
Influence,O,O
of,O,O
diet,O,O
free,O,O
of,O,O
NAD,B,B
-,O,I
precursors,O,I
on,O,O
acetaminophen,B,B
hepatotoxicity,O,I
in,O,O
mice,O,O
.,O,O
Recently,O,O
",",O,O
we,O,O
demonstrated,O,O
the,O,O
hepatoprotective,O,O
effects,O,O
of,O,O
nicotinic,B,B
acid,I,I
amide,I,I
",",O,O
a,O,O
selective,O,O
inhibitor,O,O
of,O,O
poly,B,B
(,I,I
ADP,I,I
-,I,I
ribose,I,I
),I,I
polymerase,O,I
(,O,O
PARP,O,B
;,O,O
EC,O,O
2,O,O
.,O,O
4,O,O
.,O,O
2,O,O
.,O,O
30,O,O
),O,O
on,O,O
mice,O,O
suffering,O,O
from,O,O
acetaminophen,B,B
(,O,O
AAP,B,B
),O,O
-,O,O
hepatitis,O,O
",",O,O
suggesting,O,O
that,O,O
the,O,O
AAP,B,B
-,O,O
induced,O,O
liver,O,O
injury,O,O
involves,O,O
a,O,O
step,O,O
which,O,O
depends,O,O
on,O,O
adenoribosylation,O,O
.,O,O
The,O,O
present,O,O
study,O,O
investigates,O,O
the,O,O
effects,O,O
of,O,O
a,O,O
diet,O,O
free,O,O
of,O,O
precursors,O,O
of,O,O
NAD,B,B
",",O,O
the,O,O
substrate,O,O
on,O,O
which,O,O
PARP,O,B
acts,O,O
",",O,O
in,O,O
female,O,O
NMRI,O,O
mice,O,O
with,O,O
AAP,B,B
hepatitis,O,O
and,O,O
evaluates,O,O
the,O,O
influence,O,O
of,O,O
simultaneous,O,O
ethanol,B,O
consumption,O,O
in,O,O
these,O,O
animals,O,O
.,O,O
Liver,O,O
injuries,O,O
were,O,O
quantified,O,O
as,O,O
serum,O,O
activities,O,O
of,O,O
glutamate,B,B
-,O,O
oxaloacetate,B,I
transaminase,O,I
(,O,O
GOT,O,B
),O,O
and,O,O
glutamate,B,B
-,O,O
pyruvate,B,I
transaminase,O,I
(,O,O
GPT,O,B
),O,O
.,O,O
While,O,O
AAP,B,B
caused,O,O
a,O,O
117,O,O
-,O,O
fold,O,O
elevation,O,O
of,O,O
serum,O,O
transaminase,O,O
activities,O,O
in,O,O
mice,O,O
kept,O,O
on,O,O
a,O,O
standard,O,O
laboratory,O,O
diet,O,O
",",O,O
which,O,O
was,O,O
significantly,O,O
exacerbated,O,O
by,O,O
ethanol,B,O
and,O,O
inhibited,O,O
by,O,O
nicotinic,B,B
acid,I,I
amide,I,I
(,O,O
NAA,B,O
),O,O
",",O,O
adverse,O,O
effects,O,O
were,O,O
noted,O,O
in,O,O
animals,O,O
fed,O,O
a,O,O
diet,O,O
free,O,O
of,O,O
precursors,O,O
of,O,O
NAD,B,B
.,O,O
In,O,O
these,O,O
animals,O,O
",",O,O
only,O,O
minor,O,O
increases,O,O
of,O,O
serum,O,O
transaminase,O,O
activities,O,O
were,O,O
measured,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
AAP,B,B
",",O,O
and,O,O
unlike,O,O
the,O,O
exacerbation,O,O
caused,O,O
by,O,O
ethanol,B,O
in,O,O
mice,O,O
on,O,O
a,O,O
standard,O,O
diet,O,O
",",O,O
the,O,O
liver,O,O
damage,O,O
was,O,O
inhibited,O,O
by,O,O
50,O,O
%,O,O
by,O,O
ethanol,B,O
.,O,O
A,O,O
further,O,O
64,O,O
%,O,O
reduction,O,O
of,O,O
hepatitis,O,B
was,O,O
observed,O,O
",",O,O
when,O,O
NAA,B,B
was,O,O
given,O,O
to,O,O
ethanol,B,O
/,O,O
AAP,B,B
-,O,O
mice,O,O
.,O,O
Our,O,O
results,O,O
provide,O,O
evidence,O,O
that,O,O
the,O,O
AAP,B,B
-,O,O
induced,O,O
hepatitis,O,B
and,O,O
its,O,O
exacerbation,O,O
by,O,O
ethanol,B,O
can,O,O
either,O,O
be,O,O
reduced,O,O
by,O,O
end,O,O
-,O,O
product,O,O
inhibition,O,O
of,O,O
PARP,O,B
by,O,O
NAA,B,B
or,O,O
by,O,O
dietary,O,O
depletion,O,O
of,O,O
the,O,O
enzyme,O,O
',O,O
s,O,O
substrate,O,O
NAD,B,B
.,O,O
We,O,O
see,O,O
the,O,O
main,O,O
application,O,O
of,O,O
NAA,B,B
as,O,O
for,O,O
the,O,O
combinational,O,O
use,O,O
in,O,O
pharmaceutical,O,O
preparations,O,O
of,O,O
acetaminophen,B,B
in,O,O
order,O,O
to,O,O
avoid,O,O
hepatic,O,O
damage,O,O
in,O,O
patients,O,O
treated,O,O
with,O,O
this,O,O
widely,O,O
used,O,O
analgesic,O,O
.,O,O
Nightmares,O,O
and,O,O
hallucinations,O,O
after,O,O
long,O,O
-,O,O
term,O,O
intake,O,O
of,O,O
tramadol,B,B
combined,O,O
with,O,O
antidepressants,O,O
.,O,O
Tramadol,B,B
is,O,O
a,O,O
weak,O,O
opioid,O,O
with,O,O
effects,O,O
on,O,O
adrenergic,O,O
and,O,O
serotonergic,O,O
neurotransmission,O,O
that,O,O
is,O,O
used,O,O
to,O,O
treat,O,O
cancer,O,O
pain,O,O
and,O,O
chronic,O,O
non,O,O
malignant,O,O
pain,O,O
.,O,O
This,O,O
drug,O,O
was,O,O
initiated,O,O
in,O,O
association,O,O
with,O,O
paroxetine,B,B
and,O,O
dosulepine,B,B
hydrochloride,I,I
in,O,O
a,O,O
tetraparetic,O,O
patient,O,O
with,O,O
chronic,O,O
pain,O,O
.,O,O
Fifty,O,O
-,O,O
six,O,O
days,O,O
after,O,O
initiation,O,O
of,O,O
the,O,O
treatment,O,O
the,O,O
patient,O,O
presented,O,O
hallucinations,O,O
that,O,O
only,O,O
stopped,O,O
after,O,O
the,O,O
withdrawal,O,O
of,O,O
psycho,O,B
-,O,I
active,O,I
drugs,O,I
and,O,O
tramadol,B,B
.,O,O
The,O,O
case,O,O
report,O,O
questions,O,O
the,O,O
long,O,O
term,O,O
use,O,O
of,O,O
pain,O,O
killers,O,O
combined,O,O
with,O,O
psycho,O,B
-,O,I
active,O,I
drugs,O,I
in,O,O
chronic,O,O
non,O,O
malignant,O,O
pain,O,O
",",O,O
especially,O,O
if,O,O
pain,O,O
is,O,O
under,O,O
control,O,O
.,O,O
Effect,O,O
of,O,O
calcium,B,B
chloride,I,I
and,O,O
4,B,B
-,I,I
aminopyridine,I,I
therapy,O,O
on,O,O
desipramine,B,O
toxicity,O,O
in,O,O
rats,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Hypotension,O,O
is,O,O
a,O,O
major,O,O
contributor,O,O
to,O,O
mortality,O,O
in,O,O
tricyclic,O,O
antidepressant,O,O
overdose,O,O
.,O,O
Recent,O,O
data,O,O
suggest,O,O
that,O,O
tricyclic,O,O
antidepressants,O,O
inhibit,O,O
calcium,B,B
influx,O,O
in,O,O
some,O,O
tissues,O,O
.,O,O
This,O,O
study,O,O
addressed,O,O
the,O,O
potential,O,O
role,O,O
of,O,O
calcium,B,B
channel,O,I
blockade,O,I
in,O,O
tricyclic,O,O
antidepressant,O,O
-,O,O
induced,O,O
hypotension,O,O
.,O,O
METHODS,O,O
:,O,O
Two,O,O
interventions,O,O
were,O,O
studied,O,O
that,O,O
have,O,O
been,O,O
shown,O,O
previously,O,O
to,O,O
improve,O,O
blood,O,O
pressure,O,O
with,O,O
calcium,B,B
channel,O,I
blocker,O,I
overdose,O,I
.,O,O
CaCl2,B,B
and,O,O
4,B,B
-,I,I
aminopyridine,I,I
.,O,O
Anesthetized,O,O
rats,O,O
received,O,O
the,O,O
tricyclic,O,O
antidepressant,O,O
desipramine,B,O
IP,O,O
to,O,O
produce,O,O
hypotension,O,O
",",O,O
QRS,O,O
prolongation,O,O
",",O,O
and,O,O
bradycardia,O,O
.,O,O
Fifteen,O,O
min,O,O
later,O,O
",",O,O
animals,O,O
received,O,O
CaCl2,B,B
",",O,O
NaHCO3,B,B
",",O,O
or,O,O
saline,O,O
.,O,O
In,O,O
a,O,O
second,O,O
experiment,O,O
",",O,O
rats,O,O
received,O,O
tricyclic,O,B
antidepressant,O,I
desipramine,B,I
IP,O,O
followed,O,O
in,O,O
15,O,O
min,O,O
by,O,O
4,B,B
-,I,I
aminopyridine,I,I
or,O,O
saline,O,O
.,O,O
:,O,O
NaHCO3,B,B
briefly,O,O
(,O,O
5,O,O
min,O,O
),O,O
reversed,O,O
hypotension,O,O
and,O,O
QRS,O,O
prolongation,O,O
.,O,B
and,O,O
4,B,B
-,I,I
aminopyridine,I,I
failed,O,O
to,O,O
improve,O,O
blood,O,O
pressure,O,O
.,O,O
incidence,O,O
of,O,O
ventricular,O,O
arrhythmias,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
and,O,O
seizures,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
in,O,O
the,O,O
CaCl2,B,B
group,O,O
was,O,O
higher,O,O
than,O,O
the,O,O
other,O,O
groups,O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
administration,O,O
of,O,O
CaCl2,B,B
or,O,O
4,B,B
-,I,I
aminopyridine,I,I
did,O,O
not,O,O
reverse,O,O
tricyclic,O,O
antidepressant,O,O
-,O,O
induced,O,O
hypotension,O,O
in,O,O
rats,O,O
.,O,O
CaCl2,B,B
therapy,O,O
may,O,O
possibly,O,O
worsen,O,O
both,O,O
cardiovascular,O,O
and,O,O
central,O,O
nervous,O,O
system,O,O
toxicity,O,O
.,O,O
These,O,O
findings,O,O
do,O,O
not,O,O
support,O,O
a,O,O
role,O,O
for,O,O
calcium,B,B
channel,O,I
inhibition,O,I
in,O,O
the,O,O
pathogenesis,O,O
of,O,O
tricyclic,O,O
antidepressant,O,O
-,O,O
induced,O,O
hypotension,O,O
.,O,O
Valsartan,B,B
",",O,O
a,O,O
new,O,O
angiotensin,B,B
II,I,I
antagonist,O,I
for,O,O
the,O,O
treatment,O,O
of,O,O
essential,O,O
hypertension,O,O
:,O,O
a,O,O
comparative,O,O
study,O,O
of,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
against,O,O
amlodipine,B,B
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
compare,O,O
the,O,O
antihypertensive,O,O
efficacy,O,O
of,O,O
a,O,O
new,O,O
angiotensin,B,B
II,I,I
antagonist,O,I
",",O,O
valsartan,B,B
",",O,O
with,O,O
a,O,O
reference,O,O
therapy,O,O
",",O,O
amlodipine,B,B
.,O,O
METHODS,O,O
:,O,O
One,O,O
hundred,O,O
sixty,O,O
-,O,O
eight,O,O
adult,O,O
outpatients,O,O
with,O,O
mild,O,O
to,O,O
moderate,O,O
hypertension,O,O
were,O,O
randomly,O,O
allocated,O,O
in,O,O
double,O,O
-,O,O
blind,O,O
fashion,O,O
and,O,O
equal,O,O
number,O,O
to,O,O
receive,O,O
80,O,O
mg,O,O
valsartan,B,B
or,O,O
5,O,O
mg,O,O
amlodipine,B,B
for,O,O
12,O,O
weeks,O,O
.,O,O
After,O,O
8,O,O
weeks,O,O
of,O,O
therapy,O,O
",",O,O
in,O,O
patients,O,O
whose,O,O
blood,O,O
pressure,O,O
remained,O,O
uncontrolled,O,O
",",O,O
5,O,O
mg,O,O
amlodipine,B,B
was,O,O
added,O,O
to,O,O
the,O,O
initial,O,O
therapy,O,O
.,O,O
Patients,O,O
were,O,O
assessed,O,O
at,O,O
4,O,O
",",O,O
8,O,O
",",O,O
and,O,O
12,O,O
weeks,O,O
.,O,O
The,O,O
primary,O,O
efficacy,O,O
variable,O,O
was,O,O
change,O,O
from,O,O
baseline,O,O
in,O,O
mean,O,O
sitting,O,O
diastolic,O,B
blood,O,I
pressure,O,I
at,O,O
8,O,O
weeks,O,O
.,O,O
Secondary,O,O
variables,O,O
included,O,O
change,O,O
in,O,O
sitting,O,O
systolic,O,B
blood,O,I
pressure,O,I
and,O,O
responder,O,O
rates,O,O
.,O,O
RESULTS,O,O
:,O,O
Both,O,O
valsartan,B,B
and,O,O
amlodipine,B,B
were,O,O
effective,O,O
at,O,O
lowering,O,O
blood,O,I
pressure,O,I
at,O,O
4,O,O
",",O,O
8,O,O
",",O,O
and,O,O
12,O,O
weeks,O,O
.,O,O
Similar,O,O
decreases,O,O
were,O,O
observed,O,O
in,O,O
both,O,O
groups,O,O
",",O,O
with,O,O
no,O,O
statistically,O,O
significant,O,O
differences,O,O
between,O,O
the,O,O
groups,O,O
for,O,O
any,O,O
variable,O,O
analyzed,O,O
.,O,O
For,O,O
the,O,O
primary,O,O
variable,O,O
the,O,O
difference,O,O
was,O,O
0,O,O
.,O,O
5,O,O
mm,O,O
Hg,O,O
in,O,O
favor,O,O
of,O,O
valsartan,B,B
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
68,O,O
;,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
",",O,O
-,O,O
2,O,O
.,O,O
7,O,O
to,O,O
1,O,O
.,O,O
7,O,O
.,O,O
Responder,O,O
rates,O,O
at,O,O
8,O,O
weeks,O,O
were,O,O
66,O,O
.,O,O
7,O,O
%,O,O
for,O,O
valsartan,B,B
and,O,O
60,O,O
.,O,O
2,O,O
%,O,O
for,O,O
amlodipine,B,B
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
39,O,O
),O,O
.,O,O
Both,O,O
treatments,O,O
were,O,O
well,O,O
tolerated,O,O
.,O,O
The,O,O
incidence,O,O
of,O,O
drug,O,O
-,O,O
related,O,O
dependent,O,O
edema,O,O
was,O,O
somewhat,O,O
higher,O,O
in,O,O
the,O,O
amlodipine,B,B
group,O,O
",",O,O
particularly,O,O
at,O,O
a,O,O
dose,O,O
of,O,O
10,O,O
mg,O,O
per,O,O
day,O,O
(,O,O
2,O,O
.,O,O
4,O,O
%,O,O
for,O,O
80,O,O
mg,O,O
valsartan,B,B
;,O,O
3,O,O
.,O,O
6,O,O
%,O,O
for,O,O
5,O,O
mg,O,O
amlodipine,B,B
;,O,O
0,O,O
%,O,O
for,O,O
valsartan,B,B
plus,O,O
5,O,O
mg,O,O
amlodipine,B,B
;,O,O
14,O,O
%,O,O
for,O,O
10,O,O
mg,O,O
amlodipine,B,B
),O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
data,O,O
show,O,O
that,O,O
valsartan,B,B
is,O,O
at,O,O
least,O,O
as,O,O
effective,O,O
as,O,O
amlodipine,B,O
in,O,O
the,O,O
treatment,O,O
of,O,O
mild,O,O
to,O,O
moderate,O,O
hypertension,O,O
.,O,O
The,O,O
results,O,O
also,O,O
show,O,O
valsartan,B,B
to,O,O
be,O,O
well,O,O
tolerated,O,O
and,O,O
suggest,O,O
that,O,O
it,O,O
is,O,O
not,O,O
associated,O,O
with,O,O
side,O,O
effects,O,O
characteristic,O,O
of,O,O
this,O,O
comparator,O,O
class,O,O
",",O,O
dihydropyridine,B,B
calcium,B,I
antagonists,O,I
.,O,O
A,O,O
measure,O,O
of,O,O
pupillary,O,O
oscillation,O,O
as,O,O
a,O,O
marker,O,O
of,O,O
cocaine,B,B
-,O,I
induced,O,I
paranoia,O,I
.,O,O
Cocaine,B,B
-,O,I
induced,O,I
paranoia,O,I
(,O,O
CIP,O,B
),O,O
remains,O,O
an,O,O
important,O,O
drug,O,O
-,O,O
induced,O,O
model,O,O
of,O,O
idiopathic,O,O
paranoia,O,O
for,O,O
which,O,O
no,O,O
psychophysiologic,O,O
marker,O,O
has,O,O
yet,O,O
emerged,O,O
.,O,O
Measures,O,O
of,O,O
pupillary,O,O
oscillation,O,O
were,O,O
able,O,O
to,O,O
significantly,O,O
distinguish,O,O
a,O,O
group,O,O
of,O,O
abstinent,O,O
crack,B,B
cocaine,I,I
abusers,O,O
endorsing,O,O
past,O,O
CIP,O,B
(,O,O
n,O,O
=,O,O
32,O,O
),O,O
from,O,O
another,O,O
group,O,O
of,O,O
crack,B,B
addicts,O,O
who,O,O
denied,O,O
past,O,O
CIP,O,B
(,O,O
n,O,O
=,O,O
29,O,O
),O,O
.,O,O
Serotonin,O,B
syndrome,O,I
from,O,O
venlafaxine,B,B
-,O,O
tranylcypromine,B,B
interaction,O,O
.,O,O
Excessive,O,O
stimulation,O,O
of,O,O
serotonin,B,B
5HT1A,O,I
receptors,O,O
causes,O,O
a,O,O
syndrome,O,O
of,O,O
serotonin,B,B
excess,O,O
that,O,O
consists,O,O
of,O,O
shivering,O,O
",",O,O
muscle,O,O
rigidity,O,O
",",O,O
salivation,O,O
",",O,O
confusion,O,O
",",O,O
agitation,O,O
and,O,O
hyperthermia,O,O
.,O,O
The,O,O
most,O,O
common,O,O
cause,O,O
of,O,O
this,O,O
syndrome,O,O
is,O,O
an,O,O
interaction,O,O
between,O,O
a,O,O
monoamine,O,O
oxidase,O,O
inhibitor,O,O
(,O,O
MAOI,O,B
),O,O
and,O,O
a,O,O
specific,O,O
serotonin,B,B
reuptake,O,I
inhibitor,O,I
.,O,O
Venlafaxine,B,B
is,O,O
a,O,O
new,O,O
antidepressant,O,O
agent,O,O
that,O,O
inhibits,O,O
the,O,O
reuptake,O,O
of,O,O
serotonin,B,B
and,O,O
norepinephrine,B,B
.,O,O
We,O,O
report,O,O
a,O,O
venlafaxine,B,B
-,O,O
MAOI,O,B
interaction,O,O
that,O,O
resulted,O,O
in,O,O
the,O,O
serotonin,O,B
syndrome,O,O
in,O,O
a,O,O
23,O,O
-,O,O
y,O,O
-,O,O
old,O,O
male,O,O
who,O,O
was,O,O
taking,O,O
tranylcypromine,B,B
for,O,O
depression,O,O
.,O,O
He,O,O
had,O,O
been,O,O
well,O,O
until,O,O
the,O,O
morning,O,O
of,O,O
presentation,O,O
when,O,O
he,O,O
took,O,O
1,O,O
/,O,O
2,O,O
tab,O,O
of,O,O
venlafaxine,B,B
.,O,O
Within,O,O
2,O,O
h,O,O
he,O,O
became,O,O
confused,O,O
with,O,O
jerking,O,O
movements,O,O
of,O,O
his,O,O
extremities,O,O
",",O,O
tremors,O,O
and,O,O
rigidity,O,O
.,O,O
He,O,O
was,O,O
brought,O,O
directly,O,O
to,O,O
a,O,O
hospital,O,O
where,O,O
he,O,O
was,O,O
found,O,O
to,O,O
be,O,O
agitated,O,O
and,O,O
confused,O,O
with,O,O
shivering,O,O
",",O,O
myoclonic,O,O
jerks,O,O
",",O,O
rigidity,O,O
",",O,O
salivation,O,O
and,O,O
diaphoresis,O,O
.,O,O
His,O,O
pupils,O,O
were,O,O
7,O,O
mm,O,O
and,O,O
sluggishly,O,O
reactive,O,O
to,O,O
light,O,O
.,O,O
Vital,O,O
signs,O,O
were,O,O
:,O,O
blood,O,B
pressure,O,I
120,O,O
/,O,O
67,O,O
mm,O,O
Hg,O,O
",",O,O
heart,O,B
rate,O,I
127,O,O
/,O,O
min,O,O
",",O,O
respiratory,O,B
rate,O,I
28,O,O
/,O,O
min,O,O
",",O,O
and,O,O
temperature,O,B
97,O,O
F,O,O
.,O,O
After,O,O
180,O,O
mg,O,O
of,O,O
diazepam,B,B
i,O,O
.,O,O
v,O,O
.,O,O
he,O,O
remained,O,O
tremulous,O,O
with,O,O
muscle,O,O
rigidity,O,O
and,O,O
clenched,O,O
jaws,O,O
.,O,O
He,O,O
was,O,O
intubated,O,O
for,O,O
airway,O,O
protection,O,O
and,O,O
because,O,O
of,O,O
hypoventilation,O,O
",",O,O
and,O,O
was,O,O
paralyzed,O,O
to,O,O
control,O,O
muscle,O,O
rigidity,O,O
.,O,O
His,O,O
subsequent,O,O
course,O,O
was,O,O
remarkable,O,O
for,O,O
non,O,O
-,O,O
immune,O,O
thrombocytopenia,O,B
which,O,O
resolved,O,O
.,O,O
The,O,O
patient,O,O
',O,O
s,O,O
maximal,O,O
temperature,O,O
was,O,O
101,O,O
.,O,O
2,O,O
F,O,O
and,O,O
his,O,O
CPK,O,B
remained,O,O
<,O,O
500,O,O
units,O,O
/,O,O
L,O,O
with,O,O
no,O,O
other,O,O
evidence,O,O
of,O,O
rhabdomyolysis,O,B
.,O,O
His,O,O
mental,O,O
status,O,O
normalized,O,O
and,O,O
he,O,O
was,O,O
transferred,O,O
to,O,O
a,O,O
psychiatry,O,O
ward,O,O
.,O,O
This,O,O
patient,O,O
survived,O,O
without,O,O
sequelae,O,O
due,O,O
to,O,O
the,O,O
aggressive,O,O
sedation,O,O
and,O,O
neuromuscular,O,O
paralysis,O,O
.,O,O
Cyclophosphamide,B,B
associated,O,O
bladder,O,O
cancer,O,O
-,O,O
-,O,O
a,O,O
highly,O,O
aggressive,O,O
disease,O,O
:,O,O
analysis,O,O
of,O,O
12,O,O
cases,O,O
.,O,O
PURPOSE,O,O
:,O,O
We,O,O
gained,O,O
knowledge,O,O
of,O,O
the,O,O
etiology,O,O
",",O,O
treatment,O,O
and,O,O
prevention,O,O
of,O,O
cyclophosphamide,B,B
associated,O,O
urothelial,O,O
cancer,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
The,O,O
medical,O,O
records,O,O
of,O,O
6,O,O
men,O,O
and,O,O
6,O,O
women,O,O
(,O,O
mean,O,O
age,O,O
55,O,O
years,O,O
),O,O
with,O,O
cyclophosphamide,B,B
associated,O,O
bladder,O,O
cancer,O,O
were,O,O
reviewed,O,O
.,O,O
RESULTS,O,O
:,O,O
All,O,O
tumors,O,O
were,O,O
grade,O,O
3,O,O
or,O,O
4,O,O
transitional,O,B
cell,O,I
carcinoma,O,I
.,O,O
Of,O,O
the,O,O
5,O,O
patients,O,O
initially,O,O
treated,O,O
with,O,O
endoscopic,O,O
resection,O,O
alone,O,O
only,O,O
1,O,O
is,O,O
alive,O,O
without,O,O
disease,O,O
.,O,O
Of,O,O
the,O,O
6,O,O
patients,O,O
who,O,O
underwent,O,O
early,O,O
cystectomy,O,O
4,O,O
were,O,O
alive,O,O
at,O,O
24,O,O
to,O,O
111,O,O
months,O,O
.,O,O
The,O,O
remaining,O,O
patient,O,O
with,O,O
extensive,O,O
cancer,O,O
underwent,O,O
partial,O,O
cystectomy,O,O
for,O,O
palliation,O,O
and,O,O
died,O,O
3,O,O
months,O,O
later,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
Cyclophosphamide,B,B
associated,O,O
bladder,O,O
tumor,O,O
is,O,O
an,O,O
aggressive,O,O
disease,O,O
.,O,O
However,O,O
",",O,O
long,O,O
-,O,O
term,O,O
survival,O,O
is,O,O
possible,O,O
when,O,O
radical,O,O
cystectomy,O,O
is,O,O
performed,O,O
for,O,O
bladder,O,O
tumors,O,O
with,O,O
any,O,O
sign,O,O
of,O,O
invasion,O,O
and,O,O
for,O,O
recurrent,O,O
high,O,O
grade,O,O
disease,O,O
",",O,O
even,O,O
when,O,O
noninvasive,O,O
.,O,O
A,O,O
phase,O,O
I,O,O
clinical,O,O
study,O,O
of,O,O
the,O,O
antipurine,B,B
antifolate,O,I
lometrexol,B,I
(,O,O
DDATHF,B,B
),O,O
given,O,O
with,O,O
oral,O,O
folic,B,O
acid,I,O
.,O,O
Lometrexol,B,B
is,O,O
an,O,O
antifolate,O,B
which,O,O
inhibits,O,O
glycinamide,B,B
ribonucleotide,I,I
formyltransferase,O,I
(,O,O
GARFT,O,B
),O,O
",",O,O
an,O,O
enzyme,O,O
essential,O,O
for,O,O
de,O,O
novo,O,O
purine,B,B
synthesis,O,I
.,O,O
Extensive,O,O
experimental,O,O
and,O,O
limited,O,O
clinical,O,O
data,O,O
have,O,O
shown,O,O
that,O,O
lometrexol,B,B
has,O,O
activity,O,O
against,O,O
tumours,O,O
which,O,O
are,O,O
refractory,O,O
to,O,O
other,O,O
drugs,O,O
",",O,O
notably,O,O
methotrexate,B,B
.,O,O
However,O,O
",",O,O
the,O,O
initial,O,O
clinical,O,O
development,O,O
of,O,O
lometrexol,B,B
was,O,O
curtailed,O,O
because,O,O
of,O,O
severe,O,O
and,O,O
cumulative,O,O
antiproliferative,O,O
toxicities,O,O
.,O,O
Preclinical,O,O
murine,O,O
studies,O,O
demonstrated,O,O
that,O,O
the,O,O
toxicity,O,O
of,O,O
lometrexol,B,B
can,O,O
be,O,O
prevented,O,O
by,O,O
low,O,O
dose,O,O
folic,B,B
acid,I,I
administration,O,O
",",O,O
i,O,O
.,O,O
e,O,O
.,O,O
for,O,O
7,O,O
days,O,O
prior,O,O
to,O,O
and,O,O
7,O,O
days,O,O
following,O,O
a,O,O
single,O,O
bolus,O,O
dose,O,O
.,O,O
This,O,O
observation,O,O
prompted,O,O
a,O,O
Phase,O,O
I,O,O
clinical,O,O
study,O,O
of,O,O
lometrexol,B,B
given,O,O
with,O,O
folic,B,B
acid,I,I
supplementation,O,I
which,O,O
has,O,O
confirmed,O,O
that,O,O
the,O,O
toxicity,O,O
of,O,O
lometrexol,B,B
can,O,O
be,O,O
markedly,O,O
reduced,O,O
by,O,O
folic,B,B
acid,I,I
supplementation,O,I
.,O,O
Thrombocytopenia,O,B
and,O,O
mucositis,O,B
were,O,O
the,O,O
major,O,O
toxicities,O,O
.,O,O
There,O,O
was,O,O
no,O,O
clear,O,O
relationship,O,O
between,O,O
clinical,O,O
toxicity,O,O
and,O,O
the,O,O
extent,O,O
of,O,O
plasma,O,O
folate,B,B
elevation,O,O
.,O,O
Associated,O,O
studies,O,O
demonstrated,O,O
that,O,O
lometrexol,B,B
plasma,O,O
pharmacokinetics,O,O
were,O,O
not,O,O
altered,O,O
by,O,O
folic,B,B
acid,I,I
administration,O,O
indicating,O,O
that,O,O
supplementation,O,O
is,O,O
unlikely,O,O
to,O,O
reduce,O,O
toxicity,O,O
by,O,O
enhancing,O,O
lometrexol,B,B
plasma,O,O
clearance,O,O
.,O,O
The,O,O
work,O,O
described,O,O
in,O,O
this,O,O
report,O,O
has,O,O
identified,O,O
for,O,O
the,O,O
first,O,O
time,O,O
a,O,O
clinically,O,O
acceptable,O,O
schedule,O,O
for,O,O
the,O,O
administration,O,O
of,O,O
a,O,O
GARFT,O,B
inhibitor,O,O
.,O,O
This,O,O
information,O,O
will,O,O
facilitate,O,O
the,O,O
future,O,O
evaluation,O,O
of,O,O
this,O,O
class,O,O
of,O,O
compounds,O,O
in,O,O
cancer,O,B
therapy,O,O
.,O,O
Fatal,O,O
excited,O,O
delirium,O,O
following,O,O
cocaine,B,B
use,O,O
:,O,O
epidemiologic,O,O
findings,O,O
provide,O,O
new,O,O
evidence,O,O
for,O,O
mechanisms,O,O
of,O,O
cocaine,B,B
toxicity,O,O
.,O,O
We,O,O
describe,O,O
an,O,O
outbreak,O,O
of,O,O
deaths,O,O
from,O,O
cocaine,B,B
-,O,O
induced,O,O
excited,O,O
delirium,O,O
(,O,O
EDDs,O,O
),O,O
in,O,O
Dade,O,O
County,O,O
",",O,O
Florida,O,O
between,O,O
1979,O,O
and,O,O
1990,O,O
.,O,O
From,O,O
a,O,O
registry,O,O
of,O,O
all,O,O
cocaine,B,B
-,O,O
related,O,O
deaths,O,O
in,O,O
Dade,O,O
County,O,O
",",O,O
Florida,O,O
",",O,O
from,O,O
1969,O,O
-,O,O
1990,O,O
",",O,O
58,O,O
EDDs,O,O
were,O,O
compared,O,O
with,O,O
125,O,O
victims,O,O
of,O,O
accidental,O,O
cocaine,B,B
overdose,O,O
without,O,O
excited,O,O
delirium,O,O
.,O,O
Compared,O,O
with,O,O
controls,O,O
",",O,O
EDDs,O,O
were,O,O
more,O,O
frequently,O,O
black,O,O
",",O,O
male,O,O
",",O,O
and,O,O
younger,O,O
.,O,O
They,O,O
were,O,O
less,O,O
likely,O,O
to,O,O
have,O,O
a,O,O
low,O,O
body,O,O
mass,O,O
index,O,O
",",O,O
and,O,O
more,O,O
likely,O,O
to,O,O
have,O,O
died,O,O
in,O,O
police,O,O
custody,O,O
",",O,O
to,O,O
have,O,O
received,O,O
medical,O,O
treatment,O,O
immediately,O,O
before,O,O
death,O,O
",",O,O
to,O,O
have,O,O
survived,O,O
for,O,O
a,O,O
longer,O,O
period,O,O
",",O,O
to,O,O
have,O,O
developed,O,O
hyperthermia,O,B
",",O,O
and,O,O
to,O,O
have,O,O
died,O,O
in,O,O
summer,O,O
months,O,O
.,O,O
EDDs,O,O
had,O,O
concentrations,O,O
of,O,O
cocaine,B,B
and,O,O
benzoylecgonine,B,B
in,O,O
autopsy,O,O
blood,O,O
that,O,O
were,O,O
similar,O,O
to,O,O
those,O,O
for,O,O
controls,O,O
.,O,O
The,O,O
epidemiologic,O,O
findings,O,O
are,O,O
most,O,O
consistent,O,O
with,O,O
the,O,O
hypothesis,O,O
that,O,O
chronic,O,O
cocaine,B,B
use,O,O
disrupts,O,O
dopaminergic,O,O
function,O,O
and,O,O
",",O,O
when,O,O
coupled,O,O
with,O,O
recent,O,O
cocaine,B,B
use,O,O
",",O,O
may,O,O
precipitate,O,O
agitation,O,O
",",O,O
delirium,O,O
",",O,O
aberrant,O,O
thermoregulation,O,O
",",O,O
rhabdomyolysis,O,O
",",O,O
and,O,O
sudden,O,O
death,O,O
.,O,O
Pemoline,B,B
induced,O,O
acute,O,O
choreoathetosis,O,O
:,O,O
case,O,O
report,O,O
and,O,O
review,O,O
of,O,O
the,O,O
literature,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Pemoline,B,B
is,O,O
an,O,O
oxazolidine,B,B
derivative,O,O
that,O,O
is,O,O
structurally,O,O
different,O,O
from,O,O
amphetamines,B,B
and,O,O
used,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
attention,O,O
deficit,O,O
disorder,O,O
.,O,O
Pemoline,B,B
has,O,O
not,O,O
been,O,O
commonly,O,O
associated,O,O
in,O,O
the,O,O
literature,O,O
as,O,O
a,O,O
cause,O,O
of,O,O
acute,O,O
movement,O,O
disorders,O,O
.,O,O
The,O,O
following,O,O
case,O,O
describes,O,O
two,O,O
children,O,O
acutely,O,O
poisoned,O,O
with,O,O
pemoline,B,B
who,O,O
experienced,O,O
profound,O,O
choreoathetosis,O,O
.,O,O
CASE,O,O
REPORT,O,O
:,O,O
Two,O,O
",",O,O
3,O,O
-,O,O
year,O,O
-,O,O
old,O,O
male,O,O
",",O,O
identical,O,O
twin,O,O
siblings,O,O
presented,O,O
to,O,O
the,O,O
emergency,O,O
department,O,O
after,O,O
found,O,O
playing,O,O
with,O,O
a,O,O
an,O,O
empty,O,O
bottle,O,O
of,O,O
pemoline,B,B
originally,O,O
containing,O,O
59,O,O
tablets,O,O
.,O,O
The,O,O
children,O,O
had,O,O
a,O,O
medical,O,O
history,O,O
significant,O,O
for,O,O
attention,O,B
deficit,O,I
disorder,O,I
previously,O,O
treated,O,O
with,O,O
methylphenidate,B,B
without,O,O
success,O,O
.,O,O
This,O,O
was,O,O
their,O,O
first,O,O
day,O,O
of,O,O
pemoline,B,B
therapy,O,O
.,O,O
The,O,O
choreoathetoid,O,O
movements,O,O
began,O,O
45,O,O
min,O,O
to,O,O
1,O,O
h,O,O
after,O,O
ingestion,O,O
.,O,O
The,O,O
children,O,O
gave,O,O
no,O,O
history,O,O
of,O,O
prior,O,O
movement,O,O
disorders,O,O
and,O,O
there,O,O
was,O,O
no,O,O
family,O,O
history,O,O
of,O,O
movement,O,O
disorders,O,O
.,O,O
The,O,O
children,O,O
received,O,O
gastrointestinal,O,B
decontamination,O,I
and,O,O
high,O,O
doses,O,O
of,O,O
intravenous,O,B
benzodiazepines,B,I
in,O,O
an,O,O
attempt,O,O
to,O,O
control,O,O
the,O,O
choreoathetoid,O,B
movements,O,I
.,O,O
Despite,O,O
treatment,O,O
",",O,O
the,O,O
children,O,O
continued,O,O
to,O,O
have,O,O
choreoathetosis,O,B
for,O,O
approximately,O,O
24,O,O
hours,O,O
.,O,O
Forty,O,O
-,O,O
eight,O,O
hours,O,O
after,O,O
admission,O,O
",",O,O
the,O,O
children,O,O
appeared,O,O
to,O,O
be,O,O
at,O,O
their,O,O
baseline,O,O
and,O,O
were,O,O
discharged,O,O
home,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Pemoline,B,B
associated,O,O
movement,O,O
disorder,O,O
has,O,O
been,O,O
rarely,O,O
reported,O,O
in,O,O
the,O,O
acute,O,O
toxicology,O,O
literature,O,O
.,O,O
The,O,O
possibility,O,O
of,O,O
choreoathetoid,O,O
movements,O,O
should,O,O
be,O,O
considered,O,O
in,O,O
patients,O,O
presenting,O,O
after,O,O
pemoline,B,B
overdose,O,O
.,O,O
Effect,O,O
of,O,O
myopic,O,O
excimer,O,O
laser,O,O
photorefractive,O,O
keratectomy,O,O
on,O,O
the,O,O
electrophysiologic,O,O
function,O,O
of,O,O
the,O,O
retina,O,B
and,O,O
optic,O,B
nerve,O,I
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
assess,O,O
by,O,O
electrophysiologic,O,O
testing,O,O
the,O,O
effect,O,O
of,O,O
photorefractive,O,B
keratectomy,O,I
(,O,O
PRK,O,B
),O,O
on,O,O
the,O,O
retina,O,B
and,O,O
optic,O,B
nerve,O,I
.,O,O
SETTING,O,O
:,O,O
Eye,O,B
Clinic,O,I
",",O,O
S,O,B
.,O,O
Salvatore,O,I
Hospital,O,I
",",O,O
L,O,B
',O,I
Aquila,O,I
University,O,I
",",O,O
Italy,O,B
.,O,O
METHODS,O,O
:,O,O
Standard,O,B
pattern,O,I
electroretinograms,O,I
(,O,O
P,O,B
-,O,I
ERGs,O,I
),O,O
and,O,O
standard,O,B
pattern,O,I
visual,O,I
evoked,O,I
potentials,O,I
(,O,O
P,O,B
-,O,I
VEPs,O,I
),O,O
were,O,O
done,O,O
in,O,O
25,O,O
eyes,O,O
of,O,O
25,O,O
patients,O,O
who,O,O
had,O,O
myopic,O,B
PRK,O,I
for,O,O
an,O,O
attempted,O,O
correction,O,O
between,O,O
5,O,O
.,O,O
and,O,O
15,O,O
.,O,O
diopters,O,O
(,O,O
D,O,B
),O,O
(,O,O
mean,O,O
8,O,O
.,O,O
D,O,B
.,O,O
Testing,O,O
was,O,O
done,O,O
preoperatively,O,O
and,O,O
3,O,O
",",O,O
6,O,O
",",O,O
12,O,O
",",O,O
and,O,O
18,O,O
months,O,O
postoperatively,O,O
.,O,O
The,O,O
contralateral,O,O
eyes,O,O
served,O,O
as,O,O
controls,O,O
.,O,O
During,O,O
the,O,O
follow,O,O
-,O,O
up,O,O
",",O,O
3,O,O
patients,O,O
(,O,O
12,O,O
%,O,O
),O,O
developed,O,O
steroid,B,B
-,O,O
induced,O,O
elevated,O,O
intraocular,O,O
pressure,O,O
(,O,O
IOP,O,B
),O,O
that,O,O
resolved,O,O
after,O,O
corticosteroid,B,B
therapy,O,O
was,O,O
discontinued,O,O
.,O,O
RESULTS,O,O
:,O,O
No,O,O
statistically,O,O
significant,O,O
differences,O,O
were,O,O
seen,O,O
between,O,O
treated,O,O
and,O,O
control,O,O
eyes,O,O
nor,O,O
between,O,O
treated,O,O
eyes,O,O
preoperatively,O,O
and,O,O
postoperatively,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Myopic,O,O
excimer,O,O
laser,O,O
PRK,O,O
did,O,O
not,O,O
seem,O,O
to,O,O
affect,O,O
the,O,O
posterior,O,O
segment,O,O
.,O,O
The,O,O
transient,O,O
steroid,B,B
-,O,I
induced,O,I
IOP,O,I
rise,O,O
did,O,O
not,O,O
seem,O,O
to,O,O
cause,O,O
functional,O,O
impairment,O,O
.,O,O
Neutrophil,O,O
superoxide,B,B
and,O,O
hydrogen,B,B
peroxide,I,I
production,O,O
in,O,O
patients,O,O
with,O,O
acute,O,O
liver,O,O
failure,O,O
.,O,O
Defects,O,O
in,O,O
superoxide,B,B
and,O,O
hydrogen,B,B
peroxide,I,I
production,O,O
may,O,O
be,O,O
implicated,O,O
in,O,O
the,O,O
high,O,O
incidence,O,O
of,O,O
bacterial,O,O
infections,O,O
in,O,O
patients,O,O
with,O,O
acute,O,O
liver,O,O
failure,O,O
(,O,O
ALF,O,O
),O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
oxygen,B,O
radical,O,O
production,O,O
in,O,O
patients,O,O
with,O,O
ALF,O,O
due,O,O
to,O,O
paracetamol,B,B
overdose,O,O
was,O,O
compared,O,O
with,O,O
that,O,O
of,O,O
healthy,O,O
volunteers,O,O
.,O,O
Neutrophils,O,O
from,O,O
14,O,O
ALF,O,B
patients,O,O
were,O,O
stimulated,O,O
via,O,O
the,O,O
complement,O,B
receptors,O,O
using,O,O
zymosan,O,B
opsonized,O,O
with,O,O
ALF,O,B
or,O,O
control,O,B
serum,O,O
.,O,O
Superoxide,B,O
and,O,O
hydrogen,B,B
peroxide,I,I
production,O,O
by,O,O
ALF,O,B
neutrophils,O,O
stimulated,O,O
with,O,O
zymosan,O,B
opsonized,O,O
with,O,O
ALF,O,B
serum,O,O
was,O,O
significantly,O,O
reduced,O,O
compared,O,O
with,O,O
the,O,O
control,O,B
subjects,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
This,O,O
defect,O,O
persisted,O,O
when,O,O
zymosan,O,B
opsonized,O,O
by,O,O
control,O,O
serum,O,O
was,O,O
used,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
Superoxide,B,B
and,O,O
hydrogen,B,B
peroxide,I,I
production,O,O
in,O,O
neutrophils,O,O
stimulated,O,O
with,O,O
formyl,B,B
-,I,I
methionyl,I,I
-,I,I
leucyl,I,I
-,I,I
phenylalanine,I,I
(,O,O
fMLP,B,B
),O,O
from,O,O
a,O,O
further,O,O
18,O,O
ALF,O,O
patients,O,O
was,O,O
unaffected,O,O
compared,O,O
with,O,O
control,O,O
neutrophils,O,O
.,O,O
Serum,O,O
C3,O,B
complement,O,I
levels,O,O
were,O,O
significantly,O,O
reduced,O,O
in,O,O
ALF,O,O
patients,O,O
compared,O,O
with,O,O
control,O,O
subjects,O,O
(,O,O
P,O,B
<,O,I
0,O,I
.,O,I
),O,O
.,O,O
These,O,O
results,O,O
demonstrate,O,O
a,O,O
neutrophil,O,O
defect,O,O
in,O,O
ALF,O,O
due,O,O
to,O,O
paracetamol,B,B
overdose,O,O
",",O,O
that,O,O
is,O,O
complement,O,O
dependent,O,O
but,O,O
independent,O,O
of,O,O
serum,O,O
complement,O,O
",",O,O
possibly,O,O
connected,O,O
to,O,O
the,O,O
complement,O,O
receptor,O,O
.,O,O
Cholesteryl,B,B
hemisuccinate,I,I
treatment,O,O
protects,O,O
rodents,O,O
from,O,O
the,O,O
toxic,O,O
effects,O,O
of,O,O
acetaminophen,B,B
",",O,O
adriamycin,B,B
",",O,O
carbon,B,B
tetrachloride,I,I
",",O,O
chloroform,B,B
and,O,O
galactosamine,B,B
.,O,O
In,O,O
addition,O,O
to,O,O
its,O,O
use,O,O
as,O,O
a,O,O
stabilizer,O,O
/,O,O
rigidifier,O,O
of,O,O
membranes,O,O
",",O,O
cholesteryl,B,B
hemisuccinate,I,I
",",O,O
tris,B,B
salt,I,I
(,O,I
CS,B,I
),O,I
administration,O,O
has,O,O
also,O,O
been,O,O
shown,O,O
to,O,O
protect,O,O
rats,O,O
from,O,O
the,O,O
hepatotoxic,O,O
effects,O,O
of,O,O
carbon,B,B
tetrachloride,I,I
(,O,I
CCl4,B,I
),O,I
.,O,O
To,O,O
further,O,O
our,O,O
understanding,O,O
of,O,O
the,O,O
mechanism,O,O
of,O,O
CS,B,B
cytoprotection,O,O
",",O,O
we,O,O
examined,O,O
in,O,O
rats,O,O
and,O,O
mice,O,O
the,O,O
protective,O,O
abilities,O,O
of,O,O
CS,B,B
and,O,O
the,O,O
non,O,O
-,O,O
hydrolyzable,O,O
ether,O,O
form,O,O
of,O,O
CS,B,B
",",O,O
gamma,B,B
-,I,I
cholesteryloxybutyric,I,I
acid,I,I
",",O,O
tris,B,B
salt,I,I
(,O,I
CSE,B,I
),O,I
against,O,O
acetaminophen,B,B
-,O,I
",",O,O
adriamycin,B,B
-,O,I
",",O,O
carbon,B,B
tetrachloride,I,I
-,O,I
",",O,O
chloroform,B,B
-,O,I
and,O,O
galactosamine,B,B
-,O,I
induced,O,I
toxicity,O,I
.,O,O
The,O,O
results,O,O
of,O,O
these,O,O
studies,O,O
demonstrated,O,O
that,O,O
CS,B,B
-,O,O
mediated,O,O
protection,O,O
is,O,O
not,O,O
selective,O,O
for,O,O
a,O,O
particular,O,O
species,O,O
",",O,O
organ,O,O
system,O,O
or,O,O
toxic,O,B
chemical,O,I
.,O,O
24,O,O
-,O,O
h,O,O
pretreatment,O,O
of,O,O
both,O,O
rats,O,O
and,O,O
mice,O,O
with,O,O
a,O,O
single,O,O
dose,O,O
of,O,O
CS,B,B
(,O,O
100mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
.,O,O
",",O,O
resulted,O,O
in,O,O
significant,O,O
protection,O,O
against,O,O
the,O,O
hepatotoxic,O,B
effects,O,O
of,O,O
CCl4,B,B
",",O,O
CHCl3,B,B
",",O,O
acetaminophen,B,B
and,O,O
galactosamine,B,B
and,O,O
against,O,O
the,O,O
lethal,O,O
(,O,O
and,O,O
presumably,O,O
cardiotoxic,O,B
),O,O
effect,O,O
of,O,O
adriamycin,B,B
administration,O,O
.,O,O
Maximal,O,O
CS,B,B
-,O,O
mediated,O,O
protection,O,O
was,O,O
observed,O,O
in,O,O
experimental,O,O
animals,O,O
pretreated,O,O
24,O,O
h,O,O
prior,O,O
to,O,O
the,O,O
toxic,O,O
insult,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
CS,B,B
intervenes,O,O
in,O,O
a,O,O
critical,O,O
cellular,O,O
event,O,O
that,O,O
is,O,O
an,O,O
important,O,O
common,O,O
pathway,O,O
to,O,O
toxic,O,O
cell,O,O
death,O,O
.,O,O
The,O,O
mechanism,O,O
of,O,O
CS,B,B
protection,O,O
does,O,O
not,O,O
appear,O,O
to,O,O
be,O,O
dependent,O,O
on,O,O
the,O,O
inhibition,O,O
of,O,O
chemical,O,B
bioactivation,O,I
to,O,I
a,O,I
toxic,O,I
reactive,O,I
intermediate,O,I
(,O,I
in,O,I
light,O,I
of,O,I
the,O,I
protection,O,I
observed,O,I
against,O,I
galactosamine,B,I
hepatotoxicity,O,I
),O,I
.,O,O
However,O,O
",",O,O
based,O,O
on,O,O
the,O,O
data,O,O
presented,O,O
",",O,O
we,O,O
can,O,O
not,O,O
exclude,O,O
the,O,O
possibility,O,O
that,O,O
CS,B,B
administration,O,O
inhibits,O,O
chemical,O,B
bioactivation,O,O
.,O,O
Our,O,O
findings,O,O
do,O,O
suggest,O,O
that,O,O
CS,B,B
-,O,O
mediated,O,O
protection,O,O
is,O,O
dependent,O,O
on,O,O
the,O,O
action,O,O
of,O,O
the,O,O
intact,O,O
anionic,O,O
CS,B,B
molecule,O,O
(,O,O
non,O,O
-,O,O
hydrolyzable,O,O
CSE,B,O
was,O,O
as,O,O
protective,O,O
as,O,O
CS,B,B
),O,O
",",O,O
whose,O,O
mechanism,O,O
has,O,O
yet,O,O
to,O,O
be,O,O
defined,O,O
.,O,O
A,O,O
murine,O,O
model,O,O
of,O,O
adenomyosis,O,B
:,O,O
the,O,O
effects,O,O
of,O,O
hyperprolactinemia,O,O
induced,O,O
by,O,O
fluoxetine,B,B
hydrochloride,I,I
",",O,O
a,O,O
selective,O,O
serotonin,B,O
reuptake,O,O
inhibitor,O,O
",",O,O
on,O,O
adenomyosis,O,B
induction,O,O
in,O,O
Wistar,O,O
albino,O,O
rats,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
The,O,O
aim,O,O
of,O,O
this,O,O
study,O,O
was,O,O
to,O,O
investigate,O,O
whether,O,O
fluoxetine,B,B
given,O,O
to,O,O
castrated,O,O
and,O,O
noncastrated,O,O
rats,O,O
caused,O,O
hyperprolactinemia,O,O
and,O,O
its,O,O
effects,O,O
with,O,O
respect,O,O
to,O,O
adenomyosis,O,B
.,O,O
DESIGN,O,O
:,O,O
Fluoxetine,B,B
",",O,O
a,O,O
serotonin,B,B
reuptake,O,I
inhibitor,O,I
",",O,O
was,O,O
given,O,O
to,O,O
Wistar,O,O
Albino,O,O
rats,O,O
for,O,O
98,O,O
days,O,O
to,O,O
produce,O,O
hyperprolactinemia,O,O
.,O,O
The,O,O
drug,O,O
was,O,O
given,O,O
to,O,O
two,O,O
groups,O,O
consisting,O,O
of,O,O
castrated,O,O
and,O,O
noncastrated,O,O
rats,O,O
and,O,O
compared,O,O
to,O,O
two,O,O
groups,O,O
of,O,O
castrated,O,O
and,O,O
noncastrated,O,O
controls,O,O
.,O,O
Prolactin,O,B
levels,O,O
were,O,O
measured,O,O
and,O,O
the,O,O
uteri,O,O
of,O,O
the,O,O
rats,O,O
were,O,O
removed,O,O
for,O,O
histopathological,O,O
analysis,O,O
at,O,O
the,O,O
end,O,O
of,O,O
98,O,O
days,O,O
.,O,O
SETTING,O,O
:,O,O
Marmara,O,O
University,O,O
School,O,O
of,O,O
Medicine,O,O
",",O,O
Department,O,O
of,O,O
Histology,O,O
and,O,O
Embryology,O,O
",",O,O
Zeynep,O,O
Kamil,O,O
Women,O,O
and,O,O
Children,O,O
',O,O
s,O,O
Hospital,O,O
.,O,O
MAIN,O,O
OUTCOME,O,O
MEASURES,O,O
:,O,O
Serum,O,O
prolactin,O,B
levels,O,O
",",O,O
uterine,O,O
histopathology,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
prolactin,O,B
levels,O,O
of,O,O
castrated,O,O
and,O,O
noncastrated,O,O
groups,O,O
treated,O,O
with,O,O
fluoxetine,B,B
were,O,O
statistically,O,O
significantly,O,O
higher,O,O
when,O,O
compared,O,O
to,O,O
their,O,O
respective,O,O
control,O,O
groups,O,O
.,O,O
Histological,O,O
studies,O,O
revealed,O,O
11,O,O
cases,O,O
of,O,O
adenomyosis,O,B
",",O,O
all,O,O
within,O,O
the,O,O
noncastrated,O,O
group,O,O
receiving,O,O
fluoxetine,B,B
.,O,O
CONCLUSION,O,O
:,O,O
It,O,O
was,O,O
suggested,O,O
that,O,O
high,O,O
serum,O,O
prolactin,O,O
levels,O,O
cause,O,O
degeneration,O,O
of,O,O
myometrial,O,O
cells,O,O
in,O,O
the,O,O
presence,O,O
of,O,O
ovarian,O,O
steroids,B,O
that,O,O
results,O,O
in,O,O
a,O,O
myometrial,O,O
invasion,O,O
by,O,O
endometrial,O,B
stroma,O,I
.,O,O
This,O,O
invasion,O,O
eventually,O,O
progresses,O,O
to,O,O
adenomyosis,O,B
.,O,O
Postinfarction,O,O
ventricular,O,B
septal,O,I
defect,O,I
associated,O,O
with,O,O
long,O,O
-,O,O
term,O,O
steroid,B,B
therapy,O,I
.,O,O
Two,O,O
cases,O,O
of,O,O
postinfarction,O,O
ventricular,O,B
septal,O,I
rupture,O,I
in,O,O
patients,O,O
on,O,O
long,O,O
-,O,O
term,O,O
steroid,B,B
therapy,O,I
are,O,O
presented,O,O
and,O,O
the,O,O
favourable,O,O
outcome,O,O
in,O,O
both,O,O
cases,O,O
described,O,O
.,O,O
A,O,O
possible,O,O
association,O,O
between,O,O
steroid,B,B
therapy,O,O
and,O,O
subsequent,O,O
postinfarction,O,O
septal,O,O
rupture,O,O
is,O,O
discussed,O,O
.,O,O
Neuroactive,O,O
steroids,B,B
protect,O,O
against,O,O
pilocarpine,B,B
-,O,O
and,O,O
kainic,B,B
acid,I,I
-,O,O
induced,O,O
limbic,O,O
seizures,O,O
and,O,O
status,O,O
epilepticus,O,O
in,O,O
mice,O,O
.,O,O
Several,O,O
structurally,O,O
related,O,O
metabolites,O,O
of,O,O
progesterone,B,B
(,O,O
3,B,B
alpha,I,I
-,I,I
hydroxy,I,I
pregnane,I,I
-,I,I
20,I,I
-,I,I
ones,I,I
),O,O
and,O,O
deoxycorticosterone,B,B
(,O,O
3,B,B
alpha,I,I
-,I,I
hydroxy,I,I
pregnane,I,I
-,I,I
21,I,I
-,I,I
diol,I,I
-,I,I
20,I,I
-,I,I
ones,I,I
),O,O
and,O,O
their,O,O
3,O,B
beta,O,I
-,O,I
epimers,O,I
were,O,O
evaluated,O,O
for,O,O
protective,O,O
activity,O,O
against,O,O
pilocarpine,B,B
-,O,O
",",O,O
kainic,B,B
acid,I,I
-,O,O
and,O,O
N,B,B
-,I,I
methyl,I,I
-,I,I
D,I,I
-,I,I
aspartate,I,I
(,O,I
NMDA,B,I
),O,I
-,O,O
induced,O,O
seizures,O,O
in,O,O
mice,O,O
.,O,O
Steroids,B,B
with,O,O
the,O,O
3,O,O
-,O,O
hydroxy,O,O
group,O,O
in,O,O
the,O,O
alpha,O,B
-,O,O
position,O,O
and,O,O
5,O,O
-,O,O
H,O,O
in,O,O
the,O,O
alpha,O,B
-,O,O
or,O,O
beta,O,B
-,O,O
configurations,O,O
were,O,O
highly,O,O
effective,O,O
in,O,O
protecting,O,O
against,O,O
pilocarpine,B,B
(,O,O
416,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
induced,O,O
limbic,O,O
motor,O,O
seizures,O,O
and,O,O
status,O,O
epilepticus,O,O
(,O,O
ED50,O,O
values,O,O
",",O,O
7,O,O
.,O,O
0,O,O
-,O,O
18,O,O
.,O,O
7,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
The,O,O
corresponding,O,O
epimers,O,O
with,O,O
the,O,O
3,O,O
-,O,O
hydroxy,O,O
group,O,O
in,O,O
the,O,O
beta,O,B
-,O,O
position,O,O
were,O,O
also,O,O
effective,O,O
but,O,O
less,O,O
potent,O,O
(,O,O
ED50,O,O
values,O,O
",",O,O
33,O,O
.,O,O
8,O,O
-,O,O
63,O,O
.,O,O
5,O,O
",",O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
Although,O,O
the,O,O
neuroactive,O,O
steroids,B,B
were,O,O
considerably,O,O
less,O,O
potent,O,O
than,O,O
the,O,O
benzodiazepine,B,B
clonazepam,B,I
in,O,O
protecting,O,O
against,O,O
pilocarpine,B,B
seizures,O,O
",",O,O
steroids,B,B
with,O,O
the,O,O
5,O,O
alpha,O,O
",",O,O
3,O,O
alpha,O,O
-,O,O
configuration,O,O
had,O,O
comparable,O,O
or,O,O
higher,O,O
protective,O,O
index,O,O
values,O,O
(,O,O
TD50,O,O
for,O,O
motor,O,O
impairment,O,O
divided,O,O
by,O,O
ED50,O,O
for,O,O
seizure,O,O
protection,O,O
),O,O
than,O,O
clonazepam,B,B
",",O,O
indicating,O,O
that,O,O
some,O,O
neuroactive,O,O
steroids,B,B
may,O,O
have,O,O
lower,O,O
relative,O,O
toxicity,O,O
.,O,O
Steroids,B,B
with,O,O
the,O,O
5,O,B
alpha,O,I
",",O,O
3,O,B
alpha,O,I
-,O,O
or,O,O
5,O,B
beta,O,I
",",O,O
3,O,B
alpha,O,I
-,O,O
configurations,O,O
also,O,O
produced,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
delay,O,O
in,O,O
the,O,O
onset,O,O
of,O,O
limbic,O,O
seizures,O,O
induced,O,O
by,O,O
kainic,B,B
acid,I,I
(,O,O
32,O,O
mg,O,O
/,O,O
kg,O,O
",",O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
",",O,O
but,O,O
did,O,O
not,O,O
completely,O,O
protect,O,O
against,O,O
the,O,O
seizures,O,O
.,O,O
However,O,O
",",O,O
when,O,O
a,O,O
second,O,O
dose,O,O
of,O,O
the,O,O
steroid,B,B
was,O,O
administered,O,O
1,O,O
hr,O,O
after,O,O
the,O,O
first,O,O
dose,O,O
",",O,O
complete,O,O
protection,O,O
from,O,O
the,O,O
kainic,B,B
acid,I,I
-,O,O
induced,O,O
limbic,O,O
seizures,O,O
and,O,O
status,O,O
epilepticus,O,O
was,O,O
obtained,O,O
.,O,O
The,O,O
steroids,B,B
also,O,O
caused,O,O
a,O,O
dose,O,O
-,O,O
dependent,O,O
delay,O,O
in,O,O
NMDA,B,B
(,O,O
257,O,B
mg,O,I
/,O,I
kg,O,I
",",O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
induced,O,O
lethality,O,O
",",O,O
but,O,O
did,O,O
not,O,O
completely,O,O
protect,O,O
against,O,O
NMDA,B,B
seizures,O,O
or,O,O
lethality,O,O
.,O,O
We,O,O
conclude,O,O
that,O,O
neuroactive,O,O
steroids,B,B
are,O,O
highly,O,O
effective,O,O
in,O,O
protecting,O,O
against,O,O
pilocarpine,B,B
-,O,I
and,O,I
kainic,B,B
acid,I,I
-,O,I
induced,O,I
seizures,O,O
and,O,O
status,O,O
epilepticus,O,O
in,O,O
mice,O,O
",",O,O
and,O,O
may,O,O
be,O,O
of,O,O
utility,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
some,O,O
forms,O,O
of,O,O
status,O,O
epilepticus,O,O
in,O,O
humans,O,O
.,O,O
Hepatic,O,B
and,O,O
extrahepatic,O,B
angiotensinogen,O,B
gene,O,O
expression,O,O
in,O,O
rats,O,O
with,O,O
acute,O,O
nephrotic,O,O
syndrome,O,O
.,O,O
Plasma,O,O
concentration,O,O
and,O,O
urine,O,O
excretion,O,O
of,O,O
the,O,O
renin,O,B
-,O,I
angiotensin,B,I
system,O,I
proteins,O,O
are,O,O
altered,O,O
in,O,O
rats,O,O
with,O,O
nephrotic,O,O
syndrome,O,O
(,O,O
NS,O,O
),O,O
.,O,O
In,O,O
this,O,O
work,O,O
the,O,O
messenger,O,O
ribonucleic,O,O
acid,O,O
(,O,O
mRNA,O,O
),O,O
levels,O,O
of,O,O
angiotensinogen,O,B
(,O,O
Ao,O,O
),O,O
were,O,O
analyzed,O,O
with,O,O
the,O,O
slot,O,O
-,O,O
blot,O,O
hybridization,O,O
technique,O,O
in,O,O
liver,O,B
and,O,O
other,O,O
extrahepatic,O,B
tissues,O,O
:,O,O
kidney,O,B
",",O,O
heart,O,B
",",O,O
brain,O,B
",",O,O
and,O,O
adrenal,O,B
gland,O,O
from,O,O
control,O,O
",",O,O
nephrotic,O,O
",",O,O
and,O,O
pair,O,O
-,O,O
fed,O,O
(,O,O
PF,O,O
),O,O
rats,O,O
.,O,O
NS,O,O
was,O,O
induced,O,O
by,O,O
a,O,O
single,O,O
injection,O,O
of,O,O
puromycin,B,B
amino,I,I
-,I,I
nucleoside,I,I
(,O,O
PAN,B,B
),O,O
.,O,O
Although,O,O
a,O,O
great,O,O
urinary,O,O
excretion,O,O
and,O,O
half,O,O
-,O,O
normal,O,O
plasma,O,O
levels,O,O
of,O,O
Ao,O,B
were,O,O
observed,O,O
on,O,O
day,O,O
6,O,O
after,O,O
PAN,B,O
injection,O,O
",",O,O
when,O,O
NS,O,O
was,O,O
clearly,O,O
established,O,O
",",O,O
hepatic,O,O
Ao,O,B
mRNA,O,I
levels,O,O
did,O,O
not,O,O
change,O,O
.,O,O
Furthermore,O,O
",",O,O
the,O,O
Ao,O,B
mRNA,O,I
levels,O,O
did,O,O
not,O,O
change,O,O
in,O,O
any,O,O
of,O,O
the,O,O
extrahepatic,O,O
tissues,O,O
studied,O,O
on,O,O
day,O,O
6,O,O
",",O,O
nor,O,O
did,O,O
its,O,O
hepatic,O,O
levels,O,O
at,O,O
days,O,O
1,O,O
",",O,O
3,O,O
",",O,O
5,O,O
",",O,O
or,O,O
7,O,O
after,O,O
PAN,B,O
injection,O,O
.,O,O
These,O,O
data,O,O
suggest,O,O
that,O,O
the,O,O
hepatic,O,O
and,O,O
extrahepatic,O,O
Ao,O,O
mRNA,O,O
levels,O,O
are,O,O
unaltered,O,O
during,O,O
the,O,O
development,O,O
of,O,O
the,O,O
acute,O,O
NS,O,O
induced,O,O
by,O,O
PAN,B,B
.,O,O
Neuroleptic,O,O
malignant,O,O
syndrome,O,O
with,O,O
risperidone,B,B
.,O,O
Neuroleptic,O,O
malignant,O,O
syndrome,O,O
is,O,O
thought,O,O
to,O,O
be,O,O
a,O,O
result,O,O
of,O,O
dopamine,B,B
D2,O,I
receptor,O,I
blockade,O,O
in,O,O
the,O,O
striatum,O,B
of,O,O
the,O,O
basal,O,O
ganglia,O,O
.,O,O
Risperidone,B,B
",",O,O
a,O,O
benzisoxazole,B,B
derivative,O,O
antipsychotic,O,O
",",O,O
has,O,O
high,O,O
serotonin,B,B
5,O,I
-,O,I
HT2,O,I
receptor,O,I
blockade,O,I
and,O,O
dose,O,O
-,O,O
related,O,O
D2,O,B
receptor,O,I
blockade,O,I
.,O,O
The,O,O
high,O,O
ratio,O,O
is,O,O
believed,O,O
to,O,O
impart,O,O
the,O,O
low,O,O
frequency,O,O
of,O,O
extrapyramidal,O,O
symptoms,O,O
with,O,O
risperidone,B,B
at,O,O
low,O,O
dosages,O,O
.,O,O
With,O,O
this,O,O
low,O,O
frequency,O,O
of,O,O
extrapyramidal,O,O
symptoms,O,O
",",O,O
it,O,O
was,O,O
thought,O,O
the,O,O
frequency,O,O
of,O,O
neuroleptic,O,O
malignant,O,O
syndrome,O,O
might,O,O
also,O,O
be,O,O
lowered,O,O
.,O,O
A,O,O
73,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
developed,O,O
neuroleptic,O,B
malignant,O,I
syndrome,O,I
after,O,O
monotherapy,O,O
with,O,O
risperidone,B,B
.,O,O
The,O,O
syndrome,O,O
reversed,O,O
after,O,O
discontinuing,O,O
risperidone,B,B
and,O,O
starting,O,O
treatment,O,O
with,O,O
dantrolene,B,B
and,O,O
bromocriptine,B,B
.,O,O
It,O,O
appears,O,O
that,O,O
the,O,O
protection,O,O
from,O,O
extrapyramidal,O,O
side,O,O
effects,O,O
observed,O,O
with,O,O
risperidone,B,B
does,O,O
not,O,O
ensure,O,O
protection,O,O
from,O,O
neuroleptic,O,B
malignant,O,I
syndrome,O,I
.,O,O
The,O,O
attenuating,O,O
effect,O,O
of,O,O
carteolol,B,B
hydrochloride,I,I
",",O,O
a,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
antagonist,O,I
",",O,O
on,O,O
neuroleptic,O,O
-,O,O
induced,O,O
catalepsy,O,O
in,O,O
rats,O,O
.,O,O
It,O,O
is,O,O
known,O,O
that,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
antagonists,O,I
are,O,O
effective,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
akathisia,O,O
",",O,O
one,O,O
of,O,O
the,O,O
extrapyramidal,O,O
side,O,O
effects,O,O
that,O,O
occur,O,O
during,O,O
neuroleptic,O,O
treatment,O,O
.,O,O
Neuroleptic,O,B
-,O,O
induced,O,O
catalepsy,O,O
",",O,O
a,O,O
model,O,O
of,O,O
neuroleptic,O,B
-,O,O
induced,O,O
extrapyramidal,O,O
side,O,O
effects,O,O
",",O,O
was,O,O
considered,O,O
suitable,O,O
as,O,O
a,O,O
model,O,O
for,O,O
predicting,O,O
neuroleptic,O,B
-,O,O
induced,O,O
akathisia,O,O
in,O,O
humans,O,O
",",O,O
although,O,O
neuroleptic,O,B
-,O,O
induced,O,O
catalepsy,O,O
was,O,O
not,O,O
considered,O,O
a,O,O
specific,O,O
test,O,O
for,O,O
neuroleptic,O,B
-,O,O
induced,O,O
akathisia,O,O
.,O,O
Therefore,O,O
",",O,O
the,O,O
effects,O,O
of,O,O
carteolol,B,B
",",O,O
a,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
antagonist,O,I
",",O,O
on,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
in,O,O
rats,O,O
were,O,O
behaviorally,O,O
studied,O,O
and,O,O
compared,O,O
with,O,O
those,O,O
of,O,O
propranolol,B,B
and,O,O
biperiden,B,B
",",O,O
a,O,O
muscarinic,O,B
receptor,O,I
antagonist,O,I
.,O,O
Carteolol,B,B
",",O,O
as,O,O
well,O,O
as,O,O
propranolol,B,B
and,O,O
biperiden,B,B
",",O,O
inhibited,O,O
the,O,O
haloperidol,B,B
-,O,O
induced,O,O
catalepsy,O,O
.,O,O
The,O,O
inhibitory,O,O
effect,O,O
of,O,O
carteolol,B,B
was,O,O
almost,O,O
comparable,O,O
to,O,O
that,O,O
of,O,O
propranolol,B,B
",",O,O
but,O,O
was,O,O
weaker,O,O
than,O,O
that,O,O
of,O,O
biperiden,B,B
.,O,O
Carteolol,B,B
did,O,O
not,O,O
evoke,O,O
postsynaptic,O,O
dopamine,B,B
receptor,O,I
-,O,I
stimulating,O,I
behavioral,O,I
signs,O,I
such,O,O
as,O,O
stereotypy,O,B
and,O,O
hyperlocomotion,O,B
in,O,O
rats,O,O
.,O,O
Carteolol,B,B
did,O,O
not,O,O
antagonize,O,O
the,O,O
inhibitory,O,O
effects,O,O
of,O,O
haloperidol,B,B
on,O,O
apomorphine,B,B
-,O,I
induced,O,I
stereotypy,O,I
and,O,O
locomotor,O,B
activity,O,I
in,O,O
rats,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
carteolol,B,B
did,O,O
not,O,O
evoke,O,O
5,O,B
-,O,I
HT1A,O,I
receptor,O,I
-,O,I
stimulating,O,O
behavioral,O,O
signs,O,O
such,O,O
as,O,O
flat,O,O
body,O,O
posture,O,O
and,O,O
forepaw,O,O
treading,O,O
and,O,O
did,O,O
not,O,O
inhibit,O,O
5,B,B
-,I,I
hydroxytryptophan,I,I
-,O,I
induced,O,I
head,O,I
twitch,O,I
in,O,O
rats,O,O
.,O,O
Finally,O,O
",",O,O
carteolol,B,B
did,O,O
not,O,O
inhibit,O,O
physostigmine,B,B
-,O,I
induced,O,I
lethality,O,I
in,O,O
rats,O,O
.,O,O
These,O,O
results,O,O
strongly,O,O
suggest,O,O
that,O,O
carteolol,B,B
improves,O,O
haloperidol,B,B
-,O,I
induced,O,I
catalepsy,O,I
via,O,O
its,O,O
beta,O,O
-,O,O
adrenoceptor,O,O
antagonistic,O,O
activity,O,O
and,O,O
is,O,O
expected,O,O
to,O,O
be,O,O
effective,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
akathisia,O,O
without,O,O
attenuating,O,O
neuroleptic,O,O
-,O,O
induced,O,O
antipsychotic,O,O
effects,O,O
due,O,O
to,O,O
its,O,O
postsynaptic,O,O
dopamine,B,O
receptor,O,O
antagonistic,O,O
activity,O,O
.,O,O
Granulosa,O,B
cell,O,I
tumor,O,I
of,O,O
the,O,O
ovary,O,B
associated,O,O
with,O,O
antecedent,O,O
tamoxifen,B,B
use,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Increased,O,O
attention,O,O
has,O,O
been,O,O
focused,O,O
recently,O,O
on,O,O
the,O,O
estrogenic,O,O
effects,O,O
of,O,O
tamoxifen,B,B
.,O,O
Review,O,O
of,O,O
the,O,O
literature,O,O
reveals,O,O
an,O,O
association,O,O
between,O,O
tamoxifen,B,B
use,O,O
and,O,O
gynecologic,O,O
tumors,O,O
.,O,O
CASE,O,O
:,O,O
A,O,O
52,O,O
-,O,O
year,O,O
-,O,O
old,O,O
postmenopausal,O,O
woman,O,O
was,O,O
treated,O,O
with,O,O
tamoxifen,B,B
for,O,O
stage,O,O
II,O,O
estrogen,B,O
receptor,O,O
-,O,O
positive,O,O
breast,O,O
carcinoma,O,O
.,O,O
Her,O,O
aspartate,B,B
transaminase,O,I
and,O,O
alanine,B,B
transaminase,O,I
levels,O,O
increase,O,O
markedly,O,O
after,O,O
6,O,O
months,O,O
of,O,O
tamoxifen,B,O
use,O,O
.,O,O
After,O,O
an,O,O
additional,O,O
17,O,O
months,O,O
of,O,O
elevated,O,O
serum,O,O
transaminases,O,O
",",O,O
the,O,O
patient,O,O
was,O,O
found,O,O
to,O,O
have,O,O
a,O,O
stage,O,O
Ic,O,O
granulosa,O,O
cell,O,O
tumor,O,O
of,O,O
the,O,O
ovary,O,O
.,O,O
CONCLUSION,O,O
:,O,O
Patients,O,O
with,O,O
tamoxifen,B,O
-,O,O
induced,O,O
liver,O,O
dysfunction,O,O
may,O,O
be,O,O
at,O,O
increased,O,O
risk,O,O
for,O,O
granulosa,O,O
cell,O,O
tumors,O,O
because,O,O
of,O,O
alterations,O,O
in,O,O
tamoxifen,B,O
metabolism,O,O
.,O,O
Lifetime,O,O
treatment,O,O
of,O,O
mice,O,O
with,O,O
azidothymidine,B,B
(,O,O
AZT,B,I
),O,O
produces,O,O
myelodysplasia,O,O
.,O,O
AZT,B,B
has,O,O
induced,O,O
a,O,O
macrocytic,O,O
anemia,O,O
in,O,O
AIDS,O,O
patients,O,O
on,O,O
long,O,O
term,O,O
AZT,B,B
therapy,O,O
.,O,O
It,O,O
is,O,O
generally,O,O
assumed,O,O
that,O,O
DNA,O,O
elongation,O,O
is,O,O
stopped,O,O
by,O,O
the,O,O
insertion,O,O
of,O,O
AZT,B,B
into,O,O
the,O,O
chain,O,O
in,O,O
place,O,O
of,O,O
thymidine,B,O
thus,O,O
preventing,O,O
the,O,O
phosphate,B,O
hydroxyl,O,O
linkages,O,O
and,O,O
therefore,O,O
suppresses,O,O
hemopoietic,O,O
progenitor,O,O
cell,O,O
proliferation,O,O
in,O,O
an,O,O
early,O,O
stage,O,O
of,O,O
differentiation,O,O
.,O,O
CBA,O,O
/,O,O
Ca,O,B
male,O,O
mice,O,O
started,O,O
on,O,O
AZT,B,B
0,O,O
.,O,O
75,O,O
mg,O,O
/,O,O
ml,O,O
H2O,O,O
at,O,O
84,O,O
days,O,O
of,O,O
age,O,O
and,O,O
kept,O,O
on,O,O
it,O,O
for,O,O
687,O,O
days,O,O
when,O,O
dosage,O,O
reduced,O,O
to,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
ml,O,O
H2O,O,O
for,O,O
a,O,O
group,O,O
",",O,O
another,O,O
group,O,O
removed,O,O
from,O,O
AZT,B,B
to,O,O
see,O,O
recovery,O,O
",",O,O
and,O,O
third,O,O
group,O,O
remained,O,O
on,O,O
0,O,O
.,O,O
75,O,O
mg,O,O
.,O,O
At,O,O
687,O,O
days,O,O
mice,O,O
that,O,O
had,O,O
been,O,O
on,O,O
0,O,O
.,O,O
75,O,O
mg,O,O
had,O,O
average,O,O
platelet,O,O
counts,O,O
of,O,O
2,O,O
.,O,O
5,O,O
x,O,O
10,O,O
(,O,O
6,O,O
),O,O
.,O,O
Histological,O,O
examination,O,O
on,O,O
9,O,O
of,O,O
10,O,O
mice,O,O
with,O,O
such,O,O
thrombocytopenia,O,B
showed,O,O
changes,O,O
compatible,O,O
with,O,O
myelodysplastic,O,B
syndrome,O,I
(,O,O
MDS,O,B
),O,O
.,O,O
A,O,O
variety,O,O
of,O,O
histological,O,O
patterns,O,O
was,O,O
observed,O,O
.,O,O
There,O,O
were,O,O
two,O,O
cases,O,O
of,O,O
hypocellular,O,B
myelodysplasia,O,I
",",O,O
two,O,O
cases,O,O
of,O,O
hypersegmented,O,B
myelodysplastic,O,I
granulocytosis,O,I
",",O,O
two,O,O
cases,O,O
of,O,O
hypercellular,O,B
marrow,O,I
with,O,O
abnormal,O,O
megakaryocytes,O,B
with,O,O
bizarre,O,O
nuclei,O,O
",",O,O
one,O,O
case,O,O
of,O,O
megakaryocytic,O,B
myelosis,O,I
associated,O,O
with,O,O
a,O,O
hyperplastic,O,B
marrow,O,I
",",O,O
dysmyelopoiesis,O,B
and,O,O
a,O,O
hypocellular,O,B
marrow,O,I
and,O,O
two,O,O
cases,O,O
of,O,O
myelodysplasia,O,B
with,O,O
dyserythropoiesis,O,I
",",O,O
hemosiderosis,O,I
and,O,O
a,O,O
hypocellular,O,B
marrow,O,I
.,O,O
Above,O,O
mentioned,O,O
AZT,B,B
incorporation,O,O
may,O,O
have,O,O
induced,O,O
an,O,O
ineffective,O,O
hemopoiesis,O,O
in,O,O
the,O,O
primitive,O,O
hemopoietic,O,O
progenitor,O,O
cells,O,O
",",O,O
which,O,O
is,O,O
known,O,O
to,O,O
be,O,O
seen,O,O
commonly,O,O
in,O,O
the,O,O
myelodysplastic,O,O
syndrome,O,O
.,O,O
Biphasic,O,O
response,O,O
of,O,O
the,O,O
SA,O,B
node,O,I
of,O,I
the,O,I
dog,O,I
heart,O,I
in,O,O
vivo,O,O
to,O,O
selective,O,O
administration,O,O
of,O,O
ketamine,B,B
.,O,O
of,O,O
ketamine,B,B
on,O,O
the,O,O
SA,O,B
node,O,I
of,O,I
the,O,I
dog,O,I
heart,O,I
was,O,O
studied,O,O
in,O,O
vivo,O,O
using,O,O
a,O,O
selective,O,O
perfusion,O,O
technique,O,O
of,O,O
the,O,O
SA,O,B
node,O,I
artery,O,I
.,O,O
Injections,O,O
of,O,O
ketamine,B,B
in,O,O
doses,O,O
from,O,O
100,O,O
microgram,O,O
to,O,O
3,O,O
mg,O,O
into,O,O
the,O,O
artery,O,O
produced,O,O
a,O,O
depression,O,O
of,O,O
the,O,O
SA,O,B
nodal,O,I
activity,O,O
by,O,O
a,O,O
direct,O,O
action,O,O
.,O,O
This,O,O
depression,O,O
was,O,O
followed,O,O
by,O,O
the,O,O
sudden,O,O
appearance,O,O
of,O,O
a,O,O
stimulatory,O,O
phase,O,O
.,O,O
Bilateral,O,O
vagotomy,O,O
and,O,O
sympathectomy,O,O
or,O,O
prior,O,O
administration,O,O
of,O,O
a,O,O
ganglion,O,O
blocker,O,O
failed,O,O
to,O,O
inhibit,O,O
the,O,O
occurrence,O,O
of,O,O
the,O,O
ketamine,B,B
-,O,I
induced,O,I
tachycardia,O,O
",",O,O
while,O,O
it,O,O
was,O,O
completely,O,O
abolished,O,O
in,O,O
the,O,O
reserpinized,O,O
dogs,O,O
or,O,O
by,O,O
a,O,O
prior,O,O
injection,O,O
of,O,O
a,O,O
beta,O,O
-,O,O
blocking,O,O
agent,O,O
into,O,O
the,O,O
SA,O,B
node,O,I
artery,O,O
.,O,O
This,O,O
may,O,O
indicate,O,O
that,O,O
an,O,O
activation,O,O
of,O,O
the,O,O
peripheral,O,O
adrenergic,O,B
mechanism,O,O
plays,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
induction,O,O
of,O,O
the,O,O
excitatory,O,O
effect,O,O
of,O,O
ketamine,B,B
injected,O,O
in,O,O
the,O,O
SA,O,B
node,O,I
artery,O,I
.,O,O
Over,O,O
expression,O,O
of,O,O
vascular,O,O
endothelial,O,B
growth,O,I
factor,O,I
and,O,O
its,O,O
receptor,O,O
during,O,O
the,O,O
development,O,O
of,O,O
estrogen,B,B
-,O,I
induced,O,I
rat,O,I
pituitary,O,I
tumors,O,I
may,O,O
mediate,O,O
estrogen,B,B
-,O,I
initiated,O,I
tumor,O,I
angiogenesis,O,I
.,O,O
Estrogens,B,B
",",O,O
which,O,O
have,O,O
been,O,O
associated,O,O
with,O,O
several,O,O
types,O,O
of,O,O
human,O,O
and,O,O
animal,O,O
cancers,O,B
",",O,O
can,O,O
induce,O,O
tumor,O,O
angiogenesis,O,O
in,O,O
the,O,O
pituitary,O,O
of,O,O
Fischer,O,O
344,O,O
rats,O,O
.,O,O
The,O,O
mechanistic,O,O
details,O,O
of,O,O
tumor,O,O
angiogenesis,O,O
induction,O,O
",",O,O
during,O,O
estrogen,B,B
carcinogenesis,O,O
",",O,O
are,O,O
still,O,O
unknown,O,O
.,O,O
To,O,O
elucidate,O,O
the,O,O
role,O,O
of,O,O
estrogen,B,B
in,O,O
the,O,O
regulation,O,O
of,O,O
tumor,O,O
angiogenesis,O,O
in,O,O
the,O,O
pituitary,O,O
of,O,O
female,O,O
rats,O,O
",",O,O
the,O,O
density,O,O
of,O,O
blood,O,O
vessels,O,O
was,O,O
analysed,O,O
using,O,O
factor,O,O
VIII,O,B
related,O,I
antigen,O,I
(,O,O
FVIIIRAg,O,I
),O,O
immunohistochemistry,O,O
and,O,O
the,O,O
expression,O,O
of,O,O
vascular,O,O
endothelial,O,O
growth,O,O
factor,O,B
/,O,I
vascular,O,I
permeability,O,I
factor,O,I
(,O,I
VEGF,O,I
/,O,I
VPF,O,I
),O,O
was,O,O
examined,O,O
by,O,O
Western,O,O
blot,O,O
and,O,O
immunohistochemical,O,O
analysis,O,O
.,O,O
The,O,O
expression,O,O
of,O,O
VEGF,O,B
receptor,O,O
(,O,O
VEGFR,O,B
-,O,I
2,O,I
/,O,I
Flk,O,I
-,O,I
1,O,I
/,O,I
KDR,O,I
),O,O
was,O,O
also,O,O
examined,O,O
by,O,O
immunohistochemistry,O,O
.,O,O
The,O,O
results,O,O
demonstrated,O,O
that,O,O
17beta,B,B
-,I,I
estradiol,I,I
(,O,O
E2,B,B
),O,O
induces,O,O
neovascularization,O,O
",",O,O
as,O,O
well,O,O
as,O,O
the,O,O
growth,O,O
and,O,O
enlargement,O,O
of,O,O
blood,O,O
vessels,O,O
after,O,O
7,O,O
days,O,O
of,O,O
exposure,O,O
.,O,O
The,O,O
high,O,O
tumor,O,O
angiogenic,O,O
potential,O,O
was,O,O
associated,O,O
with,O,O
an,O,O
elevated,O,O
VEGF,O,B
/,O,I
VPF,O,I
protein,O,I
expression,O,O
in,O,O
the,O,O
E2,B,B
exposed,O,O
pituitary,O,O
of,O,O
ovariectomized,O,O
(,O,O
OVEX,O,O
),O,O
rats,O,O
.,O,O
VEGF,O,B
/,O,I
VPF,O,I
and,O,O
FVIIIRAg,O,B
immunohistochemistry,O,O
and,O,O
endothelial,O,O
specific,O,O
lectin,O,O
(,O,O
UEA1,O,B
),O,O
binding,O,O
studies,O,O
",",O,O
indicate,O,O
that,O,O
the,O,O
elevation,O,O
of,O,O
VEGF,O,B
protein,O,O
expression,O,O
initially,O,O
occurred,O,O
in,O,O
both,O,O
blood,O,O
vessels,O,O
and,O,O
non,O,O
-,O,O
endothelial,O,O
cells,O,O
.,O,O
After,O,O
15,O,O
days,O,O
of,O,O
E2,B,O
exposure,O,O
",",O,O
VEGF,O,B
/,O,I
VPF,O,I
protein,O,O
expression,O,O
",",O,O
in,O,O
the,O,O
non,O,O
-,O,O
endothelial,O,O
cell,O,O
population,O,O
",",O,O
sharply,O,O
declined,O,O
and,O,O
was,O,O
restricted,O,O
to,O,O
the,O,O
blood,O,O
vessels,O,O
.,O,O
The,O,O
function,O,O
of,O,O
non,O,O
-,O,O
endothelial,O,O
-,O,O
derived,O,O
VEGF,O,B
is,O,O
not,O,O
clear,O,O
.,O,O
Furthermore,O,O
",",O,O
immunohistochemical,O,O
studies,O,O
demonstrated,O,O
that,O,O
VEGFR,O,B
-,O,O
2,O,I
(,O,O
flk,O,B
-,O,I
1,O,I
/,O,I
KDR,O,I
),O,O
",",O,O
expression,O,O
was,O,O
elevated,O,O
significantly,O,O
in,O,O
the,O,O
endothelial,O,O
cells,O,O
of,O,O
microblood,O,O
vessels,O,O
after,O,O
7,O,O
days,O,O
of,O,O
E2,B,O
exposure,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
over,O,O
expression,O,O
of,O,O
VEGF,O,B
and,O,O
its,O,O
receptor,O,O
(,O,O
VEGFR,O,B
-,O,O
2,O,I
),O,O
may,O,O
play,O,O
an,O,O
important,O,O
role,O,O
in,O,O
the,O,O
initial,O,O
step,O,O
of,O,O
the,O,O
regulation,O,O
of,O,O
estrogen,B,O
induced,O,O
tumor,O,O
angiogenesis,O,O
in,O,O
the,O,O
rat,O,O
pituitary,O,O
.,O,O
Persistent,O,O
nephrogenic,O,B
diabetes,O,I
insipidus,O,I
following,O,O
lithium,B,B
therapy,O,O
.,O,O
We,O,O
report,O,O
the,O,O
case,O,O
of,O,O
a,O,O
patient,O,O
who,O,O
developed,O,O
severe,O,O
hypernatraemic,O,O
dehydration,O,O
following,O,O
a,O,O
head,O,O
injury,O,O
.,O,O
Ten,O,O
years,O,O
previously,O,O
he,O,O
had,O,O
been,O,O
diagnosed,O,O
to,O,O
have,O,O
lithium,B,B
-,O,O
induced,O,O
nephrogenic,O,B
diabetes,O,I
insipidus,O,I
",",O,O
and,O,O
lithium,B,B
therapy,O,O
had,O,O
been,O,O
discontinued,O,O
.,O,O
He,O,O
remained,O,O
thirsty,O,O
and,O,O
polyuric,O,O
despite,O,O
cessation,O,O
of,O,O
lithium,B,B
and,O,O
investigations,O,O
on,O,O
admission,O,O
showed,O,O
him,O,O
to,O,O
have,O,O
normal,O,O
osmoregulated,O,O
thirst,O,O
and,O,O
vasopressin,B,B
secretion,O,O
",",O,O
with,O,O
clear,O,O
evidence,O,O
of,O,O
nephrogenic,O,B
diabetes,O,I
insipidus,O,I
.,O,O
Lithium,B,B
induced,O,O
nephrogenic,O,B
diabetes,O,I
insipidus,O,I
is,O,O
considered,O,O
to,O,O
be,O,O
reversible,O,O
on,O,O
cessation,O,O
of,O,O
therapy,O,O
but,O,O
polyuria,O,O
persisted,O,O
in,O,O
this,O,O
patient,O,O
for,O,O
ten,O,O
years,O,O
after,O,O
lithium,B,B
was,O,O
stopped,O,O
.,O,O
We,O,O
discuss,O,O
the,O,O
possible,O,O
renal,O,O
mechanisms,O,O
and,O,O
the,O,O
implications,O,O
for,O,O
management,O,O
of,O,O
patients,O,O
with,O,O
lithium,B,B
-,O,I
induced,O,I
nephrogenic,O,I
diabetes,O,I
insipidus,O,I
.,O,O
Effects,O,O
of,O,O
NIK,B,B
-,I,I
247,I,I
on,O,O
cholinesterase,O,B
and,O,O
scopolamine,B,B
-,O,I
induced,O,I
amnesia,O,I
.,O,O
The,O,O
effects,O,O
of,O,O
NIK,B,B
-,I,I
247,I,I
on,O,O
cholinesterase,O,B
",",O,O
scopolamine,B,B
-,O,I
induced,O,I
amnesia,O,I
and,O,O
spontaneous,O,O
movement,O,O
were,O,O
examined,O,O
and,O,O
compared,O,O
with,O,O
those,O,O
of,O,O
the,O,O
well,O,O
-,O,O
known,O,O
cholinesterase,O,B
inhibitors,O,O
tacrine,B,B
and,O,O
E,B,B
-,I,I
2020,I,I
.,O,O
NIK,B,B
-,I,O
247,I,O
",",O,O
tacrine,B,B
and,O,O
E,B,B
-,I,O
2020,I,O
all,O,O
strongly,O,O
inhibited,O,O
acetylcholinesterase,O,O
(,O,O
AChE,O,B
),O,O
in,O,O
human,O,O
red,O,O
blood,O,O
cells,O,O
(,O,O
IC50s,O,O
=,O,O
1,O,O
.,O,O
0,O,O
x,O,O
10,O,O
(,O,O
-,O,O
6,O,O
),O,O
",",O,O
2,O,O
.,O,O
9,O,O
x,O,O
10,O,O
(,O,O
-,O,O
7,O,O
),O,O
and,O,O
3,O,O
.,O,O
7,O,O
x,O,O
10,O,O
(,O,O
-,O,O
8,O,O
),O,O
M,O,O
",",O,O
respectively,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
NIK,B,B
-,I,O
247,I,O
and,O,O
tacrine,B,B
",",O,O
but,O,O
not,O,O
E,B,B
-,I,O
2020,I,O
",",O,O
strongly,O,O
inhibited,O,O
butyrylcholinestrase,O,O
(,O,O
BuChE,O,B
),O,O
in,O,O
human,O,O
serum,O,O
.,O,O
All,O,O
three,O,O
drugs,O,O
produced,O,O
mixed,O,O
inhibition,O,O
of,O,O
AChE,O,B
activity,O,O
.,O,O
Moreover,O,O
",",O,O
the,O,O
inhibitory,O,O
effect,O,O
of,O,O
NIK,B,B
-,I,I
247,I,I
on,O,O
AChE,O,B
was,O,O
reversible,O,O
.,O,O
All,O,O
compounds,O,O
at,O,O
0,O,O
.,O,O
1,O,O
-,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
improved,O,O
the,O,O
amnesia,O,O
induced,O,O
by,O,O
scopolamine,B,B
(,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
s,O,O
.,O,O
c,O,O
.,O,O
),O,O
in,O,O
rats,O,O
performing,O,O
a,O,O
passive,O,O
avoidance,O,O
task,O,O
.,O,O
The,O,O
three,O,O
compounds,O,O
at,O,O
1,O,O
and,O,O
3,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
.,O,O
did,O,O
not,O,O
significantly,O,O
decrease,O,O
spontaneous,O,O
movement,O,O
by,O,O
rats,O,O
.,O,O
These,O,O
findings,O,O
suggest,O,O
that,O,O
NIK,B,B
-,I,I
247,I,I
at,O,O
a,O,O
low,O,O
dose,O,O
(,O,O
0,O,O
.,O,O
1,O,O
-,O,O
1,O,O
mg,O,O
/,O,O
kg,O,O
p,O,O
.,O,O
o,O,O
.,O,O
),O,O
improves,O,O
scopolamine,B,B
-,O,O
induced,O,O
amnesia,O,O
but,O,O
does,O,O
not,O,O
affect,O,O
spontaneous,O,O
movement,O,O
.,O,O
The,O,O
findings,O,O
suggest,O,O
that,O,O
NIK,B,B
-,I,I
247,I,I
may,O,O
be,O,O
a,O,O
useful,O,O
drug,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
Alzheimer,O,B
',O,I
s,O,I
disease,O,I
.,O,O
Potential,O,O
therapeutic,O,O
use,O,O
of,O,O
the,O,O
selective,O,O
dopamine,B,B
D1,O,I
receptor,O,I
agonist,O,O
",",O,O
A,B,B
-,I,I
86929,I,I
:,O,O
an,O,O
acute,O,O
study,O,O
in,O,O
parkinsonian,O,O
levodopa,B,O
-,O,O
primed,O,O
monkeys,O,O
.,O,O
The,O,O
clinical,O,O
utility,O,O
of,O,O
dopamine,B,B
(,O,O
DA,B,I
),O,O
D1,O,I
receptor,O,I
agonists,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
Parkinson,O,O
',O,O
s,O,O
disease,O,O
(,O,O
PD,O,I
),O,O
is,O,O
still,O,O
unclear,O,O
.,O,O
The,O,O
therapeutic,O,O
use,O,O
of,O,O
selective,O,O
DA,B,B
D1,O,I
receptor,O,I
agonists,O,O
such,O,O
as,O,O
SKF,B,B
-,I,I
82958,I,I
(,O,O
6,B,O
-,I,O
chloro,I,B
-,I,I
7,I,I
",",I,O
8,I,O
-,I,O
dihydroxy,I,B
-,I,I
3,I,I
-,I,I
allyl,I,I
-,I,I
1,I,I
-,I,I
phenyl,I,I
-,I,I
2,I,I
",",I,O
3,I,O
",",I,O
4,I,O
",",I,O
5,I,O
-,I,O
tetrahydro,I,B
-,I,I
1H,I,I
-,I,I
3,I,I
-,I,I
benzaze,I,I
pine,I,I
hydrobromide,I,I
),O,O
and,O,O
A,B,B
-,I,I
77636,I,I
(,O,O
[,B,O
1R,I,O
",",I,O
3S,I,O
],I,O
3,I,O
-,I,O
[,I,O
1,I,O
',I,O
-,I,O
admantyl,I,I
],I,O
-,I,O
1,I,O
-,I,O
aminomethyl,I,I
-,I,I
3,I,I
",",I,O
4,I,O
-,I,O
dihydro,I,B
-,I,I
5,I,I
",",I,O
6,I,O
-,I,O
dihydroxy,I,B
-,I,I
1H,I,I
-,I,I
2,I,I
-,I,I
benzo,I,I
pyran,I,I
hydrochloride,I,I
),O,O
seems,O,O
limited,O,O
because,O,O
of,O,O
their,O,O
duration,O,O
of,O,O
action,O,O
",",O,O
which,O,O
is,O,O
too,O,O
short,O,O
for,O,O
SKF,B,B
-,I,I
82958,I,I
(,O,O
<,O,O
1,O,O
hr,O,O
),O,O
and,O,O
too,O,O
long,O,O
for,O,O
A,B,B
-,I,I
77636,I,I
(,O,O
>,O,O
20,O,O
hr,O,O
",",O,O
leading,O,O
to,O,O
behavioral,O,O
tolerance,O,O
),O,O
.,O,O
We,O,O
therefore,O,O
conducted,O,O
the,O,O
present,O,O
acute,O,O
dose,O,O
-,O,O
response,O,O
study,O,O
in,O,O
four,O,O
1,B,B
-,I,I
methyl,I,I
-,I,I
4,I,I
-,I,I
phenyl,I,I
-,I,I
1,I,I
",",I,O
2,I,O
",",I,O
3,I,O
",",I,O
6,I,O
-,I,O
tetrahydropyridine,I,O
(,O,O
MPTP,B,B
),O,O
-,O,O
exposed,O,O
cynomolgus,O,O
monkeys,O,O
primed,O,O
to,O,O
exhibit,O,O
levodopa,B,B
-,O,I
induced,O,I
dyskinesias,O,I
to,O,O
evaluate,O,O
the,O,O
locomotor,O,O
and,O,O
dyskinetic,O,O
effects,O,O
on,O,O
challenge,O,O
with,O,O
four,O,O
doses,O,O
(,O,O
from,O,O
0,O,O
.,O,O
to,O,O
1,O,O
.,O,O
0,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
of,O,O
A,B,B
-,I,O
86929,I,O
(,O,O
[,B,O
-,I,O
],I,O
-,I,O
[,I,O
5aR,I,O
",",I,O
11bS,I,O
],I,O
-,I,O
4,I,B
",",I,O
5,I,I
",",I,O
5a,I,I
",",I,O
",",I,O
",",I,O
11b,I,I
-,I,O
hexahydro,I,I
-,I,O
2,I,I
-,I,O
propyl,I,I
-,I,O
3,I,I
-,I,O
thia,I,I
-,I,O
5,I,I
-,I,O
+,I,I
+,I,I
+,I,I
azacyclopent,I,I
-,I,O
1,I,I
-,I,O
ena,I,I
[,I,O
c,I,I
],I,O
phenathrene,I,I
-,I,O
9,I,I
-,I,O
10,I,I
-,I,O
diol,I,I
),O,O
",",O,O
a,O,O
selective,O,O
and,O,O
full,O,O
DA,B,B
D1,O,I
-,O,O
like,O,O
receptor,O,O
agonist,O,O
with,O,O
an,O,O
intermediate,O,O
duration,O,O
of,O,O
action,O,O
.,O,O
Levodopa,B,B
and,O,O
the,O,O
DA,B,B
D2,O,I
-,O,O
like,O,O
receptor,O,O
agonist,O,O
",",O,O
LY,B,B
-,I,O
171555,I,O
(,O,O
[,B,O
4aR,I,O
-,I,O
trans,I,O
],I,O
-,I,O
4,I,I
",",I,O
4a,I,I
",",I,O
5,I,I
",",I,O
6,I,I
",",I,O
7,I,I
",",I,O
8,I,I
",",I,O
8a,I,I
",",I,O
9,I,I
-,I,O
o,I,I
-,I,O
dihydro,I,I
-,I,O
5n,I,I
-,I,O
propyl,I,I
-,I,O
2H,I,I
-,I,O
pyrazo,I,I
lo,I,I
-,I,O
3,I,I
-,I,O
4,I,I
-,I,O
quinoline,I,I
hydrochloride,I,I
),O,O
were,O,O
also,O,O
used,O,O
for,O,O
comparison,O,O
.,O,O
Acute,O,O
administration,O,O
of,O,O
A,B,B
-,I,O
86929,I,I
was,O,O
as,O,O
efficacious,O,O
in,O,O
alleviating,O,O
MPTP,B,B
-,O,O
induced,O,O
parkinsonism,O,O
as,O,O
levodopa,B,B
and,O,O
LY,B,B
-,I,O
171555,I,I
",",O,O
but,O,O
was,O,O
less,O,O
likely,O,O
to,O,O
reproduce,O,O
the,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
in,O,O
these,O,O
animals,O,O
than,O,O
with,O,O
either,O,O
LY,B,B
-,I,O
171555,I,I
or,O,O
subsequent,O,O
challenge,O,O
of,O,O
levodopa,B,B
.,O,O
Selective,O,O
stimulation,O,O
of,O,O
the,O,O
DA,B,B
D1,O,I
receptor,O,I
may,O,O
provide,O,O
better,O,O
integration,O,O
of,O,O
neural,O,O
inputs,O,O
transmitted,O,O
to,O,O
the,O,O
internal,O,O
segment,O,O
of,O,O
the,O,O
globus,O,O
pallidus,O,O
(,O,O
referred,O,O
to,O,O
as,O,O
the,O,O
basal,O,O
ganglia,O,O
output,O,O
),O,O
compared,O,O
with,O,O
levodopa,B,B
and,O,O
selective,O,O
DA,B,B
D2,O,I
receptor,O,I
agonist,O,O
.,O,O
Potent,O,O
DA,B,B
D1,O,I
receptor,O,O
agents,O,O
with,O,O
an,O,O
intermediate,O,O
duration,O,O
of,O,O
efficacy,O,O
such,O,O
as,O,O
A,B,B
-,I,I
86929,I,I
(,O,O
approximately,O,O
4,O,O
hr,O,O
at,O,O
higher,O,O
doses,O,O
tested,O,O
),O,O
are,O,O
potential,O,O
therapeutic,O,O
tools,O,O
in,O,O
PD,O,B
and,O,O
merit,O,O
further,O,O
attention,O,O
.,O,O
Neuropeptide,O,B
-,O,I
Y,O,I
immunoreactivity,O,O
in,O,O
the,O,O
pilocarpine,B,O
model,O,O
of,O,O
temporal,O,O
lobe,O,O
epilepsy,O,O
.,O,O
Neuropeptide,O,B
-,O,I
Y,O,I
(,O,O
NPY,O,B
),O,O
is,O,O
expressed,O,O
by,O,O
granule,O,O
cells,O,O
and,O,O
mossy,O,O
fibres,O,O
of,O,O
the,O,O
hippocampal,O,O
dentate,O,O
gyrus,O,O
during,O,O
experimental,O,O
temporal,O,O
lobe,O,O
epilepsy,O,O
(,O,O
TLE,O,B
),O,O
.,O,O
This,O,O
expression,O,O
may,O,O
represent,O,O
an,O,O
endogenous,O,O
damping,O,O
mechanism,O,O
since,O,O
NPY,O,B
has,O,O
been,O,O
shown,O,O
to,O,O
block,O,O
seizure,O,O
-,O,O
like,O,O
events,O,O
following,O,O
high,O,O
-,O,O
frequency,O,O
stimulation,O,O
in,O,O
hippocampal,O,O
slices,O,O
.,O,O
The,O,O
pilocarpine,B,B
(,O,O
PILO,B,B
),O,O
model,O,O
of,O,O
epilepsy,O,O
is,O,O
characterized,O,O
by,O,O
an,O,O
acute,O,O
period,O,O
of,O,O
status,O,O
epilepticus,O,O
followed,O,O
by,O,O
spontaneous,O,O
recurrent,O,O
seizures,O,O
and,O,O
related,O,O
brain,O,O
damage,O,O
.,O,O
We,O,O
report,O,O
peroxidase,O,B
-,O,I
antiperoxidase,O,I
immunostaining,O,O
for,O,O
NPY,O,B
in,O,O
several,O,O
brain,O,O
regions,O,O
in,O,O
this,O,O
model,O,O
.,O,O
PILO,B,B
-,O,I
injected,O,I
animals,O,O
exhibited,O,O
NPY,O,B
immunoreactivity,O,O
in,O,O
the,O,O
region,O,O
of,O,O
the,O,O
mossy,O,O
fibre,O,O
terminals,O,O
",",O,O
in,O,O
the,O,O
dentate,O,O
gyrus,O,O
inner,O,O
molecular,O,O
layer,O,O
and,O,O
",",O,O
in,O,O
a,O,O
few,O,O
cases,O,O
",",O,O
within,O,O
presumed,O,O
granule,O,O
cells,O,O
.,O,O
NPY,O,B
immunoreactivity,O,O
was,O,O
also,O,O
dramatically,O,O
changed,O,O
in,O,O
the,O,O
entorhinal,O,O
cortex,O,O
",",O,O
amygdala,O,B
and,O,O
sensorimotor,O,O
areas,O,O
.,O,O
In,O,O
addition,O,O
",",O,O
PILO,B,B
injected,O,O
animals,O,O
exhibited,O,O
a,O,O
reduction,O,O
in,O,O
the,O,O
number,O,O
of,O,O
NPY,O,B
-,O,O
immunoreactive,O,O
interneurons,O,O
compared,O,O
with,O,O
controls,O,O
.,O,O
The,O,O
results,O,O
demonstrate,O,O
that,O,O
changes,O,O
in,O,O
NPY,O,B
expression,O,O
",",O,O
including,O,O
expression,O,O
in,O,O
the,O,O
granule,O,O
cells,O,O
and,O,O
mossy,O,O
fibres,O,O
and,O,O
the,O,O
loss,O,O
of,O,O
vulnerable,O,O
NPY,O,B
neurons,O,O
",",O,O
are,O,O
present,O,O
in,O,O
the,O,O
PILO,B,B
model,O,O
of,O,O
TLE,O,O
.,O,O
However,O,O
",",O,O
the,O,O
significance,O,O
of,O,O
this,O,O
changed,O,O
synthesis,O,O
of,O,O
NPY,O,B
remains,O,O
to,O,O
be,O,O
determined,O,O
.,O,O
Posteroventral,O,O
medial,O,O
pallidotomy,O,O
in,O,O
advanced,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Posteroventral,O,O
medial,O,O
pallidotomy,O,O
sometimes,O,O
produces,O,O
striking,O,O
improvement,O,O
in,O,O
patients,O,O
with,O,O
advanced,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
",",O,O
but,O,O
the,O,O
studies,O,O
to,O,O
date,O,O
have,O,O
involved,O,O
small,O,O
numbers,O,O
of,O,O
patients,O,O
and,O,O
short,O,O
-,O,O
term,O,O
follow,O,O
-,O,O
up,O,O
.,O,O
METHODS,O,O
:,O,O
Forty,O,O
patients,O,O
with,O,O
Parkinson,O,B
',O,I
s,O,I
disease,O,I
underwent,O,O
serial,O,O
",",O,O
detailed,O,O
assessments,O,O
both,O,O
after,O,O
drug,O,O
withdrawal,O,O
(,O,O
period,O,O
),O,O
and,O,O
while,O,O
taking,O,O
their,O,O
optimal,O,O
medical,O,O
regimens,O,O
(,O,O
period,O,O
),O,O
.,O,O
All,O,O
patients,O,O
were,O,O
examined,O,O
preoperatively,O,O
and,O,O
39,O,O
were,O,O
examined,O,O
at,O,O
six,O,O
months,O,O
;,O,O
27,O,O
of,O,O
the,O,O
patients,O,O
were,O,O
also,O,O
examined,O,O
at,O,O
one,O,O
year,O,O
",",O,O
and,O,O
11,O,O
at,O,O
two,O,O
years,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
percent,O,O
improvements,O,O
at,O,O
six,O,O
months,O,O
were,O,O
as,O,O
follows,O,O
:,O,O
off,O,O
-,O,O
period,O,O
score,O,O
for,O,O
overall,O,O
motor,O,O
function,O,O
",",O,O
28,O,O
percent,O,O
(,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
19,O,O
to,O,O
38,O,O
percent,O,O
),O,O
",",O,O
with,O,O
most,O,O
of,O,O
the,O,O
improvement,O,O
in,O,O
the,O,O
contralateral,O,O
limbs,O,O
;,O,O
off,O,O
-,O,O
period,O,O
score,O,O
for,O,O
activities,O,O
of,O,O
daily,O,O
living,O,O
",",O,O
29,O,O
percent,O,O
(,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
19,O,O
to,O,O
39,O,O
percent,O,O
),O,O
;,O,O
on,O,O
-,O,O
period,O,O
score,O,O
for,O,O
contralateral,O,O
dyskinesias,O,O
",",O,O
82,O,O
percent,O,O
(,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
72,O,O
to,O,O
91,O,O
percent,O,O
),O,O
;,O,O
and,O,O
on,O,O
-,O,O
period,O,O
score,O,O
for,O,O
ipsilateral,O,O
dyskinesias,O,O
",",O,O
44,O,O
percent,O,O
(,O,O
95,O,O
percent,O,O
confidence,O,O
interval,O,O
",",O,O
29,O,O
to,O,O
59,O,O
percent,O,O
),O,O
.,O,O
The,O,O
improvements,O,O
in,O,O
dyskinesias,O,B
and,O,O
the,O,O
total,O,O
scores,O,O
for,O,O
off,O,O
-,O,O
period,O,O
parkinsonism,O,O
",",O,O
contralateral,O,O
bradykinesia,O,O
",",O,O
and,O,O
rigidity,O,O
were,O,O
sustained,O,O
in,O,O
the,O,O
11,O,O
patients,O,O
examined,O,O
at,O,O
two,O,O
years,O,O
.,O,O
The,O,O
improvement,O,O
in,O,O
ipsilateral,O,O
dyskinesias,O,B
was,O,O
lost,O,O
after,O,O
one,O,O
year,O,O
",",O,O
and,O,O
the,O,O
improvements,O,O
in,O,O
postural,O,O
stability,O,O
and,O,O
gait,O,O
lasted,O,O
only,O,O
three,O,O
to,O,O
six,O,O
months,O,O
.,O,O
Approximately,O,O
half,O,O
the,O,O
patients,O,O
who,O,O
had,O,O
been,O,O
dependent,O,O
on,O,O
assistance,O,O
in,O,O
activities,O,O
of,O,O
daily,O,O
living,O,O
in,O,O
the,O,O
off,O,O
period,O,O
before,O,O
surgery,O,O
became,O,O
independent,O,O
after,O,O
surgery,O,O
.,O,O
The,O,O
complications,O,O
of,O,O
surgery,O,O
were,O,O
generally,O,O
well,O,O
tolerated,O,O
",",O,O
and,O,O
there,O,O
were,O,O
no,O,O
significant,O,O
changes,O,O
in,O,O
the,O,O
use,O,O
of,O,O
medication,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
In,O,O
late,O,O
-,O,O
stage,O,O
Parkinson,O,B
',O,O
s,O,O
disease,O,O
",",O,O
pallidotomy,O,O
significantly,O,O
reduces,O,O
levodopa,B,B
-,O,O
induced,O,O
dyskinesias,O,O
and,O,O
off,O,O
-,O,O
period,O,O
disability,O,O
.,O,O
Much,O,O
of,O,O
the,O,O
benefit,O,O
is,O,O
sustained,O,O
at,O,O
two,O,O
years,O,O
",",O,O
although,O,O
some,O,O
improvements,O,O
",",O,O
such,O,O
as,O,O
those,O,O
on,O,O
the,O,O
ipsilateral,O,O
side,O,O
and,O,O
in,O,O
axial,O,O
symptoms,O,O
",",O,O
wane,O,O
within,O,O
the,O,O
first,O,O
year,O,O
.,O,O
The,O,O
on,O,O
-,O,O
period,O,O
symptoms,O,O
that,O,O
are,O,O
resistant,O,O
to,O,O
dopaminergic,O,O
therapy,O,O
do,O,O
not,O,O
respond,O,O
to,O,O
pallidotomy,O,O
.,O,O
Clarithromycin,B,B
-,O,I
induced,O,I
ventricular,O,I
tachycardia,O,I
.,O,O
Clarithromycin,B,B
is,O,O
a,O,O
relatively,O,O
new,O,O
macrolide,B,O
antibiotic,O,O
that,O,O
offers,O,O
twice,O,O
-,O,O
daily,O,O
dosing,O,O
.,O,O
It,O,O
differs,O,O
from,O,O
erythromycin,B,B
only,O,O
in,O,O
the,O,O
methylation,O,O
of,O,O
the,O,O
hydroxyl,O,O
group,O,O
at,O,O
position,O,O
6,O,O
.,O,O
Although,O,O
the,O,O
side,O,O
-,O,O
effect,O,O
profile,O,O
of,O,O
erythromycin,B,B
is,O,O
established,O,O
",",O,O
including,O,O
gastroenteritis,O,B
and,O,O
interactions,O,O
with,O,O
other,O,O
drugs,O,O
subject,O,O
to,O,O
hepatic,O,O
mixed,O,O
-,O,O
function,O,O
oxidase,O,O
metabolism,O,O
",",O,O
experience,O,O
with,O,O
the,O,O
newer,O,O
macrolides,B,O
is,O,O
still,O,O
being,O,O
recorded,O,O
.,O,O
Cardiotoxicity,O,O
has,O,O
been,O,O
demonstrated,O,O
after,O,O
both,O,O
intravenous,O,O
and,O,O
oral,O,O
administration,O,O
of,O,O
erythromycin,B,B
but,O,O
has,O,O
never,O,O
been,O,O
reported,O,O
with,O,O
the,O,O
newer,O,O
macrolides,B,B
.,O,O
We,O,O
report,O,O
a,O,O
case,O,O
of,O,O
ventricular,O,O
dysrhythmias,O,O
that,O,O
occurred,O,O
after,O,O
six,O,O
therapeutic,O,O
doses,O,O
of,O,O
clarithromycin,B,B
.,O,O
The,O,O
dysrhythmias,O,O
resolved,O,O
after,O,O
discontinuation,O,O
of,O,O
the,O,O
drug,O,O
.,O,O
Effect,O,O
of,O,O
glyceryl,B,B
trinitrate,I,I
on,O,O
the,O,O
sphincter,O,O
of,O,O
Oddi,O,O
spasm,O,O
evoked,O,O
by,O,O
prostigmine,B,B
-,O,O
morphine,B,B
administration,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
In,O,O
this,O,O
study,O,O
the,O,O
effect,O,O
of,O,O
glyceryl,B,B
trinitrate,I,I
on,O,O
the,O,O
prostigmine,B,B
-,O,O
morphine,B,B
-,O,O
induced,O,O
sphincter,O,O
of,O,O
Oddi,O,O
spasm,O,O
was,O,O
evaluated,O,O
in,O,O
nine,O,O
female,O,O
patients,O,O
with,O,O
sphincter,O,O
of,O,O
Oddi,O,O
dyskinesia,O,O
.,O,O
METHOD,O,O
:,O,O
Sphincter,O,O
of,O,O
Oddi,O,O
spasm,O,O
was,O,O
induced,O,O
by,O,O
prostigmine,B,B
-,O,O
morphine,B,B
administration,O,O
(,O,O
0,O,O
.,O,O
5,O,O
mg,O,O
prostigmine,B,B
intramuscularly,O,O
and,O,O
10,O,O
mg,O,O
morphine,B,B
subcutaneously,O,O
),O,O
and,O,O
visualized,O,O
by,O,O
quantitative,O,O
hepatobiliary,O,O
scintigraphy,O,O
.,O,O
The,O,O
entire,O,O
procedure,O,O
was,O,O
repeated,O,O
during,O,O
glyceryl,B,B
trinitrate,I,I
infusion,O,O
(,O,O
Nitrolingual,B,B
1,O,O
microg,O,O
/,O,O
kg,O,O
/,O,O
min,O,O
for,O,O
120,O,O
min,O,O
),O,O
.,O,O
RESULTS,O,O
:,O,O
Prostigmine,B,B
-,O,O
morphine,B,B
provocation,O,O
caused,O,O
significant,O,O
increases,O,O
in,O,O
the,O,O
time,O,O
to,O,O
peak,O,O
activity,O,O
(,O,O
Tmax,O,O
),O,O
over,O,O
the,O,O
hepatic,O,O
hilum,O,O
(,O,O
HH,O,O
:,O,O
34,O,O
.,O,O
33,O,O
+,O,O
/,O,O
-,O,O
5,O,O
.,O,O
.,O,O
77,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
26,O,O
),O,O
and,O,O
the,O,O
common,O,O
bile,O,O
duct,O,O
(,O,O
CBD,O,O
:,O,O
60,O,O
.,O,O
44,O,O
+,O,O
/,O,O
-,O,O
5,O,O
.,O,O
99,O,O
vs,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
88,O,O
),O,O
and,O,O
in,O,O
the,O,O
half,O,O
-,O,O
time,O,O
of,O,O
excretion,O,O
(,O,O
T1,O,O
/,O,O
2,O,O
),O,O
over,O,O
the,O,O
liver,O,O
parenchyma,O,O
(,O,O
LP,O,O
:,O,O
120,O,O
/,O,O
-,O,O
16,O,O
.,O,O
vs,O,O
.,O,O
27,O,O
.,O,O
37,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
19,O,O
",",O,O
HH,O,B
(,O,O
117,O,O
.,O,O
61,O,O
+,O,O
/,O,O
-,O,O
14,O,O
.,O,O
71,O,O
vs,O,O
.,O,O
31,O,O
.,O,O
85,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
99,O,O
),O,O
and,O,O
CBD,O,B
(,O,O
158,O,O
.,O,O
11,O,O
+,O,O
/,O,O
-,O,O
9,O,O
.,O,O
18,O,O
vs,O,O
.,O,O
40,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
6,O,O
.,O,O
24,O,O
),O,O
",",O,O
indicating,O,O
a,O,O
complete,O,O
spasm,O,O
at,O,O
the,O,O
level,O,O
of,O,O
the,O,O
sphincter,O,O
of,O,O
Oddi,O,O
.,O,O
Glyceryl,B,B
trinitrate,I,I
infusion,O,O
completely,O,O
normalized,O,O
the,O,O
prostigmine,B,B
-,O,O
morphine,B,B
-,O,O
induced,O,O
alterations,O,O
in,O,O
these,O,O
quantitative,O,O
parameters,O,O
(,O,O
TmaX,O,O
over,O,O
the,O,O
LP,O,O
:,O,O
11,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
13,O,O
;,O,O
over,O,O
the,O,O
HH,O,O
:,O,O
18,O,O
.,O,O
88,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
48,O,O
;,O,O
and,O,O
over,O,O
the,O,O
CBD,O,O
:,O,O
36,O,O
.,O,O
22,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
92,O,O
;,O,O
and,O,O
T1,O,O
/,O,O
2,O,O
over,O,O
the,O,O
LP,O,O
:,O,O
28,O,O
.,O,O
21,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
83,O,O
;,O,O
over,O,O
the,O,O
HH,O,O
:,O,O
33,O,O
.,O,O
42,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
10,O,O
;,O,O
and,O,O
over,O,O
the,O,O
CBD,O,O
:,O,O
41,O,O
.,O,O
66,O,O
+,O,O
/,O,O
-,O,O
6,O,O
.,O,O
33,O,O
),O,O
",",O,O
suggesting,O,O
an,O,O
effective,O,O
sphincter,O,O
-,O,O
relaxing,O,O
effect,O,O
of,O,O
glyceryl,B,B
trinitrate,I,I
.,O,O
CONCLUSION,O,O
:,O,O
These,O,O
results,O,O
provide,O,O
the,O,O
first,O,O
evidence,O,O
of,O,O
the,O,O
effectiveness,O,O
of,O,O
glyceryl,B,B
trinitrate,I,I
on,O,O
the,O,O
morphine,B,B
-,O,O
induced,O,O
sphincter,O,O
of,O,O
Oddi,O,O
spasm,O,O
in,O,O
humans,O,O
.,O,O
Since,O,O
glyceryl,B,B
trinitrate,I,I
is,O,O
able,O,O
to,O,O
overcome,O,O
even,O,O
the,O,O
drastic,O,O
effect,O,O
of,O,O
morphine,B,B
",",O,O
it,O,O
might,O,O
be,O,O
of,O,O
relevance,O,O
in,O,O
the,O,O
treatment,O,O
of,O,O
sphincter,O,O
of,O,O
Oddi,O,O
dyskinesia,O,O
.,O,O
Immunopathology,O,O
of,O,O
penicillamine,B,B
-,O,I
induced,O,I
glomerular,O,I
disease,O,I
.,O,O
Four,O,O
patients,O,O
with,O,O
rheumatoid,O,O
arthritis,O,O
developed,O,O
heavy,O,O
proteinuria,O,O
after,O,O
five,O,O
to,O,O
12,O,O
months,O,O
of,O,O
treatment,O,O
with,O,O
D,B,B
-,I,I
penicillamine,I,I
.,O,O
Light,O,O
microscopy,O,O
of,O,O
renal,O,O
biopsy,O,O
samples,O,O
showed,O,O
minimal,O,O
glomerular,O,O
capillary,O,O
wall,O,O
thickening,O,O
and,O,O
mesangial,O,O
matrix,O,O
increase,O,O
",",O,O
or,O,O
no,O,O
departure,O,O
from,O,O
normal,O,O
.,O,O
Electron,O,O
microscopy,O,O
",",O,O
however,O,O
",",O,O
revealed,O,O
subepithelial,O,O
electron,O,B
-,O,I
dense,O,I
deposits,O,O
",",O,O
fusion,O,O
of,O,O
epithelial,O,O
cell,O,O
foot,O,O
processes,O,O
",",O,O
and,O,O
evidence,O,O
of,O,O
mesangial,O,O
cell,O,O
hyperactivity,O,O
.,O,O
Immunofluorescence,O,O
microscopy,O,O
demonstrated,O,O
granular,O,O
capillary,O,O
wall,O,O
deposits,O,O
of,O,O
IgG,O,B
and,O,O
C3,O,B
.,O,O
The,O,O
findings,O,O
were,O,O
similar,O,O
to,O,O
those,O,O
in,O,O
early,O,O
membranous,O,O
glomerulonephritis,O,O
",",O,O
differences,O,O
being,O,O
observed,O,O
however,O,O
in,O,O
the,O,O
results,O,O
of,O,O
staining,O,O
for,O,O
the,O,O
early,O,O
-,O,O
acting,O,O
complement,O,B
components,O,O
C1q,O,B
and,O,O
C4,O,B
.,O,O
It,O,O
is,O,O
tentatively,O,O
concluded,O,O
that,O,O
complement,O,B
was,O,O
activated,O,O
by,O,O
the,O,O
classical,O,O
pathway,O,O
.,O,O
Experimental,O,O
cranial,O,O
pain,O,O
elicited,O,O
by,O,O
capsaicin,B,B
:,O,O
a,O,O
PET,O,B
study,O,O
.,O,O
Using,O,O
a,O,O
positron,O,B
emission,O,I
tomography,O,I
(,O,O
PET,O,I
),O,O
study,O,O
it,O,O
was,O,O
shown,O,O
recently,O,O
that,O,O
in,O,O
migraine,O,O
without,O,O
aura,O,O
certain,O,O
areas,O,O
in,O,O
the,O,O
brain,O,O
stem,O,O
were,O,O
activated,O,O
during,O,O
the,O,O
headache,O,O
state,O,O
",",O,O
but,O,O
not,O,O
in,O,O
the,O,O
headache,O,O
free,O,O
interval,O,O
.,O,O
It,O,O
was,O,O
suggested,O,O
that,O,O
this,O,O
brain,O,O
stem,O,O
activation,O,O
is,O,O
inherent,O,O
to,O,O
the,O,O
migraine,O,O
attack,O,O
itself,O,O
and,O,O
represents,O,O
the,O,O
so,O,O
called,O,O
',O,O
migraine,O,O
generator,O,O
',O,O
.,O,O
To,O,O
test,O,O
this,O,O
hypothesis,O,O
we,O,O
performed,O,O
an,O,O
experimental,O,O
pain,O,O
study,O,O
in,O,O
seven,O,O
healthy,O,O
volunteers,O,O
",",O,O
using,O,O
the,O,O
same,O,O
positioning,O,O
in,O,O
the,O,O
PET,O,O
scanner,O,O
as,O,O
in,O,O
the,O,O
migraine,O,O
patients,O,O
.,O,O
A,O,O
small,O,O
amount,O,O
of,O,O
capsaicin,B,B
was,O,O
administered,O,O
subcutaneously,O,O
in,O,O
the,O,O
right,O,O
forehead,O,O
to,O,O
evoke,O,O
a,O,O
burning,O,O
painful,O,O
sensation,O,O
in,O,O
the,O,O
first,O,O
division,O,O
of,O,O
the,O,O
trigeminal,O,O
nerve,O,O
.,O,O
Increases,O,O
of,O,O
regional,O,O
cerebral,O,O
blood,O,O
flow,O,O
(,O,O
rCBF,O,B
),O,O
were,O,O
found,O,O
bilaterally,O,O
in,O,O
the,O,O
insula,O,B
",",O,O
in,O,O
the,O,O
anterior,O,O
cingulate,O,B
cortex,O,I
",",O,O
the,O,O
cavernous,O,B
sinus,O,I
and,O,O
the,O,O
cerebellum,O,B
.,O,O
Using,O,O
the,O,O
same,O,O
stereotactic,O,O
space,O,O
limits,O,O
as,O,O
in,O,O
the,O,O
above,O,O
mentioned,O,O
migraine,O,O
study,O,O
no,O,O
brain,O,O
stem,O,O
activation,O,O
was,O,O
found,O,O
in,O,O
the,O,O
acute,O,O
pain,O,O
state,O,O
compared,O,O
to,O,O
the,O,O
pain,O,O
free,O,O
state,O,O
.,O,O
The,O,O
increase,O,O
of,O,O
activation,O,O
in,O,O
the,O,O
region,O,O
of,O,O
the,O,O
cavernous,O,B
sinus,O,I
however,O,O
",",O,O
suggests,O,O
that,O,O
this,O,O
structure,O,O
is,O,O
more,O,O
likely,O,O
to,O,O
be,O,O
involved,O,O
in,O,O
trigeminal,O,B
transmitted,O,O
pain,O,O
as,O,O
such,O,O
",",O,O
rather,O,O
than,O,O
in,O,O
a,O,O
specific,O,O
type,O,O
of,O,O
headache,O,O
as,O,O
was,O,O
suggested,O,O
for,O,O
cluster,O,O
headache,O,O
.,O,O
Value,O,O
of,O,O
methylprednisolone,B,B
in,O,O
prevention,O,O
of,O,O
the,O,O
arthralgia,O,B
-,O,I
myalgia,O,I
syndrome,O,I
associated,O,O
with,O,O
the,O,O
total,O,O
dose,O,O
infusion,O,O
of,O,O
iron,B,B
dextran,I,I
:,O,O
a,O,O
double,O,O
blind,O,O
randomized,O,O
trial,O,O
.,O,O
The,O,O
safety,O,O
and,O,O
efficacy,O,O
of,O,O
total,O,O
dose,O,O
infusion,O,O
(,O,O
TDI,O,O
),O,O
of,O,O
iron,B,B
dextran,I,I
has,O,O
been,O,O
well,O,O
documented,O,O
.,O,O
In,O,O
40,O,O
%,O,O
of,O,O
treated,O,O
patients,O,O
",",O,O
an,O,O
arthralgia,O,O
-,O,O
myalgia,O,O
syndrome,O,O
develops,O,O
.,O,O
The,O,O
purpose,O,O
of,O,O
this,O,O
randomized,O,O
",",O,O
double,O,O
-,O,O
blind,O,O
",",O,O
prospective,O,O
study,O,O
was,O,O
to,O,O
investigate,O,O
whether,O,O
intravenous,O,O
(,O,O
i,O,B
.,O,I
v,O,I
.,O,I
),O,O
administration,O,O
of,O,O
methylprednisolone,B,B
(,O,O
MP,B,O
),O,O
prevents,O,O
this,O,O
complication,O,O
.,O,O
Sixty,O,O
-,O,O
five,O,O
patients,O,O
",",O,O
34,O,O
women,O,O
and,O,O
31,O,O
men,O,O
",",O,O
ages,O,O
36,O,O
to,O,O
80,O,O
years,O,O
",",O,O
received,O,O
either,O,O
normal,O,B
saline,O,I
before,O,O
and,O,O
after,O,O
TDI,O,O
(,O,O
group,O,O
1,O,O
),O,O
",",O,O
125,O,B
mg,O,I
i,O,I
.,O,I
v,O,I
.,O,I
MP,B,I
before,O,O
and,O,O
saline,O,O
after,O,O
TDI,O,O
(,O,O
group,O,O
2,O,O
),O,O
",",O,O
or,O,O
125,O,B
mg,O,I
i,O,I
.,O,I
v,O,I
.,O,I
MP,B,I
before,O,O
and,O,O
after,O,O
TDI,O,O
(,O,O
group,O,O
3,O,O
),O,O
.,O,O
Patients,O,O
were,O,O
observed,O,O
for,O,O
72,O,O
hours,O,O
and,O,O
reactions,O,O
were,O,O
recorded,O,O
and,O,O
graded,O,O
according,O,O
to,O,O
severity,O,O
.,O,O
Fifty,O,O
-,O,O
eight,O,O
percent,O,O
of,O,O
group,O,O
1,O,O
patients,O,O
",",O,O
33,O,O
%,O,O
of,O,O
group,O,O
2,O,O
",",O,O
and,O,O
26,O,O
%,O,O
of,O,O
group,O,O
3,O,O
had,O,O
reactions,O,O
to,O,O
TDI,O,B
.,O,O
The,O,O
severity,O,O
of,O,O
reactions,O,O
(,O,O
minimal,O,O
",",O,O
mild,O,O
",",O,O
and,O,O
moderate,O,O
",",O,O
respectively,O,O
),O,O
was,O,O
as,O,O
follows,O,O
:,O,O
group,O,O
1,O,O
-,O,O
-,O,O
6,O,O
",",O,O
6,O,O
",",O,O
and,O,O
2,O,O
;,O,O
group,O,O
2,O,O
-,O,O
-,O,O
1,O,O
",",O,O
5,O,O
",",O,O
and,O,O
0,O,O
;,O,O
group,O,O
3,O,O
-,O,O
-,O,O
5,O,O
",",O,O
1,O,O
",",O,O
and,O,O
0,O,O
.,O,O
Data,O,O
were,O,O
analyzed,O,O
by,O,O
the,O,O
two,O,O
-,O,O
sided,O,O
Fisher,O,O
',O,O
s,O,O
exact,O,O
test,O,O
using,O,O
95,O,O
%,O,O
confidence,O,O
intervals,O,O
with,O,O
the,O,O
approximation,O,O
of,O,O
Woolf,O,O
.,O,O
These,O,O
data,O,O
demonstrate,O,O
that,O,O
administration,O,O
of,O,O
MP,B,B
before,O,O
and,O,O
after,O,O
TDI,O,O
reduces,O,O
the,O,O
frequency,O,O
and,O,O
severity,O,O
of,O,O
the,O,O
arthralgia,O,B
-,O,I
myalgia,O,I
syndrome,O,I
.,O,O
We,O,O
conclude,O,O
that,O,O
125,O,O
mg,O,O
i,O,O
.,O,O
v,O,O
MP,B,B
should,O,O
be,O,O
given,O,O
routinely,O,O
before,O,O
and,O,O
after,O,O
TDI,O,O
of,O,O
iron,B,B
dextran,I,I
.,O,O
Prolongation,O,O
of,O,O
the,O,O
QT,O,B
interval,O,I
related,O,O
to,O,O
cisapride,B,B
-,O,I
diltiazem,B,I
interaction,O,I
.,O,O
Cisapride,B,B
",",O,O
a,O,O
cytochrome,O,B
P450,O,I
3A4,O,I
(,O,O
CYP3A4,O,I
),O,O
substrate,O,O
",",O,O
is,O,O
widely,O,O
prescribed,O,O
for,O,O
the,O,O
treatment,O,O
of,O,O
gastrointestinal,O,O
motility,O,O
disorders,O,O
.,O,O
Prolongation,O,O
of,O,O
QT,O,B
interval,O,O
",",O,O
torsades,O,O
de,O,O
pointes,O,O
",",O,O
and,O,O
sudden,O,O
cardiac,O,O
death,O,O
have,O,O
been,O,O
reported,O,O
after,O,O
concomitant,O,O
administration,O,O
with,O,O
erythromycin,B,B
or,O,O
azole,B,B
antifungal,O,I
agents,O,O
",",O,O
but,O,O
not,O,O
with,O,O
other,O,O
CYP3A4,O,I
inhibitors,O,O
.,O,O
A,O,O
possible,O,O
drug,O,O
interaction,O,O
occurred,O,O
in,O,O
a,O,O
45,O,O
-,O,O
year,O,O
-,O,O
old,O,O
woman,O,O
who,O,O
was,O,O
taking,O,O
cisapride,B,B
for,O,O
gastroesophageal,O,O
reflux,O,O
disorder,O,O
and,O,O
diltiazem,B,B
",",O,O
an,O,O
agent,O,O
that,O,O
has,O,O
inhibitory,O,O
effect,O,O
on,O,O
CYP3A4,O,B
",",O,O
for,O,O
hypertension,O,O
.,O,O
The,O,O
patient,O,O
was,O,O
in,O,O
near,O,O
syncope,O,O
and,O,O
had,O,O
QT,O,B
-,O,I
interval,O,I
prolongation,O,I
.,O,O
After,O,O
discontinuing,O,O
cisapride,B,B
",",O,O
the,O,O
QT,O,B
interval,O,I
returned,O,O
to,O,O
normal,O,O
and,O,O
symptoms,O,O
did,O,O
not,O,O
recur,O,O
.,O,O
We,O,O
suggest,O,O
that,O,O
caution,O,O
be,O,O
taken,O,O
when,O,O
cisapride,B,B
is,O,O
prescribed,O,O
with,O,O
any,O,O
potent,O,O
inhibitor,O,O
of,O,O
CYP3A4,O,B
",",O,O
including,O,O
diltiazem,B,B
.,O,O
Cortical,O,O
motor,O,O
overactivation,O,O
in,O,O
parkinsonian,O,O
patients,O,O
with,O,O
L,B,B
-,I,O
dopa,I,I
-,O,O
induced,O,O
peak,O,O
-,O,O
dose,O,O
dyskinesia,O,O
.,O,O
We,O,O
have,O,O
studied,O,O
the,O,O
regional,O,O
cerebral,O,O
blood,O,O
flow,O,O
(,O,O
rCBF,O,B
),O,O
changes,O,O
induced,O,O
by,O,O
the,O,O
execution,O,O
of,O,O
a,O,O
finger,O,O
-,O,O
to,O,O
-,O,O
thumb,O,O
opposition,O,O
motor,O,O
task,O,O
in,O,O
the,O,O
supplementary,O,O
and,O,O
primary,O,O
motor,O,O
cortex,O,O
of,O,O
two,O,O
groups,O,O
of,O,O
parkinsonian,O,O
patients,O,O
on,O,O
L,B,B
-,I,O
dopa,I,I
medication,O,O
",",O,O
the,O,O
first,O,O
one,O,O
without,O,O
L,B,B
-,I,O
dopa,I,I
induced,O,O
dyskinesia,O,O
(,O,O
n,O,O
=,O,O
23,O,O
),O,O
and,O,O
the,O,O
other,O,O
with,O,O
moderate,O,O
peak,O,O
-,O,O
dose,O,O
dyskinesia,O,O
(,O,O
n,O,O
=,O,O
15,O,O
),O,O
",",O,O
and,O,O
of,O,O
a,O,O
group,O,O
of,O,O
14,O,O
normal,O,O
subjects,O,O
.,O,O
Single,O,O
photon,O,O
emission,O,O
tomography,O,O
with,O,O
i,O,B
.,O,O
v,O,O
.,O,O
133Xe,O,B
was,O,O
used,O,O
to,O,O
measure,O,O
the,O,O
rCBF,O,B
changes,O,O
.,O,O
The,O,O
dyskinetic,O,O
parkinsonian,O,O
patients,O,O
exhibited,O,O
a,O,O
pattern,O,O
of,O,O
response,O,O
which,O,O
was,O,O
markedly,O,O
different,O,O
from,O,O
those,O,O
of,O,O
the,O,O
normal,O,O
subjects,O,O
and,O,O
non,O,O
-,O,O
dyskinetic,O,O
parkinsonian,O,O
patients,O,O
",",O,O
with,O,O
a,O,O
significant,O,O
overactivation,O,O
in,O,O
the,O,O
supplementary,O,O
motor,O,O
area,O,O
and,O,O
the,O,O
ipsi,O,O
-,O,O
and,O,O
contralateral,O,O
primary,O,O
motor,O,O
areas,O,O
.,O,O
These,O,O
results,O,O
are,O,O
compatible,O,O
with,O,O
the,O,O
hypothesis,O,O
that,O,O
an,O,O
hyperkinetic,O,O
abnormal,O,O
involuntary,O,O
movement,O,O
",",O,O
like,O,O
L,B,B
-,I,I
dopa,I,I
-,O,I
induced,O,I
peak,O,I
dose,O,I
dyskinesia,O,I
",",O,O
is,O,O
due,O,O
to,O,O
a,O,O
disinhibition,O,O
of,O,O
the,O,O
primary,O,O
and,O,O
associated,O,O
motor,O,O
cortex,O,O
secondary,O,O
to,O,O
an,O,O
excessive,O,O
outflow,O,O
of,O,O
the,O,O
pallidothalamocortical,O,O
motor,O,O
loop,O,O
.,O,O
Open,O,O
-,O,O
label,O,O
assessment,O,O
of,O,O
levofloxacin,B,B
for,O,O
the,O,O
treatment,O,O
of,O,O
acute,O,O
bacterial,O,O
sinusitis,O,O
in,O,O
adults,O,O
.,O,O
PURPOSE,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
efficacy,O,O
and,O,O
safety,O,O
of,O,O
levofloxacin,B,B
(,O,O
500,O,B
mg,O,I
orally,O,O
once,O,O
daily,O,O
for,O,O
10,O,O
to,O,O
14,O,O
days,O,O
),O,O
in,O,O
treating,O,O
adult,O,O
outpatients,O,O
with,O,O
acute,O,O
bacterial,O,O
sinusitis,O,O
.,O,O
PATIENTS,O,O
AND,O,O
METHODS,O,O
:,O,O
A,O,O
total,O,O
of,O,O
329,O,O
patients,O,O
enrolled,O,O
in,O,O
the,O,O
study,O,O
at,O,O
24,O,O
centers,O,O
.,O,O
All,O,O
patients,O,O
had,O,O
a,O,O
pre,O,O
-,O,O
therapy,O,O
Gram,O,B
',O,I
s,O,I
stain,O,I
and,O,O
culture,O,O
of,O,O
sinus,O,O
exudate,O,O
obtained,O,O
by,O,O
antral,O,O
puncture,O,O
or,O,O
nasal,O,O
endoscopy,O,O
.,O,O
Clinical,O,O
response,O,O
was,O,O
assessed,O,O
on,O,O
the,O,O
basis,O,O
of,O,O
signs,O,O
and,O,O
symptoms,O,O
and,O,O
sinus,O,O
radiograph,O,O
or,O,O
computed,O,O
tomography,O,O
results,O,O
.,O,O
Microbiologic,O,O
cure,O,O
rates,O,O
were,O,O
determined,O,O
on,O,O
the,O,O
basis,O,O
of,O,O
presumed,O,O
plus,O,O
documented,O,O
eradication,O,O
of,O,O
the,O,O
pre,O,O
-,O,O
therapy,O,O
pathogen,O,O
(,O,O
s,O,O
),O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
most,O,O
common,O,O
pathogens,O,O
were,O,O
Haemophilus,O,B
influenzae,O,I
",",O,O
Streptococcus,O,B
pneumoniae,O,I
",",O,O
Staphylococcus,O,B
aureus,O,I
",",O,O
and,O,O
Moraxella,O,B
catarrhalis,O,I
.,O,O
Of,O,O
300,O,O
clinically,O,O
evaluable,O,O
patients,O,O
",",O,O
175,O,O
(,O,O
58,O,O
%,O,O
),O,O
were,O,O
cured,O,O
and,O,O
90,O,O
(,O,O
30,O,O
%,O,O
),O,O
were,O,O
improved,O,O
at,O,O
the,O,O
post,O,O
-,O,O
therapy,O,O
evaluation,O,O
",",O,O
resulting,O,O
in,O,O
a,O,O
clinical,O,O
success,O,O
rate,O,O
of,O,O
88,O,O
%,O,O
.,O,O
-,O,O
five,O,O
patients,O,O
(,O,O
12,O,O
%,O,O
),O,O
clinically,O,O
failed,O,O
treatment,O,O
.,O,O
microbiologic,O,O
eradication,O,O
rate,O,O
(,O,O
presumed,O,O
plus,O,O
documented,O,O
),O,O
among,O,O
138,O,O
microbiologically,O,O
evaluable,O,O
patients,O,O
was,O,O
92,O,O
%,O,O
.,O,O
Microbiologic,O,O
eradication,O,O
rates,O,O
(,O,O
presumed,O,O
plus,O,O
documented,O,O
),O,O
of,O,O
the,O,O
most,O,O
common,O,O
pathogens,O,O
ranged,O,O
from,O,O
93,O,O
%,O,O
(,O,O
M,O,B
.,O,I
catarrhalis,O,I
),O,O
to,O,O
100,O,O
%,O,O
(,O,O
S,O,B
.,O,I
pneumoniae,O,I
),O,O
at,O,O
the,O,O
post,O,O
-,O,O
therapy,O,O
visit,O,O
.,O,O
All,O,O
but,O,O
one,O,O
of,O,O
the,O,O
265,O,O
patients,O,O
who,O,O
were,O,O
cured,O,O
or,O,O
improved,O,O
at,O,O
post,O,O
-,O,O
therapy,O,O
returned,O,O
for,O,O
a,O,O
long,O,O
-,O,O
term,O,O
follow,O,O
-,O,O
up,O,O
visit,O,O
;,O,O
243,O,O
(,O,O
92,O,O
%,O,O
),O,O
remained,O,O
well,O,O
4,O,O
to,O,O
6,O,O
weeks,O,O
after,O,O
therapy,O,O
;,O,O
and,O,O
21,O,O
(,O,O
8,O,O
%,O,O
),O,O
had,O,O
a,O,O
relapse,O,O
of,O,O
symptoms,O,O
.,O,O
Adverse,O,O
events,O,O
considered,O,O
to,O,O
be,O,O
related,O,O
to,O,O
levofloxacin,B,B
administration,O,O
were,O,O
reported,O,O
by,O,O
29,O,O
patients,O,O
(,O,O
9,O,O
%,O,O
),O,O
.,O,O
The,O,O
most,O,O
common,O,O
drug,O,O
-,O,O
related,O,O
adverse,O,O
events,O,O
were,O,O
diarrhea,O,B
",",O,O
flatulence,O,B
",",O,O
and,O,O
nausea,O,B
;,O,O
most,O,O
adverse,O,O
events,O,O
were,O,O
mild,O,O
to,O,O
moderate,O,O
in,O,O
severity,O,O
.,O,O
CONCLUSION,O,O
:,O,O
The,O,O
results,O,O
of,O,O
this,O,O
study,O,O
indicate,O,O
that,O,O
levofloxacin,B,B
500,O,O
mg,O,O
once,O,O
daily,O,O
is,O,O
an,O,O
effective,O,O
and,O,O
safe,O,O
treatment,O,O
for,O,O
acute,O,O
bacterial,O,O
sinusitis,O,O
.,O,O
Iatrogenic,O,O
risks,O,O
of,O,O
endometrial,O,O
carcinoma,O,O
after,O,O
treatment,O,O
for,O,O
breast,O,O
cancer,O,O
in,O,O
a,O,O
large,O,O
French,O,O
case,O,O
-,O,O
control,O,O
study,O,O
.,O,O
F,O,O
d,O,O
ration,O,O
Nationale,O,O
des,O,O
Centres,O,O
de,O,O
Lutte,O,O
Contre,O,O
le,O,O
Cancer,O,O
(,O,O
FNCLCC,O,O
),O,O
.,O,O
Since,O,O
tamoxifen,B,B
is,O,O
widely,O,O
used,O,O
in,O,O
breast,O,O
cancer,O,O
treatment,O,O
and,O,O
has,O,O
been,O,O
proposed,O,O
for,O,O
the,O,O
prevention,O,O
of,O,O
breast,O,O
cancer,O,O
",",O,O
its,O,O
endometrial,O,O
iatrogenic,O,O
effects,O,O
must,O,O
be,O,O
carefully,O,O
examined,O,O
.,O,O
We,O,O
have,O,O
investigated,O,O
the,O,O
association,O,O
between,O,O
endometrial,O,B
cancer,O,I
and,O,O
tamoxifen,B,B
use,O,O
or,O,O
other,O,O
treatments,O,O
in,O,O
women,O,O
treated,O,O
for,O,O
breast,O,B
cancer,O,I
in,O,O
a,O,O
case,O,O
-,O,O
control,O,O
study,O,O
.,O,O
Cases,O,O
of,O,O
endometrial,O,B
cancer,O,I
diagnosed,O,O
after,O,O
breast,O,B
cancer,O,I
(,O,O
n,O,O
=,O,O
135,O,O
),O,O
and,O,O
467,O,O
controls,O,O
matched,O,O
for,O,O
age,O,O
",",O,O
year,O,O
of,O,O
diagnosis,O,O
of,O,O
breast,O,B
cancer,O,I
and,O,O
hospital,O,O
and,O,O
survival,O,O
time,O,O
with,O,O
an,O,O
intact,O,O
uterus,O,O
were,O,O
included,O,O
.,O,O
Women,O,O
who,O,O
had,O,O
received,O,O
tamoxifen,B,B
were,O,O
significantly,O,O
more,O,O
likely,O,O
to,O,O
have,O,O
endometrial,O,B
cancer,O,I
diagnosed,O,O
than,O,O
those,O,O
who,O,O
had,O,O
not,O,O
(,O,O
crude,O,O
relative,O,O
risk,O,O
=,O,O
4,O,O
.,O,O
9,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
.,O,O
Univariate,O,O
and,O,O
adjusted,O,O
analyses,O,O
showed,O,O
that,O,O
the,O,O
risk,O,O
increased,O,O
with,O,O
the,O,O
length,O,O
of,O,O
treatment,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
or,O,O
the,O,O
cumulative,O,O
dose,O,O
of,O,O
tamoxifen,B,B
received,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
irrespective,O,O
of,O,O
the,O,O
daily,O,O
dose,O,O
.,O,O
Women,O,O
who,O,O
had,O,O
undergone,O,O
pelvic,O,O
radiotherapy,O,O
also,O,O
had,O,O
a,O,O
higher,O,O
risk,O,O
(,O,O
crude,O,O
relative,O,O
risk,O,O
=,O,O
7,O,O
.,O,O
8,O,O
",",O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
After,O,O
adjusting,O,O
for,O,O
confounding,O,O
factors,O,O
",",O,O
the,O,O
risk,O,O
was,O,O
higher,O,O
for,O,O
tamoxifen,B,B
users,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
",",O,O
treatment,O,O
for,O,O
more,O,O
than,O,O
3,O,O
years,O,O
(,O,O
all,O,O
p,O,O
<,O,O
0,O,O
.,O,O
),O,O
and,O,O
pelvic,O,O
radiotherapy,O,O
(,O,O
p,O,O
=,O,O
0,O,O
.,O,O
),O,O
.,O,O
Women,O,O
who,O,O
had,O,O
endometrial,O,B
cancer,O,I
and,O,O
had,O,O
received,O,O
tamoxifen,B,B
had,O,O
more,O,O
advanced,O,O
disease,O,O
and,O,O
poorer,O,O
prognosis,O,O
than,O,O
those,O,O
with,O,O
endometrial,O,B
cancer,O,I
who,O,O
had,O,O
not,O,O
received,O,O
this,O,O
treatment,O,O
.,O,O
Our,O,O
results,O,O
suggest,O,O
a,O,O
causal,O,O
role,O,O
of,O,O
tamoxifen,B,B
in,O,O
endometrial,O,B
cancer,O,I
",",O,O
particularly,O,O
when,O,O
used,O,O
as,O,O
currently,O,O
proposed,O,O
for,O,O
breast,O,O
cancer,O,O
prevention,O,O
.,O,O
Pelvic,O,O
radiotherapy,O,O
may,O,O
be,O,O
an,O,O
additional,O,O
iatrogenic,O,O
factor,O,O
for,O,O
women,O,O
with,O,O
breast,O,B
cancer,O,I
.,O,O
Endometrial,O,B
cancers,O,I
diagnosed,O,O
in,O,O
women,O,O
treated,O,O
with,O,O
tamoxifen,B,B
have,O,O
poorer,O,O
prognosis,O,O
.,O,O
Women,O,O
who,O,O
receive,O,O
tamoxifen,B,B
for,O,O
breast,O,B
cancer,O,I
should,O,O
be,O,O
offered,O,O
gynaecological,O,O
surveillance,O,O
during,O,O
and,O,O
after,O,O
treatment,O,O
.,O,O
A,O,O
long,O,O
-,O,O
term,O,O
evaluation,O,O
of,O,O
the,O,O
risk,O,O
-,O,O
benefit,O,O
ratio,O,O
of,O,O
tamoxifen,B,B
as,O,O
a,O,O
preventive,O,O
treatment,O,O
for,O,O
breast,O,B
cancer,O,I
is,O,O
clearly,O,O
warranted,O,O
.,O,O
Contribution,O,O
of,O,O
the,O,O
glycine,B,B
site,O,O
of,O,O
NMDA,B,B
receptors,O,O
in,O,O
rostral,O,O
and,O,O
intermediate,O,O
-,O,O
caudal,O,O
parts,O,O
of,O,O
the,O,O
striatum,O,O
to,O,O
the,O,O
regulation,O,O
of,O,O
muscle,O,O
tone,O,O
in,O,O
rats,O,O
.,O,O
The,O,O
aim,O,O
of,O,O
the,O,O
present,O,O
study,O,O
was,O,O
to,O,O
assess,O,O
the,O,O
contribution,O,O
of,O,O
the,O,O
glycine,B,B
site,O,O
of,O,O
NMDA,B,B
receptors,O,O
in,O,O
the,O,O
striatum,O,O
to,O,O
the,O,O
regulation,O,O
of,O,O
muscle,O,O
tone,O,O
.,O,O
Muscle,O,B
tone,O,O
was,O,O
examined,O,O
using,O,O
a,O,O
combined,O,O
mechanoand,O,O
electromyographic,O,O
method,O,O
",",O,O
which,O,O
measured,O,O
simultaneously,O,O
the,O,O
muscle,O,B
resistance,O,O
(,O,O
MMG,O,B
),O,O
of,O,O
the,O,O
rat,O,O
',O,O
s,O,O
hind,O,O
foot,O,O
to,O,O
passive,O,O
extension,O,O
and,O,O
flexion,O,O
in,O,O
the,O,O
ankle,O,O
joint,O,O
and,O,O
the,O,O
electromyographic,O,O
activity,O,O
(,O,O
EMG,O,B
),O,O
of,O,O
the,O,O
antagonistic,O,O
muscles,O,B
of,O,O
that,O,O
joint,O,O
:,O,O
gastrocnemius,O,B
and,O,O
tibialis,O,B
anterior,O,I
.,O,O
Muscle,O,O
rigidity,O,O
was,O,O
induced,O,O
by,O,O
haloperidol,B,B
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
),O,O
.,O,O
5,B,O
",",I,O
7,I,O
-,I,O
dichlorokynurenic,I,B
acid,I,I
(,O,O
5,B,O
",",I,O
7,I,O
-,I,O
DCKA,I,O
),O,O
",",O,O
a,O,O
selective,O,O
glycine,B,B
site,O,I
antagonist,O,I
",",O,O
injected,O,O
in,O,O
doses,O,O
of,O,O
2,O,O
.,O,O
5,O,O
and,O,O
4,O,O
.,O,O
5,O,O
microg,O,O
/,O,O
0,O,O
.,O,O
5,O,O
microl,O,O
bilaterally,O,O
",",O,O
into,O,O
the,O,O
rostral,O,O
region,O,O
of,O,O
the,O,O
striatum,O,B
",",O,O
decreased,O,O
both,O,O
the,O,O
haloperidol,B,B
-,O,O
induced,O,O
muscle,O,O
rigidity,O,O
(,O,O
MMG,O,O
),O,O
and,O,O
the,O,O
enhanced,O,O
electromyographic,O,O
activity,O,O
(,O,O
EMG,O,O
),O,O
.,O,O
5,B,B
",",I,O
7,I,B
-,I,I
DCKA,I,I
injected,O,O
bilaterally,O,O
in,O,O
a,O,O
dose,O,O
of,O,O
4,O,B
.,O,O
5,O,I
microg,O,O
/,O,O
0,O,B
.,O,O
5,O,I
microl,O,O
into,O,O
the,O,O
intermediate,O,O
-,O,O
caudal,O,O
region,O,O
of,O,O
the,O,O
striatum,O,O
of,O,O
rats,O,O
not,O,O
pretreated,O,O
with,O,O
haloperidol,B,O
had,O,O
no,O,O
effect,O,O
on,O,O
the,O,O
muscle,O,O
tone,O,O
.,O,O
The,O,O
present,O,O
results,O,O
suggest,O,O
that,O,O
blockade,O,O
of,O,O
the,O,O
glycine,B,B
site,O,O
of,O,O
NMDA,B,B
receptors,O,O
in,O,O
the,O,O
rostral,O,O
part,O,O
of,O,O
the,O,O
striatum,O,O
may,O,O
be,O,O
mainly,O,O
responsible,O,O
for,O,O
the,O,O
antiparkinsonian,O,O
action,O,O
of,O,O
this,O,O
drug,O,O
.,O,O
Carboplatin,B,B
toxic,O,O
effects,O,O
on,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
of,O,O
the,O,O
rat,O,O
.,O,O
BACKGROUND,O,O
:,O,O
The,O,O
most,O,O
striking,O,O
of,O,O
carboplatin,B,B
',O,O
s,O,O
advantages,O,O
(,O,O
CBDCA,B,B
),O,O
over,O,O
cisplatin,B,B
(,O,O
CDDP,B,B
),O,O
is,O,O
its,O,O
markedly,O,O
reduced,O,O
rate,O,O
of,O,O
neurotoxic,O,O
effects,O,O
.,O,O
However,O,O
",",O,O
the,O,O
use,O,O
of,O,O
CBDCA,B,B
higher,O,O
-,O,O
intensity,O,O
schedules,O,O
and,O,O
the,O,O
association,O,O
with,O,O
other,O,O
neurotoxic,O,O
drugs,O,O
in,O,O
polychemotherapy,O,O
may,O,O
cause,O,O
some,O,O
concern,O,O
about,O,O
its,O,O
safety,O,O
with,O,O
respect,O,O
to,O,O
peripheral,O,O
nervous,O,O
system,O,O
damage,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
Two,O,O
different,O,O
schedules,O,O
of,O,O
CBDCA,B,B
administration,O,O
(,O,O
10,O,O
mg,O,O
/,O,O
kg,O,O
and,O,O
15,O,O
mg,O,O
/,O,O
kg,O,O
i,O,O
.,O,O
p,O,O
.,O,O
twice,O,O
a,O,O
week,O,O
for,O,O
nine,O,O
times,O,O
),O,O
were,O,O
evaluated,O,O
in,O,O
Wistar,O,O
rats,O,O
.,O,O
Neurotoxicity,O,O
was,O,O
assessed,O,O
for,O,O
behavioral,O,O
(,O,O
tail,O,O
-,O,O
flick,O,O
test,O,O
),O,O
",",O,O
neurophysiological,O,O
(,O,O
nerve,O,O
conduction,O,O
velocity,O,O
in,O,O
the,O,O
tail,O,O
nerve,O,O
),O,O
",",O,O
morphological,O,O
",",O,O
morphometrical,O,O
and,O,O
analytical,O,O
effects,O,O
.,O,O
RESULTS,O,O
:,O,O
CBDCA,B,B
administration,O,O
induced,O,O
dose,O,O
-,O,O
dependent,O,O
peripheral,O,O
neurotoxicity,O,O
.,O,O
Pain,O,O
perception,O,O
and,O,O
nerve,O,O
conduction,O,O
velocity,O,O
in,O,O
the,O,O
tail,O,O
were,O,O
significantly,O,O
impaired,O,O
",",O,O
particularly,O,O
after,O,O
the,O,O
high,O,O
-,O,O
dose,O,O
treatment,O,O
.,O,O
The,O,O
dorsal,O,O
root,O,O
ganglia,O,O
sensory,O,O
neurons,O,O
and,O,O
",",O,O
to,O,O
a,O,O
lesser,O,O
extent,O,O
",",O,O
satellite,O,O
cells,O,O
showed,O,O
the,O,O
same,O,O
changes,O,O
as,O,O
those,O,O
induced,O,O
by,O,O
CDDP,B,B
",",O,O
mainly,O,O
affecting,O,O
the,O,O
nucleus,O,O
and,O,O
nucleolus,O,O
of,O,O
ganglionic,O,O
sensory,O,O
neurons,O,O
.,O,O
Moreover,O,O
",",O,O
significant,O,O
amounts,O,O
of,O,O
platinum,B,B
were,O,O
detected,O,O
in,O,O
the,O,O
dorsal,O,O
root,O,O
ganglia,O,O
and,O,O
kidney,O,O
after,O,O
CBDCA,B,B
treatment,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
CBDCA,B,B
is,O,O
neurotoxic,O,O
in,O,O
our,O,O
model,O,O
",",O,O
and,O,O
the,O,O
type,O,O
of,O,O
pathological,O,O
changes,O,O
it,O,O
induces,O,O
are,O,O
so,O,O
closely,O,O
similar,O,O
to,O,O
those,O,O
caused,O,O
by,O,O
CDDP,B,B
that,O,O
it,O,O
is,O,O
probable,O,O
that,O,O
neurotoxicity,O,O
is,O,O
induced,O,O
in,O,O
the,O,O
two,O,O
drugs,O,O
by,O,O
the,O,O
same,O,O
mechanism,O,O
.,O,O
This,O,O
model,O,O
can,O,O
be,O,O
used,O,O
alone,O,O
or,O,O
in,O,O
combination,O,O
with,O,O
other,O,O
drugs,O,O
to,O,O
explore,O,O
the,O,O
effect,O,O
of,O,O
CBDCA,B,B
on,O,O
the,O,O
peripheral,O,O
nervous,O,O
system,O,O
.,O,O
Effects,O,O
of,O,O
cisapride,B,B
on,O,O
symptoms,O,O
and,O,O
postcibal,O,O
small,O,O
-,O,O
bowel,O,O
motor,O,O
function,O,O
in,O,O
patients,O,O
with,O,O
irritable,O,O
bowel,O,O
syndrome,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Irritable,O,O
bowel,O,O
syndrome,O,O
is,O,O
a,O,O
common,O,O
cause,O,O
of,O,O
abdominal,O,O
pain,O,O
and,O,O
discomfort,O,O
and,O,O
may,O,O
be,O,O
related,O,O
to,O,O
disordered,O,O
gastrointestinal,O,O
motility,O,O
.,O,O
Our,O,O
aim,O,O
was,O,O
to,O,O
assess,O,O
the,O,O
effects,O,O
of,O,O
long,O,O
-,O,O
term,O,O
treatment,O,O
with,O,O
a,O,O
prokinetic,O,O
agent,O,O
",",O,O
cisapride,B,B
",",O,O
on,O,O
postprandial,O,O
jejunal,O,O
motility,O,O
and,O,O
symptoms,O,O
in,O,O
the,O,O
irritable,O,O
bowel,O,O
syndrome,O,O
(,O,O
IBS,O,B
),O,O
.,O,O
METHODS,O,O
:,O,O
Thirty,O,O
-,O,O
eight,O,O
patients,O,O
with,O,O
IBS,O,B
(,O,O
constipation,O,B
-,O,O
predominant,O,O
",",O,O
n,O,O
=,O,O
17,O,O
;,O,O
diarrhoea,O,B
-,O,O
predominant,O,O
",",O,O
n,O,O
=,O,O
21,O,O
),O,O
underwent,O,O
24,O,O
-,O,O
h,O,O
ambulatory,O,O
jejunal,O,O
manometry,O,O
before,O,O
and,O,O
after,O,O
12,O,O
week,O,O
',O,O
s,O,O
treatment,O,O
[,O,O
cisapride,B,B
",",O,O
5,O,O
mg,O,O
three,O,O
times,O,O
daily,O,O
(,O,O
n,O,O
=,O,O
19,O,O
),O,O
or,O,O
placebo,O,O
(,O,O
n,O,O
=,O,O
19,O,O
),O,O
],O,O
.,O,O
RESULTS,O,O
:,O,O
In,O,O
diarrhoea,O,O
-,O,O
predominant,O,O
patients,O,O
significant,O,O
differences,O,O
in,O,O
contraction,O,O
characteristics,O,O
were,O,O
observed,O,O
between,O,O
the,O,O
cisapride,B,B
and,O,O
placebo,O,O
groups,O,O
.,O,O
In,O,O
cisapride,B,B
-,O,O
treated,O,O
diarrhoea,O,O
-,O,O
predominant,O,O
patients,O,O
the,O,O
mean,O,O
contraction,O,O
amplitude,O,O
was,O,O
higher,O,O
(,O,O
29,O,O
.,O,O
3,O,O
+,O,O
/,O,O
-,O,O
3,O,O
.,O,O
2,O,O
versus,O,O
24,O,O
.,O,O
9,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
6,O,O
mm,O,O
Hg,O,O
",",O,O
cisapride,B,B
versus,O,O
placebo,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
;,O,O
pretreatment,O,O
",",O,O
25,O,O
.,O,O
7,O,O
+,O,O
/,O,O
-,O,O
6,O,O
.,O,O
0,O,O
mm,O,O
Hg,O,O
mean,O,O
contraction,O,O
duration,O,O
longer,O,O
(,O,O
3,O,O
.,O,O
4,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
versus,O,O
3,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
sec,O,O
",",O,O
cisapride,B,B
versus,O,O
placebo,O,B
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
;,O,O
pretreatment,O,O
",",O,O
3,O,O
.,O,O
1,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
5,O,O
sec,O,O
),O,O
and,O,O
the,O,O
mean,O,O
contraction,O,O
frequency,O,O
lower,O,O
(,O,O
2,O,O
.,O,O
0,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
2,O,O
versus,O,O
2,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
4,O,O
cont,O,O
/,O,O
min,O,O
",",O,O
cisapride,B,B
versus,O,O
placebo,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
;,O,O
pretreatment,O,O
",",O,O
2,O,O
.,O,O
5,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
1,O,O
cont,O,O
.,O,O
/,O,O
min,O,O
],O,O
than,O,O
patients,O,O
treated,O,O
with,O,O
placebo,O,O
.,O,O
No,O,O
significant,O,O
differences,O,O
in,O,O
jejunal,O,O
motility,O,O
were,O,O
found,O,O
in,O,O
the,O,O
constipation,O,O
-,O,O
predominant,O,O
IBS,O,O
group,O,O
.,O,O
Symptoms,O,O
were,O,O
assessed,O,O
by,O,O
using,O,O
a,O,O
visual,O,O
analogue,O,O
scale,O,O
before,O,O
and,O,O
after,O,O
treatment,O,O
.,O,O
Symptom,O,O
scores,O,O
relating,O,O
to,O,O
the,O,O
severity,O,O
of,O,O
constipation,O,B
were,O,O
lower,O,O
in,O,O
cisapride,B,B
-,O,O
treated,O,O
constipation,O,B
-,O,O
predominant,O,O
IBS,O,O
patients,O,O
[,O,O
score,O,O
",",O,O
54,O,O
+,O,O
/,O,O
-,O,O
5,O,O
versus,O,O
67,O,O
+,O,O
/,O,O
-,O,O
14,O,O
mm,O,O
",",O,O
cisapride,B,B
versus,O,O
placebo,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
;,O,O
pretreatment,O,O
",",O,O
62,O,O
+,O,O
/,O,O
-,O,O
19,O,O
mm,O,O
],O,O
Diarrhoea,O,B
-,O,O
predominant,O,O
IBS,O,O
patients,O,O
had,O,O
a,O,O
higher,O,O
pain,O,O
score,O,O
after,O,O
cisapride,B,B
therapy,O,O
[,O,O
score,O,O
",",O,O
55,O,O
+,O,O
/,O,O
-,O,O
15,O,O
versus,O,O
34,O,O
+,O,O
/,O,O
-,O,O
12,O,O
mm,O,O
",",O,O
cisapride,B,B
versus,O,O
placebo,O,O
(,O,O
P,O,O
<,O,O
0,O,O
),O,O
;,O,O
pretreatment,O,O
",",O,O
67,O,O
+,O,O
/,O,O
-,O,O
19,O,O
mm,O,O
],O,O
.,O,O
CONCLUSION,O,O
:,O,O
Cisapride,B,B
affects,O,O
jejunal,O,O
contraction,O,O
characteristics,O,O
and,O,O
some,O,O
symptoms,O,O
in,O,O
IBS,O,O
.,O,O
Prevention,O,O
of,O,O
breast,O,B
cancer,O,I
with,O,O
tamoxifen,B,B
:,O,O
preliminary,O,O
findings,O,O
from,O,O
the,O,O
Italian,O,O
randomised,O,O
trial,O,O
among,O,O
hysterectomised,O,O
women,O,O
.,O,O
Italian,O,O
Tamoxifen,B,B
Prevention,O,I
Study,O,I
.,O,O
BACKGROUND,O,O
:,O,O
Tamoxifen,B,B
is,O,O
a,O,O
candidate,O,O
chemopreventive,O,O
agent,O,O
in,O,O
breast,O,B
cancer,O,I
",",O,O
although,O,O
the,O,O
drug,O,O
may,O,O
be,O,O
associated,O,O
with,O,O
the,O,O
development,O,O
of,O,O
endometrial,O,B
cancer,O,I
.,O,O
Therefore,O,O
we,O,O
did,O,O
a,O,O
trial,O,O
in,O,O
hysterectomised,O,O
women,O,O
of,O,O
tamoxifen,B,B
as,O,O
a,O,O
chemopreventive,O,O
.,O,O
METHODS,O,O
:,O,O
In,O,O
October,O,O
",",O,O
1992,O,O
",",O,O
we,O,O
started,O,O
a,O,O
double,O,O
-,O,O
blind,O,O
placebo,O,O
-,O,O
controlled,O,O
",",O,O
randomised,O,O
trial,O,O
of,O,O
tamoxifen,B,B
in,O,O
women,O,O
(,O,O
mainly,O,O
in,O,O
Italy,O,O
),O,O
who,O,O
did,O,O
not,O,O
have,O,O
breast,O,O
cancer,O,O
and,O,O
who,O,O
had,O,O
had,O,O
a,O,O
hysterectomy,O,O
.,O,O
Women,O,O
were,O,O
randomised,O,O
to,O,O
receive,O,O
tamoxifen,B,B
20,O,O
mg,O,O
per,O,O
day,O,O
or,O,O
placebo,O,O
",",O,O
both,O,O
orally,O,O
for,O,O
5,O,O
years,O,O
.,O,O
The,O,O
original,O,O
plan,O,O
was,O,O
to,O,O
follow,O,O
the,O,O
intervention,O,O
phase,O,O
by,O,O
5,O,O
years,O,O
',O,O
follow,O,O
-,O,O
up,O,O
.,O,O
In,O,O
June,O,O
",",O,O
1997,O,O
",",O,O
the,O,O
trialists,O,O
and,O,O
the,O,O
data,O,O
-,O,O
monitoring,O,O
committee,O,O
decided,O,O
to,O,O
end,O,O
recruitment,O,O
primarily,O,O
because,O,O
of,O,O
the,O,O
number,O,O
of,O,O
women,O,O
dropping,O,O
out,O,O
of,O,O
the,O,O
study,O,O
.,O,O
Recruitment,O,O
ended,O,O
on,O,O
July,O,O
11,O,O
",",O,O
1997,O,O
",",O,O
and,O,O
the,O,O
study,O,O
will,O,O
continue,O,O
as,O,O
planned,O,O
.,O,O
The,O,O
primary,O,O
endpoints,O,O
are,O,O
the,O,O
occurrence,O,O
of,O,O
and,O,O
deaths,O,O
from,O,O
breast,O,B
cancer,O,I
.,O,O
This,O,O
preliminary,O,O
interim,O,O
analysis,O,O
is,O,O
based,O,O
on,O,O
intention,O,O
-,O,O
to,O,O
-,O,O
treat,O,O
.,O,O
FINDINGS,O,O
:,O,O
5408,O,O
women,O,O
were,O,O
randomised,O,O
;,O,O
participating,O,O
women,O,O
have,O,O
a,O,O
median,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
46,O,O
months,O,O
for,O,O
major,O,O
endpoints,O,O
.,O,O
41,O,O
cases,O,O
of,O,O
breast,O,B
cancer,O,I
occurred,O,O
so,O,O
far,O,O
;,O,O
there,O,O
have,O,O
been,O,O
no,O,O
deaths,O,O
from,O,O
breast,O,B
cancer,O,I
.,O,O
There,O,O
is,O,O
no,O,O
difference,O,O
in,O,O
breast,O,B
-,O,O
cancer,O,I
frequency,O,O
between,O,O
the,O,O
placebo,O,B
(,O,O
22,O,O
cases,O,O
),O,O
and,O,O
tamoxifen,B,B
(,O,O
19,O,O
),O,O
arms,O,O
.,O,O
There,O,O
is,O,O
a,O,O
statistically,O,O
significant,O,O
reduction,O,O
of,O,O
breast,O,B
cancer,O,I
among,O,O
women,O,O
receiving,O,O
tamoxifen,B,B
who,O,O
also,O,O
used,O,O
hormone,O,B
-,O,O
replacement,O,I
therapy,O,I
during,O,O
the,O,O
trial,O,O
:,O,O
among,O,O
390,O,O
women,O,O
on,O,O
such,O,O
therapy,O,I
and,O,O
allocated,O,O
to,O,O
placebo,O,B
",",O,O
we,O,O
found,O,O
eight,O,O
cases,O,O
of,O,O
breast,O,B
cancer,O,I
compared,O,O
with,O,O
one,O,O
case,O,O
among,O,O
362,O,O
women,O,O
allocated,O,O
to,O,O
tamoxifen,B,B
.,O,O
Compared,O,O
with,O,O
the,O,O
placebo,O,O
group,O,O
",",O,O
there,O,O
was,O,O
a,O,O
significantly,O,O
increased,O,O
risk,O,O
of,O,O
vascular,O,B
events,O,O
and,O,O
hypertriglyceridaemia,O,B
among,O,O
women,O,O
on,O,O
tamoxifen,B,B
.,O,O
INTERPRETATION,O,O
:,O,O
Although,O,O
this,O,O
preliminary,O,O
analysis,O,O
has,O,O
low,O,O
power,O,O
",",O,O
in,O,O
this,O,O
cohort,O,O
of,O,O
women,O,O
at,O,O
low,O,O
-,O,O
to,O,O
-,O,O
normal,O,O
risk,O,O
of,O,O
breast,O,B
cancer,O,I
",",O,O
the,O,O
postulated,O,O
protective,O,O
effects,O,O
of,O,O
tamoxifen,B,B
are,O,O
not,O,O
yet,O,O
apparent,O,O
.,O,O
Women,O,O
using,O,O
hormone,O,B
-,O,O
replacement,O,I
therapy,O,I
appear,O,O
to,O,O
have,O,O
benefited,O,O
from,O,O
use,O,O
of,O,O
tamoxifen,B,B
.,O,O
There,O,O
were,O,O
no,O,O
deaths,O,O
from,O,O
breast,O,O
cancer,O,O
recorded,O,O
in,O,O
women,O,O
in,O,O
the,O,O
study,O,O
.,O,O
It,O,O
is,O,O
essential,O,O
to,O,O
continue,O,O
follow,O,O
-,O,O
up,O,O
to,O,O
quantify,O,O
the,O,O
long,O,O
-,O,O
term,O,O
risks,O,O
and,O,O
benefits,O,O
of,O,O
tamoxifen,B,B
therapy,O,I
.,O,O
Epileptogenic,O,O
activity,O,O
of,O,O
folic,B,B
acid,I,I
after,O,O
drug,O,O
induces,O,O
SLE,O,O
(,O,O
folic,B,B
acid,I,I
and,O,O
epilepsy,O,O
),O,O
OBJECTIVE,O,O
:,O,O
To,O,O
study,O,O
the,O,O
effect,O,O
of,O,O
folic,B,B
acid,I,I
-,O,O
containing,O,O
multivitamin,O,O
supplementation,O,O
in,O,O
epileptic,O,O
women,O,O
before,O,O
and,O,O
during,O,O
pregnancy,O,O
in,O,O
order,O,O
to,O,O
determine,O,O
the,O,O
rate,O,O
of,O,O
structural,O,O
birth,O,O
defects,O,O
and,O,O
epilepsy,O,O
-,O,O
related,O,O
side,O,O
effects,O,O
.,O,O
STUDY,O,O
DESIGN,O,O
:,O,O
First,O,O
a,O,O
randomised,O,O
trial,O,O
",",O,O
later,O,O
periconception,O,O
care,O,O
including,O,O
in,O,O
total,O,O
12225,O,O
females,O,O
.,O,O
RESULTS,O,O
:,O,O
Of,O,O
60,O,O
epileptic,O,O
women,O,O
with,O,O
periconceptional,O,O
folic,B,B
acid,I,I
(,O,O
0,O,O
.,O,O
8,O,O
mg,O,O
),O,O
-,O,O
containing,O,O
multivitamin,O,O
supplementation,O,O
",",O,O
no,O,O
one,O,O
developed,O,O
epilepsy,O,O
-,O,O
related,O,O
side,O,O
effects,O,O
during,O,O
the,O,O
periconception,O,O
period,O,O
.,O,O
One,O,O
epileptic,O,O
woman,O,O
delivered,O,O
a,O,O
newborn,O,O
with,O,O
cleft,O,B
lip,O,I
and,O,I
palate,O,I
.,O,O
Another,O,O
patient,O,O
exhibited,O,O
with,O,O
a,O,O
cluster,O,O
of,O,O
seizures,O,O
after,O,O
the,O,O
periconception,O,O
period,O,O
using,O,O
another,O,O
multivitamin,O,O
.,O,O
This,O,O
22,O,O
-,O,O
year,O,O
-,O,O
old,O,O
epileptic,O,O
woman,O,O
was,O,O
treated,O,O
continuously,O,O
by,O,O
carbamazepine,B,B
and,O,O
a,O,O
folic,B,B
acid,I,I
(,O,I
1,O,I
mg,O,I
),O,I
-,O,I
containing,O,I
multivitamin,O,I
from,O,O
the,O,O
20th,O,O
week,O,O
of,O,O
gestation,O,O
.,O,O
She,O,O
developed,O,O
status,O,O
epilepticus,O,O
and,O,O
later,O,O
symptoms,O,O
of,O,O
systemic,O,B
lupus,O,I
erythematodes,O,I
.,O,O
Her,O,O
pregnancy,O,O
ended,O,O
with,O,O
stillbirth,O,O
.,O,O
CONCLUSIONS,O,O
:,O,O
The,O,O
epileptic,O,O
pregnant,O,O
patient,O,O
',O,O
s,O,O
autoimmune,O,O
disease,O,O
(,O,O
probably,O,O
drug,O,O
-,O,O
induced,O,O
lupus,O,O
),O,O
could,O,O
damage,O,O
the,O,O
blood,O,B
-,O,I
brain,O,I
barrier,O,I
",",O,O
therefore,O,O
the,O,O
therapeutic,O,O
dose,O,O
(,O,O
>,O,O
or,O,O
=,O,O
1,O,O
mg,O,O
),O,O
of,O,O
folic,B,B
acid,I,I
triggered,O,O
a,O,O
cluster,O,O
of,O,O
seizures,O,O
.,O,O
Physiological,O,O
dose,O,O
(,O,O
<,O,O
1,O,O
mg,O,O
),O,O
of,O,O
folic,B,B
acid,I,I
both,O,O
in,O,O
healthy,O,O
and,O,O
60,O,O
epileptic,O,O
women,O,O
",",O,O
all,O,O
without,O,O
any,O,O
autoimmune,O,O
disease,O,O
",",O,O
did,O,O
not,O,O
increase,O,O
the,O,O
risk,O,O
for,O,O
epileptic,O,O
seizures,O,O
.,O,O
Stroke,O,B
and,O,O
cocaine,B,B
or,O,O
amphetamine,B,B
use,O,O
.,O,O
The,O,O
association,O,O
of,O,O
cocaine,B,B
and,O,O
amphetamine,B,B
use,O,O
with,O,O
hemorrhagic,O,O
and,O,O
ischemic,O,O
stroke,O,O
is,O,O
based,O,O
almost,O,O
solely,O,O
on,O,O
data,O,O
from,O,O
case,O,O
series,O,O
.,O,O
The,O,O
limited,O,O
number,O,O
of,O,O
epidemiologic,O,O
studies,O,O
of,O,O
stroke,O,O
and,O,O
of,O,O
cocaine,B,B
and,O,O
/,O,O
or,O,O
amphetamine,B,B
have,O,O
been,O,O
done,O,O
in,O,O
settings,O,O
that,O,O
serve,O,O
mostly,O,O
the,O,O
poor,O,O
and,O,O
/,O,O
or,O,O
minorities,O,O
.,O,O
This,O,O
case,O,O
-,O,O
control,O,O
study,O,O
was,O,O
conducted,O,O
in,O,O
the,O,O
defined,O,O
population,O,O
comprising,O,O
members,O,O
of,O,O
Kaiser,O,O
Permanente,O,O
of,O,O
Northern,O,O
and,O,O
Southern,O,O
California,O,O
.,O,O
We,O,O
attempted,O,O
to,O,O
identify,O,O
all,O,O
incident,O,O
strokes,O,O
in,O,O
women,O,O
ages,O,O
15,O,O
-,O,O
44,O,O
years,O,O
during,O,O
a,O,O
3,O,O
-,O,O
year,O,O
period,O,O
using,O,O
hospital,O,O
admission,O,O
and,O,O
discharge,O,O
records,O,O
",",O,O
emergency,O,O
department,O,O
logs,O,O
",",O,O
and,O,O
payment,O,O
requests,O,O
for,O,O
out,O,O
-,O,O
of,O,O
-,O,O
plan,O,O
hospitalizations,O,O
.,O,O
We,O,O
selected,O,O
controls,O,O
",",O,O
matched,O,O
on,O,O
age,O,O
and,O,O
facility,O,O
of,O,O
usual,O,O
care,O,O
",",O,O
at,O,O
random,O,O
from,O,O
healthy,O,O
members,O,O
of,O,O
the,O,O
health,O,O
plan,O,O
.,O,O
We,O,O
obtained,O,O
information,O,O
in,O,O
face,O,O
-,O,O
to,O,O
-,O,O
face,O,O
interviews,O,O
.,O,O
There,O,O
were,O,O
347,O,O
confirmed,O,O
stroke,O,O
cases,O,O
and,O,O
1,O,O
",",O,O
controls,O,O
.,O,O
The,O,O
univariate,O,O
matched,O,O
odds,O,O
ratio,O,O
for,O,O
stroke,O,O
in,O,O
women,O,O
who,O,O
admitted,O,O
to,O,O
using,O,O
cocaine,B,B
and,O,O
/,O,O
or,O,O
amphetamine,B,B
was,O,O
8,O,O
.,O,O
5,O,O
(,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
=,O,O
3,O,O
.,O,O
6,O,O
-,O,O
20,O,O
.,O,O
),O,O
.,O,O
After,O,O
further,O,O
adjustment,O,O
for,O,O
potential,O,O
confounders,O,O
",",O,O
the,O,O
odds,O,O
ratio,O,O
in,O,O
women,O,O
who,O,O
reported,O,O
using,O,O
cocaine,B,B
and,O,O
/,O,O
or,O,O
amphetamine,B,B
was,O,O
7,O,O
.,O,O
0,O,O
(,O,O
95,O,O
%,O,O
confidence,O,O
interval,O,O
=,O,O
2,O,O
.,O,O
8,O,O
-,O,O
17,O,O
.,O,O
9,O,O
),O,O
.,O,O
The,O,O
use,O,O
of,O,O
cocaine,B,B
and,O,O
/,O,O
or,O,O
amphetamine,B,B
is,O,O
a,O,O
strong,O,O
risk,O,O
factor,O,O
for,O,O
stroke,O,O
in,O,O
this,O,O
socioeconomically,O,O
heterogeneous,O,O
",",O,O
insured,O,O
urban,O,O
population,O,O
.,O,O
Acute,O,O
renal,O,O
failure,O,O
subsequent,O,O
to,O,O
the,O,O
administration,O,O
of,O,O
rifampicin,B,B
.,O,O
A,O,O
follow,O,O
-,O,O
up,O,O
study,O,O
of,O,O
cases,O,O
reported,O,O
earlier,O,O
.,O,O
A,O,O
clinical,O,O
presentation,O,O
is,O,O
made,O,O
of,O,O
a,O,O
2,O,O
-,O,O
3,O,O
year,O,O
follow,O,O
-,O,O
up,O,O
of,O,O
six,O,O
cases,O,O
of,O,O
acute,O,O
renal,O,B
failure,O,I
that,O,O
have,O,O
been,O,O
reported,O,O
earlier,O,O
.,O,O
The,O,O
patients,O,O
had,O,O
developed,O,O
transient,O,O
renal,O,B
failure,O,I
after,O,O
the,O,O
intermittent,O,O
administration,O,O
of,O,O
rifampicin,B,B
.,O,O
The,O,O
stage,O,O
of,O,O
olig,O,O
-,O,O
anuria,O,O
lasted,O,O
for,O,O
1,O,O
-,O,O
3,O,O
weeks,O,O
",",O,O
and,O,O
five,O,O
of,O,O
the,O,O
patients,O,O
were,O,O
treated,O,O
by,O,O
hemodialysis,O,O
.,O,O
Two,O,O
of,O,O
the,O,O
patients,O,O
died,O,O
due,O,O
to,O,O
unrelated,O,O
causes,O,O
during,O,O
the,O,O
follow,O,O
-,O,O
up,O,O
period,O,O
.,O,O
The,O,O
four,O,O
patients,O,O
re,O,O
-,O,O
examined,O,O
were,O,O
clinically,O,O
cured,O,O
.,O,O
Pathologic,O,O
findings,O,O
by,O,O
light,O,O
microscopy,O,O
and,O,O
immunofluorescence,O,O
at,O,O
biopsy,O,O
were,O,O
scarce,O,O
.,O,O
Nothing,O,O
abnormal,O,O
was,O,O
seen,O,O
by,O,O
electron,O,O
microscopy,O,O
in,O,O
two,O,O
of,O,O
the,O,O
cases,O,O
studied,O,O
.,O,O
Renal,O,O
function,O,O
was,O,O
normal,O,O
.,O,O
In,O,O
three,O,O
cases,O,O
the,O,O
excretion,O,O
at,O,O
131I,O,B
-,O,O
hippuran,O,B
renography,O,O
was,O,O
slightly,O,O
slowed,O,O
.,O,O
Although,O,O
in,O,O
the,O,O
acute,O,O
stage,O,O
the,O,O
renal,O,O
lesions,O,O
histologically,O,O
appeared,O,O
toxic,O,O
",",O,O
evidence,O,O
suggestive,O,O
of,O,O
an,O,O
immunological,O,O
mechanism,O,O
cannot,O,O
be,O,O
excluded,O,O
.,O,O
Chronic,O,O
effects,O,O
of,O,O
a,O,O
novel,O,O
synthetic,O,O
anthracycline,B,B
derivative,O,O
(,O,O
SM,B,B
-,I,O
5887,I,O
),O,O
on,O,O
normal,O,O
heart,O,O
and,O,O
doxorubicin,B,B
-,O,O
induced,O,O
cardiomyopathy,O,O
in,O,O
beagle,O,O
dogs,O,O
.,O,O
This,O,O
study,O,O
was,O,O
designed,O,O
to,O,O
investigate,O,O
the,O,O
chronic,O,O
cardiotoxic,O,O
potential,O,O
of,O,O
SM,B,B
-,I,I
5887,I,I
and,O,O
a,O,O
possible,O,O
deteriorating,O,O
effect,O,O
of,O,O
SM,B,B
-,I,I
5887,I,I
on,O,O
low,O,O
-,O,O
grade,O,O
cardiotoxicity,O,O
pre,O,O
-,O,O
induced,O,O
by,O,O
doxorubicin,B,B
in,O,O
beagle,O,O
dogs,O,O
.,O,O
In,O,O
the,O,O
chronic,O,O
treatment,O,O
",",O,O
beagle,O,O
dogs,O,O
of,O,O
each,O,O
sex,O,O
were,O,O
given,O,O
intravenously,O,O
once,O,O
every,O,O
3,O,O
weeks,O,O
",",O,O
either,O,O
a,O,O
sublethal,O,O
dose,O,O
of,O,O
doxorubicin,B,B
(,O,O
1,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
or,O,O
SM,B,B
-,I,O
5887,I,I
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
.,O,O
The,O,O
experiment,O,O
was,O,O
terminated,O,O
3,O,O
weeks,O,O
after,O,O
the,O,O
ninth,O,O
dosing,O,O
.,O,O
Animals,O,O
which,O,O
received,O,O
over,O,O
six,O,O
courses,O,O
of,O,O
doxorubicin,B,B
demonstrated,O,O
the,O,O
electrocardiogram,O,B
(,O,O
ECG,O,I
),O,O
changes,O,O
",",O,O
decrease,O,O
of,O,O
blood,O,O
pressure,O,O
and,O,O
high,O,O
-,O,O
grade,O,O
histopathological,O,O
cardiomyopathy,O,B
",",O,O
while,O,O
animals,O,O
which,O,O
were,O,O
terminally,O,O
sacrificed,O,O
after,O,O
the,O,O
SM,B,B
-,I,O
5887,I,I
administration,O,O
did,O,O
not,O,O
show,O,O
any,O,O
changes,O,O
in,O,O
ECG,O,B
",",O,O
blood,O,O
pressure,O,O
and,O,O
histopathological,O,O
examinations,O,O
.,O,O
To,O,O
examine,O,O
a,O,O
possibly,O,O
deteriorating,O,O
cardiotoxic,O,O
effect,O,O
of,O,O
SM,B,B
-,I,O
5887,I,I
",",O,O
low,O,O
-,O,O
grade,O,O
cardiomyopathy,O,O
was,O,O
induced,O,O
in,O,O
dogs,O,O
by,O,O
four,O,O
courses,O,O
of,O,O
doxorubicin,B,B
(,O,O
1,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
.,O,O
Nine,O,O
weeks,O,O
after,O,O
pre,O,O
-,O,O
treatment,O,O
",",O,O
dogs,O,O
were,O,O
given,O,O
four,O,O
courses,O,O
of,O,O
either,O,O
doxorubicin,B,B
(,O,O
1,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
or,O,O
SM,B,B
-,I,O
5887,I,I
(,O,O
2,O,O
.,O,O
5,O,O
mg,O,O
/,O,O
kg,O,O
),O,O
once,O,O
every,O,O
3,O,O
weeks,O,O
.,O,O
The,O,O
low,O,O
-,O,O
grade,O,O
cardiotoxic,O,B
changes,O,O
were,O,O
enhanced,O,O
by,O,O
the,O,O
additional,O,O
doxorubicin,B,B
treatment,O,O
.,O,O
On,O,O
the,O,O
contrary,O,O
",",O,O
the,O,O
SM,B,B
-,I,I
5887,I,I
treatment,O,O
did,O,O
not,O,O
progress,O,O
the,O,O
grade,O,O
of,O,O
cardiomyopathy,O,B
.,O,O
In,O,O
conclusion,O,O
",",O,O
SM,B,B
-,I,I
5887,I,I
does,O,O
not,O,O
have,O,O
any,O,O
potential,O,O
of,O,O
chronic,O,O
cardiotoxicity,O,B
and,O,O
deteriorating,O,O
effect,O,O
on,O,O
doxorubicin,B,B
-,O,O
induced,O,O
cardiotoxicity,O,B
in,O,O
dogs,O,O
.,O,O
Risk,O,O
for,O,O
valvular,O,O
heart,O,O
disease,O,O
among,O,O
users,O,O
of,O,O
fenfluramine,B,B
and,O,O
dexfenfluramine,B,B
who,O,O
underwent,O,O
echocardiography,O,O
before,O,O
use,O,O
of,O,O
medication,O,O
.,O,O
BACKGROUND,O,O
:,O,O
Because,O,O
uncontrolled,O,O
echocardiographic,O,O
surveys,O,O
suggested,O,O
that,O,O
up,O,O
to,O,O
30,O,O
%,O,O
to,O,O
38,O,O
%,O,O
of,O,O
users,O,O
of,O,O
fenfluramine,B,B
and,O,O
dexfenfluramine,B,B
had,O,O
valvular,O,O
disease,O,O
",",O,O
these,O,O
drugs,O,O
were,O,O
withdrawn,O,O
from,O,O
the,O,O
market,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
determine,O,O
the,O,O
risk,O,O
for,O,O
new,O,O
or,O,O
worsening,O,O
valvular,O,O
abnormalities,O,O
among,O,O
users,O,O
of,O,O
fenfluramine,B,B
or,O,O
dexfenfluramine,B,B
who,O,O
underwent,O,O
echocardiography,O,O
before,O,O
they,O,O
began,O,O
to,O,O
take,O,O
these,O,O
medications,O,O
.,O,O
DESIGN,O,O
:,O,O
Cohort,O,O
study,O,O
.,O,O
SETTING,O,O
:,O,O
Academic,O,O
primary,O,O
care,O,O
practices,O,O
.,O,O
PATIENTS,O,O
:,O,O
46,O,O
patients,O,O
who,O,O
used,O,O
fenfluramine,B,B
or,O,O
dexfenfluramine,B,B
for,O,O
14,O,O
days,O,O
or,O,O
more,O,O
and,O,O
had,O,O
echocardiograms,O,O
obtained,O,O
before,O,O
therapy,O,O
.,O,O
MEASUREMENTS,O,O
:,O,O
Follow,O,O
-,O,O
up,O,O
echocardiography,O,O
.,O,O
The,O,O
primary,O,O
outcome,O,O
was,O,O
new,O,O
or,O,O
worsening,O,O
valvulopathy,O,O
",",O,O
defined,O,O
as,O,O
progression,O,O
of,O,O
either,O,O
aortic,O,B
or,O,O
mitral,O,B
regurgitation,O,I
by,O,O
at,O,O
least,O,O
one,O,O
degree,O,O
of,O,O
severity,O,O
and,O,O
disease,O,O
that,O,O
met,O,O
U,O,B
.,O,O
S,O,I
.,O,I
Food,O,I
and,O,I
Drug,O,I
Administration,O,I
criteria,O,I
(,O,O
at,O,O
least,O,O
mild,O,O
aortic,O,B
regurgitation,O,I
or,O,O
moderate,O,O
mitral,O,B
regurgitation,O,I
),O,O
.,O,O
RESULTS,O,O
:,O,O
Two,O,O
patients,O,O
(,O,O
4,O,O
.,O,O
3,O,O
%,O,O
[,O,O
95,O,O
%,O,O
CI,O,O
",",O,O
0,O,O
.,O,O
6,O,O
%,O,O
to,O,O
14,O,O
.,O,O
8,O,O
%,O,O
],O,O
),O,O
receiving,O,O
fenfluramine,B,B
-,O,I
phentermine,B,I
developed,O,O
valvular,O,O
heart,O,O
disease,O,O
.,O,O
One,O,O
had,O,O
baseline,O,O
bicuspid,O,O
aortic,O,B
valve,O,I
and,O,O
mild,O,O
aortic,O,B
regurgitation,O,I
that,O,O
progressed,O,O
to,O,O
moderate,O,O
regurgitation,O,O
.,O,O
The,O,O
second,O,O
patient,O,O
developed,O,O
new,O,O
moderate,O,O
aortic,O,B
insufficiency,O,I
.,O,O
CONCLUSION,O,O
:,O,O
Users,O,O
of,O,O
diet,O,O
medications,O,O
are,O,O
at,O,O
risk,O,O
for,O,O
valvular,O,O
heart,O,O
disease,O,O
.,O,O
However,O,O
",",O,O
the,O,O
incidence,O,O
may,O,O
be,O,O
lower,O,O
than,O,O
that,O,O
reported,O,O
previously,O,O
.,O,O
Therapeutic,O,O
drug,O,O
monitoring,O,O
of,O,O
tobramycin,B,B
:,O,O
once,O,O
-,O,O
daily,O,O
versus,O,O
twice,O,O
-,O,O
daily,O,O
dosage,O,O
schedules,O,O
.,O,O
OBJECTIVE,O,O
:,O,O
To,O,O
evaluate,O,O
the,O,O
effect,O,O
of,O,O
dosage,O,O
regimen,O,O
(,O,O
once,O,O
-,O,O
daily,O,O
vs,O,O
.,O,O
twice,O,O
-,O,O
daily,O,O
),O,O
of,O,O
tobramicyn,B,B
on,O,O
steady,O,O
-,O,O
state,O,O
serum,O,O
concentrations,O,O
and,O,O
toxicity,O,O
.,O,O
MATERIALS,O,O
AND,O,O
METHODS,O,O
:,O,O
Patients,O,O
undergoing,O,O
treatment,O,O
with,O,O
i,O,O
.,O,O
v,O,O
.,O,O
tobramycin,B,B
(,O,O
4,O,O
mg,O,O
/,O,O
kg,O,O
/,O,O
day,O,O
),O,O
were,O,O
randomised,O,O
to,O,O
two,O,O
groups,O,O
.,O,O
Group,O,O
OD,O,O
(,O,O
n,O,O
=,O,O
22,O,O
),O,O
received,O,O
a,O,O
once,O,O
-,O,O
daily,O,O
dose,O,O
of,O,O
tobramycin,B,B
and,O,O
group,O,O
TD,O,O
(,O,O
n,O,O
=,O,O
21,O,O
),O,O
received,O,O
the,O,O
same,O,O
dose,O,O
divided,O,O
into,O,O
two,O,O
doses,O,O
daily,O,O
.,O,O
Tobramycin,B,B
serum,O,O
concentrations,O,O
(,O,O
peak,O,O
and,O,O
trough,O,O
),O,O
were,O,O
measured,O,O
by,O,O
enzyme,O,O
multiplied,O,O
immunoassay,O,O
.,O,O
The,O,O
renal,O,B
and,O,O
auditory,O,O
functions,O,O
of,O,O
the,O,O
patients,O,O
were,O,O
monitored,O,O
before,O,O
",",O,O
during,O,O
and,O,O
immediately,O,O
after,O,O
treatment,O,O
.,O,O
RESULTS,O,O
:,O,O
The,O,O
two,O,O
groups,O,O
were,O,O
comparable,O,O
with,O,O
respect,O,O
to,O,O
sex,O,O
",",O,O
age,O,O
",",O,O
body,O,O
weight,O,O
and,O,O
renal,O,B
function,O,O
.,O,O
No,O,O
statistically,O,O
significant,O,O
differences,O,O
were,O,O
found,O,O
in,O,O
mean,O,O
daily,O,O
dose,O,O
",",O,O
duration,O,O
of,O,O
treatment,O,O
",",O,O
or,O,O
cumulative,O,O
dose,O,O
.,O,O
Trough,O,O
concentrations,O,O
were,O,O
<,O,O
2,O,O
g,O,O
/,O,O
ml,O,O
in,O,O
the,O,O
two,O,O
groups,O,O
(,O,O
100,O,O
%,O,O
),O,O
.,O,O
Peak,O,O
concentrations,O,O
were,O,O
>,O,O
6,O,O
microg,O,O
/,O,O
ml,O,O
in,O,O
100,O,O
%,O,O
of,O,O
the,O,O
OD,O,B
group,O,O
and,O,O
in,O,O
67,O,O
%,O,O
of,O,O
the,O,O
TD,O,B
group,O,O
(,O,O
P,O,B
<,O,I
0,O,I
.,O,I
),O,I
.,O,O
Mean,O,O
peak,O,O
concentrations,O,O
were,O,O
markedly,O,O
different,O,O
:,O,O
11,O,O
.,O,O
+,O,O
/,O,O
-,O,O
2,O,O
.,O,O
89,O,O
microg,O,B
/,O,O
ml,O,O
in,O,O
OD,O,O
vs,O,O
.,O,O
6,O,O
.,O,O
53,O,O
+,O,O
/,O,O
-,O,O
1,O,O
.,O,O
45,O,O
microg,O,B
/,O,O
ml,O,O
in,O,O
TD,O,O
(,O,O
P,O,O
<,O,O
0,O,O
.,O,O
),O,O
.,O,O
The,O,O
pharmacokinetics,O,O
parameters,O,O
were,O,O
:,O,O
Ke,O,O
",",O,O
(,O,O
0,O,O
.,O,O
15,O,O
+,O,O
/,O,O
-,O,O
0,O,O
in,O,O
OD,O,O
vs,O,O
.,O,O
0,O,O
.,O,O
24,O,O
+,O,O
/,O,O
-,O,O
0,O,O
/,O,O
h,O,O
in,O,O
TD,O,O
),O,O
",",O,O
t1,O,O
/,O,O
2,O,O
",",O,O
(,O,O
.,O,O
+,O,O
/,O,O
-,O,O
OD,O,O
vs,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
.,O,O
in,O,O
TD,O,O
0,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
/,O,O
kg,O,O
in,O,O
OD,O,O
vs,O,O
.,O,O
.,O,O
+,O,O
/,O,O
-,O,O
0,O,O
/,O,O
kg,O,O
in,O,O
TD,O,O
),O,O
in,O,B
OD,O,O
in,O,O
TD,O,O
patients,O,O
",",O,O
of,O,O
presented,O,O
with,O,O
an,O,O
auditory,O,O
loss,O,O
of,O,O
-,O,O
30,O,O
dB,O,O
",",O,O
whereas,O,O
in,O,O
the,O,O
OD,O,O
group,O,O
only,O,O
one,O,O
patient,O,O
presented,O,O
decreased,O,O
auditory,O,O
function,O,O
.,O,O
CONCLUSION,O,O
:,O,O
This,O,O
small,O,O
study,O,O
suggests,O,O
that,O,O
a,O,O
once,O,O
-,O,O
daily,O,O
dosing,O,O
regimen,O,O
of,O,O
tobramycin,B,B
is,O,O
at,O,O
least,O,O
as,O,O
effective,O,O
as,O,O
and,O,O
is,O,O
no,O,O
more,O,O
and,O,O
possibly,O,O
less,O,O
toxic,O,O
than,O,O
the,O,O
twice,O,O
-,O,O
daily,O,O
regimen,O,O
.,O,O
Using,O,O
a,O,O
single,O,O
-,O,O
dose,O,O
therapy,O,O
",",O,O
peak,O,O
concentration,O,O
determination,O,O
is,O,O
not,O,O
necessary,O,O
",",O,O
only,O,O
trough,O,O
samples,O,O
should,O,O
be,O,O
monitored,O,O
to,O,O
ensure,O,O
levels,O,O
below,O,O
2,O,O
microg,O,O
/,O,O
ml,O,O
.,O,O
Enhanced,O,O
bradycardia,O,O
induced,O,O
by,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
antagonists,O,I
in,O,O
rats,O,O
pretreated,O,O
with,O,O
isoniazid,B,B
.,O,O
High,O,O
doses,O,O
of,O,O
isoniazid,B,B
increase,O,O
hypotension,O,O
induced,O,O
by,O,O
vasodilators,O,O
and,O,O
change,O,O
the,O,O
accompanying,O,O
reflex,O,O
tachycardia,O,O
to,O,O
bradycardia,O,O
",",O,O
an,O,O
interaction,O,O
attributed,O,O
to,O,O
decreased,O,O
synthesis,O,O
of,O,O
brain,O,O
gamma,B,B
-,I,I
aminobutyric,I,I
acid,I,I
(,O,O
GABA,B,B
),O,O
.,O,O
In,O,O
the,O,O
present,O,O
study,O,O
",",O,O
the,O,O
possible,O,O
enhancement,O,O
by,O,O
isoniazid,B,B
of,O,O
bradycardia,O,O
induced,O,O
by,O,O
beta,O,B
-,O,I
adrenoceptor,O,I
antagonists,O,I
was,O,O
determined,O,O
in,O,O
rats,O,O
anaesthetised,O,O
with,O,O
chloralose,B,B
-,O,I
urethane,B,I
.,O,O
Isoniazid,B,B
significantly,O,O
increased,O,O
bradycardia,O,O
after,O,O
propranolol,B,B
",",O,O
pindolol,B,B
",",O,O
labetalol,B,B
and,O,O
atenolol,B,B
",",O,O
as,O,O
well,O,O
as,O,O
after,O,O
clonidine,B,B
",",O,O
but,O,O
not,O,O
after,O,O
hexamethonium,B,B
or,O,O
carbachol,B,B
.,O,O
Enhancement,O,O
was,O,O
not,O,O
observed,O,O
in,O,O
rats,O,O
pretreated,O,O
with,O,O
methylatropine,B,B
or,O,O
previously,O,O
vagotomised,O,O
.,O,O
These,O,O
results,O,O
are,O,O
compatible,O,O
with,O,O
interference,O,O
by,O,O
isoniazid,B,B
with,O,O
GABAergic,O,O
inhibition,O,O
of,O,O
cardiac,O,O
parasympathetic,O,O
tone,O,O
.,O,O
Such,O,O
interference,O,O
could,O,O
be,O,O
exerted,O,O
centrally,O,O
",",O,O
possibly,O,O
at,O,O
the,O,O
nucleus,O,O
ambiguus,O,O
",",O,O
or,O,O
peripherally,O,O
at,O,O
the,O,O
sinus,O,O
node,O,O
.,O,O
Structural,O,O
and,O,O
functional,O,O
impairment,O,O
of,O,O
mitochondria,O,B
in,O,O
adriamycin,B,B
-,O,I
induced,O,I
cardiomyopathy,O,I
in,O,O
mice,O,O
:,O,O
suppression,O,O
of,O,O
cytochrome,O,B
c,O,I
oxidase,O,I
II,O,I
gene,O,O
expression,O,O
.,O,O
The,O,O
use,O,O
of,O,O
adriamycin,B,B
(,O,O
ADR,B,B
),O,O
in,O,O
cancer,O,O
chemotherapy,O,O
has,O,O
been,O,O
limited,O,O
due,O,O
to,O,O
its,O,O
cumulative,O,O
cardiovascular,O,O
toxicity,O,O
.,O,O
Earlier,O,O
observations,O,O
that,O,O
ADR,B,B
interacts,O,O
with,O,O
mitochondrial,O,B
cytochrome,O,B
c,O,I
oxidase,O,I
(,O,O
COX,O,B
),O,O
and,O,O
suppresses,O,O
its,O,O
enzyme,O,O
activity,O,O
led,O,O
us,O,O
to,O,O
investigate,O,O
ADR,B,B
',O,O
s,O,O
action,O,O
on,O,O
the,O,O
cardiovascular,O,O
functions,O,O
and,O,O
heart,O,O
mitochondrial,O,B
morphology,O,O
in,O,O
Balb,O,O
-,O,O
c,O,O
mice,O,O
i,O,O
.,O,O
p,O,O
.,O,O
treated,O,O
with,O,O
ADR,B,B
for,O,O
several,O,O
weeks,O,O
.,O,O
At,O,O
various,O,O
times,O,O
during,O,O
treatment,O,O
",",O,O
the,O,O
animals,O,O
were,O,O
assessed,O,O
for,O,O
cardiovascular,O,O
functions,O,O
by,O,O
electrocardiography,O,O
and,O,O
for,O,O
heart,O,O
tissue,O,O
damage,O,O
by,O,O
electron,O,O
microscopy,O,O
.,O,O
In,O,O
parallel,O,O
",",O,O
total,O,O
RNA,O,B
was,O,O
extracted,O,O
from,O,O
samples,O,O
of,O,O
dissected,O,O
heart,O,O
and,O,O
analyzed,O,O
by,O,O
Northern,O,O
blot,O,O
hybridization,O,O
to,O,O
determine,O,O
the,O,O
steady,O,O
-,O,O
state,O,O
level,O,O
of,O,O
three,O,O
RNA,O,B
transcripts,O,O
encoded,O,O
by,O,O
the,O,O
COXII,O,B
",",O,O
COXIII,O,B
",",O,O
and,O,O
COXIV,O,B
genes,O,O
.,O,O
Similarly,O,O
",",O,O
samples,O,O
obtained,O,O
from,O,O
the,O,O
liver,O,O
of,O,O
the,O,O
same,O,O
animals,O,O
were,O,O
analyzed,O,O
for,O,O
comparative,O,O
studies,O,O
.,O,O
Our,O,O
results,O,O
indicated,O,O
that,O,O
1,O,O
),O,O
treatment,O,O
of,O,O
mice,O,O
with,O,O
ADR,B,B
caused,O,O
cardiovascular,O,O
arrhythmias,O,O
characterized,O,O
by,O,O
bradycardia,O,O
",",O,O
extension,O,O
of,O,O
ventricular,O,O
depolarization,O,O
time,O,O
(,O,O
tQRS,O,B
),O,O
",",O,O
and,O,O
failure,O,O
of,O,O
QRS,O,B
at,O,O
high,O,O
concentrations,O,O
(,O,O
10,O,O
-,O,O
14,O,O
mg,O,O
/,O,O
kg,O,O
body,O,O
weight,O,O
cumulative,O,O
dose,O,O
),O,O
;,O,O
2,O,O
),O,O
the,O,O
heart,O,O
mitochondria,O,O
underwent,O,O
swelling,O,O
",",O,O
fusion,O,O
",",O,O
dissolution,O,O
",",O,O
and,O,O
/,O,O
or,O,O
disruption,O,O
of,O,O
mitochondrial,O,O
cristae,O,O
after,O,O
several,O,O
weeks,O,O
of,O,O
treatment,O,O
.,O,O
Such,O,O
abnormalities,O,O
were,O,O
not,O,O
observed,O,O
in,O,O
the,O,O
mitochondria,O,B
of,O,O
liver,O,B
tissue,O,O
;,O,O
and,O,O
3,O,O
),O,O
among,O,O
the,O,O
three,O,O
genes,O,O
of,O,O
COX,O,B
enzyme,O,O
examined,O,O
",",O,O
only,O,O
COXII,O,B
gene,O,O
expression,O,O
was,O,O
suppressed,O,O
by,O,O
ADR,B,B
treatment,O,O
",",O,O
mainly,O,O
after,O,O
8,O,O
weeks,O,O
in,O,O
both,O,O
heart,O,B
and,O,O
liver,O,B
.,O,O
Knowing,O,O
that,O,O
heart,O,B
mitochondria,O,B
represent,O,O
almost,O,O
40,O,O
%,O,O
of,O,O
heart,O,B
muscle,O,O
by,O,O
weight,O,O
",",O,O
we,O,O
conclude,O,O
that,O,O
the,O,O
deteriorating,O,O
effects,O,O
of,O,O
ADR,B,B
on,O,O
cardiovascular,O,O
function,O,O
involve,O,O
mitochondrial,O,B
structural,O,O
and,O,O
functional,O,O
impairment,O,O
.,O,O
